PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Burke, AP; Farb, A; Malcom, GT; Liang, YH; Smialek, J; Virmani, R				Burke, AP; Farb, A; Malcom, GT; Liang, YH; Smialek, J; Virmani, R			Coronary risk factors and plaque morphology in men with coronary disease who died suddenly	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MYOCARDIAL-INFARCTION; CLINICAL EVENTS; ARTERY DISEASE; ATHEROSCLEROSIS; REDUCTION; DEATH; PRAVASTATIN; ANGINA; DISRUPTION; THERAPY	Background Cigarette smoking and abnormal serum cholesterol concentrations are risk factors for acute coronary syndromes, but the underlying mechanisms are poorly understood. We studied whether cigarette smoking and abnormal cholesterol values may precipitate acute coronary thrombosis and sudden death resulting from either rupture of vulnerable coronary plaques or erosion of plaques. Methods We examined the hearts of 113 men with coronary disease who had died suddenly and also analyzed their coronary risk factors. We found an acute coronary thrombus in each of 59 men, and severe narrowing of the coronary artery by an atherosclerotic plaque without acute thrombosis (stable plaque) in 54. Cases of acute thrombosis were divided into two groups: 41 resulting from rupture of a vulnerable plaque (a thin fibrous cap overlying a lipid-rich core), and 18 resulting from the erosion of a fibrous plaque rich in smooth-muscle cells and proteoglycans. Vulnerable plaques that had not ruptured were counted in each heart. Results Cigarette smoking was a risk factor in 44 (75 percent) of the men with acute thrombosis, as compared with 22 (41 percent) of the men with stable plaques (P<0.001). The mean (+/-SD) ratio of serum total cholesterol to high-density lipoprotein (HDL) cholesterol was markedly elevated in the men who died of acute thrombosis with plaque rupture (8.5+/-4.0) but only mildly elevated in the men without acute thrombosis (5.5+/-2.4, P<0.001) and in the men with thrombi overlying eroded plaques (5.0+/-1.8, P<0.001). Multivariate analysis showed an association between an elevated ratio of serum total cholesterol to HDL cholesterol and the presence of vulnerable plaques (P<0.001). Conclusions Among men with coronary disease who die suddenly, abnormal serum cholesterol concentrations - particularly elevated ratios of total cholesterol to HDL cholesterol - predispose patients to rupture of vulnerable plaques, whereas cigarette smoking predisposes patients to acute thrombosis. (C) 1997, Massachusetts Medical Society.	ARMED FORCES INST PATHOL, DEPT CARDIOVASC PATHOL, WASHINGTON, DC 20306 USA; LOUISIANA STATE UNIV, NEW ORLEANS, LA USA; UNIV MARYLAND, BALTIMORE, MD 21201 USA	United States Department of Defense; Louisiana State University System; University System of Maryland; University of Maryland Baltimore								BROWN BG, 1993, CIRCULATION, V87, P1781, DOI 10.1161/01.CIR.87.6.1781; Burke AP, 1996, CIRCULATION, V94, P3138, DOI 10.1161/01.CIR.94.12.3138; BYINGTON RP, 1995, CIRCULATION, V92, P2419, DOI 10.1161/01.CIR.92.9.2419; Casscells W, 1996, LANCET, V347, P1447, DOI 10.1016/S0140-6736(96)91684-0; CHEN LJ, 1995, CHEST, V108, P364, DOI 10.1378/chest.108.2.364; DAVIES MJ, 1985, BRIT HEART J, V53, P363; FALK E, 1995, CIRCULATION, V92, P657, DOI 10.1161/01.CIR.92.3.657; FARB A, 1995, CIRCULATION, V92, P1701, DOI 10.1161/01.CIR.92.7.1701; Farb A, 1996, CIRCULATION, V93, P1354, DOI 10.1161/01.CIR.93.7.1354; Feld S, 1996, J AM COLL CARDIOL, V28, P97, DOI 10.1016/0735-1097(96)00102-7; FURBERG CD, 1995, AM J CARDIOL, V76, pC60, DOI 10.1016/S0002-9149(99)80472-X; FUSTER V, 1995, AM J CARDIOL, V76, pC24, DOI 10.1016/S0002-9149(99)80467-6; HUNG J, 1995, CIRCULATION, V92, P2432, DOI 10.1161/01.CIR.92.9.2432; KANNEL WB, 1988, AM HEART J, V115, P869, DOI 10.1016/0002-8703(88)90891-5; KITZMAN DW, 1988, MAYO CLIN PROC, V63, P137, DOI 10.1016/S0025-6196(12)64946-5; KJEKSHUS J, 1995, AM J CARDIOL, V76, pC64, DOI 10.1016/S0002-9149(99)80473-1; LACOSTE L, 1995, CIRCULATION, V92, P3172, DOI 10.1161/01.CIR.92.11.3172; LOREE HM, 1994, ARTERIOSCLER THROMB, V14, P230, DOI 10.1161/01.ATV.14.2.230; MACISAAC AI, 1993, J AM COLL CARDIOL, V22, P1228, DOI 10.1016/0735-1097(93)90442-4; MCGILL HC, 1995, ARTERIOSCL THROM VAS, V15, P431, DOI 10.1161/01.ATV.15.4.431; MCGILL HC, 1990, JAMA-J AM MED ASSOC, V264, P3018; Njolstad I, 1996, CIRCULATION, V93, P450; OLIVER MF, 1994, LANCET, V344, P633; PEDERSEN TR, 1994, LANCET, V344, P1383; PITT B, 1995, J AM COLL CARDIOL, V26, P1133, DOI 10.1016/0735-1097(95)00301-0; Rapaport Elliot, 1996, American Journal of Medicine, V101, p61S, DOI 10.1016/S0002-9343(96)00322-1; RIDKER PM, 1994, CIRCULATION, V90, P2236, DOI 10.1161/01.CIR.90.5.2236; SEGREST JP, 1994, CURR OPIN CARDIOL, V9, P404; SILVA JA, 1995, CIRCULATION, V92, P1731, DOI 10.1161/01.CIR.92.7.1731; THOMPSON SG, 1995, NEW ENGL J MED, V332, P635, DOI 10.1056/NEJM199503093321003; TREASURE CB, 1995, NEW ENGL J MED, V332, P481, DOI 10.1056/NEJM199502233320801; VAARALA O, 1995, CIRCULATION, V91, P23, DOI 10.1161/01.CIR.91.1.23; Weiss EJ, 1996, NEW ENGL J MED, V334, P1090, DOI 10.1056/NEJM199604253341703; WISSLER RW, 1993, ARTERIOSCLER THROMB, V13, P1291	34	1231	1298	0	27	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 1	1997	336	18					1276	1282		10.1056/NEJM199705013361802	http://dx.doi.org/10.1056/NEJM199705013361802			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW260	9113930				2022-12-01	WOS:A1997WW26000002
J	Weliky, M; Katz, LC				Weliky, M; Katz, LC			Disruption of orientation tuning in visual cortex by artificially correlated neuronal activity	NATURE			English	Article							BASIC NETWORK PRINCIPLES; NEURAL ARCHITECTURE; COLUMNS; CELLS; CONNECTIONS; RECEPTORS; EMERGENCE; MECHANISM; INPUTS; MODEL	In the primary visual cortex, the development of orientation selectivity is influenced by patterns of neural activity. The introduction of artificially correlated activity into the visual pathway (through synchronous activation of retinal ganglion cell axons in the optic nerve) substantially weakens the orientation selectivity of neurons In superficial and deep cortical layers. This is consistent with activity having an instructive role sin shaping cortical neuron receptive field tuning properties.	DUKE UNIV,SCH MED,DEPT NEUROBIOL,DURHAM,NC 27710	Duke University	Weliky, M (corresponding author), DUKE UNIV,SCH MED,HOWARD HUGHES MED INST,DURHAM,NC 27710, USA.							ALLENDOERFER KL, 1994, J NEUROSCI, V14, P1795; [Anonymous], [No title captured]; CHANGEUX JP, 1976, NATURE, V264, P705, DOI 10.1038/264705a0; Chapman B, 1996, J NEUROSCI, V16, P6443; CHAPMAN B, 1993, J NEUROSCI, V13, P5254; DUBIN MW, 1986, J NEUROSCI, V6, P1021; FIELD DJ, 1987, J OPT SOC AM A, V4, P2379, DOI 10.1364/JOSAA.4.002379; FREGNAC Y, 1981, EXP BRAIN RES, V42, P453; Godecke I, 1996, NATURE, V379, P251, DOI 10.1038/379251a0; HAHM JO, 1991, NATURE, V351, P568, DOI 10.1038/351568a0; HUBEL DH, 1965, J NEUROPHYSIOL, V28, P1041, DOI 10.1152/jn.1965.28.6.1041; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; KIM DS, 1994, NATURE, V370, P370, DOI 10.1038/370370a0; LINSKER R, 1986, P NATL ACAD SCI USA, V83, P8779, DOI 10.1073/pnas.83.22.8779; LINSKER R, 1986, P NATL ACAD SCI USA, V83, P8390, DOI 10.1073/pnas.83.21.8390; MASTRONARDE DN, 1983, J NEUROPHYSIOL, V49, P303, DOI 10.1152/jn.1983.49.2.303; MCCORMICK DA, 1995, J NEUROSCI, V15, P5739; MEISTER M, 1991, SCIENCE, V252, P939, DOI 10.1126/science.2035024; MILLER KD, 1994, J NEUROSCI, V14, P409; MIYASHITA M, 1992, NEUROREPORT, V3, P69, DOI 10.1097/00001756-199201000-00018; NAPLES GG, 1988, IEEE T BIO-MED ENG, V35, P905, DOI 10.1109/10.8670; REID RC, 1995, NATURE, V378, P281, DOI 10.1038/378281a0; STENT GS, 1973, P NATL ACAD SCI USA, V70, P997, DOI 10.1073/pnas.70.4.997; STRYKER MP, 1986, J NEUROSCI, V6, P2117; Weliky M, 1996, NATURE, V379, P725, DOI 10.1038/379725a0; WIESEL TN, 1974, J COMP NEUROL, V158, P308; Wong ROL, 1996, NEURON, V16, P1087, DOI 10.1016/S0896-6273(00)80135-X; WONG ROL, 1993, NEURON, V11, P923, DOI 10.1016/0896-6273(93)90122-8; WORGOTTER F, 1991, EXP BRAIN RES, V83, P665	29	152	155	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 17	1997	386	6626					680	685		10.1038/386680a0	http://dx.doi.org/10.1038/386680a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WU387	9109486				2022-12-01	WOS:A1997WU38700046
J	Nesbitt, SA; Horton, MA				Nesbitt, SA; Horton, MA			Trafficking of matrix collagens through bone-resorbing osteoclasts	SCIENCE			English	Article							TRANSFORMING GROWTH-FACTOR-BETA-2; DEGRADATION; RESORPTION	An intracellular pathway for proteins liberated from mineralized matrix during resorption was identified in osteoclasts. Analysis by confocal microscopy of sites of active bone resorption showed that released matrix proteins, including degraded type I collagen, were endocytosed along the ruffled border within the resorption compartment and transcytosed through the osteoclast to the base lateral membrane. Intracellular trafficking of degraded collagen, as typified by the resorbing osteoclast, may provide the cell with a regulatory mechanism for the control of tissue degradation.			Nesbitt, SA (corresponding author), UCL, SCH MED, DEPT MED, BONE & MINERAL CTR, MORTIMER ST, LONDON W1N 8AA, ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARON R, 1988, J CELL BIOL, V106, P1863, DOI 10.1083/jcb.106.6.1863; BILEZIKIAN JP, 1996, PRINCIPLES BONE BIOL; BLAIR HC, 1993, BIOCHEM J, V290, P873, DOI 10.1042/bj2900873; BONDE M, 1994, CLIN CHEM, V40, P2022; Bossard MJ, 1996, J BIOL CHEM, V271, P12517, DOI 10.1074/jbc.271.21.12517; BOYDE A, 1984, BRIT DENT J, V156, P216, DOI 10.1038/sj.bdj.4805313; CHAMBERS TJ, 1984, J CELL SCI, V66, P383; CRITCHLOW MA, 1995, HISTOCHEM J, V27, P505; CRITCHLOW MA, 1994, J CELL SCI, V107, P499; DAVIES J, 1989, J CELL BIOL, V109, P1817, DOI 10.1083/jcb.109.4.1817; Foged NT, 1996, J BONE MINER RES, V11, P226; Guerrero R, 1996, OSTEOPOROSIS INT, V6, P297, DOI 10.1007/BF01623388; HELFRICH MH, 1993, J CELL SCI, V104, P663; HOLTROP ME, 1977, CLIN ORTHOP RELAT R, P177; HORTON MA, 1984, J PATHOL, V144, P282; MOSTOV KE, 1995, COLD SPRING HARB SYM, V40, P775; NESBITT SA, UNPUB; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Salo J, 1996, J CELL SCI, V109, P301; SIMMONS K, 1985, ANN REV CELL BIOL, V1, P243; VAANANEN HK, 1995, J CELL SCI, V108, P2729; ZHOU H, 1993, CELL MATER, V3, P141	22	305	313	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 11	1997	276	5310					266	269		10.1126/science.276.5310.266	http://dx.doi.org/10.1126/science.276.5310.266			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WT925	9092478				2022-12-01	WOS:A1997WT92500049
J	Poulsen, AG; Aaby, P; Larsen, O; Jensen, H; Naucler, A; Lisse, IM; Christiansen, CB; Dias, F; Melbye, M				Poulsen, AG; Aaby, P; Larsen, O; Jensen, H; Naucler, A; Lisse, IM; Christiansen, CB; Dias, F; Melbye, M			9-year HIV-2-associated mortality in an urban community in Bissau, west Africa	LANCET			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-2; HIV-2 INFECTION; GUINEA-BISSAU; HIV-1-ASSOCIATED MORTALITY; POPULATION; AIDS; TRANSMISSION; PREVALENCE; DISEASE; COHORT	Background Community studies with 1-3 years of follow-up have reported four to five;times higher mortality in HIV-2-infected than in uninfected adults. In a cohort study of HIV-1, an increasing difference in mortality rates of HIV-1-infected and uninfected individuals is expected over lime, because of rising mortality with advancing HIV-1 infection. We therefore investigated long-term survival of HIV-2-infected adults. Methods Adults enrolled in 1987 in a community study of HIV-2 infection in Guinea-Bissau were followed up with serological surveys in 1989 and 1992. Survival was assessed in 1995, 9 years after enrolment. Findings The annual incidence of HIV-2 was 0.7% for adults and tended to be higher for older individuals than for participants aged 15-44 years (relative risk 3.21 [95% CI 0.91-11.37]). With control for age, HIV-2-infected adults had twice as high mortality as uninfected individuals (mortality ratio 2.32 [1.18-4.57]); the mortality ratio was highest in the first year of the study (4.50 [1.31-15.43]). The difference between infected and uninfected individuals was stronger for adults under 45 years of age (mortality ratio 4.72 [1.86-11.97]) than for older people (1.35 [0.51-3.56]). HIV-2-infected individuals living with an infected spouse had significantly higher mortality than HIV-2-infected individuals living with an uninfected spouse (p=0.027). Interpretation HIV-2-associated mortality is not increasing with length of follow-up. Mortality in HIV-2-infected adults is only twice as high as that in uninfected individuals. In the majority of adults, HIV-2 has no effect on survival.	STATENS SERUM INST,DANISH EPIDEMIOL SCI CTR,DEPT EPIDEMIOL RES,DK-2300 COPENHAGEN S,DENMARK; STATENS SERUM INST,DEPT VIROL,DK-2300 COPENHAGEN S,DENMARK; MINSAP,LAB NACL SAUDE PUBL,BISSAU,GUINEA BISSAU	Aarhus University; Statens Serum Institut; Statens Serum Institut				Poulsen, Anja/0000-0002-9656-1552; melbye, mads/0000-0001-8264-6785; Aaby, Peter/0000-0001-8331-1389				Aaby P, 1996, AIDS, V10, P1585, DOI 10.1097/00002030-199611000-00019; Ariyoshi K, 1996, J INFECT DIS, V173, P245, DOI 10.1093/infdis/173.1.245; BARIN F, 1985, LANCET, V2, P1387; BIGGAR RJ, 1990, AIDS, V4, P1059, DOI 10.1097/00002030-199011000-00002; CLAVEL F, 1987, NEW ENGL J MED, V316, P1180, DOI 10.1056/NEJM198705073161903; Cox DR., 1984, ANAL SURVIVAL DATA; KANKI PJ, 1994, LANCET, V343, P943, DOI 10.1016/S0140-6736(94)90065-5; LISSE IM, 1990, AIDS, V4, P1263, DOI 10.1097/00002030-199012000-00013; Lisse IM, 1996, J ACQ IMMUN DEF SYND, V13, P355, DOI 10.1097/00042560-199612010-00009; MARLINK R, 1994, SCIENCE, V265, P1587, DOI 10.1126/science.7915856; Marx PA, 1996, NAT MED, V2, P1084, DOI 10.1038/nm1096-1084; MOLBAK K, 1986, LANCET, V2, P1214; MULDER DW, 1994, LANCET, V343, P1021, DOI 10.1016/S0140-6736(94)90133-3; MULDER DW, 1994, AIDS, V8, P87, DOI 10.1097/00002030-199401000-00013; NAUCLER A, 1989, J ACQ IMMUN DEF SYND, V2, P88; NORRGREN H, 1995, J ACQ IMMUN DEF SYND, V9, P422, DOI 10.1097/00042560-199508000-00014; POULSEN AG, 1989, LANCET, V1, P827, DOI 10.1016/S0140-6736(89)92281-2; POULSEN AG, 1993, J ACQ IMMUN DEF SYND, V6, P941; POULSEN AG, 1992, J ACQ IMMUN DEF SYND, V5, P25; RICARD D, 1994, AIDS, V8, P977, DOI 10.1097/00002030-199407000-00016; ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59; WHITTLE H, 1994, AIDS, V8, P1617, DOI 10.1097/00002030-199411000-00015	22	116	116	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 29	1997	349	9056					911	914		10.1016/S0140-6736(96)04402-9	http://dx.doi.org/10.1016/S0140-6736(96)04402-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR254	9093252				2022-12-01	WOS:A1997WR25400011
J	Wilkinson, D; Sach, ME; Karim, SSA				Wilkinson, D; Sach, ME; Karim, SSA			Examination of attendance patterns before and after introduction of South Africa's policy of free health care for children aged under 6 years and pregnant women	BRITISH MEDICAL JOURNAL			English	Article									HLABISA HOSP,HLABISA,SOUTH AFRICA		Wilkinson, D (corresponding author), MRC,CTR EPIDEMIOL RES SO AFRICA,POB 658,ZA-3937 HLABISA,SOUTH AFRICA.		Karim, Salim Abdool/P-3117-2019; Karim, Salim Abdool/AAE-7118-2019; Wilkinson, David/A-6207-2008; Karim, Salim Safurdeen Abdool/N-5947-2013	Karim, Salim Abdool/0000-0002-4986-2133; Wilkinson, David/0000-0002-7265-9846; Karim, Salim Safurdeen Abdool/0000-0002-4986-2133				GILSON L, 1993, LANCET, V342, P800, DOI 10.1016/0140-6736(93)91560-9; WILKINSON D, IN PRESS S AFR MED	2	23	23	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 29	1997	314	7085					940	941		10.1136/bmj.314.7085.940	http://dx.doi.org/10.1136/bmj.314.7085.940			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ169	9099118	Green Published			2022-12-01	WOS:A1997WQ16900026
J	Wang, SW; Krinks, M; Lin, KM; Luyten, FP; Moos, M				Wang, SW; Krinks, M; Lin, KM; Luyten, FP; Moos, M			Frzb, a secreted protein expressed in the Spemann organizer, binds and inhibits Wnt-8	CELL			English	Article							XENOPUS-EMBRYOS; EARLY EMBRYOGENESIS; VENTRAL MESODERM; GENE; LAEVIS; LIMB; INDUCTION; XWNT-8; POLARITY; PATTERN	We isolated a Xenopus homolog of Frzb, a newly described protein containing an amino-terminal Frizzled motif. It dorsalized Xenopus embryos and was expressed in the Spemann organizer during early gastrulation. Unlike Frizzled proteins, endogenous Frzb was soluble. Frzb was secretable and could act across cell boundaries. In several functional assays, Frzb antagonized Xwnt-8, a proposed ventralizing factor with an expression pattern complementary to that of Frzb. Furthermore, Frzb blocked induction of MyoD, an action reported recently for a dominant-negative Xwnt-8. Frzb coimmunoprecipitated with Wnt proteins, providing direct biochemical evidence for Frzb-Wnt interactions. These observations implicate Frzb in axial patterning and support the concept that Frzb binds and inactivates Xwnt-8 during gastrulation, preventing inappropriate ventral signaling in developing dorsal tissues.	NIDR,CRANIOFACIAL & SKELETAL DIS BRANCH,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Wang, SW (corresponding author), US FDA,CTR BIOL EVALUAT & RES,DEV BIOL LAB,BETHESDA,MD 20892, USA.		Moos, Malcolm C/F-3673-2011; Luyten, Frank/GPS-7793-2022	Moos, Malcolm C/0000-0002-9575-9938; Wang, Shouwen/0000-0001-8484-1795				AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Carnac G, 1996, DEVELOPMENT, V122, P3055; CHRISTIAN JL, 1991, DEVELOPMENT, V111, P1045; CHRISTIAN JL, 1993, GENE DEV, V7, P13, DOI 10.1101/gad.7.1.13; DAWID IB, 1994, J BIOL CHEM, V269, P6259; DAWID IB, 1994, GROWTH FACTORS SIGNA, P199; DEALY CN, 1993, MECH DEVELOP, V43, P175, DOI 10.1016/0925-4773(93)90034-U; DeRobertis EM, 1996, NATURE, V380, P37, DOI 10.1038/380037a0; EVANS JP, 1991, METHOD CELL BIOL, V36, P117; GONT LK, 1993, DEVELOPMENT, V119, P991; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; Gurdon J.B., 1977, Methods Cell Biol, V16, P125; Gurdon JB, 1967, METHODS DEV BIOL; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; Harlow E LD, 1988, ANTIBODIES LAB MANUA, V1st; Harrison RG, 1918, J EXP ZOOL, V25, P413, DOI 10.1002/jez.1400250204; HAWLEY SHB, 1995, GENE DEV, V9, P2923, DOI 10.1101/gad.9.23.2923; HEMMATIBRIVANLOU A, 1994, CELL, V77, P283, DOI 10.1016/0092-8674(94)90320-4; HemmatiBrivanlou A, 1997, CELL, V88, P13, DOI 10.1016/S0092-8674(00)81853-X; Hoang B, 1996, J BIOL CHEM, V271, P26131, DOI 10.1074/jbc.271.42.26131; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Hoppler S, 1996, GENE DEV, V10, P2805, DOI 10.1101/gad.10.21.2805; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; KAY BL, 1991, METHOD CELL BIOL, V36, P657; KELLER R, 1991, METHOD CELL BIOL, V36, P61; KESSLER DS, 1994, SCIENCE, V266, P596, DOI 10.1126/science.7939714; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LEMAIRE P, 1995, CELL, V81, P85, DOI 10.1016/0092-8674(95)90373-9; MAENO M, 1994, P NATL ACAD SCI USA, V91, P10260, DOI 10.1073/pnas.91.22.10260; MOON RT, 1993, BIOESSAYS, V15, P91, DOI 10.1002/bies.950150204; MOON RT, 1993, DEVELOPMENT, P85; Moos M, 1995, DEVELOPMENT, V121, P4293; NIEHRS C, 1994, SCIENCE, V263, P817, DOI 10.1126/science.7905664; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Nieuwkoop P.D., 1994, NORMAL TABLES XENOPU; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; PARR BA, 1994, CURR OPIN GENET DEV, V4, P523, DOI 10.1016/0959-437X(94)90067-D; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; PARR BA, 1993, DEVELOPMENT, V119, P247; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; RICHTER K, 1988, P NATL ACAD SCI USA, V85, P8086, DOI 10.1073/pnas.85.21.8086; RUPP RAW, 1991, CELL, V65, P927, DOI 10.1016/0092-8674(91)90545-A; Sambrook J., 1989, MOL CLONING LAB MANU; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; SATO SM, 1991, DEVELOPMENT, V112, P747; Saunders Jr J.W., 1968, ECTODERMAL MESODERMA; SCALES JB, 1990, MOL CELL BIOL, V10, P1516, DOI 10.1128/MCB.10.4.1516; SIVE HL, 1993, GENE DEV, V7, P1, DOI 10.1101/gad.7.1.1; SLACK JMW, 1994, CURR BIOL, V4, P116, DOI 10.1016/S0960-9822(94)00027-8; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SMITH WC, 1995, CELL, V82, P37, DOI 10.1016/0092-8674(95)90050-0; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; SUZUKI A, 1994, P NATL ACAD SCI USA, V91, P10255, DOI 10.1073/pnas.91.22.10255; TICKLE C, 1975, NATURE, V254, P199, DOI 10.1038/254199a0; TICKLE C, 1995, CURR OPIN GENET DEV, V5, P478, DOI 10.1016/0959-437X(95)90052-I; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; VINSON CR, 1987, NATURE, V329, P549, DOI 10.1038/329549a0; Wadsworth WG, 1996, NEURON, V16, P35, DOI 10.1016/S0896-6273(00)80021-5; Wadsworth WG, 1996, BIOESSAYS, V18, P355, DOI 10.1002/bies.950180505; WANG SW, 1995, BIOTECHNIQUES, V18, P130; Wang YS, 1996, J BIOL CHEM, V271, P4468; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; YangSnyder J, 1996, CURR BIOL, V6, P1302, DOI 10.1016/S0960-9822(02)70716-1; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6	67	427	465	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 21	1997	88	6					757	766		10.1016/S0092-8674(00)81922-4	http://dx.doi.org/10.1016/S0092-8674(00)81922-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WQ100	9118219	Bronze			2022-12-01	WOS:A1997WQ10000008
J	Slooter, AJC; Tang, MX; vanDuijn, CM; Stern, Y; Ott, A; Bell, K; Breteler, MMB; Van Broeckhoven, C; Tatemichi, TK; Tycko, B; Hofman, A; Mayeux, R				Slooter, AJC; Tang, MX; vanDuijn, CM; Stern, Y; Ott, A; Bell, K; Breteler, MMB; Van Broeckhoven, C; Tatemichi, TK; Tycko, B; Hofman, A; Mayeux, R			Apolipoprotein E epsilon 4 and the risk of dementia with stroke - A population-based investigation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PARADIGM-BASED DIAGNOSIS; ALZHEIMERS-DISEASE; VASCULAR DEMENTIA; E POLYMORPHISM; HETEROGENEOUS POPULATION; CEREBROVASCULAR-DISEASE; ALLELE; PREVALENCE; ROTTERDAM; EDUCATION	Objective.-To investigate the association between the apolipoprotein E (APOE) genotypes and dementia in patients with stroke, defined as either vascular dementia (VaD) or Alzheimer disease with cerebrovascular disease (AD with CVD). Design and Setting.-Population-based, case-control study from Rotterdam, the Netherlands, and New York City. Participants.-A total of 187 patients with dementia and stroke were compared with 507 controls similar in age and ethnic group. Main Outcome Measures.-The APOE allele frequencies in patients and controls; the odds ratio of dementia with stroke, VaD, and AD with CVD, adjusted for age, sex, residency, and education; and the percent attributable risk related to the APOE epsilon 4 allele. Results.-Overall, patients with dementia and stroke had a higher APOE epsilon 4 allele frequency than controls. Compared with APOE epsilon 3 homozygote individuals, APOE epsilon 4 homozygotes had a 7-fold increased risk of dementia with stroke (OR=6.9; 95% CI, 1.6-29.4), while APOE epsilon 4 heterozygotes had nearly a 2-fold increase in risk (OR=1.8; 95% CI, 1.2-2.7). Risks associated with APOE epsilon 4 were elevated regardless of the subtype of dementia with stroke or age or sex. The percent attributable risk related to the APOE epsilon 4 allele among demented patients with stroke was 41% overall, 33% among those with VaD, and 44% among those with AD with CVD. Conclusion.-The APOE epsilon 4 allele is a genetic risk factor for dementia with stroke, including VaD and AD with CVD. This may imply shared genetic susceptibility to dementia associated with stroke and AD. Alternatively, the category of patients with dementia and stroke, including VaD as currently defined, may include patients with AD.	COLUMBIA UNIV, SCH PUBL HLTH, GERTRUDE H SERGIEVSKY CTR, NEW YORK, NY 10032 USA; COLUMBIA UNIV, SCH PUBL HLTH, DEPT NEUROL, NEW YORK, NY 10032 USA; COLUMBIA UNIV, SCH PUBL HLTH, DEPT PSYCHIAT, NEW YORK, NY 10032 USA; COLUMBIA UNIV, SCH PUBL HLTH, DEPT PATHOL, NEW YORK, NY 10032 USA; COLUMBIA UNIV, SCH PUBL HLTH, TAUB CTR ALZHEIMERS DIS RES, NEW YORK, NY 10032 USA; COLUMBIA UNIV, SCH PUBL HLTH, DIV EPIDEMIOL, NEW YORK, NY 10032 USA; ERASMUS UNIV ROTTERDAM, SCH MED, DEPT EPIDEMIOL & BIOSTAT, NL-3000 DR ROTTERDAM, NETHERLANDS; UNIV ANTWERP, DEPT BIOCHEM, B-2020 ANTWERP, BELGIUM; FLANDER INTERUNIV, INST BIOTECHNOL, BORN BUNGE FDN, NEUROGENET LAB, ANTWERP, BELGIUM	Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; Erasmus University Rotterdam; University of Antwerp			Van Broeckhoven, Christine/M-7853-2019; Van Broeckhoven, Christine/G-8362-2017; Breteler, Monique M.B./J-5058-2014	Van Broeckhoven, Christine/0000-0003-0183-7665; Van Broeckhoven, Christine/0000-0003-0183-7665; Breteler, Monique M.B./0000-0002-0626-9305; Stern, Yaakov/0000-0001-7542-3241	NIA NIH HHS [AG07232, AG10963] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG007232, R35AG010963] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALBERTS MJ, 1995, LANCET, V346, P575, DOI 10.1016/S0140-6736(95)91411-0; American Psychiatric Association, 1987, DIAGNOSTIC STAT MANU, V3rd; BETARD C, 1994, NEUROREPORT, V5, P1893, DOI 10.1097/00001756-199410000-00013; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; COUDERC R, 1993, STROKE, V24, P661, DOI 10.1161/01.STR.24.5.661; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; FRISONI GB, 1994, DEMENTIA, V5, P240, DOI 10.1159/000106730; HENDERSON AS, 1995, LANCET, V346, P1387, DOI 10.1016/S0140-6736(95)92405-1; HIXSON J, 1991, J LIPID RES, V31, P545; HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007; KIDA E, 1995, BRAIN RES, V674, P341, DOI 10.1016/0006-8993(94)01467-V; KUUSISTO J, 1995, ARTERIOSCL THROM VAS, V15, P1280, DOI 10.1161/01.ATV.15.9.1280; MAESTRE G, 1995, ANN NEUROL, V37, P254, DOI 10.1002/ana.410370217; MAHIEUX F, 1995, REV NEUROL-FRANCE, V151, P231; MARDER K, 1995, ARCH NEUROL-CHICAGO, V52, P146, DOI 10.1001/archneur.1995.00540260050015; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MIRRA SS, 1996, ALZHEIMERS DIS CAUSE, P111; National Centre for Classification in Health, 2010, INT STAT CLASS DIS R; NOGUCHI S, 1993, LANCET, V342, P737, DOI 10.1016/0140-6736(93)91728-5; OTT A, 1995, BRIT MED J, V310, P970, DOI 10.1136/bmj.310.6985.970; PEDROBOTET J, 1992, STROKE, V23, P1556, DOI 10.1161/01.STR.23.11.1556; Pirttila T, 1996, ACTA NEUROL SCAND, V93, P352; PITTMAN J, 1992, ARCH NEUROL-CHICAGO, V49, P461, DOI 10.1001/archneur.1992.00530290043010; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; ROMAN GC, 1993, NEUROLOGY, V43, P250, DOI 10.1212/WNL.43.2.250; SAKODA S, 1994, NEUROLOGY, V44, P2420, DOI 10.1212/WNL.44.12.2420; STENGARD JH, 1995, ACTA NEUROL SCAND, V92, P297; STERN Y, 1992, ARCH NEUROL-CHICAGO, V49, P453, DOI 10.1001/archneur.1992.00530290035009; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; *US BUR CENS, 1991, CENS POP; VANDUIJN CM, 1994, NAT GENET, V7, P74, DOI 10.1038/ng0594-74; WENHAM PR, 1991, LANCET, V337, P1158, DOI 10.1016/0140-6736(91)92823-K	32	297	299	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 12	1997	277	10					818	821		10.1001/jama.277.10.818	http://dx.doi.org/10.1001/jama.277.10.818			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM082	9052712				2022-12-01	WOS:A1997WM08200035
J	Ott, M; Emiliani, S; VanLint, C; Herbein, G; Lovett, J; Chirmule, N; McCloskey, T; Pahwa, S; Verdin, E				Ott, M; Emiliani, S; VanLint, C; Herbein, G; Lovett, J; Chirmule, N; McCloskey, T; Pahwa, S; Verdin, E			Immune hyperactivation of HIV-1-infected T cells mediated by Tat and the CD28 pathway	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; INTERLEUKIN-2 RECEPTOR EXPRESSION; INFECTED INDIVIDUALS; HIV-1 TAT; KAPPA-B; ACTIVATION; TYPE-1; GENE; PROMOTER; REPLICATION	Human immunodeficiency virus-type 1 (HIV-1) infection is characterized by a chronic state of immune hyperactivation in patients. Infection of human peripheral blood lymphocytes with HIV-1 in vitro resulted in increased interleukin-2 (IL-2) secretion in response to T cell activation via the CD3 and CD28 receptors. Expression of the HIV-1 transactivator Tat recapitulated this phenotype and was associated with increased IL-2 secretion in response to costimulation with CD3 plus CD28. IL-2 superinduction by Tat occurred at the transcriptional level, was mediated by the CD28-responsive element in the IL-2 promoter, and was exclusively dependent on the 29 amino acids encoded by the second exon of Tat.	PICOWER INST MED RES,MANHASSET,NY 11030; N SHORE UNIV HOSP,MANHASSET,NY 11030; NYU,SCH MED,MANHASSET,NY 11030	Northwell Health; Northwell Health; North Shore University Hospital; New York University			Pahwa, Savita/AAA-4900-2019; Emiliani, Stéphane/O-2454-2017; Lovett, Jennie/S-2996-2016; Verdin, Eric/AAB-7999-2019	Pahwa, Savita/0000-0002-4470-4216; Emiliani, Stéphane/0000-0001-7344-8429; Lovett, Jennie/0000-0002-3710-9400; Ott, Melanie/0000-0002-5697-1274; Verdin, Eric/0000-0003-3703-3183				ADAMS M, 1994, P NATL ACAD SCI USA, V91, P3862, DOI 10.1073/pnas.91.9.3862; ARYA SK, 1985, SCIENCE, V229, P69, DOI 10.1126/science.2990040; COLLMAN R, 1992, J VIROL, V66, P7517, DOI 10.1128/JVI.66.12.7517-7521.1992; FAUCI AS, 1993, SCIENCE, V262, P1011, DOI 10.1126/science.8235617; FRASER JD, 1991, SCIENCE, V251, P313, DOI 10.1126/science.1846244; GHOSH P, 1993, P NATL ACAD SCI USA, V90, P1696, DOI 10.1073/pnas.90.5.1696; Graziosi C, 1996, P NATL ACAD SCI USA, V93, P4386, DOI 10.1073/pnas.93.9.4386; GRAZIOSI C, 1994, SCIENCE, V265, P248, DOI 10.1126/science.8023143; HAFFAR OK, 1993, P NATL ACAD SCI USA, V90, P11094, DOI 10.1073/pnas.90.23.11094; KINTER AL, 1995, J IMMUNOL, V154, P2448; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; MALIM MH, 1988, NATURE, V335, P181, DOI 10.1038/335181a0; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; OPENSHAW P, 1995, J EXP MED, V182, P1357, DOI 10.1084/jem.182.5.1357; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; OTT M, UNPUB; PAGES F, 1994, NATURE, V369, P327, DOI 10.1038/369327a0; PANTALEO G, 1995, ANNU REV IMMUNOL, V13, P487, DOI 10.1146/annurev.immunol.13.1.487; PURI RK, 1995, AIDS RES HUM RETROV, V11, P31, DOI 10.1089/aid.1995.11.31; PURVIS SF, 1992, CELL IMMUNOL, V144, P32, DOI 10.1016/0008-8749(92)90223-C; SERFLING E, 1995, BBA-GENE STRUCT EXPR, V1263, P181, DOI 10.1016/0167-4781(95)00112-T; STEVENSON M, 1990, EMBO J, V9, P1551, DOI 10.1002/j.1460-2075.1990.tb08274.x; VACCA A, 1994, BIOCHEM BIOPH RES CO, V205, P467, DOI 10.1006/bbrc.1994.2689; VanLint C, 1996, EMBO J, V15, P1112, DOI 10.1002/j.1460-2075.1996.tb00449.x; VANLINT C, 1994, J VIROL, V68, P2632, DOI 10.1128/JVI.68.4.2632-2648.1994; WECHSLER AS, 1994, J IMMUNOL, V153, P2515; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; WESTENDORP MO, 1994, J VIROL, V68, P4177, DOI 10.1128/JVI.68.7.4177-4185.1994; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L	30	182	187	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 7	1997	275	5305					1481	1485		10.1126/science.275.5305.1481	http://dx.doi.org/10.1126/science.275.5305.1481			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WM081	9045614				2022-12-01	WOS:A1997WM08100047
J	Bergelson, JM; Cunningham, JA; Droguett, G; KurtJones, EA; Krithivas, A; Hong, JS; Horwitz, MS; Crowell, RL; Finberg, RW				Bergelson, JM; Cunningham, JA; Droguett, G; KurtJones, EA; Krithivas, A; Hong, JS; Horwitz, MS; Crowell, RL; Finberg, RW			Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5	SCIENCE			English	Article							DECAY-ACCELERATING FACTOR; FIBER; INFECTION; DOMAIN; CELLS; ATTACHMENT; SEQUENCE; INTEGRIN; PROTEIN; VLA-2	A complementary DNA clone has been isolated that encodes a coxsackievirus and adenovirus receptor (CAR). When transfected with CAR complementary DNA, nonpermissive hamster cells became susceptible to coxsackie B virus attachment and infection. Furthermore, consistent with previous studies demonstrating that adenovirus infection depends on attachment of a viral fiber to the target cell, CAR-transfected hamster cells bound adenovirus in a fiber-dependent fashion and showed a 100-fold increase in susceptibility to virus-mediated gene transfer. Identification of CAR as a receptor for these two unrelated and structurally distinct viral pathogens is important for understanding viral pathogenesis and has implications for therapeutic gene delivery with adenovirus vectors.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MICROBIOL IMMUNOL,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT CELL BIOL,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT PEDIAT,BRONX,NY 10461; UNIV ALABAMA,GREGORY FLEMING JAMES CYST FIBROSIS RES CTR,DEPT CELL BIOL & ANAT,BIRMINGHAM,AL 35294; MED COLL PENN & HAHNEMANN UNIV,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19102	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; University of Alabama System; University of Alabama Birmingham; Drexel University	Bergelson, JM (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV INFECT DIS,44 BINNEY ST,BOSTON,MA 02115, USA.		Finberg, Robert W/E-3323-2010		NATIONAL CANCER INSTITUTE [R01CA069703] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031628, R01AI035667] Funding Source: NIH RePORTER; NCI NIH HHS [CA69703] Funding Source: Medline; NIAID NIH HHS [AI31628, AI35667] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAI M, 1994, J VIROL, V68, P5925, DOI 10.1128/JVI.68.9.5925-5932.1994; BERGELSON JM, 1993, J VIROL, V67, P6847, DOI 10.1128/JVI.67.11.6847-6852.1993; BERGELSON JM, 1992, SCIENCE, V255, P1718, DOI 10.1126/science.1553561; BERGELSON JM, 1995, J VIROL, V69, P1903, DOI 10.1128/JVI.69.3.1903-1906.1995; BERGELSON JM, UNPUB; Brojatsch J, 1996, CELL, V87, P845, DOI 10.1016/S0092-8674(00)81992-3; CHROBOCZEK J, 1987, VIROLOGY, V161, P549, DOI 10.1016/0042-6822(87)90150-4; CLEMENTS GB, 1995, LANCET, V346, P221, DOI 10.1016/S0140-6736(95)91270-3; CROWELL RL, 1976, CELL MEMBRANE RECEPT, P179; DEFER C, 1990, J VIROL, V64, P3661, DOI 10.1128/JVI.64.8.3661-3673.1990; GOLDMAN MJ, 1995, J VIROL, V69, P5951, DOI 10.1128/JVI.69.10.5951-5958.1995; Grist N., 1993, VIRAL INFECT HEART, V88, P23; HENRY LJ, 1994, J VIROL, V68, P5239, DOI 10.1128/JVI.68.8.5239-5246.1994; HORWITZ MS, 1996, VIROLOGY, V2, P2149; HSU KHL, 1990, NEW ASPECTS OF POSITIVE-STRAND RNA VIRUSES, P271; HSU KHL, 1988, J VIROL, V62, P1647, DOI 10.1128/JVI.62.5.1647-1652.1988; Huang S, 1996, J VIROL, V70, P4502, DOI 10.1128/JVI.70.7.4502-4508.1996; IMRIE CW, 1977, GUT, V18, P53, DOI 10.1136/gut.18.1.53; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KREMER EJ, 1995, BRIT MED BULL, V51, P31, DOI 10.1093/oxfordjournals.bmb.a072951; LONBERGHOLM K, 1976, NATURE, V259, P679, DOI 10.1038/259679a0; LONGIARU M, 1981, MOL CELL BIOL, V1, P208, DOI 10.1128/MCB.1.3.208; LOUIS N, 1994, J VIROL, V68, P4104, DOI 10.1128/JVI.68.6.4104-4106.1994; MAIZEL JV, 1968, VIROLOGY, V36, P115, DOI 10.1016/0042-6822(68)90121-9; Manome Y, 1996, NAT MED, V2, P567, DOI 10.1038/nm0596-567; MAPOLES JE, 1985, J VIROL, V55, P560, DOI 10.1128/JVI.55.3.560-566.1985; MARTIN AB, 1994, CIRCULATION, V90, P330, DOI 10.1161/01.CIR.90.1.330; Mayr GA, 1997, J VIROL, V71, P412, DOI 10.1128/JVI.71.1.412-418.1997; MELNICK JL, 1996, VIROLOGY, V2, P655; MUCKELBAUER JK, 1995, STRUCTURE, V3, P653, DOI 10.1016/S0969-2126(01)00201-5; PHILIPSON L, 1968, J VIROL, V2, P1064, DOI 10.1128/JVI.2.10.1064-1075.1968; RADNA RL, 1987, VIRUS RES, V8, P277, DOI 10.1016/0168-1702(87)90001-3; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; SAVOIA MC, 1995, PRINCIPLES PRACTICE, V1, P799; SHAFREN DR, 1995, J VIROL, V69, P3873, DOI 10.1128/JVI.69.6.3873-3877.1995; STEVENSON SC, 1995, J VIROL, V69, P2850, DOI 10.1128/JVI.69.5.2850-2857.1995; TOMKO RP, 1994, CELLULAR RECEPTORS A, P75; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; YOON JW, 1979, NEW ENGL J MED, V300, P1173, DOI 10.1056/NEJM197905243002102	39	2358	2497	1	87	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 28	1997	275	5304					1320	1323		10.1126/science.275.5304.1320	http://dx.doi.org/10.1126/science.275.5304.1320			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WK644	9036860				2022-12-01	WOS:A1997WK64400047
J	Morrison, C; Woodward, M; Leslie, W; TunstallPedoe, H				Morrison, C; Woodward, M; Leslie, W; TunstallPedoe, H			Effect of socioeconomic group on incidence of, management of, and survival after myocardial infarction and coronary death; Analysis of community coronary event register	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HEART-DISEASE; MORTALITY; WOMEN; RISK; MEN; INTERVENTION; SCOTLAND; OUTCOMES; PROJECT; FINLAND	Objective: To investigate tile effect of socioeconomic group (with reference t Design: Community coronary event register from 1985 to 1991. Setting: City of Glasgow north of the River Clyde, population 196 000. Subjects: 3991 men and 1551 women aged 25-64 years on the Glasgow MONICA coronary event register with definite or fatal possible or unclassifiable events according to the criteria of the World Health Organisation's MONICA project (monitoring trends and determinants in cardiovascular disease). Main outcome measures: Rate of coronary events; proportion of subjects reaching hospital alive; case fatality in admitted patients and in community overall. Results: Event rates increased with age for both sexes and were greater in men than women at all ages. The rate increased 1.7-fold in men and 2.4-fold in women from the least (Q1) to the most (Q4) deprived socioeconomic quarter. The socioeconomic gradient decreased with age and was steeper for women than men. The proportion treated in hospital (66%) decreased with age, was greater in women than men, and decreased in both sexes with increasing deprivation (age standardised odds ratio 0.82 for Q4 v Q1) Case fatality in hospital (20%) increased with age, was greater for women than men when age was standardised, and showed no strong socioeconomic pattern. Overall case fatality in the community (50%) increased with age, was similar between the sexes, and increased from Q1 to Q4 (age standardised odds ratio 1.12 in men, 1.18 in women). Conclusions: Socioeconomic group affects not only death rates from myocardial infarction but also event rates and chance of admission. This should be taken into account when different groups of patients are compared. Because social deprivation is associated with so many more deaths outside hospital, primary and secondary prevention are more likely than acute hospital care to reduce the socioeconomic variation in mortality.	UNIV READING, DEPT APPL STAT, READING RG6 6FN, BERKS, ENGLAND; UNIV DUNDEE, NINEWELLS HOSP & MED SCH, CARDIOVASC EPIDEMIOL UNIT, DUNDEE DD1 9SY, SCOTLAND	University of Reading; University of Dundee	Morrison, C (corresponding author), ROYAL INFIRM, MONICA PROJECT, GLASGOW G31 2ER, LANARK, SCOTLAND.		Woodward, Mark/D-8492-2015; Woodward, Mark/L-6817-2017	Woodward, Mark/0000-0001-9800-5296				AYANIAN JZ, 1994, NEW ENGL J MED, V331, P1136, DOI 10.1056/NEJM199410273311707; BOSMA H, 1995, INT J EPIDEMIOL, V24, P119, DOI 10.1093/ije/24.1.119; Capewell S, 1996, HEART, V76, P70, DOI 10.1136/hrt.76.1.70; CARNON AG, 1994, BRIT MED J, V309, P1054, DOI 10.1136/bmj.309.6961.1054; Carstairs V., 1991, DEPRIVATION HLTH SCO; COBB LA, 1975, CIRCULATION, V52, P223; DEBACKER G, 1994, J EPIDEMIOL COMMUN H, V48, P344, DOI 10.1136/jech.48.4.344; *DEP HLTH, 1995, HLTH NAT VAR HLTH WH; GAFFNEY B, 1995, BRIT HEART J, V73, P385; GHALI JK, 1993, J NATL MED ASSOC, V85, P180; GREENLAND P, 1991, CIRCULATION, V83, P484, DOI 10.1161/01.CIR.83.2.484; *GRP IT STUD STREP, 1986, LANCET, V1, P397; GRUBB NR, 1995, LANCET, V346, P417, DOI 10.1016/S0140-6736(95)92784-0; HAMMAR N, 1992, SCAND J WORK ENV HEA, V18, P178, DOI 10.5271/sjweh.1590; HAWTHORNE VM, 1995, SCOT MED J, V40, P102, DOI 10.1177/003693309504000402; HEBERT PR, 1992, ARCH INTERN MED, V152, P2253, DOI 10.1001/archinte.152.11.2253; KATHLEEN E, 1994, AM J PUBLIC HEALTH, V84, P965, DOI 10.2105/AJPH.84.6.965; KESSON E, 1993, DEPRIVATION USE CHD; Leslie WS, 1996, HEART, V75, P195, DOI 10.1136/hrt.75.2.195; MAYNARD C, 1995, J NATL MED ASSOC, V87, P339; MCGOVERN PG, 1992, CIRCULATION, V85, P172, DOI 10.1161/01.CIR.85.1.172; McLoone P., 1994, CARSTAIRS SCORES SCO; PEKKANEN J, 1995, BRIT MED J, V311, P589, DOI 10.1136/bmj.311.7005.589; Pell J, 1996, BRIT MED J, V313, P267, DOI 10.1136/bmj.313.7052.267; *REG GEN, 1993, ANN REP REG GEN BIRT; SCHREIBER TL, 1995, J AM COLL CARDIOL, V26, P577, DOI 10.1016/0735-1097(95)00214-O; SMITH GD, 1990, J EPIDEMIOL COMMUN H, V44, P265, DOI 10.1136/jech.44.4.265; SMITH GD, 1992, BRIT MED J, V305, P1554, DOI 10.1136/bmj.305.6868.1554; SMITH WCS, 1990, BRIT HEART J, V64, P295; STEVENSON R, 1993, BMJ-BRIT MED J, V307, P349, DOI 10.1136/bmj.307.6900.349; TOFLER GH, 1993, AM J CARDIOL, V71, P1031, DOI 10.1016/0002-9149(93)90568-W; TunstallPedoe H, 1996, CIRCULATION, V93, P1981, DOI 10.1161/01.CIR.93.11.1981; TUNSTALLPEDOE H, 1994, CIRCULATION, V90, P583, DOI 10.1161/01.CIR.90.1.583; TUNSTALLPEDOE H, LANCET, V2, P833; VANDEWERF F, 1990, LANCET, V336, P71; VARTIAINEN E, 1994, BMJ-BRIT MED J, V309, P23, DOI 10.1136/bmj.309.6946.23; WALDEN SM, 1990, ANN INTERN MED, V113, P337, DOI 10.7326/0003-4819-113-5-337; Watt G C, 1993, Health Bull (Edinb), V51, P407; *WHO, 1989, WORLD HLTH STAT ANN; WILHELMSEN L, 1996, CIRCULATION, V17, P1619; WILKINSON P, 1994, BRIT MED J, V309, P566, DOI 10.1136/bmj.309.6954.566; Woodward M, 1996, J EPIDEMIOL COMMUN H, V50, P570, DOI 10.1136/jech.50.5.570	42	143	143	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 22	1997	314	7080					541	546		10.1136/bmj.314.7080.541	http://dx.doi.org/10.1136/bmj.314.7080.541			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WK215	9055711	Green Published			2022-12-01	WOS:A1997WK21500020
J	Chinnaiyan, AM; ORourke, K; Lane, BR; Dixit, VM				Chinnaiyan, AM; ORourke, K; Lane, BR; Dixit, VM			Interaction of CED-4 with CED-3 and CED-9: A molecular framework for cell death	SCIENCE			English	Article							C-ELEGANS; CAENORHABDITIS-ELEGANS; GENE CED-3; PROTEIN; APOPTOSIS; ENCODES; HOMOLOG; ENZYME; BCL-2	Previous genetic studies of the nematode Caenorhabditis elegans identified three important components of the cell death machinery. CED-3 and CED-4 function to kill cells, whereas CED-9 protects cells from death. Here CED-9 and its mammalian homolog Bcl-x(L) (a member of the Bcl-2 family of cell death regulators) were both found to interact with and inhibit the function of CED-4. In addition, analysis revealed that CED-4 can simultaneously interact with CED-3 and its mammalian counterparts interleukin-1 beta-converting enzyme (ICE) and FLICE. Thus, CED-4 plays a central role in the cell death pathway, biochemically linking CED-9 and the Bcl-2 family to CED3 and the ICE family of pro-apoptotic cysteine proteases.	UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan			dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326	PHS HHS [7863] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BOYD JM, 1995, ONCOGENE, V11, P1921; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; CHINNALYAN AM, UNPUB; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; Hengartner MO, 1996, CURR OPIN GENET DEV, V6, P34, DOI 10.1016/S0959-437X(96)90007-6; Lee LC, 1996, J BIOL CHEM, V271, P23284, DOI 10.1074/jbc.271.38.23284; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Nagata S, 1996, CURR BIOL, V6, P1241, DOI 10.1016/S0960-9822(02)70706-9; OLTAVI ZN, 1993, CELL, V74, P609; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; Shaham S, 1996, CELL, V86, P201, DOI 10.1016/S0092-8674(00)80092-6; Shaham S, 1996, GENE DEV, V10, P578, DOI 10.1101/gad.10.5.578; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; VAUX DL, 1993, CURR BIOL, V3, P877, DOI 10.1016/0960-9822(93)90223-B; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; YUAN JY, 1992, DEVELOPMENT, V116, P309; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H	30	535	572	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 21	1997	275	5303					1122	1126		10.1126/science.275.5303.1122	http://dx.doi.org/10.1126/science.275.5303.1122			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WJ503	9027312				2022-12-01	WOS:A1997WJ50300043
J	Lau, YL; Chan, LC; Chan, YYA; Ha, SY; Yeung, CY; Waye, JS; Chui, DHK				Lau, YL; Chan, LC; Chan, YYA; Ha, SY; Yeung, CY; Waye, JS; Chui, DHK			Prevalence and genotypes of alpha- and beta-thalassemia carriers in Hong Kong - Implications for population screening	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GLOBIN GENE-CLUSTER; SOUTH CHINA; HEMOGLOBINOPATHIES	Background The thalassemias are common in southern China. We determined the prevalence of heterozygous carriers of these genetic disorders in Hang Kong and assessed the feasibility of a community-based screening program. Methods An educational and screening program far the thalassemias was carried out in three high schools with a total of 2420 students. Seventy-five percent of the students agreed to undergo screening, which consisted of blood counts, hemoglobin electrophoresis, serum ferri tin measurements, and DNA analyses. Results Of the 1800 blood samples tested, 150 (8.3 percent) had microcytosis (mean corpuscular volume, <80 mu m(3)). Ninety students (5.0 percent) were carriers of alpha-thalassemia, of whom 81 (4.5 percent) were carriers of the Southeast Asian type of deletion, in which both alpha-globin genes on the same chromosome 16 are deleted. Sixty-one students (3.4 percent) were carriers of either beta-thalassemia or the mutation coding for hemoglobin E. Six students were carriers of both alpha- and beta-thalassemias. On the basis of these figures, the estimated numbers of pregnancies in Hang Kong in which the fetus is at risk for homozygous alpha-thalassemia and beta-thalassemia major or intermedia are 145 and 80 per year, respectively. In Hang Kong the actual numbers of women referred for prenatal diagnoses of these disorders are approximately 95 and 40 per year, respectively. Conclusions Despite the availability of hospital-based screening and prenatal diagnosis for many years in Hong Kong, many women carrying fetuses at risk for thalassemia are not referred for genetic counseling. A community-based program of education, screening, and counseling is needed in Hong Kong and southern China. (C) 1997, Massachusetts Medical Society.	MCMASTER UNIV,SCH MED,PROV HEMOGLOBINOPATHY DNA DIAGNOST LAB,HAMILTON,ON L8S 4L8,CANADA; MCMASTER UNIV,SCH MED,DEPT PATHOL,HAMILTON,ON L8S 4L8,CANADA; UNIV HONG KONG,DEPT PEDIAT,HONG KONG,HONG KONG; UNIV HONG KONG,DEPT PATHOL,HONG KONG,HONG KONG; QUEEN MARY HOSP,HONG KONG,HONG KONG	McMaster University; McMaster University; University of Hong Kong; University of Hong Kong; University of Hong Kong			Lau, Yu Lung/C-4322-2009	Chui, David/0000-0002-1475-7309; HA, Shau Yin/0000-0002-9191-8743				BRITTENHAM GM, 1994, NEW ENGL J MED, V331, P567, DOI 10.1056/NEJM199409013310902; CAO A, 1994, AM J HUM GENET, V54, P397; Chan AYY, 1996, J CLIN PATHOL, V49, P411, DOI 10.1136/jcp.49.5.411; CHAN LC, 1995, J CLIN PATHOL, V48, P861, DOI 10.1136/jcp.48.9.861; CHAN V, 1987, AM J HUM GENET, V41, P678; CHAN V, 1986, BRIT J HAEMATOL, V64, P97, DOI 10.1111/j.1365-2141.1986.tb07577.x; DOVER GJ, 1994, NEW ENGL J MED, V331, P609, DOI 10.1056/NEJM199409013310911; FUCHAROEN S, 1987, HEMOGLOBIN, V11, P65, DOI 10.3109/03630268709036587; FUCHAROEN S, 1988, HEMOGLOBIN, V12, P99; GARDNER MJ, 1991, BRIT MED J; GHOSH A, 1985, PRENATAL DIAG, V5, P59, DOI 10.1002/pd.1970050111; HIGGS DR, 1993, BAILLIERE CLIN HAEM, V6, P117, DOI 10.1016/S0950-3536(05)80068-X; HIGGS DR, 1989, BLOOD, V73, P1081; KWAN EYW, 1995, J PAEDIATR CHILD H, V31, P83, DOI 10.1111/j.1440-1754.1995.tb00752.x; LEE ACW, 1993, BONE MARROW TRANSPL, V12, P49; LI AMC, 1982, HUM HERED, V32, P62, DOI 10.1159/000153260; LIANG R, 1994, BRIT J HAEMATOL, V86, P351, DOI 10.1111/j.1365-2141.1994.tb04738.x; MAGER DL, 1985, NUCLEIC ACIDS RES, V13, P6559, DOI 10.1093/nar/13.18.6559; Mitchell JJ, 1996, AM J HUM GENET, V59, P793; MODELL B, 1993, TRENDS GENET, V9, P46, DOI 10.1016/0168-9525(93)90186-L; Nathan DG, 1995, GENE BLOOD COURAGE, P193; OLIVIERI NF, 1994, NEW ENGL J MED, V331, P574, DOI 10.1056/NEJM199409013310903; TANG WZ, 1993, LANCET, V342, P1145, DOI 10.1016/0140-6736(93)92125-D; TODD D, 1969, BRIT J HAEMATOL, V16, P551, DOI 10.1111/j.1365-2141.1969.tb00436.x; WAYE JS, 1993, CLIN INVEST MED, V16, P358; Weatheral DJ., 1995, WILLIAMS HEMATOLOGY, P581; YUEN HL, 1996, COOLEYS ANAEMIA PRES, P31; ZHANG JZ, 1988, HUM GENET, V78, P37, DOI 10.1007/BF00291231; 1989, J R COLL PHYSICIANS, V23, P215	29	178	190	0	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 1	1997	336	18					1298	1301		10.1056/NEJM199705013361805	http://dx.doi.org/10.1056/NEJM199705013361805			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW260	9113933	Green Published			2022-12-01	WOS:A1997WW26000005
J	Lin, Y; Wong, KK; Calame, K				Lin, Y; Wong, KK; Calame, K			Repression of c-myc transcription by blimp-1, an inducer of terminal B cell differentiation	SCIENCE			English	Article							MYELOID-LEUKEMIA CELLS; HEAVY-CHAIN ENHANCER; MYOGENIC DIFFERENTIATION; GENE-EXPRESSION; GROWTH ARREST; MESSENGER-RNA; MODEL SYSTEM; PROTEIN; BINDS; INTERFERON	Transcription of c-myc in plasma cells, which are terminally differentiated B cells, is repressed by plasmacytoma repressor factor. This factor was identified as Blimp-1, known for its ability to induce B cell differentiation. Blimp-1 repressed c-myc promoter activity in a binding site-dependent manner. Treatment of BCL1 lymphoma cells with interleukin-2 (IL-2) plus IL-5 induced Blimp-1 and caused a subsequent decline in c-Myc protein. Ectopic expression of Blimp-1 in Abelson-transformed precursor B cells repressed endogenous c-Myc and caused apoptosis; Blimp-1-induced death was partially overcome by ectopic expression of c-Myc. Thus, repression of c-myc is a component of the Blimp-1 program of terminal B cell differentiation.	COLUMBIA UNIV COLL PHYS & SURG,DEPT MICROBIOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,INTEGRATED PROGRAM CELLULAR MOL & BIOPHYS STUDIES,NEW YORK,NY 10032	Columbia University; Columbia University								ADAMS JM, 1982, P NATL ACAD SCI-BIOL, V79, P6966, DOI 10.1073/pnas.79.22.6966; BLACKMAN MA, 1986, CELL, V47, P609, DOI 10.1016/0092-8674(86)90625-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN YY, 1994, GENE DEV, V8, P688, DOI 10.1101/gad.8.6.688; CHISHOLM O, 1992, INT J CANCER, V51, P149, DOI 10.1002/ijc.2910510126; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; DAVIS M, COMMUNICATION; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; Dimitrovsky E., 1986, NATURE, V322, P748; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; FLANAGAN JR, 1992, MOL CELL BIOL, V12, P38, DOI 10.1128/MCB.12.1.38; GERAUDIE J, 1990, P NATL ACAD SCI USA, V87, P3797, DOI 10.1073/pnas.87.10.3797; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GRIEP AE, 1988, P NATL ACAD SCI USA, V85, P6806, DOI 10.1073/pnas.85.18.6806; HARIHARAN N, 1991, P NATL ACAD SCI USA, V88, P9799, DOI 10.1073/pnas.88.21.9799; HENDERSON AJ, 1994, MOL CELL BIOL, V14, P4286, DOI 10.1128/MCB.14.6.4286; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; HOFFMANLIEBERMANN B, 1991, ONCOGENE, V6, P903; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; KAKKIS E, 1989, NATURE, V339, P718, DOI 10.1038/339718a0; KAKKIS E, 1987, P NATL ACAD SCI USA, V84, P7031, DOI 10.1073/pnas.84.20.7031; KAPTEIN JS, 1996, J BIOL CHEM, V271, P1875; KEATH EJ, 1984, CELL, V37, P521, DOI 10.1016/0092-8674(84)90382-9; KELLER AD, 1991, GENE DEV, V5, P868, DOI 10.1101/gad.5.5.868; KLUG CA, 1994, GENE DEV, V8, P678, DOI 10.1101/gad.8.6.678; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LAROCCA SA, 1994, ONCOGENE, V9, P3499; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; LIEBERMANN DA, 1994, STEM CELLS, V12, P352, DOI 10.1002/stem.5530120402; Lin Y. P., UNPUB; Littlewood T D, 1990, Adv Dent Res, V4, P69; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MATSUI K, 1989, J IMMUNOL, V142, P2918; MIESFELD R, 1987, SCIENCE, V236, P423, DOI 10.1126/science.3563519; MINER JH, 1991, MOL CELL BIOL, V11, P2842, DOI 10.1128/MCB.11.5.2842; Nguyen HQ, 1995, ONCOGENE, V11, P2439; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; PETERSON CL, 1986, MOL CELL BIOL, V6, P4168, DOI 10.1128/MCB.6.12.4168; PETERSON MG, 1986, EUR J BIOCHEM, V160, P579, DOI 10.1111/j.1432-1033.1986.tb10077.x; PROWCHOWNIK EV, 1986, NATURE, V322, P848; RESNITZKY D, 1986, CELL, V46, P31, DOI 10.1016/0092-8674(86)90857-3; RIGGS KJ, 1991, MOL CELL BIOL, V11, P1765, DOI 10.1128/MCB.11.3.1765; RIGGS KJ, 1993, MOL CELL BIOL, V13, P7487, DOI 10.1128/MCB.13.12.7487; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; SAUER F, 1993, NATURE, V364, P454, DOI 10.1038/364454a0; SAUER F, 1991, NATURE, V353, P563, DOI 10.1038/353563a0; SELVAKUMARAN M, 1993, BLOOD, V81, P2257; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHRIVASTAVA A, 1994, NUCLEIC ACIDS RES, V22, P5152; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; TURNER CA, 1994, CELL, V77, P297, DOI 10.1016/0092-8674(94)90321-2; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2490, DOI 10.1073/pnas.79.8.2490; WICKSTROM EL, 1988, P NATL ACAD SCI USA, V85, P1028, DOI 10.1073/pnas.85.4.1028; Wu M, 1996, MOL CELL BIOL, V16, P5015; WU M, 1996, EMBO J, V15, P4662; YOKOYAMA K, 1987, P NATL ACAD SCI USA, V84, P7367; Yu J., UNPUB; ZHAO XH, 1995, SCI CHINA SER B, V38, P580	59	347	362	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 25	1997	276	5312					596	599		10.1126/science.276.5312.596	http://dx.doi.org/10.1126/science.276.5312.596			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WV721	9110979				2022-12-01	WOS:A1997WV72100046
J	Sakai, J; Kleckner, N				Sakai, J; Kleckner, N			The Tn10 synaptic complex can capture a target DNA only after transposon excision	CELL			English	Article							STRAND TRANSFER; MU-DNA; INSERTION SPECIFICITY; CONSENSUS SEQUENCE; SITE; PROTEIN; MECHANISM; CLEAVAGE; RECOMBINATION; INTERMEDIATE	Tn10 transposes nonreplicatively. Staged in vitro reactions demonstrate that a Tn10 synaptic complex can become committed to a particular target DNA molecule via a noncovalent interaction in the absence of strand transfer. Commitment occurs only after double-strand cleavage at both transposon ends (in ''double-end break'' [DEB] complexes). Stable noncovalent DEB-target DNA cocomplexes can be detected, but no cocomplexes occur with synaptic complexes containing uncleaved ends. Preincubation of DEB complexes with target DNA accelerates the rate of strand transfer. Postcleavage target capture is remarkable for Tn10; Mu and Tn7 select a target site prior to cleavage. Promiscuous target selection may favor evolution of IS-based composite elements while being suicidal for other types of transposons.	HARVARD UNIV,DEPT MOL & CELLULAR BIOL,CAMBRIDGE,MA 02138	Harvard University					NIGMS NIH HHS [GM25326] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM025326, R01GM025326] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADZUMA K, 1988, CELL, V53, P257, DOI 10.1016/0092-8674(88)90387-X; BAINTON RJ, 1993, CELL, V72, P931, DOI 10.1016/0092-8674(93)90581-A; BAKER TA, 1991, CELL, V65, P1003, DOI 10.1016/0092-8674(91)90552-A; BENDER J, 1986, CELL, V45, P801, DOI 10.1016/0092-8674(86)90555-6; BENDER J, 1992, P NATL ACAD SCI USA, V89, P7996, DOI 10.1073/pnas.89.17.7996; BENJAMIN HW, 1992, P NATL ACAD SCI USA, V89, P4648, DOI 10.1073/pnas.89.10.4648; BOLLAND S, 1995, P NATL ACAD SCI USA, V92, P7814, DOI 10.1073/pnas.92.17.7814; Bolland S, 1996, CELL, V84, P223, DOI 10.1016/S0092-8674(00)80977-0; Chalmers RM, 1996, EMBO J, V15, P5112, DOI 10.1002/j.1460-2075.1996.tb00892.x; Craig NL, 1996, CURR TOP MICROBIOL, V204, P27; CRAIG NL, 1996, ESCHERICHIA COLI SAL, P2339; CRAIGIE R, 1987, CELL, V51, P493, DOI 10.1016/0092-8674(87)90645-3; DeBoy RT, 1996, J BACTERIOL, V178, P6184, DOI 10.1128/jb.178.21.6184-6191.1996; ENGELMAN A, 1991, CELL, V67, P1211, DOI 10.1016/0092-8674(91)90297-C; Gary PA, 1996, J MOL BIOL, V257, P301; Grindley NDF, 1995, CELL, V83, P1063, DOI 10.1016/0092-8674(95)90132-9; HALLET B, 1994, MOL MICROBIOL, V14, P131, DOI 10.1111/j.1365-2958.1994.tb01273.x; HANIFORD DB, 1991, CELL, V64, P171; HANIFORD DB, 1989, CELL, V59, P385, DOI 10.1016/0092-8674(89)90299-7; HANIFORD DB, 1994, EMBO J, V13, P5847; JACK WE, 1982, P NATL ACAD SCI-BIOL, V79, P4010, DOI 10.1073/pnas.79.13.4010; JUNOP MS, 1997, IN PRESS EMBO J, V16; Kleckner N, 1996, CURR TOP MICROBIOL, V204, P49; KLECKNER N, 1989, MOBILE DNA, P335; Lavoie BD, 1996, CURR TOP MICROBIOL, V204, P83; May EW, 1996, SCIENCE, V272, P401, DOI 10.1126/science.272.5260.401; MIZUUCHI K, 1991, CELL, V66, P129, DOI 10.1016/0092-8674(91)90145-O; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; MIZUUCHI M, 1992, CELL, V70, P303, DOI 10.1016/0092-8674(92)90104-K; MORISATO D, 1984, CELL, V39, P181, DOI 10.1016/0092-8674(84)90204-6; RICHET E, 1988, CELL, V52, P9, DOI 10.1016/0092-8674(88)90526-0; SAKAI J, 1995, EMBO J, V14, P4374, DOI 10.1002/j.1460-2075.1995.tb00112.x; SAKAI J, 1996, THESIS HARVARD U CAM; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; TERRY BJ, 1985, J BIOL CHEM, V260, P3130	36	42	42	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 18	1997	89	2					205	214		10.1016/S0092-8674(00)80200-7	http://dx.doi.org/10.1016/S0092-8674(00)80200-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WU888	9108476	Bronze			2022-12-01	WOS:A1997WU88800008
J	Liu, HT; Mantyh, PW; Basbaum, AI				Liu, HT; Mantyh, PW; Basbaum, AI			NMDA-receptor regulation of substance P release from primary afferent nociceptors	NATURE			English	Article							D-ASPARTIC ACID; RAT SPINAL-CORD; DORSAL HORN; DIVALENT-CATIONS; CENTRAL NEURONS; GLUTAMATE; RESPONSES; MOUSE; AUTORECEPTORS; ENDOCYTOSIS	Severe or prolonged tissue or nerve injury can induce hyperexcitability of dorsal horn neurons of the spinal cord, resulting in persistent pain, an exacerbated response to noxious stimuli (hyperalgesia), and a lowered pain threshold (allodynia). These changes are mediated by NMDA (N-methyl-D-aspartate)-type glutamate receptors in the spinal cord(1). Here we report that activation of the NMDA receptor causes release of substance P, a peptide neurotransmitter made by small-diameter, primary, sensory 'pain' fibres. Injection of NMDA in the cerebrospinal fluid of the rat spinal cord mimicked the changes that occur with persistent injury(2), and produced not only pain, but also a large-scale internalization of the substance P receptor into dorsal horn neurons, as well as structural changes in their dendrites. Both the pain and the morphological changes produced by NMDA were significantly reduced by substance P-receptor antagonists or by elimination of substance P-containing primary afferent fibres with the neurotoxin capsaicin. We suggest that prespnaptic NMDA receptors located on the terminals of small-diameter pain fibres facilitate and prolong the transmission of nociceptive messages, through the release of substance P and glutamate. Therapies directed at the presynaptic NMDA receptor could therefore ameliorate injury-evoked persistent pain states.	UNIV CALIF SAN FRANCISCO, DEPT ANAT, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, WM KECK FDN CTR INTEGRAT NEUROSCI, SAN FRANCISCO, CA 94143 USA; UNIV MINNESOTA, MOL NEUROBIOL LAB, VET ADM MED CTR, MINNEAPOLIS, MN 55417 USA; UNIV MINNESOTA, DEPT PSYCHIAT, MINNEAPOLIS, MN 55417 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Minnesota System; University of Minnesota Twin Cities; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; University of Minnesota System; University of Minnesota Twin Cities								AANONSEN LM, 1987, J PHARMACOL EXP THER, V243, P9; ASCHER P, 1988, J PHYSIOL-LONDON, V399, P247; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; DAVIES SN, 1987, BRAIN RES, V424, P402, DOI 10.1016/0006-8993(87)91487-9; DEBIASI S, 1988, P NATL ACAD SCI USA, V85, P7820; DICKENSON AH, 1990, TRENDS PHARMACOL SCI, V11, P307, DOI 10.1016/0165-6147(90)90228-Z; DOUGHERTY PM, 1991, PAIN, V47, P85, DOI 10.1016/0304-3959(91)90015-P; Dubner R, 1994, TXB PAIN, P225; HERRERO I, 1992, NATURE, V360, P163, DOI 10.1038/360163a0; JESSELL TM, 1977, NATURE, V268, P549, DOI 10.1038/268549a0; LEBARS D, 1987, BRAIN RES, V402, P188, DOI 10.1016/0006-8993(87)91066-3; LIU H, 1994, P NATL ACAD SCI USA, V91, P8383, DOI 10.1073/pnas.91.18.8383; LIU HT, 1994, P NATL ACAD SCI USA, V91, P1009, DOI 10.1073/pnas.91.3.1009; MALENKA RC, 1993, TRENDS NEUROSCI, V16, P521, DOI 10.1016/0166-2236(93)90197-T; MALMBERG AB, 1992, SCIENCE, V257, P1276, DOI 10.1126/science.1381521; MANTYH PW, 1995, P NATL ACAD SCI USA, V92, P2622, DOI 10.1073/pnas.92.7.2622; MANTYH PW, 1995, SCIENCE, V268, P1629, DOI 10.1126/science.7539937; MAYER ML, 1987, J PHYSIOL-LONDON, V394, P501, DOI 10.1113/jphysiol.1987.sp016883; MELLER ST, 1993, PAIN, V52, P127, DOI 10.1016/0304-3959(93)90124-8; OGAWA T, 1985, BRAIN RES, V359, P152, DOI 10.1016/0006-8993(85)91423-4; PETRALIA RS, 1994, J NEUROSCI, V14, P667; RUSIN KI, 1993, J NEUROCHEM, V60, P952, DOI 10.1111/j.1471-4159.1993.tb03242.x; SHIGEMOTO R, 1992, NEUROSCI LETT, V144, P229, DOI 10.1016/0304-3940(92)90756-W; TOLLE TR, 1993, J NEUROSCI, V13, P5009, DOI 10.1523/JNEUROSCI.13-12-05009.1993; UEDA M, 1995, NEUROPHARMACOLOGY, V34, P303, DOI 10.1016/0028-3908(94)00160-T; WILKIE GI, 1993, BIOCHEM SOC T, V21, P429, DOI 10.1042/bst0210429; WOOLF CJ, 1991, PAIN, V44, P293, DOI 10.1016/0304-3959(91)90100-C; YAKSH TL, 1981, J NEUROPHYSIOL, V46, P1056, DOI 10.1152/jn.1981.46.5.1056	28	336	350	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 17	1997	386	6626					721	724		10.1038/386721a0	http://dx.doi.org/10.1038/386721a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WU387	9109489				2022-12-01	WOS:A1997WU38700057
J	Kwon, HJ; Tirumalai, R; Landy, A; Ellenberger, T				Kwon, HJ; Tirumalai, R; Landy, A; Ellenberger, T			Flexibility in DNA recombination: Structure of the lambda integrase catalytic core	SCIENCE			English	Article							SITE-SPECIFIC RECOMBINATION; GAMMA-DELTA-RESOLVASE; FLP RECOMBINASE; CRYSTAL-STRUCTURE; ACTIVE-SITE; IDENTIFYING DETERMINANTS; BACTERIOPHAGE INTEGRASES; GENETIC-RECOMBINATION; PROTEIN; MECHANISM	Lambda integrase is archetypic of site-specific recombinases that catalyze intermolecular DNA rearrangements without energetic input. DNA cleavage, strand exchange, and religation steps are linked by a covalent phosphotyrosine intermediate in which Tyr(342) is attached to the 3'-phosphate of the DNA cut site. The 1.9 angstrom crystal structure of the integrase catalytic domain reveals a protein fold that is conserved in organisms ranging from archaebacteria to yeast and that suggests a model for interaction with target DNA. The attacking Tyr(342) nucleophile is located on a flexible loop about 20 angstroms from a basic groove that contains all the other catalytically essential residues. This bipartite active site can account for several apparently paradoxical features of integrase family recombinases, including the capacity for both cis and trans cleavage of DNA.	BROWN UNIV, DIV BIOL & MED, PROVIDENCE, RI 02912 USA; HARVARD UNIV, GRAD PROGRAM BIOPHYS, CAMBRIDGE, MA 02138 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOL PHARMACOL, BOSTON, MA 02115 USA	Brown University; Harvard University; Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI013544, R01AI013544] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062723, R01GM033928] Funding Source: NIH RePORTER; NIAID NIH HHS [AI13544] Funding Source: Medline; NIGMS NIH HHS [GM33928, R01 GM033928, R01 GM062723] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABREMSKI KE, 1992, PROTEIN ENG, V5, P87, DOI 10.1093/protein/5.1.87; ARCISZEWSKA LK, 1995, EMBO J, V14, P2112, DOI 10.1002/j.1460-2075.1995.tb07203.x; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; Blakely GW, 1997, J MOL BIOL, V265, P30, DOI 10.1006/jmbi.1996.0709; Blakely GW, 1996, MOL MICROBIOL, V20, P234, DOI 10.1111/j.1365-2958.1996.tb02505.x; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BUJACZ G, 1995, J MOL BIOL, V253, P333, DOI 10.1006/jmbi.1995.0556; CAPARON MG, 1989, CELL, V59, P1027, DOI 10.1016/0092-8674(89)90759-9; CHEN JW, 1992, CELL, V69, P647, DOI 10.1016/0092-8674(92)90228-5; COWTAN KD, 1993, ACTA CRYSTALLOGR D, V49, P148, DOI 10.1107/S0907444992007698; CRAIG NL, 1988, ANNU REV GENET, V22, P77; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DEVARGAS LM, 1988, CELL, V54, P923, DOI 10.1016/0092-8674(88)90107-9; DORGAI L, 1995, J MOL BIOL, V252, P178, DOI 10.1006/jmbi.1995.0486; DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124; EVANS BR, 1990, J BIOL CHEM, V265, P18504; EVANS R, 1990, VIA, V11, P134; HAN YPW, 1994, J MOL BIOL, V235, P908, DOI 10.1006/jmbi.1994.1048; HAN YPW, 1993, EMBO J, V12, P4577, DOI 10.1002/j.1460-2075.1993.tb06146.x; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JAYARAM M, 1995, TRENDS GENET, V11, P432, DOI 10.1016/S0168-9525(00)89140-4; JONES TA, 1992, O THE MANUAL; JONES TA, 1992, MOL REPLACEMENT, P91; KIKUCHI Y, 1978, J BIOL CHEM, V253, P7149; LANDY A, 1993, CURR OPIN GENET DEV, V3, P699, DOI 10.1016/S0959-437X(05)80086-3; LANDY A, 1989, ANNU REV BIOCHEM, V58, P913, DOI 10.1146/annurev.biochem.58.1.913; LEE J, 1994, EMBO J, V13, P5346, DOI 10.1002/j.1460-2075.1994.tb06869.x; LEONG JM, 1984, COLD SPRING HARB SYM, V49, P707, DOI 10.1101/SQB.1984.049.01.080; LIMA CD, 1994, NATURE, V367, P138, DOI 10.1038/367138a0; NUNESDUBY S, UNPUB; NUNESDUBY SE, 1994, EMBO J, V13, P4421, DOI 10.1002/j.1460-2075.1994.tb06762.x; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PANIGRAHI GB, 1994, J BIOL CHEM, V269, P10940; PARGELLIS CA, 1988, J BIOL CHEM, V263, P7668; PARSONS RL, 1988, MOL CELL BIOL, V8, P3303, DOI 10.1128/MCB.8.8.3303; QIAN XH, 1995, GENE DEV, V9, P2053, DOI 10.1101/gad.9.16.2053; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RICE P, 1995, CELL, V82, P209, DOI 10.1016/0092-8674(95)90308-9; RICE PA, 1994, STRUCTURE, V2, P371, DOI 10.1016/S0969-2126(00)00039-3; ROSS W, 1983, CELL, V33, P261, DOI 10.1016/0092-8674(83)90355-0; Rossman M.G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; SADOWSKI PD, 1993, FASEB J, V7, P760, DOI 10.1096/fasebj.7.9.8392474; SANDERSON MR, 1990, CELL, V63, P1323, DOI 10.1016/0092-8674(90)90427-G; SCHWARTZ CJE, 1989, J MOL BIOL, V205, P647, DOI 10.1016/0022-2836(89)90310-0; Shaikh AC, 1997, J BIOL CHEM, V272, P5695, DOI 10.1074/jbc.272.9.5695; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; STARK WM, 1995, TRENDS GENET, V11, P121; STARK WM, 1992, TRENDS GENET, V8, P432, DOI 10.1016/0168-9525(92)90176-5; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; TIRUMALAI RS, UNPUB; TRIEUCUOT P, 1993, MOL MICROBIOL, V8, P179, DOI 10.1111/j.1365-2958.1993.tb01214.x; WEISBERG RA, 1983, J MOL BIOL, V170, P319, DOI 10.1016/S0022-2836(83)80151-X; WESTON SA, 1992, J MOL BIOL, V226, P1237, DOI 10.1016/0022-2836(92)91064-V; YAGIL E, 1995, J MOL BIOL, V252, P163, DOI 10.1006/jmbi.1995.0485; YANG W, 1995, CELL, V82, P193, DOI 10.1016/0092-8674(95)90307-0; Zhang K. Y. J., 1990, ACTA CRYST A, VA46, P41; ZHENG JH, 1993, ACTA CRYSTALLOGR D, V49, P362, DOI 10.1107/S0907444993000423; [No title captured]	60	176	179	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 4	1997	276	5309					126	131		10.1126/science.276.5309.126	http://dx.doi.org/10.1126/science.276.5309.126			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WR386	9082984	Green Accepted			2022-12-01	WOS:A1997WR38600062
J	MacKenzie, KR; Prestegard, JH; Engelman, DM				MacKenzie, KR; Prestegard, JH; Engelman, DM			A transmembrane helix dimer: Structure and implications	SCIENCE			English	Article							PROTEIN SECONDARY STRUCTURE; CHEMICAL-SHIFT INDEX; ALPHA-HELICES; GLYCOPHORIN-A; NMR-SPECTROSCOPY; C-13; DIMERIZATION; SENSITIVITY; ASSIGNMENT; SEQUENCE	The three-dimensional structure of the dimeric transmembrane domain of glycophorin A (GpA) was determined by solution nuclear magnetic resonance spectroscopy of a 40-residue peptide solubilized in aqueous detergent micelles. The GpA membrane-spanning alpha helices cross at an angle of -40 degrees and form a small but well-packed interface that lacks intermonomer hydrogen bonds. The structure provides an explanation for the previously characterized sequence dependence of GpA dimerization and demonstrates that van der Waals interactions alone can mediate stable and specific associations between transmembrane helices.	YALE UNIV,DEPT MOL BIOPHYS & BIOCHEM,NEW HAVEN,CT 06520; YALE UNIV,DEPT CHEM,NEW HAVEN,CT 06520	Yale University; Yale University			Bremner, James D/B-1632-2013		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM054160] Funding Source: NIH RePORTER; NIGMS NIH HHS [P01 GM54160] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams PD, 1996, PROTEINS, V26, P257, DOI 10.1002/(SICI)1097-0134(199611)26:3<257::AID-PROT2>3.0.CO;2-B; BAX A, 1990, J MAGN RESON, V88, P425, DOI 10.1016/0022-2364(90)90202-K; BORMANN BJ, 1989, J BIOL CHEM, V264, P4033; BURNGER AT, 1992, X PLOR VERSION 3 1 U; CHALLOU N, 1994, BIOCHEMISTRY-US, V33, P6902, DOI 10.1021/bi00188a020; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; DUNBRACK RL, 1993, J MOL BIOL, V230, P543, DOI 10.1006/jmbi.1993.1170; GRAY TM, 1984, J MOL BIOL, V175, P75, DOI 10.1016/0022-2836(84)90446-7; GRZESIEK S, 1993, J AM CHEM SOC, V115, P4369, DOI 10.1021/ja00063a068; KAY LE, 1990, J MAGN RESON, V89, P496, DOI 10.1016/0022-2364(90)90333-5; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; LEMMON MA, 1992, J BIOL CHEM, V267, P7683; LEMMON MA, 1994, NAT STRUCT BIOL, V1, P157, DOI 10.1038/nsb0394-157; LEMMON MA, 1992, BIOCHEMISTRY-US, V31, P12719, DOI 10.1021/bi00166a002; LI SC, 1993, J BIOL CHEM, V208, P22975; Mingarro I, 1996, PROTEIN SCI, V5, P1339, DOI 10.1002/pro.5560050712; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NILGES M, 1993, PROTEINS, V17, P297, DOI 10.1002/prot.340170307; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; PASCAL SM, 1994, J MAGN RESON SER B, V103, P197, DOI 10.1006/jmrb.1994.1031; PONDER JW, 1987, J MOL BIOL, V193, P75; POPOT JL, 1990, BIOCHEMISTRY-US, V29, P4031, DOI 10.1021/bi00469a001; ROSS AH, 1982, J BIOL CHEM, V257, P4152; WISHART DS, 1994, J BIOMOL NMR, V4, P171; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; YAMAZAKI T, 1994, J AM CHEM SOC, V116, P11655, DOI 10.1021/ja00105a005; ZUIDERWEG ERP, 1989, BIOCHEMISTRY-US, V28, P6150	28	861	870	3	66	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 4	1997	276	5309					131	133		10.1126/science.276.5309.131	http://dx.doi.org/10.1126/science.276.5309.131			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WR386	9082985				2022-12-01	WOS:A1997WR38600063
J	Gutthann, SP; Rodriguez, LAG; Castellsague, J; Oliart, AD				Gutthann, SP; Rodriguez, LAG; Castellsague, J; Oliart, AD			Hormone replacement therapy and risk of venous thromboembolism: Population based case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective: To evaluate the association between use of hormone replacement therapy and the risk of idiopathic venous thromboembolism. Design: Population based case-control study. Setting: Population enrolled in the General Practice Research Database, United Kingdom. Subjects: A cohort of 347 253 women aged 50 to 79 without major risk factors for venous thromboembolism was identified. Cases were 292 women admitted to hospital for a first episode of pulmonary embolism or deep venous thrombosis; 10 000 controls were randomly selected from the source cohort. Main outcome measures: Adjusted relative risks estimated from unconditional logistic regression. Results: The adjusted odds ratio of venous thromboembolism for current use of hormone replacement therapy compared with non-users, with odds ratios of 4.6 (2.5 to 8.4) during the first six months and 3.0 (1.4 to 6.5) 6-12 months after starting treatment. No major risk differences were observed between users of low and high doses of oestrogens, unopposed and opposed treatment, and oral and transdermal preparations. The risk of idiopathic venous thromboembolism among non-users, idiopathic venous thromboembolism occurs at two to three times the rate in non-users, resulting in one to two additional cases per 10 000 women per year. Conclusions: Current use of hormone replacement therapy was associated with a higher risk of venous thromboembolism, although the risk seemed to be restricted to the first year of use.	UNIV COMPLUTENSE MADRID, CTR ESPANOL INVEST FARMACOEPIDEMIOL, MADRID 28003, SPAIN	Complutense University of Madrid	Gutthann, SP (corresponding author), NOVARTIS PHARMACEUT, DEPT MED, GRAN VIA CORTS CATALANES 764, BARCELONA 08013, SPAIN.			Perez-Gutthann, Susana/0000-0001-5798-3691				[Anonymous], 1974, NEW ENGL J MED, V290, P15; *COMM SAF MED, 1996, CURRENT PROBLEMS PHA, V22, P9; Daly E, 1996, LANCET, V348, P977, DOI 10.1016/S0140-6736(96)07113-9; DEVOR M, 1992, AM J MED, V92, P275, DOI 10.1016/0002-9343(92)90077-O; FEINSTEIN AR, 1978, CANCER RES, V38, P4001; Grodstein F, 1996, AM J EPIDEMIOL, V143, P979; Grodstein F, 1996, LANCET, V348, P983, DOI 10.1016/S0140-6736(96)07308-4; HAMMOND CB, 1979, AM J OBSTET GYNECOL, V133, P525, DOI 10.1016/0002-9378(79)90288-6; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; Jick H, 1996, LANCET, V348, P981, DOI 10.1016/S0140-6736(96)07114-0; Jick H., 1992, PHARMACOEPIDEM DR S, V1, P347, DOI DOI 10.1002/PDS.2630010607; Matthews KA, 1996, AM J EPIDEMIOL, V143, P971; NACHTIGALL LE, 1979, OBSTET GYNECOL, V54, P74, DOI 10.1097/00006250-197907000-00017; PETITTI DB, 1979, JAMA-J AM MED ASSOC, V242, P1150, DOI 10.1001/jama.242.11.1150; POSTHUMA WFM, 1994, BRIT MED J, V308, P1268; *SAS I, 1992, SAS SYST PERS COMP R; STURGEON SR, 1995, EPIDEMIOLOGY, V6, P227, DOI 10.1097/00001648-199505000-00006; Walker AM, 1991, OBSERVATION INFERENC	18	288	293	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 15	1997	314	7083					796	800		10.1136/bmj.314.7083.796	http://dx.doi.org/10.1136/bmj.314.7083.796			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN646	9081000	Green Published			2022-12-01	WOS:A1997WN64600029
J	Danilevskaya, ON; Arkhipova, IR; Traverse, KL; Pardue, ML				Danilevskaya, ON; Arkhipova, IR; Traverse, KL; Pardue, ML			Promoting in tandem: The promoter for telomere transposon HeT-A and implications for the evolution of retroviral LTRs	CELL			English	Article							INACTIVE X-CHROMOSOME; DROSOPHILA-MELANOGASTER; REVERSE TRANSCRIPTION; INTERNAL PROMOTER; ELEMENT; GENE; SEQUENCES; DNA; RNA; RETROTRANSPOSONS	HeT-A elements are non-long terminal repeat (non-LTR) retrotransposons found in head-to-tail arrays on Drosophila chromosome ends, where they form telomeres. We report that HeT-A promoter activity is located in the 3' end of the element, unlike the 5' location seen for other non-LTR retrotransposons. In HeT-A arrays the 3' sequence of one element directs transcription of its downstream neighbor. Because the upstream promoter has the same sequence as the 3' end of the transcribed element, the HeT-A promoter is effectively equivalent to a 5' LTR in both structure and function. Retroviruses and LTR retrotransposons have their promoters and transcription initiation sites in their 5' LTRs. Thus HeT-A appears to have the structure of an evolutionary intermediate between non-LTR and LTR retrotransposons.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; HARVARD UNIV,DEPT MOL & CELLULAR BIOL,CAMBRIDGE,MA 02138	Massachusetts Institute of Technology (MIT); Harvard University				Arkhipova, Irina/0000-0002-4805-1339	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050315] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50315] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARKHIPOVA IR, 1995, GENETICS, V139, P1359; Arkhipova IR, 1995, DROSOPHILA RETROTRAN; BIESSMANN H, 1992, EMBO J, V11, P4459, DOI 10.1002/j.1460-2075.1992.tb05547.x; BIESSMANN H, 1990, CELL, V61, P663, DOI 10.1016/0092-8674(90)90478-W; BIESSMANN H, 1994, CHROMOSOMA, V103, P90, DOI 10.1007/s004120050011; BOEKE JD, 1989, ANNU REV MICROBIOL, V43, P403, DOI 10.1146/annurev.micro.43.1.403; BORSANI G, 1991, NATURE, V351, P325, DOI 10.1038/351325a0; BROCKDORFF N, 1991, NATURE, V351, P329, DOI 10.1038/351329a0; BROWN CJ, 1991, NATURE, V349, P38, DOI 10.1038/349038a0; CHERBAS L, 1991, GENE DEV, V5, P120, DOI 10.1101/gad.5.1.120; DANILEVSKAYA O, 1994, CHROMOSOMA, V103, P215, DOI 10.1007/s004120050027; DANILEVSKAYA ON, 1994, P NATL ACAD SCI USA, V91, P6679, DOI 10.1073/pnas.91.14.6679; DOOLITTLE RF, 1989, Q REV BIOL, V64, P1, DOI 10.1086/416128; Eickbush Thomas H., 1994, P121; HENNIG W, 1993, P NATL ACAD SCI USA, V90, P10904, DOI 10.1073/pnas.90.23.10904; LUAN DD, 1993, CELL, V72, P595, DOI 10.1016/0092-8674(93)90078-5; LUAN DD, 1995, MOL CELL BIOL, V15, P3882; MCCLURE MA, 1991, MOL BIOL EVOL, V8, P835; MCLEAN C, 1993, MOL CELL BIOL, V13, P1042, DOI 10.1128/MCB.13.2.1042; MILLER JH, 1974, EXPT MOL GENETICS, P352; MINCHIOTTI G, 1991, MOL CELL BIOL, V11, P5171, DOI 10.1128/MCB.11.10.5171; MIZROKHI LJ, 1988, CELL, V54, P685, DOI 10.1016/S0092-8674(88)80013-8; MULLER HJ, 1938, COLLECTING NET, V13, P182; Pardue ML, 1996, J MOL EVOL, V43, P572, DOI 10.1007/BF02202105; Pardue ML, 1996, TRENDS GENET, V12, P48, DOI 10.1016/0168-9525(96)81399-0; Sambrook J., 1989, MOL CLONING LAB MANU; SCHWARZSOMMER Z, 1987, EMBO J, V6, P3873, DOI 10.1002/j.1460-2075.1987.tb02727.x; SWERGOLD GD, 1990, MOL CELL BIOL, V10, P6718, DOI 10.1128/MCB.10.12.6718; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; VALGEIRSDOTTIR K, 1990, P NATL ACAD SCI USA, V87, P7998, DOI 10.1073/pnas.87.20.7998; Weiler KS, 1995, ANNU REV GENET, V29, P577, DOI 10.1146/annurev.ge.29.120195.003045; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x	33	107	111	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 7	1997	88	5					647	655		10.1016/S0092-8674(00)81907-8	http://dx.doi.org/10.1016/S0092-8674(00)81907-8			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WM413	9054504	Bronze			2022-12-01	WOS:A1997WM41300010
J	Nan, XS; Campoy, FJ; Bird, A				Nan, XS; Campoy, FJ; Bird, A			MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin	CELL			English	Article							MAJOR LATE PROMOTER; THYMIDINE KINASE GENE; DNA METHYLATION; HISTONE H1; CHROMOSOMAL PROTEIN; INVITRO METHYLATION; CPG SEQUENCES; POLYMERASE-II; EXPRESSION; INHIBITION	MeCP2 is an abundant mammalian protein that binds to methylated CpG. We have found that native and recombinant MeCP2 repress transcription in vitro from methylated promoters but do not repress nonmethylated promoters. Repression is nonlinearly dependent on the local density of methylation, becoming significant at the density found in bulk vertebrate genomic DNA. Transient transfection using fusions with the GAL4 DNA binding domain identified a region of MeCP2 that is capable of long-range repression in vivo. Moreover, MeCP2 is able to displace histone H1 from preassembled chromatin that contains methyl-CpG These properties, together with the abundance of MeCP2 and the high frequency of its 2 bp binding site, suggest a role as a global transcriptional repressor in vertebrate genomes.			Nan, XS (corresponding author), UNIV EDINBURGH, INST CELL & MOL BIOL, EDINBURGH EH9 3JR, MIDLOTHIAN, SCOTLAND.			Nan, Xinsheng/0000-0002-0865-7934; Bird, Adrian/0000-0002-8600-0372	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANTEQUERA F, 1989, CELL, V58, P509, DOI 10.1016/0092-8674(89)90431-5; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Bird A, 1995, J CELL SCI, P37; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; BOYES J, 1992, EMBO J, V11, P327, DOI 10.1002/j.1460-2075.1992.tb05055.x; BUSCHHAUSEN G, 1987, P NATL ACAD SCI USA, V84, P1177, DOI 10.1073/pnas.84.5.1177; BUSCHHAUSEN G, 1985, NUCLEIC ACIDS RES, V13, P5503, DOI 10.1093/nar/13.15.5503; CAMPOY FJ, 1995, J BIOL CHEM, V270, P26473, DOI 10.1074/jbc.270.44.26473; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; GARFINKEL S, 1990, J BIOL CHEM, V265, P10309; HannaRose W, 1996, TRENDS GENET, V12, P229, DOI 10.1016/0168-9525(96)10022-6; HEIERMANN R, 1985, NUCLEIC ACIDS RES, V13, P2709, DOI 10.1093/nar/13.8.2709; HIGURASHI M, 1991, J BIOL CHEM, V266, P8619; HOCK R, 1993, DEV BIOL, V158, P510, DOI 10.1006/dbio.1993.1209; HSIEH CL, 1994, MOL CELL BIOL, V14, P5487, DOI 10.1128/MCB.14.8.5487; HUANG LH, 1984, NATURE, V308, P293, DOI 10.1038/308293a0; Hug M, 1996, FEBS LETT, V379, P251, DOI 10.1016/0014-5793(95)01521-3; JOHNSON CA, 1995, BIOCHEM J, V305, P791, DOI 10.1042/bj3050791; JOST JP, 1992, P NATL ACAD SCI USA, V89, P9499, DOI 10.1073/pnas.89.20.9499; KASS SU, 1993, MOL CELL BIOL, V13, P7372, DOI 10.1128/MCB.13.12.7372; KERRIGAN LA, 1991, J BIOL CHEM, V266, P574; KESHET I, 1985, P NATL ACAD SCI USA, V82, P2560, DOI 10.1073/pnas.82.9.2560; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; LEVINE A, 1991, P NATL ACAD SCI USA, V88, P6515, DOI 10.1073/pnas.88.15.6515; LEVINE A, 1993, J BIOL CHEM, V268, P21754; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; LI BY, 1994, J BIOL CHEM, V269, P7756; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; LOSA R, 1987, CELL, V50, P801, DOI 10.1016/0092-8674(87)90338-2; McArthur M, 1996, EMBO J, V15, P1705, DOI 10.1002/j.1460-2075.1996.tb00516.x; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; MEEHAN RR, 1992, NUCLEIC ACIDS RES, V20, P5085, DOI 10.1093/nar/20.19.5085; MURRAY EJ, 1987, EMBO J, V6, P2329, DOI 10.1002/j.1460-2075.1987.tb02508.x; NAN X, 1996, NUCLEIC ACIDS RES, V16, P414; NAN XS, 1993, NUCLEIC ACIDS RES, V21, P4886, DOI 10.1093/nar/21.21.4886; NIGHTINGALE K, 1995, J BIOL CHEM, V270, P4197, DOI 10.1074/jbc.270.9.4197; PFEIFER GP, 1990, GENE DEV, V4, P1277, DOI 10.1101/gad.4.8.1277; RAZIN A, 1994, CELL, V77, P473, DOI 10.1016/0092-8674(94)90208-9; REACH M, 1990, J VIROL, V64, P5851, DOI 10.1128/JVI.64.12.5851-5860.1990; RIGGS AD, 1992, TRENDS GENET, V8, P169, DOI 10.1016/0168-9525(92)90219-T; STEIN R, 1982, P NATL ACAD SCI-BIOL, V79, P3418, DOI 10.1073/pnas.79.11.3418; Struhl K, 1996, CELL, V84, P179, DOI 10.1016/S0092-8674(00)80970-8; Tate P, 1996, NAT GENET, V12, P205, DOI 10.1038/ng0296-205; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; Tweedie S, 1997, MOL CELL BIOL, V17, P1469, DOI 10.1128/MCB.17.3.1469; VARDIMON L, 1982, P NATL ACAD SCI-BIOL, V79, P1073, DOI 10.1073/pnas.79.4.1073; WATT F, 1988, GENE DEV, V2, P1136, DOI 10.1101/gad.2.9.1136	48	980	1014	1	46	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 21	1997	88	4					471	481		10.1016/S0092-8674(00)81887-5	http://dx.doi.org/10.1016/S0092-8674(00)81887-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WJ691	9038338	Bronze			2022-12-01	WOS:A1997WJ69100007
J	Roberts, TJ; Marsh, RL; Weyand, PG; Taylor, CR				Roberts, TJ; Marsh, RL; Weyand, PG; Taylor, CR			Muscular force in running turkeys: The economy of minimizing work	SCIENCE			English	Article							TREADMILL LOCOMOTION; MEDIAL GASTROCNEMIUS; MUSCLE FORCE; CAT; SPEED; PERFORMANCE; ENERGETICS; LENGTH; POWER	During running, muscles and tendons must absorb and release mechanical work to maintain the cyclic movements of the body and limbs, while also providing enough force to support the weight of the body. Direct measurements of force and fiber length in the lateral gastrocnemius muscle of running turkeys revealed that the stretch and recoil of tendon and muscle springs supply mechanical work while active muscle fibers produce high forces. During level running, the active muscle shortens little and performs little work but provides the force necessary to support body weight economically. Running economy is improved by muscles that act as active struts rather than working machines.	HARVARD UNIV, MUSEUM COMPARAT ZOOL, CONCORD FIELD STN, BEDFORD, MA 01730 USA	Harvard University	Roberts, TJ (corresponding author), NORTHEASTERN UNIV, DEPT BIOL, 360 HUNTINGTON AVE, BOSTON, MA 02115 USA.			Marsh, Richard/0000-0002-4264-9890	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR018140, R01AR039318, R29AR039318] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR18140, AR39318] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Basmajian Jv., 1985, MUSCLES ALIVE THEIR; Biewener A. A., 1992, BIOMECHANICS STRUCTU; BIEWENER AA, 1992, J EXP BIOL, V164, P1; CAVAGNA GA, 1964, J APPL PHYSIOL, V19, P249, DOI 10.1152/jappl.1964.19.2.249; GREGOR RJ, 1994, MED SCI SPORT EXER, V26, P1359; GRIFFITHS RI, 1991, J PHYSIOL-LONDON, V436, P219, DOI 10.1113/jphysiol.1991.sp018547; GRIFFITHS RI, 1987, J NEUROSCI METH, V21, P159, DOI 10.1016/0165-0270(87)90113-0; HEGLUND NC, 1982, J EXP BIOL, V97, P57; Hill A. V., 1950, Science Progress London, V38, P209; Hill AV, 1938, PROC R SOC SER B-BIO, V126, P136, DOI 10.1098/rspb.1938.0050; HOFFER JA, 1989, PROG BRAIN RES, V80, P75; KER RF, 1987, NATURE, V325, P147, DOI 10.1038/325147a0; KRAM R, 1990, NATURE, V346, P265, DOI 10.1038/346265a0; LUTZ GJ, 1994, SCIENCE, V263, P370, DOI 10.1126/science.8278808; MARSH RL, 1994, J EXP BIOL, V188, P131; MARSH RL, 1992, NATURE, V357, P411, DOI 10.1038/357411a0; Prilutsky BI, 1996, J EXP BIOL, V199, P801; PUGH LGCE, 1971, J PHYSIOL-LONDON, V213, P255, DOI 10.1113/jphysiol.1971.sp009381; SHERIF MH, 1983, J BIOMECH, V16, P691, DOI 10.1016/0021-9290(83)90079-9; TAYLOR CR, 1980, J EXP BIOL, V86, P9; TAYLOR CR, 1985, J EXP BIOL, V115, P253; WALMSLEY B, 1978, J NEUROPHYSIOL, V41, P1203, DOI 10.1152/jn.1978.41.5.1203; WANG K, 1993, BIOPHYS J, V64, P1161, DOI 10.1016/S0006-3495(93)81482-6; WHITING WC, 1984, J BIOMECH, V17, P685, DOI 10.1016/0021-9290(84)90122-2	24	547	556	0	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 21	1997	275	5303					1113	1115		10.1126/science.275.5303.1113	http://dx.doi.org/10.1126/science.275.5303.1113			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WJ503	9027309				2022-12-01	WOS:A1997WJ50300040
J	Hedlund, J				Hedlund, J			Should pneumococcal infections continue to be classified as a single disease?	LANCET			English	Editorial Material							STREPTOCOCCUS-PNEUMONIAE				Hedlund, J (corresponding author), KAROLINSKA INST,DANDERYD HOSP,DEPT INFECT DIS,S-18288 DANDERYD,SWEDEN.							AUSTRIAN R, 1981, REV INFECT DIS, V3, P183; BARNES DM, 1995, J INFECT DIS, V171, P890, DOI 10.1093/infdis/171.4.890; BRUYN GAW, 1992, CLIN INFECT DIS, V14, P251, DOI 10.1093/clinids/14.1.251; HEDLUND J, 1995, CLIN INFECT DIS, V21, P948, DOI 10.1093/clinids/21.4.948; HENRICHSEN J, 1995, J CLIN MICROBIOL, V33, P2759, DOI 10.1128/JCM.33.10.2759-2762.1995; ROBBINS JB, 1983, J INFECT DIS, V148, P1136, DOI 10.1093/infdis/148.6.1136; Scott JAG, 1996, CLIN INFECT DIS, V22, P973, DOI 10.1093/clinids/22.6.973; WATSON DA, 1995, EUR J CLIN MICROBIOL, V14, P479, DOI 10.1007/BF02113425	8	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 8	1997	349	9049					371	372		10.1016/S0140-6736(97)80003-7	http://dx.doi.org/10.1016/S0140-6736(97)80003-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH296	9033458				2022-12-01	WOS:A1997WH29600003
J	Hallowell, N; Murton, F; Statham, H; Green, JM; Richards, MPM				Hallowell, N; Murton, F; Statham, H; Green, JM; Richards, MPM			Women's need for information before attending genetic counselling for familial breast or ovarian cancer: A questionnaire, interview, and observational study	BRITISH MEDICAL JOURNAL			English	Article							WRITTEN	Objectives: To describe women's information needs prior to genetic counselling for familial breast or ovarian cancer. Design: Prospective study including semistructured telephone interviews before genetic counselling, observations of consultations, completion of postal questionnaires, and face-to face interviews within two months of counselling. Subjects: 46 women attending genetic counselling for familial breast or ovarian cancer. Main outcome measures: Subjects' understanding of process and content of genetic counselling before attending and attitudes about their preparation for the counselling session. Results: Although all women interviewed before the clinic expected to discuss their risk of developing cancer and risk management options, there was evidence of a lack of knowledge about the process and content of genetic counselling; 17 (37%) women said they did not know what else would happen, Most women interviewed after counselling viewed it positively, but 26 (65%) felt they had been inadequately prepared and 11 (28%) felt that their lack of preparation meant that they could not be given an accurate estimation of their risk of cancer. Conclusions: Some women felt that they did not obtain optimum benefit from genetic counselling because they were inadequately prepared for it We suggest that cancer family history clinics should provide women with written information about the process and content of genetic counselling before their clinic attendance.	UNIV LEEDS,DEPT MIDWIFERY STUDIES,LEEDS LS2 9LN,W YORKSHIRE,ENGLAND	University of Leeds	Hallowell, N (corresponding author), UNIV CAMBRIDGE,CTR FAMILY RES,FAC SOC & POLIT SCI,CAMBRIDGE CB2 3RF,ENGLAND.		Green, Josephine M/A-2443-2010					Austoker J, 1994, J Med Screen, V1, P238; GIBBS S, 1990, J ROY SOC MED, V83, P292, DOI 10.1177/014107689008300505; HJELMKARLSSON K, 1989, INT J NURS STUD, V26, P53, DOI 10.1016/0020-7489(89)90046-1; JulianReynier C, 1996, EUR J CANCER, V32A, P398, DOI 10.1016/0959-8049(95)00601-X; Michie S, 1996, PSYCHOL HEALTH, V11, P797, DOI 10.1080/08870449608400276; POPE C, 1995, BRIT MED J, V311, P42, DOI 10.1136/bmj.311.6996.42; Richards M P, 1995, J Genet Couns, V4, P219, DOI 10.1007/BF01408411; WEINMAN J, 1990, J ROY SOC MED, V83, P303, DOI 10.1177/014107689008300508	8	63	63	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 25	1997	314	7076					281	283		10.1136/bmj.314.7076.281	http://dx.doi.org/10.1136/bmj.314.7076.281			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WE633	9022494	Green Published			2022-12-01	WOS:A1997WE63300030
J	Raghuraman, MK; Brewer, BJ; Fangman, WL				Raghuraman, MK; Brewer, BJ; Fangman, WL			Cell cycle-dependent establishment of a late replication program	SCIENCE			English	Article							FRAGILE-X SYNDROME; SACCHAROMYCES-CEREVISIAE; DNA-REPLICATION; YEAST PLASMID; S-CEREVISIAE; ORIGIN; TELOMERES; LOCALIZATION; INHERITANCE; EXPRESSION	DNA replication origins in chromosomes of eukaryotes are activated according to a temporal program. In the yeast Saccharomyces cerevisiae, activation of origins in early S phase appears to be a default state. However, cis-acting elements such as telomeres can delay origin activation until late S phase, Site-specific recombination was used to separate origin from telomere in vivo, thereby demonstrating that the signal for late activation is established between mitosis and START in the subsequent G(1) phase. Once set, the signal can persist through the next S phase in the absence of the telomere, Establishment of the temporal program and of initiation competence of origins may be coincident events.			Raghuraman, MK (corresponding author), UNIV WASHINGTON, DEPT GENET, BOX 35-7360, SEATTLE, WA 98195 USA.				PHS HHS [18926] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		APARICIO OM, 1994, GENE DEV, V8, P1133, DOI 10.1101/gad.8.10.1133; APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; ARAKI H, 1992, J MOL BIOL, V225, P25, DOI 10.1016/0022-2836(92)91023-I; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; CHU G, 1986, SCIENCE, V234, P1582, DOI 10.1126/science.3538420; Cocker JH, 1996, NATURE, V379, P180, DOI 10.1038/379180a0; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; Diffley JFX, 1995, J CELL SCI, P67; FERGUSON BM, 1991, CELL, V65, P507, DOI 10.1016/0092-8674(91)90468-E; FERGUSON BM, 1992, CELL, V68, P333, DOI 10.1016/0092-8674(92)90474-Q; Friedman KL, 1996, GENE DEV, V10, P1595, DOI 10.1101/gad.10.13.1595; GNIRKE A, 1994, GENOMICS, V24, P199, DOI 10.1006/geno.1994.1607; GOLDMAN MA, 1984, SCIENCE, V224, P686, DOI 10.1126/science.6719109; GOTTSCHLING DE, 1992, P NATL ACAD SCI USA, V89, P4062, DOI 10.1073/pnas.89.9.4062; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; HANSEN RS, 1993, CELL, V73, P1403, DOI 10.1016/0092-8674(93)90365-W; HENNESSY KM, 1990, GENE DEV, V4, P2252, DOI 10.1101/gad.4.12b.2252; HOLMQUIST G, 1982, CELL, V31, P121, DOI 10.1016/0092-8674(82)90411-1; HUBERMAN JA, 1987, CELL, V51, P473, DOI 10.1016/0092-8674(87)90643-X; LAIRD CD, 1987, GENETICS, V117, P587; LI JJ, 1995, CURR BIOL, V5, P472, DOI 10.1016/S0960-9822(95)00094-7; MATSUZAKI H, 1990, J BACTERIOL, V172, P610, DOI 10.1128/jb.172.2.610-618.1990; MCCARROLL RM, 1988, CELL, V54, P505, DOI 10.1016/0092-8674(88)90072-4; PALLADINO F, 1993, CELL, V75, P543, DOI 10.1016/0092-8674(93)90388-7; PILLUS L, 1989, CELL, V59, P637, DOI 10.1016/0092-8674(89)90009-3; RAGHURAMAN MK, 1994, GENE DEV, V8, P554, DOI 10.1101/gad.8.5.554; RENAULD H, 1993, GENE DEV, V7, P1133, DOI 10.1101/gad.7.7a.1133; Rivier DH, 1992, CURR OPIN GENET DEV, V2, P286, DOI 10.1016/S0959-437X(05)80286-2; WELLINGER RJ, 1993, CELL, V72, P51, DOI 10.1016/0092-8674(93)90049-V; YAN H, 1993, GENE DEV, V7, P2149, DOI 10.1101/gad.7.11.2149	33	135	136	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 2	1997	276	5313					806	809		10.1126/science.276.5313.806	http://dx.doi.org/10.1126/science.276.5313.806			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WW900	9115207				2022-12-01	WOS:A1997WW90000061
J	Kaplan, MR; MeyerFranke, A; Lamber, S; Bennett, V; Duncan, ID; Levinson, SR; Barres, BA				Kaplan, MR; MeyerFranke, A; Lamber, S; Bennett, V; Duncan, ID; Levinson, SR; Barres, BA			Induction of sodium channel clustering by oligodendrocytes	NATURE			English	Article							RETINAL GANGLION-CELLS; MYELIN-DEFICIENT RAT; OPTIC-NERVE; SURVIVAL; DIFFERENTIATION; EXPRESSION; RANVIER; MUTANT; BRAIN; GENE	As oligodendrocytes wrap axons of the central nervous system (CNS) with insulating myelin sheaths, sodium channels that are initially continuously distributed along axons become segregated into regularly spaced gaps in the myelin called nodes of Ranvier(1). It is not known whether the regular spacing of nodes results from regularly spaced glial contacts or is instead intrinsically specified by the axonal cytoskeleton. Contact with Schwann cells induces clustering of sodium channels along the axons of peripheral neurons in vitro and in vivo(2-4). Similarly, it has been suggested that astrocyte contact induces clustering of sodium channels along CNS axons(5,6). Here we show that oligodendrocytes are necessary for clustering of sodium channels in vitro and in vivo. The induction, but not the maintenance, of sodium-channel clustering along the axons of highly purified rat retinal ganglion cells in culture depends on a protein secreted by oligodendrocytes. Surprisingly, the oligodendrocyte-induced clusters are regularly spaced at the predicted interval in the absence of glial-axonal contact. Mutant rats that are deficient in oligodendrocytes develop few axonal sodium channel clusters in vivo. These results demonstrate a crucial role for oligodendrocytes in inducing clustering of sodium channels.	STANFORD UNIV,SCH MED,DEPT NEUROBIOL,STANFORD,CA 94305; WORCHESTER FDN,SHREWSBURY,MA 01545; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710; UNIV WISCONSIN,SCH VET MED,DEPT MED SCI,MADISON,WI 53706; UNIV COLORADO,HLTH SCI CTR,SCH MED,DEPT PHYSIOL,DENVER,CO 80262	Stanford University; Duke University; Howard Hughes Medical Institute; University of Wisconsin System; University of Wisconsin Madison; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver								BARNSTABLE CJ, 1984, NEUROSCIENCE, V11, P847, DOI 10.1016/0306-4522(84)90195-7; BARRES BA, 1988, NEURON, V1, P791, DOI 10.1016/0896-6273(88)90127-4; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; BARRES BA, 1993, DEVELOPMENT, V118, P283; Bhat RV, 1996, GLIA, V17, P169; Black Joel A., 1995, P116; CATTERALL WA, 1992, PHYSIOL REV, V72, pS15, DOI 10.1152/physrev.1992.72.suppl_4.S15; CSIZA CK, 1979, AM J PATHOL, V95, P215; Davis JQ, 1996, J CELL BIOL, V135, P1355, DOI 10.1083/jcb.135.5.1355; DUGANDZIJA NS, 1995, J NEUROSCI, V1, P492; ELLISMAN M, 1979, J NEUROCYTOL, V8, P6719; Grumet M, 1991, Curr Opin Neurobiol, V1, P370, DOI 10.1016/0959-4388(91)90055-C; HESS A, 1949, NATURE, V164; HILDEBRAND C, 1984, J COMP NEUROL, V224, P25, DOI 10.1002/cne.902240103; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HUXLEY AF, 1949, J PHYSIOL-LONDON, V108, P315, DOI 10.1113/jphysiol.1949.sp004335; ISOM LL, 1995, CELL, V83, P433, DOI 10.1016/0092-8674(95)90121-3; JOE EH, 1992, NATURE, V356, P333, DOI 10.1038/356333a0; KORDELI E, 1995, J BIOL CHEM, V270, P2352, DOI 10.1074/jbc.270.5.2352; KUMAR S, 1988, J NEUROSCI RES, V21, P268, DOI 10.1002/jnr.490210219; MEYERFRANKE A, 1995, NEURON, V15, P805, DOI 10.1016/0896-6273(95)90172-8; NADON NL, 1995, J NEUROSCI RES, V41, P96, DOI 10.1002/jnr.490410111; Peters A., 1978, FINE STRUCTURE NERVO, V4, P588; ROSENBLUTH J, 1990, ANN NY ACAD SCI, V605, P194; Sanchez I, 1996, J NEUROSCI, V16, P5095; SKOFF RP, 1976, J COMP NEUROL, V169, P313, DOI 10.1002/cne.901690304; SMITH K, 1983, J NEUROL SCI, V54, P13; UTZSCHNEIDER DA, 1993, P ROY SOC B-BIOL SCI, V254, P245, DOI 10.1098/rspb.1993.0153; Vabnick I, 1996, J NEUROSCI, V16, P4914; Waxman Stephen G., 1995, P587	30	251	257	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 17	1997	386	6626					724	728		10.1038/386724a0	http://dx.doi.org/10.1038/386724a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WU387	9109490				2022-12-01	WOS:A1997WU38700058
J	Keene, WE; Sazie, E; Kok, J; Rice, DH; Hancock, DD; Balan, VK; Zhao, T; Doyle, MP				Keene, WE; Sazie, E; Kok, J; Rice, DH; Hancock, DD; Balan, VK; Zhao, T; Doyle, MP			An outbreak of Escherichia coli O157:H7 infections traced to jerky made from deer meat	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEMOLYTIC-UREMIC SYNDROME; FOOD	Objective.-To investigate a 1995 outbreak of Escherichia coli O157:H7 infections and to assess the safety of meat dehydration methods. Design.-Survey subsequent to routine surveillance report, environmental investigations, and laboratory experimentation. Setting.-Oregon community. Participants.-Members of an extended household and their social contacts with confirmed or presumptive E coli O157:H7 infections. Results.-A total of 6 confirmed and 5 presumptive cases were identified. Homemade venison jerky was implicated as the source of transmission. E coli O157:H7 with the same distinctive, pulsed-field gel electrophoresis pattern seen in the case isolates was recovered from leftover jerky, uncooked meat from the same deer, a saw used to dismember the carcass, and fragments of the deer hide. In a subsequent survey, E coli O157:H7 was recovered from 3 (9%) of 32 deer fecal pellets collected in nearby forest land. In the laboratory, inoculated venison was dried at several time and temperature combinations, ranging up to 10 hours at 62.8 degrees C. Viable organisms were recovered under all conditions tested. Conclusions.-Deer can be colonized by E coli O157,H7 and can be a source of human infections, Conditions necessary to ensure the safety of dried meat deserve further review. Game should be handled with the same caution indicated for commercially slaughtered meat.	OREGON HLTH DIV, ACUTE & COMMUNICABLE DIS PROGRAM, PORTLAND, OR 97232 USA; BENTON CTY HLTH DEPT, CORVALLIS, OR USA; WASHINGTON STATE UNIV, FIELD DIS INVEST UNIT, PULLMAN, WA 99164 USA; UNIV GEORGIA, CTR FOOD SAFETY & QUAL ENHANCEMENT, GRIFFIN, GA USA	Oregon Health & Science University; Washington State University; University System of Georgia; University of Georgia	Keene, WE (corresponding author), OREGON HLTH DIV, OREGAON STATE PUBL HLTH LAB, 800 NE OREGON ST, SUITE 772, PORTLAND, OR 97232 USA.							Armstrong GL, 1996, EPIDEMIOL REV, V18, P29, DOI 10.1093/oxfordjournals.epirev.a017914; BARRETT TJ, 1994, J CLIN MICROBIOL, V32, P3013, DOI 10.1128/JCM.32.12.3013-3017.1994; BESSER RE, 1993, JAMA-J AM MED ASSOC, V269, P2217, DOI 10.1001/jama.269.17.2217; DOYLE MP, 1987, APPL ENVIRON MICROB, V53, P2394, DOI 10.1128/AEM.53.10.2394-2396.1987; GLASS KA, 1992, APPL ENVIRON MICROB, V58, P2513, DOI 10.1128/AEM.58.8.2513-2516.1992; Gray Larry D., 1995, P450; Harrison JA, 1996, J FOOD PROTECT, V59, P1336, DOI 10.4315/0362-028X-59.12.1336; Kudva IT, 1996, J CLIN MICROBIOL, V34, P431, DOI 10.1128/JCM.34.2.431-433.1996; MCGOWAN KL, 1989, LANCET, V1, P967; MILLEY DG, 1993, APPL ENVIRON MICROB, V59, P4223, DOI 10.1128/AEM.59.12.4223-4229.1993; PADHYE NV, 1991, APPL ENVIRON MICROB, V57, P2693, DOI 10.1128/AEM.57.9.2693-2698.1991; PAI CH, 1984, ANN INTERN MED, V101, P738, DOI 10.7326/0003-4819-101-6-738; Paton AW, 1996, J CLIN MICROBIOL, V34, P1622, DOI 10.1128/JCM.34.7.1622-1627.1996; PIERARD D, 1994, INT CONGR SER, V1072, P77; PIERARD D, 1995, 95 AM SOC MICR GEN M, P383; RICE DH, 1995, VET REC, V137, P524, DOI 10.1136/vr.137.20.524; ROWE PC, 1994, J PEDIATR-US, V124, P21, DOI 10.1016/S0022-3476(94)70249-7; SANDERSON MW, 1995, J CLIN MICROBIOL, V33, P2616, DOI 10.1128/JCM.33.10.2616-2619.1995; Shukla R, 1995, Commun Dis Rep CDR Rev, V5, pR86; SUMNER JL, 1977, J SCI FOOD AGR, V28, P829, DOI 10.1002/jsfa.2740280909; Trevena WB, 1996, VET REC, V138, P400; *US BUR CENS, 1993, 1991 NAT SURV FISH H; *US FDA, 1992, BACT AN MAN	23	218	221	0	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 16	1997	277	15					1229	1231		10.1001/jama.277.15.1229	http://dx.doi.org/10.1001/jama.277.15.1229			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WT403	9103348				2022-12-01	WOS:A1997WT40300035
J	Blaser, MJ				Blaser, MJ			Not all Helicobacter pylori strains are created equal: Should all be eliminated?	LANCET			English	Editorial Material							GASTRIC INFECTION; PEPTIC-ULCERATION; BACTERIA; STOMACH; ACID		DEPT VET AFFAIRS MED CTR,MED SERV,NASHVILLE,TN 37212	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Blaser, MJ (corresponding author), VANDERBILT UNIV,SCH MED,DEPT MED,DIV INFECT DIS,A-3310 MED CTR N,NASHVILLE,TN 37232, USA.							APELMELK BJ, 1996, INFECT IMMUN, V64, P2031; Aspinall GO, 1996, BIOCHEMISTRY-US, V35, P2489, DOI 10.1021/bi951852s; ATHERTON JC, 1995, J BIOL CHEM, V270, P17771, DOI 10.1074/jbc.270.30.17771; Blaser MJ, 1996, ALIMENT PHARM THER, V10, P73, DOI 10.1046/j.1365-2036.1996.22164008.x; BLASER MJ, 1994, J CLIN INVEST, V94, P4, DOI 10.1172/JCI117336; Blaser MJ, 1996, HELICOBACTER PYLORI, P33; DUBOIS A, 1995, J CLIN MICROBIOL, V33, P1492, DOI 10.1128/JCM.33.6.1492-1495.1995; DUBOIS A, 1994, GASTROENTEROLOGY, V106, P1405, DOI 10.1016/0016-5085(94)90392-1; ELOMAR EM, 1995, GASTROENTEROLOGY, V109, P681, DOI 10.1016/0016-5085(95)90374-7; Fairchok MP, 1996, CLIN INFECT DIS, V22, P966, DOI 10.1093/clinids/22.6.966; FUJIMOTO S, 1994, J CLIN MICROBIOL, V32, P331, DOI 10.1128/JCM.32.2.331-334.1994; Go MF, 1996, J BACTERIOL, V178, P3934, DOI 10.1128/jb.178.13.3934-3938.1996; Jiang Q, 1996, MOL MICROBIOL, V20, P833, DOI 10.1111/j.1365-2958.1996.tb02521.x; KIRSCHNER DE, 1995, J THEOR BIOL, V176, P281, DOI 10.1006/jtbi.1995.0198; KOELZ HR, 1992, SCAND J GASTROENTERO, V27, P2, DOI 10.3109/00365529209095998; Levin BR, 1996, EMERG INFECT DIS, V2, P93, DOI 10.3201/eid0202.960203; MARSHALL BJ, 1984, LANCET, V1, P1311; PASTER BJ, 1991, INT J SYST BACTERIOL, V41, P31, DOI 10.1099/00207713-41-1-31; POUNDER RE, 1995, ALIMENT PHARM THERAP, V9, pS33; SUSSER M, 1962, LANCET, V1, P115; TAYLOR DN, 1991, EPIDEMIOL REV, V13, P42, DOI 10.1093/oxfordjournals.epirev.a036078; TAYLOR NS, 1995, J CLIN MICROBIOL, V33, P918, DOI 10.1128/JCM.33.4.918-923.1995	22	161	167	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 5	1997	349	9057					1020	1022		10.1016/S0140-6736(96)09133-7	http://dx.doi.org/10.1016/S0140-6736(96)09133-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR621	9100641				2022-12-01	WOS:A1997WR62100044
J	Farrell, AM				Farrell, AM			Acquired perforating dermatosis in renal and diabetic patients	LANCET			English	Editorial Material							COLLAGENOSIS; MELLITUS; PATHOGENESIS; ELIMINATION; FAILURE				Farrell, AM (corresponding author), CHURCHILL HOSP,DEPT DERMATOL,OXFORD OX3 7LJ,ENGLAND.							BAYOUMI AHM, 1978, BRIT J DERMATOL, V99, P611, DOI 10.1111/j.1365-2133.1978.tb07054.x; COCHRAN RJ, 1983, CUTIS, V31, P55; FAVER IR, 1994, J AM ACAD DERMATOL, V30, P575, DOI 10.1016/S0190-9622(94)70065-6; HAFTEK M, 1993, J CUTAN PATHOL, V20, P350, DOI 10.1111/j.1600-0560.1993.tb01274.x; Morton CA, 1996, BRIT J DERMATOL, V135, P671; PATTERSON JW, 1992, INT J DERMATOL, V31, P201, DOI 10.1111/j.1365-4362.1992.tb03937.x; POLIAK SC, 1982, NEW ENGL J MED, V306, P81, DOI 10.1056/NEJM198201143060206; ZELGER B, 1991, ARCH DERMATOL, V127, P695, DOI 10.1001/archderm.127.5.695	8	19	20	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 29	1997	349	9056					895	896		10.1016/S0140-6736(05)62693-1	http://dx.doi.org/10.1016/S0140-6736(05)62693-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR254	9093247				2022-12-01	WOS:A1997WR25400005
J	He, X; SaintJeannet, JP; Wang, YS; Nathans, J; Dawid, I; Varmus, H				He, X; SaintJeannet, JP; Wang, YS; Nathans, J; Dawid, I; Varmus, H			A member of the frizzled protein family mediating axis induction by Wnt-5A	SCIENCE			English	Article							GLYCOGEN-SYNTHASE KINASE-3; XENOPUS-LAEVIS EMBRYOS; SPEMANN ORGANIZER; EXPRESSION; DOMAINS; HOMOLOG; PATTERN; TISSUE; XWNT-8; GENES	In Xenopus laevis embryos, the Wingless/Wnt-1 subclass of Wnt molecules induces axis duplication, whereas the Wnt-5A subclass does not. This difference could be explained by distinct signal transduction pathways or by a lack of one or more Wnt-5A receptors during axis formation. Wnt-5A induced axis duplication and an ectopic Spemann organizer in the presence of hFz5, a member of the Frizzled family of seven-transmembrane receptors. Wnt-5A/hFz5 signaling was antagonized by glycogen synthase kinase-3 and by the amino-terminal ectodomain of hFz5. These results identify hFz5 as a receptor for Wnt-5A.	NCI,NIH,BETHESDA,MD 20892; NICHHD,NIH,BETHESDA,MD 20892; JOHNS HOPKINS UNIV,SCH MED,DEPT MOL BIOL & GENET,HOWARD HUGHES MED INST,BALTIMORE,MD 21205	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Howard Hughes Medical Institute; Johns Hopkins University				Nathans, Jeremy/0000-0001-8106-5460				Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; CHAKRABARTI A, 1992, DEVELOPMENT, V115, P355; CHAN SDH, 1992, J BIOL CHEM, V267, P25202; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CHRISTIAN JL, 1993, GENE DEV, V7, P13, DOI 10.1101/gad.7.1.13; CLARK CC, 1993, GENOMICS, V18, P249, DOI 10.1006/geno.1993.1463; DOMINGUEZ I, 1995, P NATL ACAD SCI USA, V92, P8498, DOI 10.1073/pnas.92.18.8498; DU SJ, 1995, MOL CELL BIOL, V15, P2625; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; GERHART J, 1989, DEVELOPMENT, V107, P37; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; MCMAHON AP, 1992, TRENDS GENET, V8, P236, DOI 10.1016/0168-9525(92)90122-K; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; MOON RT, 1993, DEVELOPMENT, P85; MOON RT, 1993, DEVELOPMENT, V119, P97; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; PARK WJ, 1994, MECH DEVELOP, V45, P127, DOI 10.1016/0925-4773(94)90026-4; PIERCE SB, 1995, DEVELOPMENT, V121, P755; Sawa H, 1996, GENE DEV, V10, P2189, DOI 10.1101/gad.10.17.2189; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; VINSON CR, 1989, NATURE, V338, P263, DOI 10.1038/338263a0; Wang YS, 1996, J BIOL CHEM, V271, P4468; WOLDA SL, 1993, DEV BIOL, V155, P46, DOI 10.1006/dbio.1993.1005; YangSnyder J, 1996, CURR BIOL, V6, P1302, DOI 10.1016/S0960-9822(02)70716-1; ZHAO ZY, 1995, GENOMICS, V27, P370, DOI 10.1006/geno.1995.1060	29	402	421	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 14	1997	275	5306					1652	1654		10.1126/science.275.5306.1652	http://dx.doi.org/10.1126/science.275.5306.1652			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WN123	9054360	Green Submitted			2022-12-01	WOS:A1997WN12300048
J	Knauth, M; Ries, S; Pohimann, S; Kerby, T; Forsting, M; Daffertshofer, R; Hennerici, M; Sartor, K				Knauth, M; Ries, S; Pohimann, S; Kerby, T; Forsting, M; Daffertshofer, R; Hennerici, M; Sartor, K			Cohort study of multiple brain lesions in sport divers: Role of a patent foramen ovale	BRITISH MEDICAL JOURNAL			English	Article							CENTRAL-NERVOUS-SYSTEM; DECOMPRESSION-SICKNESS; PULSE SEQUENCE; MR; PREVALENCE; STROKE; SPACES	Objective: To investigate the role of a patent foramen ovale in the pathogenesis of multiple brain lesions acquired by sport divers in the absence of reported decompression symptoms. Design: Prospective double blind cohort study. Setting: Diving clubs around Heidelberg and departments of neuroradiology and neurology. Subjects: 87 sport divers with a minimum of 160 scuba dives (dives with self contained underwater breathing apparatus). Main outcome measures: Presence of multiple brain lesions visualised by cranial magnetic resonance imaging and presence and size of patent foramen ovale as documented by echocontrast transcranial Doppler ultrasonography. Results: 25 subjects were found to have a right-to-left shunt, 13 with a patent foramen ovale of high haemodynamic relevance. A total of 41 brain lesions were detected in 11 divers. There were seven brain lesions in seven divers without a right-to-left shunt and 34 lesions in four divers with a right-to-left shunt, Multiple brain lesions occurred exclusively in three divers with a large patent foramen ovale (P=0.004). Conclusions: Multiple brain lesions in sport divers were associated with presence of a large patent foramen ovale, This association suggests paradoxical gas embolism as the pathological mechanism. A patent foramen ovale of high haemodynamic relevance seems to be an important risk factor for developing multiple brain lesions in sport divers.	UNIV HEIDELBERG,KLINIKUM MANNHEIM,DEPT NEUROL,D-6900 HEIDELBERG,GERMANY; UNIV FRANKFURT KLINIKUM,DEPT BIOL,D-6000 FRANKFURT,GERMANY	Ruprecht Karls University Heidelberg; Goethe University Frankfurt; Goethe University Frankfurt Hospital	Knauth, M (corresponding author), UNIV HEIDELBERG,KLINIKUM HEIDELBERG,DEPT NEURORADIOL,NEUENHEIMER FELD 400,D-69120 HEIDELBERG,GERMANY.		Forsting, Michael/C-6925-2013					BUTLER BD, 1979, J APPL PHYSIOL, V47, P537, DOI 10.1152/jappl.1979.47.3.537; *CIB GEIG AG, 1980, WISS TAB GEIG TEILB; DECOENE B, 1992, AM J NEURORADIOL, V13, P1555; DITULLIO M, 1993, STROKE, V24, P1020, DOI 10.1161/01.STR.24.7.1020; ECKENHOFF RG, 1990, J APPL PHYSIOL, V69, P914, DOI 10.1152/jappl.1990.69.3.914; FUEREDI GA, 1991, AM J NEURORADIOL, V12, P67; HAGEN PT, 1984, MAYO CLIN PROC, V59, P17, DOI 10.1016/S0025-6196(12)60336-X; HASHEMI RH, 1995, RADIOLOGY, V196, P505, DOI 10.1148/radiology.196.2.7617868; HEIER LA, 1989, AM J NEURORADIOL, V10, P929; HOVENS MMC, 1995, LANCET, V346, P384; JUNGREIS CA, 1988, RADIOLOGY, V169, P101, DOI 10.1148/radiology.169.1.3420242; LECHAT P, 1988, NEW ENGL J MED, V318, P1148, DOI 10.1056/NEJM198805053181802; LYNCH JJ, 1984, AM J CARDIOL, V53, P1478, DOI 10.1016/S0002-9149(84)91617-5; MOON RE, 1989, LANCET, V1, P513; REUL J, 1995, LANCET, V345, P1403, DOI 10.1016/S0140-6736(95)92598-8; RINCK PA, 1991, JMRI-J MAGN RESON IM, V1, P293, DOI 10.1002/jmri.1880010306; RYDBERG JN, 1994, RADIOLOGY, V193, P173, DOI 10.1148/radiology.193.1.8090888; SCHMINKE U, 1995, CEREBROVASC DIS, V5, P133, DOI 10.1159/000107838; SCHMINKE U, 1996, CEREBROVASC DIS S2, V6, P164; SWEENEY LJ, 1979, AM HEART J, V98, P194, DOI 10.1016/0002-8703(79)90221-7; TEAGUE SM, 1991, STROKE, V22, P740, DOI 10.1161/01.STR.22.6.740; TODNEM K, 1991, ELECTROEN CLIN NEURO, V79, P322, DOI 10.1016/0013-4694(91)90127-P; WARREN LP, 1988, AM J ROENTGENOL, V151, P1003, DOI 10.2214/ajr.151.5.1003; WILMSHURST P, 1995, LANCET, V346, P384, DOI 10.1016/S0140-6736(95)92268-7; WILMSHURST PT, 1989, LANCET, V2, P1302	25	172	177	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 8	1997	314	7082					701	705		10.1136/bmj.314.7082.701	http://dx.doi.org/10.1136/bmj.314.7082.701			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM776	9116544	Green Published			2022-12-01	WOS:A1997WM77600019
J	Martin, RM; Hilton, SR; Kerry, SM; Richards, NM				Martin, RM; Hilton, SR; Kerry, SM; Richards, NM			General practitioners' perceptions of the tolerability of antidepressant drugs: A comparison of selective serotonin reuptake inhibitors and tricyclic antidepressants	BRITISH MEDICAL JOURNAL			English	Article							COST-EFFECTIVENESS; DEPRESSION; METAANALYSIS; DISCONTINUATION; PSYCHIATRISTS; PRESCRIPTION; MANAGEMENT; EFFICACY; RATES	Objective: To examine inceptions and discontinuations of antidepressants in general practice. Design: An observational study analysing data from an ongoing cross sectional postal survey, Every three months a representative sample of 250 doctors recorded prescribing activity for four weeks. This provided 4000 general practitioner weeks of recording per year. Setting: A representative panel of general practitioners in England, Wales, and Scotland. Subjects: Patients who began a new course of an antidepressant or had their treatment stopped or changed by the general practitioner between 1 July 1990 and 30 June 1995. Main outcome measures: Numbers of patients prescribed a new course of antidepressant; numbers discontinuing treatment; the ratio of antidepressant discontinuations to antidepressant inceptions; reasons for discontinuation; proportion of switches to another antidepressant Results: There were 13 619 inceptions and 3934 discontinuations of selective serotonin reuptake inhibitors and tricyclic antidepressants during the study. The number of newly prescribed courses of antidepressants increased by 116%, mostly due to an increase in prescribing of serotonin reuptake inhibitors. The ratio of total discontinuations to inceptions was significantly lower for serotonin reuptake inhibitors (22%) than for tricyclic antidepressants (33%), Differences persisted when controlled for age and sex of patients and severity of depression. However, there was more switching away from selective serotonin reuptake inhibitors when they failed (72%) than from tricyclic antidepressants (58%). Conclusions: Selective serotonin reuptake inhibitors are less likely than tricyclic antidepressants to be discontinued. A prospective study is needed in general practice to assess the implications of differences in discontinuation rates and switches on clinical and economic outcomes.	COMPUFILE LTD,SEND,WOKING GU23 7EF,SURREY,ENGLAND		Martin, RM (corresponding author), ST GEORGE HOSP,SCH MED,DIV GEN PRACTICE & PRIMARY CARE,CRANMER TERRACE,LONDON SW17 0RE,ENGLAND.							ANDERSON IM, 1994, J PSYCHOPHARMACOL, V8, P238, DOI 10.1177/026988119400800407; ANDERSON IM, 1995, BMJ-BRIT MED J, V310, P1433, DOI 10.1136/bmj.310.6992.1433; ANDRADE SE, 1995, NEW ENGL J MED, V332, P1125, DOI 10.1056/NEJM199504273321703; *BRIT ASS PSYCH, 1993, J PSYCHOPHARMACOL, V7, P19; BROWN WA, 1995, J CLIN PSYCHIAT, V56, P30; BURGESS I, 1990, HORIZONS, V4, P433; *CENTR STAT OFF, 1995, REG TRENDS, V30; COHN CK, 1990, J CLIN PSYCHIAT, V51, P28; Donoghue J, 1996, BRIT MED J, V313, P861; Donoghue J. M., 1996, British Journal of Psychiatry, V168, P164, DOI 10.1192/bjp.168.2.164; EDWARDS JG, 1994, BRIT J PSYCHIAT, V164, P387, DOI 10.1192/bjp.164.3.387; EDWARDS JG, 1992, BRIT MED J, V304, P1644, DOI 10.1136/bmj.304.6843.1644; *EFF HLTH CAR, 1993, TREATM DEPR PRIM CAR; *GEN MED SERV COMM, 1993, BAS STAT ENGL WAL NA; HARRISON G, 1994, BRIT MED J, V309, P1280, DOI 10.1136/bmj.309.6964.1280; ISACSSON G, 1994, BRIT MED J, V309, P1546, DOI 10.1136/bmj.309.6968.1546; JOHNSON DAW, 1973, BRIT MED J, V2, P18, DOI 10.1136/bmj.2.5857.18; *JOINT FORM COMM, 1995, BRIT NAT FORM, V29, P165; JONSSON B, 1994, BRIT J PSYCHIAT, V164, P665, DOI 10.1192/bjp.164.5.665; LADER M, 1988, BRIT J PSYCHIAT, V153, P51, DOI 10.1192/S0007125000297298; MacDonald TM, 1996, BRIT MED J, V313, P860; MADDOX JC, 1994, J PSYCHOPHARMACOL, V8, P48, DOI 10.1177/026988119400800108; Martin R, 1995, BRIT MED J, V311, P1645, DOI 10.1136/bmj.311.7020.1645; MONTGOMERY SA, 1994, INT CLIN PSYCHOPHARM, V9, P47, DOI 10.1097/00004850-199400910-00008; OBRIEN JT, 1994, BRIT J PSYCHIAT, V165, P411, DOI 10.1192/bjp.165.3.411a; OLFSON M, 1993, AM J PSYCHIAT, V150, P571; OWENS D, 1994, BRIT MED J, V309, P1281, DOI 10.1136/bmj.309.6964.1281; PAYKEL ES, 1992, BRIT MED J, V305, P1198, DOI 10.1136/bmj.305.6863.1198; *PRESCR PRIC AUTH, 1995, DEPR ANT PACT REP; RAMCHANDANI P, 1995, BRIT MED J, V311, P751, DOI 10.1136/bmj.311.7007.751b; SCHWARTZ D, 1967, J CHRON DIS, V20, P637, DOI 10.1016/0021-9681(67)90041-0; Simon GE, 1996, JAMA-J AM MED ASSOC, V275, P1897, DOI 10.1001/jama.275.24.1897; SIRELING LI, 1985, BRIT J PSYCHIAT, V147, P113, DOI 10.1192/bjp.147.2.113; SIRELING LI, 1985, BRIT J PSYCHIAT, V147, P119, DOI 10.1192/bjp.147.2.119; SONG FJ, 1993, BMJ-BRIT MED J, V306, P683, DOI 10.1136/bmj.306.6879.683; THOMPSON C, 1989, Human Psychopharmacology, V4, P91, DOI 10.1002/hup.470040204; 1993, BRIT MED J, V306, P1124	37	88	91	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 1	1997	314	7081					646	651		10.1136/bmj.314.7081.646	http://dx.doi.org/10.1136/bmj.314.7081.646			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WL418	9066479	Green Published			2022-12-01	WOS:A1997WL41800027
J	Martineau, A; White, M; Bhopal, R				Martineau, A; White, M; Bhopal, R			No sex differences in immunisation rates of British south Asian children: The effect of migration?	BMJ-BRITISH MEDICAL JOURNAL			English	Article									UNIV NEWCASTLE UPON TYNE, DEPT EPIDEMIOL & PUBL HLTH, NEWCASTLE UPON TYNE NE2 4HH, TYNE & WEAR, ENGLAND	Newcastle University - UK	Martineau, A (corresponding author), WANSBECK GEN HOSP, ASHINGTON NE63 9JJ, NORTHD, ENGLAND.		White, Martin J. R./G-2410-2010; Martineau, Adrian R/A-3083-2010					BHOPAL RS, 1988, COMMUNITY MED, V10, P215; BOOTH BE, 1994, BRIT MED J, V309, P1259, DOI 10.1136/bmj.309.6964.1259; CHEN LC, 1981, POPUL DEV REV, V7, P55, DOI 10.2307/1972764; Naik V A, 1991, J Postgrad Med, V37, P216; Waldron I, 1987, World Health Stat Q, V40, P194	5	12	12	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 1	1997	314	7081					642	643		10.1136/bmj.314.7081.642	http://dx.doi.org/10.1136/bmj.314.7081.642			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WL418	9066476	Green Published			2022-12-01	WOS:A1997WL41800023
J	Kuhn, C; Franceschi, VR; Schulz, A; Lemoine, R; Frommer, WB				Kuhn, C; Franceschi, VR; Schulz, A; Lemoine, R; Frommer, WB			Macromolecular trafficking indicated by localization and turnover of sucrose transporters in enucleate sieve elements	SCIENCE			English	Article							PLASMA-MEMBRANE; MINOR VEINS; COMPANION CELLS; MESSENGER-RNAS; PHLOEM; PROTEIN; PLASMODESMATA; PLANTS; LEAF	The leaf sucrose transporter SUT1 is essential for phloem loading and long-distance transport of assimilates. Both SUT1 messenger RNA (mRNA) and protein were shown to be diurnally regulated and to have high turnover rates. SUT1 protein was detected by immunolocalization in plasma membranes of enucleate sieve elements (SEs) in tobacco, potato, and tomato. Analysis by in situ hybridization showed that SUT1 mRNA localizes mainly to the SE and is preferentially associated with plasmodesmata. Antisense inhibition of SUT1 expression under control of a companion cell (CC)-specific promoter indicated synthesis of SUT1 mRNA in the CC. These results provide evidence for targeting of plant endogenous mRNA and potentially SUT1 protein through phloem plasmodesmata and for sucrose loading at the plasma membrane of SE.	UNIV TUBINGEN,INST BOT,D-72076 TUBINGEN,GERMANY; CHRISTIAN ALBRECHTS UNIV KIEL,INST BOT,D-24098 KIEL,GERMANY; WASHINGTON STATE UNIV,CTR ELECTRON MICROSCOPY,PULLMAN,WA 99164; UNIV POITIERS,LAB PHYSIOL & BIOCHIM VEGETALES,CNRS,URA 574,POITIERS,FRANCE	Eberhard Karls University of Tubingen; University of Kiel; Washington State University; Centre National de la Recherche Scientifique (CNRS); Universite de Poitiers			Frommer, Wolf B/A-8256-2008; Frommer, Wolf B/K-5042-2017; Schulz, Alexander/A-3357-2013	Frommer, Wolf B/0000-0001-6465-0115; Frommer, Wolf B/0000-0001-6465-0115; Schulz, Alexander/0000-0001-6796-3598; Kuhn, Christina/0000-0002-8370-9706				Boorer KJ, 1996, J BIOL CHEM, V271, P25139, DOI 10.1074/jbc.271.41.25139; BOSTWICK DE, 1992, PLANT CELL, V4, P1539, DOI 10.1105/tpc.4.12.1539; BOUCHEPILLON S, 1994, PLANT PHYSIOL, V105, P691, DOI 10.1104/pp.105.2.691; BROPHY PJ, 1993, TRENDS NEUROSCI, V16, P515, DOI 10.1016/0166-2236(93)90196-S; BURKLE L, UNPUB; DeWitt ND, 1995, PLANT CELL, V7, P2053, DOI 10.1105/tpc.7.12.2053; EVERT RF, 1990, SIEVE ELEMENTS, P103; FROMMER WB, 1996, MEMBRANES SPECIALIZE, P319; FUJIWARA T, 1993, PLANT CELL, V5, P1783, DOI 10.1105/tpc.5.12.1783; GRASSO JA, 1963, P NATL ACAD SCI USA, V50, P134, DOI 10.1073/pnas.50.1.134; HEIN C, 1995, MOL MICROBIOL, V18, P77, DOI 10.1111/j.1365-2958.1995.mmi_18010077.x; HEINEKE D, 1994, PLANTA, V193, P174, DOI 10.1007/BF00192527; KENNECKE M, 1971, PLANTA, V98, P330, DOI 10.1007/BF00380234; KOLLING R, 1994, EMBO J, V13, P3261, DOI 10.1002/j.1460-2075.1994.tb06627.x; Kuhn C, 1996, PLANT CELL ENVIRON, V19, P1115, DOI 10.1111/j.1365-3040.1996.tb00426.x; LACKNEY VK, 1991, PLANT CELL ENVIRON, V14, P213, DOI 10.1111/j.1365-3040.1991.tb01338.x; LEHMANN A, 1981, PFLANZENPHYSIOL, V102, P415; LEMOINE C, 1996, PLANT CELL ENVIRON, V19, P1124; LUCAS WJ, 1995, SCIENCE, V270, P1980, DOI 10.1126/science.270.5244.1980; MARKS PA, 1962, P NATL ACAD SCI USA, V48, P2163, DOI 10.1073/pnas.48.12.2163; MAYNARD JW, 1982, PLANT PHYSIOL, V70, P1436, DOI 10.1104/pp.70.5.1436; MCCAULEY MM, 1989, BOT GAZ, V150, P351, DOI 10.1086/337781; NAKAMURA S, 1993, PLANT CELL PHYSIOL, V34, P927; NEUMANN S, 1964, Z NATURFORSCH PT B, VB 19, P1066, DOI 10.1515/znb-1964-1116; NOUEIRY AO, 1994, CELL, V76, P925, DOI 10.1016/0092-8674(94)90366-2; NUSKE J, 1976, PLANTA, V132, P109, DOI 10.1007/BF00388891; PARTHASARATHY MV, 1980, BER DEUT BOT GES, V93, P57; RIESMEIER JW, 1993, PLANT CELL, V5, P1591, DOI 10.1105/tpc.5.11.1591; RLESMEIER JW, 1994, EMBO J, V13, P1; ROECKL B, 1949, PLANTA, V36, P530, DOI 10.1007/BF01909361; SCHOBERT C, 1995, PLANTA, V196, P205, DOI 10.1007/BF00201375; SJOLUND RD, 1983, J ULTRA MOL STRUCT R, V82, P189, DOI 10.1016/S0022-5320(83)90052-7; STADLER R, 1995, PLANT CELL, V7, P1545, DOI 10.1105/tpc.7.10.1545; Stadler R, 1996, BOT ACTA, V109, P299, DOI 10.1111/j.1438-8677.1996.tb00577.x; STJOHNSTON D, 1995, CELL, V81, P161, DOI 10.1016/0092-8674(95)90324-0; THORSCH J, 1981, J ULTRA MOL STRUCT R, V74, P183, DOI 10.1016/S0022-5320(81)80076-7; VANBEL AJE, 1993, ANNU REV PLANT PHYS, V44, P253, DOI 10.1146/annurev.pp.44.060193.001345; YEH JI, 1995, BIOCHEMISTRY-US, V34, P15523, DOI 10.1021/bi00047a018	38	356	396	0	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 28	1997	275	5304					1298	1300		10.1126/science.275.5304.1298	http://dx.doi.org/10.1126/science.275.5304.1298			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WK644	9036853				2022-12-01	WOS:A1997WK64400040
J	Meng, J; Wyss, AR				Meng, J; Wyss, AR			Multituberculate and other mammal hair recovered from Palaeogene excreta	NATURE			English	Article							ACCUMULATIONS	Evidence of hair from several extinct mammals has been recovered from a rich accumulation of fossil excrement from the Late Palaeocene beds of Inner Mongolia, China, This highly unusual and previously undocumented depositional occurrence consists of hundreds of mammalian carnivore coprolites (fossil faeces) and a lesser number of probably raptorial bird regurgitalites(1) (fossil pellets). The fossil hair occurs as impressions and natural casts in the extremely fine-grained, calcareous matrix that cements the skeletal remains within these faecal structures and preserves even the cuticular scale pattern on individual hair, Hair from at least four mammalian taxa, most notably the multituberculate Lambdopsalis bulla(2), has been identified. This record constitutes the first tangible evidence that, along with monotremes and therian mammals, multituberculates were hirsuite, and lends support for the presence of this mammalian feature in the most recent common ancestor of these three groups.	UNIV MASSACHUSETTS,GRAD PROGRAM ORGANISM & EVOLUTIONARY BIOL,AMHERST,MA 01003; UNIV CALIF SANTA BARBARA,DEPT GEOL,SANTA BARBARA,CA 93106	University of Massachusetts System; University of Massachusetts Amherst; University of California System; University of California Santa Barbara	Meng, J (corresponding author), UNIV MASSACHUSETTS,DEPT BIOL,AMHERST,MA 01003, USA.							ANDREWS P, 1983, PALEOBIOLOGY, V9, P289, DOI 10.1017/S0094837300007703; Brunner H., 1974, IDENTIFICATION MAMMA, DOI [10.1017/S0030605300014253, DOI 10.1017/S0030605300014253]; CHOW M, 1978, VERTEBRAT PALASIATIC, V16, P77; CIFELLI R L, 1989, Bulletin of the Museum of Comparative Zoology, V152, P1; DEBROT S, 1982, ATALS POILS MAMMIFER; EDWARDS P, 1974, Contributions to Geology University of Wyoming, V13, P67; FISHER D C, 1981, Contributions from the Museum of Paleontology University of Michigan, V25, P259; Hahn G., 1987, B SOC BELGE GEOLOGIE, V96, P39; Hopson James A., 1994, Short Courses in Paleontology, V7, P190; Hunt Adrian P., 1994, P221; HUNT AP, 1992, NEW MEXICO BUREAU MI, V138, P221; JENKINS FA, 1983, SCIENCE, V220, P712, DOI 10.1126/science.220.4598.712; Kemp T.S, 1982, MAMMAL LIKE REPTILES; Kielan-Jaworowska Zofia, 1994, Fossils and Strata, V36, P1; Krause D. W., 1986, CONTRIBUTIONS GEOLOG, V3, P95; LANDRY SO, 1967, SYST ZOOL, V16, P172, DOI 10.2307/2411412; Matthew W.D., 1925, AM MUSEUM NATURAL HI, V189, P1; MELLETT JS, 1974, SCIENCE, V185, P349, DOI 10.1126/science.185.4148.349; MENG J, 1994, NATURE, V370, P134, DOI 10.1038/370134a0; MENG J, IN PRESS B CARNEGIE; Meng Jin, 1994, Journal of Mammalian Evolution, V2, P185, DOI 10.1007/BF01473528; Miao D-S., 1988, CONTRIB GEOL U WYOMI, V4, P1; OSTRANDER G, 1984, NEBRASKA ACAD SCI T, V12, P71; Rowe T., 1988, Journal of Vertebrate Paleontology, V8, P241; RUSSELL D E, 1987, Memoires du Museum National d'Histoire Naturelle Serie C Sciences de la Terre, V52, P1; SCHAAL S, 1992, MESSEL ART INSIGHT H; Vaughan TA, 1986, MAMMALOGY	27	53	56	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 20	1997	385	6618					712	714		10.1038/385712a0	http://dx.doi.org/10.1038/385712a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WJ423	9034186				2022-12-01	WOS:A1997WJ42300043
J	Averof, M; Cohen, SM				Averof, M; Cohen, SM			Evolutionary origin of insect wings from ancestral gills	NATURE			English	Article							PATTERN-FORMATION; DROSOPHILA; EXPRESSION; PROTEIN; ENCODES; GENES; DISC	Two hypotheses have been proposed for the origin of insect wings. One holds that wings evolved by modification of limb branches that were already present in multibranched ancestral appendages and probably functioned as gills(1-5). The second proposes that wings arose as novel outgrowths of the body wall, not directly related to any pre-existing limbs(6). If wings derive from dorsal structures of multibranched appendages, we expect that some of their distinctive features will have been built on genetic functions that were already present in the structural progenitors of insect wings, and in homologous structures of other arthropod Limbs. We have isolated crustacean homologues of two genes that have wing-specific functions in insects, pdm (nubbin) and apterous. Their expression patterns support the hypothesis that insect wings evolved from gill-like appendages that were already present in the aquatic ancestors of both crustaceans and insects.			Averof, M (corresponding author), EUROPEAN MOL BIOL LAB,MEYERHOFSTR 1,D-69117 HEIDELBERG,GERMANY.		Cohen, Stephen M/G-9930-2011	Cohen, Stephen M/0000-0003-2858-9163; Averof, Michalis/0000-0002-6803-7251				AVEROF M, 1995, PHILOS T R SOC B, V347, P293, DOI 10.1098/rstb.1995.0028; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BHAT KM, 1995, MOL CELL BIOL, V15, P4052; BLAIR SS, 1994, DEVELOPMENT, V120, P1805; CARROLL SB, 1994, SCIENCE, V265, P109, DOI 10.1126/science.7912449; COHEN B, 1993, DEVELOPMENT, V117, P597; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; COHEN SM, 1989, NATURE, V338, P432, DOI 10.1038/338432a0; COHEN SM, 1983, DROSOPHILA DEV, P747; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; FRIEDRICH M, 1995, NATURE, V376, P165, DOI 10.1038/376165a0; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; Kim J, 1996, NATURE, V382, P133, DOI 10.1038/382133a0; Kukalova-Peck J., 1991, P141; KUKALOVAPECK J, 1992, CAN J ZOOL, V70, P236, DOI 10.1139/z92-037; KUKALOVAPECK J, 1983, CAN J ZOOL, V61, P1618, DOI 10.1139/z83-217; LLOYD A, 1991, MECH DEVELOP, V36, P87, DOI 10.1016/0925-4773(91)90075-H; Ng M, 1996, NATURE, V381, P316, DOI 10.1038/381316a0; NG M, 1995, DEVELOPMENT, V121, P589; PANGANIBAN G, 1995, SCIENCE, V270, P1363, DOI 10.1126/science.270.5240.1363; PATEL NH, 1989, DEVELOPMENT, V107, P201; Snodgrass RE, 1935, PRINCIPLES INSECT MO; WIGGLESW.VB, 1973, NATURE, V246, P127, DOI 10.1038/246127a0; WIGGLESWORTH VB, 1976, INSECT FLIGHT, P255; WILLIAMS JA, 1994, NATURE, V368, P299, DOI 10.1038/368299a0; WILLIAMS JA, 1993, DEVELOPMENT, V117, P571; Yeo Su Ling, 1995, Genes and Development, V9, P1223, DOI 10.1101/gad.9.10.1223	27	173	182	11	124	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 13	1997	385	6617					627	630		10.1038/385627a0	http://dx.doi.org/10.1038/385627a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WH294	9024659				2022-12-01	WOS:A1997WH29400048
J	Moarefi, I; LaFevreBernt, M; Sicheri, F; Huse, M; Lee, CH; Kuriyan, J; Miller, WT				Moarefi, I; LaFevreBernt, M; Sicheri, F; Huse, M; Lee, CH; Kuriyan, J; Miller, WT			Activation of the Src-family tyrosine kinase Hck by SH3 domain displacement	NATURE			English	Article							INTERMOLECULAR AUTOPHOSPHORYLATION; GENE HCK; BINDING; PP60C-SRC; PROTEIN; DEPHOSPHORYLATION; PHOSPHORYLATION; SPECIFICITY; TERMINUS; PEPTIDES	The protein Hck is a member of the Src family of non-receptor tyrosine kinases which is preferentially expressed in haematopoietic cells of the myeloid and B-lymphoid lineages(1,2). Src kinases are inhibited by tyrosine-phosphorylation at a carboxy-terminal site(3-9). The SH2 domains of these enzymes play an essential role in this regulation by binding to the tyrosine-phosphorylated tail(8-11). The crystal structure of the downregulated form of Hck has been determined(12) and reveals that the SH2 domain regulates enzymatic activity indirectly; intramolecular interactions between the SH3 and catalytic domains appear to stabilize an inactive form of the kinase, Here we compare the roles of the SH2 and SH3 domains in modulating the activity of Hck in an investigation of the C-terminally phosphorylated form of the enzyme, We show that addition of the HIV-1 Nef protein, which is a high-affinity ligand for the Hck SH3 domain, to either the downregulated or activated form of Hck causes a large increase in Hck catalytic activity, The intact SH3-binding motif in Nef is crucial for Hck activation. Our results indicate that binding of the Hck SH3 domain by Nef causes a more marked activation of the enzyme than does binding of the SH2 domain, suggesting a new mechanism for regulation of the activity of tyrosine kinases.	SUNY STONY BROOK, SCH MED, DEPT PHYSIOL & BIOPHYS, STONY BROOK, NY 11794 USA; ROCKEFELLER UNIV, MOL BIOPHYS LAB, NEW YORK, NY 10021 USA; ROCKEFELLER UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA	State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook; Rockefeller University; Howard Hughes Medical Institute; Rockefeller University			Lee, Chi-Hon/G-9190-2012; Sicheri, Frank/F-8856-2013	Lee, Chi-Hon/0000-0002-6138-711X				Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; BARKER SC, 1995, BIOCHEMISTRY-US, V34, P14843, DOI 10.1021/bi00045a027; Boerner RJ, 1996, BIOCHEMISTRY-US, V35, P9519, DOI 10.1021/bi960248u; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CASNELLIE JE, 1991, METHOD ENZYMOL, V200, P115; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; LEE CH, 1995, EMBO J, V14, P5006, DOI 10.1002/j.1460-2075.1995.tb00183.x; LIU XQ, 1993, ONCOGENE, V8, P1119; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SAKSELA K, 1995, EMBO J, V14, P484, DOI 10.1002/j.1460-2075.1995.tb07024.x; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SUPERTIFURGA G, 1995, BIOESSAYS, V17, P321, DOI 10.1002/bies.950170408; TILL JH, 1994, J BIOL CHEM, V269, P7423; TRONO D, 1995, CELL, V82, P189, DOI 10.1016/0092-8674(95)90306-2; ZIEGLER SF, 1987, MOL CELL BIOL, V7, P2276, DOI 10.1128/MCB.7.6.2276	24	525	529	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 13	1997	385	6617					650	653		10.1038/385650a0	http://dx.doi.org/10.1038/385650a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WH294	9024665				2022-12-01	WOS:A1997WH29400054
J	Andrews, LB; Stocking, C; Krizek, T; Gottlieb, L; Krizek, C; Vargish, T; Siegler, M				Andrews, LB; Stocking, C; Krizek, T; Gottlieb, L; Krizek, C; Vargish, T; Siegler, M			An alternative strategy for studying adverse events in medical care	LANCET			English	Article							HOSPITALIZED-PATIENTS; MALPRACTICE	Background Data about the frequency of adverse events related to inappropriate care in hospitals come from studies of medical records as if they represented a true record of adverse events. In a prospective, observational design we analysed discussion of adverse events during the care of all patients admitted to three units of a large, urban teaching hospital affiliated to a university medical school. Discussion took place during routine clinical meetings. We undertook the study to enhance understanding of the incidence and scope of adverse events as a basis for preventing them. Methods Ethnographers trained in qualitative observational research attended day-shift, weekday, regularly scheduled attending rounds, residents' work rounds, nursing shift changes, case conferences, and other scheduled meetings in three study units as well as various departmental and section meetings. They recorded all adverse events during patient care discussed at these meetings and developed a classification scheme to code the data. Data were collected about health-care providers' own assessments about the appropriateness of the care that patients received to assess the nature and impact of adverse events and how health-care providers and patients responded to the adverse events. Findings Of the 1047 patients in the study, 185 (17.7%) were said to have had at least one serious adverse event; having an initial event was linked to the seriousness of the patient's underlying illness. Patients with long slays in hospital had more adverse events than those with short stays. The likelihood of experiencing an adverse event increased about 6% for each day of hospital stay. 37.8% of adverse events were caused by an individual, 15.6% had interactive causes, and 9.8% were due to administrative decisions. Although 17.7% of patients experienced serious events that led to longer hospital stays and increased costs to the patients, only 1.2% (13) of the 1047 patients made claims for compensation. Interpretation This study shows that there is a wide range of potential causes of adverse events that should be considered, and that careful attention must be paid to errors with interactive or administrative causes. Healthcare providers' own discussions of adverse events can be a good source of data for proactive error prevention.	AMER BAR FDN,CHICAGO,IL 60611; UNIV CHICAGO,DEPT MED,MACLEAN CTR CLIN MED ETH,CHICAGO,IL 60637; UNIV CHICAGO,DEPT SURG,CHICAGO,IL 60637; UNIV S FLORIDA,DEPT SURG,TAMPA,FL 33620	University of Chicago; University of Chicago; State University System of Florida; University of South Florida	Andrews, LB (corresponding author), CHICAGO KENT COLL LAW,565 W ADAMS ST,CHICAGO,IL 60661, USA.							BOSK CL, 1989, FORGIVE REMEMBER; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; BRENNAN TA, 1991, JAMA-J AM MED ASSOC, V265, P3265, DOI 10.1001/jama.265.24.3265; BROOK RH, 1973, ANN INTERN MED, V78, P333, DOI 10.7326/0003-4819-78-3-333; *CAL MED ASS CAL H, 1977, MED INS FEAS STUD; CASSEL J, 1996, EXPECTED MIRACLES SU; Cox DR., 1984, ANAL SURVIVAL DATA; *HARV MED PRACT ST, 1990, PAT DOCT LAW MED INJ; HIATT HH, 1989, NEW ENGL J MED, V321, P480, DOI 10.1056/NEJM198908173210725; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; MEYERS AR, 1987, AM J PUBLIC HEALTH, V77, P1544, DOI 10.2105/AJPH.77.12.1544; MILLS DH, 1978, WESTERN J MED, V128, P360; RUBIN HR, 1992, JAMA-J AM MED ASSOC, V267, P2349, DOI 10.1001/jama.267.17.2349; SOWKA MP, 1981, CONN MED, V45, P91; STEEL K, 1981, NEW ENGL J MED, V304, P638, DOI 10.1056/NEJM198103123041104; Tuma N.B., 1984, SOCIAL DYNAMICS MODE	16	337	348	0	20	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 1	1997	349	9048					309	313		10.1016/S0140-6736(96)08268-2	http://dx.doi.org/10.1016/S0140-6736(96)08268-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF794	9024373				2022-12-01	WOS:A1997WF79400009
J	Kehl, LJ; Fairbanks, CA; Laughlin, TM; Wilcox, GL				Kehl, LJ; Fairbanks, CA; Laughlin, TM; Wilcox, GL			Neurogenesis in postnatal rat spinal cord: A study in primary culture	SCIENCE			English	Article							MICROTUBULE-ASSOCIATED PROTEIN-2; ADULT MAMMALIAN FOREBRAIN; NEURON-SPECIFIC ENOLASE; HIPPOCAMPAL-NEURONS; POSTTRANSLATIONAL MODIFICATION; SUBVENTRICULAR ZONE; REACTIVE ASTROCYTES; MEMBRANE-PROPERTIES; BETA-TUBULIN; ION CHANNELS	Spinal cord injuries result in paralysis, because when damaged neurons die they are not replaced. Neurogenesis of electrophysiologically functional neurons occurred in spinal cord cultured from postnatal rats. In these cultures, the numbers of immunocytochemically identified neurons increased over time. Additionally, neurons identified immunocytochemically or electrophysiologically incorporated bromodeoxyuridine, confirming they had differentiated from mitotic cells in vitro. These findings suggest that postnatal spinal cord retains the capacity to generate functional neurons. The presence of neuronal precursor cells in postnatal spinal cord may offer new therapeutic approaches for restoration of function to individuals with spinal cord injuries.	UNIV MINNESOTA,GRAD PROGRAM NEUROSCI,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,DEPT PHARMACOL,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities				Wilcox, George/0000-0002-6411-0423; Fairbanks, Carolyn/0000-0003-4252-8586	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [K15DE000225] Funding Source: NIH RePORTER; NIDA NIH HHS [DA07097, DA07234] Funding Source: Medline; NIDCR NIH HHS [DE00225] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BAUGHMAN RW, 1991, CULTURING NERVE CELL, P227; Cheng H, 1996, SCIENCE, V273, P510, DOI 10.1126/science.273.5274.510; GAGE FH, 1995, ANNU REV NEUROSCI, V18, P159, DOI 10.1146/annurev.ne.18.030195.001111; GEISERT EE, 1990, P NATL ACAD SCI USA, V87, P3967, DOI 10.1073/pnas.87.10.3967; GONCHOROFF NJ, 1985, CYTOMETRY, V6, P506, DOI 10.1002/cyto.990060604; JOHANSSON S, 1990, NEUROSCI LETT, V118, P155, DOI 10.1016/0304-3940(90)90615-G; JOHANSSON S, 1992, J PHYSIOL-LONDON, V445, P157, DOI 10.1113/jphysiol.1992.sp018917; JOHANSSON S, 1992, J PHYSIOL-LONDON, V445, P129, DOI 10.1113/jphysiol.1992.sp018915; KEHL L, UNPUB J NEUROSCI MET; KEHL L, 1996, THESIS U MINNESOTA M; LEE MK, 1990, CELL MOTIL CYTOSKEL, V17, P118, DOI 10.1002/cm.970170207; LEE MK, 1990, P NATL ACAD SCI USA, V87, P7195, DOI 10.1073/pnas.87.18.7195; LIN RCS, 1994, NEUROSCIENCE, V60, P11, DOI 10.1016/0306-4522(94)90199-6; LOCKERY SR, 1992, J NEUROSCI, V12, P2268; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; LOIS C, 1993, P NATL ACAD SCI USA, V90, P2074, DOI 10.1073/pnas.90.5.2074; LUSKIN MB, 1993, NEURON, V11, P173, DOI 10.1016/0896-6273(93)90281-U; MAGNUSON DSK, 1995, DEV BRAIN RES, V84, P130, DOI 10.1016/0165-3806(94)00166-W; MAIER DL, 1995, DEV BRAIN RES, V87, P135, DOI 10.1016/0165-3806(95)00065-L; Martin JH, 1985, PRINCIPLES NEURAL SC, P244; Menezes JRL, 1995, MOL CELL NEUROSCI, V6, P496, DOI 10.1006/mcne.1995.0002; MENEZES JRL, 1994, J NEUROSCI, V14, P5399; MORSHEAD CM, 1994, NEURON, V13, P1071, DOI 10.1016/0896-6273(94)90046-9; NORNES HO, 1974, BRAIN RES, V73, P121, DOI 10.1016/0006-8993(74)91011-7; PRIVAT A, 1975, INT REV CYTOL, V40, P281, DOI 10.1016/S0074-7696(08)60955-9; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; SCHMECHEL DE, 1980, BRAIN RES, V190, P195, DOI 10.1016/0006-8993(80)91169-5; SCHMITT J, 1991, NEUROL CLIN, V9, P779, DOI 10.1016/S0733-8619(18)30279-2; SONTHEIMER H, 1992, J NEUROPHYSIOL, V68, P1001, DOI 10.1152/jn.1992.68.4.1001; SONTHEIMER H, 1992, J NEUROPHYSIOL, V68, P985, DOI 10.1152/jn.1992.68.4.985; SULLIVAN KF, 1988, ANNU REV CELL BIOL, V4, P687, DOI 10.1146/annurev.cb.04.110188.003351; VIANA F, 1994, NEUROSCIENCE, V59, P131, DOI 10.1016/0306-4522(94)90105-8; WEBER ED, 1977, BRAIN RES, V125, P241, DOI 10.1016/0006-8993(77)90618-7; Weiss S, 1996, J NEUROSCI, V16, P7599; Zigova T, 1996, DEV BIOL, V173, P459, DOI 10.1006/dbio.1996.0040	35	63	68	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 25	1997	276	5312					586	589		10.1126/science.276.5312.586	http://dx.doi.org/10.1126/science.276.5312.586			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WV721	9110976				2022-12-01	WOS:A1997WV72100043
J	Soisson, SM; MacDougallShackleton, B; Schleif, R; Wolberger, C				Soisson, SM; MacDougallShackleton, B; Schleif, R; Wolberger, C			Structural basis for ligand-regulated oligomerization of AraC	SCIENCE			English	Article							ARABAD OPERON PROMOTER; PROTEIN; REPRESSION; OPERATOR; BINDING; MODEL; SITE	The crystal structure of the arabinose-binding and dimerization domain of the Escherchia coli gene regulatory protein AraC was determined in the presence and absence of L-arabinose. The 1.5 angstrom structure of the arabinose-bound molecule shows that the protein adopts an unusual fold, binding sugar within a beta barrel and completely burying the arabinose with the amino-terminal arm of the protein. Dimer contacts in the presence of arabinose are mediated by an antiparallel coiled-coil. In the 2.8 angstrom structure of the uncomplexed protein, the amino-terminal arm is disordered, uncovering the sugar-binding pocket and allowing it to serve as an oligomerization interface. The ligand-gated oligomerization as seen in AraC provides the basis of a plausible mechanism for modulating the protein's DNA-looping properties.	JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21218; JOHNS HOPKINS UNIV,SCH MED,DEPT BIOPHYS & BIOPHYS CHEM,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University				Schleif, Robert/0000-0002-4430-7085; Wolberger, Cynthia/0000-0001-8578-2969	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM018277, R01GM018277] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM18277] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BRUNGER AT, COMMUNICATION; BRUNGER AT, 1992, XPLOR V3 1 SYSTEM XR; BUSTOS SA, 1993, P NATL ACAD SCI USA, V90, P5638, DOI 10.1073/pnas.90.12.5638; CARRA JH, 1993, EMBO J, V12, P35, DOI 10.1002/j.1460-2075.1993.tb05629.x; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; DUNN TM, 1984, P NATL ACAD SCI-BIOL, V81, P5017, DOI 10.1073/pnas.81.16.5017; DUYNE GDV, 1996, J MOL BIOL, V256, P377; EUSTANCE RJ, 1994, J MOL BIOL, V242, P330; Eustance RJ, 1996, J BACTERIOL, V178, P7025, DOI 10.1128/jb.178.24.7025-7030.1996; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; HENDRICKSON W, 1984, J MOL BIOL, V178, P611, DOI 10.1016/0022-2836(84)90241-9; HENDRICKSON W, 1985, P NATL ACAD SCI USA, V82, P3129, DOI 10.1073/pnas.82.10.3129; Janin J, 1995, PROTEINS, V23, P580, DOI 10.1002/prot.340230413; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LAUBLE H, 1989, EUR J BIOCHEM, V185, P319, DOI 10.1111/j.1432-1033.1989.tb15118.x; LEE N, 1987, P NATL ACAD SCI USA, V84, P8814, DOI 10.1073/pnas.84.24.8814; LOBELL RB, 1990, SCIENCE, V250, P528, DOI 10.1126/science.2237403; MARTIN K, 1986, P NATL ACAD SCI USA, V83, P3654, DOI 10.1073/pnas.83.11.3654; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OTWINOWSKI Z, 1993, P CCP4 STUD WEEK DAT; RICE LM, 1994, PROTEINS, V19, P277, DOI 10.1002/prot.340190403; SCHLEIF R, 1992, ANNU REV BIOCHEM, V61, P199, DOI 10.1146/annurev.bi.61.070192.001215; SCHLEIF R, 1996, ESCHERICHIA COLI SAL, P1300; SCHLEIF RF, 1982, BIOCHEMISTRY-US, V21, P778, DOI 10.1021/bi00533a031; SOMERS WS, 1992, NATURE, V359, P387, DOI 10.1038/359387a0; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602; WILCOX G, 1974, J BIOL CHEM, V249, P6892; WILCOX G, 1976, MOL GEN GENET, V145, P97, DOI 10.1007/BF00331563; Zhang X, 1996, J MOL BIOL, V258, P14, DOI 10.1006/jmbi.1996.0230	30	173	178	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 18	1997	276	5311					421	425		10.1126/science.276.5311.421	http://dx.doi.org/10.1126/science.276.5311.421			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WU477	9103202				2022-12-01	WOS:A1997WU47700042
J	Brunell, P				Brunell, P			Diagnosing streptococcal pharyngitis in patients taking antibiotics	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											Brunell, P (corresponding author), CEDARS SINAI MED CTR,LOS ANGELES,CA 90048, USA.							Cockerill FR, 1997, JAMA-J AM MED ASSOC, V277, P38, DOI 10.1001/jama.277.1.38	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 16	1997	277	15					1197	1197		10.1001/jama.277.15.1197	http://dx.doi.org/10.1001/jama.277.15.1197			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WT403	9103335				2022-12-01	WOS:A1997WT40300016
J	Albertini, M; Rehling, P; Erdmann, R; Girzalsky, W; Kiel, JAKW; Veenhuis, M; Kunau, WH				Albertini, M; Rehling, P; Erdmann, R; Girzalsky, W; Kiel, JAKW; Veenhuis, M; Kunau, WH			Pex14p, a peroxisomal membrane protein binding both receptors of the two PTS-dependent import pathways	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; 3-OXOACYL-COA THIOLASE; TARGETING SIGNAL; HANSENULA-POLYMORPHA; SHUTTLE VECTORS; YEAST; BIOGENESIS; GENE; MATRIX; ENCODES	Pex14p, an S. cerevisiae peroxin, is attached to the outer face of the peroxisomal membrane and is a component of the protein import machinery. Pex14p interacts with both the PTS1 and PTS2 receptors. It is the only known peroxisomal membrane protein that binds the PTS2 receptor and might thus mediate the membrane docking event of PTS2-dependent protein import. These results suggest that the two import pathways overlap and, furthermore, that Pex14p represents the point of convergence. Pex14p also interacts with two other membrane-bound peroxins including Pex13p, another binding protein for the PTS1 receptor. The data presented here are consistent with the idea of a common translocation machinery for both PTS-dependent protein import pathways in the peroxisomal membrane.	RUHR UNIV BOCHUM,ABT ZELLBIOCHEM,D-44780 BOCHUM,GERMANY; RUHR UNIV BOCHUM,INST PHYSIOL CHEM 2,D-44780 BOCHUM,GERMANY; UNIV GRONINGEN,ELECTRON MICROSCOPY LAB,CTR BIOL,NL-9751 NN HAREN,NETHERLANDS	Ruhr University Bochum; Ruhr University Bochum; University of Groningen								Ausubel F.M., 1989, SHORT PROTOCOLS MOL; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; Blobel F, 1996, EUR J BIOCHEM, V240, P468, DOI 10.1111/j.1432-1033.1996.0468h.x; BROCARD C, 1994, BIOCHEM BIOPH RES CO, V204, P1016, DOI 10.1006/bbrc.1994.2564; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; Distel B, 1996, J CELL BIOL, V135, P1, DOI 10.1083/jcb.135.1.1; Dodt G, 1996, J CELL BIOL, V135, P1763, DOI 10.1083/jcb.135.6.1763; DODT G, 1995, NAT GENET, V9, P115, DOI 10.1038/ng0295-115; DOUMA AC, 1985, ARCH MICROBIOL, V143, P237, DOI 10.1007/BF00411242; Elgersma Y, 1996, J CELL BIOL, V135, P97, DOI 10.1083/jcb.135.1.97; ERDMANN R, 1994, YEAST, V10, P1173, DOI 10.1002/yea.320100905; ERDMANN R, 1994, YEAST, V10, P935, DOI 10.1002/yea.320100708; ERDMANN R, 1991, CELL, V64, P499, DOI 10.1016/0092-8674(91)90234-P; ERDMANN R, 1995, J CELL BIOL, V128, P509, DOI 10.1083/jcb.128.4.509; Erdmann R, 1996, J CELL BIOL, V135, P111, DOI 10.1083/jcb.135.1.111; ERDMANN R, 1989, P NATL ACAD SCI USA, V86, P2432; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GLOVER JR, 1994, J BIOL CHEM, V269, P7558; Gould SJ, 1996, J CELL BIOL, V135, P85, DOI 10.1083/jcb.135.1.85; Harlow E LD, 1988, ANTIBODIES LAB MANUA, V1st; HOHFELD J, 1991, J CELL BIOL, V114, P1167, DOI 10.1083/jcb.114.6.1167; HUHSE B, 1995, THESIS RUHR U BOCHUM; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; Komori M, 1997, EMBO J, V16, P44, DOI 10.1093/emboj/16.1.44; KUNAU WH, 1993, BIOCHIMIE, V75, P209, DOI 10.1016/0300-9084(93)90079-8; Lazarow P. B., 1993, TRENDS CELL BIOL, V157, P105; Lupas A, 1996, METHOD ENZYMOL, V266, P513; MARSHALL PA, 1995, J CELL BIOL, V129, P345, DOI 10.1083/jcb.129.2.345; MARZIOCH M, 1994, EMBO J, V13, P4908, DOI 10.1002/j.1460-2075.1994.tb06818.x; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; McNew JA, 1996, TRENDS BIOCHEM SCI, V21, P54, DOI 10.1016/S0968-0004(96)80181-2; RACHUBINSKI RA, 1995, CELL, V83, P525, DOI 10.1016/0092-8674(95)90091-8; Rehling P, 1996, EMBO J, V15, P2901, DOI 10.1002/j.1460-2075.1996.tb00653.x; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; SIKORSKI RS, 1989, GENETICS, V122, P19; Subramani S, 1996, CURR OPIN CELL BIOL, V8, P513, DOI 10.1016/S0955-0674(96)80029-9; SUBRAMANI S, 1993, ANNU REV CELL BIOL, V9, P445, DOI 10.1146/annurev.cb.09.110193.002305; SZILARD RK, 1995, J CELL BIOL, V131, P1453, DOI 10.1083/jcb.131.6.1453; VANDERKLEI IJ, 1995, J BIOL CHEM, V270, P17229, DOI 10.1074/jbc.270.29.17229; VANDERLEIJ I, 1993, P NATL ACAD SCI USA, V90, P11782, DOI 10.1073/pnas.90.24.11782; VEENHUIS M, 1987, YEAST, V3, P77, DOI 10.1002/yea.320030204; WIEMER EAC, 1995, J CELL BIOL, V130, P51, DOI 10.1083/jcb.130.1.51; YAFFE MP, 1984, P NATL ACAD SCI-BIOL, V81, P4819, DOI 10.1073/pnas.81.15.4819; ZHANG JW, 1995, J CELL BIOL, V129, P65, DOI 10.1083/jcb.129.1.65; Zhang JW, 1996, J CELL BIOL, V132, P325, DOI 10.1083/jcb.132.3.325	45	261	264	0	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 4	1997	89	1					83	92		10.1016/S0092-8674(00)80185-3	http://dx.doi.org/10.1016/S0092-8674(00)80185-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WR685	9094717	Bronze, Green Published			2022-12-01	WOS:A1997WR68500012
J	Odum, JR; Jungkamp, TPW; Griffin, RJ; Flagan, RC; Seinfeld, JH				Odum, JR; Jungkamp, TPW; Griffin, RJ; Flagan, RC; Seinfeld, JH			The atmospheric aerosol-forming potential of whole gasoline vapor	SCIENCE			English	Article							OUTDOOR SMOG CHAMBER; ORGANIC-COMPOUNDS; BETA-PINENE; PHOTOOXIDATION; EMISSIONS; NOX; REACTIVITY; TOLUENE; CARBON; GROWTH	A series of sunlight-irradiated, smog-chamber experiments confirmed that the atmospheric organic aerosol formation potential of whole gasoline vapor can be accounted for solely in terms of the aromatic fraction of the fuel. The total amount of secondary organic aerosol produced from the atmospheric oxidation of whole gasoline vapor can be represented as the sum of the contributions of the individual aromatic molecular constituents of the fuel. The urban atmospheric, anthropogenic hydrocarbon profile is approximated well by evaporated whole gasoline, and thus these results suggest that it is possible to model atmospheric secondary organic aerosol formation.	CALTECH,DEPT CHEM ENGN,PASADENA,CA 91125; CALTECH,DEPT ENVIRONM ENGN SCI,PASADENA,CA 91125	California Institute of Technology; California Institute of Technology				Griffin, Robert/0000-0001-7682-8769				ATKINSON R, 1994, J PHYS CHEM REF DATA, V2; Bowman FM, 1995, PROG ENERG COMBUST, V21, P387, DOI 10.1016/0360-1285(95)00008-9; BURNS VR, 1991, 912320 SAE; CALVERT JG, 1993, SCIENCE, V261, P37, DOI 10.1126/science.261.5117.37; GERY MW, 1985, INT J CHEM KINET, V17, P931, DOI 10.1002/kin.550170903; GROSJEAN D, 1989, ATMOS ENVIRON, V23, P1733, DOI 10.1016/0004-6981(89)90058-9; GROSJEAN D, 1992, ATMOS ENVIRON A-GEN, V26, P953, DOI 10.1016/0960-1686(92)90027-I; GROSJEAN D, 1977, OZONE OTHER PHOTOCHE, pCH3; HARLEY RA, 1992, ENVIRON SCI TECHNOL, V26, P2395, DOI 10.1021/es00036a010; HATAKEYAMA S, 1991, J GEOPHYS RES-ATMOS, V96, P947, DOI 10.1029/90JD02341; Hochhauser AM, 1991, 912322 SAE; HOEKMAN SK, 1992, ENVIRON SCI TECHNOL, V26, P1206, DOI 10.1021/es50002a610; IZUMI K, 1990, ATMOS ENVIRON A-GEN, V24, P1433, DOI 10.1016/0960-1686(90)90052-O; KWOK ESC, 1995, ATMOS ENVIRON, V29, P1685, DOI 10.1016/1352-2310(95)00069-B; LEONE JA, 1985, INT J CHEM KINET, V17, P177, DOI 10.1002/kin.550170206; MALLARD WG, 1994, NIST STANDARD REFERE; ODURN JR, 1996, ENVIRON SCI TECHNOL, V30, P2580; PANDIS SN, 1991, ATMOS ENVIRON A-GEN, V25, P997, DOI 10.1016/0960-1686(91)90141-S; PANKOW JF, 1994, ATMOS ENVIRON, V28, P185, DOI 10.1016/1352-2310(94)90093-0; PAUL RH, 1991, 902098 SAE; POPE CA, 1995, ENVIRON HEALTH PERSP, V103, P472, DOI 10.2307/3432586; RUSSELL A, 1995, SCIENCE, V269, P491, DOI 10.1126/science.269.5223.491; SCHWARTZ J, 1996, AIR WASTE MANAGE ASS, V46, P927; SHPRENTZ DS, 1996, BREATH TAKING PREMAT; Siegl W. O., 1993, 930142 SAE; STERN JE, 1987, ENVIRON SCI TECHNOL, V21, P1224, DOI 10.1021/es00165a011; TURPIN BJ, 1991, ATMOS ENVIRON A-GEN, V25, P207, DOI 10.1016/0960-1686(91)90291-E; TURPIN BJ, 1991, ENVIRON SCI TECHNOL, V25, P1788, DOI 10.1021/es00022a017; WANG SC, 1992, ATMOS ENVIRON A-GEN, V26, P403, DOI 10.1016/0960-1686(92)90326-G	29	444	485	3	173	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 4	1997	276	5309					96	99		10.1126/science.276.5309.96	http://dx.doi.org/10.1126/science.276.5309.96			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WR386	9082994				2022-12-01	WOS:A1997WR38600053
J	Vinson, M; Mironov, S; Mulvey, S; Pertsov, A				Vinson, M; Mironov, S; Mulvey, S; Pertsov, A			Control of spatial orientation and lifetime of scroll rings in excitable media	NATURE			English	Article							BELOUSOV-ZHABOTINSKII REACTION; 3-DIMENSIONAL CHEMICAL WAVES; SPIRAL WAVES; ACTIVE MEDIUM; ORGANIZING CENTERS; DYNAMICS; ANNIHILATION; PROPAGATION; FILAMENTS; VORTICES	Excitable media, which range from autocatalytic chemical systems(1-3) to biological cells and tissues(4-7), can maintain organized structures in the form of rotating spiral waves of excitation(8-11). The dynamics of spiral waves in two-dimensional systems have been shown to be susceptible to control by external fields (such as electric, thermal and optical)(12-14). In three dimensions, the analogues of spiral waves are scroll waves(9,15,16), Here we show that an external held-a temperature gradient-can be used to control a particular class of scroll waves called scroll rings. The gradient allows scroll rings to be precisely oriented in space, and their spontaneous shrinkage to be accelerated, decelerated or even reversed (so that the ring expands). The temperature gradient also influences the lifetimes of the scroll rings. We suggest that these dynamics are likely to be generic to other types of field gradients and other excitable media.	SUNY HLTH SCI CTR,DEPT PHARMACOL,SYRACUSE,NY 13210; SHIPPENSBURG UNIV,DEPT PHYS,SHIPPENSBURG,PA 17257; INST CELLULAR BIOPHYS,PUSHCHINO 142292,MOSCOW REGION,RUSSIA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; Pennsylvania State System of Higher Education (PASSHE); Shippensburg University of Pennsylvania; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Cell Biophysics RAS								AGLADZE KI, 1991, PHYSICA D, V49, P1, DOI 10.1016/0167-2789(91)90186-D; ALIEV RR, 1992, J PHYS CHEM-US, V96, P732, DOI 10.1021/j100181a039; BIKTASHEV VN, 1994, PHILOS T R SOC A, V347, P611, DOI 10.1098/rsta.1994.0070; DAVIDENKO JM, 1992, NATURE, V355, P349, DOI 10.1038/355349a0; GORELOVA NA, 1983, J NEUROBIOL, V14, P353, DOI 10.1002/neu.480140503; JAHNKE W, 1988, NATURE, V336, P662, DOI 10.1038/336662a0; KEENER JP, 1988, PHYSICA D, V31, P269, DOI 10.1016/0167-2789(88)90080-2; KEENER JP, 1992, SIAM REV, V34, P1, DOI 10.1137/1034001; KEENER JP, 1990, PHYSICA D, V44, P191, DOI 10.1016/0167-2789(90)90055-T; Krinsky V. I., 1984, SELF ORG AUTOWAVES S; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; Mironov S, 1996, J PHYS CHEM-US, V100, P1975, DOI 10.1021/jp952556s; MULLER SC, 1985, SCIENCE, V230, P661, DOI 10.1126/science.230.4726.661; Panfilov A. V., 1986, Biophysics, V31, P926; PERTSOV A, 1993, PHYSICA D, V63, P233, DOI 10.1016/0167-2789(93)90157-V; PERTSOV AM, 1993, CIRC RES, V72, P631, DOI 10.1161/01.RES.72.3.631; PERTSOV AM, 1990, NATURE, V345, P419, DOI 10.1038/345419a0; RUDENKO AN, 1983, STUD BIOPHYS, V98, P183; SCHUTZE J, 1992, NATURE, V356, P45, DOI 10.1038/356045a0; SIEGERT F, 1991, PHYSICA D, V49, P224, DOI 10.1016/0167-2789(91)90210-Z; STEINBOCK O, 1993, NATURE, V366, P322, DOI 10.1038/366322a0; STEINBOCK O, 1992, PHYS REV LETT, V68, P248, DOI 10.1103/PhysRevLett.68.248; SWINNEY HL, 1991, PHYSICA D, V49; WELSH BJ, 1983, NATURE, V304, P611, DOI 10.1038/304611a0; WINFREE AT, 1972, SCIENCE, V175, P634, DOI 10.1126/science.175.4022.634; WINFREE AT, 1984, NATURE, V311, P611, DOI 10.1038/311611a0; Zhabotinsky A, 1971, OSCILLATORY PROCESSE, VII	27	67	70	2	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 3	1997	386	6624					477	480		10.1038/386477a0	http://dx.doi.org/10.1038/386477a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WR256	9087404				2022-12-01	WOS:A1997WR25600046
J	Irani, K; Xia, Y; Zweier, JL; Sollott, SJ; Der, CJ; Fearon, ER; Sundaresan, M; Finkel, T; GoldschmidtClermont, PJ				Irani, K; Xia, Y; Zweier, JL; Sollott, SJ; Der, CJ; Fearon, ER; Sundaresan, M; Finkel, T; GoldschmidtClermont, PJ			Mitogenic signaling mediated by oxidants in ras-transformed fibroblasts	SCIENCE			English	Article							GTP-BINDING PROTEIN; GENERATING NADPH OXIDASE; ACTIN STRESS FIBERS; C-JUN; HYDROGEN-PEROXIDE; ENDOTHELIAL-CELLS; REGULATED KINASES; CDC42 GTPASES; GROWTH; ACTIVATION	NIH 3T3 fibroblasts stably transformed with a constitutively active isoform of p21(Ras), H-Ras(V12) (v-H-Ras or EJ-Ras), produced large amounts of the reactive oxygen species superoxide (. O-2-). . O-2(-) production was suppressed by the expression of dominant negative isoforms of Ras or Rac1, as well as by treatment with a farnesyltransferase inhibitor or with diphenylene iodonium, a flavoprotein inhibitor, The mitogenic activity of cells expressing H-Ras(V12) was inhibited by treatment with the chemical antioxidant N-acetyl-L-cysteine. Mitogen-activated protein kinase (MAPK) activity was decreased and c-Jun N-terminal kinase (JNK) was not activated in H-Ras(V12)-transformed cells. Thus, H-Ras(V12)-induced transformation can lead to the production of . O-2(-) through one or more pathways involving a flavoprotein and Rac1. The implication of a reactive oxygen species, probably . O-2(-), as a mediator of Ras-induced cell cycle progression independent of MAPK and JNK suggests a possible mechanism for the effects of antioxidants against Ras-induced cellular transformation.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV CARDIOL,BALTIMORE,MD 21205; UNIV N CAROLINA,DEPT PHARMACOL,CHAPEL HILL,NC 27599; UNIV MICHIGAN,MED CTR,ANN ARBOR,MI 48109; NHLBI,CARDIOL BRANCH,NIH,BETHESDA,MD 20892; JOHNS HOPKINS UNIV,SCH MED,DEPT CELL BIOL & ANAT,BALTIMORE,MD 21205	Johns Hopkins University; University of North Carolina; University of North Carolina Chapel Hill; University of Michigan System; University of Michigan; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Johns Hopkins University				Irani, Kaikobad/0000-0001-9194-7387; Der, Channing/0000-0002-7751-2747	NHLBI NIH HHS [HL52315] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL052315] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; AMES BN, 1988, IARC SCI PUBL, V89, P407; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOKOCH GM, 1994, CURR OPIN CELL BIOL, V6, P212, DOI 10.1016/0955-0674(94)90138-4; BOS JL, 1989, CANCER RES, V49, P4682; BULKLEY GB, 1994, LANCET, V344, P934, DOI 10.1016/S0140-6736(94)92276-4; Burdon RH, 1996, FREE RADICAL RES, V24, P81, DOI 10.3109/10715769609088004; BURDON RH, 1993, FREE RADICAL RES COM, V19, P203, DOI 10.3109/10715769309111603; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; ERZURUM SC, 1993, NUCLEIC ACIDS RES, V21, P1607, DOI 10.1093/nar/21.7.1607; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GYLLENHAMMAR H, 1987, J IMMUNOL METHODS, V97, P209, DOI 10.1016/0022-1759(87)90461-3; Heldman AW, 1996, CIRC RES, V78, P312, DOI 10.1161/01.RES.78.2.312; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P1217, DOI 10.1091/mbc.4.11.1217; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; IRANI K, UNPUB; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KNAUS UG, 1992, J BIOL CHEM, V267, P23575; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KRIEGERBRAUER HI, 1995, BIOCHEM J, V307, P549, DOI 10.1042/bj3070549; LEVINE A, 1994, CELL, V79, P583, DOI 10.1016/0092-8674(94)90544-4; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; MEIER B, 1993, BIOCHEM J, V289, P481, DOI 10.1042/bj2890481; MEIER B, 1991, BIOCHEM J, V275, P241, DOI 10.1042/bj2750241; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MIZUNO T, 1992, J BIOL CHEM, V267, P10215; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; Oldham SM, 1996, P NATL ACAD SCI USA, V93, P6924, DOI 10.1073/pnas.93.14.6924; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PENDERGAST GC, 1994, MOL CELL BIOL, V14, P4193; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RAUTALAHTI M, 1993, ANN MED, V25, P435; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Sundaresan M, 1996, BIOCHEM J, V318, P379, DOI 10.1042/bj3180379; SZATROWSKI TP, 1991, CANCER RES, V51, P794; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; ZWEIER JL, 1994, J BIOL CHEM, V269, P24156	48	1360	1403	0	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 14	1997	275	5306					1649	1652		10.1126/science.275.5306.1649	http://dx.doi.org/10.1126/science.275.5306.1649			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WN123	9054359				2022-12-01	WOS:A1997WN12300047
J	Vigers, GPA; Anderson, LJ; Caffes, P; Brandhuber, BJ				Vigers, GPA; Anderson, LJ; Caffes, P; Brandhuber, BJ			Crystal structure of the type-I interleukin-1 receptor complexed with interleukin-1 beta	NATURE			English	Article							IDENTIFICATION; ANTAGONIST; RESOLUTION; REFINEMENT; SITE	Interleukin-1 (IL-1) is an important mediator of inflammatory disease. The IL-1 family currently consists of two agonists, IL-1 alpha and IL-1 beta, and one antagonist, IL-1ra. Each of these molecules binds to the type I IL-1 receptor (IL1R)(1). The binding of IL-1 alpha or IL-1 beta to IL1R is an early step in IL-1 signal transduction and blocking this interaction may therefore be a useful target for the development of new drugs, Here we report the three-dimensional structure of IL-1 beta bound to the extracellular domain of IL1R (s-IL1R) at 2.5 Angstrom resolution. IL-1 beta binds to s-IL1R with a 1:1 stoichiometry. The crystal structure shows that s-IL1R consists of three immunoglobulin-like domains which wrap around IL-1 beta in a manner distinct from the structures of previously described cytokine-receptor complexes. The two receptor-binding regions on IL-1 beta identified by site-directed mutagenesis(2,3) both contact the receptor: one binds to the first two domains of the receptor, while the other binds exclusively to the third domain.	AMGEN INC, BOULDER, CO 80301 USA	Amgen				Vigers, Guy/0000-0003-4451-8453				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; EVANS RJ, 1995, J BIOL CHEM, V270, P11477, DOI 10.1074/jbc.270.19.11477; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LABRIOLATOMPKINS E, 1991, P NATL ACAD SCI USA, V88, P11182, DOI 10.1073/pnas.88.24.11182; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; OTWINOWSKI Z, 1993, DATA COLLECTION PROC; PRIESTLE JP, 1989, P NATL ACAD SCI USA, V86, P9667, DOI 10.1073/pnas.86.24.9667; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; SIMS JE, 1989, P NATL ACAD SCI USA, V86, P8946, DOI 10.1073/pnas.86.22.8946; VIGERS GPK, 1994, J BIOL CHEM, V269, P12874; WALTER MR, 1995, NATURE, V376, P230, DOI 10.1038/376230a0	19	213	236	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 13	1997	386	6621					190	194		10.1038/386190a0	http://dx.doi.org/10.1038/386190a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WM973	9062193				2022-12-01	WOS:A1997WM97300066
J	Dandliker, PJ; Holmlin, RE; Barton, JK				Dandliker, PJ; Holmlin, RE; Barton, JK			Oxidative thymine dimer repair in the DNA helix	SCIENCE			English	Article							PHENANTHRENEQUINONE DIIMINE COMPLEXES; CIS-SYN; DAMAGED DNA; PYRIMIDINE; RECOGNITION; PHOTOLYASE; PHOTOCLEAVAGE; RHODIUM(III); TEMPERATURE; SEQUENCE	The metallointercalator Rh(phi)(2)DMB(3+) (phi, 9,10-phenanthrenequinone diimine; DMB, 4,4'-dimethyl-2,2'-bipyridine) catalyzed the repair of a thymine dimer incorporated site-specifically in a 16-base pair DNA duplex by means of visible light, This repair could be accomplished with rhodium noncovalently bound to the duplex and at long range (16 to 26 angstroms), with the rhodium intercalator tethered to either end of the duplex assembly, This long-range repair was mediated by the DNA helix, Repair efficiency did not decrease with increasing distance between intercalated rhodium and the thymine dimer, but it diminished with disruption of the intervening pi-stack.	CALTECH,DIV CHEM & CHEM ENGN,PASADENA,CA 91125	California Institute of Technology					NIGMS NIH HHS [GM49216] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049216] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arkin MR, 1996, SCIENCE, V273, P475, DOI 10.1126/science.273.5274.475; Arkin MR, 1996, J AM CHEM SOC, V118, P2267, DOI 10.1021/ja9532998; BANERJEE SK, 1988, P NATL ACAD SCI USA, V85, P8141, DOI 10.1073/pnas.85.21.8141; BARTON JK, 1986, SCIENCE, V233, P727, DOI 10.1126/science.3016894; BEGLEY TP, 1994, ACCOUNTS CHEM RES, V27, P394, DOI 10.1021/ar00048a002; CARRELL T, 1996, ANGEW CHEM INT EDIT, V35, P620; Hall DB, 1996, NATURE, V382, P731, DOI 10.1038/382731a0; HEELIS PF, 1995, CHEM SOC REV, V24, P289, DOI 10.1039/cs9952400289; HELENE C, 1977, PHOTOCHEM PHOTOBIOL, V25, P429, DOI 10.1111/j.1751-1097.1977.tb09166.x; Holmlin RE, 1996, J AM CHEM SOC, V118, P5236, DOI 10.1021/ja953941y; JACOBSEN JR, 1995, J AM CHEM SOC, V117, P5453, DOI 10.1021/ja00125a004; KALNIK MW, 1990, J BIOL CHEM, V265, P636; KEMMINK J, 1986, PHOTOCHEM PHOTOBIOL, V44, P137, DOI 10.1111/j.1751-1097.1986.tb03577.x; KEMMINK J, 1987, NUCLEIC ACIDS RES, V15, P4645, DOI 10.1093/nar/15.11.4645; KIM ST, 1993, PHOTOCHEM PHOTOBIOL, V57, P895, DOI 10.1111/j.1751-1097.1993.tb09232.x; KIM ST, 1990, PHOTOCHEM PHOTOBIOL, V52, P789, DOI 10.1111/j.1751-1097.1990.tb08683.x; MURPHY CJ, 1993, SCIENCE, V262, P1025, DOI 10.1126/science.7802858; PAC CJ, 1990, PHOTOCHEM PHOTOBIOL, V52, P973, DOI 10.1111/j.1751-1097.1990.tb01813.x; PARK HW, 1995, SCIENCE, V268, P1866, DOI 10.1126/science.7604260; ROSEN MA, 1992, BIOCHEMISTRY-US, V31, P4015, DOI 10.1021/bi00131a017; RSTANDI RR, 1993, J AM CHEM SOC, V115, P2537; SANCAR A, 1994, BIOCHEMISTRY-US, V33, P2, DOI 10.1021/bi00167a001; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SITLANI A, 1992, J AM CHEM SOC, V114, P2303, DOI 10.1021/ja00033a003; SITLANI A, 1994, BIOCHEMISTRY-US, V33, P12100, DOI 10.1021/bi00206a013; TAYLOR JS, 1990, BIOCHEMISTRY-US, V29, P8858, DOI 10.1021/bi00489a049; TAYLOR JS, 1994, ACCOUNTS CHEM RES, V27, P76, DOI 10.1021/ar00039a003; Turro C, 1996, INORG CHIM ACTA, V243, P101, DOI 10.1016/0020-1693(95)04896-0; VASSYLYEV DG, 1995, CELL, V83, P773, DOI 10.1016/0092-8674(95)90190-6; WACHTER L, 1986, NUCLEIC ACIDS RES, V14, P7985, DOI 10.1093/nar/14.20.7985; YEH SR, 1991, J AM CHEM SOC, V113, P8557, DOI 10.1021/ja00022a072; YOUNG T, 1990, PHOTOCHEM PHOTOBIOL, V52, P661, DOI 10.1111/j.1751-1097.1990.tb08664.x; [No title captured]	33	415	426	0	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 7	1997	275	5305					1465	1468		10.1126/science.275.5305.1465	http://dx.doi.org/10.1126/science.275.5305.1465			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WM081	9045609				2022-12-01	WOS:A1997WM08100042
J	Kirk, KE; Harmon, BP; Reichardt, IK; Sedat, JW; Blackburn, EH				Kirk, KE; Harmon, BP; Reichardt, IK; Sedat, JW; Blackburn, EH			Block in anaphase chromosome separation caused by a telomerase template mutation	SCIENCE			English	Article							TETRAHYMENA-THERMOPHILA; BUDDING YEAST; MITOSIS; REPLICATION; MICROSCOPY	Telomeres are essential for chromosome stability, but their functions at specific cell-cycle stages are unknown. Telomeres are now shown to have a role in chromosome separation during mitosis. In telomeric DNA mutants of Tetrahymena thermophila, created by expression of a telomerase RNA with an altered template sequence, division of the germline nucleus was severely delayed or blocked in anaphase, The mutant chromatids failed to separate completely at the midzone, becoming stretched io up to twice their normal length. These results suggest a physical block in mutant telomere separation.	UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026259, R01GM026259] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26259] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adl SM, 1996, J EUKARYOT MICROBIOL, V43, P77, DOI 10.1111/j.1550-7408.1996.tb04484.x; AGARD DA, 1989, METHOD CELL BIOL, V30, P353; Blackburn EH, 1995, TELOMERES; BRUNS PJ, 1983, GENETICS, V104, P257; Chen H, 1996, J STRUCT BIOL, V116, P56, DOI 10.1006/jsbi.1996.0010; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; DERNBURG AF, 1995, TELOMERES, P295; EARNSHAW WC, 1994, FASEB J, V8, P947, DOI 10.1096/fasebj.8.12.8088460; FANG G, 1995, TELOMERES, P69; FUNABIKI H, 1993, J CELL BIOL, V121, P961, DOI 10.1083/jcb.121.5.961; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; GAERTIG J, 1992, P NATL ACAD SCI USA, V89, P9196, DOI 10.1073/pnas.89.19.9196; Gall JG, 1986, MOL BIOL CILIATED PR; Gilley D, 1996, MOL CELL BIOL, V16, P66; HENDERSON E, 1995, TELOMERES, P11; HIRANO T, 1986, EMBO J, V5, P2973, DOI 10.1002/j.1460-2075.1986.tb04594.x; Hiraoka Y, 1991, Semin Cell Biol, V2, P153; HIRAOKA Y, 1990, BIOPHYS J, V57, P325, DOI 10.1016/S0006-3495(90)82534-0; HOLM C, 1994, CELL, V77, P955, DOI 10.1016/0092-8674(94)90433-2; KIRK KE, 1995, GENE DEV, V9, P59, DOI 10.1101/gad.9.1.59; KIRK KE, UNPUB; McEachern MJ, 1996, GENE DEV, V10, P1822, DOI 10.1101/gad.10.14.1822; MIYAZAKI WY, 1994, ANNU REV GENET, V28, P167, DOI 10.1146/annurev.ge.28.120194.001123; ROMERO DP, 1995, J EUKARYOT MICROBIOL, V42, P32, DOI 10.1111/j.1550-7408.1995.tb01537.x; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; WEINERT TA, 1992, RADIAT RES, V132, P141, DOI 10.2307/3578518; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; YANAGIDA N, 1995, BIOESSAYS, V17, P519, DOI 10.1002/bies.950170608; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0	29	187	192	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 7	1997	275	5305					1478	1481		10.1126/science.275.5305.1478	http://dx.doi.org/10.1126/science.275.5305.1478			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WM081	9045613				2022-12-01	WOS:A1997WM08100046
J	Bottcher, B; Wynne, SA; Crowther, RA				Bottcher, B; Wynne, SA; Crowther, RA			Determination of the fold of the core protein of hepatitis B virus ky electron cryomicroscopy	NATURE			English	Article							E-ANTIGEN; ESCHERICHIA-COLI; PARTICLES; IDENTIFICATION; MICROSCOPY; EPITOPES; REGIONS; SURFACE	Hepatitis B virus, a major human pathogen with an estimated 300 million carriers worldwide, can lead to cirrhosis and liver cancer in cases of chronic infection. The virus consists of an inner nucleocapsid or core, surrounded by a lipid envelope containing virally encoded surface proteins. The core protein, when expressed in bacteria, assembles into core shell particles, closely resembling the native core of the virus. Here we use electron cryomicroscopy to solve the structure of the core protein to 7.4 Angstrom resolution. Images of about 6,400 individual particles from 34 micrographs at different levels of defocus were combined, imposing icosahedral symmetry. The three-dimensional map reveals the complete fold of the polypeptide chain, which is quite unlike previously solved viral capsid proteins and is largely alpha-helical. The dimer clustering of subunits produces spikes on the surface of the shell, which consist of radial bundles of four long alpha-helices. Our model implies that the sequence corresponding to the immunodominant region of the core protein lies at the tip of the spike and also explains other properties of the core protein.	MRC,MOL BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND	MRC Laboratory Molecular Biology			Bottcher, Bettina/E-9397-2010	Bottcher, Bettina/0000-0002-7962-4849				BELLARE JR, 1988, J ELECTRON MICR TECH, V10, P87, DOI 10.1002/jemt.1060100111; BICHKO V, 1985, FEBS LETT, V185, P208, DOI 10.1016/0014-5793(85)80771-7; BIRNBAUM F, 1990, J VIROL, V64, P3319, DOI 10.1128/JVI.64.7.3319-3330.1990; BORISOVA G, 1993, J VIROL, V67, P3696, DOI 10.1128/JVI.67.6.3696-3701.1993; Bottcher B, 1996, STRUCTURE, V4, P387; BROWN AL, 1991, VACCINE, V9, P595, DOI 10.1016/0264-410X(91)90248-5; CHOTHIA C, 1990, ANNU REV BIOCHEM, V59, P1007, DOI 10.1146/annurev.bi.59.070190.005043; COHEN BJ, 1982, NATURE, V296, P677, DOI 10.1038/296677a0; CROWTHER RA, 1994, CELL, V77, P943, DOI 10.1016/0092-8674(94)90142-2; CROWTHER RA, 1971, PHILOS T R SOC B, V261, P221, DOI 10.1098/rstb.1971.0054; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; GALLINA A, 1989, J VIROL, V63, P4645, DOI 10.1128/JVI.63.11.4645-4652.1989; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KENNEY JM, 1995, STRUCTURE, V3, P1009, DOI 10.1016/S0969-2126(01)00237-4; Khudyakov YuE, 1991, Biomed Sci, V2, P257; NASSAL M, 1992, J MOL BIOL, V225, P1013, DOI 10.1016/0022-2836(92)90101-O; NASSAL M, 1993, J VIROL, V67, P4307, DOI 10.1128/JVI.67.7.4307-4315.1993; PASEK M, 1979, NATURE, V282, P575, DOI 10.1038/282575a0; PUSHKO P, 1994, VIROLOGY, V202, P912, DOI 10.1006/viro.1994.1413; SALFELD J, 1989, J VIROL, V63, P798, DOI 10.1128/JVI.63.2.798-808.1989; SCHODEL F, 1992, J VIROL, V66, P106; TAKAHASHI K, 1991, J IMMUNOL, V147, P3156; TAKAHASHI K, 1983, J IMMUNOL, V130, P2903; VANHEEL M, 1987, ULTRAMICROSCOPY, V21, P95, DOI 10.1016/0304-3991(87)90010-6; VIGERS GPA, 1986, THESIS U CAMBRIDGE; WASENAUER G, 1993, J VIROL, V67, P1315, DOI 10.1128/JVI.67.3.1315-1321.1993; WINGFIELD PT, 1995, BIOCHEMISTRY-US, V34, P4919, DOI 10.1021/bi00015a003; ZHENG J, 1992, J BIOL CHEM, V267, P9422; Zlotnick A, 1996, BIOCHEMISTRY-US, V35, P7412, DOI 10.1021/bi9604800	30	653	692	0	42	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 6	1997	386	6620					88	91		10.1038/386088a0	http://dx.doi.org/10.1038/386088a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WL746	9052786				2022-12-01	WOS:A1997WL74600057
J	Truong, DH; Hedemark, LL; Mickman, JK; Mosher, LB; Dietrich, SE; Lowry, PW				Truong, DH; Hedemark, LL; Mickman, JK; Mosher, LB; Dietrich, SE; Lowry, PW			Tuberculosis among Tibetan immigrants from India and Nepal in Minnesota, 1992-1995	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	36th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)	SEP 15-18, 1996	NEW ORLEANS, LA				MYCOBACTERIUM-TUBERCULOSIS; UNITED-STATES; REFUGEES	Objective.-To study screening outcomes among a group of Tibetan immigrants at high risk for developing active tuberculosis (TB) after arrival in Minnesota. Design.-Retrospective cohort study. Participants.-A total of 191 Tibetan immigrants undergoing medical screening. Main Outcome Measures.-Occurrence and treatment outcomes of active TB. Setting.-A health maintenance organization and a public TB clinic in Minneapolis, Minn. Results.-Positive (induration, greater than or equal to 10 mm) tuberculin skin test results were documented in 98% of Tibetans, compared with 44% of Vietnamese, 10% of Hmong, and 51% of Russian refugees in Minnesota (P<.001 for each group). Sixteen active cases (8.4%) were confirmed by isolation of Mycobacterium tuberculosis; however, 5 (31%) were culture-negative on initial screening in Minnesota. Seven cases (44%) were diagnosed during initial screening efforts, and 9 cases (56%) were diagnosed a mean of 19 months (range, 10-27 months) after their initial medical evaluation. Of these 9 cases, 6 (38% of all Tibetan cases) had isolates resistant to 1 or more antituberculous drugs, and 3 (19% of all Tibetan cases) were multidrug resistant (MDR TB). All 3 MDR TB cases were culture-negative on initial screening; these cases constituted 75% of the MDR TB isolates in Minnesota in 1994. The presence of MDR TB was associated with a known history of active TB in Asia (P<.02), Any abnormality on chest radiograph noted either during the Immigration and Naturalization Service screening evaluation in India (relative risk [RR], 5.2; P=.006) or on arrival in Minnesota (RR, 6.8; P=.005) was associated with an increased risk of subsequent active TB. Conclusions.-Tuberculosis infection is nearly universal among Tibetans settling in Minnesota, A single screening evaluation failed to detect the majority of TB cases among Tibetans. Even in the face of negative M tuberculosis cultures, persons with a history of active TB require particularly close follow-up.	UNIV MINNESOTA,SCH PUBL HLTH,INFECT DIS RES UNIT,DIV EPIDEMIOL,MINNEAPOLIS,MN 55454; UNIV MINNESOTA,SCH PUBL HLTH,DEPT MED,MINNEAPOLIS,MN 55454; UNIV MINNESOTA,SCH MED,MINNEAPOLIS,MN 55454; HEALTHPARTNERS INC,MINNEAPOLIS,MN; MICHIGAN DEPT COMMUNITY HLTH,LANSING,MI	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; MDHHS - Michigan Department of Health & Human Services								[Anonymous], 1990, MMWR Recomm Rep, V39, P1; BARNHOORN F, 1992, SOC SCI MED, V34, P291, DOI 10.1016/0277-9536(92)90271-Q; BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280; *CDCP, 1995, MMWR-MORBID MORTAL W, V44, P18; Centers for Disease Control and Prevention (CDC), 1996, MMWR Morb Mortal Wkly Rep, V45, P365; DOLIN PJ, 1994, B WORLD HEALTH ORGAN, V72, P213; Kenyon TA, 1996, NEW ENGL J MED, V334, P933, DOI 10.1056/NEJM199604113341501; MCKENNA MT, 1995, NEW ENGL J MED, V332, P1071, DOI 10.1056/NEJM199504203321606; *NAT OFF NY ASS NE, 1993, SEL NOT ART 1990 199; NOLAN CM, 1986, AM REV RESPIR DIS, V133, P431; NOLAN CM, 1989, AM REV RESPIR DIS, V140, P996, DOI 10.1164/ajrccm/140.4.996; ORMEROD P, 1991, MED INT, V90, P3746; POWELL KE, 1983, JAMA-J AM MED ASSOC, V249, P1455, DOI 10.1001/jama.249.11.1455; RIDZON R, 1993, 34 INT C ANT AG CHEM; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406, DOI 10.1128/JCM.31.2.406-409.1993; WARES DF, 1995, THORAX S2, V50, pA76	16	31	32	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 5	1997	277	9					735	738		10.1001/jama.277.9.735	http://dx.doi.org/10.1001/jama.277.9.735			4	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WK026	9042846				2022-12-01	WOS:A1997WK02600033
J	Hughes, PE; Renshaw, MW; Pfaff, M; Forsyth, J; Keivens, VM; Schwartz, MA; Ginsberg, MH				Hughes, PE; Renshaw, MW; Pfaff, M; Forsyth, J; Keivens, VM; Schwartz, MA; Ginsberg, MH			Suppression of integrin activation: A novel function of a Ras/Raf-initiated MAP kinase pathway	CELL			English	Article							OUT SIGNAL-TRANSDUCTION; CYTOPLASMIC DOMAINS; PROTEIN-KINASE; BETA(1) INTEGRIN; CELL-ADHESION; RAS; RECEPTOR; BINDING; TRANSFORMATION; RAF-1	Rapid modulation of ligand binding affinity (''activation'') is a central property of the integrin cell adhesion receptors. Using a screen for suppressors of integrin activation, we identified the small GTP-binding protein, H-Ras, and its effector kinase, Raf-l, as negative regulators of integrin activation. H-Ras inhibited the activation of integrins with three distinct alpha and beta subunit cytoplasmic domains. Suppression was not associated with integrin phosphorylation and was independent of both mRNA transcription and protein synthesis. Furthermore, suppression correlated with activation of the ERK MAP kinase pathway. Thus, regulation of integrin affinity state is a novel, transcription-independent function of a Ras-linked MAP kinase pathway that may mediate a negative feedback loop in integrin function.	Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute				schwartz, martin/0000-0002-2071-1243				ALIG L, 1992, J MED CHEM, V35, P4393, DOI 10.1021/jm00101a017; BLYSTONE SD, 1995, J CELL BIOL, V130, P745, DOI 10.1083/jcb.130.3.745; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEN YP, 1994, J BIOL CHEM, V269, P18307; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; Clark EA, 1996, J BIOL CHEM, V271, P14814, DOI 10.1074/jbc.271.25.14814; COX AD, 1994, ONCOGENE, V9, P3281; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DiazGonzalez F, 1996, MOL BIOL CELL, V7, P1939, DOI 10.1091/mbc.7.12.1939; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; HALL A, 1992, MOL BIOL CELL, V3, P475, DOI 10.1091/mbc.3.5.475; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; Hynes R O, 1978, Ann N Y Acad Sci, V312, P317, DOI 10.1111/j.1749-6632.1978.tb16811.x; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; JOHANSSON MW, 1994, J CELL BIOL, V126, P1299, DOI 10.1083/jcb.126.5.1299; KANEMITSU MY, 1993, MOL BIOL CELL, V4, P837, DOI 10.1091/mbc.4.8.837; KUIJPERS TW, 1993, J EXP MED, V178, P279, DOI 10.1084/jem.178.1.279; LAFLAMME SE, 1992, J CELL BIOL, V117, P437, DOI 10.1083/jcb.117.2.437; Law DA, 1996, J BIOL CHEM, V271, P10811, DOI 10.1074/jbc.271.18.10811; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LEVY JB, 1986, P NATL ACAD SCI USA, V83, P4228, DOI 10.1073/pnas.83.12.4228; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LUKASHEV ME, 1994, J BIOL CHEM, V269, P18311; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; OTOOLE TE, 1995, J BIOL CHEM, V270, P8553, DOI 10.1074/jbc.270.15.8553; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; Renshaw MW, 1996, CURR BIOL, V6, P76, DOI 10.1016/S0960-9822(02)00424-4; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cb.11.110195.003001; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; VASSBOTN FS, 1994, J BIOL CHEM, V269, P13874; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Williams Michael J., 1994, Trends in Cell Biology, V4, P109, DOI 10.1016/0962-8924(94)90059-0; WU CY, 1995, CELL, V83, P715, DOI 10.1016/0092-8674(95)90184-1; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X	46	437	444	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 21	1997	88	4					521	530		10.1016/S0092-8674(00)81892-9	http://dx.doi.org/10.1016/S0092-8674(00)81892-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WJ691	9038343	Bronze			2022-12-01	WOS:A1997WJ69100012
J	Jenkins, FA; Gatesy, SM; Shubin, NH; Amaral, WW				Jenkins, FA; Gatesy, SM; Shubin, NH; Amaral, WW			Haramiyids and Triassic mammalian evolution	NATURE			English	Article								Isolated teeth referred to the family Haramiyidae are among the earliest known fossil evidence of mammals. First discovered in European Late Triassic deposits a century and a half ago(1), haramiyids have been interpreted as related to multituberculates(2-7), a diverse and widespread lineage that occupied a rodent-like niche from the Late Jurassic to the Early Tertiary. Nonetheless, haramiyid relationships have remained enigmatic(8,9) because the orientation and position of the teeth in the upper or lower jaw could not be determined with certainty; even their mammalian status has been questioned(10). The discovery of haramiyid dentaries, a maxilla and other skeletal remains in the Upper Triassic of East Greenland reveals haramiyids as highly specialized mammals with a novel pattern of puncture-crushing occlusion that differs dramatically from the grinding or shearing mechanisms of other Early Mesozoic mammals.	HARVARD UNIV,MUSEUM COMPARAT ZOOL,CAMBRIDGE,MA 02138; BROWN UNIV,DEPT ECOL & EVOLUTIONARY BIOL,PROVIDENCE,RI 02912; UNIV PENN,DEPT BIOL,PHILADELPHIA,PA 19104	Harvard University; Brown University; University of Pennsylvania	Jenkins, FA (corresponding author), HARVARD UNIV,DEPT ORGANISM & EVOLUTIONARY BIOL,CAMBRIDGE,MA 02138, USA.							BUTLER PM, 1994, PHILOS T ROY SOC B, V345, P433, DOI 10.1098/rstb.1994.0119; Clemens W.A., 1979, P99; Clemens W.A., 1980, Zitteliana, V5, P51; CROMPTON A W, 1974, Bulletin of the British Museum (Natural History) Geology, V24, P397; CROMPTON AW, 1995, FUNCTIONAL MORPHOLOGY IN VERTEBRATE PALEONTOLOGY, P55; Gregory W. K., 1910, B AM MUS NAT HIST, V27, P1, DOI DOI 10.1007/S13364-013-0165-6; Hahn G., 1989, Geologica et Palaeontologica, V23, P205; Hahn G, 1969, PALAEONTOGR ABT A, V133, P1; Hahn G., 1978, GEOLOGICA PALAEONTOL, V12, P177; HAHN G, 1973, PALAEONTOGR ABT A, V142, P1; HENNIG EN, 1922, JB MIN GEOL PALAONT, V46, P181; JENKINS FA, 1976, PHILOS T ROY SOC B, V273, P387, DOI 10.1098/rstb.1976.0022; Jenkins Farish A. Jr, 1994, Meddelelser om Gronland Geoscience, V32, P1; Kermack DM, 1968, ZOOL J LINN SOC-LOND, V47, P407; KRAUSE DW, 1990, J PALEONTOL, V64, P1051, DOI 10.1017/S0022336000019922; KRAUSE DW, 1982, PALEOBIOLOGY, V8, P265, DOI 10.1017/S0094837300006989; MARSH OC, 1887, AM J SCI, V33, P327; Mills JRE, 1971, EARLY MAMMALS, V50, P29; Osborn H. F., 1888, J ACAD NAT SCI PHILA, V9, P186; PARRINGTON FR, 1947, P ZOOL SOC LOND, V116, P707; SIGOGNEAU-RUSSELL D, 1989, Palaeontographica Abteilung A Palaeozoologie-Stratigraphie, V206, P137; SIGOGNEAURUSSELL D, 1994, IN THE SHADOW OF THE DINOSAURS, P197; SIMMONS NB, 1993, MAMMAL PHYLOGENY, P146; Simpson G. G., 1947, Journal of Paleontology Menasha, V21, P497; SIMPSON G. G., 1928, CATALOGUE MESOZOIC M; VONPLIENINGER WHT, 1847, JH VER VATERL NATURK, P164	26	82	86	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 20	1997	385	6618					715	718		10.1038/385715a0	http://dx.doi.org/10.1038/385715a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WJ423	9034187				2022-12-01	WOS:A1997WJ42300044
J	Barbey, JT; Donahue, SR				Barbey, JT; Donahue, SR			Loading dose of digoxin	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											Barbey, JT (corresponding author), GEORGETOWN UNIV,MED CTR,DIV CLIN PHARMACOL,WASHINGTON,DC 20007, USA.							Hardman J. G., 1996, GOODMAN GILMANS PHAR; Kelly R A, 1992, Heart Dis Stroke, V1, P117; KELLY RA, 1992, AM J CARDIOL, V69, pG108, DOI 10.1016/0002-9149(92)91259-7; MCEVOY GK, 1995, AHFS DRUG INFORMATIO, P1026; OPIE LH, 1995, DRUGS HEART, P148; SMIT AJ, 1990, EUR J CLIN PHARMACOL, V38, P335, DOI 10.1007/BF00315571	6	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 19	1997	277	7					518	518		10.1001/jama.277.7.518	http://dx.doi.org/10.1001/jama.277.7.518			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH297	9032144				2022-12-01	WOS:A1997WH29700004
J	Woodcock, A				Woodcock, A			Use of spacers with metered dose inhalers	LANCET			English	Editorial Material							DEVICE				Woodcock, A (corresponding author), WYTHENSHAWE HOSP,NW LUNG CTR,MANCHESTER M23 9LT,LANCS,ENGLAND.			Woodcock, Ashley/0000-0002-5428-8578				Barry PW, 1996, THORAX, V51, P835, DOI 10.1136/thx.51.8.835; BARRY PW, 1994, EUR RESPIR J, V7, P1707, DOI 10.1183/09031936.94.07091707; BISGAARD H, 1995, EUR RESPIR J, V8, P856; Clark DJ, 1996, THORAX, V51, P981, DOI 10.1136/thx.51.10.981; KRAEMER R, 1991, AM REV RESPIR DIS, V144, P347, DOI 10.1164/ajrccm/144.2.347; Wildhaber JH, 1996, THORAX, V51, P985, DOI 10.1136/thx.51.10.985	6	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 15	1997	349	9050					446	446		10.1016/S0140-6736(05)61178-6	http://dx.doi.org/10.1016/S0140-6736(05)61178-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH389	9040569				2022-12-01	WOS:A1997WH38900004
J	Spector, MS; Desnoyers, S; Hoeppner, DJ; Hengartner, MO				Spector, MS; Desnoyers, S; Hoeppner, DJ; Hengartner, MO			Interaction between the C-elegans cell-death regulators CED-9 and CED-4	NATURE			English	Article							CAENORHABDITIS-ELEGANS; MEMBRANE PROTEIN; BCL-2; APOPTOSIS; ENCODES	Programmed cell death (apoptosis) is an evolutionarily conserved process used by multicellular organisms to eliminate cells that are not needed or are potentially detrimental to the organism(1,2). Members of the Bcl-2 family of mammalian proteins are intimately involved in the regulation of apoptosis, but, their precise mechanism of action remains unresolved(3-5). In Caenorhabditis elegans, the Bcl-2 homologue CED-9 prevents cell death by antagonizing the death-promoting activities of CED-3, a member of the Caspase family of death proteases, and of CED-4, a protein with no known mammalian homologue(6-9). Here we show that CED-9 interacts physically with CED-4. Mutations that reduce or eliminate CED-9 activity also disrupt its ability to bind CED-4, suggesting that this interaction is important for CED-9 function. Thus, CED-9 might control C. elegans cell death by binding to and regulating CED-4 activity. We propose that mammalian Bcl-2 family members might control apoptosis in a similar way through interaction and regulation of CED-4 homologues or analogues.	COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724; SUNY STONY BROOK,DEPT MOL MICROBIOL,GRAD PROGRAM GENET,STONY BROOK,NY 11794	Cold Spring Harbor Laboratory; State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook			Hengartner, Michael O/E-6235-2011; Hengartner, Michael O/A-7058-2008	Hengartner, Michael/0000-0002-7584-596X				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; CHENLEVY Z, 1989, MOL CELL BIOL, V9, P701, DOI 10.1128/MCB.9.2.701; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Farrow SN, 1996, CURR OPIN GENET DEV, V6, P45, DOI 10.1016/S0959-437X(96)90009-X; HACKER G, 1995, CURR BIOL, V5, P622, DOI 10.1016/S0960-9822(95)00126-6; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1994, NATURE, V369, P318, DOI 10.1038/369318a0; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HORVITZ HR, 1994, COLD SPRING HARB SYM, V59, P377, DOI 10.1101/SQB.1994.059.01.042; Hunter JJ, 1996, MOL CELL BIOL, V16, P877; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; Miller, 1972, EXPT MOL GENETICS; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Nagata S, 1996, CURR BIOL, V6, P1241, DOI 10.1016/S0960-9822(02)70706-9; Shaham S, 1996, CELL, V86, P201, DOI 10.1016/S0092-8674(00)80092-6; Shaham S, 1996, GENE DEV, V10, P578, DOI 10.1101/gad.10.5.578; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; VanAelst L, 1996, EMBO J, V15, P3778, DOI 10.1002/j.1460-2075.1996.tb00751.x; VANAELST L, IN PRESS METHODS MOL; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; YUAN JY, 1992, DEVELOPMENT, V116, P309; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	29	258	270	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 13	1997	385	6617					653	656		10.1038/385653a0	http://dx.doi.org/10.1038/385653a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WH294	9024666				2022-12-01	WOS:A1997WH29400055
J	Yiannakou, JY; Newland, P; Calder, F; Kingsnorth, AN; Rhodes, JM				Yiannakou, JY; Newland, P; Calder, F; Kingsnorth, AN; Rhodes, JM			Prospective study of CAM 17 center dot 1/WGA mucin assay for serological diagnosis of pancreatic cancer	LANCET			English	Article							SERUM; COMBINATION; ANTIGEN; DUPAN-2; DISEASE; CA19-9	Background Serological tests for pancreatic cancer are little used, partly because such assays have proved insufficiently specific for screening. However, retrospective studies have reported results that compare well with commonly used scanning techniques. In this prospective study we assessed a new type of combined lectin/antibody enzyme-linked mucin assay, CAM 17.1, in a routine clinical setting. Methods Clinicians at a 1200-bed teaching hospital were encouraged to request the CAM 17.1 assay for any patient whose differential diagnosis included pancreatic cancer. Serum samples from 250 patients were tested during an 18-month period. Patients were followed up for at least 8 months. 75 patients who did not have symptoms of pancreatic cancer and had alternative diagnoses were also studied as a control group. Findings Of the 250 patients, 36 had pancreatic cancer, as defined by histological and imaging criteria, and eight of these patients had a resectable tumour. The sensitivity and specificity of the CAM 17.1 assay were 86% and 91%, respectively, in all patients, 85% and 81% in those who presented with jaundice, and 89% and 94% in patients who did not have jaundice. The sensitivity of the assay compared well with that of ultrasound scanning (59%) and computed tomography (83%) in these patients. Use of the CAM 17.1 assay in combination with ultrasonography allowed identification of 94% of patients with pancreatic tumours and ail of those with resectable tumours. CAM 17.1 binding activity did not correlate with tumour size. Interpretation Our study confirms the usefulness of the CAM 17.1 tumour-marker assay for the diagnosis of pancreatic cancer. Serological mucin assays should be used more widely in combination with ultrasonography in the investigation of non-jaundiced patients with unexplained abdominal pain or weight loss.	UNIV LIVERPOOL, DEPT MED, LIVERPOOL L69 3GA, MERSEYSIDE, ENGLAND; UNIV LIVERPOOL, DEPT SURG, LIVERPOOL L69 3GA, MERSEYSIDE, ENGLAND; UNIV LIVERPOOL, DEPT CLIN CHEM, LIVERPOOL L69 3GA, MERSEYSIDE, ENGLAND	University of Liverpool; University of Liverpool; University of Liverpool			Rhodes, Jonathan M/C-2496-2009					BOVO P, 1993, ITAL J GASTROENTEROL, V25, P477; COOPER EH, 1990, BRIT J CANCER, V62, P1004, DOI 10.1038/bjc.1990.426; HAGLUND C, 1986, BRIT J CANCER, V53, P197, DOI 10.1038/bjc.1986.35; KAWA S, 1991, BRIT J CANCER, V64, P899, DOI 10.1038/bjc.1991.422; Malesci A, 1987, GASTROENTEROLOGY, V92, P60, DOI 10.1016/0016-5085(87)90840-7; MOLINA L M, 1990, International Journal of Biological Markers, V5, P127; MOOSSA AR, 1986, EXOCRINE PANCREAS BI, P713; PARKER N, 1992, CANCER, V70, P1062, DOI 10.1002/1097-0142(19920901)70:5<1062::AID-CNCR2820700509>3.0.CO;2-P; RAOUF A, 1991, GUT, V32, P1139, DOI 10.1136/gut.32.10.1139; RHODES JM, 1990, CANC PANCREAS, P833; RICHTER JM, 1989, ARCH INTERN MED, V149, P2292, DOI 10.1001/archinte.149.10.2292; STEINBERG WM, 1986, GASTROENTEROLOGY, V90, P343, DOI 10.1016/0016-5085(86)90930-3; THOMPSON JN, 1990, BRIT MED J, V301, P775, DOI 10.1136/bmj.301.6755.775; UMEYAMA K, 1988, J JPN PANC SOC, V3, P528	14	25	28	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 8	1997	349	9049					389	392		10.1016/S0140-6736(97)80011-6	http://dx.doi.org/10.1016/S0140-6736(97)80011-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH296	9033465				2022-12-01	WOS:A1997WH29600011
J	Tacke, M; Kiyosawa, K; Stark, K; Schlueter, V; OfenlochHaehnle, B; Hess, G; Engel, AM				Tacke, M; Kiyosawa, K; Stark, K; Schlueter, V; OfenlochHaehnle, B; Hess, G; Engel, AM			Detection of antibodies to a putative hepatitis G virus envelope protein	LANCET			English	Article								Background A flavivirus designated hepatitis G virus (HGV) has been isolated from the serum of patients with non-A-E hepatitis. Hitherto, the presence of HGV RNA in serum has been detected with the reverse transcription-polymerase chain reaction (RT-PCR) amplification method. We have now developed an immunoassay for antibodies against an HGV protein. Methods Recombinant HGV envelope protein E2 was used as antigen in an ELISA. 80 blood donors, 99 intravenous-drug users, and 11 patients with acute post-transfusion hepatitis were tested for antibodies to E2. The HGV-RNA status was assessed by RT-PCR. Findings Anti-E2 seroprevalence was 9% among the blood donors and 41% among the drug users; HGV-RNA prevalence was 2.5% and 38%, respectively. Whereas anti-E2 prevalence increased with the duration of drug use, HGV-RNA prevalence declined in parallel. In each group, the presence of anti-E2 and HGV RNA was almost mutually exclusive: none of the blood donors and only 4% of the drug users were positive for both markers at the same time. Of the 11 post-transfusion patients-who were all HGV-RNA positive and anti-E2 negative at the onset of disease-four developed antibodies to E2 during the following year, and two of the four subsequently became HGV-RNA negative. Interpretation We conclude that a humoral immune response to E2 is associated with loss of detectable HGV viraemia. Thus, E2-specific antibodies might serve as useful marker for diagnosing recovery from HGV infections The immunoassay we describe should facilitate investigation of suspected infections and may be helpful in the elucidation of the clinical significance of HGV.	SHINSHU UNIV,SCH MED,DEPT INTERNAL MED 2,MATSUMOTO,NAGANO 390,JAPAN; INST TROP MED,BERLIN,GERMANY	Shinshu University	Tacke, M (corresponding author), BOEHRINGER MANNHEIM GMBH,NONNENWALD 2,D-82377 PENZBERG,GERMANY.							ALTER HJ, 1994, VOX SANG, V67, P19, DOI 10.1111/j.1423-0410.1994.tb04539.x; Alter HJ, 1996, NEW ENGL J MED, V334, P1536, DOI 10.1056/NEJM199606063342310; Leary TP, 1996, J MED VIROL, V48, P60, DOI 10.1002/(SICI)1096-9071(199601)48:1&lt;60::AID-JMV10&gt;3.0.CO;2-A; LESNIEWSKI R, 1995, J MED VIROL, V45, P415, DOI 10.1002/jmv.1890450411; Linnen J, 1996, SCIENCE, V271, P505, DOI 10.1126/science.271.5248.505; Schlueter V, 1996, J CLIN MICROBIOL, V34, P2660, DOI 10.1128/JCM.34.11.2660-2664.1996; SIMONS JN, 1995, NAT MED, V1, P564, DOI 10.1038/nm0695-564; Stark K, 1996, J INFECT DIS, V174, P1320, DOI 10.1093/infdis/174.6.1320	8	321	323	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 1	1997	349	9048					318	320		10.1016/S0140-6736(96)06461-6	http://dx.doi.org/10.1016/S0140-6736(96)06461-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF794	9024375				2022-12-01	WOS:A1997WF79400011
J	The, I; Hannigan, GE; Cowley, GS; Reginald, S; Zhong, Y; Gusella, JF; Hariharan, IK; Bernards, A				The, I; Hannigan, GE; Cowley, GS; Reginald, S; Zhong, Y; Gusella, JF; Hariharan, IK; Bernards, A			Rescue of a Drosophila NF1 mutant phenotype by protein kinase A	SCIENCE			English	Article							GTPASE-ACTIVATING PROTEIN; RECEPTOR TYROSINE KINASE; NEUROFIBROMATOSIS TYPE-1; SEVENLESS PROTEIN; DEVELOPMENTAL ABNORMALITIES; GENE ENCODES; EGF RECEPTOR; CELL FATE; RAS; EXPRESSION	The neurofibromatosis type 1 (NF1) tumor suppressor protein is thought to restrict cell proliferation by functioning as a Ras-specific guanosine triphosphatase-activating protein. However, Drosophila homozygous for null mutations of an NF1 homolog showed no obvious signs of perturbed Ras1-mediated signaling, Loss of NF1 resulted in a reduction in size of larvae, pupae, and adults. This size defect was not modified by manipulating Ras1 signaling but was restored by expression of activated adenosine 3',5'-monophosphate-dependent protein kinase (PKA). Thus, NF1 and PKA appear to interact in a pathway that controls the overall growth of Drosophila.	MASSACHUSETTS GEN HOSP, CTR CANC, CHARLESTOWN, MA 02129 USA; HARVARD UNIV, SCH MED, CHARLESTOWN, MA 02129 USA; MASSACHUSETTS GEN HOSP, MOL NEUROGENET UNIT, CHARLESTOWN, MA 02129 USA; COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Massachusetts General Hospital; Cold Spring Harbor Laboratory			The, Inge/B-8884-2011; Hannigan, Greg/A-5092-2009	Zhong, Yi/0000-0001-7810-9899; Zhong, Yi/0000-0002-7927-5976	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036084, R01NS034779] Funding Source: NIH RePORTER; NINDS NIH HHS [NS36084, NS34779, NS22229] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BASLER K, 1989, SCIENCE, V243, P931, DOI 10.1126/science.2493159; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; BERNARDS A, 1995, BBA-REV CANCER, V1242, P43, DOI 10.1016/0304-419X(95)00003-X; BISHOP JG, 1988, GENE DEV, V2, P567, DOI 10.1101/gad.2.5.567; Bollag G, 1996, NAT GENET, V12, P144, DOI 10.1038/ng0296-144; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BRAND AH, 1994, GENE DEV, V8, P629, DOI 10.1101/gad.8.5.629; BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; Brill S, 1996, MOL CELL BIOL, V16, P4869; DALBY B, 1995, GENETICS, V139, P757; DANGLOT G, 1995, HUM MOL GENET, V4, P915, DOI 10.1093/hmg/4.5.915; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; DICKSON B, 1994, CURR OPIN GENET DEV, V4, P64, DOI 10.1016/0959-437X(94)90092-2; Dob[r]zhansky T., 1929, Archiv fuer Entwicklungsmechanik Berlin, V115, P363, DOI 10.1007/BF02078996; DUFFY JB, 1994, DEV BIOL, V166, P380, DOI 10.1006/dbio.1994.1324; ENGELS WR, 1986, FOCUS, V8, P6; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; Glantz SA., 1997, PRIMER BIOSTATISTICS; Guo HF, 1997, SCIENCE, V276, P795, DOI 10.1126/science.276.5313.795; GUTMANN DH, 1993, HUM MOL GENET, V2, P989; HART AC, 1990, GENE DEV, V4, P1835, DOI 10.1101/gad.4.11.1835; HENKEMEYER M, 1995, NATURE, V377, P695, DOI 10.1038/377695a0; HUSON SM, 1988, BRAIN, V111, P1355, DOI 10.1093/brain/111.6.1355; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092-8674(95)90510-3; KALDERON D, 1988, GENE DEV, V2, P1539, DOI 10.1101/gad.2.12a.1539; KIM HA, 1995, ONCOGENE, V11, P325; KONGSUWAN K, 1985, NATURE, V317, P555, DOI 10.1038/317555a0; LANE ME, 1993, GENE DEV, V7, P1229, DOI 10.1101/gad.7.7a.1229; Largaespada DA, 1996, NAT GENET, V12, P137, DOI 10.1038/ng0296-137; LI Y, 1995, GENOMICS, V25, P9, DOI 10.1016/0888-7543(95)80104-T; LINDSLEY DL, 1992, GENETICS BIOL DROSOP; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; MCCORMICK F, 1995, CURR OPIN GENET DEV, V5, P51, DOI 10.1016/S0959-437X(95)90053-5; MONTE P, 1989, BEHAV GENET, V19, P267, DOI 10.1007/BF01065910; NISHI T, 1991, ONCOGENE, V6, P1555; Patel N. H, 1994, DROSOPHILA MELANOGAS; Richards S, 1996, GENETICS, V142, P1215; ROGGE RD, 1991, CELL, V64, P39, DOI 10.1016/0092-8674(91)90207-F; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SKOULAKIS EMC, 1993, NEURON, V11, P197, DOI 10.1016/0896-6273(93)90178-T; WEHNER R, 1972, J INSECT PHYSIOL, V18, P1531, DOI 10.1016/0022-1910(72)90232-6; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9	45	187	194	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 2	1997	276	5313					791	794		10.1126/science.276.5313.791	http://dx.doi.org/10.1126/science.276.5313.791			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WW900	9115203				2022-12-01	WOS:A1997WW90000057
J	Fletcher, SW				Fletcher, SW			Whither scientific deliberation in health policy recommendations? Alice in the Wonderland of breast-cancer screening	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											Fletcher, SW (corresponding author), HARVARD UNIV,SCH MED,BOSTON,MA 02115, USA.							FLETCHER SW, 1993, J NATL CANCER I, V85, P1644, DOI 10.1093/jnci/85.20.1644; *G C MERR, 1980, WEBST NEW COLL DICT; KOLATA G, 1997, NY TIMES        0224, pA1; Kolata G., 1997, NY TIMES        0128, pC1; Mathews Jessica, 1997, Washington Post, pA19; *NIH CONS STAT, 1997, BREAST CANC SCREEN W	6	104	104	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 17	1997	336	16					1180	1183		10.1056/NEJM199704173361612	http://dx.doi.org/10.1056/NEJM199704173361612			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU003	9099666				2022-12-01	WOS:A1997WU00300012
J	Waterworth, DM; Bennett, ST; Gharani, N; McCarthy, MI; Hague, S; Batty, S; Conway, GS; White, D; Todd, JA; Franks, S; Williamson, R				Waterworth, DM; Bennett, ST; Gharani, N; McCarthy, MI; Hague, S; Batty, S; Conway, GS; White, D; Todd, JA; Franks, S; Williamson, R			Linkage and association of insulin gene VNTR regulatory polymorphism with polycystic ovary syndrome	LANCET			English	Article							GROWTH FACTOR-I; OBESE WOMEN; LOCUS; HYPERANDROGENISM; SUSCEPTIBILITY; MINISATELLITE; ENDOCRINE; DISEASE; PATTERN; DEFECTS	Background Polycystic ovary syndrome (PCOS) is a common endocrine disorder affecting up to 10% of women of reproductive age. Women with anovulatory PCOS have hyperinsulinaemia, insulin resistance, and dyslipidaemia, and the syndrome is associated with greatly increased risks of non-insulin-dependent diabetes mellitus and cardiovascular disease and it often clusters in families. The VNTR (variable number of tandem repeats) locus upstream of the insulin gene (INS) regulates insulin expression. We have studied INS VNTR as a candidate genetic locus for susceptibility to PCOS. Methods We evaluated linkage of PCOS to the INS VNTR locus on chromosome 11p15.5 in 17 families with several cases, and looked for an association between VNTR and PCOS in two additional clinic populations. VNTR genotypes were designated I/I, I/III, and III/III and linkage disequilibrium mapping was used to test the primary role of the VNTR. Findings In a group of PCOS/male pattern baldness families, we obtained positive evidence for linkage to 11p15.5 (p = 0.002). The INS VNTR III/III genotype was associated with an increased risk of PCOS in two independent case-control studies (odds ratios 8.20 [p = 0.005] and 5.70 [p = 0.043]). Multilocus linkage disequilibrium mapping suggests that VNTR itself is the predisposing locus. Interpretation Mapping of susceptibility to PCOS to the INS VNTR implies that PCOS is due, in part, to an inherited alteration in insulin production, The data suggest a mechanistic link between type 2 diabetes and PCOS, which is a risk factor for diabetes later in life.	ST MARYS HOSP, UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, SCH MED, DEPT BIOCHEM & MOL GENET, LONDON W2 1PG, ENGLAND; ST MARYS HOSP, UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, SCH MED, DEPT OBSTET & GYNAECOL, LONDON W2 1PG, ENGLAND; ST MARYS HOSP, UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, SCH MED, METAB MED UNIT, LONDON W2 1PG, ENGLAND; UNIV OXFORD, NUFFIELD DEPT SURG, WELLCOME TRUST CTR HUMAN GENET, OXFORD OX3 7BN, ENGLAND; ROYAL CHILDRENS HOSP, MURDOCH INST, MELBOURNE, VIC, AUSTRALIA; MIDDLESEX HOSP, DEPT ENDOCRINOL, LONDON, ENGLAND	Imperial College London; Imperial College London; Imperial College London; University of Oxford; Wellcome Centre for Human Genetics; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; University of London; University College London			Todd, John A/A-3542-2010; McCarthy, Mark/M-3763-2015	Todd, John A/0000-0003-2740-8148; McCarthy, Mark/0000-0002-4393-0510	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADAMS J, 1986, BRIT MED J, V293, P355, DOI 10.1136/bmj.293.6543.355; BAIRD DT, 1977, J CLIN ENDOCR METAB, V45, P798, DOI 10.1210/jcem-45-4-798; Bennett ST, 1996, J AUTOIMMUN, V9, P415, DOI 10.1006/jaut.1996.0057; BENNETT ST, 1995, NAT GENET, V9, P284, DOI 10.1038/ng0395-284; Bennett ST, 1996, ANNU REV GENET, V30, P343, DOI 10.1146/annurev.genet.30.1.343; CAREY AH, 1993, CLIN ENDOCRINOL, V38, P653, DOI 10.1111/j.1365-2265.1993.tb02150.x; CONWAY GS, 1990, CLIN ENDOCRINOL, V33, P593; CONWAY GS, 1992, CLIN ENDOCRINOL, V37, P119, DOI 10.1111/j.1365-2265.1992.tb02295.x; DAHLGREN E, 1992, ACTA OBSTET GYN SCAN, V71, P599, DOI 10.3109/00016349209006227; DAHLGREN E, 1992, FERTIL STERIL, V57, P505; DUNAIF A, 1989, DIABETES, V38, P1165, DOI 10.2337/diabetes.38.9.1165; DUNAIF A, 1992, DIABETES, V41, P1257, DOI 10.2337/diabetes.41.10.1257; Dunaif A, 1996, J CLIN ENDOCR METAB, V81, P3299, DOI 10.1210/jc.81.9.3299; FRANKS S, 1995, NEW ENGL J MED, V333, P853, DOI 10.1056/NEJM199509283331307; GIDDINGS SJ, 1994, NAT GENET, V6, P310, DOI 10.1038/ng0394-310; HALES CN, 1992, DIABETOLOGIA, V35, P595, DOI 10.1007/BF00400248; HOLTE J, 1995, J CLIN ENDOCR METAB, V80, P2586, DOI 10.1210/jc.80.9.2586; KENNEDY GC, 1995, NAT GENET, V9, P293, DOI 10.1038/ng0395-293; KIDDY DS, 1992, CLIN ENDOCRINOL, V36, P105, DOI 10.1111/j.1365-2265.1992.tb02909.x; KIDDY DS, 1990, CLIN ENDOCRINOL, V32, P213, DOI 10.1111/j.1365-2265.1990.tb00857.x; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; LUCASSEN AM, 1995, HUM MOL GENET, V4, P501, DOI 10.1093/hmg/4.4.501; OMEARA NM, 1993, J CLIN ENDOCR METAB, V76, P1241, DOI 10.1210/jc.76.5.1241; Owerbach D, 1996, DIABETES, V45, P544, DOI 10.2337/diabetes.45.5.544; Poretsky L, 1994, ENDOCR REV, V2, P125; ROBINSON S, 1993, CLIN ENDOCRINOL, V39, P351, DOI 10.1111/j.1365-2265.1993.tb02376.x; SHARP PS, 1991, CLIN ENDOCRINOL, V35, P253, DOI 10.1111/j.1365-2265.1991.tb03531.x; TADOKORO K, 1991, NUCLEIC ACIDS RES, V19, P6967, DOI 10.1093/nar/19.24.6967; THOMSON G, 1995, AM J HUM GENET, V57, P487; Vafiadis P, 1996, J AUTOIMMUN, V9, P397, DOI 10.1006/jaut.1996.0054; WEAVER JU, 1992, EUR J CLIN INVEST, V22, P265, DOI 10.1111/j.1365-2362.1992.tb01461.x; Willis D, 1996, J CLIN ENDOCR METAB, V81, P302, DOI 10.1210/jc.81.1.302	32	242	258	0	12	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 5	1997	349	9057					986	990		10.1016/S0140-6736(96)08368-7	http://dx.doi.org/10.1016/S0140-6736(96)08368-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR621	9100625				2022-12-01	WOS:A1997WR62100011
J	Thome, M; Schneider, P; Hofmann, K; Fickenscher, H; Meinl, E; Neipel, F; Mattmann, C; Burns, K; Bodmer, JL; Schroter, M; Scaffidi, C; Krammer, PH; Peter, ME; Tschopp, J				Thome, M; Schneider, P; Hofmann, K; Fickenscher, H; Meinl, E; Neipel, F; Mattmann, C; Burns, K; Bodmer, JL; Schroter, M; Scaffidi, C; Krammer, PH; Peter, ME; Tschopp, J			Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors	NATURE			English	Article							INTERACTS; DOMAIN	Viruses have evolved many distinct strategies to avoid the host's apoptotic response(1,2). Here we describe a new family of viral inhibitors (v-FLIPs) which interfere with apoptosis signalled through death receptors(3) and which are present in several gamma-herpesviruses (including Kaposi's-sarcoma-associated human herpesvirus-8), as well as in the tumorigenic human molluscipoxvirus(4). v-FLIPs contain two death-effector domains which interact with the adaptor protein FADD(5,6) and this inhibits the recruitment and activation of the protease FLICE(7,8) by the CD95 death receptor(3). Cells expressing v-FLIPs are protected against apoptosis induced by CD95 or by the related death receptors TRAMP(9-12) and TRAIL-R. The herpesvirus saimiri FLIP is detected late during the lytic viral replication cycle, at a time when host cells are partially protected from CD95-ligand-mediated apoptosis, protection of virus-infected cells against death-receptor-induced apoptosis may lead to higher virus production and contribute to the persistence and oncogenicity(13) of several FLIP-encoding viruses.	UNIV LAUSANNE,INST BIOCHEM,CH-1066 EPALINGES,SWITZERLAND; SWISS INST EXPT CANC RES,BIL BIOMED RES CTR,CH-1066 EPALINGES,SWITZERLAND; UNIV ERLANGEN NURNBERG,INST CLIN & MOL VIROL,D-91054 ERLANGEN,GERMANY; GERMAN CANC RES CTR,TUMOR IMMUNOL PROGRAM,DIV IMMUNOGENET,D-69120 HEIDELBERG,GERMANY	University of Lausanne; Swiss Institute Experimental Cancer Research; University of Erlangen Nuremberg; Helmholtz Association; German Cancer Research Center (DKFZ)			Watzl, Carsten/B-4911-2013; Thome, Margot/F-8167-2011; Hofmann, Kay/D-6714-2011; Fickenscher, Helmut/A-3004-2010; Fickenscher, Helmut/J-9655-2019	Watzl, Carsten/0000-0001-5195-0995; Thome, Margot/0000-0002-5656-2139; Hofmann, Kay/0000-0002-2289-9083; Fickenscher, Helmut/0000-0003-0043-1153; Meinl, Edgar/0000-0002-2570-6785; Peter, Marcus Ernst/0000-0003-3216-036X; Schneider, Pascal/0000-0003-0677-9409				Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; Bodmer JL, 1997, IMMUNITY, V6, P79, DOI 10.1016/S1074-7613(00)80244-7; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Bucher P, 1996, COMPUT CHEM, V20, P3, DOI 10.1016/S0097-8485(96)80003-9; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Fickenscher H, 1996, J VIROL, V70, P6012, DOI 10.1128/JVI.70.9.6012-6019.1996; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; Huang DCS, 1997, ONCOGENE, V14, P405, DOI 10.1038/sj.onc.1200848; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; Marsters SA, 1996, CURR BIOL, V6, P1669, DOI 10.1016/S0960-9822(02)70791-4; MEDEMA J, IN PRESS EMBO J; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; RENSINGEHL A, 1995, EUR J IMMUNOL, V25, P2253, DOI 10.1002/eji.1830250821; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; Senkevich TG, 1996, SCIENCE, V273, P813, DOI 10.1126/science.273.5276.813; SHEN YQ, 1995, CURR OPIN GENET DEV, V5, P105, DOI 10.1016/S0959-437X(95)90061-6; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; Tschopp J, 1996, TRENDS MICROBIOL, V4, P91, DOI 10.1016/0966-842X(96)81522-8; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; YU GL, 1996, SCIENCE, V274, P990	30	902	947	0	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 3	1997	386	6624					517	521		10.1038/386517a0	http://dx.doi.org/10.1038/386517a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WR256	9087414	Green Submitted			2022-12-01	WOS:A1997WR25600058
J	Wagner, RM; Schleicher, DG				Wagner, RM; Schleicher, DG			The spectrum and spatial distribution of cyanogen in comet Hale-Bopp (C/1995 O1) at large heliocentric distance	SCIENCE			English	Article								Optical spectra of comet Hale-Bopp (C/1995 O1) at a heliocentric distance of 6.45 astronomical units showed emission from cyanogen gas. The spatial distribution of cyanogen was considerably more diffuse and extended compared to the spatial profile of the dust or grains which were sharply peaked near the center. This behavior is consistent with comets at smaller heliocentric distances suggesting the same or a similar formation mechanism, A cyanogen gas production rate of (1.2 +/- 0.3) x 10(26) molecules per second was derived. A model band profile derived from fluorescence equilibrium calculations for the comet's heliocentric velocity and distance agrees with the observed band profile.	LOWELL OBSERV,FLAGSTAFF,AZ 86001		Wagner, RM (corresponding author), OHIO STATE UNIV,DEPT ASTRON,174 W 18TH AVE,COLUMBUS,OH 43210, USA.							AHearn MF, 1995, ICARUS, V118, P223, DOI 10.1006/icar.1995.1190; BUS SJ, 1991, SCIENCE, V251, P774, DOI 10.1126/science.251.4995.774; COCHRAN AL, COMMUNICATION; COCHRAN AL, 1996, B AM ASTRON SOC, V28, P1093; Fitzsimmons A, 1996, MON NOT R ASTRON SOC, V278, pL37, DOI 10.1093/mnras/278.2.L37; GREEN D, 1995, 6191 IAU; HALE A, 1995, 6187 IAU; KLEINE M, 1994, ASTROPHYS J, V436, P885, DOI 10.1086/174966; RANDALL CA, UNPUB; RANDALL CE, 1992, B AM ASTRON SOC, V24, P1002; Schleicher DG, 1997, SCIENCE, V275, P1913, DOI 10.1126/science.275.5308.1913; SCHLEICHER DG, 1983, THESIS U MARYLAND; WAGNER RM, 1987, ASTROPHYS J, V322, P544, DOI 10.1086/165749; WAGNER RM, 1992, ASTR SOC P, V23, P160; WYCKOFF S, 1985, NATURE, V316, P241, DOI 10.1038/316241a0	15	12	12	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 28	1997	275	5308					1918	1920		10.1126/science.275.5308.1918	http://dx.doi.org/10.1126/science.275.5308.1918			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WQ513	9072965				2022-12-01	WOS:A1997WQ51300040
J	Park, HW; Boduluri, SR; Moomaw, JF; Casey, PJ; Beese, LS				Park, HW; Boduluri, SR; Moomaw, JF; Casey, PJ; Beese, LS			Crystal structure of protein farnesyltransferase at 2.25 angstrom resolution	SCIENCE			English	Article							GERANYLGERANYLTRANSFERASE TYPE-I; AWAMORI VAR X100; ALPHA-SUBUNIT; 2.2-ANGSTROM RESOLUTION; METAL REQUIREMENTS; KINETIC MECHANISM; PEPTIDE-BINDING; CDNA CLONING; FARNESYL; EXPRESSION	Protein farnesyltransferase (FTase) catalyzes the carboxyl-terminal lipidation of Ras and several other cellular signal transduction proteins, The essential nature of this modification for proper function of these proteins has led to the emergence of FTase as a target for the development of new anticancer therapy. Inhibition of this enzyme suppresses the transformed phenotype in cultured cells and causes tumor regression in animal models. The crystal structure of heterodimeric mammalian FTase was determined at 2.25 angstrom resolution. The structure shows a combination of two unusual domains: a crescent-shaped seven-helical hairpin domain and an alpha-alpha barrel domain, The active site is formed by two clefts that intersect at a bound zinc ion. One cleft contains a nine-residue peptide that may mimic the binding of the Ras substrate: the other cleft is lined with highly conserved aromatic residues appropriate for binding the farnesyl isoprenoid with required specificity.	DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MOL CANC BIOL,DURHAM,NC 27710	Duke University; Duke University			beese, lorena/G-4993-2010	Casey, Patrick/0000-0002-7366-9309	NIGMS NIH HHS [GM46372, GM52382] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM052382, R01GM052382, R01GM046372] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALESHIN A, 1992, J BIOL CHEM, V267, P19291; ALESHIN AE, 1994, J MOL BIOL, V238, P575, DOI 10.1006/jmbi.1994.1316; Alzari PM, 1996, STRUCTURE, V4, P265, DOI 10.1016/S0969-2126(96)00031-7; ANDRES DA, 1993, J BIOL CHEM, V268, P1383; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; *BIOS TECHN, 1993, INSIGHT, V2; BOGUSKI MS, 1992, NEW BIOL, V4, P408; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BUKHTIYAROV YE, 1995, J BIOL CHEM, V270, P19035, DOI 10.1074/jbc.270.32.19035; Buss JE, 1995, CHEM BIOL, V2, P787, DOI 10.1016/1074-5521(95)90083-7; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; CHEN WJ, 1993, J BIOL CHEM, V268, P9675; CHEN WJ, 1991, CELL, V66, P327, DOI 10.1016/0092-8674(91)90622-6; CHEN WJ, 1991, P NATL ACAD SCI USA, V88, P11368, DOI 10.1073/pnas.88.24.11368; Cowtan K., 1994, JT CCP4 ESF EACBM NE, V31, P34; CRISTIANSON DW, 1991, ADV PROTEIN CHEM, V42, P281; Fu HW, 1996, J BIOL CHEM, V271, P28541, DOI 10.1074/jbc.271.45.28541; FURFINE ES, 1995, BIOCHEMISTRY-US, V34, P6857, DOI 10.1021/bi00020a032; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; GLOMSET JA, 1994, ANNU REV CELL BIOL, V10, P181, DOI 10.1146/annurev.cellbio.10.1.181; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; Huang CC, 1997, J BIOL CHEM, V272, P20; JAININ J, 1988, J MOL BIOL, V204, P155; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; JAMES GL, 1995, J BIOL CHEM, V270, P6221, DOI 10.1074/jbc.270.11.6221; JONES TA, 1993, O VERSION 5 9 MANUAL; JUY M, 1992, NATURE, V357, P89, DOI 10.1038/357089a0; KNIGHT S, 1989, THESIS SWEDISH U AGR; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KOHL NE, 1995, NAT MED, V1, P792, DOI 10.1038/nm0895-792; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MOOMAW JF, 1992, J BIOL CHEM, V267, P17438; MOORES SL, 1991, J BIOL CHEM, V266, P14603; Nicholls A., 1992, GRASP GRAPHICAL REPR; OMER CA, 1993, BIOCHEMISTRY-US, V32, P5167, DOI 10.1021/bi00070a028; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; RAAG R, 1988, J MOL BIOL, V200, P553, DOI 10.1016/0022-2836(88)90542-6; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; REISS Y, 1992, J BIOL CHEM, V267, P6403; REISS Y, 1991, J BIOL CHEM, V266, P10672; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SCHAFER WR, 1992, ANNU REV GENET, V30, P209; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; STRADLEY SJ, 1993, BIOCHEMISTRY-US, V32, P12586, DOI 10.1021/bi00210a006; TARSHIS LC, 1994, BIOCHEMISTRY-US, V33, P10871, DOI 10.1021/bi00202a004; THUNNISSEN AMWH, 1994, NATURE, V367, P750, DOI 10.1038/367750a0; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; YING WL, 1994, J BIOL CHEM, V269, P470; YOKOYAMA K, 1995, BIOCHEMISTRY-US, V34, P1344, DOI 10.1021/bi00004a029; ZHANG FL, 1994, J BIOL CHEM, V269, P3175; ZHANG FL, 1994, J BIOL CHEM, V269, P23465; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	58	308	326	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 21	1997	275	5307					1800	1804		10.1126/science.275.5307.1800	http://dx.doi.org/10.1126/science.275.5307.1800			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WP056	9065406				2022-12-01	WOS:A1997WP05600044
J	vandeWetering, M; Cavallo, R; Dooijes, D; vanBeest, M; vanEs, J; Loureiro, J; Ypma, A; Hursh, D; Jones, T; Bejsovec, A; Peifer, M; Mortin, M; Clevers, H				vandeWetering, M; Cavallo, R; Dooijes, D; vanBeest, M; vanEs, J; Loureiro, J; Ypma, A; Hursh, D; Jones, T; Bejsovec, A; Peifer, M; Mortin, M; Clevers, H			Armadillo coactivates transcription driven by the product of the Drosophila segment polarity gene dTCF	CELL			English	Article							HMG BOX PROTEIN; CELL-ADHESION; MELANOGASTER; EXPRESSION; WINGLESS; MUTATIONS; PATTERN; EMBRYOGENESIS; CONNECTION; DOMINANT	The vertebrate transcription factors TCF (T cell factor) and LEF (lymphocyte enhancer binding factor) interact with beta-catenin and are hypothesized to mediate Wingless/Wnt signaling. We have cloned a maternally expressed Drosophila TCF family member, dTCF. dTCF binds a canonical TCF DNA motif and interacts with the beta-catenin homolog Armadillo. Previous studies have identified two regions in Armadillo required for Wingless signaling. One of these interacts with dTCF, while the other constitutes a transactivation domain. Mutations in dTCF and expression of a dominant-negative dTCF transgene cause a segment polarity phenotype and affect expression of the Wingless target genes engrailed and Ultrabithorax. Epistasis analysis positions dTCF downstream of armadillo. The Armadillo-dTCF complex mediates Wingless signaling as a bipartite transcription factor.	NCI, BIOCHEM LAB, NIH, BETHESDA, MD 20892 USA; AMERICAN UNIV, DEPT BIOL, WASHINGTON, DC 20016 USA; NORTHWESTERN UNIV, DEPT BIOCHEM MOL BIOL & CELL BIOL, EVANSTON, IL 60208 USA; UNIV N CAROLINA, DEPT BIOL & CURRICULUM GENET & MOL BIOL, CHAPEL HILL, NC 27599 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); American University; Northwestern University; University of North Carolina; University of North Carolina Chapel Hill	vandeWetering, M (corresponding author), UNIV UTRECHT HOSP, DEPT IMMUNOL, NL-3508 GA CHAPEL HILL, NETHERLANDS.		van+Es, Johan/ABD-5411-2021; Mortin, Mark A/B-4251-2008; Peifer, Mark/A-1152-2010	Bejsovec, Amy/0000-0002-8019-5789; Peifer, Mark/0000-0003-1412-3987; Hursh, Deborah/0000-0002-5614-7111	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007092] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07092] Funding Source: Medline; PHS HHS [47857] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARIAS AM, 1988, DEVELOPMENT, V103, P157; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; BIENZ M, 1994, TRENDS GENET, V10, P22, DOI 10.1016/0168-9525(94)90015-9; BRAND AH, 1993, DEVELOPMENT, V118, P401; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; Cox RT, 1996, J CELL BIOL, V134, P133, DOI 10.1083/jcb.134.1.133; DINARDO S, 1985, CELL, V43, P59, DOI 10.1016/0092-8674(85)90012-1; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; Florence B, 1997, DEVELOPMENT, V124, P839; FUNAYAMA N, 1995, J CELL BIOL, V128, P959, DOI 10.1083/jcb.128.5.959; HOCHMAN B, 1971, GENETICS, V67, P235; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; HURSH DA, 1993, DEVELOPMENT, V117, P1211; KLYMKOWSKY MW, 1995, CELL, V83, P5, DOI 10.1016/0092-8674(95)90226-0; KORINEK V, 1997, IN PRESS SCIENCE; LIN RL, 1995, CELL, V83, P599, DOI 10.1016/0092-8674(95)90100-0; Lindsley D.L., 1992, GENOME DROSOPHILA ME; LOCKE J, 1994, MOL GEN GENET, V243, P234, DOI 10.1007/BF00280321; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; MORIN PJ, 1997, IN PRESS SCIENCE; OOSTERWEGEL M, 1993, DEVELOPMENT, V118, P439; ORENIC T, 1987, DEV BIOL, V124, P50, DOI 10.1016/0012-1606(87)90458-1; ORENIC TV, 1990, GENE DEV, V4, P1053, DOI 10.1101/gad.4.6.1053; Orsulic S, 1996, CURR BIOL, V6, P1363, DOI 10.1016/S0960-9822(96)00731-2; Orsulic S, 1996, J CELL BIOL, V134, P1283, DOI 10.1083/jcb.134.5.1283; Pai LM, 1996, J BIOL CHEM, V271, P32411, DOI 10.1074/jbc.271.50.32411; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; PARR BA, 1994, CURR OPIN GENET DEV, V4, P523, DOI 10.1016/0959-437X(94)90067-D; PEIFER M, 1994, DEVELOPMENT, V120, P369; PEIFER M, 1995, TRENDS CELL BIOL, V5, P224, DOI 10.1016/S0962-8924(00)89015-7; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; PEIFER M, 1991, DEVELOPMENT, V111, P1029; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; RAY RP, 1991, DEVELOPMENT, V113, P35; ROBERTSON HM, 1988, GENETICS, V118, P461; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; RUBINFELD B, 1997, IN PRESS SCIENCE; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; SLUSARSKI DC, 1995, GENETICS, V139, P229; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; THURINGER F, 1993, P NATL ACAD SCI USA, V90, P3899, DOI 10.1073/pnas.90.9.3899; VANDEWETERING M, 1993, EMBO J, V12, P3847, DOI 10.1002/j.1460-2075.1993.tb06063.x; vandeWetering M, 1996, MOL CELL BIOL, V16, P745; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; VANLEEUWEN F, 1994, NATURE, V368, P342, DOI 10.1038/368342a0; Wang YS, 1996, J BIOL CHEM, V271, P4468; WIESCHAUS E, 1984, ROUX ARCH DEV BIOL, V193, P296, DOI 10.1007/BF00848158; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087; Yu X, 1996, DEVELOPMENT, V122, P849	53	1050	1063	1	37	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 21	1997	88	6					789	799		10.1016/S0092-8674(00)81925-X	http://dx.doi.org/10.1016/S0092-8674(00)81925-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WQ100	9118222	Bronze, Green Submitted			2022-12-01	WOS:A1997WQ10000011
J	Hasdai, D; Garratt, KN; Grill, DE; Lerman, A; Holmes, DR				Hasdai, D; Garratt, KN; Grill, DE; Lerman, A; Holmes, DR			Effect of smoking status on the long-term outcome after successful percutaneous coronary revascularization	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; RECEIVING THROMBOLYTIC THERAPY; CIGARETTE-SMOKING; ARTERY DISEASE; BYPASS-SURGERY; CASS REGISTRY; PTCA REGISTRY; HEART-DISEASE; RISK FACTOR; ANGIOPLASTY	Background Cigarette smoking is known to be deleterious to patients with coronary artery disease, but the effect of smoking on the clinical outcome of percutaneous coronary revascularization is unknown. Methods Patients who had undergone successful percutaneous coronary revascularization at the Mayo Clinic between 1979 and 1995 were divided into nonsmokers (n=2009), former smokers (those who had stopped smoking before the procedure, n=2259), quitters (those who stopped smoking after the procedure, n=435), and persistent smokers (those who smoked before and after the procedure, n=734). Results The maximal follow-up was 16 years (mean [+/-SD], 4.5+/-3.4). The nonsmokers and former smokers had similar base-line characteristics and outcomes. The quitters and persistent smokers were younger than the nonsmokers and former smokers and had more favorable clinical and angiographic characteristics. In analyses adjusted for confounding base-line characteristics, the persistent smokers had a greater relative risk of death (1.76 [95 percent confidence interval, 1.37 to 2.26]) and of Q-wave infarction (2.08 [95 percent confidence interval, 1.16 to 3.72]) than the nonsmokers. The quitters and persistent smokers were less likely than the nonsmokers to undergo additional percutaneous coronary procedures (relative risk, 0.80 [95 percent confidence interval, 0.64 to 0.98] and 0.67 [95 percent confidence interval, 0.56 to 0.81], respectively) or coronary bypass surgery (relative risk, 0.72 [95 percent confidence interval, 0.54 to 0.95] and 0.68 [95 percent confidence interval, 0.54 to 0.86], respectively). The persistent smokers were also at greater risk for death than the quitters (relative risk, 1.44 [95 percent confidence interval, 1.02 to 2.11]). Conclusions Patients who continued to smoke after successful percutaneous coronary revascularization were at greater risk for Q-wave infarction and death than nonsmokers. The cessation of smoking either before or after percutaneous revascularization was beneficial. Patients undergoing percutaneous revascularization should be encouraged to stop smoking. (C) 1997, Massachusetts Medical Society.	MAYO CLIN & MAYO FDN,DIV INTERNAL MED & CARDIOVASC DIS,ROCHESTER,MN 55905	Mayo Clinic								ARORA RR, 1990, CATHETER CARDIO DIAG, V19, P17, DOI 10.1002/ccd.1810190106; BARBASH GI, 1995, J AM COLL CARDIOL, V26, P1222, DOI 10.1016/0735-1097(95)00299-5; BARBASH GI, 1993, CIRCULATION, V87, P53, DOI 10.1161/01.CIR.87.1.53; BARBASH GI, 1995, EUR HEART J, V16, P313; BARRY J, 1989, JAMA-J AM MED ASSOC, V261, P398, DOI 10.1001/jama.261.3.398; BELL MR, 1990, J AM COLL CARDIOL, V16, P553, DOI 10.1016/0735-1097(90)90342-M; BLACKBURN H, 1960, CIRCULATION, V21, P1160, DOI 10.1161/01.CIR.21.6.1160; CAMPEAU L, 1976, CIRCULATION, V54, P522, DOI 10.1161/circ.54.3.947585; CAVENDER JB, 1992, J AM COLL CARDIOL, V20, P287, DOI 10.1016/0735-1097(92)90092-2; *CTR CHRON DIS PRE, 1989, DHHS PUBLICATION CDC; DETRE K, 1995, CIRCULATION, V91, P2868, DOI 10.1161/01.CIR.91.12.2868; EMOND M, 1994, CIRCULATION, V90, P2645, DOI 10.1161/01.CIR.90.6.2645; FOLTS JD, 1982, CIRCULATION, V65, P465, DOI 10.1161/01.CIR.65.3.465; FRIEDMAN GD, 1979, NEW ENGL J MED, V300, P213, DOI 10.1056/NEJM197902013000501; GALAN KM, 1988, AM J CARDIOL, V61, P260, DOI 10.1016/0002-9149(88)90927-7; GORDON T, 1974, LANCET, V2, P1345; GRINES CL, 1995, CIRCULATION, V91, P298, DOI 10.1161/01.CIR.91.2.298; HOLMES DR, 1984, AM J CARDIOL, V53, pC77, DOI 10.1016/0002-9149(84)90752-5; HOLMES DR, 1987, PERCUTANEOUS TRANSLU, P35; MARTIN JL, 1984, AM J CARDIOL, V54, P56, DOI 10.1016/0002-9149(84)90303-5; MYLER RK, 1987, CATHETER CARDIO DIAG, V13, P1, DOI 10.1002/ccd.1810130102; PENN A, 1981, CANCER RES, V41, P588; POWELL JT, 1994, BRIT MED J, V308, P607, DOI 10.1136/bmj.308.6929.607; ROSENBERG L, 1985, NEW ENGL J MED, V313, P1511, DOI 10.1056/NEJM198512123132404; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; RYAN TJ, 1993, CIRCULATION, V88, P2987, DOI 10.1161/01.CIR.88.6.2987; UNDERWOOD MJ, 1993, BMJ-BRIT MED J, V306, P1047, DOI 10.1136/bmj.306.6884.1047; VLIETSTRA RE, 1986, JAMA-J AM MED ASSOC, V255, P1023, DOI 10.1001/jama.255.8.1023; Voors AA, 1996, CIRCULATION, V93, P42, DOI 10.1161/01.CIR.93.1.42; Waters D, 1996, CIRCULATION, V94, P614, DOI 10.1161/01.CIR.94.4.614; WEINTRAUB WS, 1985, AM J CARDIOL, V55, P669, DOI 10.1016/0002-9149(85)90133-X	31	172	191	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 13	1997	336	11					755	761		10.1056/NEJM199703133361103	http://dx.doi.org/10.1056/NEJM199703133361103			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM640	9052653				2022-12-01	WOS:A1997WM64000003
J	Ross, GW; Abbott, RD; Petrovitch, H; Masaki, KH; Murdaugh, C; Trockman, C; Curb, JD; White, LR				Ross, GW; Abbott, RD; Petrovitch, H; Masaki, KH; Murdaugh, C; Trockman, C; Curb, JD; White, LR			Frequency and characteristics of silent dementia among elderly Japanese-American men - The Honolulu-Asia aging study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ALZHEIMERS-DISEASE CERAD; MULTI-INFARCT DEMENTIA; MILD SENILE DEMENTIA; NEUROPSYCHOLOGICAL ASSESSMENT; INFORMANT QUESTIONNAIRE; COGNITIVE DECLINE; STROKE; CONSORTIUM; DIAGNOSIS; ESTABLISH	Objective.-To determine the frequency of unrecognized dementia in a group of men found to have dementia by population survey, and to identify factors associated with the failure of a family informant to recognize significant memory impairment. Design and Setting.-The Honolulu-Asia Aging Study, a population-based study of dementia among elderly Japanese-American men living on the island of Oahu, Hawaii, Data for this study were from the dementia prevalence survey, 1991-1993. Study Participants.-A total of 191 noninstitutionalized men with dementia who had a reliable family informant. Main Outcome Measures.-Failure of family informants to recognize a problem with thinking or memory in subjects with dementia, Results.-A total of 21% of family informants failed to recognize a problem with memory among subjects subsequently found to have dementia, Among subjects with very mild dementia, 52% of family informants failed to recognize a significant memory problem compared with 13% among more severely demented subjects. Of the subjects with dementia whose family informants did recognize a memory problem, 53% failed to receive a medical evaluation for this problem. For all family informants, increasing age, fewer years of education, less severe dementia, fewer behavioral complications, fewer functional disabilities, and better performance on certain tests of memory and language were significantly associated with the family informant's failure to recognize a problem with memory, When the family informants were wives living with husbands, less severe dementia, fewer behavioral complications, fewer functional disabilities, and intact remote memory were associated with unrecognized dementia. Conclusions.-Unrecognized dementia was common in our population, especially among mild cases. Cognitive screening programs for the elderly and public education policies designed to increase awareness of early signs of dementia are needed if interventions for individuals with potentially treatable dementias are to be implemented.	DEPT VET AFFAIRS,HONOLULU,HI; UNIV VIRGINIA,DIV BIOSTAT,CHARLOTTESVILLE,VA; UNIV HAWAII,JOHN A BURNS SCH MED,DEPT MED,HONOLULU,HI 96822; KUAKINI MED CTR,HONOLULU ASIA AGING STUDY,HONOLULU,HI; NIA,BETHESDA,MD 20892; UNIV ARIZONA,COLL NURSING,TUCSON,AZ 85721	University of Virginia; University of Hawaii System; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University of Arizona					NIA NIH HHS [N01-AG-4-2149] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [N01AG042149] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BERG L, 1988, MT SINAI J MED, V55, P87; BLESSED G, 1968, BRIT J PSYCHIAT, V114, P797, DOI 10.1192/bjp.114.512.797; BRONNER LL, 1995, NEW ENGL J MED, V333, P1392, DOI 10.1056/NEJM199511233332106; CALLAHAN CM, 1995, ANN INTERN MED, V122, P422, DOI 10.7326/0003-4819-122-6-199503150-00004; CHIU HC, 1992, NEUROLOGY, V42, P473; COOPER PJ, 1993, J SAFETY RES, V24, P9, DOI 10.1016/0022-4375(93)90047-Q; CUMMINGS JL, 1992, DEMENTIA CLIN APPROA, P1; Dooneief G, 1996, NEUROLOGY, V46, P1746, DOI 10.1212/WNL.46.6.1746; DRICKAMER MA, 1992, NEW ENGL J MED, V326, P947, DOI 10.1056/NEJM199204023261410; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GRAVES AB, 1992, ALZHEIMERS DIS ADV C, P113; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Hasegawa K, 1983, AGING 80S, P207; HENDERSON VW, 1994, ARCH NEUROL-CHICAGO, V51, P896, DOI 10.1001/archneur.1994.00540210068014; Henon H, 1996, NEUROLOGY, V47, P852, DOI 10.1212/WNL.47.3.852-a; Hosmer DW, 2000, APPL LOGISTIC REGRES, V2nd; ISHIDA D, 1995, TRANSCULTURAL NURSIN, P317; JACOBS DM, 1995, NEUROLOGY, V45, P957, DOI 10.1212/WNL.45.5.957; JORM AF, 1989, PSYCHOL MED, V19, P1015, DOI 10.1017/S0033291700005742; JORM AF, 1991, PSYCHOL MED, V21, P785, DOI 10.1017/S0033291700022418; KAGAN A, 1994, STROKE, V25, P1170, DOI 10.1161/01.STR.25.6.1170; MASUR DM, 1994, NEUROLOGY, V44, P1427, DOI 10.1212/WNL.44.8.1427; MCDERMOTT JF, 1973, PEOPLE CULTURES HAWA; MCGEER PL, 1992, NEUROLOGY, V42, P447, DOI 10.1212/WNL.42.2.447; MCGLONE J, 1990, ARCH NEUROL-CHICAGO, V47, P1189, DOI 10.1001/archneur.1990.00530110043015; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MEYER JS, 1989, J AM GERIATR SOC, V37, P549, DOI 10.1111/j.1532-5415.1989.tb05688.x; MEYER JS, 1986, JAMA-J AM MED ASSOC, V256, P2203, DOI 10.1001/jama.256.16.2203; MORRIS JC, 1988, PSYCHOPHARMACOL BULL, V24, P641; MORRIS JC, 1989, NEUROLOGY, V39, P1159, DOI 10.1212/wnl.43.12.2457; MOSS MB, 1986, ARCH NEUROL-CHICAGO, V43, P239, DOI 10.1001/archneur.1986.00520030031008; PECK JC, 1982, ANN INTERN MED, V97, P231; Preston SH, 1994, DEMOGRAPHY AGING, P1; REISBERG B, 1987, J CLIN PSYCHIAT, V48, P9; RUBIN EH, 1989, ARCH NEUROL-CHICAGO, V46, P379, DOI 10.1001/archneur.1989.00520400033016; SAGAR HJ, 1988, BRAIN, V111, P525, DOI 10.1093/brain/111.3.525; SYME SL, 1975, AM J EPIDEMIOL, V102, P477, DOI 10.1093/oxfordjournals.aje.a112185; Tang MX, 1996, LANCET, V348, P429, DOI 10.1016/S0140-6736(96)03356-9; Teng E L, 1994, Int Psychogeriatr, V6, P45, DOI 10.1017/S1041610294001602; TENG EL, 1987, J CLIN PSYCHIAT, V48, P314; White L, 1996, JAMA-J AM MED ASSOC, V276, P955, DOI 10.1001/jama.276.12.955; WILLIAMS JBW, 1988, ARCH GEN PSYCHIAT, V45, P742	42	154	161	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 12	1997	277	10					800	805		10.1001/jama.277.10.800	http://dx.doi.org/10.1001/jama.277.10.800			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WM082	9052709				2022-12-01	WOS:A1997WM08200032
J	Mohl, DA; Gober, JW				Mohl, DA; Gober, JW			Cell cycle-dependent polar localization of chromosome partitioning proteins in Caulobacter crescentus	CELL			English	Article							UNIT-COPY MINIPLASMIDS; ESCHERICHIA-COLI; BACILLUS-SUBTILIS; P1 PLASMID; TRANSCRIPTIONAL ACTIVATOR; BACTERIAL CHROMOSOME; GEL-ELECTROPHORESIS; DAUGHTER CELLS; F-PLASMID; REPLICATION	In the bacterium C. crescentus, the cellular homologs of plasmid partitioning proteins, ParA and ParB, localize to both poles of the predivisional cell following the completion of DNA replication. pare binds to DNA sequences adjacent to the origin of replication suggesting that this region of the genome is tethered to the poles of the cell at a specific time in the cell cycle. Increasing the cellular levels of ParA and ParB disrupts polar localization and results in defects in both cell division and chromosome partitioning. These results suggest that ParA and ParB are involved in partitioning newly replicated chromosomes to the poles of the predivisional cell and may function as components of a bacterial mitotic apparatus.	UNIV CALIF LOS ANGELES,MOL BIOL INST,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles	Mohl, DA (corresponding author), UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,405 HILGARD AVE,LOS ANGELES,CA 90095, USA.				NIGMS NIH HHS [GM48417] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEY MRK, 1993, SCIENCE, V259, P1754, DOI 10.1126/science.8456303; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AUSTIN S, 1983, J MOL BIOL, V169, P373, DOI 10.1016/S0022-2836(83)80056-4; AUSTIN S, 1983, J MOL BIOL, V169, P353, DOI 10.1016/S0022-2836(83)80055-2; BEGG KJ, 1991, NEW BIOL, V3, P475; DARN M, 1994, J MOL BIOL, V236, P1289; DAVIS MA, 1992, MOL MICROBIOL, V6, P1141, DOI 10.1111/j.1365-2958.1992.tb01552.x; DAVIS MA, 1988, EMBO J, V7, P1881, DOI 10.1002/j.1460-2075.1988.tb03021.x; DEBOER PAJ, 1991, EMBO J, V10, P4371, DOI 10.1002/j.1460-2075.1991.tb05015.x; DINGWALL A, 1989, P NATL ACAD SCI USA, V86, P119, DOI 10.1073/pnas.86.1.119; ELY B, 1988, GENE, V68, P323, DOI 10.1016/0378-1119(88)90035-2; EVINGER M, 1977, J BACTERIOL, V132, P294, DOI 10.1128/JB.132.1.294-301.1977; GERDES K, 1986, J MOL BIOL, V190, P269, DOI 10.1016/0022-2836(86)90001-X; GOBER JW, 1995, MICROBIOL REV, V59, P31, DOI 10.1128/MMBR.59.1.31-47.1995; GOMES SL, 1984, J MOL BIOL, V178, P551, DOI 10.1016/0022-2836(84)90238-9; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HIRAGA S, 1992, ANNU REV BIOCHEM, V61, P283; HIRAGA S, 1989, J BACTERIOL, V171, P1496, DOI 10.1128/jb.171.3.1496-1505.1989; IRETON K, 1994, J BACTERIOL, V176, P5320, DOI 10.1128/JB.176.17.5320-5329.1994; MADDOCK JR, 1993, SCIENCE, V259, P1717; MARCZYNSKI GT, 1992, J MOL BIOL, V226, P959, DOI 10.1016/0022-2836(92)91045-Q; MARTIN KA, 1987, P NATL ACAD SCI USA, V84, P8544, DOI 10.1073/pnas.84.23.8544; MEISENZAHL AC, 1997, IN PRESS J BACTERIOL; MORI H, 1989, J BIOL CHEM, V264, P15535; MYSLIWIEC TH, 1991, J BACTERIOL, V173, P1911, DOI 10.1128/jb.173.6.1911-1919.1991; Nanninga N., 1985, MOL CYTOLOGY ESCHERI, P161; NIKI H, 1992, EMBO J, V11, P5101, DOI 10.1002/j.1460-2075.1992.tb05617.x; NIKI H, 1991, EMBO J, V10, P183, DOI 10.1002/j.1460-2075.1991.tb07935.x; OGASAWARA N, 1992, MOL MICROBIOL, V6, P629, DOI 10.1111/j.1365-2958.1992.tb01510.x; POINDEXTER JS, 1964, BACTERIOL REV, V28, P231, DOI 10.1128/MMBR.28.3.231-295.1964; ROTHFIELD LI, 1994, CELL, V77, P963, DOI 10.1016/0092-8674(94)90435-9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDHAUSER TJ, 1989, PLASMID, V21, P99, DOI 10.1016/0147-619X(89)90053-X; Sharpe ME, 1996, MOL MICROBIOL, V21, P501, DOI 10.1111/j.1365-2958.1996.tb02559.x; SHARPE ME, 1995, P NATL ACAD SCI USA, V92, P8630, DOI 10.1073/pnas.92.19.8630; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wake RG, 1995, ANNU REV GENET, V29, P41; WATANABE E, 1992, MOL GEN GENET, V234, P346, DOI 10.1007/BF00538693; WEBB CD, 1997, CELL; WINGROVE JA, 1994, GENE DEV, V8, P1839, DOI 10.1101/gad.8.15.1839; WINGROVE JA, 1993, GENE DEV, V7, P1979, DOI 10.1101/gad.7.10.1979; Wingrove JA, 1996, SCIENCE, V274, P597, DOI 10.1126/science.274.5287.597; WU LJ, 1995, GENE DEV, V9, P1316, DOI 10.1101/gad.9.11.1316; WU LJ, 1994, SCIENCE, V264, P572, DOI 10.1126/science.8160014	44	302	306	1	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 7	1997	88	5					675	684		10.1016/S0092-8674(00)81910-8	http://dx.doi.org/10.1016/S0092-8674(00)81910-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WM413	9054507				2022-12-01	WOS:A1997WM41300013
J	Farnet, CM; Bushman, FD				Farnet, CM; Bushman, FD			HIV-1 cDNA integration: Requirement of HMG I(Y) protein for function of preintegration complexes in vitro	CELL			English	Article							IMMUNODEFICIENCY-VIRUS INTEGRATION; SITE-SPECIFIC RECOMBINATION; DNA-BINDING DOMAIN; RETROVIRAL DNA; CIRCULAR DNA; CDC2 KINASE; VIRAL-DNA; PHAGE-MU; INVITRO; SEQUENCE	We present data indicating that a host protein is important for function of HIV-1 preintegration complexes (PICs) in vitro. PICs partially purified from infected cells were subjected to gel filtration in 600 mM KCl, which removed a factor required for integration without fully disrupting PICs. Addition of an extract from uninfected cells restored activity. Fractionation of the complementing activity yielded HMG IM, a nonhistone chromosomal protein important for transcriptional control and chromosomal architecture. Complementing activity could be isolated from PICs, and activity could be depleted from such fractions with an antibody against HMG IM. Recombinant HMG IM also complemented salt-stripped complexes. The finding that a host protein is required for integration by HIV PICs parallels findings in several well-studied transposition and site-specific recombination systems.			Farnet, CM (corresponding author), SALK INST BIOL STUDIES,10010 N TORREY PINES RD,LA JOLLA,CA 92024, USA.		Farnet, Chris/ABE-5463-2021	Farnet, Chris/0000-0003-4927-198X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037489, R01AI034786] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI 34786, R01 AI 37489] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aiyar A, 1996, J VIROL, V70, P3571, DOI 10.1128/JVI.70.6.3571-3580.1996; Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Berg D. E., 1989, MOBILE DNA; BROWN PO, 1987, CELL, V49, P347, DOI 10.1016/0092-8674(87)90287-X; BUKRINSKY MI, 1993, P NATL ACAD SCI USA, V90, P6125, DOI 10.1073/pnas.90.13.6125; BUSHMAN FD, 1990, J VIROL, V64, P5645, DOI 10.1128/JVI.64.11.5645-5648.1990; BUSHMAN FD, 1990, SCIENCE, V249, P1555, DOI 10.1126/science.2171144; BUSHMAN FD, 1991, P NATL ACAD SCI USA, V88, P1339, DOI 10.1073/pnas.88.4.1339; CRAIGIE R, 1990, CELL, V62, P829, DOI 10.1016/0092-8674(90)90126-Y; CRAIGIE R, 1987, CELL, V51, P493, DOI 10.1016/0092-8674(87)90645-3; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; DENG D, 1996, NATURE, V381, P661; DISNEY JE, 1989, J CELL BIOL, V109, P1975, DOI 10.1083/jcb.109.5.1975; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; ELLISON V, 1990, J VIROL, V64, P2711, DOI 10.1128/JVI.64.6.2711-2715.1990; ELTON TS, 1986, ANAL BIOCHEM, V157, P53, DOI 10.1016/0003-2697(86)90195-8; ELTON TS, 1987, BIOCHEM BIOPH RES CO, V143, P260, DOI 10.1016/0006-291X(87)90659-0; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; FAMET C, 1996, P NATL ACAD SCI USA, V93, P9742; FAMET CM, 1991, J VIROL, V65, P1910; FAMET CM, 1996, AIDS SA, V10, P3; FAMET CM, 1990, P NATL ACAD SCI USA, V87, P4164; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FUJIWARA T, 1989, P NATL ACAD SCI USA, V86, P3065, DOI 10.1073/pnas.86.9.3065; GALLAY P, 1995, CELL, V83, P569, DOI 10.1016/0092-8674(95)90097-7; Harlow E LD, 1988, ANTIBODIES LAB MANUA, V1st; JOHNSON RC, 1986, CELL, V46, P531, DOI 10.1016/0092-8674(86)90878-0; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; KANAAR R, 1986, BIOCHIM BIOPHYS ACTA, V866, P170, DOI 10.1016/0167-4781(86)90114-4; KATZ RA, 1990, CELL, V63, P87, DOI 10.1016/0092-8674(90)90290-U; KATZMAN M, 1989, J VIROL, V63, P5319, DOI 10.1128/JVI.63.12.5319-5327.1989; Lavoie BD, 1996, CELL, V85, P761, DOI 10.1016/S0092-8674(00)81241-6; LEE MS, 1994, P NATL ACAD SCI USA, V91, P9823, DOI 10.1073/pnas.91.21.9823; LEE YMH, 1990, J VIROL, V64, P5958, DOI 10.1128/JVI.64.12.5958-5965.1990; LEHMING N, 1994, NATURE, V371, P175, DOI 10.1038/371175a0; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; Maher JF, 1996, P NATL ACAD SCI USA, V93, P6716, DOI 10.1073/pnas.93.13.6716; MERKER P, 1993, COLD SPRING HARB SYM, V58, P505, DOI 10.1101/SQB.1993.058.01.057; NASH HA, 1990, TRENDS BIOCHEM SCI, V15, P222, DOI 10.1016/0968-0004(90)90034-9; Nash Howard A., 1996, P149; NISSEN MS, 1995, J BIOL CHEM, V270, P4355, DOI 10.1074/jbc.270.9.4355; NISSEN MS, 1991, J BIOL CHEM, V266, P19945; PAULL TT, 1994, BIOCHIMIE, V76, P992, DOI 10.1016/0300-9084(94)90024-8; REEVES R, 1993, J BIOL CHEM, V268, P21137; Reeves R, 1996, BIOCHEMISTRY-US, V35, P5063, DOI 10.1021/bi952424p; REEVES R, 1990, J BIOL CHEM, V265, P8573; REEVES R, 1987, P NATL ACAD SCI USA, V84, P6531, DOI 10.1073/pnas.84.18.6531; REEVES R, 1991, P NATL ACAD SCI USA, V88, P1671, DOI 10.1073/pnas.88.5.1671; ROTH MJ, 1989, CELL, V58, P47, DOI 10.1016/0092-8674(89)90401-7; Sambrook J., 1989, MOL CLONING LAB MANU; SANDERS C, 1974, BIOCHEM SOC T, V546, P546; SAVILAHTI H, 1995, EMBO J, V14, P4893, DOI 10.1002/j.1460-2075.1995.tb00170.x; SEGALL AM, 1994, EMBO J, V13, P4536, DOI 10.1002/j.1460-2075.1994.tb06775.x; SHERMAN PA, 1990, P NATL ACAD SCI USA, V87, P5119, DOI 10.1073/pnas.87.13.5119; Stevens SW, 1996, J VIROL, V70, P6459, DOI 10.1128/JVI.70.9.6459-6462.1996; STRAUSS F, 1984, CELL, V37, P889, DOI 10.1016/0092-8674(84)90424-0; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; THOMPSON JF, 1987, CELL, V50, P901, DOI 10.1016/0092-8674(87)90516-2; VARMUS H, 1989, MOBILE DNA, P53; VINCENT KA, 1990, NUCLEIC ACIDS RES, V18, P6045, DOI 10.1093/nar/18.20.6045; VINK C, 1990, J VIROL, V64, P5626, DOI 10.1128/JVI.64.11.5626-5627.1990; WOBBE CR, 1985, P NATL ACAD SCI USA, V82, P5710, DOI 10.1073/pnas.82.17.5710	64	267	283	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 21	1997	88	4					483	492		10.1016/S0092-8674(00)81888-7	http://dx.doi.org/10.1016/S0092-8674(00)81888-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WJ691	9038339	Bronze			2022-12-01	WOS:A1997WJ69100008
J	Klemm, RD; Austin, RJ; Bell, SP				Klemm, RD; Austin, RJ; Bell, SP			Coordinate binding of ATP and origin DNA regulates the ATPase activity of the origin recognition complex	CELL			English	Article							REPLICATION ORIGINS; T-ANTIGEN; SACCHAROMYCES-CEREVISIAE; CHROMOSOMAL REPLICATION; FUNCTIONAL ELEMENTS; YEAST; INITIATION; ORC; PROTEINS; SUBUNITS	The Origin Recognition Complex (ORC) is a six-protein assembly that specifies the sites of DNA replication initiation in S. cerevisiae. Origin recognition by ORC requires ATP. Here, we demonstrate that two subunits, Orc1p and Orc5p, bind ATP and that Orc1p also hydrolyzes ATP. ATP binding and hydrolysis by Orc1p are both regulated by origin DNA in a sequence-specific manner. ATP binding to Orc1p, but not ATP hydrolysis, is responsible for the ATP dependence of the ORC-origin interaction, indicating that ATP is a cofactor that locks ORC on origin DNA. These data demonstrate that occupancy of the Orc1p ATP-binding site has a profound effect on ORC function and that ATP hydrolysis by Orc1p has the potential to drive transitions between different functional states of ORC.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT)				Bell, Stephen/0000-0002-2876-610X	NIGMS NIH HHS [(GM18170), (GM52339)] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER TA, 1992, ANNU REV GENET, V26, P447; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1995, CURR OPIN GENET DEV, V5, P162, DOI 10.1016/0959-437X(95)80003-4; BELL SP, 1995, CELL, V83, P563, DOI 10.1016/0092-8674(95)90096-9; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Carpenter PB, 1996, NATURE, V379, P357, DOI 10.1038/379357a0; Cocker JH, 1996, NATURE, V379, P180, DOI 10.1038/379180a0; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; DEAN FB, 1992, J BIOL CHEM, V267, P14129; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; Diffley TFX, 1996, GENE DEV, V10, P2819, DOI 10.1101/gad.10.22.2819; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; FOX CA, 1995, GENE DEV, V9, P911, DOI 10.1101/gad.9.8.911; GAVIN KA, 1995, SCIENCE, V270, P1667, DOI 10.1126/science.270.5242.1667; GOSSEN M, 1995, SCIENCE, V270, P1674, DOI 10.1126/science.270.5242.1674; Grallert B, 1996, GENE DEV, V10, P2644, DOI 10.1101/gad.10.20.2644; HALEY BE, 1991, METHOD ENZYMOL, V200, P477; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P2541, DOI 10.1093/nar/21.11.2541; Leatherwood J, 1996, NATURE, V379, P360, DOI 10.1038/379360a0; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; LOO S, 1995, MOL BIOL CELL, V6, P741, DOI 10.1091/mbc.6.6.741; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; MASTRANGELO IA, 1989, NATURE, V338, P658, DOI 10.1038/338658a0; MICKLEM G, 1993, NATURE, V366, P87, DOI 10.1038/366087a0; MuziFalconi M, 1995, P NATL ACAD SCI USA, V92, P12475, DOI 10.1073/pnas.92.26.12475; Piatti S, 1996, GENE DEV, V10, P1516, DOI 10.1101/gad.10.12.1516; RAO H, 1994, MOL CELL BIOL, V14, P7643, DOI 10.1128/MCB.14.11.7643; RAO H, 1995, P NATL ACAD SCI USA, V92, P2224, DOI 10.1073/pnas.92.6.2224; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; ROWLEY A, 1995, EMBO J, V14, P2631, DOI 10.1002/j.1460-2075.1995.tb07261.x; SKARSTAD K, 1994, BBA-GENE STRUCT EXPR, V1217, P111, DOI 10.1016/0167-4781(94)90025-6; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; Takahara K, 1996, GENOMICS, V31, P119, DOI 10.1006/geno.1996.0018; THEIS JF, 1994, MOL CELL BIOL, V14, P7652, DOI 10.1128/MCB.14.11.7652; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; ZWERSCHKE W, 1994, J BIOL CHEM, V269, P23351	41	203	205	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 21	1997	88	4					493	502		10.1016/S0092-8674(00)81889-9	http://dx.doi.org/10.1016/S0092-8674(00)81889-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WJ691	9038340	Bronze			2022-12-01	WOS:A1997WJ69100009
J	Cooper, JP; Nimmo, ER; Allshire, RC; Cech, TR				Cooper, JP; Nimmo, ER; Allshire, RC; Cech, TR			Regulation of telomere length and function by a Myb-domain protein in fission yeast	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; RAP1; CELLS; END; ELONGATION; COMPONENT; STABILITY; POMBE	Telomeres, the specialized nucleoprotein structures that comprise the ends of eukaryotic chromosomes(1,2), are essential for complete replication(3-5), and regulation of their length has been a focus of research on tumorigenesis(6-8). In the budding yeast Saccharomyces cerevisiae, the protein Rap1p binds to telomeric DNA and functions in the regulation of telomere length(9-12). A human telomere protein, hTRF (human TTAGGG repeat factor) binds the telomere sequence in vitro(13) and localizes to telomeres cytologically(14), but its functions are not yet known. Here we use a genetic screen to identify a telomere protein in fission yeast, Taz1p (telomere-associated in Schizosaccharomycesrces pombe), that shares homology to the Myb proto-oncogene DNA-binding domain with hTRF. Disruption or deletion of the taz1(+) gene causes a massive increase in telomere length. Taz1p is required for the repression of telomere-adjacent gene expression and for normal meiosis or sporulation. It may be a negative regulator of the telomere-replicating enzyme, telomerase(1,3), or may protect against activation of telomerase-independent pathways of telomere elongation(8).	UNIV COLORADO, HOWARD HUGHES MED INST, DEPT CHEM & BIOCHEM, BOULDER, CO 80309 USA; WESTERN GEN HOSP, MRC, HUMAN GENET UNIT, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder; University of Edinburgh				Allshire, Robin/0000-0002-8005-3625; cooper, julia promisel/0000-0003-2171-2587				ALLSHIRE RC, 1995, SEMIN CELL BIOL, V6, P55, DOI 10.1016/1043-4682(95)90001-2; Bilaud T, 1996, NUCLEIC ACIDS RES, V24, P1294, DOI 10.1093/nar/24.7.1294; Blackburn EH, 1995, TELOMERES; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; CHIKASHIGE Y, 1994, SCIENCE, V264, P270, DOI 10.1126/science.8146661; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; CLARKE L, 1990, TRENDS GENET, V6, P150, DOI 10.1016/0168-9525(90)90149-Z; CONRAD MN, 1990, CELL, V63, P739, DOI 10.1016/0092-8674(90)90140-A; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HOHEISEL JD, 1993, CELL, V73, P109, DOI 10.1016/0092-8674(93)90164-L; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Konig P, 1996, CELL, V85, P125, DOI 10.1016/S0092-8674(00)81088-0; KYRION G, 1993, GENE DEV, V7, P1146, DOI 10.1101/gad.7.7a.1146; KYRION G, 1992, MOL CELL BIOL, V12, P5159, DOI 10.1128/MCB.12.11.5159; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; LINGNER J, 1995, SCIENCE, V269, P1533, DOI 10.1126/science.7545310; LIU ZP, 1991, GENE DEV, V5, P49, DOI 10.1101/gad.5.1.49; LOUIS EJ, 1994, GENETICS, V136, P789; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; LUSTIG AJ, 1990, SCIENCE, V250, P549, DOI 10.1126/science.2237406; MCEACHERN MJ, 1995, NATURE, V376, P403, DOI 10.1038/376403a0; MORENO S, 1991, METHOD ENZYMOL, V194, P795; NIMMO ER, 1994, EMBO J, V13, P3801, DOI 10.1002/j.1460-2075.1994.tb06691.x; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; Sugawara NF, 1989, THESIS HARVARD U; SUSSEL L, 1991, P NATL ACAD SCI USA, V88, P7749, DOI 10.1073/pnas.88.17.7749; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601; ZHONG Z, 1992, MOL CELL BIOL, V12, P4834, DOI 10.1128/MCB.12.11.4834	30	442	444	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 20	1997	385	6618					744	747		10.1038/385744a0	http://dx.doi.org/10.1038/385744a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WJ423	9034194				2022-12-01	WOS:A1997WJ42300052
J	vandeVen, CJM				vandeVen, CJM			Nasogastric enteral feeding in hyperemesis gravidarum!	LANCET			English	Editorial Material							HUMAN CHORIONIC-GONADOTROPIN; PREGNANCY; NAUSEA				vandeVen, CJM (corresponding author), UNIV MICHIGAN,CS MOTT CHILDRENS HOSP,DIV MATERNAL FETAL MED,ANN ARBOR,MI 48109, USA.							Barclay B A, 1990, Nutr Clin Pract, V5, P153, DOI 10.1177/0115426590005004153; GROSS S, 1989, AM J OBSTET GYNECOL, V160, P906, DOI 10.1016/0002-9378(89)90307-4; Hsu JJ, 1996, OBSTET GYNECOL, V88, P343, DOI 10.1016/0029-7844(96)00174-3; JARNFELTSAMSIOE A, 1983, GYNECOL OBSTET INVES, V16, P221; KAUPPILA A, 1979, BMJ-BRIT MED J, V1, P1670, DOI 10.1136/bmj.1.6179.1670; OBRIEN B, 1995, BIRTH-ISS PERINAT C, V22, P93, DOI 10.1111/j.1523-536X.1995.tb00566.x; SINGER AJ, 1991, AM J GASTROENTEROL, V86, P1695; SMITH CV, 1981, AM J OBSTET GYNECOL, V141, P180, DOI 10.1016/S0002-9378(16)32588-1; SOULES MR, 1980, OBSTET GYNECOL, V55, P696; Walsh JW, 1996, AM J PHYSIOL-GASTR L, V270, pG506, DOI 10.1152/ajpgi.1996.270.3.G506	10	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 15	1997	349	9050					445	446		10.1016/S0140-6736(05)61177-4	http://dx.doi.org/10.1016/S0140-6736(05)61177-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH389	9040568				2022-12-01	WOS:A1997WH38900003
J	Britton, TC				Britton, TC			Increased writing activity in neurological disease	LANCET			English	Editorial Material							HYPERGRAPHIA; HEMISPHERE; EPILEPSY				Britton, TC (corresponding author), UNIV LONDON KINGS COLL HOSP,NEUROSCI UNIT,DENMARK HILL,LONDON SE5 9RS,ENGLAND.							FRISONI GB, 1993, J NEUROL NEUROSUR PS, V56, P576, DOI 10.1136/jnnp.56.5.576-b; IMAMURA T, 1992, J NEUROL NEUROSUR PS, V55, P25, DOI 10.1136/jnnp.55.1.25; OKAMURA T, 1993, J NEUROL NEUROSUR PS, V56, P556, DOI 10.1136/jnnp.56.5.556; TRIMBLE MR, 1986, ASPECTS EPILEPSY PSY, P75; vanVugt P, 1996, J NEUROL NEUROSUR PS, V61, P510, DOI 10.1136/jnnp.61.5.510; WAXMAN SG, 1974, NEUROLOGY, V24, P629, DOI 10.1212/WNL.24.7.629; YAMADORI A, 1986, J NEUROL NEUROSUR PS, V49, P1160, DOI 10.1136/jnnp.49.10.1160	7	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 8	1997	349	9049					372	373		10.1016/S0140-6736(97)80004-9	http://dx.doi.org/10.1016/S0140-6736(97)80004-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH296	9033459				2022-12-01	WOS:A1997WH29600004
J	Burgess, DL; Jones, JM; Meisler, MH; Noebels, JL				Burgess, DL; Jones, JM; Meisler, MH; Noebels, JL			Mutation of the Ca2+ channel beta subunit gene Cchb4 is associated with ataxia and seizures in the lethargic (lh) mouse	CELL			English	Article							SENSITIVE CALCIUM-CHANNEL; FUNCTIONAL EXPRESSION; ELECTROPHYSIOLOGICAL PROPERTIES; THALAMIC NEURONS; SKELETAL-MUSCLE; RAT-BRAIN; ALPHA(1)-SUBUNIT; ALPHA-1-SUBUNIT; IDENTIFICATION; DEFICIENCY	Ca2+ channel beta subunits regulate voltage-dependent calcium currents through direct interaction with alpha(1) subunits. The beta- and alpha(1)-binding motifs are conserved, and all beta subunits can stimulate current amplitude, voltage dependence, and kinetics when coexpressed with various alpha(1) subunits. We used a positional candidate approach to determine that the ataxia and seizures in the lethargic (lh) mouse arise from mutation of the beta-subunit gene Cchb4 on mouse chromosome 2. A four-nucleotide insertion into a splice donor site results in exon skipping, translational frameshift, and protein truncation with loss of the alpha(1)-binding site. The lethargic phenotype is the first example of a mammalian neurological disease caused by an inherited defect in a non-pore-forming subunit of a voltage-gated ion channel.	UNIV MICHIGAN,SCH MED,DEPT HUMAN GENET,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan	Burgess, DL (corresponding author), BAYLOR COLL MED,DEPT NEUROL,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.		Tuluc, Petronel/C-2527-2011	Noebels, Jeffrey/0000-0002-2887-0839	NIGMS NIH HHS [GM24872] Funding Source: Medline; NINDS NIH HHS [NS29709, NS34509] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024872] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034509, R01NS029709] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AVANZINI G, 1989, J PHYSIOL-LONDON, V416, P111, DOI 10.1113/jphysiol.1989.sp017752; BROWNE DL, 1994, NAT GENET, V8, P136, DOI 10.1038/ng1094-136; BURGESS DL, 1995, NAT GENET, V10, P461, DOI 10.1038/ng0895-461; CASTELLANO A, 1994, BIOCHEM SOC T, V22, P483, DOI 10.1042/bst0220483; CASTELLANO A, 1993, J BIOL CHEM, V268, P12359; CATTERALL WA, 1991, SCIENCE, V253, P1499, DOI 10.1126/science.1654596; CHIN HM, 1995, GENOMICS, V28, P592, DOI 10.1006/geno.1995.1196; COULTER DA, 1989, J PHYSIOL-LONDON, V414, P587, DOI 10.1113/jphysiol.1989.sp017705; DEWAARD M, 1994, NEURON, V13, P495, DOI 10.1016/0896-6273(94)90363-8; DEWAARD M, 1995, J BIOL CHEM, V270, P12056, DOI 10.1074/jbc.270.20.12056; Dickie MM, 1964, MOUSE NEWS LETT, V30, P31; DUNG HC, 1977, TRANSPLANTATION, V23, P39, DOI 10.1097/00007890-197701000-00007; DUNG HC, 1971, TEX REP BIOL MED, V29, P273; DUNG HC, 1972, TEX REP BIOL MED, V30, P23; ELLINOR PT, 1993, NATURE, V363, P455, DOI 10.1038/363455a0; Fletcher CF, 1996, CELL, V87, P607, DOI 10.1016/S0092-8674(00)81381-1; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; HIDAKA Y, 1987, J CLIN INVEST, V80, P1409, DOI 10.1172/JCI113219; HOSFORD DA, 1992, SCIENCE, V257, P398, DOI 10.1126/science.1321503; HUGENARD JR, 1992, J NEUROSCI, V12, P3804; HUGUENARD JR, 1994, J NEUROSCI, V14, P5485; JAHNSEN H, 1984, J PHYSIOL-LONDON, V349, P205, DOI 10.1113/jphysiol.1984.sp015153; Kohrman DC, 1996, J BIOL CHEM, V271, P17576, DOI 10.1074/jbc.271.29.17576; LACERDA AE, 1991, NATURE, V352, P527, DOI 10.1038/352527a0; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; *MOUS GEN INF JACK, 1996, MOUS GEN DAT MGD 3 1; Murakami M, 1996, EUR J BIOCHEM, V236, P138, DOI 10.1111/j.1432-1033.1996.t01-1-00138.x; NAKAI K, 1994, GENE, V141, P171, DOI 10.1016/0378-1119(94)90567-3; Noebels J.L., 1982, NEUROSCIENCE, V7, P159; NOEBELS JL, 1979, SCIENCE, V204, P1334, DOI 10.1126/science.572084; OLCESE R, 1994, NEURON, V13, P1433, DOI 10.1016/0896-6273(94)90428-6; Ophoff RA, 1996, CELL, V87, P543, DOI 10.1016/S0092-8674(00)81373-2; PEREZREYES E, 1989, NATURE, V340, P233, DOI 10.1038/340233a0; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; SANKILA EM, 1992, NAT GENET, V1, P109, DOI 10.1038/ng0592-109; SATHER WA, 1993, NEURON, V11, P291, DOI 10.1016/0896-6273(93)90185-T; Sidman RL, 1965, CATALOG NEUROLOGICAL, P34; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; SNUTCH TP, 1990, P NATL ACAD SCI USA, V87, P3391, DOI 10.1073/pnas.87.9.3391; SOONG TW, 1993, SCIENCE, V260, P1133, DOI 10.1126/science.8388125; SOUTHARD JL, 1973, MOUSE NEWS LETT, V49, P32; STEA A, 1993, NEUROPHARMACOLOGY, V32, P1103, DOI 10.1016/0028-3908(93)90005-N; STEPHENS RM, 1992, J MOL BIOL, V228, P1124, DOI 10.1016/0022-2836(92)90320-J; TANAKA O, 1995, MOL BRAIN RES, V30, P1, DOI 10.1016/0169-328X(94)00265-G; TOMLINSON WJ, 1993, NEUROPHARMACOLOGY, V32, P1117, DOI 10.1016/0028-3908(93)90006-O; TSAKIRIDOU E, 1995, J NEUROSCI, V15, P3110, DOI 10.1523/jneurosci.15-04-03110.1995; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; VU TH, 1988, J IMMUNOL, V141, P3654; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; WILLIAMS ME, 1994, J BIOL CHEM, V269, P22347; Wiser O, 1996, FEBS LETT, V379, P15, DOI 10.1016/0014-5793(95)01475-6; WITCHER DR, 1993, SCIENCE, V261, P486, DOI 10.1126/science.8392754; ZHANG JF, 1993, NEUROPHARMACOLOGY, V32, P1075, DOI 10.1016/0028-3908(93)90003-L	54	349	358	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 7	1997	88	3					385	392		10.1016/S0092-8674(00)81877-2	http://dx.doi.org/10.1016/S0092-8674(00)81877-2			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WG479	9039265	Bronze			2022-12-01	WOS:A1997WG47900011
J	Palecek, SP; Loftus, JC; Ginsberg, MH; Lauffenburger, DA; Horwitz, AF				Palecek, SP; Loftus, JC; Ginsberg, MH; Lauffenburger, DA; Horwitz, AF			Integrin-ligand binding properties govern cell migration speed through cell-substratum adhesiveness	NATURE			English	Article							GLYCOPROTEIN-IIB-IIIA; FIBRONECTIN RECEPTOR; ADHESION; MOTILITY; LOCOMOTION; VITRONECTIN; FIBROBLASTS; ATTACHMENT; ANTIBODIES; DYNAMICS	Migration of cells in higher organisms is mediated by adhesion receptors, such as integrins, that link the cell to extracellular-matrix ligands, transmitting forces and signals necessary for locomotion(1-4). Whether cells will migrate or not on a given substratum, and also their speed, depends on several variables related to integrin-ligand interactions, including ligand levels(5,6), integrin levels(7-9), and integrin-ligand binding affinities(10-12). These and other(13) factors affect the way molecular systems integrate to effect and regulate cell migration. Here we show that changes in cell migration speed resulting from three separate variables-substratum ligand level, cell integrin expression level, and integrin-ligand binding affinity-are all quantitatively predictable through the changes they cause in a single unifying parameter: short-term cell-substratum adhesion strength. This finding is consistent with predictions of a mathematical model for cell migration(14). The ligand concentration promoting maximum migration speed decreases reciprocally as integrin expression increases. Increases in integrin-ligand affinity similarly result in maximal migration at reciprocally lower ligand concentrations. The maximum speed attainable, however, remains unchanged as ligand concentration, integrin expression, or integrin-ligand affinity vary, suggesting that integrin coupling with intracellular motors remains unaltered.	MIT, CTR BIOMED ENGN, CAMBRIDGE, MA 02139 USA; SCRIPPS RES INST, COMM VASC BIOL, LA JOLLA, CA 92037 USA; UNIV ILLINOIS, DEPT CELL & STRUCT BIOL, URBANA, IL 61801 USA	Massachusetts Institute of Technology (MIT); Scripps Research Institute; University of Illinois System; University of Illinois Urbana-Champaign	Palecek, SP (corresponding author), MIT, DEPT CHEM ENGN, CAMBRIDGE, MA 02139 USA.							ABERCROMBIE M, 1970, EXP CELL RES, V59, P393, DOI 10.1016/0014-4827(70)90646-4; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; BAJT ML, 1992, J BIOL CHEM, V267, P22211; BAUER JS, 1992, J CELL BIOL, V116, P477, DOI 10.1083/jcb.116.2.477; Cary LA, 1996, J CELL SCI, V109, P1787; Cheresh D.A., 1993, ADV MOL CELL BIOL, V6, P225; DIMILLA PA, 1993, J CELL BIOL, V122, P729, DOI 10.1083/jcb.122.3.729; DIMILLA PA, 1991, BIOPHYS J, V60, P15, DOI 10.1016/S0006-3495(91)82027-6; DUBAND JL, 1991, J CELL SCI, V98, P517; Dunn G A, 1983, Agents Actions Suppl, V12, P14; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GOODMAN SL, 1989, J CELL BIOL, V109, P799, DOI 10.1083/jcb.109.2.799; Huttenlocher A, 1996, J CELL BIOL, V134, P1551, DOI 10.1083/jcb.134.6.1551; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JAY PY, 1995, J CELL SCI, V108, P387; KEELY PJ, 1995, J CELL SCI, V108, P595; KUIJPERS TW, 1993, J EXP MED, V178, P279, DOI 10.1084/jem.178.1.279; LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; MARKS PW, 1991, J CELL BIOL, V112, P149, DOI 10.1083/jcb.112.1.149; Oliver Tim, 1994, Seminars in Cell Biology, V5, P139, DOI 10.1006/scel.1994.1018; Palecek SP, 1996, J CELL SCI, V109, P941; POWERS MJ, IN PRESS BIOTECHNOL; REGEN CM, 1992, J CELL BIOL, V119, P1347, DOI 10.1083/jcb.119.5.1347; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cb.11.110195.003001; Varner JA, 1996, CURR OPIN CELL BIOL, V8, P724, DOI 10.1016/S0955-0674(96)80115-3; WESSELS D, 1994, CELL MOTIL CYTOSKEL, V27, P1, DOI 10.1002/cm.970270102	30	1106	1137	2	131	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 6	1997	385	6616					537	540		10.1038/385537a0	http://dx.doi.org/10.1038/385537a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG235	9020360				2022-12-01	WOS:A1997WG23500048
J	Salisbury, C				Salisbury, C			Observational study of a general practice out of hours cooperative: Measures of activity	BRITISH MEDICAL JOURNAL			English	Article							NORMAL WORKING HOURS; PRIMARY-CARE; DEPUTIZING SERVICES; TELEPHONE ADVICE; HOURS WORKLOAD; HOURS CALLS; ORGANIZATION; EMERGENCY; ACCIDENT; RATES	Objective: Tb evaluate an out of hours cooperative of Department of general practitioners compared with a deputising Primary Health service. Design: Observational study of two services in overlapping geographical areas. Setting: A general practice cooperative in Kensington, Chelsea, and Westminster and a deputising service operating in that area and the neighbouring area of Brent and Harrow. Subjects: All patients contacting a doctor at either service in an eight week period beginning 1 September 1995. Main outcome measures: Patients' age and sex; rates of home visiting, telephone advice, and attendance at a primary centre; hospital admission rates prescribing rates; times of patient calls; and response times. Results: Data were collected on 5812 patient contacts. Doctors from the cooperative visited 32.0% (1253/3920) of patients, offered telephone advice to 57.8% (2267), and saw 7.1% (278) of patients at the primary care centre. By contrast, the deputising service visited 76.3% (1444/1892) of patients and gave telephone advice to 19.3% (365). Doctors from the cooperative prescribed drugs to fewer patients (37.6%; 1473/3915) than did the deputising service (51.7%; 941/1821) (odds ratio 0.56 (95% confidence interval 0.50 to 0.63) adjusted for age and sex) and admitted 8.5% (339/3888) of patients to hospital compared with 6.8% (128/1889) from the deputising service (odds ratio 1.30 (1.05 to 1.61) adjusted for age and sex). Response times for the deputising service were faster (median time to visit 65 minutes) than for the cooperative (median time to visit 75 minutes) but the time to first contact with a doctor was shorter for the cooperative because most people initially received telephone advice. Conclusions: The cooperative in this study dealt with patient contacts very differently from the way the deputising service dealt with contacts, fewer patients being visited and fewer receiving prescriptions. The data presented enable other out of hours services to compare their own performance using a standard data collection and analysis program.			Salisbury, C (corresponding author), ST MARYS HOSP,IMPERIAL COLL SCH MED,DEPT PRIMARY HLTH CARE & GEN PRACTICE,PRAED ST,LONDON W2 1PG,ENGLAND.		Salisbury, Chris/C-6724-2008	Salisbury, Chris/0000-0002-4378-3960				ANDALO D, 1996, GEN PRACTITIONE 0614, P89; BAIN DJG, 1984, BRIT MED J, V289, P471, DOI 10.1136/bmj.289.6443.471; BARDSLEY M, 1995, 1 E LOND CIT HLTH AU; BUXTON MJ, 1977, BRIT MED J, V1, P827, DOI 10.1136/bmj.1.6064.827; CRAGG DK, 1994, BRIT MED J, V309, P1627, DOI 10.1136/bmj.309.6969.1627; DALE J, 1992, BRIT J GEN PRACT, V42, P90; DALE J, 1995, BRIT MED J, V311, P423, DOI 10.1136/bmj.311.7002.423; *DEP HLTH, 1984, HCFP842; *DEP HLTH, 1995, AM STAT FEES ALL OUT; DIXON RA, 1988, BRIT MED J, V297, P1519, DOI 10.1136/bmj.297.6662.1519; DIXON RA, 1977, BRIT MED J, V1, P560, DOI 10.1136/bmj.1.6060.560; HALLAM L, 1994, BRIT MED J, V308, P249, DOI 10.1136/bmj.308.6923.249; HALLAM L, 1994, BRIT MED J, V309, P1621, DOI 10.1136/bmj.309.6969.1621; LIVINGSTONE AE, 1989, BRIT MED J, V299, P368, DOI 10.1136/bmj.299.6695.368; MARSH GN, 1987, J ROY COLL GEN PRACT, V37, P301; MCCARTHY M, 1990, BRIT J GEN PRACT, V40, P19; *NAT HLTH SERV EX, 1996, 1994 5 HLTH SERV IND; *OFF POP CENS SURV, 1996, MID POP EST 1994 GOV; *OFF POP CENS SURV, 1993, 1994 CENS COUNT REP; PITTS J, 1990, BRIT MED J, V300, P1113, DOI 10.1136/bmj.300.6732.1113; REYNOLDS M, 1995, PULSE           0311, P48; SHELDON MG, 1984, BRIT MED J, V289, P474, DOI 10.1136/bmj.289.6443.474	22	35	35	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 18	1997	314	7075					182	186		10.1136/bmj.314.7075.182	http://dx.doi.org/10.1136/bmj.314.7075.182			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WD911	9022433	Green Published			2022-12-01	WOS:A1997WD91100028
J	Kaisho, T; Schwenk, F; Rajewsky, K				Kaisho, T; Schwenk, F; Rajewsky, K			The roles of gamma 1 heavy chain membrane expression and cytoplasmic tail in IgG1 responses	SCIENCE			English	Article							CELL ANTIGEN RECEPTOR; B-CELLS; MONOCLONAL-ANTIBODIES; SWITCH RECOMBINATION; AFFINITY MATURATION; DEFICIENT MICE; MEMORY; LYMPHOCYTES; REPERTOIRE; ALPHA	In antibody responses, B cells switch from the expression of immunoglobulin (Ig) mu and delta heavy (H) chains to that of other Ig classes (alpha, gamma, or epsilon), each with a distinct effector function. Membrane-bound forms of alpha, gamma, and epsilon, but not mu and delta, have highly conserved cytoplasmic tails. Mutant mice unable to express membrane gamma 1 H chains or producing tailless gamma 1 H chains failed to generate efficient IgG1 responses and IgG1 memory. H chain membrane expression after class switching is thus required for these functions, and class switching equips the B cell antigen receptor with a regulatory cytoplasmic tail that naive B cells lack.	UNIV COLOGNE, INST GENET, D-50931 COLOGNE, GERMANY	University of Cologne			Kaisho, Tsuneyasu/B-4130-2012	Rajewsky, Klaus/0000-0002-6633-6370				Achatz G, 1997, SCIENCE, V276, P409, DOI 10.1126/science.276.5311.409; ASSENMACHER M, 1994, EUR J IMMUNOL, V24, P1097, DOI 10.1002/eji.1830240513; ESSER C, 1990, ANNU REV IMMUNOL, V8, P717, DOI 10.1146/annurev.iy.08.040190.003441; Ferradini L, 1996, SCIENCE, V271, P1416, DOI 10.1126/science.271.5254.1416; Forster I, 1989, Int Immunol, V1, P321, DOI 10.1093/intimm/1.4.321; GRUTZMAN R, 1981, THESIS U COLOGNE GER; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; HONJO T, 1979, CELL, V18, P559, DOI 10.1016/0092-8674(79)90072-2; JUNG S, 1993, SCIENCE, V259, P984, DOI 10.1126/science.8438159; KAISHO T, UNPUB; KIM KJ, 1979, J IMMUNOL, V122, P549; KIM KM, 1993, EUR J IMMUNOL, V23, P911, DOI 10.1002/eji.1830230422; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LAYTON JE, 1984, J EXP MED, V160, P1850, DOI 10.1084/jem.160.6.1850; LIU YJ, 1995, IMMUNITY, V2, P239, DOI 10.1016/1074-7613(95)90048-9; OI VT, 1979, MOL IMMUNOL, V16, P1005, DOI 10.1016/0161-5890(79)90034-8; OKUMURA K, 1976, EUR J IMMUNOL, V6, P467, DOI 10.1002/eji.1830060704; PULENDRAN B, 1995, J IMMUNOL, V155, P1141; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.immunol.10.1.97; RETH M, 1978, EUR J IMMUNOL, V8, P393, DOI 10.1002/eji.1830080605; ROES J, 1995, J IMMUNOL METHODS, V183, P231, DOI 10.1016/0022-1759(95)00059-J; ROES J, 1993, J EXP MED, V177, P45, DOI 10.1084/jem.177.1.45; Schwenk F, 1995, NUCLEIC ACIDS RES, V23, P5080, DOI 10.1093/nar/23.24.5080; SHAN H, 1990, J EXP MED, V172, P531, DOI 10.1084/jem.172.2.531; VENKITARAMAN AR, 1991, NATURE, V352, P777, DOI 10.1038/352777a0; WEISER P, 1994, EUR J IMMUNOL, V24, P665, DOI 10.1002/eji.1830240327; Weiser P, 1997, SCIENCE, V276, P407, DOI 10.1126/science.276.5311.407; WEISS U, 1990, J EXP MED, V172, P1681, DOI 10.1084/jem.172.6.1681	29	117	121	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 18	1997	276	5311					412	415		10.1126/science.276.5311.412	http://dx.doi.org/10.1126/science.276.5311.412			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WU477	9103199				2022-12-01	WOS:A1997WU47700039
J	Olivetti, G; Abbi, R; Quaini, F; Kajstura, J; Cheng, W; Nitahara, JA; Quaini, E; DiLoreto, C; Beltrami, CA; Krajewski, S; Reed, JC; Anversa, P				Olivetti, G; Abbi, R; Quaini, F; Kajstura, J; Cheng, W; Nitahara, JA; Quaini, E; DiLoreto, C; Beltrami, CA; Krajewski, S; Reed, JC; Anversa, P			Apoptosis in the failing human heart	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MYOCARDIAL BLOOD-FLOW; GROWTH-FACTOR-I; CELL-DEATH; DILATED CARDIOMYOPATHY; PRESSURE-OVERLOAD; BCL-2; FAILURE; DISEASE; DNA; CARDIOMYOCYTES	Background Loss of myocytes is an important mechanism in the development of cardiac failure of either ischemic or nonischemic origin. However, whether programmed cell death (apoptosis) is implicated in the terminal stages of heart failure is not known. We therefore studied the magnitude of myocyte apoptosis in patients with intractable congestive heart failure. Methods Myocardial samples were obtained from the hearts of 36 patients who underwent cardiac transplantation and from the hearts of 3 patients who died soon after myocardial infarction. Samples from 11 normal hearts were used as controls. Apoptosis was evaluated histochemically, biochemically, and by a combination of histochemical analysis and confocal microscopy. The expression of two proto-oncogenes that influence apoptosis, BCL2 and BAX, was also determined. Results Heart failure was characterized morphologically by a 232-fold increase in myocyte apoptosis and biochemically by DNA laddering (an indicator of apoptosis). The histochemical demonstration of DNA-strand breaks in myocyte nuclei was coupled with the documentation of chromatin condensation and fragmentation by confocal microscopy. Ail these findings reflect apoptosis of myocytes. The percentage of myocytes labeled with BCL2 (which protects cells against apoptosis) was 1.8 times as high in the hearts of patients with cardiac failure as in the normal hearts, whereas labeling with BAX (which promotes apoptosis) remained constant. The near doubling of the expression of BCL2 in the cardiac tissue of patients with heart failure was confirmed by Western blotting. Conclusions Programmed death of myocytes occurs in the decompensated human heart in spite of the enhanced expression of BCL2 this phenomenon may contribute to the progression of cardiac dysfunction. (C) 1997, Massachusetts Medical Society.	NEW YORK MED COLL,DEPT MED,VALHALLA,NY 10595; NEW YORK MED COLL,DEPT PATHOL,VALHALLA,NY 10595; UNIV PARMA,DEPT PATHOL,I-43100 PARMA,ITALY; UNIV UDINE,DEPT PATHOL,I-33100 UDINE,ITALY; DE GASPERIS DIV CARDIAC SURG,MILAN,ITALY; BURNHAM INST,LA JOLLA,CA 92037	New York Medical College; New York Medical College; University of Parma; University Hospital of Parma; University of Udine; Sanford Burnham Prebys Medical Discovery Institute			Di Loreto, Carla/A-7529-2010; beltrami, carlo a/A-8026-2008	Quaini, Federico/0000-0003-2377-4810	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038132, R01HL039902, R01HL040561] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-38132, HL-39902, HL-40561] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANVERSA P, 1993, CARDIOVASC RES, V27, P145, DOI 10.1093/cvr/27.2.145; ARENDS MJ, 1990, AM J PATHOL, V136, P593; BELTRAMI CA, 1994, CIRCULATION, V89, P151, DOI 10.1161/01.CIR.89.1.151; BELTRAMI CA, 1995, J MOL CELL CARDIOL, V27, P291, DOI 10.1016/S0022-2828(08)80028-4; BENJAMIN IJ, 1989, CIRC RES, V65, P657, DOI 10.1161/01.RES.65.3.657; BING OHL, 1994, J MOL CELL CARDIOL, V26, P943, DOI 10.1006/jmcc.1994.1115; BUERKE M, 1995, P NATL ACAD SCI USA, V92, P8031, DOI 10.1073/pnas.92.17.8031; BURSCH W, 1992, TRENDS PHARMACOL SCI, V13, P245, DOI 10.1016/0165-6147(92)90077-J; CANNON PJ, 1977, PROG CARDIOVASC DIS, V20, P95, DOI 10.1016/0033-0620(77)90002-0; Cheng W, 1996, EXP CELL RES, V226, P316, DOI 10.1006/excr.1996.0232; CHENG W, 1995, J CLIN INVEST, V96, P2247, DOI 10.1172/JCI118280; Colucci WS, 1996, NEW ENGL J MED, V335, P1224, DOI 10.1056/NEJM199610173351610; GENG YJ, 1995, AM J PATHOL, V147, P251; GORCZYCA W, 1993, CANCER RES, V53, P1945; GOTTLIEB RA, 1994, J CLIN INVEST, V94, P1621, DOI 10.1172/JCI117504; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; ITOH G, 1995, AM J PATHOL, V146, P1325; James TN, 1996, CIRCULATION, V93, P1424, DOI 10.1161/01.CIR.93.7.1424; Kajstura J, 1996, AM J PHYSIOL-HEART C, V271, pH1215, DOI 10.1152/ajpheart.1996.271.3.H1215; Kajstura J, 1996, LAB INVEST, V74, P86; KRAJEWSKI S, 1994, AM J PATHOL, V145, P515; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; Liu Y, 1995, LAB INVEST, V73, P771; Mallat Z, 1996, NEW ENGL J MED, V335, P1190, DOI 10.1056/NEJM199610173351604; Narula J, 1996, NEW ENGL J MED, V335, P1182, DOI 10.1056/NEJM199610173351603; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; Olivetti G, 1996, J MOL CELL CARDIOL, V28, P2005, DOI 10.1006/jmcc.1996.0193; OLIVETTI G, 1995, J AM COLL CARDIOL, V26, P1068, DOI 10.1016/0735-1097(95)00282-8; OLIVETTI G, 1994, CARDIOVASC RES, V28, P1199, DOI 10.1093/cvr/28.8.1199; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; PARODI O, 1993, CIRCULATION, V88, P509, DOI 10.1161/01.CIR.88.2.509; RAKUSAN K, 1992, CIRCULATION, V86, P38, DOI 10.1161/01.CIR.86.1.38; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; RESNICOFF M, 1995, CANCER RES, V55, P2463; Sharov VG, 1996, AM J PATHOL, V148, P141; TANAKA M, 1994, CIRC RES, V75, P426, DOI 10.1161/01.RES.75.3.426; WALLENSTEIN S, 1980, CIRC RES, V47, P1, DOI 10.1161/01.RES.47.1.1; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440	39	1337	1402	2	48	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 17	1997	336	16					1131	1141		10.1056/NEJM199704173361603	http://dx.doi.org/10.1056/NEJM199704173361603			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU003	9099657				2022-12-01	WOS:A1997WU00300003
J	Moloney, DM; Wall, SA; Ashworth, GJ; Oldridge, M; Glass, IA; Francomano, CA; Muenke, M; Wilkie, AOM				Moloney, DM; Wall, SA; Ashworth, GJ; Oldridge, M; Glass, IA; Francomano, CA; Muenke, M; Wilkie, AOM			Prevalence of Pro250Arg mutation of fibroblast growth factor receptor 3 in coronal craniosynostosis	LANCET			English	Article							AUTOSOMAL-DOMINANT CRANIOSYNOSTOSIS; CROUZON-SYNDROME; PFEIFFER-SYNDROME; GENE CAUSE; FGFR2; FAMILY	Background The C749G (Pro250Arg) mutation in the gene for fibroblast growth factor receptor 3 (FGFR3) has been found in patients with various types of craniosynostosis. We aimed to find out the proportion of cases of apparently nonsyndromic coronal craniosynostosis attributable to this mutation. Methods We studied 26 patients with coronal craniosynostosis but no syndromic diagnosis, who were referred to a supra-regional specialist centre. Genomic DNA was analysed by PCR and restriction-enzyme digestion to identify the C749G mutation in FGFR3, Family members of patients found to have the mutation were also tested. Findings Eight (31%) of the 26 probands were heterozygous for the C749G mutation. In two cases, the mutation showed autosomal dominant transmission with evidence of variable expressivity; the remaining six cases were sporadic. We demonstrated in six families that the mutation had arisen de novo from clinically unaffected parents. Interpretation The C749G mutation in FGFR3 is a frequent cause of apparently non-syndromic coronal craniosynostosis. Our finding will aid genetic counselling and prenatal diagnosis. The mutation rate at this nucleotide is one of the highest described in the human genome.	JOHN RADCLIFFE HOSP,INST MOL MED,OXFORD OX3 9DS,ENGLAND; RADCLIFFE INFIRM,OXFORD CRANIOFACIAL UNIT,OXFORD OX2 6HE,ENGLAND; MT SINAI SCH MED,DEPT HUMAN GENET,NEW YORK,NY; NIH,MED GENET BRANCH,NATL CTR HUMAN GENOME RES,BETHESDA,MD 20892; CHILDRENS HOSP PHILADELPHIA,DIV HUMAN GENET & MOL BIOL,PHILADELPHIA,PA 19104	University of Oxford; Radcliffe Infirmary; Icahn School of Medicine at Mount Sinai; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Pennsylvania; Childrens Hospital of Philadelphia			Wilkie, Andrew/AAC-3820-2020	Wilkie, Andrew/0000-0002-2972-5481; Muenke, Maximilian/0000-0002-7719-6545	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BELLUS GA, 1995, AM J HUM GENET, V56, P368; Bellus GA, 1996, NAT GENET, V14, P174, DOI 10.1038/ng1096-174; CARTER CO, 1982, J MED GENET, V19, P280, DOI 10.1136/jmg.19.4.280; ElGhouzzi V, 1997, NAT GENET, V15, P42; Glass I A, 1994, Clin Dysmorphol, V3, P215; GOLLA A, IN PRESS J MED GENET; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HOLLWAY GE, 1995, HUM MOL GENET, V4, P681, DOI 10.1093/hmg/4.4.681; Howard TD, 1997, NAT GENET, V15, P36, DOI 10.1038/ng0197-36; HUNTER AGW, 1977, TERATOLOGY, V15, P301, DOI 10.1002/tera.1420150312; HUNTER AGW, 1976, TERATOLOGY, V14, P185, DOI 10.1002/tera.1420140209; JABS EW, 1994, NAT GENET, V8, P275, DOI 10.1038/ng1194-275; JABS EW, 1993, CELL, V75, P443, DOI 10.1016/0092-8674(93)90379-5; Lajeunie E, 1996, AM J MED GENET, V62, P282, DOI 10.1002/(SICI)1096-8628(19960329)62:3<282::AID-AJMG15>3.0.CO;2-G; LAJEUNIE E, 1995, NAT GENET, V9, P108, DOI 10.1038/ng0295-108; LAJEUNIE E, 1995, AM J MED GENET, V55, P500, DOI 10.1002/ajmg.1320550422; MEYERS GA, 1995, NAT GENET, V11, P462, DOI 10.1038/ng1295-462; Moloney DM, 1996, NAT GENET, V13, P48, DOI 10.1038/ng0596-48; Muenke M, 1997, AM J HUM GENET, V60, P555; MUENKE M, 1994, NAT GENET, V8, P269, DOI 10.1038/ng1194-269; REARDON W, 1994, NAT GENET, V8, P98, DOI 10.1038/ng0994-98; REARDON W, 1994, J MED GENET, V31, P393, DOI 10.1136/jmg.31.5.393; RUTLAND P, 1995, NAT GENET, V9, P173, DOI 10.1038/ng0295-173; SOMMER SS, 1995, TRENDS GENET, V11, P141, DOI 10.1016/S0168-9525(00)89028-9; vonGernet S, 1996, AM J MED GENET, V63, P177; WILKIE AOM, 1995, NAT GENET, V9, P165, DOI 10.1038/ng0295-165; Winter RM, 1996, LONDON DYSMORPHOLOGY	27	108	109	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 12	1997	349	9058					1059	1062		10.1016/S0140-6736(96)09082-4	http://dx.doi.org/10.1016/S0140-6736(96)09082-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU002	9107244				2022-12-01	WOS:A1997WU00200010
J	Zetterstrom, RH; Solomin, L; Jansson, L; Hoffer, BJ; Olson, L; Perlmann, T				Zetterstrom, RH; Solomin, L; Jansson, L; Hoffer, BJ; Olson, L; Perlmann, T			Dopamine neuron agenesis in Nurr1-deficient mice	SCIENCE			English	Article							NEUROTROPHIC FACTOR; BRAIN; DEHYDROGENASE; NURR1; BDNF	Dopamine neurons of the substantia nigra and ventral tegmental area regulate movement and affective behavior and degenerate in Parkinson's disease. The orphan nuclear receptor Nurr1 was shown to be expressed in developing dopamine neurons before the appearance of known phenotypic markers for these cells. Mice lacking Nurr1 failed to generate midbrain dopaminergic neurons, were hypoactive, and died soon after birth, Nurr1 expression continued into adulthood, and brains of heterozygous animals, otherwise apparently healthy, contained reduced dopamine levels. These results suggest that putative Nurr1 ligands may be useful for treatment of Parkinson's disease and other disorders of midbrain dopamine circuitry.	LUDWIG INST CANC RES,STOCKHOLM BRANCH,S-17177 STOCKHOLM,SWEDEN; KAROLINSKA INST,DEPT NEUROSCI,S-17177 STOCKHOLM,SWEDEN; NIDA,INTRAMURAL RES PROGRAM,NIH,BALTIMORE,MD 21224	Ludwig Institute for Cancer Research; Karolinska Institutet; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); NIH National Institute on Drug Abuse (NIDA)				Zetterstrom, Rolf/0000-0002-3016-0019				ANDERSSON H, 1995, NEUROTOXICOLOGY, V16, P201; Crossley PH, 1996, NATURE, V380, P66, DOI 10.1038/380066a0; DAGERLIND A, 1992, HISTOCHEMISTRY, V98, P39, DOI 10.1007/BF00716936; DAHLSTROM A, 1964, ACTA PHYSIOL SCAND, V62, P1; Danielian PS, 1996, NATURE, V383, P332, DOI 10.1038/383332a0; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; ERICSON J, 1995, CELL, V81, P747, DOI 10.1016/0092-8674(95)90536-7; ERNFORS P, 1994, NATURE, V368, P147, DOI 10.1038/368147a0; Fallon James H., 1995, P215; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; FOSTER GA, 1988, INT J DEV NEUROSCI, V6, P367, DOI 10.1016/0736-5748(88)90020-2; HOKFELT T, 1973, HISTOCHEMISTRY, V33, P231; Hokfelt T., 1984, HDB CHEM NEUROANATOM; HYMAN C, 1991, NATURE, V350, P230, DOI 10.1038/350230a0; HYNES M, 1995, NEURON, V15, P33; JONES KR, 1994, CELL, V76, P989, DOI 10.1016/0092-8674(94)90377-8; Joyner AL, 1993, GENE TARGETING PRACT; LAW SW, 1992, MOL ENDOCRINOL, V6, P2129, DOI 10.1210/me.6.12.2129; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; LINDAHL R, 1984, J BIOL CHEM, V259, P1991; LIU FC, 1992, J NEUROSCI, V12, P4281; MCCAFFERY P, 1994, P NATL ACAD SCI USA, V91, P7772, DOI 10.1073/pnas.91.16.7772; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; OLSON L, 1972, BRAIN RES, V44, P283, DOI 10.1016/0006-8993(72)90385-X; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; SANCHEZ MP, 1996, NATURE, V382, P73; SNYDERKELLER AM, 1991, J NEUROSCI, V11, P810; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; XU M, 1994, CELL, V79, P729, DOI 10.1016/0092-8674(94)90557-6; Zetterstrom RH, 1996, MOL BRAIN RES, V41, P111, DOI 10.1016/0169-328X(96)00074-5; Zetterstrom RH, 1996, MOL ENDOCRINOL, V10, P1656, DOI 10.1210/me.10.12.1656; Zhou QY, 1995, CELL, V83, P1197, DOI 10.1016/0092-8674(95)90145-0	34	871	919	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 11	1997	276	5310					248	250		10.1126/science.276.5310.248	http://dx.doi.org/10.1126/science.276.5310.248			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WT925	9092472				2022-12-01	WOS:A1997WT92500043
J	Agrawal, A; Schatz, DG				Agrawal, A; Schatz, DG			RAG1 and RAG2 form a stable postcleavage synaptic complex with DNA containing signal ends in V(D)J recombination	CELL			English	Article							STRAND-BREAK REPAIR; PROTEINS; REARRANGEMENT; ANTIBODIES; MECHANISM; SEQUENCES; BINDING; MUTANTS; SITE; GENE	During V(D)J recombination, RAG1 and RAG2 cleave DNA adjacent to highly conserved recombination signals, but nothing is known about the protein-DNA complexes that exist after cleavage. Using a properly regulated in vitro V(D)J cleavage system, together with nuclease sensitivity, mobility shift, and immunoprecipitation experiments, we provide evidence that a stable complex is formed postcleavage between synapsed recombination signals. This complex includes the proteins RAG1, RAG2, HMG-1 or the closely related HMG-2 protein, and the components of the DNA-dependent protein kinase. The existence of such a stable complex explains a number of in vivo observations and suggests that remodeling of postcleavage synaptic complexes is an important step in the resolution of signal ends in V(D)J recombination.	YALE UNIV, SCH MED, HOWARD HUGHES MED INST, NEW HAVEN, CT 06520 USA; YALE UNIV, SCH MED, DEPT PHARMACOL, NEW HAVEN, CT 06520 USA	Howard Hughes Medical Institute; Yale University; Yale University	Agrawal, A (corresponding author), YALE UNIV, SCH MED, IMMUNOBIOL SECT, 310 CEDAR ST, NEW HAVEN, CT 06520 USA.		Schatz, David/A-6748-2013	Schatz, David/0000-0002-5669-1176	NIAID NIH HHS [AI-07019, AI-32524] Funding Source: Medline; NIGMS NIH HHS [GM-07324] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032524] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BRUGGEMANN EP, 1991, BIOTECHNIQUES, V10, P202; BUSTIN M, 1989, METHOD ENZYMOL, V170, P214; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; Chaconas G, 1996, CURR BIOL, V6, P817, DOI 10.1016/S0960-9822(02)00603-6; Cortes P, 1996, P NATL ACAD SCI USA, V93, P14008, DOI 10.1073/pnas.93.24.14008; Difilippantonio MJ, 1996, CELL, V87, P253, DOI 10.1016/S0092-8674(00)81343-4; Eastman QM, 1996, NATURE, V380, P85, DOI 10.1038/380085a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Guidos CJ, 1996, GENE DEV, V10, P2038, DOI 10.1101/gad.10.16.2038; HLOM K, 1997, CELL, V88, P65; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; JOHNSON RC, 1986, CELL, V46, P531, DOI 10.1016/0092-8674(86)90878-0; Kovalenko OV, 1996, P NATL ACAD SCI USA, V93, P2958, DOI 10.1073/pnas.93.7.2958; Kruklitis R, 1996, EMBO J, V15, P935, DOI 10.1002/j.1460-2075.1996.tb00428.x; LEU TMJ, 1995, MOL CELL BIOL, V15, P5657; LEVCHENKO I, 1995, GENE DEV, V9, P2399, DOI 10.1101/gad.9.19.2399; LEWIS S, 1989, CELL, V59, P585, DOI 10.1016/0092-8674(89)90002-0; LEWIS SM, 1991, EMBO J, V10, P3631, DOI 10.1002/j.1460-2075.1991.tb04929.x; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; Li ZY, 1995, CELL, V83, P1079, DOI 10.1016/0092-8674(95)90135-3; LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9; Livak F, 1996, MOL CELL BIOL, V16, P609; Livak F, 1997, J MOL BIOL, V267, P1, DOI 10.1006/jmbi.1996.0834; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; NASH HA, 1990, TRENDS BIOCHEM SCI, V15, P222, DOI 10.1016/0968-0004(90)90034-9; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; ONATE SA, 1994, MOL CELL BIOL, V14, P3376, DOI 10.1128/MCB.14.5.3376; PAULL TT, 1993, GENE DEV, V7, P1521, DOI 10.1101/gad.7.8.1521; PERGOLA F, 1993, MOL CELL BIOL, V13, P3464, DOI 10.1128/MCB.13.6.3464; RAMSDEN DA, 1995, GENE DEV, V9, P2409, DOI 10.1101/gad.9.19.2409; ROTH DB, 1992, CELL, V69, P41, DOI 10.1016/0092-8674(92)90117-U; ROTH DB, 1993, P NATL ACAD SCI USA, V90, P10788, DOI 10.1073/pnas.90.22.10788; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHATZ DG, 1997, IN PRESS SEMIN IMMUN, V9; Spanopoulou E, 1996, CELL, V87, P263, DOI 10.1016/S0092-8674(00)81344-6; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; vanGent DC, 1996, CELL, V85, P107, DOI 10.1016/S0092-8674(00)81086-7; VANGENT DC, 1995, CELL, V81, P925, DOI 10.1016/0092-8674(95)90012-8; vanGent DC, 1996, SCIENCE, V271, P1592, DOI 10.1126/science.271.5255.1592; WEAVER DT, 1995, TRENDS GENET, V11, P388, DOI 10.1016/S0168-9525(00)89121-0; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7; ZWILLING S, 1995, EMBO J, V14, P1198, DOI 10.1002/j.1460-2075.1995.tb07103.x	46	244	249	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 4	1997	89	1					43	53		10.1016/S0092-8674(00)80181-6	http://dx.doi.org/10.1016/S0092-8674(00)80181-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WR685	9094713	hybrid			2022-12-01	WOS:A1997WR68500008
J	Jain, N; Catania, KC; Kaas, JH				Jain, N; Catania, KC; Kaas, JH			Deactivation and reactivation of somatosensory cortex after dorsal spinal cord injury	NATURE			English	Article							MACACA-MULATTA; MONKEYS; LESIONS; DEAFFERENTATION; REPRESENTATION; REORGANIZATION; ORGANIZATION; PLASTICITY; HAND	Sensory stimuli to the body are conveyed by the spinal cord to the primary somatosensory cortex It has long been thought that dorsal column afferents of the spinal cord represent the main pathway for these signals(1-3), but the physiological and behavioural consequences of cutting the dorsal column have been reported to range from mild and transitory(4-8) to markedg(9-13). We have re-examined this issue by sectioning the dorsal columns in the cervical region and recording the responses to hand stimulation in the contralateral primary somatosensory cortex (area 3b), Following a complete section of the dorsal columns, neurons in area 3b become immediately and perhaps permanently unresponsive to hand stimulation, Following a partial section, the remaining dorsal column afferents continue to activate neurons within their normal cortical target territories, but after five or more weeks the area of activation is greatly expanded, After prolonged recovery periods of six months or more, the deprived hand territory becomes responsive to inputs from the face (which are unaffected by spinal cord section), Thus, area 3b of somatosensory cortex is highly dependent on dorsal spinal column inputs, and other spinal pathways do not substitute for the dorsal columns even after injury.	VANDERBILT UNIV,DEPT PSYCHOL,NASHVILLE,TN 37240	Vanderbilt University			Jain, Neeraj/B-2882-2010	Jain, Neeraj/0000-0002-3672-5850				ANDERSSON SA, 1975, ACTA PHYSIOL SCAND, V93, P119, DOI 10.1111/j.1748-1716.1975.tb05797.x; Beck C H, 1976, Can J Neurol Sci, V3, P1; Darian-Smith, 1984, HDB PHYSL 2 1, V3, P789; DAVIS RW, 1993, ARCH PHYS MED REHAB, V74, P79; DREYER DA, 1974, J NEUROPHYSIOL, V37, P119, DOI 10.1152/jn.1974.37.1.119; EIDELBERG E, 1975, EXP NEUROL, V47, P419, DOI 10.1016/0014-4886(75)90074-6; FLORENCE SL, 1989, J COMP NEUROL, V286, P48, DOI 10.1002/cne.902860104; Florence SL, 1995, J NEUROSCI, V15, P8083; FLORENCE SL, 1991, J COMP NEUROL, V311, P563, DOI 10.1002/cne.903110410; Gallyas F, 1979, Neurol Res, V1, P203; GIBSON AR, 1984, BRAIN RES, V298, P235, DOI 10.1016/0006-8993(84)91423-9; GLENDINNING DS, 1993, EXP BRAIN RES, V93, P104; GLENDINNING DS, 1993, NEUROLOGY, V43, P363, DOI 10.1212/WNL.43.2.363; GLENDINNING DS, 1991, SOMATOSENS MOTOR RES, V9, P61; JAIN N, 1995, J NEUROPHYSIOL, V73, P1537, DOI 10.1152/jn.1995.73.4.1537; Jain N., 1996, Society for Neuroscience Abstracts, V22, P1054; KAAS JH, 1983, PHYSIOL REV, V63, P206, DOI 10.1152/physrev.1983.63.1.206; KAAS JH, 1991, ANNU REV NEUROSCI, V14, P137, DOI 10.1146/annurev.neuro.14.1.137; MERZENICH MM, 1978, J COMP NEUROL, V181, P41, DOI 10.1002/cne.901810104; MERZENICH MM, 1983, NEUROSCIENCE, V8, P33, DOI 10.1016/0306-4522(83)90024-6; PONS TP, 1991, SCIENCE, V252, P1857, DOI 10.1126/science.1843843; SCHNEIDER RJ, 1990, EXP BRAIN RES, V83, P105; SWEET WH, 1975, NEUROCHIRURGIA, V18, P139; Tommerdahl M, 1996, CEREB CORTEX, V6, P131, DOI 10.1093/cercor/6.2.131; VIERCK CJ, 1973, BRAIN RES, V58, P69, DOI 10.1016/0006-8993(73)90824-X; VIERCK CJ, 1985, SOMATOSENS RES, V3, P45, DOI 10.3109/07367228509144576; WALL PD, 1970, BRAIN, V93, P505, DOI 10.1093/brain/93.3.505; WONGRILEY M, 1979, BRAIN RES, V171, P11, DOI 10.1016/0006-8993(79)90728-5	28	153	154	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 3	1997	386	6624					495	498		10.1038/386495a0	http://dx.doi.org/10.1038/386495a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WR256	9087408				2022-12-01	WOS:A1997WR25600052
J	Aggeli, A; Bell, M; Boden, N; Keen, JN; Knowles, PF; McLeish, TCB; Pitkeathly, M; Radford, SE				Aggeli, A; Bell, M; Boden, N; Keen, JN; Knowles, PF; McLeish, TCB; Pitkeathly, M; Radford, SE			Responsive gels formed by the spontaneous self-assembly of peptides into polymeric beta-sheet tapes	NATURE			English	Article							SUPRAMOLECULAR CHEMISTRY; SECONDARY STRUCTURE; CIRCULAR-DICHROISM; PROTEIN; STABILITY; FILAMENTS; DOMAIN; ALPHA	Molecular self-assembly is becoming an increasingly popular route to new supramolecular structures and molecular materials(1-7). The inspiration for such structures is commonly derived from self-assembling systems in biology. Here we show that a biological motif, the peptide beta-sheet, can be exploited in designed oligopeptides that self-assemble into polymeric tapes and with potentially useful mechanical properties. We describe the construction of oligopeptides, rationally designed or based on segments of native proteins, that aggregate in suitable solvents into long, semi-flexible beta-sheet tapes. These become entangled even at low volume fractions to form gels whose viscoelastic properties can be controlled by chemical (pH) or physical (shear) influences. We suggest that it should be possible to engineer a wide range of properties in these gels by appropriate choice of the peptide primary structure.	UNIV LEEDS,CTR SELF ORGANISING MOL SYST,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND; UNIV LEEDS,SCH CHEM,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND; UNIV LEEDS,DEPT BIOCHEM & MOL BIOL,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND; UNIV LEEDS,DEPT PHYS,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND; UNIV OXFORD,OXFORD CTR MOL SCI,OXFORD OX1 3QT,ENGLAND; UNIV OXFORD,NEW CHEM LAB,OXFORD OX1 3QT,ENGLAND	University of Leeds; University of Leeds; University of Leeds; University of Leeds; University of Oxford; University of Oxford				McLeish, Tom/0000-0002-2025-0299; Radford, Sheena/0000-0002-3079-8039	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Aggeli A, 1996, BIOCHEMISTRY-US, V35, P16213, DOI 10.1021/bi960891g; BALL P, 1994, NATURE, V371, P202, DOI 10.1038/371202a0; Berg RH, 1996, NATURE, V383, P505, DOI 10.1038/383505a0; Blake C, 1996, STRUCTURE, V4, P989, DOI 10.1016/S0969-2126(96)00104-9; CHIRGADZE YN, 1973, BIOPOLYMERS, V12, P1337, DOI 10.1002/bip.1973.360120610; Choo DW, 1996, MACROMOLECULES, V29, P355, DOI 10.1021/ma950703e; CLARK AH, 1987, ADV POLYM SCI, V83, P57; CLAUSEN TM, 1992, J PHYS CHEM-US, V96, P474, DOI 10.1021/j100180a086; Doi M., 1986, THEORY POLYM DYNAMIC; Ferry J. D., 1961, VISCOELASTIC PROPERT; GAY NJ, 1991, FEBS LETT, V291, P87, DOI 10.1016/0014-5793(91)81110-T; GEISLER N, 1993, J STRUCT BIOL, V110, P205, DOI 10.1006/jsbi.1993.1023; GUO H, 1994, J PHYS CHEM-US, V98, P7104, DOI 10.1021/j100080a002; HANABUSA K, 1994, J CHEM SOC CHEM COMM, P2683, DOI 10.1039/c39940002683; KAMLET MJ, 1983, J ORG CHEM, V48, P2877, DOI 10.1021/jo00165a018; KIRSCHNER DA, 1987, P NATL ACAD SCI USA, V84, P6953, DOI 10.1073/pnas.84.19.6953; KREJCHI MT, 1994, SCIENCE, V265, P1427, DOI 10.1126/science.8073284; LEHN JM, 1990, ANGEW CHEM INT EDIT, V29, P1304, DOI 10.1002/anie.199013041; LOKEY RS, 1995, NATURE, V375, P303; Mayo KH, 1996, PROTEIN SCI, V5, P1301, DOI 10.1002/pro.5560050709; Minor DL, 1996, NATURE, V380, P730, DOI 10.1038/380730a0; Muller A, 1996, NATURE, V383, P296, DOI 10.1038/383296a0; Nyrkova IA, 1996, J PHYS II, V6, P1411, DOI 10.1051/jp2:1996139; OTZEN DE, 1995, BIOCHEMISTRY-US, V34, P5718, DOI 10.1021/bi00017a003; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; SMITH CK, 1995, SCIENCE, V270, P980, DOI 10.1126/science.270.5238.980; STOCK HT, 1995, J CHEM SOC CHEM COMM, P2063, DOI 10.1039/c39950002063; STOTT K, 1995, P NATL ACAD SCI USA, V92, P6509, DOI 10.1073/pnas.92.14.6509; SUREWICZ WK, 1988, BIOCHIM BIOPHYS ACTA, V952, P115, DOI 10.1016/0167-4838(88)90107-0; TAKUMI T, 1993, NEWS PHYSIOL SCI, V8, P175; Vegners R, 1995, J Pept Sci, V1, P371, DOI 10.1002/psc.310010604; YANG JJ, 1994, BIOCHEMISTRY-US, V33, P7345, DOI 10.1021/bi00189a040; ZHANG SG, 1993, P NATL ACAD SCI USA, V90, P3334, DOI 10.1073/pnas.90.8.3334	33	749	776	5	298	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 20	1997	386	6622					259	262		10.1038/386259a0	http://dx.doi.org/10.1038/386259a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WP003	9069283				2022-12-01	WOS:A1997WP00300045
J	Giardiello, FM; Brensinger, JD; Petersen, GM; Luce, MC; Hylind, LM; Bacon, JA; Booker, SV; Parker, RD; Hamilton, SR				Giardiello, FM; Brensinger, JD; Petersen, GM; Luce, MC; Hylind, LM; Bacon, JA; Booker, SV; Parker, RD; Hamilton, SR			The use and interpretation of commercial APC gene testing for familial adenomatous polyposis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY ANGIOGRAPHY; DIAGNOSIS; IMPACT; COLI; ECHOCARDIOGRAPHY; APPROPRIATENESS; IDENTIFICATION; MANAGEMENT; LINKAGE; LOCUS	Background The use of commercially available tests for genes linked to familial cancer has aroused concern about the impact of these tests on patients. Familial adenomatous polyposis is an autosomal dominant disease caused by a germ-line mutation of the adenomatous polyposis coli (APC) gene that causes colorectal cancer if prophylactic colectomy is not performed. We evaluated the clinical use of commercial APC gene testing. Methods We assessed indications for APC gene testing, whether informed consent was obtained and genetic counseling was offered before testing, and the interpretation of the results through telephone interviews with physicians and genetic counselors in a nationwide sample of 177 patients from 125 families who underwent testing during 1995. Results Of the 177 patients tested, 83.0 percent had clinical features of familial adenomatous polyposis or were at risk for the disease - both valid indications for being tested. The appropriate strategy for presymptomatic testing was used in 79.4 percent (50 of 63 patients). Only 18.6 percent (33 of 177) received genetic counseling before the test, and only 16.9 percent (28 of 166) provided written informed consent. In 31.6 percent of the cases the physicians misinterpreted the test results. Among the patients with unconventional indications for testing, the rate of positive results was only 2.3 percent (1 of 44). Conclusions Patients who underwent genetic tests for familiar adenomatous polyposis often received inadequate counseling and would have been given incorrectly interpreted results. Physicians should be prepared to offer genetic counseling if they order genetic tests. (C) 1997, Massachusetts Medical Society.	JOHNS HOPKINS UNIV, SCH MED, DEPT MED, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PATHOL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, CTR ONCOL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT EPIDEMIOL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT HLTH POLICY & MANAGEMENT, BALTIMORE, MD 21205 USA; LABCORP, DEPT MOL BIOL, RES TRIANGLE PK, NC USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University					NCI NIH HHS [CA63721, CA53801, CA62924] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA053801, P50CA062924, R01CA063721] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERNSTEIN SJ, 1993, JAMA-J AM MED ASSOC, V269, P766, DOI 10.1001/jama.269.6.766; BROWN ML, 1995, J NATL CANCER I, V87, P1131, DOI 10.1093/jnci/87.15.1131; BULOW S, 1987, DAN MED BULL, V34, P1; Bussey HJ, 1975, FAMILIAL POLYPOSIS C; CARTER MA, 1995, J NCI MONOGRAPHS, V17, P119; CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2543, DOI 10.1001/jama.258.18.2543; COHEN MM, 1994, AM J HUM GENET, V55, pR1; Collins FS, 1996, J CLIN ONCOL, V14, P1738; COLLINS FS, 1994, JAMA-J AM MED ASSOC, V271, P785, DOI 10.1001/jama.1994.03510340075038; GOLDMAN L, 1980, CIRCULATION, V62, P680, DOI 10.1161/01.CIR.62.4.680; GOLDMAN L, 1983, AM J MED, V75, P49, DOI 10.1016/0002-9343(83)91167-1; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Holtzman N A, 1996, Oncology (Williston Park), V10, P57; HOLTZMANN NA, 1995, JNCI-J NATL CANCER I, V17, P95; Hubbard R, 1996, NEW ENGL J MED, V334, P1192, DOI 10.1056/NEJM199605023341812; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KAHN KL, 1988, ANN INTERN MED, V109, P664, DOI 10.7326/0003-4819-109-8-664; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; MCDONALD IG, 1988, J CLIN EPIDEMIOL, V41, P151, DOI 10.1016/0895-4356(88)90089-3; *NIH DOE WORK GROP, 1996, INT PRINC TASK FORC; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; Offit K, 1996, J CLIN ONCOL, V14, P1730, DOI 10.1200/JCO.1996.14.5.1730; Petersen G M, 1996, Oncology (Williston Park), V10, P89; Petersen G M, 1995, J Natl Cancer Inst Monogr, P67; PETERSEN GM, 1991, GASTROENTEROLOGY, V100, P1658, DOI 10.1016/0016-5085(91)90666-9; PETERSEN GM, 1995, SEMIN COLON RECTAL S, V6, P55; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; SPIRIO L, 1992, AM J HUM GENET, V51, P92; WERTZ DC, 1994, JAMA-J AM MED ASSOC, V272, P875, DOI 10.1001/jama.272.11.875	29	346	354	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 20	1997	336	12					823	827		10.1056/NEJM199703203361202	http://dx.doi.org/10.1056/NEJM199703203361202			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN371	9062090				2022-12-01	WOS:A1997WN37100002
J	Aguzzi, A				Aguzzi, A			Neuro-immune connection in spread of prions in the body?	LANCET			English	Editorial Material							SCRAPIE; MICE				Aguzzi, A (corresponding author), UNIV ZURICH HOSP,DEPT PATHOL,CH-8091 ZURICH,SWITZERLAND.		Aguzzi, Adriano/A-3351-2008	Aguzzi, Adriano/0000-0002-0344-6708				Brandner S, 1996, P NATL ACAD SCI USA, V93, P13148, DOI 10.1073/pnas.93.23.13148; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; EKLUND CM, 1967, J INFECT DIS, V117, P15, DOI 10.1093/infdis/117.1.15; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; Hill AF, 1997, LANCET, V349, P99, DOI 10.1016/S0140-6736(97)24002-X; KIMBERLIN RH, 1980, J GEN VIROL, V51, P183, DOI 10.1099/0022-1317-51-1-183; Lasmezas CI, 1997, SCIENCE, V275, P402, DOI 10.1126/science.275.5298.402; Lasmezas CI, 1996, J VIROL, V70, P1292; MURAMOTO T, 1993, J VIROL, V67, P6808, DOI 10.1128/JVI.67.11.6808-6810.1993; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762	11	62	64	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 15	1997	349	9054					742	743		10.1016/S0140-6736(97)22011-8	http://dx.doi.org/10.1016/S0140-6736(97)22011-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN124	9074567				2022-12-01	WOS:A1997WN12400002
J	Nightingale, SL				Nightingale, SL			Over-the-counter test system for drugs of abuse approved	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 5	1997	277	9					703	703						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WK026	9042830				2022-12-01	WOS:A1997WK02600010
J	Amano, M; Chihara, K; Kimura, K; Fukata, Y; Nakamura, N; Matsuura, Y; Kaibuchi, K				Amano, M; Chihara, K; Kimura, K; Fukata, Y; Nakamura, N; Matsuura, Y; Kaibuchi, K			Formation of actin stress fibers and focal adhesions enhanced by Rho-kinase	SCIENCE			English	Article							GTP-BINDING-PROTEIN; SIGNAL-TRANSDUCTION; CATALYTIC DOMAINS; GENE-PRODUCT; GROWTH; RAS; CELLS; INVOLVEMENT; REGULATOR; GTPASES	The small guanosine triphosphatase (GTPase) Rho is implicated in the formation of stress fibers and focal adhesions in fibroblasts stimulated by extracellular signals such as lysophosphatidic acid (LPA). Rho-kinase is activated by Rho and may mediate some biological effects of Rho. Microinjection of the catalytic domain of Rho-kinase into serum-starved Swiss 3T3 cells induced the formation of stress fibers and focal adhesions, whereas microinjection of the inactive catalytic domain, the Rho-binding domain, or the pleckstrin-homology domain inhibited the LPA-induced formation of stress fibers and focal adhesions. Thus, Rho-kinase appears to mediate signals from Rho and to induce the formation of stress fibers and focal adhesions.	NARA INST SCI & TECHNOL,DIV SIGNAL TRANSDUCT,IKOMA 63001,JAPAN; KYOTO UNIV,FAC MED,DEPT ANAT 2,KYOTO 606,JAPAN; NATL INST HLTH,DEPT VIROL 2,TOKYO 162,JAPAN	Nara Institute of Science & Technology; Kyoto University			Amano, Mutsuki/M-4820-2014; Kimura, Kazushi/ABB-4007-2020	Amano, Mutsuki/0000-0002-0662-1524; Fukata, Yuko/0000-0001-7724-8643				AKTORIES K, 1989, BIOCHEM BIOPH RES CO, V158, P209, DOI 10.1016/S0006-291X(89)80199-8; Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; AMANO M, UNPUB; Bussey H, 1996, SCIENCE, V272, P224, DOI 10.1126/science.272.5259.224; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; Gong MC, 1996, P NATL ACAD SCI USA, V93, P1340, DOI 10.1073/pnas.93.3.1340; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HIRAI S, 1994, EMBO J, V13, P2331, DOI 10.1002/j.1460-2075.1994.tb06517.x; HIRATA K, 1992, J BIOL CHEM, V267, P8719; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; KAIBUCHI K, 1989, J BIOL CHEM, V264, P13489; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Mabuchi I, 1993, ZYGOTE, V1, P325, DOI 10.1017/S0967199400001659; Madaule P, 1995, FEBS LETT, V377, P243, DOI 10.1016/0014-5793(95)01351-2; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; MATSUURA Y, 1987, J GEN VIROL, V68, P1233, DOI 10.1099/0022-1317-68-5-1233; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NOBES C, 1994, CURR OPIN GENET DEV, V4, P77, DOI 10.1016/0959-437X(94)90094-9; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; RAPP UR, 1991, ONCOGENE, V6, P495; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SATOH T, 1992, J BIOL CHEM, V267, P24149; SEKINE A, 1989, J BIOL CHEM, V264, P8602; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TAKAISHI K, 1994, ONCOGENE, V9, P273; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645	36	918	959	0	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 28	1997	275	5304					1308	1311		10.1126/science.275.5304.1308	http://dx.doi.org/10.1126/science.275.5304.1308			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WK644	9036856				2022-12-01	WOS:A1997WK64400043
J	Meller, VH; Wu, KH; Roman, G; Kuroda, MI; Davis, RL				Meller, VH; Wu, KH; Roman, G; Kuroda, MI; Davis, RL			roX1 RNA paints the X chromosome of male Drosophila and is regulated by the dosage compensation system	CELL			English	Article							DNA TOPOISOMERASE-II; MUSHROOM BODIES; SEXUAL-DIFFERENTIATION; CATALYTIC SUBUNIT; TRANSFORMER GENE; NUCLEAR MATRIX; XIST GENE; MELANOGASTER; EXPRESSION; PROTEIN	The Drosophila roX1 gene is X-linked and produces RNAs that are male-specific, somatic, and preferentially expressed in the central nervous system. These RNAs are retained in the nucleus and lack any significant open reading frame. Although all sexually dimorphic characteristics in Drosophila were thought to be controlled by the sex determination pathway through the gene transformer (tra), the expression of roX1 is independent of tra activity. Instead, the dosage compensation system is necessary and sufficient for the expression of roX1. Consistent with a potential function in dosage compensation, roX1 RNAs localize specifically to the male X chromosome. This localization occurs even when roX1 RNAs are expressed from autosomal locations in X-to-autosome translocations. The novel regulation and subnuclear localization of roX1 RNAs makes them candidates for an RNA component of the dosage compensation machinery.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT NEUROL,HOUSTON,TX 77030; BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute			Davis, Ronald/J-4998-2013; Roman, Gregg/W-1586-2019	Davis, Ronald/0000-0002-5986-7608; Roman, Gregg/0000-0003-1519-4699				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BAKER BS, 1994, ANNU REV GENET, V28, P491, DOI 10.1146/annurev.ge.28.120194.002423; BASHAW GJ, 1995, DEVELOPMENT, V121, P3245; BELL LR, 1991, CELL, V65, P229, DOI 10.1016/0092-8674(91)90157-T; BELOTE JM, 1980, NATURE, V285, P573, DOI 10.1038/285573a0; BELOTE JM, 1980, GENETICS, V96, P165; BERRIOS M, 1985, P NATL ACAD SCI USA, V82, P4142, DOI 10.1073/pnas.82.12.4142; BOGGS RT, 1987, CELL, V50, P739, DOI 10.1016/0092-8674(87)90332-1; BONE JR, 1994, GENE DEV, V8, P96, DOI 10.1101/gad.8.1.96; BORSANI G, 1991, NATURE, V351, P325, DOI 10.1038/351325a0; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; BROWN CM, 1994, NUCLEIC ACIDS RES, V22, P3620, DOI 10.1093/nar/22.17.3620; BURTIS KC, 1991, EMBO J, V10, P2577, DOI 10.1002/j.1460-2075.1991.tb07798.x; Burtis KC, 1993, CURR OPIN CELL BIOL, V5, P1006, DOI 10.1016/0955-0674(93)90085-5; Clemson CM, 1996, J CELL BIOL, V132, P259, DOI 10.1083/jcb.132.3.259; CLINE TW, 1978, GENETICS, V90, P683; CLINE TW, 1984, GENETICS, V107, P231; Cline TW, 1996, ANNU REV GENET, V30, P637, DOI 10.1146/annurev.genet.30.1.637; DAVIS RL, 1993, NEURON, V11, P1, DOI 10.1016/0896-6273(93)90266-T; DONG S, 1994, GENOMICS, V23, P540, DOI 10.1006/geno.1994.1541; EARNSHAW WC, 1985, J CELL BIOL, V100, P1716, DOI 10.1083/jcb.100.5.1716; FEY EG, 1986, J CELL BIOL, V102, P1654, DOI 10.1083/jcb.102.5.1654; FOSTER JL, 1988, J BIOL CHEM, V263, P1676; Franke A, 1996, DEVELOPMENT, V122, P2751; FUKUNAGA A, 1975, GENETICS, V81, P135; GIBSON TJ, 1994, NUCLEIC ACIDS RES, V22, P2552, DOI 10.1093/nar/22.13.2552; GORMAN M, 1995, DEVELOPMENT, V121, P463; GORMAN M, 1993, CELL, V72, P39, DOI 10.1016/0092-8674(93)90048-U; GRIFFINSHEA R, 1982, DEV BIOL, V91, P325, DOI 10.1016/0012-1606(82)90039-2; Han PL, 1996, J NEUROBIOL, V31, P88, DOI 10.1002/(SICI)1097-4695(199609)31:1<88::AID-NEU8>3.0.CO;2-B; HE DC, 1990, J CELL BIOL, V110, P569, DOI 10.1083/jcb.110.3.569; HENDRICH BD, 1993, HUM MOL GENET, V2, P663, DOI 10.1093/hmg/2.6.663; HILFIKER A, 1994, EMBO J, V13, P3542, DOI 10.1002/j.1460-2075.1994.tb06661.x; KAY GF, 1993, CELL, V72, P171, DOI 10.1016/0092-8674(93)90658-D; KELLEY RL, 1995, CELL, V81, P867, DOI 10.1016/0092-8674(95)90007-1; KELLEY RL, 1995, SCIENCE, V270, P1607, DOI 10.1126/science.270.5242.1607; KEYES LN, 1992, CELL, V68, P933, DOI 10.1016/0092-8674(92)90036-C; KURODA MI, 1991, CELL, V66, P935, DOI 10.1016/0092-8674(91)90439-6; Lee JT, 1996, CELL, V86, P83, DOI 10.1016/S0092-8674(00)80079-3; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; LUCCHESI JC, 1981, CHROMOSOMA, V82, P217, DOI 10.1007/BF00286106; Lucchesi JC, 1996, BIOESSAYS, V18, P541, DOI 10.1002/bies.950180705; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; McDowell KA, 1996, MECH DEVELOP, V57, P113, DOI 10.1016/0925-4773(96)00517-5; MCKEOWN M, 1988, CELL, V53, P887, DOI 10.1016/S0092-8674(88)90369-8; MELLER VH, 1995, J CELL SCI, V108, P1651; MELLER VH, 1994, J CELL BIOL, V126, P1331, DOI 10.1083/jcb.126.6.1331; MUKHERJEE AS, 1965, NATURE, V207, P785, DOI 10.1038/207785a0; NAGOSHI RN, 1988, CELL, V53, P229, DOI 10.1016/0092-8674(88)90384-4; NICKERSON JA, 1989, P NATL ACAD SCI USA, V86, P177, DOI 10.1073/pnas.86.1.177; ODELL KMC, 1995, NEURON, V15, P55, DOI 10.1016/0896-6273(95)90064-0; PALMER MJ, 1993, GENETICS, V134, P545; PALMER MJ, 1994, GENE DEV, V8, P698, DOI 10.1101/gad.8.6.698; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Penny GD, 1996, NATURE, V379, P131, DOI 10.1038/379131a0; RASTAN S, 1994, CURR OPIN GENET DEV, V4, P292, DOI 10.1016/S0959-437X(05)80056-5; RASTELLI L, 1995, MECH DEVELOP, V53, P1; Richter L, 1996, GENES CELLS, V1, P325, DOI 10.1046/j.1365-2443.1996.26027.x; SAMUELS ME, 1994, MOL CELL BIOL, V14, P4975, DOI 10.1128/MCB.14.7.4975; Skoulakis EMC, 1996, NEURON, V17, P931, DOI 10.1016/S0896-6273(00)80224-X; SKOULAKIS EMC, 1993, NEURON, V11, P197, DOI 10.1016/0896-6273(93)90178-T; SOLOVYEV VV, 1994, NUCLEIC ACIDS RES, V22, P5156, DOI 10.1093/nar/22.24.5156; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B; UCHIDA S, 1981, JPN J GENET, V56, P523, DOI 10.1266/jjg.56.523; WEVRICK R, 1994, HUM MOL GENET, V3, P1877, DOI 10.1093/hmg/3.10.1877; ZHOU SB, 1995, EMBO J, V14, P2884, DOI 10.1002/j.1460-2075.1995.tb07288.x	67	232	235	1	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 21	1997	88	4					445	457		10.1016/S0092-8674(00)81885-1	http://dx.doi.org/10.1016/S0092-8674(00)81885-1			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WJ691	9038336	Bronze			2022-12-01	WOS:A1997WJ69100005
J	Du, XL; Cruickshank, K; McNamee, R; Saraee, M; Sourbutts, J; Summers, A; Roberts, N; Walton, E; Holmes, S				Du, XL; Cruickshank, K; McNamee, R; Saraee, M; Sourbutts, J; Summers, A; Roberts, N; Walton, E; Holmes, S			Case-control study of stroke and the quality of hypertension control in north west England	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; HIGH BLOOD-PRESSURE; GENERAL-PRACTICE; MORTALITY; MANAGEMENT; MORBIDITY; PROJECT; RISKS; TRIAL	Objective: To examine the risk of stroke in relation to quality of hypertension control in routine general practice across an entire health district. Design: Population based matched case-control study. Setting: East Lancashire Health District with a participating population of 388 821 aged less than or equal to 80. Subjects: Cases were patients under 80 with their first stroke identified from a population based stroke register between 1 July 1994 and 30 June 1995. For each case two controls matched with the case for age and sex were selected from the same practice register. Hypertension was defined as systolic blood pressure greater than or equal to 160 mm Hg or diastolic blood pressure greater than or equal to 95 mm Hg, Or both, on at least two occasions within any three month period or any history of treatment with antihypertensive drugs. Main outcome measures: Prevalence of hypertension and quality of control of hypertension (assessed by using the mean blood pressure recorded before stroke) and odds ratios of stroke (derived from conditional logistic regression). Results: Records of 267 cases and 534 controls were examined; 61% and 42% of these subjects respectively were hypertensive. Compared with non-hypertensive subjects hypertensive patients receiving treatment whose average pre-event systolic blood pressure was controlled to <140 mm Hg had an adjusted odds ratio for stroke of 1.3 (95% confidence interval 0.6 to 2.7). Those fairly well controlled (140-149 mm Hg), moderately controlled (150-159 mm Hg), or poorly controlled (greater than or equal to 160 mm Hg) or untreated had progressively raised odds ratios of 1.6, 2.2, 3.2, and 3.5 respectively. Results for diastolic pressure were similar; both were independent of initial pressures before treatment Around 21% of strokes were thus attributable to inadequate control with treatment, or 46 first events yearly per 100 000 population aged 40-79. Conclusions: Risk of stroke was clearly related to quality of control of blood pressure with treatment In routine practice consistent control of blood pressure to below 150/90 mm Hg seems to be required for optimal stroke prevention.	UNIV MANCHESTER, SCH MED, SCH EPIDEMIOL & HLTH SCI, MANCHESTER M13 9PT, LANCS, ENGLAND; UNIV MANCHESTER, INST SCI & TECHNOL, DEPT COMPUTAT, MANCHESTER M60 1QD, LANCS, ENGLAND; E LANCASHIRE HLTH AUTHOR, DEPT PUBL HLTH, NELSON BB9 5SZ, LANCS, ENGLAND; QUEENS PK HOSP, DEPT MED ELDERLY, BLACKBURN BB2 3HH, LANCS, ENGLAND; THE SURGERY, EARBY BB8 6QT, LANCS, ENGLAND	University of Manchester; University of Manchester								ALROOMI KA, 1990, MED J AUSTRALIA, V153, P595, DOI 10.5694/j.1326-5377.1990.tb126271.x; AMERY A, 1985, LANCET, V1, P1349; [Anonymous], 1991, JAMA, V265, P3255; ARROLL B, 1996, EVIDENCE BASED MED, V1, P105; BULPITT CJ, 1994, CIRCULATION, V90, P225, DOI 10.1161/01.CIR.90.1.225; COLHOUN HM, 1996, J HYPERTENS S1, V14, P289; COLLINS R, 1994, BRIT MED BULL, V50, P272, DOI 10.1093/oxfordjournals.bmb.a072892; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; CRUICKSHANK JK, 1994, J HYPERTENS, V12, P1315; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; Fahey TP, 1996, BMJ-BRIT MED J, V313, P93, DOI 10.1136/bmj.313.7049.93; HART JT, 1993, BRIT MED J, V306, P437, DOI 10.1136/bmj.306.6875.437; HART JT, 1993, HYPERTENSION COMMUNI; HELLER RF, 1977, BRIT MED J, V1, P1442, DOI 10.1136/bmj.1.6074.1442; ISLES CG, 1986, J HYPERTENS, V4, P141, DOI 10.1097/00004872-198604000-00003; Jackson RT, 1996, BRIT MED J, V313, P64, DOI 10.1136/bmj.313.7049.64; KURJI KH, 1984, BMJ-BRIT MED J, V288, P903, DOI 10.1136/bmj.288.6421.903; LANGER RD, 1995, CLIN EXP HYPERTENS, V17, P1127, DOI 10.3109/10641969509033658; Lindenstrom E, 1995, AM J EPIDEMIOL, V142, P1279, DOI 10.1093/oxfordjournals.aje.a117595; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; PAYNE JN, 1993, BRIT MED J, V307, P1027, DOI 10.1136/bmj.307.6911.1027; Pearce K A, 1995, Arch Fam Med, V4, P943, DOI 10.1001/archfami.4.11.943; Qizilbash N, 1995, LANCET, V346, P1647; RABKIN SW, 1978, ANN INTERN MED, V88, P342, DOI 10.7326/0003-4819-88-3-342; ROSE G, 1981, BMJ-BRIT MED J, V282, P1847, DOI 10.1136/bmj.282.6279.1847; SANDERCOCK P, 1985, BRIT MED J, V290, P193, DOI 10.1136/bmj.290.6463.193; SHINTON R, 1989, BMJ-BRIT MED J, V298, P789, DOI 10.1136/bmj.298.6676.789; SMITH WCS, 1990, BRIT MED J, V300, P981, DOI 10.1136/bmj.300.6730.981; STAMLER J, 1993, ARCH INTERN MED, V153, P598, DOI 10.1001/archinte.153.5.598; *STAT EP RES CORP, 1991, EP GRAPH EST TEST PA; Tuomilehto J, 1996, STROKE, V27, P210, DOI 10.1161/01.STR.27.2.210; WHISNANT JP, 1984, STROKE, V15, P160, DOI 10.1161/01.STR.15.1.160; *WHO EXP COMM, 1978, WHO TECH REP SER, V628	34	85	86	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 25	1997	314	7076					272	276		10.1136/bmj.314.7076.272	http://dx.doi.org/10.1136/bmj.314.7076.272			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WE633	9022492	Green Published, Green Accepted			2022-12-01	WOS:A1997WE63300027
J	Hofman, A; Ott, A; Breteler, MMB; Bots, ML; Slooter, AJC; vanHarskamp, F; vanDuijn, CN; Van Broeckhoven, C; Grobbee, DE				Hofman, A; Ott, A; Breteler, MMB; Bots, ML; Slooter, AJC; vanHarskamp, F; vanDuijn, CN; Van Broeckhoven, C; Grobbee, DE			Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study	LANCET			English	Article							INTIMA-MEDIA THICKNESS; COMMON CAROTID-ARTERY; WALL THICKNESS; MENTAL STATE; POPULATION; DETERMINANTS; ALLELE; DIAGNOSIS	Background Vascular disorders have been implicated in dementia, but whether atherosclerosis is related to the most frequent type of dementia, Alzheimer's disease, is not known. The apolipoprotein-E genotype has been associated with Alzheimer's disease, and we postulate that it plays a part, together with atherosclerosis, in the aetiology of Alzheimer's disease. We investigated the frequency of dementia and its subtypes in relation to atherosclerosis and apolipoprotein E. Methods We did a population-based study of 284 patients with dementia, 207 of whom had Alzheimer's disease, and 1698 individuals who were not demented. Indicators of atherosclerosis included vessel wall thickness and plaques of the carotid arteries, assessed by ultrasonography, and the ratio of ankle-to-brachial systolic blood pressure as a measure of generalised atherosclerosis. Based on these indicators participants were scored from 0 (no atherosclerosis) to 3 (severe atherosclerosis) for degree of atherosclerosis. Apolipoprotein-E polymorphisms were assessed in 246 patients and in 928 controls. Findings All indicators of atherosclerosis were associated with dementia (odds ratios ranging from 1.3 to 1.9) and its major subtypes Alzheimer's disease (odds ratios 1.3-1.8) and vascular dementia (odds ratios 1.9-3.2). The frequencies of all dementia, Alzheimer's disease, and vascular dementia increased with the degree of atherosclerosis. The odds ratio for Alzheimer's disease in those with severe atherosclerosis compared with those without atherosclerosis was 3.0 (95% CI 1.5-6.0; p=0.001). In participants with the apolipoprotein-E epsilon 4 genotype and an atherosclerosis score of 2 or 3 the odds ratio for all dementia was 4.5 (2.0-10.1; p<0.001), for Alzheimer's disease was 3.9 (1.6-9.6; p=0.002), and for vascular dementia was 19.8 (4.1-95.0; p<0.001). Interpretation These findings suggest that dementia and its two major subtypes Alzheimer's disease and vascular dementia are associated with atherosclerosis and that there is an interaction between apolipoprotein E and atherosclerosis in the aetiology of Alzheimer's disease.	ERASMUS UNIV ROTTERDAM, SCH MED, DEPT NEUROL, NL-3000 DR ROTTERDAM, NETHERLANDS; UNIV INSTELLING ANTWERP, BORN BUNGE FDN, NEUROGENET LAB, B-2610 WILRIJK, BELGIUM	Erasmus University Rotterdam; University of Antwerp	Hofman, A (corresponding author), ERASMUS UNIV ROTTERDAM, SCH MED, DEPT EPIDEMIOL & BIOSTAT, NL-3000 DR ROTTERDAM, NETHERLANDS.		Grobbee, Diederick/C-7651-2014; Van Broeckhoven, Christine/G-8362-2017; Van Broeckhoven, Christine/M-7853-2019; Breteler, Monique M.B./J-5058-2014	Grobbee, Diederick/0000-0003-4472-4468; Van Broeckhoven, Christine/0000-0003-0183-7665; Van Broeckhoven, Christine/0000-0003-0183-7665; Breteler, Monique M.B./0000-0002-0626-9305				American Psychiatric Association, 1987, DIAGNOSTIC STAT MANU, V3rd; BOTS ML, 1993, LANCET, V341, P1232, DOI 10.1016/0140-6736(93)91144-B; BOTS ML, 1994, ARTERIOSCLER THROMB, V14, P1885, DOI 10.1161/01.ATV.14.12.1885; BOTS ML, 1992, HYPERTENSION, V19, P717, DOI 10.1161/01.HYP.19.6.717; BRETELER MMB, 1992, EPIDEMIOL REV, V14, P59, DOI 10.1093/oxfordjournals.epirev.a036092; BRETELER MMB, 1994, BRIT MED J, V308, P1604, DOI 10.1136/bmj.308.6944.1604; COPELAND JRM, 1976, PSYCHOL MED, V6, P439, DOI 10.1017/S0033291700015889; DEWEY ME, 1990, 1 I HUM AG; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FOWKES FGR, 1991, INT J EPIDEMIOL, V20, P384, DOI 10.1093/ije/20.2.384; Hachinski V, 1983, Neurol Clin, V1, P27; HACHINSKI V, 1992, LANCET, V340, P645; HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007; HOFMAN A, 1991, INT J EPIDEMIOL, V20, P736, DOI 10.1093/ije/20.3.736; JARRIK GP, 1995, NEUROLOGY, V45, P1092; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; OTT A, 1995, BRIT MED J, V310, P970, DOI 10.1136/bmj.310.6985.970; POLI A, 1988, ATHEROSCLEROSIS, V70, P253, DOI 10.1016/0021-9150(88)90176-1; POLVIKOSKI T, 1995, NEW ENGL J MED, V333, P1242, DOI 10.1056/NEJM199511093331902; Roth M, 1988, CAMDEX CAMBRIDGE EXA; SALONEN R, 1990, ATHEROSCLEROSIS, V81, P33, DOI 10.1016/0021-9150(90)90056-O; SCHROLL M, 1981, J CHRON DIS, V34, P261, DOI 10.1016/0021-9681(81)90031-X; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Thomas T, 1996, NATURE, V380, P168, DOI 10.1038/380168a0; VANDUIJN CM, 1995, ANN NEUROL, V37, P605, DOI 10.1002/ana.410370510; VANDUIJN CM, 1994, NAT GENET, V7, P74, DOI 10.1038/ng0594-74; VANGENT CM, 1977, CLIN CHIM ACTA, V75, P243, DOI 10.1016/0009-8981(77)90195-4; WENDELHAG I, 1992, ARTERIOSCLER THROMB, V12, P70, DOI 10.1161/01.ATV.12.1.70; WENHAM PR, 1991, LANCET, V337, P1158, DOI 10.1016/0140-6736(91)92823-K	29	1105	1136	0	55	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 18	1997	349	9046					151	154		10.1016/S0140-6736(96)09328-2	http://dx.doi.org/10.1016/S0140-6736(96)09328-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC861	9111537				2022-12-01	WOS:A1997WC86100007
J	Lingner, J; Hughes, TR; Shevchenko, A; Mann, M; Lundblad, V; Cech, TR				Lingner, J; Hughes, TR; Shevchenko, A; Mann, M; Lundblad, V; Cech, TR			Reverse transcriptase motifs in the catalytic subunit of telomerase	SCIENCE			English	Article							DEPENDENT DNA POLYMERASE; SACCHAROMYCES-CEREVISIAE; TETRAHYMENA TELOMERASE; TERMINAL TRANSFERASE; MAURICEVILLE PLASMID; ANGSTROM RESOLUTION; SECONDARY STRUCTURE; CRYSTAL-STRUCTURE; RNA COMPONENT; STRANDED-DNA	Telomerase is a ribonucleoprotein enzyme essential for the replication of chromosome termini in most eukaryotes. Telomerase RNA components have been identified from many organisms, but no protein component has been demonstrated to catalyze telomeric DNA extension. Telomerase was purified from Euplotes aediculatus, a ciliated protozoan, and one of its proteins was partially sequenced by nanoelectrospray tandem mass spectrometry. Cloning and sequence analysis of the corresponding gene revealed that this 123-kilodalton protein (p123) contains reverse transcriptase motifs. A yeast (Saccharomyces cerevisiae) homolog was found and subsequently identified as EST2 (ever shorter telomeres), deletion of which had independently been shown to produce telomere defects. Introduction of single amino acid substitutions within the reverse transcriptase motifs of Est2 protein led to telomere shortening and senescence in yeast, indicating that these motifs are important for catalysis of telomere elongation in vivo. In vitro telomeric DNA extension occurred with extracts from wild-type yeast but not from est2 mutants or mutants deficient in telomerase RNA. Thus, the reverse transcriptase protein fold, previously known to be involved in retroviral replication and retrotransposition, is essential for normal chromosome telomere replication in diverse eukaryotes.	EUROPEAN MOL BIOL LAB,D-69012 HEIDELBERG,GERMANY; UNIV COLORADO,DEPT CHEM & BIOCHEM,HOWARD HUGHES MED INST,BOULDER,CO 80309; BAYLOR COLL MED,DEPT MOL & HUMAN GENET,HOUSTON,TX 77030	European Molecular Biology Laboratory (EMBL); Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder; Baylor College of Medicine			Mann, Matthias/A-3454-2013	Mann, Matthias/0000-0003-1292-4799; Lingner, Joachim/0000-0002-2853-5803	NATIONAL INSTITUTE ON AGING [R37AG011728, R01AG011728] Funding Source: NIH RePORTER; NIA NIH HHS [AG11728] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARNOLD E, 1992, NATURE, V357, P85, DOI 10.1038/357085a0; BALTIMORE D, 1970, NATURE, V226, P1209, DOI 10.1038/2261209a0; BIESSMANN H, 1990, CELL, V61, P663, DOI 10.1016/0092-8674(90)90478-W; BLASCO MA, 1995, SCIENCE, V269, P1267, DOI 10.1126/science.7544492; BOEKE JD, 1989, ANNU REV MICROBIOL, V43, P403, DOI 10.1146/annurev.micro.43.1.403; COHN M, 1995, SCIENCE, V269, P396, DOI 10.1126/science.7618104; COLLINS K, 1995, CELL, V81, P677, DOI 10.1016/0092-8674(95)90529-4; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DARNELL JE, 1986, P NATL ACAD SCI USA, V83, P1271, DOI 10.1073/pnas.83.5.1271; DELANGE T, 1994, P NATL ACAD SCI USA, V91, P2882, DOI 10.1073/pnas.91.8.2882; EVANS S, UNPUB; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; FERAT JL, 1993, NATURE, V364, P358, DOI 10.1038/364358a0; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; Hammond PW, 1997, MOL CELL BIOL, V17, P296, DOI 10.1128/MCB.17.1.296; HARRINGTON L, 1997, SCIENCE, V275, P673; INOUYE M, 1991, ANNU REV MICROBIOL, V45, P163; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JOYCE M, 1994, ANN REV BIOCH, V63, P777; KENNELL JC, 1994, MOL CELL BIOL, V14, P3094, DOI 10.1128/MCB.14.5.3094; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; Lendvay TS, 1996, GENETICS, V144, P1399; LEVIS RW, 1993, CELL, V75, P1; Lin JJ, 1996, P NATL ACAD SCI USA, V93, P13760, DOI 10.1073/pnas.93.24.13760; LINGNER J, 1995, SCIENCE, V269, P1533, DOI 10.1126/science.7545310; LINGNER J, 1994, GENE DEV, V8, P1984, DOI 10.1101/gad.8.16.1984; Lingner J, 1996, P NATL ACAD SCI USA, V93, P10712, DOI 10.1073/pnas.93.20.10712; LINGNER J, UNPUB BLAST SEARCH P; LINGNER J, UNPUB; LUE NF, 1995, J BIOL CHEM, V270, P21453, DOI 10.1074/jbc.270.37.21453; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; MAIZELS N, 1993, RNA WORLD, P577; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; MCEACHERN MJ, 1995, NATURE, V376, P403, DOI 10.1038/376403a0; Nakayama JI, 1997, CELL, V88, P875, DOI 10.1016/S0092-8674(00)81933-9; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; NUGENT CI, UNPUB; OLLIS DL, 1985, NATURE, V313, P765; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; Pardue ML, 1996, TRENDS GENET, V12, P48, DOI 10.1016/0168-9525(96)81399-0; PATTERSON SD, 1995, ELECTROPHORESIS, V16, P791; POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x; PRESCOTT DM, 1994, MICROBIOL REV, V58, P233, DOI 10.1128/MMBR.58.2.233-267.1994; Prescott J, 1997, GENE DEV, V11, P528, DOI 10.1101/gad.11.4.528; ROMERO DP, 1991, CELL, V67, P343, DOI 10.1016/0092-8674(91)90186-3; SARAFIANOS SG, 1995, BIOCHEMISTRY-US, V34, P7207, DOI 10.1021/bi00021a036; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; Sousa R, 1996, TRENDS BIOCHEM SCI, V21, P186, DOI 10.1016/S0968-0004(96)10023-2; STRAHL C, 1994, NUCLEIC ACIDS RES, V22, P893, DOI 10.1093/nar/22.6.893; Strahl C, 1996, MOL CELL BIOL, V16, P53; TEMIN HM, 1970, NATURE, V226, P1211, DOI 10.1038/2261211a0; TEMIN HM, 1974, ANNU REV GENET, V8, P155, DOI 10.1146/annurev.ge.08.120174.001103; VirtaPearlman V, 1996, GENE DEV, V10, P3094, DOI 10.1101/gad.10.24.3094; WANG H, 1993, CELL, V75, P1071, DOI 10.1016/0092-8674(93)90317-J; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; WILM MS, 1994, INT J MASS SPECTROM, V136, P167, DOI 10.1016/0168-1176(94)04024-9; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x; ZAHLER AM, 1988, NUCLEIC ACIDS RES, V16, P6953, DOI 10.1093/nar/16.14.6953; ZIMMERLY S, 1995, CELL, V83, P529, DOI 10.1016/0092-8674(95)90092-6	67	962	1028	3	94	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 25	1997	276	5312					561	567		10.1126/science.276.5312.561	http://dx.doi.org/10.1126/science.276.5312.561			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WV721	9110970				2022-12-01	WOS:A1997WV72100037
J	Coquelle, A; Pipiras, E; Toledo, F; Buttin, G; Debatisse, M				Coquelle, A; Pipiras, E; Toledo, F; Buttin, G; Debatisse, M			Expression of fragile sites triggers intrachromosomal mammalian gene amplification and sets boundaries to early amplicons	CELL			English	Article							CHINESE-HAMSTER CELLS; DNA STRAND BREAKS; CHROMOSOME BREAKAGE; AMPLIFIED GENES; INSITU HYBRIDIZATION; DOUBLE MINUTES; 11Q13 REGION; CAD GENES; SEQUENCES; CANCER	Drug-selected intrachromosomal gene amplification by breakage-fusion-bridge (BFB) cycles is well documented in mammalian cells, but factors governing this mechanism are not clear. Here, we show that only some clastogenic drugs induce drug resistance through intrachromosomal amplification. We strictly correlate triggering of BFB cycles to induction of fragile site expression. We demonstrate a dual role for fragile sites in intrachromosomal amplification: a site telomeric to the selected gene is involved in initiation, while a centromeric site defines the size and organization of early amplified units. The positions of fragile sites relative to boundaries of amplicons found in human cancers support the hypothesis that fragile sites play a key role in the amplification of at least some oncogenes during tumor progression.	INST PASTEUR, UNITE GENET SOMAT, CNRS, UNITE RECH ASSOCIEE 1960, F-75724 PARIS 15, FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite			Coquelle, Arnaud/AAE-5425-2020	Toledo, Franck/0000-0003-3798-4106				BALABANMALENBAUM G, 1980, CANCER GENET CYTOGEN, V2, P339, DOI 10.1016/0165-4608(80)90065-5; BAN S, 1995, MUTAT RES-ENVIR MUTA, V334, P197, DOI 10.1016/0165-1161(95)90011-X; BARRETT M, 1992, GENE AMPLIFICATION M, P119; BERTONI L, 1994, GENOMICS, V24, P53, DOI 10.1006/geno.1994.1581; BIEDLER JL, 1988, CANCER RES, V48, P3179; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BRISON O, 1993, BIOCHIM BIOPHYS ACTA, V1155, P25, DOI 10.1016/0304-419X(93)90020-D; CARROLL SM, 1987, MOL CELL BIOL, V7, P1740, DOI 10.1128/MCB.7.5.1740; CHAMPEME MH, 1995, GENE CHROMOSOME CANC, V12, P128, DOI 10.1002/gcc.2870120207; CHEN ATL, 1989, ENVIRON MOL MUTAGEN, V13, P319, DOI 10.1002/em.2850130407; COLLINS VP, 1995, GLIA, V15, P289, DOI 10.1002/glia.440150309; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COWELL JK, 1982, ANNU REV GENET, V16, P21, DOI 10.1146/annurev.ge.16.120182.000321; DEBATISSE M, 1988, MOL CELL BIOL, V8, P17, DOI 10.1128/MCB.8.1.17; DEBATISSE M, 1982, MOL CELL BIOL, V2, P1346, DOI 10.1128/MCB.2.11.1346; DEBATISSE M, 1984, EMBO J, V3, P3123, DOI 10.1002/j.1460-2075.1984.tb02268.x; Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430; EVANS HJ, 1974, CHROMOSOMES CANCER, P191; FRITSCHE M, 1993, ONCOGENE, V8, P307; GEORGE DL, 1982, P NATL ACAD SCI-BIOL, V79, P1597, DOI 10.1073/pnas.79.5.1597; GLOVER TW, 1988, AM J HUM GENET, V43, P265; Gottesman MM, 1995, ANNU REV GENET, V29, P607, DOI 10.1146/annurev.ge.29.120195.003135; Gottesman MM, 1996, CURR OPIN GENET DEV, V6, P610, DOI 10.1016/S0959-437X(96)80091-8; HASTIE ND, 1989, TRENDS GENET, V5, P326, DOI 10.1016/0168-9525(89)90137-6; JONES C, 1995, NATURE, V376, P145, DOI 10.1038/376145a0; KAOSHAN CS, 1987, CANCER RES, V47, P6278; KUO MT, 1994, MOL CELL BIOL, V14, P5202, DOI 10.1128/MCB.14.8.5202; LEBEAU MM, 1984, NATURE, V308, P607, DOI 10.1038/308607a0; LESE CM, 1995, GENE CHROMOSOME CANC, V12, P288, DOI 10.1002/gcc.2870120409; LI JC, 1984, P NATL ACAD SCI-BIOL, V81, P5694, DOI 10.1073/pnas.81.18.5694; MA C, 1993, GENE DEV, V7, P605, DOI 10.1101/gad.7.4.605; MARTINS MB, 1993, MUTAT RES, V285, P229, DOI 10.1016/0027-5107(93)90111-R; MAURER BJ, 1987, NATURE, V327, P434, DOI 10.1038/327434a0; MCCLINTOCK B, 1951, COLD SPRING HARB SYM, V16, P13, DOI 10.1101/SQB.1951.016.01.004; MOORE RC, 1990, CHROMOSOMAL ABERRATI, P41; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; PEDEUTOUR F, 1994, GENE CHROMOSOME CANC, V10, P85, DOI 10.1002/gcc.2870100203; PINKEL D, 1988, P NATL ACAD SCI USA, V85, P9138, DOI 10.1073/pnas.85.23.9138; Poupon MF, 1996, MOL BIOL CELL, V7, P345, DOI 10.1091/mbc.7.3.345; RASSOOL FV, 1991, P NATL ACAD SCI USA, V88, P6657, DOI 10.1073/pnas.88.15.6657; RATH H, 1984, CANCER RES, V44, P3303; ROBINSON TJ, 1987, CHROMOSOMA, V96, P45, DOI 10.1007/BF00285882; ROELOFS H, 1993, GENE CHROMOSOME CANC, V7, P74, DOI 10.1002/gcc.2870070203; SALTMAN D, 1993, CHROMOSOMA, V102, P121, DOI 10.1007/BF00356029; SCHIMKE RT, 1988, J BIOL CHEM, V263, P5989; SCHUURING E, 1995, GENE, V159, P83, DOI 10.1016/0378-1119(94)00562-7; SEABRIGH.M, 1971, LANCET, V2, P971; SEN S, 1987, CHROMOSOMA, V95, P117, DOI 10.1007/BF00332184; SMITH KA, 1992, P NATL ACAD SCI USA, V89, P5427, DOI 10.1073/pnas.89.12.5427; SMITH KA, 1990, CELL, V63, P1219, DOI 10.1016/0092-8674(90)90417-D; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; SPRIGGS AI, 1962, BRIT MED J, P1431, DOI 10.1136/bmj.2.5317.1431; SUTHERLAND GR, 1979, AM J HUM GENET, V31, P125; SUTHERLAND GR, 1995, CURR OPIN GENET DEV, V5, P323, DOI 10.1016/0959-437X(95)80046-8; TISTY TD, 1984, MOL CELL BIOL, V4, P1050; TKACHUK DC, 1990, SCIENCE, V250, P559, DOI 10.1126/science.2237408; TOLEDO F, 1992, MUTAT RES, V276, P261, DOI 10.1016/0165-1110(92)90012-X; TOLEDO F, 1993, CURR BIOL, V3, P255, DOI 10.1016/0960-9822(93)90175-N; TOLEDO F, 1992, EMBO J, V11, P2665, DOI 10.1002/j.1460-2075.1992.tb05332.x; Veinot L., 1992, Gene amplification in mammalian cells: a comprehensive guide., P287; WARREN ST, 1987, SCIENCE, V237, P420, DOI 10.1126/science.3603029; WINDLE B, 1991, GENE DEV, V5, P160, DOI 10.1101/gad.5.2.160; YUNIS JJ, 1987, ONCOGENE, V1, P59; YUNIS JJ, 1983, SCIENCE, V221, P227, DOI 10.1126/science.6336310; YUNIS JJ, 1984, SCIENCE, V226, P1199, DOI 10.1126/science.6239375	67	333	338	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 18	1997	89	2					215	225		10.1016/S0092-8674(00)80201-9	http://dx.doi.org/10.1016/S0092-8674(00)80201-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WU888	9108477	Bronze			2022-12-01	WOS:A1997WU88800009
J	McKay, CP; Borucki, WJ				McKay, CP; Borucki, WJ			Organic synthesis in experimental impact shocks	SCIENCE			English	Article							LASER-INDUCED PLASMAS; PLANETARY-ATMOSPHERES; NITROGEN-FIXATION; TITAN; CARBON; ORIGIN; RATES	Laboratory simulations of shocks created with a high-energy laser demonstrate that the efficacy of organic production depends on the molecular, not just the elemental composition of the shocked gas. In a methane-rich mixture that simulates a low-temperature equilibrium mixture of cometary material, hydrogen cyanide and acetylene were produced with yields of 5 x 10(17) molecules per joule. Repeated shocking of the methane-rich mixture produced amine groups, suggesting the possible synthesis of amino acids, No organic molecules were produced in a carbon dioxide-rich mixture, which is at odds with thermodynamic equilibrium approaches to shock chemistry and has implications for the modeling of shock-produced organic molecules on early Earth.			McKay, CP (corresponding author), NASA,AMES RES CTR,DIV SPACE SCI,MOFFETT FIELD,CA 94035, USA.							BORUCKI WJ, 1987, APPL OPTICS, V26, P4319, DOI 10.1364/AO.26.004319; BORUCKI WJ, 1984, REV GEOPHYS, V22, P363, DOI 10.1029/RG022i004p00363; BORUCKI WJ, 1985, ICARUS, V64, P221, DOI 10.1016/0019-1035(85)90087-9; BORUCKI WJ, 1987, NATURE, V328, P509, DOI 10.1038/328509a0; BORUCKI WJ, 1988, ICARUS, V76, P125, DOI 10.1016/0019-1035(88)90145-5; CHAMEIDES WL, 1981, ORIGINS LIFE EVOL B, V11, P291, DOI 10.1007/BF00931483; CHAMEIDES WL, 1979, NATURE, V277, P123, DOI 10.1038/277123a0; DAVIES AM, 1980, J PHYS OCEANOGR, V10, P237, DOI 10.1175/1520-0485(1980)010<0237:OACMTC>2.0.CO;2; DELSEMME AH, 1988, PHILOS T R SOC A, V325, P509, DOI 10.1098/rsta.1988.0064; FEGLEY B, 1986, NATURE, V319, P305, DOI 10.1038/319305a0; Gordon S, 1971, NASA; Holland H. D., 1984, CHEM EVOLUTION ATMOS; JEBENS DS, 1992, GEOPHYS RES LETT, V19, P273, DOI 10.1029/91GL02937; KISSEL J, 1987, NATURE, V326, P755, DOI 10.1038/326755a0; Lewis J. S., 1982, SPEC PAP GEOL SOC AM, V190, P215; Maker P D, 1964, P 3 INT C QUANT EL P, V2, P1559; MCKAY CP, 1988, NATURE, V332, P520, DOI 10.1038/332520a0; MUKHIN LM, 1989, NATURE, V340, P46, DOI 10.1038/340046a0; POLLACK JB, 1980, ANNU REV EARTH PL SC, V8, P425, DOI 10.1146/annurev.ea.08.050180.002233; RADZIEMSKI LJ, 1983, ANAL CHEM, V55, P1246, DOI 10.1021/ac00259a016; RAIZER YP, 1966, SOV PHYS USPEKHI, V8, P650, DOI 10.1070/PU1966v008n05ABEH003027; SCATTERGOOD TW, 1989, ICARUS, V81, P413, DOI 10.1016/0019-1035(89)90061-4; SIMONELLI DP, 1989, ICARUS, V82, P1, DOI 10.1016/0019-1035(89)90020-1; YUNG YL, 1984, ASTROPHYS J SUPPL S, V55, P465, DOI 10.1086/190963; ZAHNLE K, 1995, GEOPHYS RES LETT, V22, P1593, DOI 10.1029/95GL01190	25	80	81	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 18	1997	276	5311					390	392		10.1126/science.276.5311.390	http://dx.doi.org/10.1126/science.276.5311.390			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WU477	9103191				2022-12-01	WOS:A1997WU47700031
J	Tesmer, JJG; Berman, DM; Gilman, AG; Sprang, SR				Tesmer, JJG; Berman, DM; Gilman, AG; Sprang, SR			Structure of RGS4 bound to AlF4--activated G(i alpha 1): Stabilization of the transition state for GTP hydrolysis	CELL			English	Article							PROTEIN ALPHA-SUBUNITS; CRYSTAL-STRUCTURES; ESCHERICHIA-COLI; RAS PROTEINS; GS-ALPHA; MECHANISM; MUTANTS; P21; REFINEMENT; MUTATIONS	RGS proteins are GTPase activators for heterotrimeric G proteins. We report here the 2.8 Angstrom resolution crystal structure of the RGS protein RGS4 complexed with G(i alpha 1)-Mg2+-GDP0AlF(4)(-). Only the core domain of RGS4 is visible in the crystal. The core domain binds to the three switch regions of G(i alpha 1), but does not contribute catalytic residues that directly interact with either GDP or AlF4-. Therefore, RGS4 appears to catalyze rapid hydrolysis of GTP primarily by stabilizing the switch regions of G(i alpha 1), although the conserved Asn-128 from RGS4 could also play a catalytic role by interacting with the hydrolytic water molecule or the side chain of Gln-204. The binding site for RGS4 on G(i alpha 1) is also consistent with the activity of RGS proteins as antagonists of G(alpha) effectors.	UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,HOWARD HUGHES MED INST,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Tesmer, John/0000-0003-1125-3727	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046371] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034497, R37GM034497] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46371] Funding Source: Medline; NIGMS NIH HHS [GM34497, GM07062] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmadian MR, 1996, J BIOL CHEM, V271, P16409, DOI 10.1074/jbc.271.27.16409; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barrett T, 1997, NATURE, V385, P458, DOI 10.1038/385458a0; Berghuis AM, 1996, STRUCTURE, V4, P1277, DOI 10.1016/S0969-2126(96)00136-0; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BOLIN JT, 1993, AM CRYST ASS, V21, P51; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; CHAN RK, 1982, MOL CELL BIOL, V2, P11, DOI 10.1128/MCB.2.1.11; Chen CK, 1996, P NATL ACAD SCI USA, V93, P12885, DOI 10.1073/pnas.93.23.12885; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; Dohlman HG, 1996, MOL CELL BIOL, V16, P5194; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FREISSMUTH M, 1989, J BIOL CHEM, V264, P21907; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.biochem.56.1.615; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; HAMM HE, 1996, CURR OPIN CELL BIOL, V8, P615; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLEUSS C, 1994, P NATL ACAD SCI USA, V91, P9828, DOI 10.1073/pnas.91.21.9828; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P826, DOI 10.1107/S0907444995014983; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LEE E, 1994, METHOD ENZYMOL, V237, P146; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; Mittal R, 1996, SCIENCE, V273, P115, DOI 10.1126/science.273.5271.115; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; Musacchio A, 1996, P NATL ACAD SCI USA, V93, P14373, DOI 10.1073/pnas.93.25.14373; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PRIVE GG, 1992, P NATL ACAD SCI USA, V89, P3649, DOI 10.1073/pnas.89.8.3649; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; ROSS EM, 1995, RECENT PROG HORM RES, V50, P207; Scheffzek K, 1996, NATURE, V384, P591, DOI 10.1038/384591a0; SCHWEINS T, 1994, NAT STRUCT BIOL, V1, P476, DOI 10.1038/nsb0794-476; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; TEMELES GL, 1985, NATURE, V313, P700, DOI 10.1038/313700a0; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; WEBER PC, 1980, NATURE, V287, P82, DOI 10.1038/287082a0	62	679	689	0	24	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 18	1997	89	2					251	261		10.1016/S0092-8674(00)80204-4	http://dx.doi.org/10.1016/S0092-8674(00)80204-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WU888	9108480	Bronze			2022-12-01	WOS:A1997WU88800012
J	Thiel, S; VorupJensen, T; Stover, CM; Schwaeble, W; Laursen, SB; Poulsen, K; Willis, AC; Eggleton, P; Hansen, S; Holmskov, U; Reid, KB; Jensenius, JC				Thiel, S; VorupJensen, T; Stover, CM; Schwaeble, W; Laursen, SB; Poulsen, K; Willis, AC; Eggleton, P; Hansen, S; Holmskov, U; Reid, KB; Jensenius, JC			A second serine protease associated with mannan-binding lectin that activates complement	NATURE			English	Article							RA-REACTIVE FACTOR; BACTERICIDAL FACTOR; SERUM LECTIN; SEQUENCE; CDNA; C1S; MUTATIONS; PATHWAY; OPSONIN; CLONING	The complement system comprises a complex array of enzymes and non-enzymatic proteins that is essential for the operation of the innate as well as the adaptive immune defence(1). The complement system can be activated in three ways: by the classical pathway which is initiated by antibody-antigen complexes, by the alternative pathway initiated by certain structures on microbial surfaces, and by an antibody-independent pathway(2) that is initiated by the binding of mannan-binding lectin (MEL; first described as mannan-binding protein(3)) to carbohydrates. MBL is structurally related to the complement C1 subcomponent, C1q, and seems to activate the complement system through an associated serine protease known as MASP (ref. 4) or p100 (ref. 5), which is similar to C1r and C1s of the classical pathway. MBL binds to specific carbohydrate structures found on the surface of a range of microorganisms, including bacteria, yeasts, parasitic protozoa and viruses(6), and exhibits antibacterial activity through killing mediated by the terminal, lytic complement components(7) or by promoting phagocytosis(8), The level of MBL in plasma is genetically determinedg-(9-11), and deficiency is associated with frequent infections in childhood(12,13), and possibly also in adults(14,15) (for review, see ref. 6), We have now identified a new MBL-associated serine protease (MASP-2) which shows a striking homology with the previously reported MASP (MASP-1) and the two C1q-associated serine proteases C1r and C1s. Thus complement activation through MBL, like the classical pathway, involves two serine proteases and may antedate the development of the specific immune system of vertebrates.	UNIV LEICESTER, DEPT MICROBIOL & IMMUNOL, LEICESTER LE1 9HN, LEICS, ENGLAND; UNIV OXFORD, MRC, IMMUNOCHEM UNIT, OXFORD OX1 3QU, ENGLAND; ODENSE UNIV, DEPT MED MICROBIOL, DK-5000 ODENSE, DENMARK	University of Leicester; University of Oxford; University of Southern Denmark	Thiel, S (corresponding author), AARHUS UNIV, DEPT MED MICROBIOL & IMMUNOL, DK-8000 AARHUS, DENMARK.		Holmskov, Uffe/AAA-3056-2022; Vorup-Jensen, Thomas/N-9082-2016	Holmskov, Uffe/0000-0002-2391-9445; Schwaeble, Wilhelm/0000-0001-8927-0864; Vorup-Jensen, Thomas/0000-0002-4140-6563; Thiel, Steffen/0000-0002-4817-155X; Eggleton, Paul/0000-0001-8244-2125; Hansen, Soren/0000-0002-8186-4630; Stover, Cordula/0000-0002-0125-4868	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAATRUP G, 1987, SCAND J IMMUNOL, V26, P355, DOI 10.1111/j.1365-3083.1987.tb02267.x; Endo Y, 1996, INT IMMUNOL, V8, P1355, DOI 10.1093/intimm/8.9.1355; GARRED P, 1995, LANCET, V346, P941, DOI 10.1016/S0140-6736(95)91559-1; IKEDA K, 1987, J BIOL CHEM, V262, P7451; JENSENIUS JC, 1981, J IMMUNOL METHODS, V46, P63, DOI 10.1016/0022-1759(81)90333-1; JI YH, 1993, J IMMUNOL, V150, P571; JOURNET A, 1986, BIOCHEM J, V240, P783, DOI 10.1042/bj2400783; KAWASAKI N, 1989, J BIOCHEM-TOKYO, V106, P483, DOI 10.1093/oxfordjournals.jbchem.a122878; KAWASAKI T, 1978, BIOCHEM BIOPH RES CO, V81, P1018, DOI 10.1016/0006-291X(78)91452-3; KUHLMAN M, 1989, J EXP MED, V169, P1733, DOI 10.1084/jem.169.5.1733; LAW SKA, 1996, COMPLEMENT, P1; Lipscombe R. J., 1992, Human Molecular Genetics, V1, P709, DOI 10.1093/hmg/1.9.709; LYTUS SP, 1986, BIOCHEMISTRY-US, V25, P4855; MACKINNON CM, 1987, EUR J BIOCHEM, V169, P547, DOI 10.1111/j.1432-1033.1987.tb13644.x; MADSEN HO, 1994, IMMUNOGENETICS, V40, P37, DOI 10.1007/BF00163962; MATSUSHITA M, 1992, J EXP MED, V176, P1497, DOI 10.1084/jem.176.6.1497; NIELSEN SL, 1995, CLIN EXP IMMUNOL, V100, P219; SATO T, 1994, INT IMMUNOL, V6, P665, DOI 10.1093/intimm/6.4.665; SUMIYA M, 1991, LANCET, V337, P1569, DOI 10.1016/0140-6736(91)93263-9; SUMMERFIELD JA, 1995, LANCET, V345, P886, DOI 10.1016/S0140-6736(95)90009-8; SUPER M, 1989, LANCET, V2, P1236; TAKADA F, 1993, BIOCHEM BIOPH RES CO, V196, P1003, DOI 10.1006/bbrc.1993.2349; Tan SM, 1996, BIOCHEM J, V319, P329, DOI 10.1042/bj3190329; TOSI M, 1987, BIOCHEMISTRY-US, V26, P8516, DOI 10.1021/bi00400a004; Turner MW, 1996, IMMUNOL TODAY, V17, P532, DOI 10.1016/0167-5699(96)10062-1; [No title captured]	26	712	767	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 3	1997	386	6624					506	510		10.1038/386506a0	http://dx.doi.org/10.1038/386506a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WR256	9087411				2022-12-01	WOS:A1997WR25600055
J	Biver, N; BockeleeMorvan, D; Colom, P; Crovisier, J; Davies, JK; Dent, WRF; Despois, D; Gerard, E; Lellouch, E; Rauer, H; Moreno, R; Paubert, G				Biver, N; BockeleeMorvan, D; Colom, P; Crovisier, J; Davies, JK; Dent, WRF; Despois, D; Gerard, E; Lellouch, E; Rauer, H; Moreno, R; Paubert, G			Evolution of the outgassing of comet Hale-Bopp (C/1995 O1) from radio observations	SCIENCE			English	Article							ROTATIONAL LINES; P/HALLEY; FORMALDEHYDE; EXCITATION; METHANOL; OH	Spectra obtained from ground-based radio telescopes show the progressive release of CO, CH3OH, HCN, H2O (from OH), H2S, CS, H2CO, CH3CN, and HNC as comet Hale-Bopp (C/1995 O1) approached the sun from 6.9 to 1.4 astronomical units (AU). The more volatile species were relatively more abundant in the coma far from the sun, but there was no direct correlation between overabundance and volatility. Evidence for H2O sublimation from icy grains was seen beyond 3.5 AU from the sun. The change from a GO-driven coma to an H2O-driven coma occurred at about 3 AU. The gas outflow velocity and temperature increased as Hale-Bopp approached the sun.	OBSERV PARIS, F-92195 MEUDON, FRANCE; JOINT ASTRON CTR, HILO, HI 96720 USA; OBSERV BORDEAUX, F-33270 FLOIRAC, FRANCE; INST RADIOASTRON MILLIMETRIQUE, GRANADA 18012, SPAIN	UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris								Biver N, 1996, NATURE, V380, P137, DOI 10.1038/380137a0; BIVER N, 1996, 6458 IAU; BIVER N, 1996, 6421 IAU; BIVER N, 1996, 6386 IAU; BOCKELEEMORVAN D, 1990, ASTRON ASTROPHYS, V238, P382; BOCKELEEMORVAN D, 1994, ASTRON ASTROPHYS, V287, P647; BOCKELEEMORVAN D, 1992, ASTRON ASTROPHYS, V264, P282; BOCKELEEMORVAN D, IN PRESS IAU S, V178; BOCKELEEMORVAN D, 1996, 6511 IAU; BUDZIEN SA, 1994, ICARUS, V107, P164, DOI 10.1006/icar.1994.1014; CROVISIER J, 1989, ASTRON ASTROPHYS, V213, P459; Crovisier J, 1996, ASTRON ASTROPHYS, V315, pL385; CROVISIER J, 1995, ICARUS, V115, P213, DOI 10.1006/icar.1995.1091; Crovisier J, 1997, SCIENCE, V275, P1904, DOI 10.1126/science.275.5308.1904; CROVISIER J, 1991, ICARUS, V93, P246, DOI 10.1016/0019-1035(91)90210-K; CROVISIER J, 1987, ASTRON ASTROPHYS SUP, V68, P223; CROVISIER J, 1996, 6394 IAU; DAVIES JK, IN PRESS ICARUS; EBERHARDT P, 1987, ASTRON ASTROPHYS, V187, P481; ENZIAN A, 1997, THESIS U J FOURER GR; GERARD E, UNPUB; GERARD E, 1989, ASTRON ASTROPHYS S, V77, P278; HALE A, 1995, 6187 IAU; Irvine WM, 1996, NATURE, V383, P418, DOI 10.1038/383418a0; Jewitt D, 1996, SCIENCE, V271, P1110, DOI 10.1126/science.271.5252.1110; JEWITT D, 1996, 6377 IAU; LEES RM, 1973, ASTROPHYS J, V184, P763, DOI 10.1086/152368; LIS D, 1996, 6362 IAU; MEIER R, 1993, ASTRON ASTROPHYS, V277, P677; SCHLOERB FP, 1988, ASTROPHYS J, V332, P524, DOI 10.1086/166674; SCHLOERB FP, 1987, ASTRON ASTROPHYS, V187, P475; SENAY MC, 1994, NATURE, V371, P229, DOI 10.1038/371229a0; WEAVER HA, 1996, 6376 IAU; Wilkening L. L, 1982, IAU C 61 COMET DISCO, P85; WOMACK M, 1996, 6382 IAU; WOODNEY LM, 1996, 6408 IAU; WOODNEY LM, 1996, 6344 IAU; WOOTTEN A, 1996, 6362 IAU	38	160	160	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 28	1997	275	5308					1915	1918		10.1126/science.275.5308.1915	http://dx.doi.org/10.1126/science.275.5308.1915			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WQ513	9072964				2022-12-01	WOS:A1997WQ51300039
J	Bruckner, K; Pasquale, EB; Klein, R				Bruckner, K; Pasquale, EB; Klein, R			Tyrosine phosphorylation of transmembrane ligands for Eph receptors	SCIENCE			English	Article							KINASE; FAMILY; AXONOGENESIS; HINDBRAIN; BINDING; CLONING; DOMAIN; AXONS; BRAIN; CEK5	Axonal pathfinding in the nervous system is mediated in part by cell-to-cell signaling events involving members of the Eph receptor tyrosine kinase (RTK) family and their membrane-bound ligands. Genetic evidence suggests that transmembrane ligands may transduce signals in the developing embryo. The cytoplasmic domain of the transmembrane ligand Lerk2 became phosphorylated on tyrosine residues after contact with the Nuk/Cek5 receptor ectodomain, which suggests that Lerk2 has receptorlike intrinsic signaling potential. Moreover, Lerk2 is an in vivo substrate for the platelet-derived growth factor, receptor, which suggests crosstalk between Lerk2 signaling and signaling cascades activated by tyrosine kinases. It is proposed that transmembrane ligands of Eph receptors act not only as conventional RTK ligands but also as receptorlike signaling molecules.	EUROPEAN MOL BIOL LAB,D-69117 HEIDELBERG,GERMANY; BURNHAM INST,LA JOLLA,CA 92037	European Molecular Biology Laboratory (EMBL); Sanford Burnham Prebys Medical Discovery Institute			Klein, Ruediger/C-6147-2008	Klein, Ruediger/0000-0002-3109-0163	NATIONAL EYE INSTITUTE [R01EY010576] Funding Source: NIH RePORTER; NEI NIH HHS [EY10576] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BECKER N, 1994, MECH DEVELOP, V47, P3, DOI 10.1016/0925-4773(94)90091-4; BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; BENNETT BD, 1995, P NATL ACAD SCI USA, V92, P1866, DOI 10.1073/pnas.92.6.1866; BERGEMANN AD, 1995, MOL CELL BIOL, V15, P4921; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; BRAMBILLA R, 1995, EMBO J, V14, P3116, DOI 10.1002/j.1460-2075.1995.tb07314.x; Brambilla R, 1995, MOL CELL NEUROSCI, V6, P487, DOI 10.1006/mcne.1995.0001; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; ERPEL T, 1995, EMBO J, V14, P963, DOI 10.1002/j.1460-2075.1995.tb07077.x; Gale NW, 1996, ONCOGENE, V13, P1343; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; GOGA A, 1995, ONCOGENE, V11, P791; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; Holash JA, 1995, DEV BIOL, V172, P683, DOI 10.1006/dbio.1995.8039; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; Nakamoto M, 1996, CELL, V86, P755, DOI 10.1016/S0092-8674(00)80150-6; Nicola NA, 1996, GROWTH FACTORS, V13, P141, DOI 10.3109/08977199609034574; Orioli D, 1996, EMBO J, V15, P6035, DOI 10.1002/j.1460-2075.1996.tb00992.x; OSTMANN A, 1988, J BIOL CHEM, V268, P16202; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; PASQUALE EB, 1994, DEV BIOL, V163, P491, DOI 10.1006/dbio.1994.1165; Paulson RF, 1996, NAT GENET, V13, P309, DOI 10.1038/ng0796-309; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; SHAO HN, 1994, J BIOL CHEM, V269, P26606; SMITS A, 1991, P NATL ACAD SCI USA, V88, P8159, DOI 10.1073/pnas.88.18.8159; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Xu QL, 1996, NATURE, V381, P319, DOI 10.1038/381319a0	34	336	360	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 14	1997	275	5306					1640	1643		10.1126/science.275.5306.1640	http://dx.doi.org/10.1126/science.275.5306.1640			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WN123	9054357				2022-12-01	WOS:A1997WN12300045
J	Snyder, LH; Batista, AP; Andersen, RA				Snyder, LH; Batista, AP; Andersen, RA			Coding of intention in the posterior parietal cortex	NATURE			English	Article							MONKEY CEREBRAL-CORTEX; ASSOCIATION CORTEX; BEHAVIORAL ENHANCEMENT; VISUAL RESPONSES; REPRESENTATION; ATTENTION; MECHANISMS; MODULATION; PRIMATE; SPACE	To look at or reach for what we see, spatial information from the visual system must be transformed into a motor plan, The posterior parietal cortex (PPC) is well placed to perform this function, because it Lies between visual areas, which encode spatial information(1,2), and motor cortical areas. The PPC contains several subdivisions, which are generally conceived as high-order sensory areas(3,4). Neurons in area 7a and the lateral intraparietal area fire before and during visually guided saccades. Other neurons in areas 7a and 5 are active before and during visually guided arm movements(5-10). These areas are also active during memory tasks in which the animal remembers the location of a target for hundreds of milliseconds before making an eye or arm movement. Such activity could reflect either visual attention(11-15) or the intention to make movements(16-22). This question is difficult to resolve, because even if the animal maintains fixation while directing attention to a peripheral location, the observed neuronal activity could reflect movements that are planned but not executed(22). To address this, we recorded from the PPC while monkeys planned either reaches or saccades to a single remembered location. We now report that, for most neurons, activity before the movement depended on the type of movement being planned. We conclude that PPC contains signals related to what the animal intends to do.	CALTECH,DIV BIOL,PASADENA,CA 91125	California Institute of Technology			Snyder, Lawrence H/A-4593-2017	Batista, Aaron/0000-0002-1719-0061				ANDERSEN RA, 1987, EXP BRAIN RES, V67, P316; ANDERSEN RA, 1989, ANNU REV NEUROSCI, V12, P377, DOI 10.1146/annurev.neuro.12.1.377; ANDERSEN RA, 1995, CEREB CORTEX, V5, P457, DOI 10.1093/cercor/5.5.457; BON L, 1994, EXP BRAIN RES, V102, P259; Bracewell RM, 1996, J NEUROPHYSIOL, V76, P1457, DOI 10.1152/jn.1996.76.3.1457; BUSHNELL MC, 1981, J NEUROPHYSIOL, V46, P755, DOI 10.1152/jn.1981.46.4.755; COLBY CL, 1995, CEREB CORTEX, V5, P470, DOI 10.1093/cercor/5.5.470; DUHAMEL JR, 1992, SCIENCE, V255, P90, DOI 10.1126/science.1553535; GNADT JW, 1988, EXP BRAIN RES, V70, P216; GOLDBERG ME, 1981, J NEUROPHYSIOL, V46, P773, DOI 10.1152/jn.1981.46.4.773; GOODALE MG, 1992, TRENDS NEUROSCI, V15, P220; HARTJE W, 1974, CORTEX, V9, P346; HYVARINEN J, 1974, BRAIN, V97, P673, DOI 10.1093/brain/97.1.673; KALASKA JF, 1995, CEREB CORTEX, V5, P410, DOI 10.1093/cercor/5.5.410; LYNCH JC, 1977, J NEUROPHYSIOL, V40, P362, DOI 10.1152/jn.1977.40.2.362; Mazzoni P, 1996, J NEUROPHYSIOL, V76, P1439, DOI 10.1152/jn.1996.76.3.1439; MOUNTCASTLE VB, 1975, J NEUROPHYSIOL, V38, P871, DOI 10.1152/jn.1975.38.4.871; MURATA A, 1996, NEUROPHYSIOL, V75, P2180; ROBINSON DL, 1978, J NEUROPHYSIOL, V41, P910, DOI 10.1152/jn.1978.41.4.910; SCOTT DW, 1985, ANN STAT, V13, P1024, DOI 10.1214/aos/1176349654; SEAL J, 1985, EXP BRAIN RES, V58, P144; Shadlen MN, 1996, P NATL ACAD SCI USA, V93, P628, DOI 10.1073/pnas.93.2.628; SHIBUTANI H, 1984, EXP BRAIN RES, V55, P1; STEINMETZ MA, 1994, J NEUROPHYSIOL, V72, P1020, DOI 10.1152/jn.1994.72.2.1020; Thier P, 1996, P NATL ACAD SCI USA, V93, P4962, DOI 10.1073/pnas.93.10.4962; Ungerleider L, 1982, ANAL VISUAL BEHAV, P549; [No title captured]	27	812	819	0	32	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 13	1997	386	6621					167	170		10.1038/386167a0	http://dx.doi.org/10.1038/386167a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WM973	9062187				2022-12-01	WOS:A1997WM97300060
J	LawlorSmith, L; LawlorSmith, C				LawlorSmith, L; LawlorSmith, C			Vasospasm of the nipple - A manifestation of Raynaud's phenomenon: Case reports	BRITISH MEDICAL JOURNAL			English	Article																		BELCH J J F, 1991, Current Opinion in Rheumatology, V3, P960, DOI 10.1097/00002281-199112000-00011; BELCH JJF, 1990, THER UPDATE, V6, P253; OLSEN N, 1978, SCAND J CLIN LAB INV, V37, P761; SLOPER KS, 1977, ARCH DIS CHILD, V52, P700, DOI 10.1136/adc.52.9.700; Woolridge M W, 1986, Midwifery, V2, P172, DOI 10.1016/S0266-6138(86)80042-0	5	21	22	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 1	1997	314	7081					644	645		10.1136/bmj.314.7081.644	http://dx.doi.org/10.1136/bmj.314.7081.644			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WL418	9066478	Green Published			2022-12-01	WOS:A1997WL41800025
J	Zuccala, G; Pahor, M; Landi, F; Gasparini, G; Pagano, F; Carbonin, PU; Cocchi, A				Zuccala, G; Pahor, M; Landi, F; Gasparini, G; Pagano, F; Carbonin, PU; Cocchi, A			Use of calcium antagonists and need for perioperative transfusion in older patients with hip fracture: Observational study	BRITISH MEDICAL JOURNAL			English	Article											Zuccala, G (corresponding author), UNIV CATTOLICA SACRO CUORE, DEPT INTERNAL MED & GERIATR, I-00168 ROME, ITALY.		Zuccalà, Giuseppe/AAC-4677-2022	Zuccalà, Giuseppe/0000-0002-2567-2220				AUDET AM, 1992, ANN INTERN MED, V116, P403, DOI 10.7326/0003-4819-116-5-403; GREER IA, 1985, LANCET, V1, P351; MURRAY GD, 1995, BRIT MED J, V311, P388, DOI 10.1136/bmj.311.7001.388c; Pahor M, 1996, LANCET, V347, P1061, DOI 10.1016/S0140-6736(96)90276-7; PAHOR M, IN PRESS GASTROENTER	5	36	40	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 1	1997	314	7081					643	644		10.1136/bmj.314.7081.643	http://dx.doi.org/10.1136/bmj.314.7081.643			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WL418	9066477	Green Published			2022-12-01	WOS:A1997WL41800024
J	Arnon, A; Cook, B; Montell, C; Selinger, Z; Minke, B				Arnon, A; Cook, B; Montell, C; Selinger, Z; Minke, B			Calmodulin regulation of calcium stores in phototransduction of Drosophila	SCIENCE			English	Article							CA2+ RELEASE CHANNEL; LIGHT CHAIN KINASE; RYANODINE RECEPTOR; SKELETAL-MUSCLE; PLASMA-MEMBRANE; BINDING DOMAIN; TUMOR PROMOTER; PHOTORECEPTORS; MYOSIN; THAPSIGARGIN	Phototransduction in Drosophila occurs through the ubiquitous phosphoinositide-mediated signal transduction system. Major unresolved questions in this pathway are the identity and role of the internal calcium stores in light excitation and the mechanism underlying regulation of Ca2+ release from internal stores. Treatment of Drosophila photoreceptors with ryanodine and caffeine disrupted the current induced by light, whereas subsequent application of calcium-calmodulin (Ca-CaM) rescued the inactivated photoresponse. In calcium-deprived wild-type Drosophila and in calmodulin-deficient transgenic flies, the current induced by light was disrupted by a specific inhibitor of Ca-CaM. Furthermore, inhibition of Ca-CaM revealed light-induced release of calcium from intracellular stores. It appears that functional ryanodine-sensitive stores are essential for the photoresponse. Moreover, calcium release from these stores appears to be a component of Drosophila phototransduction, and Ca-CaM regulates this process.	HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT PHYSIOL,IL-91120 JERUSALEM,ISRAEL; HEBREW UNIV JERUSALEM,HADASSAH MED SCH,KUHNE MINERVA CTR STUDIES VISUAL TRANSDUCT,IL-91120 JERUSALEM,ISRAEL; JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM & NEUROSCI,BALTIMORE,MD 21205; HEBREW UNIV JERUSALEM,DEPT BIOL CHEM,IL-91904 JERUSALEM,ISRAEL; HEBREW UNIV JERUSALEM,KUHNE MINERVA CTR STUDIES VISUAL TRANDUCT,IL-91904 JERUSALEM,ISRAEL	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Johns Hopkins University; Hebrew University of Jerusalem; Hebrew University of Jerusalem			Montell, Craig/AAH-3357-2021	Montell, Craig/0000-0001-5637-1482	NEI NIH HHS [EY10852, EY03529] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY010852, R01EY003529] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; BLUMENTHAL DK, 1988, BIOCHEM BIOPH RES CO, V156, P860, DOI 10.1016/S0006-291X(88)80923-9; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; EHRLICH BE, 1995, CURR OPIN NEUROBIOL, V5, P304, DOI 10.1016/0959-4388(95)80042-5; FUENTES O, 1994, CELL CALCIUM, V15, P305, DOI 10.1016/0143-4160(94)90070-1; Furuichi Teiichi, 1994, Current Opinion in Neurobiology, V4, P294, DOI 10.1016/0959-4388(94)90089-2; Hardie RC, 1996, J NEUROSCI, V16, P2924; HARDIE RC, 1995, CELL CALCIUM, V18, P256, DOI 10.1016/0143-4160(95)90023-3; HARDIE RC, 1995, J NEUROSCI, V15, P889; HARDIE RC, 1992, NEURON, V8, P643, DOI 10.1016/0896-6273(92)90086-S; Hofstee CA, 1996, VISUAL NEUROSCI, V13, P897, DOI 10.1017/S0952523800009147; JACKSON TR, 1988, BIOCHEM J, V253, P81, DOI 10.1042/bj2530081; KENNELLY PJ, 1987, J BIOL CHEM, V262, P11958; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; MASON MJ, 1991, J BIOL CHEM, V266, P20856; MCPHERSON PS, 1993, J BIOL CHEM, V268, P19785; MEISSNER G, 1987, J BIOL CHEM, V262, P3065; MESSNER G, 1986, J BIOL CHEM, V261, P6300; Minke B, 1996, CURR OPIN NEUROBIOL, V6, P459, DOI 10.1016/S0959-4388(96)80050-X; MONTELL C, 1988, CELL, V52, P722; PAK WL, 1995, INVEST OPHTH VIS SCI, V36, P2340; Pearn MT, 1996, J BIOL CHEM, V271, P4937; PERETZ A, 1994, NEURON, V12, P1257, DOI 10.1016/0896-6273(94)90442-1; PORTER JA, 1995, EMBO J, V14, P4450, DOI 10.1002/j.1460-2075.1995.tb00124.x; PORTER JA, 1993, SCIENCE, V262, P1038, DOI 10.1126/science.8235618; PORTER JA, 1993, J CELL BIOL, V122, P601, DOI 10.1083/jcb.122.3.601; RANGANATHAN R, 1995, ANNU REV NEUROSCI, V18, P283; RANGANATHAN R, 1994, NEURON, V13, P837, DOI 10.1016/0896-6273(94)90250-X; SITSAPESAN R, 1995, TRENDS PHARMACOL SCI, V16, P386, DOI 10.1016/S0165-6147(00)89080-X; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; TAKESHIMA H, 1994, FEBS LETT, V337, P81, DOI 10.1016/0014-5793(94)80634-9; TRIPATHY A, 1995, BIOPHYS J, V69, P106, DOI 10.1016/S0006-3495(95)79880-0; WALZ B, 1995, J GEN PHYSIOL, V105, P537, DOI 10.1085/jgp.105.4.537	34	52	54	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 21	1997	275	5303					1119	1121		10.1126/science.275.5303.1119	http://dx.doi.org/10.1126/science.275.5303.1119			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WJ503	9027311				2022-12-01	WOS:A1997WJ50300042
J	Chetverin, AB; Chetverina, HV; Demidenko, AA; Ugarov, VI				Chetverin, AB; Chetverina, HV; Demidenko, AA; Ugarov, VI			Nonhomologous RNA recombination in a cell-free system: Evidence for a transesterification mechanism guided by secondary structure	CELL			English	Article							Q-BETA-REPLICASE; INTERTYPIC POLIOVIRUS RECOMBINANTS; BROME MOSAIC-VIRUS; CROSSOVER REGIONS; SEQUENCES; TEMPLATES; INVITRO; GENOMES; PARTICLES; CLONING	Extensive nonhomologous recombinations occur between the 5' and 3' fragments of a replicable RNA in a cell-free system composed of pure Q beta phage replicase and ribonucleoside triphosphates, providing direct evidence for the ability of RNAs to recombine without DNA intermediates and in the absence of host cell proteins. The recombination events are revealed by the molecular colony technique that allows single RNA molecules to be cloned in vitro. The observed nonhomologous recombinations are entirely dependent on the 3' hydroxyl group of the 5' fragment, and are due to a splicing-like reaction in which RNA secondary structure guides the attack of this 3' hydroxyl on phosphoester bonds within the 3' fragment.			Chetverin, AB (corresponding author), RUSSIAN ACAD SCI, INST PROT RES, PUSHCHINO 142292, MOSCOW REGION, RUSSIA.		Ugarov, Victor/AAC-6502-2022; Chetverin, Alexander B/AAA-6511-2022; Ugarov, Victor/AAC-6454-2022					BERESTOWSKAYA NH, 1988, FEBS LETT, V228, P263, DOI 10.1016/0014-5793(88)80012-7; BIEBRICHER CK, 1992, EMBO J, V11, P5129, DOI 10.1002/j.1460-2075.1992.tb05620.x; BIEBRICHER CK, 1982, J MOL BIOL, V154, P629, DOI 10.1016/S0022-2836(82)80019-3; Blumenthal T, 1979, Methods Enzymol, V60, P628; CARPENTER CD, 1995, J MOL BIOL, V245, P608, DOI 10.1006/jmbi.1994.0050; CECH TR, 1986, ANNU REV BIOCHEM, V55, P599, DOI 10.1146/annurev.biochem.55.1.599; CHETVERIN AB, 1991, J MOL BIOL, V222, P3, DOI 10.1016/0022-2836(91)90729-P; CHETVERIN AB, 1995, PROG NUCLEIC ACID RE, V51, P225, DOI 10.1016/S0079-6603(08)60880-6; CHETVERIN AB, 1992, FRONTIERS BIOPROCESS, V2, P44; CHETVERINA HV, 1993, NUCLEIC ACIDS RES, V21, P2349, DOI 10.1093/nar/21.10.2349; DZIANOTT A, 1995, VIROLOGY, V208, P370, DOI 10.1006/viro.1995.1163; GILBERT W, 1986, NATURE, V319, P618, DOI 10.1038/319618a0; Hajjou M, 1996, J VIROL, V70, P5153, DOI 10.1128/JVI.70.8.5153-5164.1996; HIRST GK, 1962, COLD SPRING HARB SYM, V27, P303, DOI 10.1101/SQB.1962.027.001.028; IGLOI GL, 1983, ANAL BIOCHEM, V134, P184, DOI 10.1016/0003-2697(83)90281-6; JARVIS TC, 1992, EMBO J, V11, P3135, DOI 10.1002/j.1460-2075.1992.tb05386.x; KIRKEGAARD K, 1986, CELL, V47, P433, DOI 10.1016/0092-8674(86)90600-8; KUGE S, 1986, J MOL BIOL, V192, P473, DOI 10.1016/0022-2836(86)90270-6; LAI MMC, 1992, MICROBIOL REV, V56, P61, DOI 10.1128/MMBR.56.1.61-79.1992; LEDINKO N, 1963, VIROLOGY, V20, P107, DOI 10.1016/0042-6822(63)90145-4; MILLIGAN JF, 1989, BIOCHEMISTRY-US, V28, P2849, DOI 10.1021/bi00433a016; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MONROE SS, 1983, P NATL ACAD SCI-BIOL, V80, P3279, DOI 10.1073/pnas.80.11.3279; MOODY MD, 1994, BIOCHEMISTRY-US, V33, P13836, DOI 10.1021/bi00250a038; MOROZOV IY, 1993, P NATL ACAD SCI USA, V90, P9325, DOI 10.1073/pnas.90.20.9325; MUNISHKIN AV, 1991, J MOL BIOL, V221, P463, DOI 10.1016/0022-2836(91)80067-5; MUNISHKIN AV, 1988, NATURE, V333, P473, DOI 10.1038/333473a0; NAGY PD, 1993, P NATL ACAD SCI USA, V90, P6390, DOI 10.1073/pnas.90.14.6390; NEGRONI M, 1995, P NATL ACAD SCI USA, V92, P6971, DOI 10.1073/pnas.92.15.6971; NOREN CJ, 1990, NUCLEIC ACIDS RES, V18, P83, DOI 10.1093/nar/18.1.83; PALASINGAM K, 1992, J VIROL, V66, P2435, DOI 10.1128/JVI.66.4.2435-2442.1992; ROMANOVA LI, 1986, VIROLOGY, V155, P202, DOI 10.1016/0042-6822(86)90180-7; STEINSCHNEIDER A, 1966, BIOCHEMISTRY-US, V5, P2729, DOI 10.1021/bi00872a033; STEINSCHNEIDER A, 1966, BIOCHEMISTRY-US, V5, P2735, DOI 10.1021/bi00872a034; TOLSKAYA EA, 1987, VIROLOGY, V161, P54, DOI 10.1016/0042-6822(87)90170-X; WEISSMANN C, 1974, FEBS LETT, V43, pS10; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	37	123	132	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 21	1997	88	4					503	513		10.1016/S0092-8674(00)81890-5	http://dx.doi.org/10.1016/S0092-8674(00)81890-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WJ691	9038341	Green Published, Bronze			2022-12-01	WOS:A1997WJ69100010
J	Cooper, A; Penny, D				Cooper, A; Penny, D			Mass survival of birds across the Cretaceous-Tertiary boundary: Molecular evidence	SCIENCE			English	Article							MURINE SARCOMA-VIRUS; MOS PROTO-ONCOGENE; EVOLUTIONARY TREES; EXTINCTION; SEQUENCES; ORIGIN; DIVERSIFICATION; VOLCANISM; MAMMALS; EVENTS	The extent of terrestrial vertebrate extinctions at the end of the Cretaceous is poorly understood, and estimates have ranged from a mass extinction to limited extinctions of specific groups. Molecular and paleontological data demonstrate that modern bird orders started diverging in the Early Cretaceous; at least 22 avian lineages of modern birds cross the Cretaceous-Tertiary boundary. Data for several other terrestrial vertebrate groups indicate a similar pattern of survival and, taken together, favor incremental changes during a Cretaceous diversification of birds and mammals rather than an explosive radiation in the Early Tertiary.	VICTORIA UNIV WELLINGTON,SCH BIOL SCI,WELLINGTON,NEW ZEALAND; SMITHSONIAN INST,NATL ZOOL PK,MOL GENET LAB,WASHINGTON,DC 20008; MASSEY UNIV,SCH BIOL SCI,PALMERSTON NORTH,NEW ZEALAND	Victoria University Wellington; Smithsonian Institution; Smithsonian National Zoological Park & Conservation Biology Institute; Massey University			Penny, David/E-9410-2011; Cooper, Alan/E-8171-2012	Cooper, Alan/0000-0002-7738-7851				ALVAREZ LW, 1980, SCIENCE, V208, P1095, DOI 10.1126/science.208.4448.1095; Archibald J.D., 1996, DINOSAUR EXTINCTION; Archibald JD, 1996, SCIENCE, V272, P1150, DOI 10.1126/science.272.5265.1150; BENTON MJ, 1995, SCIENCE, V268, P52, DOI 10.1126/science.7701342; BENTON MJ, 1993, FOSSIL RECORD, V2; BOLES WE, 1995, NATURE, V374, P21, DOI 10.1038/374021b0; BUFFETAUT E, 1995, NATURE, V377, P110, DOI 10.1038/377110a0; Charleston M A, 1994, J Comput Biol, V1, P133, DOI 10.1089/cmb.1994.1.133; CHIAPPE LM, 1995, NATURE, V378, P349, DOI 10.1038/378349a0; COOPER A, 1995, P ROY SOC B-BIOL SCI, V261, P293, DOI 10.1098/rspb.1995.0150; COOPER A, 1992, P NATL ACAD SCI USA, V89, P8741, DOI 10.1073/pnas.89.18.8741; CRACRAFT J, 1986, PALEOBIOLOGY, V12, P383, DOI 10.1017/S0094837300003122; CRACRAFT J, 1973, J ZOOL, V169, P455; DErchia AM, 1996, NATURE, V381, P597, DOI 10.1038/381597a0; FEDUCCIA A, 1995, SCIENCE, V267, P637, DOI 10.1126/science.267.5198.637; Forster CA, 1996, NATURE, V382, P532, DOI 10.1038/382532a0; Gatesy J, 1996, MOL BIOL EVOL, V13, P954, DOI 10.1093/oxfordjournals.molbev.a025663; Gheerbrant E, 1996, NATURE, V383, P68, DOI 10.1038/383068a0; GINGERICH PD, 1994, NATURE, V368, P844, DOI 10.1038/368844a0; HAY JM, 1995, MOL BIOL EVOL, V12, P928; Hedges SB, 1996, NATURE, V381, P226, DOI 10.1038/381226a0; Hickson RE, 1996, MOL BIOL EVOL, V13, P150, DOI 10.1093/oxfordjournals.molbev.a025552; HOFFMAN A, 1989, J GEOL SOC LONDON, V146, P21, DOI 10.1144/gsjgs.146.1.0021; Hoss M, 1996, P NATL ACAD SCI USA, V93, P181, DOI 10.1073/pnas.93.1.181; Hou LH, 1996, SCIENCE, V274, P1164, DOI 10.1126/science.274.5290.1164; Houde P., 1987, Palaeovertebrata (Montpellier), V17, P27; Janke A, 1996, J MOL EVOL, V42, P153, DOI 10.1007/BF02198841; JANKE A, 1994, GENETICS, V137, P243; KORNEGAY JR, 1993, J MOL EVOL, V37, P367, DOI 10.1007/BF00178867; LENTO GM, 1995, MOL BIOL EVOL, V12, P28, DOI 10.1093/oxfordjournals.molbev.a040189; LOCKHART PJ, 1994, MOL BIOL EVOL, V11, P605; MACLEOD N, 1991, GEOLOGY, V19, P497, DOI 10.1130/0091-7613(1991)019<0497:HDAMEA>2.3.CO;2; MARTIN PG, 1988, TAXON, V37, P364, DOI 10.2307/1222145; Matthew W. D., 1915, Annals of the New York Academy of Sciences, V24; MCGOWAN G, 1995, NATURE, V373, P143, DOI 10.1038/373143a0; NEEFS JM, 1990, NUCLEIC ACIDS RES, V18, P2237, DOI 10.1093/nar/18.suppl.2237; OFFICER CB, 1985, SCIENCE, V227, P1161, DOI 10.1126/science.227.4691.1161; Olson S.L., 1985, Avian Biology, V8, P79; Olson S.L., 1992, Journal of Vertebrate Paleontology, V12, P122; Olson S. L., 1987, SMITHSONIAN CONTRIBU, V63, P1, DOI DOI 10.5479/SI.00810266.63.1; OLSON SL, 1994, P BIOL SOC WASH, V107, P429; PENNY D, 1993, NEW ZEAL J BOT, V31, P275, DOI 10.1080/0028825X.1993.10419505; PRAGER EM, 1980, P INT ORNITHOL C, V17, P1209; PRASAD GVR, 1995, J GEOL SOC LONDON, V152, P289, DOI 10.1144/gsjgs.152.2.0289; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; Sanz JL, 1996, NATURE, V382, P442, DOI 10.1038/382442a0; SCHMIDT M, 1988, MOL CELL BIOL, V8, P923, DOI 10.1128/MCB.8.2.923; SETH A, 1985, J VIROL, V56, P144, DOI 10.1128/JVI.56.1.144-152.1985; Sibley C.G., 1990, PHYLOGENY CLASSIFICA; Simpson George Gaylord, 1946, BULL AMER MUS NAT HIST, V87, P1; Stanhope MJ, 1996, J MOL EVOL, V43, P83, DOI 10.1007/BF02337352; Steel MA, 1996, SYST BIOL, V45, P127, DOI 10.2307/2413610; SUTHERLAND FL, 1994, EARTH-SCI REV, V36, P1, DOI 10.1016/0012-8252(94)90005-1; Swofford David L., 1996, P407; Tarr Cheryl L., 1995, P147; VEEVERS JJ, 1995, GEOLOGY, V23, P1131, DOI 10.1130/0091-7613(1995)023<1131:ELLGVS>2.3.CO;2; WATSON R, 1982, P NATL ACAD SCI-BIOL, V79, P4078, DOI 10.1073/pnas.79.13.4078; WILLIAMS ME, 1994, J PALEONTOL, V68, P183, DOI 10.1017/S0022336000022770; WILSON AC, 1991, PERSPECTIVES CELLULA, P331; WYLES JS, 1983, P NATL ACAD SCI-BIOL, V80, P4394, DOI 10.1073/pnas.80.14.4394; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]	70	368	384	2	70	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 21	1997	275	5303					1109	1113		10.1126/science.275.5303.1109	http://dx.doi.org/10.1126/science.275.5303.1109			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WJ503	9027308				2022-12-01	WOS:A1997WJ50300039
J	Bazan, JF; Bacon, KB; Hardiman, G; Wang, W; Soo, K; Rossi, D; Greaves, DR; Zlotnik, A; Schall, TJ				Bazan, JF; Bacon, KB; Hardiman, G; Wang, W; Soo, K; Rossi, D; Greaves, DR; Zlotnik, A; Schall, TJ			A new class of membrane-bound chemokine with a CX(3)C motif	NATURE			English	Article							HEPARAN-SULFATE; CELL-ADHESION; CYTOKINE; INFLAMMATION; SEQUENCE; BINDING	Chemokines direct the trafficking of white blood cells in immune surveillance, playing a key role in inflammatory and infectious diseases such as AIDS(1-5). All chemokines studied so far are secreted proteins of relative molecular mass similar to 7K-15K and fall into:three families that are defined by a cysteine signature motif: CXC, CC and C (refs 3, 6, 7), where C is a cysteine and X any amino-acid residue. We report here the identification and characterization of a fourth human chemokine type, derived from hbn-haemopoietic cells and bearing a new CX(3)C fingerprint. Unlike other chemokine types, the polypeptide chain of the human CX(3)C chemokine is predicted to be part of a 373-amino-acid protein that carries the chemokine domain on top of an extended mucin-like stalk. This molecule can exist in two forms: either membrane-anchored or as a shed 95K glycoprotein. The soluble CX(3)C chemokine has potent chemoattractant activity for T cells and monocytes, and the cell-surface-bound protein, which is induced on activated primary endothelial cells, promotes strong adhesion of those leukocytes. The structure, biochemical features, tissue distribution and chromosomal localization of CX(3)C chemokine all indicate that it represents a unique class of chemokine that may constitute part of the molecular control of leukocyte traffic at the endothelium.	DNAX RES INST MOL & CELLULAR BIOL INC,DEPT IMMUNOL,PALO ALTO,CA 94304; DNAX RES INST MOL & CELLULAR BIOL INC,DEPT MOL BIOL,PALO ALTO,CA 94304; UNIV OXFORD,SIR WILLIAM DUNN SCH PATHOL,OXFORD OX1 3RE,ENGLAND	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; University of Oxford			Bazan, J. Fernando/B-4562-2010; Zlotnik, Albert/C-3791-2011	Hardiman, Gary/0000-0003-4558-0400; Greaves, David/0000-0003-2856-9410				ALTSCHUL SF, 1994, NAT GENET, V6, P119, DOI 10.1038/ng0294-119; BAGGIOLINI M, 1994, IMMUNOL TODAY, V104, P27; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; CLORE GM, 1995, FASEB J, V9, P57, DOI 10.1096/fasebj.9.1.7821760; DAWSON PE, 1994, SCIENCE, V266, P776, DOI 10.1126/science.7973629; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; HANSEN JE, 1995, BIOCHEM J, V308, P601; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; PEMACK BP, 1996, NATURE MED, V2, P1174; SCHALL TJ, 1994, CURR OPIN IMMUNOL, V6, P865, DOI 10.1016/0952-7915(94)90006-X; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SHIMIZU Y, 1993, NATURE, V366, P630, DOI 10.1038/366630a0; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Strieter RM, 1996, J IMMUNOL, V156, P3583; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; VYAS P, 1995, GENOMICS, V29, P679, DOI 10.1006/geno.1995.9951; WEBB LMC, 1993, P NATL ACAD SCI USA, V90, P7158, DOI 10.1073/pnas.90.15.7158; Weiss RA, 1996, NATURE, V381, P647, DOI 10.1038/381647a0; Wells TNC, 1996, J LEUKOCYTE BIOL, V59, P53, DOI 10.1002/jlb.59.1.53; WITT DP, 1994, CURR BIOL, V4, P394, DOI 10.1016/S0960-9822(00)00088-9	23	1589	1689	3	41	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 13	1997	385	6617					640	644		10.1038/385640a0	http://dx.doi.org/10.1038/385640a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WH294	9024663				2022-12-01	WOS:A1997WH29400052
J	Guichet, A; Copeland, JWR; Erdelyi, M; Hlousek, D; Zavorszky, P; Ho, J; Brown, S; PercivalSmith, A; Krause, HM; Ephrussi, A				Guichet, A; Copeland, JWR; Erdelyi, M; Hlousek, D; Zavorszky, P; Ho, J; Brown, S; PercivalSmith, A; Krause, HM; Ephrussi, A			The nuclear receptor homologue Ftz-F1 and the homeodomain protein Ftz are mutually dependent cofactors	NATURE			English	Article							DROSOPHILA SEGMENTATION GENE; PAIR-RULE EXPRESSION; FUSHI-TARAZU GENE; LOCALIZATION; EMBRYOS; BINDING; SEQUENCE; CLONING; OSKAR	Nuclear hormone receptors and homeodomain proteins are two classes of transcription factor that regulate major developmental processes. Both depend on interactions with other proteins for specificity and activity. The Drosophila gene fushi tarazu (ftz), which encodes a homeodomain protein(1) (Ftz), is required zygotically for the formation of alternate segments in the developing embryo(2). Here we show that the orphan nuclear receptor alpha Ftz-F1 (ref. 3), which is deposited in the egg during oogenesis(4), is an obligatory cofactor for Ftz. The two proteins interact specifically and directly, both in vitro and in vivo, through a conserved domain in the Ftz polypeptide. This interaction suggests that other nuclear receptor/homeodomain protein interactions may be important and common in developing organisms.	UNIV TORONTO,CHARLES H BEST INST,DEPT MOL & MED GENET,TORONTO,ON M5G 1L6,CANADA; EUROPEAN MOL BIOL LAB,DEV BIOL PROGRAMME,D-69117 HEIDELBERG,GERMANY; UNIV WESTERN ONTARIO,DEPT ZOOL,LONDON,ON N6A 5B7,CANADA; KANSAS STATE UNIV,DIV BIOL,MANHATTAN,KS 66506; UNIV TORONTO,CHARLES H BEST INST,BANTING & BEST DEPT MED RES,TORONTO,ON M5G 1L6,CANADA	University of Toronto; European Molecular Biology Laboratory (EMBL); Western University (University of Western Ontario); Kansas State University; University of Toronto			Ho, Jackie/AAP-1531-2021; Ephrussi, Anne/ABD-4393-2021; Ephrussi, Anne/AAG-4075-2020	Ho, Jackie/0000-0001-7115-1381; Ephrussi, Anne/0000-0002-5061-4620; Brown, Susan/0000-0002-7984-0445; Krause, Henry/0000-0002-6182-7074				BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; BROWN SJ, 1994, P NATL ACAD SCI USA, V91, P12922, DOI 10.1073/pnas.91.26.12922; CARROLL SB, 1986, CELL, V45, P113, DOI 10.1016/0092-8674(86)90543-X; Copeland JWR, 1996, NATURE, V379, P162, DOI 10.1038/379162a0; DAWES R, 1994, DEVELOPMENT, V120, P1561; DINARDO S, 1987, GENE DEV, V1, P1212, DOI 10.1101/gad.1.10.1212; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; ERDELYI M, 1995, NATURE, V377, P524, DOI 10.1038/377524a0; FITZPATRICK VD, 1992, NATURE, V356, P610, DOI 10.1038/356610a0; Florence B, 1997, DEVELOPMENT, V124, P839; HAN W, 1993, MOL CELL BIOL, V13, P5549, DOI 10.1128/MCB.13.9.5549; INGHAM PW, 1988, NATURE, V331, P73, DOI 10.1038/331073a0; ISHHOROWICZ D, 1989, CELL, V57, P223, DOI 10.1016/0092-8674(89)90960-4; JOST W, 1995, ROUX ARCH DEV BIOL, V205, P160, DOI 10.1007/BF00357762; KASSIS JA, 1990, GENE DEV, V4, P433, DOI 10.1101/gad.4.3.433; KORNBERG T, 1985, CELL, V40, P45, DOI 10.1016/0092-8674(85)90307-1; KRAUSE HM, 1988, GENE DEV, V2, P1021, DOI 10.1101/gad.2.8.1021; LAUGHON A, 1984, NATURE, V310, P25, DOI 10.1038/310025a0; LAVORGNA G, 1991, SCIENCE, V252, P848, DOI 10.1126/science.1709303; LAVORGNA G, 1993, P NATL ACAD SCI USA, V90, P3004, DOI 10.1073/pnas.90.7.3004; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; OHNO CK, 1992, MECH DEVELOP, V40, P13; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; STAUDT LM, 1988, SCIENCE, V241, P577, DOI 10.1126/science.3399892; STEWART JJ, 1991, NATURE, V350, P72; STRUHL G, 1985, NATURE, V318, P677, DOI 10.1038/318677a0; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TSAI CC, 1995, DEVELOPMENT, V121, P453; UEDA H, 1990, GENE DEV, V4, P624, DOI 10.1101/gad.4.4.624; WAKIMOTO BT, 1981, DEV BIOL, V81, P551; WOODARD CT, 1994, CELL, V79, P607, DOI 10.1016/0092-8674(94)90546-0; YU Y, IN PRESS NATURE	32	158	163	1	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 6	1997	385	6616					548	552		10.1038/385548a0	http://dx.doi.org/10.1038/385548a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG235	9020363				2022-12-01	WOS:A1997WG23500051
J	Kushi, LH; Fee, RM; Folsom, AR; Mink, PJ; Anderson, KE; Sellers, TA				Kushi, LH; Fee, RM; Folsom, AR; Mink, PJ; Anderson, KE; Sellers, TA			Physical activity and mortality in postmenopausal women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ALL-CAUSE MORTALITY; UNITED-STATES RAILROAD; CARDIOVASCULAR-DISEASE; FOLLOW-UP; OLDER ADULTS; RISK; MEN; FITNESS; HEALTH; DEATH	Objective.-To evaluate the association between physical activity and all-cause mortality in postmenopausal women. Design.-Prospective cohort study with 7 years of follow-up through December 31, 1992. Setting and Participants.-Subjects were 40 417 postmenopausal Iowa women, aged 55 to 69 years at baseline in 1986. Physical activity was assessed by mailed questionnaire. Main Outcome Measure.-All-cause mortality (n=2260). Results.-After adjustment for potential confounders and excluding women who reported having cancer or heart disease and those who died in the first 3 years of follow-up, women who reported regular physical activity were at significantly reduced risk of death during follow-up compared with women who did not (relative risk [RR], 0.77; 95% confidence interval [CI], 0.66-0.90). Increasing frequency of moderate physical activity was associated with reduced risk of death during followup (from rarely or never engaging in activity to activity at least 4 times per week, RRs, 1.0 [referent], 0.76, 0.70, and 0.62; P value for trend < .001). A similar pattern was seen for vigorous physical activity (corresponding RRs, 1.0, 0.89, 0.74, and 0.57; P value for trend = .06). Reduced risks of death with increased physical activity were evident for cardiovascular diseases (n = 729) and respiratory illnesses (n = 147). Women who engaged only in moderate but not vigorous physical activity also benefited, with moderate activity as infrequently as once per week demonstrating a reduced mortality risk of 0.78 (95% CI, 0.64-0.96). Conclusions.-These results demonstrate a graded, inverse association between physical activity and all-cause mortality in postmenopausal women. These findings strengthen the confidence that population recommendations to engage in regular physical activity are applicable to postmenopausal women.			Kushi, LH (corresponding author), UNIV MINNESOTA, SCH PUBL HLTH, DIV EPIDEMIOL, 1300 S 2ND ST, SUITE 300, MINNEAPOLIS, MN 55454 USA.			Kushi, Lawrence/0000-0001-9136-1175	NCI NIH HHS [CA 39742] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039742] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BISGARD KM, 1994, AM J EPIDEMIOL, V139, P990, DOI 10.1093/oxfordjournals.aje.a116948; BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395; CHANGCLAUDE J, 1993, INT J EPIDEMIOL, V22, P228, DOI 10.1093/ije/22.2.228; DAVIS MA, 1994, PREV MED, V23, P369, DOI 10.1006/pmed.1994.1051; EKELUND LG, 1988, NEW ENGL J MED, V319, P1379, DOI 10.1056/NEJM198811243192104; *GALL POLL, 1988, PUBL OP 1987, P316; HARRIS SS, 1989, JAMA-J AM MED ASSOC, V261, P3588, DOI 10.1001/jama.261.24.3588; HELMRICH SP, 1991, NEW ENGL J MED, V325, P147, DOI 10.1056/NEJM199107183250302; KAPLAN GA, 1987, AM J PUBLIC HEALTH, V77, P307, DOI 10.2105/AJPH.77.3.307; LAPIDUS L, 1986, BRIT HEART J, V55, P295, DOI 10.1136/hrt.55.3.295; LEE DJ, 1990, J GERONTOL, V45, pS39, DOI 10.1093/geronj/45.1.S39; LEE IM, 1995, JAMA-J AM MED ASSOC, V273, P1179, DOI 10.1001/jama.273.15.1179; LEON AS, 1991, INT J EPIDEMIOL, V20, P690, DOI 10.1093/ije/20.3.690; LINDSTED KD, 1991, J CLIN EPIDEMIOL, V44, P355, DOI 10.1016/0895-4356(91)90074-J; Lissner L, 1996, AM J EPIDEMIOL, V143, P54; MARCUS R, 1992, MED SCI SPORT EXER, V24, pS301; Mensink GBM, 1996, EPIDEMIOLOGY, V7, P391, DOI 10.1097/00001648-199607000-00009; PAFFENBARGER RS, 1991, ANN MED, V23, P319, DOI 10.3109/07853899109148067; PAFFENBARGER RS, 1986, NEW ENGL J MED, V314, P605, DOI 10.1056/NEJM198603063141003; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; POWELL KE, 1987, ANNU REV PUBL HEALTH, V8, P325; RAKOWSKI W, 1992, J GERONTOL, V47, pM122, DOI 10.1093/geronj/47.4.M122; SALONEN JT, 1982, AM J EPIDEMIOL, V115, P526, DOI 10.1093/oxfordjournals.aje.a113334; SANDVIK L, 1993, NEW ENGL J MED, V328, P533, DOI 10.1056/NEJM199302253280803; SHERMAN SE, 1994, AM HEART J, V128, P879, DOI 10.1016/0002-8703(94)90583-5; SHERMAN SE, 1993, AM HEART J, V83, P1443; SIMONSICK EM, 1993, AM J PUBLIC HEALTH, V83, P1443, DOI 10.2105/AJPH.83.10.1443; SLATTERY ML, 1988, AM J EPIDEMIOL, V127, P571, DOI 10.1093/oxfordjournals.aje.a114832; SLATTERY ML, 1989, CIRCULATION, V79, P304, DOI 10.1161/01.CIR.79.2.304; STENDER M, 1993, INT J EPIDEMIOL, V22, P644, DOI 10.1093/ije/22.4.644; U.S. Department of Health and Human Services, 1996, PHYS ACT HLTH REP SU; U.S. Preventive Service Task Force, 1989, GUID CLIN PREV SERV; WEYERER S, 1993, PERCEPT MOTOR SKILL, V77, P499, DOI 10.2466/pms.1993.77.2.499	33	271	276	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 23	1997	277	16					1287	1292		10.1001/jama.277.16.1287	http://dx.doi.org/10.1001/jama.277.16.1287			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU135	9109466				2022-12-01	WOS:A1997WU13500028
J	Kharbanda, S; Pandey, P; Jin, SF; Inoue, S; Bharti, A; Yuan, ZM; Weichselbaum, R; Weaver, D; Kufe, D				Kharbanda, S; Pandey, P; Jin, SF; Inoue, S; Bharti, A; Yuan, ZM; Weichselbaum, R; Weaver, D; Kufe, D			Functional interaction between DNA-PK and c-Abl in response to DNA damage	NATURE			English	Article							DEPENDENT PROTEIN-KINASE; STRAND-BREAK REPAIR; V(D)J RECOMBINATION; TYROSINE KINASE; KU-AUTOANTIGEN; SH3 DOMAINS; COMPLEMENTATION; SENSITIVITY; BINDING; ANTIGEN	How DNA damage is converted into intracellular signals that can control cell behaviour is unknown. The c-Abl protein tyrosine kinase is activated by ionizing radiation and certain other DNA-damaging agents(1-5), whereas the DNA-dependent protein kinase (DNA-PK), consisting of a serine/threonine kinase and Ku DNA-binding subunits, requires DNA double-strand breaks or other DNA lesions for activation(6-8). Here we demonstrate that c-Abl interacts constitutively with DNA-PK. Ionizing radiation stimulates binding of c-Abl to DNA-PK and induces an association of c-Abl with Ku antigen. We show that DNA-PK phosphorylates and activates c-Abl in vitro. Cells deficient in DNA-PK are defective in c-Abl activation induced by ionizing radiation. In a potential feedback mechanism, c-Abl phosphorylates DNA-PK, but not Ku, in vitro. Phosphorylation of DNA-PK by c-Abl inhibits the ability of DNA-PK to form a complex with DNA. We also show that treatment of cells with ionizing radiation results in phosphorylation of DNA-PK that is dependent on c-Abl. Our results support the hypothesis that there are functional interactions between c-Abl and DNA-PK in the response to DNA damage.	HARVARD UNIV,DANA FARBER CANC INST,DIV CANC PHARMACOL,BOSTON,MA 02115; HARVARD UNIV,DANA FARBER CANC INST,DIV TUMOR IMMUNOL,BOSTON,MA 02115; UNIV CHICAGO,DEPT RADIAT & CELLULAR ONCOL,CHICAGO,IL 60637	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; University of Chicago								BANGA SS, 1994, MUTAT RES-DNA REPAIR, V315, P239, DOI 10.1016/0921-8777(94)90035-3; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; BOUBNOV NV, 1995, P NATL ACAD SCI USA, V92, P890, DOI 10.1073/pnas.92.3.890; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; Chan DW, 1996, J BIOL CHEM, V271, P8936, DOI 10.1074/jbc.271.15.8936; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; Giffin W, 1996, NATURE, V380, P265, DOI 10.1038/380265a0; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Kharbanda S, 1996, P NATL ACAD SCI USA, V93, P6898, DOI 10.1073/pnas.93.14.6898; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; REN R, 1994, GENE DEV, V8, P73; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WEAVER DT, 1995, TRENDS GENET, V11, P388, DOI 10.1016/S0168-9525(00)89121-0; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0	23	224	230	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 17	1997	386	6626					732	735		10.1038/386732a0	http://dx.doi.org/10.1038/386732a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WU387	9109492				2022-12-01	WOS:A1997WU38700060
J	Yates, CR; Krynetski, EY; Loennechen, T; Fessing, MY; Tai, HL; Pui, CH; Relling, MV; Evans, WE				Yates, CR; Krynetski, EY; Loennechen, T; Fessing, MY; Tai, HL; Pui, CH; Relling, MV; Evans, WE			Molecular diagnosis of thiopurine S-methyltransferase deficiency: Genetic basis for azathioprine and mercaptopurine intolerance	ANNALS OF INTERNAL MEDICINE			English	Article						thiopurine; S-methyltransferase deficiency; azathioprine; mercaptopurine; thioguanine; pharmacogenetics	ACUTE LYMPHOBLASTIC-LEUKEMIA; HEART-TRANSPLANT RECIPIENT; INDUCED MYELOSUPPRESSION; 6-MERCAPTOPURINE; PHARMACOGENETICS; DISEASE	Background: Thiopurine 5-methyltransferase (TPMT) catalyzes the S-methylation (that is, inactivation) of mercaptopurine, azathioprine, and thioguanine and exhibits genetic polymorphism. About 10% of patients have intermediate TPMT activity because of heterozygosity, and about 1 in 300 inherit TPMT deficiency as an autosomal recessive trait. if they receive standard doses of thiopurine medications (for example, 75 mg/m(2) body surface area per day), TPMT-deficient patients accumulate excessive thioguanine nucleotides in hematopoietic tissues, which leads to severe and possibly fatal myelosuppression. Objective: To elucidate the genetic basis and develop molecular methods for the diagnosis of TPMT deficiency and heterozygosity. Design: Diagnostic test evaluation. Setting: Research hospital. Patients: The TPMT phenotype was determined in 282 unrelated white persons, and TPMT genotype was determined in all persons who had intermediate TPMT activity (heterozygotes) and a randomly selected, equal number of persons who had high activity. In addition, genotype was determined in 6 TPMT-deficient patients. Measurements: Polymerase chain reaction (PCR) assays were developed to detect the G238C transversion in TPMT*Z and the G460A and A719G transitions in TPMT*3 alleles; Radiochemical assay was used to measure TPMT activity. Mutations of TPMT were identified in genomic DNA, and the concordance of TPMT genotype and phenotype was determined. Results: 21 patients who had a heterozygous phenotype were identified (7.4% of sample [95% Cl, 4.7% to 11.2%]). TPMT*3A was the most prevalent mutant allele (18 of 21 mutant alleles in heterozygotes; 85%); TPMT*2 and TPMT*3C were more rare(about: 5% each). All 6 patients who had TPMT deficiency had two mutant alleles, 20 of 21 patients (95% [CI, 76% to 99.9%]) who had intermediate TPMT activity had one mutant allele, and 21 of 21 patients (100% [CI, 83% to 100%]) who had high activity had no known TPMT mutation. Detection of TPMT mutations in genomic DNA by PCR coincided perfectly with genotypes detected by complementary DNA sequencing. Conclusions: The major inactivating mutations at the human TPMT locus have been identified and can be reliably detected by PCR-based methods, which show an excellent concordance between genotype and phenotype. The detection of TPMT mutations provides a molecular diagnostic method for prospectively identifying TPMT-deficient and heterozygous patients.	ST JUDE CHILDRENS RES HOSP, MEMPHIS, TN 38105 USA; UNIV TENNESSEE, MEMPHIS, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center			Relling, Mary/N-5032-2018; Pui, Ching-Hon/N-8076-2018; Evans, William E./C-2069-2012	Pui, Ching-Hon/0000-0003-0303-5658; Evans, William E./0000-0002-9333-5322; Fessing, Michael/0000-0002-3120-8707	NCI NIH HHS [CA21765, CA20180, R37 CA36401] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA036401, P30CA021765, P01CA020180] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cosi V, 1993, Acta Neurol (Napoli), V15, P123; EVANS WE, 1991, J PEDIATR-US, V119, P985, DOI 10.1016/S0022-3476(05)83063-X; FODOR SPA, 1993, NATURE, V364, P555, DOI 10.1038/364555a0; GRANT DM, 1993, PHARMACOGENETICS, V3, P45, DOI 10.1097/00008571-199302000-00005; HEIM M, 1990, LANCET, V336, P529, DOI 10.1016/0140-6736(90)92086-W; HOLLANDER AAMJ, 1995, LANCET, V345, P610, DOI 10.1016/S0140-6736(95)90520-0; JOHNSON PJ, 1995, NEW ENGL J MED, V333, P958, DOI 10.1056/NEJM199510123331502; KERSTENS PJSM, 1994, ANN RHEUM DIS, V53, P608, DOI 10.1136/ard.53.9.608; Kreiner T, 1996, AM LAB, V28, P39; Krynetski EY, 1996, PHARMACOGENETICS, V6, P279, DOI 10.1097/00008571-199608000-00001; KRYNETSKI EY, 1995, P NATL ACAD SCI USA, V92, P949, DOI 10.1073/pnas.92.4.949; LEE D, 1995, DRUG METAB DISPOS, V23, P398; LENNARD L, 1993, ARCH DIS CHILD, V69, P577, DOI 10.1136/adc.69.5.577; LENNARD L, 1987, CLIN PHARMACOL THER, V41, P18, DOI 10.1038/clpt.1987.4; LENNARD L, 1990, LANCET, V336, P225, DOI 10.1016/0140-6736(90)91745-V; MCLEOD HL, 1993, LANCET, V341, P1151, DOI 10.1016/0140-6736(93)93168-Z; MCLEOD HL, 1994, CLIN PHARMACOL THER, V55, P15, DOI 10.1038/clpt.1994.4; MILANESE C, 1993, J NEUROL, V240, P295, DOI 10.1007/BF00838165; PEARSON DC, 1995, ANN INTERN MED, V123, P132, DOI 10.7326/0003-4819-123-2-199507150-00009; SCHUTZ E, 1993, LANCET, V341, P436, DOI 10.1016/0140-6736(93)93028-Y; Szumlanski C, 1996, DNA CELL BIOL, V15, P17, DOI 10.1089/dna.1996.15.17; Tai HL, 1996, AM J HUM GENET, V58, P694; WEINSHILBOUM RM, 1980, AM J HUM GENET, V32, P651; WEINSHILBOUM RM, 1978, CLIN CHIM ACTA, V85, P323, DOI 10.1016/0009-8981(78)90311-X; WILLOUGHBY JM, 1971, LANCET, V2, P944	26	620	658	0	24	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1997	126	8					608	+		10.7326/0003-4819-126-8-199704150-00003	http://dx.doi.org/10.7326/0003-4819-126-8-199704150-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WT580	9103127				2022-12-01	WOS:A1997WT58000006
J	Hudson, N				Hudson, N			Excess long-term mortality in patients with ulcer complications	LANCET			English	Editorial Material							PEPTIC-ULCER				Hudson, N (corresponding author), CITY HOSP NHS TRUST,BIRMINGHAM B18 7QH,W MIDLANDS,ENGLAND.							GABRIEL SE, 1991, ANN INTERN MED, V115, P787, DOI 10.7326/0003-4819-115-10-787; HOSKING S W, 1992, Gastroenterology, V102, pA85; HUDSON N, 1995, GUT, V37, P177, DOI 10.1136/gut.37.2.177; JASPERSEN D, 1995, GASTROINTEST ENDOSC, V41, P5, DOI 10.1016/S0016-5107(95)70267-9; KATSCHINSKI BD, 1989, POSTGRAD MED J, V65, P913, DOI 10.1136/pgmj.65.770.913; Kubba AK, 1997, BRIT J SURG, V84, P265; REINBACH DH, 1993, GUT, V34, P1344, DOI 10.1136/gut.34.10.1344; RORBAEKMADSEN M, 1994, SCAND J GASTROENTERO, V29, P983, DOI 10.3109/00365529409094874; Svanes C, 1996, J CLIN EPIDEMIOL, V49, P1363, DOI 10.1016/S0895-4356(96)00278-8; SVANES C, 1993, GUT, V34, P1666, DOI 10.1136/gut.34.12.1666; WALT R, 1986, LANCET, V1, P489; 1974, BRIT MED J, V2, P760	12	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 5	1997	349	9057					968	969		10.1016/S0140-6736(05)62889-9	http://dx.doi.org/10.1016/S0140-6736(05)62889-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR621	9100620				2022-12-01	WOS:A1997WR62100005
J	Morin, PJ; Sparks, AB; Korinek, V; Barker, N; Clevers, H; Vogelstein, B; Kinzler, KW				Morin, PJ; Sparks, AB; Korinek, V; Barker, N; Clevers, H; Vogelstein, B; Kinzler, KW			Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC	SCIENCE			English	Article							GENE-PRODUCT; COLORECTAL-CANCER; WILD-TYPE; PROTEIN; IDENTIFICATION; ASSOCIATION; CHROMOSOME-5Q21; ARMADILLO; ROLES; LOCUS	Inactivation of the adenomatous polyposis coli (APC) tumor suppressor gene initiates colorectal neoplasia. One of the biochemical activities associated with the APC protein is down-regulation of transcriptional activation mediated by beta-catenin and T cell transcription factor 4 (Tcf-4). The protein products of mutant APC genes present in colorectal tumors were found to be defective in this activity. Furthermore, colorectal tumors with intact APC genes were found to contain activating mutations of beta-catenin that altered functionally significant phosphorylation sites. These results indicate that regulation of beta-catenin is critical to APC's tumor suppressive effect and that this regulation can be circumvented by mutations in either APC or beta-catenin.	JOHNS HOPKINS ONCOL CTR,BALTIMORE,MD 21231; HOWARD HUGHES MED INST,BALTIMORE,MD 21231; UNIV UTRECHT HOSP,DEPT IMMUNOL,NL-3508 GA UTRECHT,NETHERLANDS	Johns Hopkins University; Johns Hopkins Medicine; Howard Hughes Medical Institute; Utrecht University; Utrecht University Medical Center			Korinek, Vladimir/G-6348-2014; Barker, Nick/AAS-2774-2020; Barker, Nick/AAE-9833-2021; Barker, Nick/A-5535-2011	Korinek, Vladimir/0000-0002-9777-4664; Barker, Nick/0000-0003-3566-4475; 	NCI NIH HHS [CA57345] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057345, R37CA057345] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Eccles DM, 1996, AM J HUM GENET, V59, P1193; Friedl W, 1996, HUM GENET, V97, P579; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HULSKEN J, 1994, CURR OPIN CELL BIOL, V6, P711, DOI 10.1016/0955-0674(94)90098-1; JEN J, 1994, CANCER RES, V54, P5523; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; JOSLYN G, 1993, P NATL ACAD SCI USA, V90, P11109, DOI 10.1073/pnas.90.23.11109; KAWANISHI J, 1995, MOL CELL BIOL, V15, P1175; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; MUNEMITSU S, 1994, CANCER RES, V54, P3676; Munemitsu S, 1996, MOL CELL BIOL, V16, P4088; NAGASE H, 1993, HUM MUTAT, V2, P425, DOI 10.1002/humu.1380020602; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; PEIFER M, 1994, DEV BIOL, V166, P543, DOI 10.1006/dbio.1994.1336; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; Prescott SM, 1996, CELL, V87, P783, DOI 10.1016/S0092-8674(00)81983-2; RANSOHOFF DF, 1991, NEW ENGL J MED, V325, P37; Robbins PF, 1996, J EXP MED, V183, P1185, DOI 10.1084/jem.183.3.1185; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; RUBINFELD B, 1995, J BIOL CHEM, V270, P5549, DOI 10.1074/jbc.270.10.5549; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Scott RJ, 1996, HUM MOL GENET, V5, P1921, DOI 10.1093/hmg/5.12.1921; SMITH KJ, 1994, CANCER RES, V54, P3672; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; SU LK, 1993, CANCER RES, V53, P2728; SU LK, 1995, CANCER RES, V55, P2972; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443	37	3411	3554	4	157	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 21	1997	275	5307					1787	1790		10.1126/science.275.5307.1787	http://dx.doi.org/10.1126/science.275.5307.1787			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WP056	9065402				2022-12-01	WOS:A1997WP05600040
J	vanSteveninck, RRD; Lewen, GD; Strong, SP; Koberle, R; Bialek, W				vanSteveninck, RRD; Lewen, GD; Strong, SP; Koberle, R; Bialek, W			Reproducibility and variability in neural spike trains	SCIENCE			English	Article							MOVEMENT-SENSITIVE NEURON; RELIABILITY; EFFICIENCY; ADAPTATION; RESPONSES; SIGNALS; CORTEX; CODE	To provide information about dynamic sensory stimuli, the pattern of action potentials in spiking neurons must be variable, To ensure reliability these variations must be related, reproducibly, to the stimulus, For H1, a motion-sensitive neuron in the fly's visual system, constant-velocity motion produces irregular spike firing patterns, and spike counts typically have a variance comparable to the mean, for cells in the mammalian cortex, But more natural, time-dependent input signals yield patterns of spikes that are much more reproducible, both in terms of timing and of counting precision. Variability and reproducibility are quantified with ideas from information theory, and measured spike sequences in H1 carry more than twice the amount of information they would if they followed the variance-mean relation seen with constant inputs. Thus, models that may accurately account for the neural response to static stimuli can significantly underestimate the reliability of signal transfer under more natural conditions.	PRINCETON UNIV,DEPT PHYS,PRINCETON,NJ 08544; NEC RES INST,PRINCETON,NJ 08540	Princeton University; NEC Corporation								Adrian E.D., 1928, BASIS SENSATION; BAIR W, 1996, NEURAL COMPUT, V8, P1184; BERRY MJ, UNPUB P NATL ACAD SC; BIALEK W, 1991, SCIENCE, V252, P1854, DOI 10.1126/science.2063199; BRITTEN KH, 1993, VISUAL NEUROSCI, V10, P1157, DOI 10.1017/S0952523800010269; BULLOCK TH, 1970, J GEN PHYSIOL, V55, P565, DOI 10.1085/jgp.55.5.565; Burns BD, 1968, UNCERTAIN NERVOUS SY; DEAR SP, 1993, NATURE, V364, P620, DOI 10.1038/364620a0; FERSTER D, 1995, SCIENCE, V270, P756, DOI 10.1126/science.270.5237.756; Franceschini N., 1989, P360; HAGIWARA S, 1954, Jpn J Physiol, V4, P234; Hausen K., 1989, P391; Holden AV., 1976, MODELS STOCHASTIC AC; Kumar A, 1996, PHYS REV LETT, V76, P2778, DOI 10.1103/PhysRevLett.76.2778; LAND MF, 1974, J COMP PHYSIOL, V89, P331, DOI 10.1007/BF00695351; LEVIN J, 1996, THESIS U CALIFORNIA; MacKAY DONALD M., 1952, BULL MATH BIOPHYS, V14, P127, DOI 10.1007/BF02477711; MADDESS T, 1985, PROC R SOC SER B-BIO, V225, P251, DOI 10.1098/rspb.1985.0061; MAINEN ZF, 1995, SCIENCE, V268, P1503, DOI 10.1126/science.7770778; MILLER MI, 1992, J ACOUST SOC AM, V92, P202, DOI 10.1121/1.404284; Papoulis A., 2002, PROBABILITY RANDOM V, V4; Perkel DH, 1969, NEUROSCI RES PROG SU, P405; Rieke F, 1995, P ROY SOC B-BIOL SCI, V262, P259, DOI 10.1098/rspb.1995.0204; RIEKE F, 1993, EUROPHYS LETT, V22, P151, DOI 10.1209/0295-5075/22/2/013; Rieke F., 1997, SPIKES EXPLORING NEU; Shadlen M N, 1995, Curr Opin Neurobiol, V5, P248, DOI 10.1016/0959-4388(95)80033-6; Shannon C., 1964, MATH THEORY COMMUNIC; Snyder D. L., 1991, RANDOM POINT PROCESS, DOI DOI 10.1007/978-1-4612-3166-0; SOFTKY WR, 1995, NATURE, V376, P21; Stevens CF, 1995, CURR BIOL, V5, P1370, DOI 10.1016/S0960-9822(95)00273-9; TEICH MC, 1989, IEEE T BIO-MED ENG, V36, P150, DOI 10.1109/10.16460; TOLHURST DJ, 1983, VISION RES, V23, P775, DOI 10.1016/0042-6989(83)90200-6; VANSTEVENINCK RD, 1988, PROC R SOC SER B-BIO, V234, P379; VANSTEVENINCK RD, 1995, PHILOS T R SOC B, V348, P321; VANSTEVENINCK RRD, 1986, BIOL CYBERN, V54, P223, DOI 10.1007/BF00318418; vanSteveninck RRD, 1996, NATURAL & ARTIFICIAL PARALLEL COMPUTATION, P21; WAGNER H, 1986, PHILOS T ROY SOC B, V312, P527, DOI 10.1098/rstb.1986.0017; WERNER G, 1963, J NEUROPHYSIOL, V26, P958, DOI 10.1152/jn.1963.26.6.958; ZAAGMAN WH, 1983, IEEE T SYST MAN CYB, V13, P900, DOI 10.1109/TSMC.1983.6313085	39	485	488	3	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 21	1997	275	5307					1805	1808		10.1126/science.275.5307.1805	http://dx.doi.org/10.1126/science.275.5307.1805			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WP056	9065407	Green Submitted			2022-12-01	WOS:A1997WP05600045
J	Bonn, D				Bonn, D			Anticipating the future by counting DNA triplet repeats	LANCET			English	News Item																			0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 15	1997	349	9054					782	782		10.1016/S0140-6736(05)60212-7	http://dx.doi.org/10.1016/S0140-6736(05)60212-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN124	9091755				2022-12-01	WOS:A1997WN12400029
J	Shelling, AN				Shelling, AN			Role of p53 in drug resistance in ovarian cancer	LANCET			English	Editorial Material											Shelling, AN (corresponding author), NATL WOMENS HOSP,RES CTR REPROD MED,AUCKLAND,NEW ZEALAND.		Shelling, Andrew/E-7496-2010	Shelling, Andrew/0000-0002-5300-1934				Buttitta F, 1997, BRIT J CANCER, V75, P230, DOI 10.1038/bjc.1997.38; Herod JJO, 1996, CANCER RES, V56, P2178; Kristensen GB, 1997, LANCET, V349, P113, DOI 10.1016/S0140-6736(96)06071-0; REESE DM, 1995, NATURE, V378, P532, DOI 10.1038/378532c0; Righetti SC, 1996, CANCER RES, V56, P689; SHELLING AN, 1995, BRIT J CANCER, V72, P521, DOI 10.1038/bjc.1995.367; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72	7	36	36	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 15	1997	349	9054					744	745		10.1016/S0140-6736(05)60195-X	http://dx.doi.org/10.1016/S0140-6736(05)60195-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN124	9074569				2022-12-01	WOS:A1997WN12400004
J	Golovina, VA; Blaustein, MP				Golovina, VA; Blaustein, MP			Spatially and functionally distinct Ca2+ stores in sarcoplasmic and endoplasmic reticulum	SCIENCE			English	Article							INTRACELLULAR CALCIUM STORES; CEREBELLAR PURKINJE NEURONS; SMOOTH-MUSCLE CELLS; INOSITOL TRISPHOSPHATE; FLUORESCENT INDICATOR; RYANODINE RECEPTORS; CORTICAL ASTROCYTES; RELEASE CHANNEL; CAFFEINE; THAPSIGARGIN	The organization of calcium (Ca2+) stores in the sarco plasmic and endoplasmic reticulum (S-ER) is poorly understood. The dynamics of the storage and release of calcium in the S-ER of intact, cultured astrocytes and arterial myocytes were studied with high-resolution imaging methods. The S-ER appeared to be a continuous tubular network; nevertheless, calcium stores in the S-ER were organized into small, spatially distinct compartments that functioned as discrete units. Cyclopiazonic acid (an inhibitor of the calcium pump in the S-ER membrane) and caffeine or ryanodine unloaded different, spatially separate compartments. Heterogeneity of calcium stores was also revealed in cells activated by physiological agonists. These results suggest that cells can generate spatially and temporally distinct calcium signals to control individual calcium-dependent processes.	UNIV MARYLAND, SCH MED, DEPT PHYSIOL, BALTIMORE, MD 21201 USA; UNIV MARYLAND, SCH MED, CTR VASC BIOL & HYPERTENS, BALTIMORE, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016106] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-32276] Funding Source: Medline; NINDS NIH HHS [NS-16106] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLEN SP, 1993, J MOL CELL CARDIOL, V25, P949, DOI 10.1006/jmcc.1993.1107; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1993, NATURE, V365, P388, DOI 10.1038/365388a0; BEZPROZVANNY I, 1994, MOL BIOL CELL, V5, P97, DOI 10.1091/mbc.5.1.97; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BIAN JH, 1991, J BIOL CHEM, V266, P8801; BROWN GR, 1992, BIOCHEM J, V282, P309, DOI 10.1042/bj2820309; BURGOYNE RD, 1991, TRENDS BIOCHEM SCI, V16, P319, DOI 10.1016/0968-0004(91)90131-E; CARL SL, 1995, J CELL BIOL, V129, P673, DOI 10.1083/jcb.129.3.673; CHAMLEYCAMPBELL J, 1979, PHYSIOL REV, V59, P1, DOI 10.1152/physrev.1979.59.1.1; CHATTON JY, 1995, FEBS LETT, V368, P165, DOI 10.1016/0014-5793(95)00632-J; CHEEK TR, 1994, BIOCHEM J, V301, P879, DOI 10.1042/bj3010879; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; DUCHEN MR, 1992, J PHYSIOL-LONDON, V450, P33, DOI 10.1113/jphysiol.1992.sp019115; ENDO M, 1977, PHYSIOL REV, V57, P71, DOI 10.1152/physrev.1977.57.1.71; FRIEL DD, 1994, J NEUROSCI, V14, P4007; GLENNON MC, 1992, J BIOL CHEM, V267, P25568; GOLDMAN WF, 1994, J NEUROSCI, V14, P5834; GOLOVINA V, UNPUB; Golovina VA, 1996, GLIA, V16, P296; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAJNOCZKY G, 1994, J BIOL CHEM, V269, P10280; HENZI V, 1992, NEUROSCIENCE, V46, P251, DOI 10.1016/0306-4522(92)90049-8; Hofer AM, 1996, CELL CALCIUM, V20, P235, DOI 10.1016/S0143-4160(96)90029-9; HOFER AM, 1993, P NATL ACAD SCI USA, V90, P2598, DOI 10.1073/pnas.90.7.2598; Hollingworth S, 1996, J GEN PHYSIOL, V108, P455, DOI 10.1085/jgp.108.5.455; INESI G, 1994, J MEMBRANE BIOL, V141, P1; ISENBERG G, 1993, CARDIOVASC RES, V27, P1800, DOI 10.1093/cvr/27.10.1800; JENSEN AM, 1990, J NEUROSCI, V10, P1165; Jung DW, 1996, ARCH BIOCHEM BIOPHYS, V332, P19, DOI 10.1006/abbi.1996.0311; KONISHI M, 1991, J GEN PHYSIOL, V97, P271, DOI 10.1085/jgp.97.2.271; LATTANZIO FA, 1987, J BIOL CHEM, V262, P2711; Lawrie AM, 1996, J BIOL CHEM, V271, P10753, DOI 10.1074/jbc.271.18.10753; LONDON RE, 1996, Patent No. 5516911; MCPHERSON PS, 1993, J BIOL CHEM, V268, P13765; MEISSNER G, 1986, J BIOL CHEM, V261, P6300; MENNITI FS, 1991, J BIOL CHEM, V266, P13646; MIYATA H, 1991, AM J PHYSIOL, V261, pH1123, DOI 10.1152/ajpheart.1991.261.4.H1123; MONTERO M, 1995, EMBO J, V14, P5467, DOI 10.1002/j.1460-2075.1995.tb00233.x; MURPHY E, 1993, MINER ELECTROL METAB, V19, P250; PARKER I, 1991, J PHYSIOL-LONDON, V433, P229, DOI 10.1113/jphysiol.1991.sp018423; PARKER I, 1991, P ROY SOC B-BIOL SCI, V246, P269, DOI 10.1098/rspb.1991.0154; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; RAJU B, 1989, AM J PHYSIOL, V256, pC540, DOI 10.1152/ajpcell.1989.256.3.C540; ROBINSON IM, 1991, J NEUROCHEM, V56, P1587, DOI 10.1111/j.1471-4159.1991.tb02055.x; ROUSSEAU E, 1989, AM J PHYSIOL, V256, pH328, DOI 10.1152/ajpheart.1989.256.2.H328; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SEYMOURLAURENT KJ, 1995, J NEUROSCI, V15, P2592; SHEU SS, 1994, J BIOENERG BIOMEMBR, V26, P487, DOI 10.1007/BF00762733; SHIMA H, 1992, CIRC RES, V70, P968, DOI 10.1161/01.RES.70.5.968; SIMPSON PB, 1995, TRENDS NEUROSCI, V18, P299, DOI 10.1016/0166-2236(95)93919-O; SLODZINSKI MK, 1995, AM J PHYSIOL-CELL PH, V269, pC1340, DOI 10.1152/ajpcell.1995.269.5.C1340; SORRENTINO V, 1993, TRENDS PHARMACOL SCI, V14, P98, DOI 10.1016/0165-6147(93)90072-R; SUGIYAMA T, 1995, AM J PHYSIOL-CELL PH, V269, pC698, DOI 10.1152/ajpcell.1995.269.3.C698; TANAKA Y, 1993, BIOCHEMISTRY-US, V32, P12062, DOI 10.1021/bi00096a017; TERASAKI M, 1989, METHOD CELL BIOL, V29, P125; TERASAKI M, 1994, P NATL ACAD SCI USA, V91, P7510, DOI 10.1073/pnas.91.16.7510; TRIBE RM, 1994, P NATL ACAD SCI USA, V91, P5908, DOI 10.1073/pnas.91.13.5908; TSE FW, 1994, P NATL ACAD SCI USA, V91, P9750, DOI 10.1073/pnas.91.21.9750; WALTON PD, 1991, J CELL BIOL, V113, P1145, DOI 10.1083/jcb.113.5.1145; YAMAZAWA T, 1992, FEBS LETT, V301, P181, DOI 10.1016/0014-5793(92)81243-F; Yuan XJ, 1996, AM J PHYSIOL-CELL PH, V270, pC321, DOI 10.1152/ajpcell.1996.270.1.C321	64	407	410	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 14	1997	275	5306					1643	1648		10.1126/science.275.5306.1643	http://dx.doi.org/10.1126/science.275.5306.1643			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WN123	9054358				2022-12-01	WOS:A1997WN12300046
J	Kharitonenkov, A; Chen, ZJ; Sures, I; Wang, HY; Schilling, J; Ullrich, A				Kharitonenkov, A; Chen, ZJ; Sures, I; Wang, HY; Schilling, J; Ullrich, A			A family of proteins that inhibit signalling through tyrosine kinase receptors	NATURE			English	Article							GROWTH-FACTOR RECEPTOR; NEURONAL DIFFERENTIATION; INSULIN-RECEPTOR; PC12 CELLS; MAP KINASE; PHOSPHATASE; EXPRESSION; SH-PTP2; DOWNSTREAM; ACTIVATION	Phosphotyrosine phosphatases are critical negative or positive regulators in the intracellular signalling pathways that result in growth-factor-specific cell responses such as mitosis, differentiation, migration, survival, transformation or death(1-4). The SH2-domain-containing phosphotyrosine phosphatase SHP-2 is a positive signal transducer for several receptor tyrosine kinases (RTKs) and cytokine receptors(5-7). To investigate its mechanism of action we purified a tyrosine-phosphorylated glycoprotein which in different cell types associates tightly with SHP-2 and appears to serve as its substrate. Peptide sequencing in conjunction with complementary DNA cloning revealed a new gene family of at least fifteen members designated signal-regulatory proteins (SIRPs). They consist of two subtypes distinguished by the presence or absence of a cytoplasmic SHP-2-binding domain. The transmembrane polypeptide SIRP alpha 1 is a substrate of activated RTKs and in its tyrosine-phosphorylated form binds SHP-2 through SH2 interactions and acts as its substrate. It also binds SHP-1 and Grb2 in vitro and has negative regulatory effects on cellular responses induced by growth factors, oncogenes or insulin. Our findings indicate that proteins belonging to the SIRP family generally regulate signals defining different physiological and pathological processes.	MAX PLANCK INST BIOCHEM, DEPT MOL BIOL, D-82152 MARTINSRIED, GERMANY; SUGEN INC, REDWOOD CITY, CA 94063 USA	Max Planck Society			Wang, Hongyang/B-1340-2010					BARFORD D, 1995, NAT STRUCT BIOL, V2, P1043, DOI 10.1038/nsb1295-1043; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; FENDLY BM, 1990, CANCER RES, V50, P1550; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; GERLACH MS, 1995, J BIOL CHEM, V270, P24635, DOI 10.1074/jbc.270.42.24635; Herbst R, 1996, CELL, V85, P899, DOI 10.1016/S0092-8674(00)81273-8; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; Matozaki T, 1996, CELL SIGNAL, V8, P13, DOI 10.1016/0898-6568(95)02015-2; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; Obermeier A, 1996, EMBO J, V15, P73, DOI 10.1002/j.1460-2075.1996.tb00335.x; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; SALTIEL AR, 1994, FASEB J, V8, P1034, DOI 10.1096/fasebj.8.13.7926368; SAWADA T, 1995, BIOCHEM BIOPH RES CO, V214, P737, DOI 10.1006/bbrc.1995.2347; SOOS MA, 1986, BIOCHEM J, V235, P199, DOI 10.1042/bj2350199; Streuli M, 1996, CURR OPIN CELL BIOL, V8, P182, DOI 10.1016/S0955-0674(96)80064-0; Su L, 1996, J BIOL CHEM, V271, P10385, DOI 10.1074/jbc.271.17.10385; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1995, J BIOL CHEM, V270, P14871, DOI 10.1074/jbc.270.25.14871; YAMAUCHI K, 1995, J BIOL CHEM, V270, P17716, DOI 10.1074/jbc.270.30.17716; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; ZHAO ZZ, 1995, J BIOL CHEM, V270, P11765, DOI 10.1074/jbc.270.20.11765	31	536	563	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 13	1997	386	6621					181	186		10.1038/386181a0	http://dx.doi.org/10.1038/386181a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WM973	9062191				2022-12-01	WOS:A1997WM97300064
J	Chuang, RY; Weaver, PL; Liu, Z; Chang, TH				Chuang, RY; Weaver, PL; Liu, Z; Chang, TH			Requirement of the DEAD-box protein Ded1p for messenger RNA translation	SCIENCE			English	Article							STEM-LOOP MUTATION; SACCHAROMYCES-CEREVISIAE; INITIATION FACTOR-4A; GENE REGION; DNA-REPAIR; YEAST; HELICASE; TRANSCRIPTION; SUPPRESSOR; SEQUENCE	The DED1 gene, which encodes a putative RNA helicase, has been implicated in nuclear pre-messenger RNA splicing in the yeast Saccharomyces cerevisiae. It is shown here by genetic and biochemical analysis that translation, rather than splicing, is severely impaired in two newly isolated ded1 conditional mutants, Preliminary evidence suggests that the protein Ded1p may be required for the initiation step of translation, as is the distinct DEAD-box protein, eukaryotic initiation factor 4A (eIF4A), The DED1 gene could be functionally replaced by a mouse homolog, PL10, which suggests that the function of Ded1p in translation is evolutionarily conserved.	OHIO STATE UNIV, DEPT MOL GENET, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, MOL CELLULAR & DEV BIOL PROGRAM, COLUMBUS, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University					NIGMS NIH HHS [GM48752] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM048752, R29GM048752] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAIM SB, 1985, MOL CELL BIOL, V5, P1839, DOI 10.1128/MCB.5.8.1839; CHANG TR, UNPUB; DELACRUZ J, COMMUNICATION; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; Fuller-Pace Frances V., 1994, Trends in Cell Biology, V4, P271, DOI 10.1016/0962-8924(94)90210-0; GEE SL, 1994, GENE, V140, P171, DOI 10.1016/0378-1119(94)90541-X; GUARENTE L, 1993, TRENDS GENET, V9, P362, DOI 10.1016/0168-9525(93)90042-G; GULYAS KD, 1992, CELL, V69, P1031, DOI 10.1016/0092-8674(92)90621-I; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HUSSAIN I, 1986, GENE, V46, P13, DOI 10.1016/0378-1119(86)90162-9; IIZUKA N, 1994, MOL CELL BIOL, V14, P7322, DOI 10.1128/MCB.14.11.7322; JAMIESON DJ, 1991, NATURE, V349, P715, DOI 10.1038/349715a0; KADOWAKI T, 1994, J CELL BIOL, V126, P649, DOI 10.1083/jcb.126.3.649; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; LEROY P, 1989, CELL, V57, P549, DOI 10.1016/0092-8674(89)90125-6; LINDER P, 1989, P NATL ACAD SCI USA, V86, P2286, DOI 10.1073/pnas.86.7.2286; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; Merrick WC., 1996, TRANSLATION CONTROL, P31; NARANDA T, 1994, J BIOL CHEM, V269, P32286; PAUSE A, 1993, CURR OPIN STRUC BIOL, V3, P953, DOI 10.1016/0959-440X(93)90161-D; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; SCHMID SR, 1991, MOL CELL BIOL, V11, P3463, DOI 10.1128/MCB.11.7.3463; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; STRAUSS EJ, 1991, GENE DEV, V5, P629, DOI 10.1101/gad.5.4.629; STRUHL K, 1985, NUCLEIC ACIDS RES, V13, P8587, DOI 10.1093/nar/13.23.8587; STRUHL K, 1980, J MOL BIOL, V136, P309, DOI 10.1016/0022-2836(80)90376-9; SVEJSTRUP JQ, 1995, CELL, V80, P21, DOI 10.1016/0092-8674(95)90447-6; THUILLIER V, 1995, EMBO J, V14, P351, DOI 10.1002/j.1460-2075.1995.tb07009.x; Venema J, 1995, YEAST, V11, P1629, DOI 10.1002/yea.320111607; WASSARMAN DA, 1991, NATURE, V349, P463, DOI 10.1038/349463a0; YOON H, 1992, GENE DEV, V6, P2463, DOI 10.1101/gad.6.12b.2463; ZHONG T, 1993, CELL, V73, P1175, DOI 10.1016/0092-8674(93)90646-8	32	267	274	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 7	1997	275	5305					1468	1471		10.1126/science.275.5305.1468	http://dx.doi.org/10.1126/science.275.5305.1468			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WM081	9045610				2022-12-01	WOS:A1997WM08100043
J	Genick, UK; Borgstahl, GEO; Ng, K; Ren, Z; Pradervand, C; Burke, PM; Srajer, V; Teng, TY; Schildkamp, W; McRee, DE; Moffat, K; Getzoff, ED				Genick, UK; Borgstahl, GEO; Ng, K; Ren, Z; Pradervand, C; Burke, PM; Srajer, V; Teng, TY; Schildkamp, W; McRee, DE; Moffat, K; Getzoff, ED			Structure of a protein photocycle intermediate by millisecond time-resolved crystallography	SCIENCE			English	Article							PHOTOACTIVE YELLOW PROTEIN; PURPLE PHOTOTROPHIC BACTERIUM; LINKED 4-HYDROXYCINNAMYL CHROMOPHORE; ECTOTHIORHODOSPIRA-HALOPHILA; LAUE DIFFRACTION; PHOSPHORYLASE-B; QUANTUM YIELD; CRYSTALS; MODEL; PHOTORECEPTOR	The blue-light photoreceptor photoactive yellow protein (PYP) undergoes a self-contained light cycle. The atomic structure of the bleached signaling intermediate in the light cycle of PYP was determined by millisecond time-resolved, multiwavelength Laue crystallography and simultaneous optical spectroscopy. Light-induced trans-to-cis isomerization of the 4-hydroxycinnamyl chromophore and coupled protein rearrangements produce a new set of active-site hydrogen bonds. An arginine gateway opens, allowing solvent exposure and protonation of the chromophore's phenolic oxygen. Resulting changes in shape, hydrogen bonding, and electrostatic potential at the protein surface form a likely basis for signal transduction. The structural results suggest a general framework for the interpretation of protein photocycles.	UNIV CHICAGO, DEPT BIOCHEM & MOL BIOL, CHICAGO, IL 60637 USA	University of Chicago	Genick, UK (corresponding author), Scripps Res Inst, DEPT MOL BIOL, 10550 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Pradervand, Claude/GPF-4155-2022; Pradervand, Claude P/I-8114-2013; Borgstahl, Gloria/AAZ-4114-2020	Pradervand, Claude/0000-0001-5251-3930; Genick, Ulrich/0000-0002-6526-3552	NCRR NIH HHS [RR07707] Funding Source: Medline; NIGMS NIH HHS [GM36452, GM37684] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM036452, R01GM036452] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACA M, 1994, BIOCHEMISTRY-US, V33, P14369, DOI 10.1021/bi00252a001; BOLDUC JM, 1995, SCIENCE, V268, P1312, DOI 10.1126/science.7761851; BORGSTAHL GEO, 1995, BIOCHEMISTRY-US, V34, P6278, DOI 10.1021/bi00019a004; Bourgeois D, 1996, J SYNCHROTRON RADIAT, V3, P65, DOI 10.1107/S090904959501661X; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Campbell J. W., 1986, INF Q PROTEIN CRYSTA, V18, P23; CAMPBELL JW, 1995, J APPL CRYSTALLOGR, V28, P228, DOI 10.1107/S002188989400991X; CHEN Y, 1994, REV SCI INSTRUM, V65, P1506, DOI 10.1063/1.1144883; Cruickshank D. W. J., 1992, PHILOS T R SOC A, V340, P167; DEISENHOFER J, 1984, J MOL BIOL, V180, P385, DOI 10.1016/S0022-2836(84)80011-X; DUKE EMH, 1994, PROTEIN SCI, V3, P1178, DOI 10.1002/pro.5560030804; FULOP V, 1994, STRUCTURE, V2, P201, DOI 10.1016/S0969-2126(00)00021-6; GENICK U, UNPUB; Genick UK, 1997, BIOCHEMISTRY-US, V36, P8, DOI 10.1021/bi9622884; GETZOFF ED, 1994, NUCL INSTRUM METHODS, V79, P1249; GREENHOUGH TJ, 1994, J APPL CRYSTALLOGR, V27, P111, DOI 10.1107/S0021889893006752; HAJDU J, 1987, EMBO J, V6, P539, DOI 10.1002/j.1460-2075.1987.tb04786.x; HELLWELL JR, 1969, J APPL CRYSTALLOGR, V22, P483; HENDERSON R, 1990, J MOL BIOL, V213, P899, DOI 10.1016/S0022-2836(05)80271-2; HOFF WD, 1994, BIOPHYS J, V67, P1691, DOI 10.1016/S0006-3495(94)80643-5; HOFF WD, 1994, BIOCHEMISTRY-US, V33, P13960; KIM M, 1995, BIOCHEMISTRY-US, V34, P12669, DOI 10.1021/bi00039a024; Kort R, 1996, FEBS LETT, V382, P73, DOI 10.1016/0014-5793(96)00149-4; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; MACKERELL AD, 1992, FASEB J, V6, pA143; MACKERELL AD, UNPUB; MATHIES RA, 1991, ANNU REV BIOPHYS BIO, V20, P491, DOI 10.1146/annurev.bb.20.060191.002423; McRee D.E., 1999, PRACTICAL PROTEIN CR, V2nd ed., P91; MCREE DE, 1986, J BIOL CHEM, V261, P3850; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MEYER TE, 1991, BIOPHYS J, V59, P988, DOI 10.1016/S0006-3495(91)82313-X; MEYER TE, 1989, BIOPHYS J, V56, P559, DOI 10.1016/S0006-3495(89)82703-1; MEYER TE, 1993, ARCH BIOCHEM BIOPHYS, V306, P515, DOI 10.1006/abbi.1993.1545; MEYER TE, 1987, BIOCHEMISTRY-US, V26, P418, DOI 10.1021/bi00376a012; MEYER TE, 1985, BIOCHIM BIOPHYS ACTA, V806, P175, DOI 10.1016/0005-2728(85)90094-5; MOFFAT K, 1992, PHILOS T R SOC A, V340, P175, DOI 10.1098/rsta.1992.0059; NG K, 1995, BIOCHEMISTRY-US, V34, P879, DOI 10.1021/bi00003a022; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; NICHOLLS A, 1990, DELPHI; PARK HW, 1995, SCIENCE, V268, P1866, DOI 10.1126/science.7604260; REN Z, 1994, J SYNCHROTRON RADIAT, V1, P78, DOI 10.1107/S0909049594006692; REN Z, 1995, J APPL CRYSTALLOGR, V28, P461, DOI 10.1107/S0021889895003207; Ren Z, 1996, J APPL CRYSTALLOGR, V29, P246, DOI 10.1107/S0021889896000659; REN Z, 1995, J APPL CRYSTALLOGR, V28, P482, DOI 10.1107/S0021889895003219; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; SCHLICHTING I, 1990, NATURE, V345, P309, DOI 10.1038/345309a0; SINGER PT, 1993, SCIENCE, V259, P669, DOI 10.1126/science.8430314; SPRENGER WW, 1993, J BACTERIOL, V175, P3096, DOI 10.1128/JB.175.10.3096-3104.1993; STODDARD BL, 1991, P NATL ACAD SCI US, V88; UPSON C, 1989, IEEE COMPUT GRAPH, V9, P30, DOI 10.1109/38.31462; WANG Q, 1994, SCIENCE, V266, P422, DOI 10.1126/science.7939680	52	367	376	2	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 7	1997	275	5305					1471	1475		10.1126/science.275.5305.1471	http://dx.doi.org/10.1126/science.275.5305.1471			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WM081	9045611				2022-12-01	WOS:A1997WM08100044
J	Alderman, MH; Cohen, H; Roque, R; Madhavan, S				Alderman, MH; Cohen, H; Roque, R; Madhavan, S			Effect of long-acting and short-acting calcium antagonists on cardiovascular outcomes in hypertensive patients	LANCET			English	Article							WORK SITE	Background Short-acting calcium antagonists may increase coronary artery morbidity, mortality, and non-cardiovascular complications in hypertensive patients. We assessed whether this association was also true for long-acting calcium antagonists. Methods We did a case-control study, which was nested within a systematic hypertension control programme for a prospective cohort of 4350 people (first seen 1981-94). Cases (n=189) were hypertensive patients who had had a first cardiovascular event, including all cardiovascular deaths and hospitalisations, between 1989 and 1995. Controls (n=189) were individually matched to cases for sex, ethnic origin, age, type of previous antihypertensive treatment, year of entry into the study, and length of follow-up. We collected data on any prescribed drug regimen that was being taken on the event date for cases and on the same date for matched controls. Calcium antagonists were classified by duration of action. Findings Compared with those on beta-blocker monotherapy, patients on long-acting calcium antagonists (n=136) had no increased risk of a cardiovascular event (adjusted odds ratio 0.76 [95% CI 0.41-1.43]), whereas patients on short-acting calcium antagonists (n=27) were at significantly greater risk (adjusted odds ratio 3.88 [1.15-13.11], p=0.029). Among 38 matched pairs who were both on calcium antagonists, the adjusted risk ratio for short-acting versus long-acting was 8.56 (1.88-38.97), p<0.01. Interpretation Long-acting and short-acting calcium antagonists differ in cardiovascular outcomes. Consistent with earlier findings, the use of short-acting calcium antagonists was associated with increased risk of a cardiovascular event. This finding highlights the need to complete on-going clinical trials so that the relative cardiovascular impact of various antihypertensive agents can be assessed.			Alderman, MH (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT EPIDEMIOL & SOCIAL MED, 1300 MORRIS PK AVE, BRONX, NY 10461 USA.			Cohen, Hillel/0000-0002-4524-0898	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL018323] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL18323] Funding Source: Medline; OFP OPHS HHS [REQ QIM50053,FPDS:R499] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); OFP OPHS HHS		Alderman MH, 1996, AM J HYPERTENS, V9, P413, DOI 10.1016/0895-7061(95)00438-6; ALDERMAN MH, 1975, NEW ENGL J MED, V293, P65, DOI 10.1056/NEJM197507102930203; ALDERMAN MH, 1976, J OCCUP ENVIRON MED, V18, P793, DOI 10.1097/00043764-197612000-00004; [Anonymous], 1988, ARCH INTERN MED, V148, P1023; Barnett AA, 1996, LANCET, V347, P313; Borhani NO, 1996, JAMA-J AM MED ASSOC, V276, P785, DOI 10.1001/jama.276.10.785; Davis BR, 1996, AM J HYPERTENS, V9, P342, DOI 10.1016/0895-7061(96)00037-4; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; Mancia G, 1996, J HYPERTENS, V14, P13; MEREDITH PA, 1994, J CARDIOVASC PHARM, V23, pS26, DOI 10.1097/00005344-199423005-00006; NAFTILAN AJ, 1990, GUIDE CARDIOLOGY, P409; *NAT HEART LUNG BL, 1995, NEW ANAL REG SAF CAL; Pahor M, 1996, AM J HYPERTENS, V9, P695, DOI 10.1016/0895-7061(96)00186-0; PAHOR M, 1995, J AM GERIATR SOC, V43, P1191, DOI 10.1111/j.1532-5415.1995.tb07393.x; Pahor M, 1996, LANCET, V347, P1061, DOI 10.1016/S0140-6736(96)90276-7; PSATY BM, 1995, JAMA-J AM MED ASSOC, V274, P620, DOI 10.1001/jama.274.8.620; SIFTON DW, 1995, PHYSICIANS DESK REFE; SWALES JD, 1994, TXB HYPERTENSION, P1111	18	153	155	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 1	1997	349	9052					594	598		10.1016/S0140-6736(96)08359-6	http://dx.doi.org/10.1016/S0140-6736(96)08359-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WK915	9057730				2022-12-01	WOS:A1997WK91500008
J	Griffiths, C; Sturdy, P; Naish, J; Omar, R; Dolan, S; Feder, G				Griffiths, C; Sturdy, P; Naish, J; Omar, R; Dolan, S; Feder, G			Hospital admissions for asthma in east London: Associations with characteristics of local general practices, prescribing, and population	BRITISH MEDICAL JOURNAL			English	Article							CHILDHOOD ASTHMA; RATES	Objective: To determine the relative importance of appropriate prescribing for asthma in explaining high rates of hospital admission for asthma among east London general practices. Design: Poisson regression analysis describing relation of each general practice's admission rates for asthma with prescribing for asthma and characteristics of general practitioners, practices, and practice populations. Setting: East London, a deprived inner city area with high admission rates for asthma Subjects: All 163 general practices in East London and the City Health Authority (complete data available for 124 practices). Main outcome measures: Admission rates for asthma, excluding readmissions, for ages 5-64 years; ratio of asthma prophylaxis to bronchodilator prescribing; selected characteristics of general practitioners, practices, and practice populations. Results: Median admission rate for asthma was 0.9 (range 0-3.6) per 1000 patients per year. Higher admission rates were most strongly associated with small size of practice partnership: admission rates of singlehanded and two partner practices were higher than those of practices with three or more principals by 1.7 times (95% confidence Interval 1.4 to 2.0, P<0.001) and 1.3 times (1.1 to 1.6, P=0.001) respectively. Practices with higher rates of night visits also had significantly higher admission rates: an increase in night visiting rate by 10 visits per 1000 patients over two years was associated with an increase in admission rates for asthma by 4% (1% to 7%). These associations were independent of asthma prescribing ratios, measures of practice resources, and characteristics of practice populations. Conclusions: Higher asthma admission rates in east London practices were most strongly associated with smaller partnership size and higher rates of night visiting. Evaluating ways of helping smaller partnerships develop structured proactive care for asthma patients at high risk of admission is a priority.	ROYAL LONDON SCH MED & DENT,LONDON E1 4NS,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT MED STAT & EVALUAT,LONDON W12 0NN,ENGLAND; ST MARYS HOSP,SCH MED,IMPERIAL COLL,LONDON W2 1PG,ENGLAND	University of London; Queen Mary University London; Imperial College London; Imperial College London	Griffiths, C (corresponding author), ST BARTHOLOMEWS HOSP,CITY & E LONDON PRACTICE DATABASE PROJECT,DEPT GEN PRACTICE & PRIMARY CARE,LONDON E1 4NS,ENGLAND.			Feder, Gene/0000-0002-7890-3926; Omar, Rumana/0000-0003-1483-1932				Altman DG, 1991, PRACTICAL STAT MED R; ANDERSON HR, 1995, THORAX, V50, P1188, DOI 10.1136/thx.50.11.1188; ANDERSON HR, 1989, THORAX, V44, P614, DOI 10.1136/thx.44.8.614; CARMAN PG, 1990, MED J AUSTRALIA, V152, P23, DOI 10.5694/j.1326-5377.1990.tb124423.x; *CHART I PUBL FIN, 1993, HLTH DAT 1993; Clayton D., 1993, STAT MODELS EPIDEMIO; *CONS ASS, 1993, WHICH           0311, P735; Davidson AC, 1996, BRIT MED J, V312, P601; *DEP HLTH, 1995, ASTHM EP OV; *DEP HLTH, 1992, STAT B, V4, P2; *DEP HLTH, 1995, ID R D PRIOR NHS MAN; DEVALIA JL, 1994, LANCET, V344, P1668, DOI 10.1016/S0140-6736(94)90458-8; *E LOND CIT HLTH A, 1996, HLTH E END ANN PUBL; FEDER G, 1995, BRIT MED J, V311, P1473, DOI 10.1136/bmj.311.7018.1473; GOTTLIEB DJ, 1995, CHEST, V108, P28, DOI 10.1378/chest.108.1.28; GREEN JM, 1993, BRIT MED J, V307, P607, DOI 10.1136/bmj.307.6904.607; Griffiths C, 1996, BRIT MED J, V312, P481, DOI 10.1136/bmj.312.7029.481; *HLTH EAST PROJ, 1996, HLTH EAST PROJ ANN R; HOWARD SA, 1996, ASTHMA GEN PRACT, V4, P11; Hull S, 1996, BRIT J GEN PRACT, V46, P375; HYNDMAN SJ, 1994, BRIT MED J, V308, P1596, DOI 10.1136/bmj.308.6944.1596; JACKSON SHD, 1981, POSTGRAD MED J, V57, P777, DOI 10.1136/pgmj.57.674.777; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; MAJEED FA, 1994, BRIT MED J, V308, P1272, DOI 10.1136/bmj.308.6939.1272; *N THAM REG HLTH A, 1994, DEV ED LOND IN ZON E; NAISH J, 1995, BRIT MED J, V310, P97, DOI 10.1136/bmj.310.6972.97; ORMEROD LP, 1995, RESP MED, V89, P415, DOI 10.1016/0954-6111(95)90209-0; SCRIVENER G, 1995, BRIT MED J, V311, P163, DOI 10.1136/bmj.311.6998.163; Shahani A, 1996, BRIT MED J, V313, P1057; SILVERMAN M, 1993, THORAX, V48, P1200, DOI 10.1136/thx.48.12.1200; STORR J, 1988, ARCH DIS CHILD, V63, P778; STURDY P, 1995, BRIT MED J, V311, P1547, DOI 10.1136/bmj.311.7019.1547; Sturdy P, 1996, BRIT J GEN PRACT, V46, P375; VanSchayck CP, 1996, BRIT J GEN PRACT, V46, P193	34	51	51	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 15	1997	314	7079					482	486		10.1136/bmj.314.7079.482	http://dx.doi.org/10.1136/bmj.314.7079.482			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WJ419	9056800	Green Published			2022-12-01	WOS:A1997WJ41900028
J	Steeghs, K; Benders, A; Oerlemans, F; deHaan, A; Heerschap, A; Ruitenbeek, W; Jost, C; vanDeursen, J; Perryman, B; Pette, D; Bruckwilder, M; Koudijs, J; Jap, P; Veerkamp, J; Wieringa, B				Steeghs, K; Benders, A; Oerlemans, F; deHaan, A; Heerschap, A; Ruitenbeek, W; Jost, C; vanDeursen, J; Perryman, B; Pette, D; Bruckwilder, M; Koudijs, J; Jap, P; Veerkamp, J; Wieringa, B			Altered Ca2+ responses in muscles with combined mitochondrial and cytosolic creatine kinase deficiencies	CELL			English	Article							CELLULAR-ENERGY METABOLISM; SKELETAL-MUSCLE; SARCOPLASMIC-RETICULUM; MICE; COMPARTMENTATION; PHOSPHORYLATION; HOMEOSTASIS; CONTRACTION; RELAXATION; PHOSPHATE	We have blocked creatine kinase (CK)-mediated phosphocreatine (PCr) reversible arrow ATP transphosphorylation in skeletal muscle by combining targeted mutations in the genes encoding mitochondrial and cytosolic CK in mice. Contrary to expectation, the PCr level was only marginally affected, but the compound was rendered metabolically inert. Mutant muscles in vivo showed significantly impaired tetanic force output, increased relaxation times, altered mitochondrial volume and location, and conspicuous tubular aggregates of sarcoplasmic reticulum membranes, as seen in myopathies with electrolyte disturbances. In depolarized myotubes cultured in vitro, CK absence influenced both the release and sequestration of Ca2+. Our data point to a direct link between the CK-PCr system and Ca2+-flux regulation during the excitation and relaxation phases of muscle contraction.	UNIV NIJMEGEN,FAC MED SCI,DEPT CELL BIOL & HISTOL,NL-6500 HB NIJMEGEN,NETHERLANDS; UNIV NIJMEGEN,FAC MED SCI,DEPT BIOCHEM,NL-6500 HB NIJMEGEN,NETHERLANDS; UNIV NIJMEGEN,FAC MED SCI,DEPT DIAGNOST RADIOL,NL-6500 HB NIJMEGEN,NETHERLANDS; UNIV NIJMEGEN,FAC MED SCI,DEPT PEDIAT,NL-6500 HB NIJMEGEN,NETHERLANDS; FREE UNIV AMSTERDAM,DEPT MUSCLE & EXERCISE PHYSIOL,FAC HUMAN MOVEMENT SCI,NL-1081 BT AMSTERDAM,NETHERLANDS; UNIV COLORADO,HLTH SCI CTR,DIV CARDIOL,DENVER,CO 80262; UNIV KONSTANZ,DEPT BIOL,D-7834 CONSTANCE,GERMANY	Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; Vrije Universiteit Amsterdam; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Konstanz			Heerschap, Arend/G-5228-2010; Wieringa, Berend/A-5346-2011	Wieringa, Berend/0000-0001-9192-8020				BALABAN RS, 1990, AM J PHYSIOL, V258, pC377, DOI 10.1152/ajpcell.1990.258.3.C377; BENDERS AAGM, 1994, J CLIN INVEST, V94, P741, DOI 10.1172/JCI117393; BESSMAN SP, 1985, ANNU REV BIOCHEM, V54, P831, DOI 10.1146/annurev.bi.54.070185.004151; BRDICZKA D, 1994, MOL CELL BIOCHEM, V133, P69, DOI 10.1007/BF01267948; COOKE R, 1985, BIOPHYS J, V48, P789, DOI 10.1016/S0006-3495(85)83837-6; CRAIG ID, 1980, MUSCLE NERVE, V3, P134, DOI 10.1002/mus.880030206; DEHAAN A, 1989, PFLUG ARCH EUR J PHY, V413, P422, DOI 10.1007/BF00584493; DIDONATO S, 1978, NEUROLOGY, V28, P1110, DOI 10.1212/WNL.28.11.1110; Donoso P, 1996, BIOCHEMISTRY-US, V35, P13419, DOI 10.1021/bi9616209; DOWN WH, 1983, DRUG RES, V1, P552; DUBOWITZ V, 1985, MUSCLE BIOPSY MODERN; EBASHI S, 1976, ANNU REV PHYSIOL, V38, P293, DOI 10.1146/annurev.ph.38.030176.001453; EDWARDS RHT, 1975, J PHYSIOL-LONDON, V251, P287, DOI 10.1113/jphysiol.1975.sp011093; ERECINSKA M, 1982, J MEMBRANE BIOL, V70, P1, DOI 10.1007/BF01871584; Flucher BE, 1996, P NATL ACAD SCI USA, V93, P8101, DOI 10.1073/pnas.93.15.8101; GUNTER TE, 1994, AM J PHYSIOL, V267, pC313, DOI 10.1152/ajpcell.1994.267.2.C313; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; HAN JW, 1992, BIOCHEMISTRY-US, V31, P377, DOI 10.1021/bi00117a010; Heerschap A, 1988, NMR Biomed, V1, P27, DOI 10.1002/nbm.1940010106; Hidalgo C, 1995, BIOSCIENCE REP, V15, P387, DOI 10.1007/BF01788370; Hofer AM, 1996, FASEB J, V10, P302, DOI 10.1096/fasebj.10.2.8641563; HOFFMAN EP, 1995, CELL, V80, P681, DOI 10.1016/0092-8674(95)90345-3; Klein MG, 1996, NATURE, V379, P455, DOI 10.1038/379455a0; KORETSKY AP, 1995, PHYSIOL REV, V75, P667, DOI 10.1152/physrev.1995.75.4.667; KORGE P, 1994, AM J PHYSIOL, V267, pC357, DOI 10.1152/ajpcell.1994.267.2.C357; KUNCL RW, 1989, ACTA NEUROPATHOL, V78, P615, DOI 10.1007/BF00691288; Martonosi AN, 1996, BBA-BIOENERGETICS, V1275, P111, DOI 10.1016/0005-2728(96)00059-X; MEYER RA, 1982, AM J PHYSIOL, V242, pC1, DOI 10.1152/ajpcell.1982.242.1.C1; MILLER DS, 1986, J BIOL CHEM, V261, P13911; Minajeva A, 1996, PFLUG ARCH EUR J PHY, V432, P904, DOI 10.1007/s004240050214; OGorman E, 1996, BBA-BIOENERGETICS, V1276, P161, DOI 10.1016/0005-2728(96)00074-6; Olson LK, 1996, J BIOL CHEM, V271, P16544, DOI 10.1074/jbc.271.28.16544; Owen VJ, 1996, J PHYSIOL-LONDON, V493, P309, DOI 10.1113/jphysiol.1996.sp021385; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; ROSENBERG NL, 1985, ARCH NEUROL-CHICAGO, V42, P973, DOI 10.1001/archneur.1985.04060090055014; ROSSI AM, 1990, J BIOL CHEM, V265, P5258; SAKS VA, 1994, MOL CELL BIOCHEM, V133, P155, DOI 10.1007/BF01267954; SALVIATI G, 1985, MUSCLE NERVE, V8, P299, DOI 10.1002/mus.880080406; Sata M, 1996, CIRCULATION, V93, P310, DOI 10.1161/01.CIR.93.2.310; STEEGHS K, 1996, IN PRESS J NEUROSCI, V20; STEEGHS K, 1995, THESIS U NIJMEGEN NI; SWEENEY HL, 1988, J BIOL CHEM, V263, P9034; VALDIVIA HH, 1995, SCIENCE, V267, P1997, DOI 10.1126/science.7701323; VANDEURSEN J, 1993, CELL, V74, P621, DOI 10.1016/0092-8674(93)90510-W; VANDEURSEN J, 1994, P NATL ACAD SCI USA, V91, P9091, DOI 10.1073/pnas.91.19.9091; VENTURACLAPIER R, 1995, J BIOL CHEM, V270, P19914, DOI 10.1074/jbc.270.34.19914; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; ZELEZNIKAR RJ, 1995, J BIOL CHEM, V270, P7311, DOI 10.1074/jbc.270.13.7311	48	206	211	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 4	1997	89	1					93	103		10.1016/S0092-8674(00)80186-5	http://dx.doi.org/10.1016/S0092-8674(00)80186-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WR685	9094718	Bronze, Green Published			2022-12-01	WOS:A1997WR68500013
J	Stephens, LR; Eguinoa, A; ErdjumentBromage, H; Lui, M; Cooke, F; Coadwell, J; Smrcka, AS; Thelen, M; Cadwallader, K; Tempst, P; Hawkins, PT				Stephens, LR; Eguinoa, A; ErdjumentBromage, H; Lui, M; Cooke, F; Coadwell, J; Smrcka, AS; Thelen, M; Cadwallader, K; Tempst, P; Hawkins, PT			The G beta gamma sensitivity of a PI3K is dependent upon a tightly associated adaptor, p101	CELL			English	Article							MYELOID-DERIVED CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; 1-PHOSPHATIDYLINOSITOL 3-KINASE; ACTIVATED NEUTROPHILS; KINASE; SUBUNIT; WORTMANNIN; CLONING; IDENTIFICATION	Two highly similar, PtdIns(4,5)P-2-selective, G beta gamma-activated PI3Ks were purified from pig neutrophil cytosol. Both were heterodimers, were composed of a 101 kDa protein and either a 120 kDa or a 117 kDa catalytic subunit, and were activated greater than 100-fold by G beta gamma s. Peptide sequence-based oligonucleotide probes were used to clone cDNAs for the p120 and p101 species. The cDNA of p120 is highly related to p110 gamma, while the cDNA of p101 is not substantially related to anything in current databases. The proteins were expressed in and purified from insect and mammalian cells. They bound tightly to one another, both in vivo and in vitro, and in so doing, p101 amplified the effect of G beta gamma s on the PI3K activity of p120 from less than 2-fold to greater than 100-fold.	MEM SLOAN KETTERING CANC CTR, PROGRAM MOL BIOL, NEW YORK, NY 10021 USA; UNIV ROCHESTER, DEPT PHYSIOL & PHARMACOL, ROCHESTER, NY 14642 USA; UNIV BERN, THEODOR KOCHER INST, CH-3000 BERN 9, SWITZERLAND; ONYX PHARMACEUT, RICHMOND, CA 94806 USA	Memorial Sloan Kettering Cancer Center; University of Rochester; University of Bern	Stephens, LR (corresponding author), BABRAHAM INST, INOSITIDE LAB, DEPT SIGNALLING, CAMBRIDGE CB2 4AT, ENGLAND.			Hawkins, Phillip/0000-0002-6979-0464; Erdjument-Bromage, Hediye/0000-0003-0224-3594; stephens, len/0000-0002-2771-3487	NCI NIH HHS [5 P30 CA08748] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; ELICONE C, 1994, J CHROMATOGR A, V676, P121, DOI 10.1016/0021-9673(94)00089-1; ERDJUMENTBROMAGE H, 1994, PROTEIN SCI, V3, P2435, DOI 10.1002/pro.5560031227; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GEROMANOS S, 1994, TECHNIQUES PROTEIN C, V5, P143; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; Inukai K, 1996, J BIOL CHEM, V271, P5317, DOI 10.1074/jbc.271.10.5317; KUROSU H, 1995, BIOCHEM BIOPH RES CO, V216, P655, DOI 10.1006/bbrc.1995.2672; LEE SB, 1995, CURR BIOL, V7, P193; Lui M, 1996, ANAL BIOCHEM, V241, P156, DOI 10.1006/abio.1996.0393; Macdougall LK, 1995, CURR BIOL, V5, P1404, DOI 10.1016/S0960-9822(95)00278-8; MORRIS AJ, 1995, MOL PHARMACOL, V48, P532; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PONS S, 1995, MOL CELL BIOL, V15, P4453; Ptasznik A, 1996, J BIOL CHEM, V271, P25204, DOI 10.1074/jbc.271.41.25204; STEPHENS L, 1993, EMBO J, V12, P2265, DOI 10.1002/j.1460-2075.1993.tb05880.x; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; STERNWEIS PC, 1990, RECEPTOR EFFECTOR CO, P1; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; TEMPST P, 1990, ELECTROPHORESIS, V11, P537, DOI 10.1002/elps.1150110704; TEMPST P, 1994, METH COMPANION METH, V6, P284; THELEN M, 1994, P NATL ACAD SCI USA, V91, P4960, DOI 10.1073/pnas.91.11.4960; THOMASON PA, 1994, J BIOL CHEM, V269, P16525; TRAYNORKAPLAN AE, 1988, NATURE, V334, P353, DOI 10.1038/334353a0; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; YANO H, 1993, J BIOL CHEM, V268, P25846; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; Zvelebil MJ, 1996, PHILOS T R SOC B, V351, P217, DOI 10.1098/rstb.1996.0019	37	488	527	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 4	1997	89	1					105	114		10.1016/S0092-8674(00)80187-7	http://dx.doi.org/10.1016/S0092-8674(00)80187-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WR685	9094719	hybrid			2022-12-01	WOS:A1997WR68500014
J	Groll, M; Ditzel, L; Lowe, J; Stock, D; Bochtler, M; Bartunik, HD; Huber, R				Groll, M; Ditzel, L; Lowe, J; Stock, D; Bochtler, M; Bartunik, HD; Huber, R			Structure of 20S proteasome from yeast at 2.4 angstrom resolution	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; PROTEIN-DEGRADATION; SUBUNIT; PEPTIDES; PRODUCTS; CELL; LMP2; GENE; PROTEOLYSIS; ACIDOPHILUM	The crystal structure of the 20S proteasome from the yeast Saccharomyces cerevisiae shows that its 28 protein subunits are arranged as an (alpha 1...alpha 7, beta 1...beta 7)(2) complex in four stacked rings and occupy unique locations. The interior of the particle, which harbours the active sites, is only accessible by some very narrow side entrances, The beta-type subunits are synthesized as proproteins before being proteolytically processed for assembly into the particle, The proforms of three of the seven different beta-type subunits, beta 1/PRE3, beta 2/PUP1 and beta 5/PRE2, are cleaved between the threonlne at position 1 and the last glycine of the pro-sequence, with release of the active-site residue Thr 1. These three beta-type subunlts have inhibitor-binding sites, indicating that PRE2 has a chymotrypsin-like and a trypsin-like activity and that PRE3 has peptidylglutamyl peptide hydrolytlc specificity, Other beta-type subunits are processed to an intermediate form, indicating that an additional nonspecific endopeptidase activity may exist which is important for peptide hydrolysis and for the generation of ligands for class I molecules of the major histocompatibility complex.	MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY; MAX PLANCK GESELL,ARBEITSGRP STRUKTURELLE MOL BIOL,D-22603 HAMBURG,GERMANY	Max Planck Society; Max Planck Society			Löwe, Jan/B-3882-2011; Löwe, Jan/X-6998-2019; Groll, Michael/F-5572-2015; Bochtler, Matthias/A-4514-2010; Groll, Michael/C-1174-2010	Bochtler, Matthias/0000-0001-7884-4463; Lowe, Jan/0000-0002-5218-6615				ACHSTATTER T, 1994, J BIOL CHEM, V259, P13344; BRANNIGAN JA, 1995, NATURE, V378, P416, DOI 10.1038/378416a0; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CERUNDOLO V, 1995, EUR J IMMUNOL, V25, P554, DOI 10.1002/eji.1830250238; Chen P, 1996, CELL, V86, P961, DOI 10.1016/S0092-8674(00)80171-3; CHEN P, 1995, EMBO J, V14, P2620, DOI 10.1002/j.1460-2075.1995.tb07260.x; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DICK LR, 1991, BIOCHEMISTRY-US, V30, P2725, DOI 10.1021/bi00224a022; DICK LR, 1994, J IMMUNOL, V152, P3884; DRISCOLL J, 1993, NATURE, V365, P262, DOI 10.1038/365262a0; DUGGLEBY HJ, 1995, NATURE, V373, P264, DOI 10.1038/373264a0; Ehring B, 1996, EUR J BIOCHEM, V235, P404, DOI 10.1111/j.1432-1033.1996.00404.x; EMORI Y, 1991, MOL CELL BIOL, V11, P344, DOI 10.1128/MCB.11.1.344; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FEHLING HJ, 1994, SCIENCE, V265, P1234, DOI 10.1126/science.8066463; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FRENTZEL S, 1994, J MOL BIOL, V236, P975, DOI 10.1016/0022-2836(94)90003-5; GACZYNSKA M, 1993, NATURE, V365, P264, DOI 10.1038/365264a0; GOLDBERG AL, 1995, CHEM BIOL, V2, P503, DOI 10.1016/1074-5521(95)90182-5; GRAY CW, 1994, J MOL BIOL, V236, P7, DOI 10.1006/jmbi.1994.1113; Groettrup M, 1996, IMMUNOL TODAY, V17, P429, DOI 10.1016/0167-5699(96)10051-7; HEINEMEYER W, 1994, BIOCHEMISTRY-US, V33, P12229, DOI 10.1021/bi00206a028; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; Hilt W, 1996, TRENDS BIOCHEM SCI, V21, P96, DOI 10.1016/0968-0004(96)10012-8; HILT W, 1993, J BIOL CHEM, V268, P3479; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HOFFMAN L, 1994, J BIOL CHEM, V269, P16890; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; Kania MA, 1996, EUR J BIOCHEM, V236, P510, DOI 10.1111/j.1432-1033.1996.00510.x; KOPP F, 1995, J MOL BIOL, V248, P264; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUCKELKORN U, 1995, EUR J IMMUNOL, V25, P2605, DOI 10.1002/eji.1830250930; LESLIE AGW, 1994, ACTA CRYSTALLOGR D, V50, P760; LORD M, 1996, CURR BIOL, V6, P1067; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; Niedermann G, 1996, P NATL ACAD SCI USA, V93, P8572, DOI 10.1073/pnas.93.16.8572; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; RIVETT AJ, 1993, BIOCHEM J, V291, P1; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; RUBIN DM, 1995, CURR BIOL, V5, P854, DOI 10.1016/S0960-9822(95)00172-2; Schmidtke G, 1996, EMBO J, V15, P6887, DOI 10.1002/j.1460-2075.1996.tb01081.x; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; Seemuller E, 1996, NATURE, V382, P468, DOI 10.1038/382468a0; SIBILLE C, 1995, CURR BIOL, V5, P923, DOI 10.1016/S0960-9822(95)00182-5; Stock D, 1996, CURR OPIN BIOTECH, V7, P376, DOI 10.1016/S0958-1669(96)80111-X; Stock D, 1995, COLD SPRING HARB SYM, V60, P525, DOI 10.1101/SQB.1995.060.01.056; Stohwasser R, 1996, FEBS LETT, V383, P109, DOI 10.1016/0014-5793(96)00110-X; TURK D, 1992, THESIS TU MUNCHEN; VANKAER L, 1994, IMMUNITY, V1, P533, DOI 10.1016/1074-7613(94)90043-4; VONENGELHARD H, 1994, CURR OPIN IMMUNOL, V6, P13; WENZEL T, 1994, FEBS LETT, V349, P205, DOI 10.1016/0014-5793(94)00665-2; York IA, 1996, ANNU REV IMMUNOL, V14, P369, DOI 10.1146/annurev.immunol.14.1.369	55	1863	1925	3	100	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 3	1997	386	6624					463	471		10.1038/386463a0	http://dx.doi.org/10.1038/386463a0			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WR256	9087403				2022-12-01	WOS:A1997WR25600043
J	Mashru, M; Lant, A				Mashru, M; Lant, A			Interpractice audit of diagnosis and management of hypertension in primary care: Educational intervention and review of medical records	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED TRIAL; BLOOD-PRESSURE; GUIDELINES; HALVES; RULE	Objective: To determine whether peer review medical audit in a primary care setting changes clinical behaviour in relation to the management of hypertension. Design: Review of medical records in general practices to identify hypertensive patients followed up by assessment of the pre-educational and post-educational management of interventions. Setting: Six general practices in north west London picked at random within defined criteria of geography and size. Subjects: 740 hypertensive patients managed by 25 different general practitioners. Main outcome measures:Improved level of care in terms of better diagnosis by having at least three blood pressure readings before the start of drug treatment, better level of recordings of lifestyle parameters as shown by the level of recordings of body mass index and total lipid values, and better control of blood pressure and harm minimisation as shown by the level of recordings of urea and electrolyte values. Results:Improvement was noted in the level of recordings of body mass index, total lipid concentrations, and urea and electrolyte values but not in better diagnosis or blood pressure control. Conclusion: Clinical behaviour of general practitioners can be changed by peer review but more complex behavioural changes which require the cooperation of the patients and cognitive actions by the general practitioners need further investigation.	CHELSEA & WESTMINSTER HOSP, CHARING CROSS & WESTMINSTER MED SCH, DEPT CLIN PHARMACOL & THERAPEUT, LONDON SW10 9NH, ENGLAND	Imperial College London								BANDURA A, 1991, NEBR SYM MOTIV, V38, P69; BURT VL, 1995, HYPERTENSION, V25, P305, DOI 10.1161/01.HYP.25.3.305; BUTLER C, 1995, BMJ-BRIT MED J, V310, P784, DOI 10.1136/bmj.310.6982.784; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; Department of Health, 1992, HLTH NAT STRAT HLTH; FEDER G, 1995, BRIT MED J, V311, P1473, DOI 10.1136/bmj.311.7018.1473; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; HART JT, 1992, BRIT J GEN PRACT, V42, P116; HART JT, 1993, HYPERTENSION COMMUNI, P1; Hopkins A, 1996, J ROY COLL PHYS LOND, V30, P415; Humphrey C, 1993, Qual Health Care, V2, P232, DOI 10.1136/qshc.2.4.232; JACKSON R, 1993, BRIT MED J, V307, P107, DOI 10.1136/bmj.307.6896.107; JOHNSON R, 1994, BRIT MED J, V309, P98, DOI 10.1136/bmj.309.6947.98; MAYNARD A, 1993, HLTH SERV J, V193, P21; NEATON JD, 1993, JAMA-J AM MED ASSOC, V270, P713, DOI 10.1001/jama.270.6.713; *NHS MAN EX, 1993, EL93115 NHS MAN EX D; *ROYAL COLL GEN PR, 1985, 23 ROYAL COLL GEN PR; RUSSELL MAH, 1979, BRIT MED J, V2, P231, DOI 10.1136/bmj.2.6184.231; SEVER P, 1993, BMJ-BRIT MED J, V306, P983, DOI 10.1136/bmj.306.6883.983; SMITH WCS, 1990, BRIT MED J, V300, P981, DOI 10.1136/bmj.300.6730.981; STEWART A, 1994, AUDIT TRENDS, V2, P80; TABENKIN H, 1996, J FAM PRACTICE, V12, P309; *U LEEDS, 1995, EFF HLTH CARE, V8; WALLACE P, 1988, BRIT MED J, V297, P663, DOI 10.1136/bmj.297.6649.663; ZANCHETTI A, 1993, BMJ-BRIT MED J, V307, P1541, DOI 10.1136/bmj.307.6918.1541	25	39	38	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 29	1997	314	7085					942	946		10.1136/bmj.314.7085.942	http://dx.doi.org/10.1136/bmj.314.7085.942			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ169	9099120	Green Published			2022-12-01	WOS:A1997WQ16900028
J	Curtis, RE; Rowlings, PA; Deeg, HJ; Shriner, DA; Socie, G; Travis, LB; Horowitz, MM; Witherspoon, RP; Hoover, RN; Sobocinski, KA; Fraumeni, JF; Boice, JD				Curtis, RE; Rowlings, PA; Deeg, HJ; Shriner, DA; Socie, G; Travis, LB; Horowitz, MM; Witherspoon, RP; Hoover, RN; Sobocinski, KA; Fraumeni, JF; Boice, JD			Solid cancers after bone marrow transplantation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							APLASTIC-ANEMIA; SECONDARY MALIGNANCIES; HODGKINS-DISEASE; THYROID-CANCER; TUMORS; CHEMOTHERAPY; RADIOTHERAPY; RADIATION; CHILDHOOD; LEUKEMIA	Background The late effects of bone marrow transplantation, including cancer, need to be determined in a large population at risk. Methods We studied 19,229 patients who received allogeneic transplants (97.2 percent) or syngeneic transplants (2.8 percent) between 1964 and 1992 at 235 centers to evaluate the risk of the development of a new solid cancer. Risk factors relating to the patient, the transplant, and the course after transplantation were evaluated. Results The transplant recipients were at significantly higher risk of new solid cancers than the general population (observed cases, 80; ratio of observed to expected cases, 2.7; P<0.001). The risk was 8.3 times as high as expected among those who survived 10 or more years after transplantation. The cumulative incidence rate was 2.2 percent (95 percent confidence interval, 1.5 to 3.0 percent) at 10 years and 6.7 percent (95 percent confidence interval, 3.7 to 9.6 percent) at 15 years. The risk was significantly elevated (P<0.05) for malignant melanoma (ratio of observed to expected cases, 5.0) and cancers of the buccal cavity (11.1), liver (7.5), brain or other parts of the central nervous system (7.6), thyroid (6.6), bone (13.4), and connective tissue (8.0). The risk was high er for recipients who were younger at the time of transplantation than for those who were older (P for trend, <0.001). In multivariate analyses, higher doses of total-body irradiation were associated with a higher risk of solid cancers. Chronic graft-versus-host disease and male sex were strongly linked with an excess risk of squamous-cell cancers of the buccal cavity and skin. Conclusions Patients undergoing bone marrow transplantation have an increased risk of new solid cancers later in life. The trend toward an increased risk over time after transplantation and the greater risk among younger patients indicate the need for lifelong surveillance. (C) 1997, Massachusetts Medical Society.	MED COLL WISCONSIN,INT BONE MARROW TRANSPLANT REGISTRY,MILWAUKEE,WI 53226; FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104; HOP ST LOUIS,PARIS,FRANCE; ARMED FORCES INST PATHOL,WASHINGTON,DC 20306; UNIV MUNICH,MUNICH,GERMANY; SALICK HLTH CARE,LOS ANGELES,CA	Medical College of Wisconsin; Fred Hutchinson Cancer Center; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; United States Department of Defense; University of Munich	Curtis, RE (corresponding author), NCI,DIV CANC EPIDEMIOL & GENET,EXECUT PLAZA N,SUITE 408,BETHESDA,MD 20892, USA.		horowitz, Mary/ABH-2173-2021		NCI NIH HHS [P01-CA-18029, P01-CA-18221, P01-CA-47748] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA018221, P01CA018029, P01CA047748] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bhatia S, 1996, BLOOD, V87, P3633, DOI 10.1182/blood.V87.9.3633.bloodjournal8793633; Bhatia S, 1996, NEW ENGL J MED, V334, P745, DOI 10.1056/NEJM199603213341201; BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; COX DR, 1972, J R STAT SOC B, V34, P187; DEEG HJ, 1993, HEMATOL ONCOL CLIN N, V7, P417, DOI 10.1016/S0889-8588(18)30249-1; Deeg HJ, 1996, BLOOD, V87, P386, DOI 10.1182/blood.V87.1.386.bloodjournal871386; ENG C, 1993, JNCI-J NATL CANCER I, V85, P1121, DOI 10.1093/jnci/85.14.1121; FILIPOVICH AH, 1992, CANCER RES, V52, pS5465; GREENE MH, 1981, LANCET, V1, P1196, DOI 10.1016/S0140-6736(81)92359-X; HANCOCK SL, 1993, J NATL CANCER I, V85, P25, DOI 10.1093/jnci/85.1.25; Hawkins MM, 1996, J NATL CANCER I, V88, P270, DOI 10.1093/jnci/88.5.270; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KINLEN LJ, 1996, CANC EPIDEMIOLOGY PR, P532; KOLB HJ, 1990, BONE MARROW TRANSPL, V6, P61; KOLB HJ, 1992, BONE MARROW TRANSPL, V10, P135; Land CE, 1996, RADIAT RES, V146, P28, DOI 10.2307/3579392; LOWSKY R, 1994, J CLIN ONCOL, V12, P2187, DOI 10.1200/JCO.1994.12.10.2187; LUSTIG JP, 1995, EUR J CANC B ORAL B, V31, P68; MUIR C, 1987, IARC SCI PUBLICATION, V88; NEGLIA JP, 1991, NEW ENGL J MED, V325, P1330, DOI 10.1056/NEJM199111073251902; PARKIN DM, 1992, IARC SCI PUBLICATION, V120; Preston DL, 1993, EPICURE USERS GUIDE; RABKIN CS, 1994, J NATL CANCER I, V86, P1711, DOI 10.1093/jnci/86.22.1711; Ries L, 1994, NIH PUBLICATION, V94-2789; RON E, 1995, RADIAT RES, V141, P259, DOI 10.2307/3579003; RON E, 1988, NEW ENGL J MED, V319, P1033, DOI 10.1056/NEJM198810203191601; SHEIL AGR, 1992, TRANSPLANT P, V24, P1275; SOCIE G, 1993, NEW ENGL J MED, V329, P1152, DOI 10.1056/NEJM199310143291603; SOCIE G, 1992, LEUKEMIA LYMPHOMA, V7, P419, DOI 10.3109/10428199209049797; THOMPSON DE, 1994, RADIAT RES, V137, pS17, DOI 10.2307/3578892; THOMPSON DE, 1994, RADIAT RES, V139, P129; TRAVIS LB, 1991, CANCER-AM CANCER SOC, V67, P2002, DOI 10.1002/1097-0142(19910401)67:7<2002::AID-CNCR2820670729>3.0.CO;2-E; TUCKER MA, 1985, ANN INTERN MED, V102, P37, DOI 10.7326/0003-4819-102-1-37; TUCKER MA, 1987, NEW ENGL J MED, V317, P588, DOI 10.1056/NEJM198709033171002; TUCKER MA, 1991, CANCER RES, V51, P2885; *UN SCI COMM EFF T, 1994, UN PUBL; VITTORIO CC, 1995, DERMATOL CLIN, V13, P561, DOI 10.1016/S0733-8635(18)30062-7; VOSE JM, 1992, CANCER, V69, P784, DOI 10.1002/1097-0142(19920201)69:3<784::AID-CNCR2820690328>3.0.CO;2-M; Witherspoon R P, 1994, Transplant Sci, V4, P33; WITHERSPOON RP, 1989, NEW ENGL J MED, V321, P784, DOI 10.1056/NEJM198909213211203; WITHERSPOON RP, 1992, BLOOD, V79, P289	41	668	683	0	17	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 27	1997	336	13					897	904		10.1056/NEJM199703273361301	http://dx.doi.org/10.1056/NEJM199703273361301			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WP832	9070469				2022-12-01	WOS:A1997WP83200001
J	Looker, AC; Dallman, PR; Carroll, MD; Gunter, EW; Johnson, CL				Looker, AC; Dallman, PR; Carroll, MD; Gunter, EW; Johnson, CL			Prevalence of iron deficiency in the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DECLINING PREVALENCE; ANEMIA; POPULATION; NHANES	Objective.-To determine the prevalence of iron deficiency and iron deficiency anemia in the US population. Design.-Nationally representative cross-sectional health examination survey that included venous blood measurements of iron status. Main Outcome Measures.-Iron deficiency, defined as having an abnormal value for at least 2 of 3 laboratory tests of iron status (erythrocyte protoporphyrin, transferrin saturation, or serum ferritin); and iron deficiency anemia, defined as iron deficiency plus low hemoglobin. Participants.-A total of 24 894 persons aged 1 year and older examined in the third National Health and Nutrition Examination Survey (1988-1994). Results.-Nine percent of toddlers aged 1 to 2 years and 9% to 11% of adolescent girls and women of childbearing age were iron deficient; of these, iron deficiency anemia was found in 3% and 2% to 5%, respectively. These prevalences correspond to approximately 700 000 toddlers and 7.8 million women with iron deficiency; of these, approximately 240 000 toddlers and 3.3 million women have iron deficiency anemia. Iron deficiency occurred in no more than 7% of older children or those older than 50 years, and in no more than 1% of teenage boys and young men. Among women of childbearing age, iron deficiency was more likely in those who are minority, low income, and multiparous. Conclusion.-Iron deficiency and iron deficiency anemia are still relatively common in toddlers, adolescent girls, and women of childbearing age.	UNIV CALIF SAN FRANCISCO,SCH MED,DEPT PEDIAT,SAN FRANCISCO,CA 94143; CTR DIS CONTROL & PREVENT,NATL CTR ENVIRONM HLTH,DIV ENVIRONM HLTH LAB SCI,ATLANTA,GA	University of California System; University of California San Francisco; Centers for Disease Control & Prevention - USA	Looker, AC (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR HLTH STAT,DIV HLTH EXAMINAT STAT,6525 BELCREST RD,HYATTSVILLE,MD 20782, USA.							[Anonymous], 1984, ASSESSMENT IRON NUTR; [Anonymous], JAMA; CDC, 1989, MMWR-MORBID MORTAL W, V38, P400; COOK JD, 1976, BLOOD, V48, P449; Dallman Peter R., 1996, P65; DALLMAN PR, 1986, ANNU REV NUTR, V6, P13, DOI 10.1146/annurev.nu.06.070186.000305; Ekblom Bjorn, 1996, P195; *EXP SCI WORK GROU, 1985, AM J CLIN NUTR, V42, P1318; EZZATI T, 1992, NONRESPONSE ADJUSTME, P339; *FOOD NUTR BOARD I, 1993, IR DEF AN REC GUID P; Gunter E.W., 1996, LAB PROCEDURES USED; GUNTER EW, 1989, CLIN CHEM, V35, P1601; *INT COMM STAND HA, 1988, J CLIN PATHOL, V41, P1203; Kim I, 1992, MMWR-MORBID MORTAL W, V41, P26; LOOKER AC, 1989, AM J CLIN NUTR, V49, P553, DOI 10.1093/ajcn/49.3.553; LOOKER AC, 1995, NUTR REV, V53, P246, DOI 10.1111/j.1753-4887.1995.tb05481.x; MOHADJER L, 1996, NATL HLTH NUTR EXAMI; National Center for Health Statistics, 1994, PLAN OP 3 NAT HLTH N; PIRKLE JL, 1994, JAMA-J AM MED ASSOC, V272, P284, DOI 10.1001/jama.272.4.284; REES JM, 1985, CLIN PEDIATR, V24, P707, DOI 10.1177/000992288502401207; SHAH BV, 1991, SUDAAN USERS MANUAL; STOCKMAN JA, 1987, JAMA-J AM MED ASSOC, V258, P1645, DOI 10.1001/jama.258.12.1645; VAZQUEZSEOANE P, 1985, NEW ENGL J MED, V313, P1239, DOI 10.1056/NEJM198511073131936; YIP R, 1987, JAMA-J AM MED ASSOC, V258, P1619, DOI 10.1001/jama.258.12.1619; YIP R, 1988, AM J CLIN NUTR, V48, P1295, DOI 10.1093/ajcn/48.5.1295; YIP R, 1987, PEDIATRICS, V80, P330	26	911	935	0	73	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 26	1997	277	12					973	976		10.1001/jama.277.12.973	http://dx.doi.org/10.1001/jama.277.12.973			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN992	9091669				2022-12-01	WOS:A1997WN99200031
J	Ohayon, MM; Guilleminault, C; Priest, RG; Caulet, M				Ohayon, MM; Guilleminault, C; Priest, RG; Caulet, M			Snoring and breathing pauses during sleep: Telephone interview survey of a United Kingdom population sample	BRITISH MEDICAL JOURNAL			English	Article							APNEA; DISTURBANCES; HYPERTENSION; MEN	Objectives: To determine the prevalence of snoring, breathing pauses during sleep, and obstructive sleep apnoea syndrome and determine the relation between these events and sociodemographic variables, other health problems, driving accidents, and consumption of healthcare resources. Design: Telephone interview survey directed by a previously validated computerised system (Sleep-Eval). Setting: United Kingdom. Subjects: 2894 women and 2078 men aged 15-100 years who formed a representative sample of the non-institutionalised population. Main outcome measures: Interview responses. Results: Forty per cent of the population reported snoring regularly and 3.8% reported breathing pauses during sleep, Regular snoring was significantly associated with male sex, age 25 or more, obesity, daytime sleepiness or naps, night time awakenings, consuming large amounts of caffeine, and smoking. Breathing pauses during sleep were significantly associated with obstructive airways or thyroid disease, male sex, age 35-44 years, consumption of anxiety reducing drugs, complaints of non-restorative sleep, and consultation with a doctor in the past year. The two breathing symptoms were also significantly associated with drowsiness while driving. Based on minimal criteria of the International Classification of Sleep Disorders (1990), 1.9% of the sample had obstructive sleep apnoea syndrome, In the 35-64 year age group 1.5% of women (95% confidence interval 0.8% to 2.2%) and 3.5% of men (2.4% to 4.6%) had obstructive sleep apnoea syndrome. Conclusions: Disordered breathing during sleep is widely underdiagnosed in the United Kingdom. The condition is linked to increased use of medical resources and a greater risk of daytime sleepiness, which augments the risk of accidents. Doctors should ask patients and bed partners regularly about snoring and breathing pauses during sleep.	STANFORD UNIV,SLEEP DISORDERS CLIN & RES CTR,SCH MED,STANFORD,CA 94305; UNIV LONDON,ST MARYS,IMPERIAL COLL SCH MED,PATERSON CTR,ACAD DEPT PSYCHIAT,LONDON W2 1PD,ENGLAND	Stanford University; Imperial College London; University of London	Ohayon, MM (corresponding author), CTR RECH PHILIPPE PINEL MONTREAL,MONTREAL,PQ H1C 1H1,CANADA.		Ohayon, Maurice M/A-1338-2007	Ohayon, Maurice/0000-0002-2757-5440				American Sleep Disorders Association. Diagnostic Classification Steering Committee, 1990, INT CLASS SLEEP DIS, pxii, 396; CROSBY J, 1989, THORAX, V344, P353; GISLASON T, 1993, J INTERN MED, V234, P31, DOI 10.1111/j.1365-2796.1993.tb00701.x; HLA KM, 1994, ANN INTERN MED, V120, P382, DOI 10.7326/0003-4819-120-5-199403010-00005; Hosmer DW, 2000, APPL LOGISTIC REGRES, V2nd; Kish L, 1965, SURVEY SAMPLING; KOSKENVUO M, 1987, BRIT MED J, V294, P16, DOI 10.1136/bmj.294.6563.16; LUGARESI E, 1980, SLEEP, V3, P221, DOI 10.1093/sleep/3.3-4.221; MENDELSON WB, 1992, CHEST, V101, P903, DOI 10.1378/chest.101.4.903; Ohayon M., 1992, MEDINFO 92. Proceedings of the Seventh World Congress on Medical Informatics, P615; OHAYON M, 1994, SLEEP DISORDERS QUES; OHAYON M, 1994, P 12 INT C EUR FED M, P90; OHAYON M, 1994, P 12 INT C EUR FED M, P174; PARISH JM, 1990, CHEST, V97, P1220, DOI 10.1378/chest.97.5.1220; REDLINE S, 1994, SLEEP BREATH, P363; SHAPIRO CM, 1981, LANCET, V2, P523; SMIRNE S, 1993, EUR RESPIR J, V6, P1347; STRADLING JR, 1989, BRIT MED J, V298, P904, DOI 10.1136/bmj.298.6678.904; STRADLING JR, 1991, THORAX, V46, P85, DOI 10.1136/thx.46.2.85; TELAKIVI T, 1987, ACTA NEUROL SCAND, V76, P69, DOI 10.1111/j.1600-0404.1987.tb03547.x; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704	21	212	217	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 22	1997	314	7084					860	863						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ028	9093095				2022-12-01	WOS:A1997WQ02800023
J	Moreno, A; Carreno, V; Cano, A; Gonzalez, C				Moreno, A; Carreno, V; Cano, A; Gonzalez, C			Idiopathic biliary ductopenia in adults without symptoms of liver disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BILE-DUCT SYNDROME; AUTOIMMUNE CHOLANGITIS; CIRRHOSIS; CHOLESTASIS; ACID	Background Idiopathic adulthood ductopenia is a severe cholestatic liver disease of unknown cause characterized by loss of the interlobular bile ducts in more than 50 percent of the portal tracts. In most reported cases, cirrhosis and liver failure develop. Methods We studied 24 adults with abnormal results on liver-function tests but no symptoms of liver disease. All had liver biopsies that showed a lack of bile ducts in many of the portal tracts. Results The 17 women and 7 men had a mean age of 41 years (range, 27 to 57). All were asymptomatic and had high serum gamma-glutamyltransferase concentrations (mean [+/-SD], 179+/-84 U per liter); 75 percent also had abnormal serum alanine aminotransferase concentrations. The proportion of portal tracts that had bile ducts was 62+/-7 percent (range, 55 to 78 percent). Three patients had a second liver biopsy three to nine years after the first; there were no changes over time. In four of the five patients treated with 600 to 900 mg of ursodiol two to three times daily, results of liver-function tests returned to normal. Conclusions Idiopathic biliary ductopenia, with an apparently nonprogressive clinical course, can occur in adults who have no symptoms of biliary disease. (C) 1997, Massachusetts Medical Society.	FDN JIMENEZ DIAZ,DEPT HEPATOL,MADRID 28040,SPAIN; HOSP RAMON Y CAJAL,LIVER UNIT,E-28034 MADRID,SPAIN	Hospital Universitario Ramon y Cajal								ALAGILLE D, 1987, J PEDIATR-US, V110, P195, DOI 10.1016/S0022-3476(87)80153-1; ALAGILLE D, 1975, J PEDIATR-US, V86, P63, DOI 10.1016/S0022-3476(75)80706-2; ALTRAIF I, 1994, AM J GASTROENTEROL, V89, P1230; BENARI Z, 1993, HEPATOLOGY, V18, P10, DOI 10.1002/hep.1840180103; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIES MH, 1994, J HEPATOL, V20, P112, DOI 10.1016/S0168-8278(05)80476-3; DEGOTT C, 1992, HEPATOLOGY, V15, P244, DOI 10.1002/hep.1840150212; FAA G, 1991, J HEPATOL, V12, P14, DOI 10.1016/0168-8278(91)90902-N; GOODMAN ZD, 1995, DIGEST DIS SCI, V40, P1232, DOI 10.1007/BF02065530; HAUTEKEETE ML, 1995, J HEPATOL, V22, P71, DOI 10.1016/0168-8278(95)80262-2; ISHII M, 1993, LIVER, V13, P227; Leary TP, 1996, J MED VIROL, V48, P60, DOI 10.1002/(SICI)1096-9071(199601)48:1&lt;60::AID-JMV10&gt;3.0.CO;2-A; LUDWIG J, 1987, HEPATOLOGY, V7, P476, DOI 10.1002/hep.1840070311; LUDWIG J, 1988, J HEPATOL, V7, P193, DOI 10.1016/S0168-8278(88)80482-3; LUDWIG J, 1981, Hepatology, V1, P632, DOI 10.1002/hep.1840010612; LUDWIG J, 1992, PRACTICAL LIVER BIOP, P203; MICHIELETTI P, 1994, GUT, V35, P260, DOI 10.1136/gut.35.2.260; MULLER C, 1995, LIVER, V15, P213; MURPHY JR, 1990, J CLIN GASTROENTEROL, V12, P555, DOI 10.1097/00004836-199010000-00014; NAKAJIMA K, 1994, ENDOSCOPY, V26, P332, DOI 10.1055/s-2007-1008984; SHERLOCK S, 1987, LANCET, V2, P493; VAZQUEZ JJ, 1993, HEPATOBILIARY DIS, P141; VILLARI D, 1995, VIRCHOWS ARCH, V427, P223, DOI 10.1007/BF00196529; ZAFRANI ES, 1990, GASTROENTEROLOGY, V99, P1823, DOI 10.1016/0016-5085(90)90494-L	24	41	44	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 20	1997	336	12					835	838		10.1056/NEJM199703203361204	http://dx.doi.org/10.1056/NEJM199703203361204			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN371	9062092				2022-12-01	WOS:A1997WN37100004
J	Alter, HJ; Nakatsuji, Y; Melpolder, J; Wages, J; Wesley, R; Shih, JWK; Kim, JP				Alter, HJ; Nakatsuji, Y; Melpolder, J; Wages, J; Wesley, R; Shih, JWK; Kim, JP			The incidence of transfusion-associated hepatitis G virus infection and its relation to liver disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NON-B-HEPATITIS; NON-A; C VIRUS; ANTIBODY; BLOOD	Background The role of hepatitis G virus (HGV) in transfusion-associated infection and its relation to liver disease are not well understood. Methods Serum samples collected between 1972 and 1995 from 357 transfusion recipients, 157 controls who did not receive transfusions, 500 randomly selected volunteer blood donors, and 230 donors of blood received by HGV-infected patients were tested for HGV RNA by qualitative and quantitative polymerase-chain-reaction assays. Samples obtained before transfusion and serially after transfusion from 79 of the 81 transfusion recipients who had transfusion-associated non-A, non-B hepatitis were available for testing. Results Of the 79 patients with transfusion-associated hepatitis, 63 (80 percent) had infections related to the hepatitis C virus (HCV) and 3 had preexisting HCV and the cause of their acute hepatitis could not be determined; of the remaining 13 patients, 3 had acute HGV infection, and 10 were infected with unidentified agents. Six of the 63 patients with HCV infection who were tested (10 percent) were also infected with HGV. The three patients infected only with HGV had mild hepatitis (mean peak alanine aminotransferase level, 198 U per liter; none had jaundice); the levels of alanine aminotransferase and HGV RNA were not well correlated. The combined HCV and HGV infections were no more severe than HCV infections alone; the alanine aminotransferase values paralleled the levels of HCV RNA, but not those of HGV RNA, There were 35 HGV infections among the 357 transfusion recipients; only 3 had hepatitis with HGV as the sole viral marker. One of the 157 controls and 7 of the 500 randomly selected blood donors (1.4 percent) had detectable HGV RNA. In all eight instances in which a transfusion recipient had acute HGV infection after transfusion and samples from all donors could be tested, at least one HGV-positive donor was identified. Conclusions HGV was common in a group of volunteer blood donors, and it can be transmitted by transfusion. Most HGV infections were not associated with hepatitis. HGV did not worsen the course of concurrent HCV infection. No causal relation between HGV and hepatitis has been established. (C) 1997, Massachusetts Medical Society.	NIH,WARREN G MAGNUSON CLIN CTR,DEPT INFORMAT SYST,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA	Alter, HJ (corresponding author), NIH,WARREN G MAGNUSON CLIN CTR,DEPT TRANSFUS MED,BLDG 10,RM 1C-711,BETHESDA,MD 20892, USA.							ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ALTER HJ, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P396; ALTER HJ, 1995, J VIRAL HEPATITIS, V2, P121, DOI 10.1111/j.1365-2893.1995.tb00017.x; ALTER MJ, 1992, NEW ENGL J MED, V327, P1899, DOI 10.1056/NEJM199212313272702; ARMITAGE P, 1971, STATISTICAL METHODS, P135; BICKEL PJ, 1977, MATH STAT BASIC IDEA, P162; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; KOTZ S, 1983, ENCY STAT SCI, P709; KOU G, 1989, SCIENCE, V244, P362; KOZIOL DE, 1986, ANN INTERN MED, V104, P488, DOI 10.7326/0003-4819-104-4-488; Linnen J, 1996, SCIENCE, V271, P505, DOI 10.1126/science.271.5248.505; Masuko K, 1996, NEW ENGL J MED, V334, P1485, DOI 10.1056/NEJM199606063342301; TSAREV SA, 1993, J INFECT DIS, V168, P369, DOI 10.1093/infdis/168.2.369; WEINER AJ, 1990, LANCET, V336, P695, DOI 10.1016/0140-6736(90)92194-M	14	501	512	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 13	1997	336	11					747	754		10.1056/NEJM199703133361102	http://dx.doi.org/10.1056/NEJM199703133361102			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM640	9052652				2022-12-01	WOS:A1997WM64000002
J	Waldmann, R; Champigny, G; Bassilana, F; Heurteaux, C; Lazdunski, M				Waldmann, R; Champigny, G; Bassilana, F; Heurteaux, C; Lazdunski, M			A proton-gated cation channel involved in acid-sensing	NATURE			English	Article							SENSITIVE NA+ CHANNEL; INDUCED SODIUM CURRENT; ROOT GANGLION NEURONS; SENSORY NEURONS; HOMOLOGOUS SUBUNITS; CELLS; ACTIVATION; EXPRESSION; CLONING; CONDUCTANCE	Acid-sensing is associated with both nociception(1) and taste transduction(2). Stimulation of sensory neurons by acid is of particular interest, because acidosis accompanies many painful inflammatory and ischaemic conditions. The pain caused by acids is thought to be mediated by H+-gated cation channels present in sensory neurons(3-5). We have now cloned a H+-gated channel (ASIC, for acid-sensing ionic channel) that belongs to the amiloride-sensitive Na+ channel(6-11)/degenerin(12-14) family of ion channels. Heterologous expression of ASIC induces an amiloride-sensitive cation (Na+ > Ca2+ > K+) channel which is transiently activated by rapid extracellular acidification. The biophysical and pharmacological properties of the ASIC channel closely match the H+-gated cation channel described in sensory neurons(3,15,16). ASIC is expressed in dorsal root ganglia and is also distributed widely throughout the brain. ASIC appears to be the simplest of Ligand-gated channels.	CNRS, INST PHARMACOL MOL & CELLULAIRE, F-06560 VALBONNE, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur			HEURTEAUX, Catherine/M-4947-2016; Waldmann, Rainer/Q-2108-2016	HEURTEAUX, Catherine/0000-0002-9741-9777; Waldmann, Rainer/0000-0002-4599-2926; Bassilana, Frederic/0000-0003-2063-8450				AKAIKE N, 1994, PROG NEUROBIOL, V43, P73, DOI 10.1016/0301-0082(94)90016-7; AKAIKE N, 1990, J NEUROPHYSIOL, V63, P805, DOI 10.1152/jn.1990.63.4.805; Barnard EA, 1996, TRENDS PHARMACOL SCI, V17, P305, DOI 10.1016/0165-6147(96)10041-9; BEVAN S, 1994, TRENDS NEUROSCI, V17, P509, DOI 10.1016/0166-2236(94)90149-X; BEVAN S, 1991, J PHYSIOL-LONDON, V433, P145, DOI 10.1113/jphysiol.1991.sp018419; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CHESLER M, 1992, TRENDS NEUROSCI, V15, P396, DOI 10.1016/0166-2236(92)90191-A; DAVIES NW, 1988, J PHYSIOL-LONDON, V400, P159, DOI 10.1113/jphysiol.1988.sp017116; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; GRANTYN R, 1989, DEV BRAIN RES, V49, P150, DOI 10.1016/0165-3806(89)90070-9; HUANG MX, 1994, NATURE, V367, P467, DOI 10.1038/367467a0; KONNERTH A, 1987, J PHYSIOL-LONDON, V386, P603, DOI 10.1113/jphysiol.1987.sp016553; KORKUSHKO A O, 1984, Neirofiziologiya, V16, P557; KOVALCHUK YN, 1990, NEUROSCI LETT, V115, P237, DOI 10.1016/0304-3940(90)90461-H; KRISHTAL OA, 1987, BRAIN RES, V436, P352, DOI 10.1016/0006-8993(87)91678-7; KRISHTAL OA, 1981, NEUROSCIENCE, V6, P2599, DOI 10.1016/0306-4522(81)90105-6; LEWIS C, 1995, NATURE, V377, P432, DOI 10.1038/377432a0; Lindemann B, 1996, PHYSIOL REV, V76, P719, DOI 10.1152/physrev.1996.76.3.719; LINGUEGLIA E, 1995, NATURE, V378, P730, DOI 10.1038/378730a0; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; LINGUEGLIA E, 1994, J BIOL CHEM, V269, P13736; Liu JD, 1996, SCIENCE, V273, P361, DOI 10.1126/science.273.5273.361; OKADA Y, 1994, J EXP BIOL, V187, P19; Price MP, 1996, J BIOL CHEM, V271, P7879, DOI 10.1074/jbc.271.14.7879; RANG HP, 1991, BRIT MED BULL, V47, P534, DOI 10.1093/oxfordjournals.bmb.a072491; RENARD S, 1994, J BIOL CHEM, V269, P12981; Waldmann R, 1996, J BIOL CHEM, V271, P10433, DOI 10.1074/jbc.271.18.10433; WALDMANN R, 1995, J BIOL CHEM, V270, P11735, DOI 10.1074/jbc.270.20.11735; WALDMANN R, 1995, J BIOL CHEM, V270, P27411, DOI 10.1074/jbc.270.46.27411	30	1068	1114	4	57	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 13	1997	386	6621					173	177		10.1038/386173a0	http://dx.doi.org/10.1038/386173a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WM973	9062189				2022-12-01	WOS:A1997WM97300062
J	DiGuiseppi, C; Roberts, I; Li, L				DiGuiseppi, C; Roberts, I; Li, L			Influence of changing travel patterns on child death rates from injury: Trend analysis	BRITISH MEDICAL JOURNAL			English	Article							OBESITY	Objectives: To examine trends in child mortality from unintentional injury between 1985 and 1992 and to find how changes in modes of travel contributed to these trends. Design: Poisson regression modelling using data from death certificates, censuses, and national travel surveys. Setting: England and Wales. Subjects: Resident children aged 0-14. Main outcome measures: Deaths from unintentional injury and poisoning. Results: Child deaths from injury declined by 34% (95% confidence interval 28% to 40%) per 100 000 population between 1985 and 1992. Substantial decreases in each of the leading causes of death from injury contributed to this overall decline. On average, children walked and cycled less distance and travelled substantially more miles by car in 1992 compared with 1985. Deaths from road traffic accidents declined for pedestrians by 24% per mile walked and for cyclists by 20% per mile cycled, substantially less than the declines per 100 000 population of 37% and 38% respectively. In contrast, deaths of occupants of motor vehicles declined by 42% per mile travelled by car compared with a 21% decline per 100 000 population. Conclusions: if trends in child mortality from injury continue the government's target to reduce the rate by 33% by the year 2005 will be achieved. A substantial proportion of the decline in pedestrian traffic and pedal cycling deaths, however, seems to have been achieved at the expense of children's walking and cycling activities. Changes in travel patterns may exact a considerable price in terms of future health problems.			DiGuiseppi, C (corresponding author), UNIV LONDON,INST CHILD HLTH,DEPT EPIDEMIOL & BIOSTAT,CHILD HLTH MONITORING UNIT,LONDON WC1N 1EH,ENGLAND.		DiGuiseppi, Carolyn/AAU-1341-2020	DiGuiseppi, Carolyn/0000-0002-6440-7817				Bly Robert., 1993, RAG BONE SHOP HEART; CHINN S, 1994, PAEDIATR PERINAT EP, V8, P90, DOI 10.1111/j.1365-3016.1994.tb00438.x; *DEP TRANSP, 1995, TRANSP STAT REP NAT; Department of Health, 1992, HLTH NAT STRAT HLTH; DIGUISEPPI C, 1992, IN PRESS INJURY PREV; FIFE D, 1987, AM J EPIDEMIOL, V126, P936, DOI 10.1093/oxfordjournals.aje.a114731; FROME EL, 1983, BIOMETRICS, V39, P665, DOI 10.2307/2531094; GARROW JS, 1992, LANCET, V340, P409, DOI 10.1016/0140-6736(92)91481-M; HULLMAN M, 1990, ONE FALSE MOVE STUDY; PRENTICE AM, 1995, BRIT MED J, V311, P437, DOI 10.1136/bmj.311.7002.437; ROBERTS I, 1993, BRIT MED J, V306, P1737, DOI 10.1136/bmj.306.6894.1737; Roberts I, 1996, BRIT MED J, V313, P784; ROBERTS I, IN PRESS BMJ; TAYLOR SB, 1996, 156 TRL; TOWNER EML, 1994, BRIT MED J, V308, P449, DOI 10.1136/bmj.308.6926.449; WHO, 1977, MAN INT STAT CLASS D, V1; WOODROFFE G, 1993, CHILDREN TEENAGERS H	17	63	63	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 8	1997	314	7082					710	713		10.1136/bmj.314.7082.710	http://dx.doi.org/10.1136/bmj.314.7082.710			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM776	9116546	Green Published			2022-12-01	WOS:A1997WM77600021
J	BennettGuerrero, E; Ayuso, L; HamiltonDavies, C; White, WD; Barclay, GR; Smith, PK; King, SA; Muhlbaier, LH; Newman, MF; Mythen, MG				BennettGuerrero, E; Ayuso, L; HamiltonDavies, C; White, WD; Barclay, GR; Smith, PK; King, SA; Muhlbaier, LH; Newman, MF; Mythen, MG			Relationship of preoperative antiendotoxin core antibodies and adverse outcomes following cardiac surgery	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TUMOR NECROSIS FACTOR; HUMAN SEPTIC SHOCK; BACTERIAL TRANSLOCATION; CARDIOPULMONARY BYPASS; ORGAN FAILURE; INTESTINAL PERMEABILITY; HEMORRHAGIC-SHOCK; ESCHERICHIA-COLI; CONTROLLED TRIAL; ENDOTOXIN	Objective.-To test the hypothesis that low serum antiendotoxin core antibody (EndoCAb) level is an independent predictor of adverse outcome following cardiac surgery, Design.-Prospective, blinded, cohort study. Setting.-Tertiary care medical center. Subjects.-A total of 301 patients undergoing coronary artery bypass graft surgery and/or valvular heart surgery. Design.-Preoperative serum was assayed for IgM EndoCAb, IgG EndoCAb, total IgM, and total IgG levels. Known preoperative risk factors were assessed, and patients were assigned a risk score using a validated method, Main Outcome Measure.-A major complication, defined as either in-hospital death or postoperative length of stay greater than 10 days, Results.-Overall, a major complication occurred in 34 patients (11.3%), Lower IgM EndoCAb level independently predicted (P=.002) increased risk of major complication over and above the effects of preoperative risk score (P=.02), total IgG level (P=.07), and all other known perioperative risk factors. In contrast, IgG EndoCAb and total IgM concentrations did not predict outcome, No association existed between risk score and level of IgM EndoCAb. Conclusion.-There is marked preoperative variability in humoral immunity against endotoxin core, which is not accounted for by differences in known preoperative risk factors. In this study, low levels of IgMEndoCAb were an important independent predictor of adverse postoperative outcome, which supports the theory that endotoxemia is a cause of postoperative morbidity.	HARVARD UNIV,SCH MED,BOSTON,MA; MIDDLESEX HOSP,DEPT ANESTHESIOL,LONDON,ENGLAND; DUKE UNIV,MED CTR,DUKE HEART CTR,DEPT ANESTHESIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DUKE HEART CTR,DEPT SURG,DURHAM,NC 27710; DUKE UNIV,MED CTR,DUKE HEART CTR,DEPT COMMUNITY & FAMILY MED,DURHAM,NC 27710; SCOTTISH NATL BLOOD TRANSFUS SERV,EDINBURGH,MIDLOTHIAN,SCOTLAND	Harvard University; Harvard Medical School; University of London; University College London; Duke University; Duke University; Duke University	BennettGuerrero, E (corresponding author), MT SINAI MED CTR,DEPT ANESTHESIOL,BOX 1010,1 GUSTAVE L LEVY PL,NEW YORK,NY 10029, USA.		Mythen, Michael G/G-8682-2011					*AM HEART ASS, 1995, HEART STROK FACTS 19, P1; ANDERSEN LW, 1987, J THORAC CARDIOV SUR, V93, P115; BARCLAY GR, 1987, INFECT IMMUN, V55, P2706, DOI 10.1128/IAI.55.11.2706-2714.1987; BARCLAY GR, 1995, BACTERIAL ENDOTOXINS, P263; Baumgartner J D, 1991, Infect Dis Clin North Am, V5, P915; BION JF, 1994, CRIT CARE MED, V22, P40, DOI 10.1097/00003246-199401000-00011; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; DANNER RL, 1991, CHEST, V99, P169, DOI 10.1378/chest.99.1.169; DECAMP MM, 1988, JAMA-J AM MED ASSOC, V260, P530, DOI 10.1001/jama.260.4.530; Deitch E A, 1987, J Burn Care Rehabil, V8, P475, DOI 10.1097/00004630-198708060-00005; DEITCH EA, 1990, J TRAUMA, V30, pS184; DEITCH EA, 1990, CRIT CARE MED, V18, P529, DOI 10.1097/00003246-199005000-00014; Efron B., 1993, MONOGRAPHS STAT APPL, DOI 10.1007/978-1-4899-4541-9; EVANS ME, 1992, J INFECT DIS, V166, P803, DOI 10.1093/infdis/166.4.803; Fink M P, 1994, Semin Respir Infect, V9, P256; FINK MP, 1991, ARCH SURG-CHICAGO, V126, P211; FONG YM, 1989, J IMMUNOL, V142, P2321; FORD EG, 1991, ANN THORAC SURG, V52, P514, DOI 10.1016/0003-4975(91)90914-C; FREEMAN R, 1985, THORAX, V40, P846, DOI 10.1136/thx.40.11.846; GOLDIE AS, 1995, JAMA-J AM MED ASSOC, V274, P172, DOI 10.1001/jama.274.2.172; GORIS RJA, 1985, ARCH SURG-CHICAGO, V120, P1109; GOULD FK, 1989, AM J OBSTET GYNECOL, V160, P317, DOI 10.1016/0002-9378(89)90433-X; GREENMAN RL, 1991, JAMA-J AM MED ASSOC, V266, P1097, DOI 10.1001/jama.266.8.1097; HAMILTONDAVIES C, 1995, BRIT J ANAESTH, V74, pS34; HAMMERMEISTER KE, 1990, CIRCULATION, V82, P380; HANNAN EL, 1994, JAMA-J AM MED ASSOC, V271, P761, DOI 10.1001/jama.271.10.761; HIGGINS TL, 1992, JAMA-J AM MED ASSOC, V267, P2344, DOI 10.1001/jama.267.17.2344; Hosmer DW, 2000, APPL LOGISTIC REGRES, V2nd; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LUDERITZ O, 1966, BACTERIOL REV, V30, P192; MARTINEZPELLUS AE, 1993, CRIT CARE MED, V21, P1684, DOI 10.1097/00003246-199311000-00017; MICHIE HR, 1988, NEW ENGL J MED, V318, P1481, DOI 10.1056/NEJM198806093182301; MOORE FA, 1991, J TRAUMA, V31, P629, DOI 10.1097/00005373-199105000-00006; MORRISON DC, 1987, ANNU REV MED, V38, P417, DOI 10.1146/annurev.me.38.020187.002221; MORRISON DC, 1974, J EXP MED, V140, P797, DOI 10.1084/jem.140.3.797; MUNSTER AM, 1993, ANN SURG, V218, P321, DOI 10.1097/00000658-199309000-00011; NATANSON C, 1989, J EXP MED, V169, P823, DOI 10.1084/jem.169.3.823; OCONNOR GT, 1992, CIRCULATION, V85, P2110, DOI 10.1161/01.CIR.85.6.2110; PARSONNET V, 1989, CIRCULATION, V79, P3; POXTON IR, 1995, J IMMUNOL METHODS, V186, P1, DOI 10.1016/0022-1759(95)00123-R; QUEZADO ZMN, 1993, JAMA-J AM MED ASSOC, V269, P2221, DOI 10.1001/jama.269.17.2221; Riddington DW, 1996, JAMA-J AM MED ASSOC, V275, P1007, DOI 10.1001/jama.275.13.1007; ROCKE DA, 1987, J THORAC CARDIOV SUR, V93, P832; RUSH BF, 1988, ANN SURG, V207, P549, DOI 10.1097/00000658-198805000-00009; SUFFREDINI AF, 1989, NEW ENGL J MED, V321, P280, DOI 10.1056/NEJM198908033210503; TU JV, 1995, CIRCULATION, V91, P677, DOI 10.1161/01.CIR.91.3.677; VOLK WA, 1986, MED MICROBIOLOGY, P396; WARREN HS, 1993, J EXP MED, V177, P89, DOI 10.1084/jem.177.1.89; WATARIDA S, 1994, J THORAC CARDIOV SUR, V108, P620; WHICHER JT, 1978, ANN CLIN BIOCHEM, V15, P77, DOI 10.1177/000456327801500117; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701	51	101	104	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 26	1997	277	8					646	650						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WJ498	9039883				2022-12-01	WOS:A1997WJ49800033
J	Smith, GD; Hart, C; Blane, D; Gillis, C; Hawthorne, V				Smith, GD; Hart, C; Blane, D; Gillis, C; Hawthorne, V			Lifetime socioeconomic position and mortality: Prospective observational study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ISCHEMIC-HEART-DISEASE; LIVING-CONDITIONS; ADULT MORTALITY; CHILDHOOD; RISK; FINLAND; MORBIDITY; MODELS; WOMEN; BIRTH	Objectives: To assess the influence of socioeconomic position over a lifetime on risk factors for cardiovascular disease, on morbidity, and on mortality from various causes. Design: Prospective observational study with 21 years of follow up. Social class was determined as manual or non-manual at three stages of participants' lives: from the social class of their father's job, the social class of their first job, and the social class of their job at the time of screening. A cumulative social class indicator was constructed, ranging from non-manual social class at all three stages of life to manual social class at all three stages. Setting: 27 workplaces in the west of Scotland. Participants: 5766 men aged 35-64 at the time of examination. Main outcome measures. Prevalence and level of risk factors for cardiovascular disease, morbidity, and mortality from broad causes of death. Results: From non-manual social class locations at all three life stages to manual at all stages there were strong positive trends for blood pressure, body mass index, current cigarette smoking, angina, and bronchitis. Inverse trends were seen for height, cholesterol concentration, lung function, and being an ex-smoker. 1580 men died during follow up. Age adjusted relative death rates in comparison with the men of non-manual social class locations at all three stages of life were 1.29 (95% confidence interval 1.08 to 1.56) in men of two non-manual and one manual social class; 1.45 (1.21 to 1.73) in men of two manual and one non-manual social class; and 1.71 (1.46 to 2.01) in men of manual social class at all three stages. Mortality from cardiovascular disease showed a similar graded association with cumulative social class. Mortality from cancer was mainly raised among men of manual social class at all three stages. Adjustment for a wide range of risk factors caused little attenuation in the association of cumulative social class with mortality from all causes and from cardiovascular disease; greater attenuation was seen in the association with mortality from non-cardiovascular, non-cancer disease, Fathers having a non-manual occupation was strongly associated with mortality from cardiovascular disease: relative rate 1.41 (1.15 to 1.72). Participants' social class at the time of screening was more strongly associated than the other social class indicators with mortality from cancer and from non-cardiovascular, non-cancer causes. Conclusions: Socioeconomic factors acting over the lifetime affect health and risk of premature death. The relative importance of influences at different stages varies for the cause of death, Studies with data on socioeconomic circumstances at only one stage of life are inadequate for fully elucidating the contribution of socioeconomic factors to health and mortality risk.	UNIV GLASGOW, DEPT PUBL HLTH, GLASGOW G12 8RZ, LANARK, SCOTLAND; CHARING CROSS & WESTMINSTER MED SCH, DEPT PSYCHIAT, LONDON W6 8RP, ENGLAND; RUCHILL HOSP, W SCOTLAND CANC SURVIELLANCE UNIT, GLASGOW G20 9NB, LANARK, SCOTLAND; UNIV MICHIGAN, SCH PUBL HLTH, DEPT EPIDEMIOL, ANN ARBOR, MI 48109 USA	University of Glasgow; Imperial College London; University of Michigan System; University of Michigan	Smith, GD (corresponding author), UNIV BRISTOL, DEPT SOCIAL MED, BRISTOL BS8 2PR, AVON, ENGLAND.		Davey Smith, George/A-7407-2013	Davey Smith, George/0000-0002-1407-8314				ALTER G, 1989, POP STUD-J DEMOG, V43, P25, DOI 10.1080/0032472031000143836; [Anonymous], 1965, LANCET, V1, P775; BARKER DJP, 1995, NUTR CHILD HLTH, P77; BENSHLOMO Y, 1991, LANCET, V337, P530, DOI 10.1016/0140-6736(91)91307-G; BLANE D, 1993, SOCIOL HEALTH ILL, V15, P2; Blane D, 1996, BMJ-BRIT MED J, V313, P1434, DOI 10.1136/bmj.313.7070.1434; BURNETT JC, 1880, HOMAPATHIC WORL 1001, P437; BURR ML, 1980, J EPIDEMIOL COMMUN H, V34, P93, DOI 10.1136/jech.34.2.93; Carstairs V., 1991, DEPRIVATION HLTH SCO; COX DR, 1972, J R STAT SOC B, V34, P187; *DEP HLTH, 1995, HLTH NAT VAR HLTH WH; Eachus J, 1996, BMJ-BRIT MED J, V312, P287; ELO IT, 1992, POPUL INDEX, V58, P186, DOI 10.2307/3644718; FORSDAHL A, 1977, BRIT J PREV SOC MED, V31, P91; FORSDAHL A, 1978, J EPIDEMIOL COMMUN H, V32, P34, DOI 10.1136/jech.32.1.34; GILLUM RF, 1978, AM J EPIDEMIOL, V108, P289, DOI 10.1093/oxfordjournals.aje.a112622; GLIKSMAN MD, 1995, J EPIDEMIOL COMMUN H, V49, P10, DOI 10.1136/jech.49.1.10; GOLDBLATT P, 1990, LONGITUDINAL STUDY M, P163; GUNNELL D, 1996, J EPIDEMIOL COMMUNIT, V50, P580; HASLE H, 1990, BRIT MED J, V300, P512, DOI 10.1136/bmj.300.6723.512; HAWTHORNE VM, 1995, SCOT MED J, V40, P102, DOI 10.1177/003693309504000402; JONES H B, 1956, Adv Biol Med Phys, V4, P281; KAPLAN GA, 1990, BRIT MED J, V301, P1121, DOI 10.1136/bmj.301.6761.1121; KOSKINEN S, 1994, 41 NAWH NAT RES DEV; KUH D, 1993, SOC HIST MED, V6, P101; LEON DA, 1995, J EPIDEMIOL COMMUN H, V49, P5, DOI 10.1136/jech.49.1.5; LYNCH JW, 1994, LANCET, V343, P524, DOI 10.1016/S0140-6736(94)91468-0; MANN SL, 1992, J EPIDEMIOL COMMUN H, V46, P286, DOI 10.1136/jech.46.3.286; MARE RD, 1990, MEASUREMENT ANAL MOR, P362; Moser K., 1990, LONGITUDINAL STUDY M, P145; NOTKOLA V, 1985, SOC SCI MED, V21, P517, DOI 10.1016/0277-9536(85)90035-8; *OFF POP CENS SURV, 1986, OCC MORT 1979 1980 1; Rose G.A., 1982, CARDIOVASCULAR SURVE; Salhi M., 1995, ADULT MORTALITY DEV; *SAS I, 1991, SAS LANG PROC US 2 V; SMITH GD, 1992, BRIT MED J, V305, P757, DOI 10.1136/bmj.305.6856.757; Smith GD, 1996, AM J PUBLIC HEALTH, V86, P486, DOI 10.2105/AJPH.86.4.486; SMITH GD, 1990, J EPIDEMIOL COMMUN H, V44, P265, DOI 10.1136/jech.44.4.265; SMITH GD, 1990, BMJ-BRIT MED J, V301, P373, DOI 10.1136/bmj.301.6748.373; Smith GD, 1994, EUROPEAN J PUBLIC HL, V4, P131, DOI DOI 10.1093/EURPUB/4.2.131; VAGERO D, 1994, LANCET, V343, P1224, DOI 10.1016/S0140-6736(94)92432-5; VALKONEN T, 1987, EUR J POPUL, V3, P61, DOI 10.1007/BF01797092; Wannamethee SG, 1996, LANCET, V348, P1259, DOI 10.1016/S0140-6736(96)02465-8; Wunsch G, 1996, EUR J POPUL, V12, P167, DOI 10.1007/BF01797082	44	397	398	0	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 22	1997	314	7080					547	552		10.1136/bmj.314.7080.547	http://dx.doi.org/10.1136/bmj.314.7080.547			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WK215	9055712	Green Published			2022-12-01	WOS:A1997WK21500021
J	Brown, JE; Jacobs, DR; Hartman, TJ; Barosso, GM; Stang, JS; Gross, MD; Zeuske, MA				Brown, JE; Jacobs, DR; Hartman, TJ; Barosso, GM; Stang, JS; Gross, MD; Zeuske, MA			Predictors of red cell folate level in women attempting pregnancy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NEURAL-TUBE DEFECTS; PERICONCEPTIONAL VITAMIN SUPPLEMENTATION; FOLIC-ACID SUPPLEMENTATION; DIETARY-FOLATE; ZINC STATUS; PREVENTION; RISK; METABOLISM; RECURRENCE	Objective.-To identify predictors of red cell folate level in women attempting to become pregnant. Design.-Cohort study, Setting.-A health maintenance organization serving the Minneapolis-St Paul, Minn, area. Participants.-A total of 189 healthy, primarily white women aged 22 to 35 years enrolled in the Diana Project, a population-based prospective study of preconceptional and prenatal risks to reproductive outcomes. The sample represents 189 of 219 enrolled women who were sequentially selected from the total Diana Project sample to receive additional laboratory analyses, Main Outcome Measure.-Red cell folate level. Results.-Folic acid supplements, folic acid intake from fortified cereals, vitamin C supplements, and serum zinc level (inverse) were found to predict red cell folate levels. Previous research has shown that red cell folate levels higher than 906 nmol/L (400 ng/mL) may be optimal for the prevention of folate-responsive neural tube defects. For folic acid supplement users, folate intakes of 450 mu g per day and higher corresponded to these protective levels of red cell folate, In nonusers of supplements, intakes of more than 500 mu g of folate per day from foods and folio acid-fortified cereals may be needed to attain red cell folate levels higher than 906 nmol/L (400 ng/mL). Red cell folate levels higher than 906 nmol/L (400 ng/m L) were primarily found in women who took folio acid supplements, Only 1 in 4 women had red cell folate levels higher than 906 nmol/L (400 ng/mL), while 1 in 8 had red cell folate levels indicative of a negative folate balance. Addition of a daily, 400-mu g folic acid supplement to the usual diet would result in red cell folate levels over 906 nmol/L (400 ng/mL) in a majority of women in this study. Conclusions.-Supplementation of diets of women of childbearing potential with 400 mu g of folic acid per day would effectively raise red cell folate to levels associated with a low risk of folate-responsive neural tube defects. Protective levels of red cell folate may also be obtained by ample consumption of vegetables, fruits, and folic acid-fortified breakfast cereals. Efforts to increase folic acid supplement use and folate consumption among women of childbearing potential must go beyond fortification of refined cereal and grain products and reach women within all educational and income groups.			Brown, JE (corresponding author), UNIV MINNESOTA,SCH PUBL HLTH,DIV EPIDEMIOL,1300 S 2ND ST,SUITE 300,MINNEAPOLIS,MN 55454, USA.			Stang, Jamie/0000-0003-2607-190X; Jacobs, David/0000-0002-7232-0543	NICHD NIH HHS [HD19724] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD019724] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAILEY LB, 1992, J AM DIET ASSOC, V92, P463; BOWER C, 1989, MED J AUSTRALIA, V150, P613, DOI 10.5694/j.1326-5377.1989.tb136723.x; Brown JE, 1996, J AM DIET ASSOC, V96, P262, DOI 10.1016/S0002-8223(96)00078-8; BROWN JE, IN PRESS PAEDIAT PER; BUNDUKI V, 1995, BIOL NEONATE, V67, P154, DOI 10.1159/000244157; BUTTERWORTH CE, 1989, AM J CLIN NUTR, V50, P353, DOI 10.1093/ajcn/50.2.353; BUTTERWORTH CE, 1993, J AM COLL NUTR, V12, P438, DOI 10.1080/07315724.1993.10718334; COLMAN N, 1982, NUTR REV, V40, P225, DOI 10.1111/j.1753-4887.1982.tb05319.x; CZEIZEL AE, 1992, NEW ENGL J MED, V327, P1832, DOI 10.1056/NEJM199212243272602; DALY LE, 1995, JAMA-J AM MED ASSOC, V274, P1698, DOI 10.1001/jama.274.21.1698; DANSKY LV, 1992, NEUROLOGY, V42, P32; FULLER NJ, 1992, EUR J PEDIATR, V151, P51, DOI 10.1007/BF02073892; GHISHAN FK, 1986, AM J CLIN NUTR, V43, P258, DOI 10.1093/ajcn/43.2.258; HAMBIDGE M, 1993, BRIT J OBSTET GYNAEC, V100, P746, DOI 10.1111/j.1471-0528.1993.tb14266.x; Herbert V, 1994, MODERN NUTR HLTH DIS, V1, P402; HERBERT VD, 1988, MODERN NUTRITION HLT, P388; HIGASHI A, 1988, J PEDIATR GASTR NUTR, V7, P430, DOI 10.1097/00005176-198805000-00020; Hinman AR, 1992, MMWR, V41, P1; KAUWELL GPA, 1995, J NUTR, V125, P66; KIRKE PN, 1993, Q J MED, V86, P703; KRUMDIECK CL, 1978, AM J CLIN NUTR, V31, P88, DOI 10.1093/ajcn/31.1.88; LAURENCE KM, 1980, BRIT MED J, V281, P1592, DOI 10.1136/bmj.281.6255.1592; LAURENCE KM, 1981, BRIT MED J, V282, P1509, DOI 10.1136/bmj.282.6275.1509; LAZEBNIK N, 1989, AM J OBSTET GYNECOL, V161, P437, DOI 10.1016/0002-9378(89)90538-3; MILLS JL, 1995, LANCET, V345, P149, DOI 10.1016/S0140-6736(95)90165-5; MILNE D B, 1989, Journal of Trace Elements in Experimental Medicine, V2, P297; MILUNSKY A, 1989, JAMA-J AM MED ASSOC, V262, P2847, DOI 10.1001/jama.262.20.2847; *MRC VIT STUD RES, 1991, LANCET, V338, P131; MUKHERJEE MD, 1984, AM J CLIN NUTR, V40, P496, DOI 10.1093/ajcn/40.3.496; MULINARE J, 1988, JAMA-J AM MED ASSOC, V260, P3141, DOI 10.1001/jama.260.21.3141; OKEEFE CA, 1995, J NUTR, V125, P2717; SHAW GM, 1995, EPIDEMIOLOGY, V6, P219, DOI 10.1097/00001648-199505000-00005; Shaw GM, 1996, JAMA-J AM MED ASSOC, V275, P1093, DOI 10.1001/jama.275.14.1093; SMITHELLS RW, 1976, ARCH DIS CHILD, V51, P944, DOI 10.1136/adc.51.12.944; SMITHELLS RW, 1981, ARCH DIS CHILD, V56, P911, DOI 10.1136/adc.56.12.911; SMITHELLS RW, 1982, PEDIATRICS, V69, P498; SMITHELLS RW, 1983, NUTR PREGNANCY, P155; SOLTAN MH, 1982, BRIT J OBSTET GYNAEC, V89, P56, DOI 10.1111/j.1471-0528.1982.tb04635.x; STEEGERSTHEUNISSEN RP, 1995, EUR J OBSTET GYN R B, V61, P39, DOI 10.1016/0028-2243(95)02151-H; SUBAR AF, 1989, AM J CLIN NUTR, V50, P508, DOI 10.1093/ajcn/50.3.508; WERLER MM, 1993, JAMA-J AM MED ASSOC, V269, P1257, DOI 10.1001/jama.269.10.1257; Werler MM, 1996, JAMA-J AM MED ASSOC, V275, P1089, DOI 10.1001/jama.275.14.1089; WILLETT WC, 1987, J AM DIET ASSOC, V87, P43; YATES JRW, 1987, CLIN GENET, V31, P279; YETLEY E, 1996, FOLATE; ZIMMERMANN MB, 1993, AM J CLIN NUTR, V58, P127, DOI 10.1093/ajcn/58.2.127	46	54	56	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 19	1997	277	7					548	552		10.1001/jama.277.7.548	http://dx.doi.org/10.1001/jama.277.7.548			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH297	9032161				2022-12-01	WOS:A1997WH29700030
J	Kasting, G; Rollin, PE				Kasting, G; Rollin, PE			Wound care following needlestick injuries	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							B-VIRUS		CTR DIS CONTROL & PREVENT,SPECIAL PATHOGENS BRANCH,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA	Kasting, G (corresponding author), CTR DIS CONTROL & PREVENT,OCCUPAT HLTH CLIN,ATLANTA,GA 30333, USA.			Rollin, Pierre/0000-0002-4608-2641				GERBERDING JL, 1995, NEW ENGL J MED, V332, P444, DOI 10.1056/NEJM199502163320707; HOLMES GP, 1995, CLIN INFECT DIS, V20, P421, DOI 10.1093/clinids/20.2.421; *MICR INC, 1995, TOX OCC MED ENV SER, P27; WEIGLER BJ, 1992, CLIN INFECT DIS, V14, P555, DOI 10.1093/clinids/14.2.555	4	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 19	1997	277	7					517	517		10.1001/jama.1997.03540310015007	http://dx.doi.org/10.1001/jama.1997.03540310015007			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH297	9032142				2022-12-01	WOS:A1997WH29700002
J	Piccinelli, M; Tessari, E; Bortolomasi, M; Piasere, O; Semenzin, M; Garzotto, N; Tansella, M				Piccinelli, M; Tessari, E; Bortolomasi, M; Piasere, O; Semenzin, M; Garzotto, N; Tansella, M			Efficacy of the alcohol use disorders identification test as a screening tool for hazardous alcohol intake and related disorders in primary care: A validity study	BRITISH MEDICAL JOURNAL			English	Article							INSTRUMENT; MAST; QUESTIONNAIRE; VALIDATION; ABUSE; CAGE	Objective: To determine the properties of the alcohol use disorders identification test in screening primary care attenders for alcohol problems. Design: A validity study among consecutive primary care attenders aged 18-65 years. Every third subject completed the alcohol use disorders identification test (a 10 item self report questionnaire on alcohol intake and related problems) and nas interviewed by an investigator with the composite international diagnostic interview alcohol use module (a standardised interview for the independent assessment of alcohol intake and related disorders). Setting: 10 primary care clinics in Verona, north eastern Italy. Patients: 500 subjects were approached and 482 (96.4%) completed evaluation. Results: When the alcohol use disorders identification test nas used to detect subjects with alcohol problems the area under the receiver operating characteristic curve was 0.95. The cut off score of 5 was associated with a sensitivity of 0.84, a specificity of 0.90, and a positive predictive value of 0.60. The screening ability of the total score derived from summing the responses to the five items minimising the probability of misclassification between subjects with and without alcohol problems provided an area under the receiver operating characteristic curve of 0.93. A score of 5 or more on the five items was associated with a sensitivity of 0.79, a specificity of 0.95, and a positive predictive value of 0.73. Conclusions: The alcohol use disorders identification test performs well in detecting subjects with formal alcohol disorders and those with hazardous alcohol intake. Using five of the 10 items on the questionnaire gives reasonable accuracy, and these are recommended as questions of choice to screen patients for alcohol problems.	UNIV VERONA,IST PSICHIAT,SERV PSICOL MED,I-37100 VERONA,ITALY	University of Verona	Piccinelli, M (corresponding author), OSPED POLICLIN,SERV PSICOL MED,IST PSICHIAT,I-37134 VERONA,ITALY.		Tansella, Michele/B-4106-2010; Rao, Rahul/P-7158-2014					American Psychiatric Association, 1987, DIAGNOSTIC STAT MANU, V3rd; ANDERSON P, 1990, EUROPEAN SERIES, V32, P44; Babor T.F., 1989, ALCOHOL USE DISORDER; CATARINO PA, 1992, ALCOHOL ALCOHOLISM, V27, P465; DORFMAN D, 1966, J MATH PSYCHOL, V6, P487; FEUERLEIN W, 1979, INT J REHABIL RES, V2, P533, DOI 10.1097/00004356-197912000-00023; GOLDBERG D, 1995, MENTAL ILLNESS GEN H, P324; KITCHENS JM, 1994, JAMA-J AM MED ASSOC, V272, P1782, DOI 10.1001/jama.272.22.1782; KRISTENSON H, 1982, BRIT J ADDICT, V77, P297; MAGRUDERHABIB K, 1982, J STUD ALCOHOL, V43, P910, DOI 10.15288/jsa.1982.43.910; MAGRUDERHABIB K, 1993, J CLIN EPIDEMIOL, V46, P435, DOI 10.1016/0895-4356(93)90020-2; MAYFIELD D, 1974, AM J PSYCHIAT, V131, P1121; Metz C. E., 1984, ROCFIT; MODONUTTI G, 1993, ALCOLOGIA ITALIA UNA, P51; NAKAMURA K, 1993, J STUD ALCOHOL, V54, P618, DOI 10.15288/jsa.1993.54.618; POKORNY AD, 1972, AM J PSYCHIAT, V129, P342, DOI 10.1176/ajp.129.3.342; Rey J., 1992, INT J METHODS PSYCHI, V2, P39; RICE DP, 1991, PUBLIC HEALTH REP, V106, P280; ROBINS LN, 1988, ARCH GEN PSYCHIAT, V45, P1069; Saunders J. B., 1987, WHO COLLABORATIVE PR; SELZER ML, 1975, J STUD ALCOHOL, V36, P117, DOI 10.15288/jsa.1975.36.117; SELZER ML, 1971, AM J PSYCHIAT, V127, P1653, DOI 10.1176/ajp.127.12.1653; SPITZER RL, 1994, JAMA-J AM MED ASSOC, V272, P1749, DOI 10.1001/jama.272.22.1749; *WHO, 1990, CIDI COR COMP INT DI; World Health Organization, 1992, INT CLASS DIS; 1995, ALCOHOL ALCOHOLISM, V30, P571; 1991, PRESIDENTS REPORT AC	27	225	228	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 8	1997	314	7078					420	424		10.1136/bmj.314.7078.420	http://dx.doi.org/10.1136/bmj.314.7078.420			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WH295	9040389	Green Published			2022-12-01	WOS:A1997WH29500031
J	Starr, JM; Rogers, TR; Impallomeni, M				Starr, JM; Rogers, TR; Impallomeni, M			Hospital-acquired Clostridium difficile diarrhoea and herd immunity	LANCET			English	Article							RISK-FACTORS; ANTIBIOTICS; DISEASE	Clostridium difficile diarrhoea represents a significant hearth-service burden. We recently experienced an outbreak of C difficile diarrhoea associated with increased use of cefotaxime. The question we pose in this paper is how did the introduction and withdrawal of a single antibiotic so greatly affect rates of C difficile diarrhoea? Other antibiotics had nearly as high a risk of causing diarrhoea as cefotaxime, and the majority of patients never received cefotaxime. We believe that such outbreaks of C difficile diarrhoea are best understood in terms of a population model, and that taking antibiotics like cefotaxime should be thought of as a population rather than an individual risk factor. We postulate a herd-immunity model of C difficile diarrhoea, and examine the implications of this hypothesis.	HAMMERSMITH HOSP, DEPT INFECT DIS, LONDON, ENGLAND; HAMMERSMITH HOSP, DIV GERIATR MED, LONDON, ENGLAND	Imperial College London; Imperial College London	Starr, JM (corresponding author), UNIV EDINBURGH, ROYAL VICTORIA HOSP, DEPT GERIATR MED, EDINBURGH EH4 2DN, MIDLOTHIAN, SCOTLAND.		Starr, John/C-8951-2011	Rogers, Thomas/0000-0003-4336-7729				AMBROSE NS, 1985, J ANTIMICROB CHEMOTH, V15, P319, DOI 10.1093/jac/15.3.319; ANDERSON RM, 1990, LANCET, V335, P641, DOI 10.1016/0140-6736(90)90420-A; *DEP HLTH PHLS JOI, 1994, CLOSTR DIFF INF PREV; FINCH R, 1993, BRIT J HOSP MED, V49, P346; Funada H, 1984, Jpn J Antibiot, V37, P555; Gibson GJ, 1996, PLANT PATHOL, V45, P172, DOI 10.1046/j.1365-3059.1996.d01-116.x; HEARD SR, 1988, EPIDEMIOL INFECT, V100, P63, DOI 10.1017/S0950268800065560; IMPALLOMENI M, 1995, BRIT MED J, V311, P1345, DOI 10.1136/bmj.311.7016.1345; LEUNG ACT, 1985, CLIN NEPHROL, V24, P242; MCFARLAND LV, 1990, J INFECT DIS, V162, P678, DOI 10.1093/infdis/162.3.678; MCFARLAND LV, 1994, JAMA-J AM MED ASSOC, V271, P1913, DOI 10.1001/jama.271.24.1913; PEAR SM, 1994, ANN INTERN MED, V120, P272, DOI 10.7326/0003-4819-120-4-199402150-00003; Rhodes CJ, 1996, NATURE, V381, P600, DOI 10.1038/381600a0; Ross R, 1915, BRIT MED J, V1915, P546, DOI 10.1136/bmj.1.2830.546; SCHWAN A, 1984, SCAND J INFECT DIS, V16, P211, DOI 10.3109/00365548409087145; WALKER KJ, 1993, J AM GERIATR SOC, V41, P940, DOI 10.1111/j.1532-5415.1993.tb06759.x	16	50	51	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 8	1997	349	9049					426	428		10.1016/S0140-6736(97)80053-0	http://dx.doi.org/10.1016/S0140-6736(97)80053-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH296	9033485				2022-12-01	WOS:A1997WH29600050
J	Simon, AM; Goodenough, DA; Li, E; Paul, DL				Simon, AM; Goodenough, DA; Li, E; Paul, DL			Female infertility in mice lacking connexin 37	NATURE			English	Article							GAP JUNCTION PROTEINS; CUMULUS-OOCYTE COMPLEX; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; GENE; MUTATIONS; LETHALITY; CELLS	The signals regulating ovarian follicle development and the mechanisms by which they are communicated are largely undefined(1). At birth, the ovary contains primordial follicles consisting of meiotically arrested oocytes surrounded by a single layer of supporting (granulosa) cells. Periodically, subsets of primordial follicles undergo further development during which the oocyte increases in size and the granulosa cells proliferate, stratify and develop a fluid-filled antrum. After ovulation, oocytes resume meiosis and granulosa cells retained in the follicle differentiate into steroidogenic cells, forming the corpus luteum(1,2). It has been proposed that intercellular signalling through gap junction channels may influence aspects of follicular development(3,4). Gap junctions are aggregations of intercellular channels composed of connexins, a family of at least 13 related proteins that directly connect adjacent cells allowing the diffusional movement of ions, metabolites, and other potential signalling molecules(5). Here we show that connexin 37 is present in gap junctions between oocyte and granulosa cells and that connexin-37-deficient mice lack mature (Graafian) follicles, fail to ovulate and develop numerous inappropriate corpora lutea. In addition, oocyte development arrests before meiotic competence is achieved. Thus, cell-cell signalling through intercellular channels critically regulates the highly coordinated set of cellular interactions required for successful oogenesis and ovulation.	HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP EAST,CARDIOVASC RES CTR,CHARLESTOWN,MA 02129	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital								ANDERSON E, 1976, J CELL BIOL, V71, P680, DOI 10.1083/jcb.71.2.680; BERGOFFEN J, 1993, SCIENCE, V262, P2039, DOI 10.1126/science.8266101; BJORKMAN N, 1962, ACTA ANAT, V51, P125, DOI 10.1159/000141943; BORNSLAEGER EA, 1985, BIOL REPROD, V66, P698; BRITZCUNNINGHAM SH, 1995, NEW ENGL J MED, V332, P1323, DOI 10.1056/NEJM199505183322002; CHO WK, 1974, J EXP ZOOL, V187, P383, DOI 10.1002/jez.1401870307; DEKEL N, 1978, P NATL ACAD SCI USA, V75, P4369, DOI 10.1073/pnas.75.9.4369; EOFOULU MA, 1970, ENDOCRINOLOGY, V87, P286; EPPIG JJ, 1991, BIOESSAYS, V13, P569, DOI 10.1002/bies.950131105; GILULA NB, 1978, J CELL BIOL, V78, P58, DOI 10.1083/jcb.78.1.58; GOLIGER JA, 1994, DEV DYNAM, V200, P1, DOI 10.1002/aja.1002000102; Goodenough DA, 1996, ANNU REV BIOCHEM, V65, P475, DOI 10.1146/annurev.bi.65.070196.002355; HAEFLIGER JA, 1992, J BIOL CHEM, V267, P2057; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MATTSON BA, 1990, MOL REPROD DEV, V25, P374, DOI 10.1002/mrd.1080250411; MEYER EC, 1989, J CELL BIOL, V108, P596; NELSON LM, 1994, J CLIN ENDOCR METAB, V79, P1470, DOI 10.1210/jc.79.5.1470; REAUME AG, 1995, SCIENCE, V267, P1831, DOI 10.1126/science.7892609; REED KE, 1993, J CLIN INVEST, V91, P997, DOI 10.1172/JCI116321; SORENSEN RA, 1976, DEV BIOL, V50, P5531; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VALDIMARSSON G, 1993, MOL REPROD DEV, V36, P7, DOI 10.1002/mrd.1080360103; Wassarman Paul M., 1994, P79; WILLECKE K, 1991, J CELL BIOL, V114, P1049, DOI 10.1083/jcb.114.5.1049	24	530	546	0	31	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 6	1997	385	6616					525	529		10.1038/385525a0	http://dx.doi.org/10.1038/385525a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG235	9020357				2022-12-01	WOS:A1997WG23500045
J	Brown, MA				Brown, MA			Pre-eclampsia: A case of nerves?	LANCET			English	Editorial Material							PREECLAMPSIA; PREGNANCY		ST GEORGE HOSP,DEPT OBSTET,KOGARAH,NSW 2217,AUSTRALIA; UNIV NEW S WALES,KOGARAH,NSW 2217,AUSTRALIA	St George Hospital; University of New South Wales Sydney	Brown, MA (corresponding author), ST GEORGE HOSP,DEPT MED,KOGARAH,NSW 2217,AUSTRALIA.							*AUSTR SOC STUD HY, 1995, AUST NZ J OBSTET GYN, V35, P39; BROWN MA, 1995, CLIN EXP PHARMACOL P, V22, P781, DOI 10.1111/j.1440-1681.1995.tb01937.x; Chesley LC, 1978, HYPERTENSIVE DISORDE, P17; HEESCH CM, 1995, CLIN EXP PHARMACOL P, V22, P136, DOI 10.1111/j.1440-1681.1995.tb01970.x; PEDERSEN EB, 1988, HDB HYPERTENSION, V10, P152; ROBERTS JM, 1993, LANCET, V341, P1447, DOI 10.1016/0140-6736(93)90889-O; Schobel HP, 1996, NEW ENGL J MED, V335, P1480, DOI 10.1056/NEJM199611143352002	7	16	16	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 1	1997	349	9048					297	298		10.1016/S0140-6736(05)62819-X	http://dx.doi.org/10.1016/S0140-6736(05)62819-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF794	9024368				2022-12-01	WOS:A1997WF79400003
J	Westendorp, RGJ; Langermans, JAM; Huizinga, TWJ; Elouali, AH; Verweij, CL; Boomsma, DI; Vandenbroucke, JP				Westendorp, RGJ; Langermans, JAM; Huizinga, TWJ; Elouali, AH; Verweij, CL; Boomsma, DI; Vandenbroucke, JP			Genetic influence on cytokine production and fatal meningococcal disease	LANCET			English	Article							TUMOR-NECROSIS-FACTOR; TNF-ALPHA; PEDIGREE ANALYSIS; PROMOTER; RELEASE; DEATH	Background To assess the genetic influence on cytokine production and its contribution to fatal outcome, we determined the capacity to produce tumour necrosis factor-alpha (TNF alpha) and interleukin-10 (IL-10) in families of patients who had had meningococcal disease. Methods We studied 190 first-degree relatives of 61 patients with meningococcal disease; we also studied 26 monozygotic twins. Production of cytokines was determined during endotoxin stimulation of whole-blood samples ex-vivo. Heritability was estimated in a pedigree-based maximum-likelihood model. DNA was typed for the G to A transition polymorphisms at position -308 and -238 in the TNF gene promoter. Findings Heritability in monozygotic twins was 0 . 60 for the production of TNF and 0 . 75 for the production of IL-10, Families with low TNF production had a tenfold increased risk for fatal outcome (OR 8 . 9, 95% Cl 1 . 8-45), whereas high IL-10 production increased the risk 20-fold (19 . 5, 2 . 3-165). Families with both characteristics had the greatest risk. The transition polymorphisms in the TNF gene promoter were not associated with outcome. Interpretation Genetic factors substantially influence production of cytokines. An innate anti-inflammatory cytokine profile may contribute to fatal meningococcal disease.	UNIV LEIDEN HOSP, DEPT GEN INTERNAL MED, NL-2300 RC LEIDEN, NETHERLANDS; UNIV LEIDEN HOSP, DEPT INFECT DIS, NL-2300 RC LEIDEN, NETHERLANDS; UNIV LEIDEN HOSP, DEPT RHEUMATOL, NL-2300 RC LEIDEN, NETHERLANDS; FREE UNIV AMSTERDAM, DEPT PSYCHONOM, AMSTERDAM, NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC); Vrije Universiteit Amsterdam	Westendorp, RGJ (corresponding author), UNIV LEIDEN HOSP, DEPT CLIN EPIDEMIOL, CO-P, NL-2300 RC LEIDEN, NETHERLANDS.		Vandenbroucke, Jan/AAM-3928-2020; Boomsma, Dorret I/AAX-4470-2020	Vandenbroucke, Jan/0000-0001-5668-6716; Langermans, Jan/0000-0002-4806-4412				ALEXANDER HR, 1991, J CLIN INVEST, V88, P34, DOI 10.1172/JCI115298; BRANDTZAEG P, 1989, J INFECT DIS, V159, P195, DOI 10.1093/infdis/159.2.195; Brinkman BMN, 1996, J INFLAMM, V46, P32; DEGROOTE D, 1992, CYTOKINE, V4, P239, DOI 10.1016/1043-4666(92)90062-V; DERKX HHF, 1992, MONONUCLEAR PHAGOCYTES, P355; Entzian P, 1996, AM J RESP CRIT CARE, V153, P1080, DOI 10.1164/ajrccm.153.3.8630548; FERNANDES DM, 1995, INFECT IMMUN, V63, P1130, DOI 10.1128/IAI.63.3.1130-1133.1995; FIGUEROA JE, 1991, CLIN MICROBIOL REV, V4, P359, DOI 10.1128/CMR.4.3.359-395.1991; Fisher CJ, 1996, NEW ENGL J MED, V334, P1697, DOI 10.1056/NEJM199606273342603; Gazzinelli RT, 1996, J IMMUNOL, V157, P798; GIRARDIN E, 1988, NEW ENGL J MED, V319, P397, DOI 10.1056/NEJM198808183190703; LANGE K, 1976, ANN HUM GENET, V39, P485, DOI 10.1111/j.1469-1809.1976.tb00156.x; LANGE K, 1988, GENET EPIDEMIOL, V5, P471, DOI 10.1002/gepi.1370050611; MCGUIRE W, 1994, NATURE, V371, P508, DOI 10.1038/371508a0; POCIOT F, 1995, SCAND J IMMUNOL, V42, P501, DOI 10.1111/j.1365-3083.1995.tb03686.x; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; SORENSEN TIA, 1988, NEW ENGL J MED, V318, P727, DOI 10.1056/NEJM198803243181202; VANDEVENTER SJH, 1990, BLOOD, V76, P2520; WESTENDORP RGJ, 1995, J INFECT DIS, V171, P1057, DOI 10.1093/infdis/171.4.1057	19	650	673	0	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 18	1997	349	9046					170	173		10.1016/S0140-6736(96)06413-6	http://dx.doi.org/10.1016/S0140-6736(96)06413-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC861	9111542				2022-12-01	WOS:A1997WC86100012
J	Stowell, MHB; McPhillips, TM; Rees, DC; Soltis, SM; Abresch, E; Feher, G				Stowell, MHB; McPhillips, TM; Rees, DC; Soltis, SM; Abresch, E; Feher, G			Light-induced structural changes in photosynthetic reaction center: Implications for mechanism of electron-proton transfer	SCIENCE			English	Article							SPHAEROIDES REACTION CENTERS; BACTERIAL REACTION CENTERS; RHODOBACTER-SPHAEROIDES; RHODOPSEUDOMONAS-SPHAEROIDES; CRYOGENIC TEMPERATURES; PARAMAGNETIC-RESONANCE; TRANSFER KINETICS; FREE-ENERGY; RESOLUTION; PATHWAY	High resolution x-ray diffraction data from crystals of the Rhodobacter sphaeroides photosynthetic reaction center (RC) have been collected at cryogenic temperature in the dark and under illumination, and the structures were refined at 2.2 and 2.6 angstrom resolution, respectively. In the charge-separated D(+)Q(A)Q(B)(-) state (where D is the primary electron donor (a bacteriochlorophyll dimer), and Q(A) and Q(B) are the primary and secondary quinone accepters, respectively), Q(B)(-) is located approximately 5 angstroms from the Q(B) position in the charge-neutral (DQ(A)Q(B)) slate, and has undergone a 180 degrees propeller twist around the isoprene chain. A model based on the difference between the two structures is proposed to explain the observed kinetics of electron transfer from Q(A)-Q(B) to Q(A)Q(B)(-) and the relative binding affinities of the different ubiquinone species in the Q(B) pocket. In addition, several water channels (putative proton pathways) leading from the Q(B) pocket to the surface of the RC were delineated, one of which leads directly to the membrane surface.	CALTECH,DIV CHEM & CHEM ENGN,PASADENA,CA 91125; STANFORD SYNCHROTRON RADIAT LAB,STANFORD,CA 94309; UNIV CALIF SAN DIEGO,DEPT PHYS,LA JOLLA,CA 92093	California Institute of Technology; Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory; University of California System; University of California San Diego			Feher, George/E-3050-2010	STOWELL, MICHAEL/0000-0001-7250-1419	NIGMS NIH HHS [GM13191, GM45162] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM013191, R37GM045162, R01GM013191, R01GM045162] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; ALLEN JP, 1994, PROTEINS, V20, P283, DOI 10.1002/prot.340200309; ALLEN JP, 1988, P NATL ACAD SCI USA, V85, P8487, DOI 10.1073/pnas.85.22.8487; ALLEN JP, 1987, P NATL ACAD SCI USA, V84, P5730, DOI 10.1073/pnas.84.16.5730; ALLEN JP, 1986, P NATL ACAD SCI USA, V83, P8589, DOI 10.1073/pnas.83.22.8589; ARATA H, 1981, BIOCHIM BIOPHYS ACTA, V636, P70, DOI 10.1016/0005-2728(81)90077-3; ARATA H, 1981, BIOCHIM BIOPHYS ACTA, V638, P201, DOI 10.1016/0005-2728(81)90228-0; ARNOUX B, 1995, ACTA CRYSTALLOGR D, V51, P368, DOI 10.1107/S0907444994013120; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARBER J, 1980, BIOCHIM BIOPHYS ACTA, V594, P253, DOI 10.1016/0304-4173(80)90003-8; BELLAMY HD, 1994, J APPL CRYSTALLOGR, V27, P967, DOI 10.1107/S0021889894006357; BEROZA P, 1992, PHOTOSYNTHETIC BACTE, V2, P363; Blankenship RE, 1995, ANOXYGENIC PHOTOSYNT; Breton J, 1996, BBA-BIOENERGETICS, V1275, P84, DOI 10.1016/0005-2728(96)00054-0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Brzezinski P, 1992, PHOTOSYNTHETIC BACTE, P321; CHANG CH, 1986, FEBS LETT, V205, P82, DOI 10.1016/0014-5793(86)80870-5; Cramer W.A., 1990, ENERGY TRANSDUCTION; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; DEISENHOFER J, 1995, J MOL BIOL, V246, P429, DOI 10.1006/jmbi.1994.0097; DINER BA, 1984, BIOCHIM BIOPHYS ACTA, V776, P9; ERMLER U, 1994, STRUCTURE, V2, P925, DOI 10.1016/S0969-2126(94)00094-8; Ermler Ulrich, 1992, P341; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FEHER G, 1989, NATURE, V339, P111, DOI 10.1038/339111a0; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GRAIGE M, 1996, BIOPHYS J, V70; HARTSEL SC, 1986, BIOCHEMISTRY-US, V25, P8214, DOI 10.1021/bi00373a014; Hendrickson W. A., 1970, Acta Crystallographica, Section B (Structural Crystallography and Crystal Chemistry), Vb26, P136, DOI 10.1107/S0567740870002078; HOPE H, 1995, STANF SYNCHR RAD LAB; ISAACSON RA, 1995, BIOPHYS J, V69, P311, DOI 10.1016/S0006-3495(95)79936-2; JONES TA, 1985, METHOD ENZYMOL, V115, P157; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABBANI OE, 1986, BIOCHEMISTRY-US, V30, P5352; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; KIRMAIER C, 1985, BIOCHIM BIOPHYS ACTA, V810, P33, DOI 10.1016/0005-2728(85)90204-X; KLEINFELD D, 1984, BIOCHEMISTRY-US, V23, P5780, DOI 10.1021/bi00319a017; KLEINFELD D, 1984, BIOCHIM BIOPHYS ACTA, V766, P126, DOI 10.1016/0005-2728(84)90224-X; LANCASTER CRD, 1995, REACTION CTR PHOTOSY, P23; MANCINO LJ, 1984, BIOCHIM BIOPHYS ACTA, V764, P46, DOI 10.1016/0005-2728(84)90139-7; MCELROY JD, 1974, BIOCHIM BIOPHYS ACTA, V333, P261, DOI 10.1016/0005-2728(74)90010-3; MCLAUGHLIN S, 1977, CURR TOP MEMBR TRANS, V9, P71; MCPHERSON PH, 1990, BIOCHIM BIOPHYS ACTA, V1016, P289, DOI 10.1016/0005-2728(90)90071-B; NABEDRYK E, 1990, FEBS LETT, V266, P59, DOI 10.1016/0014-5793(90)81506-J; NOKS P P, 1977, Molekulyarnaya Biologiya (Moscow), V11, P1090; OKAMURA MY, 1975, P NATL ACAD SCI USA, V72, P3491, DOI 10.1073/pnas.72.9.3491; OKAMURA MY, 1992, ANNU REV BIOCHEM, V61, P861; OKAMURA MY, 1982, FUNCTION QUINONES EN, V5, P99; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PADDOCK ML, 1994, BIOCHEMISTRY-US, V33, P734, DOI 10.1021/bi00169a015; PADDOCK ML, 1990, P NATL ACAD SCI USA, V87, P6803, DOI 10.1073/pnas.87.17.6803; PADDOCK ML, 1997, BIOPHYS J, V72; PAROT P, 1988, PHOTOSYNTHETIC BACTE, P251; Rongey S. H., 1995, Biophysical Journal, V68, pA247; RONGEY SH, 1993, P NATL ACAD SCI USA, V90, P1325, DOI 10.1073/pnas.90.4.1325; SINNING I, 1989, BIOCHEMISTRY-US, V28, P5544, DOI 10.1021/bi00439a031; STOWELL MHB, UNPUB; Takahashi E, 1996, P NATL ACAD SCI USA, V93, P2640, DOI 10.1073/pnas.93.7.2640; TAKAHASHI E, 1990, BIOCHIM BIOPHYS ACTA, V1020, P107, DOI 10.1016/0005-2728(90)90100-I; WINISKI AP, 1986, BIOCHEMISTRY-US, V23, P8206; WOODBURY NWT, 1984, BIOCHIM BIOPHYS ACTA, V767, P345, DOI 10.1016/0005-2728(84)90205-6; WRAIGHT CA, 1981, ISRAEL J CHEM, V21, P348; WRAIGHT CA, 1983, OXYGEN EVOLVING SYST, V2, P383	64	724	750	3	102	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 2	1997	276	5313					812	816		10.1126/science.276.5313.812	http://dx.doi.org/10.1126/science.276.5313.812			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WW900	9115209				2022-12-01	WOS:A1997WW90000063
J	Vandenbroucke, JP; Rosendaal, FR				Vandenbroucke, JP; Rosendaal, FR			End of the line for ''third-generation-pill'' controversy?	LANCET			English	Editorial Material							THROMBOSIS; RISK		LEIDEN UNIV HOSP,THROMBOSIS & HAEMOSTASIS RES CTR,NL-3200 RC LEIDEN,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC)	Vandenbroucke, JP (corresponding author), LEIDEN UNIV HOSP,DEPT CLIN EPIDEMIOL,NL-3200 RC LEIDEN,NETHERLANDS.		Vandenbroucke, Jan/AAM-3928-2020; Rosendaal, Frits/Q-3842-2017	Vandenbroucke, Jan/0000-0001-5668-6716; Rosendaal, Frits/0000-0003-2558-7496				BLOEMENKAMP KWM, 1995, LANCET, V346, P1593, DOI 10.1016/S0140-6736(95)91929-5; Farley TMM, 1996, CONTRACEPTION, V54, P193, DOI 10.1016/S0010-7824(96)00166-7; ROSENDAAL FR, 1995, BLOOD, V85, P1504, DOI 10.1182/blood.V85.6.1504.bloodjournal8561504; Rosing J, 1997, BRIT J HAEMATOL, V97, P233, DOI 10.1046/j.1365-2141.1997.192707.x	4	58	58	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 19	1997	349	9059					1113	1114		10.1016/S0140-6736(05)63015-2	http://dx.doi.org/10.1016/S0140-6736(05)63015-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU544	9113005				2022-12-01	WOS:A1997WU54400003
J	Essers, J; Hendriks, RW; Swagemakers, SMA; Troelstra, C; deWit, J; Bootsma, D; Hoeijmakers, JHJ; Kanaar, R				Essers, J; Hendriks, RW; Swagemakers, SMA; Troelstra, C; deWit, J; Bootsma, D; Hoeijmakers, JHJ; Kanaar, R			Disruption of mouse RAD54 reduces ionizing radiation resistance	CELL			English	Article							STRAND-BREAK-REPAIR; DEPENDENT PROTEIN-KINASE; V(D)J RECOMBINATION; SCID MUTATION; DNA; RECA; MICE; GENE; SACCHAROMYCES; DEFICIENCY	Double-strand DNA break (DSB) repair by homologous recombination occurs through the RAD52 pathway in Saccharomyces cerevisiae. Its biological importance is underscored by the conservation of many RAD52 pathway genes, including RAD54, from fungi to humans. We have analyzed the phenotype of mouse RAD54(-/)- (mRAD54(-/-)) cells. Consistent with a DSB repair defect, these cells are sensitive to ionizing radiation, mitomycin C, and methyl methanesulfonate, but not to ultraviolet light. Gene targeting experiments demonstrate that homologous recombination in mRAD54(-/-) cells is reduced compared to wild-type cells. These results imply that, besides DNA end-joining mediated by DNA-dependent protein kinase, homologous recombination contributes to the repair of DSBs in mammalian cells. Furthermore, we show that mRAD54(-/-) mice are viable and exhibit apparently normal V(D)J and immunoglobulin class-switch recombination. Thus, mRAD54 is not required for the recombination processes that generate functional immunoglobulin and T cell receptor genes.	DR DANIEL DEN HOED CANC CTR, DEPT RADIOTHERAPY, DIV CLIN RADIOTHERAPY, NL-3075 EA ROTTERDAM, NETHERLANDS	Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute	Essers, J (corresponding author), ERASMUS UNIV ROTTERDAM, DEPT CELL BIOL & GENET, CTR MED GENET, POB 1738, NL-3000 DR ROTTERDAM, NETHERLANDS.		Hoeijmakers, Jan/AAX-6972-2021					Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; BENSON FE, 1994, EMBO J, V13, P5764, DOI 10.1002/j.1460-2075.1994.tb06914.x; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; CLEVER B, 1997, IN PRESS EMBO J; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; DUNNICK W, 1993, NUCLEIC ACIDS RES, V21, P365, DOI 10.1093/nar/21.3.365; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; Eki T, 1996, YEAST, V12, P177; GAME JC, 1993, SEMIN CANCER BIOL, V4, P73; Gellert M, 1996, GENES CELLS, V1, P269, DOI 10.1046/j.1365-2443.1996.22023.x; Gupta RC, 1997, P NATL ACAD SCI USA, V94, P463, DOI 10.1073/pnas.94.2.463; HABER JE, 1995, BIOESSAYS, V17, P609, DOI 10.1002/bies.950170707; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HARRIMAN W, 1993, ANNU REV IMMUNOL, V11, P361, DOI 10.1146/annurev.iy.11.040193.002045; HAYS SL, 1995, P NATL ACAD SCI USA, V92, P6925, DOI 10.1073/pnas.92.15.6925; HENDRICKSON EA, 1991, P NATL ACAD SCI USA, V88, P4061, DOI 10.1073/pnas.88.10.4061; Hendriks RW, 1996, EMBO J, V15, P4862, DOI 10.1002/j.1460-2075.1996.tb00867.x; JEGGO PA, 1990, MUTAT RES, V239, P1, DOI 10.1016/0165-1110(90)90028-A; JEGGO PA, 1995, BIOESSAYS, V17, P949, DOI 10.1002/bies.950171108; Jiang H, 1996, J BIOL CHEM, V271, P33181, DOI 10.1074/jbc.271.52.33181; JOHNSON RD, 1995, MOL CELL BIOL, V15, P4843; Kanaar R, 1996, CURR BIOL, V6, P828, DOI 10.1016/S0960-9822(02)00606-1; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; Li MJ, 1996, P NATL ACAD SCI USA, V93, P10222, DOI 10.1073/pnas.93.19.10222; Lim DS, 1996, MOL CELL BIOL, V16, P7133; MEYN MS, 1995, CANCER RES, V55, P5991; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Muris DFR, 1996, J CELL SCI, V109, P73; MURIS DFR, 1997, IN PRESS CURR GENET; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; PETERSON SR, 1995, P NATL ACAD SCI USA, V92, P3171, DOI 10.1073/pnas.92.8.3171; PETRINI JHJ, 1997, IN PRESS SEMIN IMMUN; RIELE HT, 1992, P NATL ACAD SCI USA, V89, P5128, DOI 10.1073/pnas.89.11.5128; ROTH DB, 1995, CURR BIOL, V5, P496, DOI 10.1016/S0960-9822(95)00101-1; SCHIESTL RH, 1994, MOL CELL BIOL, V14, P4493, DOI 10.1128/MCB.14.7.4493; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; STAYTON CL, 1994, HUM MOL GENET, V3, P1957, DOI 10.1093/hmg/3.11.1957; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; TOMASZ M, 1987, SCIENCE, V235, P1204, DOI 10.1126/science.3103215; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; VANDERHORST GTJ, 1997, IN PRESS CELL, V89; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; ZHOU XY, 1995, GENE DEV, V9, P2623, DOI 10.1101/gad.9.21.2623; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	49	363	370	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 18	1997	89	2					195	204		10.1016/S0092-8674(00)80199-3	http://dx.doi.org/10.1016/S0092-8674(00)80199-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WU888	9108475	Bronze, Green Published			2022-12-01	WOS:A1997WU88800007
J	Yip, R; Limburg, PJ; Ahlquist, DA; Carpenter, HA; ONeill, A; Kruse, D; Stitham, S; Gold, BD; Gunter, EW; Looker, AC; Parkinson, AJ; Nobmann, ED; Petersen, KM; Ellefson, M; Schwartz, S				Yip, R; Limburg, PJ; Ahlquist, DA; Carpenter, HA; ONeill, A; Kruse, D; Stitham, S; Gold, BD; Gunter, EW; Looker, AC; Parkinson, AJ; Nobmann, ED; Petersen, KM; Ellefson, M; Schwartz, S			Pervasive occult gastrointestinal bleeding in an Alaska native population with prevalent iron deficiency - Role of Helicobacter pylori gastritis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	1995 Swedish-Society-of-Medicine Berzeliuos Symposium XXXI on Iron Nutrition in Health and Disease	SEP, 1995	STOCKHOLM, SWEDEN	Swedish soc Med			PEPTIC-ULCER DISEASE; CAMPYLOBACTER-PYLORI; INFECTION; HEMOQUANT; BLOOD; SEROEPIDEMIOLOGY; HEMOGLOBIN; ESKIMOS; ADULTS; HEME	Objective.-To confirm prevalent iron deficiency among Yupik Eskimos living in Alaska and to explore the frequency of and potential lesions accounting for occult gastrointestinal bleeding. Design.-Descriptive survey. Setting.-Rural Arctic community. Subjects.-A total of 140 adult volunteers from 3 villages in the Yukon-Kuskokwim Delta region of western Alaska. Main Outcome Measures.-Daily iron intake, hematologic and biochemical indexes of iron status, fecal hemoglobin levels, stool parasites, and endoscopic findings. Results.-While dietary iron intake by Yupiks was similar to that of a reference population, iron deficiency prevalence was increased 13-fold in Yupik men and 4-fold in Yupik women, Fecal hemoglobin levels were elevated in 90% of subjects contrasted with only 4% of a reference group; median levels were 5.9 and 0.5 mg of hemoglobin per gram of stool, respectively, Among 70 Yupik subjects with elevated fecal hemoglobin levels who had endoscopy performed, 68 (97%) had an abnormal gastric appearance consisting of erythema, mucosal thickening, diffuse mucosal hemorrhages, erosions, or ulcerations. Gastric biopsies revealed chronic active gastritis with associated Helicobacter pylori in 68 (99%) of 69. No other hemorrhagic gastrointestinal disease was detected. Conclusions.-Based on this study sample, occult gastrointestinal bleeding appears to be pervasive in the Yupik population and likely underlies the prevalent iron deficiency. An atypical hemorrhagic gastritis associated with H pylori infection is present almost universally and may represent the bleeding source.	MAYO CLIN, DIV GASTROENTEROL, DEPT INTERNAL MED, ROCHESTER, MN 55905 USA; CTR DIS CONTROL & PREVENT, DIV NUTR, NATL CTR CHRON DIS PREVENT & HLTH PROMOT, ATLANTA, GA USA; CTR DIS CONTROL & PREVENT, DIV BACTERIAL & MYCOT DIS, NATL CTR INFECT DIS, ATLANTA, GA USA; CTR DIS CONTROL & PREVENT, DIV ENVIRONM HLTH LAB SCI, NATL CTR ENVIRONM HLTH, ATLANTA, GA USA; YUKON KUSKOKWIM HLTH CORP, BETHEL, AK USA; EMORY UNIV, SCH MED, DEPT PEDIAT, ATLANTA, GA USA; CDC, DIV HLTH EXAMINAT STAT, NATL CTR HLTH STAT, HYATTSVILLE, MD USA; CDC, ARCTIC INVEST PROGRAM, NATL CTR INFECT DIS, ANCHORAGE, AK USA; ALASKA AREA NATIVE HLTH SERV, INDIAN HLTH SERV, ANCHORAGE, AK USA; ELLEFSON ANALYT INC, LINO LAKES, MN USA; MINNEAPOLIS MED RES FDN INC, MINNEAPOLIS, MN USA; MAYO CLIN, DEPT LAB MED & PATHOL, ROCHESTER, MN 55905 USA	Mayo Clinic; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Emory University; Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS); Centers for Disease Control & Prevention - USA; Minneapolis Medical Research Foundation; Mayo Clinic								AHLQUIST DA, 1988, ANN INTERN MED, V108, P609, DOI 10.7326/0003-4819-108-4-609; AHLQUIST DA, 1993, JAMA-J AM MED ASSOC, V269, P1262, DOI 10.1001/jama.269.10.1262; AHLQUIST DA, 1985, NEW ENGL J MED, V312, P1422, DOI 10.1056/NEJM198505303122204; ANDERSEN LP, 1988, SCAND J GASTROENTERO, V23, P760, DOI 10.3109/00365528809093946; BORSCH G, 1988, EUR J CLIN INVEST, V18, P133; CDC, 1989, MMWR-MORBID MORTAL W, V38, P400; DAVIDSON M, 1989, JAMA-J AM MED ASSOC, V261, P715, DOI 10.1001/jama.261.5.715; FISHER KD, 1985, AM J CLIN NUTR, V42, P1318; Garby L., 1973, Clinics in Haematology, V2, P245; GRAHAM DY, 1991, DIGEST DIS SCI, V36, P1084, DOI 10.1007/BF01297451; HOLCOMBE C, 1992, AM J GASTROENTEROL, V87, P28; Ito A, 1996, J GASTROENTEROL, V31, P1, DOI 10.1007/BF01211179; KERLIN P, 1979, AUST NZ J MED, V9, P402, DOI 10.1111/j.1445-5994.1979.tb04167.x; KHANNA B, 1995, GASTROENTEROLOGY, V108, pA130; KUWAYAMA H, 1995, GASTROENTEROLOGY, V108, pA139; LANIER AP, 1989, PUBLIC HEALTH REP, V104, P658; LEE TH, 1985, NEW ENGL J MED, V312, P1217, DOI 10.1056/NEJM198505093121903; MARCHETTI M, 1995, SCIENCE, V267, P1655, DOI 10.1126/science.7886456; MEGRAUD F, 1989, J CLIN MICROBIOL, V27, P1870; MONSON RR, 1969, NEW ENGL J MED, V281, P11, DOI 10.1056/NEJM196907032810103; National Center for Health Statistics, 1994, PLAN OP 3 NAT HLTH N; NOBMANN ED, 1992, AM J CLIN NUTR, V55, P1024, DOI 10.1093/ajcn/55.5.1024; ORMAND JE, 1990, DIGEST DIS SCI, V35, P879, DOI 10.1007/BF01536802; Peek RM, 1995, LAB INVEST, V73, P760; Petersen KM, 1996, J NUTR, V126, P2774; PETERSON WL, 1988, GASTROENTEROLOGY, V95, P1185, DOI 10.1016/0016-5085(88)90349-6; PORTER VS, 1953, SCI ALASKA, P217; RAED AK, 1995, GASTROENTEROLOGY, V108, pA199; ROCHE M, 1966, AM J TROP MED HYG, V15, P1032, DOI 10.4269/ajtmh.1966.15.1032; SASSA S, 1973, BIOCHEM MED METAB B, V8, P135, DOI 10.1016/0006-2944(73)90017-3; SCHWARTZ S, 1983, CLIN CHEM, V29, P2061; SCHWARTZ S, 1985, GASTROENTEROLOGY, V89, P19, DOI 10.1016/0016-5085(85)90740-1; SCOTT EM, 1964, AM J CLIN NUTR, V15, P282, DOI 10.1093/ajcn/15.5.282; SCOTT EM, 1955, J NUTR, V55, P137, DOI 10.1093/jn/55.1.137; SCOTT EM, 1954, SCI ALASKA, P92; TYTGAT GNJ, 1990, GASTROENTEROL CLIN N, V19, P183; WARD JI, 1981, LANCET, V1, P1281; Weel JFL, 1996, J INFECT DIS, V173, P1171, DOI 10.1093/infdis/173.5.1171; Yamada, 1995, TXB GASTROENTEROLOGY, V1, P699; YOSHIMURA HH, 1993, DIGEST DIS SCI, V38, P1128, DOI 10.1007/BF01295731; 1988, MMWR MORB MORTAL WEE, V37, P200	41	121	125	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 9	1997	277	14					1135	1139		10.1001/jama.277.14.1135	http://dx.doi.org/10.1001/jama.277.14.1135			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	WR342	9087468				2022-12-01	WOS:A1997WR34200032
J	Tajbakhsh, S; Rocancourt, D; Cossu, G; Buckingham, M				Tajbakhsh, S; Rocancourt, D; Cossu, G; Buckingham, M			Redefining the genetic hierarchies controlling skeletal myogenesis: Pax-3 and Myf-5 act upstream of MyoD	CELL			English	Article							REGULATORY FACTOR PROTEINS; MUSCLE DEVELOPMENT; PRECURSOR CELLS; MESSENGER-RNA; EXPRESSION; MICE; DIFFERENTIATION; RECEPTOR; MUTATION; SPECIFICATION	We analyzed Pax-3 (splotch), Myf-5 (targeted with nlacZ), and splotch/Myf-5 homozygous mutant mice to investigate the roles that these genes play in programming skeletal myogenesis. In splotch and Myf-5 homozygous embryos, myogenic progenitor cell perturbations and early muscle defects are distinct. Remarkably, splotch/Myf-5 double homozygotes have a dramatic phenotype not seen in the individual mutants: body muscles are absent. MyoD does not rescue this double mutant phenotype since activation of this gene proves to be dependent on either Pax-3 or Myf-5. Therefore, Pax-3 and Myf-5 define two distinct myogenic pathways, and MyoD acts genetically downstream of these genes for myogenesis in the body. This genetic hierarchy does not appear to operate for head muscle formation.	UNIV ROMA LA SAPIENZA, DEPT HISTOL & MED EMBRYOL, I-00161 ROME, ITALY	Sapienza University Rome	Tajbakhsh, S (corresponding author), INST PASTEUR, DEPT MOL BIOL, CNRS, URA 1947, F-75724 PARIS 15, FRANCE.				Telethon [A.067] Funding Source: Medline	Telethon(Fondazione Telethon)		BATE M, 1992, SEMIN DEV BIOL, V3, P267; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; BOBER E, 1994, DEVELOPMENT, V120, P603; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; Braun T, 1996, EMBO J, V15, P310, DOI 10.1002/j.1460-2075.1996.tb00361.x; BRAUN T, 1994, DEVELOPMENT, V120, P3083; BUCKINGHAM M, 1992, TRENDS GENET, V8, P144, DOI 10.1016/0168-9525(92)90373-C; CHRIST B, 1995, ANAT EMBRYOL, V191, P381, DOI 10.1007/BF00304424; Cossu G, 1996, DEVELOPMENT, V122, P429; Cossu G, 1996, TRENDS GENET, V12, P218, DOI 10.1016/0168-9525(96)10025-1; Daston G, 1996, DEVELOPMENT, V122, P1017; EPSTEIN DJ, 1993, P NATL ACAD SCI USA, V90, P532, DOI 10.1073/pnas.90.2.532; EPSTEIN JA, 1995, J BIOL CHEM, V270, P11719, DOI 10.1074/jbc.270.20.11719; Epstein JA, 1996, P NATL ACAD SCI USA, V93, P4213, DOI 10.1073/pnas.93.9.4213; FAN CM, 1994, CELL, V79, P1175, DOI 10.1016/0092-8674(94)90009-4; FRANZ T, 1993, ANAT EMBRYOL, V187, P153; Gamel AJ, 1995, DEV BIOL, V172, P625, DOI 10.1006/dbio.1995.8028; GOULDING M, 1994, DEVELOPMENT, V120, P957; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HENRIQUE D, 1995, NATURE, V375, P787, DOI 10.1038/375787a0; JOSTES B, 1990, MECH DEVELOP, V33, P27, DOI 10.1016/0925-4773(90)90132-6; KENNYMOBBS T, 1987, DEVELOPMENT, V100, P449; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; Mansouri A, 1996, DEVELOPMENT, V122, P831; MARCELLE C, 1995, DEV BIOL, V172, P100, DOI 10.1006/dbio.1995.0008; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; Olson EN, 1996, CELL, V85, P1, DOI 10.1016/S0092-8674(00)81073-9; OTT MO, 1991, DEVELOPMENT, V111, P1097; PATAPOUTIAN A, 1995, DEVELOPMENT, V121, P3347; PICARD JK, 1994, TRANSGENICS, V1, P241; Pourquie O, 1996, CELL, V84, P461, DOI 10.1016/S0092-8674(00)81291-X; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SMITH TH, 1994, J CELL BIOL, V127, P95, DOI 10.1083/jcb.127.1.95; SMITH TH, 1993, DEVELOPMENT, V117, P1125; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; STRACHAN T, 1994, CURR OPIN GENET DEV, V4, P427, DOI 10.1016/0959-437X(94)90032-9; Tajbakhsh S, 1995, DEVELOPMENT, V121, P4077; Tajbakhsh S, 1996, NATURE, V384, P266, DOI 10.1038/384266a0; Tajbakhsh S, 1996, DEV DYNAM, V206, P291, DOI 10.1002/(SICI)1097-0177(199607)206:3<291::AID-AJA6>3.0.CO;2-D; TAJBAKHSH S, 1994, P NATL ACAD SCI USA, V91, P747, DOI 10.1073/pnas.91.2.747; TAJBAKHSH S, 1995, TRENDS GENET, V11, P42, DOI 10.1016/S0168-9525(00)88994-5; TREMBLAY P, 1994, PHARMACOL THERAPEUT, V61, P205, DOI 10.1016/0163-7258(94)90063-9; Wachtler F., 1992, SEMIN DEV BIOL, V3, P217; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WILLIAMS BA, 1994, DEVELOPMENT, V120, P785; Yang XM, 1996, DEVELOPMENT, V122, P2163	49	637	651	0	25	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 4	1997	89	1					127	138		10.1016/S0092-8674(00)80189-0	http://dx.doi.org/10.1016/S0092-8674(00)80189-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WR685	9094721	Bronze			2022-12-01	WOS:A1997WR68500016
J	Zhang, YH; Yao, B; Delikat, S; Bayoumy, S; Lin, XH; Basu, S; McGinley, M; ChanHui, PY; Lichenstein, H; Kolesnick, R				Zhang, YH; Yao, B; Delikat, S; Bayoumy, S; Lin, XH; Basu, S; McGinley, M; ChanHui, PY; Lichenstein, H; Kolesnick, R			Kinase suppressor of Ras is ceramide-activated protein kinase	CELL			English	Article							NECROSIS-FACTOR-ALPHA; KSR-1 GENE ENCODES; SIGNAL-TRANSDUCTION; C-ELEGANS; RAF-1; SPHINGOMYELINASE; PHOSPHORYLATION; IDENTIFICATION; STIMULATION; C-RAF-1	A proline-directed serine/threonine ceramide-activated protein (CAP) kinase mediates transmembrane signaling through the sphingomyelin pathway. CAP kinase reportedly initiates proinflammatory TNF alpha action by phosphorylating and activating Raf-1. The present studies delineate kinase suppressor of Ras (KSR), identified genetically in Caenorhabditis elegans and Drosophila, as CAP kinase. Mouse KSR, like CAP kinase, renatures and autophosphorylates as a 100-kDa membrane-bound polypeptide. KSR overexpression constitutively activates Raf-1. TNF alpha or ceramide analogs markedly enhance KSR autophosphorylation and its ability to complex with, phosphorylate, and activate Raf-1. In vitro, low nanomolar concentrations of natural ceramide stimulate KSR to autophosphorylate, and transactivate Raf-1. Other lipid second messengers were ineffective. Moreover, Thr(269), the Raf-1 site phosphorylated by CAP kinase, is also recognized by KSR. Thus, by previously established criteria, KSR appears to be CAP kinase.	MEM SLOAN KETTERING CANC CTR,LAB SIGNAL TRANSDUCT,NEW YORK,NY 10021; AMGEN INC,BOULDER,CO 80301	Memorial Sloan Kettering Cancer Center; Amgen					NCI NIH HHS [CA42385] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adam D, 1996, J BIOL CHEM, V271, P14617, DOI 10.1074/jbc.271.24.14617; AdamKlages S, 1996, CELL, V86, P937, DOI 10.1016/S0092-8674(00)80169-5; BELKA C, 1995, EMBO J, V14, P1156, DOI 10.1002/j.1460-2075.1995.tb07099.x; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; DOWNWARD J, 1995, CELL, V83, P831, DOI 10.1016/0092-8674(95)90198-1; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Huwiler A, 1996, P NATL ACAD SCI USA, V93, P6959, DOI 10.1073/pnas.93.14.6959; Jarvis WD, 1996, CLIN CANCER RES, V2, P1; JOSEPH CK, 1993, J BIOL CHEM, V268, P20002; KOLESNICK RN, 1991, PROG LIPID RES, V30, P1, DOI 10.1016/0163-7827(91)90005-P; KORNFELD K, 1995, CELL, V83, P903, DOI 10.1016/0092-8674(95)90206-6; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LIU J, 1994, J BIOL CHEM, V269, P3047; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; RAPP UR, 1991, ONCOGENE, V6, P495; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; STEPHENS RM, 1992, MOL CELL BIOL, V12, P3733, DOI 10.1128/MCB.12.9.3733; STORM SM, 1990, ONCOGENE, V5, P345; SUNDARAM M, 1995, CELL, V83, P889, DOI 10.1016/0092-8674(95)90205-8; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X; Therrien M, 1996, GENE DEV, V10, P2684, DOI 10.1101/gad.10.21.2684; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WILLIAMS NG, 1994, CANCER METAST REV, V13, P105, DOI 10.1007/BF00690421; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	33	375	386	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 4	1997	89	1					63	72		10.1016/S0092-8674(00)80183-X	http://dx.doi.org/10.1016/S0092-8674(00)80183-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WR685	9094715	Bronze			2022-12-01	WOS:A1997WR68500010
J	Seckl, JR; Miller, WL				Seckl, JR; Miller, WL			How safe is long-term prenatal glucocorticoid treatment?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CONGENITAL ADRENAL-HYPERPLASIA; TYPE-2 11-BETA-HYDROXYSTEROID DEHYDROGENASE; 21-HYDROXYLASE DEFICIENCY; ADULT HYPERTENSION; SEXUAL-BEHAVIOR; BLOOD-PRESSURE; BIRTH-WEIGHT; DIAGNOSIS; DEXAMETHASONE; MANAGEMENT		UNIV CALIF SAN FRANCISCO,DEPT PEDIAT,SAN FRANCISCO,CA 94143; UNIV EDINBURGH,WESTERN GEN HOSP,MOL MED CTR,EDINBURGH,MIDLOTHIAN,SCOTLAND	University of California System; University of California San Francisco; University of Edinburgh			Seckl, Jonathan R/C-3555-2013; Miller, Walter L/J-3696-2012		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037922, R01DK042154] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK37922, DK42154] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBISTON AL, 1994, MOL CELL ENDOCRINOL, V105, pR11, DOI 10.1016/0303-7207(94)90176-7; BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A; BEITINS IZ, 1973, PEDIATR RES, V7, P509, DOI 10.1203/00006450-197305000-00004; BENEDIKTSSON R, 1993, LANCET, V341, P339, DOI 10.1016/0140-6736(93)90138-7; BENEDIKTSSON R, 1995, CLIN ENDOCRINOL, V42, P551, DOI 10.1111/j.1365-2265.1995.tb02676.x; Brown RW, 1996, BIOCHEM J, V313, P1007, DOI 10.1042/bj3131007; Brown RW, 1996, ENDOCRINOLOGY, V137, P794, DOI 10.1210/en.137.2.794; BUESCHER MA, 1992, OBSTET GYNECOL, V79, P130; CROWLEY P, 1990, BRIT J OBSTET GYNAEC, V97, P11, DOI 10.1111/j.1471-0528.1990.tb01711.x; DIAZ R, 1995, NEUROSCIENCE, V66, P467, DOI 10.1016/0306-4522(94)00605-5; DITTMANN RW, 1992, PSYCHONEUROENDOCRINO, V17, P153, DOI 10.1016/0306-4530(92)90054-B; EDWARDS CRW, 1993, LANCET, V341, P355, DOI 10.1016/0140-6736(93)90148-A; FOREST MG, 1993, J STEROID BIOCHEM, V45, P75, DOI 10.1016/0960-0760(93)90125-G; FOREST MG, 1989, ENDOCR RES, V15, P277, DOI 10.1080/07435808909039101; HAAN EA, 1992, MED J AUSTRALIA, V156, P132; HOLSON RR, 1995, NEUROTOXICOL TERATOL, V17, P393, DOI 10.1016/0892-0362(94)00074-N; KUHNLE U, 1993, J STEROID BIOCHEM, V45, P123, DOI 10.1016/0960-0760(93)90131-F; LEVINE RS, 1994, BMJ-BRIT MED J, V308, P298, DOI 10.1136/bmj.308.6924.298; Lindsay RS, 1996, HYPERTENSION, V27, P1200, DOI 10.1161/01.HYP.27.6.1200; Lindsay RS, 1996, DIABETOLOGIA, V39, P1299, DOI 10.1007/s001250050573; MAGIAKOU MA, 1994, J CLIN ENDOCR METAB, V79, P1082, DOI 10.1210/jc.79.4.1082; MEANEY MJ, 1988, SCIENCE, V239, P766, DOI 10.1126/science.3340858; MERCADO AB, 1995, J CLIN ENDOCR METAB, V80, P2014, DOI 10.1210/jc.80.7.2014; MILLER WL, 1994, J CLIN ENDOCR METAB, V78, P241, DOI 10.1210/jc.78.2.241; Miller WL., 1995, ENDOCRINOL METAB, P555; Morel Y, 1991, Adv Hum Genet, V20, P1; MUNE T, 1995, NAT GENET, V10, P394, DOI 10.1038/ng0895-394; NOVY MJ, 1983, AM J OBSTET GYNECOL, V145, P920, DOI 10.1016/0002-9378(83)90841-4; PANG SY, 1992, J CLIN ENDOCR METAB, V75, P249, DOI 10.1210/jc.75.1.249; REINISCH JM, 1978, SCIENCE, V202, P436, DOI 10.1126/science.705336; SECKL JR, 1994, Q J MED, V87, P259; SPEISER PW, 1994, CLIN PERINATOL, V21, P631, DOI 10.1016/S0095-5108(18)30335-X; STEWART PM, 1994, J CLIN ENDOCR METAB, V78, P1529, DOI 10.1210/jc.78.6.1529; STEWART PM, 1995, J CLIN ENDOCR METAB, V80, P885, DOI 10.1210/jc.80.3.885; STYNE DM, 1984, NEW ENGL J MED, V310, P889, DOI 10.1056/NEJM198404053101405; TRAUTMAN PD, 1995, PSYCHONEUROENDOCRINO, V20, P439, DOI 10.1016/0306-4530(94)00070-0; VanWyk JJ, 1996, J CLIN ENDOCR METAB, V81, P3180, DOI 10.1210/jc.81.9.3180; WARD RM, 1994, CLIN PERINATOL, V21, P523, DOI 10.1016/S0095-5108(18)30330-0; WEINSTOCK M, 1992, BRAIN RES, V595, P195, DOI 10.1016/0006-8993(92)91049-K; WHINCUP P, 1995, BRIT MED J, V311, P773, DOI 10.1136/bmj.311.7008.773	40	86	89	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 2	1997	277	13					1077	1079		10.1001/jama.277.13.1077	http://dx.doi.org/10.1001/jama.277.13.1077			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ089	9091698				2022-12-01	WOS:A1997WQ08900035
J	Burke, GAA; Chambers, TL				Burke, GAA; Chambers, TL			Musculoskeletal side-effects of varicella	LANCET			English	Editorial Material							CHILDREN				Burke, GAA (corresponding author), SOUTHMEAD GEN HOSP,DEPT MED,BRISTOL BS10 5NB,AVON,ENGLAND.		Burke, Amos/AAT-1358-2021	Burke, Amos/0000-0003-2671-9972				BERNSTEIN HH, 1993, PEDIATRICS, V92, P833; DOCTOR A, 1995, PEDIATRICS, V96, P428; DUNKLE LM, 1991, NEW ENGL J MED, V325, P1539, DOI 10.1056/NEJM199111283252203; GIVNER LB, 1991, J PEDIATR-US, V118, P341, DOI 10.1016/S0022-3476(05)82144-4; SCHRECK P, 1996, J BONE JOINT SURG, V11, P1713	5	10	10	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 22	1997	349	9055					818	819		10.1016/S0140-6736(05)61746-1	http://dx.doi.org/10.1016/S0140-6736(05)61746-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WP403	9121252				2022-12-01	WOS:A1997WP40300005
J	Riese, J; Yu, XN; Munnerlyn, A; Eresh, S; Hsu, SC; Grosschedl, R; Bienz, M				Riese, J; Yu, XN; Munnerlyn, A; Eresh, S; Hsu, SC; Grosschedl, R; Bienz, M			LEF-1, a nuclear factor coordinating signaling inputs from wingless and decapentaplegic	CELL			English	Article							SEGMENT POLARITY GENE; HOMEOTIC DROSOPHILA GENE; ALPHA-ENHANCER; HMG DOMAIN; NUCLEOPROTEIN STRUCTURES; ACTIVATION DOMAIN; DORSAL MESODERM; CELL-ADHESION; BETA-CATENIN; PROTEIN	wingless and decapentaplegic signal during endoderm induction in Drosophila to regulate expression of the homeotic gene Ultrabithorax. Here, we define a minimal wingless response sequence in the midgut enhancer of Ultrabithorax. We show that this sequence is recognized by the murine transcription factor LEF-1 (lymphocyte enhancer binding factor 1) in a ternary complex with armadillo protein, the cytoplasmic target of the wingless signaling pathway. In stable transformants, transcriptional stimulation of the Ultrabithorax enhancer by LEF-1 depends on armadillo. Furthermore, overexpression of LEF-1 bypasses the need for wingless signaling and causes phenotypes in the midgut, notum, and wing that mimic wingless hyperstimulation. Finally, efficient transcriptional stimulation by LEF-1 in the midgut depends also on the decapentaplegic response sequence and is limited spatially by decapentaplegic signaling. Thus, LEF-1 coordinates inputs from multiple positional signals, consistent with its architectural role in regulating the assembly of multiprotein enhancer complexes.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT MICROBIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT BIOCHEM,SAN FRANCISCO,CA 94143	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Riese, J (corresponding author), MRC,MOL BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.							Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bienz M, 1996, SEMIN CELL DEV BIOL, V7, P113, DOI 10.1006/scdb.1996.0016; BIENZ M, 1988, NATURE, V333, P576, DOI 10.1038/333576a0; BIENZ M, 1994, TRENDS GENET, V10, P22, DOI 10.1016/0168-9525(94)90015-9; BRAND AH, 1994, METHOD CELL BIOL, V44, P635, DOI 10.1016/S0091-679X(08)60936-X; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; CARLSSON P, 1993, GENE DEV, V7, P2418, DOI 10.1101/gad.7.12a.2418; CHRISTEN B, 1995, THESIS U ZURICH SWIT; COUSO JP, 1994, DEVELOPMENT, V120, P621; Cox RT, 1996, J CELL BIOL, V134, P133, DOI 10.1083/jcb.134.1.133; ERESH S, 1997, IN PRESS EMBO J; FUNAYAMA N, 1995, J CELL BIOL, V128, P959, DOI 10.1083/jcb.128.5.959; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GIESE K, 1993, EMBO J, V12, P4667, DOI 10.1002/j.1460-2075.1993.tb06155.x; Grobstein C, 1967, Natl Cancer Inst Monogr, V26, P279; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; GURDON JB, 1992, CELL, V68, P185, DOI 10.1016/0092-8674(92)90465-O; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; HOPPLER S, 1995, EMBO J, V14, P5016, DOI 10.1002/j.1460-2075.1995.tb00184.x; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; KESSLER DS, 1995, DEVELOPMENT, V121, P2155; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; Kratochwil K, 1996, GENE DEV, V10, P1382, DOI 10.1101/gad.10.11.1382; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morimura S, 1996, DEV BIOL, V177, P136, DOI 10.1006/dbio.1996.0151; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; NOORDERMEER J, 1992, DEVELOPMENT, V116, P711; NOORDERMEER J, 1994, NATURE, V367, P80, DOI 10.1038/367080a0; Orsulic S, 1996, J CELL BIOL, V134, P1283, DOI 10.1083/jcb.134.5.1283; PEIFER M, 1994, DEVELOPMENT, V120, P369; PEIFER M, 1993, DEVELOPMENT, V118, P1191; PEIFER M, 1995, TRENDS CELL BIOL, V5, P224, DOI 10.1016/S0962-8924(00)89015-7; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; PHILLIPS RG, 1993, DEVELOPMENT, V118, P427; POSAKONY LG, 1991, MECH DEVELOP, V33, P69; RIGGLEMAN B, 1989, GENE DEV, V3, P96, DOI 10.1101/gad.3.1.96; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; Sanson B, 1996, NATURE, V383, P627, DOI 10.1038/383627a0; Schneider S, 1996, MECH DEVELOP, V57, P191, DOI 10.1016/0925-4773(96)00546-1; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; SIMPSON P, 1988, DEVELOPMENT, V103, P391; SIMPSON P, 1989, DEVELOPMENT, V106, P57; STAEHLINGHAMPTON K, 1994, DEV BIOL, V164, P502, DOI 10.1006/dbio.1994.1219; STANOJEVIC D, 1991, SCIENCE, V254, P1385, DOI 10.1126/science.1683715; THURINGER F, 1993, EMBO J, V12, P2419, DOI 10.1002/j.1460-2075.1993.tb05896.x; THURINGER F, 1993, P NATL ACAD SCI USA, V90, P3899, DOI 10.1073/pnas.90.9.3899; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; VANGENDEREN C, 1994, GENE DEV, V8, P2691, DOI 10.1101/gad.8.22.2691; VERBEEK S, 1995, NATURE, V374, P70, DOI 10.1038/374070a0; WATERMAN ML, 1991, GENE DEV, V5, P656, DOI 10.1101/gad.5.4.656; WHITE RAH, 1984, CELL, V39, P163, DOI 10.1016/0092-8674(84)90202-2; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Yu X, 1996, DEVELOPMENT, V122, P849	61	388	390	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 21	1997	88	6					777	787		10.1016/S0092-8674(00)81924-8	http://dx.doi.org/10.1016/S0092-8674(00)81924-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WQ100	9118221	Bronze			2022-12-01	WOS:A1997WQ10000010
J	Dong, HL; OBrien, RJ; Fung, ET; Lanahan, AA; Worley, PF; Huganir, RL				Dong, HL; OBrien, RJ; Fung, ET; Lanahan, AA; Worley, PF; Huganir, RL			GRIP: A synaptic PDZ domain-containing protein that interacts with AMPA receptors	NATURE			English	Article							GUANYLATE KINASES; NMDA RECEPTOR; GLUTAMATE; CHANNELS; SUBUNIT; SYNAPSES; CLONING; SYSTEM; BRAIN; YEAST	AMPA glutamate receptors mediate the majority of rapid excitatory synaptic transmission in the central nervous system(1,2) and play a role in the synaptic plasticity underlying learning and memory(3,4). AMPA receptors are heteromeric complexes of four homologous subunits (GluR1-4) that differentially combine to form a variety of AMPA receptor subtypes(1,2). These subunits are thought to have a large extracellular amino-terminal domain, three transmembrane domains and an intracellular carboxyterminal domain(5). AMPA receptors are localized at excitatory synapses and are not found on adjacent inhibitory synapses enriched in GABAA receptors(6). The targeting of neurotransmitter receptors, such as AMPA receptors, and ion channels to synapses is essential for efficient transmission(7,8). A protein motif called a PDZ domain is important in the targeting of a variety of membrane proteins to cell-cell junctions including synapses(8-10). Here we identify a synaptic PDZ domain-containing protein GRIP (glutamate receptor interacting protein) that specifically interacts with the C termini of AMPA receptors. GRIP is a new member of the PDZ domain-containing protein family which has seven PDZ domains and no catalytic domain. GRIP appears to serve as an adapter protein that links AMPA receptors to other proteins and may be critical for the clustering of AMPA receptors at excitatory synapses in the brain.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205	Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University								Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; CRAIG AM, 1994, P NATL ACAD SCI USA, V91, P12373, DOI 10.1073/pnas.91.26.12373; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Durand GM, 1996, NATURE, V381, P71, DOI 10.1038/381071a0; EHLERS MD, 1995, SCIENCE, V269, P1734, DOI 10.1126/science.7569904; EHLERS MD, 1996, CURR OPIN CELL BIOL, V8, P490; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FROEHNER SC, 1993, ANNU REV NEUROSCI, V16, P347, DOI 10.1146/annurev.ne.16.030193.002023; GALLO V, 1992, J NEUROSCI, V12, P1010; Gomperts SN, 1996, CELL, V84, P659, DOI 10.1016/S0092-8674(00)81043-0; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2; KENNEDY MB, 1995, TRENDS BIOCHEM SCI, V20, P350, DOI 10.1016/S0968-0004(00)89074-X; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KIM SK, 1995, CURR OPIN CELL BIOL, V7, P641, DOI 10.1016/0955-0674(95)80105-7; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KOHLER M, 1994, J BIOL CHEM, V269, P17367; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; LINDEN DJ, 1994, NEURON, V12, P457, DOI 10.1016/0896-6273(94)90205-4; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; NICOLL RA, 1995, NATURE, V377, P115, DOI 10.1038/377115a0; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; SEEBURG PH, 1993, TRENDS NEUROSCI, V16, P359, DOI 10.1016/0166-2236(93)90093-2; STAUDINGER J, 1995, J CELL BIOL, V128, P263, DOI 10.1083/jcb.128.3.263; STRICKER NL, IN PRESS NATURE BIOT; WO ZG, 1995, TRENDS NEUROSCI, V18, P161; XIA Z, 1996, J NEUROSCI, V16, P5424	30	708	730	1	32	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 20	1997	386	6622					279	284		10.1038/386279a0	http://dx.doi.org/10.1038/386279a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WP003	9069286				2022-12-01	WOS:A1997WP00300051
J	Wyman, C; Rombel, I; North, AK; Bustamante, C; Kustu, S				Wyman, C; Rombel, I; North, AK; Bustamante, C; Kustu, S			Unusual oligomerization required for activity of NtrC, a bacterial enhancer-binding protein	SCIENCE			English	Article							SCANNING FORCE MICROSCOPY; TRANSCRIPTIONAL ACTIVATION; ATPASE ACTIVITY; ENTERIC BACTERIA; ESCHERICHIA-COLI; RNA-POLYMERASE; PHOSPHORYLATION; DETERMINANTS; COMPLEXES; PROMOTER	Nitrogen regulatory protein G (NtrC) contacts a bacterial RNA polymerase from distant enhancers by means of DNA loops and activates transcription by allowing polymerase to gain access to the template DNA strand. It was shown that NtrC from Salmonella typhimurium must build large oligomers to activate transcription. In contrast to eukaryotic enhancer-binding proteins, most of which must bind directly to DNA, some NtrC dimers were bound solely by protein-protein interactions. NtrC oligomers were visualized with scanning force microscopy. Evidence of their functional importance was provided by showing that some inactive non-DNA-binding and DNA-binding mutant forms of NtrC can cooperate to activate transcription.	UNIV OREGON,HOWARD HUGHES MED INST,DEPT CHEM,EUGENE,OR 97403; UNIV CALIF BERKELEY,DEPT MOL & CELL BIOL,BERKELEY,CA 94720; ERASMUS UNIV ROTTERDAM,DEPT CELL BIOL & GENET,NL-3000 DR ROTTERDAM,NETHERLANDS; UNIV OREGON,INST MOL BIOL,EUGENE,OR 97403; UNIV CALIF BERKELEY,DEPT PLANT BIOL,BERKELEY,CA 94720	Howard Hughes Medical Institute; University of Oregon; University of California System; University of California Berkeley; Erasmus University Rotterdam; University of Oregon; University of California System; University of California Berkeley				Bustamante, Carlos/0000-0002-2970-0073	NIGMS NIH HHS [GM38361, GM17078, GM32543] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032543, R01GM032543, R37GM038361, R01GM038361] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSTIN S, 1992, EMBO J, V11, P2219, DOI 10.1002/j.1460-2075.1992.tb05281.x; BENTLEY DL, 1995, CURR OPIN GENET DEV, V5, P210, DOI 10.1016/0959-437X(95)80010-7; BUSTAMANTE C, 1993, CURR OPIN STRUC BIOL, V3, P363, DOI 10.1016/S0959-440X(05)80107-1; BUSTAMANTE C, 1994, CURR OPIN STRUC BIOL, V4, P750, DOI 10.1016/S0959-440X(94)90175-9; BUSTAMANTE C, 1995, PHYS TODAY, V48, P32, DOI 10.1063/1.881478; CHAMBERLIN MJ, 1992, NUCL ACIDS B, V15, P61; CHI TH, 1995, NATURE, V377, P254, DOI 10.1038/377254a0; FLASHNER Y, 1995, J MOL BIOL, V249, P700, DOI 10.1006/jmbi.1995.0330; GREEN MR, 1995, HARVEY LECT, V88, P67; GROSSCHEDL R, 1995, CURR OPIN CELL BIOL, V7, P362, DOI 10.1016/0955-0674(95)80091-3; GUARENTE L, 1995, TRENDS BIOCHEM SCI, V20, P517, DOI 10.1016/S0968-0004(00)89120-3; HOPPER S, 1995, J BACTERIOL, V177, P2798, DOI 10.1128/jb.177.10.2798-2803.1995; KINGSTON RE, 1994, CURR BIOL, V4, P325, DOI 10.1016/S0960-9822(00)00071-3; KLOSE KE, 1993, J MOL BIOL, V232, P67, DOI 10.1006/jmbi.1993.1370; KLOSE KE, 1994, J MOL BIOL, V241, P233, DOI 10.1006/jmbi.1994.1492; LEE JH, 1994, J BIOL CHEM, V269, P20401; LIS J, 1993, CELL, V74, P1, DOI 10.1016/0092-8674(93)90286-Y; MAGASANIK B, 1993, J CELL BIOCHEM, V51, P34, DOI 10.1002/jcb.240510108; Magasanik Boris, 1996, P281; NORTH A, IN PRESS J MOL BIOL; North AK, 1996, J MOL BIOL, V260, P317, DOI 10.1006/jmbi.1996.0403; NORTH AN, UNPUB; PerezMartin J, 1996, CELL, V86, P331, DOI 10.1016/S0092-8674(00)80104-X; PerezMartin J, 1996, J MOL BIOL, V258, P575, DOI 10.1006/jmbi.1996.0270; PORTER SC, 1993, GENE DEV, V7, P2258, DOI 10.1101/gad.7.11.2258; Porter SC, 1995, 2 COMPONENT SIGNAL T, P147; RANISH A, 1996, CURR OPIN GENE DEV, V6, P151; ROMBEL I, UNPUB; Struhl K, 1996, CELL, V84, P179, DOI 10.1016/S0092-8674(00)80970-8; SU W, 1990, P NATL ACAD SCI USA, V87, P5504, DOI 10.1073/pnas.87.14.5504; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; WEISS DS, 1991, CELL, V67, P155, DOI 10.1016/0092-8674(91)90579-N; WEISS V, 1992, P NATL ACAD SCI USA, V89, P5088, DOI 10.1073/pnas.89.11.5088; WYMAN C, 1995, EMBO J, V14, P117, DOI 10.1002/j.1460-2075.1995.tb06981.x; Yang NN, 1996, SCIENCE, V273, P1222, DOI 10.1126/science.273.5279.1222	36	212	213	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 14	1997	275	5306					1658	1661		10.1126/science.275.5306.1658	http://dx.doi.org/10.1126/science.275.5306.1658			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WN123	9054362				2022-12-01	WOS:A1997WN12300050
J	Rodionov, VI; Borisy, GG				Rodionov, VI; Borisy, GG			Self-centring activity of cytoplasm	NATURE			English	Article							INTRACELLULAR-TRANSPORT; MICROTUBULE POLARITY; PIGMENT TRANSPORT; FISH MELANOPHORES; KINESIN; PROTEIN; CHROMATOPHORES; ORGANIZATION; DIRECTION; GRANULES	Fish melanophore cells aggregate pigment granules at the centre or redisperse them throughout the cytoplasm. The granules move along radial microtubules by means of molecular motors(1-3) Cytoplasmic fragments of melanophores organize a radial array of microtubules and aggregate pigment at its centre(4-7). Here we report self-centring in microsurgically produced cytoplasmic fragments of black tetra melanophores. We observed rapid (10 min) formation of a radial microtubule array after stimulation of aggregation. Arrangement of microtubules in the fragments returned to random during pigment redispersion. Apparently, formation of the radial array does not depend on a pre-existing microtubule-organizing centre. The array did not form in granule-free fragments nor in fragments treated with inhibitors of the intracellular motor protein cytoplasmic dynein. We conclude that formation of the radial microtubule array is induced by directional motion of pigment granules along microtubules and present evidence that its position is defined by interaction of microtubules with the surface.	UNIV WISCONSIN,MOL BIOL LAB,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison				Borisy, Gary/0000-0002-0266-8018				BECKERLE MC, 1982, NATURE, V295, P701, DOI 10.1038/295701a0; CLARK TG, 1982, P NATL ACAD SCI-BIOL, V79, P4655, DOI 10.1073/pnas.79.15.4655; DOXSEY SJ, 1994, CELL, V76, P639, DOI 10.1016/0092-8674(94)90504-5; GYOEVA FK, 1987, J CELL SCI, V88, P649; HAIMO LT, 1994, BIOESSAYS, V16, P727, DOI 10.1002/bies.950161007; Heald R, 1996, NATURE, V382, P420, DOI 10.1038/382420a0; Matthews SA, 1931, J EXP ZOOL, V58, P471, DOI 10.1002/jez.1400580121; MCNIVEN MA, 1988, J CELL BIOL, V106, P1593, DOI 10.1083/jcb.106.5.1593; MCNIVEN MA, 1986, J CELL BIOL, V103, P1547, DOI 10.1083/jcb.103.4.1547; MCNIVEN MA, 1984, CELL, V37, P753, DOI 10.1016/0092-8674(84)90411-2; Oakley Berl R., 1994, V13, P33; OBIKA M, 1986, ZOOL SCI, V3, P1; PASCHAL BM, 1987, NATURE, V330, P181, DOI 10.1038/330181a0; RODIONOV VI, 1994, J CELL BIOL, V126, P1455, DOI 10.1083/jcb.126.6.1455; RODIONOV VI, 1991, P NATL ACAD SCI USA, V88, P4956, DOI 10.1073/pnas.88.11.4956; Schliwa M., 1984, Cell and Muscle Motility, V5, P1; SHPETNER HS, 1988, J CELL BIOL, V107, P1001, DOI 10.1083/jcb.107.3.1001; URRUTIA R, 1991, P NATL ACAD SCI USA, V88, P6701, DOI 10.1073/pnas.88.15.6701; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VERDE F, 1991, J CELL BIOL, V112, P1177, DOI 10.1083/jcb.112.6.1177	20	97	100	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 13	1997	386	6621					170	173		10.1038/386170a0	http://dx.doi.org/10.1038/386170a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WM973	9062188				2022-12-01	WOS:A1997WM97300061
J	Zerrahn, J; Held, W; Raulet, DH				Zerrahn, J; Held, W; Raulet, DH			The MHC reactivity of the T cell repertoire prior to positive and negative selection	CELL			English	Article							CLASS-II MOLECULES; MICE; THYMOCYTES; ANTIGENS; THYMUS; BETA; SUPERANTIGENS; RECOGNITION; FREQUENCY; ONTOGENY	T cell antigen receptors (TCRs) on mature T cells react with peptide antigens presented by self-MHC proteins and also frequently cross-react with foreign MHC proteins. The fundamental question whether MHC reactivity is inherent in the germline TCR sequences or is imposed by thymic selection was addressed here by inducing nonselective maturation of immature thymocytes in the absence of MHC molecules. MHC reactivity in the preselection repertoire is very high, but no higher than in the normal repertoire. cross-reactivity of clones with multiple MHC molecules occurred to a similar extent in the preselection and MHC-selected repertoires. The results establish the MHC reactivity of the germline TCR repertoire, indicate the minimum fraction of immature thymocytes that must undergo negative selection, and suggest that some TCR-MHC contacts may be conserved.	UNIV CALIF BERKELEY,DEPT MOL & CELL BIOL,CANC RES LAB,BERKELEY,CA 94720	University of California System; University of California Berkeley				Raulet, David/0000-0002-1257-8649	NIAID NIH HHS [AI31650] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031650] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASHTONRICKARDT PG, 1994, CELL, V76, P651, DOI 10.1016/0092-8674(94)90505-3; ASHWELL JD, 1986, J IMMUNOL, V136, P389; BEVAN MJ, 1977, P NATL ACAD SCI USA, V74, P2094, DOI 10.1073/pnas.74.5.2094; BIX M, 1992, J EXP MED, V176, P829, DOI 10.1084/jem.176.3.829; BLACKMAN M, 1986, CELL, V47, P349, DOI 10.1016/0092-8674(86)90591-X; BRAUN MY, 1995, EUR J IMMUNOL, V25, P857, DOI 10.1002/eji.1830250334; Brock R, 1996, P NATL ACAD SCI USA, V93, P13108, DOI 10.1073/pnas.93.23.13108; CEREDIG R, 1983, J EXP MED, V158, P1654, DOI 10.1084/jem.158.5.1654; CHAN SH, 1993, CELL, V73, P225, DOI 10.1016/0092-8674(93)90225-F; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; EHRICH EW, 1993, J EXP MED, V178, P713, DOI 10.1084/jem.178.2.713; FISCHERLINDAHL K, 1977, J EXP MED, V145, P508; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; Garcia KC, 1996, SCIENCE, V274, P209, DOI 10.1126/science.274.5285.209; Gavin MA, 1995, IMMUNITY, V3, P793, DOI 10.1016/1074-7613(95)90068-3; GILFILLAN S, 1994, INT IMMUNOL, V6, P1681, DOI 10.1093/intimm/6.11.1681; GOTZE D, 1980, J IMMUNOL, V124, P2675; GRUSBY MJ, 1993, P NATL ACAD SCI USA, V90, P3913, DOI 10.1073/pnas.90.9.3913; HERMAN A, 1991, ANNU REV IMMUNOL, V9, P745, DOI 10.1146/annurev.iy.09.040191.003525; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; HONG SC, 1992, CELL, V69, P999, DOI 10.1016/0092-8674(92)90618-M; HUNT DF, 1992, SCIENCE, V256, P1817, DOI 10.1126/science.1319610; Ignatowicz L, 1996, CELL, V84, P521, DOI 10.1016/S0092-8674(00)81028-4; ITOH T, 1990, THYMUS, V16, P89; JAMESON SC, 1995, ANNU REV IMMUNOL, V13, P93, DOI 10.1146/annurev.immunol.13.1.93; JERNE N K, 1971, European Journal of Immunology, V1, P1, DOI 10.1002/eji.1830010102; Laufer TM, 1996, NATURE, V383, P81, DOI 10.1038/383081a0; LIAO NS, 1989, J EXP MED, V170, P135, DOI 10.1084/jem.170.1.135; MATZINGER P, 1977, CELL IMMUNOL, V29, P1, DOI 10.1016/0008-8749(77)90269-6; Miyazaki T, 1996, CELL, V84, P531, DOI 10.1016/S0092-8674(00)81029-6; PIRCHER H, 1991, NATURE, V351, P482, DOI 10.1038/351482a0; PUNT JA, 1993, J IMMUNOL, V151, P1290; ROBEY E, 1994, ANNU REV IMMUNOL, V12, P675, DOI 10.1146/annurev.iy.12.040194.003331; SantAngelo DB, 1996, IMMUNITY, V4, P367, DOI 10.1016/S1074-7613(00)80250-2; SCHERER MT, 1995, J EXP MED, V182, P1493, DOI 10.1084/jem.182.5.1493; Sim BC, 1996, SCIENCE, V273, P963, DOI 10.1126/science.273.5277.963; SURH CD, 1994, NATURE, V372, P100, DOI 10.1038/372100a0; TAKAHAMA Y, 1994, NATURE, V371, P67, DOI 10.1038/371067a0; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; WHITE J, 1989, J IMMUNOL, V143, P1822; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	41	260	267	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 7	1997	88	5					627	636		10.1016/S0092-8674(00)81905-4	http://dx.doi.org/10.1016/S0092-8674(00)81905-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WM413	9054502	Bronze			2022-12-01	WOS:A1997WM41300008
J	Goodrich, J; Puangsomlee, P; Martin, M; Long, D; Meyerowitz, EM; Coupland, G				Goodrich, J; Puangsomlee, P; Martin, M; Long, D; Meyerowitz, EM; Coupland, G			A polycomb-group gene regulates homeotic gene expression in Arabidopsis	NATURE			English	Article							FLORAL ORGAN IDENTITY; FLOWER DEVELOPMENT; ANTIRRHINUM-MAJUS; TRANSCRIPTION FACTORS; DROSOPHILA EMBRYOS; ECTOPIC EXPRESSION; CELL FATE; PROTEIN; ENHANCER; BINDING	Cell fate is determined when the commitment of cells to a particular fate Is autonomously maintained, irrespective of their environment. In Drosophila, fate determination is maintained through the action of the Polycomb-group and trithorax-group genes, which are required so that states of homeotic gene activity are inherited through cell division. It is shown here that the CURLY LEAF gene of Arabidopsis is necessary for stable repression of a floral homeotic gene and encodes a protein with homology to the product of the Polycomb-group gene Enhancer of zeste. We suggest that Polycomb-group genes have a similar role in fate determination in plants and animals.	JOHN INNES CTR PLANT SCI RES,NORWICH NR4 7UH,NORFOLK,ENGLAND; CALTECH,DIV BIOL 15629,PASADENA,CA 91125	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; California Institute of Technology			Basanta, Marta Martin/AAI-5459-2020; Meyerowitz, Elliot M/A-7118-2009; Coupland, George/AAP-8609-2020; martin, marta/H-2169-2015	Basanta, Marta Martin/0000-0003-2498-9768; Coupland, George/0000-0001-6988-4172; martin, marta/0000-0003-2498-9768				Akasaka T, 1996, DEVELOPMENT, V122, P1513; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BOWMAN JL, 1989, PLANT CELL, V1, P37, DOI 10.1105/tpc.1.1.37; Bradley D, 1996, DEVELOPMENT, V122, P1535; BREEN TR, 1993, DEVELOPMENT, V117, P119; CARPENTER R, 1990, GENE DEV, V4, P1483, DOI 10.1101/gad.4.9.1483; Carrington EA, 1996, DEVELOPMENT, V122, P4073; COEN ES, 1991, NATURE, V353, P31, DOI 10.1038/353031a0; COEN ES, 1986, CELL, V47, P285, DOI 10.1016/0092-8674(86)90451-4; COEN ES, 1990, CELL, V63, P1311, DOI 10.1016/0092-8674(90)90426-F; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; DREWS GN, 1991, CELL, V65, P991, DOI 10.1016/0092-8674(91)90551-9; Finnegan EJ, 1996, P NATL ACAD SCI USA, V93, P8449, DOI 10.1073/pnas.93.16.8449; GRINDHART JGJ, 1995, GENETICS, V139, P797; HEEMSKERK J, 1991, NATURE, V352, P404, DOI 10.1038/352404a0; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; IRISH EE, 1991, DEVELOPMENT, V112, P891; JACK T, 1992, CELL, V68, P683, DOI 10.1016/0092-8674(92)90144-2; JACK T, 1994, CELL, V76, P703, DOI 10.1016/0092-8674(94)90509-6; JOFUKU KD, 1994, PLANT CELL, V6, P1211, DOI 10.1105/tpc.6.9.1211; JONES RS, 1993, MOL CELL BIOL, V13, P6357, DOI 10.1128/MCB.13.10.6357; JONES RS, 1990, GENETICS, V126, P185; KENNISON JA, 1993, TRENDS GENET, V9, P75, DOI 10.1016/0168-9525(93)90227-9; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Lawrence PA, 1976, INSECT DEV, P132; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LIU ZC, 1995, DEVELOPMENT, V121, P975; LONG D, 1993, P NATL ACAD SCI USA, V90, P10370, DOI 10.1073/pnas.90.21.10370; LUTTKE HA, 1987, EMBO J, V6, P43; MIZUKAMI Y, 1992, CELL, V71, P119, DOI 10.1016/0092-8674(92)90271-D; MULLER J, 1995, EMBO J, V14, P1209, DOI 10.1002/j.1460-2075.1995.tb07104.x; PARO R, 1991, P NATL ACAD SCI USA, V88, P263, DOI 10.1073/pnas.88.1.263; PARO R, 1990, TRENDS GENET, V6, P416, DOI 10.1016/0168-9525(90)90303-N; PUTTERILL J, 1995, CELL, V80, P847, DOI 10.1016/0092-8674(95)90288-0; RASTELLI L, 1993, EMBO J, V12, P1513, DOI 10.1002/j.1460-2075.1993.tb05795.x; Ronemus MJ, 1996, SCIENCE, V273, P654, DOI 10.1126/science.273.5275.654; SIMCOX AA, 1983, DEV BIOL, V97, P212, DOI 10.1016/0012-1606(83)90078-7; SIMON J, 1995, CURR OPIN CELL BIOL, V7, P376, DOI 10.1016/0955-0674(95)80093-X; STRUHL G, 1985, EMBO J, V4, P3259, DOI 10.1002/j.1460-2075.1985.tb04075.x; STRUHL G, 1982, P NATL ACAD SCI-BIOL, V79, P7380, DOI 10.1073/pnas.79.23.7380; SUTTON WD, 1984, SCIENCE, V223, P1265, DOI 10.1126/science.223.4642.1265; TROBNER W, 1992, EMBO J, V11, P4693, DOI 10.1002/j.1460-2075.1992.tb05574.x; TSCHIERSCH B, 1994, EMBO J, V13, P3822, DOI 10.1002/j.1460-2075.1994.tb06693.x; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; VANDENBERG C, 1995, NATURE, V378, P62, DOI 10.1038/378062a0; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; Weigel D, 1996, CURR BIOL, V6, P10, DOI 10.1016/S0960-9822(02)00408-6; WEIGEL D, 1994, CELL, V78, P203, DOI 10.1016/0092-8674(94)90291-7; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0	50	610	640	4	57	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 6	1997	386	6620					44	51		10.1038/386044a0	http://dx.doi.org/10.1038/386044a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WL746	9052779				2022-12-01	WOS:A1997WL74600044
J	Finn, JT; Solessio, EC; Yau, KW				Finn, JT; Solessio, EC; Yau, KW			A cGMP-gated cation channel in depolarizing photoreceptors of the lizard parietal eye	NATURE			English	Article							SALAMANDER RETINAL RODS; GMP-ACTIVATED CHANNEL; CYCLIC-GMP; INVERTEBRATE PHOTORECEPTORS; DIVALENT-CATIONS; ION CHANNELS; PINEAL-GLAND; K+ CHANNELS; PERMEATION; CA2+	Rods and cones of the two vertebrate lateral eyes hyperpolarize when illuminated, a response generated by a cyclic GMP cascade leading to cGMP hydrolysis and consequently the closure of cGMP-gated, non-selective cation channels that are open in darkness(1-4). Lizards and other lower vertebrates also have a parietal (third) eye(5), which contains ciliary photoreceptors that under dark-adapted conditions depolarize to light instead(6). Depolarizing Light responses are characteristic of most invertebrate rhabdomeric photoreceptors, and are thought to involve a phosphoinositide signalling pathway (see, for example, refs 7-9). Surprisingly, we have found in excised membrane patches a cGMP-gated channel that is selectively present at high density on the outer segment (the presumptive light-sensitive part) of the parietal eye photoreceptor. Like the light-activated channel of the cell, it is non-selective among cations. Inositol trisphosphate (InsP(3)) had no effect on the same membrane patches. These findings suggest that the photoreceptors of the parietal eye, like rods and cones, use a cGMP cascade and not an InsP(3)-mediated pathway for phototransduction, but in this case light increases cGMP. A unifying principle of evolutionary significance emerges: that phototransductions in various ciliary photoreceptors, whether hyperpolarizing or depolarizing, uniformly use a cGMP cascade and a cGMP-gated channel to generate the Light response, although there are rich variations in the details.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,THOMAS C JENKINS DEPT BIOPHYS,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT OPHTHALMOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,BALTIMORE,MD 21205; UNIV UTAH,HLTH SCI CTR,JOHN A MORAN EYE CTR,SALT LAKE CITY,UT 84132	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; Utah System of Higher Education; University of Utah								AUTRUM H, 1979, HDB SENSORY PHYSL, V7; Bonigk W, 1996, J NEUROSCI, V16, P7458; BUTLER JN, 1968, BIOPHYS J, V8, P1426, DOI 10.1016/S0006-3495(68)86564-6; COLAMARTINO G, 1991, J PHYSIOL-LONDON, V440, P189, DOI 10.1113/jphysiol.1991.sp018703; DEGUCHI T, 1981, NATURE, V290, P706, DOI 10.1038/290706a0; DRYER SE, 1991, NATURE, V353, P756, DOI 10.1038/353756a0; EAKIN RM, 1973, 3 EYE; Finn JT, 1996, ANNU REV PHYSIOL, V58, P395, DOI 10.1146/annurev.ph.58.030196.002143; FRINGS S, 1995, NEURON, V15, P169, DOI 10.1016/0896-6273(95)90074-8; GOMEZ M, IN PRESS J PHYSL LON; GOMEZ MD, 1995, NEURON, V15, P607, DOI 10.1016/0896-6273(95)90149-3; GOTOW T, 1994, BRAIN RES, V662, P268, DOI 10.1016/0006-8993(94)90824-9; HARDIE RC, 1995, CELL CALCIUM, V18, P256, DOI 10.1016/0143-4160(95)90023-3; HAYNES LW, 1990, J PHYSIOL-LONDON, V429, P451, DOI 10.1113/jphysiol.1990.sp018267; HAYNES LW, 1995, J GEN PHYSIOL, V106, P507, DOI 10.1085/jgp.106.3.507; Hille B., 1992, IONIC CHANNELS EXCIT; KARPEN JW, 1992, J PHYSIOL-LONDON, V448, P257, DOI 10.1113/jphysiol.1992.sp019040; Koutalos Y, 1996, TRENDS NEUROSCI, V19, P73; LAGNADO L, 1992, NEURON, V8, P995, DOI 10.1016/0896-6273(92)90122-T; LEWIS CA, 1979, J PHYSIOL-LONDON, V286, P417, DOI 10.1113/jphysiol.1979.sp012629; MARCHIAFAVA PL, 1993, PROG BRAIN RES, V95, P3, DOI 10.1016/S0079-6123(08)60352-0; NEHER E, 1995, SINGLE CHANNEL RECOR, P637; PICONES A, 1995, BIOPHYS J, V69, P120, DOI 10.1016/S0006-3495(95)79881-2; PU GA, 1981, J NEUROPHYSIOL, V46, P1018, DOI 10.1152/jn.1981.46.5.1018; PUGH EN, 1993, BIOCHIM BIOPHYS ACTA, V1141, P111, DOI 10.1016/0005-2728(93)90038-H; RANGANATHAN R, 1995, ANNU REV NEUROSCI, V18, P283; Robinson R., 1959, ELECTROLYTE SOLUTION, DOI DOI 10.1073?PNAS.0305836101; SHIN JH, 1993, NEURON, V11, P845, DOI 10.1016/0896-6273(93)90114-7; SOLESSIO E, 1993, NATURE, V364, P442, DOI 10.1038/364442a0; TAMOTSU S, 1986, J COMP PHYSIOL A, V159, P1, DOI 10.1007/BF00612489; YARFITZ S, 1994, J BIOL CHEM, V269, P14329	31	35	36	1	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 27	1997	385	6619					815	819		10.1038/385815a0	http://dx.doi.org/10.1038/385815a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WK570	9039913				2022-12-01	WOS:A1997WK57000053
J	Bruning, JC; Winnay, J; BonnerWeir, S; Taylor, SI; Accili, D; Kahn, CR				Bruning, JC; Winnay, J; BonnerWeir, S; Taylor, SI; Accili, D; Kahn, CR			Development of a novel polygenic model of NIDDM in mice heterozygous for IR and IRS-1 null alleles	CELL			English	Article							INSULIN-RECEPTOR SUBSTRATE-1; DEPENDENT DIABETES-MELLITUS; BETA-CELL MASS; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; SKELETAL-MUSCLE; KINASE-ACTIVITY; OBESE SUBJECTS; RESISTANCE; GENE	NIDDM is a polygenic disease characterized by insulin resistance in muscle, fat, and liver, followed by a failure of pancreatic beta cells to adequately compensate for this resistance despite increased insulin secretion. Mice double heterozygous for null alleles in the insulin receptor and insulin receptor substrate-1 genes exhibit the expected similar to 50% reduction in expression of these two proteins, but a synergism at a level of insulin resistance with 5- to 50-fold elevated plasma insulin levels and comparable levels of beta cell hyperplasia. At 4-6 months of age, 40% of these double heterozygotes become overtly diabetic. This NIDDM mouse model in which diabetes arises in an age-dependent manner from the interaction between two genetically determined, subclinical defects in the insulin signaling cascade demonstrates the role of epistatic interactions in the pathogenesis of common diseases with non-Mendelian genetics.	HARVARD UNIV,SCH MED,DIV RES,JOSLIN DIABET CTR,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02215; NIDDK,DIABET BRANCH,NATL INST HLTH,BETHESDA,MD 20892; NICHHD,DEV ENDOCRINOL BRANCH,NATL INST HLTH,BETHESDA,MD 20892	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)			Kahn, Ronald/AAY-2435-2021	Kahn, Ronald/0000-0002-7583-9228	NIDDK NIH HHS [DK 31036, DK 33201, DK 44523] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK031036, R01DK031036, R01DK033201, R01DK044523] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Accili D, 1996, NAT GENET, V12, P106, DOI 10.1038/ng0196-106; Almind K, 1996, J CLIN INVEST, V97, P2569, DOI 10.1172/JCI118705; ALMIND K, 1993, LANCET, V342, P828, DOI 10.1016/0140-6736(93)92694-O; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BAR RS, 1976, J CLIN INVEST, V58, P1123, DOI 10.1172/JCI108565; BISBIS S, 1993, AM J PHYSIOL, V265, pE807, DOI 10.1152/ajpendo.1993.265.5.E807; BONNERWEIR S, 1994, RECENT PROG HORM RES, V49, P91; BONNERWEIR S, 1989, DIABETES, V38, P49, DOI 10.2337/diabetes.38.1.49; CARO JF, 1987, J CLIN INVEST, V79, P1330, DOI 10.1172/JCI112958; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Chua SC, 1996, SCIENCE, V271, P994, DOI 10.1126/science.271.5251.994; CLAUSEN JO, 1995, LANCET, V346, P397, DOI 10.1016/S0140-6736(95)92779-4; FLIER JS, 1992, DIABETES, V41, P1207, DOI 10.2337/diabetes.41.9.1207; FROGUEL P, 1992, NATURE, V356, P162, DOI 10.1038/356162a0; GOODYEAR LJ, 1995, J CLIN INVEST, V95, P2195, DOI 10.1172/JCI117909; Joshi RL, 1996, EMBO J, V15, P1542, DOI 10.1002/j.1460-2075.1996.tb00498.x; KAHN CR, 1973, J BIOL CHEM, V248, P244; KAHN CR, 1994, DIABETES, V43, P1066, DOI 10.2337/diab.43.8.1066; KOLTERMAN OG, 1981, J CLIN INVEST, V68, P957, DOI 10.1172/JCI110350; LAAKSO M, 1994, J CLIN INVEST, V94, P1141, DOI 10.1172/JCI117429; LILLIOJA S, 1993, NEW ENGL J MED, V329, P1988, DOI 10.1056/NEJM199312303292703; MARTIN BC, 1992, LANCET, V340, P925, DOI 10.1016/0140-6736(92)92814-V; MONTANA E, 1993, J CLIN INVEST, V91, P780, DOI 10.1172/JCI116297; NEWMAN B, 1987, DIABETOLOGIA, V30, P763; OLEFSKY JM, 1982, AM J PHYSIOL, V243, pE15, DOI 10.1152/ajpendo.1982.243.1.E15; PARSONS JA, 1992, ENDOCRINOLOGY, V130, P1459, DOI 10.1210/en.130.3.1459; PATTI ME, 1995, J BIOL CHEM, V270, P24670, DOI 10.1074/jbc.270.42.24670; PIPELEERS DG, 1992, DIABETES, V41, P777, DOI 10.2337/diabetes.41.7.777; PRINCE MJ, 1981, DIABETES, V30, P596, DOI 10.2337/diabetes.30.7.596; RICH SS, 1990, DIABETES, V39, P1315, DOI 10.2337/diabetes.39.11.1315; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; SAAD MJA, 1992, J CLIN INVEST, V90, P1839, DOI 10.1172/JCI116060; SAAD MJA, 1993, J CLIN INVEST, V92, P2065, DOI 10.1172/JCI116803; SINHA MK, 1987, DIABETES, V36, P620, DOI 10.2337/diabetes.36.5.620; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TAYLOR SI, 1992, DIABETES, V41, P1473, DOI 10.2337/diabetes.41.11.1473; Ura S, 1996, DIABETOLOGIA, V39, P600; VAXILLAIRE M, 1995, NAT GENET, V9, P418, DOI 10.1038/ng0495-418; WARRAM JH, 1995, JOSLINS DIABETES MEL, P201; WATERS SB, 1993, J BIOL CHEM, V268, P22231; WERTHEIMER E, 1993, NAT GENET, V5, P71, DOI 10.1038/ng0993-71; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0; Yamagata K, 1996, NATURE, V384, P455, DOI 10.1038/384455a0; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	52	428	443	1	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 21	1997	88	4					561	572		10.1016/S0092-8674(00)81896-6	http://dx.doi.org/10.1016/S0092-8674(00)81896-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WJ691	9038347	Bronze			2022-12-01	WOS:A1997WJ69100016
J	Jonkman, MF; Scheffer, H; Stulp, R; Pas, HH; Nijenhuis, M; Heeres, K; Owaribe, K; Pulkkinen, L; Uitto, J				Jonkman, MF; Scheffer, H; Stulp, R; Pas, HH; Nijenhuis, M; Heeres, K; Owaribe, K; Pulkkinen, L; Uitto, J			Revertant mosaicism in epidermolysis bullosa caused by mitotic gene conversion	CELL			English	Article							SOMATIC REVERSION SUPPRESSION; PEMPHIGOID ANTIGEN; MECHANISMS; COLLAGEN; EXPRESSION; PHENOTYPE; MUTATIONS; BP180; CELLS	Mitotic gene conversion acting as reverse mutation has not been previously demonstrated in human. We report here that the revertant mosaicism of a compound heterozygous proband with an autosomal recessive genodermatosis, generalized atrophic benign epidermolysis bullosa, is caused by mitotic gene conversion of one of the two mutated COL17A1 alleles. Specifically, the maternal allele surrounding the mutation site on COL17A1 (1706delA) showed reversion of the mutation and loss of heterozygosity along a tract of at least 381 bp in revertant keratinocytes derived from clinically unaffected skin patches; the paternal mutation (R1226X) remained present in all cell samples. Revertant mosaicism represents a way of natural gene therapy.	UNIV GRONINGEN,DEPT MED GENET,NL-9713 AW GRONINGEN,NETHERLANDS; NAGOYA UNIV,SCH MED,DEPT BIOL MOL,NAGOYA,AICHI 46401,JAPAN; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT DERMATOL & CUTANEOUS BIOL,PHILADELPHIA,PA 19107	University of Groningen; Nagoya University; Jefferson University	Jonkman, MF (corresponding author), UNIV GRONINGEN HOSP,DEPT DERMATOL,NL-9700 RB GRONINGEN,NETHERLANDS.		Pas, Hendri H/G-9749-2011; Scheffer, Hans/E-4644-2012; Jonkman, Marcel F./H-4647-2011	Pas, Hendri H/0000-0001-8823-2591; Scheffer, Hans/0000-0002-2986-0915; 	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR038923] Funding Source: NIH RePORTER; NIAMS NIH HHS [P01-AR38923] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHRISTIANO AM, 1994, GENOMICS, V21, P160, DOI 10.1006/geno.1994.1238; FINE JD, 1991, J AM ACAD DERMATOL, V24, P119, DOI 10.1016/0190-9622(91)70021-S; Gangloff S, 1996, EMBO J, V15, P1715, DOI 10.1002/j.1460-2075.1996.tb00517.x; GANGULY A, 1993, P NATL ACAD SCI USA, V90, P10325, DOI 10.1073/pnas.90.21.10325; Gatalica B, 1997, AM J HUM GENET, V60, P352; GIUDICE GJ, 1992, J INVEST DERMATOL, V99, P243, DOI 10.1111/1523-1747.ep12616580; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HALL JG, 1988, AM J HUM GENET, V43, P355; HAPPLE R, 1993, ARCH DERMATOL, V129, P1460, DOI 10.1001/archderm.129.11.1460; HINTNER H, 1982, ARCH DERMATOL, V118, P375, DOI 10.1001/archderm.118.6.375; Hirschhorn R, 1996, NAT GENET, V13, P290, DOI 10.1038/ng0796-290; HOFFMAN EP, 1990, J NEUROL SCI, V99, P9, DOI 10.1016/0022-510X(90)90195-S; Jonkman MF, 1996, ARCH DERMATOL, V132, P145, DOI 10.1001/archderm.132.2.145; JONKMAN MF, 1995, J CLIN INVEST, V95, P1345, DOI 10.1172/JCI117785; JONKMAN MF, 1992, J INVEST DERMATOL, V99, P489, DOI 10.1111/1523-1747.ep12616168; KLEIN CJ, 1992, AM J HUM GENET, V50, P950; KOURILSKY P, 1986, TRENDS GENET, V2, P60, DOI 10.1016/0168-9525(86)90179-4; KVITTINGEN EA, 1994, J CLIN INVEST, V94, P1657, DOI 10.1172/JCI117509; LI K, 1991, J BIOL CHEM, V266, P24064; LI KH, 1993, J BIOL CHEM, V268, P8825; McGrath JA, 1996, J INVEST DERMATOL, V106, P771, DOI 10.1111/1523-1747.ep12345821; MCGRATH JA, 1995, NAT GENET, V11, P83, DOI 10.1038/ng0995-83; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MITRA R, 1994, KERATINOCYTE METHODS, P17; NISHIZAWA Y, 1993, J BIOCHEM-TOKYO, V113, P493, DOI 10.1093/oxfordjournals.jbchem.a124072; OWARIBE K, 1991, EXP CELL RES, V192, P622, DOI 10.1016/0014-4827(91)90084-8; PALLER AS, 1994, NEW ENGL J MED, V331, P1408, DOI 10.1056/NEJM199411243312103; Pas H H, 1995, Exp Dermatol, V4, P372, DOI 10.1111/j.1600-0625.1995.tb00062.x; Pohla-Gubo G, 1995, Exp Dermatol, V4, P199, DOI 10.1111/j.1600-0625.1995.tb00245.x; SHERRAT TG, 1993, AM J HUM GENET, V53, P1007; SMITHIES O, 1986, PHILOS T ROY SOC B, V312, P291, DOI 10.1098/rstb.1986.0008; UNRAU P, 1995, J THEOR BIOL, V177, P73, DOI 10.1006/jtbi.1995.0226; URLAUB G, 1989, MOL CELL BIOL, V9, P2868, DOI 10.1128/MCB.9.7.2868; VANLEEUWEN F, 1989, P NATL ACAD SCI USA, V86, P6417, DOI 10.1073/pnas.86.16.6417	35	196	200	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 21	1997	88	4					543	551		10.1016/S0092-8674(00)81894-2	http://dx.doi.org/10.1016/S0092-8674(00)81894-2			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WJ691	9038345	Bronze			2022-12-01	WOS:A1997WJ69100014
J	vanSteensel, B; deLange, T				vanSteensel, B; deLange, T			Control of telomere length by the human telomeric protein TRF1	NATURE			English	Article							IMMORTAL CELLS; YEAST; GENE; VARIABILITY; ELONGATION; CARCINOMA	Human telomeres, the nucleoprotein complexes at chromosome ends, consist of tandem arrays of TTAGGG repeats bound to specific proteins. In normal human cells, telomeres shorten with successive cell divisions(1,2), probably due to the terminal sequence loss that accompanies DNA replication. In tumours and immortalized cells, this decline is halted through the activation of telomerase(3-5), a reverse transcriptase that extends the telomeric TTAGGG-repeat arrays(6-7). Telomere length is stable in several immortal human-tell lines(3), suggesting that a regulatory mechanism exists for limiting telomere elongation by telomerase. Here we show that the human telomeric-repeat binding factor TRF1 (ref. 8) is involved in this regulation, Long-term overexpression of TRF1 in the telomerase-positive tumour-cell Line HT1080 resulted in a gradual and progressive telomere shortening, Conversely, telomere elongation was induced by expression of a dominant-negative TRF1 mutant that inhibited binding of endogenous TRF1 to telomeres. Our results identify TRF1 as a suppressor of telomere elongation and indicate that TRF1 is involved in the negative feedback mechanism that stabilizes telomere length. As TRF1 does not detectably affect the expression of telomerase, we propose that the binding of TRF1 controls telomere length in cis by inhibiting the action of telomerase at the ends of individual telomeres.	ROCKEFELLER UNIV,NEW YORK,NY 10021	Rockefeller University			de Lange, Titia/B-8263-2011	de Lange, Titia/0000-0002-9267-367X				BARNETT MA, 1993, NUCLEIC ACIDS RES, V21, P27, DOI 10.1093/nar/21.1.27; BIANCHI A, IN PRESS EMBO J; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; Broccoli D, 1997, HUM MOL GENET, V6, P69, DOI 10.1093/hmg/6.1.69; BRYAN TM, IN PRESS EUR J CANC; CARSON MJ, 1985, CELL, V42, P249, DOI 10.1016/S0092-8674(85)80120-3; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; CONRAD MN, 1990, CELL, V63, P739, DOI 10.1016/0092-8674(90)90140-A; COOKE HJ, 1986, COLD SPRING HARB SYM, V51, P213, DOI 10.1101/SQB.1986.051.01.026; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HANISH JP, 1994, P NATL ACAD SCI USA, V91, P8861, DOI 10.1073/pnas.91.19.8861; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; INSTIG AJ, 1990, SCIENCE, V250, P549; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KIPLING D, 1990, NATURE, V347, P347; Krauskopf A, 1996, NATURE, V383, P354, DOI 10.1038/383354a0; Luderus ME, 1996, J CELL BIOL, V135, P867, DOI 10.1083/jcb.135.4.867; LUSTIG AJ, 1986, P NATL ACAD SCI USA, V83, P1398, DOI 10.1073/pnas.83.5.1398; MARCAND S, IN PRESS SCIENCE; MCEACHERN MJ, 1995, NATURE, V376, P403, DOI 10.1038/376403a0; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; SHAMPAY J, 1988, P NATL ACAD SCI USA, V85, P534, DOI 10.1073/pnas.85.2.534; Smith S, 1997, TRENDS GENET, V13, P21, DOI 10.1016/S0168-9525(96)10052-4; ZHONG Z, 1992, MOL CELL BIOL, V12, P4834, DOI 10.1128/MCB.12.11.4834	29	1004	1040	0	58	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 20	1997	385	6618					740	743		10.1038/385740a0	http://dx.doi.org/10.1038/385740a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WJ423	9034193				2022-12-01	WOS:A1997WJ42300051
J	Payne, N; Saul, C				Payne, N; Saul, C			Variations in use of cardiology services in a health authority: Comparison of coronary artery revascularisation rates with prevalence of angina and coronary mortality	BRITISH MEDICAL JOURNAL			English	Article							BYPASS-SURGERY; CARE; QUESTIONNAIRE; DEPRIVATION; MORBIDITY; SYMPTOMS; EQUITY; ACCESS; CASS	Objective: To explore the relation between rates of coronary artery revascularisation and prevalence of angina to assess whether use of health services reflects need. Design: Prevalence of angina symptoms determined by postal questionnaire on 16 750 subjects (18 to 94 years), Comparison of data on use of coronary artery revascularisation with prevalence of symptoms and mortality from coronary heart disease. Setting: Health authority with population of 530 000. Subjects: Patients admitted to hospital for coronary heart disease; patients who died; and patients undergoing angiography, angioplasty, or coronary artery bypass graft Cohort of 491 people with symptoms from survey. Main outcome measures: Pearson's product moment correlation coefficients for relation between variables. Results: Overall, 4.0% (95% confidence interval 3.7% to 4.4%) of subjects had symptoms, Prevalences varied widely between electoral wards and were positively associated with Townsend score (r = 0.79; P < 0.001), as was mortality, but the correlation between admission rates and Townsend score was less clear (r = 0.47; P < 0.01), Revascularisation rate and Townsend score were not associated. The ratio of revascularisation to number experiencing symptoms was inversely related to Townsend score (r = -0.67; P < 0.001), The most deprived wards had only about half the number of revascularisations per head of population with angina than did the more affluent wards, In affluent wards 11% (13/116) of those with symptoms had coronary angiograms compared with only 4% (9/216) in poorer wards (chi(2) = 4.96; P = 0.026). Townsend score also inversely correlated with revascularisations per public health premature death from coronary heart disease Carol Saul, (r = -0.55; P < 0.01) and revascularisations per admission for myocardial infarction (r = -0.47; P < 0.01). Conclusion: The use of interventional cardiology services is not commensurate with need, thus exhibiting the inverse care law.			Payne, N (corresponding author), SHEFFIELD HLTH,SHEFFIELD S10 3TG,S YORKSHIRE,ENGLAND.		Payne, Nick/A-3073-2010					*AUD COMM, 1995, DEAR OUR HEARTS COMM; BENSHLOMO Y, 1995, J EPIDEMIOL COMMUN H, V49, P200, DOI 10.1136/jech.49.2.200; CAMERON AAC, 1995, J AM COLL CARDIOL, V26, P895, DOI 10.1016/0735-1097(95)00280-4; CAVENDER JB, 1992, J AM COLL CARDIOL, V20, P287, DOI 10.1016/0735-1097(92)90092-2; *CENTR HLTH MON UN, 1994, COR HEART DIS EP OV; *CLIN STAND ADV GR, 1993, COR ART BYP GRAFT CO; COLHOUN H, 1996, HLTH SURVEY ENGLAND; DEAN AG, EPIINFO VERSION 5 WO; ELDER AT, 1991, BRIT MED J, V303, P950, DOI 10.1136/bmj.303.6808.950; GARBER CE, 1992, J CLIN EPIDEMIOL, V45, P715, DOI 10.1016/0895-4356(92)90048-R; HARRIS RB, 1991, J CLIN EPIDEMIOL, V44, P1071, DOI 10.1016/0895-4356(91)90009-X; HART JT, 1971, LANCET, V1, P405, DOI 10.1016/S0140-6736(71)92410-X; KEE F, 1993, BRIT MED J, V307, P1305, DOI 10.1136/bmj.307.6915.1305; MAJEED FA, 1994, BMJ-BRIT MED J, V308, P1426, DOI 10.1136/bmj.308.6941.1426; MCCORMICK A, 1995, MORBIDITY STAT GEN P; McKee M, 1993, Qual Health Care, V2, P104, DOI 10.1136/qshc.2.2.104; *OFF POP CENS SURV, 1984, GEN HOUS SURV 1982; Office of Population Censuses and Surveys, 1990, TAB LIST CLASS SURG; PAYNE JN, 1993, J PUBLIC HEALTH MED, V15, P161; ROBERTS H, 1994, TRENT HLTH LIFESTYLE; ROSE G, 1977, BRIT J PREV SOC MED, V31, P42; THOMAS M, 1994, OPCS SERIES GHS, V23; TOWNSEND P, 1987, J SOC POLICY, V16, P125, DOI 10.1017/S0047279400020341; UNDERWOOD MJ, 1993, BMJ-BRIT MED J, V306, P1047, DOI 10.1136/bmj.306.6884.1047; *VAR SUBGR CHIEF M, 1995, VAR HLTH WHAT CAN DE; Voors AA, 1996, CIRCULATION, V93, P42, DOI 10.1161/01.CIR.93.1.42; WENNBERG D, 1995, C ABSTRACTS SCI BASI; *WORK GROUP BRIT C, 1994, BRIT HEART J, V72, P303	28	85	87	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 25	1997	314	7076					257	261		10.1136/bmj.314.7076.257	http://dx.doi.org/10.1136/bmj.314.7076.257			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WE633	9022488	Green Published			2022-12-01	WOS:A1997WE63300023
J	LaMontagne, JR				LaMontagne, JR			RSV pneumonia, a community-acquired infection in adults	LANCET			English	Editorial Material							RESPIRATORY SYNCYTIAL VIRUS; YOUNG-CHILDREN; INFANTS; RISK				LaMontagne, JR (corresponding author), NIAID,DIV MICROBIOL & INFECT DIS,ROCKVILLE,MD 20892, USA.							COLLINS PL, 1995, FIELDS VIROLOGY, V1, P1313; Dowell SF, 1996, J INFECT DIS, V174, P456, DOI 10.1093/infdis/174.3.456; FALSEY AR, 1995, J INFECT DIS, V172, P389, DOI 10.1093/infdis/172.2.389; GLEZEN WP, 1986, AM J DIS CHILD, V140, P543, DOI 10.1001/archpedi.1986.02140200053026; GROOTHUIS JR, 1993, NEW ENGL J MED, V329, P1524, DOI 10.1056/NEJM199311183292102; HALL CB, 1983, NEW ENGL J MED, V308, P1443, DOI 10.1056/NEJM198306163082403; HEMMING VG, 1987, ANTIMICROB AGENTS CH, V31, P1882, DOI 10.1128/AAC.31.12.1882	7	12	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 18	1997	349	9046					149	150		10.1016/S0140-6736(05)60974-9	http://dx.doi.org/10.1016/S0140-6736(05)60974-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC861	9111535				2022-12-01	WOS:A1997WC86100005
J	Kennedy, S				Kennedy, S			Primary dysmenorrhoea	LANCET			English	Editorial Material							YOUNG-WOMEN				Kennedy, S (corresponding author), JOHN RADCLIFFE HOSP,NUFFIELD DEPT OBSTET & GYNAECOL,OXFORD OX3 9DU,ENGLAND.		Kennedy, Stephen/B-8950-2009					ANDERSCH B, 1982, AM J OBSTET GYNECOL, V144, P655, DOI 10.1016/0002-9378(82)90433-1; Hadfield R, 1996, HUM REPROD, V11, P878; Harlow SD, 1996, BRIT J OBSTET GYNAEC, V103, P1134, DOI 10.1111/j.1471-0528.1996.tb09597.x; JAMIESON DJ, 1996, OBSTET GYNECOL, V1, P55; KLEIN JR, 1981, PEDIATRICS, V68, P661; SUNDELL G, 1990, BRIT J OBSTET GYNAEC, V97, P588, DOI 10.1111/j.1471-0528.1990.tb02545.x; SVANBERG L, 1981, ARCH GYNECOL, V230, P173, DOI 10.1007/BF02111800	7	47	52	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 19	1997	349	9059					1116	1116		10.1016/S0140-6736(05)63018-8	http://dx.doi.org/10.1016/S0140-6736(05)63018-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU544	9113008				2022-12-01	WOS:A1997WU54400006
J	Achatz, G; Nitschke, L; Lamers, MC				Achatz, G; Nitschke, L; Lamers, MC			Effect of transmembrane and cytoplasmic domains of IgE on the IgE response	SCIENCE			English	Article							CELL ANTIGEN RECEPTOR; GERMINAL-CENTERS; STEM-CELLS; RECOMBINATION; DISRUPTION	B cells use immunoglobulin M (IgM) and IgD as antigen receptors, but after contact with antigen they can switch and use IgG, IgA, or IgE. In mice lacking the transmembrane and cytoplasmic domains of IgE, serum IgE is reduced by more than 95 percent and, after immunization, specific responses are negligible. In mice lacking most of the cytoplasmic tail of IgE, serum IgE levels are reduced by 50 percent and specific responses are reduced by 40 to 80 percent, without a clear secondary response. Thus, membrane expression is indispensable for IgE secretion in vivo, and the cytoplasmic tail influences the degree and quality of the response.	MAX PLANCK INST IMMUNBIOL, D-79108 FREIBURG, GERMANY	Max Planck Society			Achatz, Gernot/E-5073-2011					Ahmed R, 1996, SCIENCE, V272, P54, DOI 10.1126/science.272.5258.54; BEREK C, 1991, CELL, V67, P1121, DOI 10.1016/0092-8674(91)90289-B; COFFMAN RL, 1986, J IMMUNOL, V136, P4538; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; JACOB J, 1991, NATURE, V354, P389, DOI 10.1038/354389a0; Kaisho T, 1997, SCIENCE, V276, P412, DOI 10.1126/science.276.5311.412; KELSOE G, 1995, IMMUNOL TODAY, V16, P324, DOI 10.1016/0167-5699(95)80146-4; KOHLER G, 1996, TRANSGENIC RES, V5, P487; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; KUPPERS R, 1993, EMBO J, V12, P4955, DOI 10.1002/j.1460-2075.1993.tb06189.x; Lamers MC, 1995, IMMUNOL REV, V148, P71, DOI 10.1111/j.1600-065X.1995.tb00094.x; LEBRUN P, 1987, J IMMUNOL, V139, P1459; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; NITSCHKE L, 1993, BIOTECHNIQUES, V14, P914; NITSCHKE L, 1997, IMMUNOLOGY METHODS M, P218; PATEL KJ, 1993, CELL, V74, P939, DOI 10.1016/0092-8674(93)90473-4; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.immunol.10.1.97; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SAUER B, 1993, METHOD ENZYMOL, V225, P890; SEDGWICK JD, 1983, J EXP MED, V157, P2178, DOI 10.1084/jem.157.6.2178; STREET NE, 1990, J IMMUNOL, V144, P1629; SUTTON BJ, 1993, NATURE, V366, P421, DOI 10.1038/366421a0; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; VENKITARAMAN AR, 1991, NATURE, V352, P777, DOI 10.1038/352777a0; Weiser P, 1997, SCIENCE, V276, P407, DOI 10.1126/science.276.5311.407; YU P, 1994, NATURE, V369, P753, DOI 10.1038/369753a0	26	102	103	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 18	1997	276	5311					409	411		10.1126/science.276.5311.409	http://dx.doi.org/10.1126/science.276.5311.409			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WU477	9103198				2022-12-01	WOS:A1997WU47700038
J	Gebo, DL; MacLatchy, L; Kityo, R; Deino, A; Kingston, J; Pilbeam, D				Gebo, DL; MacLatchy, L; Kityo, R; Deino, A; Kingston, J; Pilbeam, D			A hominoid genus from the early Miocene of Uganda	SCIENCE			English	Article							PROCONSUL-NYANZAE; BODY-WEIGHT; KENYA; MORPHOLOGY; ALLOMETRY; VARIABLES; PRIMATES; MACACA; ISLAND; TIBIA	Fossils from a large-bodied hominoid from early Miocene sediments of Uganda, along with material recovered in the 1960s, show features of the shoulder and vertebral column that are significantly similar to those of living apes and humans. The large-bodied hominoid from Uganda dates to at least 20.6 million years ago and thus represents the oldest known hominoid sharing these derived characters with living apes and humans.	SUNY STONY BROOK, DEPT ANAT SCI, STONY BROOK, NY 11794 USA; MAKERERE UNIV, DEPT ZOOL, KAMPALA, UGANDA; BERKELEY GEOCHRONOL CTR, BERKELEY, CA 94709 USA; YALE UNIV, DEPT GEOL & GEOPHYS, NEW HAVEN, CT 06520 USA; HARVARD UNIV, DEPT ANTHROPOL, CAMBRIDGE, MA 02138 USA	State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook; Makerere University; Berkeley Geochronolgy Center; Yale University; Harvard University	Gebo, DL (corresponding author), NO ILLINOIS UNIV, DEPT ANTHROPOL, DE KALB, IL 60115 USA.		Klein, Richard G/B-5910-2009					AIELLO LC, 1994, AM J PHYS ANTHROPOL, V95, P409, DOI 10.1002/ajpa.1330950405; ALLBROOK D, 1963, NATURE, V197, P1187, DOI 10.1038/1971187a0; ANDREWS P, 1991, PHILOS T R SOC B, V334, P199, DOI 10.1098/rstb.1991.0109; ANDREWS P, 1992, NATURE, V360, P641, DOI 10.1038/360641a0; Andrews P.J., 1978, Bulletin of the British Museum (Natural History) Geology, V30, P85; AZZAROLI A, 1986, J HUM EVOL, V15, P533, DOI 10.1016/S0047-2484(86)80072-0; BEARD KC, 1986, FOLIA PRIMATOL, V47, P97; BENEFIT BR, 1995, ANNU REV ANTHROPOL, V24, P237; BISHOP WW, 1969, AM J SCI, V267, P669, DOI 10.2475/ajs.267.6.669; Cebula G. T., 1986, TERRA COGNITA, V6, P139; CONROY GC, 1987, INT J PRIMATOL, V8, P115, DOI 10.1007/BF02735160; CONROY GC, 1994, J HUM EVOL, V27, P373, DOI 10.1006/jhev.1994.1051; CORRUCCINI R S, 1978, Primates, V19, P35, DOI 10.1007/BF02373225; DAGOSTO M, 1992, INT J PRIMATOL, V13, P307, DOI 10.1007/BF02547818; DEAN D, 1992, NATURE, V359, P676, DOI 10.1038/359676a0; ELLIOT DG, 1912, REV PRIMATES, V3, P225; FILLER AG, 1981, AM J PHYS ANTHROPOL, V54, P218; GINGERICH PD, 1977, AM J PHYS ANTHROPOL, V47, P395, DOI 10.1002/ajpa.1330470308; Groves CP, 1972, GIBBON SIAMANG, V1, P1; HARRISON T, 1996, NATURE, V379, P541; Leakey L.S.B., 1962, ANN MAG NAT HIST, V13, P689, DOI DOI 10.1080/00222936108651194; LEAKEY RE, 1988, AM J PHYS ANTHROPOL, V76, P289, DOI 10.1002/ajpa.1330760303; MacLatchy LM, 1996, J HUM EVOL, V31, P425, DOI 10.1006/jhev.1996.0070; MCHENRY HM, 1980, FOLIA PRIMATOL, V33, P241, DOI 10.1159/000155939; MoyaSola S, 1996, NATURE, V379, P156, DOI 10.1038/379156a0; PICKFORD M, 1981, J HUM EVOL, V10, P73, DOI 10.1016/S0047-2484(81)80026-7; PICKFORD M, 1986, C R ACAD SCI PARIS 2, V9, P681; PILBEAM D, 1986, AM ANTHROPOL, V88, P295, DOI 10.1525/aa.1986.88.2.02a00010; Pilbeam D, 1996, MOL PHYLOGENET EVOL, V5, P155, DOI 10.1006/mpev.1996.0010; Pilbeam D. R., 1969, Bulletin of the Peabody Museum of Natural History, V31, P1; RAFFERTY KL, 1995, AM J PHYS ANTHROPOL, V97, P391, DOI 10.1002/ajpa.1330970406; Roberts D., 1974, P171; Rose M.D., 1983, P405; ROSE MD, 1992, J HUM EVOL, V22, P171, DOI 10.1016/S0047-2484(05)80006-5; Rose Michael D., 1993, P252; RUFF C, 1988, J HUM EVOL, V17, P687, DOI 10.1016/0047-2484(88)90025-5; RUFF C, 1987, FOLIA PRIMATOL, V48, P9, DOI 10.1159/000156283; RUFF CB, 1992, ANNU REV ANTHROPOL, V21, P407; RUFF CB, 1993, AM J PHYS ANTHROPOL, V91, P21, DOI 10.1002/ajpa.1330910103; RUNESTAD JA, 1994, THESIS J HOPKINS U B; SAMSON SD, 1987, CHEM GEOL, V66, P27, DOI 10.1016/0168-9622(87)90025-X; SANDERS WJ, 1994, J HUM EVOL, V26, P203, DOI 10.1006/jhev.1994.1012; SARMIENTO EE, 1987, AM MUS NOVIT, P1; Tyler DE, 1993, EVOLVING LANDSCAPES, P228; WALKER A, 1968, NATURE, V217, P980, DOI 10.1038/217980a0; Walker A.C., 1983, P325; WARD CV, 1993, AM J PHYS ANTHROPOL, V90, P77, DOI 10.1002/ajpa.1330900106; WARD CV, 1993, AM J PHYS ANTHROPOL, V92, P291, DOI 10.1002/ajpa.1330920306; WARD CV, 1991, J HUM EVOL, V21, P215, DOI 10.1016/0047-2484(91)90062-Z; WARD SC, 1983, AM J PHYS ANTHROPOL, V61, P157, DOI 10.1002/ajpa.1330610204; WARD SC, COMMUNICATION	51	115	120	1	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 18	1997	276	5311					401	404		10.1126/science.276.5311.401	http://dx.doi.org/10.1126/science.276.5311.401			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	WU477	9103195				2022-12-01	WOS:A1997WU47700035
J	Soderlund, M; vonEssen, R; Haapasaari, J; Kiistala, U; Kiviluoto, O; Hedman, K				Soderlund, M; vonEssen, R; Haapasaari, J; Kiistala, U; Kiviluoto, O; Hedman, K			Persistence of parvoviris B19 DNA in synovial membranes of young patients with and without chronic arthropathy	LANCET			English	Article							RHEUMATOID-ARTHRITIS; PROTEINS VP1; BONE-MARROW; INFECTION; VIRUS; FLUID	Background Human parvovirus B19 replicates in erythroid precursors of the bone marrow, and several diseases have been attributed to this virus including some cases of juvenile chronic arthropathy. Methods Tissue samples from children with juvenile arthritis and from healthy young adults with recent joint trauma were examined for B19 DNA by PCR. We also studied the timing of the parvovirus infection serologically. Findings All samples of synovial fluid, bone marrow, and blood were negative for B19 DNA. Eight (28%) of the 29 children with chronic arthritis had B19 DNA in synovial tissue. However, an even higher proportion of the non-arthropathy controls were positive for B19 DNA in synovial membranes (13 [48%] of 27). All the individuals with B19 DNA in synovial membrane had serum IgG antibodies to B19. Interpretation Genomic B19 DNA can persist in the synovial membranes not only in patients with chronic arthropathy but also in healthy immunocompetent individuals. The diagnostic criteria for parvovirus arthropathy must be reevaluated.	UNIV HELSINKI,HAARTMAN INST,DEPT VIROL,FIN-00014 HELSINKI,FINLAND; RHEUMATISM FDN HOSP,SF-18120 HEINOLA,FINLAND; CENT MIL HOSP,HELSINKI,FINLAND	University of Helsinki; Rheumatism Foundation Hospital			Söderlund-Venermo, Maria/AAX-2112-2020; Hedman, Klaus/D-5379-2009					ANDERSON MJ, 1982, J CLIN PATHOL, V35, P744, DOI 10.1136/jcp.35.7.744; BROWN CS, 1990, VIRUS RES, V15, P197, DOI 10.1016/0168-1702(90)90028-A; BROWN KE, 1993, SCIENCE, V262, P114, DOI 10.1126/science.8211117; DIJKMANS BAC, 1988, ARTHRITIS RHEUM, V31, P279, DOI 10.1002/art.1780310218; EDWARDS JCW, 1994, J ANAT, V184, P493; FOTO F, 1993, J INFECT DIS, V167, P744, DOI 10.1093/infdis/167.3.744; Franssila R, 1996, CLIN DIAGN VIROL, V6, P41, DOI 10.1016/0928-0197(96)00156-0; Hedman K., 1993, REV MED MICROBIOL, V4, P123, DOI DOI 10.1097/00013542-199307000-00001; KERR JR, 1995, BRIT J RHEUMATOL, V34, P809; KOTIN RM, 1990, P NATL ACAD SCI USA, V87, P2211, DOI 10.1073/pnas.87.6.2211; LINDE A, 1988, MONOGR ALLERGY, V23, P27; MIKI NPH, 1992, J GEN VIROL, V73, P1559, DOI 10.1099/0022-1317-73-6-1559; NAIDES SJ, 1993, RHEUM DIS CLIN N AM, V19, P457; NIKKARI S, 1995, ANN RHEUM DIS, V54, P597, DOI 10.1136/ard.54.7.597; REID DM, 1985, LANCET, V1, P422; SAAL JG, 1992, RHEUMATOL INT, V12, P147, DOI 10.1007/BF00274934; SHADE RO, 1986, J VIROL, V58, P921, DOI 10.1128/JVI.58.3.921-936.1986; Soderlund M, 1997, SCAND J INFECT DIS, V29, P129, DOI 10.3109/00365549709035872; SODERLUND M, 1995, J INFECT DIS, V171, P710, DOI 10.1093/infdis/171.3.710; SODERLUND M, 1995, J INFECT DIS, V172, P1431, DOI 10.1093/infdis/172.6.1431; TAYLOR HG, 1992, CLIN RHEUMATOL, V11, P548, DOI 10.1007/BF02283117; VONPOBLOTZKI A, 1995, J INFECT DIS, V172, P1356, DOI 10.1093/infdis/172.5.1356; WHITE DG, 1985, LANCET, V1, P419; WOOLF AD, 1995, ANN RHEUM DIS, V54, P535, DOI 10.1136/ard.54.7.535	24	198	204	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 12	1997	349	9058					1063	1065		10.1016/S0140-6736(96)09110-6	http://dx.doi.org/10.1016/S0140-6736(96)09110-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU002	9107245				2022-12-01	WOS:A1997WU00200011
J	Shupliakov, O; Low, P; Grabs, D; Gad, H; Chen, H; David, C; Takei, K; DeCamilli, P; Brodin, L				Shupliakov, O; Low, P; Grabs, D; Gad, H; Chen, H; David, C; Takei, K; DeCamilli, P; Brodin, L			Synaptic vesicle endocytosis impaired by disruption of dynamin-SH3 domain interactions	SCIENCE			English	Article							NEUROTRANSMITTER RELEASE; SH3 DOMAINS; MEMBRANE; PROTEINS; AMPHIPHYSIN; DISTINCT; SHIBIRE; BINDING; GTPASE; GAMMA	The proline-rich COOH-terminal region of dynamin binds various Src homology 3 (SH3) domain-containing proteins, but the physiological role of these interactions is unknown. In living nerve terminals, the function of the interaction with SH3 domains was examined. Amphiphysin contains an SH3 domain and is a major dynamin binding partner at the synapse. Microinjection of amphiphysin's SH3 domain or of a dynamin peptide containing the SH3 binding site inhibited synaptic vesicle endocytosis at the stage of invaginated clathrin-coated pits, which resulted in an activity-dependent distortion of the synaptic architecture and a depression of transmitter release. These findings demonstrate that SH3-mediated interactions are required for dynamin function and support an essential role of clathrin-mediated endocytosis in synaptic vesicle recycling.	YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; KAROLINSKA INST,NOBEL INST NEUROPHYSIOL,DEPT NEUROSCI,S-17177 STOCKHOLM,SWEDEN	Yale University; Howard Hughes Medical Institute; Yale University; Karolinska Institutet			Gad, Helge/J-2238-2014; Shupliakov, Oleg/R-9148-2016	Shupliakov, Oleg/0000-0001-5352-6848; Gad, Helge/0000-0001-6530-1443; Takei, Kohji/0000-0002-6555-9425	NATIONAL CANCER INSTITUTE [P01CA046128] Funding Source: NIH RePORTER; NCI NIH HHS [CA46128] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRODIN L, 1994, J NEUROPHYSIOL, V75, P592; BUCHANAN JT, 1992, BIOL CYBERN, V67, P123, DOI 10.1007/BF00201019; Chen H. M., UNPUB; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; DAVID C, 1994, FEBS LETT, V351, P73, DOI 10.1016/0014-5793(94)00826-4; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; DeCamilli P, 1996, NEURON, V16, P481, DOI 10.1016/S0896-6273(00)80068-9; Estes PS, 1996, J NEUROSCI, V16, P5443; Fesce Riccardo, 1994, Trends in Cell Biology, V4, P1, DOI 10.1016/0962-8924(94)90025-6; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; GRABS D, IN PRESS J BIOL CHEM; GUNDERSEN V, 1995, J NEUROSCI, V15, P4417; Henkel AW, 1995, J NEUROSCI, V15, P8246; HERSKOVITS JS, 1993, P NATL ACAD SCI USA, V90, P11468, DOI 10.1073/pnas.90.24.11468; HEUSER J, 1989, CELL BIOL INT REP, V13, P1063, DOI 10.1016/0309-1651(89)90020-9; KOENIG JH, 1989, J NEUROSCI, V9, P3844; LICHTE B, 1992, EMBO J, V11, P2521, DOI 10.1002/j.1460-2075.1992.tb05317.x; LINIAL M, 1994, NEUROREPORT, V5, P2009, DOI 10.1097/00001756-199410270-00005; LOW PJ, UNPUB; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; PIERIBONE VA, 1995, NATURE, V375, P493, DOI 10.1038/375493a0; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; SCAIFE R, 1994, EMBO J, V13, P2574, DOI 10.1002/j.1460-2075.1994.tb06547.x; SEEDORF K, 1994, J BIOL CHEM, V269, P16009; Shpetner HS, 1996, J BIOL CHEM, V271, P13, DOI 10.1074/jbc.271.1.13; SHUPLIAKOV O, 1995, EUR J NEUROSCI, V7, P1111, DOI 10.1111/j.1460-9568.1995.tb01099.x; SHUPLIAKOV O, UNPUB; SHUPLIAKOV O, 1992, J NEUROSCI, V7, P1111; SONTAG JM, 1994, J BIOL CHEM, V269, P4547; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; Wang ZX, 1996, SCIENCE, V272, P1935, DOI 10.1126/science.272.5270.1935	33	382	388	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 11	1997	276	5310					259	263		10.1126/science.276.5310.259	http://dx.doi.org/10.1126/science.276.5310.259			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WT925	9092476				2022-12-01	WOS:A1997WT92500047
J	Inskip, H				Inskip, H			Childhood leukaemia near nuclear sites re-examined	LANCET			English	Editorial Material							LEUKEMIA; ENGLAND; WALES				Inskip, H (corresponding author), UNIV SOUTHAMPTON,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON SO16 6YD,HANTS,ENGLAND.		Inskip, Hazel/L-5467-2018	Inskip, Hazel/0000-0001-8897-1749				BARON JA, 1984, BRIT J CANCER, V50, P815, DOI 10.1038/bjc.1984.261; BITHELL JF, 1994, BRIT MED J, V309, P501, DOI 10.1136/bmj.309.6953.501; GARDNER MJ, 1990, BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423; HEASMAN MA, 1986, LANCET, V1, P266; HEASMAN MA, 1986, LANCET, V1, P355; KINLEN L, 1988, LANCET, V2, P1323; ROMAN E, 1987, BRIT MED J, V294, P597, DOI 10.1136/bmj.294.6572.597; Sharp L, 1996, OCCUP ENVIRON MED, V53, P823, DOI 10.1136/oem.53.12.823	8	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 5	1997	349	9057					969	970		10.1016/S0140-6736(05)62890-5	http://dx.doi.org/10.1016/S0140-6736(05)62890-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR621	9100621				2022-12-01	WOS:A1997WR62100006
J	Olesen, AB; Ellingsen, AR; Olesen, H; Juul, S; ThestrupPedersen, K				Olesen, AB; Ellingsen, AR; Olesen, H; Juul, S; ThestrupPedersen, K			Atopic dermatitis and birth factors: Historical follow up by record linkage	BRITISH MEDICAL JOURNAL			English	Article							CHILDHOOD ECZEMA; PREVALENCE; POPULATION	Objective: To study if factors at birth are associated with later development of atopic dermatitis. Design: Historical follow up by record linkage from Danish medical birth register. Children were followed up for 5.5 to 8.5 years. Second historical follow up study comprising questionnaire to mothers of singleborn children 6.5 to 9.5 years after birth. Setting: Private dermatology clinics and dermatology and paediatric departments in the municipality of Aarhus, Denmark, Subjects: 7862 singletons born in hospital between 1 January 1984 and 31 December 1986 to mothers living in the municipality of Aarhus. Questionnaires sent to 985 mothers. Main outcome measures: Gestational age, birth weight, parity, and age of mother at the time of birth. Atopy in children diagnosed by specialists in dermatology and physicians. Family size; diagnosis of atopic dermatitis, allergic rhinitis, and asthma; family predisposition; and mothers' smoking habits during pregnancy determined from questionnaires. Results: Of 7862 children, 403 were diagnosed as having atopic dermatitis by a specialist; the cumulative incidence at age 7 was 5.6%. High gestational age and low parity were associated with an increased risk of atopic dermatitis, Among 985 children atopic dermatitis had been diagnosed by any physician in 184; the cumulative incidence at age 7 was 18.7%. High birth weight high gestational age, and family history of atopy were associated with increased risk of atopic dermatitis. Conclusion: In both studies the incidence of atopic dermatitis was associated with high gestational age and in one with high birth weight also. The causes for these associations are at present unknown but may indicate that even during gestation factors associated with atopic dermatitis influence maturation.	AARHUS UNIV,INST EPIDEMIOL & SOCIAL MED,DK-8000 AARHUS C,DENMARK	Aarhus University	Olesen, AB (corresponding author), AARHUS UNIV HOSP,DEPT DERMATOL,DK-8000 AARHUS C,DENMARK.			Ellingsen, Anne Ringer/0000-0001-9173-9617				ABERG N, 1989, ACTA PAEDIATR SCAND, V78, P246, DOI 10.1111/j.1651-2227.1989.tb11064.x; ARSHAD SH, 1992, LANCET, V339, P1493, DOI 10.1016/0140-6736(92)91260-F; BRYAN EM, 1983, MATERNAL CHILD H MAY, P201; CARR RD, 1964, ARCH DERMATOL, V89, P27, DOI 10.1001/archderm.1964.01590250033006; *DAN NAT HLTH BOAR, 1993, MED BIRTH STAT 1991; DAVID TJ, 1988, ARCH DIS CHILD, V63, P435, DOI 10.1136/adc.63.4.435; FREIDRICH L, 1983, TWINS HDB; Golding J, 1987, Paediatr Perinat Epidemiol, V1, P67, DOI 10.1111/j.1365-3016.1987.tb00091.x; GOLDING J, 1986, BIRTH 5 STUDY HLTH B, P171; HANIFIN JM, 1987, MONOGR ALLERGY, V21, P116; KALTOFT K, 1994, ARCH DERMATOL RES, V287, P42, DOI 10.1007/BF00370717; Kaltoft K, 1995, CANCER GENET CYTOGEN, V85, P68, DOI 10.1016/0165-4608(95)00118-2; KAY J, 1994, J AM ACAD DERMATOL, V30, P35, DOI 10.1016/S0190-9622(94)70004-4; KENDALL MD, 1991, J ANAT, V177, P1; Kristensen J, 1996, J CLIN EPIDEMIOL, V49, P893, DOI 10.1016/0895-4356(96)00018-2; LARSEN FS, 1986, J AM ACAD DERMATOL, V15, P487; LARSEN FS, 1992, ACTA DERM-VENEREOL, V176, P7; LARSEN FS, 1985, THESIS U ODENSE ODEN; LINNEY J, 1983, MULTIPLE BIRTHS; MacGillivray I, 1988, TWINNING TWINS; NINAN TK, 1992, BRIT MED J, V304, P873, DOI 10.1136/bmj.304.6831.873; Peters T J, 1987, Paediatr Perinat Epidemiol, V1, P80, DOI 10.1111/j.1365-3016.1987.tb00092.x; RAJKA G, 1986, INT J DERMATOL, V25, P301, DOI 10.1111/j.1365-4362.1986.tb02249.x; RAJKA G, 1989, ESSENTIAL ASPECTS AT; SANDBANK AC, 1988, ACTA GENET MED GEMEL, V37, P161, DOI 10.1017/S0001566000004086; SPSS, 1995, STAT PACK SOC SCI VE; Storm K, 1986, Ugeskr Laeger, V148, P3295; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; TAYLOR B, 1984, LANCET, V2, P1255, DOI 10.1016/S0140-6736(84)92805-8; ThestrupPedersen K, 1997, ACTA DERM-VENEREOL, V77, P20; VICKERS CFH, 1980, ACTA DERM-VENEREOL, V92, P113; WILLIAMS HC, 1992, CLIN EXP DERMATOL, V17, P385, DOI 10.1111/j.1365-2230.1992.tb00244.x; WILLIAMS HC, 1994, BRIT MED J, V308, P1132, DOI 10.1136/bmj.308.6937.1132	33	121	122	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 5	1997	314	7086					1003	1008		10.1136/bmj.314.7086.1003	http://dx.doi.org/10.1136/bmj.314.7086.1003			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WT152	9112844	Green Published			2022-12-01	WOS:A1997WT15200021
J	Nightingale, SL				Nightingale, SL			Gradual phaseout of CFC metered dose inhalers planned	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		1997, FED REG         0306, V62, P10242	1	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 2	1997	277	13					1029	1029						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ089	9091680				2022-12-01	WOS:A1997WQ08900005
J	Wang, J; Whetsell, M; Klein, JR				Wang, J; Whetsell, M; Klein, JR			Local hormone networks and intestinal T cell homeostasis	SCIENCE			English	Article							INTRAEPITHELIAL LYMPHOCYTES; THYROTROPIN; EXPRESSION; MOUSE; RECEPTOR; THYMUS; GENE; IDENTIFICATION; HETEROGENEITY; EPITHELIUM	Neuroendocrine hormones of the hypothalamus-pituitary-thyroid axis can exert positive or negative immunoregulatory effects on intestinal lymphocytes, Small intestine epithelial cells were found to express receptors for thyrotropin-releasing hormone (TRH) and to be a primary source of intestine-derived thyroid-stimulating hormone (TSH). The gene for the TSH receptor (TSH-R) was expressed in intestinal T cells but not in epithelial cells, which suggested a hormone-mediated link between lymphoid and nonhematopoietic components of the intestine, Because mice with congenitally mutant TSH-R (hyt/hyt mice) have a selectively impaired intestinal T cell repertoire, TSH may be a key immunoregulatory mediator in the intestine.	UNIV TULSA,DEPT BIOL SCI,TULSA,OK 74104; UNIV TULSA,MERVIN BOVAIRD CTR STUDIES MOL BIOL & BIOTECHNOL,TULSA,OK 74104	University of Tulsa; University of Tulsa					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035566, R23DK035566] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK35566, R01 DK035566] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOISMENU R, 1994, SCIENCE, V266, P1253, DOI 10.1126/science.7973709; FARR A, 1991, J HISTOCHEM CYTOCHEM, V39, P645, DOI 10.1177/39.5.2016514; GREEN RP, 1988, P NATL ACAD SCI USA, V85, P5592, DOI 10.1073/pnas.85.15.5592; GURR J, 1983, P NATL ACAD SCI USA, V80, P2121; HAMAD M, 1994, IMMUNOLOGY, V82, P611; HARBOUR DV, 1989, MOL CELL ENDOCRINOL, V64, P229, DOI 10.1016/0303-7207(89)90150-0; HERSHBERG R, 1990, P NATL ACAD SCI USA, V87, P9727, DOI 10.1073/pnas.87.24.9727; KLEIN JR, 1990, P SOC EXP BIOL MED, V195, P329; KLEIN JR, 1994, MUCOSAL IMMUNOLOGY I, P33; KOMANO K, 1995, P NATL ACAD SCI USA, V92, P6147; KRUGER TE, 1989, J IMMUNOL, V142, P744; LABRIE F, 1990, HORMONES MOL DIS, P261; MOSLEY RL, 1992, J IMMUNOL METHODS, V156, P19; MOSLEY RL, 1994, INT IMMUNOL, V6, P231, DOI 10.1093/intimm/6.2.231; OHNO H, 1993, EMBO J, V12, P4357, DOI 10.1002/j.1460-2075.1993.tb06120.x; PEKONEN F, 1978, ENDOCRINOLOGY, V103, P1668, DOI 10.1210/endo-103-5-1668; PELLETIER G, 1974, J CELL BIOL, V62, P185, DOI 10.1083/jcb.62.1.185; SATOH T, 1994, NEUROPEPTIDES, V27, P195, DOI 10.1016/0143-4179(94)90070-1; SMITH EM, 1983, P NATL ACAD SCI-BIOL, V80, P6010, DOI 10.1073/pnas.80.19.6010; Stein S A, 1991, Thyroid, V1, P257, DOI 10.1089/thy.1991.1.257; STEIN SA, 1994, MOL ENDOCRINOL, V8, P129, DOI 10.1210/me.8.2.129; STICKNEY DG, 1994, BLOOD, V84, P3034, DOI 10.1182/blood.V84.9.3034.bloodjournal8493034; STRAUB RE, 1990, P NATL ACAD SCI USA, V87, P9514, DOI 10.1073/pnas.87.24.9514; VIDAL K, 1993, J IMMUNOL METHODS, V166, P63, DOI 10.1016/0022-1759(93)90329-6; WANG J, 1994, SCIENCE, V265, P1860, DOI 10.1126/science.8091211; Wang J, 1996, INT IMMUNOL, V8, P231, DOI 10.1093/intimm/8.2.231; WANG J, 1995, CELL IMMUNOL, V161, P299, DOI 10.1006/cimm.1995.1040; XIA W, 1995, ENDOCRINOLOGY, V136, P3146	28	103	110	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 28	1997	275	5308					1937	1939		10.1126/science.275.5308.1937	http://dx.doi.org/10.1126/science.275.5308.1937			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WQ513	9072972				2022-12-01	WOS:A1997WQ51300047
J	Brugada, R; Tapscott, T; Czernuszewicz, GZ; Marian, AJ; Iglesias, A; Mont, L; Brugada, J; Girona, J; Domingo, A; Bachinski, LL; Roberts, R				Brugada, R; Tapscott, T; Czernuszewicz, GZ; Marian, AJ; Iglesias, A; Mont, L; Brugada, J; Girona, J; Domingo, A; Bachinski, LL; Roberts, R			Identification of a genetic locus for familial atrial fibrillation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							STROKE	Background Atrial fibrillation, the most common sustained cardiac-rhythm disturbance, affects over 2 million Americans and accounts for one third of all strokes in patients over 65 years of age. The molecular basis for atrial fibrillation is unknown, and palliative therapy is used to control the ventricular rate and prevent systemic emboli. We identified a family of 26 members of whom 10 had atrial fibrillation that segregated as an autosomal dominant disease. We subsequently identified two additional families in which the disease was linked to the same locus. Methods We screened the human genome with 300 polymorphic dinucleotide-repeat markers using an unconventional strategy of pooling the DNA samples into two groups (affected and unaffected), which reduced the sample size by approximately 90 percent, before performing linkage analysis to map the locus. This made it possible to identify potential loci within a few weeks. Results The lod scores for markers D10S569 and D10S607, located at 10q22-q24, were 3.60 in Family 1. The disease locus in Families 2 and 3 was also linked to the same markers, with lod scores of 6.02 and 5.35 for markers D10S569 and D10S607, respectively, when data on all three families were combined. Haplotype analysis of the three families showed that the locus was between D10S1694 and D10S1786, an interval of 11.3 centimorgans. Conclusions Identification of the gene for familial atrial fibrillation will help to elucidate the molecular basis of the disease and provide insights into acquired forms. The strategy of pooling DNA samples for analysis is more time and cost effective than conventional screening and should accelerate the process of gene mapping in the future. (C) 1997, Massachusetts Medical Society.	BAYLOR COLL MED, DEPT CARDIOL, HOUSTON, TX 77030 USA; UNIV BARCELONA, HOSP CLIN, DEPT CARDIOL, CARDIAC ARRHYTHMIA SERV, BARCELONA, SPAIN; HOSP MATERNO INFANTIL VALL HEBRON, DEPT CARDIOL, BARCELONA, SPAIN	Baylor College of Medicine; University of Barcelona; Hospital Clinic de Barcelona; Hospital Universitari Vall d'Hebron			Mont, Lluís/AAO-9518-2021	Mont, Lluís/0000-0002-8115-5906; BRUGADA, JOSEP/0000-0002-5662-8302; Marian, AJ/0000-0002-1252-7120	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007706] Funding Source: NIH RePORTER; NHLBI NIH HHS [P50-HL313-01, T32-HL-07706] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBERS GW, 1994, ARCH INTERN MED, V154, P1443, DOI 10.1001/archinte.154.13.1443; ANTMAN E, 1993, J AM COLL CARDIOL, V22, P1830; BEYER F, 1993, Z KARDIOL, V82, P674; BULLRICH F, 1995, CYTOGENET CELL GENET, V70, P250, DOI 10.1159/000134045; DURAND JB, 1995, CIRCULATION, V92, P3387, DOI 10.1161/01.CIR.92.12.3387; FEINBERG WM, 1995, ARCH INTERN MED, V155, P469, DOI 10.1001/archinte.155.5.469; GUYER M, 1992, SCIENCE, V258, P67; HOEHE M, 1989, American Journal of Human Genetics, V45, pA143; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; NEITZEL H, 1986, HUM GENET, V73, P320, DOI 10.1007/BF00279094; Ott J., 1991, ANAL HUMAN GENETIC L; Scott DA, 1996, AM J HUM GENET, V59, P385; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WOLF PA, 1987, ARCH INTERN MED, V147, P1561, DOI 10.1001/archinte.147.9.1561; YANGFENG TL, 1990, P NATL ACAD SCI USA, V87, P1516, DOI 10.1073/pnas.87.4.1516	15	403	418	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 27	1997	336	13					905	911		10.1056/NEJM199703273361302	http://dx.doi.org/10.1056/NEJM199703273361302			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WP832	9070470				2022-12-01	WOS:A1997WP83200002
J	Boyartchuk, VL; Ashby, MN; Rine, J				Boyartchuk, VL; Ashby, MN; Rine, J			Modulation of Ras and a-factor function by carboxyl-terminal proteolysis	SCIENCE			English	Article							GTP-BINDING PROTEINS; SACCHAROMYCES-CEREVISIAE; STE14 GENE; ISOPRENOID MODIFICATION; MATING PHEROMONE; SHUTTLE VECTORS; AMINO-ACIDS; YEAST; METHYLATION; METHYLTRANSFERASE	Prenylated proteins contain a covalently linked cholesterol intermediate near their carboxyl-termini. Maturation of most prenylated proteins involves proteolytic removal of the last three amino acids. Two genes in Saccharomyces cerevisiae, RCE1 and AFC1, were identified that appear to be responsible for this processing, The Afc1 protein is a zinc protease that participates in the processing of yeast a-factor mating pheromone. The Reel protein contributes to the processing of both Ras protein and a-factor. Deletion of both AFC1 and RCE1 resulted in the loss of proteolytic processing of prenylated proteins. Disruption of RCE1 led to defects in Ras localization and signaling and suppressed the activated phenotype associated with the allele RAS2(val19).	UNIV CALIF BERKELEY, DEPT MOL & CELL BIOL, BERKELEY, CA 94720 USA; ACACIA BIOSCI INC, RICHMOND, CA 94806 USA	University of California System; University of California Berkeley					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035827] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35827] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHBY MN, 1992, P NATL ACAD SCI USA, V89, P4613, DOI 10.1073/pnas.89.10.4613; ASHBY MN, 1995, METHOD ENZYMOL, V250, P235; ASHBY MN, 1993, YEAST, V9, P907, DOI 10.1002/yea.320090810; BENDER A, 1986, CELL, V47, P929, DOI 10.1016/0092-8674(86)90808-1; BOYARTCHUCK VL, UNPUB; BROEK D, 1985, CELL, V41, P763, DOI 10.1016/S0092-8674(85)80057-X; BUSS JE, 1989, SCIENCE, V243, P1600, DOI 10.1126/science.2648572; CASEY PJ, 1994, CURR OPIN CELL BIOL, V6, P219, DOI 10.1016/0955-0674(94)90139-2; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; CODY CW, 1993, BIOCHEMISTRY-US, V32, P1212, DOI 10.1021/bi00056a003; COX AD, 1992, MOL CELL BIOL, V12, P2606, DOI 10.1128/MCB.12.6.2606; FINEGOLD AA, 1991, P NATL ACAD SCI USA, V88, P4448, DOI 10.1073/pnas.88.10.4448; FUJIYAMA A, 1987, EMBO J, V6, P223, DOI 10.1002/j.1460-2075.1987.tb04742.x; FUJIYAMA A, 1990, J BIOL CHEM, V265, P3362; GAYNOR EC, 1994, J CELL BIOL, V127, P653, DOI 10.1083/jcb.127.3.653; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GOODMAN LE, 1990, P NATL ACAD SCI USA, V87, P9665, DOI 10.1073/pnas.87.24.9665; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x; HE B, 1991, P NATL ACAD SCI USA, V88, P11373, DOI 10.1073/pnas.88.24.11373; HEILMEYER LMG, 1992, P NATL ACAD SCI USA, V89, P9554, DOI 10.1073/pnas.89.20.9554; HRYCYNA CA, 1992, J BIOL CHEM, V267, P10457; HRYCYNA CA, 1991, EMBO J, V10, P1699, DOI 10.1002/j.1460-2075.1991.tb07694.x; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; JANG GF, 1993, BIOCHEMISTRY-US, V32, P9500, DOI 10.1021/bi00087a031; KATAOKA T, 1985, CELL, V40, P19, DOI 10.1016/0092-8674(85)90304-6; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KHOSRAVIFAR R, 1991, P NATL ACAD SCI USA, V88, P6264, DOI 10.1073/pnas.88.14.6264; KINSELLA BT, 1992, J BIOL CHEM, V267, P3940; KINSELLA BT, 1991, P NATL ACAD SCI USA, V88, P8934, DOI 10.1073/pnas.88.20.8934; KOHL NE, 1995, NAT MED, V1, P792, DOI 10.1038/nm0895-792; KOHL NE, 1995, J CELL BIOCHEM, P145; Kuchler K, 1990, CURR OPIN CELL BIOL, V2, P617, DOI 10.1016/0955-0674(90)90102-K; MA YT, 1992, P NATL ACAD SCI USA, V89, P6275, DOI 10.1073/pnas.89.14.6275; MARR RS, 1990, J BIOL CHEM, V265, P20057; MITSUZAWA H, 1989, GENETICS, V123, P739; Parish CA, 1996, BIOCHEMISTRY-US, V35, P8473, DOI 10.1021/bi960603g; PEREZSALA D, 1992, BIOCHEM J, V284, P835, DOI 10.1042/bj2840835; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SAPPERSTEIN S, 1994, MOL CELL BIOL, V14, P1438, DOI 10.1128/MCB.14.2.1438; SCHAFER WR, 1990, SCIENCE, V249, P1133, DOI 10.1126/science.2204115; SCHAFER WR, 1992, ANNU REV GENET, V26, P209, DOI 10.1146/annurev.ge.26.120192.001233; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; SIKORSKI RS, 1989, GENETICS, V122, P19; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P77; STEPHENSON RC, 1992, J BIOL CHEM, V267, P13314; TAMANOI F, 1993, TRENDS BIOCHEM SCI, V18, P349, DOI 10.1016/0968-0004(93)90072-U; THISSEN JA, 1993, J BIOL CHEM, V268, P13780; WHISTLER JL, 1996, THESIS U CALIFORNIA	51	295	313	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 21	1997	275	5307					1796	1800		10.1126/science.275.5307.1796	http://dx.doi.org/10.1126/science.275.5307.1796			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WP056	9065405				2022-12-01	WOS:A1997WP05600043
J	Covinsky, KE; Fortinsky, RH; Palmer, RM; Kresevic, DM; Landefeld, CS				Covinsky, KE; Fortinsky, RH; Palmer, RM; Kresevic, DM; Landefeld, CS			Relation between symptoms of depression and health status outcomes in acutely ill hospitalized older persons	ANNALS OF INTERNAL MEDICINE			English	Article						depression; age factors; activities of daily living; outcome assessment (health care); health status	FUNCTIONAL STATUS; MAJOR DEPRESSION; DISABILITY; CARE; IMPACT; SYMPTOMATOLOGY; VALIDATION; MORBIDITY; MORTALITY; PATIENT	Background: Older patients often have poor health status outcomes after hospitalization. Symptoms of depression are common in hospitalized older persons and may be a risk factor for these poor outcomes. Objective: To determine whether symptoms of depression predict worse health status outcomes in acutely ill, older medical patients, independent of health status and severity of illness at hospital admission. Design: Prospective cohort study. Setting: Medical service of a teaching hospital. Patients: 572 hospitalized medical patients older than 70 years of age. Measurements: 15 symptoms of depression, health status, and severity of illness were measured at admission. The main outcome was dependence in basic activities of daily living at discharge and 30 and 90 days after discharge. Other outcome measures were dependence in instrumental activities of daily living, fair or poor global health status, and poor global satisfaction with life. Results: The median number of symptoms of depression on admission was 4. Patients with 6 or more symptoms on admission (n = 196) were more likely than patients with 0 to 2 symptoms (n = 181) to be dependent in basic activities of daily living (odds ratio, 2.47 [95% Cl, 1.58 to 3.86]) after controlling for demographic characteristics and severity of illness. At each subsequent time point, patients with more symptoms of depression on admission were more likely to be dependent in basic activities of daily living. This association persisted after adjustment for dependence in basic activities of daily living, severity of illness, and demographic characteristics on admission. The odds ratios comparing patients who had 6 or more symptoms with those who had 0 to 2 symptoms were 3.23 (Cl, 1.76 to 5.95) at discharge, 3.45 (Cl, 1.81 to 6.60) 30 days after discharge, and 2.15 (Cl, 1.15 to 4.03) 90 days after discharge. At each time point, patients with 6 or more symptoms of depression were more likely to have more dependence in instrumental activities of daily living, worse global health status, and less satisfaction with life. Conclusions: Symptoms of depression identified a vulnerable group of hospitalized older persons. The health status of patients with more symptoms of depression was after hospitalization. This association was not attributable to health status or severity of illness on admission. The temporal sequence and magnitude of this association, its consistency over time with different measures, and its independence from the severity of the somatic illness strongly support a relation between symptoms of depression on admission and subsequent health status outcomes.	VET AFFAIRS MED CTR, CLEVELAND, OH 44106 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center	Covinsky, KE (corresponding author), UNIV HOSP CLEVELAND, DIV GEN INTERNAL MED & HLTH CARE RES, 11100 EUCLID AVE, CLEVELAND, OH 44106 USA.				NATIONAL INSTITUTE ON AGING [K08AG000714, P60AG010418] Funding Source: NIH RePORTER; NIA NIH HHS [1K08AG00714-01, AG-10418-03] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		*AM PSYCH ASS, 1994, DIAGN STAT MAN MENT, P323; BERKMAN LF, 1986, AM J EPIDEMIOL, V124, P372, DOI 10.1093/oxfordjournals.aje.a114408; BLAZER D, 1989, NEW ENGL J MED, V320, P164, DOI 10.1056/NEJM198901193200306; BLUMENTHAL MD, 1975, ARCH GEN PSYCHIAT, V32, P985; BROADHEAD WE, 1990, JAMA-J AM MED ASSOC, V264, P2524, DOI 10.1001/jama.264.19.2524; BRUCE ML, 1994, AM J PSYCHIAT, V151, P716; BRUCE ML, 1994, AM J PUBLIC HEALTH, V84, P1796, DOI 10.2105/AJPH.84.11.1796; Caine E.D., 1994, DIAGNOSIS TREATMENT, P21; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; CRAIG TJ, 1983, AM J PSYCHIAT, V140, P598; CREDITOR MC, 1993, ANN INTERN MED, V118, P219, DOI 10.7326/0003-4819-118-3-199302010-00011; Dunham N C, 1994, Arch Fam Med, V3, P676, DOI 10.1001/archfami.3.8.676; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FRASURESMITH N, 1993, JAMA-J AM MED ASSOC, V270, P1819, DOI 10.1001/jama.270.15.1819; GALLO JJ, 1994, J GERONTOL, V49, pP251, DOI 10.1093/geronj/49.6.P251; GILLICK MR, 1982, SOC SCI MED, V16, P1033, DOI 10.1016/0277-9536(82)90175-7; GORDON HS, 1995, ARCH INTERN MED, V155, P2465, DOI 10.1001/archinte.155.22.2465; GURLAND BJ, 1988, INT J GERIATR PSYCH, V3, P163, DOI 10.1002/gps.930030304; HERBERT TB, 1993, PSYCHOL BULL, V113, P472, DOI 10.1037/0033-2909.113.3.472; IMBODEN JB, 1961, JAMA-J AM MED ASSOC, V178, P1182, DOI 10.1001/jama.1961.73040520003003a; INOUYE SK, 1993, J GEN INTERN MED, V8, P645, DOI 10.1007/BF02598279; JOHNSON J, 1992, JAMA-J AM MED ASSOC, V267, P1478, DOI 10.1001/jama.267.11.1478; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KOENIG HG, 1988, INT J PSYCHIAT MED, V18, P17; KOENIG HG, 1988, J AM GERIATR SOC, V36, P699, DOI 10.1111/j.1532-5415.1988.tb07171.x; LANDEFELD CS, 1995, NEW ENGL J MED, V332, P1338, DOI 10.1056/NEJM199505183322006; LAWTON MP, 1982, J GERONTOL, V37, P91, DOI 10.1093/geronj/37.1.91; MCVEY LJ, 1989, ANN INTERN MED, V110, P79, DOI 10.7326/0003-4819-110-1-79; MORLEY JE, 1988, ANN INTERN MED, V109, P890, DOI 10.7326/0003-4819-109-11-890; MOSSEY JM, 1990, J GERONTOL, V45, pM163, DOI 10.1093/geronj/45.5.M163; ORMEL J, 1994, JAMA-J AM MED ASSOC, V272, P1741, DOI 10.1001/jama.272.22.1741; ORMEL J, 1993, AM J PUBLIC HEALTH, V83, P385, DOI 10.2105/AJPH.83.3.385; ROVNER BW, 1991, JAMA-J AM MED ASSOC, V265, P993, DOI 10.1001/jama.265.8.993; Sackett D, 1991, CLIN EPIDEMIOLOGY BA; SAS Institute, 1990, SAS PROC GUID VERS 6; SHEIKH J I, 1986, Clinical Gerontologist, V5, P165; VONKORFF M, 1992, ARCH GEN PSYCHIAT, V49, P91; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914; WILSON IB, 1995, JAMA-J AM MED ASSOC, V273, P59, DOI 10.1001/jama.273.1.59; WU AW, 1995, ANN INTERN MED, V122, P342, DOI 10.7326/0003-4819-122-5-199503010-00004; YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4	42	162	163	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1997	126	6					417	+		10.7326/0003-4819-126-6-199703150-00001	http://dx.doi.org/10.7326/0003-4819-126-6-199703150-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WM530	9072926				2022-12-01	WOS:A1997WM53000001
J	Kohler, S; Delwiche, CF; Denny, PW; Tilney, LG; Webster, P; Wilson, RJM; Palmer, JD; Roos, DS				Kohler, S; Delwiche, CF; Denny, PW; Tilney, LG; Webster, P; Wilson, RJM; Palmer, JD; Roos, DS			A plastid of probable green algal origin in apicomplexan parasites	SCIENCE			English	Article							ELONGATION-FACTOR-TU; PLASMODIUM-FALCIPARUM; TOXOPLASMA-GONDII; EXTRACHROMOSOMAL DNAS; PHYLOGENETIC ANALYSIS; SEQUENCES; PLANT; EVOLUTION; MALARIA; GENE	Protozoan parasites of the phylum Apicomplexa contain three genetic elements: the nuclear and mitochondrial genomes characteristic of virtually all eukaryotic cells and a 35-kilobase circular extrachromosomal DNA. In situ hybridization techniques were used to localize the 35-kilobase DNA of Toxoplasma gondii to a discrete organelle surrounded by four membranes. Phylogenetic analysis of the tufA gene encoded by the 35-kilobase genomes of coccidians T. gondii and Eimeria tenella and the malaria parasite Plasmodium falciparum grouped this organellar genome with cyanobacteria and plastids, showing consistent clustering with green algal plastids. Taken together, these observations indicate that the Apicomplexa acquired a plastid by secondary endosymbiosis, probably from a green alga.	UNIV PENN, DEPT BIOL, PHILADELPHIA, PA 19104 USA; INDIANA UNIV, DEPT BIOL, BLOOMINGTON, IN 47405 USA; NATL INST MED RES, LONDON NW7 1AA, ENGLAND; YALE UNIV, SCH MED, DEPT CELL BIOL, NEW HAVEN, CT 06520 USA	University of Pennsylvania; Indiana University System; Indiana University Bloomington; MRC National Institute for Medical Research; Yale University			Delwiche, Charles F/C-6549-2008; Palmer, Jeffrey/P-6747-2014; Denny, Paul/B-8431-2013	Delwiche, Charles F/0000-0001-7854-8584; Palmer, Jeffrey/0000-0002-4626-2220; Denny, Paul/0000-0002-5051-1613; Roos, David Siker/0000-0001-6725-4089	MRC [MC_U117532072] Funding Source: UKRI; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI031808, U01AI031808] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM052857] Funding Source: NIH RePORTER; Medical Research Council [MC_U117532072] Funding Source: Medline; NIAID NIH HHS [AI-31808] Funding Source: Medline; NIGMS NIH HHS [GM-52857] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALDAUF SL, 1993, P NATL ACAD SCI USA, V90, P11558, DOI 10.1073/pnas.90.24.11558; Baldauf SL, 1996, P NATL ACAD SCI USA, V93, P7749, DOI 10.1073/pnas.93.15.7749; BECKERS CJM, 1995, J CLIN INVEST, V95, P367, DOI 10.1172/JCI117665; CAVALIERSMITH T, 1993, MICROBIOL REV, V57, P953, DOI 10.1128/MMBR.57.4.953-994.1993; COUSINEAU B, 1992, GENE, V120, P33, DOI 10.1016/0378-1119(92)90006-B; DELWICHE CF, 1995, MOL PHYLOGENET EVOL, V4, P110, DOI 10.1006/mpev.1995.1012; DEPAMPHILIS CW, 1990, NATURE, V348, P337, DOI 10.1038/348337a0; DODGE JD, 1989, SYST ASSOC SPEC VOL, V38, P207; FEAGIN JE, 1992, NUCLEIC ACIDS RES, V20, P879, DOI 10.1093/nar/20.4.879; FEAGIN JE, 1995, EXP PARASITOL, V80, P430, DOI 10.1006/expr.1995.1055; FEAGIN JE, 1994, ANNU REV MICROBIOL, V48, P81, DOI 10.1146/annurev.mi.48.100194.000501; FELSENSTEIN J, 1988, ANNU REV GENET, V22, P521, DOI 10.1146/annurev.ge.22.120188.002513; FELSENSTEIN J, 1978, SYST ZOOL, V27, P401, DOI 10.2307/2412923; FICHERA ME, 1995, ANTIMICROB AGENTS CH, V39, P1530, DOI 10.1128/AAC.39.7.1530; GAJADHAR AA, 1991, MOL BIOCHEM PARASIT, V45, P147, DOI 10.1016/0166-6851(91)90036-6; GARDNER MJ, 1994, MOL BIOCHEM PARASIT, V66, P221, DOI 10.1016/0166-6851(94)90149-X; GRAY MW, 1989, ANNU REV CELL BIOL, V5, P25, DOI 10.1146/annurev.cb.05.110189.000325; HACKSTEIN JHP, 1995, PARASITOL RES, V81, P207; HILLIS DM, 1994, SCIENCE, V264, P671, DOI 10.1126/science.8171318; Hillis DM, 1996, MOL SYSTEMATICS; HOWE CJ, 1992, J THEOR BIOL, V158, P199, DOI 10.1016/S0022-5193(05)80718-0; HRAZDINA G, 1992, ANNU REV PLANT PHYS, V43, P241, DOI 10.1146/annurev.pp.43.060192.001325; JOSEPH JT, 1989, MOL CELL BIOL, V9, P3621, DOI 10.1128/MCB.9.9.3621; Katz LA, 1996, J MOL EVOL, V43, P453, DOI 10.1007/BF02337517; Kim JH, 1996, SYST BIOL, V45, P363, DOI 10.2307/2413570; LEVINE ND, 1988, J PROTOZOOL, V35, P518, DOI 10.1111/j.1550-7408.1988.tb04141.x; LOCKHART PJ, 1994, MOL BIOL EVOL, V11, P605; LUDWIG W, 1993, ANTON LEEUW INT J G, V64, P285, DOI 10.1007/BF00873088; McFadden GI, 1996, NATURE, V381, P482, DOI 10.1038/381482a0; MCFADDEN GI, 1995, TRENDS ECOL EVOL, V12, P12; MORRISSETTE NS, 1994, EXP PARASITOL, V79, P445, DOI 10.1006/expr.1994.1106; OLSEN GJ, 1994, COMPUT APPL BIOSCI, V10, P41; PALMER JD, 1985, ANNU REV GENET, V19, P325, DOI 10.1146/annurev.ge.19.120185.001545; PUKRITTAYAKAMEE S, 1994, ANTIMICROB AGENTS CH, V38, P511, DOI 10.1128/AAC.38.3.511; READ M, 1994, EUR J BIOCHEM, V220, P513, DOI 10.1111/j.1432-1033.1994.tb18650.x; ROOS DS, 1994, METHOD CELL BIOL, V45, P27; SIDDALL ME, 1992, PARASITOL TODAY, V8, P90, DOI 10.1016/0169-4758(92)90244-V; VAIDYA AB, 1989, MOL BIOCHEM PARASIT, V35, P3614; VAN DER STRAETEN D, 1991, PLANT CELL, V3, P719, DOI 10.2307/3869253; VanDePeer Y, 1996, P NATL ACAD SCI USA, V93, P7732, DOI 10.1073/pnas.93.15.7732; WILSON RJM, 1994, INFECT AGENT DIS, V3, P29; Wilson RJM, 1996, J MOL BIOL, V261, P155, DOI 10.1006/jmbi.1996.0449; WOLFE KH, 1992, P NATL ACAD SCI USA, V89, P10648, DOI 10.1073/pnas.89.22.10648	43	558	581	1	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 7	1997	275	5305					1485	1489		10.1126/science.275.5305.1485	http://dx.doi.org/10.1126/science.275.5305.1485			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WM081	9045615				2022-12-01	WOS:A1997WM08100048
J	Goldstein, DS; Holmes, C; Cannon, RO; Eisenhofer, G; Kopin, IJ				Goldstein, DS; Holmes, C; Cannon, RO; Eisenhofer, G; Kopin, IJ			Sympathetic cardioneuropathy in dysautonomias	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ORTHOSTATIC HYPOTENSION; PLASMA NOREPINEPHRINE; AUTONOMIC FAILURE; INNERVATION; HUMANS; DIHYDROXYPHENYLGLYCOL; NEUROSECRETION; RESPONSES; CATECHOLS; HEART	Background The classification of dysautonomias has been confusing, and the pathophysiology obscure, We examined sympathetic innervation of the heart in patients with acquired, idiopathic dysautonomias using thoracic positron-emission tomography and assessments of the entry rate of the sympathetic neurotransmitter norepinephrine into the cardiac venous drainage (cardiac norepinephrine spillover). We related the laboratory findings to signs of sympathetic neurocirculatory failure (orthostatic hypotension and abnormal blood-pressure responses associated with the Valsalva maneuver), central neural degeneration, and responsiveness to treatment with levodopa-carbidopa (Sinemet). Methods Cardiac scans were obtained after intravenous administration of 6-[F-18]fluorodopamine in 26 patients with dysautonomia. Fourteen had sympathetic neurocirculatory failure - three with no signs of central neurodegeneration (pure autonomic failure), two with parkinsonism responsive to treatment with levodopa-carbidopa, and nine with central neurodegeneration unresponsive to treatment with levodopa-carbidopa (the Shy-Drager syndrome). The rates of cardiac norepinephrine spillover were estimated on the basis of concentrations of intravenously infused [H-3]norepinephrine during catheterization of the right side of the heart. Results Patients with pure autonomic failure or parkinsonism and sympathetic neurocirculatory failure had no myocardial 6-[F-18]fluorodopamine-derived radioactivity or cardiac norepinephrine spillover, indicating loss of myocardial sympathetic-nerve terminals, whereas patients with the Shy-Drager syndrome had increased levels of 6-[F-18]fluorodopamine-derived radioactivity, indicating intact sympathetic terminals and absent nerve traffic, Patients with dysautonomia who did not have sympathetic neurocirculatory failure had normal levels of 6-[F-18]fluorodopamine-derived radioactivity in myocardium and normal rates of cardiac norepinephrine spillover. Conclusions The results of 6-[F-18]fluorodopamine positron-emission tomography and neurochemical analyses support a new clinical pathophysiologic classification of dysautonomias, based on the occurrence of sympathetic neurocirculatory failure, signs of central neurodegeneration, and responsiveness to levodopa-carbidopa. (C) 1997, Massachusetts Medical Society.	NINCDS, CARDIOL BRANCH, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Goldstein, DS (corresponding author), NINCDS, CLIN NEUROSCI BRANCH,NIH,BLDG 10,RM 6N252, 10 CTR DR, MSC-1424, BETHESDA, MD 20892 USA.		Eisenhofer, Graeme/AAU-9829-2021	Eisenhofer, Graeme/0000-0002-8601-9903				BANNISTER R, 1993, CLIN AUTONOMIC DISOR, P517; EISENHOFER G, 1992, CIRCULATION, V85, P1775, DOI 10.1161/01.CIR.85.5.1775; Eisenhofer G, 1996, CIRCULATION, V93, P1667, DOI 10.1161/01.CIR.93.9.1667; GOLDING DW, 1991, BIOL CELL, V73, P157, DOI 10.1016/0248-4900(91)90098-8; Goldstein DS, 1996, CLIN AUTON RES, V6, P17, DOI 10.1007/BF02291401; GOLDSTEIN DS, 1993, J AM COLL CARDIOL, V22, P1961, DOI 10.1016/0735-1097(93)90786-Z; GOLDSTEIN DS, 1989, ANN NEUROL, V26, P558, DOI 10.1002/ana.410260410; GOLDSTEIN DS, 1991, J HYPERTENS, V9, P417, DOI 10.1097/00004872-199105000-00005; GOLDSTEIN DS, 1990, CIRCULATION, V81, P1606, DOI 10.1161/01.CIR.81.5.1606; GOLDSTEIN DS, 1991, J AUTONOM NERV SYST, V36, P85; GOLDSTEIN DS, 1991, J AUTONOM NERV SYST, V34, P17, DOI 10.1016/0165-1838(91)90005-N; Goldstein DS, 1995, ANN NY ACAD SCI, V771, P570, DOI 10.1111/j.1749-6632.1995.tb44711.x; GOLDSTEIN DS, IN PRESS CLIN AUTON; HOLMES C, 1994, J CHROMATOGR B, V653, P131, DOI 10.1016/0378-4347(93)E0430-X; JOHNSON RH, 1966, Q J MED, V35, P276; JOHNSON RH, 1984, NEUROCARDIOLOGY INTE, V13, P113; KACHI T, 1988, NEUROLOGY, V38, P1091, DOI 10.1212/WNL.38.7.1091; KVETNANSKY R, 1992, J PHARMACOL EXP THER, V261, P899; Low PA, 1993, CLIN AUTONOMIC DISOR; Martin Thomas F. J., 1994, Current Opinion in Neurobiology, V4, P626, DOI 10.1016/0959-4388(94)90002-7; MATHIAS CJ, 1995, CLIN AUTON RES, V5, P307, DOI 10.1007/BF01819025; Meredith I T, 1991, Clin Auton Res, V1, P187, DOI 10.1007/BF01824986; MEREDITH IT, 1992, HYPERTENSION, V19, P628, DOI 10.1161/01.HYP.19.6.628; Oppenheimer D., 1988, AUTONOMIC FAILURE TX, P451; OPPENHEIMER DR, 1980, J NEUROL SCI, V46, P393, DOI 10.1016/0022-510X(80)90064-7; REA RF, 1990, AM J PHYSIOL, V258, pR982, DOI 10.1152/ajpregu.1990.258.4.R982; ROSE CP, 1994, AM J PHYSIOL, V266, pH1386, DOI 10.1152/ajpheart.1994.266.4.H1386; Saito F, 1992, Rinsho Shinkeigaku, V32, P1238; Schatz IJ, 1996, ANN INTERN MED, V125, P74, DOI 10.7326/0003-4819-125-1-199607010-00012; Schatz IJ, 1996, NEUROLOGY, V46, P1470, DOI 10.1212/wnl.46.5.1470; WALLIN BG, 1993, CLIN AUTONOMIC DISOR, P243; ZIEGLER MG, 1977, NEW ENGL J MED, V296, P293, DOI 10.1056/NEJM197702102960601	32	234	238	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 6	1997	336	10					696	702		10.1056/NEJM199703063361004	http://dx.doi.org/10.1056/NEJM199703063361004			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WL419	9041100	Bronze			2022-12-01	WOS:A1997WL41900004
J	Nightingale, SL				Nightingale, SL			Proposal for treatment use of investigational devices	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							FED REGISTER, V61, P66954	1	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 5	1997	277	9					703	703						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WK026	9042830				2022-12-01	WOS:A1997WK02600007
J	Everson, SA; Lynch, JW; Chesney, MA; Kaplan, GA; Goldberg, DE; Shade, SB; Cohen, RD; Salonen, R; Salonen, JT				Everson, SA; Lynch, JW; Chesney, MA; Kaplan, GA; Goldberg, DE; Shade, SB; Cohen, RD; Salonen, R; Salonen, JT			Interaction of workplace demands and cardiovascular reactivity in progression of carotid atherosclerosis: Population based study	BRITISH MEDICAL JOURNAL			English	Article							ISCHEMIC-HEART-DISEASE; INTIMA-MEDIA THICKNESS; CYNOMOLGUS MONKEYS; ULTRASOUND; ARTERY; MEN	Objective: To examine the combined influence of workplace demands and changes in blood pressure induced by stress on the progression of carotid atherosclerosis. Design: Population based follow up study of unestablished as well as traditional risk factors for carotid atherosclerosis, ischaemic heart disease, and other outcomes. Setting: Eastern Finland. Subjects: 591 men aged 42-60 who were fully employed at baseline and had complete data oil the measures of carotid atherosclerosis, job demands, blood pressure reactivity, and covariates. Main outcome measures: Change in ultrasonographically assessed intima-media thickness of the right and left common carotid arteries from baseline to 4 year follow up. Results: Significant interactions between workplace demands and str ess induced reactivity were observed for all measures of progression (P < 0.04). Men with large changes in systolic blood pressure (20 mm Hg or greater) in anticipation of a maximal exercise test and with high job demands had 10-40% greater progression of mean (0.138 v 0.123 mm) and maximum (0.320 v 0.261 mm) intima-media thickness and plaque height (0.347 v 0.264) than men who were less reactive and had fewer job demands. Similar results were obtained after excluding men with prevalent ischaemic heart disease at baseline. Findings were strongest among men with at least 20% stenosis or non-stenotic plaque at baseline. In this subgroup reactive men with high job demands had more than 46% greater atherosclerotic progression than the others. Adjustment for atherosclerotic risk factors did not alter the results. Conclusions: Men who showed stress induced blood pressure reactivity and who reported high job demands experienced the greatest atherosclerotic progression, showing the association between dispositional risk characteristics and contextual determinants of disease and suggesting that behaviourally evoked cardiovascular reactivity may have a role in atherogenesis.	UNIV CALIF SAN FRANCISCO, PREVENT SCI GRP, SAN FRANCISCO, CA 94105 USA; UNIV KUOPIO, PUBL HLTH RES INST, FIN-70211 KUOPIO, FINLAND	University of California System; University of California San Francisco; University of Eastern Finland	Everson, SA (corresponding author), INST PUBL HLTH, HUMAN POPULAT LAB, BERKELEY, CA 94704 USA.		Tanaka, Gohichi/A-1684-2010; Kaplan, George/AAJ-2398-2020; Lynch, John W/A-4797-2008; Everson-Rose, Susan A/L-7582-2017	Lynch, John W/0000-0003-2781-7902; Everson-Rose, Susan/0000-0002-9839-2537	NHLBI NIH HHS [HL 44199] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLANKENHORN DH, 1993, CIRCULATION, V88, P20, DOI 10.1161/01.CIR.88.1.20; EVANS GW, 1996, CIRCULATION, V93, P629; Everson SA, 1996, HYPERTENSION, V27, P1059, DOI 10.1161/01.HYP.27.5.1059; KAPLAN JR, 1991, CIRCULATION, V84, P23; KARASEK R, 1981, AM J PUBLIC HEALTH, V71, P694, DOI 10.2105/AJPH.71.7.694; KARASEK RA, 1988, AM J PUBLIC HEALTH, V78, P910, DOI 10.2105/AJPH.78.8.910; Keys A., 1980, SCIENCE, DOI DOI 10.1126/SCIENCE.208.4448.1138; Lovallo WR, 1992, INDIVIDUAL DIFFERENC, P165; LYNCH JL, IN PRESS ARTERIOSCLE; LYNCH JL, IN PRESS AM J PUBLIC; Manuck S B, 1994, Int J Behav Med, V1, P4, DOI 10.1207/s15327558ijbm0101_2; MANUCK S B, 1990, Annals of Behavioral Medicine, V12, P17, DOI 10.1207/s15324796abm1201_2; MANUCK SB, 1989, PSYCHOSOM MED, V51, P306, DOI 10.1097/00006842-198905000-00005; MANUCK SB, 1983, PSYCHOSOM MED, V45, P95, DOI 10.1097/00006842-198305000-00002; Rose G.A., 1982, CARDIOVASCULAR SURVE; SALONEN JT, 1989, ANN MED, V21, P227, DOI 10.3109/07853898909149939; SALONEN JT, 1993, LANCET, V341, P1158, DOI 10.1016/0140-6736(93)93184-3; SALONEN JT, 1993, CIRCULATION, V87, P56; SALONEN JT, 1988, ANN CLIN RES, V20, P46; SALONEN R, 1995, CIRCULATION, V92, P1758, DOI 10.1161/01.CIR.92.7.1758; SALONEN R, 1993, INT CONGR SER, V1018, P301; *SAS I, 1990, SAS US GUID; SCHNALL PL, 1994, ANNU REV PUBL HEALTH, V15, P381, DOI 10.1146/annurev.pu.15.050194.002121; SIEGRIST J, 1990, SOC SCI MED, V31, P1127, DOI 10.1016/0277-9536(90)90234-J; WIKSTRAND J, 1994, J INTERN MED, V236, P555, DOI 10.1111/j.1365-2796.1994.tb00845.x	25	181	187	0	9	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 22	1997	314	7080					553	558		10.1136/bmj.314.7080.553	http://dx.doi.org/10.1136/bmj.314.7080.553			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WK215	9055713	Green Submitted, Green Published			2022-12-01	WOS:A1997WK21500022
J	Kluck, RM; BossyWetzel, E; Green, DR; Newmeyer, DD				Kluck, RM; BossyWetzel, E; Green, DR; Newmeyer, DD			The release of cytochrome c from mitochondria: A primary site for Bcl-2 regulation of apoptosis	SCIENCE			English	Article							PROGRAMMED CELL-DEATH; ENDOPLASMIC-RETICULUM; SUBCELLULAR-LOCALIZATION; NUCLEAR-ENVELOPE; OUTER-MEMBRANE; CA2+ FLUXES; PROTEIN; ONCOPROTEIN; INHIBITION; REDUCTION	In a cell-free apoptosis system, mitochondria spontaneously released cytochrome c, which activated DEVD-specific caspases, leading to fodrin cleavage and apoptotic nuclear morphology. Bcl-2 acted in situ on mitochondria to prevent the release of cytochrome c and thus caspase activation. During apoptosis in intact cells, cytochrome c translocation was similarly blocked by Bcl-2 but not by a caspase inhibitor, zVAb-fmk. In vitro, exogenous cytochrome c bypassed the inhibitory effect of Bcl-2. Cytochrome c release was unaccompanied by changes in mitochondrial membrane potential. Thus, Bcl-2 acts to inhibit cytochrome c translocation, thereby blocking caspase activation and the apoptotic process.	LA JOLLA INST ALLERGY & IMMUNOL,DIV CELLULAR IMMUNOL,SAN DIEGO,CA 92121	La Jolla Institute for Immunology			Kluck, Ruth M/C-8413-2013; Green, Douglas R/N-8083-2018	Kluck, Ruth M/0000-0002-7101-1925; Green, Douglas R/0000-0002-7332-1417	NCI NIH HHS [CA69381] Funding Source: Medline; NIGMS NIH HHS [GM52735, GM50284] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA069381] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM052735, R01GM052735] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKAO Y, 1994, CANCER RES, V54, P2468; Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; BABA ML, 1981, J MOL EVOL, V17, P197, DOI 10.1007/BF01732758; BAFFY G, 1993, J BIOL CHEM, V268, P6511; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Cosulich SC, 1996, CURR BIOL, V6, P997, DOI 10.1016/S0960-9822(02)00644-9; DEJONG D, 1994, CANCER RES, V54, P256; Distelhorst CW, 1996, ONCOGENE, V12, P2051; DUMONT ME, 1991, MOL CELL BIOL, V11, P5487, DOI 10.1128/MCB.11.11.5487; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; Erhardt P, 1996, J BIOL CHEM, V271, P17601, DOI 10.1074/jbc.271.30.17601; FARSCHON DM, UNPUB; KLUCK R, UNPUB; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LITHGOW T, 1994, CELL GROWTH DIFFER, V5, P411; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Marin MC, 1996, ONCOGENE, V12, P2259; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; Martin SJ, 1996, J BIOL CHEM, V271, P28753, DOI 10.1074/jbc.271.46.28753; MAYER A, 1995, J BIOL CHEM, V270, P12390, DOI 10.1074/jbc.270.21.12390; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Murphy AN, 1996, P NATL ACAD SCI USA, V93, P9893, DOI 10.1073/pnas.93.18.9893; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; Nunez Gabriel, 1994, Trends in Cell Biology, V4, P399, DOI 10.1016/0962-8924(94)90053-1; Pastorino JG, 1996, J BIOL CHEM, V271, P29792, DOI 10.1074/jbc.271.47.29792; PETIT PX, 1995, J CELL BIOL, V130, P157, DOI 10.1083/jcb.130.1.157; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; RIVETT AJ, 1994, METHOD ENZYMOL, V244, P331; Shimizu S, 1996, ONCOGENE, V13, P21; Shimizu S, 1996, ONCOGENE, V12, P2251; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; Vance BA, 1996, J BIOL CHEM, V271, P30811, DOI 10.1074/jbc.271.48.30811; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A; ZORNIG M, 1995, ONCOGENE, V11, P2165	50	4147	4293	4	353	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 21	1997	275	5303					1132	1136		10.1126/science.275.5303.1132	http://dx.doi.org/10.1126/science.275.5303.1132			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WJ503	9027315				2022-12-01	WOS:A1997WJ50300046
J	Moss, ML; Jin, SLC; Milla, ME; Burkhart, W; Carter, HL; Chen, WJ; Clay, WC; Didsbury, JR; Hassler, D; Hoffman, CR; Kost, TA; Lambert, MH; Leesnitzer, MA; McCauley, P; McGeehan, G; Mitchell, J; Moyer, M; Pahel, G; Rocque, W; Overton, LK; Schoenen, F; Seaton, T; Su, JL; Warner, J; Willard, D; Becherer, JD				Moss, ML; Jin, SLC; Milla, ME; Burkhart, W; Carter, HL; Chen, WJ; Clay, WC; Didsbury, JR; Hassler, D; Hoffman, CR; Kost, TA; Lambert, MH; Leesnitzer, MA; McCauley, P; McGeehan, G; Mitchell, J; Moyer, M; Pahel, G; Rocque, W; Overton, LK; Schoenen, F; Seaton, T; Su, JL; Warner, J; Willard, D; Becherer, JD			Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha	NATURE			English	Article							CYSTEINE SWITCH; TNF RECEPTOR; CELL-LINE; INHIBITOR; MECHANISM; FAMILY	Tumour-necrosis factor-alpha (TNF-alpha) is a cytokine that contributes to a variety of inflammatory disease states(1). The protein exists as a membrane-bound precursor(2,3) of relative molecular mass 26K which can be processed by a TNF-alpha-converting enzyme (TACE), to generate secreted 17K mature TNF-alpha. We have purified TACE and cloned its complementary DNA. TACE is a membrane-bound disintegrin metalloproteinase. Structural comparisons with other disintegrin-containing enzymes indicate that TACE is unique, with noteable sequence identity to MADM(4), an enzyme implicated in myelin degradation, and to KUZ(5), a Drosophila homologue of MADM important for neuronal development. The expression of recombinant TACE (rTACE) results in the production of functional enzyme that correctly processes precursor TNF-alpha to the mature form. The rTACE provides a readily available source of enzyme to help in the search for new anti-inflammatory agents that target the final processing stage of TNF-alpha production.	GLAXO WELLCOME RES & DEV LTD,DEPT DIVERS SCI,RES TRIANGLE PK,NC 27709; GLAXO WELLCOME RES & DEV LTD,DEPT MOL SCI,RES TRIANGLE PK,NC 27709; GLAXO WELLCOME RES & DEV LTD,DEPT ANALYT CHEM,RES TRIANGLE PK,NC 27709; GLAXO WELLCOME RES & DEV LTD,DEPT STRUCT CHEM,RES TRIANGLE PK,NC 27709; GLAXO WELLCOME RES & DEV LTD,DEPT MOL PHARMACOL,RES TRIANGLE PK,NC 27709	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Moss, ML (corresponding author), GLAXO WELLCOME RES & DEV LTD,DEPT MOL BIOCHEM,5 MOORE DR RES,RES TRIANGLE PK,NC 27709, USA.			Schoenen, Frank/0000-0003-2711-1117				Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Bennett TA, 1996, J IMMUNOL, V156, P3093; CROWE PD, 1995, J EXP MED, V181, P1205, DOI 10.1084/jem.181.3.1205; DECKER T, 1987, J IMMUNOL, V138, P957; GEARING A, 1994, NATURE, V370, P558; GOMISRUTH FX, 1994, J MOL BIOL, V239, P513, DOI 10.1006/jmbi.1994.1392; GOULD RJ, 1990, P SOC EXP BIOL MED, V195, P168, DOI 10.3181/00379727-195-43129B; GRAMS F, 1993, FEBS LETT, V335, P76, DOI 10.1016/0014-5793(93)80443-X; GRANADOS RR, 1994, J INVERTEBR PATHOL, V64, P260, DOI 10.1016/S0022-2011(94)90400-6; Howard L, 1996, BIOCHEM J, V317, P45, DOI 10.1042/bj3170045; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; MORRIS SA, 1995, CANCER RES, V55, P3629; MOYER MB, 1994, TECHNIQUES IN PROTEIN CHEMISTRY V, P195; MULLBERG J, 1995, J IMMUNOL, V155, P5198; O'Byrne E. M., 1995, Inflammation Research, V44, pS117, DOI 10.1007/BF01778290; Rooke J, 1996, SCIENCE, V273, P1227, DOI 10.1126/science.273.5279.1227; SHANNON JD, 1989, J BIOL CHEM, V264, P11575; SUFFYS P, 1988, EUR J BIOCHEM, V178, P257, DOI 10.1111/j.1432-1033.1988.tb14451.x; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; Weskamp G, 1996, J CELL BIOL, V132, P717, DOI 10.1083/jcb.132.4.717; Wolfsberg TG, 1996, DEV BIOL, V180, P389, DOI 10.1006/dbio.1996.0313; Zhou Q, 1996, BIOCHEM BIOPH RES CO, V219, P720, DOI 10.1006/bbrc.1996.0301; ZIEGLERHEITBROCK HWL, 1988, INT J CANCER, V41, P456, DOI 10.1002/ijc.2910410324	25	1410	1472	2	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 20	1997	385	6618					733	736		10.1038/385733a0	http://dx.doi.org/10.1038/385733a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WJ423	9034191				2022-12-01	WOS:A1997WJ42300049
J	Murphy, DJ; Hope, PL; Johnson, A				Murphy, DJ; Hope, PL; Johnson, A			Neonatal risk factors for cerebral palsy in very preterm babies: Case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BIRTH-WEIGHT INFANTS; CRANIAL ULTRASOUND; WESTERN-AUSTRALIA; HEMORRHAGE; LEUKOMALACIA; PREDICTION; LESIONS; NEWBORN; TRENDS; EVENTS	Objective: To identify neonatal risk factors for cerebral palsy among very preterm babies and in particular the associations independent of the coexistence of antenatal and intrapartum factors. Design: Case-control study. Setting: Oxford health region. Subjects: Singleton babies born between 1984 and 1990 at less than 39 weeks' gestation who survived to discharge from hospital: 59 with cerebral palsy and 234 randomly selected controls without cerebral palsy. Main outcome measures: Adverse neonatal factors expressed as odds ratios and 95% confidence intervals. Results: Factors associated with an increased risk of cerebral palsy after adjustment for gestational age and the presence of previously identified antenatal and intrapartum risk factors were patent ductus arteriosus (odds ratio 2.3; 95% confidence interval 1.2 to 4.5), hypotension (2.3; 1.3 to 4.7), blood transfusion (4.8; 2.5 to 9.3), prolonged ventilation (4.8; 2.5 to 9.0), pneumothorax (3.5; 1.6 to 7.6), sepsis (3.6; 1.8 to 7.4), hyponatraemia (7.9; 2.1 to 29.6) and total parenteral nutrition (5.5; 2.8 to 10.5). Seizures were associated with an increased risk of cerebral palsy (10.0; 4.1 to 24.7), as were parenchymal damage (32; 12.4 to 84.4) and appreciable ventricular dilatation (5.4; 3.0 to 9.8) detected by cerebral ultrasound. Conclusion: A reduction in the Tate of cerebral palsy in very preterm babies requires an integrated approach to management throughout the antenatal intrapartum, and neonatal periods.	ST MICHAELS HOSP, DEPT OBSTET & GYNAECOL, BRISTOL BS2 8EG, AVON, ENGLAND; JOHN RADCLIFFE HOSP, DEPT PAEDIAT, OXFORD OX3 9DU, ENGLAND; RADCLIFFE INFIRM, NATL PERINATAL EPIDEMIOL UNIT, OXFORD OX2 6HE, ENGLAND	University of Oxford; Radcliffe Infirmary; University of Oxford				Johnson, Anne/0000-0003-1330-7100; Murphy, Deirdre/0000-0001-6074-6718				BOZYNSKI MEA, 1988, DEV MED CHILD NEUROL, V30, P342; CALVERT SA, 1987, ACTA PAEDIATR SCAND, V76, P254, DOI 10.1111/j.1651-2227.1987.tb10456.x; COOKE RWI, 1987, ARCH DIS CHILD, V62, P931, DOI 10.1136/adc.62.9.931; DEVRIES LS, 1988, AM J DIS CHILD, V142, P732, DOI 10.1001/archpedi.1988.02150070046023; DEVRIES LS, 1985, LANCET, V2, P137; ESCOBAR GJ, 1991, ARCH DIS CHILD, V66, P204, DOI 10.1136/adc.66.2.204; GARDNER MJ, 1989, STAT CONFIDENCE CONF; GRAHAM M, 1987, LANCET, V2, P593; GRAZIANI LJ, 1986, PEDIATRICS, V78, P88; Grether JK, 1996, J PEDIATR-US, V128, P407, DOI 10.1016/S0022-3476(96)70292-5; JOHNSON A, 1989, COMMUNITY MED, V11, P352; LEVITON A, 1990, EARLY HUM DEV, V24, P1, DOI 10.1016/0378-3782(90)90002-Z; LOW JA, 1986, AM J OBSTET GYNECOL, V155, P750, DOI 10.1016/S0002-9378(86)80013-8; MARLOW N, 1988, ARCH DIS CHILD-FETAL, V63, P1131, DOI 10.1136/adc.63.10_Spec_No.1131; Murphy DJ, 1996, ARCH DIS CHILD-FETAL, V74, pF105, DOI 10.1136/fn.74.2.F105; MURPHY DJ, 1995, LANCET, V346, P1449, DOI 10.1016/S0140-6736(95)92471-X; NELSON KB, 1985, AM J DIS CHILD, V139, P1031, DOI 10.1001/archpedi.1985.02140120077032; NELSON KB, 1995, PEDIATRICS, V95, P263; NORUSSIS MJ, 1985, SPSS ADV STAT GUIDE; O'Shea M, 1992, Paediatr Perinat Epidemiol, V6, P352, DOI 10.1111/j.1365-3016.1992.tb00775.x; PETTERSON B, 1993, BRIT MED J, V307, P1239, DOI 10.1136/bmj.307.6914.1239; PHAROAH POD, 1990, ARCH DIS CHILD, V65, P602, DOI 10.1136/adc.65.6.602; PIDCOCK FS, 1990, J PEDIATR-US, V116, P417, DOI 10.1016/S0022-3476(05)82836-7; PINTOMARTIN JA, 1995, PEDIATRICS, V95, P249; POWELL TG, 1988, DEV MED CHILD NEUROL, V30, P19, DOI 10.1111/j.1469-8749.1988.tb04722.x; SINHA SK, 1990, ARCH DIS CHILD-FETAL, V65, P1017, DOI 10.1136/adc.65.10_Spec_No.1017; SOLA A, 1992, LANCET, V340, P1363; STANLEY FJ, 1988, AM J OBSTET GYNECOL, V158, P89, DOI 10.1016/0002-9378(88)90784-3; VANDEBOR M, 1992, PEDIATRICS, V90, P196; WATKINS AMC, 1989, EARLY HUM DEV, V19, P103, DOI 10.1016/0378-3782(89)90120-5; WEINDLING AM, 1985, BRIT J OBSTET GYNAEC, V92, P1218, DOI 10.1111/j.1471-0528.1985.tb04865.x; WEISGLASKUPERUS N, 1992, EARLY HUM DEV, V31, P131, DOI 10.1016/0378-3782(92)90040-N	32	123	128	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 8	1997	314	7078					404	408		10.1136/bmj.314.7078.404	http://dx.doi.org/10.1136/bmj.314.7078.404			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH295	9040385	Green Published			2022-12-01	WOS:A1997WH29500027
J	Cullinan, P; Acquilla, S; Dhara, VR				Cullinan, P; Acquilla, S; Dhara, VR			Respiratory morbidity 10 years after the Union Carbide gas leak at Bhopal: A cross sectional survey	BMJ-BRITISH MEDICAL JOURNAL			English	Article							METHYL ISOCYANATE; EXPOSURE	Objective: To examine the role of exposure to the 1984 Bhopal gas leak in the development of persistent obstructive airways disease. Design: Cross sectional survey. Setting: Bhopal, India. Subjects: Random sample of 454 adults stratified by distance of residence from the Union Carbide plant. Main outcome measures: Self reported respiratory symptoms; indices of lung function measured by simple spirometry and adjusted for age, sex, and height according to Indian derived regression equations. Results: Respiratory symptoms were significantly more common and lung function (percentage predicted forced expiratory volume in one second (FEV(1)), forced vital capacity (FVC), forced expiratory now between 25% and 75% of vital capacity (FEF(25-75)), and FEV(1)/FVC ratio) was reduced among those reporting exposure to the gas leak. The frequency of symptoms fell as exposure decreased (as estimated by distance lived from the plant), and lung function measurements displayed similar trends. These findings were not wholly accounted for by confounding by smoking or literacy, a measure of socioeconomic status. Lung function measurements were consistently lower in those reporting symptoms. Conclusion: Our results suggest that persistent small airways obstruction among survivors of the 1984 disaster may be attributed to gas exposure.	UNIV NEWCASTLE UPON TYNE, DEPT EPIDEMIOL & PUBL HLTH, NEWCASTLE UPON TYNE NE2 4HH, TYNE & WEAR, ENGLAND; AGCY TOX SUBST & DIS REGISTRY, ATLANTA, GA 30333 USA	Newcastle University - UK; Centers for Disease Control & Prevention - USA	Cullinan, P (corresponding author), UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, NATL HEART & LUNG INST, DEPT OCCUPAT & ENVIRONM MED, LONDON SW3 6LR, ENGLAND.							ANDERSSON N, 1990, BRIT J IND MED, V47, P553; [Anonymous], 1987, Am Rev Respir Dis, V136, P1285; BARKER DJP, 1992, FETAL INFANT ORIGINS, P150; BROOKS SM, 1985, CHEST, V88, P376, DOI 10.1378/chest.88.3.376; *CARB CORP, 1985, BHOP METH IS INC INV; Cullinan P, 1996, NATL MED J INDIA, V9, P5; DARKE CHRISTOPHER S., 1958, THORAX, V13, P327, DOI 10.1136/thx.13.4.327; GALEA M, 1964, CAN MED ASSOC J, V91, P345; HARKONEN H, 1983, AM REV RESPIR DIS, V128, P890; *IND COUNC MED RES, 1985, HLTH EFF EXP TOX GAS; KAMAT SR, 1992, ENVIRON HEALTH PERSP, V97, P241, DOI 10.2307/3431360; RASTOGI SK, 1988, INDIAN J EXP BIOL, V26, P161; SINGH MP, 1987, J HAZARD MATER, V17, P1, DOI 10.1016/0304-3894(87)85039-2; UDWADIA FE, 1987, J ASSOC PHYSICIAN I, V36, P454; VIJAYAN V K, 1989, Indian Journal of Medical Research Section B, V90, P407; VIJAYAN VK, 1995, RESP MED, V89, P105, DOI 10.1016/0954-6111(95)90192-2; WEILL H, 1987, B EUR PHYSIOPATH RES, V23, P587	17	52	53	0	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 1	1997	314	7077					338	342		10.1136/bmj.314.7077.338	http://dx.doi.org/10.1136/bmj.314.7077.338			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF861	9040323	Green Published			2022-12-01	WOS:A1997WF86100029
J	Robson, J				Robson, J			Information needed to decide about cardiovascular treatment in primary care	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY-HEART-DISEASE; COST-EFFECTIVENESS; RISK-DISK; MEDICAL LITERATURE; GENERAL-PRACTICE; BLOOD-PRESSURE; USERS GUIDES; HELP ME; PREVENTION; HEALTH	There is growing consensus that treatment of cardiovascular risks should be based on multiple rather than single factors and on absolute rather than relative risks. Thresholds for treatment should reflect the level of absolute risk at which the benefits and hazards of treating outweigh the benefits and hazards of not treating. Once a decision has been made to initiate a treatment programme, clinicians need to know the patient's absolute risk. At this level of risk, do the benefits of treatment outweigh the hazards? Given this information, which treatment option does the patient prefer? Using cardiovascular disease as an example, I review some measures that assist decision making in primary care. Practice guidelines should routinely include accessible presentation of treatment outcomes on benefit, hazard, and costs for a range of absolute risks. These measures enable patients and their doctors to weigh the pros and cons of treatment in their particular circumstances.	UNIV LONDON QUEEN MARY & WESTFIELD COLL, LONDON HOSP, SCH MED, LONDON E1 4NS, ENGLAND	University of London; Queen Mary University London	Robson, J (corresponding author), ST BARTHOLOMEWS HOSP, ACAD DEPT GEN PRACTICE, LONDON E1 4NS, ENGLAND.		Robson, John/H-3904-2014	Robson, John/0000-0001-6889-0415				ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; BEARD K, 1992, BRIT MED J, V304, P142; CHALMERS I, 1995, BRIT MED J, V310, P1315, DOI 10.1136/bmj.310.6990.1315; COOK RJ, 1995, BRIT MED J, V310, P452, DOI 10.1136/bmj.310.6977.452; COPPOLA WGT, 1995, BRIT J GEN PRACT, V45, P185; Cranney M, 1996, BRIT J GEN PRACT, V46, P661; DRUMMOND MF, 1993, MED DECIS MAKING, V13, P184, DOI 10.1177/0272989X9301300303; FIELD K, 1995, BRIT MED J, V310, P1109, DOI 10.1136/bmj.310.6987.1109; FLETCHER A, 1991, J HYPERTENS, V9, P193, DOI 10.1097/00004872-199103000-00001; GOLDMAN L, 1991, JAMA-J AM MED ASSOC, V265, P1145, DOI 10.1001/jama.265.9.1145; GREENBERG G, 1985, BMJ-BRIT MED J, V291, P97; GUYATT GH, 1994, JAMA-J AM MED ASSOC, V271, P59, DOI 10.1001/jama.271.1.59; HAQ IU, 1995, LANCET, V346, P1467, DOI 10.1016/S0140-6736(95)92477-9; HUX JE, 1995, MED DECIS MAKING, V15, P152, DOI 10.1177/0272989X9501500208; JACKSON R, 1993, BRIT MED J, V307, P107, DOI 10.1136/bmj.307.6896.107; JACKSON R, 1995, LANCET, V346, P1440, DOI 10.1016/S0140-6736(95)92466-3; Kannel W B, 1995, Hypertens Res, V18, P181, DOI 10.1291/hypres.18.181; KANNEL WB, 1991, J HYPERTENS, V9, pS13, DOI 10.1097/00004872-199112007-00005; KAWACHI I, 1991, J HYPERTENS, V9, P199, DOI 10.1097/00004872-199103000-00002; LAW MR, 1991, BMJ-BRIT MED J, V302, P819, DOI 10.1136/bmj.302.6780.819; Lindholm L, 1996, J EPIDEMIOL COMMUN H, V50, P190, DOI 10.1136/jech.50.2.190; LOGAN AG, 1994, CANADIAN GUIDE CLIN; MCPHERSON K, 1994, J EPIDEMIOL COMMUN H, V48, P6, DOI 10.1136/jech.48.1.6; PEDERSEN TR, 1994, LANCET, V344, P1383; Pettiti DB, 1994, META ANAL DECISION A; PYORALA K, 1994, EUR HEART J, V15, P1300; Ramsay LE, 1996, LANCET, V348, P1251, DOI 10.1016/S0140-6736(05)65536-5; RANDALL T, 1992, BRIT MED J, V305, P227, DOI 10.1136/bmj.305.6847.227; RAYNER MJ, 1991, BMJ-BRIT MED J, V303, P748; RICHARDSON WS, 1995, JAMA-J AM MED ASSOC, V273, P1610, DOI 10.1001/jama.273.20.1610; ROBERTSON JAL, 1995, RISK ANAL, V15, P289, DOI 10.1111/j.1539-6924.1995.tb00322.x; RUSSELL LB, 1993, NEW ENGL J MED, V329, P352, DOI 10.1056/NEJM199307293290511; RUSSELL LB, 1989, HYPERTENSION S1, V13, P141; RUSSELL LB, 1986, IS PREVENTION REALLY; Shaper A G, 1987, Health Trends, V19, P37; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; SMITH GD, 1993, BMJ-BRIT MED J, V306, P1367, DOI 10.1136/bmj.306.6889.1367; SUTHERLAND HJ, 1995, MED DECIS MAKING, V15, P286; SWALES JD, 1989, BMJ-BRIT MED J, V298, P694; TENGS TO, 1995, RISK ANAL, V15, P369, DOI 10.1111/j.1539-6924.1995.tb00330.x; TUNSTALLPEDOE H, 1991, BRIT MED J, V303, P744, DOI 10.1136/bmj.303.6805.744; TUNSTALLPEDOE H, 1992, BRIT MED J, V305, P231, DOI 10.1136/bmj.305.6847.231; Ubel PA, 1996, NEW ENGL J MED, V334, P1174, DOI 10.1056/NEJM199605023341807; Warren K, 1993, DOING MORE GOOD HARM; WENNBERG JE, 1993, ANN NY ACAD SCI, V703, P52, DOI 10.1111/j.1749-6632.1993.tb26335.x; WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983; Yusuf S, 1996, CIRCULATION, V93, P1774, DOI 10.1161/01.CIR.93.10.1774	47	13	13	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 25	1997	314	7076					277	280		10.1136/bmj.314.7076.277	http://dx.doi.org/10.1136/bmj.314.7076.277			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WE633	9022493	Green Published			2022-12-01	WOS:A1997WE63300029
J	Gomez, AM; Valdivia, HH; Cheng, H; Lederer, MR; Santana, LF; Cannell, MB; McCune, SA; Altschuld, RA; Lederer, WJ				Gomez, AM; Valdivia, HH; Cheng, H; Lederer, MR; Santana, LF; Cannell, MB; McCune, SA; Altschuld, RA; Lederer, WJ			Defective excitation-contraction coupling in experimental cardiac hypertrophy and heart failure	SCIENCE			English	Article							RAT VENTRICULAR MYOCYTES; BETA-ADRENERGIC STIMULATION; SALT-RESISTANT RATS; SARCOPLASMIC-RETICULUM; CALCIUM-RELEASE; GUINEA-PIG; RYANODINE RECEPTORS; PURKINJE-CELL; MUSCLE CELLS; PHOSPHOLAMBAN PHOSPHORYLATION	Cardiac hypertrophy and heart failure caused by high blood pressure were studied in single myocytes taken from hypertensive rats (Dahl SS/Jr) and SH-HF rats in heart failure. Confocal microscopy and patch-clamp methods were used to examine excitation-contraction (EC) coupling, and the relation between the plasma membrane calcium current (I-Ca) and evoked calcium release from the sarcoplasmic reticulum (SR), which was visualized as ''calcium sparks.'' The ability of I-Ca to trigger calcium release from the SR in both hypertrophied and failing hearts was reduced. Because I-Ca density and SR calcium-release channels were normal, the defect appears to reside in a change in the relation between SR calcium-release channels and sarcolemmal calcium channels. beta-Adrenergic stimulation largely overcame the defect in hypertrophic but not failing heart cells. Thus, the same defect in EC coupling that develops during hypertrophy may contribute to heart failure when compensatory mechanisms fail.	UNIV MARYLAND, SCH MED, DEPT PHYSIOL, BALTIMORE, MD 21201 USA; UNIV MARYLAND, SCH MED, CTR MED BIOTECHNOL, BALTIMORE, MD 21201 USA; UNIV WISCONSIN, SCH MED, DEPT PHYSIOL, MADISON, WI 53706 USA; NIA, SECT CARDIOVASC RES, BALTIMORE, MD 21224 USA; UNIV LONDON ST GEORGES HOSP, SCH MED, DEPT PHARMACOL & CLIN PHARMACOL, LONDON SW17 0RE, ENGLAND; OHIO STATE UNIV, DEPT FOOD SCI & TECHNOL, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, DEPT MED BIOCHEM, COLUMBUS, OH 43210 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University of Wisconsin System; University of Wisconsin Madison; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); St Georges University London; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University			Lederer, William/B-1285-2010; Heping, Cheng/AAE-2680-2019; Gomez, Ana M./B-5376-2013; Santana, Luis/AAF-9298-2019	Heping, Cheng/0000-0002-9604-6702; Gomez, Ana M./0000-0003-0009-2884; Santana, Luis/0000-0002-4297-8029	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AKAHANE SA, 1996, J GEN PHYSIOL, V108, P1; ANTZELEVITCH C, 1994, J AM COLL CARDIOL, V23, P259, DOI 10.1016/0735-1097(94)90529-0; ARAI M, 1994, CIRC RES, V74, P555, DOI 10.1161/01.RES.74.4.555; BARCENASRUIZ L, 1987, CIRC RES, V61, P148, DOI 10.1161/01.RES.61.1.148; BASSANI JWM, 1995, AM J PHYSIOL-CELL PH, V268, pC1313, DOI 10.1152/ajpcell.1995.268.5.C1313; BASSANI RA, 1995, BIOPHYS J, V68, P2015, DOI 10.1016/S0006-3495(95)80378-4; BEAN BP, 1984, NATURE, V307, P371, DOI 10.1038/307371a0; BERS DM, 1991, EXCITATION CONTRACTI; BEUCKELMANN DJ, 1992, CIRCULATION, V85, P1046, DOI 10.1161/01.CIR.85.3.1046; BEUCKELMANN DJ, 1992, BASIC RES CARDIOL, V87, P235; BRAUNWALD E, 1988, HEART DISEASE TXB CA, P426; Braunwald E, 1979, HDB PHYSL 2, P533; BRISTOW MR, 1990, CIRCULATION, V82, P12; CANNELL MB, 1987, SCIENCE, V238, P1419, DOI 10.1126/science.2446391; CANNELL MB, 1995, SCIENCE, V268, P1045, DOI 10.1126/science.7754384; CANNELL MB, 1994, BIOPHYS J, V67, P1942, DOI 10.1016/S0006-3495(94)80677-0; CANNELL MB, 1994, J PHYSIOL-LONDON, V477P, pP25; CHENG H, 1995, CIRC RES, V76, P236, DOI 10.1161/01.RES.76.2.236; Cheng H, 1996, AM J PHYSIOL-CELL PH, V270, pC148; Cheng H, 1996, CELL CALCIUM, V20, P129, DOI 10.1016/S0143-4160(96)90102-5; CHENG H, 1993, SCIENCE, V262, P740, DOI 10.1126/science.8235594; CHEVALIER B, 1992, BASIC RES CARDIOL, V87, P187; Chua SC, 1996, SCIENCE, V271, P994, DOI 10.1126/science.271.5251.994; DAHL LK, 1962, NATURE, V194, P480, DOI 10.1038/194480b0; DUBELL WH, 1987, CELL CALCIUM, V8, P259, DOI 10.1016/0143-4160(87)90002-9; DUBELL WH, 1989, AM J PHYSIOL, V257, pH746, DOI 10.1152/ajpheart.1989.257.3.H746; DUBUS I, 1993, EUR HEART J, V14, P76; Esler Murray, 1995, P755; FABIATO A, 1985, J GEN PHYSIOL, V85, P189, DOI 10.1085/jgp.85.2.189; FABIATO A, 1985, J GEN PHYSIOL, V85, P291, DOI 10.1085/jgp.85.2.291; FABIATO A, 1985, J GEN PHYSIOL, V85, P247, DOI 10.1085/jgp.85.2.247; FERRANTE F, 1992, J HYPERTENS, V10, P507, DOI 10.1097/00004872-199206000-00002; GOMEZ AM, IN PRESS AM J PHYSL; Grantham CJ, 1996, CIRC RES, V79, P194, DOI 10.1161/01.RES.79.2.194; HART G, 1994, CARDIOVASC RES, V28, P933, DOI 10.1093/cvr/28.7.933; HASS GJ, 1995, AM HEART J, V130, P806, DOI 10.1016/0002-8703(95)90081-0; IKEMOTO N, 1989, BIOCHEMISTRY-US, V28, P6764, DOI 10.1021/bi00442a033; INOKO M, 1994, AM J PHYSIOL-HEART C, V267, pH2471, DOI 10.1152/ajpheart.1994.267.6.H2471; JAMES P, 1989, NATURE, V342, P90, DOI 10.1038/342090a0; JANUARY CT, 1988, PHARMACOL REV, V40, P219; KAPLAN N, 1990, CLIN HYPERTENSION, P95; KAWAMURA K, 1976, JPN CIRC J, V40, P1119, DOI 10.1253/jcj.40.1119; KLEIMAN RB, 1988, AM J PHYSIOL, V255, pH1434, DOI 10.1152/ajpheart.1988.255.6.H1434; LI Q, 1994, AM J PHYSIOL, V266, pH1738; LINDEMANN JP, 1983, J BIOL CHEM, V258, P464; LOKUTA AJ, 1995, J PHYSIOL-LONDON, V487, P609, DOI 10.1113/jphysiol.1995.sp020904; LOMPRE AM, 1979, NATURE, V282, P105, DOI 10.1038/282105a0; LOPEZLOPEZ JR, 1995, SCIENCE, V268, P1042, DOI 10.1126/science.7754383; McCune SA, 1990, ILAR J, V32, P23; MCDONALD TF, 1994, PHYSIOL REV, V74, P365, DOI 10.1152/physrev.1994.74.2.365; MING Z, 1994, J MOL CELL CARDIOL, V26, P1133, DOI 10.1006/jmcc.1994.1132; MOALIC JM, 1993, CIRCULATION S4, V87; NABAUER M, 1989, SCIENCE, V244, P800, DOI 10.1126/science.2543067; NARAYAN P, 1995, J MOL CELL CARDIOL, V27, P523, DOI 10.1016/S0022-2828(08)80047-8; NEGRETTI N, 1995, J PHYSIOL-LONDON, V486, P581, DOI 10.1113/jphysiol.1995.sp020836; NIGGLI E, 1990, SCIENCE, V250, P565, DOI 10.1126/science.2173135; PAGE E, 1973, AM J CARDIOL, V31, P172, DOI 10.1016/0002-9149(73)91030-8; PHILLIPS RA, UNPUB; PRIMOT I, 1991, CARDIOVASC RES, V25, P875, DOI 10.1093/cvr/25.10.875; RAPP JP, 1982, HYPERTENSION, V4, P753, DOI 10.1161/01.HYP.4.6.753; RAPP JP, 1985, HYPERTENSION, V7, P340, DOI 10.1161/01.HYP.7.3_Pt_1.340; Santana LF, 1996, CIRC RES, V78, P166, DOI 10.1161/01.RES.78.1.166; SANTOS PED, 1995, J CARDIOVASC ELECTR, V6, P1004; SCAMPS F, 1990, CIRC RES, V67, P199, DOI 10.1161/01.RES.67.1.199; SCHAPER J, 1991, CIRCULATION, V83, P504, DOI 10.1161/01.CIR.83.2.504; SHACKLOCK PS, 1995, J PHYSIOL-LONDON, V487, P601, DOI 10.1113/jphysiol.1995.sp020903; SHAM JSK, 1995, P NATL ACAD SCI USA, V92, P121, DOI 10.1073/pnas.92.1.121; Soeller C, 1996, BIOPHYS J, V70, pTUAM8; SOELLER C, COMMUNICATION; SPENCER CI, 1995, J PHYSIOL-LONDON, V488, P267, DOI 10.1113/jphysiol.1995.sp020965; STERN MD, 1992, BIOPHYS J, V63, P497, DOI 10.1016/S0006-3495(92)81615-6; TATE CA, 1985, J BIOL CHEM, V260, P9618; THANDROYEN FT, 1991, CIRC RES, V69, P810, DOI 10.1161/01.RES.69.3.810; VALDIVIA HH, 1995, SCIENCE, V267, P1997, DOI 10.1126/science.7701323; WEGENER AD, 1989, J BIOL CHEM, V264, P11468	75	627	650	0	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 2	1997	276	5313					800	806		10.1126/science.276.5313.800	http://dx.doi.org/10.1126/science.276.5313.800			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WW900	9115206				2022-12-01	WOS:A1997WW90000060
J	Carroll, RG; Riley, JL; Levine, BL; Feng, Y; Kaushal, S; Ritchey, DW; Bernstein, W; Weislow, OS; Brown, CR; Berger, EA; June, CH; StLouis, DC				Carroll, RG; Riley, JL; Levine, BL; Feng, Y; Kaushal, S; Ritchey, DW; Bernstein, W; Weislow, OS; Brown, CR; Berger, EA; June, CH; StLouis, DC			Differential regulation of HIV-1 fusion cofactor expression by CD28 costimulation of CD4(+) T cells	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; MOLECULAR-CLONING; MONOCLONAL-ANTIBODIES; CROSS-LINKING; HUMAN HOMOLOG; NPY BINDING; ACTIVATION; RECEPTOR; GENE; RESPONSES	Activation of CD4(+) T lymphocytes from human immunodeficiency virus-type 1 (HIV-1)-infected donors with immobilized antibodies to CD3 and CD28 induces a virus-resistant state. This effect is specific for macrophage-tropic HIV-I, Transcripts encoding CXCR4/Fusin, the fusion cofactor used by T cell line-tropic isolates, were abundant in CD3/CD28-stimulated cells, but transcripts encoding CCR5, the fusion cofactor used by macrophage-tropic viruses, were not detectable. Thus, CD3/CD28 costimulation induces an HIV-1-resistant phenotype similar to that seen in some highly exposed and HIV-uninfected individuals.	HENRY M JACKSON FDN ADVANCEMENT MIL MED,ROCKVILLE,MD 20850; USN,MED RES INST,IMMUNE CELL BIOL PROGRAM,BETHESDA,MD 20889; WALTER REED ARMY INST RES,DIV RETROVIROL,ROCKVILLE,MD 20850; NIAID,VIRAL DIS LAB,NIH,BETHESDA,MD 20889; SRA TECHNOL,ROCKVILLE,MD 20850; NIAID,INFECT DIS LAB,NIH,ROCKVILLE,MD 20852	Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc; Naval Medical Research Center (NMRC); United States Department of Defense; United States Navy; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Riley, James L/D-1255-2009; Levine, Bruce L/D-1688-2009	June, Carl/0000-0003-0241-3557; Riley, James/0000-0002-1057-576X				ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; BEYERS AD, 1992, P NATL ACAD SCI USA, V89, P2945, DOI 10.1073/pnas.89.7.2945; BREITMEYER JB, 1987, J IMMUNOL, V139, P2899; BRETSCHER P, 1992, IMMUNOL TODAY, V13, P74, DOI 10.1016/0167-5699(92)90138-W; BRODER CC, 1995, P NATL ACAD SCI USA, V92, P9004, DOI 10.1073/pnas.92.19.9004; CARROLL RI, UNPUB; CEUPPENS JL, 1986, J IMMUNOL, V137, P1816; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; FEDERSPPIEL B, 1993, GENOMICS, V16, P707, DOI 10.1006/geno.1993.1251; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; GEPPERT TD, 1988, J IMMUNOL, V140, P2155; GEPPERT TD, 1988, J CLIN INVEST, V81, P1497, DOI 10.1172/JCI113481; HERZOG H, 1993, DNA CELL BIOL, V12, P465, DOI 10.1089/dna.1993.12.465; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; JAZIN EE, 1993, REGUL PEPTIDES, V47, P247, DOI 10.1016/0167-0115(93)90392-L; JUNE CH, 1987, MOL CELL BIOL, V7, P4472, DOI 10.1128/MCB.7.12.4472; KIMPTON J, 1992, J VIROL, V66, P2232, DOI 10.1128/JVI.66.4.2232-2239.1992; LEDBETTER JA, 1985, J IMMUNOL, V135, P2331; LEDBETTER JA, 1988, EUR J IMMUNOL, V18, P1601, DOI 10.1002/eji.1830181020; LEDBETTER JA, 1988, EUR J IMMUNOL, V18, P525, DOI 10.1002/eji.1830180406; LEVINE BL, 1995, INT IMMUNOL, V7, P891, DOI 10.1093/intimm/7.6.891; Levine BL, 1996, SCIENCE, V272, P1939, DOI 10.1126/science.272.5270.1939; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; LOETSCHER M, 1994, J BIOL CHEM, V269, P232; Loetscher P, 1996, J EXP MED, V184, P569, DOI 10.1084/jem.184.2.569; LORI F, 1992, J VIROL, V66, P5067, DOI 10.1128/JVI.66.8.5067-5074.1992; MASCOLA JR, 1994, J INFECT DIS, V169, P48, DOI 10.1093/infdis/169.1.48; MIEDEMA F, 1994, IMMUNOL REV, V140, P35, DOI 10.1111/j.1600-065X.1994.tb00864.x; NOMURA H, 1993, INT IMMUNOL, V5, P1239, DOI 10.1093/intimm/5.10.1239; NUSSBAUM O, 1994, J VIROL, V68, P5411, DOI 10.1128/JVI.68.9.5411-5422.1994; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; RILEY J, IN PRESS J IMMUNOL; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; SATTENTAU QJ, 1993, PHILOS T R SOC B, V342, P59, DOI 10.1098/rstb.1993.0136; SCHREZENMEIER H, 1988, J IMMUNOL, V141, P398; Schwartz RH, 1996, J EXP MED, V184, P1, DOI 10.1084/jem.184.1.1; THOMPSON CB, 1989, P NATL ACAD SCI USA, V86, P1333, DOI 10.1073/pnas.86.4.1333; TRONO D, 1992, J VIROL, V66, P4893, DOI 10.1128/JVI.66.8.4893-4900.1992; Vahey Maryanne T., 1995, P17; Vahey Maryanne T., 1995, P313; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L	51	172	184	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 11	1997	276	5310					273	276		10.1126/science.276.5310.273	http://dx.doi.org/10.1126/science.276.5310.273			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WT925	9092480				2022-12-01	WOS:A1997WT92500051
J	Pellegrini, G; Traverso, CE; Franzi, AT; Zingirian, M; Cancedda, R; DeLuca, M				Pellegrini, G; Traverso, CE; Franzi, AT; Zingirian, M; Cancedda, R; DeLuca, M			Long-term restoration of damaged corneal surfaces with autologous cultivated corneal epithelium	LANCET			English	Article							AUTOGRAFT TRANSPLANTATION; STEM-CELLS; LIMBAL; RECONSTRUCTION; INVITRO	Background Complete loss of the corneal-limbal epithelium leads to re-epithelialisation by bulbar conjunctival cells. Since conjunctival and corneal-limbal epithelial cells represent two different cell lines, this conjunctival healing of the cornea is followed by stromal scarring, decreased visual acuity, and severe discomfort. Unilateral corneal-limbal epithelial defects can be resolved by the transplantation of limbal grafts taken from the uninjured eye. However, this procedure requires a large limbal graft to be taken from the healthy eye, and is not possible for bilateral lesions. We investigated the possibility of restoring the human corneal surface with autologous corneal epithelial sheets generated by serial cultivation of limbal cells. Methods Cells were cultivated from a 1 mm(2) biopsy sample taken from the limbus of the healthy eye of two patients with severe alkali burns, and thus complete loss of the corneal-limbal surface, of one eye. Normal corneal differentiation was tested with a specific biochemical marker. Autologous cultured corneal sheets were then grafted onto the damaged eyes of the two patients. The patients were followed up at more than 2 years after grafting. Findings We have shown that corneal progenitor cells are localised in the limbus, that cultured limbal cells generate cohesive sheets of authentic corneal epithelium, and that autologous cultured corneal epithelium restored the corneal surface of two patients with complete loss of the corneal-limbus epithelium. Long-term follow-up showed the stability of regenerated corneal epithelium and the striking improvement in patients' comfort and visual acuity. Interpretation The cultivation of corneal epithelium might offer an alternative to patients with unilateral lesions and a therapeutic chance to patients with severe bilateral corneal-limbal epithelial defects. Our findings give a new perspective on the treatment of ocular disorders characterised by stem-cell deficiency.	IST DERMOPAT IMMACOLATA,LAB TISSUE ENGN,I-00040 ROME,ITALY; IST NAZL RIC CANC,I-16132 GENOA,ITALY; UNIV GENOA,CLIN OCULLIST,GENOA,ITALY; UNIV GENOA,IST ANAT UMANA NORMALE,GENOA,ITALY	IRCCS Istituto Dermopatico dell'Immacolata (IDI); University of Genoa; IRCCS AOU San Martino IST; University of Genoa; University of Genoa			Pellegrini, Graziella/E-1189-2015; De Luca, Michele/N-5883-2014	Pellegrini, Graziella/0000-0001-9861-0736; De Luca, Michele/0000-0002-0850-8445	Telethon [A.041] Funding Source: Medline	Telethon(Fondazione Telethon)		BARRANDON Y, 1987, P NATL ACAD SCI USA, V84, P2302, DOI 10.1073/pnas.84.8.2302; CHEN WYW, 1994, CURR EYE RES, V13, P765, DOI 10.3109/02713689409047012; COTSARELIS G, 1989, CELL, V57, P201, DOI 10.1016/0092-8674(89)90958-6; DELUCA M, 1989, BURNS, V15, P303, DOI 10.1016/0305-4179(89)90007-7; DELUCA M, 1990, TRANSPLANTATION, V50, P454, DOI 10.1097/00007890-199009000-00019; DUA HS, 1990, AM J OPHTHALMOL, V110, P646, DOI 10.1016/S0002-9394(14)77062-X; FRIEND J, 1987, CORNEA, P16; KENYON KR, 1989, OPHTHALMOLOGY, V96, P709; KRUSE F E, 1989, Investigative Ophthalmology and Visual Science, V30, P520; LINDBERG K, 1993, INVEST OPHTH VIS SCI, V34, P2672; Mathor MB, 1996, P NATL ACAD SCI USA, V93, P10371, DOI 10.1073/pnas.93.19.10371; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; ROMAGNOLI G, 1990, NEW ENGL J MED, V323, P527, DOI 10.1056/NEJM199008233230806; SHAPIRO MS, 1981, INVEST OPHTH VIS SCI, V21, P135; SHERMER A, 1986, J CELL BIOL, V103, P49; THOFT RA, 1977, ARCH OPHTHALMOL-CHIC, V95, P1425; THOFT RA, 1977, INVEST OPHTH VIS SCI, V16, P14; TSAI RJF, 1990, OPHTHALMOLOGY, V97, P446, DOI 10.1016/S0161-6420(90)32575-7; TSAI RJF, 1994, CORNEA, V13, P389, DOI 10.1097/00003226-199409000-00003; Wei ZG, 1996, INVEST OPHTH VIS SCI, V37, P523; WEI ZG, 1993, INVEST OPHTH VIS SCI, V34, P1814; WEI ZG, 1995, INVEST OPHTH VIS SCI, V36, P236	22	1012	1080	2	74	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 5	1997	349	9057					990	993		10.1016/S0140-6736(96)11188-0	http://dx.doi.org/10.1016/S0140-6736(96)11188-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR621	9100626				2022-12-01	WOS:A1997WR62100012
J	Chervonsky, AV; Wang, Y; Wong, FS; Visintin, I; Flavell, RA; Janeway, CA; Matis, LA				Chervonsky, AV; Wang, Y; Wong, FS; Visintin, I; Flavell, RA; Janeway, CA; Matis, LA			The role of Fas in autoimmune diabetes	CELL			English	Article							ACTIVATION-INDUCED CELL; PANCREATIC BETA-CELLS; TUMOR-NECROSIS-FACTOR; T-CELLS; TRANSGENIC MICE; LYMPHOPROLIFERATIVE SYNDROME; MEDIATED CYTOTOXICITY; MONOCLONAL-ANTIBODY; ANTIGEN; LIGAND	Immunologically privileged sites express Fas ligand (FasL), which protects them from attack by activated T cells that express Fas and die upon contact with FasL. In an attempt to protect nonobese diabetic mice (NOD) from autoimmune diabetes, we made FasL transgenic NOD mice using the beta cell-specific rat insulin-1 promoter. Surprisingly, these transgenic mice showed heightened sensitivity to diabetogenic T cells, which was due to self-destruction of beta cells upon T cell-mediated induction of Fas. Fas-negative NODlpr/lpr animals were resistant to diabetogenic T cells and to spontaneous diabetes. Thus, induction of Fas expression on beta cells and their subsequent destruction constitutes the main pathogenic mechanism in autoimmune diabetes.	HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; ALEXION PHARMACEUT,NEW HAVEN,CT 06511	Howard Hughes Medical Institute	Chervonsky, AV (corresponding author), YALE UNIV,SCH MED,IMMUNOBIOL SECT,310 CEDAR ST,NEW HAVEN,CT 06510, USA.			Chervonsky, Alexander/0000-0001-7547-871X; Wong, F. Susan/0000-0002-2812-8845	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026810, R13AI126810] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-26810] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADACHI M, 1993, P NATL ACAD SCI USA, V90, P1756, DOI 10.1073/pnas.90.5.1756; ALDERSON MR, 1995, J EXP MED, V181, P71, DOI 10.1084/jem.181.1.71; ALLEN RD, 1990, J EXP MED, V172, P1367, DOI 10.1084/jem.172.5.1367; ALLISON J, 1991, P NATL ACAD SCI USA, V88, P2070, DOI 10.1073/pnas.88.6.2070; Andre I, 1996, P NATL ACAD SCI USA, V93, P2260, DOI 10.1073/pnas.93.6.2260; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DHEIN J, 1995, NATURE, V375, P78; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; GILETTEFERGUSON I, 1994, EUR J IMMUNOL, V24, P1181; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; GUERDER S, 1994, P NATL ACAD SCI USA, V91, P5138, DOI 10.1073/pnas.91.11.5138; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; HAMAGUCHI K, 1991, DIABETES, V40, P842, DOI 10.2337/diabetes.40.7.842; Han HS, 1996, J AUTOIMMUN, V9, P331, DOI 10.1006/jaut.1996.0045; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HUGHES DPM, 1995, J EXP MED, V182, P1395, DOI 10.1084/jem.182.5.1395; JANEWAY CA, 1987, J MOL CELL IMMUNOL, V3, P121; KLAS C, 1993, INT IMMUNOL, V5, P625, DOI 10.1093/intimm/5.6.625; Lau HT, 1996, SCIENCE, V273, P109, DOI 10.1126/science.273.5271.109; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; Lenschow DJ, 1996, IMMUNITY, V5, P285, DOI 10.1016/S1074-7613(00)80323-4; LO D, 1988, CELL, V53, P159, DOI 10.1016/0092-8674(88)90497-7; LYNCH DH, 1994, IMMUNITY, V1, P131, DOI 10.1016/1074-7613(94)90106-6; Murphy E. D., 1978, Genetic control of autoimmune disease. Proceedings of the workshop on the genetic control of autoimmune disease held in Bloomfield Hills, Michigan, USA, on July 10-12, 1978., P207; NAGATA M, 1994, J IMMUNOL, V152, P2042; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; RAMSDELL F, 1994, INT IMMUNOL, V6, P1545, DOI 10.1093/intimm/6.10.1545; RIEUXLAUCAT F, 1995, SCIENCE, V268, P1347, DOI 10.1126/science.7539157; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; RUSSELL JH, 1993, P NATL ACAD SCI USA, V90, P4409, DOI 10.1073/pnas.90.10.4409; STASSI G, 1996, AUTOIMMUNITY S1, V24, P6; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; TAKAHASHI H, 1995, J INVEST DERMATOL, V105, P810, DOI 10.1111/1523-1747.ep12326577; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; Tisch R, 1996, CELL, V85, P291, DOI 10.1016/S0092-8674(00)81106-X; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; VIGNAUX F, 1994, EUR J IMMUNOL, V24, P923, DOI 10.1002/eji.1830240421; Vyse TJ, 1996, CELL, V85, P311, DOI 10.1016/S0092-8674(00)81110-1; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WICKER LS, 1995, ANNU REV IMMUNOL, V13, P179, DOI 10.1146/annurev.iy.13.040195.001143; Wong FS, 1996, J EXP MED, V183, P67, DOI 10.1084/jem.183.1.67; Yagita H, 1996, NATURE, V379, P682, DOI 10.1038/379682a0; Yamada K, 1996, DIABETOLOGIA, V39, P1306, DOI 10.1007/s001250050574; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	47	448	464	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 4	1997	89	1					17	24		10.1016/S0092-8674(00)80178-6	http://dx.doi.org/10.1016/S0092-8674(00)80178-6			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WR685	9094710	hybrid			2022-12-01	WOS:A1997WR68500005
J	Hammond, KA; Diamond, J				Hammond, KA; Diamond, J			Maximal sustained energy budgets in humans and animals	NATURE			English	Review							METABOLIC-RATE; LACTATING MICE; EXPENDITURE; ENERGETICS; MAMMALS; CONSTRAINTS; ADAPTATION; LIMITS; BASAL; BIRDS	Why are sustained energy budgets of humans and other vertebrates limited to not more than about seven times resting metabolic: rate? The answer to this question has potential applications to growth rates, foraging ecology, blogeography, plant metabolism, burn patients and sports medicine.	UNIV CALIF LOS ANGELES, SCH MED, DEPT PHYSIOL, LOS ANGELES, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Hammond, KA (corresponding author), UNIV CALIF RIVERSIDE, DEPT BIOL, RIVERSIDE, CA 92521 USA.							ADAMS NJ, 1991, MAR ECOL PROG SER, V70, P1, DOI 10.3354/meps070001; Amthor J.S., 1989, RESP CROP PRODUCTIVI, DOI [10.1007/978-1-4615-9667-7, DOI 10.1007/978-1-4615-9667-7]; BALLANCE LT, 1995, PHYSIOL ZOOL, V68, P887, DOI 10.1086/physzool.68.5.30163937; BIRTFRIESEN VL, 1989, ECOLOGY, V70, P357, DOI 10.2307/1937540; BRYANT DM, 1984, AUK, V101, P25, DOI 10.1093/auk/101.1.25; DAAN S, 1990, AM J PHYSIOL, V259, pR333, DOI 10.1152/ajpregu.1990.259.2.R333; DRENT RH, 1980, ARDEA, V68, P225; ELSE PL, 1981, AM J PHYSIOL, V240, pR3, DOI 10.1152/ajpregu.1981.240.1.R3; HAMMOND K, 1994, PHYSIOL ZOOL, V67, P282, DOI 10.1086/physzool.67.1.30163847; HAMMOND KA, 1992, PHYSIOL ZOOL, V65, P952, DOI 10.1086/physzool.65.5.30158552; HAMMOND KA, 1994, PHYSIOL ZOOL, V67, P1479, DOI 10.1086/physzool.67.6.30163908; HANSEN LD, 1989, CAN J FOREST RES, V19, P606, DOI 10.1139/x89-095; HAYES JP, 1989, J COMP PHYSIOL B, V159, P453, DOI 10.1007/BF00692417; JOHNSON DE, 1990, J NUTR, V120, P649, DOI 10.1093/jn/120.6.649; KARASOV WH, 1985, AM J PHYSIOL, V249, pG271, DOI 10.1152/ajpgi.1985.249.2.G271; KENAGY GJ, 1990, J ANIM ECOL, V59, P73, DOI 10.2307/5159; KONARZEWSKI M, 1994, PHYSIOL ZOOL, V67, P1186, DOI 10.1086/physzool.67.5.30163889; Konarzewski M, 1995, EVOLUTION, V49, P1239, DOI [10.1111/j.1558-5646.1995.tb04450.x, 10.2307/2410448]; KOTEJA P, 1991, FUNCT ECOL, V5, P56, DOI 10.2307/2389555; Koteja P, 1995, COMP BIOCHEM PHYS A, V112, P479, DOI 10.1016/0300-9629(95)02016-0; Koteja P, 1996, PHYSIOL ZOOL, V69, P994, DOI 10.1086/physzool.69.5.30164243; Koteja P, 1996, PHYSIOL ZOOL, V69, P981, DOI 10.1086/physzool.69.5.30164242; Koteja Pawel, 1994, Polish Ecological Studies, V20, P369; MARTIN ARTHUR W., 1955, PHYSIOL ZOOL, V28, P18; MCDEVITT RM, 1994, PHYSIOL ZOOL, V67, P1117, DOI 10.1086/physzool.67.5.30163885; NAGY KA, 1987, ECOL MONOGR, V57, P111, DOI 10.2307/1942620; OBST BS, 1987, PHYSIOL ZOOL, V60, P200, DOI 10.1086/physzool.60.2.30158644; PANTERBRICK C, 1993, AM J CLIN NUTR, V57, P620, DOI 10.1093/ajcn/57.5.620; PETERSON CC, 1990, P NATL ACAD SCI USA, V87, P2324, DOI 10.1073/pnas.87.6.2324; Portner HO, 2008, SCIENCE, V322, P690, DOI 10.1126/science.1163156; POPPITT SD, 1994, PHYSIOL ZOOL, V67, P976, DOI 10.1086/physzool.67.4.30163874; Rensch I., 1956, Zoologischer Anzeiger, V156, P106; Ricklefs RE, 1996, AM NAT, V147, P1047, DOI 10.1086/285892; RICKLEFS RE, 1979, BIOL REV, V54, P269, DOI 10.1111/j.1469-185X.1979.tb01013.x; ROBY DD, 1986, PHYSIOL ZOOL, V59, P661, DOI 10.1086/physzool.59.6.30158613; ROOT T, 1988, ECOLOGY, V69, P330, DOI 10.2307/1940431; ROYALL D, 1994, CRIT CARE MED, V22, P399, DOI 10.1097/00003246-199403000-00008; SECOR SM, 1994, AM J PHYSIOL, V266, pG695, DOI 10.1152/ajpgi.1994.266.4.G695; SECOR SM, 1995, J EXP BIOL, V198, P1313; TAYLOR CR, 1981, RESP PHYSIOL, V44, P1, DOI 10.1016/0034-5687(81)90073-6; TOLOZA EM, 1991, AM J PHYSIOL, V261, pG608, DOI 10.1152/ajpgi.1991.261.4.G608; WEIBEL ER, 1997, DIVERSITY BIOL DESIG; WEINER J, 1989, ACTA THERIOL, V34, P3, DOI 10.4098/AT.arch.89-1; WESTERTERP KR, 1986, J APPL PHYSIOL, V61, P2162, DOI 10.1152/jappl.1986.61.6.2162	44	407	432	1	112	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 3	1997	386	6624					457	462		10.1038/386457a0	http://dx.doi.org/10.1038/386457a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WR256	9087402				2022-12-01	WOS:A1997WR25600042
J	Campbell, MJ				Campbell, MJ			Circaseptennial rhythm is an artefact	BRITISH MEDICAL JOURNAL			English	Letter											Campbell, MJ (corresponding author), SOUTHAMPTON GEN HOSP,SOUTHAMPTON SO16 6YD,HANTS,ENGLAND.							Slutzky E, 1937, ECONOMETRICA, V5, P105, DOI 10.2307/1907241; Verhulst J, 1996, BRIT MED J, V313, P1597, DOI 10.1136/bmj.313.7072.1597	2	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 29	1997	314	7085					978	978		10.1136/bmj.314.7085.978	http://dx.doi.org/10.1136/bmj.314.7085.978			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ169	9099140	Green Published			2022-12-01	WOS:A1997WQ16900052
J	Rauer, H; Arpigny, C; Boehnhardt, H; Colas, F; Crovisier, J; Jorda, L; Kuppers, M; Manfroid, J; Rembor, K; Thomas, N				Rauer, H; Arpigny, C; Boehnhardt, H; Colas, F; Crovisier, J; Jorda, L; Kuppers, M; Manfroid, J; Rembor, K; Thomas, N			Optical observations of comet Hale-Bopp (C/1995 O1) at large heliocentric distances before perihelion	SCIENCE			English	Article							GAS-PRODUCTION; 17 COMETS; P/HALLEY; HALLEY	The activity of comet Hale-Bopp (C/1995 O1) was monitored monthly by optical imaging and long-slit spectroscopy of its dust and gas distribution over heliocentric distances of 4.6 to 2.9 astronomical units, The observed band intensities of the NH2 radical and the H2O+ ion cannot be explained by existing models of fluorescence excitation, warranting a reexamination of the corresponding production rates, at least at large heliocentric distances, Comparing the production rate of the CN radical to its proposed parent, HCN, shows no evidence for the need of a major additional source for CN in Hale-Bopp at large heliocentric distances, The dust and CN production rates are consistent with a significant amount of sublimation occurring from icy dust grains surrounding Hale-Bopp.	INST ASTROPHYS, B-4000 LIEGE, BELGIUM; UNIV MUNICH, INST ASTRON & ASTROPHYS, D-81679 MUNICH, GERMANY; BUR LONGITUDES, F-75014 PARIS, FRANCE; MAX PLANCK INST AERON, D-37191 KATLENBURG DUHM, GERMANY	University of Munich; Max Planck Society	Rauer, H (corresponding author), OBSERV PARIS, 5 PL JULES JANSSEN, F-92190 MEUDON, FRANCE.		Jorda, Laurent/AAA-1718-2021; Thomas, Nicolas/G-4693-2015	Thomas, Nicolas/0000-0002-0146-0071				AHearn MF, 1995, ICARUS, V118, P223, DOI 10.1006/icar.1995.1190; AHEARN MF, 1985, ICARUS, V64, P1, DOI 10.1016/0019-1035(85)90033-8; AHEARN MF, 1984, ASTRON J, V89, P579, DOI 10.1086/113552; AHEARN MF, 1986, NATURE, V324, P649, DOI 10.1038/324649a0; ARPIGNY C, 1994, AIP C P, V312, P205; Biver N, 1996, NATURE, V380, P137, DOI 10.1038/380137a0; Biver N, 1997, SCIENCE, V275, P1915, DOI 10.1126/science.275.5308.1915; COCHRAN AL, 1992, ICARUS, V98, P151, DOI 10.1016/0019-1035(92)90086-M; CRIFO JF, 1987, ASTRON ASTROPHYS, V187, P438; Crovisier J, 1996, ASTRON ASTROPHYS, V315, pL385; DAVIES JK, 1995, IN PRESS ICARUS, V118; DUTREY A, 1996, 6364 IAU; Fink U, 1996, ASTROPHYS J, V459, P729, DOI 10.1086/176938; Fitzsimmons A, 1996, MON NOT R ASTRON SOC, V278, pL37, DOI 10.1093/mnras/278.2.L37; FITZSIMMONS A, 1996, 6361 IAU; HASER L, 1957, B ACAD R BELG, V5, P43; Irvine WM, 1996, NATURE, V383, P418, DOI 10.1038/383418a0; JEWITT D, 1991, ASTROPHYS SPACE SC L, V167, P19; Jewitt D, 1996, SCIENCE, V271, P1110, DOI 10.1126/science.271.5252.1110; JOCKERS K, 1996, 6468 IAU; KIDGER MR, UNPUB; Kurucz R. L., 1984, SUNSPOT; LECACHEUX J, 1997, 6560 IAU; LUTZ BL, 1987, ASTROPHYS J, V315, pL147, DOI 10.1086/184877; MEECH KJ, 1987, ASTRON ASTROPHYS, V187, P585; NEWBURN RL, 1985, ASTRON J, V90, P2591, DOI 10.1086/113965; SCHLEICHER DG, 1983, THESIS U MARYLAND; SEKANINA Z, 1997, 6542 IAU; TEGLER S, 1989, ASTROPHYS J, V343, P445, DOI 10.1086/167717; WEAVER HA, 1996, 6376 IAU; WOMACK M, 1996, B AM ASTRON SOC, V28, P1091; YAMAMOTO T, 1985, ASTRON ASTROPHYS, V142, P31	32	58	58	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 28	1997	275	5308					1909	1912		10.1126/science.275.5308.1909	http://dx.doi.org/10.1126/science.275.5308.1909			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WQ513	9072962				2022-12-01	WOS:A1997WQ51300037
J	Leyns, L; Bouwmeester, T; Kim, SH; Piccolo, S; DeRobertis, EM				Leyns, L; Bouwmeester, T; Kim, SH; Piccolo, S; DeRobertis, EM			Frzb-1 is a secreted antagonist of Wnt signaling expressed in the Spemann organizer	CELL			English	Article							CELL LUNG-CARCINOMA; XENOPUS EMBRYOS; DROSOPHILA; GENE; POLARITY; MESODERM; PROTEIN; XWNT-8; AXIS; PATTERN	Frzb-1 is a secreted protein containing a domain similar to the putative Wnt-binding region of the frizzled family of transmembrane receptors. Frzb-1 is widely expressed in adult mammalian tissues. In the Xenopus gastrula, it is expressed and regulated as a typical Spemann organizer component. Injection of frzb-1 mRNA blocks expression of XMyoD mRNA and leads to embryos with enlarged heads and shortened trunks. Frzb-1 antagonizes the effects of Xwnt-8 ectopic expression in a non-cell-autonomous manner. Cultured cells transfected with a membrane-tethered form of Wnt-1 bind epitope-tagged Frzb-1 in the 10(-10) M range. The results strengthen the view that the Spemann organizer is a source of secreted inhibitory factors.	UNIV CALIF LOS ANGELES,DEPT BIOL CHEM,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles	Leyns, L (corresponding author), UNIV CALIF LOS ANGELES,HOWARD HUGHES MED INST,LOS ANGELES,CA 90095, USA.			De Robertis, Edward/0000-0002-7843-1869; PICCOLO, STEFANO/0000-0002-2037-0004; Leyns, Luc/0000-0001-7124-3155	NICHD NIH HHS [R37 HD021502-13, HD21502-11, R01 HD021502, R37 HD021502] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD021502, R37HD021502] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Bouwmeester T, 1996, NATURE, V382, P595, DOI 10.1038/382595a0; BURRUS LW, 1995, EXP CELL RES, V220, P363, DOI 10.1006/excr.1995.1327; CHAKRABARTI A, 1992, DEVELOPMENT, V115, P355; CHAN SDH, 1992, J BIOL CHEM, V267, P25202; CHRISTIAN JL, 1991, DEVELOPMENT, V111, P1045; CHRISTIAN JL, 1993, GENE DEV, V7, P13, DOI 10.1101/gad.7.1.13; CUI YZ, 1995, DEVELOPMENT, V121, P2177; DeRobertis EM, 1996, NATURE, V380, P37, DOI 10.1038/380037a0; DU SJ, 1995, MOL CELL BIOL, V15, P2625; FRANK D, 1991, DEVELOPMENT, V113, P1387; GUBB D, 1982, J EMBRYOL EXP MORPH, V68, P37; Hoang B, 1996, J BIOL CHEM, V271, P26131, DOI 10.1074/jbc.271.42.26131; Hoppler S, 1996, GENE DEV, V10, P2805, DOI 10.1101/gad.10.21.2805; JONES CM, 1995, DEVELOPMENT, V121, P3651; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; KOHNO T, 1994, ONCOGENE, V9, P103; KU M, 1993, DEVELOPMENT, V119, P1161; LEMAIRE P, 1995, CELL, V81, P85, DOI 10.1016/0092-8674(95)90373-9; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; PARKIN NT, 1993, GENE DEV, V7, P2181, DOI 10.1101/gad.7.11.2181; PARR BA, 1994, CURR OPIN GENET DEV, V4, P523, DOI 10.1016/0959-437X(94)90067-D; Perrimon N, 1996, CELL, V86, P513, DOI 10.1016/S0092-8674(00)80124-5; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; Schneider S, 1996, MECH DEVELOP, V57, P191, DOI 10.1016/0925-4773(96)00546-1; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SMITH WC, 1995, CELL, V82, P37, DOI 10.1016/0092-8674(95)90050-0; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; Sokol SY, 1996, CURR BIOL, V6, P1456, DOI 10.1016/S0960-9822(96)00750-6; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; TAIRA M, 1994, NATURE, V372, P677, DOI 10.1038/372677a0; TSUCHIYA E, 1992, CANCER RES, V52, P2478; VINSON CR, 1989, NATURE, V338, P263, DOI 10.1038/338263a0; VINSON CR, 1987, NATURE, V329, P549, DOI 10.1038/329549a0; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Wang YS, 1996, J BIOL CHEM, V271, P4468; YangSnyder J, 1996, CURR BIOL, V6, P1302, DOI 10.1016/S0960-9822(02)70716-1; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; ZHENG L, 1995, DEVELOPMENT, V121, P3045; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6	46	595	684	2	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 21	1997	88	6					747	756		10.1016/S0092-8674(00)81921-2	http://dx.doi.org/10.1016/S0092-8674(00)81921-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WQ100	9118218	Bronze, Green Accepted			2022-12-01	WOS:A1997WQ10000007
J	Makarov, VL; Hirose, Y; Langmore, JP				Makarov, VL; Hirose, Y; Langmore, JP			Long G tails at both ends of human chromosomes suggest a C strand degradation mechanism for telomere shortening	CELL			English	Article							AQUATICUS DNA-POLYMERASE; MACRONUCLEAR DNA; 3' TERMINUS; S-PHASE; CELLS; ELONGATION; ORIGIN; YEAST; ORGANIZATION; TETRAHYMENA	The chromosomes of lower eukaryotes have short telomeric 3' extensions. Using a primer-extension/nick-translation technique and nondenaturing hybridization, we find long 3' G-rich tails at human chromosome ends in mortal primary fibroblasts, umbilical vein endothelial cells, and leukocytes, as well as in immortalized fibroblasts. For all cells tested, >80% of the telomeres have long G-rich overhangs, averaging 130-210 bases in length, in disagreement with the conventional model for incomplete lagging-strand replication, which predicts overhangs on 50% of the chromosome ends. The observed G tails must exist during most of the cell cycle and probably result from degradation of both chromosome ends. The average lengths of the G tails are quantitatively consistent with the observed rates of human chromosome shortening.	UNIV MICHIGAN,DEPT BIOL SCI,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan	Makarov, VL (corresponding author), UNIV MICHIGAN,DIV BIOPHYS RES,ANN ARBOR,MI 48109, USA.							ALLSHIRE RC, 1989, NUCLEIC ACIDS RES, V17, P4611, DOI 10.1093/nar/17.12.4611; BIESSMANN H, 1988, EMBO J, V7, P1081, DOI 10.1002/j.1460-2075.1988.tb02916.x; Birren BW, 1993, PULSED FIELD GEL ELE, DOI [10.1016/B978-0-12-101290-8.50002-X, DOI 10.1016/B978-0-12-101290-8.50002-X]; BLACKBURN EH, 1978, J MOL BIOL, V120, P33, DOI 10.1016/0022-2836(78)90294-2; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; CARDENAS ME, 1993, GENE DEV, V7, P870; COLLINS K, 1993, GENE DEV, V7, P1364, DOI 10.1101/gad.7.7b.1364; DELANGE T, 1994, P NATL ACAD SCI USA, V91, P2882, DOI 10.1073/pnas.91.8.2882; DIXIT VM, 1989, J BIOL CHEM, V264, P16905; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; GOTTSCHLING DE, 1986, CELL, V47, P195, DOI 10.1016/0092-8674(86)90442-3; GOULIAN M, 1990, J BIOL CHEM, V265, P18461; Greider Carol W., 1995, Cold Spring Harbor Monograph Series, V29, P35; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HARLEY CB, 1995, CURR OPIN GENET DEV, V5, P249, DOI 10.1016/0959-437X(95)80016-6; HARLEY CB, 1995, COLD SPRING HARBOR M, V29, P247; HENDERSON E, 1988, EUKARYOTIC DNA REPLI, V6, P453; HENDERSON ER, 1989, MOL CELL BIOL, V9, P345, DOI 10.1128/MCB.9.1.345; Henderson Eric, 1995, Cold Spring Harbor Monograph Series, V29, P11; HOLLAND PM, 1991, P NATL ACAD SCI USA, V88, P7276, DOI 10.1073/pnas.88.16.7276; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KLOBUTCHER LA, 1981, P NATL ACAD SCI-BIOL, V78, P3015, DOI 10.1073/pnas.78.5.3015; LEJNINE S, 1995, P NATL ACAD SCI USA, V92, P2393, DOI 10.1073/pnas.92.6.2393; LEVIS RW, 1989, CELL, V58, P791, DOI 10.1016/0092-8674(89)90112-8; Li BB, 1996, GENE DEV, V10, P1310, DOI 10.1101/gad.10.11.1310; LINGNER J, 1995, SCIENCE, V269, P1533, DOI 10.1126/science.7545310; Lingner J, 1996, P NATL ACAD SCI USA, V93, P10712, DOI 10.1073/pnas.93.20.10712; LONGLEY MJ, 1990, NUCLEIC ACIDS RES, V18, P7317, DOI 10.1093/nar/18.24.7317; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; MAKAROV VL, 1993, CELL, V73, P775, DOI 10.1016/0092-8674(93)90256-P; Maniatis T., 1982, MOL CLONING; McClintock B, 1939, P NATL ACAD SCI USA, V25, P405, DOI 10.1073/pnas.25.8.405; MURNANE JP, 1994, EMBO J, V13, P4953, DOI 10.1002/j.1460-2075.1994.tb06822.x; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; PLUTA AF, 1982, NUCLEIC ACIDS RES, V10, P8145, DOI 10.1093/nar/10.24.8145; PRICE CM, 1990, MOL CELL BIOL, V10, P3421, DOI 10.1128/MCB.10.7.3421; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; SHAY JW, 1994, METH MOL G, V5, P263; SIEGAL G, 1992, P NATL ACAD SCI USA, V89, P9377, DOI 10.1073/pnas.89.20.9377; Strahl C, 1996, MOL CELL BIOL, V16, P53; TSENG BY, 1979, J MOL BIOL, V129, P531, DOI 10.1016/0022-2836(79)90467-4; WANG SS, 1990, NATURE, V345, P456, DOI 10.1038/345456a0; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; WELLINGER RJ, 1993, MOL CELL BIOL, V13, P4057, DOI 10.1128/MCB.13.7.4057; Wellinger RJ, 1996, CELL, V85, P423, DOI 10.1016/S0092-8674(00)81120-4; WELLINGER RJ, 1993, CELL, V72, P51, DOI 10.1016/0092-8674(93)90049-V; ZAKIAN VA, 1989, ANNU REV GENET, V23, P579, DOI 10.1146/annurev.genet.23.1.579; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601	54	719	750	0	47	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 7	1997	88	5					657	666		10.1016/S0092-8674(00)81908-X	http://dx.doi.org/10.1016/S0092-8674(00)81908-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WM413	9054505	Bronze			2022-12-01	WOS:A1997WM41300011
J	Madhani, HD; Fink, GR				Madhani, HD; Fink, GR			Combinatorial control required for the specificity of yeast MAPK signaling	SCIENCE			English	Article							DNA-BINDING DOMAIN; SACCHAROMYCES-CEREVISIAE; FILAMENTOUS GROWTH; STE12 PROTEIN; CELL-TYPE; TRANSCRIPTION; ELEMENTS; GENE; ACTIVATION; EXPRESSION	In yeast, an overlapping set of mitogen-activated protein kinase (MAPK) signaling components controls mating, haploid invasion, and pseudohyphal development. Paradoxically, a single downstream transcription factor, Ste12, is necessary for the execution of these distinct programs. Developmental specificity was found to require a transcription factor of the TEA/ATTS family, Tec1, which cooperates with Ste12 during filamentous and invasive growth. Purified derivatives of Ste12 and Tec1 bind cooperatively to enhancer elements called filamentation and invasion response elements (FREs), which program transcription that is specifically responsive to the MAPK signaling components required for filamentous growth. An FRE in the TEC1 promoter functions in a positive feedback loop required for pseudohyphal development.			Madhani, HD (corresponding author), WHITEHEAD INST BIOMED RES, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA.			Madhani, Hiten/0000-0001-7400-6657				ADRIANOPOULOS A, 1991, PLANT CELL, V3, P747, DOI 10.1105/tpc.3.8.747; ANDRIANOPOULOS A, 1994, MOL CELL BIOL, V14, P2503, DOI 10.1128/MCB.14.4.2503; BURGLIN TR, 1991, CELL, V66, P11, DOI 10.1016/0092-8674(91)90132-I; CHIANG CM, 1993, PEPTIDE RES, V6, P62; DOLAN JW, 1989, P NATL ACAD SCI USA, V86, P5703, DOI 10.1073/pnas.86.15.5703; ERREDE B, 1989, GENE DEV, V3, P1349, DOI 10.1101/gad.3.9.1349; Gavrias V, 1996, MOL MICROBIOL, V19, P1255, DOI 10.1111/j.1365-2958.1996.tb02470.x; GIMENO CJ, 1992, CELL, V68, P1077, DOI 10.1016/0092-8674(92)90079-R; GUARENTE L, 1981, P NATL ACAD SCI-BIOL, V78, P2199, DOI 10.1073/pnas.78.4.2199; HAGEN DC, 1991, MOL CELL BIOL, V11, P2952, DOI 10.1128/MCB.11.6.2952; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HWANG JJ, 1993, EMBO J, V12, P2337, DOI 10.1002/j.1460-2075.1993.tb05888.x; LALOUX I, 1994, NUCLEIC ACIDS RES, V22, P999, DOI 10.1093/nar/22.6.999; LIU HP, 1993, SCIENCE, V262, P1741, DOI 10.1126/science.8259520; MADHANI HD, UNPUB; Mosch HU, 1996, P NATL ACAD SCI USA, V93, P5352, DOI 10.1073/pnas.93.11.5352; MOSCH HU, IN PRESS GENETICS; ROBERTS RL, 1994, GENE DEV, V8, P2974, DOI 10.1101/gad.8.24.2974; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Wittenberg C, 1996, CURR OPIN CELL BIOL, V8, P223, DOI 10.1016/S0955-0674(96)80069-X; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; YUAN YLO, 1991, MOL CELL BIOL, V11, P5910, DOI 10.1128/MCB.11.12.5910	22	325	334	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 28	1997	275	5304					1314	1317		10.1126/science.275.5304.1314	http://dx.doi.org/10.1126/science.275.5304.1314			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WK644	9036858				2022-12-01	WOS:A1997WK64400045
J	Zhang, YQ; Kiel, DP; Kreger, BE; Cupples, LA; Ellison, RC; Dorgan, JF; Schatzkin, A; Levy, D; Felson, DT				Zhang, YQ; Kiel, DP; Kreger, BE; Cupples, LA; Ellison, RC; Dorgan, JF; Schatzkin, A; Levy, D; Felson, DT			Bone mass and the risk of breast cancer among postmenopausal women	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ESTROGEN REPLACEMENT THERAPY; HORMONE-BINDING GLOBULIN; MINERAL DENSITY; ELDERLY WOMEN; SEX-HORMONES; ENDOGENOUS HORMONES; MENSTRUAL-CYCLE; HIP-FRACTURES; METAANALYSIS; COMMUNITY	Background Recent studies have shown a direct relation between serum estrogen levels assessed at a single point in time and the risk of breast cancer, but no evidence links estrogen levels assessed repeatedly over an extended interval to the risk of breast cancer. Bone mass has been proposed as a marker of cumulative exposure to estrogen in women. We therefore studied the association between bone mass and the incidence of breast cancer. Methods Between 1967 and 1970, 1373 women who were 47 to 80 years old and had no history of breast cancer underwent posteroanterior hand radiography in the Framingham Study. We used radiogrametry to measure the cortical width cif each woman's second metacarpal. Participants were followed until the end of 1993. All incident cases of breast cancer were confirmed by pathological reports. We used a Cox proportional-hazards model to examine the relation of metacarpal bone mass to the risk of postmenopausal breast cancer. Results Postmenopausal breast cancer developed in 91 subjects. Incidence rates per 1000 person-years increased from 2.0 among the women in the lowest age-specific quartile of metacarpal bone mass to 2.6, 2.71 and 7.0 among the women in the second, third, and highest quartiles, respectively. After adjustments for age and other potential confounding factors, the rate ratios for the risk of breast cancer were 1.0, 1.3, 1.3, and 3.5 from the lowest quartile to the highest (P for trend, <0.001). Conclusions Women in the highest quartile of bone mass are at higher risk for postmenopausal breast cancer than those in the lowest quartile. The mechanisms underlying this relation are not understood, but cumulative exposure to estrogen may play a part. (C) 1997, Massachusetts Medical Society.	BOSTON UNIV,SCH MED,EVANS DEPT MED,PREVENT MED & EPIDEMIOL SECT,BOSTON,MA 02118; BOSTON UNIV,SCH MED,EVANS DEPT MED,GEN INTERNAL MED SECT,BOSTON,MA 02118; HARVARD UNIV,SCH MED,HEBREW REHABIL CTR AGED,BOSTON,MA; HARVARD UNIV,SCH MED,DIV AGING,BOSTON,MA 02115; BOSTON UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL & BIOSTAT,BOSTON,MA; NCI,DIV CANC PREVENT & CONTROL,BETHESDA,MD 20892; FRAMINGHAM HEART DIS EPIDEMIOL STUDY,FRAMINGHAM,MA; NHLBI,BETHESDA,MD 20892	Boston University; Boston University; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Boston University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Framingham Heart Study; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Zhang, YQ (corresponding author), BOSTON UNIV,MED CTR,CTR ARTHRITIS,RM B-612,88 E NEWTON ST,BOSTON,MA 02118, USA.		Levy, Daniel/ABF-6873-2021; Levy, Daniel/ABB-2752-2021	Levy, Daniel/0000-0003-1843-8724; Zhang, Yuqing/0000-0001-7954-1149; Kreger, Bernard/0000-0002-8593-3795; Ellison, Robert Curtis/0000-0002-0582-7467; Felson, David/0000-0002-2668-2447; Kiel, Douglas/0000-0001-8474-0310	NHLBI NIH HHS [N01-HC-38038] Funding Source: Medline; NIAMS NIH HHS [AR20613, AR41398] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020613, R01AR041398] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AITKEN JM, 1974, J BONE JOINT SURG BR, VB 56, P370, DOI 10.1302/0301-620X.56B2.370; Anttila L, 1991, ACTA OBSTET GYN SCAN, V70, P475, DOI 10.3109/00016349109007163; ARMSTRONG BK, 1988, MED J AUSTRALIA, V148, P213, DOI 10.5694/j.1326-5377.1988.tb99424.x; BERNSTEIN L, 1993, EPIDEMIOL REV, V15, P48, DOI 10.1093/oxfordjournals.epirev.a036116; Berrino F, 1996, JNCI-J NATL CANCER I, V88, P291, DOI 10.1093/jnci/88.5.291; Bonjour J P, 1993, Osteoporos Int, V3 Suppl 1, P67, DOI 10.1007/BF01621867; BONJOUR JP, 1991, J CLIN ENDOCR METAB, V73, P555, DOI 10.1210/jcem-73-3-555; BRINTON LA, 1993, EPIDEMIOL REV, V15, P66, DOI 10.1093/oxfordjournals.epirev.a036117; BROWNER WS, 1993, STROKE, V24, P940, DOI 10.1161/01.STR.24.7.940; BROWNER WS, 1991, LANCET, V338, P355, DOI 10.1016/0140-6736(91)90489-C; BUCHANAN JR, 1988, J BONE MINER RES, V3, P673, DOI 10.1002/jbmr.5650030613; BULBROOK RD, 1986, ANN NY ACAD SCI, V464, P378, DOI 10.1111/j.1749-6632.1986.tb16017.x; Cauley JA, 1996, JAMA-J AM MED ASSOC, V276, P1404, DOI 10.1001/jama.276.17.1404; CAULEY JA, 1994, AM J EPIDEMIOL, V139, P1035, DOI 10.1093/oxfordjournals.aje.a116943; CAULEY JA, 1986, AM J EPIDEMIOL, V124, P752, DOI 10.1093/oxfordjournals.aje.a114451; CAULEY JA, 1989, JAMA-J AM MED ASSOC, V261, P1154; CAULEY JA, 1988, JAMA-J AM MED ASSOC, V260, P3150, DOI 10.1001/jama.260.21.3150; COLDITZ GA, 1993, AM J OBSTET GYNECOL, V168, P1473, DOI 10.1016/S0002-9378(11)90784-4; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; DEWAARD F, 1988, INT J CANCER, V41, P666, DOI 10.1002/ijc.2910410505; Dorgan JF, 1996, CANCER EPIDEM BIOMAR, V5, P533; DUPONT WD, 1991, ARCH INTERN MED, V151, P67, DOI 10.1001/archinte.151.1.67; EGELAND GM, 1988, PREV MED, V17, P403, DOI 10.1016/0091-7435(88)90039-4; ETTINGER B, 1985, ANN INTERN MED, V102, P319, DOI 10.7326/0003-4819-102-3-319; EXTONSMITH AN, 1969, LANCET, V2, P1153; FALCH JA, 1990, BONE, V11, P425, DOI 10.1016/8756-3282(90)90138-O; FELSON DT, 1993, NEW ENGL J MED, V329, P1141, DOI 10.1056/NEJM199310143291601; GARLAND CF, 1992, AM J EPIDEMIOL, V135, P1220, DOI 10.1093/oxfordjournals.aje.a116228; GARN SM, 1967, AM J PHYS ANTHROPOL, V26, P313, DOI 10.1002/ajpa.1330260306; GARN SM, 1964, RELATIONS DEVELOPMEN, P41; GENANT HK, 1982, ANN INTERN MED, V97, P699, DOI 10.7326/0003-4819-97-5-699; HARRIS RB, 1990, AM J PUBLIC HEALTH, V80, P1266, DOI 10.2105/AJPH.80.10.1266; HELZLSOUER KJ, 1994, CANCER DETECT PREV, V18, P79; HORSMAN A, 1975, BRIT J RADIOL, V48, P471, DOI 10.1259/0007-1285-48-570-470; KANNEL WB, 1979, ARCH INTERN MED, V139, P857, DOI 10.1001/archinte.139.8.857; KELSEY JL, 1993, EPIDEMIOL REV, V15, P256, DOI 10.1093/oxfordjournals.epirev.a036112; KIEL DP, 1987, NEW ENGL J MED, V317, P1169, DOI 10.1056/NEJM198711053171901; KREGER BE, 1991, CANCER, V67, P1, DOI 10.1002/1097-0142(19910101)67:1<1::AID-CNCR2820670102>3.0.CO;2-W; LEE ET, 1980, STATISTICAL METHODS; LEONARD PJ, 1976, HORMONE ASSAYS THEIR, P657; MADIGAN MP, 1995, J NATL CANCER I, V87, P1681, DOI 10.1093/jnci/87.22.1681; MAZZUOLI G, 1990, J STEROID BIOCHEM, V37, P457, DOI 10.1016/0960-0760(90)90498-A; MCINTOSH JEA, 1980, FERTIL STERIL, V34, P125; MEEMA HE, 1974, J AM GERIATR SOC, V22, P443, DOI 10.1111/j.1532-5415.1974.tb04812.x; MURPHY S, 1992, POSTGRAD MED J, V68, P908, DOI 10.1136/pgmj.68.805.908; OLSSON H, 1992, AM J EPIDEMIOL, V136, P422, DOI 10.1093/oxfordjournals.aje.a116515; PAGANINIHILL A, 1981, ANN INTERN MED, V95, P28, DOI 10.7326/0003-4819-95-1-28; PERSSON I, 1994, CANCER CAUSE CONTROL, V5, P523, DOI 10.1007/BF01831380; PLYMATE SR, 1985, J CLIN ENDOCR METAB, V61, P993, DOI 10.1210/jcem-61-5-993; SILLEROARENAS M, 1992, OBSTET GYNECOL, V79, P286; STEINBERG KK, 1991, JAMA-J AM MED ASSOC, V266, P1362; STEINBERG KK, 1991, JAMA-J AM MED ASSOC, V265, P1985, DOI 10.1001/jama.265.15.1985; STEINBERG KK, 1994, EPIDEMIOLOGY, V5, P415, DOI 10.1097/00001648-199407000-00007; TONIOLO PG, 1995, JNCI-J NATL CANCER I, V87, P190, DOI 10.1093/jnci/87.3.190; VANHEMERT AM, 1989, CLIN ENDOCRINOL, V31, P499; VANHEMERT AM, 1990, J CLIN EPIDEMIOL, V43, P579, DOI 10.1016/0895-4356(90)90162-I; WEISS NS, 1980, NEW ENGL J MED, V303, P1195, DOI 10.1056/NEJM198011203032102; World Health Organization, 1976, ICD O INT CLASS DIS; WYSOWSKI DK, 1987, AM J EPIDEMIOL, V125, P791, DOI 10.1093/oxfordjournals.aje.a114596; ZIEGLER R, 1995, J NUTR, V125, pS2033, DOI 10.1093/jn/125.suppl_7.2033S	60	228	231	1	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 27	1997	336	9					611	617		10.1056/NEJM199702273360903	http://dx.doi.org/10.1056/NEJM199702273360903			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WK028	9032046				2022-12-01	WOS:A1997WK02800003
J	Bregeon, F; Papazian, L; Visconti, A; Gregoire, R; Thirion, X; Gouin, F				Bregeon, F; Papazian, L; Visconti, A; Gregoire, R; Thirion, X; Gouin, F			Relationship of microbiologic diagnostic criteria to morbidity and mortality in patients with ventilator-associated pneumonia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROTECTED SPECIMEN BRUSH; INTENSIVE-CARE UNITS; CONTINUOUS MECHANICAL VENTILATION; QUANTITATIVE CULTURE TECHNIQUES; RANDOMIZED CONTROLLED TRIAL; CRITICALLY ILL PATIENTS; NOSOCOMIAL PNEUMONIA; ATTRIBUTABLE MORTALITY; BACTERIAL PNEUMONIA; HOSPITAL STAY	Objective.-To evaluate whether the mortality and the morbidity of ventilator-associated pneumonia, defined by positive result of protected specimen brush culture, was different from that defined by other methods, Design.-Matched-cohort study. All patients with clinical suspicion of pneumonia were investigated with protected specimen brush, bronchoalveolar lavage, and blind bronchial samplings. Two groups were defined: brush-positive patients (positive culture of the protected specimen brush) and brush-negative patients (negative culture of the protected specimen brush, but positive culture with another method). Setting.-A 14-bed medicosurgical intensive care unit (ICU) in an 850-bed teaching hospital, Patients.-All patients with documented ventilator-associated pneumonia over 4 years 9 months, A total of 102 cases documented by protected specimen brush culture and 223 documented by another sampling procedure, Patients were matched according to diagnosis on admission, age, sex, date of admission, Acute Physiology and Chronic Health Evaluation II (APACHE II) score, and date of onset of pneumonia, Main Outcome Measures.-Mortality rate, duration of mechanical ventilation, duration of ICU stay, duration of hospital stay, sampling methods, and microbiologic cultures, Results.-A total of 76 pairs were submitted for analysis, The effectiveness of matching was 81.85%, There was no difference in mortality between brush-positive patients and brush-negative patients, The ICU fatality rate was 38% in the brush-positive group and 39.4% in the brush-negative group (odds ratio [OR], 0.95; 95% confidence interval [CI], 0.46-1.93), The hospital fatality rate was 41% (OR, 1;95% CI, 0.5-2.01), The mean (SD) duration of ventilation was 26 (23) days in the 2 groups (range, 3-132 days). The duration of ICU stay was 33 (27.4) days in the 2 groups (range, 3-152 days), Conclusions.-When confounding factors are controlled, patient outcome is the same if ventilator-associated pneumonia has been diagnosed by protected specimen brush or by another sampling method.	HOP ST MARGUERITE, DEPT ANESTHESIA & INTENS CARE, MARSEILLE, FRANCE; HOP ST MARGUERITE, DEPT MED INFORMAT, MARSEILLE, FRANCE	UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille								ANDREWS CP, 1981, CHEST, V80, P254, DOI 10.1378/chest.80.3.254; [Anonymous], 1982, EPIDEMIOLOGIC RES; AUBAS S, 1994, AM J RESP CRIT CARE, V149, P860, DOI 10.1164/ajrccm.149.4.8143047; BAKER AM, 1995, CHEST, V107, P85, DOI 10.1378/chest.107.1.85; Baker AM, 1996, AM J RESP CRIT CARE, V153, P343, DOI 10.1164/ajrccm.153.1.8542141; CHASTRE J, 1984, AM REV RESPIR DIS, V130, P924; CHEVRET S, 1993, INTENS CARE MED, V19, P256, DOI 10.1007/BF01690545; COHEN IL, 1995, CHEST, V107, P1673, DOI 10.1378/chest.107.6.1673; CRAIG CP, 1984, AM J INFECT CONTROL, V12, P233, DOI 10.1016/0196-6553(84)90114-7; CRAVEN DE, 1986, AM REV RESPIR DIS, V133, P792; DJEDAINI K, 1995, AM J RESP CRIT CARE, V152, P1562, DOI 10.1164/ajrccm.152.5.7582295; FAGON JY, 1993, AM J MED, V94, P281, DOI 10.1016/0002-9343(93)90060-3; FAGON JY, 1988, AM REV RESPIR DIS, V138, P110, DOI 10.1164/ajrccm/138.1.110; FAGON JY, 1989, AM REV RESPIR DIS, V139, P877, DOI 10.1164/ajrccm/139.4.877; FAGON JY, 1993, CHEST, V103, P547, DOI 10.1378/chest.103.2.547; GASTINNE H, 1992, NEW ENGL J MED, V326, P594, DOI 10.1056/NEJM199202273260903; GROSS PA, 1983, AM J MED, V75, P658, DOI 10.1016/0002-9343(83)90453-9; JIMENEZ P, 1989, CRIT CARE MED, V17, P882, DOI 10.1097/00003246-198909000-00007; KAPPSTEIN I, 1992, EUR J CLIN MICROBIOL, V11, P504, DOI 10.1007/BF01960804; KNAUS W A, 1989, American Review of Respiratory Disease, V140, pS8; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1985, ANN SURG, V202, P685, DOI 10.1097/00000658-198512000-00004; KOLLEF MH, 1995, CHEST, V108, P1655, DOI 10.1378/chest.108.6.1655; KOLLEF MH, 1993, JAMA-J AM MED ASSOC, V270, P1965, DOI 10.1001/jama.270.16.1965; KOLLEF MH, 1995, ANN INTERN MED, V123, P168, DOI 10.7326/0003-4819-123-3-199508010-00002; LANGER M, 1989, AM REV RESPIR DIS, V140, P302, DOI 10.1164/ajrccm/140.2.302; LANGER M, 1987, INTENS CARE MED, V13, P342; LEU HS, 1989, AM J EPIDEMIOL, V129, P1258, DOI 10.1093/oxfordjournals.aje.a115245; MARQUETTE CH, 1995, AM J RESP CRIT CARE, V151, P1878, DOI 10.1164/ajrccm.151.6.7767535; MCCABE WR, 1962, ARCH INTERN MED, V110, P847, DOI 10.1001/archinte.1962.03620240029006; MOORE RD, 1984, AM J MED, V77, P657, DOI 10.1016/0002-9343(84)90358-9; NIEDERMAN MS, 1994, AM J RESP CRIT CARE, V150, P565, DOI 10.1164/ajrccm.150.2.8049849; Papazian L, 1996, AM J RESP CRIT CARE, V154, P91, DOI 10.1164/ajrccm.154.1.8680705; PAPAZIAN L, 1995, AM J RESP CRIT CARE, V152, P1982, DOI 10.1164/ajrccm.152.6.8520766; PHAM LH, 1991, AM REV RESPIR DIS, V143, P1055, DOI 10.1164/ajrccm/143.5_Pt_1.1055; PINGLETON SK, 1992, CHEST, V102, pS553, DOI 10.1378/chest.102.5_Supplement_1.553S; PRODHOM G, 1994, ANN INTERN MED, V120, P653, DOI 10.7326/0003-4819-120-8-199404150-00005; RELLO J, 1993, CHEST, V104, P1230, DOI 10.1378/chest.104.4.1230; RELLO J, 1994, AM J RESP CRIT CARE, V150, P1545, DOI 10.1164/ajrccm.150.6.7952612; RELLO J, 1991, CHEST, V100, P439, DOI 10.1378/chest.100.2.439; ROUBY JJ, 1994, INTENS CARE MED, V20, P187, DOI 10.1007/BF01704698; ROUBY JJ, 1989, ANESTHESIOLOGY, V71, P679, DOI 10.1097/00000542-198911000-00010; SALATA RA, 1987, AM REV RESPIR DIS, V135, P426; *SAS I INC, 1988, SAS US GUID, P126; TORRES A, 1994, AM J RESP CRIT CARE, V149, P324, DOI 10.1164/ajrccm.149.2.8306025; TORRES A, 1990, AM REV RESPIR DIS, V142, P523, DOI 10.1164/ajrccm/142.3.523; TORRES A, 1995, AM J RESP CRIT CARE, V152, P137, DOI 10.1164/ajrccm.152.1.7599812; VANSAENE HKF, 1992, REAN URG, V1, P385; VINCENT JL, 1995, JAMA-J AM MED ASSOC, V274, P639, DOI 10.1001/jama.274.8.639; WAYNE WD, 1995, BIOSTATISTICS FDN AN, P235; WIMBERLEY N, 1979, AM REV RESPIR DIS, V119, P337	51	45	47	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 26	1997	277	8					655	662		10.1001/jama.277.8.655	http://dx.doi.org/10.1001/jama.277.8.655			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WJ498	9039885				2022-12-01	WOS:A1997WJ49800035
J	Schmidt, A; Bickle, M; Beck, T; Hall, MN				Schmidt, A; Bickle, M; Beck, T; Hall, MN			The yeast phosphatidylinositol kinase homolog TOR2 activates RHO1 and RHO2 via the exchange factor ROM2	CELL			English	Article							GTP-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE GENE; RAS SUPERFAMILY GENES; CELL POLARITY; BUDDING YEAST; BUD FORMATION; CDC42; RAPAMYCIN; ENCODES; GROWTH	The Saccharomyces cerevisiae phosphatidylinositol kinase homolog TOR2 is required for organization of the actin cytoskeleton. Overexpression of RHO1 or RHO2, encoding Rho-like GTPases, or ROM2, encoding a GDP/GTP exchange factor for RHO1 and RHO2, suppresses a tor2 mutation. Deletion of SAC7, a gene originally identified as a suppressor of an actin mutation, also suppresses a tor2 mutation. SAC7 is a novel GTPase-activating protein for RHO1. ROM2 exchange activity is reduced in a tor2 mutant, and overexpression of ROM2 lacking its PH domain can no longer suppress a tor2 mutation. Thus, TOR2 signals to the actin cytoskeleton through a GTPase switch composed of RHO1, RHO2, ROM2, and SAC7. TOR2 activates this switch via ROM2, possibly via the ROM2 PH domain.	UNIV BASEL, DEPT BIOCHEM, BIOZENTRUM, CH-4056 BASEL, SWITZERLAND	University of Basel				Hall, Michael N/0000-0002-2998-0757				ADAMS AEM, 1984, J CELL BIOL, V98, P934, DOI 10.1083/jcb.98.3.934; ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; BARFOD ET, 1993, J BIOL CHEM, V268, P26059; BENEDETTI H, 1994, MOL BIOL CELL, V5, P1023, DOI 10.1091/mbc.5.9.1023; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; CAFFERKEY R, 1993, MOL CELL BIOL, V13, P6012, DOI 10.1128/MCB.13.10.6012; Chen GC, 1996, MOL CELL BIOL, V16, P1376; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; DOWNWARD J, 1995, NATURE, V376, P553, DOI 10.1038/376553a0; Drgonova J, 1996, SCIENCE, V272, P277, DOI 10.1126/science.272.5259.277; DRUBIN DG, 1991, CELL, V65, P1093, DOI 10.1016/0092-8674(91)90001-F; DUNN TM, 1990, MOL CELL BIOL, V10, P2308, DOI 10.1128/MCB.10.5.2308; Errede B, 1993, CURR OPIN CELL BIOL, V5, P254, DOI 10.1016/0955-0674(93)90112-4; Guthrie C., 1991, METHODS ENZYMOLOGY G, V194; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; Hall MN, 1996, BIOCHEM SOC T, V24, P234, DOI 10.1042/bst0240234; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; HELLIWELL SB, 1994, MOL BIOL CELL, V5, P105, DOI 10.1091/mbc.5.1.105; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; Igual JC, 1996, EMBO J, V15, P5001, DOI 10.1002/j.1460-2075.1996.tb00880.x; Imai J, 1996, GENETICS, V142, P359; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; Kamada Y, 1996, J BIOL CHEM, V271, P9193, DOI 10.1074/jbc.271.16.9193; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; KRON SJ, 1995, CURR OPIN CELL BIOL, V7, P845, DOI 10.1016/0955-0674(95)80069-7; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; LANCASTER CA, 1994, J BIOL CHEM, V269, P1137; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; LEVIN DE, 1992, J CELL BIOL, V116, P1221, DOI 10.1083/jcb.116.5.1221; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; MADAULE P, 1987, P NATL ACAD SCI USA, V84, P779, DOI 10.1073/pnas.84.3.779; MASUDA T, 1994, J BIOL CHEM, V269, P19713; MATSUI Y, 1992, GENE, V114, P43, DOI 10.1016/0378-1119(92)90705-T; MATSUI Y, 1992, MOL CELL BIOL, V12, P5690, DOI 10.1128/MCB.12.12.5690; MAZZONI C, 1993, J CELL BIOL, V123, P1821, DOI 10.1083/jcb.123.6.1821; Mosch HU, 1996, P NATL ACAD SCI USA, V93, P5352, DOI 10.1073/pnas.93.11.5352; MULLER L, 1994, NUCLEIC ACIDS RES, V22, P3151, DOI 10.1093/nar/22.15.3151; NONAKA H, 1995, EMBO J, V14, P5931, DOI 10.1002/j.1460-2075.1995.tb00281.x; Ozaki K, 1996, EMBO J, V15, P2196, DOI 10.1002/j.1460-2075.1996.tb00573.x; PARK HO, 1993, NATURE, V365, P269, DOI 10.1038/365269a0; PETERSON J, 1994, J CELL BIOL, V127, P1395, DOI 10.1083/jcb.127.5.1395; Qadota H, 1996, SCIENCE, V272, P279, DOI 10.1126/science.272.5259.279; QADOTA H, 1994, P NATL ACAD SCI USA, V91, P9317, DOI 10.1073/pnas.91.20.9317; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; ROEMER T, 1994, J CELL BIOL, V127, P567, DOI 10.1083/jcb.127.2.567; Sambrook J., 1989, MOL CLONING LAB MANU, V3; Schmidt A, 1996, P NATL ACAD SCI USA, V93, P13780, DOI 10.1073/pnas.93.24.13780; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; STEVENSON BJ, 1995, GENE DEV, V9, P2949, DOI 10.1101/gad.9.23.2949; TANAKA K, 1991, P NATL ACAD SCI USA, V88, P468, DOI 10.1073/pnas.88.2.468; vonManteuffel SR, 1996, P NATL ACAD SCI USA, V93, P4076, DOI 10.1073/pnas.93.9.4076; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8; ZHENG XF, 1995, CELL, V82, P121, DOI 10.1016/0092-8674(95)90058-6; ZHENG Y, 1994, J BIOL CHEM, V269, P2369; ZHENG Y, 1993, J BIOL CHEM, V268, P24629; ZIMAN M, 1991, MOL CELL BIOL, V11, P3537, DOI 10.1128/MCB.11.7.3537	69	256	266	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 21	1997	88	4					531	542		10.1016/S0092-8674(00)81893-0	http://dx.doi.org/10.1016/S0092-8674(00)81893-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WJ691	9038344	Bronze			2022-12-01	WOS:A1997WJ69100013
J	Yin, CY; Knudson, CM; Korsmeyer, SJ; VanDyke, T				Yin, CY; Knudson, CM; Korsmeyer, SJ; VanDyke, T			Bax suppresses tumorigenesis and stimulates apoptosis in vivo	NATURE			English	Article							PROGRAMMED CELL-DEATH; VIRUS-40 T-ANTIGEN; WILD-TYPE P53; IN-VIVO; GENE AMPLIFICATION; TRANSGENIC MICE; EXPRESSION; DEFICIENT; MUTANT; BCL-2	The protein p53 is a key tumour-suppressor, as evidenced by its frequent inactivation in human cancers. Animal models have indicated that attenuation of p53-dependent cell death (apoptosis) can contribute to both the initiation and progression of cancer, but the molecular mechanisms are unknown, Although p53-mediated transcriptional activation is one possible explanation, none of the known p53-responsive genes has been shown to function in p53-dependent apoptosis. Here we test the role of the death-promoting gene bax in a transgenic mouse brain tumour, a model in which p53-mediated apoptosis attenuates tumour growth, Inactivation of p53 causes a dramatic acceleration of tumour growth owing to a reduction in apoptosis of over ninety per cent(1). We show that p53-dependent expression of bax is induced in slow-growing apoptotic tumours. Moreover, tumour growth is accelerated and apoptosis drops by fifty per cent in Bax-deficient mice, indicating that it is required for a full p53-mediated response. To our knowledge this is the first demonstration that Bax acts as a tumour suppressor, and our findings indicate that Bax could be a component of the p53-mediated apoptotic response in this system.	UNIV N CAROLINA, SCH MED, LINEBERGER COMPREHENS CANC CTR, DEPT BIOCHEM & BIOPHYS, CHAPEL HILL, NC 27599 USA; WASHINGTON UNIV, SCH MED, HOWARD HUGHES MED INST, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DIV MOL ONCOL, ST LOUIS, MO 63110 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL)				Knudson, Charles Michael/0000-0003-3964-5466				Brady HJM, 1996, EMBO J, V15, P1221, DOI 10.1002/j.1460-2075.1996.tb00463.x; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MCCURRACH ME, UNPUB P NATL ACAD SC; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PIPAS JM, 1983, MOL CELL BIOL, V3, P203, DOI 10.1128/MCB.3.2.203; ROBLES MTS, 1994, MOL CELL BIOL, V14, P2686, DOI 10.1128/MCB.14.4.2686; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; SYMONDS HS, 1993, MOL CELL BIOL, V13, P3255, DOI 10.1128/MCB.13.6.3255; Van Dyke Terry A., 1993, P287; YAN C, 1990, EMBO J, V9, P869, DOI 10.1002/j.1460-2075.1990.tb08184.x; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	21	556	590	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 13	1997	385	6617					637	640		10.1038/385637a0	http://dx.doi.org/10.1038/385637a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WH294	9024662				2022-12-01	WOS:A1997WH29400051
J	Johansson, JE; Holmberg, L; Johansson, S; Bergstrom, R; Adami, HO				Johansson, JE; Holmberg, L; Johansson, S; Bergstrom, R; Adami, HO			Fifteen-year survival in prostate cancer - A prospective, population-based study in Sweden	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LONG-TERM SURVIVAL; NATURAL-HISTORY; FOLLOW-UP; DIAGNOSIS; ANTIGEN; MEN; ESTRAMUSTINE; MANAGEMENT; ASPIRATION; CARCINOMA	Objective.-To describe the natural history of initially untreated early-stage prostate cancer. A key secondary objective was to calculate long-term survival rates by stage, grade, and age at diagnosis. Design.-Prospective cohort study, Setting.-Population-based in 1 county of Sweden, without screening for prostate cancer. Patients.-A group of 642 patients with prostate cancer of any stage, consecutively diagnosed between 1977 and 1984 at a mean age of 72 years with complete follow-up to 1994. Main Outcome Measures.-Proportion of patients who died from prostate cancer, and 15-year survival (with 95% confidence interval [CI]), corrected for causes of death other than prostate cancer. Results.-In the entire cohort, prostate cancer accounted for 201 (37%) of all 541 deaths. Among 300 patients with a diagnosis of localized disease (T0-T2), 33 (11%) died of prostate cancer. In this group, the corrected 15-year survival rate was similar in 223 patients with deferred treatment (81%; 95% CI, 72%-89%) and in 77 who received initial treatment (81%; 95% CI, 67%-95%). The corrected 15-year survival was 57% (95% CI, 45%-68%) in 183 patients with locally advanced cancer (T3-T4) and 6% (95% CI, 0%-12%) in those 159 who had distant metastases at the time of diagnosis. Conclusion.-Patients with localized prostate cancer have a favorable outlook following watchful waiting, and the number of deaths potentially avoidable by radical initial treatment is limited. Without reliable prognostic indicators, an aggressive approach to all patients with early disease would entail substantial overtreatment. In contrast, patients with locally advanced or metastatic disease need trials of aggressive therapy to improve their poor prognosis.	UNIV UPPSALA HOSP, DEPT CANC EPIDEMIOL, UPPSALA, SWEDEN; UPPSALA UNIV, DEPT STAT, UPPSALA, SWEDEN; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, CTR CANC PREVENT, BOSTON, MA 02115 USA	Uppsala University; Uppsala University Hospital; Uppsala University; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Johansson, JE (corresponding author), OREBRO MED CTR HOSP, DEPT UROL, S-70185 OREBRO, SWEDEN.							ABRAHAMSSON PA, 1996, J UROLOGY, V155, P296; ADAMI HO, 1994, LANCET, V343, P958, DOI 10.1016/S0140-6736(94)90071-X; ADOLFSSON J, 1993, CANCER-AM CANCER SOC, V72, P310, DOI 10.1002/1097-0142(19930715)72:2<310::AID-CNCR2820720203>3.0.CO;2-T; ALBERTSEN PC, 1995, JAMA-J AM MED ASSOC, V274, P626, DOI 10.1001/jama.274.8.626; AUS G, 1995, J UROLOGY, V154, P460, DOI 10.1016/S0022-5347(01)67074-5; AUSTENFELD MS, 1994, J UROLOGY, V152, P1866, DOI 10.1016/S0022-5347(17)32403-5; Cancer Registry of Norway, 1980, SURV CANC PAT CAS DI; CATALONA WJ, 1993, JAMA-J AM MED ASSOC, V270, P948, DOI 10.1001/jama.270.8.948; CHODAK GW, 1994, NEW ENGL J MED, V330, P242, DOI 10.1056/NEJM199401273300403; CHODAK GW, 1984, J UROLOGY, V132, P480, DOI 10.1016/S0022-5347(17)49699-6; CHODAK GW, 1993, UROLOGY, V42, P116, DOI 10.1016/0090-4295(93)90633-L; CHODAK GW, 1995, J UROLOGY, V154, P2132, DOI 10.1016/S0022-5347(01)66714-4; COX DR, 1972, J R STAT SOC B, V34, P187; CUTLER SJ, 1958, J CHRON DIS, V8, P699; EDERER FRED, 1961, NATL CANCER INST MONOGR, V6, P101; FRACCHIA JA, 1993, PRIM CARE CANC, V13, P31; FRANZEN S, 1960, Br J Urol, V32, P193, DOI 10.1111/j.1464-410X.1960.tb03763.x; GRAVERSEN PH, 1990, UROLOGY, V36, P493, DOI 10.1016/0090-4295(90)80184-O; GRONBERG H, 1995, THESIS UMEA U UMEA; HAKULINEN T, 1977, J CHRON DIS, V30, P431, DOI 10.1016/0021-9681(77)90036-4; HAKULINEN T, 1981, ANN CLIN RES, V13, P1; Helgesen F, 1996, JNCI-J NATL CANCER I, V88, P1216, DOI 10.1093/jnci/88.17.1216; *INT UN CANC, 1978, TNM CLASS MAL TUM; IVERSEN P, 1995, SCAND J UROL NEPHROL, P65; JOHANSSON JE, 1989, LANCET, V1, P799; JOHANSSON JE, 1992, JAMA-J AM MED ASSOC, V267, P2191, DOI 10.1001/jama.267.16.2191; JOHANSSON JE, 1987, UROLOGY, V29, P55, DOI 10.1016/0090-4295(87)90599-1; JOHANSSON JE, 1991, BRIT J UROL, V68, P67, DOI 10.1111/j.1464-410X.1991.tb15259.x; JOHANSSON JE, 1991, J UROLOGY, V145, P519, DOI 10.1016/S0022-5347(17)38385-4; JOHANSSON JE, 1995, 126 SWED COUNC TECHN; LEVI F, 1992, EUR J CANCER, V28A, P1490, DOI 10.1016/0959-8049(92)90551-C; LITTRUP PJ, 1993, CA-CANCER J CLIN, V43, P134, DOI 10.3322/canjclin.43.3.134; NITTI V, 1995, LANCET S26, V346; OTNES B, 1995, BRIT J UROL, V76, P587, DOI 10.1111/j.1464-410X.1995.tb07783.x; PEARSON JD, 1994, J UROLOGY, V152, P1743, DOI 10.1016/S0022-5347(17)32375-3; SCARDINO PT, 1989, UROL CLIN N AM, V16, P635; SCHRODER FH, 1995, BRIT MED J, V310, P140, DOI 10.1136/bmj.310.6973.140; STENBECK M, 1995, ACTA ONCOL, V34, P61, DOI 10.3109/02841869509094060; STENMAN UH, 1994, LANCET, V344, P1594, DOI 10.1016/S0140-6736(94)90405-7; TIBBLIN G, 1995, J UROLOGY, V154, P1386, DOI 10.1016/S0022-5347(01)66872-1; Tretli S, 1996, J NATL CANCER I, V88, P128, DOI 10.1093/jnci/88.2.128; WAISMAN J, 1991, UROLOGY, V37, P301, DOI 10.1016/0090-4295(91)80253-4; Wasson J H, 1993, Arch Fam Med, V2, P487, DOI 10.1001/archfami.2.5.487; WATERBOR JW, 1995, CANCER CAUSE CONTROL, V6, P267, DOI 10.1007/BF00051798; *WHO, 1980, INT HIST CLASS TUM H; WINGO PA, 1995, CA-CANCER J CLIN, V45, P8, DOI 10.3322/canjclin.45.1.8	46	335	346	2	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 12	1997	277	6					467	471		10.1001/jama.277.6.467	http://dx.doi.org/10.1001/jama.277.6.467			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WG054	9020270				2022-12-01	WOS:A1997WG05400033
J	Kedes, DH; Ganem, D; Ameli, N; Bacchetti, P; Greenblatt, R				Kedes, DH; Ganem, D; Ameli, N; Bacchetti, P; Greenblatt, R			The prevalence of serum antibody to human herpesvirus 8 (Kaposi sarcoma-associated herpesvirus) among HIV-seropositive and high-risk HIV-seronegative women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INFECTED WOMEN; HOMOSEXUAL MEN; DNA-SEQUENCES; FORMS; AIDS; TRANSMISSION	Objective.-To determine the prevalence of human herpesvirus 8 (HHV-8) seropositivity among women who are known to be infected with human immunodeficiency virus type 1 (HIV-1) or who are at high risk for HIV infection. Design.-A cross-sectional and blinded study of the prevalence of serological reactivity to HHV-8 infection as determined by an indirect immunofluorescence assay using nuclei from cells latently infected with HHV-8. Data and specimens were collected at baseline assessments of a longitudinal natural history cohort study. Setting.-Four San Francisco Bay Area outpatient HIV specialty clinics participating in the cohort study. Patients.-A total of 387 participants in the Women's Interagency HIV Study whose HIV infection status was documented and serum was available in a local specimen repository. Main Outcome Measure.-Serological reactivity to HHV-8. Results.-Serological reactivity to latent HHV-8 antigens was uncommon among study participants: 13 (3.4%) demonstrated serum antibodies. HHV-8 reactivity was more common among HIV-infected women; 12 (4.0%; 95% confidence interval [CI], 2.1%-6.9%) of the 302 HIV-infected participants vs 1 (1.2%; 95% CI, 0.03%-6.4%) of the 84 HIV-uninfected participants were seropositive for HHV-8, though the difference did not attain statistical significance (odds ratio=3.43; 95% CI, 0.49-148.6). Two of the HIV-infected women had Kaposi sarcoma lesions and both were seropositive. Conclusions.-The prevalence of HHV-8 seropositivity among the group of HIV-infected women was dramatically lower than that recently reported among HIV-infected homosexual and bisexual men (30%-35%). This finding parallels the lower prevalence of Kaposi sarcoma among women in contrast to men with HIV infection. These data further extend the correlation of HHV-8 serological reactivity with risk of Kaposi sarcoma and are consistent with an important role for HHV-8 infection in development of Kaposi sarcoma.	UNIV CALIF SAN FRANCISCO,DEPT MED,DIV INFECT DIS,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco					NIAID NIH HHS [U01-AI-34989] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI034989] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBRECHT H, 1994, GENITOURIN MED, V70, P394; AMBROZIAK JA, 1995, SCIENCE, V268, P582, DOI 10.1126/science.7725108; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BERAL V, 1991, CANCER HIV AIDS, P5; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chuck S, 1996, J INFECT DIS, V173, P248, DOI 10.1093/infdis/173.1.248; Corbellino M, 1996, NEW ENGL J MED, V335, P1237, DOI 10.1056/NEJM199610173351614; FRANCESCHI S, 1995, J ACQ IMMUN DEF SYND, V9, P313, DOI 10.1097/00042560-199507000-00016; FRIEDMANKIEN AE, 1990, LANCET, V335, P168, DOI 10.1016/0140-6736(90)90041-3; Gao SJ, 1996, NAT MED, V2, P925, DOI 10.1038/nm0896-925; GEDDES M, 1994, BRIT J CANCER, V69, P333, DOI 10.1038/bjc.1994.60; HUANG YQ, 1995, LANCET, V345, P759, DOI 10.1016/S0140-6736(95)90641-X; Jacobson Lisa P., 1995, Current Opinion in Oncology, V7, P450, DOI 10.1097/00001622-199509000-00011; Kedes DH, 1996, NAT MED, V2, P918, DOI 10.1038/nm0896-918; Lennette ET, 1996, LANCET, V348, P858, DOI 10.1016/S0140-6736(96)03240-0; LIN JC, 1995, LANCET, V346, P1601, DOI 10.1016/S0140-6736(95)91931-7; MEHTA CR, 1985, J AM STAT ASSOC, V80, P969, DOI 10.2307/2288562; Monini P, 1996, NEW ENGL J MED, V334, P1168, DOI 10.1056/NEJM199605023341805; MOORE P, 1995, AIDS, V10, P175; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; MORLAT P, 1992, AIDS, V6, P1187, DOI 10.1097/00002030-199210000-00020; PENN I, 1979, TRANSPLANTATION, V27, P8, DOI 10.1097/00007890-197901000-00003; RABKIN CS, 1993, INT J CANCER, V55, P208, DOI 10.1002/ijc.2910550207; Renne R, 1996, NAT MED, V2, P342, DOI 10.1038/nm0396-342; SCHALLING M, 1995, NAT MED, V1, P707, DOI 10.1038/nm0795-707; SERRAINO D, 1995, AIDS, V9, P971, DOI 10.1097/00002030-199508000-00022; Simpson GR, 1996, LANCET, V348, P1133, DOI 10.1016/S0140-6736(96)07560-5; Tasaka T, 1996, NEW ENGL J MED, V335, P1237; WHITBY D, 1995, LANCET, V346, P799, DOI 10.1016/S0140-6736(95)91619-9; ZIEGLER JL, 1984, SEMIN ONCOL, V11, P47	30	122	125	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 12	1997	277	6					478	481		10.1001/jama.277.6.478	http://dx.doi.org/10.1001/jama.277.6.478			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WG054	9020272				2022-12-01	WOS:A1997WG05400035
J	Mocroft, A; Youle, M; Morcinek, J; Sabin, CA; Gazzard, B; Johnson, MA; Phillips, AN				Mocroft, A; Youle, M; Morcinek, J; Sabin, CA; Gazzard, B; Johnson, MA; Phillips, AN			Survival after diagnosis of AIDS: A prospective observational study of 2625 patients	BRITISH MEDICAL JOURNAL			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; PNEUMOCYSTIS-CARINII PNEUMONIA; NEW-YORK-CITY; EUROPEAN PATIENTS; CONTROLLED TRIAL; ZIDOVUDINE; TRENDS; EXPERIENCE; PATTERNS; EFFICACY	Objective: To estimate median survival and changes in survival in patients diagnosed as having AIDS. Design: Prospective observational study. Setting: Clinics in two large London hospitals. Subjects: 2625 patients with AIDS seen between 1982 and July 1995. Main outcome measures: Survival, estimated using lifetable analyses, and factors associated with survival, identified from Cox proportional hazards models. Results: Median survival (20 months) was longer than previous estimates. The CD4 lymphocyte count at or before initial AIDS defining illness decreased significantly over time from 90 x 10(6)/l during 1987 or earlier to 40x10(6)/l during 1994 and 1995 (P < 0.0001). In the first three months after diagnosis, patients in whom AIDS was diagnosed after 1987 had a much lower risk of death (relative risk 0.44, 95% confidence interval 0.22 to 0.86; P=0.0.017) than patients diagnosed before 1987. When the diagnosis was based on oesophageal candidiasis or Kaposi's sarcoma, patients had a lower risk of death than when the diagnosis was based on Pneumocystis carinii pneumonia (0.21 (0.07 to 0.59), P=0.0030 and 0.37 (0.16 to 0.83), P=0.016). Three months after AIDS diagnosis, the risk of death was similar in patients whose diagnosis was made after and before 1987 (1.02 (0.79 to 1.31), P=0.91). There were no differences in survival between patients diagnosed during 1958-90, 1991-3, or 1994-5. Conclusions:In later years, patients were much more likely to survive their initial illness, but long term survival has remained poor. The decrease in CD4 lymphocyte count at AIDS diagnosis indicates that patients are being diagnosed as having AIDS at ever more advanced stages of immunodeficiency.	ROYAL FREE HOSP,DEPT THORAC MED,LONDON NW3 2PF,ENGLAND; CHELSEA & WESTMINSTER HOSP,KOBLER CTR,ST STEPHENS CLIN,LONDON SW10 9TH,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Imperial College London	Mocroft, A (corresponding author), ROYAL FREE HOSP,SCH MED,HIV RES UNIT,DEPT PRIMARY CARE & POPULAT,LONDON NW3 2PF,ENGLAND.		Mocroft, Amanda/C-1527-2008; Sabin, Caroline/C-2464-2008; Phillips, Andrew N/B-4427-2008; Mocroft, Amanda/G-8748-2011	Sabin, Caroline/0000-0001-5173-2760; Phillips, Andrew N/0000-0003-2384-4807; Mocroft, Amanda/0000-0001-8316-1122				Centers for Disease Control (CDC), 1992, MMWR Morb Mortal Wkly Rep, V41, P1; BLUM S, 1994, AM J EPIDEMIOL, V139, P351, DOI 10.1093/oxfordjournals.aje.a117007; Centers for Disease Control, 1987, MMWR-MORBID MORTAL W, V21, p1S; CHANG HGH, 1993, AM J EPIDEMIOL, V138, P341, DOI 10.1093/oxfordjournals.aje.a116864; CHEQUER P, 1992, AIDS, V6, P483, DOI 10.1097/00002030-199205000-00007; DOURNON E, 1988, LANCET, V2, P1297; Enger C, 1996, JAMA-J AM MED ASSOC, V275, P1329, DOI 10.1001/jama.275.17.1329; FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185, DOI 10.1001/jama.259.8.1185; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; HILL AB, 1984, SHORT TXB MED STATIS; JACOBSON LP, 1993, AM J EPIDEMIOL, V138, P952, DOI 10.1093/oxfordjournals.aje.a116815; LEMP GF, 1990, JAMA-J AM MED ASSOC, V263, P402, DOI 10.1001/jama.263.3.402; LUNDGREN JD, 1995, ARCH INTERN MED, V155, P822, DOI 10.1001/archinte.155.8.822; LUNDGREN JD, 1994, BMJ-BRIT MED J, V308, P1068, DOI 10.1136/bmj.308.6936.1068; LUO KH, 1995, AIDS, V9, P57, DOI 10.1097/00002030-199501000-00008; MCLEOD GX, 1992, ANN INTERN MED, V117, P487, DOI 10.7326/0003-4819-117-6-487; MUNOZ A, 1993, AM J EPIDEMIOL, V137, P423, DOI 10.1093/oxfordjournals.aje.a116691; OSMOND D, 1994, JAMA-J AM MED ASSOC, V271, P1083, DOI 10.1001/jama.271.14.1083; PAYNE SF, 1990, J ACQ IMMUN DEF SYND, V3, pS14; PIETTE J, 1991, HEALTH SERV RES, V26, P75; PIETTE JD, 1992, EPIDEMIOLOGY, V3, P310, DOI 10.1097/00001648-199207000-00006; Rogers PA, 1996, AIDS, V10, P1571, DOI 10.1097/00002030-199611000-00017; ROTHENBERG R, 1987, NEW ENGL J MED, V317, P1297, DOI 10.1056/NEJM198711193172101; SAAH AJ, 1994, J ACQ IMMUN DEF SYND, V7, P287; *SAS I, 1990, SAS US GUID; SCHWARTLANDER B, 1992, AIDS, V6, P413, DOI 10.1097/00002030-199204000-00009; SEAGE GR, 1993, AM J PUBLIC HEALTH, V83, P72, DOI 10.2105/AJPH.83.1.72; TURNER BJ, 1991, J ACQ IMMUN DEF SYND, V4, P1059; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; WHITMOREOVERTON SE, 1993, AIDS, V7, P415, DOI 10.1097/00002030-199303000-00017; 1996, COMMUN DI SREP CDR W, V6, P141	31	50	56	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 8	1997	314	7078					409	413		10.1136/bmj.314.7078.409	http://dx.doi.org/10.1136/bmj.314.7078.409			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH295	9040386	Green Published			2022-12-01	WOS:A1997WH29500028
J	Jin, FY; Nathan, C; Radzioch, D; Ding, A				Jin, FY; Nathan, C; Radzioch, D; Ding, A			Secretory leukocyte protease inhibitor: A macrophage product induced by and antagonistic to bacterial lipopolysaccharide	CELL			English	Article							STABLE PROTEINASE-INHIBITOR; AIRWAY EPITHELIAL-CELLS; NITRIC-OXIDE SYNTHASE; AMINO-ACID SEQUENCE; LEUKOPROTEASE INHIBITOR; MONOCLONAL-ANTIBODIES; ENDOTOXIN RESISTANCE; DIFFERENTIAL DISPLAY; INDUCED EMPHYSEMA; GAMMA-INTERFERON	To explore regulation of potentially lethal responses to bacterial lipopolysaccharide (LPS), we used differential display under LPS-free conditions to compare macrophage cell lines from two strains of mice congenic for a locus affecting LPS sensitivity. LPS-hyporesponsive cells, primary macrophages, and polymorphonuclear leukocytes transcribed secretory leukocyte protease inhibitor (SLPI), a known epithelial cell-derived inhibitor of leukocyte serine proteases. Transfection of macrophages with SLPI suppressed LPS-induced activation of NF-kappa B and production of nitric oxide and TNF alpha. The ability of interferon-gamma (IFN gamma) to restore LPS responsiveness is a hallmark of the LPS-hyporesponsive phenotype. IFN gamma suppressed expression of SLPI and restored LPS responsiveness to SLPI-producing cells. Thus, SLPI is an LPS-induced IFN gamma-suppressible phagocyte product that serves to inhibit LPS responses.	MCGILL UNIV, DEPT MED, MONTREAL, PQ H3G 1A4, CANADA	McGill University	Jin, FY (corresponding author), CORNELL UNIV, COLL MED, BEATRICE & SAMUEL A SEAVER LAB, DEPT MED, NEW YORK, NY 10021 USA.			Radzioch, Danuta/0000-0002-1601-2757	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030165, R01AI034543, R29AI030165, R21AI034543] Funding Source: NIH RePORTER; NIAID NIH HHS [AI34543, AI30165] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABBINANTENISSEN JM, 1993, AM J PHYSIOL, V265, pL286, DOI 10.1152/ajplung.1993.265.3.L286; ABBINANTENISSEN JM, 1995, AM J PHYSIOL-LUNG C, V268, pL601, DOI 10.1152/ajplung.1995.268.4.L601; ABE T, 1991, J CLIN INVEST, V87, P2207, DOI 10.1172/JCI115255; BEESON PB, 1947, J EXP MED, V86, P29, DOI 10.1084/jem.86.1.29; BEUTLER B, 1986, J EXP MED, V164, P1791, DOI 10.1084/jem.164.5.1791; BEUTLER B, 1986, SCIENCE, V232, P977, DOI 10.1126/science.3754653; BLASI E, 1987, EUR J IMMUNOL, V17, P1491, DOI 10.1002/eji.1830171016; BOGDAN C, 1991, J EXP MED, V174, P1549, DOI 10.1084/jem.174.6.1549; BOHM B, 1992, EUR J BIOCHEM, V207, P773, DOI 10.1111/j.1432-1033.1992.tb17108.x; BONE RC, 1991, ANN INTERN MED, V115, P457, DOI 10.7326/0003-4819-115-6-457; Brandtzaeg P, 1996, J EXP MED, V184, P51, DOI 10.1084/jem.184.1.51; COSTA TE, 1992, J EXP MED, V175, P1669, DOI 10.1084/jem.175.6.1669; COUTINHO A, 1975, SCAND J IMMUNOL, V4, P129; COX GW, 1989, J NATL CANCER I, V81, P1492, DOI 10.1093/jnci/81.19.1492; Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563; DEWATER R, 1986, AM REV RESPIR DIS, V133, P882; DING A, 1990, J IMMUNOL, V145, P940; DING AH, 1995, J LEUKOCYTE BIOL, V57, P174, DOI 10.1002/jlb.57.1.174; DING AH, 1987, J EXP MED, V165, P733, DOI 10.1084/jem.165.3.733; DING AH, 1987, J IMMUNOL, V139, P1971; DRENTH J, 1980, J BIOL CHEM, V255, P2652; EISENBERG SP, 1990, J BIOL CHEM, V265, P7976; FINK E, 1986, BIOL CHEM H-S, V367, P567, DOI 10.1515/bchm3.1986.367.2.567; GRUTTER MG, 1988, EMBO J, V7, P345, DOI 10.1002/j.1460-2075.1988.tb02819.x; HEINZEL R, 1986, EUR J BIOCHEM, V160, P61, DOI 10.1111/j.1432-1033.1986.tb09940.x; HELMIG R, 1995, EUR J OBSTET GYN R B, V59, P95, DOI 10.1016/0028-2243(94)02023-8; HOGAN MM, 1988, J IMMUNOL, V140, P513; Hutchison D C, 1987, Eur J Respir Dis Suppl, V153, P78; INGALLS RR, 1995, J EXP MED, V181, P1473, DOI 10.1084/jem.181.4.1473; KANAYAMA N, 1995, BIOCHEM BIOPH RES CO, V207, P324, DOI 10.1006/bbrc.1995.1191; KRAMPS JA, 1989, AM REV RESPIR DIS, V140, P471, DOI 10.1164/ajrccm/140.2.471; KU GSB, 1981, J IMMUNOL, V126, P2209; KUUSREICHEL K, 1986, J IMMUNOL, V137, P472; LEE CH, 1993, AM REV RESPIR DIS, V147, P710, DOI 10.1164/ajrccm/147.3.710; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; LUCEY EC, 1990, J LAB CLIN MED, V115, P224; MARUYAMA M, 1994, J CLIN INVEST, V94, P368, DOI 10.1172/JCI117331; MCNEELY TB, 1995, J CLIN INVEST, V96, P456, DOI 10.1172/JCI118056; NATHAN CF, 1987, J CLIN INVEST, V79, P319, DOI 10.1172/JCI112815; Ohlsson K, 1988, Adv Exp Med Biol, V240, P123; OHLSSON K, 1995, J ANDROL, V16, P64; PARKER MM, 1983, JAMA-J AM MED ASSOC, V250, P3324, DOI 10.1001/jama.250.24.3324; PEARSE RN, 1991, P NATL ACAD SCI USA, V88, P11305, DOI 10.1073/pnas.88.24.11305; RANDOW F, 1995, J EXP MED, V181, P1887, DOI 10.1084/jem.181.5.1887; ROSENSTREICH DL, 1975, J IMMUNOL, V115, P777; RUDOLPHUS A, 1993, AM REV RESPIR DIS, V147, P442, DOI 10.1164/ajrccm/147.2.442; SALLENAVE JM, 1993, AM J RESP CELL MOL, V8, P126, DOI 10.1165/ajrcmb/8.2.126; SALLENAVE JM, 1994, AM J RESP CELL MOL, V11, P733, DOI 10.1165/ajrcmb.11.6.7946401; SEEMULLER U, 1986, FEBS LETT, V199, P43, DOI 10.1016/0014-5793(86)81220-0; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; STETLER G, 1986, NUCLEIC ACIDS RES, V14, P7883, DOI 10.1093/nar/14.20.7883; STOLK J, 1993, PULM PHARMACOL, V6, P33, DOI 10.1006/pulp.1993.1006; SULTZER BM, 1993, IMMUNOBIOLOGY, V187, P257, DOI 10.1016/S0171-2985(11)80343-8; SULTZER BM, 1968, NATURE, V219, P1253, DOI 10.1038/2191253a0; SULTZER BM, 1976, INFECT IMMUN, V13, P1579, DOI 10.1128/IAI.13.6.1579-1584.1976; Sweet MJ, 1996, J LEUKOCYTE BIOL, V60, P8, DOI 10.1002/jlb.60.1.8; TEGNER H, 1978, ACTA OTO-LARYNGOL, V85, P282, DOI 10.3109/00016487809111936; THOMPSON RC, 1986, P NATL ACAD SCI USA, V83, P6692, DOI 10.1073/pnas.83.18.6692; TOBIAS PS, 1986, J EXP MED, V164, P777, DOI 10.1084/jem.164.3.777; Tomova Svetlana, 1994, Journal of Molecular Recognition, V7, P31, DOI 10.1002/jmr.300070105; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; WATSON J, 1977, J IMMUNOL, V120, P422; WRIGHT SD, 1986, J EXP MED, V164, P1876, DOI 10.1084/jem.164.6.1876; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; XIE QW, 1994, J BIOL CHEM, V269, P4705; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; YUROCHKO AD, 1992, P NATL ACAD SCI USA, V89, P9034, DOI 10.1073/pnas.89.19.9034	68	316	333	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 7	1997	88	3					417	426		10.1016/S0092-8674(00)81880-2	http://dx.doi.org/10.1016/S0092-8674(00)81880-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WG479	9039268	hybrid			2022-12-01	WOS:A1997WG47900014
J	Harrison, CJ; HayerHartl, M; DiLiberto, M; Hartl, FU; Kuriyan, J				Harrison, CJ; HayerHartl, M; DiLiberto, M; Hartl, FU; Kuriyan, J			Crystal structure of the nucleotide exchange factor GrpE bound to the ATPase domain of the molecular chaperone DnaK	SCIENCE			English	Article							HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI; REACTION CYCLE; HSP70; GROEL; TRANSLOCATION; DISSOCIATION; HYDROLYSIS; KINETICS; BINDING	The crystal structure of the adenine nucleotide exchange factor GrpE in complex with the adenosine triphosphatase (ATPase) domain of Escherichia coli DnaK [heat shock protein 70 (Hsp70)] was determined at 2.8 angstrom resolution. A dimer of GrpE binds asymmetrically to a single molecule of DnaK. The structure of the nucleotide-free ATPase domain in complex with GrpE resembles closely that of the nucleotide-bound mammalian Hsp70 homolog, except for an outward rotation of one of the subdomains of the protein. This conformational change is not consistent with tight nucleotide binding. Two long alpha helices extend away from the GrpE dimer and suggest a role for GrpE in peptide release from DnaK.	ROCKEFELLER UNIV, LAB MOL BIOPHYS, NEW YORK, NY 10021 USA; ROCKEFELLER UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, NEW YORK, NY 10021 USA; HOWARD HUGHES MED INST, CELLULAR BIOCHEM & BIOPHYS PROGRAM, NEW YORK, NY USA	Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute			Hayer-Hartl, Manajit/V-8078-2017; Hartl, F. Ulrich/Y-8206-2019	Hayer-Hartl, Manajit/0000-0001-8213-6742; 				BUCHBERGER A, 1994, NAT STRUCT BIOL, V1, P95, DOI 10.1038/nsb0294-95; CARSON M, 1986, J MOL GRAPHICS, V4, P121, DOI 10.1016/0263-7855(86)80010-8; CRAIG EA, 1993, MICROBIOL REV, V57, P402, DOI 10.1128/MMBR.57.2.402-414.1993; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cellbio.9.1.601; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HAYERHARTL MK, 1995, SCIENCE, V269, P836, DOI 10.1126/science.7638601; HAYERHARTL MK, 1994, EMBO J, V13, P3192, DOI 10.1002/j.1460-2075.1994.tb06618.x; HOHFELD J, 1995, CELL, V83, P589; JANIN J, 1995, BIOCHIMIE, V77, P497, DOI 10.1016/0300-9084(96)88166-1; JIANG JS, 1994, J MOL BIOL, V243, P100, DOI 10.1006/jmbi.1994.1633; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kawashima T, 1996, NATURE, V379, P511, DOI 10.1038/379511a0; LALORAYA S, 1995, MOL CELL BIOL, V15, P7098; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/S0968-0004(96)10052-9; MINOR W, UNPUB; Naylor DJ, 1996, FEBS LETT, V396, P181, DOI 10.1016/0014-5793(96)01100-3; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; RICE LM, 1994, PROTEINS, V19, P277, DOI 10.1002/prot.340190403; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; SCHONFELD HJ, 1995, J BIOL CHEM, V270, P2183, DOI 10.1074/jbc.270.5.2183; STUART RA, 1994, TRENDS BIOCHEM SCI, V19, P87, DOI 10.1016/0968-0004(94)90041-8; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; Turk D., UNPUB; VANDUYNE GD, UNPUB; WESTERMANN B, 1995, EMBO J, V14, P3452, DOI 10.1002/j.1460-2075.1995.tb07351.x; WU B, 1994, J BACTERIOL, V176, P6965, DOI 10.1128/JB.176.22.6965-6973.1994; Wu B, 1996, EMBO J, V15, P4806, DOI 10.1002/j.1460-2075.1996.tb00861.x; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606; ZIEGELHOFFER T, 1995, J BIOL CHEM, V270, P10412, DOI 10.1074/jbc.270.18.10412	35	397	410	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 18	1997	276	5311					431	435		10.1126/science.276.5311.431	http://dx.doi.org/10.1126/science.276.5311.431			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WU477	9103205				2022-12-01	WOS:A1997WU47700045
J	Liu, XS; Zou, H; Slaughter, C; Wang, XD				Liu, XS; Zou, H; Slaughter, C; Wang, XD			DFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis	CELL			English	Article							POLY(ADP-RIBOSE) POLYMERASE; RAT THYMOCYTES; LEUCINE-ZIPPER; CELL-DEATH; IDENTIFICATION; PURIFICATION; CLEAVES; ENZYME; CED-3; GENE	We have identified and purified from HeLa cytosol a protein that induces DNA fragmentation in coincubated nuclei after it is activated by caspase-3. This protein, designated DNA Fragmentation Factor (DFF), is a heterodimer of 40 kDa and 45 kDa subunits. The amino acid sequence of the 45 kDa subunit, determined from its cDNA sequence, reveals it to be a novel protein. Caspase-3 cleaves the 45 kDa subunit at two sites to generate an active factor that produces DNA fragmentation without further requirement for caspase-3 or other cytosolic proteins. In cells undergoing apoptosis, the 45 kDa subunit is cleaved in the same pattern as it is cleaved by caspase-3 in vitro. These data delineate a direct signal transduction pathway during apoptosis: caspase-3 to DFF to DNA fragmentation.	UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; EMORY UNIV,SCH MED,GRAD DIV BIOL & BIOMED SCI,ATLANTA,GA 30322; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Emory University; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Wang, Xiaodong/0000-0001-9885-356X				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Boulakia CA, 1996, ONCOGENE, V12, P529; CACIOLAROSEN L, 1996, J EXP MED, V183, P1957; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Darmon AJ, 1996, J BIOL CHEM, V271, P21709, DOI 10.1074/jbc.271.36.21709; Datta R, 1996, BLOOD, V88, P1936, DOI 10.1182/blood.V88.6.1936.bloodjournal8861936; Datta R, 1997, J BIOL CHEM, V272, P1965, DOI 10.1074/jbc.272.3.1965; Dubrez L, 1996, EMBO J, V15, P5504, DOI 10.1002/j.1460-2075.1996.tb00935.x; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Erhardt P, 1996, J BIOL CHEM, V271, P17601, DOI 10.1074/jbc.271.30.17601; GAIDO ML, 1991, J BIOL CHEM, V266, P18580; GERNANDESALNEMR.G, 1994, J BIOL CHEM, V269, P30761; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; Hasegawa J, 1996, CANCER RES, V56, P1713; Ibrado AM, 1996, CANCER RES, V56, P4743; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu XS, 1996, J BIOL CHEM, V271, P13371, DOI 10.1074/jbc.271.23.13371; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; McConkey DJ, 1996, J BIOL CHEM, V271, P22398, DOI 10.1074/jbc.271.37.22398; Monney L, 1996, BIOCHEM BIOPH RES CO, V221, P340, DOI 10.1006/bbrc.1996.0597; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NIKONOVA LV, 1993, EUR J BIOCHEM, V215, P893, DOI 10.1111/j.1432-1033.1993.tb18107.x; PEITSCH MC, 1993, EMBO J, V12, P371, DOI 10.1002/j.1460-2075.1993.tb05666.x; Quan LT, 1996, P NATL ACAD SCI USA, V93, P1972, DOI 10.1073/pnas.93.5.1972; Sambrook J., 1989, MOL CLONING LAB MANU; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Song ZW, 1997, SCIENCE, V275, P536, DOI 10.1126/science.275.5299.536; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; WANG XD, 1993, J BIOL CHEM, V268, P14497; WANG XD, 1995, J BIOL CHEM, V270, P18044, DOI 10.1074/jbc.270.30.18044; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WYLLIE AH, 1995, CURR OPIN GENET DEV, V5, P97, DOI 10.1016/S0959-437X(95)90060-8; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZAMZAMI N, 1996, J EXP MED, V183, P1523	51	1588	1666	1	41	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 18	1997	89	2					175	184		10.1016/S0092-8674(00)80197-X	http://dx.doi.org/10.1016/S0092-8674(00)80197-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WU888	9108473	Bronze			2022-12-01	WOS:A1997WU88800005
J	Stratton, JF; Gayther, SA; Russell, P; Dearden, J; Gore, M; Blake, P; Easton, D; Ponder, BAJ				Stratton, JF; Gayther, SA; Russell, P; Dearden, J; Gore, M; Blake, P; Easton, D; Ponder, BAJ			Contribution of BRCA1 mutations to ovarian cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GERMLINE MUTATIONS; BREAST; GENE; FAMILIES; HETERODUPLEX	Background Inherited mutations in the BRCA1 gene confer a high risk of breast and ovarian cancer in some families. To determine the contribution of BRCA1 mutations to ovarian cancer in the general population, we analyzed DNA samples from a consecutive series of women with ovarian cancer seen at one center. Methods We studied 374 women who received a diagnosis of epithelial ovarian cancer before the age of 70 years and were treated at the Royal Marsden Hospital between July 1993 and September 1995. Genomic DNA was analyzed by multiplex heteroduplex analysis. Variants were further identified by sequencing. Results Probable germ-line BRCA1 mutations were identified in 13 of the 374 women (3 percent; 95 percent confidence interval, 2 to 6 percent). Six of the variants have not been described previously. Of the 13 mutations, 12 are predicted to result in a truncated protein product. An additional variant results in an in-frame deletion just outside the putative zinc-finger domain. Nine of the 12 women with truncating mutations had family histories of breast or ovarian cancer or both. Conclusions Assuming that our method has a sensitivity of 70 percent, mutations in BRCA1 occur in approximately 5 percent (95 percent confidence interval, 3 to 8 percent) of women in whom ovarian cancer is diagnosed before the age of 70 years. (C) 1997, Massachusetts Medical Society.	CANC RES CAMPAIGN, HUMAN CANC GENET RES GRP, CAMBRIDGE, ENGLAND; ROYAL MARSDEN HOSP, DEPT CLIN ONCOL, LONDON SW3 6JJ, ENGLAND; INST PUBL HLTH, CANC RES CAMPAIGN, GENET EPIDEMIOL UNIT, CAMBRIDGE, ENGLAND	CRUK Cambridge Institute; Royal Marsden NHS Foundation Trust; CRUK Cambridge Institute; University of Cambridge	Stratton, JF (corresponding author), ADDENBROOKES HOSP, WELLBEING OVARIAN CANC RES CTR, BOX 238, CAMBRIDGE CB2 2QQ, ENGLAND.							ABEL KJ, 1995, HUM MOL GENET, V4, P2265, DOI 10.1093/hmg/4.12.2265; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; Couch FJ, 1996, HUM MUTAT, V8, P8, DOI 10.1002/humu.1380080102; EASTON DF, 1995, AM J HUM GENET, V56, P265; FitzGerald MG, 1996, NEW ENGL J MED, V334, P143, DOI 10.1056/NEJM199601183340302; FORD D, 1995, AM J HUM GENET, V57, P1457; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; GAYTHER SA, 1995, NAT GENET, V11, P428, DOI 10.1038/ng1295-428; Gayther SA, 1996, AM J HUM GENET, V58, P451; GLAVAC D, 1995, HUM MUTAT, V6, P281, DOI 10.1002/humu.1380060402; Langston AA, 1996, NEW ENGL J MED, V334, P137, DOI 10.1056/NEJM199601183340301; Mathew CG, 1996, NEW ENGL J MED, V334, P1198; MATSUSHIMA M, 1995, HUM MOL GENET, V4, P1953, DOI 10.1093/hmg/4.10.1953; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; NAROD SA, 1994, BRIT MED BULL, V50, P656, DOI 10.1093/oxfordjournals.bmb.a072915; ROSSETTI S, 1995, MOL CELL PROBE, V9, P195, DOI 10.1006/mcpr.1994.0028; Rubin SC, 1996, NEW ENGL J MED, V335, P1413, DOI 10.1056/NEJM199611073351901; SIMARD J, 1994, NAT GENET, V8, P392, DOI 10.1038/ng1294-392; TAKAHASHI H, 1995, CANCER RES, V55, P2998	20	196	199	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 17	1997	336	16					1125	1130		10.1056/NEJM199704173361602	http://dx.doi.org/10.1056/NEJM199704173361602			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU003	9099656				2022-12-01	WOS:A1997WU00300002
J	Lumley, J				Lumley, J			How important is social class a factor in preterm birth?	LANCET			English	Editorial Material											Lumley, J (corresponding author), LA TROBE UNIV,CTR STUDY MOTHERS & CHILDRENS HLTH,CARLTON,VIC 3053,AUSTRALIA.							FEDRICK J, 1976, BRIT J OBSTET GYNAEC, V83, P342, DOI 10.1111/j.1471-0528.1976.tb00840.x; Logan S, 1996, BRIT MED J, V313, P1332; LUMLEY J, 1993, BAILLIERE CLIN OB GY, V7, P477, DOI 10.1016/S0950-3552(05)80445-6; MACFARLANE A, 1988, BRIT MED BULL, V44, P861, DOI 10.1093/oxfordjournals.bmb.a072298; Wildschut HIJ, 1997, BRIT J OBSTET GYNAEC, V104, P57, DOI 10.1111/j.1471-0528.1997.tb10650.x	5	11	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 12	1997	349	9058					1040	1041		10.1016/S0140-6736(05)62287-8	http://dx.doi.org/10.1016/S0140-6736(05)62287-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU002	9107238				2022-12-01	WOS:A1997WU00200004
J	Soutter, WP; Lopes, AD; Fletcher, A; Monaghan, JM; Duncan, ID; Paraskevaidis, E; Kitchener, HC				Soutter, WP; Lopes, AD; Fletcher, A; Monaghan, JM; Duncan, ID; Paraskevaidis, E; Kitchener, HC			Invasive cervical cancer after conservative therapy for cervical intraepithelial neoplasia	LANCET			English	Article							SEMM COLD COAGULATOR; CARCINOMA-INSITU; HYSTERECTOMY; DESTRUCTION; EXPERIENCE; LASER	Background Conservative outpatient therapy for cervical intraepithelial neoplasia (CIN) by ablative or excisional techniques is widely used. The main objective of this treatment is the prevention of invasive cervical cancer. We assessed the rate of invasive disease and the duration of the risk of developing invasive cervical cancer after such treatment. Methods Four UK centres have used life-table methods to analyse the long-term results of conservative treatment of GIN. We combined and updated data from these studies to investigate the rate of invasive disease after treatment and the duration of that risk. Findings The data comprised 44 699 woman-years of follow-up, with 2116 women under observation 8 years after treatment. 33 women developed invasive cancer, 14 of whom had microinvasion. The cumulative rate of invasion 8 years after treatment was 5.8 per 1000 women and the rate of invasive cancer during this period was 85 (95% CI 60-119) per 100 000 woman-years. The risk of developing cancer did not change throughout the 8 years of follow-up. Interpretation These data show that conservative outpatient therapy in women with CIN reduces the risk of invasive cancer of the cervix by 95% during the first 8 years after treatment. However, even with careful, long-term follow-up, the risk of invasive cervical cancer among these women is about five times greater than that among the general population of women throughout that period. Careful follow-up is essential for at least 10 years after conservative treatment of CIN.	QUEEN ELIZABETH HOSP, GATESHEAD HOSP NHS TRUST, GATESHEAD, TYNE & WEAR, ENGLAND; LONDON SCH HYG & TROP MED, DEPT EPIDEMIOL & POPULAT STUDIES, LONDON, ENGLAND; UNIV DUNDEE, NINEWELLS HOSP & MED SCH, DUNDEE DD1 9SY, SCOTLAND; ABERDEEN ROYAL INFIRM, DEPT OBSTET & GYNAECOL, ABERDEEN, SCOTLAND	University of London; London School of Hygiene & Tropical Medicine; University of Dundee; University of Aberdeen	Soutter, WP (corresponding author), HAMMERSMITH HOSP, ROYAL POSTGRAD MED SCH, INST OBSTET & GYNAECOL, LONDON W12 0NN, ENGLAND.		de Barros Lopes, Alberto/B-2116-2018; Paraskevaidis, Evangelos/ABH-4990-2020	de Barros Lopes, Alberto/0000-0002-8796-3891; 				Armitage P, 1971, STAT METHODS MED RES; BOYES D A, 1970, Journal of Obstetrics and Gynaecology of the British Commonwealth, V77, P769; BURGHARDT E, 1980, OBSTET GYNECOL, V55, P539; DRAEBYKRISTIANSEN J, 1991, AM J OBSTET GYNECOL, V165, P43, DOI 10.1016/0002-9378(91)90220-L; FAWDRY RDS, 1984, BRIT J OBSTET GYNAEC, V91, P67, DOI 10.1111/j.1471-0528.1984.tb05281.x; Fleiss J L, 1993, Stat Methods Med Res, V2, P121, DOI 10.1177/096228029300200202; GEMMELL J, 1990, BRIT J OBSTET GYNAEC, V97, P58, DOI 10.1111/j.1471-0528.1990.tb01717.x; GORDON HK, 1991, BRIT J OBSTET GYNAEC, V98, P14, DOI 10.1111/j.1471-0528.1991.tb10304.x; KOLSTAD P, 1976, OBSTET GYNECOL, V48, P125; LOOBUYCK HA, 1993, BRIT J OBSTET GYNAEC, V100, P465, DOI 10.1111/j.1471-0528.1993.tb15273.x; MCINDOE WA, 1984, OBSTET GYNECOL, V64, P451; PARASKEVAIDIS E, 1991, OBSTET GYNECOL, V78, P80; PEARSON SE, 1989, BRIT J OBSTET GYNAEC, V96, P486, DOI 10.1111/j.1471-0528.1989.tb02429.x; SOUTTER P, 1993, PRACTICAL GUIDE COLP, P98; SOUTTER WP, 1986, COLP GYNECOL LAS SUR, V2, P35	15	197	216	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 5	1997	349	9057					978	980		10.1016/S0140-6736(96)08295-5	http://dx.doi.org/10.1016/S0140-6736(96)08295-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR621	9100623				2022-12-01	WOS:A1997WR62100009
J	Barry, MJ; Roberts, RG				Barry, MJ; Roberts, RG			Indications for PSA testing	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							PROSTATE-SPECIFIC ANTIGEN; CANCER; MEN		UNIV WISCONSIN, SCH MED, DEPT FAMILY MED, MADISON, WI USA	University of Wisconsin System; University of Wisconsin Madison	Barry, MJ (corresponding author), HARVARD UNIV, MASSACHUSETTS GEN HOSP, SCH MED, MED PRACTICES EVALUAT CTR, BOSTON, MA 02114 USA.							Barry M. J., 1996, JGIM, V11, P62; CATALONA WJ, 1994, J UROLOGY, V151, P1283, DOI 10.1016/S0022-5347(17)35233-3; Collins M. F. Mcnaughton, 1996, JGIM, V11, P81; Flood AB, 1996, J GEN INTERN MED, V11, P342, DOI 10.1007/BF02600045; Fowler Floyd J., 1996, Journal of Urology, V155, p681A; MANDELSON MT, 1995, ANNU REV PUBL HEALTH, V16, P283; METTLIN C, 1993, CA-CANCER J CLIN, V43, P42, DOI 10.3322/canjclin.43.1.42; SERSHON PD, 1994, EUR UROL, V25, P281; *US PREV SERV TASK, 1996, GUID CLIN PREV SERV, P119; WOOLF SH, 1995, NEW ENGL J MED, V333, P1401, DOI 10.1056/NEJM199511233332107	10	8	8	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 26	1997	277	12					955	956		10.1001/jama.277.12.955	http://dx.doi.org/10.1001/jama.277.12.955			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN992	9091657				2022-12-01	WOS:A1997WN99200012
J	Williams, AE; Thomson, RA; Schreiber, GB; Watanabe, K; Bethel, J; Lo, A; Kleinman, SH; Hollingsworth, CG; Nemo, GJ				Williams, AE; Thomson, RA; Schreiber, GB; Watanabe, K; Bethel, J; Lo, A; Kleinman, SH; Hollingsworth, CG; Nemo, GJ			Estimates of infectious disease risk factors in US blood donors	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CONFIDENTIAL UNIT EXCLUSION; HIV-INFECTION; STATES; PREVALENCE; QUESTIONS; DONATION; BEHAVIOR; IMPACT	Objective.-Individuals who do not respond accurately to questions about infectious disease risk factors at the time of blood donation represent a potential threat to the safety of the blood supply. This study was designed to estimate the prevalence of undetected behavioral and other risks in current blood donors. Design.-Anonymous mail surveys to collect demographic, medical, and behavioral information were administered to individuals who had donated blood within the previous 2 months. Sampling weights were used in the analysis to adjust for differential sampling and response rates among demographic groups to provide prevalence estimates for the donor population. Setting.-Five geographically and demographically diverse US blood centers. Participants.-A stratified probability sample of 50 162 allogeneic blood donors. Main Outcome Measures.-Estimated prevalence rates for risk behaviors that would have been a basis for deferral if reported at the time of the donor screening interview (deferrable risk). Results.-Completed questionnaires were received for 34 726 donors (69.2% of the sample). A total of 186 per 10 000 respondents (1.9%) reported a deferrable risk that was present at the time of their past donation, while 39 per 10 000 (0.4%) reported this behavior within the 3 months prior to donation. Rates (with 95% confidence intervals [CIs]) of deferrable risk behaviors were 1.4 (95% CI, 1.2-1.6) times higher for men than women, 1.6 (95% CI, 1.3-2.0) times higher for first-time vs repeat donors, 2.7 (95% CI, 2.0-3.6) times higher for donors with reactive screening tests, and 7.6 (95% CI, 3.6-15.8) times higher for donors who used the confidential unit exclusion option. Conclusions.-Despite the high degree of transfusion safety in the United States today, a measurable percentage of active blood donors when assessed by anonymous survey report risks for human immunodeficiency virus and other infections not reported at the time of screening, suggesting the need for further refinements in the blood donor qualification process.	GREATER CHESAPEAKE & POTOMAC REG,BALTIMORE,MD; WESTAT CORP,ROCKVILLE,MD; AMER RED CROSS,BLOOD SERV,LOS ANGELES,CA 90006; NHLBI,NIH,BETHESDA,MD 20892	Westat; American Red Cross; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Williams, AE (corresponding author), AMER RED CROSS,JEROME H HOLLAND LAB,BLOOD SERV,15601 CRABBS BRANCH WAY,ROCKVILLE,MD 20855, USA.				NHLBI NIH HHS [N01-HB-97077, N01-HB-97078, N01-HB-47114] Funding Source: Medline; DIVISION OF BLOOD DISEASES AND RESOURCES [N01HB097077, N01HB097078, N01HB047114] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF BLOOD DISEASES AND RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGUILER SM, 1993, ADV DATA, V225; CATANIA JA, 1992, SCIENCE, V258, P1101, DOI 10.1126/science.1439818; *CTR BIOL ENV RES, 1992, REC PREV HUM IMM VIR; DODD RY, 1994, BLOOD SUPPLY RISKS P, P1; DOLL LS, 1991, TRANSFUSION, V31, P704, DOI 10.1046/j.1537-2995.1991.31892023494.x; JAFFE HW, 1983, J INFECT DIS, V148, P339, DOI 10.1093/infdis/148.2.339; JOHNSON ES, 1994, TRANSFUSION, V34, P769, DOI 10.1046/j.1537-2995.1994.34994378277.x; KAPLAN EH, 1990, EVALUATION REV, V14, P686, DOI 10.1177/0193841X9001400609; Kish L, 1965, SURVEY SAMPLING; KLEINMAN SH, 1995, 48 ANN M AM ASS BLOO; KORELITZ JJ, 1994, TRANSFUSION, V34, P870, DOI 10.1046/j.1537-2995.1994.341095026972.x; KORN EL, 1991, AM J PUBLIC HEALTH, V81, P1166, DOI 10.2105/AJPH.81.9.1166; LAUMANN EO, 1994, SOCIAL ORG SEXUALITY, P294; LEIGH BC, 1993, AM J PUBLIC HEALTH, V83, P1400, DOI 10.2105/AJPH.83.10.1400; LEITMAN SF, 1989, NEW ENGL J MED, V321, P17; LOIACONO BR, 1989, TRANSFUSION, V29, P823, DOI 10.1046/j.1537-2995.1989.29990070189.x; MAYO DJ, 1991, TRANSFUSION, V31, P466, DOI 10.1046/j.1537-2995.1991.31591263204.x; MCQUILLAN GM, 1994, AM J PUBLIC HEALTH, V84, P747, DOI 10.2105/AJPH.84.5.747; MILLER HG, 1990, AIDS 2ND DECADE, P289; MILLER RG, 1974, BIOMETRIKA, V61, P1; MOHADJER L, 1986, P AM STAT ASS, P258; *OFF BIOL RES REV, 1983, MAM ALL EST COLL HUM; PETERSEN LR, 1991, TRANSFUSION, V31, P698, DOI 10.1046/j.1537-2995.1991.31892023493.x; PETERSEN LR, 1994, TRANSFUSION, V34, P865, DOI 10.1046/j.1537-2995.1994.341095026971.x; ROSENBERG PS, 1995, SCIENCE, V270, P1372, DOI 10.1126/science.270.5240.1372; Schreiber GB, 1996, NEW ENGL J MED, V334, P1685, DOI 10.1056/NEJM199606273342601; SCREIBER GB, IN PRESS J ACQUIR IM; SILVERGLEID AJ, 1989, TRANSFUSION, V29, P362, DOI 10.1046/j.1537-2995.1989.29489242806.x; *US DEP HHS, 1986, ADD REC RED FURTH NU	29	145	147	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 26	1997	277	12					967	972		10.1001/jama.277.12.967	http://dx.doi.org/10.1001/jama.277.12.967			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WN992	9091668				2022-12-01	WOS:A1997WN99200030
J	Bergqvist, D; Jendteg, S; Johansen, L; Persson, U; Odegaard, K				Bergqvist, D; Jendteg, S; Johansen, L; Persson, U; Odegaard, K			Cos of long-term complications of deep venous thrombosis of the lower extremities: An analysis of a defined patient population in Sweden	ANNALS OF INTERNAL MEDICINE			English	Article							VEIN THROMBOSIS; PROPHYLAXIS	Background: Little information is available on the epidemiology and economic effect of long-term complications developing after deep venous thrombosis. Objective: To determine the extent of, timing of, and treatment costs associated with long-term complications developing after deep venous thrombosis of the lower extremities. Design: 15-year retrospective cohort study. Setting: County hospital in Sweden. Patients: 257 patients with deep venous thrombosis and 241 age- and sex-matched controls without deep venous thrombosis. Measurements: Data on use of health care resources and costs of inpatient and outpatient care, pharmaceutical agents, and treatment of complications. Results: After 15 years of follow-up, 35% of the patients with thrombosis and 57% of the controls were alive. Two hundred forty-two complications were reported among the patients with thrombosis, and 25 similar events were reported among the controls. The average expected present value of the health care cost of treating complications of thrombosis was estimated to be about $4659 in the patients with thrombosis and $375 in the controls. In controls, primary deep venous thrombosis cost about $6000; thus, the additional long-term health care cost of post-thrombotic complications is about 75% of the cost of primary deep venous thrombosis. Conclusions: The economic effect of post-thrombotic complications is considerable. The use of measures to prevent thromboembolism and its long-term complications are justified on both clinical and economic grounds.	CENT HOSP SKOVDE, DEPT SURG, S-54185 SKOVDE, SWEDEN; UNIV UPPSALA HOSP, DEPT SURG, S-75185 UPPSALA, SWEDEN; INST HLTH ECON, S-22002 LUND, SWEDEN	Uppsala University; Uppsala University Hospital								BAUER G, 1942, ACTA CHIR SCAND S74, V86, P1; BERGQVIST D, 1993, HAEMOSTASIS, V23, P15; BERGQVIST D, 1988, WORLD J SURG, V12, P349, DOI 10.1007/BF01655669; BERGQVIST D, 1983, POSTOPERATIVE THROMB; BEYTH RJ, 1995, ARCH INTERN MED, V155, P1031, DOI 10.1001/archinte.155.10.1031; Hartunian NS, 1981, INCIDENCE EC COSTS M; KAKKAR VV, 1985, AM J SURG, V150, P54; LINDHAGEN A, 1985, ACTA MED SCAND, V217, P389; NELZEN O, 1994, PERSPECTIVES VASCULA, V7, P33; NORDSTROM M, 1994, BRIT MED J, V308, P891, DOI 10.1136/bmj.308.6933.891; NORDSTROM M, 1992, J INTERN MED, V232, P155, DOI 10.1111/j.1365-2796.1992.tb00565.x; OSTER G, 1987, JAMA-J AM MED ASSOC, V257, P203, DOI 10.1001/jama.257.2.203	12	198	199	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1997	126	6					454	457		10.7326/0003-4819-126-6-199703150-00006	http://dx.doi.org/10.7326/0003-4819-126-6-199703150-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM530	9072931				2022-12-01	WOS:A1997WM53000006
J	Darling, MRN				Darling, MRN			Elective or selective caesarean delivery of the small baby?	LANCET			English	Editorial Material							PRETERM				Darling, MRN (corresponding author), ROTUNDA HOSP,DUBLIN 1,IRELAND.							COLLINS R, 1836, PRACTICAL TREATISE M; Gilbert R, 1996, ARCH DIS CHILD, V75, P465, DOI 10.1136/adc.75.6.465; Grant A, 1996, BRIT J OBSTET GYNAEC, V103, P1197, DOI 10.1111/j.1471-0528.1996.tb09628.x; LAMONT RF, 1983, BMJ-BRIT MED J, V286, P454, DOI 10.1136/bmj.286.6363.454; NARAYAN H, 1994, BRIT J OBSTET GYNAEC, V101, P936, DOI 10.1111/j.1471-0528.1994.tb13034.x	5	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 8	1997	349	9053					666	666		10.1016/S0140-6736(05)60132-8	http://dx.doi.org/10.1016/S0140-6736(05)60132-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM080	9078196				2022-12-01	WOS:A1997WM08000006
J	Chawengsaksophak, K; James, R; Hammond, VE; Kontgen, F; Beck, F				Chawengsaksophak, K; James, R; Hammond, VE; Kontgen, F; Beck, F			Homeosis and intestinal tumours in Cdx2 mutant mice	NATURE			English	Article							GENE-EXPRESSION; MOUSE; DISRUPTION; EPITHELIUM; NEOPLASIA; PATTERN; MIN	In Drosophila, disturbing the expression of the homeobox gene caudal causes a severe disruption in body segmentation and global body patterning(1). There are three mouse homologues of Drosophila caudal: Cdx1 (ref. 2), Cdx2 (ref. 3) and Cdx4 (ref. 4). We have generated a null mutation of murine Cdx2 by homologous recombination. Cdx2 homozygote null mutants die between 3.5 and 5.5 days post coitum (d.p.c.). Cdx2 heterozygote mutants exhibit a variable phenotype, with many showing tail abnormalities or stunted growth. Skeletal analysis demonstrates a homeotic shift of vertebrae and compatible malformations of the ribs. Within the first three months of life, 90% of Cdx2 heterozygotes develop multiple intestinal adenomatous polyps, particularly in the proximal colon. These polyps occasionally contain areas of true metaplasia. In contrast to the surrounding intestinal epithelium, the neoplastic cells do not express Cdx2 from the remaining allele, These results suggest that Cdx2 mutation is the primary event in the genesis of some intestinal tumours.	QUEEN ELIZABETH HOSP,DEPT MED,WOODVILLE,SA 5011,AUSTRALIA; UNIV MELBOURNE,HOWARD FLOREY INST EXPT PHYSIOL & MED,PARKVILLE,VIC 3052,AUSTRALIA; ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,MELBOURNE,VIC 3050,AUSTRALIA	Florey Institute of Neuroscience & Mental Health; University of Melbourne; Royal Melbourne Hospital; Walter & Eliza Hall Institute			Chawengsaksophak, Kallayanee/G-4427-2014	Chawengsaksophak, Kallayanee/0000-0001-9401-2122				BECK F, 1995, DEV DYNAM, V204, P217; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; Chawengsaksophak K, 1996, GENOMICS, V34, P270, DOI 10.1006/geno.1996.0286; DUBOULE D, 1995, CURR OPIN GENET DEV, V5, P525, DOI 10.1016/0959-437X(95)90058-O; DUPREY P, 1988, GENE DEV, V2, P1647, DOI 10.1101/gad.2.12a.1647; EE HC, 1995, AM J PATHOL, V147, P586; GAMER LW, 1993, MECH DEVELOP, V43, P71, DOI 10.1016/0925-4773(93)90024-R; GERMAN MS, 1994, GENOMICS, V24, P403, DOI 10.1006/geno.1994.1639; INOUYE M, 1976, Congenital Anomalies, V16, P171; JAMES R, 1991, J BIOL CHEM, V266, P3246; JAMES R, 1994, J BIOL CHEM, V269, P15229; Kontgen Frank, 1993, V225, P878; LUONGO C, 1993, GENOMICS, V15, P3, DOI 10.1006/geno.1993.1002; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; MOSER AR, 1995, DEV DYNAM, V203, P422, DOI 10.1002/aja.1002030405; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; RAMIREZSOLIS R, 1993, METHOD ENZYMOL, V225, P855; ROBB L, 1995, P NATL ACAD SCI USA, V92, P7075, DOI 10.1073/pnas.92.15.7075; RUBIN H, 1985, CANCER RES, V45, P2935; SABRAMANIAN V, 1995, CELL, V83, P641; SLACK JMW, 1985, J THEOR BIOL, V114, P463, DOI 10.1016/S0022-5193(85)80179-X; SZABO P, 1994, DEVELOPMENT, V120, P1651; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M	23	523	544	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 6	1997	386	6620					84	87		10.1038/386084a0	http://dx.doi.org/10.1038/386084a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WL746	9052785				2022-12-01	WOS:A1997WL74600056
J	Smirnakis, SM; Berry, MJ; Warland, DK; Bialek, W; Meister, M				Smirnakis, SM; Berry, MJ; Warland, DK; Bialek, W; Meister, M			Adaptation of retinal processing to image contrast and spatial scale	NATURE			English	Article							TIGER SALAMANDER; GANGLION-CELLS; VISUAL-CORTEX; NEURONS; RABBIT; FIELD	Owing to the limited dynamic range of a neuron's output, neural circuits are faced with a trade-off between encoding the full range of their inputs and resolving gradations among those inputs. For example, the ambient light level varies daily over more than nine orders of magnitude(1), whereas the firing rate of optic nerve fibres spans less than two(2). This discrepancy is alleviated by light adaptation(3): as the mean intensity increases, the retina becomes proportionately less sensitive. However, image statistics other than the mean intensity also vary drastically during routine visual processing. Theory predicts that an efficient visual encoder should adapt its strategy not only to the mean, but to the full shape of the intensity distribution(4-6). Here we report that retinal ganglion cells, the output neurons of the retina, adapt to both image contrast-the range of light intensities-and to spatial correlations within the scene, even at constant mean intensity. The adaptation occurs on a scale of seconds, one hundred times more slowly than the immediate light response, and involves 2-5-fold changes in the firing rate. It is mediated within the retinal network: two independent sites of modulation after the photoreceptor cells appear to be involved. Our results demonstrate a remarkable plasticity in retinal processing that may contribute to the contrast adaptation of human vision(7).	HARVARD UNIV,DEPT PHYS,CAMBRIDGE,MA 02138; HARVARD UNIV,DEPT MOL & CELLULAR BIOL,CAMBRIDGE,MA 02138; HARVARD UNIV,SCH MED,DIV HLTH SCI & TECHNOL,BOSTON,MA 02215; NEC RES INST,PRINCETON,NJ 08540	Harvard University; Harvard University; Harvard University; Harvard Medical School; NEC Corporation				Meister, Markus/0000-0003-2136-6506				ALBRECHT DG, 1984, J PHYSIOL-LONDON, V347, P713, DOI 10.1113/jphysiol.1984.sp015092; BARLOW HB, 1963, NATURE, V200, P1345, DOI 10.1038/2001345a0; BARLOW HB, 1981, PROC R SOC SER B-BIO, V212, P1, DOI 10.1098/rspb.1981.0022; BARLOW HB, 1963, NATURE, V200, P1347, DOI 10.1038/2001347a0; BLAKEMORE C, 1969, J PHYSIOL-LONDON, V203, P237, DOI 10.1113/jphysiol.1969.sp008862; BLOOMFIELD SA, 1992, J NEUROPHYSIOL, V68, P711, DOI 10.1152/jn.1992.68.3.711; BRAINARD DH, 1989, COLOR RES APPL, V14, P23, DOI 10.1002/col.5080140107; COPENHAGEN DR, 1985, J PHYSIOL-LONDON, V369, P161, DOI 10.1113/jphysiol.1985.sp015894; DACHEUX RF, 1982, J NEUROSCI, V2, P1486; DAWIS SM, 1981, VISION RES, V21, P1427, DOI 10.1016/0042-6989(81)90250-9; DEWEESE M, 1995, NUOVO CIMENTO D, V17, P733, DOI 10.1007/BF02451830; GIASCHI D, 1993, J NEUROPHYSIOL, V70, P2024, DOI 10.1152/jn.1993.70.5.2024; HARE WA, 1990, J PHYSIOL-LONDON, V421, P223, DOI 10.1113/jphysiol.1990.sp017942; HO WA, 1988, VISION RES, V28, P1287, DOI 10.1016/0042-6989(88)90059-4; LAUGHLIN S, 1981, Z NATURFORSCH C, V36, P910; MEISTER M, 1994, J NEUROSCI METH, V51, P95, DOI 10.1016/0165-0270(94)90030-2; MEISTER M, 1995, SCIENCE, V270, P1207, DOI 10.1126/science.270.5239.1207; NUBOER JFW, 1983, J COMP PHYSIOL, V151, P353, DOI 10.1007/BF00623910; OHZAWA I, 1985, J NEUROPHYSIOL, V54, P651, DOI 10.1152/jn.1985.54.3.651; RUSHTON WAH, 1965, PROC R SOC SER B-BIO, V162, P20, DOI 10.1098/rspb.1965.0024; SAKAI HM, 1987, J NEUROPHYSIOL, V58, P1329, DOI 10.1152/jn.1987.58.6.1329; SCHIETING S, 1987, VISION RES, V27, P277, DOI 10.1016/0042-6989(87)90190-8; Shapley R., 1984, PROG RETIN RES, V3, P263, DOI DOI 10.1016/0278-4327(84)90011-7; SHAPLEY RM, 1978, J PHYSIOL-LONDON, V285, P275, DOI 10.1113/jphysiol.1978.sp012571; VANSTEVENINCK RRD, 1994, P IEEE C SYST MAN CY, P302; VICTOR JD, 1987, J PHYSIOL-LONDON, V386, P219, DOI 10.1113/jphysiol.1987.sp016531; Wang J.-L., 1995, Society for Neuroscience Abstracts, V21, P1644; WERBLIN F, 1988, VISUAL NEUROSCI, V1, P317, DOI 10.1017/S0952523800001978	28	329	335	1	31	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 6	1997	386	6620					69	73		10.1038/386069a0	http://dx.doi.org/10.1038/386069a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WL746	9052781				2022-12-01	WOS:A1997WL74600052
J	Isaac, A; Sargent, MG; Cooke, J				Isaac, A; Sargent, MG; Cooke, J			Control of vertebrate left-right asymmetry by a snail-related zinc finger gene	SCIENCE			English	Article							CHICK HEART; HANDEDNESS; EXPRESSION; EMBRYO	A gene encoding a zinc finger protein of the Snail family, cSnR, is expressed in the right-hand lateral mesoderm during normal chick development. Antisense disruption of cSnR function during the hours immediately preceding heart formation randomized the normally reliable direction of heart looping and subsequent embryo torsion. Implanted ectopic sources of intercellular signal proteins that are involved in establishing normal left-right information randomized the handedness of heart development and also altered the asymmetry of cSnR expression. cSnR thus appears to act downstream of these signals, or perhaps in parallel with the latest expressed of them, the Nodal protein, in controlling the anatomical asymmetry.	NATL INST MED RES, LONDON NW7 1AA, ENGLAND	MRC National Institute for Medical Research								BROWN NA, 1990, DEVELOPMENT, V110, P949; BROWN NA, 1990, DEVELOPMENT, V109, P1; CAMPBELL M, 1966, BRIT HEART J, V28, P472; Collignon J, 1996, NATURE, V381, P155, DOI 10.1038/381155a0; COOKE J, 1995, NATURE, V374, P681, DOI 10.1038/374681a0; COOKE J, MOL EMBRYOLOGY METHO; ESSEX LJ, 1993, DEV DYNAM, V198, P108, DOI 10.1002/aja.1001980205; GIERER A, 1972, KYBERNETIK, V12, P30, DOI 10.1007/BF00289234; GRAY S, 1994, GENE DEV, V8, P1829, DOI 10.1101/gad.8.15.1829; Gray S, 1996, GENE DEV, V10, P700, DOI 10.1101/gad.10.6.700; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HOYLE C, 1992, DEVELOPMENT, V115, P1071; ITASAKI N, 1991, ANAT EMBRYOL, V183, P29; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; Lowe LA, 1996, NATURE, V381, P158, DOI 10.1038/381158a0; Meno C, 1996, NATURE, V381, P151, DOI 10.1038/381151a0; NEW DAT, 1955, J EMBRYOL EXP MORPH, V3, P320; NIETO MA, 1992, DEVELOPMENT, V116, P227; NIETO MA, 1994, SCIENCE, V264, P835, DOI 10.1126/science.7513443; Nieto MA, 1996, METHOD CELL BIOL, V51, P219, DOI 10.1016/S0091-679X(08)60630-5; SARGENT M, UNPUB; SCHLINGENSIEPEN KH, 1992, GENE REGULATION BIOL, P317; SMITH DE, 1992, DEVELOPMENT, V116, P1033; SRIVASTAVA D, 1995, SCIENCE, V270, P1995, DOI 10.1126/science.270.5244.1995; STALSBER.H, 1969, DEV BIOL, V19, P109, DOI 10.1016/0012-1606(69)90051-7; STALSBER.H, 1970, AM J CARDIOL, V25, P265, DOI 10.1016/S0002-9149(70)80002-9; STALSBERG H, 1969, DEV BIOL, V19, P128, DOI 10.1016/0012-1606(69)90052-9; TORGERSEN J, 1949, ARCH PATHOL, V47, P566; Tsuda T, 1996, DEV BIOL, V173, P39, DOI 10.1006/dbio.1996.0005; WETZEL R, 1924, VERH PHYS MED GES WU, V49, P227; YOKOYAMA T, 1993, SCIENCE, V260, P679, DOI 10.1126/science.8480178	31	165	166	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 28	1997	275	5304					1301	1304		10.1126/science.275.5304.1301	http://dx.doi.org/10.1126/science.275.5304.1301			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WK644	9036854				2022-12-01	WOS:A1997WK64400041
J	Bean, AJ; Seifert, R; Chen, YA; Sacks, R; Scheller, RH				Bean, AJ; Seifert, R; Chen, YA; Sacks, R; Scheller, RH			Hrs-2 is an ATPase implicated in calcium-regulated secretion	NATURE			English	Article							SENSITIVE FUSION PROTEIN; SYNAPTIC VESICLE DOCKING; TRANSMITTER RELEASE; DOMAIN; CELLS; HYDROLYSIS; MECHANISM; TRANSPORT; SNAP-25; ZINC	Associations between proteins present on neurotransmitter-containing vesicles and on the presynaptic membrane are thought to underlie docking and fusion of synaptic vesicles with the plasma membrane, which are obligate steps in regulated neurotransmission(1-4). SNAP-25 resides on the plasma membrane and interacts with syntaxin (a plasma membrane t-SNARE) and VAMP (a vesicle V-SNARE)(1-9) to form a core protein complex thought to be an intermediate in a biochemical pathway that is essential for vesicular transport. We have now characterized a protein, Hrs-2, that interacts with SNAP-25. The binding of Hrs-2 to SNAP-25 is inhibited by calcium in the physiological concentration range that supports synaptic transmission. Furthermore, Hrs-2 binds and hydrolyses nucleoside triphosphates with kinetics that suggest that ATP is the physiological substrate for this enzyme. Hrs-2 is expressed throughout the brain and is present in nerve terminals. Moreover, recombinant Hrs-2 inhibits calcium-triggered H-3-noradrenaline release from permeabilized PC12 cells. Our results suggest a role for Hrs-2 in regulating secretory processes through calcium- and nucleotide-dependent modulation of vesicle-trafficking protein complexes.	STANFORD UNIV,HOWARD HUGHES MED INST,DEPT CELLULAR & MOL PHYSIOL,BECKMAN CTR MOLEC & GENET MED,STANFORD,CA 94305	Howard Hughes Medical Institute; Stanford University			Seifert, Roland/G-3189-2013					BENNETT MK, 1994, ANNU REV BIOCHEM, V63, P63, DOI 10.1146/annurev.bi.63.070194.000431; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; CHENG YSE, 1991, MOL CELL BIOL, V11, P4717, DOI 10.1128/MCB.11.9.4717; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GIETZ RD, 1991, YEAST, V7, P253, DOI 10.1002/yea.320070307; HAY JC, 1992, J CELL BIOL, V119, P139, DOI 10.1083/jcb.119.1.139; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; KOMADA M, 1995, MOL CELL BIOL, V15, P6213; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LOMNETH R, 1991, J NEUROCHEM, V57, P1413, DOI 10.1111/j.1471-4159.1991.tb08308.x; MORGAN A, 1994, J BIOL CHEM, V269, P29347; NISHIMURA M, 1988, BRIT J PHARMACOL, V93, P430, DOI 10.1111/j.1476-5381.1988.tb11450.x; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; PARSONS TD, 1995, NEURON, V15, P1085, DOI 10.1016/0896-6273(95)90097-7; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHELLER RH, 1995, NEURON, V14, P893; SMITH SJ, 1988, TRENDS NEUROSCI, V11, P458, DOI 10.1016/0166-2236(88)90199-3; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; TAGAYA M, 1993, J BIOL CHEM, V268, P2662; WANG YX, 1990, PFLUG ARCH EUR J PHY, V415, P582, DOI 10.1007/BF02583509; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945	26	111	115	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 27	1997	385	6619					826	829		10.1038/385826a0	http://dx.doi.org/10.1038/385826a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WK570	9039916				2022-12-01	WOS:A1997WK57000056
J	Brody, H; Campbell, ML; FaberLangendoen, K; Ogle, KS				Brody, H; Campbell, ML; FaberLangendoen, K; Ogle, KS			Withdrawing intensive life-sustaining treatment - Recommendations for compassionate clinical management	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CRITICALLY ILL PATIENTS; TERMINALLY ILL; PALLIATIVE CARE; DEHYDRATION; DIALYSIS; DEATH; SUPPORT; DISCONTINUATION; PHYSICIANS; VECURONIUM		DETROIT RECEIVING HOSP & UNIV HLTH CTR, DETROIT, MI 48201 USA; UNIV MINNESOTA, MINNEAPOLIS, MN 55455 USA	Detroit Receiving Hospital & University Health Center; University of Minnesota System; University of Minnesota Twin Cities	Brody, H (corresponding author), MICHIGAN STATE UNIV, E LANSING, MI 48824 USA.		Brody, Howard/GQA-6310-2022	Campbell, Margaret/0000-0003-4517-690X				ANDREWS M, 1993, POSTGRAD MED, V93, P201; Asch DA, 1996, MED CARE, V34, P103, DOI 10.1097/00005650-199602000-00002; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; BILLINGS JA, 1985, J AM GERIATR SOC, V33, P808, DOI 10.1111/j.1532-5415.1985.tb04196.x; BILLINGS JA, 1985, OUTPATIENT MANAGEMEN; Bruera E, 1990, J Pain Symptom Manage, V5, P341, DOI 10.1016/0885-3924(90)90027-H; Campbell M L, 1992, Am J Crit Care, V1, P52; Campbell M L, 1996, Dimens Crit Care Nurs, V15, P4, DOI 10.1097/00003465-199601000-00002; Campbell M L, 1991, ANNA J, V18, P202; Campbell M L, 1993, Am J Crit Care, V2, P354; Campbell M L, 1996, Am J Crit Care, V5, P339; Carlson RW, 1996, CHEST, V109, P852, DOI 10.1378/chest.109.3.852-b; CARLSON RW, 1995, ARCH INTERN MED, V155, P13; CHERNOW B, 1994, PHARM APPROACH CRITI; CITRON ML, 1984, AM J MED, V77, P199, DOI 10.1016/0002-9343(84)90691-0; COHEN LM, 1995, ARCH INTERN MED, V155, P42, DOI 10.1001/archinte.155.1.42; COHEN MH, 1991, SOUTHERN MED J, V84, P229, DOI 10.1097/00007611-199102000-00019; Daly B J, 1996, Am J Crit Care, V5, P331; Doyle D, 1993, OXFORD TXB PALLIATIV; EDDY DM, 1994, JAMA-J AM MED ASSOC, V272, P179, DOI 10.1001/jama.272.3.179; EDWARDS MJ, 1992, ANN INTERN MED, V117, P254, DOI 10.7326/0003-4819-117-3-254; ELLERSHAW JE, 1995, J PAIN SYMPTOM MANAG, V10, P192, DOI 10.1016/0885-3924(94)00123-3; ENCK RE, 1994, MED CARE TERMINALLY; FaberLangendoen K, 1996, ARCH INTERN MED, V156, P2130, DOI 10.1001/archinte.156.18.2130; FABERLANGENDOEN K, 1994, CHEST, V106, P880, DOI 10.1378/chest.106.3.880; FABERLANGENDOEN K, 1992, CRIT CARE MED, V20, P570, DOI 10.1097/00003246-199205000-00005; FABERLANGENDOEN K, 1996, AM J RESP CRIT CARE, V153, pA365; GIANAKOS D, 1995, CHEST, V108, P1405, DOI 10.1378/chest.108.5.1405; GILLIGAN T, 1995, CHEST, V108, P1407, DOI 10.1378/chest.108.5.1407; GRENVIK A, 1983, CRIT CARE MED, V11, P394, DOI 10.1097/00003246-198305000-00019; *HAST CTR, 1987, GUID TERM LIF SUST T; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; KNAUS WA, 1985, ANN SURG, V202, P685, DOI 10.1097/00000658-198512000-00004; LO B, 1989, ARCH INTERN MED, V149, P1925, DOI 10.1001/archinte.149.9.1925; LUCE JM, 1991, RESP CARE, V109, P417; MAILLOUX LU, 1993, J AM SOC NEPHROL, V3, P1631; MALONE N, 1994, NURSING STANDAR 0720, P29; *MAN CANC PAIN GUI, 1994, AHCPR PUBL; MAX MB, 1995, JAMA-J AM MED ASSOC, V274, P1874, DOI 10.1001/jama.1995.03530230060032; MCCANN RM, 1994, JAMA-J AM MED ASSOC, V272, P1263, DOI 10.1001/jama.272.16.1263; Miller FG, 1996, NEW ENGL J MED, V334, P1740, DOI 10.1056/NEJM199606273342612; *MULT TASK FORC PV, 1995, NEW ENGL J MED, V33, P130; NEU S, 1986, NEW ENGL J MED, V314, P14, DOI 10.1056/NEJM198601023140103; PARTRIDGE BL, 1990, CRIT CARE MED, V18, P1177, DOI 10.1097/00003246-199010000-00025; Payne K, 1996, ANN INTERN MED, V125, P104, DOI 10.7326/0003-4819-125-2-199607150-00004; *PRES COMM STUD ET, 1983, DEC FOR LIF SUST TRE; PRINTZ LA, 1992, ARCH INTERN MED, V152, P697, DOI 10.1001/archinte.152.4.697; ROUSSEAU PC, 1992, PATIENT CARE, V26, P71; Rushton C H, 1995, Am J Crit Care, V4, P112; SAUNDERS C, 1993, MANAGEMENT TERMINAL; SEGREDO V, 1992, NEW ENGL J MED, V327, P524, DOI 10.1056/NEJM199208203270804; Shekleton M E, 1994, AACN Clin Issues Crit Care Nurs, V5, P523; Siegel MD, 1996, CHEST, V109, P852, DOI 10.1378/chest.109.3.852; SLOMKA J, 1995, ARCH INTERN MED, V155, P1258, DOI 10.1001/archinte.155.12.1258; SOLOMON MZ, 1993, AM J PUBLIC HEALTH, V83, P14, DOI 10.2105/AJPH.83.1.14; SULLIVAN RJ, 1993, J GEN INTERN MED, V8, P220, DOI 10.1007/BF02599271; TRUOG RD, 1994, J CLIN ETHIC, V5, P39; VACHON MLS, 1995, PALLIATIVE MED, V9, P91, DOI 10.1177/026921639500900202; Vachon MLS., 1987, OCCUPATIONAL STRESS; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; Weatherill G G, 1995, AACN Clin Issues, V6, P344, DOI 10.1097/00044067-199505000-00018; WEIR RF, 1990, JAMA-J AM MED ASSOC, V264, P1846, DOI 10.1001/jama.264.14.1846; WILSON WC, 1992, JAMA-J AM MED ASSOC, V267, P949	63	174	175	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 27	1997	336	9					652	657		10.1056/NEJM199702273360910	http://dx.doi.org/10.1056/NEJM199702273360910			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WK028	9032053				2022-12-01	WOS:A1997WK02800010
J	Duggan, DJ; Gorospe, JR; Fanin, M; Hoffman, EP; Angelini, C; Pegoraro, E; Noguchi, S; Ozawa, E; Pendlebury, W; Waclawik, AJ; Duenas, DA; HausmanowaPetrusewicz, I; Fidzianska, A; Bean, SC; Haller, JS; Bodensteiner, J; Greco, CM; Pestronk, A; Berardinelli, A; Gelinas, DF; Abram, H; Kunel, RW				Duggan, DJ; Gorospe, JR; Fanin, M; Hoffman, EP; Angelini, C; Pegoraro, E; Noguchi, S; Ozawa, E; Pendlebury, W; Waclawik, AJ; Duenas, DA; HausmanowaPetrusewicz, I; Fidzianska, A; Bean, SC; Haller, JS; Bodensteiner, J; Greco, CM; Pestronk, A; Berardinelli, A; Gelinas, DF; Abram, H; Kunel, RW			Mutations in the sarcoglycan genes in patients with myopathy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RECESSIVE MUSCULAR-DYSTROPHY; ADHALIN GENE; BETA-SARCOGLYCAN; 50DAG A2; COMPLEX; PROTEINS; DEFICIENCY; GLYCOPROTEINS; EXPRESSION; MUSCLES	Background Some patients with autosomal recessive limb-girdle muscular dystrophy have mutations in the genes coding for the sarcoglycan proteins (alpha-, beta-, gamma-, and delta-sarcoglycan). To determine the frequency of sarcoglycan-gene mutations and the relation between the clinical features and genotype, we studied several hundred patients with myopathy. Methods Antibody against alpha-sarcoglycan was used to stain muscle-biopsy specimens from 556 patients with myopathy and normal dystrophin genes (the gene frequently deleted in X-linked muscular dystrophy). Patients whose biopsy specimens showed a deficiency of alpha-sarcoglycan on immunostaining were studied for mutations of the alpha-, beta-, and gamma-sarcoglycan genes with reverse transcription of muscle RNA, analysis involving single-strand conformation polymerphisms, and sequencing, Results Levels of alpha-sarcoglycan were found to be decreased on immunostaining of muscle-biopsy specimens from 54 of the 556 patients (10 percent); in 25 of these patients no alpha-sarcoglycan was detected. Screening for sarcoglycan-gene mutations in 50 of the 54 patients revealed mutations in 29 patients (58 percent): 17 (34 percent) had mutations in the alpha-sarcoglycan gene, 8 (16 percent) in the beta-sarcoglycan gene, and 4 (8 percent) in the gamma-sarcoglycan gene. No mutations were found in 21 patients (42 percent). The prevalence of sarcoglycan-gene mutations was highest among patients with severe (Duchenne-like) muscular dystrophy that began in childhood (18 of 83 patients, or 22 percent); the prevalence among patients with proximal (limb-girdle) muscular dystrophy with a later onset was 6 percent (11 of 180 patients). Conclusions Defects in the genes coding for the sarcoglycan proteins are limited to patients with Duchenne-like and limb-girdle muscular dystrophy with normal dystrophin and occur in 11 percent of such patients. (C) 1997, Massachusetts Medical Society.	UNIV PITTSBURGH, SCH MED, DEPT MOL GENET & BIOCHEM, PITTSBURGH, PA 15261 USA; UNIV PITTSBURGH, DEPT HUMAN GENET, PITTSBURGH, PA 15261 USA; UNIV PITTSBURGH, DEPT PEDIAT, PITTSBURGH, PA 15260 USA; UNIV PITTSBURGH, DEPT NEUROL, PITTSBURGH, PA 15260 USA; UNIV PADUA, DEPT NEUROL, REG NEUROMUSCULAR CTR, PADUA, ITALY; NATL CTR NEUROL & PSYCHIAT, TOKYO, JAPAN; UNIV VERMONT, BURLINGTON, VT USA; UNIV WISCONSIN, SCH MED, MADISON, WI USA; MIAMI CHILDRENS HOSP, MIAMI, FL USA; POLISH ACAD SCI, WARSAW, POLAND; MED CTR DELAWARE, NEWARK, DE USA; ALBANY MED CTR, ALBANY, NY USA; ROBERT C BYRD HLTH SCI CTR, MORGANTOWN, WV USA; CALIF PACIFIC MED CTR, SAN FRANCISCO, CA 94115 USA; WASHINGTON UNIV, ST LOUIS, MO USA; UNIV PAVIA, NEUROL INST C MONDINO, I-27100 PAVIA, ITALY; NEMOURS CHILDRENS CLIN, JACKSONVILLE, AL USA; JOHNS HOPKINS UNIV, BALTIMORE, MD USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Padua; National Center for Neurology & Psychiatry - Japan; University of Vermont; University of Wisconsin System; University of Wisconsin Madison; Polish Academy of Sciences; Albany Medical College; California Pacific Medical Center; Washington University (WUSTL); IRCCS Fondazione Casimiro Mondino; University of Pavia; Johns Hopkins University			Angelini, Corrado I/J-3655-2019; Berardinelli, angela/AAA-9496-2019	Angelini, Corrado I/0000-0002-9554-8794; berardinelli, angela/0000-0002-4645-8055; Hoffman, Eric/0000-0001-6470-5139	NINDS NIH HHS [NS-28403] Funding Source: Medline; Telethon [552, 695] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Telethon(Fondazione Telethon)		Ahn AH, 1996, J BIOL CHEM, V271, P2724, DOI 10.1074/jbc.271.5.2724; Bonnemann CG, 1996, HUM MOL GENET, V5, P1953, DOI 10.1093/hmg/5.12.1953; BONNEMANN CG, 1995, NAT GENET, V11, P266, DOI 10.1038/ng1195-266; BUENO MRP, 1995, HUM MOL GENET, V4, P1163, DOI 10.1093/hmg/4.7.1163; Duggan DJ, 1996, J NEUROL SCI, V140, P30, DOI 10.1016/0022-510X(96)00028-7; FANIN M, 1996, BASIC APPL MYOL, V6, P95; HOFFMAN EP, 1988, NEW ENGL J MED, V318, P1363, DOI 10.1056/NEJM198805263182104; HOFFMAN EP, 1992, NEUROLOGY, V42, P967, DOI 10.1212/WNL.42.5.967; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; KAWAI H, 1995, J CLIN INVEST, V96, P1202, DOI 10.1172/JCI118152; LIM LE, 1995, NAT GENET, V11, P257, DOI 10.1038/ng1195-257; LITTLE S, 1994, CURRENT PROTOCOLS HU; LJUNGGREN A, 1995, ANN NEUROL, V38, P367, DOI 10.1002/ana.410380305; MCNALLY EM, 1994, P NATL ACAD SCI USA, V91, P9690, DOI 10.1073/pnas.91.21.9690; McNally EM, 1996, HUM MOL GENET, V5, P1841, DOI 10.1093/hmg/5.11.1841; McNally EM, 1996, AM J HUM GENET, V59, P1040; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MIZUNO Y, 1993, J BIOCHEM-TOKYO, V114, P936, DOI 10.1093/oxfordjournals.jbchem.a124281; MIZUNO Y, 1994, MUSCLE NERVE, V17, P206, DOI 10.1002/mus.880170212; MIZUNO Y, 1994, BIOCHEM BIOPH RES CO, V203, P979, DOI 10.1006/bbrc.1994.2278; Nigro V, 1996, NAT GENET, V14, P195, DOI 10.1038/ng1096-195; NOGUCHI S, 1995, SCIENCE, V270, P819, DOI 10.1126/science.270.5237.819; OHLENDIECK K, 1993, NEUROLOGY, V43, P795, DOI 10.1212/WNL.43.4.795; OZAWA E, 1995, HUM MOL GENET, V4, P1711, DOI 10.1093/hmg/4.suppl_1.1711; PEGORARO E, 1995, NEUROLOGY, V45, P677, DOI 10.1212/WNL.45.4.677; PICCOLO F, 1995, NAT GENET, V10, P243, DOI 10.1038/ng0695-243; ROBERDS SL, 1994, CELL, V78, P625, DOI 10.1016/0092-8674(94)90527-4; SPINARDI L, 1991, NUCLEIC ACIDS RES, V19, P4009, DOI 10.1093/nar/19.14.4009; TINSLEY JM, 1994, P NATL ACAD SCI USA, V91, P8307, DOI 10.1073/pnas.91.18.8307; WORTON R, 1995, SCIENCE, V270, P755, DOI 10.1126/science.270.5237.755; YAMAMOTO H, 1994, J BIOCHEM-TOKYO, V115, P162, DOI 10.1093/oxfordjournals.jbchem.a124294; YOSHIDA M, 1994, EUR J BIOCHEM, V222, P1055, DOI 10.1111/j.1432-1033.1994.tb18958.x	32	174	181	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 27	1997	336	9					618	624		10.1056/NEJM199702273360904	http://dx.doi.org/10.1056/NEJM199702273360904			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WK028	9032047				2022-12-01	WOS:A1997WK02800004
J	Stockton, D; Davies, T; Day, N; McCann, J				Stockton, D; Davies, T; Day, N; McCann, J			Retrospective study of reasons for improved survival in patients with breast cancer in East Anglia: Earlier diagnosis or better treatment?	BRITISH MEDICAL JOURNAL			English	Article							PROGRAM	Objectives: To investigate the recent fall in mortality from breast cancer in England and Wales, and to determine the relative contributions of improvements in treatment and earlier detection of tumours. Design: Retrospective study of all women with breast cancer registered by the East Anglian cancer registry and diagnosed between 1982 and 1989. Subjects: 3965 patients diagnosed 1982-5 compared with 4665 patients diagnosed 1986-9, in three age groups 0-49, 50-64, greater than or equal to 65 years, with information on stage at diagnosis and survival. Main outcome measures: Three year relative survival rates by time period, age group, and stage; relative hazard ratios for each time period and age group derived from Cox's proportional hazards model, adjusted for single year of age and stage. Results: Survival improved in the later time period, although there was little stage specific improvement. The proportion of early stage tumours increased especially in the 50-64 year age group, and adjustment for stage accounted for over half of the improvement in survival in women aged under 65 years. Conclusion: Over half of the drop in mortality in women aged under 65 years seems to be attributable to earlier detection of tumours, which has been observed since the mid-1980s. This could have resulted from an increase in breast awareness predating the start of the breast screening programme.			Stockton, D (corresponding author), UNIV CAMBRIDGE,INST PUBL HLTH,E ANGLIAN CANC INTELLIGENCE UNIT,DEPT COMMUNITY MED,CAMBRIDGE CB2 2SR,ENGLAND.							ALEXANDER FE, 1994, BRIT J CANCER, V70, P542, DOI 10.1038/bjc.1994.342; BERAL V, 1995, LANCET, V345, P1642, DOI 10.1016/S0140-6736(95)90151-5; CHOUILLET AM, 1994, BRIT MED J, V308, P168, DOI 10.1136/bmj.308.6922.168; COX DR, 1972, J R STAT SOC B, V34, P187; *EARL BREAST CANC, 1992, LANCET, V339, P1; Forrest APM, 1987, BREAST CANC SCREEN R, V3rd, P102; HAKULINEN T, 1985, COMPUT PROG BIOMED, V19, P197, DOI 10.1016/0010-468X(85)90011-X; *KINGS FUND, 1986, BRIT MED J, V293, P496; NAB HW, 1994, BRIT J CANCER, V70, P285, DOI 10.1038/bjc.1994.293; QUINN M, 1995, BRIT MED J, V311, P1391, DOI 10.1136/bmj.311.7017.1391; TABAR L, 1992, RADIOL CLIN N AM, V30, P187; *YORKSH CANC ORG, 1995, CANC REG REP SER, V3	12	68	70	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 15	1997	314	7079					472	475		10.1136/bmj.314.7079.472	http://dx.doi.org/10.1136/bmj.314.7079.472			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WJ419	9056796	Green Published			2022-12-01	WOS:A1997WJ41900024
J	He, JL; Chen, YZ; Farzan, M; Choe, HY; Ohagen, A; Gartner, S; Busciglio, J; Yang, XY; Hofmann, W; Newman, W; Mackay, CR; Sodroski, J; Gabuzda, D				He, JL; Chen, YZ; Farzan, M; Choe, HY; Ohagen, A; Gartner, S; Busciglio, J; Yang, XY; Hofmann, W; Newman, W; Mackay, CR; Sodroski, J; Gabuzda, D			CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia	NATURE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; BRAIN; CELLS; TROPISM; IDENTIFICATION; SEQUENCES; AIDS	Several members of the chemokine receptor family are used together with CD4 for HIV-1 entry into target cells(1-6). T cell line-tropic (T-tropic) HIV-1 viruses use the chemokine receptor CXCR4 as a co-receptor(1), whereas macrophage-tropic (M-tropic) primary viruses use CCR5 (refs 2-6). Individuals with defective CCR5 alleles exhibit resistance to HIV-1 infection(7,8), suggesting that CCR5 has an important role in vivo in HIV-1 replication. A subset of primary viruses can use CCR3 as well as CCR5 as a co-receptor(5,6), but the in vivo contribution of CCR3 to HIV-1 infection and pathogenesis is unknown. HIV-1 infects the central nervous system (CNS) and causes the dementia associated with AIDS(9). Here we report that the major target cells for HIV-1 infection in the CNS, the microglia(9-11), express both CCR3 and CCR5. The CCR3 ligand, eotaxin, and an anti-CCR3 antibody inhibited HIV-1 infection of microglia, as did MIP-1 beta, which is a CCR5 ligand. Our results suggest that both CCR3 and CCR5 promote efficient infection of the CNS by HIV-1.	LEUKOSITE INC,CAMBRIDGE,MA 02142; DANA FARBER CANC INST,DIV HUMAN RETROVIROL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02115; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205; CHILDRENS HOSP,MED CTR,DEPT NEUROL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Johns Hopkins University; Harvard University; Boston Children's Hospital			Mackay, Charles R/A-9673-2008	Mackay, Charles R/0000-0002-6338-7340; Farzan, Michael/0000-0002-2990-5319				ALKAHATIB G, 1996, SCIENCE, V272, P1955; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; COLLMAN R, 1992, J VIROL, V66, P7517, DOI 10.1128/JVI.66.12.7517-7521.1992; Daugherty BL, 1996, J EXP MED, V183, P2349, DOI 10.1084/jem.183.5.2349; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; GARTNER S, 1990, AIDS RES HUM RETROV, V6, P1017, DOI 10.1089/aid.1990.6.1017; HAROUSE JM, 1989, J VIROL, V63, P2527, DOI 10.1128/JVI.63.6.2527-2533.1989; HE JL, 1995, J VIROL, V69, P4587, DOI 10.1128/JVI.69.7.4587-4592.1995; HEATH H, IN PRESS J CLIN INVE; KORBER BTM, 1994, J VIROL, V68, P7467, DOI 10.1128/JVI.68.11.7467-7481.1994; LI YX, 1992, J VIROL, V66, P6587, DOI 10.1128/JVI.66.11.6587-6600.1992; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; OBERLIN E, 1996, NATURE, V382, P883; OBRIEN WA, 1990, NATURE, V348, P69, DOI 10.1038/348069a0; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; POWER C, 1994, J VIROL, V68, P4643, DOI 10.1128/JVI.68.7.4643-4649.1994; PRICE RW, 1988, SCIENCE, V239, P586, DOI 10.1126/science.3277272; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Schmidtmayerova H, 1996, P NATL ACAD SCI USA, V93, P700, DOI 10.1073/pnas.93.2.700; Shi B, 1996, J CLIN INVEST, V98, P1979, DOI 10.1172/JCI119002; Strizki JM, 1996, J VIROL, V70, P7654, DOI 10.1128/JVI.70.11.7654-7662.1996; Takahashi K, 1996, ANN NEUROL, V39, P705, DOI 10.1002/ana.410390606; TORNATORE C, 1991, J VIROL, V65, P6094, DOI 10.1128/JVI.65.11.6094-6100.1991; WATKINS BA, 1990, SCIENCE, V249, P549, DOI 10.1126/science.2200125; WESTERVELT P, 1991, P NATL ACAD SCI USA, V88, P3097, DOI 10.1073/pnas.88.8.3097	30	776	815	1	48	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 13	1997	385	6617					645	649		10.1038/385645a0	http://dx.doi.org/10.1038/385645a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WH294	9024664				2022-12-01	WOS:A1997WH29400053
J	Frey, U; Morris, RGM				Frey, U; Morris, RGM			Synaptic tagging and long-term potentiation	NATURE			English	Article							PROTEIN-SYNTHESIS; DENTATE GYRUS; HIPPOCAMPAL-NEURONS; CA1 REGION; LATE-PHASE; RAT; TETANIZATION; MAINTENANCE; ANISOMYCIN; INDUCTION	Repeated stimulation of hippocampal neurons can induce an immediate and prolonged increase in synaptic strength that is called long-term potentiation (LTP)-the primary cellular model of memory in the mammalian brain(1). An early phase of LTP (lasting less than three hours) can be dissociated from late-phase LTP by using inhibitors of transcription and translation(2-8) Because protein synthesis occurs mainly in the cell body(9-12), whereas LTP is input-specific, the question arises of how the synapse specificity of late LTP is achieved without elaborate intracellular protein trafficking. We propose that LTP initiates the creation of a short-lasting protein-synthesis-independent 'synaptic tag' at the potentiated synapse which sequesters the relevant protein(s) to establish late LTP. In support of this idea, we now show that weak tetanic stimulation, which ordinarily leads only to early LTP, or repeated tetanization in the presence of protein-synthesis inhibitors, each results in protein-synthesis-dependent late LTP, provided repeated tetanization has already been applied at another input to the same population of neurons. The synaptic tag decays in less than three hours. These findings indicate that the persistence of LTP depends not only on local events during its induction, but also on the prior activity of the neuron.	UNIV EDINBURGH,CTR NEUROSCI,EDINBURGH EH8 9LE,MIDLOTHIAN,SCOTLAND	University of Edinburgh	Frey, U (corresponding author), FED INST NEUROBIOL GENE REGULAT & PLAST,POB 1860,BRENNECKESTR 6,D-39008 MAGDEBURG,GERMANY.		Morris, Richard G M/C-9982-2013					Abraham WC, 1996, TRENDS NEUROSCI, V19, P126, DOI 10.1016/S0166-2236(96)80018-X; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BROWN R, 1977, COGNITION, V5, P73, DOI 10.1016/0010-0277(77)90018-X; DAVIS L, 1987, NATURE, V330, P477, DOI 10.1038/330477a0; DIAMOND DM, 1988, J NEUROSCI, V8, P4079; FAZELI MS, 1988, BRAIN RES, V473, P51, DOI 10.1016/0006-8993(88)90314-9; FAZELI MS, 1993, J NEUROSCI, V13, P1346; FREY U, 1995, NEUROSCIENCE, V67, P799, DOI 10.1016/0306-4522(95)00117-2; FREY U, 1988, BRAIN RES, V452, P57, DOI 10.1016/0006-8993(88)90008-X; Frey U, 1996, J PHYSIOL-LONDON, V490, P703, DOI 10.1113/jphysiol.1996.sp021179; HEBB DO, 1949, ORG BEHAVIOR; Huang Y Y, 1994, Learn Mem, V1, P74; Kang HJ, 1996, SCIENCE, V273, P1402, DOI 10.1126/science.273.5280.1402; KLEIMAN R, 1990, NEURON, V5, P821, DOI 10.1016/0896-6273(90)90341-C; KRUG M, 1984, BRAIN RES BULL, V13, P39, DOI 10.1016/0361-9230(84)90005-4; LARSON J, 1986, SCIENCE, V232, P985, DOI 10.1126/science.3704635; LINK W, 1995, P NATL ACAD SCI USA, V92, P5734, DOI 10.1073/pnas.92.12.5734; LOVINGER DM, 1988, J PHYSIOL-LONDON, V400, P321, DOI 10.1113/jphysiol.1988.sp017122; MALENKA RC, 1991, NEURON, V6, P53, DOI 10.1016/0896-6273(91)90121-F; NGUYEN PV, 1994, SCIENCE, V265, P1104, DOI 10.1126/science.8066450; OTANI S, 1989, NEUROSCIENCE, V28, P519, DOI 10.1016/0306-4522(89)90001-8; RAWLINS JNP, 1985, BEHAV BRAIN SCI, V8, P479, DOI 10.1017/S0140525X00001291; SQUIRE LR, 1981, ANNU REV PHARMACOL, V21, P323, DOI 10.1146/annurev.pa.21.040181.001543; STANTON PK, 1984, J NEUROSCI, V4, P3080; Staubli U, 1996, J NEUROSCI, V16, P853; STEWARD O, 1986, J NEUROSCI, V6, P412	26	1182	1203	3	90	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 6	1997	385	6616					533	536		10.1038/385533a0	http://dx.doi.org/10.1038/385533a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG235	9020359				2022-12-01	WOS:A1997WG23500047
J	Roberts, AG; Whatley, SD; Morgan, RR; Worwood, M; Elder, GH				Roberts, AG; Whatley, SD; Morgan, RR; Worwood, M; Elder, GH			Increased frequency of the haemochromatosis Cys282Tyr mutation in sporadic porphyria cutanea tarda	LANCET			English	Article							HLA-LINKED HEMOCHROMATOSIS; UROPORPHYRINOGEN DECARBOXYLASE	Background Sporadic porphyria cutanea tarda is a skin disease associated with hepatic siderosis. Depletion of iron stores by phlebotomy is curative. The role of haemochromatosis genes in determining susceptibility to this disorder is controversial, We have examined the frequency in sporadic porphyria cutanea tarda of mutations (Cys282Tyr, His63Asp) in a novel MHC class-I-like gene, one of which (Cys282Tyr) is believed to cause haemochromatosis. Methods 41 patients with sporadic porphyria cutanea tarda, in whom the frequency of microsatellite alleles that define the ancestral haemochromatosis haplotype had previously been determined, and 101 healthy blood donors were studied for the presence of the Cys282Tyr and His63Asp mutations. We used restriction-enzyme digestion of PCR-amplified genomic DNA. Findings The Cys282Tyr mutation occurred in 18 (44%) of patients compared with 11 (11%) of controls (relative risk 6.2, 95% CI 2.6-14.5, p=0.00003). Seven (17%) patients, aged 48-79 years, were homozygotes. In 12 patients, the Cys282Tyr mutation was associated with markers of the HLA-A3-containing ancestral haemochromatosis haplotype. Ages at presentation were the same for those with or without the Cys282Tyr mutation. There was no difference in the frequency of the His63Asp mutation. Interpretation Inheritance of one or more haemochromatosis genes is an important susceptibility factor for sporadic porphyria cutanea tarda. Some homozygotes for the Cys282Tyr mutation present late in life with porphyria cutanea tarda, indicating that not all homozygotes present clinically with haemochromatosis. The relation between this genotype and disease needs further investigation.	UNIV WALES COLL MED,DEPT BIOCHEM MED,CARDIFF CF4 4XN,S GLAM,WALES; UNIV WALES COLL MED,DEPT HAEMATOL,CARDIFF CF4 4XN,S GLAM,WALES	Cardiff University; Cardiff University								ADAMS PC, 1987, GASTROENTEROLOGY, V92, P2033, DOI 10.1016/0016-5085(87)90643-3; BEAUMONT C, 1987, GASTROENTEROLOGY, V92, P1833, DOI 10.1016/0016-5085(87)90612-3; Beutler Ernest, 1996, Blood Cells Molecules and Diseases, V22, P187, DOI 10.1006/bcmd.1996.0027; BOTTOMLEY SS, 1986, B I DERMATOLOGICO S, V8, P237; EDWARDS CQ, 1989, GASTROENTEROLOGY, V97, P972, DOI 10.1016/0016-5085(89)91506-0; EDWARDS CQ, 1988, NEW ENGL J MED, V318, P1355, DOI 10.1056/NEJM198805263182103; ELDER GH, 1985, LANCET, V2, P229; ELDER GH, 1995, J BIOENERG BIOMEMBR, V27, P207, DOI 10.1007/BF02110035; Fargion S, 1996, J HEPATOL, V24, P564, DOI 10.1016/S0168-8278(96)80141-3; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; GAREY JR, 1993, GASTROENTEROLOGY, V105, P165, DOI 10.1016/0016-5085(93)90022-5; Kappas A, 1995, METABOLIC MOL BASES, P2103; KOSTLER VE, 1984, DTSCH Z VERDAU STOFF, V44, P95; KUNTZ BME, 1984, TISSUE ANTIGENS, V24, P67; LLORENTE L, 1980, ARCH DERMATOL RES, V269, P209, DOI 10.1007/BF00406542; LUNDVALL O, 1970, ACTA MED SCAND, V188, P37; LUNDVALL O, 1971, ACTA MED SCAND, V189, P33; MERRYWEATHERCLA.AT, IN PRESS J MED GENET; RAHACHOWDHURY, 1996, HUM MOL GENET, V4, P1869; Roberts AG, 1997, HEPATOLOGY, V25, P159, DOI 10.1002/hep.510250129; SANTOIANNI P, 1980, DERMATOLOGICA, V160, P371, DOI 10.1159/000250524; SMITH AG, 1993, BIOCHEM J, V291, P29, DOI 10.1042/bj2910029; TIWAWRI JL, 1985, HLA DIS ASS; WORWOOD M, 1993, TRANSFUSION MED, V3, P21, DOI 10.1111/j.1365-3148.1993.tb00100.x; WORWOOD M, 1996, BRIT J HAEMATOL, V93, P833	25	269	278	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 1	1997	349	9048					321	323		10.1016/S0140-6736(96)09436-6	http://dx.doi.org/10.1016/S0140-6736(96)09436-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF794	9024376				2022-12-01	WOS:A1997WF79400012
J	Wright, MC; Joyce, GF				Wright, MC; Joyce, GF			Continuous in vitro evolution of catalytic function	SCIENCE			English	Article							RNA; RIBOZYMES; SEQUENCES	A population of RNA molecules that catalyze the template-directed ligation of RNA substrates was made to evolve in a continuous manner in the test tube. A simple serial transfer procedure was used to achieve approximately 300 successive rounds of catalysis and selective amplification in 52 hours. During this time, the population size was maintained against an overall dilution of 3 x 10(298). Both the catalytic rate and amplification rate of the RNAs improved substantially as a consequence of mutations that accumulated during the evolution process. Continuous in vitro evolution makes it possible to maintain laboratory ''cultures'' of catalytic molecules that can be perpetuated indefinitely.	Scripps Res Inst, DEPT CHEM, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT MOL BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, SKAGGS INST CHEM BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute								BARTEL DP, 1993, SCIENCE, V261, P1411, DOI 10.1126/science.7690155; BEAUDRY AA, 1992, SCIENCE, V257, P635, DOI 10.1126/science.1496376; Breaker RR, 1996, CURR OPIN BIOTECH, V7, P442, DOI 10.1016/S0958-1669(96)80122-4; BREAKER RR, 1994, P NATL ACAD SCI USA, V91, P6093, DOI 10.1073/pnas.91.13.6093; EKLAND EH, 1995, SCIENCE, V269, P364, DOI 10.1126/science.7618102; Ekland EH, 1996, NATURE, V382, P373, DOI 10.1038/382373a0; Hager AJ, 1996, CHEM BIOL, V3, P717, DOI 10.1016/S1074-5521(96)90246-X; KUMAR PKR, 1995, FASEB J, V9, P1183, DOI 10.1096/fasebj.9.12.7672511; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MILLS DR, 1967, P NATL ACAD SCI USA, V58, P217, DOI 10.1073/pnas.58.1.217; MORL M, 1992, CELL, V70, P803, DOI 10.1016/0092-8674(92)90313-2; TSANG J, 1994, BIOCHEMISTRY-US, V33, P5966, DOI 10.1021/bi00185a038; Tsang J, 1996, J MOL BIOL, V262, P31, DOI 10.1006/jmbi.1996.0496; TSANG J, 1996, METHOD ENZYMOL, V267, P411	14	143	159	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 25	1997	276	5312					614	617		10.1126/science.276.5312.614	http://dx.doi.org/10.1126/science.276.5312.614			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WV721	9110984				2022-12-01	WOS:A1997WV72100051
J	Harden, PN; MacLeod, MJ; Rodger, RSC; Baxter, GM; Connell, JMC; Dominiczak, AF; Junor, BJR; Briggs, JD; Moss, JG				Harden, PN; MacLeod, MJ; Rodger, RSC; Baxter, GM; Connell, JMC; Dominiczak, AF; Junor, BJR; Briggs, JD; Moss, JG			Effect of renal-artery stenting on progression of renovascular renal failure	LANCET			English	Article							WALLSTENT ENDOPROSTHESIS; DISEASE; STENOSIS; ANGIOPLASTY; PLACEMENT	Background Placement of renal-artery stents has a high technical success rate in atherosclerotic renovascular disease, but little is known about the clinical benefits of the procedure. We monitored renal function serially before and after stent insertion in patients with renovascular renal failure. Methods Renal function was assessed before and after stent placement by means of serial serum creatinine Values in 32 patients with atherosclerotic renal-artery stenosis. The effect on the progression of renal failure was analysed in 23 patients by comparison of the reciprocal slopes of serum creatinine versus time plots before and after stent placement. Findings 33 transluminal stents were placed in 32 patients with atherosclerotic renovascular disease. Immediate patency was achieved in all cases; the angiographic restenosis rate at 6 months was 12% (n=24). One patient died after a procedure-related haemorrhage. Median diastolic blood pressure was significantly lower after stenting than before (95 [IQR 86-103] vs 87 [81-90] mm Hg; p>0.01) but the requirement for antihypertensive drugs was unchanged. Renal function improved or stabilised in 22 (69%) of the 32 patients. Progression of renal failure was significantly slowed after the procedure; the mean (SE) of the slopes of reciprocal serum creatinine values was -4.34 (0.85) L mu mol(-1) day(-1) before stent placement, and -0.55 (1.0) L mu mol(-1) day(-1) after stent placement (p<0.01, two-sample t test). Interpretation Renal-stent placement in selected patients slows the progression of renovascular renal failure and may delay the need for renal replacement therapy.	UNIV GLASGOW,WESTERN INFIRM,RENAL UNIT,GLASGOW G11 6NT,LANARK,SCOTLAND; UNIV GLASGOW,WESTERN INFIRM,DEPT MED & RADIOL,GLASGOW G11 6NT,LANARK,SCOTLAND	University of Glasgow; University of Glasgow			Dominiczak, Anna F/D-2262-2009; Dominiczak, Anna F/P-9390-2017	Dominiczak, Anna F/0000-0003-4913-3608; Macleod, Mary Joan/0000-0003-2115-8184				HENNEQUIN LM, 1994, RADIOLOGY, V191, P713, DOI 10.1148/radiology.191.3.8184051; Henry M, 1996, J VASC INTERV RADIOL, V7, P343, DOI 10.1016/S1051-0443(96)72864-6; JOFFRE F, 1992, CARDIOVASC INTER RAD, V15, P313, DOI 10.1007/BF02733956; KUHN FP, 1991, RADIOLOGY, V180, P367, DOI 10.1148/radiology.180.2.1829842; NOVICK AC, 1987, JAMA-J AM MED ASSOC, V257, P498, DOI 10.1001/jama.257.4.498; PATTISON JM, 1992, Q J MED, V85, P883; PATTYNAMA PMT, 1994, CARDIOVASC INTER RAD, V17, P143; REES CR, 1991, RADIOLOGY, V181, P507, DOI 10.1148/radiology.181.2.1924796; ROWE PA, 1989, AM J NEPHROL, V9, P38, DOI 10.1159/000167932; SCOBLE JE, 1993, POSTGRAD MED J, V69, P461, DOI 10.1136/pgmj.69.812.461; SCOBLE JE, 1989, CLIN NEPHROL, V31, P119; VANDEVEN PJG, 1995, LANCET, V346, P672, DOI 10.1016/S0140-6736(95)92283-0; WILMS GE, 1991, RADIOLOGY, V179, P457, DOI 10.1148/radiology.179.2.2014292; WOLLENWEBER J, 1968, AM J CARDIOL, V21, P60, DOI 10.1016/0002-9149(68)90014-3; ZIERLER RE, 1994, J VASC SURG, V19, P250, DOI 10.1016/S0741-5214(94)70100-8	15	339	349	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 19	1997	349	9059					1133	1136		10.1016/S0140-6736(96)10093-3	http://dx.doi.org/10.1016/S0140-6736(96)10093-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU544	9113012				2022-12-01	WOS:A1997WU54400010
J	Zheng, LB; Cornel, AJ; Wang, R; Erfle, H; Voss, H; Ansorge, W; Kafatos, FC; Collins, FH				Zheng, LB; Cornel, AJ; Wang, R; Erfle, H; Voss, H; Ansorge, W; Kafatos, FC; Collins, FH			Quantitative trait loci for refractoriness of Anopheles gambiae to Plasmodium cynomolgi B	SCIENCE			English	Article							MALARIA VECTOR; AEDES-AEGYPTI; SUSCEPTIBILITY; ASSOCIATION; GALLINACEUM; MOSQUITO; MAP	The severity of the malaria pandemic in the tropics is aggravated by the ongoing spread of parasite resistance to antimalarial drugs and mosquito resistance to insecticides. A strain of Anopheles gambiae, normally a major vector for human malaria in Africa, can encapsulate and kill the malaria parasites within a melanin-rich capsule in the mosquito midgut. Genetic mapping revealed one major and two minor quantitative trait loci (QTLs) for this encapsulation reaction. Understanding such antiparasite mechanisms in mosquitoes may lead to new strategies for malaria control.	EUROPEAN MOL BIOL LAB,D-69117 HEIDELBERG,GERMANY; CTR DIS CONTROL & PREVENT,CHAMBLEE,GA 30341	European Molecular Biology Laboratory (EMBL); Centers for Disease Control & Prevention - USA			Ansorge, Wilhelm/AAN-8780-2020; Wang-Sattler, Rui/B-5354-2014	Wang-Sattler, Rui/0000-0002-8794-8229				ALMASHHADANI HM, 1980, T ROY SOC TROP MED H, V74, P585, DOI 10.1016/0035-9203(80)90146-7; BEARD CB, 1995, J HERED, V86, P375, DOI 10.1093/oxfordjournals.jhered.a111606; COLLINS FH, 1986, SCIENCE, V234, P607, DOI 10.1126/science.3532325; COLLINS FS, UNPUB; COLUZZI M, 1979, T ROY SOC TROP MED H, V73, P483, DOI 10.1016/0035-9203(79)90036-1; CREWSOYEN AE, 1993, AM J TROP MED HYG, V49, P341, DOI 10.4269/ajtmh.1993.49.341; Dimopoulos G, 1996, GENETICS, V143, P953; Gorman MJ, 1996, EXP PARASITOL, V84, P380, DOI 10.1006/expr.1996.0126; GORMAN MJ, IN PRESS GENETICS; GRAVES PM, 1982, ANN TROP MED PARASIT, V76, P633, DOI 10.1080/00034983.1982.11687594; KILAMA WL, 1969, ANN TROP MED PARASIT, V63, P419, DOI 10.1080/00034983.1969.11686645; LANDER E S, 1987, Genomics, V1, P174, DOI 10.1016/0888-7543(87)90010-3; Lee W., UNPUB; MACDONALD WW, 1965, ANN TROP MED PARASIT, V59, P64, DOI 10.1080/00034983.1965.11686284; MANSFIELD DC, 1994, GENOMICS, V24, P225, DOI 10.1006/geno.1994.1610; PATERSON AH, 1988, NATURE, V335, P721, DOI 10.1038/335721a0; Severson David W., 1994, Insect Molecular Biology, V3, P67, DOI 10.1111/j.1365-2583.1994.tb00153.x; SEVERSON DW, 1995, GENETICS, V139, P1711; Shahabuddin M, 1995, EXP PARASITOL, V81, P386, DOI 10.1006/expr.1995.1129; STAM P, 1993, PLANT J, V3, P739, DOI 10.1111/j.1365-313X.1993.00739.x; VERNICK KD, 1989, AM J TROP MED HYG, V40, P593, DOI 10.4269/ajtmh.1989.40.593; VERNICK KD, 1995, EXP PARASITOL, V80, P583, DOI 10.1006/expr.1995.1074; WARBURG A, 1991, PARASITOL TODAY, V7, P179, DOI 10.1016/0169-4758(91)90127-A; ZHENG LB, 1993, SCIENCE, V261, P605, DOI 10.1126/science.8342025; Zheng LB, 1996, GENETICS, V143, P941	25	160	169	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 18	1997	276	5311					425	428		10.1126/science.276.5311.425	http://dx.doi.org/10.1126/science.276.5311.425			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WU477	9103203				2022-12-01	WOS:A1997WU47700043
J	Troy, CJ; Peeling, RW; Ellis, AG; Hockin, JC; Bennett, DA; Murphy, MR; Spika, JS				Troy, CJ; Peeling, RW; Ellis, AG; Hockin, JC; Bennett, DA; Murphy, MR; Spika, JS			Chlamydia pneumoniae as a new source of infectious outbreaks in nursing homes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							STRAIN-TWAR; FAMILY; TRANSMISSION; EPIDEMIC; PSITTACI	Objective.-To determine the extent and severity of illness and mode of transmission of Chlamydia pneumoniae infection in 3 nursing home outbreaks. Design and Setting.-Retrospective cohort study in 3 nursing homes in Ontario from September to November 1994. Subjects.-A total of 549 residents and 65 staff members. Main Outcome Measures.-Morbidity and mortality were determined by a review of disease surveillance forms, residents' charts, and a self-administered questionnaire to staff. Single and paired serum samples for C pneumoniae serological testing and nasopharyngeal swabs for C pneumoniae culture were collected, and direct fluorescent antibody assays were performed to confirm C pneumoniae infection. Results.-The attack rates for confirmed and suspected cases combined were 68%, 46%, and 44% among residents in nursing homes A, B, and C, respectively, and 34% among nursing home C staff. A total of 16 cases of pneumonia confirmed by chest x-ray and 6 deaths were identified. The spectrum of illness among nursing home C residents included a new cough in 58 (100%), fever in 37 (64%), sore throat in 14 (24%), and hoarseness in 8 (14%). Staff members at nursing home C were more likely to report hoarseness (P<.001) and sore throat (P<.001). Residents who smoked had onset of illness earlier than nonsmokers (P=.007), which perhaps is related to airborne transmission in a designated smoking room. Conclusions.-Chlamydia pneumoniae caused serious morbidity and mortality among residents and morbidity among staff; C pneumoniae is an important cause of respiratory disease outbreaks in nursing homes, and diagnostic tests must be readily available for early recognition of C pneumoniae infections.	HLTH CANADA,LAB CTR DIS CONTROL,FIELD EPIDEMIOL TRAINING PROGRAM,OTTAWA,ON K1A 0L2,CANADA; ONTARIO MINIST HLTH,TORONTO,ON M5W 1R5,CANADA; WINDSOR ESSEX CTY HLTH UNIT,WINDSOR,ON,CANADA; WINDSOR REG PUBL HLTH LAB,WINDSOR,ON,CANADA; HLTH CANADA,LAB CTR DIS CONTROL,BUR INFECT DIS,OTTAWA,ON K1A 0L2,CANADA; HLTH CANADA,LAB CTR DIS CONTROL,BUR MICROBIOL,OTTAWA,ON K1A 0L2,CANADA	Health Canada; Health Canada; Health Canada								BANNATYNE RM, 1979, CUMITECH 10 LAB DIAG; BLASI F, 1994, EUR RESPIR J, V7, P102, DOI 10.1183/09031936.94.07010102; CASEY HL, 1965, PHS PUBLICATION, V1228; DAVIS C, 1989, CHEST S, V95, P206; EKMAN MR, 1993, CLIN INFECT DIS, V17, P420, DOI 10.1093/clinids/17.3.420; FALSEY AR, 1995, J INFECT DIS, V172, P389, DOI 10.1093/infdis/172.2.389; FALSEY AR, 1993, J INFECT DIS, V168, P493, DOI 10.1093/infdis/168.2.493; GHOSH K, 1992, J INFECTION, V25, P99, DOI 10.1016/0163-4453(92)92223-6; GRAYSTON JT, 1989, EUR J CLIN MICROBIOL, V8, P191, DOI 10.1007/BF01965260; GRAYSTON JT, 1993, J INFECT DIS, V168, P1231, DOI 10.1093/infdis/168.5.1231; GRAYSTON JT, 1992, CLIN INFECT DIS, V15, P757, DOI 10.1093/clind/15.5.757; GRAYSTON JT, 1986, NEW ENGL J MED, V315, P161, DOI 10.1056/NEJM198607173150305; GRAYSTON JT, 1990, J INFECT DIS, V161, P618, DOI 10.1093/infdis/161.4.618; HYMAN CL, 1991, J CLIN MICROBIOL, V29, P2082, DOI 10.1128/JCM.29.9.2082-2083.1991; KISHIMOTO T, 1994, CHLAMYDIAL INFECT, P465; KLEEMOLA M, 1988, J INFECT DIS, V157, P230, DOI 10.1093/infdis/157.2.230; KUO CC, 1988, ANTIMICROB AGENTS CH, V32, P257, DOI 10.1128/AAC.32.2.257; MARRIE TJ, 1994, CLIN INFECT DIS, V18, P501, DOI 10.1093/clinids/18.4.501; MCKINNEY RM, 1979, J CLIN MICROBIOL, V9, P103; MORDHORST CH, 1992, EUR J CLIN MICROBIOL, V11, P617, DOI 10.1007/BF01961668; MORDHORST CH, 1994, CHLAMYDIAL INFECTION, P488; Nicolle LE, 1996, CLIN MICROBIOL REV, V9, P1; PETHER JVS, 1989, EPIDEMIOL INFECT, V103, P395, DOI 10.1017/S0950268800030752; ROBLIN PM, 1992, J CLIN MICROBIOL, V30, P1968, DOI 10.1128/JCM.30.8.1968-1971.1992; SAIKKU P, 1985, J INFECT DIS, V151, P832, DOI 10.1093/infdis/151.5.832; Schmidt NJ, 1989, DIAGNOSTIC PROCEDURE; TANG PW, 1986, J CLIN MICROBIOL, V24, P556, DOI 10.1128/JCM.24.4.556-558.1986; THEUNISSEN HJH, 1993, APPL ENVIRON MICROB, V59, P2589, DOI 10.1128/AEM.59.8.2589-2593.1993; WANG SP, 1997, NONGONOCOCCAL URETHR, P237; YAMAZAKI T, 1990, J INFECT DIS, V162, P1390, DOI 10.1093/infdis/162.6.1390	30	74	74	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 16	1997	277	15					1214	1218		10.1001/jama.277.15.1214	http://dx.doi.org/10.1001/jama.277.15.1214			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WT403	9103345				2022-12-01	WOS:A1997WT40300032
J	Greenwood, R				Greenwood, R			Value of recording duration of posttraumatic amnesia	LANCET			English	Editorial Material							HEAD-INJURY				Greenwood, R (corresponding author), HOMERTON HOSP,REG NEUROL REHABIL UNIT,LONDON E9 6SR,ENGLAND.							BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; Ellenberg JH, 1996, ARCH NEUROL-CHICAGO, V53, P782, DOI 10.1001/archneur.1996.00550080104018; King NS, 1997, J NEUROL NEUROSUR PS, V62, P38, DOI 10.1136/jnnp.62.1.38; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; Russell W.R., 1961, ARCH NEUROL-CHICAGO, V5, P16, DOI DOI 10.1001/ARCHNEUR.1961.00450130006002; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; WILSON JTL, 1993, J NEUROL NEUROSUR PS, V56, P198; 1961, LANCET, V2, P1445	9	16	17	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 12	1997	349	9058					1041	1042		10.1016/S0140-6736(05)62288-X	http://dx.doi.org/10.1016/S0140-6736(05)62288-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU002	9107239				2022-12-01	WOS:A1997WU00200005
J	Han, J; Jiang, Y; Li, Z; Kravchenko, VV; Ulevitch, RJ				Han, J; Jiang, Y; Li, Z; Kravchenko, VV; Ulevitch, RJ			Activation of the transcription factor MEF2C by the MAP kinase p38 in inflammation	NATURE			English	Article							PROTEIN; CELLS; GENE; BIOSYNTHESIS; ENDOTOXIN; THREONINE; PROMOTER	For cells of the innate immune system to mount a host defence response to infection, they must recognize products of microbial pathogens such as lipopolysaccharide (LPS), the endotoxin secreted by Gram-negative bacterial, These cellular responses require intracellular signalling pathways, such as the four MAP kinase (MAPK) pathways(2-6). In mammalian cells the MAPK p38 is thought to play an important role in the regulation of cellular responses during infection through its effects on the expression of proinflammatory molecules(7-9). One means of understanding the role of p38 in these responses is to identify proteins with functions regulated by p38-catalysed phosphorylation, Here we demonstrate a link between the p38 pathway and a member of the myocyte-enhancer factor 2 (MEF2) group of transcription factors, We found that in monocytic cells, LPS increases the transactivation activity of MEF2C(10-12) through p38-catalysed phosphorylation, One consequence of MEF2C activation is increased c-jun gene transcription. Our results show that p38 may influence host defence and inflammation by maintaining the balance of c-Jun protein consumed during infection.			Han, J (corresponding author), Scripps Res Inst, DEPT IMMUNOL, 10550 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Han, J/G-4671-2010; Ulevitch, Richard J/Q-3393-2017					Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FUJIHARA M, 1993, J BIOL CHEM, V268, P14898; Hambleton J, 1996, P NATL ACAD SCI USA, V93, P2774, DOI 10.1073/pnas.93.7.2774; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HAN TH, 1995, MOL CELL BIOL, V15, P2907; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEE JD, 1995, BIOCHEM BIOPH RES CO, V213, P715, DOI 10.1006/bbrc.1995.2189; LEIFER D, 1993, P NATL ACAD SCI USA, V90, P1546, DOI 10.1073/pnas.90.4.1546; MACKMAN N, 1991, J EXP MED, V174, P1517, DOI 10.1084/jem.174.6.1517; MARTIN JF, 1994, MOL CELL BIOL, V14, P1647, DOI 10.1128/MCB.14.3.1647; MARTIN JF, 1993, P NATL ACAD SCI USA, V90, P5282, DOI 10.1073/pnas.90.11.5282; MCDERMOTT JC, 1993, MOL CELL BIOL, V13, P2564, DOI 10.1128/MCB.13.4.2564; Molkentin JD, 1996, MOL CELL BIOL, V16, P2627; MORRISON DC, 1994, J ENDOTOXIN RES, V1, P71; NEWELL CL, 1994, J LEUKOCYTE BIOL, V56, P27, DOI 10.1002/jlb.56.1.27; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; SHIN HS, 1996, MOL CELL BIOL; WANG HCR, 1992, MOL BIOL CELL, V3, P1329, DOI 10.1091/mbc.3.12.1329; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	27	659	704	1	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 20	1997	386	6622					296	299		10.1038/386296a0	http://dx.doi.org/10.1038/386296a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WP003	9069290				2022-12-01	WOS:A1997WP00300055
J	Bodner, C; Ross, S; Douglas, G; Little, J; Legge, J; Friend, J; Godden, D				Bodner, C; Ross, S; Douglas, G; Little, J; Legge, J; Friend, J; Godden, D			The prevalence of adult onset wheeze: Longitudinal study	BRITISH MEDICAL JOURNAL			English	Article							ASTHMA		UNIV ABERDEEN,DEPT MED & THERAPEUT,ABERDEEN AB9 2ZD,SCOTLAND	University of Aberdeen			Little, Julian/AAR-6117-2020	Little, Julian/0000-0001-5026-5531				DODGE RR, 1980, AM REV RESPIR DIS, V122, P567; HAHN DL, 1994, J FAM PRACTICE, V38, P373; LITTLEJOHNS P, 1989, THORAX, V44, P797, DOI 10.1136/thx.44.10.797; ROSS S, 1992, BRIT MED J, V305, P545, DOI 10.1136/bmj.305.6853.545; Strachan DP, 1996, BRIT MED J, V312, P1195	5	31	32	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 15	1997	314	7083					792	793		10.1136/bmj.314.7083.792	http://dx.doi.org/10.1136/bmj.314.7083.792			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN646	9080997	Green Published			2022-12-01	WOS:A1997WN64600025
J	Ancilotto, F; Chiarotti, GL; Scandolo, S; Tosatti, E				Ancilotto, F; Chiarotti, GL; Scandolo, S; Tosatti, E			Dissociation of methane into hydrocarbons at extreme (planetary) pressure and temperature	SCIENCE			English	Article							NEPTUNE; URANUS; APPROXIMATION; INTERIOR; BEHAVIOR; ENERGY	Constant-pressure, first-principles molecular dynamic simulations were used to investigate the behavior of methane at high pressure and temperature. Contrary to the current interpretation of shock-wave experiments, the simulations suggest that, below 100 gigapascals, methane dissociates into a mixture of hydrocarbons, and it separates into hydrogen and carbon only above 300 gigapascals. The simulation conditions (100 to 300 gigapascals; 4000 to 5000 kelvin) were chosen to follow the isentrope in the middle ice layers of Neptune and Uranus. implications on the physics of these planets are discussed.	SISSA,I-34014 TRIESTE,ITALY; UNIV PADUA,DIPARTIMENTO FIS G GALILEI,I-35131 PADUA,ITALY; IST NAZL FIS MAT,TRIESTE,ITALY	International School for Advanced Studies (SISSA); University of Padua; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Padua			Scandolo, Sandro/AAC-9081-2019; Chiarotti, Guido/A-9909-2012	Scandolo, Sandro/0000-0003-3826-4813; 				BECKE AD, 1988, PHYS REV A, V38, P3098, DOI 10.1103/PhysRevA.38.3098; BERNASCONI M, 1996, P JOINT 15 AIRAPT 33, P846; BEZARD B, 1991, J GEOPHYS RES-PLANET, V96, P18961, DOI 10.1029/91JA01930; ECK RV, 1966, SCIENCE, V153, P628, DOI 10.1126/science.153.3736.628; FOCHER P, 1994, EUROPHYS LETT, V26, P345, DOI 10.1209/0295-5075/26/5/005; Focher P., 1995, PROGR COMPUTATIONAL, P1; Hoover W. G., 1991, COMPUTATIONAL STAT M; HUBBARD WB, 1980, J GEOPHYS RES, V85, P225, DOI 10.1029/JB085iB01p00225; HUBBARD WB, 1991, SCIENCE, V253, P648, DOI 10.1126/science.253.5020.648; KOHANOFF J, UNPUB; MOSES JI, 1995, ICARUS, V113, P232, DOI 10.1006/icar.1995.1022; NELLIS WJ, 1981, J CHEM PHYS, V75, P3055, DOI 10.1063/1.442401; NELLIS WJ, 1984, J CHEM PHYS, V80, P2789, DOI 10.1063/1.447027; NELLIS WJ, 1988, SCIENCE, V240, P779, DOI 10.1126/science.240.4853.779; PERDEW JP, 1986, PHYS REV B, V33, P8822, DOI 10.1103/PhysRevB.33.8822; REE FH, 1979, J CHEM PHYS, V70, P974, DOI 10.1063/1.437487; ROSS M, 1981, NATURE, V292, P435, DOI 10.1038/292435a0; Scandolo S, 1996, PHYS REV B, V53, P5051, DOI 10.1103/PhysRevB.53.5051; SCANDOLO S, 1995, PHYS REV LETT, V74, P4015, DOI 10.1103/PhysRevLett.74.4015; Somayazulu MS, 1996, SCIENCE, V271, P1400, DOI 10.1126/science.271.5254.1400	20	117	119	1	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 28	1997	275	5304					1288	1290		10.1126/science.275.5304.1288	http://dx.doi.org/10.1126/science.275.5304.1288			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WK644	9036849				2022-12-01	WOS:A1997WK64400036
J	Hager, KM; Hajduk, SL				Hager, KM; Hajduk, SL			Mechanism of resistance of African trypanosomes to cytotoxic human HDL	NATURE			English	Article							HIGH-DENSITY-LIPOPROTEIN; HUMAN SERUM-RESISTANT; BRUCEI-RHODESIENSE; IDENTIFICATION; HAPTOGLOBIN; PROTEIN; CLONES; LYSIS; GENE	Trypanosoma brucei brucei the causative agent of ngana in cattle, is non-infectious to humans because of its sensitivity to the cytolytic activity of normal human serum(1). The toxin in normal human serum is human haptoglobin-related protein (Hpr)(2-5) which is found either as an apolipoprotein associated with a minor subclass of high-density lipoprotein (HDL), named trypanosome lytic factor (TLF1)(6-8), or as an unstable, high-molecular-mass protein complex known as TLF2 (refs 5, 9-12). TLF-mediated lysis of T. b. brucei requires binding, internalization and lysosomal targeting(13). The human sleeping-sickness trypanosome, Trypanosoma brucei rhodesiense is resistant to TLF. Our studies reveal that resistant trypanosomes fail to endocytose TLF yet continue to bind TLF through cell-surface receptors. On the basis of these results, we conclude that one mechanism of resistance of human sleeping-sickness trypanosomes to human serum is decreased internalization of receptor-bound TLF.	UNIV ALABAMA,SCH MED,DEPT BIOCHEM & MOL GENET,BIRMINGHAM,AL 35294; UNIV ALABAMA,SCH DENT,DEPT BIOCHEM & MOL GENET,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham								BANGS JD, 1985, P NATL ACAD SCI USA, V82, P3208; CROSS GAM, 1990, ANNU REV IMMUNOL, V8, P83, DOI 10.1146/annurev.iy.08.040190.000503; DEGREEF C, 1994, MOL BIOCHEM PARASIT, V68, P277, DOI 10.1016/0166-6851(94)90172-4; DEGREEF C, 1989, MOL BIOCHEM PARASIT, V36, P169, DOI 10.1016/0166-6851(89)90189-8; HAGER KM, 1994, J CELL BIOL, V126, P155, DOI 10.1083/jcb.126.1.155; HAJDUK SL, 1989, J BIOL CHEM, V264, P5210; HAWKING F, 1976, T  SOC TROP MED HYG, V90, P504; Hoare C, 1972, TRYPANOSOMES MAMMALS; LANHAM SM, 1968, NATURE, V218, P1273, DOI 10.1038/2181273a0; Laveran A, 1902, CR HEBD ACAD SCI, V134, P735; LORENZ P, 1994, MOL BIOCHEM PARASIT, V64, P153, DOI 10.1016/0166-6851(94)90143-0; MATHIEUDAUDE F, 1994, EXP PARASITOL, V78, P1, DOI 10.1006/expr.1994.1001; MOORE DR, 1995, EXP PARASITOL, V81, P216, DOI 10.1006/expr.1995.1111; ORTIZ JC, 1994, J PARASITOL, V80, P550, DOI 10.2307/3283190; OVERATH P, 1994, PARASITOL TODAY, V10, P53, DOI 10.1016/0169-4758(94)90393-X; OWEN JS, 1987, BIOCHEM SOC T, V15, P478, DOI 10.1042/bst0150478; PRIEST JM, 1994, MOL BIOCHEM PARASIT, V65, P294; Raper J, 1996, J EXP MED, V183, P1023, DOI 10.1084/jem.183.3.1023; RICKMAN L, 1980, T ROY SOC TROP MED H, V74, P817, DOI 10.1016/0035-9203(80)90214-X; RIFKIN MR, 1994, MOL BIOCHEM PARASIT, V66, P211, DOI 10.1016/0166-6851(94)90148-1; RIFKIN MR, 1978, P NATL ACAD SCI USA, V75, P3450, DOI 10.1073/pnas.75.7.3450; SALMON D, 1994, CELL, V78, P75, DOI 10.1016/0092-8674(94)90574-6; SMITH AB, 1995, P NATL ACAD SCI USA, V92, P10262, DOI 10.1073/pnas.92.22.10262; SMITH AB, 1995, SCIENCE, V268, P284, DOI 10.1126/science.7716520; SMITH AB, MOL BIOCH PARASITOL; TOMLINSON S, 1995, MOL BIOCHEM PARASIT, V70, P131, DOI 10.1016/0166-6851(95)00019-W; TYTLER E, 1995, MOL BIOCHEM PARASIT, V62, P9	27	50	53	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 27	1997	385	6619					823	826		10.1038/385823a0	http://dx.doi.org/10.1038/385823a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WK570	9039915				2022-12-01	WOS:A1997WK57000055
J	Goldhaber, SZ; Grodstein, F; Stampfer, MJ; Manson, JE; Colditz, GA; Speizer, FE; Willett, WC; Hennekens, CH				Goldhaber, SZ; Grodstein, F; Stampfer, MJ; Manson, JE; Colditz, GA; Speizer, FE; Willett, WC; Hennekens, CH			A prospective study of risk factors for pulmonary embolism in women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; VENOUS THROMBOSIS; FACTOR-V; WEIGHT; FIBRINOGEN; OBESITY; MEN	Objective.-To investigate risk factors for pulmonary embolism in women. Design.-Prospective study based on biennial, mailed questionnaires. Setting.-Nurses' Health Study with 16 years of follow-up from 1976 to 1992. Patients.-A group of 112 822 women aged 30 to 55 years in 1976, free from diagnosed cardiovascular disease or cancer at baseline. Overall, there were 1 619 770 person-years of follow-up. Measurements.-Based on self-report and medical records, we documented 280 cases of pulmonary embolism, of which 125 were primary (no identified antecedent cancer, trauma, surgery, or immobilization). information on height, weight, cigarette smoking, hypertension, diabetes, and hypercholesterolemia was collected by questionnaire. Results.-In multivariate analysis, obesity, cigarette smoking, and hypertension were independent predictors of pulmonary embolism. Specifically, obese women (body mass index greater than or equal to 29.0 kg/m(2)) had an increased risk of primary pulmonary embolism (multivariate relative risk=2.9; 95% confidence interval [CI], 1.5-5.4). Heavy cigarette smokers also had an increased risk of primary pulmonary embolism. The relative risk (RR) of primary pulmonary embolism was 1.9 (95% CI, 0.9-3.7) for women currently smoking 25 to 34 cigarettes per day and 3.3 (95% CI, 1.7-6.5) for those smoking 35 cigarettes or more daily as compared with never smokers. Hypertension, even after adjustment for body mass index, was also associated with an increased risk of primary pulmonary embolism (RR=1,9; 95% CI, 1.2-2.8), High serum cholesterol levels (RR=1.1;95% CI, 0.62-1.8) and diabetes (RR=0.7; 95% CI, 0.3-1.9) did not appear to be related to primary pulmonary embolism. Conclusion.-These prospective data indicate that obesity, cigarette smoking, and hypertension are associated with increased risk of pulmonary embolism in women. Control of these risk factors will decrease risks of pulmonary embolism as well as coronary heart disease.	BRIGHAM & WOMENS HOSP,CHANNING LAB,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DIV PREVENT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT AMBULATORY CARE & PREVENT,CAMBRIDGE,MA 02138; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Goldhaber, SZ (corresponding author), BRIGHAM & WOMENS HOSP,DEPT MED,DIV CARDIOVASC,75 FRANCIS ST,BOSTON,MA 02115, USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NCI NIH HHS [CA 40935] Funding Source: Medline; NHLBI NIH HHS [HL 24074, HL 34594] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040935] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034594] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		COLDITZ GA, 1986, AM J EPIDEMIOL, V123, P894, DOI 10.1093/oxfordjournals.aje.a114319; COLDITZ GA, 1995, ANN INTERN MED, V122, P481, DOI 10.7326/0003-4819-122-7-199504010-00001; COX DR, 1972, J R STAT SOC B, V34, P187; GOLDHABER SZ, 1983, AM J MED, V74, P1023, DOI 10.1016/0002-9343(83)90805-7; GOLDHABER SZ, 1993, PREVENTION VENOUS TH; Grodstein F, 1996, LANCET, V348, P983, DOI 10.1016/S0140-6736(96)07308-4; Hirsch DR, 1996, AM HEART J, V131, P1145, DOI 10.1016/S0002-8703(96)90089-7; KANNEL WB, 1987, AM HEART J, V113, P1006, DOI 10.1016/0002-8703(87)90063-9; MANSON JAE, 1990, NEW ENGL J MED, V322, P882, DOI 10.1056/NEJM199003293221303; MANSON JE, 1995, NEW ENGL J MED, V333, P677, DOI 10.1056/NEJM199509143331101; MOSER KM, 1994, JAMA-J AM MED ASSOC, V271, P223, DOI 10.1001/jama.271.3.223; PRIMROSE JN, 1992, THROMB HAEMOSTASIS, V68, P396; QUINN DA, 1992, JAMA-J AM MED ASSOC, V268, P1689, DOI 10.1001/jama.268.13.1689; RICHEDWARDS JW, 1995, NEW ENGL J MED, V332, P1758, DOI 10.1056/NEJM199506293322607; RIDKER PM, 1995, NEW ENGL J MED, V332, P912, DOI 10.1056/NEJM199504063321403; RIDKER PM, 1995, CIRCULATION, V92, P2800, DOI 10.1161/01.CIR.92.10.2800; Rimm E B, 1990, Epidemiology, V1, P466, DOI 10.1097/00001648-199011000-00009; ROTHMAN KJ, 1979, PHS PUBLICATION; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; STAMPFER MJ, 1992, AM J CLIN NUTR, V55, P652, DOI 10.1093/ajcn/55.3.652; WILLETT WC, 1995, JAMA-J AM MED ASSOC, V273, P461, DOI 10.1001/jama.273.6.461; WITTEMAN JCM, 1989, CIRCULATION, V80, P1320, DOI 10.1161/01.CIR.80.5.1320	22	440	455	1	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 26	1997	277	8					642	645		10.1001/jama.277.8.642	http://dx.doi.org/10.1001/jama.277.8.642			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WJ498	9039882				2022-12-01	WOS:A1997WJ49800032
J	Schubert, I; Oud, JL				Schubert, I; Oud, JL			There is an upper limit of chromosome size for normal development of an organism	CELL			English	Article							MINICHROMOSOME; CENTROMERE	A clearly definable upper tolerance limit for chromosome arm length has been found. As a rule we postulate that, for normal development of an organism, the longest chromosome arm must not exceed half of the average length of the spindle axis at telophase. Above this length, fertility and viability of the carrier individuals become severely impaired due to increasingly incomplete separation of the longest chromatids during mitosis, resulting finally in the loss of DNA. The experimental work that points to a limit in genome plasticity has been carried out on a series of field bean lines with karyotypes of considerable variation in length of individual chromosomes.	UNIV AMSTERDAM,BIOCENTRUM AMSTERDAM,INST MOL CELL BIOL,NL-1098 SM AMSTERDAM,NETHERLANDS	University of Amsterdam	Schubert, I (corresponding author), INST PLANT GENET & CROP PLANT RES,CORRENSSTR 3,D-06466 GATERSLEBEN,GERMANY.		Schubert, Ingo/AAF-5882-2020	Schubert, Ingo/0000-0002-6300-2068				Adames KA, 1996, CELL MOTIL CYTOSKEL, V34, P13; Karpen GH, 1996, SCIENCE, V273, P118, DOI 10.1126/science.273.5271.118; MURPHY TD, 1995, CELL, V82, P599, DOI 10.1016/0092-8674(95)90032-2; NIWA O, 1989, EMBO J, V8, P3045, DOI 10.1002/j.1460-2075.1989.tb08455.x; OUD JL, 1992, J CELL SCI, V103, P847; SCHRIEVERSCHWEMMER G, 1993, CYTOGENET CELL GENET, V64, P122, DOI 10.1159/000133567; SCHUBERT I, 1986, BIOL ZBL, V105, P9; SCHUBERT I, 1982, BIOL ZBL, V101, P793; Schubert I., 1991, Chromosome engineering in plants: genetics, breeding, evolution. Part A., P113; SCHUBERT I, 1990, BIOL ZBL, V109, P207; Schubert I., 1991, FABIS Newsletter, P14; VISCHER NOE, 1994, BINARY-COMPUT MICROB, V6, P160; VISSER TD, 1994, SCANNING, V16, P198, DOI 10.1002/sca.4950160403	13	72	73	1	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 21	1997	88	4					515	520		10.1016/S0092-8674(00)81891-7	http://dx.doi.org/10.1016/S0092-8674(00)81891-7			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WJ691	9038342	Bronze			2022-12-01	WOS:A1997WJ69100011
J	Zwijsen, RML; Wientjens, E; Klompmaker, R; vanderSman, J; Bernards, R; Michalides, RJAM				Zwijsen, RML; Wientjens, E; Klompmaker, R; vanderSman, J; Bernards, R; Michalides, RJAM			CDK-independent activation of estrogen receptor by cyclin D1	CELL			English	Article							HUMAN-BREAST-CANCER; RETINOBLASTOMA PROTEIN; RESPONSIVE ELEMENT; CELL-CYCLE; TRANSCRIPTIONAL ACTIVATION; HORMONE RECEPTOR; GENE-PRODUCT; EXPRESSION; PHOSPHORYLATION; ONCOGENE	Both cyclin D1 and estrogens have an essential role in regulating proliferation of breast epithelial cells. We show here a novel role for cyclin D1 in growth regulation of estrogen-responsive tissues by potentiating transcription of estrogen receptor-regulated genes. Cyclin D1 mediates this activation independent of complex formation to a CDK partner. Cyclin D1 activates estrogen receptor-mediated transcription in the absence of estrogen and enhances transcription in its presence. The activation of estrogen receptor by cyclin D1 is not inhibited by anti-estrogens. A direct physical binding of cyclin D1 to the hormone binding domain of the estrogen receptor results in an increased binding of the receptor to estrogen response element sequences, and upregulates estrogen receptor-mediated transcription. These results highlight a novel role for cyclin D1 as a CDK-independent activator of the estrogen receptor.	NETHERLANDS CANC INST,ANTONI VAN LEEUWENHOEK HUIS,DEPT MOL CARCINOGENESIS,NL-1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute	Zwijsen, RML (corresponding author), NETHERLANDS CANC INST,ANTONI VAN LEEUWENHOEK HUIS,DEPT TUMOR BIOL,PLESMANLAAN 121,NL-1066 CX AMSTERDAM,NETHERLANDS.			Bernards, Rene/0000-0001-8677-3423				ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; BARTKOVA J, 1995, CANCER RES, V55, P949; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; BEATO M, 1991, FASEB J, V5, P2044, DOI 10.1096/fasebj.5.7.2010057; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; DEFRIEND DJ, 1994, CANCER RES, V54, P408; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DUBIK D, 1988, J BIOL CHEM, V263, P12705; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; IGNARTROWBRIDGE DM, 1993, MOL ENDOCRINOL, V7, P992, DOI 10.1210/me.7.8.992; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KLEINHITPASS L, 1988, NUCLEIC ACIDS RES, V16, P647, DOI 10.1093/nar/16.2.647; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LAMMIE GA, 1991, ONCOGENE, V6, P439; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; Michalides R, 1996, BRIT J CANCER, V73, P728, DOI 10.1038/bjc.1996.128; MIGLIACCIO A, 1991, J STEROID BIOCHEM, V38, P407, DOI 10.1016/0960-0760(91)90328-3; MOTOKURA T, 1992, J BIOL CHEM, V267, P20412; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; OMALLEY BW, 1995, RECENT PROG HORM RES, V50, P333; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; PRATT WB, 1993, J BIOL CHEM, V268, P21455; REEVES SA, 1995, BIOTECHNIQUES, V18, P18; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SCHUURING E, 1992, ONCOGENE, V7, P355; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WANG YL, 1991, MOL ENDOCRINOL, V5, P1707, DOI 10.1210/mend-5-11-1707; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEISZ A, 1988, MOL ENDOCRINOL, V2, P816, DOI 10.1210/mend-2-9-816; WILTSCHKE C, 1995, TRENDS ENDOCRIN MET, V6, P77, DOI 10.1016/1043-2760(95)00005-3; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; ZHANG QX, 1993, CANCER RES, V53, P5882; ZHANG YX, 1994, MOL ENDOCRINOL, V8, P577, DOI 10.1210/me.8.5.577; ZWILJSEN R, 1996, MOL CELL BIOL, V16, P2554	50	595	616	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 7	1997	88	3					405	415		10.1016/S0092-8674(00)81879-6	http://dx.doi.org/10.1016/S0092-8674(00)81879-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WG479	9039267	Green Published, Bronze			2022-12-01	WOS:A1997WG47900013
J	Gooley, AA; Williams, KL				Gooley, AA; Williams, KL			How to find, identify and quantitate the sugars on proteins	NATURE			English	Article							LINKED GLYCOSYLATION MOTIFS; EDMAN DEGRADATION; MASS-SPECTROMETRY; IDENTIFICATION	A new sequenator allows the identification, quantification and characterization of sites of glycosylation on proteins, making it possible to analyse the glycosylation at serine and threonine sites in mucin-like domains.										Bures EJ, 1995, METHODS IN PROTEIN STRUCTURE ANALYSIS, P57; CARR SA, 1991, ANAL CHEM, V63, P2802, DOI 10.1021/ac00024a003; CARR SA, 1993, PROTEIN SCI, V2, P183; GOOLEY AA, 1991, BIOCHEM BIOPH RES CO, V178, P1194, DOI 10.1016/0006-291X(91)91019-9; GOOLEY AA, 1995, TECH PROT CHEM, V6, P83, DOI 10.1016/S1080-8914(06)80013-X; GOOLEY AA, 1992, GENETICS, V130, P749; GRINNELL BW, 1991, J BIOL CHEM, V266, P9778; HARRIS RJ, 1993, GLYCOBIOLOGY, V3, P219, DOI 10.1093/glycob/3.3.219; Jenkins N, 1996, NAT BIOTECHNOL, V14, P975, DOI 10.1038/nbt0896-975; PISANO A, 1993, GLYCOBIOLOGY, V3, P429, DOI 10.1093/glycob/3.5.429; PISANO A, 1994, GLYCOBIOLOGY, V4, P837, DOI 10.1093/glycob/4.6.837; Pisano A, 1995, METHODS IN PROTEIN STRUCTURE ANALYSIS, P69; PISANO A, 1996, TECHNIQUES GLYCOBIOL, P299; REDMOND JW, 1994, Patent No. 164; ShakinEshleman SH, 1996, J BIOL CHEM, V271, P6363, DOI 10.1074/jbc.271.11.6363; WROTNOWSKI C, 1996, GENET ENG NEWS  0515, P7; Zachara NE, 1996, EUR J BIOCHEM, V238, P511, DOI 10.1111/j.1432-1033.1996.0511z.x	17	26	29	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 6	1997	385	6616					557	559		10.1038/385557a0	http://dx.doi.org/10.1038/385557a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG235	9020365				2022-12-01	WOS:A1997WG23500055
J	More, RS; Chauhan, A				More, RS; Chauhan, A			Antiplatelet rather than anticoagulant therapy with coronary stenting	LANCET			English	Editorial Material							ANGIOPLASTY		PAPWORTH HOSP,DEPT CARDIAC,CAMBRIDGE,ENGLAND	Papworth Hospital	More, RS (corresponding author), ST MARYS HOSP,ACAD CARDIAC DEPT,PRAED ST,LONDON W2 1NY,ENGLAND.							BRUNEL P, 1995, CIRCULATION S1, V92, P87; COLOMBO A, 1995, CIRCULATION, V91, P1676, DOI 10.1161/01.CIR.91.6.1676; Hall P, 1996, CIRCULATION, V93, P215, DOI 10.1161/01.CIR.93.2.215; Inoue T, 1996, CIRCULATION, V94, P1523; JORDAN C, 1994, CIRCULATION, V90, P125; SCHATZ RA, 1991, CIRCULATION, V83, P148, DOI 10.1161/01.CIR.83.1.148; Schomig A, 1996, NEW ENGL J MED, V334, P1084, DOI 10.1056/NEJM199604253341702; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; SIGWART U, 1987, NEW ENGL J MED, V316, P701, DOI 10.1056/NEJM198703193161201	9	22	22	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 18	1997	349	9046					146	147		10.1016/S0140-6736(97)22003-9	http://dx.doi.org/10.1016/S0140-6736(97)22003-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC861	9111532				2022-12-01	WOS:A1997WC86100002
J	Zhang, JR; Hardham, JM; Barbour, AG; Norris, SJ				Zhang, JR; Hardham, JM; Barbour, AG; Norris, SJ			Antigenic variation in Lyme disease borreliae by promiscuous recombination of VMP-like sequence cassettes	CELL			English	Article							HUMAN EPITHELIAL-CELLS; NEISSERIA-GONORRHOEAE; SURFACE PROTEIN; IMMUNOCOMPETENT MICE; RELAPSING FEVER; BURGDORFERI; GENES; HERMSII; PILUS; EXPRESSION	We have identified and characterized an elaborate genetic system in the Lyme disease spirochete Borrelia burgdorferi that promotes extensive antigenic variation of a surface-exposed lipoprotein, VlsE. A 28 kb linear plasmid of B. burgdorferi B31 (Ip28-1) was found to contain a vmp-like sequence (vls) locus that closely resembles the variable major protein (vmp) system for antigenic variation of relapsing fever organisms. Portions of several of the 15 nonexpressed (silent) vls cassette sequences located upstream of vlsE recombined into the central vlsE cassette region during infection of C3H/HeN mice, resulting in antigenic variation of the expressed lipoprotein. This combinatorial variation could potentially produce millions of antigenic variants in the mammalian host.	UNIV TEXAS, SCH MED, DEPT MICROBIOL & MOL GENET, HOUSTON, TX 77030 USA; UNIV CALIF IRVINE, COLL MED, DEPT MICROBIOL & MOL GENET, IRVINE, CA 92697 USA	University of Texas System; University of California System; University of California Irvine	Zhang, JR (corresponding author), UNIV TEXAS, SCH MED, DEPT PATHOL & LAB MED, HOUSTON, TX 77030 USA.		Barbour, Alan/B-3160-2009; Norris, Steven James/K-6586-2019	Barbour, Alan/0000-0002-0719-5248; Norris, Steven James/0000-0002-2501-8034	NIAID NIH HHS [R01 AI037277, AI24424, AI37277] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024424, R37AI024424, R01AI037277, R56AI037277] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Barbour A G, 1993, Trends Microbiol, V1, P236, DOI 10.1016/0966-842X(93)90139-I; BARBOUR AG, 1991, MOL MICROBIOL, V5, P489, DOI 10.1111/j.1365-2958.1991.tb02132.x; BARBOUR AG, 1991, INFECT IMMUN, V59, P390, DOI 10.1128/IAI.59.1.390-397.1991; BARTHOLD SW, 1993, INFECT IMMUN, V61, P4955, DOI 10.1128/IAI.61.12.4955-4961.1993; BORST P, 1987, SCIENCE, V235, P658, DOI 10.1126/science.3544215; BORST P, 1995, CELL, V82, P1, DOI 10.1016/0092-8674(95)90044-6; CADAVID D, 1994, J EXP MED, V179, P631, DOI 10.1084/jem.179.2.631; Carroll JA, 1996, INFECT IMMUN, V64, P392, DOI 10.1128/IAI.64.2.392-398.1996; CASJENS S, 1995, J BACTERIOL, V177, P2769, DOI 10.1128/jb.177.10.2769-2780.1995; DEMOLIS N, 1995, BIOTECHNIQUES, V18, P453; HAAS R, 1986, CELL, V44, P107, DOI 10.1016/0092-8674(86)90489-7; HAGBLOM P, 1985, NATURE, V315, P156, DOI 10.1038/315156a0; HINNEBUSCH J, 1990, MOL MICROBIOL, V4, P811, DOI 10.1111/j.1365-2958.1990.tb00651.x; JONSSON AB, 1994, MOL MICROBIOL, V13, P403, DOI 10.1111/j.1365-2958.1994.tb00435.x; KITTEN T, 1990, P NATL ACAD SCI USA, V87, P6077, DOI 10.1073/pnas.87.16.6077; KOOMEY M, 1987, GENETICS, V117, P391; KUPSCH EM, 1993, EMBO J, V12, P641, DOI 10.1002/j.1460-2075.1993.tb05697.x; LIVEY I, 1995, MOL MICROBIOL, V18, P257, DOI 10.1111/j.1365-2958.1995.mmi_18020257.x; MARCONI RT, 1993, INFECT IMMUN, V61, P2611, DOI 10.1128/IAI.61.6.2611-2617.1993; MARCONI RT, 1994, J BACTERIOL, V176, P4572, DOI 10.1128/JB.176.15.4572-4582.1994; MEYER TF, 1982, CELL, V30, P45, DOI 10.1016/0092-8674(82)90010-1; NASSIF X, 1993, MOL MICROBIOL, V8, P719, DOI 10.1111/j.1365-2958.1993.tb01615.x; NORRIS SJ, 1995, INFECT IMMUN, V63, P2206, DOI 10.1128/IAI.63.6.2206-2212.1995; NORRIS SJ, 1992, INFECT IMMUN, V60, P4662, DOI 10.1128/IAI.60.11.4662-4672.1992; Pennington PM, 1997, INFECT IMMUN, V65, P285, DOI 10.1128/IAI.65.1.285-292.1997; PERSING DH, 1994, INFECT IMMUN, V62, P3521, DOI 10.1128/IAI.62.8.3521-3527.1994; PLASTERK RHA, 1985, NATURE, V318, P257, DOI 10.1038/318257a0; RESTREPO BI, 1994, MOL MICROBIOL, V13, P287, DOI 10.1111/j.1365-2958.1994.tb00423.x; RESTREPO BI, 1994, CELL, V78, P867, DOI 10.1016/S0092-8674(94)90642-4; Rosa P, 1996, J BACTERIOL, V178, P5946, DOI 10.1128/jb.178.20.5946-5953.1996; ROSA PA, 1992, MOL MICROBIOL, V6, P3031, DOI 10.1111/j.1365-2958.1992.tb01761.x; RUDEL T, 1992, MOL MICROBIOL, V6, P3439, DOI 10.1111/j.1365-2958.1992.tb02211.x; SADZIENE A, 1992, J EXP MED, V176, P799, DOI 10.1084/jem.176.3.799; Sambrook J., 1989, MOL CLONING LAB MANU, V3; SAMUELS DS, 1994, J BACTERIOL, V176, P6045, DOI 10.1128/jb.176.19.6045-6049.1994; Schutzer S, 1992, LYME DIS MOL IMMUNOL; SCHWAN TG, 1991, CAN J MICROBIOL, V37, P450, DOI 10.1139/m91-074; SCHWAN TG, 1988, INFECT IMMUN, V56, P1831, DOI 10.1128/IAI.56.8.1831-1836.1988; SEAL SE, 1992, APPL ENVIRON MICROB, V58, P3751, DOI 10.1128/AEM.58.11.3751-3758.1992; SEGAL E, 1986, P NATL ACAD SCI USA, V83, P2177, DOI 10.1073/pnas.83.7.2177; SEIFERT HS, 1988, MICROBIOL REV, V52, P327, DOI 10.1128/MMBR.52.3.327-336.1988; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; STEVENSON B, 1994, INFECT IMMUN, V62, P3568, DOI 10.1128/IAI.62.8.3568-3571.1994; STOENNER HG, 1982, J EXP MED, V156, P1297, DOI 10.1084/jem.156.5.1297; Swanson J., 1989, MOBILE DNA, P743; WAINWRIGHT LA, 1994, MOL MICROBIOL, V13, P75, DOI 10.1111/j.1365-2958.1994.tb00403.x; WALKER EM, 1995, J BACTERIOL, V177, P1797, DOI 10.1128/jb.177.7.1797-1804.1995; WILSKE B, 1992, RES MICROBIOL, V143, P583, DOI 10.1016/0923-2508(92)90116-6; WU HC, 1986, CURR TOP MICROBIOL, V125, P127; Xu YN, 1996, INFECT IMMUN, V64, P3870, DOI 10.1128/IAI.64.9.3870-3876.1996	51	492	507	1	25	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 18	1997	89	2					275	285		10.1016/S0092-8674(00)80206-8	http://dx.doi.org/10.1016/S0092-8674(00)80206-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WU888	9108482	Bronze			2022-12-01	WOS:A1997WU88800014
J	Guo, L; Lim, KB; Gunn, JS; Bainbridge, B; Darveau, RP; Hackett, M; Miller, SI				Guo, L; Lim, KB; Gunn, JS; Bainbridge, B; Darveau, RP; Hackett, M; Miller, SI			Regulation of lipid a modifications by Salmonella typhimurium virulence genes phoP-phoQ	SCIENCE			English	Article							TANDEM MASS-SPECTROMETRY; ELECTROSPRAY-IONIZATION; STRUCTURAL DETERMINATION; BACTERIAL-ENDOTOXINS; BINDING-PROTEIN; PMRA MUTANTS; SOLUBLE CD14; LIPOPOLYSACCHARIDES; EXPRESSION; RESISTANCE	Bacterial pathogenesis requires proteins that sense host microenvironments and respond by regulating virulence gene transcription. For Salmonellae, one such regulatory system is PhoP-PhoQ, which regulates genes required for intracellular survival and resistance to cationic peptides. Analysis by mass spectrometry revealed that Salmonella typhimurium PhoP-PhoQ regulated structural modifications of lipid A, the host signaling portion of lipopolysaccharide (LPS), by the addition of aminoarabinose and 2-hydroxymyristate. Structurally modified lipid A altered LPS-mediated expression of the adhesion molecule E-selectin by endothelial cells and tumor necrosis factor-alpha expression by adherent monocytes. Thus, altered responses to environmentally induced lipid A structural modifications may represent a mechanism for bacteria to gain advantage within host tissues.	UNIV WASHINGTON, DEPT MED, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT MICROBIOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT MED CHEM, SEATTLE, WA 98195 USA; BRISTOL MYERS SQUIBB PHARMACEUT RES INST, INFLAMMAT DEPT, SEATTLE, WA 98121 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Bristol-Myers Squibb					NIAID NIH HHS [R01 AI30479] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030479] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARANDA CMA, 1992, P NATL ACAD SCI USA, V89, P10079, DOI 10.1073/pnas.89.21.10079; BRYN K, 1982, J CHROMATOGR, V240, P405, DOI 10.1016/S0021-9673(00)99620-1; CAROFF M, 1988, CARBOHYD RES, V175, P273, DOI 10.1016/0008-6215(88)84149-1; CHAN S, 1994, ANAL BIOCHEM, V218, P63, DOI 10.1006/abio.1994.1141; CHWARTZ JC, 1996, METHOD ENZYMOL, V270, P552; DARVEAU RP, 1995, INFECT IMMUN, V63, P1311, DOI 10.1128/IAI.63.4.1311-1317.1995; DARVEAU RP, 1983, J BACTERIOL, V155, P831, DOI 10.1128/JB.155.2.831-838.1983; Dole M, 1971, ADV CHEM SER, V125, P73; FENN JB, 1990, MASS SPECTROM REV, V9, P37, DOI 10.1002/mas.1280090103; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; FIELDS PI, 1989, SCIENCE, V243, P1059, DOI 10.1126/science.2646710; FREY EA, 1992, J EXP MED, V176, P1665, DOI 10.1084/jem.176.6.1665; Gunn JS, 1996, J BACTERIOL, V178, P6369, DOI 10.1128/jb.178.21.6369-6373.1996; Gunn JS, 1996, J BACTERIOL, V178, P6857, DOI 10.1128/jb.178.23.6857-6864.1996; HARRATA AK, 1993, BIOL MASS SPECTROM, V22, P59, DOI 10.1002/bms.1200220108; Heithoff DM, 1997, P NATL ACAD SCI USA, V94, P934, DOI 10.1073/pnas.94.3.934; HELANDER IM, 1994, MOL MICROBIOL, V11, P481, DOI 10.1111/j.1365-2958.1994.tb00329.x; JENSEN NJ, 1987, MASS SPECTROM REV, V6, P497, DOI 10.1002/mas.1280060403; Jonscher KR, 1997, ANAL BIOCHEM, V244, P1, DOI 10.1006/abio.1996.9877; KARAS M, 1987, INT J MASS SPECTROM, V78, P53, DOI 10.1016/0168-1176(87)87041-6; KARAS M, 1988, ANAL CHEM, V60, P2299, DOI 10.1021/ac00171a028; LOURIS JN, 1987, ANAL CHEM, V59, P1677, DOI 10.1021/ac00140a021; MEKALANOS JJ, 1992, J BACTERIOL, V174, P1; MILLER SI, 1990, INFECT IMMUN, V58, P3706, DOI 10.1128/IAI.58.11.3706-3710.1990; MILLER SI, 1990, J BACTERIOL, V172, P2485, DOI 10.1128/jb.172.5.2485-2490.1990; MILLER SI, 1989, P NATL ACAD SCI USA, V86, P5054, DOI 10.1073/pnas.86.13.5054; MILLER SI, 1995, SIGNAL TRANSDUCTION, P61; NUMMILA K, 1995, MOL MICROBIOL, V16, P271, DOI 10.1111/j.1365-2958.1995.tb02299.x; Odham G., 1972, BIOCH APPLICATIONS M, P211; PUGIN J, 1993, P NATL ACAD SCI USA, V90, P2744, DOI 10.1073/pnas.90.7.2744; QURESHI N, 1983, J BIOL CHEM, V258, P2947; QURESHI N, 1982, J BIOL CHEM, V257, P1808; RAETZ CRH, 1993, J BACTERIOL, V175, P5745, DOI 10.1128/JB.175.18.5745-5753.1993; ROLAND KL, 1993, J BACTERIOL, V175, P4154, DOI 10.1128/JB.175.13.4154-4164.1993; SIELING PA, 1995, SCIENCE, V269, P227, DOI 10.1126/science.7542404; Somerville JE, 1996, J CLIN INVEST, V97, P359, DOI 10.1172/JCI118423; TAKADA H, 1992, BACTERIAL ENDOTOXIC, V1, P107; TAKAYAMA K, 1983, J BIOL CHEM, V258, P2801; TODD JFJ, 1995, PRACTICAL ASPECTS IO, V3, P4; VAARA M, 1981, J BACTERIOL, V148, P426, DOI 10.1128/JB.148.2.426-434.1981; Vescovi EG, 1996, CELL, V84, P165, DOI 10.1016/S0092-8674(00)81003-X; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; YOST RA, 1990, METHOD ENZYMOL, V193, P154, DOI 10.1016/0076-6879(90)93415-H	43	453	471	4	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 11	1997	276	5310					250	253		10.1126/science.276.5310.250	http://dx.doi.org/10.1126/science.276.5310.250			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WT925	9092473				2022-12-01	WOS:A1997WT92500044
J	Reyburn, HT; Mandelboim, O; ValesGomez, M; Davis, DM; Pazmany, L; Strominger, JL				Reyburn, HT; Mandelboim, O; ValesGomez, M; Davis, DM; Pazmany, L; Strominger, JL			The class I MHC homologue of human cytomegalovirus inhibits attack by natural killer cells	NATURE			English	Article							ANTI-KP43 MONOCLONAL-ANTIBODY; LYMPHOCYTES-T; EXPRESSION; COMPLEX; RECEPTOR; CHAINS; VIRUS; GENES	Recognition and destruction of virus-infected cells by class I major histocompatibility complex (MHC) restricted cytotoxic T lymphocytes (CTL) is a central part of the immune system's attempts to control and eliminate virus infection. It is therefore not surprising that many viruses have evolved strategies to interfere with the processing and presentation of peptide antigen on class I MHC molecules (reviewed in ref. 1). These mechanisms act to prevent or reduce expression of MHC molecules at the cell surface. However, many natural killer (NK) cells are able to recognize and destroy host cells that no longer express class I MHC molecules (the 'missing self' hypothesis(2)). Thus, any virus-infected cell that has lost cell-surface expression of MHC class I to avoid CTL attack should become susceptible to NK-cell-mediated destruction. We describe here the first example, to our knowledge, of a viral strategy to evade immune surveillance by NK cells.	HARVARD UNIV,DEPT MOL & CELLULAR BIOL,CAMBRIDGE,MA 02138	Harvard University			Reyburn, Hugh T/B-4338-2009; Valés-Gómez, Mar/F-5351-2012; Vales-Gomez, Mar/ABG-7808-2020	Reyburn, Hugh T/0000-0003-2855-1595; Valés-Gómez, Mar/0000-0001-7424-3206; Vales-Gomez, Mar/0000-0001-7424-3206; Davis, Daniel/0000-0002-9182-291X; Mandelboim, Ofer/0000-0002-9354-1855				Ahn KS, 1996, P NATL ACAD SCI USA, V93, P10990, DOI 10.1073/pnas.93.20.10990; ARAMBURU J, 1991, J IMMUNOL, V147, P714; ARAMBURU J, 1990, J IMMUNOL, V144, P3238; BECK S, 1988, NATURE, V331, P269, DOI 10.1038/331269a0; BEERSMA MFC, 1993, J IMMUNOL, V151, P4455; BROCKER T, 1993, EUR J IMMUNOL, V23, P1435, DOI 10.1002/eji.1830230705; BROWNE H, 1990, NATURE, V347, P770, DOI 10.1038/347770a0; FAHNESTOCK ML, 1995, IMMUNITY, V3, P583, DOI 10.1016/1074-7613(95)90129-9; FUHRMANN U, 1985, BIOCHIM BIOPHYS ACTA, V825, P95, DOI 10.1016/0167-4781(85)90095-8; Hengel H, 1996, J GEN VIROL, V77, P2287, DOI 10.1099/0022-1317-77-9-2287; JONES TR, 1995, J VIROL, V69, P4830, DOI 10.1128/JVI.69.8.4830-4841.1995; Jones TR, 1996, P NATL ACAD SCI USA, V93, P11327, DOI 10.1073/pnas.93.21.11327; Lazetic S, 1996, J IMMUNOL, V157, P4741; LJUNGGREN HG, 1990, IMMUNOL TODAY, V11, P237, DOI 10.1016/0167-5699(90)90097-S; Mandelboim O, 1996, J EXP MED, V184, P913, DOI 10.1084/jem.184.3.913; MCGEOCH DJ, 1995, J MOL BIOL, V247, P443, DOI 10.1006/jmbi.1995.0152; PARHAM P, 1983, J BIOL CHEM, V258, P6179; PEREZVILLAR JJ, 1995, J IMMUNOL, V154, P5779; PerezVillar JJ, 1996, J IMMUNOL, V157, P5367; Phillips JH, 1996, IMMUNITY, V5, P163, DOI 10.1016/S1074-7613(00)80492-6; SHIMIZU Y, 1989, J IMMUNOL, V142, P3320; SHIMIZU Y, 1988, P NATL ACAD SCI USA, V85, P227, DOI 10.1073/pnas.85.1.227; Spriggs MK, 1996, ANNU REV IMMUNOL, V14, P101, DOI 10.1146/annurev.immunol.14.1.101; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; WILEY D, 1988, NATURE, V331, P209, DOI 10.1038/331209a0	26	257	260	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 3	1997	386	6624					514	517		10.1038/386514a0	http://dx.doi.org/10.1038/386514a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WR256	9087413				2022-12-01	WOS:A1997WR25600057
J	Quartin, AA; Schein, RMH; Kett, DH; Peduzzi, PN				Quartin, AA; Schein, RMH; Kett, DH; Peduzzi, PN			Magnitude and duration of the effect of sepsis on survival	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESPIRATORY-DISTRESS SYNDROME; GRAM-NEGATIVE BACTEREMIA; LONG-TERM SURVIVAL; CONTROLLED CLINICAL-TRIAL; PLACEBO-CONTROLLED TRIAL; CRITICALLY ILL PATIENTS; INTENSIVE-CARE UNITS; ACUTE-RENAL-FAILURE; SEPTIC SHOCK; MONOCLONAL-ANTIBODY	Objective.-To determine the magnitude and duration of the effects of sepsis on survival. Design.-Cohort study. Setting.-The 10 Department of Veterans Affairs Medical Centers of the Systemic Sepsis Cooperative Studies Group, which from 1983 to 1986 conducted the Department of Veterans Affairs Cooperative Study of Corticosteroids in Systemic Sepsis. Patients.-The septic population consisted of 1505 patients with evaluable data from the screening log of the Cooperative Study of Corticosteroids in Systemic Sepsis, All 91 830 nonpsychiatric, noninfected patients discharged from the participating medical centers between October 1, 1984, and September 30, 1985, were included in the control population. Main Outcome Measure.-Death through 8 years after the index hospitalization. Results.-On the basis of a proportional hazards model constructed from the demographic and illness characteristics of the control population, the septic population was at significant risk of dying of nonseptic causes (26% predicted 1-year mortality), In the septic population, the daily risk of dying exceeded predictions from this model for 5 years, and the hazard rate rose with increasing severity of the septic episode throughout the first year (P<.05). Among 30-day survivors, sepsis reduced the remaining mean life span from a predicted 8.03 years to 4.08 years. Conclusions.-Sepsis not only causes deaths acutely, but also increases the risk of death for up to 5 years after the septic episode even after comorbidities are accounted for. The risk of late death during the first year is associated with the severity of the septic episode.	UNIV MIAMI, DIV PULM & CRIT CARE MED, MIAMI, FL 33152 USA; DEPT VET AFFAIRS, COOPERAT STUDIES PROGRAM COORDINATING CTR, West Haven, CT USA	University of Miami	Quartin, AA (corresponding author), VET AFFAIRS MED CTR, SECT CRIT CARE 111, 1201 NW 16TH ST, MIAMI, FL 33125 USA.							ALOY DA, 1990, ENFERM INFEC MICR CL, V8, P540; BATES DW, 1995, ARCH INTERN MED, V155, P593, DOI 10.1001/archinte.155.6.593; BONE RC, 1987, NEW ENGL J MED, V317, P653, DOI 10.1056/NEJM198709103171101; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; BRUNBUISSON C, 1995, JAMA-J AM MED ASSOC, V274, P968, DOI 10.1001/jama.274.12.968; BRYANT RE, 1971, ARCH INTERN MED, V127, P120, DOI 10.1001/archinte.127.1.120; CHERTOW GM, 1995, ARCH INTERN MED, V155, P1505, DOI 10.1001/archinte.155.14.1505; ELLIOTT CG, 1987, AM REV RESPIR DIS, V135, P634; ELLIOTT CG, 1990, CLIN CHEST MED, V11, P789; FINLAND M, 1959, JAMA-J AM MED ASSOC, V170, P2188, DOI 10.1001/jama.1959.63010180008012; FISHER CJ, 1994, JAMA-J AM MED ASSOC, V271, P1836, DOI 10.1001/jama.271.23.1836; FISHER CJ, 1994, JAMA-J AM MED ASSOC, V272, P1170; GHIO AJ, 1989, AM REV RESPIR DIS, V139, P1158, DOI 10.1164/ajrccm/139.5.1158; GREEN J, 1995, J AM SOC NEPHROL, V5, P1853; GREENMAN RL, 1991, JAMA-J AM MED ASSOC, V266, P1097, DOI 10.1001/jama.266.8.1097; HALL JW, 1970, ANN INTERN MED, V73, P515, DOI 10.7326/0003-4819-73-4-515; HODGIN UG, 1965, AM J MED, V39, P952, DOI 10.1016/0002-9343(65)90118-X; KNAUS WA, 1993, JAMA-J AM MED ASSOC, V270, P1233, DOI 10.1001/jama.270.10.1233; KNAUS WA, 1995, ANN INTERN MED, V122, P191, DOI 10.7326/0003-4819-122-3-199502010-00007; KOCHANEK KD, 1995, MONTHLY VITAL STAT S, P43; KREGER BE, 1980, AM J MED, V68, P344, DOI 10.1016/0002-9343(80)90102-3; LEIBOVICI L, 1995, JAMA-J AM MED ASSOC, V274, P807, DOI 10.1001/jama.274.10.807; LEIJTEN FSS, 1995, JAMA-J AM MED ASSOC, V274, P1221, DOI 10.1001/jama.274.15.1221; LEWERS DT, 1970, ANN INTERN MED, V73, P523, DOI 10.7326/0003-4819-73-4-523; MCCABE WR, 1962, ARCH INTERN MED, V110, P847, DOI 10.1001/archinte.1962.03620240029006; Moss M, 1996, JAMA-J AM MED ASSOC, V275, P50, DOI 10.1001/jama.275.1.50; *OFF PLANN EXTR PR, 1990, MMWR-MORBID MORTAL W, V39, P31; PEDUZZI P, 1992, ARCH INTERN MED, V152, P529, DOI 10.1001/archinte.152.3.529; PEDUZZI P, 1987, NEW ENGL J MED, V317, P659; PERL TM, 1995, JAMA-J AM MED ASSOC, V274, P338, DOI 10.1001/jama.274.4.338; PETERS JI, 1989, AM REV RESPIR DIS, V139, P1163, DOI 10.1164/ajrccm/139.5.1163; PITTET D, 1993, INTENS CARE MED, V19, P265, DOI 10.1007/BF01690546; RANGELFRAUSTO MS, 1995, JAMA-J AM MED ASSOC, V273, P117, DOI 10.1001/jama.273.2.117; RUTENBURG AM, 1959, P SOC EXP BIOL MED, V101, P279, DOI 10.3181/00379727-101-24910; SASSE KC, 1995, CRIT CARE MED, V23, P1040, DOI 10.1097/00003246-199506000-00008; SCHULMAN KA, 1991, JAMA-J AM MED ASSOC, V266, P3466, DOI 10.1001/jama.266.24.3466; VINCENT JL, 1995, JAMA-J AM MED ASSOC, V274, P639, DOI 10.1001/jama.274.8.639; World Health Organization, 1977, INT CLASS DIS; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701	39	293	304	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 2	1997	277	13					1058	1063		10.1001/jama.277.13.1058	http://dx.doi.org/10.1001/jama.277.13.1058			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ089	9091694				2022-12-01	WOS:A1997WQ08900031
J	Ridker, PM; Glynn, RJ; Miletich, JP; Goldhaber, SZ; Stampfer, MJ; Hennekens, CH				Ridker, PM; Glynn, RJ; Miletich, JP; Goldhaber, SZ; Stampfer, MJ; Hennekens, CH			Age-specific incidence rates of venous thromboembolism among heterozygous carriers of factor V Leiden mutation	ANNALS OF INTERNAL MEDICINE			English	Article							ACTIVATED PROTEIN-C; POOR ANTICOAGULANT RESPONSE; COAGULATION-FACTOR-V; THROMBOSIS; RESISTANCE; THROMBOPHILIA; RISK	Background: Previous reports suggest that younger carriers of the factor V Leiden mutation are at greater risk for venous thromboembolism than are older carriers. However, available data on thromboembolic risk are limited. Objective: To determine age-specific incidence rates of venous thromboembolism associated with the factor V Leiden mutation. Design: Prospective cohort study. Patients: 14 916 initially healthy men participating in the Physicians' Health Study who were followed from 1982 to August 1994 for the occurrence of deep venous thrombosis or pulmonary embolism. Measurements: Polymerase chain reaction was used to determine factor V Leiden mutation status in 156 study participants who developed venous thromboembolism during follow-up and in 2406 study participants who remained free of vascular disease. Results: Risks for venous thromboembolism in heterozygous carriers of factor V Leiden mutation increased with age at a rate significantly greater than that in noncarriers. Whereas incidence rates of venous thromboembolism were similar in men with and men without the factor V Leiden mutation who were younger than 50 years of age, incidence rate differences (per 1000 person-years of observation) between affected and unaffected men increased significantly from 1.23 (95% CI, -0.4 to 2.9) for those aged 50 to 59 years to 1.61 (CI, -0.5 to 3.7) for those aged 60 to 69 years of age to 5.97 (CI, 0.6 to 11.3) for those aged 70 years or older (P for trend = 0.008). For idiopathic venous thromboembolism, age-specific incidence rate differences between men with and without the factor V Leiden mutation increased significantly with age (P = 0.017). However, no significant relation was found for secondary events (P > 0.2). Conclusions: The findings support the hypothesis that the pathogenesis of venous thromboembolism involves acquired as well as genetic risk factors and indicate that determination of factor V Leiden mutation status should not be limited to young patients.	BRIGHAM & WOMENS HOSP, DIV CARDIOVASC DIS, BOSTON, MA 02215 USA; WASHINGTON UNIV, SCH MED, DIV LAB MED, ST LOUIS, MO 63110 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; HARVARD UNIV, SCH PUBL HLTH, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DIV LAB MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Washington University (WUSTL); Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital	Ridker, PM (corresponding author), BRIGHAM & WOMENS HOSP, DEPT MED, BOSTON, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R01CA042182] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034595] Funding Source: NIH RePORTER; NCI NIH HHS [CA-42182] Funding Source: Medline; NHLBI NIH HHS [HL-26490, HL-34595] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON FA, 1991, ARCH INTERN MED, V151, P933, DOI 10.1001/archinte.151.5.933; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; GRIZZLE JE, 1969, BIOMETRICS, V25, P489, DOI 10.2307/2528901; Hennekens C., 1987, EPIDEMIOLOGY MED; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; KOELEMAN BPC, 1994, BLOOD, V84, P1031; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; LINDGREN BW, 1976, STATISTICAL THEORY, P130; RIDKER PM, 1995, NEW ENGL J MED, V332, P912, DOI 10.1056/NEJM199504063321403; RIDKER PM, 1995, CIRCULATION, V92, P2800, DOI 10.1161/01.CIR.92.10.2800; RIDKER PM, 1997, IN PRESS CIRCULATION; SVENSSON PJ, 1994, NEW ENGL J MED, V330, P517, DOI 10.1056/NEJM199402243300801; VANDENBROUCKE JP, 1994, LANCET, V344, P1453, DOI 10.1016/S0140-6736(94)90286-0	14	116	118	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1997	126	7					528	531		10.7326/0003-4819-126-7-199704010-00005	http://dx.doi.org/10.7326/0003-4819-126-7-199704010-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ195	9092318				2022-12-01	WOS:A1997WQ19500014
J	Boulton, RA; Adams, DH				Boulton, RA; Adams, DH			Gallbladder polyps: When to wait and when to act	LANCET			English	Editorial Material							LESIONS; DIAGNOSIS				Boulton, RA (corresponding author), QUEEN ELIZABETH HOSP,LIVER UNIT,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND.		Adams, David H/C-9092-2009	Adams, David H/0000-0001-6776-0336				ALBORESSAAVEDRA J, 1993, PATHOL ANNU, V28, P145; ALDRIDGE MC, 1990, BRIT J SURG, V77, P363, DOI 10.1002/bjs.1800770403; JORGENSEN T, 1990, SCAND J GASTROENTERO, V25, P281; KOGA A, 1988, ARCH SURG-CHICAGO, V123, P26; KUBOTA K, 1995, SURGERY, V117, P481, DOI 10.1016/S0039-6060(05)80245-4; Moriguchi H, 1996, GUT, V39, P860, DOI 10.1136/gut.39.6.860; YANG HL, 1992, BRIT J SURG, V79, P227, DOI 10.1002/bjs.1800790312	7	60	66	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 22	1997	349	9055					817	817		10.1016/S0140-6736(05)61744-8	http://dx.doi.org/10.1016/S0140-6736(05)61744-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WP403	9121250				2022-12-01	WOS:A1997WP40300003
J	Eskes, R; Yang, JA; Lambowitz, AM; Perlman, PS				Eskes, R; Yang, JA; Lambowitz, AM; Perlman, PS			Mobility of yeast mitochondrial group II introns: Engineering a new site specificity and retrohoming via full reverse splicing	CELL			English	Article							DNA; RNA; MATURASE; TRANSPOSITION; INVITRO; GENE	The mobile group II introns al1 and al2 of yeast mtDNA encode endonuclease activities that cleave intronless DNA target sites to initiate mobility by target DNA-primed reverse transcription. For al2, sense-strand cleavage occurs mainly by a partial reverse splicing reaction, whereas for al1, complete reverse splicing occurs, leading to insertion of the linear intron RNA into double-stranded DNA. Here, we show that al1 homing and reverse splicing depend on the EBS1 (RNA)/IBS1(DNA) pairing and that target specificity can be changed by compensatory changes in the target site and the donor intron. Using well-marked strains to follow coconversion of flanking DNA, we show that homing occurs by both RT-dependent and -independent pathways. Remarkably, in mast RT-dependent events, the reverse spliced intron is the initial template for first-strand cDNA synthesis.	OHIO STATE UNIV,DEPT MOL GENET,COLUMBUS,OH 43210; OHIO STATE UNIV,DEPT BIOCHEM,COLUMBUS,OH 43210; OHIO STATE UNIV,DEPT BIOCHEM MED,COLUMBUS,OH 43210	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Eskes, R (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MOL BIOL & ONCOL,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.				NIGMS NIH HHS [GM31480, GM37949] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031480, R01GM037949] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BONITZ SG, 1980, J BIOL CHEM, V255, P1927; Butow R A, 1996, Methods Enzymol, V264, P265, DOI 10.1016/S0076-6879(96)64026-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Curcio MJ, 1996, CELL, V84, P9, DOI 10.1016/S0092-8674(00)80987-3; HUDSPETH MES, 1980, BIOCHIM BIOPHYS ACTA, V610, P221, DOI 10.1016/0005-2787(80)90003-9; JACQUIER A, 1987, CELL, V50, P17, DOI 10.1016/0092-8674(87)90658-1; KENNELL JC, 1993, CELL, V73, P133, DOI 10.1016/0092-8674(93)90166-N; LAMBOWITZ AM, 1993, ANNU REV BIOCHEM, V62, P587, DOI 10.1146/annurev.bi.62.070193.003103; LAZOWSKA J, 1994, EMBO J, V13, P4963, DOI 10.1002/j.1460-2075.1994.tb06823.x; LORSCH JR, 1995, NUCLEIC ACIDS RES, V23, P2811, DOI 10.1093/nar/23.15.2811; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; MICHEL F, 1995, ANNU REV BIOCHEM, V64, P435, DOI 10.1146/annurev.bi.64.070195.002251; MORAN JV, 1994, NUCLEIC ACIDS RES, V22, P2057, DOI 10.1093/nar/22.11.2057; MORAN JV, 1995, MOL CELL BIOL, V15, P2828; MORL M, 1990, NUCLEIC ACIDS RES, V18, P6545, DOI 10.1093/nar/18.22.6545; MORL M, 1990, CELL, V60, P629, DOI 10.1016/0092-8674(90)90666-3; MUELLER MW, 1993, NATURE, V366, P174, DOI 10.1038/366174a0; Sambrook J., 1989, MOL CLONING LAB MANU; SELLEM CH, 1993, NATURE, V366, P176, DOI 10.1038/366176a0; Sherman F., 1986, METHODS YEAST GENETI; WENZLAU JM, 1989, CELL, V56, P421, DOI 10.1016/0092-8674(89)90245-6; Yang J, 1996, NATURE, V381, P332, DOI 10.1038/381332a0; ZIMMERLY S, 1995, CELL, V83, P529, DOI 10.1016/0092-8674(95)90092-6; ZIMMERLY S, 1995, CELL, V82, P545, DOI 10.1016/0092-8674(95)90027-6	24	93	94	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 21	1997	88	6					865	874		10.1016/S0092-8674(00)81932-7	http://dx.doi.org/10.1016/S0092-8674(00)81932-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WQ100	9118229	Bronze			2022-12-01	WOS:A1997WQ10000018
J	Zhang, GY; Liu, Y; Ruoho, AE; Hurley, JH				Zhang, GY; Liu, Y; Ruoho, AE; Hurley, JH			Structure of the adenylyl cyclase catalytic core	NATURE			English	Article							CALMODULIN-BINDING DOMAIN; ELECTRON-DENSITY MAPS; PROTEIN STRUCTURES; FORSKOLIN; TRANSPORTER; MUTAGENESIS; DITERPENE; CALCIUM; MUTANTS; PROGRAM	Mammalian adenylyl cyclases contain two conserved regions, C-1 and C-2, which are responsible for forskolin- and G-protein-stimulated catalysis. The structure of the C-2 catalytic region of type II rat adenylyl cyclase has an alpha/beta class fold in a wreath-like dimer, which has a central cleft. Two forskolin molecules bind in hydrophobic pockets at the ends of cleft. The central part of the cleft is lined by charged residues implicated in ATP binding. Forskolin appears to activate adenylyl cyclase by promoting the assembly of the active dimer and by direct interaction within the catalytic cleft. Other adenylyl cyclase regulators act at the dimer interface or on a flexible C-terminal region.	NIDDKD,MOL BIOL LAB,NIH,BETHESDA,MD 20892; UNIV WISCONSIN,SCH MED,DEPT PHARMACOL,MADISON,WI 53706	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Wisconsin System; University of Wisconsin Madison								ARNEZ JG, 1994, J APPL CRYSTALLOGR, V27, P649, DOI 10.1107/S0021889894001858; BRUNGER AT, 1996, XPLOR VERSION 3 8; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; Cowtan K., 1994, JT CCP4 ESF EACBM NE, V31, P34; Desaubry L, 1996, J BIOL CHEM, V271, P14028, DOI 10.1074/jbc.271.24.14028; Dessauer CW, 1996, J BIOL CHEM, V271, P16967, DOI 10.1074/jbc.271.28.16967; Droste M, 1996, FEBS LETT, V391, P209, DOI 10.1016/0014-5793(96)00735-1; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; ERIKSSON AE, 1992, NATURE, V355, P371, DOI 10.1038/355371a0; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; FUREY W, IN PRESS METHODS ENZ; Gonzalez L, 1996, NAT STRUCT BIOL, V3, P510, DOI 10.1038/nsb0696-510; IYENGAR R, 1993, FASEB J, V7, P768, DOI 10.1096/fasebj.7.9.8330684; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLEYWEGT GJ, 1994, ESF CCP4 NEWSLETTER, V31, P9; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAURENZA A, 1989, TRENDS PHARMACOL SCI, V10, P442, DOI 10.1016/S0165-6147(89)80008-2; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LEVIN LR, 1995, J BIOL CHEM, V270, P7573, DOI 10.1074/jbc.270.13.7573; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P219; MILLER M, 1989, NATURE, V337, P576, DOI 10.1038/337576a0; MORRIS DI, 1991, J BIOL CHEM, V266, P13377; MURZIN AG, 1994, J MOL BIOL, V242, P309; NICHOLLS A, 1992, GRASP MANUAL; OTWINOWSKI Z, IN PRESS METHODS ENZ; PARENT CA, 1995, J BIOL CHEM, V270, P22693, DOI 10.1074/jbc.270.39.22693; Robbins JD, 1996, J MED CHEM, V39, P2745, DOI 10.1021/jm960191+; ROBISON GA, 1968, ANNU REV BIOCHEM, V37, P149, DOI 10.1146/annurev.bi.37.070168.001053; RODBELL M, 1980, NATURE, V284, P17, DOI 10.1038/284017a0; SEAMON KB, 1981, P NATL ACAD SCI-BIOL, V78, P3363, DOI 10.1073/pnas.78.6.3363; SHARP KA, 1991, SCIENCE, V252, P106, DOI 10.1126/science.2011744; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; Sutkowski EM, 1996, MOL PHARMACOL, V50, P299; TANG WJ, 1995, BIOCHEMISTRY-US, V34, P14563, DOI 10.1021/bi00044a035; TANG WJ, 1995, SCIENCE, V268, P1769, DOI 10.1126/science.7792604; TANG WJ, IN PRESS ADV SEC MES; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; TERWILLIGER TC, 1987, ACTA CRYSTALLOGR A, V43, P34; VORHERR T, 1993, BIOCHEMISTRY-US, V32, P6081, DOI 10.1021/bi00074a020; Weng GZ, 1996, J BIOL CHEM, V271, P26445, DOI 10.1074/jbc.271.43.26445; Whisnant RE, 1996, P NATL ACAD SCI USA, V93, P6621, DOI 10.1073/pnas.93.13.6621; WU ZL, 1993, J BIOL CHEM, V268, P23766; Yan SZ, 1996, J BIOL CHEM, V271, P10941, DOI 10.1074/jbc.271.18.10941; YAN SZ, IN PRESS J BIOL CHEM; ZHANG G, IN PRESS PROT SCI; 1994, ACTA CRYSTALLOGR D, V50, P670	50	310	317	3	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 20	1997	386	6622					247	253		10.1038/386247a0	http://dx.doi.org/10.1038/386247a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WP003	9069282				2022-12-01	WOS:A1997WP00300042
J	Bonneux, L; Looman, CWN; Barendregt, JJ; Van der Maas, PJ				Bonneux, L; Looman, CWN; Barendregt, JJ; Van der Maas, PJ			Regression analysis of recent changes in cardiovascular morbidity and mortality in the Netherlands	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ISCHEMIC-HEART-DISEASE; RISK FACTOR LEVELS; DECLINE; STROKE; POPULATION; FAILURE; TRENDS; RATES; EPIDEMIOLOGY; DEATH	Objectives: To test whether recent declines in mortality from coronary heart disease were associated with increased mortality from other cardiovascular diseases. Design: Poisson regression analysis of national data on causes of death and hospital discharges. Setting and subjects: Population of the Netherlands, 1969-93. Main outcome measures: Annual changes in mortality from coronary heart disease, stroke, and other cardiovascular diseases and annual changes in hospital discharge rates for acute coronary events, stroke, and congestive heart failures. Results: Patterns of cardiovascular mortality changed abruptly in 1987-93. Annual decline in mortality from coronary heart disease increased sharply for women and men: from - 1.9% (95% confidence interval -2.2% to -1.6%) and -1.7% (-1.9% to -1.4%) respectively in 1979-86 to -3.1% (-3.5% to -2.6%) and -4.2% (-4.6% to -3.9%) in 1987-93. The longstanding decline in mortality from stroke levelled off: from annual change of -3.3% (-3.7% to -2.8%) and -3.2% (-3.7% to -2.8%) in 1979-86 to -0.1% (-0.7% to 0.4%) and -1.1% (-1.7% to -0.5%) in 1987-93. Mortality from other cardiovascular diseases, however, started to increase: from -2.0% (-2.4% to -1.6%) and -0.2% (-0.5% to 0.2%) in 1979-86 to 1.5% (1.0% to 2.0%) and 1.9% (1.5% to 2.3%) in 1987-93. Hospital discharge rates for acute coronary heart disease, congestive heart failure, and stroke increased during 1980-6. During 1987-93 discharge rates for stroke and coronary heart disease stabilised but rates for congestive heart failure increased. Conclusion: Improved management of coronary heart disease seems to have reduced mortality, but some of the gains are lost to deaths from stroke and other cardiovascular diseases. The increasing numbers of patients with coronary heart disease who survive will increase demands on health services for long term care.			Bonneux, L (corresponding author), ERASMUS UNIV ROTTERDAM, DEPT PUBL HLTH, POB 1738, NL-3000 DR ROTTERDAM, NETHERLANDS.		Barendregt, Jan J/F-6895-2010					ASINGER RW, 1989, ARCH NEUROL-CHICAGO, V46, P727; BONITA R, 1992, LANCET, V339, P342, DOI 10.1016/0140-6736(92)91658-U; BONNEUX L, 1994, AM J PUBLIC HEALTH, V84, P20, DOI 10.2105/AJPH.84.1.20; BRESLOW NE, 1987, DESIGN ANAL COHORT S, P48; BRODERICK JP, 1989, STROKE, V20, P577, DOI 10.1161/01.STR.20.5.577; *CENTR BUR STAT, STAT NETH DEATHS CAU; FRACHEBOUD J, 1987, CORONARY CTR CARE HO; GHALI JK, 1990, ARCH INTERN MED, V150, P769, DOI 10.1001/archinte.150.4.769; Gheorghiade M, 1996, AM HEART J, V131, P250, DOI 10.1016/S0002-8703(96)90349-X; GOLDMAN L, 1984, ANN INTERN MED, V101, P825, DOI 10.7326/0003-4819-101-6-825; HACHINSKI V, 1992, LANCET, V340, P645; KANNEL WB, 1991, AM HEART J, V121, P951, DOI 10.1016/0002-8703(91)90225-7; KANNEL WB, 1985, J AM COLL CARDIOL, V5, pB141, DOI 10.1016/S0735-1097(85)80545-3; MACKENBACH JP, 1987, J EPIDEMIOL COMMUN H, V41, P156, DOI 10.1136/jech.41.2.156; MCGOVERN P G, 1992, Journal of the American Medical Association, V268, P753, DOI 10.1001/jama.268.6.753; McGovern PG, 1996, NEW ENGL J MED, V334, P884, DOI 10.1056/NEJM199604043341403; Meeter K, 1993, Ned Tijdschr Geneeskd, V137, P1922; NIESSEN LW, 1993, STROKE, V24, P931, DOI 10.1161/01.STR.24.7.931; Reitsma J B, 1994, Ned Tijdschr Geneeskd, V138, P866; RUWAARD D, 1994, PUBLIC HLTH STATUS D; SIGFUSSON N, 1991, BRIT MED J, V302, P1371, DOI 10.1136/bmj.302.6789.1371; STEVENSON R, 1993, BMJ-BRIT MED J, V307, P349, DOI 10.1136/bmj.307.6900.349; SYTKOWSKI PA, 1990, NEW ENGL J MED, V322, P1635, DOI 10.1056/NEJM199006073222304; UEMURA K, 1988, World Health Statistics Quarterly, V41, P155; 1994, MORTALITY MORTALITY, V43, P77	25	46	47	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 15	1997	314	7083					789	792		10.1136/bmj.314.7083.789	http://dx.doi.org/10.1136/bmj.314.7083.789			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN646	9080996	Green Published			2022-12-01	WOS:A1997WN64600024
J	Bowen, J; Teri, L; Kukull, W; McCormick, W; McCurry, SM; Larson, EB				Bowen, J; Teri, L; Kukull, W; McCormick, W; McCurry, SM; Larson, EB			Progression to dementia in patients with isolated memory loss	LANCET			English	Article							MILD SENILE DEMENTIA; ALZHEIMERS-DISEASE; CLINICAL-DIAGNOSIS; IMPAIRMENT	Background The diagnosis of dementia requires both memory loss and at least one other type of cognitive impairment. The natural history of patients with severe memory loss but no other type of cognitive impairment is poorly understood. We studied progression to dementia in patients with isolated memory loss. Methods From a registry of 811 patients with cognitive complaints, 21 patients with severe isolated memory loss of unknown cause were identified and followed up for a mean of 48 months. A comparison group of 198 patients on the same register was identified with newly recognised cognitive complaints but without dementia or isolated memory loss (mean follow-up 31 months). We did a range of neuropsychological tests at intake. Findings During follow-up, 48% (n=10) of patients with isolated memory loss developed dementia compared with 18% (n=36) of the comparison group. Life-table analysis showed the mean times to a diagnosis of dementia was 3.77 years (95% CI 2.99-4.56) and 5.96 years (5.60-6.31), respectively (p=0.01). The neuropsychological tests did not predict which patients would progress to dementia. Interpretation Patients with severe isolated memory loss have an increased risk of developing dementia and should be closely followed-up.	WASHINGTON UNIV,DEPT NEUROL,SEATTLE,WA; WASHINGTON UNIV,DEPT MED,SEATTLE,WA; WASHINGTON UNIV,DEPT EPIDEMIOL,SEATTLE,WA; WASHINGTON UNIV,DEPT PSYCHIAT & BEHAV SCI,SEATTLE,WA				McCurry, Susan M/E-4731-2015	McCurry, Susan M/0000-0001-8624-3772; Kukull, Walter/0000-0001-8761-9014	NIA NIH HHS [U01-AG06781] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [U01AG006781] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		A. P. Association, 1987, DIAGN STAT MAN MENT; *AP ASS, 1995, DIAGN STAT MAN MENT; BLESSED G, 1968, BRIT J PSYCHIAT, V114, P797, DOI 10.1192/bjp.114.512.797; Colsher Patricia L., 1991, Annals of Epidemiology, V1, P215; Crook T, 1986, DEV NEUROPSYCHOL, V2, P261, DOI 10.1080/87565648609540348; FLICKER C, 1991, NEUROLOGY, V41, P1006, DOI 10.1212/WNL.41.7.1006; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fuld PA, 1981, FULD OBJECT MEMORY E; HUFF FJ, 1987, NEUROLOGY, V37, P1119, DOI 10.1212/WNL.37.7.1119; HUGHES CP, 1982, BRIT J PSYCHIAT, V140, P566, DOI 10.1192/bjp.140.6.566; LARRABEE GJ, 1995, NEUROLOGY, V45, P611, DOI 10.1212/WNL.45.4.611; Larson E B, 1990, Aging (Milano), V2, P404; LINN RT, 1995, ARCH NEUROL-CHICAGO, V52, P485, DOI 10.1001/archneur.1995.00540290075020; MATTIS S, 1989, DEMENTIA RATING SCAL; MCCORMICK WC, 1994, J AM GERIATR SOC, V42, P517, DOI 10.1111/j.1532-5415.1994.tb04974.x; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MORRIS JC, 1991, NEUROLOGY, V41, P469, DOI 10.1212/WNL.41.4.469; MORRIS JC, 1989, NEUROLOGY, V39, P1159, DOI 10.1212/wnl.43.12.2457; PETERSEN RC, 1995, JAMA-J AM MED ASSOC, V273, P1274, DOI 10.1001/jama.273.16.1274; Reitan R.M., 1985, REITAN NEUROPSYCHOLO, V4; RUBIN EH, 1989, ARCH NEUROL-CHICAGO, V46, P379, DOI 10.1001/archneur.1989.00520400033016; Schmand B, 1996, NEUROLOGY, V46, P121, DOI 10.1212/WNL.46.1.121; STORANDT M, 1989, ARCH NEUROL-CHICAGO, V46, P383, DOI 10.1001/archneur.1989.00520400037017; Tierney MC, 1996, NEUROLOGY, V46, P661, DOI 10.1212/WNL.46.3.661; Wechsler D, 1981, ADULT INTELLIGENCE S; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223	26	238	245	1	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 15	1997	349	9054					763	765		10.1016/S0140-6736(96)08256-6	http://dx.doi.org/10.1016/S0140-6736(96)08256-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WN124	9074575				2022-12-01	WOS:A1997WN12400010
J	Tuomainen, TP; Salonen, R; Nyyssonen, K; Salonen, JT				Tuomainen, TP; Salonen, R; Nyyssonen, K; Salonen, JT			Cohort study of relation between donating blood and risk of myocardial infarction in 2682 men in eastern Finland	BRITISH MEDICAL JOURNAL			English	Article							IRON		UNIV KUOPIO,PUBL HLTH RES INST,FIN-70211 KUOPIO,FINLAND	University of Eastern Finland								SALONEN JT, 1988, ANN CLIN RES, V20, P46; SALONEN JT, 1992, CIRCULATION, V86, P803, DOI 10.1161/01.CIR.86.3.803; Salonen Jukka T., 1996, P293; Salonen Jukka T., 1993, Current Opinion in Lipidology, V4, P277, DOI 10.1097/00041433-199308000-00003; SULLIVAN JL, 1989, AM HEART J, V117, P1177, DOI 10.1016/0002-8703(89)90887-9	5	109	111	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 15	1997	314	7083					793	794		10.1136/bmj.314.7083.793	http://dx.doi.org/10.1136/bmj.314.7083.793			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN646	9080998	Green Published			2022-12-01	WOS:A1997WN64600026
J	Schreuder, H; Tardif, C; TrumpKallmeyer, S; Soffientini, A; Sarubbi, E; Akeson, A; Bowlin, T; Yanofsky, S; Barrett, RW				Schreuder, H; Tardif, C; TrumpKallmeyer, S; Soffientini, A; Sarubbi, E; Akeson, A; Bowlin, T; Yanofsky, S; Barrett, RW			A new cytokine-receptor binding mode revealed by the crystal structure of the IL-1 receptor with an antagonist	NATURE			English	Article							IMMUNOGLOBULIN SUPERFAMILY; COMPLEX; MUTAGENESIS; REFINEMENT; CLONING; DOMAINS; SITE	Inflammation, regardless of whether it is provoked by infection or by tissue damage, starts with the activation of macrophages which initiate a cascade of inflammatory responses by producing the cytokines interleukin-1 (IL-1) and tumour necrosis factor-alpha (ref. 1). Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1 alpha and IL-1 beta and the IL-1-receptor antagonist IL1RA. (ref. 2). IL-1 is the only cytokine for which a naturally occurring antagonist is known. Here we describe the crystal structure at 2.7 Angstrom resolution of the soluble extracellular part of type-I IL1R complexed with IL1RA. The receptor consists of three immunoglobulin-like domains. Domains 1 and 2 are tightly - linked, but domain three is completely separate and connected by a flexible linker. Residues of all three domains contact the antagonist and include the five critical IL1RA residues which were identified by site-directed mutagenesis(3). A region that is important for biological function in IL-1 beta, the 'receptor trigger site' is not in direct contact with the receptor in the IL1RA complex. Modelling studies suggest that this IL-1 beta trigger site might induce a movement of domain 3.	MARION MERRELL DOW RES INST, F-67080 STRASBOURG, FRANCE; LEPETIT RES CTR, I-21040 GERENZANO, ITALY; HOECHST MARION ROUSSEL INC, CINCINNATI, OH 45215 USA; AFFYMAX, PALO ALTO, CA 94304 USA					Schreuder, Herman/0000-0003-2249-2782				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; DINARELLO CA, 1994, FASEB J, V8, P1314, DOI 10.1096/fasebj.8.15.8001745; EVANS RJ, 1995, J BIOL CHEM, V270, P11477, DOI 10.1074/jbc.270.19.11477; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; HARPAZ Y, 1994, J MOL BIOL, V238, P528, DOI 10.1006/jmbi.1994.1312; HEMMINGSEN JM, 1994, PROTEIN SCI, V3, P1927, DOI 10.1002/pro.5560031104; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JU G, 1991, P NATL ACAD SCI USA, V88, P2658, DOI 10.1073/pnas.88.7.2658; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OTWINOWSKY W, 1994, ISOMORPHOUS REPLACEM, P80; PRIESTLE JP, 1988, EMBO J, V7, P339, DOI 10.1002/j.1460-2075.1988.tb02818.x; READ RJ, 1988, J APPL CRYSTALLOGR, V21, P490, DOI 10.1107/S002188988800562X; SCHREUDER H, 1995, FEBS LETT, V373, P39, DOI 10.1016/0014-5793(95)01009-4; SCHREUDER HA, 1995, EUR J BIOCHEM, V227, P838, DOI 10.1111/j.1432-1033.1995.tb20209.x; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; VOS AM, 1992, SCIENCE, V255, P306; WALTER MR, 1995, NATURE, V376, P230, DOI 10.1038/376230a0; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; Yanofsky SD, 1996, P NATL ACAD SCI USA, V93, P7381, DOI 10.1073/pnas.93.14.7381; ZHANG KYJ, 1993, ACTA CRYSTALLOGR D, V49, P213, DOI 10.1107/S0907444992007911	30	170	185	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 13	1997	386	6621					194	200		10.1038/386194a0	http://dx.doi.org/10.1038/386194a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WM973	9062194				2022-12-01	WOS:A1997WM97300067
J	Dietrich, RA; Richberg, MH; Schmidt, R; Dean, C; Dangl, JL				Dietrich, RA; Richberg, MH; Schmidt, R; Dean, C; Dangl, JL			A novel zinc finger protein is encoded by the arabidopsis LSD1 gene and functions as a negative regulator of plant cell death	CELL			English	Article							DNA-BINDING DOMAIN; INSULIN-RECEPTOR SUBSTRATE-1; SYSTEMIC ACQUIRED-RESISTANCE; TOBACCO MOSAIC-VIRUS; SALICYLIC-ACID; DISEASE RESISTANCE; TRANSCRIPTION FACTOR; OXIDATIVE BURST; DEFENSE RESPONSES; THALIANA	Arabidopsis Isd1 mutants are hyperresponsive to cell death initiators and fail to limit the extent of cell death. Superoxide is a necessary and sufficient signal for cell death propagation. Thus, LSD1 monitors a superoxide-dependent signal and negatively regulates a plant cell death pathway. We isolated LSD1 via its map position. The predicted LSD1 protein contains three zinc finger domains, defined by CxxCxRxxLMYxxGASxVxCxxC. These domains are present in three additional Arabidopsis genes, suggesting that LSD1 defines a zinc finger protein subclass. LSD1 is constitutively expressed, consistent with the mutant phenotype. Alternate splicing gives rise to a low abundance mRNA encoding an extra five amino-terminal amino acids. We propose that LSD1 regulates transcription, via either repression of a prodeath pathway or activation of an antideath pathway, in response to signals emanating from cells undergoing pathogen-induced hypersensitive cell death.	UNIV N CAROLINA, CURRICULUM GENET & MOL BIOL, CHAPEL HILL, NC 27599 USA; JOHN INNES CTR PLANT SCI RES, DEPT MOL GENET, NORWICH NR4 7UH, NORFOLK, ENGLAND; MAX DELBRUCK LAB, D-50829 COLOGNE, GERMANY	University of North Carolina; University of North Carolina Chapel Hill; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Dietrich, RA (corresponding author), UNIV N CAROLINA, DEPT BIOL, CB 3280, CHAPEL HILL, NC 27599 USA.			Schmidt, Renate/0000-0002-8037-3581				ARAKI E, 1994, BBA-MOL CELL RES, V1221, P353, DOI 10.1016/0167-4889(94)90261-5; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAKER CJ, 1995, ANNU REV PHYTOPATHOL, V33, P299, DOI 10.1146/annurev.py.33.090195.001503; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BECKER D, 1992, PLANT MOL BIOL, V20, P1195, DOI 10.1007/BF00028908; BENNETZEN JL, 1988, SCIENCE, V241, P208, DOI 10.1126/science.241.4862.208; Bent AF, 1996, PLANT CELL, V8, P1757, DOI 10.1105/tpc.8.10.1757; BLOK LJ, 1995, MOL ENDOCRINOL, V9, P1610, DOI 10.1210/me.9.11.1610; BOLWELL GP, 1995, FREE RADICAL RES, V23, P517, DOI 10.3109/10715769509065273; CHEN ZX, 1993, SCIENCE, V262, P1883, DOI 10.1126/science.8266079; CHOI S, 1995, PLANT MOL BIOL REP, V13, P124, DOI 10.1007/BF02668782; DANGL JL, 1995, CELL, V80, P363, DOI 10.1016/0092-8674(95)90485-9; Dangl JL, 1996, PLANT CELL, V8, P1793, DOI 10.1105/tpc.8.10.1793; DAVIS D, 1993, PHYTOCHEMISTRY, V32, P607, DOI 10.1016/S0031-9422(00)95144-6; DAWSON SR, 1995, MOL CELL BIOL, V15, P6923; DePaolis A, 1996, PLANT J, V10, P215, DOI 10.1046/j.1365-313X.1996.10020215.x; DIETRICH RA, 1994, CELL, V77, P565, DOI 10.1016/0092-8674(94)90218-6; DURNER J, 1995, P NATL ACAD SCI USA, V92, P11312, DOI 10.1073/pnas.92.24.11312; ENYEDI AJ, 1992, P NATL ACAD SCI USA, V89, P2480, DOI 10.1073/pnas.89.6.2480; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; FELDMANN KA, 1991, PLANT J, V1, P71, DOI 10.1111/j.1365-313X.1991.00071.x; Goodman R.N., 1994, HYPERSENSITIVE REACT; Gopalan S, 1996, PLANT CELL, V8, P1095, DOI 10.1105/tpc.8.7.1095; GREENBERG JT, 1993, PLANT J, V4, P327, DOI 10.1046/j.1365-313X.1993.04020327.x; GREENBERG JT, 1994, CELL, V77, P551, DOI 10.1016/0092-8674(94)90217-8; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; HammondKosack KE, 1996, PLANT CELL, V8, P1773, DOI 10.1105/tpc.8.10.1773; Jabs T, 1996, SCIENCE, V273, P1853, DOI 10.1126/science.273.5283.1853; JABS T, 1997, IN PRESS P NATL ACAD; JANKNECHT R, 1992, NUCLEIC ACIDS RES, V20, P3317, DOI 10.1093/nar/20.13.3317; JOHAL GS, 1995, BIOESSAYS, V17, P685, DOI 10.1002/bies.950170805; KAPTEIN R, 1991, CURR OPIN STRUC BIOL, V2, P109; KAUSS H, 1992, PLANT J, V2, P655, DOI 10.1111/j.1365-313X.1992.tb00134.x; KAUSS H, 1995, PLANT PHYSIOL, V108, P1171, DOI 10.1104/pp.108.3.1171; KELLER SR, 1993, BIOCHIM BIOPHYS ACTA, V1172, P323, DOI 10.1016/0167-4781(93)90222-Y; KONIECZNY A, 1993, PLANT J, V4, P403, DOI 10.1046/j.1365-313X.1993.04020403.x; Kosslak RM, 1996, J HERED, V87, P415, DOI 10.1093/oxfordjournals.jhered.a023030; Kosuge T., 1983, GENETIC ENG PLANTS A, P431, DOI [10.1007/978-1-4684-4544-2_29, DOI 10.1007/978-1-4684-4544-2_29, DOI 10.1007/978-1-4684-4544-2_]; LEON J, 1995, PLANT PHYSIOL, V108, P1673, DOI 10.1104/pp.108.4.1673; LEVINE A, 1994, CELL, V79, P583, DOI 10.1016/0092-8674(94)90544-4; Levine A, 1996, CURR BIOL, V6, P427, DOI 10.1016/S0960-9822(02)00510-9; Lippuner V, 1996, J BIOL CHEM, V271, P12859, DOI 10.1074/jbc.271.22.12859; LISTER C, 1993, PLANT J, V4, P745, DOI 10.1046/j.1365-313X.1993.04040745.x; Low PS, 1996, PHYSIOL PLANTARUM, V96, P533, DOI 10.1111/j.1399-3054.1996.tb00469.x; LUGERT T, 1994, PLANT MOL BIOL, V25, P493, DOI 10.1007/BF00043877; Lukowitz W, 1996, CELL, V84, P61, DOI 10.1016/S0092-8674(00)80993-9; MALAMY J, 1992, PLANT CELL, V4, P359, DOI 10.1105/tpc.4.3.359; Matallana E., 1992, Methods in Arabidopsis research., P144; MauchMani B, 1996, PLANT CELL, V8, P203, DOI 10.1105/tpc.8.2.203; May MJ, 1996, PLANT PHYSIOL, V110, P1367, DOI 10.1104/pp.110.4.1367; MITTLER R, 1995, PLANT CELL, V7, P29, DOI 10.1105/tpc.7.1.29; NEWMAN T, 1994, PLANT PHYSIOL, V106, P1241, DOI 10.1104/pp.106.4.1241; Nose K, 1996, BIOCHEM J, V316, P381, DOI 10.1042/bj3160381; NURNBERGER T, 1994, CELL, V78, P449, DOI 10.1016/0092-8674(94)90423-5; OMICHINSKI JG, 1993, SCIENCE, V261, P438, DOI 10.1126/science.8332909; PUTTERILL J, 1995, CELL, V80, P847, DOI 10.1016/0092-8674(95)90288-0; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAMAIN P, 1993, DEVELOPMENT, V119, P1277; Reuber TL, 1996, PLANT CELL, V8, P241, DOI 10.1105/tpc.8.2.241; Ritter C, 1996, PLANT CELL, V8, P251, DOI 10.1105/tpc.8.2.251; ROGERS SO, 1985, PLANT MOL BIOL, V5, P69, DOI 10.1007/BF00020088; Rounsley SD, 1996, PLANT PHYSIOL, V112, P1177, DOI 10.1104/pp.112.3.1177; Ruffer M, 1995, FEBS LETT, V377, P175, DOI 10.1016/0014-5793(95)01334-2; Rusterucci C, 1996, PLANT PHYSIOL, V111, P885, DOI 10.1104/pp.111.3.885; Ryals JA, 1996, PLANT CELL, V8, P1809, DOI 10.1105/tpc.8.10.1809; Ryerson DE, 1996, PLANT CELL, V8, P393, DOI 10.1105/tpc.8.3.393; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; Schmidt R, 1996, PLANT J, V9, P755, DOI 10.1046/j.1365-313X.1996.9050755.x; SCHMIDT R, 1995, SCIENCE, V270, P480, DOI 10.1126/science.270.5235.480; Scofield SR, 1996, SCIENCE, V274, P2063, DOI 10.1126/science.274.5295.2063; Song HY, 1996, P NATL ACAD SCI USA, V93, P6721, DOI 10.1073/pnas.93.13.6721; STASKAWICZ BJ, 1995, SCIENCE, V268, P661, DOI 10.1126/science.7732374; Subramaniam M, 1995, NUCLEIC ACIDS RES, V23, P4907, DOI 10.1093/nar/23.23.4907; Tang XY, 1996, SCIENCE, V274, P2060, DOI 10.1126/science.274.5295.2060; UKNES S, 1993, MOL PLANT MICROBE IN, V6, P692, DOI 10.1094/MPMI-6-692; UKNES S, 1993, PLANT CELL, V5, P159, DOI 10.1105/tpc.5.2.159; VandenAckerveken G, 1996, CELL, V87, P1307, DOI 10.1016/S0092-8674(00)81825-5; Wang H, 1996, PLANT CELL, V8, P375, DOI 10.1105/tpc.8.3.375; WOLTER M, 1993, MOL GEN GENET, V239, P122, DOI 10.1007/BF00281610; YANAGISAWA S, 1995, NUCLEIC ACIDS RES, V23, P3403, DOI 10.1093/nar/23.17.3403	81	350	414	0	54	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 7	1997	88	5					685	694		10.1016/S0092-8674(00)81911-X	http://dx.doi.org/10.1016/S0092-8674(00)81911-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WM413	9054508	Bronze			2022-12-01	WOS:A1997WM41300014
J	Bosma, H; Marmot, MG; Hemingway, H; Nicholson, AC; Brunner, E; Stansfeld, SA				Bosma, H; Marmot, MG; Hemingway, H; Nicholson, AC; Brunner, E; Stansfeld, SA			Low job control and risk of coronary heart disease in Whitehall II (prospective cohort) study	BRITISH MEDICAL JOURNAL			English	Article							CARDIOVASCULAR-DISEASE; CIVIL-SERVANTS; NEGATIVE AFFECTIVITY; DECISION LATITUDE; WORK; STRESS; MEN; HEALTH; INEQUALITIES; DEMANDS	Objective: To determine the association between adverse psychosocial characteristics at work and risk of coronary heart disease among male and female civil servants. Design: Prospective cohort study (Whitehall II study). At the baseline examination (1985-8) and twice during follow up a self report questionnaire provided information on psychosocial factors of the work environment and coronary heart disease, Independent assessments of the work environment were obtained from personnel managers at baseline, Mean length of follow up was 5.3 years. Setting: London based office staff in 20 civil service departments. Subjects: 10 308 civil servants aged 35-55 were examined-6895 men (67%) and 3413 women (33%). Main outcome measures: New: cases of angina (Rose questionnaire), severe pain across the chest, diagnosed ischaemic heart disease, and any coronary event Results: Men and women with low job control, either self reported or independently assessed, had a higher risk of newly reported coronary heart disease during follow up. Job control assessed on two occasions three years apart although intercorrelated, had cumulative effects on newly reported disease, Subjects with low job control on both occasions had an odds ratio for any subsequent coronary event of 1.93 (95% confidence interval 1.34 to 2-77) compared with subjects with high job control at both occasions. This association could not be explained by employment grade, negative affectivity or classic coronary risk factors. Job demands and social support at work were not related to the risk of coronary heart disease. Conclusions: Low control in the work environment is associated with an increased risk of future coronary heart disease among men and women employed in government offices. The cumulative effect of low job control assessed on two occasions indicates that giving employees more variety in tasks and a stranger say in decisions about work may decrease the risk of coronary heart disease.	UCL, SCH MED, INT CTR HLTH & SOC, DEPT EPIDEMIOL & PUBL HLTH, LONDON WC1E 6BT, ENGLAND	University of London; University College London; UCL Medical School			Marmot, M G/Y-3920-2019; Brunner, Eric/H-2114-2011; Bosma, Hans/A-6184-2013; Hemingway, Harry/C-1219-2009; Blewett, Verna L/A-5270-2012	Marmot, M G/0000-0002-2431-6419; Brunner, Eric/0000-0002-0595-4474; Hemingway, Harry/0000-0003-2279-0624; 	AHRQ HHS [5 RO1 HS06516] Funding Source: Medline; Medical Research Council [G8802774] Funding Source: Medline; NHLBI NIH HHS [2 RO1 HL 36310] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS006516] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036310] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beksinska M, 1995, WHITEHALL 2 STUDY MA; Bradburn NM, 1969, STRUCTURE PSYCHOL WE; BRIEF AP, 1988, J APPL PSYCHOL, V73, P193, DOI 10.1037/0021-9010.73.2.193; Brunner E, 1996, LANCET, V347, P1008, DOI 10.1016/S0140-6736(96)90147-6; CHEN PY, 1991, J APPL PSYCHOL, V76, P398, DOI 10.1037/0021-9010.76.3.398; DEJONGE J, 1996, THESIS U MAASTRICHT; FERRIE JE, 1995, BRIT MED J, V311, P1264, DOI 10.1136/bmj.311.7015.1264; FRESE M, 1985, J APPL PSYCHOL, V70, P314, DOI 10.1037/0021-9010.70.2.314; FRESE M, 1990, CAUSES COPINT CONSEQ, P375; HOUSE JS, 1986, J HEALTH SOC BEHAV, V27, P62, DOI 10.2307/2136503; JOHNSON JV, 1993, SCAND J WORK ENV HEA, V19, P21, DOI 10.5271/sjweh.1508; Johnson JV, 1995, SOC HLTH, P247; KARASEK R, 1981, AM J PUBLIC HEALTH, V71, P694, DOI 10.2105/AJPH.71.7.694; Karasek R.A., 1990, HLTH WORK STRESS PRO; KARASEK RA, 1979, ADMIN SCI QUART, V24, P285, DOI 10.2307/2392498; KASL SV, 1981, AM J PUBLIC HEALTH, V71, P682, DOI 10.2105/AJPH.71.7.682; KASL SV, 1987, STRESS HLTH ISSUES R, P307; KRISTENSEN TS, 1995, STRESS MEDICINE, V11, P17, DOI 10.1002/smi.2460110104; MARMOT M, 1988, INT J HEALTH SERV, V18, P659, DOI 10.2190/KTC1-N5LK-J1PM-9GRQ; MARMOT MG, 1991, LANCET, V337, P1387, DOI 10.1016/0140-6736(91)93068-K; MARMOT MG, 1984, LANCET, V1, P1003; MCCRAE RR, 1990, STRESS MEDICINE, V6, P237, DOI 10.1002/smi.2460060309; Quinn R. P., 1979, 1977 QUALITY EMPLOYM; REID DD, 1974, LANCET, V1, P469; ROSE G, 1977, LANCET, V1, P105; ROSE G, 1968, BRIT J PREV SOC MED, V22, P12; Sauter S. L., 1989, JOB CONTROL WORKER H; SCHNALL PL, 1994, ANNU REV PUBL HEALTH, V15, P381, DOI 10.1146/annurev.pu.15.050194.002121; SIEGRIST J, 1990, SOC SCI MED, V31, P1127, DOI 10.1016/0277-9536(90)90234-J; Spector Paul E, 1992, CONSIDERATION VALIDI; STANSFELD SA, 1995, J EPIDEMIOL COMMUN H, V49, P48, DOI 10.1136/jech.49.1.48; STEPTOE A, 1989, STRESS PERSONAL CONT; WENGER NK, 1990, ANN INTERN MED, V112, P557, DOI 10.7326/0003-4819-112-8-557; WILCOSKY T, 1987, AM J EPIDEMIOL, V125, P400, DOI 10.1093/oxfordjournals.aje.a114546	34	622	630	0	55	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 22	1997	314	7080					558	565		10.1136/bmj.314.7080.558	http://dx.doi.org/10.1136/bmj.314.7080.558			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WK215	9055714	Green Published			2022-12-01	WOS:A1997WK21500023
J	YkiJarvinen, H				YkiJarvinen, H			MODY genes and mutations in hepatocyte nuclear factors	LANCET			English	Editorial Material							GLUCOKINASE; ONSET				YkiJarvinen, H (corresponding author), UNIV HELSINKI,DEPT ENDOCRINOL & DIABETOL,FIN-00290 HELSINKI,FINLAND.							AYAMGATA K, 1996, NATURE, V384, P458; EMENS LA, 1992, P NATL ACAD SCI USA, V89, P7300, DOI 10.1073/pnas.89.16.7300; FROGUEL P, 1993, NEW ENGL J MED, V328, P697, DOI 10.1056/NEJM199303113281005; HATTERSLEY AT, 1992, LANCET, V339, P1307, DOI 10.1016/0140-6736(92)91958-B; LEHTO M, 1997, J CLIN INVEST, V99, P1; MENZEL S, 1995, DIABETES, V44, P1408, DOI 10.2337/diabetes.44.12.1408; TATTERSALL RB, 1975, DIABETES, V24, P44, DOI 10.2337/diabetes.24.1.44; Todd JA, 1996, NATURE, V384, P407, DOI 10.1038/384407a0; VAXILLAIRE M, 1995, NAT GENET, V9, P418, DOI 10.1038/ng0495-418; Yamagata K, 1996, NATURE, V384, P455, DOI 10.1038/384455a0; Zhang B, 1996, J BIOL CHEM, V271, P31771, DOI 10.1074/jbc.271.50.31771	11	7	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 22	1997	349	9051					516	517		10.1016/S0140-6736(97)80078-5	http://dx.doi.org/10.1016/S0140-6736(97)80078-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WJ512	9048783				2022-12-01	WOS:A1997WJ51200002
J	Nyce, JW; Metzger, WJ				Nyce, JW; Metzger, WJ			DNA antisense therapy for asthma in an animal model	NATURE			English	Article							ADENOSINE-INDUCED BRONCHOCONSTRICTION; ALLERGIC RABBIT MODEL; RECEPTOR; THEOPHYLLINE; ANTAGONISM; CONTRACTION; SURFACTANT; AIRWAYS; HOE-140; TISSUE	Asthma is an inflammatory disease characterized by bronchial hyper-responsiveness that can proceed to life-threatening airway obstruction. It is one of the most common diseases in industrialized countries, and in the United States accounts for about 1% of all healthcare costs(1). Asthma prevalence and mortality have increased dramatically over the past decade(2), and occupational asthma is predicted to be the pre-eminent occupational lung disease in the next decade(3). Increasing evidence suggests that adenosine, an endogenous purine that is involved in normal physiological processes, may be an important mediator of bronchial asthma(4-15). In contrast to normal individuals, asthmatic individuals respond to adenosine challenge with marked airway obstruction(6,7), and concentrations of adenosine are elevated in the bronchoalveolar lavage fluid of asthma patients(9). We performed a randomized crossover study using the dust mite-conditioned allergic rabbit model of human asthma. Administration of an aerosolized phosphorothioate antisense oligodeoxynucleotide targeting the adenosine A(1) receptor desensitized the animals to subsequent challenge with either adenosine or dust-mite allergen.	EPIGENESIS PHARMACEUT, DEPT MOL PHARMACOL & THERAPEUT, GREENVILLE, NC 27834 USA; E CAROLINA UNIV, SCH MED, DEPT PHARMACOL, GREENVILLE, NC 27858 USA; E CAROLINA UNIV, SCH MED, DEPT MED, SECT ALLERGY ASTHMA & IMMUNOL, GREENVILLE, NC 27858 USA	University of North Carolina; East Carolina University; University of North Carolina; East Carolina University								ALI S, 1992, AGENTS ACTIONS, V37, P165, DOI 10.1007/BF02028098; ALI S, 1994, AM J PHYSIOL, V266, pL271, DOI 10.1152/ajplung.1994.266.3.L271; ALI S, 1994, J PHARMACOL EXP THER, V268, P1328; BENNETT CF, 1992, MOL PHARMACOL, V41, P1023; BJORCK T, 1992, AM REV RESPIR DIS, V145, P1087; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANYEUNG M, 1994, EUR RESPIR J, V7, P346, DOI 10.1183/09031936.94.07020346; CHURCH MK, 1986, TRENDS PHARMACOL SCI, V7, P49, DOI 10.1016/0165-6147(86)90248-8; CUSHLEY MJ, 1983, BRIT J CLIN PHARMACO, V15, P161, DOI 10.1111/j.1365-2125.1983.tb01481.x; CUSHLEY MJ, 1984, AM REV RESPIR DIS, V129, P380; DRIVER AG, 1993, AM REV RESPIR DIS, V148, P91, DOI 10.1164/ajrccm/148.1.91; FELETOU M, 1995, EUR J PHARMACOL, V274, P57, DOI 10.1016/0014-2999(94)00709-G; HOLGATE ST, 1991, ANN NY ACAD SCI, V629, P227; HULSMANN AR, 1994, AM J RESP CRIT CARE, V150, P1012, DOI 10.1164/ajrccm.150.4.7921430; JARVIS MF, 1989, J PHARMACOL EXP THER, V251, P888; MANN JS, 1985, BRIT J CLIN PHARMACO, V19, P685, DOI 10.1111/j.1365-2125.1985.tb02696.x; METZGER WJ, 1990, LATE PHASE ALLERGIC, P347; Pauwels R, 1991, Clin Exp Allergy, V21 Suppl 1, P48, DOI 10.1111/j.1365-2222.1991.tb01706.x; PAUWELS RA, 1995, ARCH INT PHARMACOD T, V329, P151; PISON U, 1994, EUR J CLIN INVEST, V24, P586, DOI 10.1111/j.1365-2362.1994.tb01110.x; ROSS GF, 1995, HUM GENE THER, V6, P31, DOI 10.1089/hum.1995.6.1-31; SAIJO Y, 1994, ONCOL RES, V6, P243; Stein Cy A., 1994, Current Opinion in Oncology, V6, P587, DOI 10.1097/00001622-199411000-00010; TRIFILIEFF A, 1992, J PHARMACOL EXP THER, V263, P1377; TSUKAGOSHI H, 1995, J PHARMACOL EXP THER, V273, P1257; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; WEISS KB, 1992, NEW ENGL J MED, V326, P862, DOI 10.1056/NEJM199203263261304; 1992, MMWR-MORBID MORTAL W, V41, P733	28	215	275	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 20	1997	385	6618					721	725		10.1038/385721a0	http://dx.doi.org/10.1038/385721a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WJ423	9034188				2022-12-01	WOS:A1997WJ42300046
J	Pryor, JL; KentFirst, M; Muallem, A; VanBergen, AH; Nolten, WE; Meisner, L; Roberts, KP				Pryor, JL; KentFirst, M; Muallem, A; VanBergen, AH; Nolten, WE; Meisner, L; Roberts, KP			Microdeletions in the Y chromosome of infertile men	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN SPERMATOGENESIS; DELETION MAP; LONG ARM; GENE; AZF; AZOOSPERMIA; YQ11	Background Some infertile men with azoospermia or severe oligospermia have small deletions in regions of the Y chromosome. However, the frequency of such microdeletions among men with infertility in general is unknown. We sought to determine the prevalence of Y-chromosome microdeletions among infertile men and to correlate the clinical presentation of the men with specific deletions. Methods We studied 200 consecutive infertile men. Each man was evaluated comprehensively for known causes of infertility, and Y-chromosome microdeletions were studied with use of the polymerase chain reaction to amplify specific regions of the chromosome. The Y chromosomes of 200 normal men were also analyzed. Results Fourteen infertile men (7 percent) and four normal men (2 percent) had microdeletions of the Y chromosome. Nine of the infertile men had azoospermia or severe oligospermia (sperm concentration, <5 million per milliliter), four had oligospermia (sperm concentration, 5 million to <20 million per milliliter), and one had normospermia (sperm concentration, greater than or equal to 20 million per milliliter). The size and location of the deletions varied and did not correlate with the severity of spermatogenic failure. The fathers of six infertile men with microdeletions were studied; two had the same deletions as their sons, and four had no deletions. Conclusions A small proportion of men with infertility have Y-chromosome microdeletions, but the size and position of the deletions correlate poorly with the severity of spermatogenic failure, and a deletion does not preclude the presence of viable sperm and possible conception. (C) 1997, Massachusetts Medical Society.	UNIV MINNESOTA,SCH MED,DEPT UROL SURG,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,SCH MED,DEPT CELL BIOL & NEUROANAT,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,SCH MED,DEPT OBSTET & GYNECOL,MINNEAPOLIS,MN 55455; PROMEGA CORP,MADISON,WI; UNIV WISCONSIN,DEPT MEAT & ANIM SCI,MADISON,WI 53706; UNIV WISCONSIN,DEPT PREVENT MED,MADISON,WI 53706	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Promega Corporation; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison			Roberts, Ken/D-5701-2012					AFFARA N, 1996, CYTOGENET CELL GENET, V73, P34; ANDERSSON M, 1988, HUM GENET, V79, P2, DOI 10.1007/BF00291700; BARDONI B, 1991, GENOMICS, V11, P443, DOI 10.1016/0888-7543(91)90153-6; CHANDLEY AC, 1989, J MED GENET, V26, P145, DOI 10.1136/jmg.26.3.145; DUBIN L, 1971, FERTIL STERIL, V22, P469; GREENBERG SH, 1978, J UROLOGY, V119, P507, DOI 10.1016/S0022-5347(17)57531-X; HENDRY W F, 1973, British Journal of Urology, V45, P684, DOI 10.1111/j.1464-410X.1973.tb12240.x; HENEGARIU O, 1994, ANDROLOGIA, V26, P97; KOBAYASHI K, 1995, HUM MOL GENET, V4, P974, DOI 10.1093/hmg/4.5.974-a; KOBAYASHI K, 1994, HUM MOL GENET, V3, P1965, DOI 10.1093/hmg/3.11.1965; KRUGER TF, 1988, FERTIL STERIL, V49, P112; MA K, 1993, CELL, V75, P1287, DOI 10.1016/0092-8674(93)90616-X; MOSHER WD, 1985, DEMOGRAPHY, V22, P415, DOI 10.2307/2061069; NAGAFUCHI S, 1993, J UROLOGY, V150, P1155, DOI 10.1016/S0022-5347(17)35712-9; Najmabadi H, 1996, J CLIN ENDOCR METAB, V81, P1347, DOI 10.1210/jc.81.4.1347; REIJO R, 1995, NAT GENET, V10, P383, DOI 10.1038/ng0895-383; Reijo R, 1996, LANCET, V347, P1290, DOI 10.1016/S0140-6736(96)90938-1; Sambrook J., 1989, MOL CLONING LAB MANU; Stuppia L, 1996, CYTOGENET CELL GENET, V72, P155, DOI 10.1159/000134174; Sylora J A, 1994, Curr Ther Endocrinol Metab, V5, P309; TIEPOLO L, 1976, HUM GENET, V34, P119, DOI 10.1007/BF00278879; TORRONI A, 1990, ANN HUM GENET, V54, P287; VERGNAUD G, 1986, AM J HUM GENET, V38, P109; Verma RS, 1995, HUMAN CHROMOSOMES PR, P11; VOGT P, 1992, HUM GENET, V89, P491; Vogt PH, 1996, HUM MOL GENET, V5, P933, DOI 10.1093/hmg/5.7.933; VOLLRATH D, 1992, SCIENCE, V258, P52, DOI 10.1126/science.1439769	27	395	418	1	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 20	1997	336	8					534	539		10.1056/NEJM199702203360802	http://dx.doi.org/10.1056/NEJM199702203360802			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WJ240	9023089				2022-12-01	WOS:A1997WJ24000002
J	Okubo, Y; Suhara, T; Suzuki, K; Kobayashi, K; Inoue, O; Terasaki, O; Someya, Y; Sassa, T; Sudo, Y; Matsushima, E; Iyo, M; Tateno, Y; Toru, M				Okubo, Y; Suhara, T; Suzuki, K; Kobayashi, K; Inoue, O; Terasaki, O; Someya, Y; Sassa, T; Sudo, Y; Matsushima, E; Iyo, M; Tateno, Y; Toru, M			Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET	NATURE			English	Article							POSITRON EMISSION TOMOGRAPHY; CEREBRAL BLOOD-FLOW; PREFRONTAL CORTEX; COGNITIVE ACTIVATION; WORKING-MEMORY; HUMAN-BRAIN; DYSFUNCTION; MODULATION; BINDING; INVIVO	Schizophrenia is believed to involve altered activation of dopamine receptors, and support for this hypothesis comes from the antipsychotic effect of antagonists of the dopamine D2 receptor (D2R)(1). D2R is expressed most highly in the striatum, but most of the recent positron emission tomography (PET) studies have failed to show any change in D2R densities in the striatum of schizophrenics(2-5), raising the possibility that other receptors may also be involved. In particular, the dopamine D1 receptor (D1R), which is highly expressed in the prefrontal cortex(6), has been implicated in the control of working memory(7,8), and working memory dysfunction is a prominent feature of schizophrenia(9). We have therefore used PET to examine the distribution of D1R and D2R in brains of drug-naive or drug-free schizophrenic patients. Although no differences were observed in the striatum relative to control subjects, binding of radioligand to D1R was reduced in the prefrontal cortex of schizophrenics. This reduction was related to the severity of the negative symptoms (for instance, emotional withdrawal) and to poor performance in the Wisconsin Card Sorting Test(10). We propose that dysfunction of D1R signalling in the prefrontal cortex may contribute to the negative symptoms and cognitive deficits seen in schizophrenia.	NATL INST RADIOL SCI,DIV ADV TECHNOL MED IMAGING,INAGE KU,CHIBA 263,JAPAN	National Institutes for Quantum Science & Technology	Okubo, Y (corresponding author), TOKYO MED & DENT UNIV,SCH MED,DEPT NEUROPSYCHIAT,BUNKYO KU,1-5-45 YUSHIMA,TOKYO 113,JAPAN.							ANDERSEN PH, 1986, LIFE SCI, V38, P1507, DOI 10.1016/0024-3205(86)90564-3; ASAHINA M, 1995, ACTA NEUROL SCAND, V91, P437; BROZOSKI TJ, 1979, SCIENCE, V205, P929, DOI 10.1126/science.112679; DANIEL DG, 1991, J NEUROSCI, V11, P1907; DAVIDSON M, 1988, ARCH GEN PSYCHIAT, V45, P561; DOLAN RJ, 1995, NATURE, V378, P180, DOI 10.1038/378180a0; FARDE L, 1987, PSYCHOPHARMACOLOGY, V92, P278, DOI 10.1007/BF00210831; FARDE L, 1990, ARCH GEN PSYCHIAT, V47, P213; GOLDMANRAKIC PS, 1994, J NEUROPSYCH CLIN N, V6, P348; HALL H, 1994, NEUROPSYCHOPHARMACOL, V11, P245, DOI 10.1038/sj.npp.1380111; HESS EJ, 1987, LIFE SCI, V40, P1487, DOI 10.1016/0024-3205(87)90381-X; HIETALA J, 1994, ARCH GEN PSYCHIAT, V51, P116; KASHIMA H, 1991, JPN J PSYCHOPHARMACO, V11, P83; MARTINOT JL, 1990, AM J PSYCHIAT, V147, P44; MINTUN MA, 1984, ANN NEUROL, V15, P217, DOI 10.1002/ana.410150302; NORDSTROM AL, 1995, PSYCHIAT RES-NEUROIM, V61, P67, DOI 10.1016/0925-4927(95)02732-D; PATLAK CS, 1985, J CEREBR BLOOD F MET, V5, P584, DOI 10.1038/jcbfm.1985.87; SAWAGUCHI T, 1991, SCIENCE, V251, P947, DOI 10.1126/science.1825731; SEDVALL G, 1995, LANCET, V346, P743, DOI 10.1016/S0140-6736(95)91508-7; SEEMAN P, 1976, NATURE, V261, P717, DOI 10.1038/261717a0; SUHARA T, 1991, PSYCHOPHARMACOLOGY, V103, P41, DOI 10.1007/BF02244071; WEINBERGER DR, 1986, ARCH GEN PSYCHIAT, V43, P114; WILLIAMS GV, 1995, NATURE, V376, P572, DOI 10.1038/376572a0; WONG DF, 1984, SCIENCE, V226, P1393, DOI 10.1126/science.6334363	24	550	573	0	33	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 13	1997	385	6617					634	636		10.1038/385634a0	http://dx.doi.org/10.1038/385634a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	WH294	9024661				2022-12-01	WOS:A1997WH29400050
J	Arber, S; Hunter, JJ; Ross, J; Hongo, M; Sansig, G; Borg, J; Perriard, JC; Chien, KR; Caroni, P				Arber, S; Hunter, JJ; Ross, J; Hongo, M; Sansig, G; Borg, J; Perriard, JC; Chien, KR; Caroni, P			MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy, and heart failure	CELL			English	Article							CYSTEINE-RICH PROTEIN; LIM-PROTEIN; HYPERTROPHY; MYOFIBRILLOGENESIS; INVOLVEMENT; EXPRESSION; MYOCYTES; GROWTH; DOMAIN	MLP is a LIM-only protein of terminally differentiated striated muscle cells, where it accumulates at actin-based structures involved in cytoarchitecture organization. To assess its role in muscle differentiation, we disrupted the MLP gene in mice. MLP (-/-) mice developed dilated cardiomyopathy with hypertrophy and heart failure after birth. Ultrastructural analysis revealed dramatic disruption of cardiomyocyte cytoarchitecture. At birth, these hearts were not hypertrophic, but already abnormally soft, with cell-autonomous and MLP-sensitive alterations in cytoarchitecture. Thus, MLP promotes proper cardiomyocyte cytoarchitecture, whose perturbation can lead to dilated cardiomyopathy. In vivo analysis revealed that MLP-deficient mice reproduce the morphological and clinical picture of dilated cardiomyopathy and heart failure in humans, providing the first model for this condition in a genetically manipulatable organism.	UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, CTR MOL GENET, LA JOLLA, CA 92093 USA; CIBA GEIGY AG, PHARMA RES, CH-4002 BASEL, SWITZERLAND; UNIV LOUIS PASTEUR STRASBOURG 1, DEPT PHARMACOL, F-67401 ILLKIRCH GRAFFENSTADEN, FRANCE; SWISS FED INST TECHNOL, INST CELL BIOL, CH-8093 ZURICH, SWITZERLAND	University of California System; University of California San Diego; University of California System; University of California San Diego; Novartis; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Swiss Federal Institutes of Technology Domain; ETH Zurich	Arber, S (corresponding author), FRIEDRICH MIESCHER INST, CH-4002 BASEL, SWITZERLAND.			Arber, Silvia/0000-0002-6261-250X				Arber S, 1996, GENE DEV, V10, P289, DOI 10.1101/gad.10.3.289; ARBER S, 1994, CELL, V79, P221, DOI 10.1016/0092-8674(94)90192-9; Chien KR, 1996, J CLIN INVEST, V97, P901, DOI 10.1172/JCI118512; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; CRAWFORD AW, 1994, J CELL BIOL, V124, P117, DOI 10.1083/jcb.124.1.117; DAWID IB, 1995, CR ACAD SCI III-VIE, V318, P295; DEC GW, 1994, NEW ENGL J MED, V331, P1564, DOI 10.1056/NEJM199412083312307; FUNG YW, 1995, GENOMICS, V28, P602, DOI 10.1006/geno.1995.1200; GONCHAROVA EJ, 1992, DEVELOPMENT, V114, P173; GRINNELL F, 1994, J CELL BIOL, V124, P401, DOI 10.1083/jcb.124.4.401; KASPER EK, 1994, J AM COLL CARDIOL, V23, P586, DOI 10.1016/0735-1097(94)90740-4; Keating MT, 1996, SCIENCE, V272, P681, DOI 10.1126/science.272.5262.681; KOCH WJ, 1995, SCIENCE, V268, P1350, DOI 10.1126/science.7761854; KUBALAK SW, 1996, METH MOL G, V8, P470; MESSERLI JM, 1993, HISTOCHEMISTRY, V100, P193, DOI 10.1007/BF00269092; Olson EN, 1996, SCIENCE, V272, P671, DOI 10.1126/science.272.5262.671; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; SEN A, 1988, J BIOL CHEM, V263, P19132; SIMPSON DG, 1993, J CELL BIOL, V123, P323, DOI 10.1083/jcb.123.2.323; SOLER AP, 1994, DEV BIOL, V162, P9, DOI 10.1006/dbio.1994.1062; Tanaka N, 1996, CIRCULATION, V94, P1109, DOI 10.1161/01.CIR.94.5.1109; THIERFELDER L, 1994, CELL, V77, P701, DOI 10.1016/0092-8674(94)90054-X; WANG XK, 1992, J BIOL CHEM, V267, P9176; WIDMER F, 1993, J CELL BIOL, V120, P503, DOI 10.1083/jcb.120.2.503; YAMAZAKI T, 1995, J MOL CELL CARDIOL, V27, P133, DOI 10.1016/S0022-2828(08)80013-2; ZHOU MD, 1995, P NATL ACAD SCI USA, V92, P7391, DOI 10.1073/pnas.92.16.7391	26	661	674	3	36	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 7	1997	88	3					393	403		10.1016/S0092-8674(00)81878-4	http://dx.doi.org/10.1016/S0092-8674(00)81878-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WG479	9039266	Bronze			2022-12-01	WOS:A1997WG47900012
J	Oro, AE; Higgins, KM; Hu, ZL; Bonifas, JM; Epstein, EH; Scott, MP				Oro, AE; Higgins, KM; Hu, ZL; Bonifas, JM; Epstein, EH; Scott, MP			Basal cell carcinomas in mice overexpressing sonic hedgehog	SCIENCE			English	Article							KERATIN EXPRESSION; BASEMENT-MEMBRANE; GENES; DIFFERENTIATION; DROSOPHILA; PROTEINS; POLARITY; SKIN; TRANSPLANTATION; XENOGRAFTS	Mutations in the tumor suppressor gene PATCHED (PTC) are found in human patients with the basal cell nevus syndrome, a disease causing developmental defects and tumors, including basal cell carcinomas. Gene regulatory relationships defined in the fruit fly Drosophila suggest that overproduction of Sonic hedgehog (SHH), the ligand for PTC, will mimic loss of ptc function. It is shown here that transgenic mice overexpressing SHH in the skin develop many features of basal cell nevus syndrome, demonstrating that SHH is sufficient to induce basal cell carcinomas in mice. These data suggest that SHH may have a role in human tumorigenesis.	UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,DEPT DERMATOL,SAN FRANCISCO,CA 94110; STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT DEV BIOL,STANFORD,CA 94305; STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT GENET,STANFORD,CA 94305; STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT DERMATOL,STANFORD,CA 94305	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; Howard Hughes Medical Institute; Stanford University; Howard Hughes Medical Institute; Stanford University; Howard Hughes Medical Institute; Stanford University					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039959] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39959] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Arbeit JM, 1996, CANCER SURV, V26, P7; BARLOGIE B, 1983, CANCER RES, V43, P3982; Belloni E, 1996, NAT GENET, V14, P353, DOI 10.1038/ng1196-353; BITGOOD MJ, 1995, DEV BIOL, V172, P126, DOI 10.1006/dbio.1995.0010; BYRNE C, 1994, DEVELOPMENT, V120, P2369; Chidambaram A, 1996, CANCER RES, V56, P4599; Cohn MJ, 1996, TRENDS GENET, V12, P253, DOI 10.1016/0168-9525(96)10030-5; COOPER M, 1977, CANCER RES, V37, P2544; Dean M, 1996, NAT GENET, V14, P245, DOI 10.1038/ng1196-245; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; FAIRLEY JA, 1995, BRIT J DERMATOL, V133, P385, DOI 10.1111/j.1365-2133.1995.tb02665.x; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FRANCISWEST PH, 1995, DEV DYNAM, V203, P187, DOI 10.1002/aja.1002030207; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; GORLIN RJ, 1995, DERMATOL CLIN, V13, P113, DOI 10.1016/S0733-8635(18)30114-1; GRIMWOOD RE, 1985, CANCER, V56, P519, DOI 10.1002/1097-0142(19850801)56:3<519::AID-CNCR2820560319>3.0.CO;2-W; GUO LF, 1993, EMBO J, V12, P973, DOI 10.1002/j.1460-2075.1993.tb05738.x; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; HALES SA, 1989, BRIT J DERMATOL, V120, P351, DOI 10.1111/j.1365-2133.1989.tb04159.x; HALL T, 1996, NATURE, V378, P212; Hammerschmidt M, 1997, TRENDS GENET, V13, P14, DOI 10.1016/S0168-9525(96)10051-2; INGHAM PW, 1995, CURR OPIN GENET DEV, V5, P492, DOI 10.1016/0959-437X(95)90054-K; INGHAM PW, 1993, NATURE, V366, P560, DOI 10.1038/366560a0; Iseki S, 1996, BIOCHEM BIOPH RES CO, V218, P688, DOI 10.1006/bbrc.1996.0123; IZPISUABELMONTE JC, 1992, DEVELOPMENT, V114, P959; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Lazarova Z, 1995, Exp Dermatol, V4, P121, DOI 10.1111/j.1600-0625.1995.tb00235.x; Lever WF, 1990, HISTOPATHOLOGY SKIN; LIEM KF, 1995, CELL, V82, P969, DOI 10.1016/0092-8674(95)90276-7; LUFKIN T, 1992, NATURE, V359, P835, DOI 10.1038/359835a0; MARIGO V, 1995, GENOMICS, V28, P44, DOI 10.1006/geno.1995.1104; MARKEY AC, 1992, BRIT J DERMATOL, V126, P154, DOI 10.1111/j.1365-2133.1992.tb07813.x; MARKS R, 1988, ARCH DERMATOL, V124, P1039, DOI 10.1001/archderm.124.7.1039; Medalie DA, 1996, J INVEST DERMATOL, V107, P121, DOI 10.1111/1523-1747.ep12298363; MILLER DL, 1994, J AM ACAD DERMATOL, V30, P774, DOI 10.1016/S0190-9622(08)81509-5; MILLER SJ, 1991, J AM ACAD DERMATOL, V24, P161, DOI 10.1016/0190-9622(91)70022-T; MILLER SJ, 1991, J AM ACAD DERMATOL, V24, P1, DOI 10.1016/0190-9622(91)70001-I; Perrimon N, 1996, CELL, V86, P513, DOI 10.1016/S0092-8674(00)80124-5; QUINN AG, 1994, J INVEST DERMATOL, V102, P300, DOI 10.1111/1523-1747.ep12371786; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; Roessler E, 1996, NAT GENET, V14, P357, DOI 10.1038/ng1196-357; SAITOU M, 1995, NATURE, V374, P159, DOI 10.1038/374159a0; SAVOIA P, 1993, J INVEST DERMATOL, V101, P352, DOI 10.1111/1523-1747.ep12365531; STAMP GWH, 1988, J PATHOL, V156, P213, DOI 10.1002/path.1711560306; STANLEY JR, 1982, CANCER, V50, P1486, DOI 10.1002/1097-0142(19821015)50:8<1486::AID-CNCR2820500807>3.0.CO;2-F; STOLER A, 1988, J CELL BIOL, V107, P427, DOI 10.1083/jcb.107.2.427; TABIN C, 1995, CELL, V80, P671, DOI 10.1016/0092-8674(95)90343-7; TingBerreth SA, 1996, DEV DYNAM, V207, P157, DOI 10.1002/(SICI)1097-0177(199610)207:2<157::AID-AJA4>3.0.CO;2-G; Unden AB, 1996, CANCER RES, V56, P4562	52	556	607	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 2	1997	276	5313					817	821		10.1126/science.276.5313.817	http://dx.doi.org/10.1126/science.276.5313.817			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WW900	9115210				2022-12-01	WOS:A1997WW90000064
J	Andrews, TC; Cull, DL; Pelton, JJ; Massey, SO; Bostwick, JM				Andrews, TC; Cull, DL; Pelton, JJ; Massey, SO; Bostwick, JM			Self-mutilation and malingering among Cuban migrants detained at Guantanamo Bay	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MILITARY				Andrews, TC (corresponding author), WILFORD HALL USAF MED CTR,LACKLAND AFB,TX 78236, USA.							BENNUN I, 1984, SUICIDE LIFE-THREAT, V14, P166; DRUMMOND T, 1994, TIME            1219, P23; GIBBS N, 1994, TIME            0620, P28; GORMAN WF, 1982, J FORENSIC SCI, V27, P401; MARK M, 1987, MIL MED, V152, P260, DOI 10.1093/milmed/152.5.260; PODVOLL E, 1969, BR J MED PSYCHOL, V14, P213; POST T, 1994, NEWSWEEK        0905, P22; ROBINSON L, 1994, US NEWS WORLD R 0926, P55; SHARP TW, 1994, JAMA-J AM MED ASSOC, V272, P386, DOI 10.1001/jama.272.5.386	9	7	7	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 24	1997	336	17					1251	1253		10.1056/NEJM199704243361712	http://dx.doi.org/10.1056/NEJM199704243361712			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WV332	9110917				2022-12-01	WOS:A1997WV33200012
J	Shibasaki, F; Kondo, E; Akagi, T; McKeon, F				Shibasaki, F; Kondo, E; Akagi, T; McKeon, F			Suppression of signalling through transcription factor NF-AT by interactions between calcineurin and Bcl-2	NATURE			English	Article							PROGRAMMED CELL-DEATH; PROTEIN; GENE; ONCOPROTEIN; EXPRESSION; REGULATOR; SURVIVAL; MEMBERS; FAMILY	It is not known how the protein Bcl-2 inhibits cell death induced by calcium signalling and growth-factor withdrawal(1-3). Here we report that Bcl-2 forms a tight complex with calcineurin, resulting in the targeting of calcineurin to Bcl-2 sites on cytoplasmic membranes, and show that this interaction is dependent on the BH4 domain of Bcl-2. Calcineurin bound to Bcl-2 is an active phosphatase but is unable to promote the nuclear translocation of NF-AT, a transcription-factor required for induction of interleukin-2 expression, suggesting a mechanism by which Bcl-2 suppresses NF-AT activity(4). We also show that Bar, a pro-apoptotic member of the Bcl-2 family, interferes with interactions between calcineurin and Bcl-2. We propose that the ability of Bcl-2 to block NF-AT signalling is due to the sequestering of active calcineurin to the same domain of Bcl-2 which associates with Rad-1 (ref. 5), and that calcineurin may act in Bcl-2-regulated functions.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; OKAYAMA UNIV,SCH MED,DEPT PATHOL 2,OKAYAMA 700,JAPAN	Harvard University; Harvard Medical School; Okayama University								BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BRAUN W, 1995, FASEB J, V9, P63, DOI 10.1096/fasebj.9.1.7529736; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; GONZALEZGARCIA M, 1990, DEVELOPMENT, V20, P3033; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; KONDO E, 1992, BLOOD, V80, P2044; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Lee LC, 1996, J BIOL CHEM, V271, P23284, DOI 10.1074/jbc.271.38.23284; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; NGUYEN M, 1994, J BIOL CHEM, V269, P16521; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; SHIBASAKI F, 1995, J CELL BIOL, V131, P735, DOI 10.1083/jcb.131.3.735; TANAKA S, 1993, J BIOL CHEM, V268, P10920; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440	23	322	327	1	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 17	1997	386	6626					728	731		10.1038/386728a0	http://dx.doi.org/10.1038/386728a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WU387	9109491				2022-12-01	WOS:A1997WU38700059
J	Birmingham, ME; Lee, LA; Ndayimirije, N; Nkurikiye, S; Hersh, BS; Wells, JG; Deming, MS				Birmingham, ME; Lee, LA; Ndayimirije, N; Nkurikiye, S; Hersh, BS; Wells, JG; Deming, MS			Epidemic cholera in Burundi: Patterns of transmission in the Great Rift Valley Lake region	LANCET			English	Article							VIBRIO-CHOLERAE; RISK	Background After a 14-year hiatus, epidemic cholera swept through Burundi between January and May, 1992, The pattern of transmission was similar to that in 1978, when the seventh pandemic first reached this region, Communities affected were limited to those near Lake Tanganyika and the Rusizi River, The river connects Lake Tanganyika with Lake Kivu to the north in Zaire and Rwanda. Methods To identify sources of infection and risk factors for illness, an epidemiological study was carried out in Rumonge, a lake-shore town where 318 people were admited to hospital with cholera between April 9 and May 31, 1992, The investigation included a case-control study of 56 case-patients and 112 matched controls. Findings Attack rates according to street increased with the street's proximity to Lake Tanganyika (chi(2) test for linear trend, p < 0.01) which suggests that exposure to the lake was a risk factor for illness, Comparison of the 56 case-patients with matched controls showed that bathing in the lake (odds ratio 1.6, attributable risk percentage 37%) and drinking its water (2.78, 14%) were independently and significantly (p < 0.05) linked with illness, No food-borne risk factors were identified, Vibrio cholera 01 was isolated from Lake Tanganyiha during, but not after, the outbreak in Rumonge, Isolates from the lake and from patients with acute watery diarrhoea had the same serotype, biotype, and antimicrobial susceptibility profiles, The number of cases rapidly declined when access to the lake was blocked. Interpretation This study identifies bathing in contaminated surface water as a major risk factor for cholera in sub-Saharan Africa, and suggests that improving the quality of drinking water alone will have only limited impact on the transmission of the disease in the Great Rift Valley Lake region. The similarity in the patterns of transmission during the 1978 and 1992 epidemics suggests that extensive use of the Great Lakes and connecting rivers for transportation and domestic purposes may be the reason for the explosive cholera outbreaks that occur sporadically in this region.	CTR DIS CONTROL & PREVENT,INT HLTH PROGRAM OFF,ATLANTA,GA 30333; CTR DIS CONTROL & PREVENT,DIV BACTERIAL & MYCOT DIS,NATL CTR INFECT DIS,ATLANTA,GA 30333; MINIST PUBL HLTH,BUJUMBURA,BURUNDI	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA								[Anonymous], 1995, Wkly Epidemiol Rec, V70, P201; BRUZZI P, 1985, AM J EPIDEMIOL, V122, P904, DOI 10.1093/oxfordjournals.aje.a114174; CASH RA, 1974, J INFECT DIS, V129, P45, DOI 10.1093/infdis/129.1.45; DEB BC, 1986, B WORLD HEALTH ORGAN, V64, P127; FIELDS PI, 1992, J CLIN MICROBIOL, V30, P2118, DOI 10.1128/JCM.30.8.2118-2121.1992; GANGAROSA EJ, 1974, CHOLERA, P381; Global Task Force on Cholera Control, 1993, GUID CHOL CONTR; *GOM EP GROUP, 1994, LANCET, V345, P339; GOODGAME RW, 1975, ANN INTERN MED, V82, P101, DOI 10.7326/0003-4819-82-1-101; HUGHES JM, 1982, B WORLD HEALTH ORGAN, V60, P395; MINTZ ED, 1995, JAMA-J AM MED ASSOC, V273, P948, DOI 10.1001/jama.273.12.948; *NAT COMM CLIN LAB, 1990, PERF STAND ANT SUSC, V10, pM2; ROBINS J, 1986, AM J EPIDEMIOL, V124, P719, DOI 10.1093/oxfordjournals.aje.a114447; *SAS I INC, 1993, P229 SAS I INC, P465; SCHHYNS C, 1979, ANN SOC BELG MED TR, P391; SINCLAIR GS, 1982, S AFR MED J, V62, P753; SPIRA WM, 1981, APPL ENVIRON MICROB, V42, P730, DOI 10.1128/AEM.42.4.730-733.1981; STLOUIS ME, 1990, AM J EPIDEMIOL, V131, P719; STORME B, 1979, ANN SOC BELG MED TR, V59, P413; Swerdlow David L., 1994, P297; TAUXE RV, 1988, EPIDEMIOL INFECT, V100, P279, DOI 10.1017/S0950268800067418; WEBBER RH, 1983, E AFR MED J, V60, P848; WEST PA, 1989, EPIDEMIOL INFECT, V103, P1, DOI 10.1017/S0950268800030326; *WHO, 1987, CCC833 WHO	24	49	51	3	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 5	1997	349	9057					981	985		10.1016/S0140-6736(96)08478-4	http://dx.doi.org/10.1016/S0140-6736(96)08478-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR621	9100624				2022-12-01	WOS:A1997WR62100010
J	Gillespie, ND; McNeill, G; Pringle, T; Ogston, S; Struthers, AD; Pringle, SD				Gillespie, ND; McNeill, G; Pringle, T; Ogston, S; Struthers, AD; Pringle, SD			Cross sectional study of contribution of clinical assessment and simple cardiac investigations to diagnosis of left ventricular systolic dysfunction in patients admitted with acute dyspnoea	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HEART-FAILURE; ECHOCARDIOGRAPHY	Objective: To assess the comparative contribution of clinical assessment, electrocardiography, and chest radiography to the diagnosis of left ventricular systolic dysfunction in patients admitted to a general medical ward with acute dyspnoea Design: Prospective cross sectional study. Setting: Acute medical admissions ward of a teaching hospital. Subjects: 71 randomly selected patients admitted with acute dyspnoea. Main outcome measures: Sensitivity and specificity of each investigation and logistic regression analysis of each variable in identifying left ventricular systolic dysfunction, Results: Clinical assessment in this cohort of patients with severe dyspnoea was generally sensitive (sensitivity 81%), Patients were divided into three groups on the basis of clinical assessment In the first group (37 patients) the diagnosis of systolic dysfunction was clear, in the second (22) it was in doubt, and in the third (12) it was unlikely. The sensitivity of clinical assessment in identifying left ventricular systolic dysfunction was 81% and the specificity was 41%, The specificity of diagnosis was improved by electrocardiography (69%) and chest radiography (92%), Logistic regression analysis showed that isolated pulmonary crepitations were a comparatively poor predictor of left ventricular systolic dysfunction (chi(2)=10.215, P=0.0014) but that a full clinical examination had reasonable predictive value (chi(2)=24.82, P<0.00001). The combination of clinical assessment and chest radiography improved the accuracy of diagnosis (chi(2)=28.08, P<0.00001), as did the combination of clinical assessment and electrocardiography (chi(2)=32.41, P<0.00001), Conclusion: Clinical assessment in patients admitted with acute dyspnoea is comparatively accurate, Patients with abnormal results on chest radiography, electrocardiography, and clinical examination have a high likelihood of having left ventricular systolic dysfunction. Echocardiography contributes little more to the diagnosis in these patients and may be more efficiently directed towards patients in whom the diagnosis is still in doubt after clinical assessment, chest radiography, and electrocardiography.			Gillespie, ND (corresponding author), UNIV DUNDEE, NINEWELLS HOSP & MED SCH, DEPT MED, SECT AGEING & HLTH, DUNDEE DD1 9SY, SCOTLAND.			Struthers, Allan/0000-0002-2926-2528				CLARKE KW, 1994, BRIT HEART J, V71, P584; CLELAND JG, 1995, EUR HEART J, V16, P741; DARGIE HJ, 1994, BMJ-BRIT MED J, V308, P321, DOI 10.1136/bmj.308.6924.321; Davie AP, 1996, BRIT MED J, V312, P222; Gillespie N D, 1996, Health Bull (Edinb), V54, P395; HEGER JJ, 1979, CIRCULATION, V60, P531, DOI 10.1161/01.CIR.60.3.531; HOBBS R, 1995, BRIT MED J, V310, P207, DOI 10.1136/bmj.310.6974.207; ISOM OW, 1975, CIRCULATION, V52, P119; MONAGHAN M, 1994, BRIT HEART J, V71, P2; PARAMESHWAR J, 1992, J ROY COLL PHYS LOND, V26, P139; REMES J, 1991, EUR HEART J, V12, P315, DOI 10.1093/oxfordjournals.eurheartj.a059896; SLOVICK DI, 1995, BRIT MED J, V311, P327, DOI 10.1136/bmj.311.7000.327; STRUTHERS AD, 1994, CURR OPIN CARDIOL, V9, pS12, DOI 10.1097/00001573-199407000-00003; WHEELDON NM, 1993, Q J MED, V86, P17; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; ZARIFIS J, 1995, BRIT MED J, V311, P326, DOI 10.1136/bmj.311.7000.326a	16	64	64	1	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 29	1997	314	7085					936	940		10.1136/bmj.314.7085.936	http://dx.doi.org/10.1136/bmj.314.7085.936			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ169	9099117	Green Published			2022-12-01	WOS:A1997WQ16900025
J	Schleicher, DG; Lederer, SM; Millis, RL; Farnham, TL				Schleicher, DG; Lederer, SM; Millis, RL; Farnham, TL			Photometric behavior of comet Hale-Bopp (C/1995 O1) before perihelion	SCIENCE			English	Article								Narrowband photometric observations of comet Hale-Bopp (C/1995 O1) between 25 July 1995 and 15 February 1997 indicated gas and dust production rates of 20 and 100 times greater, respectively, than observed at the same heliocentric distances for comet P/Halley in 1985, Hale-Bopp produced dust at a rate greater than has been observed for any other comet at any distance since at least 1977. On the basis of the observed production rate of the hydroxyl molecule, the calculated minimum effective diameter of Hale-Bopp's nucleus is 17 kilometers, but the actual diameter of the nucleus is likely to be at least two to three times larger. The chemical composition of Hale-Bopp is consistent with that of other long-period comets originating from the Oort Cloud.	UNIV FLORIDA,DEPT ASTRON,GAINESVILLE,FL 32611	State University System of Florida; University of Florida	Schleicher, DG (corresponding author), LOWELL OBSERV,1400 W MARS HILL RD,FLAGSTAFF,AZ 86001, USA.							AHearn MF, 1995, ICARUS, V118, P223, DOI 10.1006/icar.1995.1190; COCHRAN AL, COMMUNICATION; COCHRAN AL, 1996, B AM ASTRON SOC, V28, P1093; COWAN JJ, 1979, MOON PLANETS, V21, P155, DOI 10.1007/BF00897085; Fitzsimmons A, 1996, MON NOT R ASTRON SOC, V278, pL37, DOI 10.1093/mnras/278.2.L37; FITZSIMMONS A, 1995, 6252 IAU; GREEN D, 1995, 6191 IAU; HALE A, 1995, 6187 IAU; HERGENROTHER CW, 1997, 6555 IAU; LECACHEUX J, 1997, 6560 IAU; MARSDEN B, 1995, 6198 IAU; MARSDEN BG, 1995, 6224 IAU; MARSDEN BG, 1996, 6463 IAU; MATTHEWS HE, 1995, 6234 IAU, P6234; Oort J., 1950, BAIN, V11, P91; RANDALL CA, UNPUB; RANDALL CE, 1992, B AM ASTRON SOC, V24, P1002; RAUER H, 1995, 6236 IAU; SCHLEICHER DG, 1989, ASTROPHYS J, V339, P1107, DOI 10.1086/167365; SCHLEICHER DG, UNPUB; SEKANINA Z, 1997, 6542 IAU; Wagner RM, 1997, SCIENCE, V275, P1918, DOI 10.1126/science.275.5308.1918; WHIPPLE FL, 1978, MOON PLANETS, V18, P343, DOI 10.1007/BF00896489	23	59	59	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 28	1997	275	5308					1913	1915		10.1126/science.275.5308.1913	http://dx.doi.org/10.1126/science.275.5308.1913			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WQ513	9072963				2022-12-01	WOS:A1997WQ51300038
J	Metzlaff, M; ODell, M; Cluster, PD; Flavell, RB				Metzlaff, M; ODell, M; Cluster, PD; Flavell, RB			RNA-mediated RNA degradation and chalcone synthase A silencing in Petunia	CELL			English	Article							GENE-EXPRESSION; TRANSGENIC PLANTS; CO-SUPPRESSION; VIRUS-RESISTANCE; CLEAVAGE; PATHWAY; HYBRIDA; DNA	Transgenic Petunia plants with a chsA coding sequence under the control of a 35S promoter sometimes lose endogene and transgene chalcone synthase activity and purple flower pigment through posttranscriptional chsA RNA degradation. In these plants, shorter poly(A)(+) and poly(A)(-) chsA RNAs are found, and a 3' end-specific RNA fragment from the endogene is more resistant to degradation. The termini of this RNA fragment are located in a region of complementarity between the chsA 3' coding region and its 3' untranslated region. Equivalent chsA RNA fragments remain in the white flower tissue of a nontransgenic Petunia variety. We present a model involving cycles of RNA-RNA pairing between complementary sequences followed by endonucleolytic RNA cleavages to describe how RNA degradation is likely to be promoted.			Metzlaff, M (corresponding author), JOHN INNES CTR PLANT SCI RES, NORWICH RES PK, NORWICH NR4 7UH, NORFOLK, ENGLAND.							Baulcombe DC, 1996, CURR OPIN BIOTECH, V7, P173, DOI 10.1016/S0958-1669(96)80009-7; BINDER R, 1994, EMBO J, V13, P1969, DOI 10.1002/j.1460-2075.1994.tb06466.x; Cogoni C, 1996, EMBO J, V15, P3153, DOI 10.1002/j.1460-2075.1996.tb00678.x; DE CARVALHO-NIEBEL F, 1995, PLANT CELL, V7, P347, DOI 10.2307/3869856; Depicker A., 1996, MECH APPL GENE SILEN, P71; DOUGHERTY WG, 1994, MOL PLANT MICROBE IN, V7, P544, DOI 10.1094/MPMI-7-0554; English JJ, 1996, PLANT CELL, V8, P179, DOI 10.1105/tpc.8.2.179; FLAVELL RB, 1994, P NATL ACAD SCI USA, V91, P3490, DOI 10.1073/pnas.91.9.3490; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P3998; Goodwin J, 1996, PLANT CELL, V8, P95, DOI 10.1105/tpc.8.1.95; GRIERSON D, 1991, TRENDS BIOTECHNOL, V9, P122, DOI 10.1016/0167-7799(91)90042-G; HAMILTON AJ, 1996, MECH APPL GENE SILEN, P105; Jorgensen RA, 1996, STADLER GEN, P159; JORGENSEN RA, 1995, SCIENCE, V268, P686, DOI 10.1126/science.268.5211.686; Jorgensen RA, 1996, PLANT MOL BIOL, V31, P957, DOI 10.1007/BF00040715; LI HL, 1993, NUCLEIC ACIDS RES, V21, P1919, DOI 10.1093/nar/21.8.1919; MARTIN CR, 1993, INT REV CYTOL, V147, P233, DOI 10.1016/S0074-7696(08)60770-6; MATZKE MA, 1995, PLANT PHYSIOL, V107, P679, DOI 10.1104/pp.107.3.679; Meins F. Jr., 1994, Homologous recombination and gene silencing in plants., P335; MEYER P, 1994, MOL GEN GENET, V243, P390, DOI 10.1007/BF00280469; MEYER P, 1995, GENE SILENCING HIGHE; MOL J, 1991, TRENDS BIOTECHNOL, V9, P182, DOI 10.1016/0167-7799(91)90060-U; MOL JNM, 1983, MOL GEN GENET, V192, P424, DOI 10.1007/BF00392185; MURRAY V, 1989, NUCLEIC ACIDS RES, V17, P8889, DOI 10.1093/nar/17.21.8889; NAPOLI C, 1990, PLANT CELL, V2, P279, DOI 10.1105/tpc.2.4.279; Scheper W, 1996, NUCLEIC ACIDS RES, V24, P1000, DOI 10.1093/nar/24.6.1000; SMITH HA, 1994, PLANT CELL, V6, P1441, DOI 10.1105/tpc.6.10.1441; VANBLOKLAND R, 1994, PLANT J, V6, P861, DOI 10.1046/j.1365-313X.1994.6060861.x; VANDERKROL AR, 1990, PLANT CELL, V2, P291, DOI 10.1105/tpc.2.4.291; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	31	240	273	1	19	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	MAR 21	1997	88	6					845	854		10.1016/S0092-8674(00)81930-3	http://dx.doi.org/10.1016/S0092-8674(00)81930-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WQ100	9118227	Bronze			2022-12-01	WOS:A1997WQ10000016
J	Washburn, T; Schweighoffer, E; Gridley, T; Chang, D; Fowlkes, BJ; Cado, D; Robey, E				Washburn, T; Schweighoffer, E; Gridley, T; Chang, D; Fowlkes, BJ; Cado, D; Robey, E			Notch activity influences the alpha beta versus gamma delta T cell lineage decision	CELL			English	Article							DROSOPHILA-NOTCH; THYMOCYTE DEVELOPMENT; RAG-1-DEFICIENT MICE; CD8 EXPRESSION; RECEPTOR GENE; HOMOLOG; DIFFERENTIATION; REARRANGEMENT; COMMITMENT; PRECURSOR	The choice between the alpha beta or gamma delta T cell fates is influenced by the production of functional, in-frame rearrangements of the TCR genes, but the mechanism that controls the lineage choice is not known. Here, we show that T cells that are heterozygous for a mutation of the Notch1 gene are more likely to develop as gamma delta T cells than as alpha beta T cells, implying that reduced Notch activity favors the ya T cell fate over the alpha beta T cell fate. A constitutively activated form of Notch produces a reciprocal phenotype and induces thymocytes that have functional gamma delta TCR gene rearrangements to adopt the alpha beta T cell fate. Our data indicate that Notch acts together with the newly formed T cell antigen receptor to direct the alpha beta versus gamma delta T cell lineage decision.	JACKSON LAB,BAR HARBOR,ME 04609; NIAID,CELLULAR & MOL IMMUNOL LAB,NIH,BETHESDA,MD 20892	Jackson Laboratory; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Washburn, T (corresponding author), UNIV CALIF BERKELEY,DEPT MOL & CELL BIOL,229 STANLEY HALL,BERKELEY,CA 94720, USA.							ALLISON JP, 1993, CURR OPIN IMMUNOL, V5, P241, DOI 10.1016/0952-7915(93)90011-G; ALLISON JP, 1987, IMMUNOL TODAY, V8, P293, DOI 10.1016/0167-5699(87)90014-4; Beitel GJ, 1995, GENE DEV, V9, P3149, DOI 10.1101/gad.9.24.3149; BLUESTONE JA, 1991, IMMUNOL REV, V120, P5, DOI 10.1111/j.1600-065X.1991.tb00585.x; BONNEVILLE M, 1990, NATURE, V344, P163, DOI 10.1038/344163a0; CHAFFIN KE, 1990, EMBO J, V9, P3821, DOI 10.1002/j.1460-2075.1990.tb07600.x; CHIEN YH, 1987, NATURE, V327, P677, DOI 10.1038/327677a0; CHITNIS A, 1995, NATURE, V375, P761, DOI 10.1038/375761a0; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; Coligan JE., 1994, CURRENT PROTOCOLS IM; CONLON RA, 1995, DEVELOPMENT, V121, P1533; DELAMO FF, 1992, DEVELOPMENT, V115, P737; DENT AL, 1990, NATURE, V343, P714, DOI 10.1038/343714a0; DUDLEY EC, 1995, CURR BIOL, V5, P659, DOI 10.1016/S0960-9822(95)00131-X; FEHLING HJ, 1995, NATURE, V375, P795, DOI 10.1038/375795a0; Girard L, 1996, GENE DEV, V10, P1930, DOI 10.1101/gad.10.15.1930; GODFREY DI, 1993, J IMMUNOL, V150, P4244; Hasserjian RP, 1996, BLOOD, V88, P970, DOI 10.1182/blood.V88.3.970.bloodjournal883970; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; KANG J, 1995, EUR J IMMUNOL, V25, P2706, DOI 10.1002/eji.1830250946; KATZ WS, 1995, CELL, V82, P297, DOI 10.1016/0092-8674(95)90317-8; KERSH GJ, 1995, J IMMUNOL, V154, P5706; LARDELLI M, 1993, EXP CELL RES, V204, P364, DOI 10.1006/excr.1993.1044; LARDELLI M, 1994, MECH DEVELOP, V46, P123, DOI 10.1016/0925-4773(94)90081-7; LIVAK F, 1995, IMMUNITY, V2, P617, DOI 10.1016/1074-7613(95)90006-3; LYNCH F, 1993, INT IMMUNOL, V5, P991, DOI 10.1093/intimm/5.8.991; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; PARDOLL DM, 1987, NATURE, V326, P79, DOI 10.1038/326079a0; PETRIE HT, 1992, EUR J IMMUNOL, V22, P2185, DOI 10.1002/eji.1830220836; RAULET DH, 1991, IMMUNOL REV, V120, P185, DOI 10.1111/j.1600-065X.1991.tb00592.x; Robey E, 1996, CELL, V87, P483, DOI 10.1016/S0092-8674(00)81368-9; ROBEY E, 1994, ANNU REV IMMUNOL, V12, P675, DOI 10.1146/annurev.iy.12.040194.003331; SAINTRUF C, 1994, SCIENCE, V266, P1208, DOI 10.1126/science.7973703; Schweighoer E, 1996, J EXP MED, V183, P2033, DOI 10.1084/jem.183.5.2033; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; SHORES EW, 1990, EUR J IMMUNOL, V20, P69, DOI 10.1002/eji.1830200111; SIM GK, 1995, J IMMUNOL, V154, P5821; SPANOPOULOU E, 1994, GENE DEV, V8, P1030, DOI 10.1101/gad.8.9.1030; STIFANI S, 1992, NAT GENET, V2, P119, DOI 10.1038/ng1092-119; SWIATEK PJ, 1994, GENE DEV, V8, P707, DOI 10.1101/gad.8.6.707; WEINMASTER G, 1991, DEVELOPMENT, V113, P199; WEINMASTER G, 1992, DEVELOPMENT, V116, P931; WILKINSON HA, 1994, CELL, V79, P1187, DOI 10.1016/0092-8674(94)90010-8	44	352	367	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 21	1997	88	6					833	843		10.1016/S0092-8674(00)81929-7	http://dx.doi.org/10.1016/S0092-8674(00)81929-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WQ100	9118226	Bronze			2022-12-01	WOS:A1997WQ10000015
J	Neal, KR; Hebden, J; Spiller, R				Neal, KR; Hebden, J; Spiller, R			Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: Postal survey of patients	BRITISH MEDICAL JOURNAL			English	Article							CAMPYLOBACTER; SALMONELLA; RAT	Objective: To measure the prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and determine risk factors and associations with postdysenteric symptoms. Design: Postal questionnaire. Setting: Nottingham Health Authority. Subjects: 544 people with microbiologically confirmed bacterial gastroenteritis between July 1994 and December 1994. Main outcome measures: Prevalence of gastrointestinal symptoms and relative risks for development of the irritable bowel syndrome and self reported altered bowel habit. Results: A quarter of subjects reported persistence of altered bowel habit six months after an episode of infective gastroenteritis. Increasing duration of diarrhoea, younger age, and female sex increased this risk, whereas vomiting as part of the illness reduced the risk. One in 14 developed the irritable bowel University of syndrome with an increased risk seen in women Nottingham, (relative risk 3.4; 95% confidence interval 1.2 to 9.8) and with duration of diarrhoea (6.5; 1.3 to 34 for 15-21 days). Conclusions: Persistence of bowel symptoms commonly occurs after bacterial gastroenteritis and is responsible for considerable morbidity and health care costs.	UNIV NOTTINGHAM,QUEENS MED CTR,DEPT GASTROENTEROL,NOTTINGHAM NG7 2UH,ENGLAND	University of Nottingham	Neal, KR (corresponding author), UNIV NOTTINGHAM,DEPT PUBL HLTH MED,NOTTINGHAM NG7 2UH,ENGLAND.		spiller, robin/ABE-6690-2021	spiller, robin/0000-0001-6371-4500				CHAUDHARY NA, 1962, Q J MED, V31, P307; COLLINS SM, 1994, EUR J GASTROEN HEPAT, V6, P478, DOI 10.1097/00042737-199406000-00005; EVEREST PH, 1992, J MED MICROBIOL, V37, P319, DOI 10.1099/00222615-37-5-319; FELDMAN RA, 1994, EPIDEMIOL INFECT, V113, P41, DOI 10.1017/S095026880005144X; Gwee KA, 1996, LANCET, V347, P150, DOI 10.1016/S0140-6736(96)90341-4; HARVEY RF, 1987, LANCET, V1, P963; KUBOTA Y, 1992, GASTROENTEROLOGY, V102, P1242; MCHUGH KJ, 1993, GASTROENTEROLOGY, V104, pA1051; MCKENDRICK MW, 1994, J INFECTION, V29, P1, DOI 10.1016/S0163-4453(94)94871-2; SANDLER RS, 1984, GASTROENTEROLOGY, V87, P314; SKIRROW MB, 1987, EPIDEMIOL INFECT, V99, P647, DOI 10.1017/S0950268800066504; SWAIN MG, 1991, GASTROENTEROLOGY, V100, P675, DOI 10.1016/0016-5085(91)80011-W; Thompson WG., 1989, GASTROENTEROL INT, V2, P92; Wall P G, 1996, Commun Dis Rep CDR Rev, V6, pR93; WILLIAMS CL, 1995, NEUROGASTROENT MOTIL, V7, P292	15	424	464	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 15	1997	314	7083					779	782		10.1136/bmj.314.7083.779	http://dx.doi.org/10.1136/bmj.314.7083.779			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN646	9080994	Green Published			2022-12-01	WOS:A1997WN64600021
J	Miller, A; Wood, D; Ebright, RH; RothmanDenes, OB				Miller, A; Wood, D; Ebright, RH; RothmanDenes, OB			RNA polymerase beta' subunit: A target of DNA binding-independent activation	SCIENCE			English	Article							ESCHERICHIA-COLI; IN-VITRO; TRANSCRIPTION; PROTEIN; DOMAIN; PROMOTER; IDENTIFICATION; NIFA	The bacteriophage N4 single-stranded DNA binding protein (N4SSB) activates transcription by the Escherichia coli sigma 70-RNA polymerase at N4 late promoters. Here it is shown that the single-stranded DNA binding activity of N4SSB is not required for transcriptional activation. N4SSB interacts with the carboxyl terminus of the RNA polymerase beta' subunit in a region that is highly conserved in the largest subunits of prokaryotic and eukaryotic RNA polymerases.	UNIV CHICAGO,DEPT MOL GENET & CELL BIOL,CHICAGO,IL 60637; UNIV CHICAGO,DEPT BIOCHEM & MOL BIOL,CHICAGO,IL 60637; RUTGERS STATE UNIV,DEPT CHEM,NEW BRUNSWICK,NJ 08855; RUTGERS STATE UNIV,WAKSMAN INST,NEW BRUNSWICK,NJ 08855	University of Chicago; University of Chicago; Rutgers State University New Brunswick; Rutgers State University New Brunswick			Ebright, Richard/O-3321-2019	Ebright, Richard/0000-0001-8915-7140	NIGMS NIH HHS [GM54431, GM35170, GM41376] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041376] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akhtar A, 1996, EMBO J, V15, P4654, DOI 10.1002/j.1460-2075.1996.tb00842.x; BARBERIS A, 1995, CELL, V81, P359, DOI 10.1016/0092-8674(95)90389-5; BERGER DK, 1994, P NATL ACAD SCI USA, V91, P103, DOI 10.1073/pnas.91.1.103; BORUKHOV S, 1993, J BIOL CHEM, V268, P23477; BUSBY S, 1994, CELL, V79, P743, DOI 10.1016/0092-8674(94)90063-9; CHEN Y, 1994, SCIENCE, V265, P90, DOI 10.1126/science.8016656; CHO NJ, UNPUB; CHO NY, 1995, J MOL BIOL, V246, P461, DOI 10.1006/jmbi.1994.0098; CHOI MY, 1995, J BIOL CHEM, V270, P22541, DOI 10.1074/jbc.270.38.22541; Christie GE, 1996, J BACTERIOL, V178, P6991, DOI 10.1128/jb.178.23.6991-6993.1996; CORDEN JL, 1992, TRANSCRIPTIONAL REGU, P81; DOVE SL, UNPUB; Ebright YW, 1996, BIOCONJUGATE CHEM, V7, P380, DOI 10.1021/bc9600168; EMILI A, 1995, CURR OPIN GENET DEV, V5, P204, DOI 10.1016/0959-437X(95)80009-3; Farrell S, 1996, GENE DEV, V10, P2359, DOI 10.1101/gad.10.18.2359; GERBER HP, 1995, NATURE, V374, P660, DOI 10.1038/374660a0; HUALA E, 1989, J BACTERIOL, V171, P3354, DOI 10.1128/jb.171.6.3354-3365.1989; ISAKSSON LA, 1977, MOL GEN GENET, V156, P233, DOI 10.1007/BF00267177; JOKERST RS, 1989, MOL GEN GENET, V215, P266, DOI 10.1007/BF00339727; JOSAITIS CA, 1995, P NATL ACAD SCI USA, V92, P1117, DOI 10.1073/pnas.92.4.1117; KASHLEV M, 1993, GENE, V130, P9, DOI 10.1016/0378-1119(93)90340-9; KUDELL N, 1994, J BACTERIOL, V176, P2991; Leuther KK, 1996, CELL, V85, P773, DOI 10.1016/S0092-8674(00)81242-8; LI M, 1994, SCIENCE, V263, P75, DOI 10.1126/science.8272867; LINDBERG G, 1989, J BIOL CHEM, V264, P12700; MARTIN C, 1990, MOL CELL BIOL, V10, P1908, DOI 10.1128/MCB.10.5.1908; Meredith GD, 1996, J MOL BIOL, V258, P413, DOI 10.1006/jmbi.1996.0258; MILLER A, 1996, METHOD ENZYMOL, V174, P9; Miller A.B., UNPUB; Niu W, 1996, CELL, V87, P1123, DOI 10.1016/S0092-8674(00)81806-1; NONET ML, 1989, GENETICS, V123, P715; NORTH A, IN PRESS J MOL BIOL; OBRIEN T, 1994, NATURE, V370, P75, DOI 10.1038/370075a0; SARIS CJM, 1983, ANAL BIOCHEM, V132, P54, DOI 10.1016/0003-2697(83)90425-6; SCAFE C, 1990, NATURE, V347, P491, DOI 10.1038/347491a0; TANG H, 1995, P NATL ACAD SCI USA, V92, P4902, DOI 10.1073/pnas.92.11.4902; XIAO H, 1994, MOL CELL BIOL, V14, P7507, DOI 10.1128/MCB.14.11.7507; ZIVIN R, 1981, J MOL BIOL, V152, P335, DOI 10.1016/0022-2836(81)90246-1	38	59	60	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 14	1997	275	5306					1655	1657		10.1126/science.275.5306.1655	http://dx.doi.org/10.1126/science.275.5306.1655			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WN123	9054361				2022-12-01	WOS:A1997WN12300049
J	Stern, Y; Tang, MX; Albert, MS; Brandt, J; Jacobs, DM; Bell, K; Marder, K; Sano, M; Devanand, D; Albert, SM; Bylsma, F; Tsai, WY				Stern, Y; Tang, MX; Albert, MS; Brandt, J; Jacobs, DM; Bell, K; Marder, K; Sano, M; Devanand, D; Albert, SM; Bylsma, F; Tsai, WY			Predicting time to nursing home care and death in individuals with Alzheimer disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							APOLIPOPROTEIN-E; EXTRAPYRAMIDAL SIGNS; ONSET; SURVIVAL; PROGRESSION; IMPAIRMENT; DECLINE; MEMORY; ALLELE	Objective.-To develop and validate an approach that uses clinical features that can be determined in a standard patient visit to estimate the length of time before an individual patient with Alzheimer disease (AD) requires care equivalent to nursing home placement or dies. Design.-Prospective cohort study of 236 patients, followed up semiannually for up to 7 years, A second validation cohort of 105 patients was also followed. Setting.-Three AD research centers. Patients.-All patients met National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria for probable AD and had mild dementia at the initial visit. Intervention.-Predictive features, ascertained at the initial visit, were sex, duration of illness, age at onset, modified Mini-Mental State Examination (mMMS) score, and the presence or absence of extrapyramidal signs or psychotic features. Main Outcome Measures.-(1) Requiring the equivalent of nursing home placement and (2) death. Results.-Prediction algorithms were constructed for the 2 outcomes based on Cox proportional hazard models, For each algorithm, a predictor index is calculated based on the status of each predictive feature at the initial visit, A table that specifies the number of months in which 25%, 50%, and 75% of patients with any specific predictor index value are likely to reach the end point is then consulted. Survival curves for time to need for care equivalent to nursing home placement and for time to death derived from the algorithms for selected predictor indexes fell within the 95% confidence bands of actual survival curves for patients. When the predictor variables from the initial visit for the validation cohort patients were entered into the algorithm, the predicted survival curves for time to death fell within the 95% confidence bands of actual survival curves for the patients. Conclusions.-The prediction algorithms are a first but promising step toward providing specific prognoses to patients, families, and practitioners, This approach also has clear implications for the design and interpretation of clinical trials in patients with AD.	COLUMBIA UNIV COLL PHYS & SURG, DEPT NEUROL, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT PSYCHIAT, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT BIOSTAT, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, TAUB CTR ALZHEIMERS DIS RES, NEW YORK, NY 10032 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PSYCHIAT & BEHAV SCI, BALTIMORE, MD 21205 USA; HARVARD UNIV, MASSACHUSETTS GEN HOSP, SCH MED, DEPT PSYCHIAT, BOSTON, MA USA; HARVARD UNIV, MASSACHUSETTS GEN HOSP, SCH MED, DEPT NEUROL, BOSTON, MA USA	Columbia University; Columbia University; Columbia University; Columbia University; Johns Hopkins University; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital	Stern, Y (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, GERTRUDE H SERGIEVSKY CTR, 630 W 168TH ST, NEW YORK, NY 10032 USA.			Albert, Steven/0000-0001-6786-9956; Jacobs, Diane/0000-0003-0886-6784; Stern, Yaakov/0000-0001-7542-3241; Brandt, Jason/0000-0001-7381-6244	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000645] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG007370, P01AG007232] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00645] Funding Source: Medline; NIA NIH HHS [AG07370, AG07232] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BLESSED G, 1968, BRIT J PSYCHIAT, V114, P797, DOI 10.1192/bjp.114.512.797; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; CHUI HC, 1992, RES PER ALZ, P12; COLLET D, 1994, MODELLING SUVIVAL DA, P153; CORDER EH, 1995, NEUROLOGY, V45, P1323, DOI 10.1212/WNL.45.7.1323; DEVANAND DP, 1992, ARCH NEUROL-CHICAGO, V49, P371, DOI 10.1001/archneur.1992.00530280051022; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FRISONI GB, 1995, ANN NEUROL, V37, P596, DOI 10.1002/ana.410370509; HIXSON J, 1991, J LIPID RES, V31, P545; HUGHES CP, 1982, BRIT J PSYCHIAT, V140, P566, DOI 10.1192/bjp.140.6.566; JACOBS D, 1994, NEUROLOGY, V44, P1215, DOI 10.1212/WNL.44.7.1215; KATZMAN R, 1983, AM J PSYCHIAT, V140, P734; MAYEUX R, 1987, NEUROLOGY, V37, P1130, DOI 10.1212/WNL.37.7.1130; MAYEUX R, 1981, NEUROLOGY, V31, P645, DOI 10.1212/WNL.31.6.645; MAYEUX RP, 1987, NEUROLOGY, V37, P1693, DOI 10.1212/WNL.37.10.1693-a; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MORTIMER JA, 1992, NEUROLOGY, V42, P1689, DOI 10.1212/WNL.42.9.1689; RICHARDS M, 1991, ARCH NEUROL-CHICAGO, V48, P1147, DOI 10.1001/archneur.1991.00530230055021; SANO M, 1987, J CLIN EXP NEUROPSYC, V9, P65; STERN MB, 1978, COMPREHENSIVE MANAGE, P3; STERN Y, 1987, Neurology, V37, P179; STERN Y, 1987, NEUROLOGY, V37, P1649, DOI 10.1212/WNL.37.10.1649; STERN Y, 1994, NEUROLOGY, V44, P2300, DOI 10.1212/WNL.44.12.2300; STERN Y, 1993, ALZ DIS ASSOC DIS, V7, P3, DOI 10.1097/00002093-199307010-00002; STERN Y, 1989, B CLIN NEUROSCI, V54, P73; STERN Y, 1994, J GERONTOL, V49, P7216; TYSNES OB, 1994, NEUROEPIDEMIOLOGY, V13, P226, DOI 10.1159/000110384; VANDUIJN CM, 1995, ANN NEUROL, V37, P605, DOI 10.1002/ana.410370510; Wechsler D, 1981, ADULT INTELLIGENCE S	29	264	264	0	17	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 12	1997	277	10					806	812		10.1001/jama.277.10.806	http://dx.doi.org/10.1001/jama.277.10.806			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WM082	9052710	Green Submitted			2022-12-01	WOS:A1997WM08200033
J	Kristenson, M; Zieden, B; Kucinskiene, Z; Elinder, LS; Bergdahl, B; Elwing, B; Abaravicius, A; Razinkoviene, L; Calkauskas, H; Olsson, AG				Kristenson, M; Zieden, B; Kucinskiene, Z; Elinder, LS; Bergdahl, B; Elwing, B; Abaravicius, A; Razinkoviene, L; Calkauskas, H; Olsson, AG			Antioxidant state and mortality from coronary heart disease in Lithuanian and Swedish men: Concomitant cross sectional study of men aged 50	BRITISH MEDICAL JOURNAL			English	Article							LOW-DENSITY-LIPOPROTEIN; MYOCARDIAL-INFARCTION; RISK-FACTORS; VITAMIN-C; PLASMA; OXIDATION; CAROTENE; ATHEROSCLEROSIS; SUSCEPTIBILITY		LINKOPING UNIV,FAC HLTH SCI,DEPT MED & CARE,S-58185 LINKOPING,SWEDEN; FAC HLTH SCI,CLIN RES CTR,S-58185 LINKOPING,SWEDEN; FAC MED VILNIUS,DEPT PHYSIOL & BIOCHEM,LT-2021 VILNIUS,LITHUANIA; KAROLINSKA INST,FAC MED,DEPT MED BIOCHEM & BIOPHYS,S-17177 STOCKHOLM,SWEDEN; CTR PUBL HLTH SCI,DEPT PREVENT MED,S-58185 LINKOPING,SWEDEN; FAC MED VILNIUS,DEPT GASTROENTEROL & DIETET,LT-2021 VILNIUS,LITHUANIA; LINKOPING UNIV,FAC HLTH SCI,DEPT HLTH & ENVIRONM,S-58185 LINKOPING,SWEDEN	Linkoping University; Karolinska Institutet; Linkoping University			Elinder, Liselotte Schäfer/R-4500-2019; Elinder, Liselotte S/J-4677-2012	Elinder, Liselotte Schäfer/0000-0001-7270-1162; Elinder, Liselotte S/0000-0001-7270-1162				ANDREWS B, 1995, ATHEROSCLEROSIS, V112, P77, DOI 10.1016/0021-9150(94)05401-4; BINGHAM SA, 1987, MANUAL METHODOLOGY F, V57, P53; Bobak M, 1996, BRIT MED J, V312, P421; BOSMA H, 1994, INT J EPIDEMIOL, V23, P12, DOI 10.1093/ije/23.1.12; COMINACINI L, 1993, ATHEROSCLEROSIS, V99, P63, DOI 10.1016/0021-9150(93)90051-U; ELINDER LS, 1992, J LIPID RES, V33, P131; EVANS AE, 1995, QJM-INT J MED, V88, P469; FEACHEM R, 1994, NATURE, V367, P313, DOI 10.1038/367313a0; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GEY KF, 1993, CLIN INVESTIGATOR, V71, P3, DOI 10.1007/BF00210955; Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801; KARDINAAL AFM, 1993, LANCET, V342, P1379, DOI 10.1016/0140-6736(93)92751-E; KARDINAAL AFM, 1995, ARTERIOSCL THROM VAS, V15, P726, DOI 10.1161/01.ATV.15.6.726; KLEINVELD HA, 1992, CLIN CHEM, V38, P2066; LOGAN RL, 1978, LANCET, V1, P949; MENSINK RP, 1992, ARTERIOSCLER THROMB, V12, P911, DOI 10.1161/01.ATV.12.8.911; MOLGAARD J, 1988, EUR HEART J, V9, P541; *NAT FOOD ADM, 1993, FOOD COMP TABL EN NU; Ohrvall M, 1996, J INTERN MED, V239, P111, DOI 10.1046/j.1365-2796.1996.410753000.x; OLSSON AG, 1988, ACTA MED SCAND, V223, P3; Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802; PAJAK A, 1988, World Health Statistics Quarterly, V41, P115; REGNSTROM J, 1992, LANCET, V339, P1183, DOI 10.1016/0140-6736(92)91129-V; RIEMERSMA RA, 1991, LANCET, V337, P1, DOI 10.1016/0140-6736(91)93327-6; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; SKURIHIN IM, 1987, FOOD CHEM COMPOSITIO; Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1; STREET DA, 1994, CIRCULATION, V90, P1154, DOI 10.1161/01.CIR.90.3.1154; UEMURA K, 1988, World Health Statistics Quarterly, V41, P155; *UN, 1994, CRIS MORT HLTH NUTR; *WHO, 1989, MEAS OB CLASS DESCR; WILLIAMSON DF, 1993, AM J HUM BIOL, V15, P159; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499	33	140	143	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 1	1997	314	7081					629	633		10.1136/bmj.314.7081.629	http://dx.doi.org/10.1136/bmj.314.7081.629			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WL418	9066473	Green Published			2022-12-01	WOS:A1997WL41800019
J	Xu, XH; Yeung, ES				Xu, XH; Yeung, ES			Direct measurement of single-molecule diffusion and photodecomposition in free solution	SCIENCE			English	Article							LASER-INDUCED FLUORESCENCE; DNA-MOLECULES; MICRODROPLETS	Continuous monitoring of submillisecond free-solution dynamics of individual rhodamine-6G molecules and 30-base single-stranded DNA tagged with rhodamine was achieved. Fluorescence images were recorded from the same set of isolated molecules excited either through the evanescent field at the quartz-liquid interface or as a thin layer of solution defined by micron-sized wires, giving diffraction-limited resolution of interconnected attoliter volume elements. The single-molecule diffusion coefficients were smaller and the unimolecular photodecomposition lifetimes were longer for the dye-DNA covalent complex as compared with those of the dye molecule itself. Unlike bulk studies, stochastic behavior was found for individual molecules of each type, and smaller diffusion coefficients were observed.	IOWA STATE UNIV SCI & TECHNOL,DEPT CHEM,AMES LAB,US DOE,AMES,IA 50011	Iowa State University; United States Department of Energy (DOE); Ames National Laboratory								ANDERSON LB, 1967, J CHEM EDUC, V44, P9, DOI 10.1021/ed044p9; ATKINS PW, 1982, PHYSICAL CHEM, P823; BARNES MD, 1995, ANAL CHEM, V67, pA418, DOI 10.1021/ac00109a001; BETZIG E, 1993, SCIENCE, V262, P1422, DOI 10.1126/science.262.5138.1422; CASTRO A, 1993, ANAL CHEM, V65, P849, DOI 10.1021/ac00055a004; COLLINSON MM, 1995, SCIENCE, V268, P1883, DOI 10.1126/science.268.5219.1883; Dickson RM, 1996, SCIENCE, V274, P966, DOI 10.1126/science.274.5289.966; DOVICHI NJ, 1983, SCIENCE, V219, P845, DOI 10.1126/science.6823553; EIGEN M, 1994, P NATL ACAD SCI USA, V91, P5740, DOI 10.1073/pnas.91.13.5740; FAN FRF, 1995, SCIENCE, V267, P871, DOI 10.1126/science.267.5199.871; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; JETT JH, 1989, J BIOMOL STRUCT DYN, V7, P301, DOI 10.1080/07391102.1989.10507773; LEE YH, 1994, ANAL CHEM, V66, P4142, DOI 10.1021/ac00095a005; Macklin JJ, 1996, SCIENCE, V272, P255, DOI 10.1126/science.272.5259.255; MATHIES RA, 1990, ANAL CHEM, V62, P1786, DOI 10.1021/ac00216a012; Mets U, 1994, J Fluoresc, V4, P259, DOI 10.1007/BF01878461; NG KC, 1992, ANAL CHEM, V64, P2914, DOI 10.1021/ac00047a007; NIE SM, 1995, ANAL CHEM, V67, P2849, DOI 10.1021/ac00113a019; ROTMAN B, 1961, P NATL ACAD SCI USA, V47, P1981, DOI 10.1073/pnas.47.12.1981; Schmidt T, 1996, P NATL ACAD SCI USA, V93, P2926, DOI 10.1073/pnas.93.7.2926; SMITH SB, 1989, SCIENCE, V243, P203, DOI 10.1126/science.2911733; SOPER SA, 1991, ANAL CHEM, V63, P432, DOI 10.1021/ac00005a009; TELLINGHUISEN J, 1994, ANAL CHEM, V66, P64, DOI 10.1021/ac00073a013; Vale RD, 1996, NATURE, V380, P451, DOI 10.1038/380451a0; WANG J, 1995, PHYS REV LETT, V74, P4317, DOI 10.1103/PhysRevLett.74.4317; WHITTEN WB, 1991, ANAL CHEM, V63, P1027, DOI 10.1021/ac00010a019; XUE QF, 1995, NATURE, V373, P681, DOI 10.1038/373681a0	27	197	220	1	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 21	1997	275	5303					1106	1109		10.1126/science.275.5303.1106	http://dx.doi.org/10.1126/science.275.5303.1106			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WJ503	9027307				2022-12-01	WOS:A1997WJ50300038
J	Lam, YA; Xu, W; DeMartino, GN; Cohen, RE				Lam, YA; Xu, W; DeMartino, GN; Cohen, RE			Editing of ubiquitin conjugates by an isopeptidase in the 26S proteasome	NATURE			English	Article							ATP-DEPENDENT ACTIVATOR; TERMINAL HYDROLASE; 20-S PROTEASOME; PROTEIN; PROTEOLYSIS; INHIBITION; IDENTIFICATION; PURIFICATION; DEGRADATION; NITRILES	In eukaryotes, ubiquitin (Ub)-dependent proteolysis is essential for bulk protein turnover as well as diverse processes including cell-cycle control, differentiation, antigen presentation, and the stress response(1-3). Generally, multiple ubiquitins are added onto a substrate to form an isopeptide-linked 'polyubiquitin' chain, which targets substrates for degradation by the 26S proteasome(4-7). The specificity of Ub-dependent degradation was thought to depend primarily on the selection of targets for ubiquitination, but recently we have reported evidence(8) for a second level of specificity in which (poly)Ub-protein conjugates are partitioned among two fates: degradation of the protein substrate by the 26S proteasome; and disassembly by Ub isopeptidase(s) to regenerate the protein substrate. Potentially, an isopeptidase could influence degradation by 'editing' (poly)Ub-protein conjugates according to the extent of ubiquitination rather than the structure of the ubiquitination target itself. Here we describe a bovine isopeptidase that is well suited to such an editing function because of its unique localization and specificity, This enzyme is an intrinsic subunit of PA700, the 19S regulatory complex of the 26S proteasome. By disassembling the degradation signal from only the distal end of (poly)Ub chains, this isopeptidase can selectively rescue poorly ubiquitinated or slowly degraded Ub-protein conjugates from proteolysis.	UNIV IOWA, DEPT BIOCHEM, IOWA CITY, IA 52242 USA; UNIV TEXAS, SW MED CTR, DEPT PHYSIOL, DALLAS, TX 75235 USA	University of Iowa; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								Beal R, 1996, P NATL ACAD SCI USA, V93, P861, DOI 10.1073/pnas.93.2.861; CHATURVEDI RK, 1967, J AM CHEM SOC, V89, P6984, DOI 10.1021/ja01002a029; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DEMARTINO GN, 1994, J BIOL CHEM, V269, P20878; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; DUFOUR E, 1995, BIOCHEMISTRY-US, V34, P9136, DOI 10.1021/bi00028a024; DUNTEN RL, 1989, J BIOL CHEM, V264, P16739; ECKER DJ, 1989, J BIOL CHEM, V264, P1887; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; EYTAN E, 1993, J BIOL CHEM, V268, P4668; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; HERSHKO A, 1980, P NATL ACAD SCI-BIOL, V77, P1783, DOI 10.1073/pnas.77.4.1783; HERSHKO A, 1987, P NATL ACAD SCI USA, V84, P1829, DOI 10.1073/pnas.84.7.1829; Hilt W, 1996, TRENDS BIOCHEM SCI, V21, P96, DOI 10.1016/0968-0004(96)10012-8; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; Larsen CN, 1996, BIOCHEMISTRY-US, V35, P6735, DOI 10.1021/bi960099f; LIANG TC, 1987, ARCH BIOCHEM BIOPHYS, V252, P626, DOI 10.1016/0003-9861(87)90068-3; MA CP, 1994, J BIOL CHEM, V269, P3539; MA CP, 1992, J BIOL CHEM, V267, P10515; MOON JB, 1986, J AM CHEM SOC, V108, P1350, DOI 10.1021/ja00266a066; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; PICKART CM, 1986, J BIOL CHEM, V261, P210; RUBIN DM, 1995, CURR BIOL, V5, P854, DOI 10.1016/S0960-9822(95)00172-2; SHAEFFER JR, 1995, BIOCHEMISTRY-US, V34, P4015, DOI 10.1021/bi00012a020; Shaeffer JR, 1996, BIOCHEMISTRY-US, V35, P10886, DOI 10.1021/bi9530705; Stock D, 1996, CURR OPIN BIOTECH, V7, P376, DOI 10.1016/S0958-1669(96)80111-X	31	360	369	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 20	1997	385	6618					737	740		10.1038/385737a0	http://dx.doi.org/10.1038/385737a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WJ423	9034192				2022-12-01	WOS:A1997WJ42300050
J	Sporton, SC; Taggart, P; Sutton, PM; Walker, JM; Hardman, SM				Sporton, SC; Taggart, P; Sutton, PM; Walker, JM; Hardman, SM			Acute ischaemia: A dynamic influence on QT dispersion	LANCET			English	Article							VENTRICULAR ARRHYTHMIAS; MYOCARDIAL-ISCHEMIA; CARDIAC DEATH; INFARCTION; INTERVAL; HEART; RECORDINGS	Background The aim of this study was to test the hypothesis that acute myocardial ischaemia increases QT dispersion measured from the 12-lead electrocardiogram. Methods Incremental atrial pacing was used to induce myocardial ischaemia in 18 patients with coronary artery disease and QT dispersion was measured. Six patients with normal coronary arteries served as the control group. Findings All the patients with coronary artery disease developed angina and/or ST depression accompanied by marked increases in QT dispersion (mean increase 38 ms, 95% CI 30 to 45 ms, p<0.001). In contrast patients with normal coronary arteries who without symptoms and without ST changes, there was no significant change in QT dispersion in response to pacing. Baseline QT dispersion did not distinguish those patients with coronary artery disease from those with normal coronary arteries (44 ms [95% CI 39-49 ms] vs 40 ms [25-55 ms]), respectively. Interpretation These results demonstrate that myocardial ischaemia induced by incremental atrial pacing in patients with coronary artery disease causes an acute increase in QT dispersion. Such ''inducible'' QT dispersion may prove more useful than resting QT dispersion in assessing the individual risk of arrhythmic events in patients with coronary artery disease.	UCL, SCH MED, DEPT ACAD & CLIN CARDIOL, LONDON W1N 8AA, ENGLAND; UCL HOSP, DEPT ACAD & CLIN CARDIOL, LONDON, ENGLAND	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of London; University College London				Walker, John Malcolm/0000-0002-8559-7218				BARR CS, 1994, LANCET, V343, P327, DOI 10.1016/S0140-6736(94)91164-9; Bazett HC, 1920, HEART-J STUD CIRC, V7, P353; BUJA G, 1993, AM J CARDIOL, V72, P973, DOI 10.1016/0002-9149(93)91118-2; COWAN JC, 1988, AM J CARDIOL, V61, P83, DOI 10.1016/0002-9149(88)91309-4; DAVIES MJ, 1981, BRIT HEART J, V45, P88; DAY CP, 1990, BRIT HEART J, V63, P342; DAY CP, 1992, BRIT HEART J, V67, P39; GLANCY JM, 1995, LANCET, V345, P945, DOI 10.1016/S0140-6736(95)90697-5; HARDMAN SMC, 1995, CIRCULATION S1, V92, P275; HIGHAM P, 1994, BRIT HEART J, V71, P508; HIGHAM PD, 1995, BRIT HEART J, V73, P32; HNATKOVA K, 1994, BRIT HEART J, V72, P390; JANSE MJ, 1989, PHYSIOL REV, V69, P1049, DOI 10.1152/physrev.1989.69.4.1049; JOHN RM, 1991, AM HEART J, V122, P1599, DOI 10.1016/0002-8703(91)90277-O; KLEBER AG, 1978, CIRC RES, V42, P603, DOI 10.1161/01.RES.42.5.603; LINKER NJ, 1992, AM J CARDIOL, V69, P634, DOI 10.1016/0002-9149(92)90155-R; MORENA H, 1980, CIRC RES, V46, P634, DOI 10.1161/01.RES.46.5.634; PYE M, 1994, BRIT HEART J, V71, P511; ZAREBA W, 1994, AM J CARDIOL, V74, P550, DOI 10.1016/0002-9149(94)90742-0	19	141	149	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	FEB 1	1997	349	9048					306	309		10.1016/S0140-6736(96)06143-0	http://dx.doi.org/10.1016/S0140-6736(96)06143-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF794	9024372				2022-12-01	WOS:A1997WF79400008
J	Holby, N; Jarlov, JO; Kemp, M; Tvede, M; Bangsborg, JM; Kjerulf, A; Pers, C; Hansen, H				Holby, N; Jarlov, JO; Kemp, M; Tvede, M; Bangsborg, JM; Kjerulf, A; Pers, C; Hansen, H			Excretion of ciprofloxacin in sweat and multiresistant Staphylococcus epidermidis	LANCET			English	Article							COAGULASE-NEGATIVE STAPHYLOCOCCI; PSEUDOMONAS-AERUGINOSA; RESISTANT; SKIN; UNIT	Background Staphylococcus epidermidis develops resistance to ciprofloxacin rapidly. That this antibiotic is excreted in apocrine and eccrine sweat of healthy individuals might be the reason for the development of such resistance. We assessed whether S epidermidis isolated from the axilla and nasal flora of healthy people could develop resistance to ciprofloxacin after a 1-week course of this antibiotic. Methods The concentration of ciprofloxacin in sweat was measured in seven volunteers after oral administration of 750 mg ciprofloxacin twice daily for 7 days, and the development of resistance in S epidermidis from axilla and nostrils was monitored during and 2 months after the treatment. Genotyping of S epidermidis was done by restriction fragment length polymorphism. Findings The mean concentration of ciprofloxacin in sweat increased during the 7 days of treatment-from 2.2 mu g/mL 2.5 h after the first tablet to 2.5 mu g/mL after the fifth tablet, and 5.5 mu g/mL after the 13th tablet. All persons harboured susceptible S epidermidis (minimal inhibitory concentration [MIC] 0.25 mu g/ml) in axilla and nostrils before treatment. Four resistant drains were detected, two intermediate level (MIC 4-12 mu g/ml) and two high-level (MI >32 mu g/mL). Three of these strains were found in all the participants, and a ciprofloxacin-sensitive variant of one of the high-level resistant strains was also found before the start of the treatment. The high-level resistant strains were also resistant to methicillin, erythromycin, gentamicin, sulphonamide, and trimethoprim. A mean of 2 7 days after the start of the treatment, development of ciprofloxacin resistance was detected in S epidermidis from the axilla of all persons, compared with 11 days for the appearance of resistant S epidermidis in nostrils. The resistant strains persisted for an average of 37 and 39 days in axilla and nostrils, respectively, after the end of the treatment. Interpretation The rapid development of resistance to ciprofloxacin due to excretion of this drug into the sweat might be involved in the development of multiresistant S epidermidis and possibly other shin bacteria in hospitals and in communities with high use of ciprofloxacin or related drugs.			Holby, N (corresponding author), UNIV COPENHAGEN,RIGSHOSP,DEPT CLIN MICROBIOL 9301,JULIANE MARIES VEJ 22,DK-2100 COPENHAGEN O,DENMARK.		Kemp, Michael/AAY-3017-2021	Kemp, Michael/0000-0001-5989-0421; Hoiby, Niels/0000-0002-1347-725X				ARCHER GL, 1991, REV INFECT DIS S10, V13, P805; COYLE MB, 1990, CLIN MICROBIOL REV, V3, P227, DOI 10.1128/CMR.3.3.227-246.1990; DALHOFF A, 1994, INFECTION, V22, pS111, DOI 10.1007/BF01793575; Davis R, 1996, DRUGS, V51, P1019, DOI 10.2165/00003495-199651060-00010; DRYDEN MS, 1992, EPIDEMIOL INFECT, V109, P97; FORSTALL GJ, 1991, ANTIMICROB AGENTS CH, V35, P1679, DOI 10.1128/AAC.35.8.1679; HARRIS R, 1983, ANTIMICROB AGENTS CH, V24, P876, DOI 10.1128/AAC.24.6.876; HEDIN G, 1991, J HOSP INFECT, V17, P95, DOI 10.1016/0195-6701(91)90173-6; HOIBY N, 1995, LANCET, V346, P1235, DOI 10.1016/S0140-6736(95)92946-0; IMAYAMA S, 1994, J ALLERGY CLIN IMMUN, V94, P195, DOI 10.1016/0091-6749(94)90040-X; Jarlov JO, 1996, J HOSP INFECT, V32, P217, DOI 10.1016/S0195-6701(96)90148-6; JARLOV JO, 1994, APMIS, V102, P272, DOI 10.1111/j.1699-0463.1994.tb04875.x; JONES HE, 1990, J AM ACAD DERMATOL, V23, P779, DOI 10.1016/0190-9622(90)70287-R; MONTES LF, 1970, ARCH DERMATOL, V101, P145, DOI 10.1001/archderm.101.2.145; Ng EY, 1996, ANTIMICROB AGENTS CH, V40, P1881, DOI 10.1128/AAC.40.8.1881; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; OJENIYI B, 1991, APMIS, V99, P492, DOI 10.1111/j.1699-0463.1991.tb05181.x; OPPENHEIM BA, 1989, BRIT MED J, V299, P294, DOI 10.1136/bmj.299.6694.294; ROTH RR, 1988, ANNU REV MICROBIOL, V42, P441, DOI 10.1146/annurev.mi.42.100188.002301; SATO K, 1987, DERMATOLOGY GEN MED, P195; SHAH VP, 1974, J CLIN INVEST, V53, P1673, DOI 10.1172/JCI107718; Sloos Jacobus H., 1996, Clin Microbiol Infect, V2, P44, DOI 10.1111/j.1469-0691.1996.tb00199.x; SORGEL F, 1988, J ANTIMICROB CHEMOTH, V22, P155, DOI 10.1093/jac/22.Supplement_D.155; SORGEL F, 1991, AM J MED, V91, P51; STRAUSBAUGH LJ, 1976, ANTIMICROB AGENTS CH, V10, P450, DOI 10.1128/AAC.10.3.450; Takenouchi T, 1996, ANTIMICROB AGENTS CH, V40, P1835, DOI 10.1128/AAC.40.8.1835; TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233, DOI 10.1128/JCM.33.9.2233-2239.1995	27	103	104	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 18	1997	349	9046					167	169		10.1016/S0140-6736(96)09229-X	http://dx.doi.org/10.1016/S0140-6736(96)09229-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC861	9111541				2022-12-01	WOS:A1997WC86100011
J	Crosthwaite, SK; Dunlap, JC; Loros, JJ				Crosthwaite, SK; Dunlap, JC; Loros, JJ			Neurospora wc-1 and wc-2: Transcription, photoresponses, and the origins of circadian rhythmicity	SCIENCE			English	Article							CLOCK-CONTROLLED GENE; PHYTOCHROME-A; SUPRACHIASMATIC NUCLEUS; SIGNAL-TRANSDUCTION; REGULATORY ACTIVITY; DROSOPHILA PERIOD; BIOLOGICAL CLOCK; LIGHT INDUCTION; TERMINAL-DOMAIN; CRASSA	Circadian rhythmicity is universally associated with the ability to perceive light, and the oscillators (''clocks'') giving rise to these rhythms, which are feedback loops based on transcription and translation, are reset by light. Although such loops must contain elements of positive and negative regulation, the clock genes analyzed to date-frq in Neurospora and per and tim in Drosophila-are associated only with negative feedback and their biochemical functions are largely inferred. The white collar-1 and white collar-2 genes, both global regulators of photoresponses in Neurospora, encode DNA binding proteins that contain PAS domains and are believed to act as transcriptional activators. Data shown here suggest that wc-1 is a clock-associated gene and wc-2 is a clock component; both play essential roles in the assembly or operation of the Neurospora circadian oscillator. Thus DNA binding and transcriptional activation can now be associated with a clock gene that may provide a positive element in the feedback loop. In addition, similarities between the PAS-domain regions of molecules involved in light perception and circadian rhythmicity in several organisms suggest an evolutionary link between ancient photoreceptor proteins and more modern proteins required for circadian oscillation.	DARTMOUTH COLL SCH MED,DEPT BIOCHEM,HANOVER,NH 03755	Dartmouth College			Dunlap, Jay/L-6232-2013; Loros, Jennifer/B-6293-2014	Dunlap, Jay/0000-0003-1577-0457; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034985, R01GM034985] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [K05MH001186, R01MH044651] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 34985] Funding Source: Medline; NIMH NIH HHS [MH01186, MH44651] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARONSON BD, 1994, P NATL ACAD SCI USA, V91, P7683, DOI 10.1073/pnas.91.16.7683; ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; ARPAIA G, 1993, PLANT PHYSIOL, V102, P1299, DOI 10.1104/pp.102.4.1299; ARPAIA G, 1995, MOL GEN GENET, V247, P157, DOI 10.1007/BF00705645; Ballario P, 1996, EMBO J, V15, P1650, DOI 10.1002/j.1460-2075.1996.tb00510.x; BELLPEDERSEN D, 1992, GENE DEV, V6, P2382, DOI 10.1101/gad.6.12a.2382; BELLPEDERSEN D, IN PRESS J GENET; BLOCK G, 1995, CIBA F SYMP, V183, P51; BLOCK GD, 1995, SEMIN NEUROSCI, V7, P37, DOI 10.1016/1044-5765(95)90015-2; BORGSTAHL GEO, 1995, BIOCHEMISTRY-US, V34, P6278, DOI 10.1021/bi00019a004; CAHILL GM, 1995, PROG RETIN EYE RES, V14, P267, DOI 10.1016/1350-9462(94)00001-Y; CHIANG TY, 1994, BIOCHEMISTRY-US, V33, P576, DOI 10.1021/bi00168a024; CORROCHANO LM, 1995, DEV BIOL, V167, P190, DOI 10.1006/dbio.1995.1016; COSTA R, 1992, P ROY SOC B-BIOL SCI, V250, P43, DOI 10.1098/rspb.1992.0128; CROSTHWAITE SK, 1995, CELL, V81, P1003, DOI 10.1016/S0092-8674(05)80005-4; Davis R.H., 1970, METHODS ENZYMOL, V17, P79, DOI DOI 10.1016/0076-6879(71)17168-6; Degli Innocenti F, 1984, BLUE LIGHT EFFECTS B, P213; Dunlap JC, 1996, ANNU REV GENET, V30, P579, DOI 10.1146/annurev.genet.30.1.579; ELICH TD, 1994, PLANT MOL BIOL, V26, P1315, DOI 10.1007/BF00016477; FRANCIS CD, 1979, PLANT PHYSIOL, V64, P1000, DOI 10.1104/pp.64.6.1000; GARCEAU N, IN PRESS CELL; GEKAKIS N, 1995, SCIENCE, V270, P811, DOI 10.1126/science.270.5237.811; GILES NH, 1985, MICROBIOL REV, V49, P338, DOI 10.1128/MMBR.49.3.338-358.1985; GOLDBETTER A, 1996, BIOCH OSCILLATIONS C; GOOCH VD, 1994, J BIOL RHYTHM, V9, P83, DOI 10.1177/074873049400900108; Goodwin B., 1963, TEMPORAL ORG CELLS; Grace MS, 1996, J COMP NEUROL, V367, P575; HALL JC, 1995, TRENDS NEUROSCI, V18, P230, DOI 10.1016/0166-2236(95)93908-G; Hall JC, 1996, NEURON, V17, P799, DOI 10.1016/S0896-6273(00)80211-1; HARDIN P, 1995, SEMIN NEUROSCI, V7, P15, DOI 10.1016/1044-5765(95)90013-6; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HARDIN PE, 1992, EMBO J, V12, P1; Harding R, 1983, PLANT PHYSIOL, V72, P745; HARDING RW, 1980, ANNU REV PLANT PHYS, V31, P217, DOI 10.1146/annurev.pp.31.060180.001245; HASTINGS MH, 1995, CIBA F SYMP, V183, P175; HOTZVITATERNA M, 1994, SCIENCE, V264, P719; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; Koh M, 1996, BIOCHEMISTRY-US, V35, P2526, DOI 10.1021/bi951494t; KUDLA B, 1990, EMBO J, V9, P1355, DOI 10.1002/j.1460-2075.1990.tb08250.x; Lagarias DM, 1995, PLANT MOL BIOL, V29, P1127, DOI 10.1007/BF00020457; LANKINEN P, 1993, BEHAV GENET, V23, P359, DOI 10.1007/BF01067437; LAUTER FR, 1991, NUCLEIC ACIDS RES, V19, P6883, DOI 10.1093/nar/19.24.6883; Linden H, 1997, EMBO J, V16, P98, DOI 10.1093/emboj/16.1.98; LIU Y, IN PRESS CELL; LOROS J, 1995, SEMIN NEUROSCI, V7, P3, DOI 10.1016/1044-5765(95)90012-8; LOROS JJ, 1989, SCIENCE, V243, P385, DOI 10.1126/science.2563175; MACINO G, COMMUNICATION; MARZLUF GA, 1994, ADV GENET, V31, P187, DOI 10.1016/S0065-2660(08)60398-3; MCCLUNG CR, 1989, NATURE, V339, P558, DOI 10.1038/339558a0; MENAKER M, 1983, P NATL ACAD SCI-BIOL, V80, P6119, DOI 10.1073/pnas.80.19.6119; MERROW M, IN PRESS P NATL ACAD; MERROW M, UNPUB; MOORE RY, 1995, CIBA F SYMP, V183, P88; MOORE RY, 1992, DISCUSS NEUROSCI, V8, P26; NEWBY LM, 1993, GENETICS, V135, P1077; ORKIN SH, 1992, BLOOD, V80, P575; PALETTA J, 1981, P NATL ACAD SCI USA, V78, P5573; PARKS BM, 1993, PLANT CELL, V5, P39, DOI 10.1105/tpc.5.1.39; PERKINS DD, 1962, CAN J GENET CYTOL, V4, P187, DOI 10.1139/g62-024; Pittendrigh C, 1993, ANNU REV PHYSIOL, V55, P17; QUAIL PH, 1995, SCIENCE, V268, P675, DOI 10.1126/science.7732376; RAJU U, 1991, SCIENCE, V253, P673, DOI 10.1126/science.1871602; REED JW, 1994, PLANT PHYSIOL, V104, P1139, DOI 10.1104/pp.104.4.1139; REPPERT SM, 1995, NEURON, V15, P983, DOI 10.1016/0896-6273(95)90086-1; ROENNBERG T, 1995, CIBA FDN S, V183, P177; RUSSO VEA, 1988, J PHOTOCH PHOTOBIO B, V2, P59, DOI 10.1016/1011-1344(88)85037-1; Saez L, 1996, NEURON, V17, P911, DOI 10.1016/S0896-6273(00)80222-6; SASSONECORSI P, 1994, CELL, V78, P361, DOI 10.1016/0092-8674(94)90415-4; SCHNEIDERPOETSCH HAW, 1991, FEBS LETT, V281, P245, DOI 10.1016/0014-5793(91)80403-P; SCHWARTZ WJ, 1995, SEMIN NEUROSCI, V7, P53, DOI 10.1016/1044-5765(95)90017-9; SEHGAL A, 1995, SEMIN NEUROSCI, V7, P27, DOI 10.1016/1044-5765(95)90014-4; SEHGAL A, 1995, SCIENCE, V270, P808, DOI 10.1126/science.270.5237.808; Silver R, 1996, NATURE, V382, P810, DOI 10.1038/382810a0; SIWICKI KK, 1995, SEMIN NEUROSCI, V7, P1, DOI 10.1016/1044-5765(95)90011-X; SOMMER T, 1989, NUCLEIC ACIDS RES, V17, P5713, DOI 10.1093/nar/17.14.5713; SWEENEY BM, 1960, COLD SPRING HARB SYM, V25, P87, DOI 10.1101/SQB.1960.025.01.009; Tosini G, 1996, SCIENCE, V272, P419, DOI 10.1126/science.272.5260.419; WAGNER D, 1995, P NATL ACAD SCI USA, V92, P8596, DOI 10.1073/pnas.92.19.8596; Worden, 1974, NEUROSCIENCES 3RD ST, P437; XU Y, 1995, PLANT CELL, V7, P1433, DOI 10.1105/tpc.7.9.1433; YARDEN O, 1992, EMBO, V11, P259; ZATZ M, 1992, CIRCADIAN RHYTHMS DI, V8; ZATZ M, 1993, BRAIN RES REV, V18, P326; Zeng HK, 1996, NATURE, V380, P129, DOI 10.1038/380129a0	84	418	433	0	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 2	1997	276	5313					763	769		10.1126/science.276.5313.763	http://dx.doi.org/10.1126/science.276.5313.763			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WW900	9115195				2022-12-01	WOS:A1997WW90000049
J	Wu, ZR; Ebrahimian, S; Zawrotny, ME; Thornburg, LD; PerezAlvarado, GC; Brothers, P; Pollack, RM; Summers, MF				Wu, ZR; Ebrahimian, S; Zawrotny, ME; Thornburg, LD; PerezAlvarado, GC; Brothers, P; Pollack, RM; Summers, MF			Solution structure of 3-oxo-Delta(5)-steroid isomerase	SCIENCE			English	Article							PROTEIN SECONDARY STRUCTURE; SITE-DIRECTED MUTAGENESIS; CHEMICAL-SHIFT INDEX; DELTA-5-3-KETOSTEROID ISOMERASE; NMR-SPECTROSCOPY; PSEUDOMONAS-TESTOSTERONI; 3-OXO-DELTA-5-STEROID ISOMERASE; ESCHERICHIA-COLI; PROTON-TRANSFER; CATALYSIS	The three-dimensional structure of the enzyme 3-oxo-Delta(5)-steroid isomerase (E.C. 5.3.3.1), a 28-kilodalton symmetrical dimer, was solved by multidimensional heteronuclear magnetic resonance spectroscopy. The two independently folded monomers pack together by means of extensive hydrophobic and electrostatic interactions. Each monomer comprises three alpha helices and a six-strand mixed beta-pleated sheet arranged to form a deep hydrophobic cavity. Catalytically important residues Tyr(14) (general acid) and Asp(38) (general base) are located near the bottom of the cavity and positioned as expected from mechanistic hypotheses. An unexpected acid group (Asp(99)) is also located in the active site adjacent to Tyr(14), and kinetic and binding studies of the Asp(99) to Ala mutant demonstrate that Asp(99) contributes to catalysis by stabilizing the intermediate.	UNIV MARYLAND,HOWARD HUGHES MED INST,BALTIMORE,MD 21250; UNIV MARYLAND,DEPT CHEM & BIOCHEM,BALTIMORE,MD 21250	Howard Hughes Medical Institute; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038155] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49082, GM38155] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAX A, 1990, J MAGN RESON, V88, P425, DOI 10.1016/0022-2364(90)90202-K; BAX A, 1992, J MAGN RESON, V96, P432; BENISEK WF, 1980, ANN NY ACAD SCI, V346, P115; BOUNDS PL, 1987, BIOCHEMISTRY-US, V26, P2263, DOI 10.1021/bi00382a029; BROTHERS PN, 1995, BIOCHEMISTRY-US, V34, P15453, DOI 10.1021/bi00047a009; Brunger A. T., 1993, XPLOR SYSTEM XRAY CR; CHOI KY, 1988, GENE, V69, P121; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; FALCOZKELLY F, 1968, BIOCHEMISTRY-US, V7, P4119, DOI 10.1021/bi00851a047; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FESIK SW, 1988, J MAGN RESON, V78, P588, DOI 10.1016/0022-2364(88)90144-8; GANDOUR RD, 1981, BIOORG CHEM, V10, P169, DOI 10.1016/0045-2068(81)90020-1; GERLT JA, 1991, J AM CHEM SOC, V113, P9667, DOI 10.1021/ja00025a039; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; GUNTERT P, 1991, Journal of Biomolecular NMR, V1, P447, DOI 10.1007/BF02192866; GUNTERT P, 1991, J MOL BIOL, V217, P517, DOI 10.1016/0022-2836(91)90754-T; HAWKINSON DC, 1993, BIOCHEMISTRY-US, V32, P694, DOI 10.1021/bi00053a038; HAWKINSON DC, 1994, BIOCHEMISTRY-US, V33, P12172, DOI 10.1021/bi00206a021; HAWKINSON DC, 1991, BIOCHEMISTRY-US, V30, P10849, DOI 10.1021/bi00109a007; HOLMAN CM, 1995, BIOCHEMISTRY-US, V34, P14245, DOI 10.1021/bi00043a032; IKURA M, 1991, Journal of Biomolecular NMR, V1, P299, DOI 10.1007/BF01875522; IKURA M, 1992, J AM CHEM SOC, V114, P2433, DOI 10.1021/ja00033a019; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KULIOPULOS A, 1987, P NATL ACAD SCI USA, V84, P8893, DOI 10.1073/pnas.84.24.8893; KULIOPULOS A, 1989, BIOCHEMISTRY-US, V28, P149, DOI 10.1021/bi00427a022; KULIOPULOS A, 1991, BIOCHEMISTRY-US, V30, P3169, DOI 10.1021/bi00227a003; LEE W, 1994, FEBS LETT, V350, P87, DOI 10.1016/0014-5793(94)00740-3; LI YK, 1993, BIOCHEMISTRY-US, V32, P1816, DOI 10.1021/bi00058a016; MACURA S, 1980, MOL PHYS, V41, P95, DOI 10.1080/00268978000102601; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; POLLACK RM, 1979, BIOCHEM BIOPH RES CO, V91, P783, DOI 10.1016/0006-291X(79)91948-X; POLLACK RM, 1986, BIOCHEMISTRY-US, V25, P1905, DOI 10.1021/bi00356a011; RADZICKA A, 1995, SCIENCE, V267, P90, DOI 10.1126/science.7809611; Sambrook J., 1989, MOL CLONING LAB MANU; SAYERS JR, 1992, BIOTECHNIQUES, V13, P592; Shan SO, 1996, SCIENCE, V272, P97, DOI 10.1126/science.272.5258.97; Shan SO, 1996, J AM CHEM SOC, V118, P5515, DOI 10.1021/ja954205x; SHAND RF, 1991, BIOCHEMISTRY-US, V30, P3082, DOI 10.1021/bi00226a015; SPERA S, 1991, J AM CHEM SOC, V113, P5490, DOI 10.1021/ja00014a071; TALALAY P, 1955, BIOCHIM BIOPHYS ACTA, V18, P300, DOI 10.1016/0006-3002(55)90079-2; TIVOL WF, 1975, J BIOL CHEM, V250, P271; VENTERS RA, 1991, BIOCHEMISTRY-US, V30, P4491, DOI 10.1021/bi00232a017; VIGER A, 1981, J AM CHEM SOC, V103, P451, DOI 10.1021/ja00392a034; WEINTRAUB H, 1970, EUR J BIOCHEM, V12, P217, DOI 10.1111/j.1432-1033.1970.tb00840.x; WESTBROOK EM, 1976, J MOL BIOL, V103, P665, DOI 10.1016/0022-2836(76)90225-4; WESTBROOK EM, 1984, J BIOL CHEM, V259, P9096; WESTBROOK EM, 1976, J MOL BIOL, V103, P659, DOI 10.1016/0022-2836(76)90224-2; WILSON NA, 1995, BIOCHEMISTRY-US, V34, P8931, DOI 10.1021/bi00028a001; WISHART DS, 1994, J BIOMOL NMR, V4, P171; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Wuthrich K., 1986, NMR PROTEINS NUCL AC; Zawrotny ME, 1996, BIOCHEMISTRY-US, V35, P6438, DOI 10.1021/bi953025x; ZAWROTNY ME, 1994, BIOCHEMISTRY-US, V33, P13896, DOI 10.1021/bi00250a044; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413; Zhao QJ, 1996, P NATL ACAD SCI USA, V93, P8220, DOI 10.1073/pnas.93.16.8220	61	134	135	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 18	1997	276	5311					415	418		10.1126/science.276.5311.415	http://dx.doi.org/10.1126/science.276.5311.415			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WU477	9103200				2022-12-01	WOS:A1997WU47700040
J	Calvert, GM; Steenland, K; Palu, S				Calvert, GM; Steenland, K; Palu, S			End-stage renal disease among silica-exposed gold miners - A new method for assessing incidence among epidemiologic cohorts	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LUNG-CANCER MORTALITY; GRANITE WORKERS; NEPHROPATHY; MERCURY; GLOMERULONEPHRITIS; NEPHROTOXICITY; FAILURE	Objective.-To examine the association between silica exposure and end-stage renal disease (ESRD). Design.-Retrospective cohort study. Participants.-A cohort of 2412 white male gold miners was studied. Eligible gold miners worked underground for at least 1 year between 1940 and 1965 in a South Dakota gold mine and were alive on January 1, 1977. Of primary interest was exposure to silica. Methods.-The ESRD Program Management and Medical Information System (PMMIS) was used to identify members of the gold mine cohort who had treated ESRD and to create a US rate file for treated ESRD. The ESRD incidence among the gold miners was compared with that in the US population. Results.-Based on the 11 cohort members identified with treated ESRD, the risk for ESRD in the cohort was elevated (standardized incidence ratio [SIR], 1.37; 95% confidence interval [CI], 0.68-2.46). The risk was greatest for nonsystemic ESRD (ESRD caused by glomerulonephritis or interstitial nephritis) for which the SIR was 4.22 (95% CI, 1.54-9.19), increasing to 7.70 (95% CI, 1.59-22.48) among workers with 10 or more years of employment underground. Conclusions.-To our knowledge this is the first epidemiologic study to examine ESRD incidence in an occupational cohort. This study provides evidence that silica exposure is associated with an increased risk for ESRD, especially ESRD caused by glomerulonephritis. This study also demonstrates the usefulness of the ESRD PMMIS to assess ESRD risk among cohorts exposed to potential nephrotoxins.			Calvert, GM (corresponding author), CTR DIS CONTROL & PREVENT,NIOSH,DIV SURVEILLANCE HAZARD EVALUAT & FIELD STUDIES,CINCINNATI,OH 45226, USA.							BANKS DE, 1983, AM J NEPHROL, V3, P279, DOI 10.1159/000166730; BARREGARD L, 1990, BRIT J IND MED, V47, P99; BOLTON WK, 1981, AM J MED, V71, P823; BROWN DP, 1986, SILICA SILICOSIS CAN, P335; CARTA P, 1994, AM J IND MED, V25, P489, DOI 10.1002/ajim.4700250404; COCCO PL, 1994, J OCCUP ENVIRON MED, V36, P894; CRAGLE DL, 1984, J OCCUP ENVIRON MED, V26, P817, DOI 10.1097/00043764-198411000-00011; DAVIS LK, 1983, AM J IND MED, V4, P705, DOI 10.1002/ajim.4700040604; ELLINGSEN DG, 1993, BRIT J IND MED, V50, P881; GERHARDT RE, 1978, ARCH INTERN MED, V138, P1267, DOI 10.1001/archinte.138.8.1267; GILBERSON A, 1976, ARCH INTERN MED, V136, P1303; GILES RD, 1978, AM J MED, V64, P336, DOI 10.1016/0002-9343(78)90063-3; GREENBERGER JS, 1982, CANC KIDNEY, P814; HANDKE J, 1981, HLTH HAZARD EVALUATI; HAUGLUSTAINE D, 1980, NEPHRON, V26, P219, DOI 10.1159/000181988; Kolev K, 1970, Med Lav, V61, P205; KOSKELA RS, 1987, SCAND J WORK ENV HEA, V13, P18, DOI 10.5271/sjweh.2085; LANDRIGAN PJ, 1984, ARCH ENVIRON HEALTH, V39, P225, DOI 10.1080/00039896.1984.9939529; NAJDA J, 1994, BIOL TRACE ELEM RES, V42, P63, DOI 10.1007/BF02990489; *NAT I OCC SAF HLT, 1992, DHHS NIOSH PUBL; NG TP, 1992, BRIT J IND MED, V49, P35; NG TP, 1993, BRIT J IND MED, V50, P907; *NIH, 1996, US REN DAT SYST 1996; NUYTS GD, 1995, NEPHROL DIAL TRANSPL, V10, P1162, DOI 10.1093/ndt/10.7.1162; NUYTS GD, 1995, LANCET, V346, P7, DOI 10.1016/S0140-6736(95)92648-8; OSORIO AM, 1987, AM J KIDNEY DIS, V9, P224, DOI 10.1016/S0272-6386(87)80059-8; Rothman KJ, 1979, DHEW PUBLICATION, P79; SAITA G., 1951, MED LAVORO, V42, P41; SALDANHA LF, 1975, AM J MED, V59, P95, DOI 10.1016/0002-9343(75)90326-5; SHERSON D, 1989, BRIT J IND MED, V46, P675; STEENLAND K, 1995, AM J IND MED, V27, P217, DOI 10.1002/ajim.4700270207; STEENLAND K, 1990, J OCCUP ENVIRON MED, V32, P1091, DOI 10.1097/00043764-199011000-00008; STEENLAND NK, 1990, AM J PUBLIC HEALTH, V80, P153, DOI 10.2105/AJPH.80.2.153; WEDEEN RP, 1992, OCCUP MED, V7, P449; WYNDHAM CH, 1986, BRIT J IND MED, V43, P677; Zumwalde R, 1981, IND HYGIENE REPORT H; 1989, FED REG         0119, V54, P2521	37	54	54	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 16	1997	277	15					1219	1223		10.1001/jama.277.15.1219	http://dx.doi.org/10.1001/jama.277.15.1219			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WT403	9103346				2022-12-01	WOS:A1997WT40300033
J	Ong, ACM; Harris, PC				Ong, ACM; Harris, PC			Molecular basis of renal cyst formation - One hit or two?	LANCET			English	Editorial Material							POLYCYSTIC KIDNEY-DISEASE				Ong, ACM (corresponding author), UNIV OXFORD,MRC,INST MOL MED,MOL HAEMATOL UNIT,OXFORD OX3 9DU,ENGLAND.		Ong, Albert/AAN-9430-2021	Ong, Albert/0000-0002-7211-5400				[Anonymous], 1994, CELL, V77, P881; BAERT L, 1978, KIDNEY INT, V13, P519, DOI 10.1038/ki.1978.75; Brasier JL, 1997, J CLIN INVEST, V99, P194, DOI 10.1172/JCI119147; BROOKCARTER PT, 1994, NAT GENET, V8, P328, DOI 10.1038/ng1294-328; GENGL, 1996, J CLIN INVEST, V98, P2674; HUGHES J, 1995, NAT GENET, V10, P151, DOI 10.1038/ng0695-151; *INT POL KIDN DIS, 1995, CELL, V81, P289; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; Moy GW, 1996, J CELL BIOL, V133, P809, DOI 10.1083/jcb.133.4.809; Peral B, 1996, HUM MOL GENET, V5, P539, DOI 10.1093/hmg/5.4.539; Peral B, 1996, AM J HUM GENET, V58, P86; Qian F, 1996, CELL, V87, P979, DOI 10.1016/S0092-8674(00)81793-6; WARD CJ, 1996, NATL ACAD SCI US, V93, P1524	13	43	43	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 12	1997	349	9058					1039	1040		10.1016/S0140-6736(05)62286-6	http://dx.doi.org/10.1016/S0140-6736(05)62286-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU002	9107237				2022-12-01	WOS:A1997WU00200003
J	Daviglus, ML; Stamler, J; Orencia, AJ; Dyer, AR; Liu, K; Greenland, P; Walsh, MK; Morris, D; Shekelle, RB				Daviglus, ML; Stamler, J; Orencia, AJ; Dyer, AR; Liu, K; Greenland, P; Walsh, MK; Morris, D; Shekelle, RB			Fish consumption and the 30-year risk of fatal myocardial infarction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; N-3 FATTY-ACIDS; SUDDEN-DEATH; CARDIOVASCULAR-DISEASE; DIETARY-INTAKE; MORTALITY; MINNESOTA; DECLINE; HEALTH; OILS	Background Epidemiologic data on the possible benefit of eating fish to reduce the risk of coronary heart disease have been inconsistent. We used data from the Chicago Western Electric Study to examine the relation between base-line fish consumption and the 30-year risk of death from coronary heart disease. Methods The study participants were 1822 men who were 40 to 55 years old and free of cardiovascular disease at base line. Fish consumption, as determined from a detailed dietary history, was stratified (0, 1 to 17, 18 to 34, and greater than or equal to 35 g per day). Mortality from coronary heart disease, ascertained from death certificates, was classified as death from myocardial infarction (sudden or nonsudden) or death from other coronary causes. Results During 47,153 person-years of follow-up, there were 430 deaths from coronary heart disease; 293 were due to myocardial infarctions (196 were sudden, 94 were nonsudden, and 3 were not classifiable). Cox proportional-hazards regression showed that for men who consumed 35 g or more of fish dally as compared with those who consumed none, the relative risks of death from coronary heart disease and from sudden or nonsudden myocardial infarction were 0.62 (95 percent confidence interval, 0.40 to 0.94) and 0.56 (95 percent confidence interval, 0.33 to 0.93), respectively, with a graded relation between the relative risks and the strata of fish consumption (P for trend = 0.04 and 0.02, respectively). These findings were accounted for by the relation of fish consumption to nonsudden death from myocardial infarction (relative risk, 0.33; 95 percent confidence interval, 0.12 to 0.91; P for trend = 0.007). Conclusions These data show an inverse association between fish consumption and death from coronary heart disease, especially nonsudden death from myocardial infarction. (C) 1997, Massachusets Medical Society.	INDIANA UNIV, SCH MED, DEPT NEUROL, INDIANAPOLIS, IN 46202 USA; UNIV TEXAS, HLTH SCI CTR, SCH PUBL HLTH, DEPT EPIDEMIOL, HOUSTON, TX USA	Indiana University System; Indiana University-Purdue University Indianapolis; University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health	Daviglus, ML (corresponding author), NORTHWESTERN UNIV, SCH MED, DEPT PREVENT MED, 680 N LAKE SHORE DR, SUITE 1102, CHICAGO, IL 60611 USA.		Walsh, Molly/AAG-3274-2021; Greenland, Philip/ABD-5528-2021	Walsh, Molly/0000-0002-0656-2050; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL021010, K14HL003387] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 21010, HL 15174, HL 03387] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBERT CM, 1996, CIRCULATION S1, V94, P578; ANASTASIOUNANA M, 1982, CIRCULATION, V66, P236; ASCHERIO A, 1995, NEW ENGL J MED, V332, P977, DOI 10.1056/NEJM199504133321501; BAIRATI I, 1992, CIRCULATION, V85, P950, DOI 10.1161/01.CIR.85.3.950; BILLMAN GE, 1996, CIRCULATION S1, V94, P307; BOWES ADP, 1956, FOOD VALUES PORTIONS; Burke Bertha S., 1947, JOUR AMER DIETETIC ASSOC, V23, P1041; BURR ML, 1989, LANCET, V2, P757; COX DR, 1972, J R STAT SOC B, V34, P187; CURB JD, 1985, NEW ENGL J MED, V313, P821; *DEP HLTH ED WELF, 1967, PHS DHEW PUBL, V1693; DREVON CA, 1992, NUTR REV, V50, P38; ELVEBACK LR, 1981, MAYO CLIN PROC, V56, P665; FRASER GE, 1992, ARCH INTERN MED, V152, P1416, DOI 10.1001/archinte.152.7.1416; GILLUM RF, 1983, NEW ENGL J MED, V309, P1353, DOI 10.1056/NEJM198312013092203; GILLUM RF, 1984, AM J MED, V76, P1055, DOI 10.1016/0002-9343(84)90857-X; GILLUM RF, 1989, CIRCULATION, V79, P756, DOI 10.1161/01.CIR.79.4.756; GRAMENZI A, 1990, BMJ-BRIT MED J, V300, P771, DOI 10.1136/bmj.300.6727.771; HARDINGE MARVYN, 1958, JOUR AMER DIETETIC ASSOC, V34, P1065; HARRIS WS, 1989, J LIPID RES, V30, P785; HAYES OLIVE B., 1957, JOUR AMER DIETETIC ASSOC, V33, P26; *HYP DET FOLL UP P, 1979, JAMA-J AM MED ASSOC, V242, P2562; KEYS A, 1965, METABOLIS, V14, P747, DOI 10.1016/0026-0495(65)90001-6; KINSELLA JE, 1990, AM J CLIN NUTR, V52, P1; KJELSBERG MO, 1990, JAMA-J AM MED ASSOC, V263, P1795; Kjelsberg MO, 1996, CIRCULATION, V94, P946; Kromhout D, 1996, NUTR METAB CARDIOVAS, V6, P65; KROMHOUT D, 1995, INT J EPIDEMIOL, V24, P340, DOI 10.1093/ije/24.2.340; KROMHOUT D, 1985, NEW ENGL J MED, V312, P1205, DOI 10.1056/NEJM198505093121901; KROMHOUT D, 1989, J INTERN MED, V225, P47, DOI 10.1111/j.1365-2796.1989.tb01435.x; KULLER LH, 1986, J CHRON DIS, V39, P1001, DOI 10.1016/0021-9681(86)90136-0; KULLER LH, 1987, J CHRON DIS, V40, P1071; LEAF A, 1988, NEW ENGL J MED, V318, P549, DOI 10.1056/NEJM198803033180905; MORRIS MC, 1995, AM J EPIDEMIOL, V142, P166, DOI 10.1093/oxfordjournals.aje.a117615; *MULT RISK FACT IN, 1990, JAMA-J AM MED ASSOC, V263, P3151; *NAT CTR HLTH STAT, 1995, MON VIT STAT REP S, V43; *NAT I HLTH, 1981, NIH PUBL, P175; NORELL SE, 1986, BRIT MED J, V293, P426, DOI 10.1136/bmj.293.6544.426; PAUL O, 1963, CIRCULATION, V28, P20, DOI 10.1161/01.CIR.28.1.20; SCHMIDT EB, 1994, DRUGS, V47, P405, DOI 10.2165/00003495-199447030-00003; SEIDELIN KN, 1992, AM J CLIN NUTR, V55, P1117, DOI 10.1093/ajcn/55.6.1117; SHEKELLE RB, 1985, NEW ENGL J MED, V313, P820; SHEKELLE RB, 1993, NUTR METAB CARDIOVAS, V3, P46; SISCOVICK DS, 1995, JAMA-J AM MED ASSOC, V274, P1363, DOI 10.1001/jama.274.17.1363; STAMLER J, 1993, CARDIOLOGY, V82, P191, DOI 10.1159/000175868; TRAVEN ND, 1995, AM J EPIDEMIOL, V142, P45, DOI 10.1093/oxfordjournals.aje.a117544; VANHOUWELINGEN AC, 1989, ATHEROSCLEROSIS, V75, P157, DOI 10.1016/0021-9150(89)90172-X; VOLLSET SE, 1985, NEW ENGL J MED, V313, P820; WAHLQVIST ML, 1989, LANCET, V2, P944; WOOD DA, 1987, LANCET, V1, P177	50	670	694	0	22	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 10	1997	336	15					1046	1053		10.1056/NEJM199704103361502	http://dx.doi.org/10.1056/NEJM199704103361502			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WT161	9091800				2022-12-01	WOS:A1997WT16100002
J	Bruzzi, P; Dogliotti, L; Naldoni, C; Bucchi, L; Costantini, M; Cicognani, A; Torta, M; Buzzi, GF; Angeli, A				Bruzzi, P; Dogliotti, L; Naldoni, C; Bucchi, L; Costantini, M; Cicognani, A; Torta, M; Buzzi, GF; Angeli, A			Cohort study of association of risk of breast cancer with cyst type in women with gross cystic disease of the breast	BMJ-BRITISH MEDICAL JOURNAL			English	Article; Proceedings Paper	4th Cherasco Meeting on Gross Cystic Disease of the Breast	JUN 23, 1995	CHERASCO, ITALY				FLUID; SUBSEQUENT; HISTORY	Objective: To assess correlation between type of breast cyst and risk of breast cancer in women with gross cystic disease of the breast. Design: Cohort study of women with breast cysts aspirated between 1983 and 1993 who were followed up until December 1994 for occurrence of breast cancer. Setting: Major cancer prevention centre. Subjects: 802 women with aspirated breast cysts. Main outcome measures: Type of breast cyst based on cationic content of cyst fluid: type I (potassium:sodium ratio > 1.5), type II (potassium:sodium ratio < 1.5), or mixed (both types). Subsequent occurrence and type of breast cancer. Results: After median follow up of six years (range 2-12 years) 15 cases of invasive breast cancer and two ductal carcinomas in situ were diagnosed in the cohort: 12 invasive cancers (and two carcinomas in situ) among the 417 women with type I cysts, two cancers among the 325 women with type II cysts, and one among the 60 women with mixed cysts. The incidence of breast cancer in women with type I cysts was significantly higher than that in women with type II cysts (relative risk 4.62 (95% confidence interval 1.26 to 29.7)). These results were confirmed after adjustment for several risk factors for breast cancer (relative risk 4.24 (1.12 to 27.5)). Conclusions: The increased risk of breast cancer of women with breast cysts seems to be concentrated among women with type I breast cysts.	ST LUIGI HOSP, UNIV TURIN, DEPT CLIN & BIOL SCI, I-10043 ORBASSANO, TORINO, ITALY; ST MARIA CROCI HOSP, CANC PREV CTR, I-48100 RAVENNA, ITALY	University of Turin	Bruzzi, P (corresponding author), IST NAZL RIC CANC, UNIT CLIN EPIDEMIOL & TRIALS, LARGO ROSANNA BENZI 10, I-16132 GENOA, ITALY.		Bucchi, Lauro/W-5033-2018; Bruzzi, Paolo/AAU-3363-2021; costantini, massimo/AAK-5388-2021	Bucchi, Lauro/0000-0002-6771-8119; costantini, massimo/0000-0002-5293-7079; Bruzzi, Paolo/0000-0002-7874-2077				AMADORI D, 1992, REGISTRO TUMORI ROMA; ANGELI A, 1990, ANN NY ACAD SCI, V586, P49, DOI 10.1111/j.1749-6632.1990.tb17788.x; ANGELI A, 1994, J STEROID BIOCHEM, V49, P333, DOI 10.1016/0960-0760(94)90276-3; BELANGER A, 1990, EUR J CANCER, V26, P277, DOI 10.1016/0277-5379(90)90222-F; BOCCARDO F, 1988, CANCER RES, V48, P5860; BODIAN CA, 1993, CANCER, V71, P3896, DOI 10.1002/1097-0142(19930615)71:12<3896::AID-CNCR2820711217>3.0.CO;2-I; BODIAN CA, 1993, EPIDEMIOL REV, V15, P177, DOI 10.1093/oxfordjournals.epirev.a036103; BODIAN CA, 1992, CANCER DETECT PREV, V16, P7; BRADLOW HL, 1983, ENDOCRINOLOGY CYSTIC, P197; BUCCHI L, 1995, J CLIN EPIDEMIOL, V48, P969, DOI 10.1016/0895-4356(94)00226-G; BUNDRED NJ, 1991, BRIT J CANCER, V64, P953, DOI 10.1038/bjc.1991.433; BUNDRED NJ, 1992, BREAST DIS, V5, P21; CIATTO S, 1990, EUR J CANCER, V26, P555, DOI 10.1016/0277-5379(90)90074-4; Clayton D., 1993, STAT MODELS EPIDEMIO; DIXON JM, 1985, EUR J CANCER CLIN ON, V21, P1047, DOI 10.1016/0277-5379(85)90289-5; DIXON JM, 1983, BRIT J SURG, V70, P604, DOI 10.1002/bjs.1800701012; DOGLIOTTI L, 1986, EUR J CANCER CLIN ON, V22, P1301, DOI 10.1016/0277-5379(86)90137-9; DUPONT WD, 1985, NEW ENGL J MED, V312, P146, DOI 10.1056/NEJM198501173120303; EBBS SR, 1988, BRIT J SURG, V75, P702, DOI 10.1002/bjs.1800750726; HAAGENSEN CD, 1981, BREAST CARCINOMA RIS; HARRINGTON E, 1981, BREAST, V7, P13; HUTCHINSON WB, 1980, J NATL CANCER I, V65, P13; JONES BM, 1980, BRIT J SURG, V67, P669, DOI 10.1002/bjs.1800670922; LAI LC, 1995, J CLIN ENDOCR METAB, V80, P711, DOI 10.1210/jc.80.2.711; LAI LC, 1993, CANCER, V24, P668; MILLER B, 1983, J ACAD LIBR, V9, P227; MILLER WR, 1992, CANCER DETECT PREV, V16, P99; NALDONI C, 1992, CANCER RES, V52, P1791; NALDONI C, 1990, ANN NY ACAD SCI, V586, P272, DOI 10.1111/j.1749-6632.1990.tb17816.x; NESS JC, 1993, AM J SURG, V166, P237, DOI 10.1016/S0002-9610(05)80965-1; ROBERTS MM, 1984, BRIT MED J, V288, P275, DOI 10.1136/bmj.288.6413.275	31	39	39	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 29	1997	314	7085					925	928		10.1136/bmj.314.7085.925	http://dx.doi.org/10.1136/bmj.314.7085.925			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	WQ169	9099114	Green Published			2022-12-01	WOS:A1997WQ16900022
J	Wyatt, JP; McLeod, L; Beard, D; Busuttil, A; Beattie, TF; Robertson, CE				Wyatt, JP; McLeod, L; Beard, D; Busuttil, A; Beattie, TF; Robertson, CE			Timing of paediatric deaths after trauma	BRITISH MEDICAL JOURNAL			English	Article									ROYAL EDINBURGH INFIRM,SCOTTISH TRAUMA AUDIT GRP,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,SCH MED,FORENS MED UNIT,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND; ROYAL EDINBURGH INFIRM,DEPT ACCID & EMERGENCY,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND	Royal Infirmary of Edinburgh; University of Edinburgh; Royal Infirmary of Edinburgh	Wyatt, JP (corresponding author), ROYAL HOSP SICK CHILDREN,DEPT ACCID & EMERGENCY MED,EDINBURGH EH9 1LF,MIDLOTHIAN,SCOTLAND.							Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL 1990 R; *CHILD ACC PREV TR, 1989, BAS PRINC CHILD ACC; *SECR STAT HLTH, 1992, HLTH NAT, P102; SHARPLES PM, 1990, BRIT MED J, V300, P87, DOI 10.1136/bmj.300.6717.87; WYATT J, 1995, BRIT MED J, V310, P1502, DOI 10.1136/bmj.310.6993.1502	5	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 22	1997	314	7084					868	868						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ028	9093097				2022-12-01	WOS:A1997WQ02800027
J	Jacobs, C; Frere, JM; Normark, S				Jacobs, C; Frere, JM; Normark, S			Cytosolic intermediates for cell wall biosynthesis and degradation control inducible beta-lactam resistance in gram-negative bacteria	CELL			English	Article							CITROBACTER-FREUNDII AMPR; L-ALANINE AMIDASE; ESCHERICHIA-COLI; MUREIN HYDROLASES; DIVISION CYCLE; INDUCTION; EXPRESSION; REGULATOR; BINDING; PROTEIN	beta-lactam induction of chromosomal beta-lactamase in gram-negative bacteria requires the transcriptional regulator AmpR and the transport of murein breakdown products (muropeptides) into the cytoplasm. In vitro transcription shows that purified AmpR acts as an activator for ampC beta-lactamase synthesis. The murein precursor, UDP-MurNAc-pentapeptide, decreases AmpR-mediated transcriptional activation in vitro, but has no effect on an AmpR(G102E) mutant that mediates constitutive activation of ampC in vivo. Addition of the muropeptide, anhMurNAc-tripeptide, which accumulates in beta-lactamase-overproducing mutants, counteracts the negative effect of UDP-MurNAc-pentapeptide, restoring the innate ability of AmpR to induce ampC expression in vitro. Cytosolic intermediates of murein biosynthesis and degradation thus act antagonistically to control beta-lactamase expression, thereby operating as a cell-wall sensing device.	KAROLINSKA INST,MICROBIOL & TUMORBIOL CTR,S-17177 STOCKHOLM,SWEDEN	Karolinska Institutet	Jacobs, C (corresponding author), UNIV LIEGE,CTR INGN PROT,INST CHEM,BATIMENT B6,B-4000 SART 1,BELGIUM.							BALBAS P, 1986, GENE, V50, P3, DOI 10.1016/0378-1119(86)90307-0; BARTOWSKY E, 1991, MOL MICROBIOL, V5, P1715, DOI 10.1111/j.1365-2958.1991.tb01920.x; BECK BD, 1976, J BACTERIOL, V126, P1250, DOI 10.1128/JB.126.3.1250-1260.1976; BISHOP RE, 1993, EUR J BIOCHEM, V213, P405, DOI 10.1111/j.1432-1033.1993.tb17775.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DJORDJEVIC MA, 1987, EMBO J, V6, P1173, DOI 10.1002/j.1460-2075.1987.tb02351.x; GALLAGHER SR, 1995, CURRENT PROTOCOLS PR; GEIS A, 1978, BIOCHIM BIOPHYS ACTA, V527, P414, DOI 10.1016/0005-2744(78)90355-8; GOODELL EW, 1985, J BACTERIOL, V163, P305, DOI 10.1128/JB.163.1.305-310.1985; HAKENBECK R, 1977, J BACTERIOL, V129, P1239, DOI 10.1128/JB.129.3.1239-1244.1977; HENIKOFF S, 1988, P NATL ACAD SCI USA, V85, P6602, DOI 10.1073/pnas.85.18.6602; HINKS RP, 1978, J BACTERIOL, V133, P822, DOI 10.1128/JB.133.2.822-829.1978; HOLTJE JV, 1991, J GEN MICROBIOL, V137, P441, DOI 10.1099/00221287-137-3-441; HOLTJE JV, 1994, FEMS MICROBIOL LETT, V122, P159, DOI 10.1111/j.1574-6968.1994.tb07159.x; Innis MA, 1990, PCR PROTOCOLS GUIDE; JACOBS C, 1995, MOL MICROBIOL, V15, P553, DOI 10.1111/j.1365-2958.1995.tb02268.x; JACOBS C, 1994, EMBO J, V13, P4684, DOI 10.1002/j.1460-2075.1994.tb06792.x; KORFMANN G, 1989, ANTIMICROB AGENTS CH, V33, P1946, DOI 10.1128/AAC.33.11.1946; LINDBERG F, 1987, J BACTERIOL, V169, P1923, DOI 10.1128/jb.169.5.1923-1928.1987; LINDBERG F, 1985, P NATL ACAD SCI USA, V82, P4620, DOI 10.1073/pnas.82.14.4620; LINDQUIST S, 1989, J BACTERIOL, V171, P3746, DOI 10.1128/jb.171.7.3746-3753.1989; LINDQUIST S, 1993, MOL MICROBIOL, V9, P703, DOI 10.1111/j.1365-2958.1993.tb01731.x; Maxam A M, 1980, Methods Enzymol, V65, P499; MENGINLECREULX D, 1989, J BACTERIOL, V171, P3282, DOI 10.1128/jb.171.6.3282-3287.1989; MENGINLECREULX D, 1982, J BACTERIOL, V151, P1109, DOI 10.1128/JB.151.3.1109-1117.1982; MenginLecreulx D, 1996, J BACTERIOL, V178, P5347, DOI 10.1128/jb.178.18.5347-5352.1996; NORMARK S, 1994, N COMP BIOC, V27, P485; OGAWA J, 1995, GENE DEV, V9, P714, DOI 10.1101/gad.9.6.714; OLIJHOEK AJM, 1982, J BACTERIOL, V152, P1248; OSTROWSKI J, 1990, J BACTERIOL, V172, P779, DOI 10.1128/jb.172.2.779-785.1990; RAETZ CRH, 1996, ESCHERICHIA COLI SAL, P1035; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHELL MA, 1993, ANNU REV MICROBIOL, V47, P597, DOI 10.1146/annurev.mi.47.100193.003121; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VANHEIJENOORT J, 1994, N COMP BIOC, V27, P39	35	259	268	0	17	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 21	1997	88	6					823	832		10.1016/S0092-8674(00)81928-5	http://dx.doi.org/10.1016/S0092-8674(00)81928-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WQ100	9118225	Bronze			2022-12-01	WOS:A1997WQ10000014
J	Herzing, LBK; Romer, JT; Horn, JM; Ashworth, A				Herzing, LBK; Romer, JT; Horn, JM; Ashworth, A			Xist has properties of the X-chromosome inactivation centre	NATURE			English	Article							GENE; EXPRESSION; MICE; RECOMBINATION; CONSERVATION; PROMOTER; EMBRYO; CELLS	X-chromosome inactivation is the process by which female mammals (with two X chromosomes) achieve expression of X-chromosomal genes equivalent to that of males (one X and one Y chromosome)(1,2). This results in the transcriptional silencing of virtually all genes on one of the X chromosomes in female somatic cells, X-chromosome inactivation has been shown to act in cis and to initiate and spread from a single site on the X chromosome known as the X-inactivation centre (Xic)(2,3). The Xic has been localized to a 450-kilobase region of the mouse X chromosome(4). The Xist gene also maps to this region and is expressed exclusively from the inactive X chromosome(3-7). Xist is unusual in that it appears not to code for a protein but produces a nuclear RNA which colocalizes with the inactive X chromosome(4,8). The creation of a null allele of Xist in embryonic stem cells has demonstrated that this gene is required for X inactivation to occur in cis(9). Here we show that Xist, introduced onto an autosome, is sufficient by itself far inactivation in cis and that Xist RNA becomes localized close to the autosome into which the gene is integrated. In addition, the presence of autosomal Xist copies leads to activation of the endogeneous Xist gene in some cells, suggesting that elements required for some aspects of chromosome counting are contained within the construct, Thus the Xist gene exhibits properties of the X-inactivation centre.	INST CANC RES, CHESTER BEATTY LABS, CRC, CTR CELL & MOL BIOL, LONDON SW3 6JB, ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK								BORSANI G, 1991, NATURE, V351, P325, DOI 10.1038/351325a0; BROCKDORFF N, 1991, NATURE, V351, P329, DOI 10.1038/351329a0; BROWN CJ, 1991, NATURE, V349, P38, DOI 10.1038/349038a0; Clemson CM, 1996, J CELL BIOL, V132, P259, DOI 10.1083/jcb.132.3.259; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; GAUTIER C, 1989, NUCLEIC ACIDS RES, V17, P8389, DOI 10.1093/nar/17.20.8389; HENDRICH BD, 1993, HUM MOL GENET, V2, P663, DOI 10.1093/hmg/2.6.663; HERZING LBK, 1993, GENE, V137, P163, DOI 10.1016/0378-1119(93)90002-K; HERZING LBK, 1995, NUCLEIC ACIDS RES, V23, P4005, DOI 10.1093/nar/23.19.4005; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; KAY GF, 1993, CELL, V72, P171, DOI 10.1016/0092-8674(93)90658-D; Lee JT, 1996, CELL, V86, P83, DOI 10.1016/S0092-8674(00)80079-3; LEHRACH H., 1990, GENOME ANAL, P39; LYON MF, 1992, ANNU REV GENET, V26, P17, DOI 10.1146/annurev.ge.26.120192.000313; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; Matsuura S, 1996, HUM MOL GENET, V5, P451, DOI 10.1093/hmg/5.4.451; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; Penny GD, 1996, NATURE, V379, P131, DOI 10.1038/379131a0; RAMIREZSOLIS R, 1995, NATURE, V378, P720, DOI 10.1038/378720a0; RASTAN S, 1982, GENET RES, V40, P139, DOI 10.1017/S0016672300019017; RASTAN S, 1994, CURR OPIN GENET DEV, V4, P292, DOI 10.1016/S0959-437X(05)80056-5; RASTAN S, 1985, J EMBRYOL EXP MORPH, V90, P379; TAN SS, 1993, NAT GENET, V3, P170, DOI 10.1038/ng0293-170	23	214	216	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 20	1997	386	6622					272	275		10.1038/386272a0	http://dx.doi.org/10.1038/386272a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WP003	9069284				2022-12-01	WOS:A1997WP00300049
J	Abzug, MJ				Abzug, MJ			Assault against respiratory syncytial virus: Beginning of an era	LANCET			English	Editorial Material							IMMUNE GLOBULIN; INFANTS		CHILDRENS HOSP,DENVER,CO 80218	Children's Hospital Colorado	Abzug, MJ (corresponding author), UNIV COLORADO,SCH MED,DENVER,CO 80218, USA.							Connor E, 1997, PEDIATRICS, V99, P93; GROOTHUIS JR, 1993, NEW ENGL J MED, V329, P1524, DOI 10.1056/NEJM199311183292102; GROOTHUIS JR, 1995, PEDIATRICS, V95, P463; HAY JW, 1996, AM J MANAG CARE, V2, P851; Meissner HC, 1996, PEDIATR INFECT DIS J, V15, P1059, DOI 10.1097/00006454-199612000-00001; Nightingale SL, 1996, JAMA-J AM MED ASSOC, V275, P902; Simoes Eric A. F., 1996, Pediatric Research, V39, p113A; WHIMBEY E, 1995, BONE MARROW TRANSPL, V16, P393	8	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 15	1997	349	9054					743	744		10.1016/S0140-6736(05)60194-8	http://dx.doi.org/10.1016/S0140-6736(05)60194-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN124	9074568				2022-12-01	WOS:A1997WN12400003
J	Printen, JA; Brady, MJ; Saltiel, AR				Printen, JA; Brady, MJ; Saltiel, AR			PTG, a protein phosphatase 1-binding protein with a role in glycogen metabolism	SCIENCE			English	Article							3T3-L1 ADIPOCYTES; INSULIN; KINASE; STIMULATION; EXPRESSION; ACTIVATION; SUBUNIT; PHOSPHORYLATION; IDENTIFICATION; SUFFICIENT	Protein dephosphorylation by phosphatase PP1 plays a central role in mediating the effects of insulin on glucose and lipid metabolism, A PP1C-targeting protein expressed in 3T3-L1 adipocytes (called PTG, for protein targeting to glycogen) was cloned and characterized. PTG was expressed predominantly in insulin-sensitive tissues. In addition to binding and localizing PP1C to glycogen, PTG formed complexes with phosphorylase kinase, phosphorylase a, and glycogen synthase, the primary enzymes involved in the hormonal regulation of glycogen metabolism. Overexpression of PTG markedly increased basal and insulin-stimulated glycogen synthesis in Chinese hamster ovary cells overexpressing the insulin receptor, which do not express endogenous PTG. These results suggest that PTG is critical for glycogen metabolism, possibly functioning as a molecular scaffold.	UNIV MICHIGAN, SCH MED, DEPT PHYSIOL, ANN ARBOR, MI 48109 USA; WARNER LAMBERT PARKE DAVIS, PARKE DAVIS PHARMACEUT RES DIV, DEPT CELL BIOL, ANN ARBOR, MI 48105 USA	University of Michigan System; University of Michigan; Pfizer			Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828				COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; DEHERREROS AG, 1989, J BIOL CHEM, V264, P19994; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DOHERTY MJ, 1995, FEBS LETT, V375, P294, DOI 10.1016/0014-5793(95)01184-G; DONELLADEANA A, 1993, BIOCHIM BIOPHYS ACTA, V1178, P189, DOI 10.1016/0167-4889(93)90008-D; FRANCOIS JM, 1992, EMBO J, V11, P87, DOI 10.1002/j.1460-2075.1992.tb05031.x; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KREBS EG, 1964, BIOCHEMISTRY-US, V3, P1022, DOI 10.1021/bi00896a003; KREBS EG, 1956, BIOCHIM BIOPHYS ACTA, V20, P150, DOI 10.1016/0006-3002(56)90273-6; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; Lin Tai-An, 1994, Journal of Biological Chemistry, V269, P21255; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; REED BC, 1977, P NATL ACAD SCI USA, V74, P4876, DOI 10.1073/pnas.74.11.4876; ROBINSON LJ, 1993, J BIOL CHEM, V268, P26422; RUBIN CS, 1978, J BIOL CHEM, V253, P7570; Saltiel AR, 1996, AM J PHYSIOL-ENDOC M, V270, pE375, DOI 10.1152/ajpendo.1996.270.3.E375; SALTIEL AR, 1994, FASEB J, V8, P1034, DOI 10.1096/fasebj.8.13.7926368; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; SHIMA H, 1993, BIOCHEM BIOPH RES CO, V192, P1289, DOI 10.1006/bbrc.1993.1556; SHIMA H, 1993, BIOCHEM BIOPH RES CO, V194, P930, DOI 10.1006/bbrc.1993.1910; SUTHERLAND C, 1993, EUR J BIOCHEM, V212, P581, DOI 10.1111/j.1432-1033.1993.tb17696.x; TANG PM, 1991, J BIOL CHEM, V266, P15782; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; WIESE RJ, 1995, J BIOL CHEM, V270, P3442, DOI 10.1074/jbc.270.7.3442	26	233	239	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 7	1997	275	5305					1475	1478		10.1126/science.275.5305.1475	http://dx.doi.org/10.1126/science.275.5305.1475			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WM081	9045612				2022-12-01	WOS:A1997WM08100045
J	Nightingale, SL				Nightingale, SL			Action plan for providing useful prescription information	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1996, JAMA-J AM MED ASSOC, V276, P1128	1	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 5	1997	277	9					703	703						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WK026	9042830				2022-12-01	WOS:A1997WK02600009
J	Quinn, JP				Quinn, JP			Rational antibiotic therapy for intraabdominal infections	LANCET			English	Editorial Material											Quinn, JP (corresponding author), UNIV ILLINOIS,DEPT MED,CHICAGO,IL 60612, USA.							BOHNEN JMA, 1992, ARCH SURG-CHICAGO, V127, P83; Christou NV, 1996, ARCH SURG-CHICAGO, V131, P1193; GORBACH SL, 1993, CLIN INFECT DIS, V17, P961, DOI 10.1093/clinids/17.6.961; Montravers P, 1996, CLIN INFECT DIS, V23, P486, DOI 10.1093/clinids/23.3.486; SCHEIN M, 1994, BRIT J SURG, V81, P989, DOI 10.1002/bjs.1800810720	5	9	9	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 22	1997	349	9051					517	518		10.1016/S0140-6736(97)80079-7	http://dx.doi.org/10.1016/S0140-6736(97)80079-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WJ512	9048784				2022-12-01	WOS:A1997WJ51200003
J	Kurahashi, T; Menini, A				Kurahashi, T; Menini, A			Mechanism of odorant adaptation in the olfactory receptor cell	NATURE			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; NUCLEOTIDE-GATED CHANNELS; ADAPTIVE PROPERTIES; NEURONS; CALCIUM; NEWT; PHOSPHORYLATION; TRANSDUCTION; SENSITIVITY; CONDUCTANCE	Adaptation to odorants begins at the level of sensory receptor cells(1-5), presumably through modulation of their transduction machinery, The olfactory signal transduction involves the activation of the adenylyl cyclase/cyclic AMP second messenger system which leads to the sequential opening of cAMP-gated channels and Ca2+-activated chloride ion channels(4-7). Several reports of results obtained from in vitro preparations describe the possible molecular mechanisms involved in odorant adaptation; namely, ordorant receptor phosphorylation(8,9), activation of phosphodiesterase(10), and ion channel regulation(11-14). However, it is still unknown whether these putative mechanisms work in the intact olfactory receptor cell. Here we investigate the nature of the adaptational mechanism in intact olfactory cells by using a combination of odorant stimulation and caged cAMP photolysis(15) which produces current responses that bypass the early stages of signal transduction (involving the receptor, G protein and adenylyl cyclase). Odorant- and cAMP-induced responses showed the same adaptation in a Ca2+-dependent manner, indicating that adaptation occurs entirely downstream of the cyclase. Moreover, we show that phosphodiesterase activity remains constant during adaptation and that an affinity change of the cAMP-gated channel for ligands accounts well for our results. We conclude that the principal mechanism underlying odorant adaptation is actually a modulation of the cAMP-gated channel by Ca2+ feedback.	OSAKA UNIV, DEPT BIOL, TOYOAKE, AICHI 560, JAPAN; CNR, IST CIBERNET & BIOFIS, I-16149 GENOA, ITALY	Osaka University; Consiglio Nazionale delle Ricerche (CNR)	Kurahashi, T (corresponding author), NATL INST PHYSIOL SCI, OKAZAKI, AICHI 444, JAPAN.			Menini, Anna/0000-0001-9304-0412				Balasubramanian S, 1996, J MEMBRANE BIOL, V152, P13, DOI 10.1007/s002329900081; BOEKHOFF I, 1992, P NATL ACAD SCI USA, V89, P11983, DOI 10.1073/pnas.89.24.11983; BOEKHOFF I, 1992, P NATL ACAD SCI USA, V89, P471, DOI 10.1073/pnas.89.2.471; BORISY FF, 1992, J NEUROSCI, V12, P915; BREER H, 1992, SOC GEN PHY, V47, P93; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; CHEN TY, 1994, NATURE, V368, P545, DOI 10.1038/368545a0; FIRESTEIN S, 1993, J PHYSIOL-LONDON, V468, P1; FIRESTEIN S, 1990, J PHYSIOL-LONDON, V430, P135, DOI 10.1113/jphysiol.1990.sp018286; GETCHELL TV, 1978, J PHYSIOL-LONDON, V282, P541, DOI 10.1113/jphysiol.1978.sp012480; HSU YT, 1993, NATURE, V361, P76, DOI 10.1038/361076a0; KAWAMURA S, 1991, NATURE, V349, P420, DOI 10.1038/349420a0; KAWAMURA S, 1993, NATURE, V362, P855, DOI 10.1038/362855a0; Kawamura S, 1996, J BIOL CHEM, V271, P21359, DOI 10.1074/jbc.271.35.21359; Koutalos Y, 1996, TRENDS NEUROSCI, V19, P73; KRAMER RH, 1992, NEURON, V9, P897, DOI 10.1016/0896-6273(92)90242-6; KURAHASHI T, 1991, NEUROREPORT, V2, P5, DOI 10.1097/00001756-199101000-00001; KURAHASHI T, 1990, J PHYSIOL-LONDON, V430, P355, DOI 10.1113/jphysiol.1990.sp018295; KURAHASHI T, 1990, BRAIN RES, V515, P261, DOI 10.1016/0006-8993(90)90605-B; KURAHASHI T, 1989, J PHYSIOL-LONDON, V419, P177, DOI 10.1113/jphysiol.1989.sp017868; KURAHASHI T, 1994, CURR BIOL, V4, P256, DOI 10.1016/S0960-9822(00)00058-0; LAMB TD, 1992, TRENDS NEUROSCI, V15, P291, DOI 10.1016/0166-2236(92)90079-N; LOWE G, 1993, NATURE, V366, P283, DOI 10.1038/366283a0; LYNCH JW, 1994, J GEN PHYSIOL, V103, P87, DOI 10.1085/jgp.103.1.87; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; NERBONNE JM, 1984, NATURE, V310, P74, DOI 10.1038/310074a0; REED RR, 1992, NEURON, V8, P205, DOI 10.1016/0896-6273(92)90287-N; Torre V, 1995, J NEUROSCI, V15, P7757; YAMAGATA K, 1990, NEURON, V4, P469, DOI 10.1016/0896-6273(90)90059-O; ZUFALL F, 1991, P ROY SOC B-BIOL SCI, V246, P225, DOI 10.1098/rspb.1991.0148	30	258	262	1	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 20	1997	385	6618					725	729		10.1038/385725a0	http://dx.doi.org/10.1038/385725a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WJ423	9034189				2022-12-01	WOS:A1997WJ42300047
J	Merson, MH; Feldman, EA; Bayer, R; Stryker, J				Merson, MH; Feldman, EA; Bayer, R; Stryker, J			Rapid self testing for HIV infection	LANCET			English	Editorial Material							HOME		YALE UNIV,INST SOCIAL & POLICY STUDIES,NEW HAVEN,CT; COLUMBIA UNIV,SCH PUBL HLTH,NEW YORK,NY; UNIV CALIF SAN FRANCISCO,CTR AIDS PREVENT STUDIES,SAN FRANCISCO,CA	Yale University; Columbia University; University of California System; University of California San Francisco	Merson, MH (corresponding author), YALE UNIV,SCH MED,DEPT EPIDEMIOL & PUBL HLTH,POB 208034,NEW HAVEN,CT 06520, USA.							ALLEN S, 1992, BRIT MED J, V304, P1605, DOI 10.1136/bmj.304.6842.1605; BAYER R, 1995, NEW ENGL J MED, V332, P1296, DOI 10.1056/NEJM199505113321911; BERRIOS DC, 1993, JAMA-J AM MED ASSOC, V270, P1576, DOI 10.1001/jama.270.13.1576; BRANSON BM, 1996, AIDS SOC NEWSLET MAR; NIGHTINGALE SL, 1995, JAMA-J AM MED ASSOC, V273, P613; PHILLIPS KA, 1995, NEW ENGL J MED, V332, P1308, DOI 10.1056/NEJM199505113321918; Schopper D, 1996, AIDS, V10, P1455, DOI 10.1097/00002030-199611000-00002; Starace F, 1993, Int J Soc Psychiatry, V39, P64, DOI 10.1177/002076409303900107; WALL PG, 1993, AIDS, V7, P1523, DOI 10.1097/00002030-199311000-00018; WORTLEY PM, 1995, AIDS, V9, P487, DOI 10.1097/00002030-199509050-00011; 1995, FED REG         0223, V60, P10087	11	23	23	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 1	1997	349	9048					352	353		10.1016/S0140-6736(96)08260-8	http://dx.doi.org/10.1016/S0140-6736(96)08260-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF794	9024392				2022-12-01	WOS:A1997WF79400045
J	CroninStubbs, D; Beckett, LA; Scherr, PA; Field, TS; Chown, MJ; Pilgrim, DM; Bennett, DA; Evans, DA				CroninStubbs, D; Beckett, LA; Scherr, PA; Field, TS; Chown, MJ; Pilgrim, DM; Bennett, DA; Evans, DA			Weight loss in people with Alzheimer's disease: A prospective population based analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article									CTR DIS CONTROL & PREVENT, HLTH CARE & AGING STUDIES BRANCH, ATLANTA, GA USA; HARVARD UNIV, SCH MED, DIV MED, BOSTON, MA USA; HARVARD UNIV, SCH MED, HARVARD COMMUNITY HLTH PLAN, BOSTON, MA USA	Centers for Disease Control & Prevention - USA; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	CroninStubbs, D (corresponding author), RUSH INST AGING, 1645 W JACKSON BLVD, SUITE 675, CHICAGO, IL 60612 USA.				NIA NIH HHS [N01-AG-12106, AG-10161, N01-AG-02107] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P30AG010161, N01AG012106, N01AG002107] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		*AM HOSP ASS DIV Q, 1989, INT CLASS DIS; GALANOS AN, 1994, J AM GERIATR SOC, V42, P368, DOI 10.1111/j.1532-5415.1994.tb07483.x; RHEAUME Y, 1987, Journal of Nutrition for the Elderly, V7, P43, DOI 10.1300/J052v07n01_05; SPARKS DL, 1988, ARCH NEUROL-CHICAGO, V45, P994, DOI 10.1001/archneur.1988.00520330084014; Wolf-Klein G P, 1994, Int Psychogeriatr, V6, P135, DOI 10.1017/S1041610294001705	5	87	89	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 18	1997	314	7075					178	179		10.1136/bmj.314.7075.178	http://dx.doi.org/10.1136/bmj.314.7075.178			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WD911	9022430	Green Submitted, Green Published			2022-12-01	WOS:A1997WD91100024
J	Neal, KR; Dornan, J; Irving, WL				Neal, KR; Dornan, J; Irving, WL			Prevalence of hepatitis C antibodies among healthcare workers of two teaching hospitals. Who is at risk?	BRITISH MEDICAL JOURNAL			English	Article							VIRUS; TRANSMISSION		QUEENS MED CTR,NOTTINGHAM OCCUPAT HLTH,NOTTINGHAM NG7 2UH,ENGLAND; UNIV NOTTINGHAM,DEPT MICROBIOL,NOTTINGHAM NG7 2UH,ENGLAND	University of Nottingham; University of Nottingham	Neal, KR (corresponding author), UNIV NOTTINGHAM,DEPT PUBL HLTH MED,NOTTINGHAM NG7 2UH,ENGLAND.			Irving, William/0000-0002-7268-3168	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLANDER T, 1995, LANCET, V345, P603, DOI 10.1016/S0140-6736(95)90518-9; Esteban JI, 1996, NEW ENGL J MED, V334, P555, DOI 10.1056/NEJM199602293340902; NEAL KR, 1994, EPIDEMIOL INFECT, V112, P595, DOI 10.1017/S0950268800051293; SUZUKI K, 1994, J INFECT DIS, V170, P1575, DOI 10.1093/infdis/170.6.1575; ZUCKERMAN J, 1994, LANCET, V343, P1618, DOI 10.1016/S0140-6736(94)93064-3	5	23	24	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 18	1997	314	7075					179	180		10.1136/bmj.314.7075.179	http://dx.doi.org/10.1136/bmj.314.7075.179			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WD911	9022431	Green Published			2022-12-01	WOS:A1997WD91100025
J	Thune, I; Brenn, T; Lunk, E; Gaard, M				Thune, I; Brenn, T; Lunk, E; Gaard, M			Physical activity and the risk of breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MENSTRUAL-CYCLE PATTERNS; DIETARY-FAT; EXERCISE; WOMEN; PROGESTERONE; RESTRICTION; MORTALITY; MENARCHE; OVARIAN; WEIGHT	Background Because physical activity may affect hormonal concentrations and energy balance, we decided to investigate whether everyday exercise is related to the risk of breast cancer. Methods During 1974 to 1978 and 1977 to 1983, a total of 25,624 women, 20 to 54 years of age at entry, enrolled in health surveys and answered questionnaires about leisure-time and work activity. Results During a median follow-up of 13.7 years, we identified 351 cases of invasive breast cancer among the 25,624 women in the cohort. Greater leisure-time activity was associated with a reduced risk of breast cancer, after adjustments for age, body mass index (the weight in kilograms divided by the square of the height in meters), height, parity, and county of residence (relative risk, 0.63; 95 percent confidence interval, 0.42 to 0.95), among women who exercised regularly, as compared with sedentary women (P for trend = 0.04). In regularly exercising women, the reduction in risk was greater in premenopausal women than in postmenopausal women, and greater in younger women (<45 years at study entry) than in older women (greater than or equal to 45 years) (relative risk, 0.38; 95 percent confidence interval, 0.19 to 0.79). In stratified analyses the risk of breast cancer was lowest in lean women (body-mass index, <22.8) who exercised at least four hours per week (relative risk, 0.28; 95 percent confidence interval, 0.11 to 0.70). The risk was also reduced with higher levels of activity at work, and again there was a more pronounced effect among premenopausal than postmenopausal women. Conclusions Physical activity during leisure time and at work is associated with a reduced risk of breast cancer. (C) 1997, Massachusetts Medical Society.	CANC REGISTRY NORWAY,OSLO,NORWAY	University of Oslo	Thune, I (corresponding author), UNIV TROMSO,INST COMMUNITY MED,N-9037 TROMSO,NORWAY.		Brenn, Tormod/AAY-5357-2021	Brenn, Tormod/0000-0003-3717-8323; Lund, Eiliv/0000-0002-8071-8711				ALBANES D, 1989, AM J PUBLIC HEALTH, V79, P744, DOI 10.2105/AJPH.79.6.744; BEITINS IZ, 1991, J CLIN ENDOCR METAB, V72, P1350, DOI 10.1210/jcem-72-6-1350; BERNSTEIN L, 1987, BRIT J CANCER, V55, P681, DOI 10.1038/bjc.1987.139; BERNSTEIN L, 1994, J NATL CANCER I, V86, P1403, DOI 10.1093/jnci/86.18.1403; Bjartveit K, 1979, Acta Med Scand Suppl, V634, P1; BOISSONNEAULT GA, 1986, J NATL CANCER I, V76, P335; BROOCKS A, 1990, J APPL PHYSIOL, V68, P2083, DOI 10.1152/jappl.1990.68.5.2083; BULLEN BA, 1985, NEW ENGL J MED, V312, P1349, DOI 10.1056/NEJM198505233122103; COHEN LA, 1988, CANCER RES, V48, P4276; *COLL GROUP HORM F, 1996, LANCET, V347, P1713; DAvanzo B, 1996, CANCER EPIDEM BIOMAR, V5, P155; DORGAN JF, 1994, AM J EPIDEMIOL, V139, P662, DOI 10.1093/oxfordjournals.aje.a117056; DOSEMECI M, 1993, CANCER CAUSE CONTROL, V4, P313, DOI 10.1007/BF00051333; ELLISON PT, 1986, AM J OBSTET GYNECOL, V154, P1000, DOI 10.1016/0002-9378(86)90737-4; Freni SC, 1996, CANCER CAUSE CONTROL, V7, P358, DOI 10.1007/BF00052942; FRIEDENREICH CM, 1995, EUR J CANCER PREV, V4, P145, DOI 10.1097/00008469-199504000-00004; FRISCH RE, 1981, JAMA-J AM MED ASSOC, V246, P1559, DOI 10.1001/jama.246.14.1559; FRISCH RE, 1985, BRIT J CANCER, V52, P885, DOI 10.1038/bjc.1985.273; GAARD M, 1996, 1 CANC REG NORW; HAFFNER SM, 1991, INT J OBESITY, V15, P471; HARLOW SD, 1991, AM J EPIDEMIOL, V133, P38, DOI 10.1093/oxfordjournals.aje.a115800; HENDERSON BE, 1985, CANCER, V56, P1206, DOI 10.1002/1097-0142(19850901)56:5<1206::AID-CNCR2820560541>3.0.CO;2-9; HOLME I, 1981, ACTA MED SCAND, V209, P277; KRITCHEVSKY D, 1992, ADV EXP MED BIOL, V322, P131; KVALE G, 1988, CANCER-AM CANCER SOC, V62, P1625, DOI 10.1002/1097-0142(19881015)62:8<1625::AID-CNCR2820620828>3.0.CO;2-K; LOCHEN ML, 1992, J EPIDEMIOL COMMUNIT, V26, P103; LOKEN EB, 1987, VAR FODA S, V1, P33; LOUCKS AB, 1989, J CLIN ENDOCR METAB, V68, P402, DOI 10.1210/jcem-68-2-402; MERZENICH H, 1993, AM J EPIDEMIOL, V138, P217, DOI 10.1093/oxfordjournals.aje.a116850; Meyer F, 1990, Epidemiology, V1, P377, DOI 10.1097/00001648-199009000-00007; MITTENDORF R, 1995, CANCER CAUSE CONTROL, V6, P347, DOI 10.1007/BF00051410; MOISAN J, 1991, Medicine and Science in Sports and Exercise, V23, P1170; *NAT HLTH SCREEN S, 1988, CARD DIS STUD NORW C; PAFFENBARGER RS, 1987, AM J CLIN NUTR, V45, P312, DOI 10.1093/ajcn/45.1.312; PERUSSE L, 1989, AM J EPIDEMIOL, V129, P1012, DOI 10.1093/oxfordjournals.aje.a115205; PIKE MC, 1993, EPIDEMIOL REV, V15, P17, DOI 10.1093/oxfordjournals.epirev.a036102; PRIOR JC, 1990, NEW ENGL J MED, V323, P1221, DOI 10.1056/NEJM199011013231801; PRIOR JC, 1993, NEW ENGL J MED, V328, P1724; RUSSELL JB, 1984, OBSTET GYNECOL, V63, P452; SLATTERY ML, 1992, AM J CLIN NUTR, V55, P943, DOI 10.1093/ajcn/55.5.943; TAIOLI E, 1995, EUR J CANCER, V31A, P723, DOI 10.1016/0959-8049(95)00046-L; TRETLI S, 1989, INT J CANCER, V44, P23, DOI 10.1002/ijc.2910440105; VENA JE, 1987, AM J CLIN NUTR, V45, P318, DOI 10.1093/ajcn/45.1.318; VIHKO VJ, 1992, ACTA ONCOL, V31, P201, DOI 10.3109/02841869209088903; WALBERGRANKIN J, 1992, INT J SPORTS MED, V13, P542, DOI 10.1055/s-2007-1021313; WARREN MP, 1980, J CLIN ENDOCR METAB, V51, P1150, DOI 10.1210/jcem-51-5-1150; WELSCH CW, 1985, CANCER RES, V45, P6147; WHELAN EA, 1994, AM J EPIDEMIOL, V140, P1081, DOI 10.1093/oxfordjournals.aje.a117208; Wilhelmsen L, 1976, Adv Cardiol, V18, P217; ZHENG W, 1993, CANCER-AM CANCER SOC, V71, P3620, DOI 10.1002/1097-0142(19930601)71:11<3620::AID-CNCR2820711125>3.0.CO;2-S; Ziegler RG, 1996, J NATL CANCER I, V88, P650, DOI 10.1093/jnci/88.10.650	51	408	413	3	33	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 1	1997	336	18					1269	1275		10.1056/NEJM199705013361801	http://dx.doi.org/10.1056/NEJM199705013361801			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW260	9113929				2022-12-01	WOS:A1997WW26000001
J	Bezzubova, O; Silbergleit, A; YamaguchiIwai, Y; Takeda, S; Buerstedde, JM				Bezzubova, O; Silbergleit, A; YamaguchiIwai, Y; Takeda, S; Buerstedde, JM			Reduced X-ray resistance and homologous recombination frequencies in a RAD54(-/-) mutant of the chicken DT40 cell line	CELL			English	Article							STRAND-BREAK REPAIR; ESCHERICHIA-COLI RECA; LIGHT CHAIN GENE; SACCHAROMYCES-CEREVISIAE; V(D)J RECOMBINATION; DNA-REPAIR; YEAST RECOMBINATION; SENSITIVE MUTANTS; HIGHER EUKARYOTES; MOUSE HOMOLOG	rad54 mutants of the yeast Saccharomyces cerevisiae are extremely X-ray sensitive and have decreased mitotic recombination frequencies because of a defect in double-strand break repair. A RAD54 homolog was disrupted in the chicken B cell line DT40, which undergoes immunoglobulin gene conversion and exhibits unusually high ratios of targeted to random integration after DNA transfection. Homozygous RAD54(-/-) mutant clones were highly X-ray sensitive compared to wildtype cells. The rate of immunoglobulin gene conversion was 6- to 8-fold reduced, and the frequency of targeted integration was at least two orders of magnitude decreased in the mutant clones. Reexpression of the RAD54 cDNA restored radiation resistance and targeted integration activity. The reported phenotype provides the first genetic evidence of a link between double-strand break repair and homologous recombination in vertebrate cells.	KYOTO UNIV, SCH MED, BAYER CHAIR DEPT MOL IMMUNOL, KYOTO 606, JAPAN	Kyoto University	Bezzubova, O (corresponding author), BASEL INST IMMUNOL, GRENZACHERSTR 487, CH-4005 BASEL, SWITZERLAND.			Takeda, Shunichi/0000-0002-7924-7991				BENDIXEN C, 1994, GENOMICS, V23, P300, DOI 10.1006/geno.1994.1503; BENSON FE, 1994, EMBO J, V13, P5764, DOI 10.1002/j.1460-2075.1994.tb06914.x; BEZZUBOVA O, 1993, NUCLEIC ACIDS RES, V21, P1577, DOI 10.1093/nar/21.7.1577; BEZZUBOVA OY, 1994, EXPERIENTIA, V50, P270, DOI 10.1007/BF01924010; BEZZUBOVA OY, 1993, NUCLEIC ACIDS RES, V21, P5945, DOI 10.1093/nar/21.25.5945; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; BUDD M, 1982, MUTAT RES, V103, P19, DOI 10.1016/0165-7992(82)90080-X; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; BUERSTEDDE JM, 1990, EMBO J, V9, P921, DOI 10.1002/j.1460-2075.1990.tb08190.x; CALDERON IL, 1983, CURR GENET, V7, P93, DOI 10.1007/BF00365632; CHOULIKA A, 1995, MOL CELL BIOL, V15, P1968; CONTOPOULOU CR, 1987, YEAST, V3, P71, DOI 10.1002/yea.320030203; Dieken ES, 1996, NAT GENET, V12, P174, DOI 10.1038/ng0296-174; EMERY HS, 1991, GENE, V104, P103, DOI 10.1016/0378-1119(91)90473-O; GAME JC, 1993, SEMIN CANCER BIOL, V4, P73; GAME JC, 1974, MUTAT RES, V24, P281, DOI 10.1016/0165-1218(74)90185-2; HARTMAN SC, 1988, P NATL ACAD SCI USA, V85, P8047, DOI 10.1073/pnas.85.21.8047; JEGGO PA, 1991, MUTAT RES, V254, P125, DOI 10.1016/0921-8777(91)90003-8; JEGGO PA, 1995, BIOESSAYS, V17, P949, DOI 10.1002/bies.950171108; Kanaar R, 1996, CURR BIOL, V6, P828, DOI 10.1016/S0960-9822(02)00606-1; Liang F, 1996, P NATL ACAD SCI USA, V93, P8929, DOI 10.1073/pnas.93.17.8929; Luria SE, 1943, GENETICS, V28, P491; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MORITA T, 1993, P NATL ACAD SCI USA, V90, P6577, DOI 10.1073/pnas.90.14.6577; Muris DFR, 1996, J CELL SCI, V109, P73; MURIS DFR, 1994, MUTAT RES-DNA REPAIR, V315, P295, DOI 10.1016/0921-8777(94)90040-X; MURIS DFR, 1997, IN PRESS CURR GENET; ORRWEAVER TL, 1983, P NATL ACAD SCI-BIOL, V80, P4417, DOI 10.1073/pnas.80.14.4417; ORRWEAVER TL, 1981, P NATL ACAD SCI-BIOL, V78, P6354, DOI 10.1073/pnas.78.10.6354; PERGOLA F, 1993, MOL CELL BIOL, V13, P3464, DOI 10.1128/MCB.13.6.3464; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; RESNICK MA, 1976, J THEOR BIOL, V59, P97, DOI 10.1016/S0022-5193(76)80025-2; REYNAUD CA, 1987, CELL, V48, P379, DOI 10.1016/0092-8674(87)90189-9; RIELE HT, 1992, P NATL ACAD SCI USA, V89, P5128, DOI 10.1073/pnas.89.11.5128; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SAEKI T, 1980, MUTAT RES, V73, P251, DOI 10.1016/0027-5107(80)90192-X; SHINOHARA A, 1993, NAT GENET, V5, P312, DOI 10.1038/ng1193-312c; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SMITHIES O, 1985, NATURE, V317, P230, DOI 10.1038/317230a0; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; TAKEDA S, 1992, P NATL ACAD SCI USA, V89, P4023, DOI 10.1073/pnas.89.9.4023; THOMAS KR, 1986, CELL, V44, P419, DOI 10.1016/0092-8674(86)90463-0; THOMPSON CB, 1987, CELL, V48, P369, DOI 10.1016/0092-8674(87)90188-7; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; WEAVER DT, 1995, TRENDS GENET, V11, P388, DOI 10.1016/S0168-9525(00)89121-0	49	233	239	1	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 18	1997	89	2					185	193		10.1016/S0092-8674(00)80198-1	http://dx.doi.org/10.1016/S0092-8674(00)80198-1			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WU888	9108474	Bronze			2022-12-01	WOS:A1997WU88800006
J	Schlozman, S				Schlozman, S			The Bard in his outcast state	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 9	1997	277	14					1118	1118						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR342	9087460				2022-12-01	WOS:A1997WR34200015
J	Hegde, AN; Inokuchi, K; Pei, WZ; Casadio, A; Ghirardi, M; Chain, DG; Martin, KC; Kandel, ER; Schwartz, JH				Hegde, AN; Inokuchi, K; Pei, WZ; Casadio, A; Ghirardi, M; Chain, DG; Martin, KC; Kandel, ER; Schwartz, JH			Ubiquitin C-terminal hydrolase is an immediate-early gene essential for long-term facilitation in Aplysia	CELL			English	Article							DEPENDENT PROTEIN-KINASE; SIPHON-WITHDRAWAL REFLEX; CAMP-RESPONSIVE ELEMENT; SENSORY NEURONS; REGULATORY SUBUNITS; TRANSMITTER RELEASE; MOLECULAR MECHANISM; CYCLIC-AMP; DEGRADATION; PROTEOLYSIS	The switch from short-term to long-term facilitation of the synapses between sensory and motor neurons mediating gill and tail withdrawal reflexes in Aplysia requires CREB-mediated transcription and new protein synthesis. We isolated several downstream genes, one of which encodes a neuron-specific ubiquitin C-terminal hydrolase. This rapidly induced gene encodes an enzyme that associates with the proteasome and increases its proteolytic activity. This regulated proteolysis is essential for long-term facilitation. Inhibiting the expression or function of the hydrolase blocks induction of long-term but not short-term facilitation. We suggest that the enhanced proteasome activity increases degradation of substrates that normally inhibit long-term facilitation. Thus, through induction of the hydrolase and the resulting up-regulation of the ubiquitin pathway, learning recruits a regulated form of proteolysis that removes inhibitory constraints on long-term memory storage.	COLUMBIA UNIV COLL PHYS & SURG,NEW YORK STATE PSYCHIAT INST,HOWARD HUGHES MED INST,NEW YORK,NY 10032; MITSUBISHI KASEI INST LIFE SCI,MACHIDA,TOKYO 194,JAPAN; UNIV TURIN,DIPARTIMENTO NEUROSCI,I-10125 TURIN,ITALY	Columbia University; Howard Hughes Medical Institute; New York State Psychiatry Institute; University of Turin	Hegde, AN (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,NEW YORK STATE PSYCHIAT INST,CTR NEUROBIOL & BEHAV,722 W 168TH ST,NEW YORK,NY 10032, USA.		ghirardi, mirella/AEQ-0420-2022; Schwartz, John/AAO-8158-2021; Inokuchi, Kaoru/AAI-9693-2020	Schwartz, John/0000-0002-1660-8681; Inokuchi, Kaoru/0000-0002-5393-3133	NIMH NIH HHS [MH00921] Funding Source: Medline; NINDS NIH HHS [NS29255] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [K05MH000921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R55NS029255, R01NS029255] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBERINI CM, 1994, CELL, V76, P1099, DOI 10.1016/0092-8674(94)90386-7; BAILEY CH, 1992, SCIENCE, V256, P645, DOI 10.1126/science.1585177; BAILEY CH, 1993, ANNU REV PHYSIOL, V55, P397, DOI 10.1146/annurev.ph.55.030193.002145; BAKER RT, 1992, J BIOL CHEM, V267, P23364; BARTSCH D, 1995, CELL, V83, P979, DOI 10.1016/0092-8674(95)90213-9; BARZILAI A, 1989, NEURON, V2, P1577, DOI 10.1016/0896-6273(89)90046-9; BEERS EP, 1993, J BIOL CHEM, V268, P21645; BERGOLD PJ, 1990, P NATL ACAD SCI USA, V87, P3788, DOI 10.1073/pnas.87.10.3788; BERNIER L, 1982, J NEUROSCI, V2, P1682; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; BRUNELLI M, 1976, SCIENCE, V194, P1178, DOI 10.1126/science.186870; Byrne JH, 1996, J NEUROSCI, V16, P425; Carew TJ, 1996, NEURON, V16, P5, DOI 10.1016/S0896-6273(00)80016-1; CHAIN DG, 1995, J NEUROSCI, V15, P7592; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DALE N, 1987, J NEUROSCI, V7, P2232; DASH PK, 1990, NATURE, V345, P718, DOI 10.1038/345718a0; EYTAN E, 1993, J BIOL CHEM, V268, P4668; FAGAN JM, 1986, J BIOL CHEM, V261, P5705; FROST WN, 1985, P NATL ACAD SCI USA, V82, P8266, DOI 10.1073/pnas.82.23.8266; GHIRARDI M, 1995, NEURON, V14, P413, DOI 10.1016/0896-6273(95)90297-X; GHIRARDI M, 1992, NEURON, V9, P479, DOI 10.1016/0896-6273(92)90185-G; GOELET P, 1986, NATURE, V322, P419, DOI 10.1038/322419a0; GREENBERG SM, 1987, NATURE, V329, P62, DOI 10.1038/329062a0; GREGORI L, 1995, J BIOL CHEM, V270, P19702, DOI 10.1074/jbc.270.34.19702; HADARI T, 1992, J BIOL CHEM, V267, P719; HEGDE AN, 1993, P NATL ACAD SCI USA, V90, P7436, DOI 10.1073/pnas.90.16.7436; HOUGH R, 1986, J BIOL CHEM, V261, P2391; HUANG YZ, 1995, SCIENCE, V270, P1828, DOI 10.1126/science.270.5243.1828; KAANG BK, 1993, NEURON, V10, P427, DOI 10.1016/0896-6273(93)90331-K; KANDEL ER, 1982, SCIENCE, V218, P433, DOI 10.1126/science.6289442; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; KREUTZERSCHMID C, 1990, FEBS LETT, V267, P142, DOI 10.1016/0014-5793(90)80309-7; Larsen CN, 1996, BIOCHEMISTRY-US, V35, P6735, DOI 10.1021/bi960099f; MILLER HI, 1989, BIO-TECHNOL, V7, P698, DOI 10.1038/nbt0789-698; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; MONTAROLO PG, 1988, NATURE, V333, P171, DOI 10.1038/333171a0; MURALIDHAR MG, 1993, NEURON, V11, P253, DOI 10.1016/0896-6273(93)90182-Q; OH CE, 1994, J NEUROSCI, V14, P3166; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Sambrook J., 1989, MOL CLONING LAB MANU; SCHACHER S, 1983, J NEUROSCI, V3, P2403; SCHACHER S, 1988, SCIENCE, V240, P1667, DOI 10.1126/science.2454509; SCHOLZ KP, 1988, SCIENCE, V240, P1664, DOI 10.1126/science.2837826; SCHWARTZ JH, 1971, J NEUROPHYSIOL, V34, P939, DOI 10.1152/jn.1971.34.6.939; SIEGELBAUM SA, 1982, NATURE, V299, P413, DOI 10.1038/299413a0; SWEATT JD, 1989, NATURE, V339, P51, DOI 10.1038/339051a0; TAMURA T, 1991, FEBS LETT, V292, P154, DOI 10.1016/0014-5793(91)80856-X; TULLY T, 1994, CELL, V79, P35, DOI 10.1016/0092-8674(94)90398-0; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WILKINSON KD, 1995, BIOCHEMISTRY-US, V34, P14535, DOI 10.1021/bi00044a032; WILKINSON KD, 1995, ANNU REV NUTR, V15, P161, DOI 10.1146/annurev.nu.15.070195.001113; WILKINSON KD, 1989, SCIENCE, V246, P670, DOI 10.1126/science.2530630; Zhu Y, 1996, P NATL ACAD SCI USA, V93, P3275, DOI 10.1073/pnas.93.8.3275	55	305	313	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 4	1997	89	1					115	126		10.1016/S0092-8674(00)80188-9	http://dx.doi.org/10.1016/S0092-8674(00)80188-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WR685	9094720	hybrid			2022-12-01	WOS:A1997WR68500015
J	Schneider, E; Hajjeh, RA; Spiegel, RA; Jibson, RW; Harp, EL; Marshall, GA; Gunn, RA; McNeil, MM; Pinner, RW; Baron, RC; Burger, RC; Hutwagner, LC; Crump, C; Kaufman, L; Reef, SE; Feldman, GM; Pappagianis, D; Werner, SB				Schneider, E; Hajjeh, RA; Spiegel, RA; Jibson, RW; Harp, EL; Marshall, GA; Gunn, RA; McNeil, MM; Pinner, RW; Baron, RC; Burger, RC; Hutwagner, LC; Crump, C; Kaufman, L; Reef, SE; Feldman, GM; Pappagianis, D; Werner, SB			A coccidioidomycosis outbreak following the Northridge, Calif, earthquake	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To describe a coccidioidomycosis outbreak in Ventura County following the January 1994 earthquake, centered in Northridge, Calif, and to identify factors that increased the risk for acquiring acute coccidioidomycosis infection. Design.-Epidemic investigation, population-based skin test survey, and case-control study. Setting.-Ventura County, California. Results.-In Ventura County, between January 24 and March 15, 1994, 203 outbreak-associated coccidioidomycosis cases, including 3 fatalities, were identified (attack rate [AR], 30 cases per 100 000 population). The majority of cases (56%) and the highest AR (114 per 100 000 population) occurred in the town of Simi Valley, a community located at the base of a mountain range that experienced numerous landslides associated with the earthquake. Disease onset for cases peaked 2 weeks after the earthquake. The AR was 2.8 times greater for persons 40 years of age and older than for younger persons (relative risk, 2.8; 95% confidence interval [CI], 2.1-3.7; P<.001). Environmental data indicated that large dust clouds, generated by landslides following the earthquake and strong aftershocks in the Santa Susana Mountains north of Simi Valley, were dispersed into nearby valleys by northeast winds. Simi Valley case-control study data indicated that physically being in a dust cloud (odds ratio, 3.0; 95% CI, 1.6-5.4; P<.001) and time spent in a dust cloud (P<.001) significantly increased the risk for being diagnosed with acute coccidioidomycosis. Conclusions.-Both the location and timing of cases strongly suggest that the coccidioidomycosis outbreak in Ventura County was caused when arthrospores were spread in dust clouds generated by the earthquake. This is the first report of a coccidioidomycosis outbreak following an earthquake. Public and physician awareness, especially in endemic areas following similar dust cloud-generating events, may result in prevention and early recognition of acute coccidioidomycosis.	EPIDEM INTELLIGENCE SERV, COMMUNITY DIS CONTROL, DEPT HLTH SERV, SAN DIEGO, CA USA; CTR DIS CONTROL & PREVENT, DEPT FIELD EPIDEMIOL, EPIDEMIOL PROGRAM OFF, ATLANTA, GA USA; CDC, EPIDEM INTELLIGENCE SERV, DIV BACTERIAL & MYCOT DIS, NATL CTR INFECT DIS, ATLANTA, GA 30333 USA; DEPT INTERIOR, CENT REG GEOL HAZARDS TEAM, US GEOL SURVEY, GOLDEN, CO USA; DEPT INTERIOR, US GEOL SURVEY, MENLO PK, CA USA; CDC, DIV STD HIV PREVENT, NATL CTR HIV STD & TB PREVENT, ATLANTA, GA 30333 USA; DEPT HLTH SERV, COMMUNITY DIS CONTROL, SAN DIEGO, CA USA; CDC, OFF DIRECTOR, NATL CTR INFECT DIS, ATLANTA, GA 30333 USA; CDC, DEPT FIELD EPIDEMIOL, EPIDEMIOL PROGRAM OFF, ATLANTA, GA 30333 USA; CDC, EMERGENCY RESPONSE COORDINAT GRP, NATL CTR ENVIRONM HLTH, ATLANTA, GA 30333 USA; VENTURA CTY PUBL HLTH, HLTH OFF, VENTURA, CA USA; UNIV CALIF DAVIS, SCH MED, DEPT MED MICROBIOL & IMMUNOL, SACRAMENTO, CA 95817 USA; CALIF DEPT HLTH SERV, DIV COMMUNICABLE DIS CONTROL, BERKELEY, CA 94704 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; United States Department of the Interior; United States Geological Survey; United States Department of the Interior; United States Geological Survey; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; University of California System; University of California Davis; California Department of Health Care Services			Crump, Casey/AAO-8802-2021	Crump, Casey/0000-0002-2990-1166; McNeil, Michael/0000-0003-0713-8312				AMPEL NM, 1989, REV INFECT DIS, V11, P897; *CAL GOV OFF EM SE, 1997, FEMADR1008CAPR OES; *CDCP, 1994, MMWR-MORBID MORTAL W, V43, P421; Centers for Disease Control and Prevention, 1996, MMWR MORB MORTAL WKL, V45, P1069; Centers for Disease Control and Prevention (CDC), 1994, MMWR Morb Mortal Wkly Rep, V43, P194; *COUNT LOS ANG DEP, 1994, 1994 COMM DIS MORB R; Dean AG, 1994, EPI INFO VERSION 6 0; DRUTZ DJ, 1978, AM REV RESPIR DIS, V117, P559; DRUTZ DJ, 1978, AM REV RESPIR DIS, V117, P727; EDWARDS PQ, 1957, DIS CHEST, V31, P35, DOI 10.1378/chest.31.1.35; EINSTEIN HE, 1993, CLIN INFECT DIS, V16, P349, DOI 10.1093/clind/16.3.349; Elconin AF, 1967, COCCIDIOIDOMYCOSIS, P319; FIESE MJ, 1958, COCCIDIOIDOMYCOSIS, P53; FLYNN NM, 1979, NEW ENGL J MED, V301, P358, DOI 10.1056/NEJM197908163010705; GALGIANI JN, 1992, CLIN INFECT DIS, V14, pS100, DOI 10.1093/clinids/14.Supplement_1.S100; *HAIN CO INC, 1994, AMERICALIST; Harp EL, 1996, B SEISMOL SOC AM, V86, pS319; JONES L, 1994, SCIENCE, V266, P389, DOI 10.1126/science.266.5184.398; Pappagianis D, 1988, Curr Top Med Mycol, V2, P199; PAPPAGIANIS D, 1994, CLIN INFECT DIS, V19, pS14, DOI 10.1093/clinids/19.Supplement_1.14; PAPPAGIANIS D, 1978, WESTERN J MED, V129, P527; PAPPAGIANIS D, 1990, CLIN MICROBIOL REV, V3, P247, DOI 10.1128/CMR.3.3.247-268.1990; *SAS I, 1993, SAS SOFTW REL 6 08; SMITH CE, 1946, JAMA-J AM MED ASSOC, V132, P833, DOI 10.1001/jama.1946.02870490011003; STEVENS DA, 1995, NEW ENGL J MED, V332, P1077, DOI 10.1056/NEJM199504203321607; STEVENS DA, 1975, CHEST, V68, P697, DOI 10.1378/chest.68.5.697; Swatek F., 1967, P 2 COCCIDIOIDOMYCOS; *US DEP COMM, 1993, 1990 CENS POP HOUS P; WERNER SB, 1972, NEW ENGL J MED, V286, P507, DOI 10.1056/NEJM197203092861003	29	153	154	0	15	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 19	1997	277	11					904	908		10.1001/jama.277.11.904	http://dx.doi.org/10.1001/jama.277.11.904			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM774	9062329				2022-12-01	WOS:A1997WM77400034
J	Westergaard, T; Wohlfahrt, J; Aaby, P; Melbye, M				Westergaard, T; Wohlfahrt, J; Aaby, P; Melbye, M			Population based study of rates of multiple pregnancies in Denmark, 1980-94	BMJ-BRITISH MEDICAL JOURNAL			English	Article							IN-VITRO FERTILIZATION; INFANT-MORTALITY; INDUCTION; OVULATION; TRIPLETS; BIRTHS; RULE	Objective: To study trends in multiple pregnancies not explained by changes in maternal age and parity patterns. Design: Trends in population based figures for multiple pregnancies in Denmark studied from complete national records on parity history and vital status. Population: 497 979 Danish women and 803 019 pregnancies, 1980-94. Main outcome measures: National rates of multiple pregnancies, infant mortality, and stillbirths controlled for maternal age and parity. Special emphasis on primiparous women greater than or equal to 30 years of age, who are most likely to undergo fertility treatment. Results: The national incidence of multiple pregnancies increased 1.7-fold during 1980-94, the increase primarily in 1989-94 and almost exclusively in primiparous women aged greater than or equal to 30 years, for whom the adjusted population based twinning rate increased 2.7-fold and the triplet rate 9.1-fold. During 1989-94, the adjusted yearly increase in multiple pregnancies for these women was 19% (95% confidence interval 16% to 21%) and in dizygotic twin pregnancies 25% (21% to 28%). The proportion of multiple births among infant deaths in primiparous women greater than or equal to 30 years increased from 11.5% to 26.9% during the study period. The total infant mortality, however, did not increase for these women because of a simultaneous significant decrease in infant mortality among singletons. Conclusions: A relatively small group of women has drastically changed the overall national rates of multiple pregnancies. The introduction of ne-cy treatments to enhance fertility has probably caused these changes and has also affected the otherwise decreasing trend in infant mortality. Consequently, the resources, both economical and otherwise, associated with these treatments go well beyond those invested in specific fertility enhancing treatments.	STATE SERUM INST, DANISH EPIDEMIOL SCI CTR, DEPT EPIDEMIOL RES, DK-2300 COPENHAGEN S, DENMARK	Aarhus University; Statens Serum Institut				melbye, mads/0000-0001-8264-6785; Aaby, Peter/0000-0001-8331-1389				[Anonymous], 1994, FERTIL STERIL, V62, P1121; BERAL V, 1990, BMJ-BRIT MED J, V300, P1229; CALLAHAN TL, 1994, NEW ENGL J MED, V331, P244, DOI 10.1056/NEJM199407283310407; DEROM C, 1987, LANCET, V1, P1236; Derom R, 1995, MULTIPLE PREGNANCY E, P145; EDWARDS R G, 1986, Journal of In Vitro Fertilization and Embryo Transfer, V3, P114, DOI 10.1007/BF01139357; FRIEDLER S, 1992, HUM REPROD, V7, P1159, DOI 10.1093/oxfordjournals.humrep.a137813; Hecht B. R., 1995, MULTIPLE PREGNANCY E, P175; JAMES WH, 1992, ACTA GENET MED GEMEL, V41, P33, DOI 10.1017/S0001566000002488; KEITH LG, 1991, INT J GYNECOL OBSTET, V36, P109, DOI 10.1016/0020-7292(91)90764-V; KIELY JL, 1992, AM J DIS CHILD, V146, P862, DOI 10.1001/archpedi.1992.02160190094029; KYVIK KO, 1995, INT J EPIDEMIOL, V24, P589, DOI 10.1093/ije/24.3.589; Little J., 1988, TWINNING TWINS, P37; LUKE B, 1992, J REPROD MED, V37, P661; McCullagh P., 1989, STANDARD BOOK GEN LI, DOI DOI 10.1007/978-1-4899-3242-6; *NAT BOARD HLTH, 1993, VEJL LAEG ANV KUNST; *NAT BOARD HLTH, 1996, NOT IVF BEH 1994 BAS; NEUMANN PJ, 1994, NEW ENGL J MED, V331, P239, DOI 10.1056/NEJM199407283310406; Nygren K G, 1991, Acta Obstet Gynecol Scand, V70, P561, DOI 10.3109/00016349109007917; PETERSEN K, 1995, ACTA OBSTET GYN SCAN, V74, P129, DOI 10.3109/00016349509008921; *SAS I, 1993, GENMOD PROC REL 6 09; SCHENKER JG, 1981, FERTIL STERIL, V35, P105; Taffel SM, 1995, MULTIPLE PREGNANCY E, P133; VANDUIVENBODEN YA, 1991, EUR J OBSTET GYN R B, V42, P201, DOI 10.1016/0028-2243(91)90220-F; VLIETINCK R, 1988, ACTA GENET MED GEMEL, V37, P137, DOI 10.1017/S0001566000004049; Weinberg W, 1901, ARCH GESAMTE PHYSIOL, V88, P346, DOI 10.1007/BF01657695; Westergaard L G, 1993, Ugeskr Laeger, V155, P2511	27	73	73	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 15	1997	314	7083					775	779		10.1136/bmj.314.7083.775	http://dx.doi.org/10.1136/bmj.314.7083.775			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN646	9080993	Green Published			2022-12-01	WOS:A1997WN64600020
J	Serrano, M; Lin, AW; McCurrach, ME; Beach, D; Lowe, SW				Serrano, M; Lin, AW; McCurrach, ME; Beach, D; Lowe, SW			Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16(INK4a)	CELL			English	Article							HUMAN-DIPLOID FIBROBLASTS; CYCLIN-DEPENDENT KINASES; EMBRYO FIBROBLASTS; ALTERED REGULATION; NUCLEAR ONCOGENES; INVITRO LIFESPAN; TUMOR SUPPRESSOR; GROWTH ARREST; SKIN TUMORS; HA-RAS	Oncogenic ras can transform most immortal rodent cells to a tumorigenic state. However, transformation of primary cells by ras requires either a cooperating oncogene or the inactivation of tumor suppressors such as p53 or p16. Here we show that expression of oncogenic ras in primary human or rodent cells results in a permanent G1 arrest The arrest induced by ras is accompanied by accumulation of p53 and p16, and is phenotypically indistinguishable from cellular senescence. Inactivation of either p53 or p16 prevents ras-induced arrest in rodent cells, and E1A achieves a similar effect in human cells. These observations suggest that the onset of cellular senescence does not simply reflect the accumulation of cell divisions, but can be prematurely activated in response to an oncogenic stimulus. Negation of ras-induced senescence may be relevant during multistep tumorigenesis.	COLD SPRING HARBOR LAB,HOWARD HUGHES MED INST,COLD SPRING HARBOR,NY 11724	Cold Spring Harbor Laboratory; Howard Hughes Medical Institute			Serrano, Manuel/H-2634-2015	Serrano, Manuel/0000-0001-7177-9312	NCI NIH HHS [CA13106, CA68040] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068040, P01CA013106] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AFSHARI CA, 1993, EXP CELL RES, V209, P231, DOI 10.1006/excr.1993.1306; Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; Bartkova J, 1996, CANCER RES, V56, P5475; BENITO M, 1991, SCIENCE, V253, P565, DOI 10.1126/science.1857988; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Cahill MA, 1996, CURR BIOL, V6, P16, DOI 10.1016/S0960-9822(02)00410-4; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; FAIRWEATHER DS, 1987, EXP CELL RES, V168, P153, DOI 10.1016/0014-4827(87)90424-1; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; GOLDSTEIN S, 1994, J CELL PHYSIOL, V161, P571, DOI 10.1002/jcp.1041610321; Hara E, 1996, MOL CELL BIOL, V16, P859; HARVEY DM, 1991, GENE DEV, V5, P2357; HARVEY M, 1993, ONCOGENE, V8, P2457; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HICKS GG, 1991, MOL CELL BIOL, V11, P1344, DOI 10.1128/MCB.11.3.1344; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; HIRAMA T, 1995, BLOOD, V86, P841; HOLLIDAY R, 1986, EXP CELL RES, V166, P543, DOI 10.1016/0014-4827(86)90499-4; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LINARDOPOULOS S, 1995, CANCER RES, V55, P5168; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; LOVEC H, 1994, ONCOGENE, V9, P323; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LUMPKIN CK, 1986, MOL CELL BIOL, V6, P2990, DOI 10.1128/MCB.6.8.2990; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCCURRACH ME, 1997, IN PRESS P NATL ACAD; METZ T, 1995, CELL, V82, P29, DOI 10.1016/0092-8674(95)90049-7; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MU XC, 1995, J CELL PHYSIOL, V165, P647, DOI 10.1002/jcp.1041650324; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Ogryzko VV, 1996, MOL CELL BIOL, V16, P5210; QUELLE DE, 1995, ONCOGENE, V11, P635; Reznikoff CA, 1996, CANCER RES, V56, P2886; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; ROHME D, 1981, P NATL ACAD SCI-BIOL, V78, P5009, DOI 10.1073/pnas.78.8.5009; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; RULEY HE, 1990, CANCER CELL-MON REV, V2, P258; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SESHADRI T, 1990, SCIENCE, V247, P205, DOI 10.1126/science.2104680; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; STEIN GH, 1995, BIOESSAYS, V17, P537, DOI 10.1002/bies.950170610; SULLIVAN NF, 1986, CANCER RES, V46, P6427; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; Venable ME, 1995, J BIOL CHEM, V270, P30701, DOI 10.1074/jbc.270.51.30701; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; VOTJA PJ, 1995, BIOCHIM BIOPHYS ACTA, V1242, P29; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINBERG RA, 1989, CANCER RES, V49, P3413; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572	73	3787	3892	11	199	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 7	1997	88	5					593	602		10.1016/S0092-8674(00)81902-9	http://dx.doi.org/10.1016/S0092-8674(00)81902-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WM413	9054499	Bronze			2022-12-01	WOS:A1997WM41300005
J	Booth, DR; Sunde, M; Bellotti, V; Robinson, CV; Hutchinson, WL; Fraser, PE; Hawkins, PN; Dobson, CM; Radford, SE; Blake, CCF; Pepys, MB				Booth, DR; Sunde, M; Bellotti, V; Robinson, CV; Hutchinson, WL; Fraser, PE; Hawkins, PN; Dobson, CM; Radford, SE; Blake, CCF; Pepys, MB			Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis	NATURE			English	Article							ALPHA-LACTALBUMIN; FIBRIL FORMATION; HEN LYSOZYME; MASS-SPECTROMETRY; MOLTEN GLOBULE; PROTEIN; DISULFIDE; PEPTIDES; DISEASES; SHEET	Tissue deposition of soluble proteins as amyloid fibrils underlies a range of fatal diseases. The two naturally occurring human lysozyme variants are both amyloidogenic, and are shown here to be unstable. They aggregate to form amyloid fibrils with transformation of the mainly helical native fold, observed in crystal structures, to the amyloid fibril cross-beta fold. Biophysical studies suggest that partly folded intermediates are involved in fibrillogenesis, and this may be relevant to amyloidosis generally.	HAMMERSMITH HOSP, ROYAL POSTGRAD MED SCH, IMMUNOL MED UNIT, LONDON W12 0NN, ENGLAND; UNIV OXFORD, LAB MOL BIOPHYS, OXFORD OX1 3QT, ENGLAND; UNIV OXFORD, OXFORD CTR MOL SCI, NEW CHEM LAB, OXFORD OX1 3QT, ENGLAND; UNIV TORONTO, CTR RES NEURODEGENERAT DIS, TORONTO, ON M5S 3H2, CANADA	Imperial College London; University of Oxford; University of Oxford; University of Toronto			Sunde, Margaret/A-5186-2016; Hawkins, Philip N/C-5573-2008; Bellotti, Vittorio/A-6201-2014; Sunde, Margaret/ABH-2584-2020	Sunde, Margaret/0000-0002-0150-3203; Bellotti, Vittorio/0000-0001-8678-662X; Sunde, Margaret/0000-0002-0150-3203; robinson, carol/0000-0001-7829-5505; Radford, Sheena/0000-0002-3079-8039				ABRAHAMSON M, 1994, P NATL ACAD SCI USA, V91, P1416, DOI 10.1073/pnas.91.4.1416; ARTYMIUK PJ, 1981, J MOL BIOL, V152, P737, DOI 10.1016/0022-2836(81)90125-X; BAI YW, 1993, PROTEINS, V17, P75, DOI 10.1002/prot.340170110; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Blake C, 1996, STRUCTURE, V4, P989, DOI 10.1016/S0969-2126(96)00104-9; BLAKE CCF, 1965, NATURE, V206, P757, DOI 10.1038/206757a0; BLAKE CCF, 1983, J MOL BIOL, V167, P693, DOI 10.1016/S0022-2836(83)80105-3; Booth DR, 1996, J CLIN INVEST, V97, P2714, DOI 10.1172/JCI118725; BRUNGER AT, 1992, XPLOR MANUAL VERSION; BYCHKOVA VE, 1995, FEBS LETT, V359, P6, DOI 10.1016/0014-5793(95)00004-S; CHUNG LP, 1988, P NATL ACAD SCI USA, V85, P6227, DOI 10.1073/pnas.85.17.6227; DOBSON CM, 1995, NAT STRUCT BIOL, V2, P513, DOI 10.1038/nsb0795-513; EYLES SJ, 1994, BIOCHEMISTRY-US, V33, P13038, DOI 10.1021/bi00248a013; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; FRASER PE, 1992, BIOCHEMISTRY-US, V31, P10716, DOI 10.1021/bi00159a011; Funahashi J, 1996, J BIOCHEM, V120, P1216; GLENNER GG, 1980, NEW ENGL J MED, V302, P1283, DOI 10.1056/NEJM198006053022305; GOLDFARB LG, 1993, P NATL ACAD SCI USA, V90, P4451, DOI 10.1073/pnas.90.10.4451; HAEZEBROUCK P, 1995, J MOL BIOL, V246, P382, DOI 10.1006/jmbi.1994.0093; Harrison RF, 1996, GUT, V38, P151, DOI 10.1136/gut.38.1.151; HURLE MR, 1994, P NATL ACAD SCI USA, V91, P5446, DOI 10.1073/pnas.91.12.5446; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kelly JW, 1996, CURR OPIN STRUC BIOL, V6, P11, DOI 10.1016/S0959-440X(96)80089-3; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; LANSBURY PT, 1995, NAT STRUCT BIOL, V2, P990, DOI 10.1038/nsb1195-990; MAURY CPJ, 1994, LAB INVEST, V70, P558; MCCUTCHEN SL, 1995, BIOCHEMISTRY-US, V34, P13527, DOI 10.1021/bi00041a032; MCKENZIE HA, 1991, ADV PROTEIN CHEM, V41, P173; Minor DL, 1996, NATURE, V380, P730, DOI 10.1038/380730a0; NANJO F, 1988, J BIOCHEM-TOKYO, V104, P255, DOI 10.1093/oxfordjournals.jbchem.a122453; NELSON SR, 1991, BIOCHEM J, V275, P67, DOI 10.1042/bj2750067; OSSERMAN EF, 1966, J EXP MED, V124, P921, DOI 10.1084/jem.124.5.921; OTWINOWSKI Z, 1993, P CCP4 STUD WEEK; PEPYS MB, 1993, NATURE, V362, P553, DOI 10.1038/362553a0; PEPYS MB, 1994, SAMTERS IMMUNOLOGIC; PERRY LJ, 1986, BIOCHEMISTRY-US, V25, P733, DOI 10.1021/bi00351a034; Ptitsyn OB, 1995, ADV PROTEIN CHEM, V47, P83, DOI 10.1016/S0065-3233(08)60546-X; PUCHTLER H, 1962, J HISTOCHEM CYTOCHEM, V10, P355, DOI 10.1177/10.3.355; RADFORD SE, 1992, NATURE, V358, P302, DOI 10.1038/358302a0; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; ROBINSON CV, 1994, NATURE, V372, P646, DOI 10.1038/372646a0; SHIH P, 1995, PROTEIN SCI, V4, P2050, DOI 10.1002/pro.5560041010; STOTT K, 1995, P NATL ACAD SCI USA, V92, P6509, DOI 10.1073/pnas.92.14.6509; TAN SY, 1994, HISTOPATHOLOGY, V25, P403, DOI 10.1111/j.1365-2559.1994.tb00001.x; WU LC, 1995, NAT STRUCT BIOL, V2, P281, DOI 10.1038/nsb0495-281; YAMADA T, 1994, BBA-MOL BASIS DIS, V1226, P323, DOI 10.1016/0925-4439(94)90044-2; YANG JJ, 1994, BIOCHEMISTRY-US, V33, P7345, DOI 10.1021/bi00189a040	48	952	984	0	177	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 27	1997	385	6619					787	793		10.1038/385787a0	http://dx.doi.org/10.1038/385787a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WK570	9039909				2022-12-01	WOS:A1997WK57000044
J	Charbonnier, JB; GolinelliPimpaneau, B; Gigant, B; Tawfik, DS; Chap, R; Schindler, DG; Kim, SH; Green, BS; Eshhar, Z; Knossow, M				Charbonnier, JB; GolinelliPimpaneau, B; Gigant, B; Tawfik, DS; Chap, R; Schindler, DG; Kim, SH; Green, BS; Eshhar, Z; Knossow, M			Structural convergence in the active sites of a family of catalytic antibodies	SCIENCE			English	Article							TRANSITION-STATE ANALOG; CRYSTAL-STRUCTURE; FAB FRAGMENT; IMMUNIZATION	The x-ray structures of three esterase-like catalytic antibodies identified by screening for catalytic activity the entire hybridoma repertoire, elicited in response to a phosphonate transition state analog (TSA) hapten, were analyzed. The high resolution structures account for catalysis by transition state stabilization, and in all three antibodies a tyrosine residue participates in the oxyanion hole. Despite significant conformational differences in their combining sites, the three antibodies, which are the most efficient among those elicited, achieve catalysis in essentially the same mode, suggesting that evolution for binding to a single TSA followed by screening for catalysis lead to antibodies with structural convergence.	HEBREW UNIV JERUSALEM,FAC MED,DEPT PHARMACEUT CHEM,IL-91120 JERUSALEM,ISRAEL; CNRS,LAB ENZYMOL & BIOCHIM STRUCT,F-91198 GIF SUR YVETTE,FRANCE; WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL	Hebrew University of Jerusalem; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Weizmann Institute of Science			Golinelli, Beatrice/ABB-8347-2021; Charbonnier, Jean-Baptiste/A-3868-2009	Golinelli, Beatrice/0000-0001-8248-4704; Charbonnier, Jean-Baptiste/0000-0002-5219-1983; Gigant, Benoit/0000-0002-5946-6759				ALZARI PM, 1990, EMBO J, V9, P3807, DOI 10.1002/j.1460-2075.1990.tb07598.x; ANGELES TS, 1993, BIOCHEMISTRY-US, V32, P12128, DOI 10.1021/bi00096a025; Brunger A.T., 1992, X PLOR VERSION 3 1 M; CHARBONNIER JB, 1995, P NATL ACAD SCI USA, V92, P11721, DOI 10.1073/pnas.92.25.11721; GUO JC, 1995, P NATL ACAD SCI USA, V92, P1694, DOI 10.1073/pnas.92.5.1694; HAYNES MR, 1994, SCIENCE, V263, P646, DOI 10.1126/science.8303271; HE XM, 1992, P NATL ACAD SCI USA, V89, P7154, DOI 10.1073/pnas.89.15.7154; HsiehWilson LC, 1996, P NATL ACAD SCI USA, V93, P5363, DOI 10.1073/pnas.93.11.5363; Jencks W. P., 1969, CATALYSIS CHEM ENZYM; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kabat EA, 1991, SEQUENCES PROTEINS I, V5th; LERNER RA, 1991, SCIENCE, V252, P659, DOI 10.1126/science.2024118; LERNER RA, 1995, INTERFACE CHEM BIOL; Leslie A. G. W.., 1992, PROTEIN CRYSTALLOGR, V26; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MacBeath G, 1996, CHEM BIOL, V3, P433, DOI 10.1016/S1074-5521(96)90091-5; MIYASHITA H, 1994, P NATL ACAD SCI USA, V91, P6045, DOI 10.1073/pnas.91.13.6045; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Patten PA, 1996, SCIENCE, V271, P1086, DOI 10.1126/science.271.5252.1086; STEWART JD, 1995, NATURE, V375, P388, DOI 10.1038/375388a0; TAWFIK DS, 1993, P NATL ACAD SCI USA, V90, P373, DOI 10.1073/pnas.90.2.373; TAWFIK DS, 1995, THESIS WEIZMANN I SC; TAWFIK DS, IN PRESS EUR J BIOCH; UPSON C, 1989, IEEE COMPUT GRAPH, V9, P30, DOI 10.1109/38.31462; ZEMEL R, 1994, MOL IMMUNOL, V31, P127, DOI 10.1016/0161-5890(94)90085-X; ZHOU GW, 1994, SCIENCE, V265, P1059, DOI 10.1126/science.8066444	26	76	79	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 21	1997	275	5303					1140	1142		10.1126/science.275.5303.1140	http://dx.doi.org/10.1126/science.275.5303.1140			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WJ503	9027317				2022-12-01	WOS:A1997WJ50300048
J	Schneider, DL; BarrettConnor, EL; Morton, DJ				Schneider, DL; BarrettConnor, EL; Morton, DJ			Timing of postmenopausal estrogen for optimal bone mineral density - The Rancho Bernardo study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HORMONAL REPLACEMENT THERAPY; POST-MENOPAUSAL WOMEN; ELDERLY WOMEN; HIP FRACTURE; OSTEOPOROSIS; PREVENTION; CALCIUM; MASS; GESTAGEN; SPINE	Objective-To determine the effect of the timing of initiation and the duration of postmenopausal estrogen therapy on bone mineral density (BMD). Design.-Cross-sectional study. Setting.-White, middle-class to upper middle-class community-dwelling women, Participants.-A total of 740 women aged 60 to 98 years who participated in a study of osteoporosis. Measurements.-Questionnaire, validated medication use, and height and weight. Bone mineral density at the ultradistal radius and midshaft radius using single-photon absorptiometry (SPA) and at the hip and lumbar spine using dual-energy x-ray absorptiometry (DEXA). Results-Of the 740 women, 69% had used oral estrogen after menopause and 30% were current users. Five groups of estrogen use were identified: never users, past users who started at menopause, past users who started after age 60 years, current users who started after age 60 years, and current users who started at menopause, At all 4 bone sites, current users who started at menopause had the highest BMD levels, which were significantly higher than never users or past users who started at menopause (with 10 years' duration of use). These differences persisted after controlling for all major risk factors for osteoporosis. Among current users, there was no significant difference in BMD levels at any site between those who started estrogen at menopause (with 20 years of use) and those who started after age 60 years (with 9 years of use), Conclusions.-Estrogen initiated in the menopausal period and continued into late life is associated with the highest bone density. Nevertheless, estrogen begun after age 60 years and continued appears to offer nearly equal bone-conserving benefit.	UNIV CALIF SAN DIEGO, DEPT FAMILY & PREVENT MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego					NATIONAL INSTITUTE ON AGING [R01AG007181, R37AG007181] Funding Source: NIH RePORTER; NIA NIH HHS [AG 07181] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AITKEN JM, 1973, BMJ-BRIT MED J, V3, P515, DOI 10.1136/bmj.3.5879.515; BIRKENHAGER JC, 1992, BONE MINER, V18, P251, DOI 10.1016/0169-6009(92)90811-Q; BRODY JA, 1984, AM J PUBLIC HEALTH, V74, P1397, DOI 10.2105/AJPH.74.12.1397; CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003-4819-122-1-199501010-00002; CHRISTIANSEN C, 1990, J CLIN ENDOCR METAB, V71, P836, DOI 10.1210/jcem-71-4-836; CHRISTIANSEN C, 1981, LANCET, V1, P459; ERDTSIECK RJ, 1994, J BONE MINER RES, V9, P277; ETTINGER B, 1985, ANN INTERN MED, V102, P319, DOI 10.7326/0003-4819-102-3-319; ETTINGER B, 1987, ANN INTERN MED, V106, P40, DOI 10.7326/0003-4819-106-1-40; ETTINGER B, 1994, MENOPAUSE, V1, P19; ETTINGER B, 1993, NEW ENGL J MED, V329, P1192, DOI 10.1056/NEJM199310143291610; ETTINGER B, 1994, CURRENT THERAPY ENDO, P596; FELSON DT, 1993, NEW ENGL J MED, V329, P1141, DOI 10.1056/NEJM199310143291601; GREY AB, 1994, CLIN ENDOCRINOL, V40, P671, DOI 10.1111/j.1365-2265.1994.tb03020.x; HEANEY RP, 1990, BONE MINER, V11, P67, DOI 10.1016/0169-6009(90)90016-9; HUTCHINSON TA, 1979, LANCET, V2, P705; KIEL DP, 1987, NEW ENGL J MED, V317, P1169, DOI 10.1056/NEJM198711053171901; KOHRT WM, 1995, OSTEOPOROSIS INT, V5, P150, DOI 10.1007/BF02106093; KREIGER N, 1982, AM J EPIDEMIOL, V116, P141, DOI 10.1093/oxfordjournals.aje.a113388; LINDSAY R, 1980, LANCET, V2, P1151; LINDSAY R, 1976, LANCET, V1, P1038; LINDSAY R, 1978, LANCET, V1, P1325; LINDSAY R, 1990, OBSTET GYNECOL, V76, P290; LINDSAY R, 1984, OBSTET GYNECOL, V63, P759; LUFKIN EG, 1992, ANN INTERN MED, V117, P1, DOI 10.7326/0003-4819-117-1-1; MARX CW, 1992, J BONE MINER RES, V7, P1275; MAXIM P, 1995, OSTEOPOROSIS INT, V5, P23, DOI 10.1007/BF01623654; NACHTIGALL LE, 1979, OBSTET GYNECOL, V53, P277; NGUYEN TV, 1995, J CLIN ENDOCR METAB, V80, P2709, DOI 10.1210/jc.80.9.2709; QUIGLEY MET, 1987, AM J OBSTET GYNECOL, V156, P1516; RICHELSON LS, 1984, NEW ENGL J MED, V311, P1273, DOI 10.1056/NEJM198411153112002; *SAS I INC, 1990, SAS STAT US GUID VER, P2; STEINICHE T, 1989, BONE, V10, P313, DOI 10.1016/8756-3282(89)90126-9; SZEJNFELD VL, 1994, SAO PAULO MED J, V112, P514; WEISS NS, 1980, NEW ENGL J MED, V303, P1195, DOI 10.1056/NEJM198011203032102; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086	36	181	184	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 19	1997	277	7					543	547		10.1001/jama.277.7.543	http://dx.doi.org/10.1001/jama.277.7.543			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH297	9032160				2022-12-01	WOS:A1997WH29700029
J	Adams, DH; Lloyd, AR				Adams, DH; Lloyd, AR			Chemokines: Leucocyte recruitment and activation cytokines	LANCET			English	Review							GENE-EXPRESSION; T-CELLS; INTERLEUKIN-8; MIP-1-ALPHA; MIP-1-BETA; RECEPTORS; INJURY; IDENTIFICATION; MIGRATION; SIGNALS	Chemokines are a family of structurally related proteins that share the ability to induce migration of specific subsets of leucocytes. These specialised cytokines play a critical part in the generation of cellular inflammation, both in the protective responses to invading pathogens and in the pathological processes associated with infection and immune-mediated diseases. Chemokines are more than simple chemotactic factors, since they are also implicated in leucocyte activation, angiogenesis, and antimicrobial functions, Including a protective role in HIV infection. These molecules provide potentially valuable targets for therapeutic intervention in a wide range of diseases.	UNIV BIRMINGHAM,QUEEN ELIZABETH HOSP,DEPT MED,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND; UNIV NEW S WALES,SCH PATHOL,INFLAMMAT RES UNIT,SYDNEY,NSW,AUSTRALIA; PRINCE HENRY HOSP,DEPT INFECT DIS,SYDNEY,NSW,AUSTRALIA	University of Birmingham; University of New South Wales Sydney	Adams, DH (corresponding author), UNIV BIRMINGHAM,QUEEN ELIZABETH HOSP,LIVER RES LABS,CLIN RES BLOCK,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND.		Adams, David H/C-9092-2009; Lloyd, Andrew/AFJ-8960-2022; Lloyd, Andrew/AAF-6071-2022; Lloyd, Andrew/E-7334-2017	Adams, David H/0000-0001-6776-0336; Lloyd, Andrew/0000-0001-6277-8887; Lloyd, Andrew/0000-0001-6277-8887; 				Adams DH, 1996, TRANSPLANTATION, V61, P817, DOI 10.1097/00007890-199603150-00024; ADAMS DH, 1994, LANCET, V343, P831, DOI 10.1016/S0140-6736(94)92029-X; AHUJA SK, 1994, IMMUNOL TODAY, V15, P281, DOI 10.1016/0167-5699(94)90008-6; ALCAMI A, 1995, IMMUNOL TODAY, V16, P474, DOI 10.1016/0167-5699(95)80030-1; AZUMA H, 1994, CURR OPIN IMMUNOL, V6, P770, DOI 10.1016/0952-7915(94)90083-3; BACON KB, 1995, SCIENCE, V269, P1727, DOI 10.1126/science.7569902; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BAGGIOLINI M, 1995, INT J IMMUNOPHARMACO, V17, P103, DOI 10.1016/0192-0561(94)00088-6; BENBARUCH A, 1995, J BIOL CHEM, V270, P11703, DOI 10.1074/jbc.270.20.11703; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; COLLETTI LM, 1995, J CLIN INVEST, V95, P134, DOI 10.1172/JCI117630; COOK DN, 1995, SCIENCE, V269, P1583, DOI 10.1126/science.7667639; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Ebnet K, 1996, ANNU REV IMMUNOL, V14, P155, DOI 10.1146/annurev.immunol.14.1.155; ERGER RA, 1995, AM J PHYSIOL-LUNG C, V12, pL117; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FURIE MB, 1995, AM J PATHOL, V146, P1287; GRAHAM GJ, 1994, J BIOL CHEM, V269, P4974; GRAHAM GJ, 1990, NATURE, V344, P442, DOI 10.1038/344442a0; KARAKURUM M, 1994, J CLIN INVEST, V93, P1564, DOI 10.1172/JCI117135; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; Kunkel SL, 1996, J LEUKOCYTE BIOL, V59, P6, DOI 10.1002/jlb.59.1.6; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; LUKACS MW, 1996, J LEUKOCYTE BIOL, V59, P13; LUSCINSKAS FW, 1992, J IMMUNOL, V149, P2163; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Ponath PD, 1996, J CLIN INVEST, V97, P604, DOI 10.1172/JCI118456; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; SCHALL TJ, 1994, CURR OPIN IMMUNOL, V6, P865, DOI 10.1016/0952-7915(94)90006-X; SCHALL TJ, 1994, CYTOKINE HDB, P419; Schmidtmayerova H, 1996, P NATL ACAD SCI USA, V93, P700, DOI 10.1073/pnas.93.2.700; SEKIDO N, 1993, NATURE, V365, P654, DOI 10.1038/365654a0; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STEITER RM, 1995, SHOCK, V4, P155; STIETER RM, 1995, J BIOL CHEM, V270, P27348; Strieter RM, 1996, J IMMUNOL, V156, P3583; SYLVESTER I, 1993, J IMMUNOL, V151, P3292; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; TAUB DD, 1993, SCIENCE, V260, P355, DOI 10.1126/science.7682337; Taub DD, 1996, J IMMUNOL, V156, P2095; Taub DD, 1996, J LEUKOCYTE BIOL, V59, P81, DOI 10.1002/jlb.59.1.81; Tedla N, 1996, AM J PATHOL, V148, P1367; VANZEE KJ, 1992, J IMMUNOL, V148, P1746; Wells TNC, 1996, J LEUKOCYTE BIOL, V59, P53, DOI 10.1002/jlb.59.1.53; WITT DP, 1994, CURR BIOL, V4, P394, DOI 10.1016/S0960-9822(00)00088-9; ZHANG YH, 1995, J CLIN INVEST, V95, P586, DOI 10.1172/JCI117702	51	388	394	0	16	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 15	1997	349	9050					490	495		10.1016/S0140-6736(96)07524-1	http://dx.doi.org/10.1016/S0140-6736(96)07524-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH389	9040590				2022-12-01	WOS:A1997WH38900044
J	Adler, MW				Adler, MW			HIV: The other dimension	LANCET			English	Editorial Material											Adler, MW (corresponding author), UCL, SCH MED, DEPT SEXUALLY TRANSMITTED DIS, LONDON WC1E 6AU, ENGLAND.							Ainsworth Martha, 1994, P559; Ankrah E. Maxine, 1994, P547; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; ELLIOT L, 1996, GUARDIAN        0117; *GLOB PROGR AIDS, 1995, CURR GLOB SIT HIV AI; *HARV SCH PUBL HLT, 1993, GLOB AIDS POL COAL N; HILLYARD M, 1995, 95122 HOUS COMM LIB; LURIE P, 1994, JAMA-J AM MED ASSOC, V271, P295, DOI 10.1001/jama.271.4.295; NOVAK R, 1995, SCIENCE, V269, P1332; REID E, 1994, UNDP; *WORLD BANK, 1993, WORLD BANK DEV REP 1	11	6	6	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	FEB 15	1997	349	9050					498	500		10.1016/S0140-6736(96)03233-3	http://dx.doi.org/10.1016/S0140-6736(96)03233-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH389	9040592				2022-12-01	WOS:A1997WH38900046
J	Tenenbaum, SA; Rice, JC; Espinoza, LR; Cuellar, ML; Plymale, DR; Sander, DM; Williamson, LL; Haislip, AM; Gluck, OS; Tesser, JRP; Nogy, L; Stribrny, KM; Bevan, JA; Garry, RF				Tenenbaum, SA; Rice, JC; Espinoza, LR; Cuellar, ML; Plymale, DR; Sander, DM; Williamson, LL; Haislip, AM; Gluck, OS; Tesser, JRP; Nogy, L; Stribrny, KM; Bevan, JA; Garry, RF			Use of antipolymer antibody assay in recipients of silicone breast implants	LANCET			English	Article							CONNECTIVE-TISSUE DISEASES; HUMAN ADJUVANT DISEASE; AUGMENTATION MAMMOPLASTY; WOMEN; AUTOANTIBODIES; CONTROVERSY; SYMPTOMS; RISK	Background Local complications (encapsulation, rashes, rupture, and leakage) can occur after placement of silicone-gel-containing breast implants (SBI). Whether SBI exposure results in systemic manifestations in some recipients is controversial. We have carried out a blinded study to assess whether there is any difference between SBI recipients and non-exposed controls in the proportions positive for serum antibodies directed against polymeric substances. Methods We recruited female SBI recipients (including those without symptoms) who presented to a single rheumatology clinic, A physician global assessment was used to classify SBI recipients who did not meet criteria for specific autoimmune diseases according to the severity of local and systemic signs and symptoms. Controls were recruited from among clinic staff and their acquaintances. Results of the antipolymer antibody (APA) assay were compared with those of an assay for antinuclear antibodies (ANA) and with the severity of the signs and symptoms. Findings Positive APA results were found in one (3%) of 34 SBI recipients with limited symptoms, two (8%) of 26 with mild symptoms, seven (44%) of 16 with moderate symptoms, and 13 (68%) of 19 with advanced symptoms. Four (17%) of 23 healthy non-SBI-exposed controls and two (10%) of 20 non-exposed women with classic autoimmune diseases were positive for APA. Thus, women with moderate or advanced symptoms were significantly more likely than those with limited or mild symptoms, or nonexposed controls to have APA (p<0.001). The proportion with positive ANA results was higher for women with classic autoimmune diseases 14 (70%) of 20 than for any SBI-exposed subgroup (0-33%). Interpretation The APA assay can objectively contribute to distinguishing between SBI recipients with limited or mild signs and symptoms, SBI recipients with more severe manifestations, and patients with specific autoimmune diseases. Further studies will be needed to define the signs and symptoms associated with exposure to SBI.	TULANE UNIV, SCH MED, DEPT MICROBIOL & IMMUNOL SL38, NEW ORLEANS, LA 70112 USA; TULANE UNIV, SCH MED, MOL & CELLULAR BIOL PROGRAM, NEW ORLEANS, LA 70112 USA; TULANE UNIV, SCH PUBL HLTH & TROP MED, DEPT BIOSTAT & EPIDEMIOL, NEW ORLEANS, LA 70112 USA; LOUISIANA STATE UNIV, MED CTR, DEPT RHEUMATOL, NEW ORLEANS, LA USA; ARIZONA RHEUMATOL CTR, PHOENIX, AZ USA; AFFINTECH, BENTONVILLE, AR USA	Tulane University; Tulane University; Tulane University; Louisiana State University System			Tenenbaum, Scott A/H-4744-2019	Garry, Robert/0000-0002-5683-3250				ANGELL M, 1994, NEW ENGL J MED, V330, P1748, DOI 10.1056/NEJM199406163302409; Angell M, 1996, NEW ENGL J MED, V334, P1513, DOI 10.1056/NEJM199606063342306; BRAUN G, 1995, CLIN ORAL IMPLAN RES, V6, P1, DOI 10.1034/j.1600-0501.1995.060101.x; Brautbar N., 1995, NATL MED LEG J, V6, P4; BRIDGES AJ, 1994, SEMIN ARTHRITIS RHEU, V24, P54, DOI 10.1016/0049-0172(94)90110-4; BRIDGES AJ, 1994, LANCET, V344, P1451, DOI 10.1016/S0140-6736(94)90284-4; BRIDGES AJ, 1993, ANN INTERN MED, V118, P929, DOI 10.7326/0003-4819-118-12-199306150-00003; BRIDGES AJ, 1993, ARCH INTERN MED, V153, P2638, DOI 10.1001/archinte.153.23.2638; BROZENA SJ, 1988, ARCH DERMATOL, V124, P1383, DOI 10.1001/archderm.124.9.1383; CLAMAN HN, 1994, WESTERN J MED, V160, P225; COOK RR, 1994, JAMA-J AM MED ASSOC, V272, P767, DOI 10.1001/jama.1994.03520100031021; COOK RR, 1994, ARTHRITIS RHEUM, V37, P153, DOI 10.1002/art.1780370202; CUELLAR ML, 1995, J RHEUMATOL, V22, P236; FOX RI, 1986, SCAND J RHEUMATOL, P28; GABRIEL SE, 1994, NEW ENGL J MED, V330, P1697, DOI 10.1056/NEJM199406163302401; GERMAIN BF, 1992, B RHEUM DIS, V41, P1; GUILLAUME JC, 1984, ANN DERMATOL VENER, V111, P703; Hennekens CH, 1996, JAMA-J AM MED ASSOC, V275, P616, DOI 10.1001/jama.275.8.616; KESSLER DA, 1993, JAMA-J AM MED ASSOC, V270, P2607, DOI 10.1001/jama.270.21.2607; LEVINE MD, 1994, JAMA-J AM MED ASSOC, V272, P769, DOI 10.1001/jama.1994.03520100031025; PRESS RI, 1992, LANCET, V340, P1304, DOI 10.1016/0140-6736(92)92491-W; SANCHEZGUERRERO J, 1995, NEW ENGL J MED, V332, P1666, DOI 10.1056/NEJM199506223322502; SERGOTT TJ, 1986, PLAST RECONSTR SURG, V78, P104, DOI 10.1097/00006534-198607000-00018; Silverman BG, 1996, ANN INTERN MED, V124, P744, DOI 10.7326/0003-4819-124-8-199604150-00008; SPIERA H, 1988, JAMA-J AM MED ASSOC, V260, P236, DOI 10.1001/jama.260.2.236; STEINBROCKER O, 1949, JAMA-J AM MED ASSOC, V140, P659, DOI 10.1001/jama.1949.02900430001001; TENENBAUM SA, 1992, ARTHRITIS RHEUM S, V73, P25; TENENBAUM SA, 1993, ARTHRITIS RHEUM S, V118, pA123; TEUBER SS, 1994, INT ARCH ALLERGY IMM, V103, P105, DOI 10.1159/000236613; ZAMBINSKI M, 1989, P 53 GEN M AM COLL R, pS25	30	51	53	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 15	1997	349	9050					449	454		10.1016/S0140-6736(96)07131-0	http://dx.doi.org/10.1016/S0140-6736(96)07131-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH389	9040573				2022-12-01	WOS:A1997WH38900008
J	Keeney, S; Giroux, CN; Kleckner, N				Keeney, S; Giroux, CN; Kleckner, N			Meiosis-specific DNA double-strand breaks are catalyzed by Spo11, a member of a widely conserved protein family	CELL			English	Article							SYNAPTONEMAL COMPLEX-FORMATION; SACCHAROMYCES-CEREVISIAE; MEIOTIC RECOMBINATION; CHROMOSOME SYNAPSIS; TOPOISOMERASE-II; INITIATION SITE; ESCHERICHIA-COLI; YEAST; GENE; RAD50	Meiotic recombination in S. cerevisiae is initiated by double-strand breaks (DSBs). In certain mutants, breaks accumulate with a covalently attached protein, suggesting that cleavage is catalyzed by the DSB-associated protein via a topoisomerase-like transesterase mechanism. We have purified these protein-DNA complexes and identified the protein as Spo11, one of several proteins required for DSB formation. These findings strongly implicate Spo11 as the catalytic subunit of the meiotic DNA cleavage activity. This is the first identification of a biochemical function for any of the gene products involved in DSB formation. Spo11 defines a protein family with other members in fission yeast, nematodes, and archaebacteria. The S. pombe homolog, rec12p, is also known to be required for meiotic recombination. Thus, these findings provide direct evidence that the mechanism of meiotic recombination initiation is evolutionarily conserved.	WAYNE STATE UNIV, CTR MOL MED & GENET, DETROIT, MI 48202 USA	Wayne State University	Keeney, S (corresponding author), HARVARD UNIV, DEPT MOL & CELLULAR BIOL, CAMBRIDGE, MA 02138 USA.		Keeney, Scott/GVR-8515-2022	Keeney, Scott/0000-0002-1283-6417	NIGMS NIH HHS [R01-GM44794] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044794] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AJIMURA M, 1993, GENETICS, V133, P51; ALANI E, 1990, CELL, V61, P419, DOI 10.1016/0092-8674(90)90524-I; BERGERAT A, 1994, J BIOL CHEM, V269, P27663; BERNARD P, 1993, J MOL BIOL, V234, P534, DOI 10.1006/jmbi.1993.1609; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; Bullard SA, 1996, P NATL ACAD SCI USA, V93, P13054, DOI 10.1073/pnas.93.23.13054; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; Connelly JC, 1996, GENES CELLS, V1, P285, DOI 10.1046/j.1365-2443.1996.23024.x; DEMASSY B, 1995, EMBO J, V14, P4589, DOI 10.1002/j.1460-2075.1995.tb00138.x; ESPOSITO MS, 1969, GENETICS, V61, P79; GAME JC, 1989, GENETICS, V123, P695; GIROUX CN, 1989, GENOME, V31, P88, DOI 10.1139/g89-017; GIROUX CN, 1993, MEIOSIS, V2, P1; HOLLINGSWORTH NM, 1990, CELL, V61, P73, DOI 10.1016/0092-8674(90)90216-2; IVANOV EL, 1994, MOL CELL BIOL, V14, P3414, DOI 10.1128/MCB.14.5.3414; IVANOV EL, 1992, GENETICS, V132, P651; JOHZUKA K, 1995, GENETICS, V139, P1521; Kaiser C., 1994, METHODS YEAST GENETI; KANE SM, 1974, J BACTERIOL, V118, P8, DOI 10.1128/JB.118.1.8-14.1974; Keeney S, 1996, GENES CELLS, V1, P475, DOI 10.1046/j.1365-2443.1996.d01-257.x; KEENEY S, 1995, P NATL ACAD SCI USA, V92, P11274, DOI 10.1073/pnas.92.24.11274; KLAPHOLZ S, 1985, GENETICS, V110, P187; Kleckner N, 1996, P NATL ACAD SCI USA, V93, P8167, DOI 10.1073/pnas.93.16.8167; KLECKNER N, 1993, COLD SPRING HARB SYM, V58, P553, DOI 10.1101/SQB.1993.058.01.062; LIN YK, 1994, GENETICS, V136, P769; LIU JH, 1995, EMBO J, V14, P4599, DOI 10.1002/j.1460-2075.1995.tb00139.x; LIU LF, 1983, J BIOL CHEM, V258, P5365; LOIDL J, 1994, J CELL BIOL, V125, P1191, DOI 10.1083/jcb.125.6.1191; MaoDraayer Y, 1996, GENETICS, V144, P71; MCKEE AHZ, 1997, IN PRES GENETICS; MCKEE BD, 1993, CHROMOSOMA, V102, P180, DOI 10.1007/BF00387733; MENEES TM, 1992, MOL CELL BIOL, V12, P1340, DOI 10.1128/MCB.12.3.1340; ORRWEAVER TL, 1995, P NATL ACAD SCI USA, V92, P10443, DOI 10.1073/pnas.92.23.10443; PADMORE R, 1991, CELL, V66, P1239, DOI 10.1016/0092-8674(91)90046-2; PRINZ S, 1997, IN PRESS GENETICS; RAYMOND WE, 1993, NUCLEIC ACIDS RES, V21, P3851, DOI 10.1093/nar/21.16.3851; ROCA J, 1993, J BIOL CHEM, V268, P14250; Rocco V, 1996, GENES CELLS, V1, P645, DOI 10.1046/j.1365-2443.1996.00256.x; ROCKMILL B, 1995, GENETICS, V141, P49; ROEDER GS, 1995, P NATL ACAD SCI USA, V92, P10450, DOI 10.1073/pnas.92.23.10450; ROTHBERG PG, 1978, P NATL ACAD SCI USA, V75, P4868, DOI 10.1073/pnas.75.10.4868; SCHLESTL RH, 1994, MOL CELL BIOL, V14, P4493; Shabarova Z A, 1970, Prog Nucleic Acid Res Mol Biol, V10, P145; SHARPLES GJ, 1995, MOL MICROBIOL, V17, P1215, DOI 10.1111/j.1365-2958.1995.mmi_17061215_1.x; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH AV, 1997, IN PRESS J CELL BIOL; SMITH RF, 1990, P NATL ACAD SCI USA, V87, P118, DOI 10.1073/pnas.87.1.118; SUGAWARA N, 1992, MOL CELL BIOL, V12, P563, DOI 10.1128/MCB.12.2.563; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SUN H, 1989, NATURE, V338, P87, DOI 10.1038/338087a0; THOMAS CA, 1979, ANAL BIOCHEM, V93, P158, DOI 10.1016/S0003-2697(79)80130-X; WALTER J, 1994, GENE DEV, V8, P1678, DOI 10.1101/gad.8.14.1678; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WEINER BM, 1994, CELL, V77, P977, DOI 10.1016/0092-8674(94)90438-3; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; Xu F, 1996, GENETICS, V143, P1115; XU L, 1997, IN PRESS GENES DEV; XU LH, 1995, EMBO J, V14, P5115, DOI 10.1002/j.1460-2075.1995.tb00194.x; Yang SW, 1996, P NATL ACAD SCI USA, V93, P11534, DOI 10.1073/pnas.93.21.11534; ZUBENKO GS, 1981, GENETICS, V97, P45	61	1257	1291	2	99	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 7	1997	88	3					375	384		10.1016/S0092-8674(00)81876-0	http://dx.doi.org/10.1016/S0092-8674(00)81876-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WG479	9039264	Bronze			2022-12-01	WOS:A1997WG47900010
J	Ersfeld, K; Gull, K				Ersfeld, K; Gull, K			Partitioning of large and minichromosomes in Trypanosoma brucei	SCIENCE			English	Article							NUCLEOTIDE-SEQUENCE; DNA; ORGANIZATION; GENES; CYCLE	The Trypanosoma brucei nuclear genome contains about 100 minichromosomes of between 50 to 150 kilobases and about 20 chromosomes of 0.2 to 6 megabase pairs. Minichromosomes contain nontranscribed copies of variant surface glycoprotein (VSG) genes and are thought to expand the VSG gene pool. Varying VSG expression allows the parasite to avoid elimination by the host immune system. The mechanism of inheritance of T. brucei chromosomes was investigated by in situ hybridization in combination with immunofluorescence. The minichromosome population segregated with precision, by association with the central intranuclear mitotic spindle. However, their positional dynamics differed from that of the large chromosomes, which were partitioned by kinetochore microtubules.			Ersfeld, K (corresponding author), UNIV MANCHESTER,SCH BIOL SCI,2 205 STOPFORD BLDG,OXFORD RD,MANCHESTER M13 9PT,LANCS,ENGLAND.							ALLEVA I, UNPUB; BIRKETT CR, 1985, FEBS LETT, V187, P211, DOI 10.1016/0014-5793(85)81244-8; BURRI M, 1995, BIOL CELL, V83, P23, DOI 10.1016/0248-4900(96)89928-X; CHUNG HMM, 1990, EMBO J, V9, P2611, DOI 10.1002/j.1460-2075.1990.tb07443.x; CORDINGLEY JS, 1985, MOL BIOCHEM PARASIT, V17, P321, DOI 10.1016/0166-6851(85)90006-4; Cross GAM, 1996, BIOESSAYS, V18, P283, DOI 10.1002/bies.950180406; GOTTESDIENER K, 1990, MOL CELL BIOL, V10, P6079, DOI 10.1128/MCB.10.11.6079; HASAN G, 1984, GENE, V27, P75, DOI 10.1016/0378-1119(84)90240-3; MELVILLE S, COMMUNICATION; ROBINSON DR, 1995, J CELL BIOL, V128, P1163, DOI 10.1083/jcb.128.6.1163; SASSE R, 1988, J CELL SCI, V90, P577; SHERWIN T, 1989, PHILOS T R SOC B, V323, P573, DOI 10.1098/rstb.1989.0037; SLOOF P, 1983, J MOL BIOL, V167, P1, DOI 10.1016/S0022-2836(83)80031-X; SOGIN L, 1991, CURR OPIN GENE DEV, V1, P453; SOLARI AJ, 1995, BIOCELL, V19, P65; VANDERPLOEG LHT, 1984, EMBO J, V3, P3109, DOI 10.1002/j.1460-2075.1984.tb02266.x; VANDERPLOEG LHT, 1984, CELL, V37, P77, DOI 10.1016/0092-8674(84)90302-7; VICKERMAN K, 1970, J CELL SCI, V6, P365; VICKERMAN K, 1994, INT J PARASITOL, V24, P1317, DOI 10.1016/0020-7519(94)90198-8; WEIDEN M, 1991, MOL CELL BIOL, V11, P3823, DOI 10.1128/MCB.11.8.3823; WILLIAMS RO, 1982, NATURE, V299, P417, DOI 10.1038/299417a0; ZOMERDIJK JCBM, 1992, NUCLEIC ACIDS RES, V20, P2725, DOI 10.1093/nar/20.11.2725	22	79	82	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 25	1997	276	5312					611	614		10.1126/science.276.5312.611	http://dx.doi.org/10.1126/science.276.5312.611			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WV721	9110983				2022-12-01	WOS:A1997WV72100050
J	Feldkamp, M; Jones, KL; Ornoy, A; Pastuszak, A; Rosenwasser, TS; Schick, B; Bar, J				Feldkamp, M; Jones, KL; Ornoy, A; Pastuszak, A; Rosenwasser, TS; Schick, B; Bar, J			Postmarketing surveillance for angiotensin-converting enzyme inhibitor use during the first trimester of pregnancy - United States, Canada, and Israel, 1987-1995 (Reprinted from MMWR, vol 46, pg 240-242, 1997)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Reprint									CALIF TERATOGEN INFORMAT SERV,SAN DIEGO,CA; ISRAEL TERATOL INFORMAT SERV,JERUSALEM,ISRAEL; MOTHERISK PROGRAM,TORONTO,ON,CANADA; MASSACHUSETTS TERATOGEN INFORMAT SERV,BOSTON,MA; PREGNANCY HEALTHLINE,PHILADELPHIA,PA; BEILINSON TERATOL INFORMAT SERV,PETAH TIQWA,ISRAEL; CDC,BIRTH DEFECTS & GENET DIS BR,DIV BERTH DEFECTS & DEV DISABIL,NATL CTR ENVIRONM HLTH,ATLANTA,GA 30333	Rabin Medical Center; Centers for Disease Control & Prevention - USA	Feldkamp, M (corresponding author), PREGNANCY RISKLINE,SALT LAKE CITY,UT, USA.		ornoy, asher/J-8038-2018	ornoy, asher/0000-0002-7268-3512				BAKRIS GL, 1993, ANN INTERN MED, V118, P643, DOI 10.7326/0003-4819-118-8-199304150-00013; BARR M, 1994, TERATOLOGY, V50, P399, DOI 10.1002/tera.1420500606; Erickson J D, 1991, Int J Risk Saf Med, V2, P239, DOI 10.3233/JRS-1991-2502; Feldkamp ML, 1997, MMWR-MORBID MORTAL W, V46, P240; KALLEN B, 1991, CONTRACEPTION, V44, P173, DOI 10.1016/0010-7824(91)90117-X; Robert E, 1994, Int J Risk Saf Med, V6, P75, DOI 10.3233/JRS-1994-6201; SHOTAN A, 1994, AM J MED, V96, P451, DOI 10.1016/0002-9343(94)90172-4; VENTURA SJ, 1995, MONTHLY VITAL STAT S, V43	8	27	27	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 16	1997	277	15					1193	1194						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WT403	9103332				2022-12-01	WOS:A1997WT40300011
J	Cronin, CC; Shanahan, F				Cronin, CC; Shanahan, F			Insulin-dependent diabetes mellitus and coeliac disease	LANCET			English	Editorial Material							CELIAC-DISEASE; PREVALENCE; CHILDREN; ANTIBODIES; ADOLESCENTS; POPULATION		NATL UNIV IRELAND UNIV COLL CORK,CORK,IRELAND	University College Cork	Cronin, CC (corresponding author), CORK UNIV HOSP,DEPT MED,CORK,IRELAND.			Shanahan, Fergus/0000-0003-0467-0936				BARDELLA MT, 1994, ARCH DIS CHILD, V70, P211, DOI 10.1136/adc.70.3.211; BARERA G, 1991, ARCH DIS CHILD, V66, P491, DOI 10.1136/adc.66.4.491; CACCIARI E, 1987, ACTA PAEDIATR SCAND, V76, P671, DOI 10.1111/j.1651-2227.1987.tb10542.x; CATASSI C, 1994, LANCET, V343, P200, DOI 10.1016/S0140-6736(94)90989-X; COLLIN P, 1989, SCAND J GASTROENTERO, V24, P81, DOI 10.3109/00365528909092243; COOPER BT, 1987, Q J MED, V63, P269; CRONIN CC, 1996, IR J MED SCI S4, V165, P2; DEVITIS I, 1996, GASTROENTEROLOGY S, V110, pA13; FERREIRA M, 1992, GUT, V33, P1633, DOI 10.1136/gut.33.12.1633; GADD S, 1992, AUST NZ J MED, V22, P256, DOI 10.1111/j.1445-5994.1992.tb02121.x; GOBBI G, 1992, LANCET, V340, P439; Hadjivassiliou M, 1996, LANCET, V347, P369, DOI 10.1016/S0140-6736(96)90540-1; HOLMES GKT, 1989, GUT, V30, P333, DOI 10.1136/gut.30.3.333; KOLETZKO S, 1988, EUR J PEDIATR, V148, P113, DOI 10.1007/BF00445915; LOGAN RFA, 1989, GASTROENTEROLOGY, V97, P265, DOI 10.1016/0016-5085(89)90060-7; MAKI M, 1984, ARCH DIS CHILD, V59, P739, DOI 10.1136/adc.59.8.739; MAKI M, 1995, GUT, V36, P239, DOI 10.1136/gut.36.2.239; PAGE SR, 1994, Q J MED, V87, P631; Rensch MJ, 1996, ANN INTERN MED, V124, P564, DOI 10.7326/0003-4819-124-6-199603150-00004; ROSSI TM, 1993, J PEDIATR-US, V123, P262, DOI 10.1016/S0022-3476(05)81699-3; SATEGNAGUIDETTI C, 1994, DIGEST DIS SCI, V39, P1633, DOI 10.1007/BF02087768; Saukkonen T, 1996, DIABETIC MED, V13, P464, DOI 10.1002/(SICI)1096-9136(199605)13:5<464::AID-DIA101>3.0.CO;2-R; SAVILAHTI E, 1986, J PEDIATR-US, V108, P690, DOI 10.1016/S0022-3476(86)81042-3; SHANAHAN F, 1982, Q J MED, V51, P329; SHER KS, 1994, DIGEST DIS, V12, P186, DOI 10.1159/000171452; SIGURS N, 1993, ACTA PAEDIATR, V82, P748, DOI 10.1111/j.1651-2227.1993.tb12551.x; Valdimarsson T, 1996, GUT, V38, P322, DOI 10.1136/gut.38.3.322; VERGE CF, 1994, DIABETOLOGIA, V37, P1113, DOI 10.1007/BF00418375; WALSH CH, 1978, Q J MED, V47, P89	29	181	188	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 12	1997	349	9058					1096	1097		10.1016/S0140-6736(96)09153-2	http://dx.doi.org/10.1016/S0140-6736(96)09153-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU002	9107261				2022-12-01	WOS:A1997WU00200042
J	Evangelista, M; Blundell, K; Longtine, MS; Chow, CJ; Adames, N; Pringle, JR; Peter, M; Boone, C				Evangelista, M; Blundell, K; Longtine, MS; Chow, CJ; Adames, N; Pringle, JR; Peter, M; Boone, C			Bni1p, a yeast formin linking Cdc42p and the actin cytoskeleton during polarized morphogenesis	SCIENCE			English	Article							GTP-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE GENE; MAP KINASE CASCADE; BUD-SITE SELECTION; CELL POLARITY; MUTATIONAL ANALYSIS; PHEROMONE-RESPONSE; ACTIVATING PROTEIN; BUDDING YEAST; IDENTIFICATION	The Saccharomyces cerevisiae BNI1 gene product (Bni1p) is a member of the formin family of proteins, which participate in cell polarization, cytokinesis, and vertebrate limb formation. During mating pheromone response, bni1 mutants showed defects both in polarized morphogenesis and in reorganization of the underlying actin cytoskeleton, In two-hybrid experiments, Bni1p formed complexes, with the activated form of the Rho-related guanosine triphosphatase Cdc42p, with actin, and with two actin-associated proteins, profilin and Bud6p (Aip3p). Both Bni1p and Bud6p (like Cdc42p and actin) localized to the tips of mating projections. Bni1p may function as a Cdc42p target that links the pheromone response pathway to the actin cytoskeleton.	SIMON FRASER UNIV, INST MOL BIOL & BIOCHEM, BURNABY, BC V5A 1S6, CANADA; UNIV N CAROLINA, DEPT BIOL, CHAPEL HILL, NC 27599 USA; SWISS INST EXPT CANC RES, CH-1066 EPALINGES, SWITZERLAND	Simon Fraser University; University of North Carolina; University of North Carolina Chapel Hill; Swiss Institute Experimental Cancer Research			Adames, Neil/C-8863-2012; Adames, Neil/AAO-7913-2020; Adames, Neil/S-1460-2017	Adames, Neil/0000-0003-4331-9348; Adames, Neil/0000-0003-4331-9348; Adames, Neil/0000-0003-4331-9348	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031006, R37GM031006] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31006] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMES N, 1995, SCIENCE, V270, P464, DOI 10.1126/science.270.5235.464; ADAMS AEM, 1991, NATURE, V354, P404, DOI 10.1038/354404a0; ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; ADAMS AEM, 1991, METHOD ENZYMOL, V194, P729; AMATRUDA JF, 1990, NATURE, V344, P352, DOI 10.1038/344352a0; AMBERG DC, IN PRESS MOL BIOL CE; BOONE C, 1992, NUCLEIC ACIDS RES, V20, P4661, DOI 10.1093/nar/20.17.4661; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CASTRILLON DH, 1994, DEVELOPMENT, V120, P3367; CHAN DC, 1995, DEVELOPMENT, V121, P3151; Chan DC, 1996, EMBO J, V15, P1045, DOI 10.1002/j.1460-2075.1996.tb00442.x; CHANG F, IN PRESS J CELL BIOL; Chant J, 1996, CURR OPIN CELL BIOL, V8, P557, DOI 10.1016/S0955-0674(96)80035-4; CHENEVERT J, 1994, MOL BIOL CELL, V5, P1169, DOI 10.1091/mbc.5.11.1169; CHENEVERT J, 1994, GENETICS, V136, P1287; DORER R, 1995, J CELL BIOL, V131, P845, DOI 10.1083/jcb.131.4.845; DREES B, 1995, J CELL BIOL, V128, P383, DOI 10.1083/jcb.128.3.383; Drgonova J, 1996, SCIENCE, V272, P277, DOI 10.1126/science.272.5259.277; DRUBIN DG, 1993, MOL BIOL CELL, V4, P1277, DOI 10.1091/mbc.4.12.1277; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EMMONS S, 1995, GENE DEV, V9, P2482, DOI 10.1101/gad.9.20.2482; EVANGELISTA M, UNPUB; FARES H, UNPUB; GEITZ RD, 1988, GENE, V74, P527; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HAARER BK, 1990, J CELL BIOL, V110, P105, DOI 10.1083/jcb.110.1.105; HAARER BK, 1993, MOL CELL BIOL, V13, P7864, DOI 10.1128/MCB.13.12.7864; HAGEN DC, 1991, MOL CELL BIOL, V11, P2952, DOI 10.1128/MCB.11.6.2952; HARRIS SD, IN PRESS EMBO J; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Imai J, 1996, GENETICS, V142, P359; James P, 1996, GENETICS, V144, P1425; Jansen RP, 1996, CELL, V84, P687, DOI 10.1016/S0092-8674(00)81047-8; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; JOHNSTON GC, 1991, J CELL BIOL, V113, P539, DOI 10.1083/jcb.113.3.539; Kaiser DA, 1996, J MOL BIOL, V256, P89, DOI 10.1006/jmbi.1996.0070; Kirchhausen T, 1996, CURR BIOL, V6, P676, DOI 10.1016/S0960-9822(09)00447-3; Kohno H, 1996, EMBO J, V15, P6060, DOI 10.1002/j.1460-2075.1996.tb00994.x; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; LEEUW T, 1995, SCIENCE, V270, P1210, DOI 10.1126/science.270.5239.1210; LI R, 1995, J CELL BIOL, V128, P599, DOI 10.1083/jcb.128.4.599; LIU HP, 1992, GENETICS, V132, P665; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; MADAULE P, 1987, P NATL ACAD SCI USA, V84, P779, DOI 10.1073/pnas.84.3.779; Manseau L, 1996, DEVELOPMENT, V122, P2109; MARHOUL JF, 1995, GENETICS, V139, P537; MATSUI Y, 1992, MOL CELL BIOL, V12, P5690, DOI 10.1128/MCB.12.12.5690; NONAKA H, 1995, EMBO J, V14, P5931, DOI 10.1002/j.1460-2075.1995.tb00281.x; PARK HO, 1993, NATURE, V365, P269, DOI 10.1038/365269a0; Peter M, 1996, EMBO J, V15, P7046, DOI 10.1002/j.1460-2075.1996.tb01096.x; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; PETERSEN J, 1995, MOL CELL BIOL, V15, P3697; PHIZICKY EM, 1995, MICROBIOL REV, V59, P94, DOI 10.1128/MMBR.59.1.94-123.1995; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; Qadota H, 1996, SCIENCE, V272, P279, DOI 10.1126/science.272.5259.279; REINHARD M, 1995, EMBO J, V14, P1583, DOI 10.1002/j.1460-2075.1995.tb07146.x; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SIKORSKI RS, 1989, GENETICS, V122, P19; SIMON MN, 1995, NATURE, V376, P702, DOI 10.1038/376702a0; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P77; STEVENSON BJ, 1995, GENE DEV, V9, P2949, DOI 10.1101/gad.9.23.2949; SUN HQ, 1995, CURR OPIN CELL BIOL, V7, P102, DOI 10.1016/0955-0674(95)80051-4; VALTZ N, 1995, J CELL BIOL, V131, P863, DOI 10.1083/jcb.131.4.863; WERTMAN KF, 1992, GENETICS, V132, P337; Yang S, 1997, J CELL BIOL, V136, P111, DOI 10.1083/jcb.136.1.111; Zahner JE, 1996, MOL CELL BIOL, V16, P1857; ZIMAN M, 1993, MOL BIOL CELL, V4, P1307, DOI 10.1091/mbc.4.12.1307; ZIMAN M, 1991, MOL CELL BIOL, V11, P3537, DOI 10.1128/MCB.11.7.3537	72	527	530	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 4	1997	276	5309					118	122		10.1126/science.276.5309.118	http://dx.doi.org/10.1126/science.276.5309.118			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WR386	9082982				2022-12-01	WOS:A1997WR38600060
J	Zadina, JE; Hackler, L; Ge, LJ; Kastin, AJ				Zadina, JE; Hackler, L; Ge, LJ; Kastin, AJ			A potent and selective endogenous agonist for the mu-opiate receptor	NATURE			English	Article							TYR-W-MIF-1; ANALOGS; TYR-PRO-TRP-GLY-NH2; HEMOGLOBIN; TYR-MIF-1; ANALGESIA; ASSAY	Peptides have been identified in mammalian brain that are considered to be endogenous agonists for the delta (enkephalins) and kappa (dynorphins) opiate receptors, but none has been found to have any preference for the mu receptor(1-3). Because morphine and other compounds that are clinically useful and open to abuse act primarily at the mu receptor(4), it could be important to identify endogenous peptides specific for this site. Here we report the discovery and isolation from brain of such a peptide, endomorphin-1 (Tyr-Pro-Trp-Phe-NH2), which has a high affinity (K-i = 360 pM) and selectivity (4,000- and 15,000-fold preference over the delta and kappa receptors) for the mu, receptor. This peptide is more effective than the mu-selective analogue DAMGO in vitro and it produces potent and prolonged analgesia in mice. A second peptide, endomorphin-2 (Tyr-Pro-Phe-Phe-NH2), which differs by one amino acid, was also isolated. The new peptides have the highest specificity and affinity for the mu receptor of any endogenous substance so far described and they maybe natural ligands fbr this receptor.	TULANE UNIV, SCH MED, NEW ORLEANS, LA 70146 USA	Tulane University	Zadina, JE (corresponding author), VET AFFAIRS MED CTR, NEW ORLEANS, LA 70146 USA.		Ge, Li/T-3955-2018	Ge, Li/0000-0002-1824-8034				AKIL H, 1984, ANNU REV NEUROSCI, V7, P223, DOI 10.1146/annurev.ne.07.030184.001255; BRANTL V, 1984, EUR J PHARMACOL, V106, P213, DOI 10.1016/0014-2999(84)90702-7; BRANTL V, 1986, EUR J PHARMACOL, V125, P309, DOI 10.1016/0014-2999(86)90044-0; BUSCHER HH, 1976, NATURE, V261, P423, DOI 10.1038/261423a0; Corbett A.D., 1993, OPIOIDS, P645, DOI [10.1007/978-3-642-77460-7_26, DOI 10.1007/978-3-642-77460-7_26]; ELDE R, 1995, DIVERSITY INTERACTIN, P390; ERCHEGYI J, 1992, INT J PEPT PROT RES, V39, P477; ERCHEGYI J, 1993, PEPTIDE RES, V6, P31; ERCHEGYI J, 1992, PEPTIDES, V13, P623, DOI 10.1016/0196-9781(92)90165-Y; EVANS CJ, 1988, OPIATE RECEPTORS, P23; Gergen KA, 1996, EUR J PHARMACOL, V298, P235, DOI 10.1016/0014-2999(95)00823-3; Gergen KA, 1996, EUR J PHARMACOL, V316, P33, DOI 10.1016/S0014-2999(96)00656-5; GLAMSTA EL, 1991, REGUL PEPTIDES, V34, P169, DOI 10.1016/0167-0115(91)90176-H; HACKLER L, 1993, NEUROPEPTIDES, V24, P159, DOI 10.1016/0143-4179(93)90080-T; HALEY TJ, 1957, BRIT J PHARM CHEMOTH, V12, P12, DOI 10.1111/j.1476-5381.1957.tb01354.x; HAMEL E, 1984, NATURE, V312, P155, DOI 10.1038/312155a0; HERKENHAM M, 1991, ADV NEUROSC, V1, P63; HYLDEN JLK, 1980, EUR J PHARMACOL, V67, P313, DOI 10.1016/0014-2999(80)90515-4; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lenz G. R., 1986, OPIATES; MANSOUR A, 1995, TRENDS NEUROSCI, V18, P22, DOI 10.1016/0166-2236(95)93946-U; Reisine T., 1996, GOODMAN GILMANS PHAR, P521; SCHILLER PW, 1978, J MED CHEM, V21, P1110, DOI 10.1021/jm00209a004; WANG JX, 1993, INT J PEPT PROT RES, V42, P384; YAMAZAKI T, 1993, J MED CHEM, V36, P708, DOI 10.1021/jm00058a007; YOBURN BC, 1985, BRAIN RES, V331, P327, DOI 10.1016/0006-8993(85)91558-6; Zadina JE, 1996, NEUROSCI LETT, V215, P65, DOI 10.1016/S0304-3940(96)12928-1; ZADINA JE, 1992, LIFE SCI, V51, P869, DOI 10.1016/0024-3205(92)90615-V; ZADINA JE, 1993, NEUROSCI LETT, V155, P220, DOI 10.1016/0304-3940(93)90712-T; ZADINA JE, 1994, LIFE SCI, V55, P461	30	1159	1244	2	53	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 3	1997	386	6624					499	502		10.1038/386499a0	http://dx.doi.org/10.1038/386499a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WR256	9087409				2022-12-01	WOS:A1997WR25600053
J	Dong, ZY; Kumar, R; Yang, XL; Fidler, IJ				Dong, ZY; Kumar, R; Yang, XL; Fidler, IJ			Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma	CELL			English	Article							HUMAN ALVEOLAR MACROPHAGES; 2ND TUMOR CHALLENGE; CANCER METASTASIS; MOUSE MACROPHAGE; STIMULATING FACTOR; GENE-EXPRESSION; IV COLLAGENASE; MURINE TUMORS; CELLS; ELASTASE	To determine the mechanism responsible for the in vivo production of angiostatin that inhibits growth and metastasis in Lewis lung carcinoma (3LL), we implanted 3LL variant cells into the subcutis of syngeneic C57BL/6 mice. The tumors were infiltrated by macrophages and expressed high levels of steady-state mRNA for metalloelastase (MME). Successive passages (more than three) of cultures established from the tumors resulted in complete depletion of macrophages; steady-state MME mRNA, elastinolytic activity, and production of angiostatin (in the presence of plasminogen) were correspondingly reduced. Coculture of macrophages with either 3LL cells or their conditioned media containing granulocyte-macrophage colony-stimulating factor resulted in secretion of MME and production of angiostatin by the macrophages, suggesting that angiostatin is produced by tumor-infiltrating macrophages whose MME expression is stimulated by tumor cell-derived granulocyte-macrophage colony-stimulating factor.			Dong, ZY (corresponding author), UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT CELL BIOL,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.				NATIONAL CANCER INSTITUTE [R35CA042107, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16672, R35-CA42107] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUKERMAN SL, 1986, JNCI-J NATL CANCER I, V77, P915; AUSTYN JM, 1981, EUR J IMMUNOL, V11, P805, DOI 10.1002/eji.1830111013; BANDA MJ, 1981, BIOCHEM J, V193, P589, DOI 10.1042/bj1930589; BANDA MJ, 1983, J EXP MED, V157, P1184, DOI 10.1084/jem.157.4.1184; BANDA MJ, 1980, J EXP MED, V152, P1563, DOI 10.1084/jem.152.6.1563; BELAAOUAJ A, 1995, J BIOL CHEM, V270, P14568, DOI 10.1074/jbc.270.24.14568; BUCANA CD, 1992, AM J PATHOL, V141, P1225; BUSIEK DF, 1992, J BIOL CHEM, V267, P9087; DONG Z, 1993, J EXP MED, V173, P1071; DONG ZY, 1994, JNCI-J NATL CANCER I, V86, P913, DOI 10.1093/jnci/86.12.913; Dong ZY, 1995, J LEUKOCYTE BIOL, V58, P725, DOI 10.1002/jlb.58.6.725; Fidler I J, 1994, Adv Pharmacol, V30, P271, DOI 10.1016/S1054-3589(08)60177-5; FIDLER IJ, 1985, CANCER RES, V45, P4714; FIDLER IJ, 1988, BIOCHIM BIOPHYS ACTA, V948, P151, DOI 10.1016/0304-419X(88)90009-1; FIDLER IJ, 1990, CANCER RES, V50, P6130; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; FIDLER IJ, 1995, J NATL CANCER I, V87, P1588, DOI 10.1093/jnci/87.21.1588; FISHER B, 1989, CANCER RES, V49, P1996; Gately S, 1996, CANCER RES, V56, P4887; GORELIK E, 1978, INT J CANCER, V21, P617, DOI 10.1002/ijc.2910210512; GORELIK E, 1981, INT J CANCER, V27, P847, DOI 10.1002/ijc.2910270618; GORELIK E, 1983, CANCER RES, V43, P138; GORELIK E, 1983, ADV CANCER RES, V39, P71, DOI 10.1016/S0065-230X(08)61033-7; GORELLK E, 1980, J NATL CANCER I, V65, P1257; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; JONES PDE, 1977, BRIT J CANCER, V35, P519, DOI 10.1038/bjc.1977.85; KATSUDA S, 1994, AM J PATHOL, V145, P1208; KELLER R, 1982, ADV EXP MED BIOL, V155, P289; Kumar R, 1996, J IMMUNOL, V157, P5104; LACRAZ S, 1992, J CLIN INVEST, V90, P382, DOI 10.1172/JCI115872; LEVY AT, 1991, CANCER RES, V51, P439; MANTOVANI A, 1992, IMMUNOL TODAY, V13, P265, DOI 10.1016/0167-5699(92)90008-U; MANTOVANI A, 1980, INT J CANCER, V25, P617, DOI 10.1002/ijc.2910250511; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; NATHAN CF, 1987, J CLIN INVEST, V79, P319, DOI 10.1172/JCI112815; NORMANN SJ, 1985, CANCER METAST REV, V4, P277, DOI 10.1007/BF00048093; OHLSSON K, 1974, SCAND J CLIN LAB INV, V34, P349, DOI 10.3109/00365517409049891; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; POLVERINI PJ, 1989, MACROPHAGE DERIVED C, P54; POSTE G, 1980, NATURE, V283, P139, DOI 10.1038/283139a0; PREHN RT, 1993, CANCER RES, V53, P3266; PREHN RT, 1991, CANCER RES, V51, P2; SENIOR RM, 1991, J BIOL CHEM, V266, P7870; SHAPIRO SD, 1992, J BIOL CHEM, V267, P4664; SHAPIRO SD, 1993, J BIOL CHEM, V268, P23824; SHAPIRO SD, 1993, J BIOL CHEM, V268, P8170; Shipley JM, 1996, J BIOL CHEM, V271, P4335; Shipley JM, 1996, P NATL ACAD SCI USA, V93, P3942, DOI 10.1073/pnas.93.9.3942; SHOTTON D M, 1970, Nature (London), V225, P802, DOI 10.1038/225802a0; SUGARBAKER EV, 1977, PROGR CANC RES THERA, P227; TAKEDA K, 1991, JPN J CANCER RES, V82, P1299, DOI 10.1111/j.1349-7006.1991.tb01796.x; TAKEDA K, 1991, INT J CANCER, V47, P413, DOI 10.1002/ijc.2910470318; TALMADGE JE, 1982, J NATL CANCER I, V69, P975; TALMADGE JE, 1981, J IMMUNOL, V126, P2245; Tyzzer EE, 1913, J MED RES, V28, P309; WELGUS HG, 1985, J CLIN INVEST, V76, P219, DOI 10.1172/JCI111949; WERB Z, 1975, J EXP MED, V142, P361, DOI 10.1084/jem.142.2.361; WERB Z, 1986, HDB EXPT IMMUNOLOGY, V2; WHITWORTH PW, 1990, CANCER METAST REV, V8, P319, DOI 10.1007/BF00052607; XIE B, 1994, J IMMUNOL, V152, P3637; YOUNG MRI, 1992, INT J CANCER, V50, P628, DOI 10.1002/ijc.2910500424	62	418	450	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 21	1997	88	6					801	810		10.1016/S0092-8674(00)81926-1	http://dx.doi.org/10.1016/S0092-8674(00)81926-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WQ100	9118223	Bronze			2022-12-01	WOS:A1997WQ10000012
J	Brakeman, PR; Lanahan, AA; OBrien, R; Roche, K; Barnes, CA; Huganir, RL; Worley, PF				Brakeman, PR; Lanahan, AA; OBrien, R; Roche, K; Barnes, CA; Huganir, RL; Worley, PF			Homer: A protein that selectively binds metabotropic glutamate receptors	NATURE			English	Article							ACTIVITY-REGULATED GENE; SYNAPTIC ACTIVITY; GROWTH-FACTOR; RAT-BRAIN; TRANSCRIPTION; ACTIVATION; LONG; LOCALIZATION; MEMBRANE; STRIATUM	Spatial localization and clustering of membrane proteins is critical to neuronal development and synaptic plasticity. Recent studies have identified a family of proteins, the PDZ proteins, that contain modular PDZ domains and interact with synaptic ionotropic glutamate receptors(1) and ion channels(2). PDZ proteins are thought to have a role in defining the cellular distribution of the proteins that interact with them, Here we report a novel dendritic protein, Homer, that contains a single, PDZ-like domain and binds specifically to the carboxy terminus of phosphoinositide-linked metabotropic glutamate receptors. Homer is highly divergent from known PDZ proteins and seems to represent a novel family. The Homer gene is also distinct from members of the PDZ family in that its expression is regulated as an immediate early gene and is dynamically responsive to physiological synaptic activity, particularly during cortical development. This dynamic transcriptional control suggests that Homer mediates a novel cellular mechanism that regulates metabotropic glutamate signalling.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT BIOCHEM,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,BALTIMORE,MD 21205; NIH,BETHESDA,MD 20892; UNIV ARIZONA,DEPT PSYCHOL & NEUROL,TUCSON,AZ; UNIV ARIZONA,DIV NEURONAL SYST MEMORY & AGING,TUCSON,AZ	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; National Institutes of Health (NIH) - USA; University of Arizona; University of Arizona			Roche, Katherine/W-9893-2019	Roche, Katherine/0000-0001-7282-6539				BAUDE A, 1993, NEURON, V11, P771, DOI 10.1016/0896-6273(93)90086-7; BHAT RV, 1993, J PHARMACOL EXP THER, V267, P496; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Flor PJ, 1996, J NEUROCHEM, V67, P58; GOELET P, 1986, NATURE, V322, P419, DOI 10.1038/322419a0; HYMAN SE, 1995, CHEM SENSES, V20, P257, DOI 10.1093/chemse/20.2.257; JOLY C, 1995, J NEUROSCI, V15, P3970; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; LYFORD GL, 1995, NEURON, V14, P433, DOI 10.1016/0896-6273(95)90299-6; MARTIN LJ, 1992, NEURON, V9, P259, DOI 10.1016/0896-6273(92)90165-A; NAKANISHI S, 1994, NEURON, V13, P1031, DOI 10.1016/0896-6273(94)90043-4; NEDIVI E, 1993, NATURE, V363, P713; NGUYEN PV, 1994, SCIENCE, V265, P1104, DOI 10.1126/science.8066450; NUSSER Z, 1994, NEUROSCIENCE, V61, P421, DOI 10.1016/0306-4522(94)90421-9; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; PIN JP, 1994, EMBO J, V13, P342, DOI 10.1002/j.1460-2075.1994.tb06267.x; QIAN Z, 1993, NATURE, V361, P453, DOI 10.1038/361453a0; ROMANO C, 1995, J COMP NEUROL, V355, P455, DOI 10.1002/cne.903550310; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Tsui CC, 1996, J NEUROSCI, V16, P2463; WORLEY PF, 1993, J NEUROSCI, V13, P4776; WORLEY PF, 1990, COLD SPRING HARB SYM, V55, P213, DOI 10.1101/SQB.1990.055.01.023; YAMAGATA K, 1993, NEURON, V11, P371, DOI 10.1016/0896-6273(93)90192-T; YAMAGATA K, 1994, J BIOL CHEM, V269, P16333; Yee WM, 1997, MOL CELL BIOL, V17, P921, DOI 10.1128/MCB.17.2.921	28	885	916	0	35	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 20	1997	386	6622					284	288		10.1038/386284a0	http://dx.doi.org/10.1038/386284a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WP003	9069287				2022-12-01	WOS:A1997WP00300052
J	Cookson, B				Cookson, B			Controversies - Is it time to stop searching for MRSA? Screening is still important	BRITISH MEDICAL JOURNAL			English	Article							RESISTANT STAPHYLOCOCCUS-AUREUS; OUTBREAK; EUROPE				Cookson, B (corresponding author), CENT PUBL HLTH LAB,PUBL HLTH LAB SERV,COLINDALE,LONDON NW9 5HT,ENGLAND.							ABOU YZ, 1995, 957 WHO CDS BVI; Asensio A, 1996, INFECT CONT HOSP EP, V17, P20; AYLIFFE GAJ, 1990, J HOSP INFECT, V16, P351; CASEWELL M, 1996, J HOSP INFECT S, V30, P45; COELLO R, 1994, EUR J CLIN MICROBIOL, V13, P74, DOI 10.1007/BF02026130; COOKSON B, 1995, J CHEMOTHERAPY, V7, P93; COOKSON BD, 1993, J MED MICROBIOL, V38, P309, DOI 10.1099/00222615-38-5-309; Cookson BD, 1993, STANDARDS INFECT CON; COOKSON BD, IN PRESS J MED MICRO; COX RA, 1995, J HOSP INFECT, V29, P87, DOI 10.1016/0195-6701(95)90191-4; GOODMAN DA, 1991, AM J MED, V16, P8; HARTSTEIN AI, 1995, INFECT CONT HOSP EP, V16, P257; JOHNSON AP, IN PRESS J MED MICRO; PANLILIO AL, 1992, INFECT CONT HOSP EP, V13, P582; RAHRNAN A, 1995, J HOSP INFECT, V30, P76; RICHET H, 1995, 4 M RAP C MED SCI, P101; SHERIDAN RL, 1994, AM J INFECT CONTROL, V22, P340, DOI 10.1016/0196-6553(94)90032-9; VOSS A, 1994, EUR J CLIN MICROBIOL, V13, P50, DOI 10.1007/BF02026127; WENZEL RP, 1991, AM J MED S3B, V91, P221; 1996, COMMUN DIS REP CDR W, V23, P197	20	39	39	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 1	1997	314	7081					664	665		10.1136/bmj.314.7081.664	http://dx.doi.org/10.1136/bmj.314.7081.664			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WL418	9066484	Green Published			2022-12-01	WOS:A1997WL41800034
J	Boyington, JC; Gladyshev, VN; Khangulov, SV; Stadtman, TC; Sun, PD				Boyington, JC; Gladyshev, VN; Khangulov, SV; Stadtman, TC; Sun, PD			Crystal structure of formate dehydrogenase H: Catalysis involving Mo, molybdopterin, selenocysteine, and an Fe4S4 cluster	SCIENCE			English	Article							ESCHERICHIA-COLI; SELENIUM; OXIDOREDUCTASE; PROGRAM	Formate dehydrogenase H from Escherichia coli contains selenocysteine (SeCys), molybdenum, two molybdopterin guanine dinucleotide (MGD) cofactors, and an Fe4S4 cluster at the active site and catalyzes the two-electron oxidation of formate to carbon dioxide. The crystal structures of the oxidized [Mo(VI), Fe4S4(ox)] form of formate dehydrogenase H (with and without bound inhibitor) and the reduced [Mo(IV), Fe4S4(red)] form have been determined, revealing a four-domain alpha beta structure with the molybdenum directly coordinated to selenium and both MGD cofactors. These structures suggest a reaction mechanism that directly involves SeCys(140) and His(141) in proton abstraction and the molybdenum, molybdopterin, Lys(44), and the Fe4S4 cluster in electron transfer.	NIAID,STRUCT BIOL SECT,MOL STRUCT LAB,NIH,ROCKVILLE,MD 20852; NHLBI,BIOCHEM LAB,BETHESDA,MD 20892; PRINCETON UNIV,HOYT LAB,DEPT CHEM,PRINCETON,NJ 08544	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Princeton University			Gladyshev, Vadim N/J-6187-2013; Albers, Pieter/I-2563-2017	Gladyshev, Vadim/0000-0002-0372-7016				AXLEY MJ, 1990, J BIOL CHEM, V265, P18213; AXLEY MJ, 1991, P NATL ACAD SCI USA, V88, P8450, DOI 10.1073/pnas.88.19.8450; AXLEY MJ, 1991, J BIOL CHEM, V266, P13731; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAIROCH A, 1992, NUCLEIC ACIDS RES, V20, P2019, DOI 10.1093/nar/20.suppl.2019; BARBER MJ, 1986, BIOCHEMISTRY-US, V25, P8150, DOI 10.1021/bi00373a004; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CHAN MK, 1995, SCIENCE, V267, P1463, DOI 10.1126/science.7878465; *DAR LAB, 1979, CCP4 SUIT PROGR PROT; Das SK, 1996, J AM CHEM SOC, V118, P1387, DOI 10.1021/ja9511580; Dong J.-K., UNPUB; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; George GN, 1996, J AM CHEM SOC, V118, P1113, DOI 10.1021/ja953317l; GLADYSHEV VN, 1994, P NATL ACAD SCI USA, V91, P7708, DOI 10.1073/pnas.91.16.7708; Gladyshev VN, 1996, J BIOL CHEM, V271, P8095, DOI 10.1074/jbc.271.14.8095; HOUSE KL, 1993, BIOCHEMISTRY-US, V32, P3468, DOI 10.1021/bi00064a034; Huber R, 1996, P NATL ACAD SCI USA, V93, P8846, DOI 10.1073/pnas.93.17.8846; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KHANGULOV SV, UNPUB; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lesk AM, 1995, CURR OPIN STRUC BIOL, V5, P775, DOI 10.1016/0959-440X(95)80010-7; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; PILATO RS, 1993, BIOINORGANIC CATALYS, pCH6; *RIG CORP, 1994, RAX DAT PROC SOFTW V; ROMAO MJ, 1995, SCIENCE, V270, P1170, DOI 10.1126/science.270.5239.1170; SAWERS G, 1994, ANTON LEEUW INT J G, V66, P57, DOI 10.1007/BF00871633; Schindelin H, 1996, SCIENCE, V272, P1615, DOI 10.1126/science.272.5268.1615; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; SIDMAN KE, 1988, NUCLEIC ACIDS RES, V16, P1869, DOI 10.1093/nar/16.5.1869; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503	31	464	474	4	114	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 28	1997	275	5304					1305	1308		10.1126/science.275.5304.1305	http://dx.doi.org/10.1126/science.275.5304.1305			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WK644	9036855	Green Submitted			2022-12-01	WOS:A1997WK64400042
J	Goldman, AP; Kerr, SJ; Butt, W; Marsh, MJ; Murdoch, IA; Paul, T; Firmin, RK; Tasker, RC; Macrae, DJ				Goldman, AP; Kerr, SJ; Butt, W; Marsh, MJ; Murdoch, IA; Paul, T; Firmin, RK; Tasker, RC; Macrae, DJ			Extracorporeal support for intractable cardiorespiratory failure due to meningococcal disease	LANCET			English	Article							PEDIATRIC RESPIRATORY-FAILURE; LIFE-SUPPORT; CHILDREN; MORTALITY	Background Meningococcal disease is still associated with considerable mortality, despite the use of early antibiotics and management in specialised intensive care units, due principally to early refractory myocardial depression and hypotension as well as severe acute respiratory distress syndrome. Extracorporeal membrane oxygenation (ECMO) is a complex technology that uses a modified ''heart-lung'' machine to provide temporary cardiac and respiratory support. We reviewed the UK and Australian experience of the use of ECMO in patients with refractory cardiorespiratory failure due to meningococcal disease. Methods The records from all 12 known patients supported with ECMO for meningococcal disease in the UK and Australia since 1989 were reviewed. Findings 12 patients (aged 4 months to 18 years, median 26 months) with meningococcal disease received ECMO over 8 years. In seven patients, ECMO was required early for cardiac support for intractable shock within 36 h of admission to intensive care. In the other five patients, ECMO was indicated for respiratory failure due to severe adult respiratory distress syndrome, which tended to occur later in the disease. The paediatric risk of mortality score ranged from 13 to 40 (median 29, median predicted risk of mortality 72%). Six of the 12 patients required cardiopulmonary resuscitation before ECMO and the other six were deteriorating despite maximal conventional therapy, Overall, eight of the 12 patients survived, with six leading functionally normal lives at a median of 1 year (range 4 months to 4 years) of follow-up. Interpretation ECMO might be considered to support patients with intractable cardiorespiratory failure due to meningococcal disease who are not responding to conventional treatment.	GUYS HOSP,LONDON,ENGLAND; GLENFIELD GEN HOSP,LEICESTER LE3 9QP,LEICS,ENGLAND; ROYAL CHILDRENS HOSP,MELBOURNE,VIC,AUSTRALIA	Guy's & St Thomas' NHS Foundation Trust; University Hospitals of Leicester NHS Trust; University of Leicester; Glenfield Hospital; Royal Children's Hospital Melbourne	Goldman, AP (corresponding author), GREAT ORMOND ST HOSP CHILDREN,CARDIAC INTENS CARE UNIT,GREAT ORMOND ST,LONDON WC1N 3JH,ENGLAND.		Macrae, Duncan/AAC-9564-2020; Tasker, Robert C/R-5837-2019	Tasker, Robert/0000-0003-3647-8113; Macrae, Duncan/0000-0002-7158-6585				BECA J, 1994, PEDIATRICS, V93, P726; BELLOMO R, 1993, CRIT CARE MED, V21, P522, DOI 10.1097/00003246-199304000-00011; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Best C, 1996, LANCET, V347, P202, DOI 10.1016/S0140-6736(96)90389-X; Champion MP, 1996, LANCET, V347, P201, DOI 10.1016/S0140-6736(96)90388-8; GIDELMAN LA, 1995, INTENS CARE MED, V21, pS269; GRIFFIN HD, 1991, BRIT POULTRY SCI, V32, P195, DOI 10.1080/00071669108417340; HEYDERMAN RS, 1993, ARCH DIS CHILD, V68, P621, DOI 10.1136/adc.68.5.621; MELIONES JN, 1991, CIRCULATION, V84, P168; Mok Q, 1996, INTENS CARE MED, V22, P259, DOI 10.1007/BF01712247; MOLER FW, 1994, J PEDIATR-US, V124, P875, DOI 10.1016/S0022-3476(05)83174-9; Parrillo J E, 1993, N Engl J Med, V328, P1471; RIVERA RA, 1990, ANAESTH INTENS CARE, V18, P385, DOI 10.1177/0310057X9001800316; TAMBURRO RF, 1991, J PEDIATR-US, V119, P935, DOI 10.1016/S0022-3476(05)83048-3; THOMSON APJ, 1991, CRIT CARE MED, V19, P26, DOI 10.1097/00003246-199101000-00010; TIMMONS OD, 1991, J PEDIATR-US, V119, P896, DOI 10.1016/S0022-3476(05)83039-2; 1995, CDR REV, V5, pR189	17	84	87	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 15	1997	349	9050					466	469		10.1016/S0140-6736(96)12106-1	http://dx.doi.org/10.1016/S0140-6736(96)12106-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH389	9040577				2022-12-01	WOS:A1997WH38900012
J	Siewert, JR; Fink, U				Siewert, JR; Fink, U			Commentary: Britain does better than Germany before patients reach hospital	BRITISH MEDICAL JOURNAL			English	Editorial Material											Siewert, JR (corresponding author), TECH UNIV MUNICH,DEPT SURG,SECT SURG ONCOL,D-8000 MUNICH,GERMANY.							SCHONBERGER B, 1996, THESIS TU MUNCHEN	1	2	2	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 15	1997	314	7079					471	471		10.1136/bmj.314.7079.471	http://dx.doi.org/10.1136/bmj.314.7079.471			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WJ419	9056795	Green Published			2022-12-01	WOS:A1997WJ41900023
J	Guo, HF; The, I; Hannan, F; Bernards, A; Zhong, Y				Guo, HF; The, I; Hannan, F; Bernards, A; Zhong, Y			Requirement of Drosophila NF1 for activation of adenylyl cyclase by PACAP38-like neuropeptides	SCIENCE			English	Article							NEUROFIBROMATOSIS TYPE-1 GENE; PROTEIN TYROSINE KINASE; PACAP-LIKE NEUROPEPTIDE; POTASSIUM CURRENTS; RAS GTPASE; SACCHAROMYCES-CEREVISIAE; SIGNAL-TRANSDUCTION; RUTABAGA; RECEPTOR; ENCODES	The human neurofibromatosis type 1 (NF1) tumor suppressor protein functions as a Ras-specific guanosine triphosphatase-activating protein, but the identity of Ras-mediated pathways modulated by NF1 remains unknown. A study of Drosophila NF1 mutants revealed that NF1 is essential for the cellular response to the neuropeptide PACAP38 (pituitary adenylyl cyclase-activating polypeptide) at the neuromuscular junction, The peptide induced a 100-fold enhancement of potassium currents by activating the Ras-Raf and adenylyl cyclase-adenosine 3',5'-monophosphate (cAMP) pathways, This response was eliminated in NF1 mutants, NF1 appears to regulate the rutabaga-encoded adenylyl cyclase rather than the Ras-Raf pathway, Moreover, the NF1 defect was rescued by the exposure of cells to pharmacological treatment that increased concentrations of cAMP.	COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	Cold Spring Harbor Laboratory			The, Inge/B-8884-2011	Zhong, Yi/0000-0001-7810-9899; Zhong, Yi/0000-0002-7927-5976	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031747, R01NS034779] Funding Source: NIH RePORTER; NINDS NIH HHS [R01-NS31747, R01-NS34779] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; ARIMURA A, 1992, REGUL PEPTIDES, V37, P287; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BERS DM, 1994, METHOD CELL BIOL, V40, P3; BRAND AH, 1994, GENE DEV, V8, P629, DOI 10.1101/gad.8.5.629; BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; BUCHBERG AM, 1990, NATURE, V347, P291, DOI 10.1038/347291a0; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DUDAI Y, 1985, J NEUROGENET, V2, P365, DOI 10.3109/01677068509101423; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; JAN LY, 1976, J PHYSIOL-LONDON, V262, P189, DOI 10.1113/jphysiol.1976.sp011592; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; LIVINGSTONE MS, 1985, P NATL ACAD SCI USA, V82, P5992, DOI 10.1073/pnas.82.17.5992; LIVINGSTONE MS, 1984, CELL, V37, P205, DOI 10.1016/0092-8674(84)90316-7; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MCCORMICK F, 1995, CURR OPIN GENET DEV, V5, P51, DOI 10.1016/S0959-437X(95)90053-5; MITTS MR, 1991, MOL CELL BIOL, V11, P4591, DOI 10.1128/MCB.11.9.4591; NORTH K, 1994, NEUROLOGY, V44, P878, DOI 10.1212/WNL.44.5.878; SEAMON KB, 1981, J CYCLIC NUCL PROT, V7, P201; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SINGH S, 1989, NEURON, V2, P1325, DOI 10.1016/0896-6273(89)90070-6; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; STEWART BA, 1994, J COMP PHYSIOL A, V175, P179, DOI 10.1007/BF00215114; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; The I, 1997, SCIENCE, V276, P791, DOI 10.1126/science.276.5313.791; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; VISKOCHIL D, 1993, ANNU REV NEUROSCI, V16, P183, DOI 10.1146/annurev.ne.16.030193.001151; WU CF, 1983, SCIENCE, V220, P1076, DOI 10.1126/science.6302847; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; ZHONG Y, 1995, NATURE, V375, P588, DOI 10.1038/375588a0; ZHONG Y, 1993, J NEUROGENET, V9, P15, DOI 10.3109/01677069309167273; ZHONG Y, 1995, NEURON, V14, P527, DOI 10.1016/0896-6273(95)90309-7	34	158	161	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 2	1997	276	5313					795	798		10.1126/science.276.5313.795	http://dx.doi.org/10.1126/science.276.5313.795			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WW900	9115204				2022-12-01	WOS:A1997WW90000058
J	Pazin, MJ; Bhargava, P; Geiduschek, EP; Kadonaga, JT				Pazin, MJ; Bhargava, P; Geiduschek, EP; Kadonaga, JT			Nucleosome mobility and the maintenance of nucleosome positioning	SCIENCE			English	Article							YEAST ALPHA-2 REPRESSOR; CHROMATIN STRUCTURE; TRANSCRIPTIONAL ACTIVATION; REMODELING FACTOR; DNA-REPLICATION; LAC REPRESSOR; PROMOTER; DISRUPTION; OPERATOR; BINDING	To study nucleosome mobility and positioning, the R3 lac repressor was used with an adenosine triphosphate (ATP)-dependent chromatin assembly system to establish the positioning of five nucleosomes, with one nucleosome located between two R3 lac operators, When R3 protein was dissociated from DNA with isopropyl beta-D-thiogalactopyranoside, the R3-induced nucleosome positions remained unchanged for at least 60 minutes in the absence of ATP but rearranged within 15 minutes in the presence of ATP. These results suggest that nucleosomes are dynamic and mobile rather than static and that a DNA binding factor is continuously required for the maintenance of nucleosome positioning.	UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, CTR MOL GENET, LA JOLLA, CA 92093 USA; CTR CELLULAR & MOL BIOL, HYDERABAD 500007, ANDHRA PRADESH, INDIA	University of California System; University of California San Diego; University of California System; University of California San Diego; Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)				Pazin, Michael/0000-0002-7561-3640				ALBERTI S, 1993, EMBO J, V12, P3227, DOI 10.1002/j.1460-2075.1993.tb05992.x; Armstrong JA, 1996, MOL CELL BIOL, V16, P5634; BEARD P, 1978, CELL, V15, P955, DOI 10.1016/0092-8674(78)90279-9; BROWN M, 1987, CELL, V49, P603, DOI 10.1016/0092-8674(87)90536-8; Bulger M., 1994, METH MOL G, V5, P241; CHASMAN DI, 1990, GENE DEV, V4, P503, DOI 10.1101/gad.4.4.503; CHEN J, 1994, J BIOL CHEM, V269, P12482; ELGIN SCR, 1995, CHROMATIN STRUCTURE; FEDOR MJ, 1989, MOL CELL BIOL, V9, P1721, DOI 10.1128/MCB.9.4.1721; FEDOR MJ, 1988, J MOL BIOL, V204, P109, DOI 10.1016/0022-2836(88)90603-1; Felsenfeld G, 1996, CELL, V86, P13, DOI 10.1016/S0092-8674(00)80073-2; GOSSEN M, 1993, TRENDS BIOCHEM SCI, V18, P471, DOI 10.1016/0968-0004(93)90009-C; GRUNSTEIN M, 1992, SCI AM, V267, P68, DOI 10.1038/scientificamerican1092-68; HAGER GL, 1993, COLD SPRING HARB SYM, V58, P63, DOI 10.1101/SQB.1993.058.01.010; Ho SN, 1996, NATURE, V382, P822, DOI 10.1038/382822a0; HU MCT, 1987, CELL, V48, P555, DOI 10.1016/0092-8674(87)90234-0; KAMAKAKA RT, 1993, GENE DEV, V7, P1779, DOI 10.1101/gad.7.9.1779; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; KORNBERG RD, 1995, CURR OPIN CELL BIOL, V7, P371, DOI 10.1016/0955-0674(95)80092-1; Krude T, 1996, CURR BIOL, V6, P511, DOI 10.1016/S0960-9822(02)00529-8; NEDOSPASOV SA, 1980, BIOCHEM BIOPH RES CO, V92, P532, DOI 10.1016/0006-291X(80)90366-6; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.bi.63.070194.001405; PAZIN MJ, 1994, SCIENCE, V266, P2007, DOI 10.1126/science.7801129; Pazin MJ, 1996, GENE DEV, V10, P37, DOI 10.1101/gad.10.1.37; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; REIK A, 1991, EMBO J, V10, P2569, DOI 10.1002/j.1460-2075.1991.tb07797.x; ROTH SY, 1992, GENE DEV, V6, P411, DOI 10.1101/gad.6.3.411; ROTH SY, 1990, MOL CELL BIOL, V10, P2247, DOI 10.1128/MCB.10.5.2247; SCHMID A, 1992, CELL, V71, P853, DOI 10.1016/0092-8674(92)90560-Y; SHIMIZU M, 1991, EMBO J, V10, P3033, DOI 10.1002/j.1460-2075.1991.tb07854.x; SIMPSON RT, 1991, PROG NUCLEIC ACID RE, V40, P143; SPADAFORA C, 1979, EUR J BIOCHEM, V100, P225, DOI 10.1111/j.1432-1033.1979.tb02053.x; SVAREN J, 1993, CURR OPIN GENET DEV, V3, P219, DOI 10.1016/0959-437X(93)90026-L; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; TSUKIYAMA T, 1995, CELL, V83, P1021, DOI 10.1016/0092-8674(95)90217-1; van Holde K.E., 1989, CHROMATIN; VARGAWEISZ PD, 1995, EMBO J, V14, P2209, DOI 10.1002/j.1460-2075.1995.tb07215.x; VERDIN E, 1993, EMBO J, V12, P3249, DOI 10.1002/j.1460-2075.1993.tb05994.x; WALL G, 1995, EMBO J, V14, P1727, DOI 10.1002/j.1460-2075.1995.tb07162.x; Wolffe A., 1995, CHROMATIN STRUCTURE; WORKMAN JL, 1993, TRENDS BIOCHEM SCI, V18, P90, DOI 10.1016/0968-0004(93)90160-O; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0	43	88	88	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 2	1997	276	5313					809	812		10.1126/science.276.5313.809	http://dx.doi.org/10.1126/science.276.5313.809			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WW900	9115208				2022-12-01	WOS:A1997WW90000062
J	Sandrock, AW; Dryer, SE; Rosen, KM; Gozani, SN; Kramer, R; Theill, LE; Fischbach, GD				Sandrock, AW; Dryer, SE; Rosen, KM; Gozani, SN; Kramer, R; Theill, LE; Fischbach, GD			Maintenance of acetylcholine receptor number by neuregulins at the neuromuscular junction in vivo	SCIENCE			English	Article							BUNGAROTOXIN-TREATED RATS; ORIGINAL SYNAPTIC SITES; EPSILON-SUBUNIT GENE; ADULT MUSCLE-FIBERS; DIFFERENTIAL EXPRESSION; REGENERATING MUSCLE; CARDIAC DEVELOPMENT; MYASTHENIA-GRAVIS; CHICK MYOTUBES; MESSENGER-RNA	ARIA (for acetylcholine receptor-inducing activity), a protein purified on the basis of its ability to stimulate acetylcholine receptor (AChR) synthesis in cultured myotubes, is a member of the neuregulin family and is present at motor endplates. This suggests an important role for neuregulins in mediating the nerve-dependent accumulation of AChRs in the postsynaptic membrane. Nerve-muscle synapses have now been analyzed in neuregulin-deficient animals. Mice that are heterozygous for the deletion of neuregulin isoforms containing an immunoglobulin-like domain are myasthenic. Postsynaptic AChR density is significantly reduced, as judged by the decrease in the mean amplitude of spontaneous miniature endplate potentials and bungarotoxin binding. On the other hand, the mean amplitude of evoked end plate potentials was not decreased, due to an increase in the number of quanta released per impulse, a compensation that has been observed in other myasthenic states. Thus, the density of AChRs in the postsynaptic membrane depends on immunoglobulin-containing neuregulin isoforms throughout the life of the animal.	HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,DEPT NEUROL,BOSTON,MA 02114; AMGEN INC,THOUSAND OAKS,CA 91320	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Amgen					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001580, R01NS018458] Funding Source: NIH RePORTER; NINDS NIH HHS [R01-NS18458, K08-NS01580] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTIOK N, 1995, EMBO J, V14, P4258, DOI 10.1002/j.1460-2075.1995.tb00100.x; BRENNER HR, 1978, NATURE, V271, P366, DOI 10.1038/271366a0; BRENNER HR, 1992, DEVELOPMENT, V116, P41; BRENNER HR, 1990, NATURE, V344, P544, DOI 10.1038/344544a0; BRENNER HR, 1983, J PHYSIOL-LONDON, V337, P159, DOI 10.1113/jphysiol.1983.sp014617; BUCCARON MH, 1983, DEV BIOL, V95, P378, DOI 10.1016/0012-1606(83)90039-8; BURDEN SJ, 1979, J CELL BIOL, V82, P412, DOI 10.1083/jcb.82.2.412; CHEN MS, 1994, J COMP NEUROL, V349, P389, DOI 10.1002/cne.903490306; CHU GC, 1995, NEURON, V14, P329, DOI 10.1016/0896-6273(95)90289-9; CORFAS G, 1995, NEURON, V14, P103, DOI 10.1016/0896-6273(95)90244-9; CULLCANDY SG, 1980, J PHYSIOL-LONDON, V299, P621, DOI 10.1113/jphysiol.1980.sp013145; DENNIS MJ, 1981, DEV BIOL, V81, P266, DOI 10.1016/0012-1606(81)90290-6; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FISCHBACH GD, IN PRESS ANN REV NEU; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; Gautam M, 1996, CELL, V85, P525, DOI 10.1016/S0092-8674(00)81253-2; GAUTAM M, 1995, NATURE, V377, P232, DOI 10.1038/377232a0; GOLDMAN D, 1991, NEURON, V7, P649, DOI 10.1016/0896-6273(91)90377-C; GOLDMAN D, 1989, NEURON, V3, P219, DOI 10.1016/0896-6273(89)90035-4; GOODEARL ADJ, 1995, J CELL BIOL, V130, P1423, DOI 10.1083/jcb.130.6.1423; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; HO WH, 1995, J BIOL CHEM, V270, P14523, DOI 10.1074/jbc.270.24.14523; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; JESSELL TM, 1979, P NATL ACAD SCI USA, V76, P5397, DOI 10.1073/pnas.76.10.5397; JO SA, 1995, NATURE, V373, P158, DOI 10.1038/373158a0; Kramer R, 1996, P NATL ACAD SCI USA, V93, P4833, DOI 10.1073/pnas.93.10.4833; KUO Y, 1994, SOC NEUR ABSTR, V20, P45218; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; LOEB JA, 1995, J CELL BIOL, V130, P127, DOI 10.1083/jcb.130.1.127; MALLART A, 1968, J PHYSIOL-LONDON, V196, P593, DOI 10.1113/jphysiol.1968.sp008525; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARTINOU JC, 1991, P NATL ACAD SCI USA, V88, P7669, DOI 10.1073/pnas.88.17.7669; MCMAHAN UJ, 1990, COLD SH Q B, V55, P407; MERLIE JP, 1985, NATURE, V317, P66, DOI 10.1038/317066a0; MEYER D, 1994, P NATL ACAD SCI USA, V91, P1064, DOI 10.1073/pnas.91.3.1064; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; MOSCOSO LM, 1995, DEV BIOL, V172, P158, DOI 10.1006/dbio.1995.0012; ORRURTREGER A, 1993, P NATL ACAD SCI USA, V90, P1867, DOI 10.1073/pnas.90.5.1867; PLOMP JJ, 1994, J PHYSIOL-LONDON, V478, P125, DOI 10.1113/jphysiol.1994.sp020236; PLOMP JJ, 1992, J PHYSIOL-LONDON, V458, P487, DOI 10.1113/jphysiol.1992.sp019429; PLOMP JJ, 1995, ANN NEUROL, V37, P627, DOI 10.1002/ana.410370513; ROLE LW, 1985, J NEUROSCI, V5, P2197; ROSEN KM, IN PRESS COLD SPRING; SANDROCK AW, 1995, J NEUROSCI, V15, P6124; SANES JR, 1991, DEVELOPMENT, V113, P1181; SIMON AM, 1992, DEVELOPMENT, V114, P545; USDIN TB, 1986, J CELL BIOL, V103, P493, DOI 10.1083/jcb.103.2.493; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; ZHU XJ, 1995, EMBO J, V14, P5842, DOI 10.1002/j.1460-2075.1995.tb00272.x	49	239	242	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 25	1997	276	5312					599	603		10.1126/science.276.5312.599	http://dx.doi.org/10.1126/science.276.5312.599			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WV721	9110980				2022-12-01	WOS:A1997WV72100047
J	DiCarli, MF; Tobes, MC; Mangner, T; Levine, AB; Muzik, O; Chakroborty, P; Levine, TB				DiCarli, MF; Tobes, MC; Mangner, T; Levine, AB; Muzik, O; Chakroborty, P; Levine, TB			Effects of cardiac sympathetic innervation on coronary blood flow	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POSITRON EMISSION TOMOGRAPHY; ENDOTHELIUM-DEPENDENT RELAXATION; MYOCARDIAL-INFARCTION; NERVOUS-SYSTEM; HUMAN HEART; TRANSPLANTATION; DENERVATION; ARTERIES; ANGINA; METAIODOBENZYLGUANIDINE	Background The role of cardiac sympathetic nerves in regulating coronary blood flow is controversial. We sought to determine the degree to which cardiac efferent sympathetic signals modulate coronary blood flow. The heterogeneous sympathetic reinnervation in transplanted hearts provides a model for studying the vasomotor responses to adrenergic stimulation in reinnervated and denervated coronary territories of the same heart. Methods We studied 14 cardiac-transplant recipients who had normal coronary arteries and no evidence of rejection and 8 normal subjects. We used positron-emission tomography with [C-11]hydroxyephedrine, an analogue of norepinephrine, to delineate sympathetic innervation. Using [N-13]ammonia, we measured myocardial blood flow at rest, during adenosine-induced hyperemia, and in response to sympathetic stimulation induced by cold presser testing. Results In the transplant recipients, the uptake of [C-11]hydroxyephedrine was greater in the territory served by the left anterior descending artery (mean +/-SE, 0.15+/-0.01) than in those served by the right coronary artery (0.07+/-0.01, P<0.001) or the circumflex artery (0.09+/-0.01, P<0.001). The basal flow was similar in all three regions, as was the percent increase in flow during hyperemia. However, the increase in flow in response to cold presser testing was higher in the territory of the left anterior descending artery (46+/-10 percent) than in those of the right coronary artery (16+/-5 percent, P=0.01) or the circumflex artery (23+/-6 percent, P=0.06), although the changes in hemodynamics and levels of circulating catecholamines were similar, No such regional differences were observed in the normal subjects. Conclusions Increases in coronary blood flow in response to sympathetic stimulation correlated with the regional norepinephrine content in the cardiac sympathetic-nerve terminals. These findings suggest that cardiac adrenergic signals play an important part in regulating myocardial blood flow. (C) 1997, Massachusetts Medical Society.	WAYNE STATE UNIV, SCH MED, DEPT INTERNAL MED, DIV CARDIOL, DETROIT, MI 48201 USA; WAYNE STATE UNIV, SCH MED, DEPT RADIOL, DETROIT, MI 48201 USA; HENRY FORD HEART & VASC INST, DETROIT, MI USA	Wayne State University; Wayne State University; Henry Ford Health System								Allman KC, 1993, J AM COLL CARDIOL, V22, P368, DOI 10.1016/0735-1097(93)90039-4; ANDERSON TJ, 1993, CIRCULATION, V88, P1093, DOI 10.1161/01.CIR.88.3.1093; BERKENBOOM G, 1991, J CARDIOVASC PHARM, V17, pS127, DOI 10.1097/00005344-199117003-00024; BERNE RM, 1964, PHYSIOL REV, V44, P1, DOI 10.1152/physrev.1964.44.1.1; BOGATY P, 1994, CIRCULATION, V90, P5, DOI 10.1161/01.CIR.90.1.5; CHILIAN WM, 1981, CIRC RES, V49, P866, DOI 10.1161/01.RES.49.4.866; COCKS TM, 1983, NATURE, V305, P627, DOI 10.1038/305627a0; DAE MW, 1991, J AM COLL CARDIOL, V17, P1416, DOI 10.1016/S0735-1097(10)80156-1; FAERMAN I, 1977, DIABETES, V26, P1147, DOI 10.2337/diabetes.26.12.1147; FUSTER V, 1988, CIRCULATION, V77, P1213, DOI 10.1161/01.CIR.77.6.1213; GOLDSTEIN DS, 1981, LIFE SCI, V28, P467, DOI 10.1016/0024-3205(81)90139-9; GRAVES J, 1993, BRIT J PHARMACOL, V108, P631, DOI 10.1111/j.1476-5381.1993.tb12853.x; HACKETT D, 1987, NEW ENGL J MED, V317, P1055, DOI 10.1056/NEJM198710223171704; HODGSON JM, 1989, CIRCULATION, V79, P797, DOI 10.1161/01.CIR.79.4.797; HUTCHINS GD, 1992, J NUCL MED, V33, P1243; INOUE H, 1988, CIRC RES, V62, P1111, DOI 10.1161/01.RES.62.6.1111; JONES CJH, 1993, CIRCULATION, V87, P1264, DOI 10.1161/01.CIR.87.4.1264; KAHN JK, 1986, J AM COLL CARDIOL, V7, P1303, DOI 10.1016/S0735-1097(86)80150-4; Kichuk MR, 1996, CIRCULATION, V94, P44, DOI 10.1161/01.CIR.94.1.44; LANGER A, 1995, J AM COLL CARDIOL, V25, P610, DOI 10.1016/0735-1097(94)00459-4; MUGGE A, 1993, J AM COLL CARDIOL, V21, P163; MUZIK O, 1993, J NUCL MED, V34, P83; NORVELL JE, 1973, TRANSPLANTATION, V15, P337, DOI 10.1097/00007890-197303000-00015; SAWADA S, 1995, J NUCL CARDIOL, V2, P413, DOI 10.1016/S1071-3581(05)80029-7; SCHOEN FJ, 1991, TRENDS CARDIOVAS MED, V1, P216, DOI 10.1016/1050-1738(91)90041-C; SCHWAIGER M, 1990, J NUCL MED, V31, P1352; SCHWAIGER M, 1990, CIRCULATION, V82, P457, DOI 10.1161/01.CIR.82.2.457; SCHWAIGER M, 1991, J CLIN INVEST, V87, P1681, DOI 10.1172/JCI115185; STANTON MS, 1989, J AM COLL CARDIOL, V14, P1519, DOI 10.1016/0735-1097(89)90391-4; Vanhoutte PM, 1988, VASODILATATION VASCU; VENTURA HO, 1995, AM HEART J, V129, P791, DOI 10.1016/0002-8703(95)90331-3; WILSON RF, 1993, CIRCULATION, V88, P165, DOI 10.1161/01.CIR.88.1.165; WILSON RF, 1991, CIRCULATION, V83, P1210, DOI 10.1161/01.CIR.83.4.1210; YASUE H, 1974, CIRCULATION, V50, P534, DOI 10.1161/01.CIR.50.3.534; YASUE H, 1979, AM J CARDIOL, V43, P647, DOI 10.1016/0002-9149(79)90026-2; YOUNG MA, 1987, PROG CARDIOVASC DIS, V30, P211, DOI 10.1016/0033-0620(87)90013-2; YOUNG MA, 1986, AM J PHYSIOL, V250, pH892, DOI 10.1152/ajpheart.1986.250.5.H892; ZEIHER AM, 1991, CIRCULATION, V84, P1984, DOI 10.1161/01.CIR.84.5.1984; ZEIHER AM, 1989, J AM COLL CARDIOL, V14, P1181, DOI 10.1016/0735-1097(89)90414-2	39	179	180	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 24	1997	336	17					1208	1215		10.1056/NEJM199704243361703	http://dx.doi.org/10.1056/NEJM199704243361703			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WV332	9110908				2022-12-01	WOS:A1997WV33200003
J	Schrott, HG; Bittner, V; Vittinghoff, E; Herrington, DM; Hulley, S				Schrott, HG; Bittner, V; Vittinghoff, E; Herrington, DM; Hulley, S			Adherence to national cholesterol education program treatment goals in postmenopausal women with heart disease - The heart and estrogen/progestin replacement study (HERS)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DENSITY-LIPOPROTEIN CHOLESTEROL; ACUTE MYOCARDIAL-INFARCTION; CORONARY-ARTERY DISEASE; COLESTIPOL-NIACIN; FOLLOW-UP; MORTALITY; ATHEROSCLEROSIS; MEN; REDUCTION; PREDICTOR	Objectives.-To determine the proportion of volunteer women with established heart disease who have low-density lipoprotein cholesterol (LDL-C) levels at or below the National Cholesterol Education Program Adult Treatment Panel goals and to determine what factors are associated with levels above goal or not receiving lipid-lowering medication when indicated. Design.-Cross-sectional measurement of lipids and lipoproteins, blood pressure, height, weight, and other demographic and cardiovascular risk factors in 2763 postmenopausal women with heart disease. Setting.-At 18 centers throughout the United States, participants were recruited by means of lists of women with coronary heart disease from coronary units and catheterization laboratories, direct mail to age-eligible women, and advertisements. Patients.-Mean age of the cohort was 66.7 years (range, 44-79 years) and the distribution by race/ethnicity was 88.7% white, 7.9% African American, 2.0% Hispanic/Latina, 0.8% Asian/Pacific Islander, and 0.7% other. Intervention.-We report cross-sectional analysis of the cohort at baseline. Outcome Measures.-We measured the frequency of achieving 1988 and 1993 Adult Treatment Panel treatment goals, and of being on a regimen of lipid-lowering medication. Results.-Although 47% of participants were taking a lipid-lowering medication, 63% did not meet the 1988 treatment goal of LDL-C level less than 3.4 mmol/L (130 mg/dL) and 91% did not meet the 1993 goal of LDL-C level less than 2.6 mmol/L (100 mg/dL). Factors independently associated with achieving the earlier goal were use of lipid-lowering medication, marital status, education, body mass index, exercise, hypertension, diabetes, gallbladder disease, and first diagnosis of coronary heart disease after 1990. Failure to use lipid-lowering medication was associated with age, being African American, marital status, body mass index, lack of exercise, alcohol consumption, current smoking, and first diagnosis of coronary heart disease before 1985. Conclusion.-The majority of women enrolled in the trial had LDL-C levels that significantly exceeded the treatment goals set by the 1988 and 1993 Adult Treatment Panel guidelines. Better implementation of these guidelines among women with coronary disease would be highly desirable.	UNIV ALABAMA, DEPT MED, BIRMINGHAM, AL 35294 USA; UNIV CALIF SAN FRANCISCO, HERS COORDINATING CTR, DEPT EPIDEMIOL & BIOSTAT, SAN FRANCISCO, CA 94143 USA; WAKE FOREST UNIV, BOWMAN GRAY SCH MED, CARDIOL SECT, WINSTON SALEM, NC USA	University of Alabama System; University of Alabama Birmingham; University of California System; University of California San Francisco; Wake Forest University; Wake Forest Baptist Medical Center	Schrott, HG (corresponding author), UNIV IOWA, COLL MED, DEPT PREVENT MED, WESTLAWN S-231, IOWA CITY, IA 52242 USA.							BABIRAK SP, 1996, CIRCULATION S, V94, P50; BACHORIK PS, 1984, CLIN CHEM, V30, P839; BLANKENHORN DH, 1987, JAMA-J AM MED ASSOC, V257, P3233, DOI 10.1001/jama.257.23.3233; CASHINHEMPHILL L, 1990, JAMA-J AM MED ASSOC, V264, P3013, DOI 10.1001/jama.264.23.3013; CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36; COWLEY MJ, 1985, CIRCULATION, V71, P90, DOI 10.1161/01.CIR.71.1.90; DAVIS KB, 1995, J AM COLL CARDIOL, V25, P1000, DOI 10.1016/0735-1097(94)00518-U; DITTRICH H, 1988, AM J CARDIOL, V62, P1, DOI 10.1016/0002-9149(88)91356-2; Eaker E D, 1989, Cardiovasc Clin, V19, P129; EAKER ED, 1993, CIRCULATION, V88, P1999, DOI 10.1161/01.CIR.88.4.1999; *EXP PAN, 1993, JAMA-J AM MED ASSOC, V289, P3015; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; Garber Alan J., 1996, Clinical Diabetes, V14, P9; GREENLAND P, 1991, CIRCULATION, V83, P484, DOI 10.1161/01.CIR.83.2.484; HALL WD, 1991, CARDIVOASCULAR DIS B, P157; HASKELL WL, 1994, CIRCULATION, V89, P975, DOI 10.1161/01.CIR.89.3.975; Hosmer DW, 2000, APPL LOGISTIC REGRES, V2nd; KANE JP, 1990, JAMA-J AM MED ASSOC, V264, P3007, DOI 10.1001/jama.264.23.3007; KHAN SS, 1990, ANN INTERN MED, V112, P561, DOI 10.7326/0003-4819-112-8-561; LERNER DJ, 1986, AM HEART J, V111, P383, DOI 10.1016/0002-8703(86)90155-9; Lewis SJ, 1996, CIRCULATION, V94, P69; MANOLIO TA, 1992, AM J MED, V92, P1, DOI 10.1016/0002-9343(92)90007-X; Marcelino JJ, 1996, AM J MED, V100, P605, DOI 10.1016/S0002-9343(96)00011-3; Miettinen TA, 1996, CIRCULATION, V94, P68; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; MYERS GL, 1989, CLIN LAB MED, V9, P105, DOI 10.1016/S0272-2712(18)30645-0; NAWROCKI JW, 1995, ARTERIOSCL THROM VAS, V15, P678, DOI 10.1161/01.ATV.15.5.678; PEDERSEN TR, 1994, LANCET, V344, P1383; RICH MW, 1992, AM J MED, V92, P7, DOI 10.1016/0002-9343(92)90008-Y; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; *SAS I INC, 1995, STAT AN SYST VERS 6; SCHROTT HG, 1995, AM J CARDIOL, V75, P34, DOI 10.1016/S0002-9149(99)80523-2; SCHROTT HG, 1994, J WOMENS HEALTH, V3, P155; WERBEL BL, 1994, J CARDIAC REHABIL, V14, P320; *WRIT GROUP PEPI T, 1995, JAMA-J AM MED ASSOC, V274, P1676	35	207	210	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 23	1997	277	16					1281	1286		10.1001/jama.277.16.1281	http://dx.doi.org/10.1001/jama.277.16.1281			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU135	9109465				2022-12-01	WOS:A1997WU13500027
J	Chan, DC; Fass, D; Berger, JM; Kim, PS				Chan, DC; Fass, D; Berger, JM; Kim, PS			Core structure of gp41 from the HIV envelope glycoprotein	CELL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HEMAGGLUTININ MEMBRANE GLYCOPROTEIN; SOLUBLE RECEPTOR-BINDING; GCN4 LEUCINE-ZIPPER; TRANSMEMBRANE GLYCOPROTEIN; INFLUENZA HEMAGGLUTININ; TYPE-1 GP41; HEPTAD REPEAT; COILED COILS; FUSION	The envelope glycoprotein of human immunodeficiency virus type 1 (HIV-1) consists of a complex of gp120 and gp41. gp120 determines viral tropism by binding to target-cell receptors, while gp41 mediates fusion between viral and cellular membranes. Previous studies identified an cu-helical domain within gp41 composed of a trimer of two interacting peptides. The crystal structure of this complex, composed of the peptides N36 and C34, is a six-helical bundle. Three N36 helices form an interior, parallel coiled-coil trimer, while three C34 helices pack in an oblique, antiparallel manner into highly conserved, hydrophobic grooves on the surface of this trimer. This structure shows striking similarity to the low-pH-induced conformation of influenza hemagglutinin and likely represents the core of fusion-active gp41. Avenues for the design/discovery of small-molecule inhibitors of HIV infection are directly suggested by this structure.	MIT, HOWARD HUGHES MED INST, DEPT BIOL, CAMBRIDGE, MA 02142 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Chan, DC (corresponding author), WHITEHEAD INST BIOMED RES, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA.		Chan, Doris/O-1227-2014	Chan, Doris/0000-0002-4990-986X				ALLAN JS, 1990, SCIENCE, V247, P1084, DOI 10.1126/science.2309120; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BLACKLOW SC, 1995, BIOCHEMISTRY-US, V34, P14955, DOI 10.1021/bi00046a001; Broder CC, 1996, PATHOBIOLOGY, V64, P171, DOI 10.1159/000164032; Brunger A. T., 1992, SYSTEM XRAY CRYSTALL; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CAO J, 1993, J VIROL, V67, P2747, DOI 10.1128/JVI.67.5.2747-2755.1993; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; CHAMBERS P, 1990, J GEN VIROL, V71, P3075, DOI 10.1099/0022-1317-71-12-3075; CHEN CH, 1995, J VIROL, V69, P3771, DOI 10.1128/JVI.69.6.3771-3777.1995; Chen J, 1995, P NATL ACAD SCI USA, V92, P12205, DOI 10.1073/pnas.92.26.12205; CHEN SSL, 1994, J VIROL, V68, P2002, DOI 10.1128/JVI.68.3.2002-2010.1994; CHEN SSL, 1993, J VIROL, V67, P3615, DOI 10.1128/JVI.67.6.3615-3619.1993; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; Cohen J, 1996, SCIENCE, V274, P502, DOI 10.1126/science.274.5287.502; Cowtan K., 1994, JT CCP4 ESF EACBM NE, V31, P34; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; DAAR ES, 1990, P NATL ACAD SCI USA, V87, P6574, DOI 10.1073/pnas.87.17.6574; DELWART EL, 1990, AIDS RES HUM RETROV, V6, P703, DOI 10.1089/aid.1990.6.703; DSouza MP, 1996, NAT MED, V2, P1293, DOI 10.1038/nm1296-1293; DUBAY JW, 1992, J VIROL, V66, P4748, DOI 10.1128/JVI.66.8.4748-4756.1992; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Fass D, 1996, NAT STRUCT BIOL, V3, P465, DOI 10.1038/nsb0596-465; Fass D, 1995, CURR BIOL, V5, P1377, DOI 10.1016/S0960-9822(95)00275-2; FREED EO, 1995, J BIOL CHEM, V270, P23883, DOI 10.1074/jbc.270.41.23883; GALLAHER WR, 1989, AIDS RES HUM RETROV, V5, P431, DOI 10.1089/aid.1989.5.431; HARBURY PB, 1994, NATURE, V371, P80, DOI 10.1038/371080a0; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HART TK, 1991, P NATL ACAD SCI USA, V88, P2189, DOI 10.1073/pnas.88.6.2189; HELSETH E, 1991, J VIROL, V65, P2119, DOI 10.1128/JVI.65.4.2119-2123.1991; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HUNTER E, 1990, CURR TOP MICROBIOL, V157, P187; JIANG SB, 1993, NATURE, V365, P113, DOI 10.1038/365113a0; JONES TA, 1992, O MANUAL; KALYANARAMAN VS, 1990, AIDS RES HUM RETROV, V6, P371, DOI 10.1089/aid.1990.6.371; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lambert DM, 1996, P NATL ACAD SCI USA, V93, P2186, DOI 10.1073/pnas.93.5.2186; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lawless MK, 1996, BIOCHEMISTRY-US, V35, P13697, DOI 10.1021/bi9606962; Lipsky JJ, 1996, LANCET, V348, P800, DOI 10.1016/S0140-6736(95)12333-4; LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075; Luciw PA, 1996, FIELD VIROLOGY, P1881; MOORE JP, 1995, J VIROL, V69, P101, DOI 10.1128/JVI.69.1.101-109.1995; MOORE JP, 1990, SCIENCE, V250, P1139, DOI 10.1126/science.2251501; NARA PL, 1988, J VIROL, V62, P2622, DOI 10.1128/JVI.62.8.2622-2628.1988; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OAS TG, 1988, NATURE, V336, P42, DOI 10.1038/336042a0; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PALKER TJ, 1988, P NATL ACAD SCI USA, V85, P1932, DOI 10.1073/pnas.85.6.1932; Poumbourios P, 1997, J VIROL, V71, P2041, DOI 10.1128/JVI.71.3.2041-2049.1997; RABENSTEIN M, 1995, BIOCHEMISTRY-US, V34, P13390, DOI 10.1021/bi00041a016; Rabenstein MD, 1996, BIOCHEMISTRY-US, V35, P13922, DOI 10.1021/bi961743t; SATTENTAU QJ, 1991, J EXP MED, V174, P407, DOI 10.1084/jem.174.2.407; SATTENTAU QJ, 1993, PHILOS T R SOC B, V342, P59, DOI 10.1098/rstb.1993.0136; SATTENTAU QJ, 1993, J VIROL, V67, P7383, DOI 10.1128/JVI.67.12.7383-7393.1993; Shugars DC, 1996, J VIROL, V70, P2982, DOI 10.1128/JVI.70.5.2982-2991.1996; STAMATATOS L, 1995, J VIROL, V69, P6191, DOI 10.1128/JVI.69.10.6191-6198.1995; STEGMANN T, 1991, J BIOL CHEM, V266, P18404; STEGMANN T, 1993, VIRAL FUSION MECHANI, P89; SULLIVAN N, 1995, J VIROL, V69, P4413, DOI 10.1128/JVI.69.7.4413-4422.1995; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; TSURUDOME M, 1992, J BIOL CHEM, V267, P20225; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; WILD C, 1994, P NATL ACAD SCI USA, V91, P12676, DOI 10.1073/pnas.91.26.12676; WILD C, 1995, AIDS RES HUM RETROV, V11, P323, DOI 10.1089/aid.1995.11.323; WILD C, 1992, P NATL ACAD SCI USA, V89, P10537, DOI 10.1073/pnas.89.21.10537; WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053; Wilkinson D, 1996, CURR BIOL, V6, P1051, DOI 10.1016/S0960-9822(02)70661-1; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0	76	1763	1882	0	162	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 18	1997	89	2					263	273		10.1016/S0092-8674(00)80205-6	http://dx.doi.org/10.1016/S0092-8674(00)80205-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WU888	9108481	Bronze			2022-12-01	WOS:A1997WU88800013
J	Simonet, WS; Lacey, DL; Dunstan, CR; Kelley, M; Chang, MS; Luthy, R; Nguyen, HQ; Wooden, S; Bennett, L; Boone, T; Shimamoto, G; DeRose, M; Elliott, R; Colombero, A; Tan, HL; Trail, G; Sullivan, J; Davy, E; Bucay, N; RenshawGegg, L; Hughes, TM; Hill, D; Pattison, W; Campbell, P; Sander, S; Van, G; Tarpley, J; Derby, P; Lee, R; Boyle, WJ				Simonet, WS; Lacey, DL; Dunstan, CR; Kelley, M; Chang, MS; Luthy, R; Nguyen, HQ; Wooden, S; Bennett, L; Boone, T; Shimamoto, G; DeRose, M; Elliott, R; Colombero, A; Tan, HL; Trail, G; Sullivan, J; Davy, E; Bucay, N; RenshawGegg, L; Hughes, TM; Hill, D; Pattison, W; Campbell, P; Sander, S; Van, G; Tarpley, J; Derby, P; Lee, R; Boyle, WJ			Osteoprotegerin: A novel secreted protein involved in the regulation of bone density	CELL			English	Article							TUMOR NECROSIS FACTORS; C-FOS; V-FPS; MICE; GENE; DIFFERENTIATION; MACROPHAGE; RESORPTION; ACTIVATION; CELLS	A novel secreted glycoprotein that regulates bone resorption has been identified. The protein, termed Osteoprotegerin (OPG), is a novel member of the TNF receptor superfamily. In vivo, hepatic expression of OPG in transgenic mice results in a profound yet nonlethal osteopetrosis, coincident with a decrease in later stages of osteoclast differentiation. These same effects are observed upon administration of recombinant OPG into normal mice. In vitro, osteoclast differentiation from precursor cells is blocked in a dose-dependent manner by recombinant OPG. Furthermore, OPG blocks ovariectomy-associated bone loss in rats. These data show that OPG can act as a soluble factor in the regulation of bone mass and imply a utility for OPG in the treatment of osteoporosis associated with increased osteoclast activity.	AMGEN INC, DEPT CELL BIOL, THOUSAND OAKS, CA 91320 USA; AMGEN INC, DEPT PROT CHEM, THOUSAND OAKS, CA 91320 USA; AMGEN INC, DEPT COMPUTAT BIOL, THOUSAND OAKS, CA 91320 USA; AMGEN INC, DEPT MAMMALIAN CELL MOL BIOL, THOUSAND OAKS, CA 91320 USA; AMGEN INC, DEPT IMMUNOL, THOUSAND OAKS, CA 91320 USA; AMGEN INC, DEPT PATHOL, THOUSAND OAKS, CA 91320 USA; AMGEN INC, DEPT BACTERIAL EXPRESS, THOUSAND OAKS, CA 91320 USA; AMGEN INC, DEPT PROT STRUCT, THOUSAND OAKS, CA 91320 USA; AMGEN INC, DEPT PROC SCI, THOUSAND OAKS, CA 91320 USA	Amgen; Amgen; Amgen; Amgen; Amgen; Amgen; Amgen; Amgen; Amgen	Simonet, WS (corresponding author), AMGEN INC, DEPT MOL GENET, 1840 DEHAVILLAND DR, THOUSAND OAKS, CA 91320 USA.		Dunstan, Colin/G-6214-2013	Dunstan, Colin/0000-0001-7586-4071; De Rose, Margaret/0000-0001-9481-7334; Sullivan, John/0000-0001-9840-852X				ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; AHN J, 1995, NAT GENET, V11, P137, DOI 10.1038/ng1095-137; AUSTYN JM, 1981, EUR J IMMUNOL, V11, P805, DOI 10.1002/eji.1830111013; BERTOLINI DR, 1986, NATURE, V319, P516, DOI 10.1038/319516a0; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; BYRN RA, 1990, NATURE, V344, P667, DOI 10.1038/344667a0; CHRISTIANSEN C, 1980, EUR J CLIN INVEST, V10, P273, DOI 10.1111/j.1365-2362.1980.tb00033.x; DECLERCK YA, 1991, J BIOL CHEM, V266, P3893; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; HUGHES DPM, 1995, J EXP MED, V182, P1395, DOI 10.1084/jem.182.5.1395; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; KALU DN, 1989, ENDOCRINOLOGY, V124, P7, DOI 10.1210/endo-124-1-7; KAMPS MP, 1988, ONCOGENE, V2, P305; KOHNO T, 1990, P NATL ACAD SCI USA, V87, P8331, DOI 10.1073/pnas.87.21.8331; LACEY DL, 1995, ENDOCRINOLOGY, V136, P2367, DOI 10.1210/en.136.6.2367; LUTHY R, 1994, PROTEIN SCI, V3, P139; MARKS SC, 1989, AM J MED GENET, V34, P43, DOI 10.1002/ajmg.1320340110; MUNDY GR, 1992, INT J CELL CLONING, V10, P215, DOI 10.1002/stem.5530100404; MUNDY GR, 1993, GROWTH REGULAT, V3, P124; NIJWEIDE PJ, 1986, PHYSIOL REV, V66, P855, DOI 10.1152/physrev.1986.66.4.855; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; RODAN GA, 1981, CALCIFIED TISSUE INT, V33, P349, DOI 10.1007/BF02409454; Schreiber M, 1996, J BIOL CHEM, V271, P13333, DOI 10.1074/jbc.271.23.13333; SIETSEMA WK, 1989, DRUG EXP CLIN RES, V15, P389; SIMONET WS, 1994, J CLIN INVEST, V94, P1310, DOI 10.1172/JCI117450; SIMONET WS, 1993, J BIOL CHEM, V268, P8221; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66; TABAS JA, 1991, GENOMICS, V9, P283, DOI 10.1016/0888-7543(91)90254-C; THOMSON BM, 1987, J IMMUNOL, V138, P775; UDAGAWA N, 1989, ENDOCRINOLOGY, V125, P1805, DOI 10.1210/endo-125-4-1805; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WRONSKI TJ, 1989, ENDOCRINOLOGY, V125, P810, DOI 10.1210/endo-125-2-810; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0	38	3953	4374	12	237	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 18	1997	89	2					309	319		10.1016/S0092-8674(00)80209-3	http://dx.doi.org/10.1016/S0092-8674(00)80209-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WU888	9108485	Bronze			2022-12-01	WOS:A1997WU88800017
J	Ekpini, ER; Wiktor, SZ; Satten, GA; AdjorloloJohnson, GT; Sibailly, TS; Ou, CY; Karon, JM; Brattegaard, K; Whitaker, JP; Gnaore, E; DeCock, KM; Greenberg, AE				Ekpini, ER; Wiktor, SZ; Satten, GA; AdjorloloJohnson, GT; Sibailly, TS; Ou, CY; Karon, JM; Brattegaard, K; Whitaker, JP; Gnaore, E; DeCock, KM; Greenberg, AE			Late postnatal mother-to-child transmission of HIV-1 in Abidjan, Cote d'Ivoire	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; BREAST-MILK; TYPE-1; INFANT; INFECTION; RISK	Background HIV-1 can be transmitted from an infected mother to her infant through breastfeeding, although the precise risk of transmission by this route is unknown. A long-term follow-up of children born to HIV-infected women in Abidjan, Gate d'lvoire, has enabled us to estimate this risk. Methods Children born to 138 HIV-1-seropositive women, 132 HIV-2-seropositive women, 69 women seroreactive to both HIV-1 and HIV-2, and 274 HIV-seronegative women were enrolled at birth and followed up for as long as 48 months. All chidren were breastfed (median duration 20 months). Blood samples for either or both HIV PCR and HIV serology were obtained at 1, 2, and 3 months of age, and every 3 months thereafter. Early HIV infection was defined as a positive HIV-1 PCR result obtained in the first 6 months of life. Late postnatal transmission was diagnosed when a child had a negative PCR at 3 or 6 months of age, followed by either or both a positive HIV-1 PCR at 9 months or older, or persistently positive HIV-1 serology at 15 months or older. Findings 82 children born to HIV-1-seropositive mothers and 57 children born to mothers seropositive for both HIV-1 and HIV-2 had PCR results for samples taken within the first 6 months. By 6 months of age, 23 (28%; 95% CI 19-39) of the 82 children born to HIV-l-seropositive mothers and ten (18%; 95% CI 9-30) of the 57 children born to dually seropositive mothers were HIV-1 infected, Among children whose PCR results were negative at or before age 6 months, and who were followed up beyond 6 months, an additional four (9%) of the 45 children born to HIV-1-seropositive mothers and two (5%) of the 39 children born to dually seropositive mothers became HIV infected. The estimated rates of late postnatal transmission, with account taken of loss to follow-up and the observed pattern of weaning, were 12% (95% CI 3-23) and 6% (0-14), respectively. One of the five children whose mothers seroconverted from HIV-negative to HIV-1, and one of seven children whose mothers seroconverted from HIV-2 to dual reactivity, became HIV-1 positive. No case of late postnatal transmission occurred in children born to HIV-2-positive or persistently HIV-negative mothers. Interpretation Breastfed children born to mothers seropositive for HIV-1 alone or seropositive for HIV-1 and HIV-2 in Abidjan are at substantial risk of late postnatal transmission. Early cessation of breastfeeding at 6 months of age should be assessed as a possible intervention to reduce postnatal transmission of HIV.	PROJET RETRO CI,ABIDJAN 01,COTE IVOIRE; NATL AIDS CONTROL PROGRAM,ABIDJAN,COTE IVOIRE; CTR DIS CONTROL & PREVENT,DIV HIV AIDS PREVENT,ATLANTA,GA; UNIV LONDON LONDON SCH HYG & TROP MED,LONDON WC1E 7HT,ENGLAND	Centers for Disease Control & Prevention - USA; University of London; London School of Hygiene & Tropical Medicine				Satten, Glen/0000-0001-7275-5371				ADJORLOLOJOHNSON G, 1994, JAMA-J AM MED ASSOC, V272, P462, DOI 10.1001/jama.272.6.462; BLANCHE S, 1989, NEW ENGL J MED, V320, P1643, DOI 10.1056/NEJM198906223202502; COHEN J, 1995, SCIENCE, V269, P624, DOI 10.1126/science.7624786; DABIS F, 1993, AIDS, V7, P1139, DOI 10.1097/00002030-199308000-00027; DATTA P, 1994, J INFECT DIS, V170, P1134, DOI 10.1093/infdis/170.5.1134; DECOCK KM, 1990, AIDS, V4, P875, DOI 10.1097/00002030-199009000-00007; DOUGLAS GC, 1992, CLIN INFECT DIS, V15, P678, DOI 10.1093/clind/15.4.678; DUNN DT, 1995, AIDS, V9, pF7, DOI 10.1097/00002030-199509000-00001; DUNN DT, 1992, LANCET, V340, P585, DOI 10.1016/0140-6736(92)92115-V; GEORGE JR, 1992, LANCET, V340, P337, DOI 10.1016/0140-6736(92)91406-X; HUTTO C, 1991, J PEDIATR-US, V118, P347, DOI 10.1016/S0022-3476(05)82145-6; NEWELL ML, 1992, LANCET, V339, P1007; PALASANTHIRAN P, 1993, J INFECT DIS, V167, P441, DOI 10.1093/infdis/167.2.441; RYDER RW, 1991, AIDS, V5, P709, DOI 10.1097/00002030-199106000-00010; THIRY L, 1985, LANCET, V2, P891; TURNBULL BW, 1976, J R STAT SOC B, V38, P290; VANDEPERRE P, 1992, CLIN INFECT DIS, V15, P502, DOI 10.1093/clind/15.3.502; VANDEPERRE P, 1991, NEW ENGL J MED, V325, P593, DOI 10.1056/NEJM199108293250901; ZIEGLER JB, 1985, LANCET, V1, P896; [No title captured]; [No title captured]	21	123	126	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 12	1997	349	9058					1054	1059		10.1016/S0140-6736(96)06444-6	http://dx.doi.org/10.1016/S0140-6736(96)06444-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU002	9107243				2022-12-01	WOS:A1997WU00200009
J	Huber, C; Wachtershauser, G				Huber, C; Wachtershauser, G			Activated acetic acid by carbon fixation on (Fe,Ni)S under primordial conditions	SCIENCE			English	Article							CO DEHYDROGENASE; PYRITE FORMATION; NICKEL; BACTERIA; IRON; BIOCHEMISTRY; EVOLUTION; MONOXIDE; COENZYME; SULFIDE	In experiments modeling the reactions of the reductive acetyl-coenzyme A pathway at hydrothermal temperatures, it was found that an aqueous slurry of coprecipitated NiS and FeS converted CO and CH3SH into the activated thioester CH3-CO-SCH3, which hydrolyzed to acetic acid. In the presence of aniline, acetanilide was formed. When NiS-FeS was modified with catalytic amounts of selenium, acetic acid and CH3SH were formed from CO and H2S alone. The reaction can be considered as the primordial initiation reaction for a chemoautotrophic origin of life.	TECH UNIV MUNICH,DEPT ORGAN CHEM & BIOCHEM,D-85747 GARCHING,GERMANY	Technical University of Munich								BLOCHL E, 1992, P NATL ACAD SCI USA, V89, P8117, DOI 10.1073/pnas.89.17.8117; BRAY CJ, 1991, J GEOCHEM EXPLOR, V42, P167, DOI 10.1016/0375-6742(91)90066-4; COLLIN J, 1988, B SOC CHIM FR, P976; CRABTREE RH, 1994, ORGANOMETALLIC CHEM, P313; de Duve, 1991, BLUEPRINT CELL; DROBNER E, 1990, NATURE, V346, P742, DOI 10.1038/346742a0; FERRY JG, 1995, ANNU REV MICROBIOL, V49, P305, DOI 10.1146/annurev.mi.49.100195.001513; FUCHS G, 1985, EVOLUTION PROKARYOTE, P235; HAFENBRADL D, 1995, TETRAHEDRON LETT, V36, P5179; HALCROW MA, 1994, CHEM REV, V94, P2421, DOI 10.1021/cr00032a008; Heinen W, 1996, ORIGINS LIFE EVOL B, V26, P131, DOI 10.1007/BF01809852; Holland H. D., 1984, CHEM EVOLUTION ATMOS; HOLLEMAN AF, 1985, LEHRBUCH ANORGANISCH, P1126; Hu ZG, 1996, J AM CHEM SOC, V118, P830, DOI 10.1021/ja9528386; KASTING JF, 1990, ORIGINS LIFE EVOL B, V20, P199, DOI 10.1007/BF01808105; KELLER M, 1994, NATURE, V368, P836, DOI 10.1038/368836a0; KUMAR M, 1995, SCIENCE, V270, P628, DOI 10.1126/science.270.5236.628; LU Z, 1995, J AM CHEM SOC, V117, P3994, DOI 10.1021/ja00119a014; MATSUNAGA PT, 1994, ANGEW CHEM, V17, P1841; MATTIOLI GS, 1986, NATURE, V322, P626, DOI 10.1038/322626a0; Menon S, 1996, BIOCHEMISTRY-US, V35, P12119, DOI 10.1021/bi961014d; MERLIVAT L, 1987, EARTH PLANET SC LETT, V84, P100, DOI 10.1016/0012-821X(87)90180-4; MILLER SL, 1953, SCIENCE, V117, P528, DOI 10.1126/science.117.3046.528; NI SS, 1993, BIOGEOCHEMISTRY OF GLOBAL CHANGE, P796; PFALTZ A, 1982, HELV CHIM ACTA, V65, P828, DOI 10.1002/hlca.19820650320; QIU D, 1994, SCIENCE, V264, P817, DOI 10.1126/science.8171334; RAGSDALE SW, 1994, ACETOGENESIS, P88; Shim S. C., 1995, J ORG CHEM, V50, P149; SIGVALDASON GE, 1974, PHYSICAL VOLCANOLOGY, V6, P214; TANIMOTO Y, 1994, APPL ENVIRON MICROB, V60, P2450, DOI 10.1128/AEM.60.7.2450-2455.1994; THAUER RK, 1980, TRENDS BIOCHEM SCI, V5, P304, DOI 10.1016/0968-0004(80)90166-8; TUCCI GC, 1995, J AM CHEM SOC, V117, P6489, DOI 10.1021/ja00129a011; WACHTERSHAUSER G, 1990, P NATL ACAD SCI USA, V87, P200, DOI 10.1073/pnas.87.1.200; WACHTERSHAUSER G, 1988, SYST APPL MICROBIOL, V10, P207; WACHTERSHAUSER G, 1988, MICROBIOL REV, V52, P452; WACHTERSHAUSER G, 1992, PROG BIOPHYS MOL BIO, V58, P85, DOI 10.1016/0079-6107(92)90022-X; Walker J. C. G., 1977, EVOLUTION ATMOSPHERE; ZENKEVICH VA, 1991, VULKANOL SEISMOL, V3, P19; 1929, GMELINS HDB ANORGANI, P62	39	486	498	7	212	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 11	1997	276	5310					245	247		10.1126/science.276.5310.245	http://dx.doi.org/10.1126/science.276.5310.245			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WT925	9092471				2022-12-01	WOS:A1997WT92500042
J	Matricardi, PM; Rosmini, F; Ferrigno, L; Nisini, R; Rapicetta, M; Chionne, P; Stroffolini, T; Pasquini, P; DAmelio, R				Matricardi, PM; Rosmini, F; Ferrigno, L; Nisini, R; Rapicetta, M; Chionne, P; Stroffolini, T; Pasquini, P; DAmelio, R			Cross sectional retrospective study of prevalence of atopy among Italian military students with antibodies against hepatitis A virus	BRITISH MEDICAL JOURNAL			English	Article							SERUM IMMUNOGLOBULIN-E; SKIN-TEST REACTIVITY; HAY-FEVER; POPULATION; CHILDHOOD; DISEASE; ASTHMA	Objective: To investigate the working hypothesis that common infections occurring early in life prevent atopy. Design: Cross sectional, retrospective study of young Italian men with results for hepatitis A serology and atopy. Setting: Air force school for military students in Caserta Italy. Subjects: 1659 male students aged 17-24, most of whom (90%) were from central and southern Italy. Main outcome measures: Skin sensitisation and specific IgE antibodies to locally relevant airborne allergens; diagnosis of respiratory allergy (asthma or rhinitis, or both); hepatitis A seropositivity. Results: 443 of the 1659 subjects (26.7%) were positive for hepatitis A virus antibody. Atopy was less common among seropositive than seronegative subjects according to skin sensitization (weal reaction greater than or equal to 3 mm) to one or more allergens (21.9% (97/443) v 30.2% (367/1216), P<0.001); polysensitisation (sensitive to three or more allergens) (2.7% (12/443) v 6.4% (78/1216), P<0.01); high specific IgE concentration (9.7% (43/443) v 18.4% (224/1216), P<0.00005); and lifetime prevalence of allergic rhinitis or asthma, or both (8.4% (37/443) v 16.7% (203/1216), P<0.001). Hepatitis A seropositivity remained inversely associated with atopy after adjusting for father's education, the number of older siblings, and the area of residence (based on the number of inhabitants). The prevalence of atopy was constantly low among seropositive subjects, whatever the number of older siblings; by contrast, it increased with a decreasing number of older siblings among seronegative subjects. Conclusion: Indirect but important evidence is added to the working hypothesis as common infections acquired early in life because of the presence of many older siblings (among seronegative subjects) or because of unhygienic living conditions (among seropositive subjects) may have reduced the risk of developing atopy.	IST SUPER SANITA,EPIDEMIOL & BIOSTAT LAB,I-00161 ROME,ITALY; IST SUPER SANITA,VIROL LAB,I-00161 ROME,ITALY; WHO,DIV EMERGING & OTHER COMMUNICABLE DIS SURVEILLANC,CH-1211 GENEVA 27,SWITZERLAND	Istituto Superiore di Sanita (ISS); Istituto Superiore di Sanita (ISS); World Health Organization	Matricardi, PM (corresponding author), DIV AEREA STUDI RIC & SPERIMENTAZ,LAB IMMUNOL & ALLERGOL,A PRAT DI MARE,I-00040 POMEZIA,ROMA,ITALY.		Nisini, Roberto/M-4363-2015; CHIONNE, PAOLA/M-2959-2015	Nisini, Roberto/0000-0003-1077-423X; 				BARBEE RA, 1981, J ALLERGY CLIN IMMUN, V68, P15, DOI 10.1016/0091-6749(81)90117-2; BURNEY PGJ, 1993, CLIN EXP ALLERGY, V23, P484; ENGELMAN L, 1990, BMDP STATISTICAL SOF, V2, P1013; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MARTINEZ FD, 1994, THORAX, V49, P1189, DOI 10.1136/thx.49.12.1189; MATRICARDI PM, 1994, J ALLERGY CLIN IMMUN, V93, P68, DOI 10.1016/0091-6749(94)90234-8; MATRICARDI PM, 1994, INFECTION, V22, P51, DOI 10.1007/BF01780768; PAPAEVANGELOU G, 1992, VACCINE S1, V10, P63; PASQUINI P, 1984, INT J EPIDEMIOL, V13, P83, DOI 10.1093/ije/13.1.83; ROMAGNANI S, 1992, INT ARCH ALLERGY IMM, V98, P279, DOI 10.1159/000236199; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; STRACHAN DP, 1995, CLIN EXP ALLERGY, V25, P296, DOI 10.1111/j.1365-2222.1995.tb01046.x; STRACHAN DP, 1994, CLIN EXP ALLERGY, V24, P603, DOI 10.1111/j.1365-2222.1994.tb00961.x; STRACHAN DP, 1994, THORAX, V49, pP1053; SZMUNESS W, 1977, AM J EPIDEMIOL, V106, P392, DOI 10.1093/oxfordjournals.aje.a112481; VONMUTIUS E, 1994, AM J RESP CRIT CARE, V149, P358, DOI 10.1164/ajrccm.149.2.8306030; VONMUTIUS E, 1994, BRIT MED J, V308, P692, DOI 10.1136/bmj.308.6930.692; WILLIAMS HC, 1994, BRIT MED J, V308, P1132, DOI 10.1136/bmj.308.6937.1132; Woolcock AJ, 1995, PROG ALLER CLIN IMM, V3, P167	20	403	421	0	15	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 5	1997	314	7086					999	1003		10.1136/bmj.314.7086.999	http://dx.doi.org/10.1136/bmj.314.7086.999			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WT152	9112843	Green Published			2022-12-01	WOS:A1997WT15200020
J	Hay, JC; Chao, DS; Kuo, CS; Scheller, RH				Hay, JC; Chao, DS; Kuo, CS; Scheller, RH			Protein interactions regulating vesicle transport between the endoplasmic reticulum and Golgi apparatus in mammalian cells	CELL			English	Article							INTEGRAL MEMBRANE-PROTEIN; VESICULAR TRANSPORT; YEAST; COMPLEX; DOCKING; FUSION; ACTIVATION; SECRETION; RECEPTORS; ENCODES	The proposed cis-Golgi vesicle receptor syntaxin 5 was found in a complex with Golgi-associated SNARE of 28 kDa (GOS-28), rbet1, rsly1, and two novel proteins characterized herein: rat sec22b and membrin, both cytoplasmically oriented integral membrane proteins. The complex appears to recapitulate vesicle docking interactions of proteins originating from distinct compartments, since syntaxin 5, rbet1, and GOS-28 localize to Golgi membranes, whereas mouse sec22b and membrin accumulate in the endoplasmic reticulum. Protein interactions in the complex are dramatically rearranged by N-ethylmaleimide-sensitive factor. The complex consists of two or more subcomplexes with some members (rat sec22b and syntaxin 5) in common and others (rbet1 and GOS-28) mutually exclusively associated. We propose that these protein interactions determine vesicle docking/fusion fidelity between the endoplasmic reticulum and Golgi.			Hay, JC (corresponding author), STANFORD UNIV,HOWARD HUGHES MED INST,SCH MED,DEPT CELLULAR & MOL PHYSIOL,STANFORD,CA 94305, USA.			Chao, Daniel/0000-0002-3544-5283				Banerjee A, 1996, J BIOL CHEM, V271, P20223, DOI 10.1074/jbc.271.34.20223; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BLOOM GS, 1989, J BIOL CHEM, V264, P16083; Bock JB, 1996, J BIOL CHEM, V271, P17961, DOI 10.1074/jbc.271.30.17961; Dascher C, 1996, J BIOL CHEM, V271, P15866, DOI 10.1074/jbc.271.27.15866; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; DASCHER C, 1994, J BIOL CHEM, V269, P29363; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; Hay JC, 1996, J BIOL CHEM, V271, P5671, DOI 10.1074/jbc.271.10.5671; LAWTON MP, 1990, J BIOL CHEM, V265, P5855; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LIAN JP, 1993, CELL, V73, P735, DOI 10.1016/0092-8674(93)90253-M; LIAN JP, 1994, NATURE, V372, P698, DOI 10.1038/372698a0; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; Nagahama M, 1996, J CELL BIOL, V133, P507, DOI 10.1083/jcb.133.3.507; NEWMAN AP, 1992, EMBO J, V11, P3609, DOI 10.1002/j.1460-2075.1992.tb05445.x; Peterson MR, 1996, GENE, V169, P293, DOI 10.1016/0378-1119(95)00819-5; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; REXACH MF, 1994, J CELL BIOL, V126, P1133, DOI 10.1083/jcb.126.5.1133; SHIM J, 1991, J CELL BIOL, V113, P55, DOI 10.1083/jcb.113.1.55; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Subramaniam VN, 1996, SCIENCE, V272, P1161, DOI 10.1126/science.272.5265.1161; TING AE, 1995, P NATL ACAD SCI USA, V92, P9613, DOI 10.1073/pnas.92.21.9613	26	167	175	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 4	1997	89	1					149	158		10.1016/S0092-8674(00)80191-9	http://dx.doi.org/10.1016/S0092-8674(00)80191-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WR685	9094723	Bronze			2022-12-01	WOS:A1997WR68500018
J	LuYao, GL; Yao, SL				LuYao, GL; Yao, SL			Population-based study of long-term survival in patients with clinically localised prostate cancer	LANCET			English	Article							RADICAL PROSTATECTOMY; DECISION-ANALYSIS; MANAGEMENT; ANTIGEN	Background Choice of treatment in localised prostate cancer has been hampered by a lack of unbiased, representative data on outcome. Most existing data have come from small cohorts at specialised academic centres; precise overall and cancer-grade-specifc data are not available, and the data are subject to differential staging bias. Randomised clinical trials have been undertaken, but the results will not be available for another decade. We have carried out a large population-based study to ascertain overall and prostate-cancer-specific survival in men treated by prostatectomy, radiotherapy, or conservative management. Methods Data for 59 876 cancer-registry patients aged 50-79 were analysed. We examined the effect of differential staging of prostate cancer by analysing the data both by intention to treat and by treatment received. Estimated survival was calculated by the Kaplan-Meier method. Findings By the intention-to-treat approach, 10-year prostate-cancer-specific survival for grade 1 cancer was 94% (95% CI 91-95) after prostatectomy, 90% (87-92) after radiotherapy, and 93% (91-94) after conservative management. The corresponding survival figures in grade 2 cancers were 87% (85-89), 76% (72-79), and 77% (74-80); those in grade 3 cancer were 67% (62-71), 53% (47-58), and 45% (40-51). Although the intention-to-treat and treatment-received analyses yielded similar results for radiotherapy and conservative management, the 10-year disease-specific survival after prostatectomy differed substantially (83% [81-84] by intention to treat vs 89% [87-91] by treatment received). Interpretation The overall and cancer-grade-specific survival found in this study differ substantially from those in previous studies. Previous studies that used a treatment-received approach have generally overestimated the benefits of radical prostatectomy. We found that grade 3 tumours are highly aggressive irrespective of stage.	HLTH CARE FINANCING ADM, OFF RES & DEMONSTRAT, DIV HLTH INFORMAT & OUTCOMES, BALTIMORE, MD 21244 USA; JOHNS HOPKINS ONCOL CTR, BALTIMORE, MD USA	Johns Hopkins University; Johns Hopkins Medicine				Lu-Yao, Grace/0000-0002-6017-9175	AHRQ HHS [HS 08397] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS008397] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Albertsen PC, 1996, J UROLOGY, V156, P127, DOI 10.1016/S0022-5347(01)65964-0; ALBERTSEN PC, 1995, JAMA-J AM MED ASSOC, V274, P626, DOI 10.1001/jama.274.8.626; *AM JOINT COMM CAN, 1992, MAN STAG CANC; AUSTENFELD MS, 1994, J UROLOGY, V152, P1866, DOI 10.1016/S0022-5347(17)32403-5; BAGSHAW MA, 1994, J UROLOGY, V152, P1781, DOI 10.1016/S0022-5347(17)32385-6; BARRY MJ, 1995, UROLOGY, V46, P2, DOI 10.1016/S0090-4295(99)80151-4; BECK JR, 1994, J UROLOGY, V152, P1894, DOI 10.1016/S0022-5347(17)32409-6; BECK JR, 1994, J UROLOGY, V152, P1677, DOI 10.1016/S0022-5347(17)32357-1; Bell Felicitie C., 1992, LIFE TABLES US SOCIA; CHODAK GW, 1994, NEW ENGL J MED, V330, P242, DOI 10.1056/NEJM199401273300403; FLEMING C, 1993, JAMA-J AM MED ASSOC, V269, P2650, DOI 10.1001/jama.269.20.2650; Gerber GS, 1996, JAMA-J AM MED ASSOC, V276, P615; GLEASON DF, 1974, J UROLOGY, V111, P58, DOI 10.1016/S0022-5347(17)59889-4; HORM JW, 1984, SURVEILLANCE EPIDMEI; JOHANSSON JE, 1992, JAMA-J AM MED ASSOC, V267, P2191, DOI 10.1001/jama.267.16.2191; MIDDLETON RG, 1995, J UROLOGY, V154, P2144, DOI 10.1016/S0022-5347(01)66718-1; Middleton RG, 1996, CA-CANCER J CLIN, V46, P249, DOI 10.3322/canjclin.46.4.249; NARAYAN P, 1995, UROLOGY, V46, P205, DOI 10.1016/S0090-4295(99)80195-2; *NAT CANC I, 1995, SURV EP END RES PROG; Norlen B J, 1994, Can J Oncol, V4 Suppl 1, P38; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; PERCY C, 1981, AM J PUBLIC HEALTH, V71, P242, DOI 10.2105/AJPH.71.3.242; POTOSKY AL, 1993, MED CARE, V31, P732; SHAMBAUGH EM, 1986, SUMMARY STAGING GUID; WALSH PC, 1994, J UROLOGY, V152, P1831, DOI 10.1016/S0022-5347(17)32396-0; Wasson J H, 1993, Arch Fam Med, V2, P487, DOI 10.1001/archfami.2.5.487; WILT TJ, 1994, J UROLOGY, V152, P1910, DOI 10.1016/S0022-5347(17)32413-8; ZIETMAN AL, 1995, INT J RADIAT ONCOL, V32, P287, DOI 10.1016/0360-3016(95)00123-G; ZINCKE H, 1994, J UROLOGY, V152, P1850, DOI 10.1016/S0022-5347(17)32399-6; ZINCKE H, 1994, J CLIN ONCOL, V12, P2254, DOI 10.1200/JCO.1994.12.11.2254	30	285	289	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 29	1997	349	9056					906	910		10.1016/S0140-6736(96)09380-4	http://dx.doi.org/10.1016/S0140-6736(96)09380-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR254	9093251				2022-12-01	WOS:A1997WR25400010
J	Crovisier, J; Leech, K; BockeleeMorvan, D; Brooke, TY; Hanner, MS; Altieri, B; Keller, HU; Lellouch, E				Crovisier, J; Leech, K; BockeleeMorvan, D; Brooke, TY; Hanner, MS; Altieri, B; Keller, HU; Lellouch, E			The spectrum of comet Hale-Bopp (C/1995 O1) observed with the Infrared Space Observatory at 2.9 astronomical units from the sun	SCIENCE			English	Article							INTERSTELLAR SILICATE MINERALOGY; AIRBORNE SPECTROPHOTOMETRY; EMISSION FEATURES; WATER-VAPOR; P/HALLEY; MICRONS; SIMULATION; 2.8-MU-M; OLIVINE; GRAINS	Comet Hale-Bopp (C/1995 O1) was observed at wavelengths from 2.4 to 195 micrometers with the Infrared Space Observatory when the comet was about 2.9 astronomical units (AU) from the sun, The main observed volatiles that sublimated from the nucleus ices were water, carbon monoxide, and carbon dioxide in a ratio (by number) of 10:6:2. These species are also the main observed constituents of ices in dense interstellar molecular clouds; this observation strengthens the links between cometary and interstellar material. Several broad emission features observed in the 7- to 45-micrometer region suggest the presence of silicates, particularly magnesium-rich crystalline olivine. These features are similar to those observed in the dust envelopes of Vega-type stars.	EUROPEAN SPACE AGCY, DIV ASTROPHYS, ISO SCI OPERAT CTR, E-28080 VILLAFRANCA DASTI, SPAIN; CALTECH, JET PROP LAB, PASADENA, CA 91109 USA; MAX PLANCK INST AERON, D-37189 KATLENBURG DUHM, GERMANY	European Space Agency; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); Max Planck Society	Crovisier, J (corresponding author), OBSERV PARIS, F-92195 MEUDON, FRANCE.			Altieri, Bruno/0000-0003-3936-0284				BENKHOFF J, 1995, ICARUS, V114, P348, DOI 10.1006/icar.1995.1067; Biver N, 1997, SCIENCE, V275, P1915, DOI 10.1126/science.275.5308.1915; BOCKELEEMORVAN D, 1995, ICARUS, V116, P18, DOI 10.1006/icar.1995.1111; BOCKELEEMORVAN D, 1989, ASTRON ASTROPHYS, V216, P278; BOCKELEEMORVAN D, 1987, ASTRON ASTROPHYS, V181, P169; BOCKELEEMORVAN D, IN PRESS IAU S, V178; BOCKELEEMORVAN D, 1990, ASTEROIDS COMETS MET, V3, P263; BREGMAN JD, 1987, ASTRON ASTROPHYS, V187, P616; BROOKE TY, 1989, ASTROPHYS J, V336, P971, DOI 10.1086/167068; CAMPINS H, 1989, ASTROPHYS J, V341, P1059, DOI 10.1086/167563; Capria MT, 1996, PLANET SPACE SCI, V44, P987, DOI 10.1016/0032-0633(96)00016-5; COLANGELI L, 1995, ASTRON ASTROPHYS, V293, P927; COMBES M, 1988, ICARUS, V76, P44; Crovisier J, 1996, ASTRON ASTROPHYS, V315, pL385; CROVISIER J, 1992, LES HOUCHES, P221; CROVISIER J, 1994, ASTEROIDS COMETS MET, P149; deGraauw T, 1996, ASTRON ASTROPHYS, V315, pL49; dHendecourt L, 1996, ASTRON ASTROPHYS, V315, pL365; DORSCHNER J, 1995, ASTRON ASTROPHYS, V300, P503; ESPINASSE S, 1991, ICARUS, V92, P350, DOI 10.1016/0019-1035(91)90058-2; GLACCUM W, 1987, ASTRON ASTROPHYS, V187, P635; GRADY CA, 1993, IN PRESS ASTROPHYS J, V418; HANNER MS, 1994, ASTROPHYS J, V425, P274, DOI 10.1086/173984; Hayward TL, 1997, SCIENCE, V275, P1907, DOI 10.1126/science.275.5308.1907; HERTER T, 1987, ASTRON ASTROPHYS, V187, P629; HUEBNER WF, 1992, ASTROPHYS SPACE SCI, V195, P1, DOI 10.1007/BF00644558; JAGER C, 1994, ASTRON ASTROPHYS, V292, P641; JESSBERGER EK, 1991, ASTROPHYS SPACE SC L, V167, P1075, DOI 10.1017/S0252921100012823; Kessler MF, 1996, ASTRON ASTROPHYS, V315, pL27; KESSLER MF, 1996, ASTRON ASTROPHYS, V315, pL38; KNACKE RF, 1993, ASTROPHYS J, V418, P440, DOI 10.1086/173405; KOIKE C, 1993, MON NOT R ASTRON SOC, V264, P654, DOI 10.1093/mnras/264.3.654; KOIKE C, 1992, MON NOT R ASTRON SOC, V255, P248, DOI 10.1093/mnras/255.2.248; LAWLER ME, 1989, ICARUS, V80, P225, DOI 10.1016/0019-1035(89)90135-8; Lemke D, 1996, ASTRON ASTROPHYS, V315, pL64; MUMMA MJ, 1986, SCIENCE, V232, P1523, DOI 10.1126/science.232.4757.1523; Mumma MJ, 1996, SCIENCE, V272, P1310, DOI 10.1126/science.272.5266.1310; MUMMA MJ, 1987, ASTRON ASTROPHYS, V187, P419; MUMMA MJ, 1988, FORMATION EVOLUTION; SCHLEICHER DG, 1988, ASTROPHYS J, V331, P1058, DOI 10.1086/166622; TOKUNAGA AT, 1987, ASTRON ASTROPHYS, V187, P519; Waelkens C, 1996, ASTRON ASTROPHYS, V315, pL245; Waters LBFM, 1996, ASTRON ASTROPHYS, V315, pL361; WEAVER HA, 1996, B AM ASTRON SOC, V28, P1094; WEAVER HA, 1988, FORMATION EVOLUTION; Whittet DCB, 1996, ASTRON ASTROPHYS, V315, pL357	46	468	469	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 28	1997	275	5308					1904	1907		10.1126/science.275.5308.1904	http://dx.doi.org/10.1126/science.275.5308.1904			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WQ513	9072960				2022-12-01	WOS:A1997WQ51300035
J	Doorey, AJ				Doorey, AJ			Normal ECG in patients with severe coronary artery disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							ACUTE MYOCARDIAL-INFARCTION		THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, DEPT MED, CARDIOL SECT, PHILADELPHIA, PA 19107 USA	Jefferson University	Doorey, AJ (corresponding author), MED CTR DELAWARE, NEWARK, DE USA.							Antman EM, 1996, NEW ENGL J MED, V335, P1342, DOI 10.1056/NEJM199610313351802; BRAUNWALD E, 1989, CIRCULATION, V80, P410, DOI 10.1161/01.CIR.80.2.410; CHRISTIAN TF, 1994, ANN INTERN MED, V121, P825, DOI 10.7326/0003-4819-121-11-199412010-00001; DEWINTER RJ, 1995, CIRCULATION, V92, P3401, DOI 10.1161/01.CIR.92.12.3401; FISCH C, 1992, HEART DIS TXB CARDIO, P138; KRUMHOLZ HM, 1994, J AM GERIATR SOC, V42, P127, DOI 10.1111/j.1532-5415.1994.tb04938.x; Ohman EM, 1996, NEW ENGL J MED, V335, P1333, DOI 10.1056/NEJM199610313351801; RUTHERFORD JD, 1992, HEART DIS TXB CARDIO, P1335; TOPAZ O, 1991, AM HEART J, V121, P450, DOI 10.1016/0002-8703(91)90711-P	9	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 26	1997	277	12					956	956		10.1001/jama.277.12.956	http://dx.doi.org/10.1001/jama.277.12.956			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN992	9091658				2022-12-01	WOS:A1997WN99200013
J	Noji, H; Yasuda, R; Yoshida, M; Kinosita, K				Noji, H; Yasuda, R; Yoshida, M; Kinosita, K			Direct observation of the rotation of F-1-ATPase	NATURE			English	Article							ESCHERICHIA-COLI; F1-ATPASE; FORCE; MOLECULE; SUBUNITS; MOTOR	Cells employ a variety of linear motors, such as myosin(1-3), kinesin(4) and RNA polymerase(5), which move along and exert force on a filamentous structure. But only one rotary motor has been investigated in detail, the bacterial flagellum(6) (a complex of about 100 protein molecules(7)). We now show that a single molecule of F-1-ATPase acts as a rotary motor, the smallest known, by direct observation of its motion. A central rotor of radius similar to 1 nm, formed by its gamma-subunit, turns in a stator barrel of radius similar to 5nm formed by three alpha- and three beta-subunits(8). F-1-ATPase, together with the membrane-embedded proton-conducting unit F-0, forms the H+-ATP synthase that reversibly couples transmembrane proton flow to ATP synthesis/hydrolysis in respiring and photosynthetic cells(9,10). It has been suggested that the gamma-subunit of F-1-ATPase rotates within the alpha beta-hexamer(11), a conjecture supported by structural(8), biochemical(12,13) and spectroscopic(14) studies. We attached a fluorescent actin filament to the gamma-subunit as a marker, which enabled us to observe this motion directly. In the presence of ATP, the filament rotated for more than 100 revolutions in an anticlockwise direction when viewed from the 'membrane' side. The rotary torque produced reached more than 40 pN nm(-1) under high load.	TOKYO INST TECHNOL, RESOURCES UTILIZAT RES LAB, MIDORI KU, YOKOHAMA, KANAGAWA 226, JAPAN; KEIO UNIV, FAC SCI & TECHNOL, DEPT PHYS, YOKOHAMA, KANAGAWA 223, JAPAN	Tokyo Institute of Technology; Keio University			Yasuda, Ryohei/E-7726-2011	Yasuda, Ryohei/0000-0001-6263-9297				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Aggeler R, 1996, J BIOL CHEM, V271, P13888, DOI 10.1074/jbc.271.23.13888; AIZAWA S, 1991, ADV MICROB PHYSL, V32, P110; BERG HC, 1973, NATURE, V245, P380, DOI 10.1038/245380a0; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; HARADA Y, 1990, J MOL BIOL, V216, P49, DOI 10.1016/S0022-2836(05)80060-9; HUNT AJ, 1994, BIOPHYS J, V67, P766, DOI 10.1016/S0006-3495(94)80537-5; ISHIJIMA A, 1994, BIOCHEM BIOPH RES CO, V199, P1057, DOI 10.1006/bbrc.1994.1336; KAGAWA Y, 1966, J BIOL CHEM, V241, P2467; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; MATSUI T, 1995, BBA-BIOENERGETICS, V1231, P139, DOI 10.1016/0005-2728(95)00070-Y; MEISTER M, 1987, CELL, V49, P643, DOI 10.1016/0092-8674(87)90540-X; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; MIYATA H, 1995, BIOPHYS J, V68, pS286; Noji H, 1996, J BIOENERG BIOMEMBR, V28, P451, DOI 10.1007/BF02113988; Oosawa F, 1986, Adv Biophys, V22, P151, DOI 10.1016/0065-227X(86)90005-5; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; SASE I, 1995, BIOPHYS J, V69, P323, DOI 10.1016/S0006-3495(95)79937-4; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; YIN H, 1995, SCIENCE, V270, P1653, DOI 10.1126/science.270.5242.1653; YOSHIDA M, 1977, J BIOL CHEM, V252, P3480; Zhou YT, 1996, BBA-BIOENERGETICS, V1275, P96, DOI 10.1016/0005-2728(96)00056-4	24	1863	1914	10	361	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 20	1997	386	6622					299	302		10.1038/386299a0	http://dx.doi.org/10.1038/386299a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WP003	9069291				2022-12-01	WOS:A1997WP00300056
J	Gall, MA; Hougaard, P; BorchJohnsen, K; Parving, HH				Gall, MA; Hougaard, P; BorchJohnsen, K; Parving, HH			Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: Prospective, observational study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							URINARY ALBUMIN EXCRETION; GLYCEMIC CONTROL; PIMA-INDIANS; MICROALBUMINURIA; PROGRESSION; PROTEINURIA; NIDDM; COMPLICATIONS; PREVALENCE; CAPTOPRIL	Objective: To evaluate putative risk factors for the development of incipient diabetic nephropathy (persistent microalbuminuria) and overt diabetic nephropathy (persistent macroalbuminuria) in patients with non-insulin dependent diabetes. Design: Prospective, observational study of a cohort of white, non-insulin dependent diabetic patients followed for a median period of 5.8 years. Setting: Outpatient clinic in tertiary referral centre. Subjects: 191 patients aged under 66 years with noninsulin dependent diabetes and normoalbuminuria (urinary albumin excretion rate < 30 mg/24 h) who attended the clinic during 1987. Main outcome measures: Incipient and overt diabetic nephropathy. Results: Fifteen patients were lost to follow up. Thirty six of the 176 remaining developed persistent microalbuminuria (30-299 mg/24 h in two out of three consecutive 24 hour urine collections) and five developed persistent macroalbuminuria (greater than or equal to 300 mg/24 h in two out of three consecutive collections) during follow up. The five year cumulative incidence of incipient diabetic nephropathy was 23% (95% confidence interval 17% to 30%). Cox's multiple stepwise regression analysis revealed the following risk factors for the development of incipient or overt diabetic nephropathy: increased baseline log urinary albumin excretion rate (relative risk 11.1 (3.4 to 35.9); P<0.0001); male sex (2.6 (1.2 to 5.4); P < 0.02); presence of retinopthy (2.4 (1.3 to 4.7); P < 0.01); increased serum cholesterol concentration (1.4 (1.1 to 1.7); P < 0.01); haemoglobin A(1c) concentration (1.2 (1.0 to 1.4); P < 0.05); and age (1.07 (1.02 to 1.12); P < 0.01). Known duration of diabetes, body mass index, arterial blood pressure, serum creatinine concentration, pre-existing coronary heart disease, and history of smoking were not risk factors. Conclusion: Several potentially modifiable risk factors predict the development of incipient and overt diabetic nephropathy in normoalbuminuric patients with non-insulin dependent diabetes.	UNIV COPENHAGEN, GLOSTRUP HOSP, CTR PREVENT MED, DK-2600 GLOSTRUP, DENMARK; NOVO NORDISK AS, STAT, DK-2880 BAGSVAERD, DENMARK	University of Copenhagen; Novo Nordisk	Gall, MA (corresponding author), STENO DIABET CTR, DK-2820 GENTOFTE, DENMARK.							Andersen PK, 2012, STAT MODELS BASED CO; BLACKBURN H, 1960, CIRCULATION, V21, P1160, DOI 10.1161/01.CIR.21.6.1160; CHRISTENSEN CK, 1984, DIABETIC NEPHROPATHY, V3, P92; CLOSE CF, 1995, BMJ-BRIT MED J, V311, P973; COX DR, 1972, J R STAT SOC B, V34, P187; Diabet Control Complications DCCT Res Grp, 1995, KIDNEY INT, V47, P1703; FRIER BM, 1977, DIABETES, V26, P369; GALL MA, 1993, DIABETOLOGIA, V36, P1071, DOI 10.1007/BF02374501; GALL MA, 1995, DIABETES, V44, P1303, DOI 10.2337/diabetes.44.11.1303; GALL MA, 1991, DIABETOLOGIA, V34, P655, DOI 10.1007/BF00400995; HOTHERNIELSEN O, 1988, DIABETES CARE, V11, P531, DOI 10.2337/diacare.11.7.531; JOHN L, 1994, DIABETES CARE, V17, P888, DOI 10.2337/diacare.17.8.888; KATTERMANN R, 1984, J CLIN CHEM CLIN BIO, V22, P245; KLEIN R, 1995, DIABETES, V44, P916, DOI 10.2337/diabetes.44.8.916; MARRE M, 1988, BMJ-BRIT MED J, V297, P1092, DOI 10.1136/bmj.297.6656.1092; MATHIESEN ER, 1995, DIABETIC MED, V12, P482, DOI 10.1111/j.1464-5491.1995.tb00528.x; MATHIESEN ER, 1991, BMJ-BRIT MED J, V303, P81, DOI 10.1136/bmj.303.6794.81; MATHIESEN ER, 1984, DIABETOLOGIA, V26, P406; MOGENSEN CE, 1985, UREMIA INVEST, V9, P85, DOI 10.3109/08860228509088195; MOGENSEN CE, 1984, NEW ENGL J MED, V311, P89, DOI 10.1056/NEJM198407123110204; MOORHEAD JF, 1982, LANCET, V2, P1309; MORTENSEN HB, 1980, J CHROMATOGR, V182, P325, DOI 10.1016/S0378-4347(00)81481-4; NELSON RG, 1993, DIABETOLOGIA, V36, P998, DOI 10.1007/BF02374490; NELSON RG, 1995, DIABETES CARE, V18, P182, DOI 10.2337/diacare.18.2.182; OHKUBO Y, 1995, DIABETES RES CLIN PR, V28, P103, DOI 10.1016/0168-8227(95)01064-K; PARVING HH, 1982, ACTA ENDOCRINOL-COP, V100, P550, DOI 10.1530/acta.0.1000550; PARVING HH, 1992, KIDNEY INT, V41, P758, DOI 10.1038/ki.1992.118; PARVING HH, 1995, BRENNER RECTORS KIDN, P1864; POWRIE JK, 1994, BRIT MED J, V309, P1608, DOI 10.1136/bmj.309.6969.1608; RAVID M, 1995, KIDNEY INT, V47, P907, DOI 10.1038/ki.1995.135; RAVID M, 1993, ANN INTERN MED, V118, P577, DOI 10.7326/0003-4819-118-8-199304150-00001; SCHMITZ A, 1994, DIABETOLOGIA, V37, P1251, DOI 10.1007/BF00399799; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Ullmann R, 1976, Med Lab (Stuttg), V29, P137; VIBERTI G, 1994, JAMA-J AM MED ASSOC, V271, P275, DOI 10.1001/jama.271.4.275; VIBERTI GC, 1982, LANCET, V1, P1430; WANG PH, 1993, LANCET, V341, P1306, DOI 10.1016/0140-6736(93)90816-Y; YIP J, 1993, BRIT MED J, V306, P1235	38	288	305	1	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 15	1997	314	7083					783	788		10.1136/bmj.314.7083.783	http://dx.doi.org/10.1136/bmj.314.7083.783			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN646	9080995	Green Published			2022-12-01	WOS:A1997WN64600022
J	Snowdon, DA; Greiner, LH; Mortimer, JA; Riley, KP; Greiner, PA; Markesbery, WR				Snowdon, DA; Greiner, LH; Mortimer, JA; Riley, KP; Greiner, PA; Markesbery, WR			Brain infarction and the clinical expression of Alzheimer disease - The nun study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VASCULAR DEMENTIA; NEUROFIBRILLARY TANGLES; CONSORTIUM; ESTABLISH; REGISTRY; PLAQUES; CERAD; POPULATION	Objective.-To determine the relationship of brain infarction to the clinical expression of Alzheimer disease (AD). Design.-Cognitive function and the prevalence of dementia were determined for participants in the Nun Study who later died. At autopsy, lacunar and larger brain infarcts were identified, and senile plaques and neurofibrillary tangles in the neocortex were quantitated, Participants with abundant senile plaques and some neurofibrillary tangles in the neocortex were classified as having met the neuropathologic criteria for AD. Setting.-Convents in the Midwestern, Eastern, and Southern United States. Participants.-A total of 102 college-educated women aged 76 to 100 years. Main Outcome Measures.-Cognitive function assessed by standard tests and dementia and AD assessed by clinical and neuropathologic criteria. Results.-Among 61 participants who met the neuropathologic criteria for AD, those with brain infarcts had poorer cognitive function and a higher prevalence of dementia than those without infarcts. Participants with lacunar infarcts in the basal ganglia, thalamus, or deep white matter had an especially high prevalence of dementia, compared with those without infarcts (the odds ratio [OR] for dementia was 20.7, 95% confidence interval [95% CI], 1.5-288.0). Fewer neuropathologic lesions of AD appeared to result in dementia in those with lacunar infarcts in the basal ganglia, thalamus, or deep white matter than in those without infarcts. In contrast, among 41 participants who did not meet the neuropathologic criteria for AD, brain infarcts were only weakly associated with poor cognitive function and dementia. Among all 102 participants, atherosclerosis df the circle of Willis was strongly associated with lacunar and large brain infarcts. Conclusion.-These findings suggest that cerebrovascular disease may play an important role in determining the presence and severity of the clinical symptoms of AD.	UNIV KENTUCKY,COLL MED,DEPT PREVENT MED,LEXINGTON,KY 40536; UNIV KENTUCKY,COLL MED,DEPT PATHOL,LEXINGTON,KY 40536; UNIV KENTUCKY,COLL MED,DEPT NEUROL,LEXINGTON,KY 40536; FAIRFIELD UNIV,SCH NURSING,FAIRFIELD,CT 06430; UNIV S FLORIDA,INST AGING,TAMPA,FL	University of Kentucky; University of Kentucky; University of Kentucky; Fairfield University; State University System of Florida; University of South Florida	Snowdon, DA (corresponding author), UNIV KENTUCKY,SANDERS BROWN CTR AGING,COLL MED,101 SANDERS BROWN BLDG,LEXINGTON,KY 40536, USA.				NATIONAL INSTITUTE ON AGING [R01AG009862, P50AG005144, K04AG000553] Funding Source: NIH RePORTER; NIA NIH HHS [KO4AG00553, R01AG09862, 5P50AG05144] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BIERER LM, 1995, ARCH NEUROL-CHICAGO, V52, P81, DOI 10.1001/archneur.1995.00540250089017; BOURAS C, 1994, CEREB CORTEX, V4, P138, DOI 10.1093/cercor/4.2.138; BOWLER JV, 1995, BAILLIERE CLIN NEUR, V4, P357; CONOVER WJ, 1981, AM STAT, V35, P124, DOI 10.2307/2683975; CRYSTAL H, 1988, NEUROLOGY, V38, P1682, DOI 10.1212/WNL.38.11.1682; GARCIA JH, 1992, J NEUROL SCI, V109, P121, DOI 10.1016/0022-510X(92)90158-H; KATZMAN R, 1988, ANN NEUROL, V23, P138, DOI 10.1002/ana.410230206; KHACHATURIAN ZS, 1985, ARCH NEUROL-CHICAGO, V42, P1097, DOI 10.1001/archneur.1985.04060100083029; KURIANSKY J, 1976, INT J AGING HUM DEV, V7, P343, DOI 10.2190/X45L-TWW7-WXXY-KA6K; LARSON EB, 1993, NEW ENGL J MED, V328, P203, DOI 10.1056/NEJM199301213280308; MARKESBERY WR, 1991, ALZ DIS ASSOC DIS, V5, P149, DOI 10.1097/00002093-199100520-00012; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; MORRIS JC, 1989, NEUROLOGY, V39, P1159, DOI 10.1212/wnl.43.12.2457; NAGY Z, 1995, DEMENTIA, V6, P21, DOI 10.1159/000106918; POTVIN AR, 1972, ARCH PHYS MED REHAB, V53, P476; POTVIN AR, 1972, ARCH PHYS MED REHAB, V53, P498; ROCCA WA, 1986, ANN NEUROL, V19, P415, DOI 10.1002/ana.410190502; *SAS I INC, 1990, SAS STAT US GUID VER, P1024; *SAS I INC, 1958, ECONOMETRICA, V26, P24; Saunders AM, 1996, LANCET, V348, P90, DOI 10.1016/S0140-6736(96)01251-2; Skoog I, 1996, LANCET, V347, P1141, DOI 10.1016/S0140-6736(96)90608-X; SKOOG I, 1993, NEW ENGL J MED, V328, P153, DOI 10.1056/NEJM199301213280301; Snowdon DA, 1996, JAMA-J AM MED ASSOC, V275, P528, DOI 10.1001/jama.275.7.528; Tatemichi Thomas K., 1994, P123; WELSH KA, 1994, NEUROLOGY, V44, P609, DOI 10.1212/WNL.44.4.609; WOLF PA, 1991, STROKE, V22, P312, DOI 10.1161/01.STR.22.3.312	26	1872	1928	1	83	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 12	1997	277	10					813	817		10.1001/jama.1997.03540340047031	http://dx.doi.org/10.1001/jama.1997.03540340047031			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM082	9052711				2022-12-01	WOS:A1997WM08200034
J	Camargo, CA; Stampfer, MJ; Glynn, RJ; Grodstein, F; Gaziano, JM; Manson, JE; Buring, JE; Hennekens, CH				Camargo, CA; Stampfer, MJ; Glynn, RJ; Grodstein, F; Gaziano, JM; Manson, JE; Buring, JE; Hennekens, CH			Moderate alcohol consumption and risk for angina pectoris or myocardial infarction in US male physicians	ANNALS OF INTERNAL MEDICINE			English	Article							HIGH-DENSITY-LIPOPROTEIN; CORONARY HEART-DISEASE; CHOLESTEROL	Background: Although previous studies have found that moderate alcohol intake decreases the risk for myocardial infarction, many clinicians question the validity of this finding. Furthermore, the relation of moderate drinking to the risk for other events, such as angina pectoris, is not known, Objective: To determine whether moderate alcohol in take decreases the risk for angina pectoris or myocardial infarction in apparently healthy men. Design: Prospective cohort study. Setting: United States. Participants: 22 071 apparently healthy male physicians who were 40 to 84 years of age between 1981 and 1984. Measurements: Responses to annual questionnaires. Results: Through 1994, 1368 cases of new-onset angina and 690 cases of myocardial infarction had been documented. In multivariate analyses that controlled for several potential confounders, alcohol intake was strongly and inversely associated with the risk for each event (P for trend < 0.001). Compare with men who consumed less than one drink per week, those who consumed one drink per day had relative risks of 0.69 (95% CI, 0.59 to 0.81) for angina and 0.65 (CI, 0.52 to 0.81) for myocardial infarction. These associations were seen when either nondrinkers or occasional drinkers were used as the reference group. Conclusions: Moderate drinking decreases the risk for angina pectoris and myocardial infarction in apparently heal-thy men.	HARVARD UNIV, BRIGHAM & WOMENS HOSP, DIV PREVENT MED, BOSTON, MA 02215 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP, CHANNING LAB, BOSTON, MA 02215 USA; HARVARD UNIV, MASSACHUSETTS GEN HOSP, SCH MED, BOSTON, MA USA; HARVARD UNIV, SCH PUBL HLTH, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard T.H. Chan School of Public Health			Camargo, Carlos A./C-2145-2008	Camargo, Carlos A./0000-0002-5071-7654	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034595] Funding Source: NIH RePORTER; NCI NIH HHS [CA-34944] Funding Source: Medline; NHLBI NIH HHS [HL-34595, HL-26490] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CAMARGO CA, 1985, JAMA-J AM MED ASSOC, V253, P2854; Camargo CA, 1997, ARCH INTERN MED, V157, P79, DOI 10.1001/archinte.157.1.79; COLDITZ GA, 1991, AM J CLIN NUTR, V54, P49, DOI 10.1093/ajcn/54.1.49; COX DR, 1972, J R STAT SOC B, V34, P187; *DIET GUID ADV COM, 1995, NUTR HLTH DIET GUID; *GALL POLL, 1992, GALL POLL NEWS SERV; GAZIANO JM, 1993, NEW ENGL J MED, V329, P1829, DOI 10.1056/NEJM199312163292501; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V133, P810; Hennekens C., 1987, EPIDEMIOLOGY MED; Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; LANGER RD, 1992, CIRCULATION, V85, P910, DOI 10.1161/01.CIR.85.3.910; MACMAHON S, 1987, HYPERTENSION, V9, P111, DOI 10.1161/01.HYP.9.2.111; MIDANIK LT, 1988, BRIT J ADDICT, V83, P1019; *NAT I ALC AB ALC, 1993, 8 SPEC REP US C ALC; *NAT I ALC AB ALC, 1992, ALC AL MOD DRINK; RIDKER PM, 1994, JAMA-J AM MED ASSOC, V272, P929, DOI 10.1001/jama.272.12.929; ROSNER B, 1992, AM J EPIDEMIOL, V136, P1400, DOI 10.1093/oxfordjournals.aje.a116453; SHAPER AG, 1993, AM J PUBLIC HEALTH, V83, P799, DOI 10.2105/AJPH.83.6.799; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P373, DOI 10.1056/NEJM199108083250601; STAMPFER MJ, 1993, AM J PUBLIC HEALTH, V83, P801, DOI 10.2105/AJPH.83.6.801; STEINBERG D, 1991, ANN INTERN MED, V114, P967, DOI 10.7326/0003-4819-114-11-967; SUH I, 1992, ANN INTERN MED, V116, P881, DOI 10.7326/0003-4819-116-11-881; World Health Organization, 1971, IHD REG REP 5 WORK G	24	105	107	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1997	126	5					372	375		10.7326/0003-4819-126-5-199703010-00005	http://dx.doi.org/10.7326/0003-4819-126-5-199703010-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WL104	9054281				2022-12-01	WOS:A1997WL10400005
J	Vaizey, CJ; Kamm, MA; Bartram, CI				Vaizey, CJ; Kamm, MA; Bartram, CI			Primary degeneration of the internal anal sphincter as a cause of passive faecal incontinence	LANCET			English	Article							NEUROGENIC FECAL INCONTINENCE; ENDOSONOGRAPHY; STIMULATION; MANOMETRY; SYMPTOMS; DAMAGE	Background Faecal incontinence is usually attributed to pelvic-floor denervation of striated muscle or direct sphincter trauma. We have identified a cause of passive faecal incontinence related to degeneration of the internal anal sphincter smooth muscle, in the absence of denervation, structural damage, external-sphincter weakness, or sensory abnormalities. Methods Patients were included on the basis of: passive faecal incontinence, no urge faecal incontinence, low anal pressure whilst at rest, normal anal-squeeze pressure, endosonographically confirmed circumferentially intact internal and external anal sphincters, and normal pudendal nerve terminal nerve latencies. In a second analysis done to assess the proportion of patients with this disorder, we recorded the cause of incontinence in consecutive patients seen during a 6-month period. Findings 45 patients (35 women, median age 63 years, range 23-80 years) fulfilled the diagnostic criteria. Median duration of symptoms was 2 years (3 months to 20 years). Nine of the 35 women were nulliparous. The median resting anal pressure was 40 cm water (16-56 cm water, normal >60 cm water). Endosonography revealed an internal sphincter that was thin and hyperechogenic, and had a poorly defined edge. The normal increase in the thickness of the internal anal sphincter with age was not seen, Anal-squeeze pressure, sensitivity, and pudendal nerve latencies were normal. In the second analysis the condition was identified in eight of 230 patients, representing 4% of new referrals. Interpretation Primary degeneration of the internal anal sphincter smooth muscle is a discrete clinical condition causing passive faecal incontinence.	ST MARKS HOSP,HARROW HA1 3UJ,MIDDX,ENGLAND	Imperial College London								BAETEN CGMI, 1995, NEW ENGL J MED, V332, P1600, DOI 10.1056/NEJM199506153322403; BARTOLO DCC, 1983, GASTROENTEROLOGY, V85, P68; BURNETT SJD, 1991, BRIT J RADIOL, V64, P225, DOI 10.1259/0007-1285-64-759-225; BURNETT SJD, 1991, INT J COLORECTAL DIS, V6, P2, DOI 10.1007/BF00703951; CARRARO PS, 1994, BRIT J SURG, V81, P140, DOI 10.1002/bjs.1800810151; CHERRY DA, 1988, SURG CLIN N AM, V68, P1217; CHRISTIANSEN J, 1992, ANN SURG, V215, P383, DOI 10.1097/00000658-199204000-00013; DELECHENAUT P, 1992, DIS COLON RECTUM, V35, P847, DOI 10.1007/BF02047871; ENGEL AF, 1995, INT J COLORECTAL DIS, V10, P152, DOI 10.1007/BF00298538; ENGEL AF, 1994, GUT, V35, P857, DOI 10.1136/gut.35.6.857; FELTBERSMA RJF, 1994, NETH J MED, V44, P182; JAMESON JS, 1994, BRIT J SURG, V81, P1689, DOI 10.1002/bjs.1800811143; KAMM MA, 1989, GUT, V30, P935, DOI 10.1136/gut.30.7.935; KAMM MA, 1990, DIS COLON RECTUM, V33, P419, DOI 10.1007/BF02156270; KAMM MA, 1994, LANCET, V344, P730, DOI 10.1016/S0140-6736(94)92213-6; KIFF ES, 1984, BRIT J SURG, V71, P614, DOI 10.1002/bjs.1800710817; LUBOWSKI DZ, 1988, GASTROENTEROLOGY, V95, P997, DOI 10.1016/0016-5085(88)90175-8; MILLER R, 1988, BRIT J SURG, V75, P44, DOI 10.1002/bjs.1800750116; PARKS AG, 1977, GUT, V18, P656, DOI 10.1136/gut.18.8.656; SPEAKMAN CTM, 1995, DIS COLON RECTUM, V38, P407, DOI 10.1007/BF02054231; SULTAN AH, 1993, NEW ENGL J MED, V329, P1905, DOI 10.1056/NEJM199312233292601; SULTAN AH, 1994, CLIN RADIOL, V49, P368, DOI 10.1016/S0009-9260(05)81819-7; WILLIAMS NS, 1990, ANN ROY COLL SURG, V72, P108	23	121	123	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 1	1997	349	9052					612	615		10.1016/S0140-6736(96)09188-X	http://dx.doi.org/10.1016/S0140-6736(96)09188-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WK915	9057734				2022-12-01	WOS:A1997WK91500012
J	Waters, MR; Forman, SL; Pierson, JM				Waters, MR; Forman, SL; Pierson, JM			Diring Yuriakh: A lower paleolithic site in central Siberia	SCIENCE			English	Article							LATE PLEISTOCENE; LOESS; LUMINESCENCE; CHINA; ASIA	Lower Paleolithic artifacts have been recovered from a single occupation surface within stratified deposits at Diring Yuriakh, an archaeological site in central Siberia. Thermoluminescence age estimates from eolian sediments indicate that the cultural horizon is greater than 260,000 years old. Diring Yuriakh is an order of magnitude older than documented Paleolithic sites in Siberia and is important for understanding the timing of human expansion into the far north, early adaptations to cold climates, and the peopling of the Americas.	TEXAS A&M UNIV, DEPT GEOG, COLLEGE STN, TX 77843 USA; UNIV ILLINOIS, DEPT GEOL SCI, CHICAGO, IL 60607 USA	Texas A&M University System; Texas A&M University College Station; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Waters, MR (corresponding author), TEXAS A&M UNIV, DEPT ANTHROPOL, COLLEGE STN, TX 77843 USA.		Pierson, Jean-Marc/V-2290-2019; Klein, Richard G/B-5910-2009; Waters, Michael R/A-9430-2009; Forman, Steven/ABD-7720-2021; Waters, Michael/ABI-2377-2020	Waters, Michael/0000-0003-2660-3355; Forman, Steven/0000-0002-2080-7915				ACKERMAN RE, 1991, CURRENT RES PLEISTOC, V8, P1; AITKEN MJ, 1975, ARCHAEOMETRY, V17, P132, DOI 10.1111/j.1475-4754.1975.tb00127.x; ALEKSEEV MN, 1990, UNPUB PROBLEMS GEOLO; DUMOND, 1994, SCI NEWS, V145, P243; FORMAN SL, 1991, QUATERNARY RES, V36, P19, DOI 10.1016/0033-5894(91)90014-V; FRECHEN M, 1992, QUATERNARY SCI REV, V11, P93, DOI 10.1016/0277-3791(92)90048-D; HUNTLEY DJ, 1981, CAN J EARTH SCI, V18, P419, DOI 10.1139/e81-036; HUNTLEY DJ, 1987, NUCL TRACKS RAD MEAS, V105, P279; KRINSLEY D.H., 1973, ATLAS QUARTZ SAND SU; Kuzmin Y.V., 1994, GEOARCHAEOLOGY, V9, P287; LARICHEV V, 1987, J WORLD PREHIST, V1, P415, DOI 10.1007/BF00974881; LU YC, 1987, QUATERNARY RES, V28, P356, DOI 10.1016/0033-5894(87)90003-2; MARTINSON DG, 1987, QUATERNARY RES, V27, P1, DOI 10.1016/0033-5894(87)90046-9; MICHAEL HN, 1984, ARCTIC ANTHROPOL, V21, P1; MOCHANOV YA, 1993, ARCTIC ANTHROPOL, V30, P22; MOCHANOV YA, 1996, AM BEGINNINGS PREHIS, P157; MOCHANOV YA, 1992, ANCIENT PALEOLITHIC; MOCHANOV YA, 1978, EARLY MAN AM CIRCUMP, P54; PACKMAN SC, 1992, QUATERNARY SCI REV, V11, P103, DOI 10.1016/0277-3791(92)90049-E; PAVLOV AG, 1992, ARCHAEOLOGICAL RES Y, P20; Pewe T. L., 1983, 1262 US GEOL SURV; POWERS WR, 1973, ARCTIC ANTHROPOL, V10, P1; PRESCOTT JR, 1994, RADIAT MEAS, V23, P497, DOI 10.1016/1350-4487(94)90086-8; Pye K., 1990, AEOLIAN SAND SAND DU; Ranov V.A., 1991, BIOULLETEN KOMISSII, V60, P79; SINGHVI AK, 1982, NATURE, V295, P313, DOI 10.1038/295313a0; West F.H., 1996, AM BEGINNINGS PREHIS; WINTLE AG, 1990, QUATERNARY SCI REV, V9, P385, DOI 10.1016/0277-3791(90)90029-A; YI SB, 1985, CURR ANTHROPOL, V26, P1, DOI 10.1086/203221	29	34	35	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 28	1997	275	5304					1281	1284		10.1126/science.275.5304.1281	http://dx.doi.org/10.1126/science.275.5304.1281			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	WK644	9036846				2022-12-01	WOS:A1997WK64400033
J	Salmeron, J; Manson, JE; Stampfer, MJ; Colditz, GA; Wing, AL; Willett, WC				Salmeron, J; Manson, JE; Stampfer, MJ; Colditz, GA; Wing, AL; Willett, WC			Dietary fiber, glycemic load, and risk of non-insulin-dependent diabetes mellitus in women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FOOD FREQUENCY QUESTIONNAIRE; PHYSICAL-ACTIVITY; INDEX DIET; CARBOHYDRATE FOODS; CIGARETTE-SMOKING; FAT DISTRIBUTION; NIDDM SUBJECTS; GLUCOSE; MAGNESIUM; MEN	Objective.-To examine prospectively the relationship between glycemic diets, low fiber intake, and risk of noninsulin-dependent diabetes mellitus. Design.-Cohort study. Setting.-in 1986, a total of 65173 US women 40 to 65 years of age and free from diagnosed cardiovascular disease, cancer, and diabetes completed a detailed dietary questionnaire from which we calculated usual intake of total and specific sources of dietary fiber, dietary glycemic index, and glycemic load. Main Outcome Measure.-Non-insulin-dependent diabetes mellitus. Results.-During 6 years of follow-up, 915 incident cases of diabetes were documented. The dietary glycemic index was positively associated with risk of diabetes after adjustment for age, body mass index, smoking, physical activity, family history of diabetes, alcohol and cereal fiber intake, and total energy intake. Comparing the highest with the lowest quintite, the relative risk (RR) of diabetes was 1.37 (95% confidence interval [CI], 1.09-1.71, Ptrend=.005). The glycemic load (an indicator of a global dietary insulin demand) was also positively associated with diabetes (RR=-1.47; 95% CI, 1.16-1.86, Ptrend=.003). Cereal fiber intake was inversely associated with risk of diabetes when comparing the extreme quintiles (RR=0.72, 95% CI, 0.58-0.90, Ptrend=.001). The combination of a high glycemic load and a low cereal fiber intake further increased the risk of diabetes (RR=2.50, 95% CI,1.14-5.51) when compared with a low glycemic load and high cereal fiber intake. Conclusions.-Our results support the hypothesis that diets with a high glycemic load and a low cereal fiber content increase risk of diabetes in women. Further, they suggest that grains should be consumed in a minimally refined form to reduce the incidence of diabetes.	BRIGHAM & WOMENS HOSP, CHANNING LAB, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; BRIGHAM & WOMENS HOSP, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; INST MEXICANO SEGURO SOCIAL, UNIDAD INVEST EPIDEMIOL, MEXICO CITY, DF, MEXICO; INST MEXICANO SEGURO SOCIAL, SERV SALUD, MEXICO CITY, DF, MEXICO	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Instituto Mexicano del Seguro Social; Instituto Mexicano del Seguro Social			Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291; Salmeron, Jorge/0000-0002-5113-299X	NATIONAL CANCER INSTITUTE [R01CA040356, R37CA040356] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036798] Funding Source: NIH RePORTER; NCI NIH HHS [CA40356] Funding Source: Medline; NIDDK NIH HHS [DK36798] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS CF, 1975, HDB US DEP AGR, V456; ANDERSON JW, 1987, J AM DIET ASSOC, V87, P1189; BARRETTCONNOR E, 1989, EPIDEMIOL REV, V11, P172, DOI 10.1093/oxfordjournals.epirev.a036035; BENNETT PH, 1984, DIET DIABETES ATHERO, P109; BRAND JC, 1991, DIABETES CARE, V14, P95, DOI 10.2337/diacare.14.2.95; CHAN JM, 1994, DIABETES CARE, V17, P961, DOI 10.2337/diacare.17.9.961; CLANDININ MT, 1993, ANN NY ACAD SCI, V683, P151; COLDITZ GA, 1986, AM J EPIDEMIOL, V123, P48, DOI 10.1093/oxfordjournals.aje.a114223; COLDITZ GA, 1992, AM J CLIN NUTR, V55, P1018, DOI 10.1093/ajcn/55.5.1018; COLDITZ GA, 1990, AM J EPIDEMIOL, V132, P501, DOI 10.1093/oxfordjournals.aje.a115686; CREMEL G, 1993, ANN NY ACAD SCI, V683, P164; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; FESKANICH D, 1993, J AM DIET ASSOC, V93, P790, DOI 10.1016/0002-8223(93)91754-E; FESKENS EJM, 1994, AM J EPIDEMIOL, V140, P350, DOI 10.1093/oxfordjournals.aje.a117257; FESKENS EJM, 1989, AM J EPIDEMIOL, V130, P1101, DOI 10.1093/oxfordjournals.aje.a115437; FONTVIEILLE AM, 1992, DIABETIC MED, V9, P444, DOI 10.1111/j.1464-5491.1992.tb01815.x; FRYER LG, 1993, ANN NY ACAD SCI, V683, P91; GROOP LC, 1992, ANN MED, V24, P483, DOI 10.3109/07853899209167000; HAFFNER SM, 1990, DIABETES, V39, P283, DOI 10.2337/diabetes.39.3.283; HAFFNER SM, 1988, NEW ENGL J MED, V319, P1297, DOI 10.1056/NEJM198811173192001; HARRIS M, 1979, DIABETES, V28, P1039; HELMRICH SP, 1991, NEW ENGL J MED, V325, P147, DOI 10.1056/NEJM199107183250302; JARRETT RJ, 1989, EPIDEMIOL REV, V11, P151, DOI 10.1093/oxfordjournals.epirev.a036034; JENKINS DJA, 1978, BRIT MED J, V2, P1744, DOI 10.1136/bmj.2.6154.1744; JENKINS DJA, 1984, LANCET, V2, P388; JENKINS DJA, 1981, AM J CLIN NUTR, V34, P362, DOI 10.1093/ajcn/34.3.362; JENKINS DJA, 1987, AM J CLIN NUTR, V46, P968, DOI 10.1093/ajcn/46.6.968; JENKINS DJA, 1988, AM J CLIN NUTR, V48, P248, DOI 10.1093/ajcn/48.2.248; KAHN CR, 1994, DIABETES, V43, P1066, DOI 10.2337/diab.43.8.1066; Kleinbaum D.G, 1988, APPL REGRESSION ANAL; KLIMES I, 1993, ANN NY ACAD SCI, V683, P69; LEAHY JL, 1992, DIABETES CARE, V15, P442, DOI 10.2337/diacare.15.3.442; LECLERE CJ, 1994, AM J CLIN NUTR, V59, P914, DOI 10.1093/ajcn/59.4.914; LEE IM, 1992, AM J EPIDEMIOL, V135, P915, DOI 10.1093/oxfordjournals.aje.a116387; LUNDGREN H, 1989, AM J CLIN NUTR, V49, P708, DOI 10.1093/ajcn/49.4.708; MANSON JE, 1991, LANCET, V338, P774, DOI 10.1016/0140-6736(91)90664-B; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; Marshall J A, 1993, Ann Epidemiol, V3, P18, DOI 10.1016/1047-2797(93)90005-O; MARSHALL JA, 1991, AM J EPIDEMIOL, V134, P590, DOI 10.1093/oxfordjournals.aje.a116132; MARSHALL JA, 1994, OBESITY DIABETES INS; MARTIN BC, 1992, LANCET, V340, P925, DOI 10.1016/0140-6736(92)92814-V; MEDALIE JH, 1974, ISRAEL J MED SCI, V10, P681; MILLER JCB, 1994, AM J CLIN NUTR, V59, p747S, DOI 10.1093/ajcn/59.3.747S; Morris R D, 1992, Ann Epidemiol, V2, P657, DOI 10.1016/1047-2797(92)90010-N; PAOLISSO G, 1989, DIABETES CARE, V12, P265, DOI 10.2337/diacare.12.4.265; PAOLISSO G, 1990, DIABETOLOGIA, V33, P511, DOI 10.1007/BF00404136; PAOLISSO G, 1992, AM J CLIN NUTR, V55, P1161, DOI 10.1093/ajcn/55.6.1161; PORTE D, 1991, DIABETES, V40, P166, DOI 10.2337/diabetes.40.2.166; REAVEN GM, 1993, DIABETES METAB REV, V9, pS5, DOI 10.1002/dmr.5610090503; RESNICK LM, 1993, AM J HYPERTENS, V6, pS123, DOI 10.1093/ajh/6.4S.123S; Rimm E B, 1990, Epidemiology, V1, P466, DOI 10.1097/00001648-199011000-00009; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; RIMM EB, 1993, AM J PUBLIC HEALTH, V83, P211, DOI 10.2105/AJPH.83.2.211; RIMM EB, 1995, BRIT MED J, V310, P555, DOI 10.1136/bmj.310.6979.555; RIVELLESE A, 1980, LANCET, V2, P447; ROSSETTI L, 1990, DIABETES CARE, V13, P610, DOI 10.2337/diacare.13.6.610; Rothman KJ, 1986, MODERN EPIDEMIOLOGY; SAAD MF, 1988, NEW ENGL J MED, V319, P1500, DOI 10.1056/NEJM198812083192302; SALMERON J, 1994, OBESITYY DIABETES IN; SALVINI S, 1989, INT J EPIDEMIOL, V18, P858, DOI 10.1093/ije/18.4.858; SIMPSON HCR, 1981, LANCET, V1, P1; SJOGREN A, 1988, MAGNESIUM, V7, P117; STAMPFER MJ, 1988, AM J EPIDEMIOL, V128, P549, DOI 10.1093/oxfordjournals.aje.a115002; STORLIEN LH, 1993, ANN NY ACAD SCI, V683, P82; SWINBURN BA, 1993, ANN NY ACAD SCI, V683, P102; Trowell H., 1985, DIETARY FIBER FIBER; TROWELL HC, 1975, DIABETES, V24, P762, DOI 10.2337/diab.24.8.762; TURNER R, 1992, ANN MED, V24, P511, DOI 10.3109/07853899209167004; WARRAM JH, 1990, ANN INTERN MED, V113, P909, DOI 10.7326/0003-4819-113-12-909; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; WILLETT WC, 1988, AM J EPIDEMIOL, V127, P188, DOI 10.1093/oxfordjournals.aje.a114780; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; Wolever T M, 1990, World Rev Nutr Diet, V62, P120; Wolever Thomas M. S., 1993, International Journal of Food Sciences and Nutrition, V43, P205, DOI 10.3109/09637489309027544; WOLEVER TMS, 1994, NUTR RES, V14, P651, DOI 10.1016/S0271-5317(05)80201-5; WOLEVER TMS, 1994, AM J CLIN NUTR, V59, P1265, DOI 10.1093/ajcn/59.6.1265; WOLEVER TMS, 1986, AM J CLIN NUTR, V43, P167, DOI 10.1093/ajcn/43.1.167; WOLEVER TMS, 1992, DIABETIC MED, V9, P451, DOI 10.1111/j.1464-5491.1992.tb01816.x; WOLEVER TMS, 1991, AM J CLIN NUTR, V54, P846, DOI 10.1093/ajcn/54.5.846; WOLEVER TMS, 1992, DIABETES CARE, V15, P562, DOI 10.2337/diacare.15.4.562; WOLEVER TMS, 1991, MEDITERRANEAN DIETS, P160; World Health Organization, 1985, WHO TECHN REP SER, V727	82	1309	1359	2	134	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 12	1997	277	6					472	477		10.1001/jama.277.6.472	http://dx.doi.org/10.1001/jama.277.6.472			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WG054	9020271				2022-12-01	WOS:A1997WG05400034
J	Dent, AL; Shaffer, AL; Yu, X; Allman, D; Staudt, LM				Dent, AL; Shaffer, AL; Yu, X; Allman, D; Staudt, LM			Control of inflammation, cytokine expression, and germinal center formation by BCL-6	SCIENCE			English	Article							CENTER B-CELLS; NON-HODGKINS-LYMPHOMA; FINGER ENCODING GENE; TRANSCRIPTION FACTOR; PROTEIN; BINDING; SEQUENCE; LAZ3; IL-4; TRANSLOCATIONS	The gene encoding the BCL-6 transcriptional repressor is frequently translocated and mutated in diffuse large cell lymphoma. Mice with a disrupted BCL-6 gene developed myocarditis and pulmonary vasculitis, had no germinal centers, and had increased expression of T helper cell type 2 cytokines. The BCL-6 DNA recognition motif resembled sites bound by the STAT (signal transducers and activators of transcription) transcription factors, which mediate cytokine signaling. BCL-6 could repress interleukin-4 (IL-4)-induced transcription when bound to a site recognized by the IL-4-responsive transcription factor Stat6. Thus, dysregulation of STAT-responsive genes may underlie the inflammatory disease in BCL-6-deficient mice and participate in lymphoid malignancies.	NCI,METAB BRANCH,NATL INST HLTH,BETHESDA,MD 20892; NCI,EXPT IMMUNOL BRANCH,NATL INST HLTH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Staudt, Louis/AAC-5324-2019					Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Allman D, 1996, BLOOD, V87, P5257, DOI 10.1182/blood.V87.12.5257.bloodjournal87125257; BARON BW, 1993, P NATL ACAD SCI USA, V90, P5262, DOI 10.1073/pnas.90.11.5262; BARON BW, 1995, GENE CHROMOSOME CANC, V13, P221, DOI 10.1002/gcc.2870130314; BASTARD C, 1994, BLOOD, V83, P2423; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; DENT AJ, UNPUB; DEWEINDT C, 1995, CELL GROWTH DIFFER, V6, P1495; Dhordain P, 1995, ONCOGENE, V11, P2689; FLENGHI L, 1995, AM J PATHOL, V147, P405; HOU J, 1994, SCIENCE, V265; JACOB J, 1992, J EXP MED, V176, P679, DOI 10.1084/jem.176.3.679; KAWAMATA N, 1994, BIOCHEM BIOPH RES CO, V204, P366, DOI 10.1006/bbrc.1994.2468; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; KOHLER I, 1993, EUR J IMMUNOL, V23, P3066, DOI 10.1002/eji.1830231204; KOLLER BH, 1989, P NATL ACAD SCI USA, V86, P8932, DOI 10.1073/pnas.86.22.8932; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; LOCOCO F, 1994, BLOOD, V83, P1757, DOI 10.1182/blood.V83.7.1757.bloodjournal8371757; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.immunol.12.1.117; Matsumoto M, 1996, SCIENCE, V271, P1289, DOI 10.1126/science.271.5253.1289; Migliazza A, 1995, P NATL ACAD SCI USA, V92, P12520, DOI 10.1073/pnas.92.26.12520; MIKI T, 1994, BLOOD, V83, P26; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; ONIZUKA T, 1995, BLOOD, V86, P28, DOI 10.1182/blood.V86.1.28.bloodjournal86128; OTSUKI T, 1995, BLOOD, V85, P2877, DOI 10.1182/blood.V85.10.2877.bloodjournal85102877; PASCUAL V, 1994, J EXP MED, V180, P329, DOI 10.1084/jem.180.1.329; Pasparakis M, 1996, J EXP MED, V184, P1397, DOI 10.1084/jem.184.4.1397; SCHINDLER C, 1994, EMBO J, V13, P1350, DOI 10.1002/j.1460-2075.1994.tb06388.x; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.immunol.12.1.635; Seyfert VL, 1996, ONCOGENE, V12, P2331; SHIMODA K, 1996, IMMUNITY, V4, P313; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596	38	732	750	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 25	1997	276	5312					589	592		10.1126/science.276.5312.589	http://dx.doi.org/10.1126/science.276.5312.589			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WV721	9110977				2022-12-01	WOS:A1997WV72100044
J	Ooi, WL; Barrett, S; Hossain, M; KelleyGagnon, M; Lipsitz, LA				Ooi, WL; Barrett, S; Hossain, M; KelleyGagnon, M; Lipsitz, LA			Patterns of orthostatic blood pressure change and their clinical correlates in a frail, elderly population	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSTURAL HYPOTENSION; RESIDENT ASSESSMENT; RANDOM-ZERO; HYPERTENSION; PREVALENCE; HEALTH; RISK; ASSOCIATION; FALLS; MDS	Objectives.-To determine patterns of within-day orthostatic blood pressure (BP) changes and clinical factors correlated with them in frail, elderly nursing home residents. Design.-Prevalence study of orthostatic BP change. Setting.-Sample of 45 nursing homes. Participants.-A total of 911 long-stay residents, aged 60 years or older, able to stand for at least 1 minute. Main Outcome Measures.-Supine and 1-minute and 3-minute standing BP measurements and heart rates, taken by a random-zero sphygmomanometer before and after breakfast and before and after lunch, symptoms upon standing, medication use, and clinical and functional assessments. Results.-Four orthostatic hypotension (OH) groups were defined based on the frequency of a 20 mm Hg or greater orthostatic BP decline during any of 8 postural change measures: no OH group (48.5%); isolated OH group (only once, 18.3%); variable OH group (2-3 times, 19.9%); and persistent OH group (greater than or equal to 4 times, 13.3%), Orthostatic hypotension was most prevalent before breakfast, especially 1 minute after standing (21.3%), and least prevalent after lunch after 3 minutes of standing (4.9%) (P=.001). A regression approach to repeated measures analysis (method of general estimating equations) showed the following to be significantly associated with OH (P less than or equal to.05): elevated supine systolic BP before breakfast, dizziness/light-headedness on standing, male sex, medication for Parkinson disease, time of day (particularly before breakfast), greater independence in activities of daily living, and low body mass index. Conclusions.-Orthostatic hypotension occurs in more than half of frail, elderly nursing home residents, but is highly variable over time. It is most prevalent in the morning when subjects first arise and when supine BP is highest. The relationship of OH with elevated BP, but not antihypertensive medication use, suggests that the treatment of hypertension may improve postural BP regulation.	BETH ISRAEL MED CTR,DEPT MED,BOSTON,MA; HARVARD UNIV,SCH MED,DIV AGING,BOSTON,MA 02115	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Ooi, WL (corresponding author), HEBREW REHABIL CTR AGED,RES & TRAINING INST,1200 CTR ST,BOSTON,MA 02131, USA.				NIA NIH HHS [AG04390, AG09538, AG11023] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG009538, P01AG004390, R01AG011023] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		APPLEGATE WB, 1991, J AM GERIATR SOC, V39, P1057, DOI 10.1111/j.1532-5415.1991.tb02869.x; ARONOW WS, 1988, AM J CARDIOL, V62, P336, DOI 10.1016/0002-9149(88)90243-3; CAIRD FI, 1973, BRIT HEART J, V35, P527; DAVIS BR, 1987, CIRCULATION, V75, P340, DOI 10.1161/01.CIR.75.2.340; HARRIS T, 1991, J GERONTOL, V46, pM159, DOI 10.1093/geronj/46.5.M159; HAWES C, 1995, GERONTOLOGIST, V35, P172, DOI 10.1093/geront/35.2.172; Jansen RWMM, 1996, J AM GERIATR SOC, V44, P383, DOI 10.1111/j.1532-5415.1996.tb06406.x; JANSEN RWMM, 1995, ANN INTERN MED, V122, P286, DOI 10.7326/0003-4819-122-4-199502150-00009; JOHNSON RH, 1965, LANCET, V1, P731; JONSSON PV, 1990, ARCH INTERN MED, V150, P1518; KARIM MR, 1988, 674 J HOPK U DEP BIO; KOBRIN I, 1984, J AM GERIATR SOC, V32, P896, DOI 10.1111/j.1532-5415.1984.tb00890.x; KUWAJIMA I, 1992, AM HEART J, V67, P1307; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; LIPSITZ LA, 1985, CLIN SCI, V69, P337, DOI 10.1042/cs0690337; LIPSITZ LA, 1986, J CHRON DIS, V39, P619, DOI 10.1016/0021-9681(86)90187-6; LIPSITZ LA, 1989, NEW ENGL J MED, V321, P952; MACLENAN WJ, 1993, CARDIOL ELDER, V1, P33; MADER SL, 1987, JAMA-J AM MED ASSOC, V258, P1511, DOI 10.1001/jama.258.11.1511; MESSERLI FH, 1985, NEW ENGL J MED, V312, P1548, DOI 10.1056/NEJM198506133122405; MORRIS JN, 1990, GERONTOLOGIST, V30, P293, DOI 10.1093/geront/30.3.293; MORRIS JN, 1994, J GERONTOL, V49, pM174, DOI 10.1093/geronj/49.4.M174; MORRIS JN, 1991, RESIDENT ASSESSMENT; MYERS MG, 1978, CAN MED ASSOC J, V119, P581; PALMER KT, 1983, NEW ZEAL MED J, V96, P43; PARKER D, 1988, HYPERTENSION, V11, P269, DOI 10.1161/01.HYP.11.3.269; RAY WA, 1987, NEW ENGL J MED, V316, P363, DOI 10.1056/NEJM198702123160702; RODSTEIN M, 1957, J Chronic Dis, V6, P581, DOI 10.1016/0021-9681(57)90012-7; RUTAN GH, 1992, HYPERTENSION, V19, P508, DOI 10.1161/01.HYP.19.6.508; SHIMADA K, 1992, J HYPERTENS, V10, P875; TILVIS RS, 1996, J AM GERIATR SOC, V4, P809; TINETTI ME, 1986, AM J MED, V80, P429, DOI 10.1016/0002-9343(86)90717-5; TOHGI H, 1991, STROKE, V22, P603, DOI 10.1161/01.STR.22.5.603; TONKIN A, 1992, CLIN PHARMACOL THER, V52, P277, DOI 10.1038/clpt.1992.142; VERDECCHIA P, 1993, CIRCULATION, V88, P986, DOI 10.1161/01.CIR.88.3.986; WRIGHT BM, 1970, LANCET, V1, P337; YIP YB, 1994, MED J AUSTRALIA, V160, P14, DOI 10.5694/j.1326-5377.1994.tb138194.x; 1996, CLIN AUTON RES, V6, P125	38	162	168	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 23	1997	277	16					1299	1304		10.1001/jama.277.16.1299	http://dx.doi.org/10.1001/jama.277.16.1299			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU135	9109468				2022-12-01	WOS:A1997WU13500030
J	Chandrasekharappa, SC; Guru, SC; Manickam, P; Olufemi, SE; Collins, FS; EmmertBuck, MR; Debelenko, LV; Zhuang, ZP; Lubensky, IA; Liotta, LA; Crabtree, JS; Wang, YP; Roe, BA; Weisemann, J; Boguski, MS; Agarwal, SK; Kester, MB; Kim, YS; Heppner, C; Dong, QH; Spiegel, AM; Burns, AL; Marx, SJ				Chandrasekharappa, SC; Guru, SC; Manickam, P; Olufemi, SE; Collins, FS; EmmertBuck, MR; Debelenko, LV; Zhuang, ZP; Lubensky, IA; Liotta, LA; Crabtree, JS; Wang, YP; Roe, BA; Weisemann, J; Boguski, MS; Agarwal, SK; Kester, MB; Kim, YS; Heppner, C; Dong, QH; Spiegel, AM; Burns, AL; Marx, SJ			Positional cloning of the gene for multiple endocrine neoplasia-type 1	SCIENCE			English	Article							PROTEIN SEQUENCES; TUMORS; MUTATIONS; 11Q13	Multiple endocrine neoplasia-type 1 (MEN1) is an autosomal dominant familial cancer syndrome characterized by tumors in parathyroids, enteropancreatic endocrine tissues, and the anterior pituitary. DNA sequencing from a previously identified minimal interval on chromosome 11q13 identified several candidate genes, one of which contained 12 different frameshift, nonsense, missense, and in-frame deletion mutations in 14 probands from 15 families. The MEN1 gene contains 10 exons and encodes a ubiquitously expressed 2.8-kilobase transcript. The predicted 610-amino acid protein product, termed menin, exhibits no apparent similarities to any previously known proteins. The identification of MEN? will enable improved understanding of the mechanism of endocrine tumorigenesis and should facilitate early diagnosis.	NATL HUMAN GENOME RES INST,LAB GENE TRANSFER,NIH,BETHESDA,MD 20892; NCI,PATHOL LAB,NIH,BETHESDA,MD 20892; UNIV OKLAHOMA,DEPT CHEM & BIOCHEM,NORMAN,OK 73019; NATL LIB MED,NATL CTR BIOTECHNOL INFORMAT,NIH,BETHESDA,MD 20894; NIDDKD,METAB DIS BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Oklahoma System; University of Oklahoma - Norman; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Agarwal, Sunita K/D-1428-2016; Lima, Thaísa/AAG-6483-2021	Agarwal, Sunita K/0000-0002-7557-3191; 				Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; BALLARD HS, 1964, MEDICINE, V43, P481, DOI 10.1097/00005792-196407000-00003; BEAUDET AL, 1993, HUM MUTAT, V2, P245, DOI 10.1002/humu.1380020402; BRENDEL V, 1992, P NATL ACAD SCI USA, V89, P2002, DOI 10.1073/pnas.89.6.2002; BYSTROM C, 1990, P NATL ACAD SCI USA, V87, P1968, DOI 10.1073/pnas.87.5.1968; COLLINS FS, 1995, NAT GENET, V9, P347, DOI 10.1038/ng0495-347; Courseaux A, 1996, GENOMICS, V37, P354, DOI 10.1006/geno.1996.0570; Debelenko LV, 1997, CANCER RES, V57, P1039; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; EMMERTBUCK MR, UNPUB; EMMERTBUCK MR, IN PRESS CANC RES; FRIEDMAN E, 1989, NEW ENGL J MED, V321, P213, DOI 10.1056/NEJM198907273210402; GURU SC, UNPUB; HEATH H, 1980, NEW ENGL J MED, V302, P189, DOI 10.1056/NEJM198001243020402; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; LARSSON C, 1988, NATURE, V332, P85, DOI 10.1038/332085a0; Lubensky IA, 1996, CANCER RES, V56, P5272; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MANICKAM P, UNPUB; Metz David C., 1994, P591; MOLDAWER MP, 1954, AM J MED SCI, V228, P190, DOI 10.1097/00000441-195408000-00008; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; PAN HQ, 1994, GENET ANAL-BIOMOL E, V11, P181; PETTY EM, 1994, AM J HUM GENET, V54, P1060; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; SMITH CM, 1995, HUM GENET, V96, P377; Trump D, 1996, QJM-INT J MED, V89, P653; WERMER P, 1954, AM J MED, V16, P363, DOI 10.1016/0002-9343(54)90353-8; WOOTTON JC, 1994, COMPUT CHEM, V18, P269, DOI 10.1016/0097-8485(94)85023-2; [No title captured]	31	1508	1542	0	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 18	1997	276	5311					404	407		10.1126/science.276.5311.404	http://dx.doi.org/10.1126/science.276.5311.404			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WU477	9103196	Green Submitted			2022-12-01	WOS:A1997WU47700036
J	Crabb, BS; Cooke, BM; Reeder, JC; Waller, RF; Caruana, SR; Davern, KM; Wickham, ME; Brown, GV; Coppel, RL; Cowman, AF				Crabb, BS; Cooke, BM; Reeder, JC; Waller, RF; Caruana, SR; Davern, KM; Wickham, ME; Brown, GV; Coppel, RL; Cowman, AF			Targeted gene disruption shows that knobs enable malaria-infected red cells to cytoadhere under physiological shear stress	CELL			English	Article							HISTIDINE-RICH PROTEIN; HUMAN CEREBRAL MALARIA; PLASMODIUM-FALCIPARUM; ADHESION MOLECULE-1; KNOBLESS CLONE; ANTIGEN CD36; BLOOD-CELLS; CDNA CLONE; ERYTHROCYTES; MEMBRANE	Knobs at the surface of erythrocytes infected with Plasmodium falciparum have been proposed to be important in adherence of these cells to the vascular endothelium. This structure contains the knob-associated histidine-rich protein (KAHRP) and the adhesion receptor P. falciparum erythrocyte membrane protein 1. We have disrupted the gene encoding KAHRP and show that it is essential for knob formation. Knob transfectants adhere to CD36 in static assays; when tested under flow conditions that mimic those of postcapillary venules, however, the binding to CD36 was dramatically reduced. These data suggest that knobs on P. falciparum-infected erythrocytes exert an important influence on adherence of parasitized-erythrocytes to microvascular endothelium, an important process in the pathogenesis of P. falciparum infections.	MONASH UNIV,DEPT MICROBIOL,CLAYTON,VIC 3168,AUSTRALIA; UNIV MELBOURNE,DEPT BOT,PLANT CELL BIOL RES CTR,PARKVILLE,VIC 3052,AUSTRALIA	Monash University; University of Melbourne	Crabb, BS (corresponding author), WALTER & ELIZA HALL INST MED RES,MELBOURNE,VIC 3050,AUSTRALIA.		Cowman, Alan F/C-7642-2013; Wickham, Mark/A-1396-2009; Crabb, Brendan/F-5287-2013; Coppel, Ross L/A-6626-2008; Wickham, Mark E/HCI-4959-2022; Waller, Ross F/D-5761-2016	Cowman, Alan F/0000-0001-5145-9004; Wickham, Mark/0000-0002-3473-7196; Coppel, Ross L/0000-0002-4476-9124; Wickham, Mark E/0000-0002-3473-7196; Waller, Ross F/0000-0001-6961-9344; Reeder, John/0000-0003-1395-1289	NIDDK NIH HHS [DK32094-10] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK032094] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AIKAWA M, 1988, AM J TROP MED HYG, V39, P3, DOI 10.4269/ajtmh.1988.39.3; BARNWELL JW, 1989, J CLIN INVEST, V84, P765, DOI 10.1172/JCI114234; Baruch DI, 1996, P NATL ACAD SCI USA, V93, P3497, DOI 10.1073/pnas.93.8.3497; BARUCH DI, 1995, CELL, V82, P77, DOI 10.1016/0092-8674(95)90054-3; BERENDT AR, 1989, NATURE, V341, P57, DOI 10.1038/341057a0; BIANCO AE, 1986, P NATL ACAD SCI USA, V83, P8713, DOI 10.1073/pnas.83.22.8713; BIGGS BA, 1990, J EXP MED, V171, P1883, DOI 10.1084/jem.171.6.1883; BIGGS BA, 1989, EXP PARASITOL, V69, P189, DOI 10.1016/0014-4894(89)90187-2; Chien S., 1972, HEMODILUTION THEORET, P1; CHU G, 1986, SCIENCE, V234, P1582, DOI 10.1126/science.3538420; Cooke BM, 1996, BLOOD, V88, P4040, DOI 10.1182/blood.V88.10.4040.bloodjournal88104040; COOKE BM, 1995, EXP PARASITOL, V80, P116, DOI 10.1006/expr.1995.1013; COOKE BM, 1994, BRIT J HAEMATOL, V87, P162, DOI 10.1111/j.1365-2141.1994.tb04887.x; COPPEL RL, 1987, MOL BIOCHEM PARASIT, V25, P73, DOI 10.1016/0166-6851(87)90020-X; CORCORAN LM, 1986, CELL, V44, P87, DOI 10.1016/0092-8674(86)90487-3; COWMAN AF, 1991, J CELL BIOL, V113, P1033, DOI 10.1083/jcb.113.5.1033; Crabb BS, 1996, P NATL ACAD SCI USA, V93, P7289, DOI 10.1073/pnas.93.14.7289; CRANDALL I, 1993, P NATL ACAD SCI USA, V90, P4703, DOI 10.1073/pnas.90.10.4703; CULVENOR JG, 1987, EXP PARASITOL, V63, P58, DOI 10.1016/0014-4894(87)90078-6; Deitsch KW, 1996, MOL BIOCHEM PARASIT, V76, P1, DOI 10.1016/0166-6851(95)02575-8; HOWARD RJ, 1988, MOL BIOCHEM PARASIT, V27, P207, DOI 10.1016/0166-6851(88)90040-0; KILEJIAN A, 1991, MOL BIOCHEM PARASIT, V44, P175, DOI 10.1016/0166-6851(91)90003-O; KILEJIAN A, 1977, B WORLD HEALTH ORGAN, V55, P191; KILEJIAN A, 1979, P NATL ACAD SCI USA, V76, P4650, DOI 10.1073/pnas.76.9.4650; LANGRETH SG, 1985, INFECT IMMUN, V47, P760, DOI 10.1128/IAI.47.3.760-766.1985; LANZER M, 1993, NATURE, V361, P654, DOI 10.1038/361654a0; LEECH JH, 1984, J EXP MED, V159, P1567, DOI 10.1084/jem.159.6.1567; MACPHERSON GG, 1985, AM J PATHOL, V119, P385; OCKENHOUSE CF, 1988, J INFECT DIS, V157, P584, DOI 10.1093/infdis/157.3.584; OCKENHOUSE CF, 1991, P NATL ACAD SCI USA, V88, P3175, DOI 10.1073/pnas.88.8.3175; OCKENHOUSE CF, 1992, J EXP MED, V176, P1183, DOI 10.1084/jem.176.4.1183; PASLOSKE BL, 1993, MOL BIOCHEM PARASIT, V59, P59, DOI 10.1016/0166-6851(93)90007-K; POLOGE LG, 1986, NATURE, V322, P474, DOI 10.1038/322474a0; POLOGE LG, 1987, P NATL ACAD SCI USA, V84, P7139, DOI 10.1073/pnas.84.20.7139; RAVENTOSSUAREZ C, 1985, P NATL ACAD SCI USA, V82, P3829, DOI 10.1073/pnas.82.11.3829; ROGERSON SJ, 1995, J EXP MED, V182, P15, DOI 10.1084/jem.182.1.15; SMITH JD, 1995, CELL, V82, P101, DOI 10.1016/0092-8674(95)90056-X; SU XZ, 1995, CELL, V82, P89, DOI 10.1016/0092-8674(95)90055-1; TRAGER W, 1978, NATURE, V273, P621, DOI 10.1038/273621a0; TURITTO VT, 1982, PROG HEMOST THROMB, V6, P139; UDEINYA IJ, 1981, SCIENCE, V213, P555, DOI 10.1126/science.7017935; UDOMSANGPETCH R, 1989, NATURE, V338, P763, DOI 10.1038/338763a0; WAHLGREN M, 1994, PARASITOL TODAY, V10, P73, DOI 10.1016/0169-4758(94)90400-6; WU YM, 1995, P NATL ACAD SCI USA, V92, P973, DOI 10.1073/pnas.92.4.973; Wu YM, 1996, P NATL ACAD SCI USA, V93, P1130, DOI 10.1073/pnas.93.3.1130	45	352	356	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 18	1997	89	2					287	296		10.1016/S0092-8674(00)80207-X	http://dx.doi.org/10.1016/S0092-8674(00)80207-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WU888	9108483	Bronze			2022-12-01	WOS:A1997WU88800015
J	Drewes, G; Ebneth, A; Preuss, U; Mandelkow, EM; Mandelkow, E				Drewes, G; Ebneth, A; Preuss, U; Mandelkow, EM; Mandelkow, E			MARK, a novel family of protein kinases that phosphorylate microtubule-associated proteins and trigger microtubule disruption	CELL			English	Article							HAMSTER OVARY CELLS; DYNAMIC INSTABILITY; TAU-PROTEIN; MAMMALIAN-CELLS; POLARITY; SEQUENCE; BRAIN; ORGANIZATION; EXPRESSION; INHIBITION	MARK phosphorylates the microtubule-associated proteins tau, MAP2, and MAP4 on their microtubule-binding domain, causing their dissociation from microtubules and increased microtubule dynamics. We describe the molecular cloning, distribution, activation mechanism, and overexpression of two MARK proteins from rat that arise from distinct genes. They encode Ser/Thr kinases of 88 and 81 kDa, respectively, and show similarity to the yeast kin1(+) and C. elegans par-1 genes that are involved in the establishment of cell polarity. Expression of both isoforms is ubiquitous, and homologous genes are present in humans. Catalytic activity depends on phosphorylation of two residues in subdomain VIII. Overexpression of MARK in cells leads to hyperphosphorylation of MAPs on KXGS motifs and to disruption of the microtubule array, resulting in morphological changes and cell death.			Drewes, G (corresponding author), DESY,MAX PLANCK UNIT STRUCT MOL BIOL,NOTKESTR 85,GEBAUDE 25B,D-22603 HAMBURG,GERMANY.			Drewes, Gerard/0000-0003-0575-6766				BARLOW S, 1994, J CELL BIOL, V126, P1017, DOI 10.1083/jcb.126.4.1017; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; BIERNAT J, 1993, NEURON, V11, P153, DOI 10.1016/0896-6273(93)90279-Z; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; CACERES A, 1990, NATURE, V343, P461, DOI 10.1038/343461a0; Chang F, 1996, CELL, V84, P191, DOI 10.1016/S0092-8674(00)80973-3; DINSMORE JH, 1991, CELL, V64, P817, DOI 10.1016/0092-8674(91)90510-6; DONOVAN M, 1994, YEAST, V10, P113, DOI 10.1002/yea.320100111; DREWES G, 1995, J BIOL CHEM, V270, P7679, DOI 10.1074/jbc.270.13.7679; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; Guo S, 1996, NATURE, V382, P455, DOI 10.1038/382455a0; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HARADA A, 1994, NATURE, V369, P488, DOI 10.1038/369488a0; HASEGAWA M, 1992, J BIOL CHEM, V267, P17047; Hofmann K, 1996, TRENDS BIOCHEM SCI, V21, P172, DOI 10.1016/S0968-0004(96)30015-7; Hyman AA, 1996, CELL, V84, P401, DOI 10.1016/S0092-8674(00)81285-4; Illenberger S, 1996, J BIOL CHEM, V271, P10834, DOI 10.1074/jbc.271.18.10834; INGLIS JD, 1993, MAMM GENOME, V4, P401, DOI 10.1007/BF00360595; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEVIN DE, 1990, P NATL ACAD SCI USA, V87, P8272, DOI 10.1073/pnas.87.21.8272; LEVIN DE, 1987, P NATL ACAD SCI USA, V84, P6035, DOI 10.1073/pnas.84.17.6035; LOPEZ LA, 1995, J BIOL CHEM, V270, P12511, DOI 10.1074/jbc.270.21.12511; MANDELKOW EM, 1995, NEUROBIOL AGING, V16, P355, DOI 10.1016/0197-4580(95)00025-A; Mangan ME, 1996, DEVELOPMENT, V122, P771; McDermott JB, 1996, BIOCHEMISTRY-US, V35, P9415, DOI 10.1021/bi952646n; Mercken M, 1995, J NEUROSCI, V15, P8259; MEYER HE, 1993, FASEB J, V7, P776, DOI 10.1096/fasebj.7.9.7687226; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; PARSA I, 1988, CANCER RES, V48, P2265; PREUSS U, 1995, MOL BIOL CELL, V6, P1397, DOI 10.1091/mbc.6.10.1397; PRYER NK, 1992, J CELL SCI, V103, P965; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SAMMAK PJ, 1988, NATURE, V332, P724, DOI 10.1038/332724a0; SAXTON WM, 1984, J CELL BIOL, V99, P2175, DOI 10.1083/jcb.99.6.2175; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; SEUBERT P, 1995, J BIOL CHEM, V270, P18917, DOI 10.1074/jbc.270.32.18917; SHIINA N, 1992, EMBO J, V11, P3977, DOI 10.1002/j.1460-2075.1992.tb05491.x; STEINER B, 1990, EMBO J, V9, P3539, DOI 10.1002/j.1460-2075.1990.tb07563.x; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TIBBETTS M, 1994, EXP CELL RES, V213, P93, DOI 10.1006/excr.1994.1177; TRINCZEK B, 1995, MOL BIOL CELL, V6, P1887, DOI 10.1091/mbc.6.12.1887; UMEYAMA T, 1993, J CELL BIOL, V120, P451, DOI 10.1083/jcb.120.2.451; VALLEE R, 1980, P NATL ACAD SCI-BIOL, V77, P3206, DOI 10.1073/pnas.77.6.3206; VANDRE DD, 1991, J CELL SCI, V98, P577; Walczak CE, 1996, CELL, V84, P37, DOI 10.1016/S0092-8674(00)80991-5; Wang XM, 1996, J CELL BIOL, V132, P345, DOI 10.1083/jcb.132.3.345; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; WATANABE A, 1993, J BIOL CHEM, V268, P25712; White J, 1996, CELL, V84, P195, DOI 10.1016/S0092-8674(00)80974-5; WITKE W, 1992, CELL, V68, P53, DOI 10.1016/0092-8674(92)90205-Q	54	668	706	1	38	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 18	1997	89	2					297	308		10.1016/S0092-8674(00)80208-1	http://dx.doi.org/10.1016/S0092-8674(00)80208-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WU888	9108484	Bronze			2022-12-01	WOS:A1997WU88800016
J	Hickman, AB; Waninger, S; Scocca, JJ; Dyda, F				Hickman, AB; Waninger, S; Scocca, JJ; Dyda, F			Molecular organization in site-specific recombination: The catalytic domain of bacteriophage HP1 integrase at 2.7 angstrom resolution	CELL			English	Article							4-WAY DNA JUNCTION; CRYSTAL-STRUCTURE; ACTIVE-SITE; HEMOPHILUS-INFLUENZAE; FLP RECOMBINATION; PROTEIN; IDENTIFICATION; BINDING; CHROMOSOME; CLEAVAGE	HP1 integrase promotes site-specific recombination of the HP1 genome into that of Haemophilus influenzae. The isolated C-terminal domain (residues 165-337) of the protein interacts with the recombination site and contains the four catalytic residues conserved in the integrase family. This domain represents a novel fold consisting principally of well-packed cu helices, a surface beta sheet, and an ordered 17-residue C-terminal tail. The conserved triad of basic residues and the active-site tyrosine are contributed by a single monomer and occupy fixed positions in a defined active-site cleft. Dimers are formed by mutual interactions of the tail of one monomer with an adjacent monomer; this orients active-site clefts antiparallel to each other.	NIDDK, MOL BIOL LAB, NIH, BETHESDA, MD 20892 USA; JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT BIOCHEM, BALTIMORE, MD 21205 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Johns Hopkins University			Waninger, Shani/AAX-7617-2020		NCI NIH HHS [CA09110] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABREMSKI KE, 1992, PROTEIN ENG, V5, P87, DOI 10.1093/protein/5.1.87; ARGOS P, 1986, EMBO J, V5, P433, DOI 10.1002/j.1460-2075.1986.tb04229.x; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BLAKELY G, 1993, CELL, V75, P351, DOI 10.1016/0092-8674(93)80076-Q; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHEN JW, 1992, CELL, V69, P647, DOI 10.1016/0092-8674(92)90228-5; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; Craigie R., 1995, HIV, V2, P53; DEVARGAS LM, 1988, CELL, V54, P923, DOI 10.1016/0092-8674(88)90107-9; DUCKETT DR, 1990, EMBO J, V9, P583, DOI 10.1002/j.1460-2075.1990.tb08146.x; DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; ESPOSITO D, 1994, MOL MICROBIOL, V13, P685, DOI 10.1111/j.1365-2958.1994.tb00462.x; Esposito D, 1996, NUCLEIC ACIDS RES, V24, P2360, DOI 10.1093/nar/24.12.2360; EVANS BR, 1990, J BIOL CHEM, V265, P18504; FUREY W, 1997, IN PRESS METH ENZYMO; GOODMAN SD, 1989, J BACTERIOL, V171, P4232, DOI 10.1128/JB.171.8.4232-4240.1989; Hakimi JM, 1996, MOL MICROBIOL, V21, P147, DOI 10.1046/j.1365-2958.1996.6311351.x; HAKIMI JM, 1994, J BIOL CHEM, V269, P21340; HAKIMIASTUMIAN J, 1989, J BACTERIOL, V171, P1747; HAN YPW, 1993, EMBO J, V12, P4577, DOI 10.1002/j.1460-2075.1993.tb06146.x; HATFULL GF, 1989, GENETIC RECOMBINATIO, P357; HAUSER MA, 1992, J BIOL CHEM, V267, P6859; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HOLM L, 1994, NUCLEIC ACIDS RES, V22, P3600; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JAYARAM M, 1995, TRENDS GENET, V11, P432, DOI 10.1016/S0168-9525(00)89140-4; JAYARAM M, 1994, TRENDS BIOCHEM SCI, V19, P78, DOI 10.1016/0968-0004(94)90039-6; JOHNSON RC, 1995, DNA PROTEIN STRUCTUR, P141; JONES S, 1995, PROG BIOPHYS MOL BIO, V63, P31, DOI 10.1016/0079-6107(94)00008-W; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIM SH, 1990, CELL, V63, P773, DOI 10.1016/0092-8674(90)90143-3; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANDY A, 1993, CURR OPIN GENET DEV, V3, P699, DOI 10.1016/S0959-437X(05)80086-3; LANDY A, 1989, ANNU REV BIOCHEM, V58, P913, DOI 10.1146/annurev.biochem.58.1.913; LIMA CD, 1994, NATURE, V367, P138, DOI 10.1038/367138a0; Nash H, 1996, ESCHERICHIA COLI SAL, P2363; NICHOLIS A, 1991, GRASP MANUAL; NUNESDUBY SE, 1994, EMBO J, V13, P4421, DOI 10.1002/j.1460-2075.1994.tb06762.x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAN H, 1991, J BIOL CHEM, V266, P11347; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; RICE P, 1995, CELL, V82, P209, DOI 10.1016/0092-8674(95)90308-9; SADOWSKI P, 1986, J BACTERIOL, V165, P341, DOI 10.1128/jb.165.2.341-347.1986; SADOWSKI PD, 1993, FASEB J, V7, P760, DOI 10.1096/fasebj.7.9.8392474; SHERRATT DJ, 1995, PHILOS T ROY SOC B, V347, P37, DOI 10.1098/rstb.1995.0006; STARK WM, 1995, TRENDS GENET, V11, P121; Tronrud DE, 1996, J APPL CRYSTALLOGR, V29, P100, DOI 10.1107/S002188989501421X; VONKITZING E, 1990, NUCLEIC ACIDS RES, V18, P2671, DOI 10.1093/nar/18.9.2671; WALDMAN AS, 1987, J BACTERIOL, V169, P238, DOI 10.1128/jb.169.1.238-246.1987; WANG BC, 1985, METHOD ENZYMOL, V115, P90; YANG W, 1995, CELL, V82, P193, DOI 10.1016/0092-8674(95)90307-0	53	121	130	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 18	1997	89	2					227	237		10.1016/S0092-8674(00)80202-0	http://dx.doi.org/10.1016/S0092-8674(00)80202-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WU888	9108478	hybrid			2022-12-01	WOS:A1997WU88800010
J	Akimaru, H; Chen, Y; Dai, P; Hou, DX; Nonaka, M; Smolik, SM; Armstrong, S; Goodman, RH; Ishii, S				Akimaru, H; Chen, Y; Dai, P; Hou, DX; Nonaka, M; Smolik, SM; Armstrong, S; Goodman, RH; Ishii, S			Drosophila CBP is a co-activator of cubitus interruptus in hedgehog signalling	NATURE			English	Article							NUCLEAR-PROTEIN CBP; GENE; EXPRESSION; MUTATIONS; EMBRYOS; CREB	The transcription factor CBP, originally identified as a coactivator for CREB(1,2), enhances transcription mediated by many other transcription factors(3-7). Mutations in the human CBP gene are associated with Rubinstein-Taybi syndrome, a haploinsufficiency disorder characterized by abnormal pattern formations, but the mechanism by which decreased CBP levels affect pattern formation is unclear. The hedgehog (hh) signalling pathway is an important determinant of pattern formation. cubitus interruptus (ci), a component in hh signalling; encodes a transcription factor homologous to the Gli family of proteins(9) and is required for induction of the hh-dependent expression of patched (ptc), decapentaplegic (dpp) and wingless (wg)(10). Haploinsufficiency for the ci-related transcription factor Gli3 causes phenotypic changes in mice (known as 'extra-toes)(11) and humans (Greig's cephalopolysyndactyly syndrome)(12) that have similarities to Rubinstein-Taybi syndrome. Here we show that Drosophila CBP (dCBP) functions as a coactivator of Ci, suggesting that the dCBF-Ci interaction may shed light on the contribution of CBP to pattern formation in mammals.	INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,MOL GENET LAB,TSUKUBA,IBARAKI 305,JAPAN; OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT MOL & MED GENET,PORTLAND,OR 97201	RIKEN; Oregon Health & Science University; Oregon Health & Science University			Ishii, Shunsuke/A-5271-2016; Hou, De-Xing/C-9296-2011	Ishii, Shunsuke/0000-0002-6530-2478; 				Alexandre C, 1996, GENE DEV, V10, P2003, DOI 10.1101/gad.10.16.2003; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; BLAIR SS, 1995, NATURE, V373, P656, DOI 10.1038/373656a0; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; Dominguez M, 1996, SCIENCE, V272, P1621, DOI 10.1126/science.272.5268.1621; HAMA C, 1990, GENE DEV, V4, P1079, DOI 10.1101/gad.4.7.1079; HUI CC, 1993, NAT GENET, V3, P241, DOI 10.1038/ng0393-241; Johnson RL, 1995, DEVELOPMENT, V121, P4161; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KRASNOW MA, 1989, CELL, V57, P1031, DOI 10.1016/0092-8674(89)90341-3; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LOCKE J, 1994, MOL GEN GENET, V243, P234, DOI 10.1007/BF00280321; ORENIC TV, 1990, GENE DEV, V4, P1053, DOI 10.1101/gad.4.6.1053; PETRIJ F, 1996, NATURE, V376, P344; SCHUSKE K, 1994, DEV BIOL, V164, P300, DOI 10.1006/dbio.1994.1200; SLUSARSKI DC, 1995, GENETICS, V139, P229; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; VORTKAMP A, 1991, NATURE, V352, P539, DOI 10.1038/352539a0; XU T, 1993, DEVELOPMENT, V117, P1223	25	238	247	1	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 17	1997	386	6626					735	738		10.1038/386735a0	http://dx.doi.org/10.1038/386735a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WU387	9109493				2022-12-01	WOS:A1997WU38700061
J	Toscani, A; Mettus, RV; Coupland, R; Simpkins, H; Litvin, J; Orth, J; Hatton, KS; Reddy, EP				Toscani, A; Mettus, RV; Coupland, R; Simpkins, H; Litvin, J; Orth, J; Hatton, KS; Reddy, EP			Arrest of spermatogenesis and defective breast development in mice lacking A-myb	NATURE			English	Article							CULTURED-CELLS; MOUSE GENES; EXPRESSION; TESTIS; TISSUE; PROTEIN	The Myb gene family currently consists of three members, named A-, B- and c-myb(1,2). These genes encode nuclear proteins that bind DNA in a sequence-specific manner and function as regulators of transcription. In adult male mice, A-myb is expressed predominantly in male germ cells(2,3). In female mice, A-myb is expressed in breast ductal epithelium, mainly during pregnancy-induced ductal branching and alveolar development. We report here that mice homozygous for a germline mutation in A-myb develop to term but show defects in growth after birth and male infertility due to a block in spermatogenesis. Morphological examination of the testes of A-myb(-/-) males revealed that the germ cells enter meiotic prophase and arrest at pachytene. In adult homozygous null A-myb female mice, the breast epithelial compartment showed underdevelopment of breast tissue following pregnancy and the female mice were unable to nurse their newborn pups, These results demonstrate that A-myb plays a critical role in spermatogenesis and mammary gland development.	TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOL BIOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,DEPT PATHOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,DEPT ANAT & CELL BIOL,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University			Reddy, E. Premkumar/F-6233-2011					AMANN RP, 1976, BIOL REPROD, V15, P586, DOI 10.1095/biolreprod15.5.586; BABA T, 1994, J BIOL CHEM, V269, P10133; Blendy JA, 1996, NATURE, V380, P162, DOI 10.1038/380162a0; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; COHEN DR, 1993, ONCOGENE, V8, P443; Dix DJ, 1996, DEV BIOL, V174, P310, DOI 10.1006/dbio.1996.0076; Dix DJ, 1996, P NATL ACAD SCI USA, V93, P3264, DOI 10.1073/pnas.93.8.3264; GOTO M, 1990, EXP CELL RES, V186, P273, DOI 10.1016/0014-4827(90)90306-U; HOWLETT AR, 1993, EPITHELIAL CELL BIOL, V2, P79; ITO E, 1993, NATURE, V362, P466, DOI 10.1038/362466a0; KANEKO Y, 1995, ONCOGENE, V10, P945; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; METTUS RV, 1994, ONCOGENE, V9, P3077; MORI C, 1995, ANAT REC, V242, P103, DOI 10.1002/ar.1092420114; Nantel F, 1996, NATURE, V380, P159, DOI 10.1038/380159a0; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; PROPST F, 1988, ONCOGENE, V2, P227; ROSAI J, 1989, ACKERMANS SURG PATHO, P949; RUBIN MR, 1986, SCIENCE, V233, P663, DOI 10.1126/science.3726554; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; SORRENTINO V, 1991, ONCOGENE, V6, P149; SUN ZM, 1995, MOL CELL BIOL, V15, P561, DOI 10.1128/MCB.15.1.561; TRAUTH K, 1994, EMBO J, V13, P5994, DOI 10.1002/j.1460-2075.1994.tb06945.x; WANG SQ, 1990, ENDOCRINOLOGY, V127, P2183, DOI 10.1210/endo-127-5-2183; WOLFES H, 1989, SCIENCE, V245, P740, DOI 10.1126/science.2475907; WOLGEMUTH DJ, 1991, MAMM GENOME, V1, P283, DOI 10.1007/BF00352340; WONG TW, 1973, ARCH PATHOL, V95, P151	28	185	191	4	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 17	1997	386	6626					713	717		10.1038/386713a0	http://dx.doi.org/10.1038/386713a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WU387	9109487				2022-12-01	WOS:A1997WU38700055
J	Gurwitz, JH; McLaughlin, TJ; Willison, DJ; Guadagnoli, E; Hauptman, PJ; Gao, XM; Soumerai, SB				Gurwitz, JH; McLaughlin, TJ; Willison, DJ; Guadagnoli, E; Hauptman, PJ; Gao, XM; Soumerai, SB			Delayed hospital presentation in patients who have had acute myocardial infarction	ANNALS OF INTERNAL MEDICINE			English	Article						myocardial infarction; patient education; age factors; sex factors; emergency medical services	WORCESTER-HEART-ATTACK; THROMBOLYTIC THERAPY; TIME DELAYS; MORTALITY; ARRIVAL; DISEASE; TRENDS; AGE; POPULATION; OUTCOMES	Background: In patients who have had acute myocardial infarction, the delay between the onset of symptoms and hospital presentation is a critical factor in determining the initial management strategy and outcomes of treatment. Objective: To examine the determinants of delayed hospital presentation in patients who have had acute myocardial infarction. Design: Retrospective chart review. Setting: 37 hospitals in Minnesota. Patients: 2409 persons hospitalized with acute myocardial infarction between October 1992 and July 1993. Main Outcome Measure: Hospital presentation delayed more than 6 hours after the onset of symptoms of acute myocardial infarction. Results: Information on length of delay was available for 2404 patients. Of these patients, 969 (40%) delayed presentation to the hospital for more than 6 hours after the onset of symptoms. Factors associated with prolonged delay included advanced age and female sex. The presence of chest discomfort and a history of mechanical revascularization significantly reduced the risk for prolonged delay. Risk for delay was greatest during the evening and early morning hours (6:00 p.m. to 6:00 a.m.) Patients with a history of hypertension were more likely to delay presentation. Only 42% of all patients hospitalized with acute myocardial infarction had used emergency medical transport services. Conclusions: Patients who have had acute myocardial infarction often delay hospital presentation. Educational interventions that encourage the prompt use of emergency medical transport services and target specific patient populations, such as elderly persons, women, and persons with ca rd iac risk factors, may be most successful in reducing the length of delay and improving the outcomes of patients with acute myocardial infarction.	HARVARD UNIV, SCH MED, HARVARD PILGRIM HLTH CARE, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; MCMASTER UNIV, HLTH SCI CTR, HAMILTON, ON L8N 3Z5, CANADA	Harvard Pilgrim Health Care; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba	Gurwitz, JH (corresponding author), UNIV MASSACHUSETTS, MED CTR & FALLON HEALTHCARE SYST, MEYERS PRIMARY CARE INST, 100 CENT ST, WORCESTER, MA 01608 USA.				AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R18HS007357] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K08AG000510] Funding Source: NIH RePORTER; AHRQ HHS [HSO 7357-03] Funding Source: Medline; NIA NIH HHS [KO8 AG00510] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; BIRKHEAD JS, 1992, BMJ-BRIT MED J, V305, P445, DOI 10.1136/bmj.305.6851.445; BLEEKER JK, 1995, BRIT J GEN PRACT, V45, P181; DRACUP K, 1995, SOC SCI MED, V40, P379, DOI 10.1016/0277-9536(94)00278-2; FRANZOSI MG, 1995, ARCH INTERN MED, V155, P1481, DOI 10.1001/archinte.1995.00430140035003; GOLDBERG RJ, 1992, AM J CARDIOL, V70, P421, DOI 10.1016/0002-9149(92)91183-5; GREENFIELD S, 1993, MED CARE, V31, P141, DOI 10.1097/00005650-199302000-00005; GREENFIELD S, 1994, AM J KIDNEY DIS, V24, P298, DOI 10.1016/S0272-6386(12)80195-8; Gurwitz JH, 1996, ANN INTERN MED, V124, P283, DOI 10.7326/0003-4819-124-3-199602010-00001; GURWITZ JH, 1992, JAMA-J AM MED ASSOC, V268, P1417, DOI 10.1001/jama.268.11.1417; GURWITZ JH, 1994, ARCH INTERN MED, V154, P2202; HACKETT TP, 1969, AM J CARDIOL, V24, P651, DOI 10.1016/0002-9149(69)90452-4; HUNGERBUHLER P, 1992, SCHWEIZ MED WSCHR, V122, P1919; Johnson J A, 1995, Am J Crit Care, V4, P29; KANNEL WB, 1984, NEW ENGL J MED, V311, P1144, DOI 10.1056/NEJM198411013111802; KATHLEEN E, 1994, AM J PUBLIC HEALTH, V84, P965, DOI 10.2105/AJPH.84.6.965; KEREIAKES DJ, 1990, AM HEART J, V120, P773, DOI 10.1016/0002-8703(90)90192-Z; MAGGIONI AP, 1993, NEW ENGL J MED, V329, P1442, DOI 10.1056/NEJM199311113292002; MAYNARD C, 1989, AM J CARDIOL, V63, P1296, DOI 10.1016/0002-9149(89)91038-2; MAYNARD C, 1995, AM J CARDIOL, V76, P548, DOI 10.1016/S0002-9149(99)80152-0; McLaughlin TJ, 1996, ARCH INTERN MED, V156, P799, DOI 10.1001/archinte.156.7.799; MEDALIE JH, 1976, ANN INTERN MED, V84, P526, DOI 10.7326/0003-4819-84-5-526; MEISCHKE H, 1995, ANN EMERG MED, V25, P193, DOI 10.1016/S0196-0644(95)70323-3; MEISCHKE H, 1993, ANN EMERG MED, V22, P1597, DOI 10.1016/S0196-0644(05)81267-3; *NAT HEART ATT COO, 1993, NIH PUBL; Newby LK, 1996, J AM COLL CARDIOL, V27, P1646; OLIN HS, 1964, JAMA-J AM MED ASSOC, V190, P977; RAWLES JM, 1988, BRIT MED J, V296, P882, DOI 10.1136/bmj.296.6626.882; ROWLEY JM, 1992, BRIT HEART J, V67, P255; *SAS I, 1989, SAS STAT US GUID VER; SCHMIDT SB, 1990, AM J CARDIOL, V65, P1411, DOI 10.1016/0002-9149(90)91345-7; SIGURDSSON E, 1995, ANN INTERN MED, V122, P96, DOI 10.7326/0003-4819-122-2-199501150-00003; TURI ZG, 1986, AM J CARDIOL, V58, P203, DOI 10.1016/0002-9149(86)90047-0; UDVARHELYI IS, 1992, JAMA-J AM MED ASSOC, V268, P2530, DOI 10.1001/jama.268.18.2530; WEAVER WD, 1991, J AM COLL CARDIOL, V18, P657, DOI 10.1016/0735-1097(91)90784-7; WEAVER WD, 1995, J AM COLL CARDIOL, V25, pS3; WENGER NK, 1993, NEW ENGL J MED, V329, P247, DOI 10.1056/NEJM199307223290406; YARZEBSKI J, 1994, AM HEART J, V128, P255, DOI 10.1016/0002-8703(94)90477-4	38	134	136	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1997	126	8					593	+		10.7326/0003-4819-126-8-199704150-00001	http://dx.doi.org/10.7326/0003-4819-126-8-199704150-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WT580	9103125				2022-12-01	WOS:A1997WT58000004
J	Doebley, J; Stec, A; Hubbard, L				Doebley, J; Stec, A; Hubbard, L			The evolution of apical dominance in maize	NATURE			English	Article							TEOSINTE	The domestication of crop plants has often involved an increase in apical dominance (the concentration of resources in the main stem of the plant and a corresponding suppression of axillary branches)(1). A striking example of this phenomenon is seen in maize (Zea mays spp. mays), which exhibits a profound increase in apical dominance compared with its probable wild ancestor, teosinte (Zea mays ssp. parviglumis)(2). Previous research has identified the teosinte branched1 (tb1) gene as a major contributor to this evolutionary change in maize(3). We have cloned tb1 by transposon tagging and show here that it encodes a protein with homology to the cycloidea gene of snapdragon(4). The pattern of tb1 expression and the morphology of tb1 mutant plants suggest that tb1 acts both to repress the growth of axillary organs and to enable the formation of female inflorescences. The maize allele of tb1 is expressed at twice the level of the teosinte allele, suggesting that gene regulatory changes underlie the evolutionary divergence of maize from teosinte.	UNIV CALIF BERKELEY,USDA,CTR PLANT GENE EXPRESS,ALBANY,CA 94710; UNIV CALIF BERKELEY,DEPT PLANT BIOL,BERKELEY,CA 94720	United States Department of Agriculture (USDA); University of California System; University of California Berkeley; University of California System; University of California Berkeley	Doebley, J (corresponding author), UNIV MINNESOTA,DEPT PLANT BIOL,ST PAUL,MN 55108, USA.							BRIGGS S, 1993, MAIZE HDB, P653; Burnham C., 1959, MAIZE GENET COOP NEW, V33, P74; CHANDLER VL, 1992, ADV GENET, V30, P77, DOI 10.1016/S0065-2660(08)60319-3; CHRISTENSEN AH, 1989, PLANT MOL BIOL, V12, P619, DOI 10.1007/BF00044153; COEN ES, 1991, NATURE, V353, P31, DOI 10.1038/353031a0; DOEBLEY J, 1993, GENETICS, V134, P559; DOEBLEY J, 1995, GENETICS, V141, P333; Harlan JR., 1992, CROPS MAN; ILTIS HH, 1983, SCIENCE, V222, P886, DOI 10.1126/science.222.4626.886; Luo D, 1996, NATURE, V383, P794, DOI 10.1038/383794a0; PATERSON AH, 1995, SCIENCE, V269, P1714, DOI 10.1126/science.269.5231.1714; Sambrook J., 1989, MOL CLONING LAB MANU; SCHNABLE P, 1992, MAIZE GENET COOP NEW, V66, P5; WOODMAN JC, 1985, PLANT GENETICS, P834	14	1005	1131	9	266	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 3	1997	386	6624					485	488		10.1038/386485a0	http://dx.doi.org/10.1038/386485a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WR256	9087405				2022-12-01	WOS:A1997WR25600049
J	Colloms, SD; Bath, J; Sherratt, DJ				Colloms, SD; Bath, J; Sherratt, DJ			Topological selectivity in Xer site-specific recombination	CELL			English	Article							TN3 RESOLVASE; BACTERIOPHAGE-LAMBDA; STRAND EXCHANGE; MECHANISM; PLASMID; CATENATION; PROTEIN; FLP; CER; RESOLUTION	The product topology of Xer-mediated site-specific recombination at plasmid sites has been determined. The product of deletion at pSC101 psi is a right-handed antiparallel 4-noded catenane. The ColE1 cer deletion product has an identical topology, except that only one pair of strands is exchanged. These specific product topologies imply that the productive synaptic complex and the strand exchange mechanism have fixed topologies. Further analysis suggests that synapsis traps exactly three negative supercoils between recombining sites, and that strand exchange introduces a further negative topological node in the deletion reaction. We present a model in which the requirement for a specific synaptic stucture, with two recombination sites interwrapped around the accessory proteins ArgR and PepA, ensures that recombination only occurs efficiently between directly repeated sites on the same DNA molecule.			Colloms, SD (corresponding author), UNIV OXFORD,DEPT BIOCHEM,MICROBIOL UNIT,S PK RD,OXFORD OX1 3QU,ENGLAND.		Bath, Jonathan/E-9569-2011	Bath, Jonathan/0000-0002-7144-662X; Colloms, Sean/0000-0003-2369-8168	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABREMSKI K, 1986, J MOL BIOL, V192, P17, DOI 10.1016/0022-2836(86)90460-2; ABREMSKI K, 1985, J MOL BIOL, V184, P211, DOI 10.1016/0022-2836(85)90374-2; BEATTY LG, 1986, J MOL BIOL, V188, P529, DOI 10.1016/S0022-2836(86)80003-1; BENJAMIN HW, 1990, J BIOL CHEM, V265, P6441; Benjamin KR, 1996, J MOL BIOL, V256, P50, DOI 10.1006/jmbi.1996.0067; BLAKELY G, 1993, CELL, V75, P351, DOI 10.1016/0092-8674(93)80076-Q; BLISKA JB, 1987, J MOL BIOL, V194, P205, DOI 10.1016/0022-2836(87)90369-X; CHARLIER D, 1995, J MOL BIOL, V250, P392, DOI 10.1006/jmbi.1995.0385; Colloms SD, 1996, EMBO J, V15, P1172, DOI 10.1002/j.1460-2075.1996.tb00456.x; CRAIGIE R, 1986, CELL, V45, P793, DOI 10.1016/0092-8674(86)90554-4; DROGE P, 1989, P NATL ACAD SCI USA, V86, P6062, DOI 10.1073/pnas.86.16.6062; DROGE P, 1992, METHOD ENZYMOL, V212, P120; GIANSDORFF N, 1987, SALMONELLA TYPHIMURI, P321; GRONOSTAJSKI RM, 1985, J BIOL CHEM, V260, P2328; Hatfull GF, 1988, GENETIC RECOMBINATIO, P357; Johnson RC, 1991, CURR OPIN GENET DEV, V1, P404, DOI 10.1016/S0959-437X(05)80307-7; KANAAR R, 1990, CELL, V62, P353, DOI 10.1016/0092-8674(90)90372-L; KANAAR R, 1989, CELL, V58, P147, DOI 10.1016/0092-8674(89)90411-X; KANAAR R, 1988, P NATL ACAD SCI USA, V85, P752, DOI 10.1073/pnas.85.3.752; KOSAK HG, 1990, EUR J BIOCHEM, V194, P779, DOI 10.1111/j.1432-1033.1990.tb19469.x; LANDY A, 1993, CURR OPIN GENET DEV, V3, P699, DOI 10.1016/S0959-437X(05)80086-3; LANDY A, 1989, ANNU REV BIOCHEM, V58, P913, DOI 10.1146/annurev.biochem.58.1.913; MIZUUCHI K, 1980, J MOL BIOL, V141, P485, DOI 10.1016/0022-2836(80)90256-9; NUNESDUBY SE, 1995, CURR BIOL, V5, P139, DOI 10.1016/S0960-9822(95)00035-2; PENG H, 1993, J BIOL CHEM, V268, P24481; POLLOCK TJ, 1983, J MOL BIOL, V170, P1, DOI 10.1016/S0022-2836(83)80224-1; SADOWSKI P, 1986, J BACTERIOL, V165, P341, DOI 10.1128/jb.165.2.341-347.1986; STARK WM, 1989, TRENDS GENET, V5, P304, DOI 10.1016/0168-9525(89)90113-3; STARK WM, 1989, CELL, V58, P779, DOI 10.1016/0092-8674(89)90111-6; STARK WM, 1992, TRENDS GENET, V8, P432, DOI 10.1016/0168-9525(92)90176-5; STARK WM, 1995, MOBILE GENETIC ELEME, P101; Stasiak A, 1996, NATURE, V384, P122, DOI 10.1038/384122a0; STIRLING CJ, 1989, EMBO J, V8, P1623, DOI 10.1002/j.1460-2075.1989.tb03547.x; STIRLING CJ, 1988, EMBO J, V7, P4389, DOI 10.1002/j.1460-2075.1988.tb03338.x; SUMMERS DK, 1988, EMBO J, V7, P851, DOI 10.1002/j.1460-2075.1988.tb02884.x; TAYLOR A, 1993, TRENDS BIOCHEM SCI, V18, P167; THOMPSON JF, 1989, MOBILE DNA, P1; VOLOGODSKII AV, 1993, J MOL BIOL, V232, P1130, DOI 10.1006/jmbi.1993.1465; WASSERMAN SA, 1985, SCIENCE, V229, P171, DOI 10.1126/science.2990045; WASSERMAN SA, 1988, NATURE, V334, P448, DOI 10.1038/334448a0; WASSERMAN SA, 1985, P NATL ACAD SCI USA, V82, P1079, DOI 10.1073/pnas.82.4.1079; Watson MA, 1996, CELL, V85, P435, DOI 10.1016/S0092-8674(00)81121-6	42	86	87	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 21	1997	88	6					855	864		10.1016/S0092-8674(00)81931-5	http://dx.doi.org/10.1016/S0092-8674(00)81931-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WQ100	9118228	Bronze			2022-12-01	WOS:A1997WQ10000017
J	Schimmel, MS; Eidelman, AI; Zadka, P; Kornbluth, E; Hammerman, C				Schimmel, MS; Eidelman, AI; Zadka, P; Kornbluth, E; Hammerman, C			Increased parity and risk of trisomy 21: Review of 37110 live births	BRITISH MEDICAL JOURNAL			English	Article; Proceedings Paper	63rd Annual Meeting of the Society-for-Pediatric-Research	MAY 02-05, 1994	SEATTLE, WA	Soc Pediat Res			AGE	Routine amniocentesis for all women over the age of 35 for detecting trisomy 21 has been the world standard for nearly two decades. It is based on a calculated tradeoff: the documented increased risk of trisomy 21 with advancing age versus the risk of fetal loss secondary to the amniocentesis procedure. Recent data suggest that more specific individual estimates of risk can be made with a combination of maternal age and serum markers.(1) We have reported a trend towards an increased risk of trisomy 21 with increased parity.(2) Given the uniqueness of our population-ultra-Orthodox Jewish mothers who have a high rate of delivery over the age of 35, high parity, and who abstain from prenatal screening and abortion-we had an opportunity to study the interrelation of age and parity.	SHAARE ZEDEK MED CTR,DEPT NEONATOL,IL-91031 JERUSALEM,ISRAEL; ISRAEL CENT BUR STAT,HLTH DIV,JERUSALEM,ISRAEL	Hebrew University of Jerusalem; Shaare Zedek Medical Center								EIDELMAN AI, 1988, AM J OBSTET GYNECOL, V158, P389, DOI 10.1016/0002-9378(88)90161-5; Fleiss JL, 1981, STATISTICAL METHODS, P75; HADDOW JE, 1994, NEW ENGL J MED, V330, P1114, DOI 10.1056/NEJM199404213301603; HADDOW JE, 1994, LANCET, V344, P956, DOI 10.1016/S0140-6736(94)92308-6; PHILLIPS OP, 1992, OBSTET GYNECOL, V80, P353	5	23	24	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 8	1997	314	7082					720	721		10.1136/bmj.314.7082.720	http://dx.doi.org/10.1136/bmj.314.7082.720			2	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM776	9116549	Green Published			2022-12-01	WOS:A1997WM77600024
J	Fan, H; Sakulich, AL; Goodier, JL; Zhang, XL; Qin, J; Maraia, RJ				Fan, H; Sakulich, AL; Goodier, JL; Zhang, XL; Qin, J; Maraia, RJ			Phosphorylation of the human La antigen on serine 366 can regulate recycling of RNA polymerase III transcription complexes	CELL			English	Article							CASEIN KINASE-II; BINDING-PROTEIN; SACCHAROMYCES-CEREVISIAE; EXPRESSION; INVITRO; TFIIIB; GENES; AUTOANTIGEN; TERMINATION; INITIATION	The human La antigen is an RNA-binding protein that facilitates transcriptional termination and reinitiation by RNA polymerase III. Native La protein fractionates into transcriptionally active and inactive forms that are unphosphorylated and phosphorylated at serine 366, respectively, as determined by enzymatic and mass spectrometric analyses. Serine 366 comprises a casein kinase II phosphorylation site that resides within a conserved region in the La proteins from several species. RNA synthesis from isolated transcription complexes is inhibited by casein kinase Ii-mediated phosphorylation of La serine 366 and is reversible by dephosphorylation. This work demonstrates a novel mechanism of transcriptional control at the level of recycling of stable transcription complexes.	NHLBI,BIOPHYS CHEM LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Fan, H (corresponding author), NICHHD,LAB MOL GROWTH REGULAT,NIH,BETHESDA,MD 20892, USA.		Maraia, Richard/ABC-1442-2020	Maraia, Richard/0000-0002-5209-0066				ALLISON DS, 1985, EMBO J, V4, P2657, DOI 10.1002/j.1460-2075.1985.tb03984.x; Bairoch A, 1996, NUCLEIC ACIDS RES, V24, P189, DOI 10.1093/nar/24.1.189; BARSH GS, 1981, P NATL ACAD SCI-BIOL, V78, P5142, DOI 10.1073/pnas.78.8.5142; BEEMON K, 1978, J VIROL, V28, P551, DOI 10.1128/JVI.28.2.551-566.1978; BOGENHAGEN DF, 1982, CELL, V28, P413, DOI 10.1016/0092-8674(82)90359-2; CHAIT BT, 1992, SCIENCE, V257, P1885, DOI 10.1126/science.1411504; CHANG YN, 1994, J VIROL, V68, P7008, DOI 10.1128/JVI.68.11.7008-7020.1994; CHU WM, 1995, NUCLEIC ACIDS RES, V23, P1750, DOI 10.1093/nar/23.10.1750; DEAN N, 1988, MOL CELL BIOL, V8, P3017, DOI 10.1128/MCB.8.8.3017; Dieci G, 1996, CELL, V84, P245, DOI 10.1016/S0092-8674(00)80979-4; DIECI G, 1993, J BIOL CHEM, V268, P11199; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.bi.56.070187.003031; FRANCOEUR AM, 1985, MOL CELL BIOL, V5, P586, DOI 10.1128/MCB.5.3.586; GOTTESFELD JM, 1994, SCIENCE, V263, P81, DOI 10.1126/science.8272869; GOTTLIEB E, 1989, EMBO J, V8, P851, DOI 10.1002/j.1460-2075.1989.tb03446.x; GOTTLIEB EL, 1989, EMBO J, V8, P841, DOI 10.1002/j.1460-2075.1989.tb03445.x; Hockman DJ, 1996, MOL CELL BIOL, V16, P892; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KASSAVETIS GA, 1995, P NATL ACAD SCI USA, V92, P9786, DOI 10.1073/pnas.92.21.9786; KENAN DJ, 1995, THESIS DUKE U RALEIG; KOVELMAN R, 1990, GENE DEV, V4, P646, DOI 10.1101/gad.4.4.646; KUENZEL EA, 1985, P NATL ACAD SCI USA, V82, P737, DOI 10.1073/pnas.82.3.737; LASSAR AB, 1983, SCIENCE, V222, P740, DOI 10.1126/science.6356356; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; MARAIA RJ, 1994, MOL CELL BIOL, V14, P2147, DOI 10.1128/MCB.14.3.2147; Maraia RJ, 1996, P NATL ACAD SCI USA, V93, P3383, DOI 10.1073/pnas.93.8.3383; MAURIDES PA, 1989, ANAL BIOCHEM, V183, P144, DOI 10.1016/0003-2697(89)90182-6; McBryant SJ, 1996, MOL CELL BIOL, V16, P4639; PFEIFLE J, 1987, BIOCHIM BIOPHYS ACTA, V928, P217, DOI 10.1016/0167-4889(87)90124-8; PIZER LI, 1983, MOL CELL BIOL, V3, P1235, DOI 10.1128/MCB.3.7.1235; SKLAR VEF, 1976, J BIOL CHEM, V251, P1064; SRUTH J, 1996, EMBO J, V15, P1941; STEFANO JE, 1984, CELL, V36, P145, DOI 10.1016/0092-8674(84)90083-7; VOIT R, 1992, EMBO J, V11, P2211, DOI 10.1002/j.1460-2075.1992.tb05280.x; WANG ZX, 1995, P NATL ACAD SCI USA, V92, P7026, DOI 10.1073/pnas.92.15.7026; Wang ZX, 1996, MOL CELL BIOL, V16, P6841; WHITE RJ, 1995, MOL CELL BIOL, V15, P1983; WILLIS IM, 1993, EUR J BIOCHEM, V212, P1, DOI 10.1111/j.1432-1033.1993.tb17626.x; YOO CJ, 1994, MOL CELL BIOL, V14, P5412, DOI 10.1128/MCB.14.8.5412; YOSHINAGA SK, 1987, P NATL ACAD SCI USA, V84, P3585, DOI 10.1073/pnas.84.11.3585	40	97	98	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 7	1997	88	5					707	715		10.1016/S0092-8674(00)81913-3	http://dx.doi.org/10.1016/S0092-8674(00)81913-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WM413	9054510	Bronze			2022-12-01	WOS:A1997WM41300016
J	Gabriel, SE; Woods, JE; OFallon, M; Beard, CM; Kurland, LT; Melton, LJ				Gabriel, SE; Woods, JE; OFallon, M; Beard, CM; Kurland, LT; Melton, LJ			Complications leading to surgery after breast implantation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONNECTIVE-TISSUE DISEASES; AUGMENTATION MAMMAPLASTY; CLINICAL-EXPERIENCE; RECONSTRUCTION; CANCER; RISK	Background Local complications that require additional surgical procedures are an important problem for women with breast implants. Methods We studied 749 women who lived in Olmsted County, Minnesota, and received a first breast implant at the Mayo Clinic between 1964 and 1991. We identified complications that occurred after the initial procedure and after any subsequent implantation. A complication was defined as a surgical procedure performed for any of the following reasons: capsular contracture; rupture of the implant; hematoma or bleeding; infection or seroma of the wound; chronic pain; extrusion, leakage, or sweating of the implant; necrosis of the nipple, areola, or flap; malfunction of the filler port of a tissue expander; and wound dehiscence. Results During follow-up (mean, 7.8 years; range, 0 to 25.8), 208 (27.8 percent) of the women underwent 450 additional implant-related surgical procedures. Ninety-one (20.2 percent) were anticipated, staged procedures or were done because the patient requested a size change or aesthetic improvement, and 359 procedures (79.8 percent) had at least one clinical indication (thus constituting a complication). Complications occurred in 178 (23.8 percent) of the 749 women and involved 274 (18.8 percent) of the 1454 breasts with implants and 321 (18.8 percent) of the 1703 implants. The most frequent problem was capsular contraction (131 women), followed by implant rupture (43 [5.7 percent]), hematoma (43), and wound infection (19). The rate of complications was significantly lower (P<0.001) among women with cosmetic implants (6.5 percent at one year, 12 percent at five years) than among those who received implants after mastectomy for breast cancer (21.8 percent at one year, 34 percent at five years) or prophylactic mastectomy (17.3 percent at one year, 30.4 percent at five years). Conclusions Women who have had breast implantation frequently experience local complications during the subsequent five years. Complications were significantly less frequent among patients who received implants for cosmetic reasons than among those who received implants after mastectomy for cancer or for cancer prophylaxis. (C) 1997, Massachusetts Medical Society.	MAYO CLIN & MAYO FDN,DIV RHEUMATOL & INTERNAL MED,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DIV PLAST SURG,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic	Gabriel, SE (corresponding author), MAYO CLIN & MAYO FDN,DEPT HLTH SCI RES,200 1ST ST SW,ROCHESTER,MN 55905, USA.				NIAMS NIH HHS [AR30582] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030582] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Baker JL, 1979, PLASTIC SURGERY, P719; Baker JL, 1978, P S ED FDN AM SOC PL, P256; BURNS CG, 1994, THESIS U MICHIGAN; DEAPEN DM, 1986, PLAST RECONSTR SURG, V77, P361, DOI 10.1097/00006534-198603000-00001; DECAMARA DL, 1993, PLAST RECONSTR SURG, V91, P828, DOI 10.1097/00006534-199304001-00012; DUFFY MJ, 1994, PLAST RECONSTR SURG, V94, P295, DOI 10.1097/00006534-199408000-00012; ENGLERT HJ, 1994, AUST NZ J MED, V24, P74, DOI 10.1111/j.1445-5994.1994.tb04439.x; GABRIEL SE, 1995, J CLIN EPIDEMIOL, V48, P527, DOI 10.1016/0895-4356(94)00209-9; GABRIEL SE, 1994, NEW ENGL J MED, V330, P1697, DOI 10.1056/NEJM199406163302401; GABRIEL SE, 1993, ARTHRITIS RHEUM, V36, pS70; Hagerty R C, 1990, J S C Med Assoc, V86, P545; Hochberg M. C., 1994, Arthritis and Rheumatism, V37, pS369; HOLLEY DT, 1995, AM SURGEON, V61, P60; KROLL SS, 1989, PLAST RECONSTR SURG, V84, P886, DOI 10.1097/00006534-198912000-00003; LeRoy E C, 1990, J S C Med Assoc, V86, P556; LIN DY, 1989, J AM STAT ASSOC, V84, P1074, DOI 10.2307/2290085; MAY DS, 1991, PLAST RECONSTR SURG, V87, P193, DOI 10.1097/00006534-199101000-00045; MCGRATH MH, 1984, PLAST RECONSTR SURG, V74, P550, DOI 10.1097/00006534-198410000-00019; MELTON LJ, 1996, MAYO CLIN P, V71, P1266; OBRIEN W, 1993, AM J SURG, V166, P1, DOI 10.1016/S0002-9610(05)80572-0; PETERS W, 1994, ANN PLAS SURG, V32, P449, DOI 10.1097/00000637-199405000-00001; PICKERING PP, 1978, S AESTH SURG BREAST, P293; ROBINSON OG, 1995, ANN PLAS SURG, V34, P1, DOI 10.1097/00000637-199501000-00001; ROSEN PB, 1990, ANN PLAS SURG, V25, P249, DOI 10.1097/00000637-199010000-00002; SANCHEZGUERRERO J, 1995, NEW ENGL J MED, V332, P1666, DOI 10.1056/NEJM199506223322502; STROM BL, 1994, J CLIN EPIDEMIOL, V47, P1211, DOI 10.1016/0895-4356(94)90109-0; THERNEAU TM, 1996, TECHNICAL REPORT SER, V58; TRUPPMAN ES, 1978, S AESTHETIC SURGERY, P344; WEI LJ, 1989, J AM STAT ASSOC, V84, P1065, DOI 10.2307/2290084; WORSEG A, 1995, BR J PLAST SURG, V48, P153	30	304	311	1	20	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 6	1997	336	10					677	682		10.1056/NEJM199703063361001	http://dx.doi.org/10.1056/NEJM199703063361001			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WL419	9041097	Bronze			2022-12-01	WOS:A1997WL41900001
J	Brown, P				Brown, P			Muscle sounds in Parkinson's disease	LANCET			English	Article								Background A sound with a frequency of around 40 Hz can be heard, with a stethoscope, in the muscles of the hand and forearm during tonic contraction or movement. This sound is the acoustic correlate of the Piper rhythm seen in electromyographic records of muscle activity. The way in which motor activity is organised at the cortical level may determine the frequency of the sound heard. Methods The wrist extensor muscles in the forearm of seven patients with idiopathic Parkinson's disease, studied with and without antiparkinsonian treatment, and a control group of seven healthy men were auscultated during very strong extension of the wrist and during repeated slow flexion and extension of this joint. Findings In healthy people, the Piper-band sound made by muscle activity is 40-50 Hz. In all seven parkinsonian patients, when off medication, the normal Piper-band sound was replaced by a pulsatile muscle activity of 10 Hz during strong wrist extension, and in four patients during repeated flexion and extension of the wrist. After treatment. with dopaminergic drugs, the Piper mode of muscle discharge was restored and motor performance was improved. Interpretation The Piper mode of muscle discharge is dependent on the normal functioning of pallidal projections to the motor areas of the cortex. In abnormal function a muscle discharge of 10 Hz dominates, which is suboptimal when fast or powerful contractions are necessary.	UCL NATL HOSP NEUROL & NEUROSURG, LONDON WC1 3BG, ENGLAND	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust	Brown, P (corresponding author), INST NEUROL, MRC, HUMAN MOVEMENT & BALANCE UNIT, LONDON WC1 3BG, ENGLAND.		Brown, Peter/J-4307-2016	Brown, Peter/0000-0002-5201-3044				Brown P, 1996, BRAIN, V119, P1307, DOI 10.1093/brain/119.4.1307; Brown P, 1996, J PHYSIOL-LONDON, V494P, pP68; BROWN P, 1995, LANCET, V346, P306, DOI 10.1016/S0140-6736(95)92190-7; BROWN P, 1996, BRAIN, V11, P171; BROWN P, 1996, MOV DISORD S, V11, P171; Crick F, 1995, ASTONISHING HYPOTHES; FEX J, 1957, ACTA PSYCHIAT NEUROL, V33, P54; HAGBARTH KE, 1983, ACTA PHYSIOL SCAND, V117, P263, DOI 10.1111/j.1748-1716.1983.tb07205.x; HILL AV, 1921, J PHYSL, V55, pP14; LANCE JW, 1963, BRAIN, V86, P95, DOI 10.1093/brain/86.1.95; MARSDEN CD, 1970, J PHYSIOL-LONDON, V207, P429, DOI 10.1113/jphysiol.1970.sp009071; MERTON PA, 1981, J NEUROL NEUROSUR PS, V44, P861, DOI 10.1136/jnnp.44.10.861; Piper H.E., 1912, ELEKTROPHYSIOLOGIE M; Rutherford W, 1886, J Anat Physiol, V21, P166; STOKES MJ, 1992, J APPL PHYSIOL, V72, P1908, DOI 10.1152/jappl.1992.72.5.1908	15	38	39	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	FEB 22	1997	349	9051					533	535		10.1016/S0140-6736(97)80086-4	http://dx.doi.org/10.1016/S0140-6736(97)80086-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WJ512	9048791				2022-12-01	WOS:A1997WJ51200010
J	Rowe, PM				Rowe, PM			Changing the risky behaviour of politicians	LANCET			English	Editorial Material																		Coates TJ, 1996, LANCET, V348, P1143, DOI 10.1016/S0140-6736(96)02307-0	1	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 22	1997	349	9051					520	520		10.1016/S0140-6736(97)80082-7	http://dx.doi.org/10.1016/S0140-6736(97)80082-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WJ512	9048787				2022-12-01	WOS:A1997WJ51200006
J	Black, RA; Rauch, CT; Kozlosky, CJ; Peschon, JJ; Slack, JL; Wolfson, MF; Castner, BJ; Stocking, KL; Reddy, P; Srinivasan, S; Nelson, N; Boiani, N; Schooley, KA; Gerhart, M; Davis, R; Fitzner, JN; Johnson, RS; Paxton, RJ; March, CJ; Cerretti, DP				Black, RA; Rauch, CT; Kozlosky, CJ; Peschon, JJ; Slack, JL; Wolfson, MF; Castner, BJ; Stocking, KL; Reddy, P; Srinivasan, S; Nelson, N; Boiani, N; Schooley, KA; Gerhart, M; Davis, R; Fitzner, JN; Johnson, RS; Paxton, RJ; March, CJ; Cerretti, DP			A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells	NATURE			English	Article							MOLECULAR-CLONING; SURFACE; PROTEIN; INHIBITOR; PRECURSOR; RECEPTOR; FUSION; TNF	Mammalian cells proteolytically release (shed) the extracellular domains of many cell-surface proteins(1). Modification of the cell surface in this way can alter the cell's responsiveness to its environment(2) and release potent soluble regulatory factors'. The release of soluble tumour-necrosis factor-alpha (TNF-alpha) from its membrane-bound precursor(4,5) is one of the most intensively studied shedding events because this inflammatory cytokine is so physiologically important(6,7). The inhibition of TNF-alpha release (and many other shedding phenomena) by hydroxamic acid-based inhibitors indicates that one or more metalloproteinases is involved(3,8,9). We have now purified and cloned a metalloproteinase that specifically cleaves precursor TNF-alpha. Inactivation of the gene in mouse cells caused a marked decrease in soluble TNF-alpha production. This enzyme (called the TNF-alpha-converting enzyme, or TACE) is a new member of the family of mammalian adamalysins (or ADAMs)(10), for which no physiological catalytic function has previously been identified. Our results should facilitate the development of therapeutically useful inhibitors of TNF-alpha release, and they indicate that an important function of adamalysins may be to shed cell-surface proteins.			Black, RA (corresponding author), IMMUNEX RES & DEV CORP,51 UNIV ST,SEATTLE,WA 98101, USA.		Robles-Sardin, Alma E/M-7714-2015	Robles-Sardin, Alma E/0000-0003-2044-7793				BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; Bazzoni F, 1996, NEW ENGL J MED, V334, P1717, DOI 10.1056/NEJM199606273342607; Black RA, 1996, BIOCHEM BIOPH RES CO, V225, P400, DOI 10.1006/bbrc.1996.1186; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; DECKER T, 1987, J IMMUNOL, V138, P957; DEXTER TM, 1977, J CELL PHYSIOL, V91, P335, DOI 10.1002/jcp.1040910303; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; Howard L, 1996, BIOCHEM J, V317, P45, DOI 10.1042/bj3170045; Kratzschmar J, 1996, J BIOL CHEM, V271, P4593; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; LIBBY P, 1986, J CLIN INVEST, V77, P127, DOI 10.1172/JCI112266; MCGEEHAN GM, 1994, NATURE, V370, P558, DOI 10.1038/370558a0; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MEIER T, 1992, ANAL BIOCHEM, V204, P220, DOI 10.1016/0003-2697(92)90165-4; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; SHERRY B, 1988, J CELL BIOL, V107, P1269, DOI 10.1083/jcb.107.4.1269; Snell WJ, 1996, CELL, V85, P629, DOI 10.1016/S0092-8674(00)81230-1; STOCKER W, 1995, PROTEIN SCI, V4, P823; TEETER MM, 1993, J MOL BIOL, V230, P292, DOI 10.1006/jmbi.1993.1143; Walcheck B, 1996, NATURE, V380, P720, DOI 10.1038/380720a0; WARNER SJC, 1989, J IMMUNOL, V142, P100; Weskamp G, 1996, J CELL BIOL, V132, P717, DOI 10.1083/jcb.132.4.717; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; WOLFSBERG TG, 1993, P NATL ACAD SCI USA, V90, P10783, DOI 10.1073/pnas.90.22.10783; Wolfsberg TG, 1996, DEV BIOL, V180, P389, DOI 10.1006/dbio.1996.0313; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0; YOSHIDA S, 1990, INT IMMUNOL, V2, P585, DOI 10.1093/intimm/2.6.585	30	2546	2646	6	104	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 20	1997	385	6618					729	733		10.1038/385729a0	http://dx.doi.org/10.1038/385729a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WJ423	9034190				2022-12-01	WOS:A1997WJ42300048
J	Ronkainen, A; Hernesniemi, J; Puranen, M; Niemitukia, L; Vanninen, R; Ryynanen, M; Kuivaniemi, H; Tromp, G				Ronkainen, A; Hernesniemi, J; Puranen, M; Niemitukia, L; Vanninen, R; Ryynanen, M; Kuivaniemi, H; Tromp, G			Familial intracranial aneurysms	LANCET			English	Article							MAGNETIC-RESONANCE ANGIOGRAPHY; UNRUPTURED CEREBRAL ANEURYSMS; POLYCYSTIC KIDNEY-DISEASE; SUBARACHNOID HEMORRHAGE; CEREBROVASCULAR-DISEASE; UNKNOWN ETIOLOGY; NATURAL-HISTORY; SURGERY; RISK; IMPACT	Background We set out to determine the prevalence of incidental intracranial aneurysms in first-degree relatives aged 30 years or more of people with intracranial aneurysms, and to see if polycystic kidney disease contributes to the aggregation of familial intracranial aneurysms. Methods 91 families with two or more affected members had previously been identified from a 14 year series of 1150 intracranial aneurysm patients treated at the University Hospital of Kuopio, Finland. Magnetic resonance angiography was used as a preliminary screening method, followed by conventional four-vessel angiography to verify suspected aneurysms. Participants were also screened for polycystic kidneys by ultrasonography. Findings Incidental aneurysms were detected in 40 individuals: 38 of 438 individuals from 85 families without polycystic kidney disease or other diagnosed heritable disorders, and two of 22 individuals from six families known to have polycystic kidney disease. The crude and age-adjusted prevalence of incidental intracranial aneurysms among screened first-degree relatives was 8.7 (SE 1.3)% (95% CI 6.2-11.7) and 9.1(1.4)% (6.2-11.7), respectively, for the familial group and the crude prevalence for the polycystic kidney group was 9.1 (6.1)% (1.1-29.2). Interpretation Our results demonstrate a high prevalence of incidental intracranial aneurysms among first-degree relatives aged 30 years or older of patients with the condition and indicate that the risk of having an aneurysm is about four times higher for a close relative than for someone from the general population. Also, polycystic kidney disease families are a small fraction of the familial intracranial aneurysm families.	KUOPIO UNIV HOSP,DEPT CLIN RADIOL,KUOPIO 70210,FINLAND; KUOPIO UNIV HOSP,DEPT OBSTET & GYNAECOL,KUOPIO 70210,FINLAND; WAYNE STATE UNIV,SCH MED,CTR MOL MED & GENET,DETROIT,MI	Kuopio University Hospital; University of Eastern Finland; Kuopio University Hospital; University of Eastern Finland; Wayne State University	Ronkainen, A (corresponding author), KUOPIO UNIV HOSP,DEPT NEUROSURG,PL 1777,KUOPIO 70210,FINLAND.		Tromp, Gerard/B-2677-2017; Kuivaniemi, Helena/Q-8178-2019	Tromp, Gerard/0000-0002-7761-0806; Kuivaniemi, Helena/0000-0001-5753-8766				ASARI S, 1993, CLIN NEUROL NEUROSUR, V95, P205, DOI 10.1016/0303-8467(93)90125-Z; ATLAS SW, 1994, RADIOLOGY, V193, P1; Awad Issam A., 1992, Neurological Research, V14, P360; CHALOUPKA JC, 1995, CLIN PLAST SURG, V22, P417; CHAPMAN AB, 1993, AM J KIDNEY DIS, V22, P526, DOI 10.1016/S0272-6386(12)80924-3; Donner T R, 1994, J La State Med Soc, V146, P54; FOGELHOLM R, 1993, STROKE, V24, P1649, DOI 10.1161/01.STR.24.11.1649; HANKEY GJ, 1990, STROKE, V21, P209, DOI 10.1161/01.STR.21.2.209; HARBAUGH RE, 1992, J NEUROSURG, V76, P408, DOI 10.3171/jns.1992.76.3.0408; HERNESNIEMI J, 1993, ACTA NEUROCHIR, V122, P1, DOI 10.1007/BF01446980; JUVELA S, 1992, NEUROSURGERY, V30, P7, DOI 10.1227/00006123-199201000-00002; JUVELA S, 1993, J NEUROSURG, V79, P174, DOI 10.3171/jns.1993.79.2.0174; KING JT, 1994, J NEUROSURG, V81, P837, DOI 10.3171/jns.1994.81.6.0837; Linn FHH, 1996, STROKE, V27, P625, DOI 10.1161/01.STR.27.4.625; LOZANO AM, 1987, J NEUROSURG, V66, P522, DOI 10.3171/jns.1987.66.4.0522; LOZANO AM, 1992, CAN J NEUROL SCI, V19, P222, DOI 10.1017/S031716710004230X; MEYER FB, 1995, MAYO CLIN PROC, V70, P153, DOI 10.4065/70.2.153; NAKAGAWA T, 1994, J NEUROSURG, V80, P217, DOI 10.3171/jns.1994.80.2.0217; NORRGARD O, 1987, NEUROSURGERY, V20, P236, DOI 10.1227/00006123-198702000-00006; RONKAINEN A, 1995, RADIOLOGY, V195, P35, DOI 10.1148/radiology.195.1.7892491; RONKAINEN A, 1992, ACTA NEUROCHIR, V119, P29, DOI 10.1007/BF01541778; RONKAINEN A, 1995, NEUROSURGERY, V37, P43, DOI 10.1227/00006123-199507000-00006; RONKAINEN A, 1994, NEUROSURGERY, V35, P208, DOI 10.1227/00006123-199408000-00005; RONKAINEN A, 1993, NEUROSURGERY, V33, P787; SCHIEVINK WI, 1994, STROKE, V25, P2028, DOI 10.1161/01.STR.25.10.2028; SCHIEVINK WI, 1995, J NEUROSURG, V83, P426, DOI 10.3171/jns.1995.83.3.0426; Vanninen RL, 1996, NEUROSURGERY, V38, P838, DOI 10.1227/00006123-199604000-00041; WARNOCK NG, 1993, BRIT J RADIOL, V66, P855, DOI 10.1259/0007-1285-66-790-855; WEIR B, 1985, NEUROSURGERY, P1308; WIEBERS DO, 1992, STROKE, V23, P1416, DOI 10.1161/01.STR.23.10.1416	30	189	197	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 8	1997	349	9049					380	384		10.1016/S0140-6736(97)80009-8	http://dx.doi.org/10.1016/S0140-6736(97)80009-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH296	9033463				2022-12-01	WOS:A1997WH29600009
J	vanDonselaar, CA; Brouwer, OF; Geerts, AT; Arts, WFM; Stroink, H; Peters, ACB				vanDonselaar, CA; Brouwer, OF; Geerts, AT; Arts, WFM; Stroink, H; Peters, ACB			Clinical course of untreated tonic-clonic seizures in childhood: Prospective, hospital based study	BMJ-BRITISH MEDICAL JOURNAL			English	Article; Proceedings Paper	21st International Epilepsy Congress	SEP 03-08, 1995	SYDNEY, AUSTRALIA				EPILEPSY; PROGNOSIS	Objective: To assess decleration and acceleration in the disease process in the initial phase of epilepsy in children with new onset tonic-clonic seizures. Study design:Hospital based follow up study. Setting: Two university hospitals, a general hospital, and a children's hospital in the Netherlands. Patients: 204 children aged 1 month to 16 years with idiopathic or remote symptomatic, newly diagnosed, tonic-clonic seizures, of whom 123 were enrolled at time of their first ever seizure; all children were followed until the start of drug treatment (78 children), the occurrence of the fourth untreated seizure (41 children), or the end of the follow up period of two years (85 untreated children). Main outcome measures: Analysis of disease pattern from first ever seizure. The pattern was categorised as decelerating if the child became free of seizures despite treatment being withheld. In cases with four seizures, the pattern was categorised as decelerating if successive intervals increased or as accelerating if intervals decreased. Patterns in the remaining children were classified as uncertain. Results: A decelerating pattern was found in 83 of 85 children who became free of seizures without treatment. Three of the 41 children with four or more untreated seizures showed a decelerating pattern and eight an accelerating pattern. In 110 children the disease process could not be classified, mostly because drug treatment was started after the first, second,or third seizure. The proportion of children with a decelerating pattern (42%, 95% confidence interval 35% to 49%) may be a minimum estimate because of the large number of patients with an uncertain disease pattern. Conclusions: Though untreated epilepsy is commonly considered to be a progressive disorder with decreasing intervals between seizures, a large proportion of children with newly diagnosed, unprovoked tonic-clonic seizures have a decelerating disease process. The fear that tonic-clonic seizures commonly evolve into a progressive disease should not be used as an argument in favour of early drug treatment in children with epilepsy.	UNIV HOSP ROTTERDAM DIJKZIGT & SOPHIA, DEPT NEUROL, NL-3015 GJ ROTTERDAM, NETHERLANDS; LEIDEN UNIV HOSP, DEPT NEUROL, NL-2333 AA LEIDEN, NETHERLANDS; ERASMUS UNIV ROTTERDAM, DEPT PUBL HLTH, NL-3000 DR ROTTERDAM, NETHERLANDS; JULIANA CHILDRENS HOSP, NL-2566 ER THE HAGUE, NETHERLANDS; WESTEINDE ZIEKENHUIS, NL-2566 ER THE HAGUE, NETHERLANDS	Erasmus University Rotterdam; Erasmus MC; Leiden University; Leiden University Medical Center (LUMC); Erasmus University Rotterdam								[Anonymous], 1981, Epilepsia, V22, P489; ELWES RDC, 1984, NEW ENGL J MED, V311, P944, DOI 10.1056/NEJM198410113111503; ELWES RDC, 1988, BRIT MED J, V297, P948, DOI 10.1136/bmj.297.6654.948; GASTAUT H, 1969, EPILEPSIA, VS 10, pS14; HAUSER WA, 1975, EPILEPSIA, V16, P1, DOI 10.1111/j.1528-1157.1975.tb04721.x; REYNOLDS EH, 1995, BRIT MED J, V310, P176, DOI 10.1136/bmj.310.6973.176; REYNOLDS EH, 1987, EPILEPSIA, V28, P97, DOI 10.1111/j.1528-1157.1987.tb03633.x; REYNOLDS EH, 1983, LANCET, V2, P952; VANDONSELAAR CA, 1989, NEUROLOGY, V39, P267, DOI 10.1212/WNL.39.2.267	9	25	25	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 8	1997	314	7078					401	404						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	WH295	9040384				2022-12-01	WOS:A1997WH29500026
J	Hogan, SC; Stratford, KJ; Moore, DR				Hogan, SC; Stratford, KJ; Moore, DR			Duration and recurrence of otitis media with effusion in children from birth to 3 years: Prospective study using monthly otoscopy and tympanometry	BRITISH MEDICAL JOURNAL			English	Article							LIFE	Objective: To monitor the natural course of otitis media with effusion. Design: Prospective, longitudinal assessment of the state of the middle ear by otoscopy and tympanometry at monthly intervals from birth to 3 years. Setting: Domiciliary visits to family homes. Subjects: 95 full term infants born between August 1991 and November 1993. Main outcome measures: Observed and simulated data (Monte Carlo) for the duration of single episodes of otitis media with effusion. Results: 17 of the children had unilateral or bilateral otitis media with effusion for more than half of their first three years of life. Thirty three of the 95 children had tympanograms suggestive of otitis media with effusion at more than a third of observations; the remaining 62 had such tympanograms at less than a third of observations. The data of each group were described by a first order Markov model, yielding a mean duration of unilateral effusion episodes of 5-6 weeks in both groups; the mean duration of bilateral effusion was 6 and 10 weeks in the low and high incidence groups, respectively. However, the main difference between the groups was the time spent between episodes of effusion: effusion free periods were, on average, three times longer in the children who experienced less otitis media with effusion. Conclusion: Children who are susceptible to otitis media with effusion tend to have more separate episodes of effusion rather than an increased overall duration of episodes. Such children are primarily distinguished by the likelihood with which they acquire the disease than by their ability to recover from it.			Hogan, SC (corresponding author), UNIV OXFORD,PHYSIOL LAB,PARKS RD,OXFORD OX1 3PT,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		FIELLAUNIKOLAJSEN M, 1980, ANN OTO RHINOL LARYN, V89, P223, DOI 10.1177/00034894800890S351; HAGGARD M, 1993, OBJECTIVES VALUES ME; HOLTE L, 1990, AUDIOLOGY, V29, P1; Karlin S., 1975, 1 COURSE STOCHASTIC, V2; MOORE DR, 1991, AUDIOLOGY, V30, P91; MOORE DR, 1997, SPRINGER HDB AUDITOR, V8; ODIO CM, 1985, PEDIATRICS, V75, P819; PARADISE JL, 1981, PEDIATRICS, V68, P869; PILLSBURY HC, 1991, ARCH OTOLARYNGOL, V117, P718; Press W.H., 1986, NUMERICAL RECIPES AR; SHURIN PA, 1979, NEW ENGL J MED, V300, P1121, DOI 10.1056/NEJM197905173002001; TEELE DW, 1984, PEDIATRICS, V74, P282; TOS M, 1980, ARCH OTOLARYNGOL, V106, P345; ZIELHUIS GA, 1989, LANCET, V1, P311	14	40	41	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 1	1997	314	7077					350	353		10.1136/bmj.314.7077.350	http://dx.doi.org/10.1136/bmj.314.7077.350			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF861	9040332	Green Published			2022-12-01	WOS:A1997WF86100038
J	Delamarche, E; Bernard, A; Schmid, H; Michel, B; Biebuyck, H				Delamarche, E; Bernard, A; Schmid, H; Michel, B; Biebuyck, H			Patterned delivery of immunoglobulins to surfaces using microfluidic networks	SCIENCE			English	Article							COPLANAR MOLECULAR ASSEMBLIES; MONOLAYERS	Microfluidic networks (mu FNs) were used to pattern biomolecules with high resolution on a variety of substrates (gold, glass, or polystyrene). Elastomeric mu FNs localized chemical reactions between the biomolecules and the surface, requiring only microliters of reagent to cover square millimeter-sized areas. The networks were designed to ensure stability and filling of the mu FN and allowed a homogeneous distribution and robust attachment of material to the substrate along the conduits in the mu FN. Immunoglobulins patterned on substrates by means of mu FNs remained strictly confined to areas enclosed by the network with submicron resolution and were viable for subsequent use in assays. The approach is simple and general enough to suggest a practical way to incorporate biological material on technological substrates.	IBM CORP,ZURICH RES LAB,DIV RES,CH-8803 RUSCHLIKON,SWITZERLAND; UNIV ZURICH,INST BIOCHEM,CH-8057 ZURICH,SWITZERLAND	International Business Machines (IBM); University of Zurich			Delamarche, Emmanuel/G-6342-2013	Delamarche, Emmanuel/0000-0002-8753-8895				BERNARD A, 1995, EUR J BIOCHEM, V230, P416; Delamarche E, 1996, LANGMUIR, V12, P1997, DOI 10.1021/la950836t; DELAMARCHE E, UNPUB; DELAMARCHE E, IN PRESS ADV MAT; DULCEY CS, 1991, SCIENCE, V252, P551, DOI 10.1126/science.2020853; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; HARRIS JM, 1992, POLYETHYLENE GLYCOLC; Kim E, 1996, J AM CHEM SOC, V118, P5722, DOI 10.1021/ja960151v; KIM E, 1995, NATURE, V376, P581, DOI 10.1038/376581a0; LOPEZ GP, 1993, J AM CHEM SOC, V115, P10774, DOI 10.1021/ja00076a038; Mrksich M, 1996, P NATL ACAD SCI USA, V93, P10775, DOI 10.1073/pnas.93.20.10775; SINGHVI R, 1994, SCIENCE, V264, P696, DOI 10.1126/science.8171320; STENGER DA, 1992, J AM CHEM SOC, V114, P8435, DOI 10.1021/ja00048a013; SUNDBERG SA, 1995, J AM CHEM SOC, V117, P12050, DOI 10.1021/ja00154a003; Tender LM, 1996, LANGMUIR, V12, P5515, DOI 10.1021/la960627o; XIA Y, 1996, SCIENCE, V273, P547	16	580	723	3	118	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 2	1997	276	5313					779	781		10.1126/science.276.5313.779	http://dx.doi.org/10.1126/science.276.5313.779			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WW900	9115199				2022-12-01	WOS:A1997WW90000053
J	Ridker, PM; Miletich, JP; Hennekens, CH; Buring, JE				Ridker, PM; Miletich, JP; Hennekens, CH; Buring, JE			Ethnic distribution of factor V Leiden in 4047 men and women - Implications for venous thromboembolism screening	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACTIVATED PROTEIN-C; DEEP-VEIN-THROMBOSIS; COAGULATION-FACTOR-V; POOR ANTICOAGULANT RESPONSE; ADDITIONAL RISK FACTOR; ORAL-CONTRACEPTIVES; PULMONARY-EMBOLISM; DEFICIENT FAMILIES; RESISTANCE; MUTATION	Objective.-To estimate ethnic-specific prevalence rates of factor V Leiden, an inherited defect of hemostasis associated with risk of venous thrombosis. Design.-Survey of 4047 American men and women participating in the Physicians' Health Study (PHS) or in the Women's Health Study (WHS). All study participants were free of myocardial infarction, stroke, or venous thrombosis. Main Outcome Measure.-Prevalence of G1691A Leiden mutation in the gene coding for coagulation factor V was determined in the PHS group using polymerase chain reaction techniques and, in the WHS group, a second-generation activated protein C (APC)-resistance screening test with genetic confirmation of all borderline and low-value results. Results.-In 2468 Caucasian Americans, carrier frequency of factor V Leiden was 5.27% (95% confidence interval [CI], 4.42%-6.22%). Carrier frequency was 2.21% in 407 Hispanic Americans, 1.23% in 650 African Americans, 0.45% in 442 Asian Americans, and 1.25% in 80 Native Americans. Thus, prevalence of factor V Leiden was less among minority subjects (P=.001). Carrier frequencies were similar in Caucasian men and women (5.53% vs 4.85% respectively, P=.5). Conclusion.-These data indicate that prevalence of factor V Leiden is greater among Caucasians than minority Americans. These data have implications for clinicians considering whether to screen for factor V Leiden in high-risk groups such as those with prior venous thromboses or coexistent defects of anticoagulation and women at risk for postpartum thrombosis or seeking oral contraceptives.	HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED, DIV CARDIOVASC DIS, BOSTON, MA 02215 USA; WASHINGTON UNIV, SCH MED, DIV LAB MED, ST LOUIS, MO 63110 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Washington University (WUSTL)	Ridker, PM (corresponding author), HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED, DIV PREVENT MED, 900 COMMONWEALTH AVE E, BOSTON, MA 02215 USA.				NCI NIH HHS [CA-40360] Funding Source: Medline; NHLBI NIH HHS [HL-43851] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040360] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043851] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON FA, 1991, ARCH INTERN MED, V151, P933, DOI 10.1001/archinte.151.5.933; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BLOEMENKAMP KWM, 1995, LANCET, V346, P1593, DOI 10.1016/S0140-6736(95)91929-5; Buring JE, 1992, J MYOCARDIAL ISCHEMI, V4, P27; BURKITT DP, 1972, BMJ-BRIT MED J, V2, P556, DOI 10.1136/bmj.2.5813.556; Chan LC, 1996, THROMB HAEMOSTASIS, V75, P522; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; Dahlback B, 1996, LANCET, V347, P1346, DOI 10.1016/S0140-6736(96)91004-1; DUTHIE SJ, 1989, BRIT J OBSTET GYNAEC, V96, P4, DOI 10.1111/j.1471-0528.1989.tb01568.x; GOLDHABER SZ, 1985, PULMONARY EMBOLISM D; HELLGREN M, 1995, AM J OBSTET GYNECOL, V173, P210, DOI 10.1016/0002-9378(95)90192-2; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; KNIFFIN WD, 1994, ARCH INTERN MED, V154, P861, DOI 10.1001/archinte.154.8.861; KOELEMAN BPC, 1995, THROMB HAEMOSTASIS, V74, P580; KOELEMAN BPC, 1994, BLOOD, V84, P1031; KOST K, 1991, FAM PLANN PERSPECT, V23, P54, DOI 10.2307/2135450; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; NATHWANI AC, 1992, BAILLIERE CLIN HAEM, V5, P383, DOI 10.1016/S0950-3536(11)80025-9; PETERSON LS, 1995, CONTRACEPTIVE USE US, V260, P1; REES DC, 1995, LANCET, V346, P1133, DOI 10.1016/S0140-6736(95)91803-5; RIDKER PM, 1995, NEW ENGL J MED, V332, P912, DOI 10.1056/NEJM199504063321403; Ridker PM, 1997, ANN INTERN MED, V126, P528, DOI 10.7326/0003-4819-126-7-199704010-00005; RIDKER PM, 1995, CIRCULATION, V92, P2800, DOI 10.1161/01.CIR.92.10.2800; Ridker PM, 1997, CIRCULATION, V95, P1777; ROSEN S, 1994, THROMB HAEMOSTASIS, V72, P255; Simioni P, 1997, NEW ENGL J MED, V336, P399, DOI 10.1056/NEJM199702063360602; SVENSSON PJ, 1994, NEW ENGL J MED, V330, P517, DOI 10.1056/NEJM199402243300801; TAKAMIYA O, 1995, THROMB HAEMOSTASIS, V74, P996; TSO SC, 1980, BRIT J HAEMATOL, V46, P603, DOI 10.1111/j.1365-2141.1980.tb06018.x; *US BUR CENS, 1996, US POP EST AG SEX RA; Vandenbroucke JP, 1996, BRIT MED J, V313, P1127, DOI 10.1136/bmj.313.7065.1127; VANDENBROUCKE JP, 1994, LANCET, V344, P1453, DOI 10.1016/S0140-6736(94)90286-0; ZOLLER B, 1994, LANCET, V343, P1536, DOI 10.1016/S0140-6736(94)92940-8	33	477	494	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 23	1997	277	16					1305	1307		10.1001/jama.277.16.1305	http://dx.doi.org/10.1001/jama.277.16.1305			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU135	9109469				2022-12-01	WOS:A1997WU13500031
J	Salo, J; Lehenkari, P; Mulari, M; Metsikko, K; Vaananen, HK				Salo, J; Lehenkari, P; Mulari, M; Metsikko, K; Vaananen, HK			Removal of osteoclast bone resorption products by transcytosis	SCIENCE			English	Article							PROTON PUMP; OSTEOPETROSIS; ACTIN; TETRACYCLINES; EXOCYTOSIS; INVITRO; DEFECT; CELLS; MICE	Osteoclasts are multinucleated cells responsible for bone resorption. During the resorption cycle, osteoclasts undergo dramatic changes in their polarity, and resorbing cells reveal four functionally and structurally different membrane domains. Bone degradation products, both organic and inorganic, were endocytosed from the ruffled border membrane. They were then found to be transported in vesicles through the cell to the plasma membrane domain, located in the middle of the basal membrane, where they were liberated into the extracellular space. These results explain how resorbing osteoclasts can simultaneously remove large amounts of matrix degradation products and penetrate into bone.	UNIV UPPSALA, DEPT MED CELL BIOL, S-75123 UPPSALA, SWEDEN; UNIV OULU, DEPT ANAT, SF-90220 OULU, FINLAND; UNIV OULU, BIOCTR, SF-90220 OULU, FINLAND	Uppsala University; University of Oulu; University of Oulu			Lehenkari, Petri/O-3009-2016; Salo, Jari/AAH-9112-2019	Lehenkari, Petri/0000-0002-0055-5183; 				BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207; BOYDE A, 1987, SCANNING MICROSCOPY, V1, P369; BOYDE A, 1984, BRIT DENT J, V156, P216, DOI 10.1038/sj.bdj.4805313; CHAMBERS TJ, 1984, J CELL SCI, V66, P383; CHOWDHURY MH, 1993, AGENTS ACTIONS, V40, P124, DOI 10.1007/BF01976761; COHLAN SQ, 1963, AM J DIS CHILD, V105, P453, DOI 10.1001/archpedi.1963.02080040455005; FROST HM, 1961, J AM GERIATR SOC, V9, P1078, DOI 10.1111/j.1532-5415.1961.tb00455.x; HOLTROP ME, 1977, CLIN ORTHOP RELAT R, V123, P177; Key L. Lyndon Jr., 1996, P941; KOFFER A, 1990, J CELL BIOL, V111, P919, DOI 10.1083/jcb.111.3.919; Lakkakorpi PT, 1996, MICROSC RES TECHNIQ, V33, P171, DOI 10.1002/(SICI)1097-0029(19960201)33:2<171::AID-JEMT7>3.0.CO;2-W; LAKKAKORPI PT, 1991, J BONE MINER RES, V6, P817; LOWE C, 1993, P NATL ACAD SCI USA, V90, P4485, DOI 10.1073/pnas.90.10.4485; MUALLEM S, 1995, J CELL BIOL, V128, P589, DOI 10.1083/jcb.128.4.589; RIFKIN BR, 1994, ANN NY ACAD SCI, V732, P165, DOI 10.1111/j.1749-6632.1994.tb24733.x; Rodan Gideon A., 1996, P979; Salo J, 1996, J CELL SCI, V109, P301; SILVER IA, 1988, EXP CELL RES, V175, P266, DOI 10.1016/0014-4827(88)90191-7; SLY WS, 1983, P NATL ACAD SCI-BIOL, V80, P2752, DOI 10.1073/pnas.80.9.2752; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; VAANANEN HK, 1990, J CELL BIOL, V111, P1305, DOI 10.1083/jcb.111.3.1305; VAANANEN HK, 1995, J CELL SCI, V108, P2729; VITALE ML, 1991, J CELL BIOL, V113, P1057, DOI 10.1083/jcb.113.5.1057; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0	24	318	328	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 11	1997	276	5310					270	273		10.1126/science.276.5310.270	http://dx.doi.org/10.1126/science.276.5310.270			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WT925	9092479				2022-12-01	WOS:A1997WT92500050
J	Katz, MH; Gerberding, JL				Katz, MH; Gerberding, JL			Postexposure treatment of people exposed to the human immunodeficiency virus through sexual contact or injection-drug use	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HEALTH-CARE WORKERS; HIV SEROCONVERSION; ORAL INTERCOURSE; TRANSMISSION; INFECTION; BLOOD; MEN; PROPHYLAXIS; INSURANCE; RAPE		UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143; SAN FRANCISCO DEPT PUBL HLTH,SAN FRANCISCO,CA 94102	University of California System; University of California San Francisco; San Francisco Department of Public Health								ALBERT J, 1994, J VIROL, V68, P5918, DOI 10.1128/JVI.68.9.5918-5924.1994; *AM MED ASS, 1996, PHYS GUID HIV PREV; BLAUVELT A, 1995, J INVEST DERMATOL, V105, pS122, DOI 10.1111/1523-1747.ep12316662; Carpenter CCJ, 1996, JAMA-J AM MED ASSOC, V276, P146, DOI 10.1001/jama.276.2.146; Claydon E, 1991, Int J STD AIDS, V2, P200; CLERICI M, 1994, JAMA-J AM MED ASSOC, V271, P42, DOI 10.1001/jama.271.1.42; DEGRUTTOLA V, 1989, J CLIN EPIDEMIOL, V42, P849, DOI 10.1016/0895-4356(89)90098-X; Downs AM, 1996, J ACQ IMMUN DEF SYND, V11, P388, DOI 10.1097/00042560-199604010-00010; FAHRNER R, 1994, 34 INT C ANT AG CHEM, P133; FLEISHMAN JA, 1993, INQUIRY-J HEALTH CAR, V30, P180; FOSTER I, 1989, BRIT MED J, V299, P1282, DOI 10.1136/bmj.299.6710.1282; GAUGHWIN MD, 1991, AIDS, V5, P1025, DOI 10.1097/00002030-199108000-00016; Gerberding JL, 1996, ANN INTERN MED, V125, P497, DOI 10.7326/0003-4819-125-6-199609150-00011; GOSTIN LO, 1994, JAMA-J AM MED ASSOC, V271, P1436, DOI 10.1001/jama.271.18.1436; HELLINGER FJ, 1993, JAMA-J AM MED ASSOC, V270, P474, DOI 10.1001/jama.270.4.474; Holmberg SD, 1996, AM J PUBLIC HEALTH, V86, P642, DOI 10.2105/AJPH.86.5.642; KAPLAN EH, 1992, J ACQ IMMUN DEF SYND, V5, P1116; KATZ MH, 1995, J ACQ IMMUN DEF SYND, V8, P58; LAFON SW, 1990, 30TH INT C ANT AG CH, P167; LANE HC, 1991, AM J PUBLIC HEALTH, V81, P658, DOI 10.2105/AJPH.81.5.658; LIFSON AR, 1990, AM J PUBLIC HEALTH, V80, P1509, DOI 10.2105/AJPH.80.12.1509; Lu YC, 1996, J VIROL, V70, P3045, DOI 10.1128/JVI.70.5.3045-3050.1996; MARTIN LN, 1993, J INFECT DIS, V168, P825, DOI 10.1093/infdis/168.4.825; MATHES LE, 1992, ANTIMICROB AGENTS CH, V36, P2715, DOI 10.1128/AAC.36.12.2715; Miller C J, 1994, Curr Top Microbiol Immunol, V188, P107; MILMAN G, 1994, AIDS RES HUM RETROV, V10, P1305, DOI 10.1089/aid.1994.10.1305; PETERMAN TA, 1988, JAMA-J AM MED ASSOC, V259, P55, DOI 10.1001/jama.259.1.55; PETERMAN TA, 1989, JAMA-J AM MED ASSOC, V262, P502; POPE M, 1995, J EXP MED, V182, P2045, DOI 10.1084/jem.182.6.2045; PURO V, 1992, AIDS, V6, P963, DOI 10.1097/00002030-199209000-00009; Royce RA, 1997, NEW ENGL J MED, V336, P1072, DOI 10.1056/NEJM199704103361507; ROZENBAUM W, 1988, LANCET, V1, P1395; SAMUEL MC, 1994, MODELING THE AIDS EPIDEMIC: PLANNING, POLICY, AND PREDICTION, P423; SPARROW MJ, 1994, CONTRACEPTION, V50, P117, DOI 10.1016/0010-7824(94)90048-5; Spira AI, 1996, J EXP MED, V183, P215, DOI 10.1084/jem.183.1.215; THOMPSON JLP, 1993, AM J PUBLIC HEALTH, V83, P1409, DOI 10.2105/AJPH.83.10.1409; TOKARS JI, 1993, ANN INTERN MED, V118, P913, DOI 10.7326/0003-4819-118-12-199306150-00001; Voelker R, 1996, JAMA-J AM MED ASSOC, V276, P585, DOI 10.1001/jama.276.8.585; WILEY JA, 1989, STAT MED, V8, P93, DOI 10.1002/sim.4780080110; 1993, MMWR-MORBID MORTAL W, V42, P11; 1995, MMWR-MORBID MORTAL W, V44, P929; 1996, MMWR-MORBID MORTAL W, V45, P468	42	137	137	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 10	1997	336	15					1097	1100		10.1056/NEJM199704103361512	http://dx.doi.org/10.1056/NEJM199704103361512			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WT161	9091810				2022-12-01	WOS:A1997WT16100012
J	Kennedy, M; Firpo, M; Chol, K; Wall, C; Robertson, S; Kabrun, N; Keller, G				Kennedy, M; Firpo, M; Chol, K; Wall, C; Robertson, S; Kabrun, N; Keller, G			A common precursor for primitive erythropoiesis and definitive haematopoiesis	NATURE			English	Article							HEMATOPOIETIC STEM-CELLS; YOLK-SAC; FETAL DEVELOPMENT; PROGENITOR CELLS; BLOOD-ISLAND; MOUSE; DIFFERENTIATION; MICE; BINDING; EMBRYO	The generation of blood cells, haematopoiesis, in the mouse embryo begins with the development of primitive nucleated erythroid cells in the yolk sac followed by the appearance of precursors for multiple definitive haematopoietic lineages(1-4) The later developing lineages arise from multipotential stem cells(5,6), but the relationship of primitive erythroid cells to these other haematopoietic populations is unknown. Using an in vitro embryonic stem (ES) cell differentiation system(7), we show that primitive erythrocytes and other haematopoietic lineages arise from a common multipotential precursor that develops within embryoid bodies generated from differentiated ES cells, In response to vascular endothelial growth factor and c-kit Ligand these precursors give rise to colonies containing immature cells (blasts) expressing marker genes characteristic of haematopoietic precursors, Many blast colonies also expressed beta H1 and beta major globins but not Brachyury, a mesodermal marker, Kinetic analysis demonstrated that the blast colony-forming cells represent a transient population, preceding the establishment of the primitive erythroid and other lineage-restricted precursors, This precursor population may represent the earliest stage of embryonic haematopoietic commitment.	NATL JEWISH MED & RES CTR, DENVER, CO 80206 USA; UNIV COLORADO, HLTH SCI CTR, DEPT IMMUNOL, DENVER, CO 80262 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver			Robertson, Scott/B-9018-2013	Keller, Gordon/0000-0001-9309-9297				BARKER JE, 1968, DEV BIOL, V18, P14, DOI 10.1016/0012-1606(68)90020-1; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BRADY G, 1990, Methods in Molecular and Cellular Biology, V2, P17; BROTHERTON TW, 1979, P NATL ACAD SCI USA, V76, P2853, DOI 10.1073/pnas.76.6.2853; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CIVIN CI, 1984, J IMMUNOL, V133, P157; CUMANO A, 1993, P NATL ACAD SCI USA, V90, P6429, DOI 10.1073/pnas.90.14.6429; Cumano A, 1996, CELL, V86, P907, DOI 10.1016/S0092-8674(00)80166-X; DIETERLENLIEVRE F, 1975, J EMBRYOL EXP MORPH, V33, P607; HERRMANN BG, 1990, NATURE, V343, P617, DOI 10.1038/343617a0; Hole N, 1996, BLOOD, V88, P1266, DOI 10.1182/blood.V88.4.1266.bloodjournal8841266; JOHNSON GR, 1985, EXP HEMATOL, V13, P200; JORDAN CT, 1990, GENE DEV, V4, P220, DOI 10.1101/gad.4.2.220; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KATZ FE, 1985, LEUKEMIA RES, V9, P191, DOI 10.1016/0145-2126(85)90082-7; KAU CL, 1983, J IMMUNOL, V131, P2262; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; KELLER G, 1990, J EXP MED, V171, P1407, DOI 10.1084/jem.171.5.1407; KELLER GM, 1995, CURR OPIN CELL BIOL, V7, P862, DOI 10.1016/0955-0674(95)80071-9; LIU CP, 1991, DEVELOPMENT, V113, P1315; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MULLER AM, 1994, IMMUNITY, V1, P291, DOI 10.1016/1074-7613(94)90081-7; Nakano T, 1996, SCIENCE, V272, P722, DOI 10.1126/science.272.5262.722; ORKIN SH, 1992, BLOOD, V80, P575; ROBB L, 1995, P NATL ACAD SCI USA, V92, P7075, DOI 10.1073/pnas.92.15.7075; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; WILLIAMS RL, 1988, CELL, V52, P121; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489	30	452	477	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 3	1997	386	6624					488	493		10.1038/386488a0	http://dx.doi.org/10.1038/386488a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WR256	9087406				2022-12-01	WOS:A1997WR25600050
J	Hill, JA; Friedman, PL				Hill, JA; Friedman, PL			Measurement of QT interval and QT dispersion	LANCET			English	Editorial Material											Hill, JA (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV CARDIOVASC,BOSTON,MA 02115, USA.							COWAN JC, 1988, AM J CARDIOL, V61, P83, DOI 10.1016/0002-9149(88)91309-4; KAUTZNER J, 1994, PACE, V17, P928, DOI 10.1111/j.1540-8159.1994.tb01435.x; McLaughlin NB, 1996, HEART, V76, P422, DOI 10.1136/hrt.76.5.422; MCLAUGHLIN NB, 1995, BRIT HEART J, V74, P84; MURRAY A, 1994, BRIT HEART J, V71, P386; VOLKA ME, 1996, J INVASIVE CARDIOL, V8, P363	6	25	25	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 29	1997	349	9056					894	895		10.1016/S0140-6736(05)62692-X	http://dx.doi.org/10.1016/S0140-6736(05)62692-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR254	9093246				2022-12-01	WOS:A1997WR25400004
J	Allen, G; Buxton, RB; Wong, EC; Courchesne, E				Allen, G; Buxton, RB; Wong, EC; Courchesne, E			Attentional activation of the cerebellum independent of motor involvement	SCIENCE			English	Article							SHIFTING ATTENTION; VERBAL MEMORY; HUMAN BRAIN; MOVEMENT; PATTERNS; AREAS; RAT; MRI	The cerebellum traditionally has been viewed as a neural device dedicated to motor control. Although recent evidence shows that it is involved in nonmotor operations as well, an important question is whether this involvement is independent of motor control and motor guidance, Functional magnetic resonance imaging was used to demonstrate that attention and motor performance independently activate distinct cerebellar regions. These findings support a broader concept of cerebellar function, in which the cerebellum is involved in diverse cognitive and noncognitive neurobehavioral systems, including the attention and motor systems, in order to anticipate imminent information acquisition, analysis, or action.	UNIV CALIF SAN DIEGO, SCH MED, DEPT NEUROSCI, SAN DIEGO, CA 92103 USA; SAN DIEGO STATE UNIV UNIV CALIF, SAN DIEGO JOINT DOCTORAL PROGRAM CLIN PSYCHOL, SAN DIEGO, CA 92120 USA; CHILDRENS HOSP, RES CTR, LAB NEUROSCI AUTISM, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, SCH MED, DEPT RADIOL, SAN DIEGO, CA 92103 USA	University of California System; University of California San Diego; California State University System; San Diego State University; Children's Hospital Los Angeles; University of California System; University of California San Diego					NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH036840] Funding Source: NIH RePORTER; NIMH NIH HHS [R01-MH36840] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AKSHOOMOFF NA, 1992, BEHAV NEUROSCI, V106, P731, DOI 10.1037/0735-7044.106.5.731; AKSHOOMOFF NA, 1994, J COGNITIVE NEUROSCI, V6, P388, DOI 10.1162/jocn.1994.6.4.388; ANDREASEN NC, 1995, P NATL ACAD SCI USA, V92, P5111, DOI 10.1073/pnas.92.11.5111; ARTIGES E, 1995, HUM BRAIN MAPP S, V1, P227; BANDETTINI PA, 1993, MAGNET RESON MED, V30, P161, DOI 10.1002/mrm.1910300204; BLINKENBERG M, 1995, HUMAN BRAIN MAPPIN S, V1, P280; BONDE CT, 1995, HUM BRAIN MAPP S, V1, P313; BOWER JM, 1990, J COMP NEUROL, V302, P768, DOI 10.1002/cne.903020409; BRAITENBERG V, IN PRESS BEHAV BRAIN; Carpenter M.B, 1991, CORE TEXT NEUROANATO; Coenen OJMD, 1996, ADV NEUR IN, V8, P89; Courchesne E, 1995, EEG CL N SU, P315; COURCHESNE E, 1994, BEHAV NEUROSCI, V108, P848, DOI 10.1037/0735-7044.108.5.848; CRISPINO L, 1984, P NATL ACAD SCI-BIOL, V81, P2917, DOI 10.1073/pnas.81.9.2917; Eccles J. C. M., 1967, CEREBELLUM NEURONAL; ELLERMAN JM, 1994, NMR BIOMED, V7, P63, DOI 10.1002/nbm.1940070110; Fiez JA, 1996, J NEUROSCI, V16, P808; Flament D, 1996, HUM BRAIN MAPP, V4, P210, DOI 10.1002/hbm.460040302; Gao JH, 1996, SCIENCE, V272, P545, DOI 10.1126/science.272.5261.545; Gilman, 1981, DISORDERS CEREBELLUM; GRASBY PM, 1993, BRAIN, V116, P1, DOI 10.1093/brain/116.1.1; Ito M., 1984, CEREBELLUM NEURAL CO; KIM SG, 1994, SCIENCE, V265, P949, DOI 10.1126/science.8052851; Klingberg T, 1996, EUR J NEUROSCI, V8, P1965, DOI 10.1111/j.1460-9568.1996.tb01340.x; LE TH, 1996, NEUROIMAGE, V3, P246; Llinas R. R., 1992, CEREBELLUM REVISITED; MARTIN A, 1995, SCIENCE, V270, P102, DOI 10.1126/science.270.5233.102; MIDDLETON FA, 1994, SCIENCE, V266, P458, DOI 10.1126/science.7939688; NEWMAN PP, 1979, J PHYSIOL-LONDON, V287, P405, DOI 10.1113/jphysiol.1979.sp012667; PAULIN MG, 1993, BRAIN BEHAV EVOLUT, V41, P39, DOI 10.1159/000113822; Petersen S E, 1989, J Cogn Neurosci, V1, P153, DOI 10.1162/jocn.1989.1.2.153; Petit L, 1996, J NEUROSCI, V16, P3714; PRESS GA, 1990, AM J NEURORADIOL, V11, P41; RAICHLE ME, 1994, CEREB CORTEX, V4, P8, DOI 10.1093/cercor/4.1.8; RAO SL, 1995, HUM BRAIN MAPP S, V1, P412; Raymond JL, 1996, SCIENCE, V272, P1126, DOI 10.1126/science.272.5265.1126; RYDING E, 1993, COGNITIVE BRAIN RES, V1, P94, DOI 10.1016/0926-6410(93)90015-W; SABATINI U, 1993, J CEREBR BLOOD F MET, V13, P639, DOI 10.1038/jcbfm.1993.82; Schmahmann JD, 1996, HUM BRAIN MAPP, V4, P174, DOI 10.1002/(SICI)1097-0193(1996)4:3<174::AID-HBM3>3.0.CO;2-0; SHIBASAKI H, 1993, BRAIN, V116, P1387, DOI 10.1093/brain/116.6.1387; SNYDER LH, 1992, VISION RES, V32, P569, DOI 10.1016/0042-6989(92)90249-I; Stuss DT, 1995, ANN NY ACAD SCI, V769, P191, DOI 10.1111/j.1749-6632.1995.tb38140.x; THACH WT, 1992, ANNU REV NEUROSCI, V15, P403, DOI 10.1146/annurev.neuro.15.1.403; Townsend J, 1996, DEV PSYCHOPATHOL, V8, P563, DOI 10.1017/S0954579400007276; WILLIAMS RW, 1988, ANNU REV NEUROSCI, V11, P423, DOI 10.1146/annurev.neuro.11.1.423	45	629	642	0	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 28	1997	275	5308					1940	1943		10.1126/science.275.5308.1940	http://dx.doi.org/10.1126/science.275.5308.1940			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WQ513	9072973				2022-12-01	WOS:A1997WQ51300048
J	Klarlund, JK; Guilherme, A; Holik, JJ; Virbasius, JV; Chawla, A; Czech, MP				Klarlund, JK; Guilherme, A; Holik, JJ; Virbasius, JV; Chawla, A; Czech, MP			Signaling by phosphoinositide-3,4,5-trisphosphate through proteins containing pleckstrin and Sec7 homology domains	SCIENCE			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; SH2 DOMAINS; PH DOMAIN; KINASE; RECEPTOR; CLONING; ACTIVATION; WORTMANNIN; BINDING	Signal transmission by many cell surface receptors results in the activation of phosphoinositide (PI) 3-kinases that phosphorylate the 3' position of polyphosphoinositides. From a screen for mouse proteins that bind phosphoinositides, the protein GRP1 was identified. GRP1 binds phosphatidylinositol-3,4,5-trisphosphate [PtdIns(3,4,5)P-3] through a pleckstrin homology (PH) domain and displaysa region of high sequence similarity to the yeast Sec7 protein. The PH domain of the closely related protein cytohesin-1, which, through its Sec7 homology domain, regulates integrin beta 2 and catalyzes guanine nucleotide exchange of the small guanine nucleotide-binding protein ARF1, was also found to specifically bind PtdIns(3,4,5)P-3. GRP1 and cytohesin-1 appear to connect receptor-activated PI 3-kinase signaling pathways with proteins that mediate biological responses such as cell adhesion and membrane trafficking.	UNIV MASSACHUSETTS, MED CTR, DEPT BIOCHEM & MOL BIOL, WORCESTER, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester				Virbasius, Joseph/0000-0003-1784-6793	NIDDK NIH HHS [DK30898, DK30648] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK030898, R01DK030648, R01DK030898] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACHSTETTER T, 1988, J BIOL CHEM, V263, P11711; BONNEMA JD, 1994, J EXP MED, V180, P1427, DOI 10.1084/jem.180.4.1427; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FERGUSON KM, 1995, NAT STRUCT BIOL, V2, P715, DOI 10.1038/nsb0995-715; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Fukuda M, 1996, J BIOL CHEM, V271, P30303, DOI 10.1074/jbc.271.48.30303; HARLAN JE, 1995, BIOCHEMISTRY-US, V34, P9859, DOI 10.1021/bi00031a006; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HellerHarrison RA, 1996, J BIOL CHEM, V271, P10200, DOI 10.1074/jbc.271.17.10200; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU P, 1994, MOL CELL BIOL, V14, P2577, DOI 10.1128/MCB.14.4.2577; James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KANAI F, 1993, BIOCHEM BIOPH RES CO, V195, P762, DOI 10.1006/bbrc.1993.2111; KLARLUND JK, UNPUB; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; LIU L, 1992, BIOCHIM BIOPHYS ACTA, V1132, P75, DOI 10.1016/0167-4781(92)90055-5; Molz L, 1996, J BIOL CHEM, V271, P13892, DOI 10.1074/jbc.271.23.13892; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; OKADA T, 1994, J BIOL CHEM, V269, P3568; PARKER PJ, 1995, CURR BIOL, V5, P577, DOI 10.1016/S0960-9822(95)00113-8; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SHEPHERD PR, 1995, BIOCHEM J, V305, P25, DOI 10.1042/bj3050025; SHEVELL DE, 1994, CELL, V77, P1051, DOI 10.1016/0092-8674(94)90444-8; Shimizu Y, 1995, J CELL BIOL, V131, P1867, DOI 10.1083/jcb.131.6.1867; Shpetner H, 1996, J CELL BIOL, V132, P595, DOI 10.1083/jcb.132.4.595; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Thelen M, 1995, BIOCHEM BIOPH RES CO, V217, P1255, DOI 10.1006/bbrc.1995.2903; TOKER A, 1994, J BIOL CHEM, V269, P32358; Virbasius JV, 1996, J BIOL CHEM, V271, P13304, DOI 10.1074/jbc.271.23.13304; VOLINIA S, 1995, EMBO J, V14, P3339, DOI 10.1002/j.1460-2075.1995.tb07340.x; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; YANO H, 1993, J BIOL CHEM, V268, P25846; Zell T, 1996, J IMMUNOL, V156, P883; Zvelebil MJ, 1996, PHILOS T R SOC B, V351, P217, DOI 10.1098/rstb.1996.0019	45	353	361	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 28	1997	275	5308					1927	1930		10.1126/science.275.5308.1927	http://dx.doi.org/10.1126/science.275.5308.1927			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WQ513	9072969				2022-12-01	WOS:A1997WQ51300044
J	Wermers, RA; Khosla, S; Atkinson, EJ; Hodgson, SF; OFallon, WM; Melton, LJ				Wermers, RA; Khosla, S; Atkinson, EJ; Hodgson, SF; OFallon, WM; Melton, LJ			The rise and fall of primary hyperparathyroidism: A population-based study in Rochester, Minnesota, 1965-1992	ANNALS OF INTERNAL MEDICINE			English	Article						hyperparathyroidism; calcium; hypercalcemia; parathyroid hormones; population surveillance	RADIATION-INDUCED HYPERPARATHYROIDISM; PRIMARY HYPER-PARATHYROIDISM; NECK IRRADIATION; CALCIUM-ABSORPTION; HYPOCALCIURIC HYPERCALCEMIA; BONE-RESORPTION; VITAMIN-D; AGE; HORMONE; WOMEN	Background: The introduction of routine measurement of serum calcium levels led to a sharp increase in the incidence of primary hyperparathyroidism in the early 1970s. Objective: To evaluate the trends in the incidence of primary hyperparathyroidism since the mid-1970s. Setting: Rochester and Olmsted County, Minnesota. Design: Population-based descriptive study. Patients: All residents of Rochester, Minnesota, who received an initial diagnosis of primary hyperparathyroidism between 1965 and 1992 were identified through the medical records linkage system of the Rochester Epidemiology Project. Included as persons having definite cases (92% of the total) were patients with pathologically confirmed hyperparathyroidism, hypercalcemia with inappropriately elevated parathyroid hormone levels, or hypercalcemia that had lasted for more than a year and had no cause other than primary hyperparathyroidism. Measurements: Incidence rates were calculated and directly standardized to the population structure of white persons in the United States in 1990. Results: From 1965 to June 1974 (the prescreening era), the age- and sex-adjusted incidence of primary hyperparathyroidism in Rochester was 15 cases per 100 000 person-years. After measurement of calcium levels was added to the automated serum chemistry panel in July 1974, the incidence increased to 112 per 100 000 person-years in 1975 and then decreased somewhat, reflecting a sweeping effect. Despite improved case ascertainment, however, the incidence rate has continued to decrease; in 1992, the incidence was 4 per 100 000 person-years. A few patients had complications that might have been caused by hyperparathyroidism (22% between 1965 and June 1974 and 6% thereafter), and survival was not impaired in either period. The maximum serum calcium levels did not change (P = 0.15). Conclusions: The progressive decrease in the incidence of primary hyperparathyroidism is unexpected and suggests a significant change in the epidemiology of this disease.	MAYO CLIN & MAYO FDN, ROCHESTER, MN 55905 USA	Mayo Clinic			Khosla, Sundeep/AAE-6170-2020	Khosla, Sundeep/0000-0002-2936-4372	NIAMS NIH HHS [AR 30582] Funding Source: Medline; NIA NIH HHS [AG 04875] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG004875] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AITKEN RE, 1975, AUST NZ J MED, V5, P224, DOI 10.1111/j.1445-5994.1975.tb04572.x; ARNAUD CD, 1971, J CLIN INVEST, V50, P21, DOI 10.1172/JCI106476; ARNOLD A, 1995, J CLIN INVEST, V95, P2047, DOI 10.1172/JCI117890; AVIS NE, 1990, ANN NY ACAD SCI, V592, P228; BATES B, 1972, J AMER MED ASSOC, V222, P74, DOI 10.1001/jama.222.1.74; BEARD CM, 1989, ARCH INTERN MED, V149, P1887, DOI 10.1001/archinte.149.8.1887; Bergstralh EJ., 1992, CALCULATING INCIDENC; BOONSTRA CE, 1971, AM J CLIN PATHOL, V55, P523; BULLAMORE JR, 1970, LANCET, V2, P535; CHRISTMAS TJ, 1988, BRIT J SURG, V75, P873, DOI 10.1002/bjs.1800750914; DEJONG SA, 1991, SURGERY, V110, P691; DENT DM, 1987, POSTGRAD MED J, V63, P745, DOI 10.1136/pgmj.63.743.745; DERBY CA, 1993, AM J EPIDEMIOL, V137, P1125, DOI 10.1093/oxfordjournals.aje.a116616; EASTELL R, 1992, J CLIN ENDOCR METAB, V74, P487, DOI 10.1210/jc.74.3.487; ESSELSTYN C B JR, 1970, Cleveland Clinic Quarterly, V37, P87; FAVUS MJ, 1976, NEW ENGL J MED, V294, P1019, DOI 10.1056/NEJM197605062941901; FRIEDMAN GD, 1972, ARCH INTERN MED, V129, P91, DOI 10.1001/archinte.129.1.91; FUJIWARA S, 1992, RADIAT RES, V130, P372, DOI 10.2307/3578384; GALLAGHER JC, 1979, J CLIN INVEST, V64, P729, DOI 10.1172/JCI109516; HAFF RC, 1970, ANN SURG, V171, P85, DOI 10.1097/00000658-197001000-00013; HEANEY RP, 1989, J BONE MINER RES, V4, P469; Heaney RP, 1996, J CLIN ENDOCR METAB, V81, P1697, DOI 10.1210/jc.81.5.1697; HEATH H, 1989, ENDOCRIN METAB CLIN, V18, P723, DOI 10.1016/S0889-8529(18)30362-1; HEATH H, 1980, NEW ENGL J MED, V302, P189, DOI 10.1056/NEJM198001243020402; Heath H 3rd, 1991, J Bone Miner Res, V6 Suppl 2, pS63; HEDMAN I, 1984, WORLD J SURG, V8, P96, DOI 10.1007/BF01658376; HEMMINKI E, 1988, AM J PUBLIC HEALTH, V78, P1478, DOI 10.2105/AJPH.78.11.1479; Innes A, 1987, J R Coll Surg Edinb, V32, P263; JOHANSSON H, 1972, UPSALA J MED SCI, V77, P41, DOI 10.1517/03009734000000008; KAO PC, 1982, CLIN CHEM, V28, P69; KAO PC, 1992, MAYO CLIN PROC, V67, P637, DOI 10.1016/S0025-6196(12)60717-4; KENNEDY DL, 1985, OBSTET GYNECOL, V65, P441; KURLAND LT, 1981, SCI AM, V245, P54, DOI 10.1038/scientificamerican1081-54; LANDINWILHELMSEN K, 1995, CALCIFIED TISSUE INT, V56, P104, DOI 10.1007/BF00296339; LAW WM, 1985, ANN INTERN MED, V102, P511, DOI 10.7326/0003-4819-102-4-511; LEDGER GA, 1995, J CLIN ENDOCR METAB, V80, P3304, DOI 10.1210/jc.80.11.3304; LEDGER GA, 1994, J CLIN ENDOCR METAB, V79, P211, DOI 10.1210/jc.79.1.211; LINK K, 1984, HUM PATHOL, V15, P75, DOI 10.1016/S0046-8177(84)80333-0; MARCUS R, 1984, J CLIN ENDOCR METAB, V58, P223, DOI 10.1210/jcem-58-2-223; MAYS ET, 1971, SURG GYNECOL OBSTETR, V133, P603; MCGEOWN MG, 1969, LANCET, V1, P887; McKane WR, 1996, J CLIN ENDOCR METAB, V81, P1699, DOI 10.1210/jc.81.5.1699; Melton LJ, 1996, MAYO CLIN PROC, V71, P266, DOI 10.4065/71.3.266; MODAN B, 1977, RADIOLOGY, V123, P741, DOI 10.1148/123.3.741; MOLLERUP CL, 1994, EUR J SURG, V160, P485; MULLER H, 1969, LANCET, V1, P449; MUNDY GR, 1980, LANCET, V1, P1317, DOI 10.1016/S0140-6736(80)91783-3; NISHIYAMA RH, 1979, SURG CLIN N AM, V59, P65; NORDIN BEC, 1994, CLIN ENDOCRINOL, V41, P41, DOI 10.1111/j.1365-2265.1994.tb03782.x; PALMER M, 1987, J CHRON DIS, V40, P121, DOI 10.1016/0021-9681(87)90063-4; PREISMAN RA, 1971, ARCH SURG-CHICAGO, V103, P12; PRINCE RL, 1995, J BONE MINER RES, V10, P835; PRINZ RA, 1977, SURGERY, V82, P296; RAO SD, 1980, ARCH INTERN MED, V140, P205, DOI 10.1001/archinte.140.2.205; RUSS JE, 1979, CANCER, V43, P1078, DOI 10.1002/1097-0142(197903)43:3<1078::AID-CNCR2820430344>3.0.CO;2-R; SCALLEY EK, 1993, J WOMENS HEALTH, V2, P289; SCHNEIDER AB, 1995, J CLIN ENDOCR METAB, V80, P254, DOI 10.1210/jc.80.1.254; STENSTROM G, 1974, ACTA MED SCAND, V195, P473; TISELL LE, 1976, ACTA CHIR SCAND, V142, P367; TISELL LE, 1977, CANCER, V40, P846, DOI 10.1002/1097-0142(197708)40:2<846::AID-CNCR2820400238>3.0.CO;2-2; TISELL LE, 1985, CANCER, V56, P1529, DOI 10.1002/1097-0142(19851001)56:7<1529::AID-CNCR2820560710>3.0.CO;2-D; TRIGONIS C, 1983, ACTA CHIR SCAND, V149, P675; WALDENSTROM JG, 1973, ACTA MED SCAND, V193, P145; WEMEAU JL, 1989, HORM RES, V32, P93, DOI 10.1159/000181255; WISKE PS, 1979, NEW ENGL J MED, V300, P1419, DOI 10.1056/NEJM197906213002506	65	206	213	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1997	126	6					433	+		10.7326/0003-4819-126-6-199703150-00003	http://dx.doi.org/10.7326/0003-4819-126-6-199703150-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM530	9072928				2022-12-01	WOS:A1997WM53000003
J	Conway, JF; Cheng, N; Zlotnick, A; Wingfield, PT; Stahl, SJ; Steven, AC				Conway, JF; Cheng, N; Zlotnick, A; Wingfield, PT; Stahl, SJ; Steven, AC			Visualization of a 4-helix bundle in the hepatitis B virus capsid by cryo-electron microscopy	NATURE			English	Article							3-DIMENSIONAL STRUCTURE; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; ALPHA-HELICES; CORE ANTIGEN; PROTEIN	Despite the development of vaccines, the hepatitis B virus remains a major cause of human liver disease(1). The virion consists of a lipoprotein envelope surrounding an icosahedral capsid composed of dimers of a 183-residue protein, 'core antigen' (HBcAg)(2). Knowledge of its structure is important for the design of antiviral drugs, but it has yet to be determined. Residues 150-183 are known to form a protamine-like domain required for packaging RNA, and residues 1-149 form the 'assembly domain' that polymerizes into capsids(2) and, unusually for a capsid protein, is highly alpha-helical(3). Density maps calculated from cryo-electron micrographs(4-6) show that the assembly domain dimer is T-shaped: its stem constitutes the dimer interface and the tips of its arms make the polymerization contacts. By refining the procedures used to calculate the map, we have extended the resolution to 9 Angstrom, revealing major elements of secondary structure. In particular, the stem, which protrudes as a spike on the capsid's outer surface, is a 4-helix bundle, formed by the pairing of alpha-helical hairpins from both subunits.	NIAMSD,STRUCT BIOL LAB,NIH,BETHESDA,MD 20892; NIAMSD,PROT EXPRESS LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)			Conway, James F/A-2296-2010	Conway, James F/0000-0002-6581-4748; Zlotnick, Adam/0000-0001-9945-6267; Wingfield, Paul/0000-0002-9515-4752				ARENTS G, 1991, P NATL ACAD SCI USA, V88, P10148, DOI 10.1073/pnas.88.22.10148; BAKER TS, 1989, BIOPHYS J, V55, P243, DOI 10.1016/S0006-3495(89)82799-7; Baker TS, 1996, J STRUCT BIOL, V116, P120, DOI 10.1006/jsbi.1996.0020; BAMFORD JKH, 1993, J MOL BIOL, V230, P473, DOI 10.1006/jmbi.1993.1164; BANNER DW, 1987, J MOL BIOL, V196, P657, DOI 10.1016/0022-2836(87)90039-8; BOOY FP, 1996, P 11 EUR C MICR DUBL; BRINGAS R, IN PRESS J STRUCT; CHOTHIA C, 1984, ANNU REV BIOCHEM, V53, P537; CONWAY JF, 1993, J STRUCT BIOL, V111, P222, DOI 10.1006/jsbi.1993.1052; CROWTHER RA, 1994, CELL, V77, P943, DOI 10.1016/0092-8674(94)90142-2; HOLLINGER FB, 1996, FIELDS VIROLOGY, P2738; JENG TW, 1989, J MOL BIOL, V205, P251, DOI 10.1016/0022-2836(89)90379-3; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KENNEY JM, 1995, STRUCTURE, V3, P1009, DOI 10.1016/S0969-2126(01)00237-4; MILBURN MV, 1993, NATURE, V363, P172, DOI 10.1038/363172a0; Momany C, 1996, NAT STRUCT BIOL, V3, P763, DOI 10.1038/nsb0996-763; MORGAN DG, 1995, J MOL BIOL, V249, P88, DOI 10.1006/jmbi.1995.0282; NASSAL M, 1993, VIRUS STRATEGIES, P41; PRESNELL SR, 1989, P NATL ACAD SCI USA, V86, P6592, DOI 10.1073/pnas.86.17.6592; RAO ZH, 1995, NATURE, V378, P743, DOI 10.1038/378743a0; ROSSMANN MG, 1989, ANNU REV BIOCHEM, V58, P533, DOI 10.1146/annurev.bi.58.070189.002533; SALFELD J, 1989, J VIROL, V63, P798, DOI 10.1128/JVI.63.2.798-808.1989; UNWIN PNT, 1975, J MOL BIOL, V94, P425, DOI 10.1016/0022-2836(75)90212-0; VANHEEL M, 1987, ULTRAMICROSCOPY, V21, P95, DOI 10.1016/0304-3991(87)90010-6; WINGFIELD PT, 1995, BIOCHEMISTRY-US, V34, P4919, DOI 10.1021/bi00015a003; WINKELMANN DA, 1991, J CELL BIOL, V114, P701, DOI 10.1083/jcb.114.4.701; Xie XL, 1996, NATURE, V380, P316, DOI 10.1038/380316a0; Yu MS, 1996, J VIROL, V70, P7085, DOI 10.1128/JVI.70.10.7085-7091.1996; ZEMLIN F, 1994, MICRON, V25, P223, DOI 10.1016/0968-4328(94)90026-4; Zlotnick A, 1996, BIOCHEMISTRY-US, V35, P7412, DOI 10.1021/bi9604800	30	385	409	1	47	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 6	1997	386	6620					91	94		10.1038/386091a0	http://dx.doi.org/10.1038/386091a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WL746	9052787				2022-12-01	WOS:A1997WL74600058
J	Lurie, P; Drucker, E				Lurie, P; Drucker, E			An opportunity lost: HIV infections associated with lack of a national needle-exchange programme in the USA	LANCET			English	Article							INJECTION-DRUG USERS; SYRINGE; RISK; AIDS	Background Our aim was to estimate the number of HIV infections that could have been prevented had needle-exchange programmes been implemented during the early stages of the AIDS epidemic in the USA. We also estimated the cost to the US health-care system to treat these preventable HIV infections. Methods The formula we used to calculate the annual number of preventable HIV infections accounted for the effectiveness and level of use of needle-exchange programmes, as well as sexual transmission to injection drug users (IDUs) and secondary transmission to their sexual partners and children. Data for the model were obtained from epidemiological and mathematical studies in peer-reviewed published research, government reports, and consultations with experts. Using data from Australia as a model, we calculated the number of HIV infections that could have been prevented by a national needle-exchange programme in the USA between 1987 and 1995. Cost calculations were based on the current US government estimate of the discounted lifetime cost of treating an HIV infection (US$55 640). Findings Our conservative calculation of the number of HIV infections that could have been prevented ranged from 4394 (15% incidence reduction due to needle exchanges) to 9666 (33% incidence reduction). The cost to the US health-care system of treating these preventable HIV infections is between US$ 244 million and US$ 538 million, respectively. If current US policies are not changed. we estimate that an additional 5150-11 329 preventable HIV infections could occur by the year 2000. Interpretation The failure of the federal government in the USA to implement a national needle-exchange programme, despite six government-funded reports in support of needle exchanges, may have led to HIV infection among thousands of IDUs, their sexual partners, and their children. Revoking the US government ban on funding for needle-exchange programmes and accelerating the growth of such programmes in the USA are urgent public-health priorities.	MONTEFIORE MED CTR,ALBERT EINSTEIN COLL MED,DEPT EPIDEMIOL & SOCIAL MED,BRONX,NY 10467	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	Lurie, P (corresponding author), UNIV CALIF SAN FRANCISCO,CTR AIDS PREVENT STUDIES,SUITE 600,SAN FRANCISCO,CA 94105, USA.							*AUSTR NAT AIDS IN, 1991, NEITH BORR NOR LEND; BRACHMAN PS, 1985, PRINCIPLES PRACTICE; *CTR DIS CONTR, 1990, MMWR-MORBID MORTAL W, V39, P8; *CTR DIS CONTR PRE, 1994, HIV AIDS SURVEILLANC, V6, P10; FEACHEM RGA, 1995, VALUING PAST INVESTI; *GEN ACC OFF, 1993, GAOHRD9360; GROSECLOSE SL, 1995, J ACQ IMMUN DEF SYND, V10, P82; GUINAN ME, 1994, AM J PREV MED, V10, P1; HAGAN H, 1995, AM J PUBLIC HEALTH, V85, P1531, DOI 10.2105/AJPH.85.11.1531; Holmberg SD, 1996, AM J PUBLIC HEALTH, V86, P642, DOI 10.2105/AJPH.86.5.642; Jarlais DCD, 1996, LANCET, V348, P987, DOI 10.1016/S0140-6736(96)02536-6; JARLAIS DCD, 1989, JAMA-J AM MED ASSOC, V261, P1008; JARLAIS DCD, 1995, JAMA-J AM MED ASSOC, V274, P1226; KAPLAN EH, 1995, OPER RES, V43, P558, DOI 10.1287/opre.43.4.558; KAPLAN EH, 1994, STAT MED, V13, P2179, DOI 10.1002/sim.4780131923; KOXLEY W, 1995, SAME VEIN 1 REPORT A; Lurie P, 1995, B NEW YORK ACAD MED, V72, P380; LURIE P, 1993, PUBLIC HLTH IMPACT N, V1; *NAT COMM ACQ IMM, 1991, TWIN EP SUBS US HIV; NORMAND J, 1995, PREVENTING HIV TRANS; *OFF TECHN ASS, 1995, EFF AIDS PREV EFF; PAONE D, 1995, MMWR-MORBID MORTAL W, V44, P684; SATCHER D, 1993, COMMUNICATION   1210; VANDENHOEK JAR, 1989, AM J PUBLIC HEALTH, V79, P1355, DOI 10.2105/AJPH.79.10.1355; WALDHOLZ M, 1985, WALL STREET J   0903, pA14; WATTERS JK, 1994, JAMA-J AM MED ASSOC, V271, P115, DOI 10.1001/jama.271.2.115; 1996, KAISER SURVEY AM AID	27	114	115	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 1	1997	349	9052					604	608		10.1016/S0140-6736(96)05439-6	http://dx.doi.org/10.1016/S0140-6736(96)05439-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WK915	9057732				2022-12-01	WOS:A1997WK91500010
J	Zilberstein, M; Feingold, M; Seibel, MM				Zilberstein, M; Feingold, M; Seibel, MM			Umbilical-cord-blood banking: Lessons learned from gamete donation	LANCET			English	Article									BOSTON UNIV,MED CTR,DEPT OBSTET & GYNECOL,BOSTON,MA	Boston University	Zilberstein, M (corresponding author), FAULKNER CTR REPROD MED,HARVARD DEACONESS SURG PROBLEM,1153 CTR ST,BOSTON,MA 02130, USA.							ANDREWS LB, 1994, EXECUTIVE SUMMARY AS; BATES B, 1996, OB GYN NEWS, V31, P1; KONG D, 1996, BOSTON GLOBE    0122, P27; Kurtzberg J, 1996, NEW ENGL J MED, V335, P157, DOI 10.1056/NEJM199607183350303; MCCULLOUGH J, 1994, BLOOD CELLS, V20, P609; Varadi G, 1995, Obstet Gynecol Surv, V50, P611, DOI 10.1097/00006254-199508000-00022; ZILBERSTEIN M, 1996, UNDERSTANDING FAMILY, P94	7	16	16	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 1	1997	349	9052					642	643		10.1016/S0140-6736(96)05267-1	http://dx.doi.org/10.1016/S0140-6736(96)05267-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WK915	9057746	hybrid			2022-12-01	WOS:A1997WK91500043
J	Wu, DY; Wallen, HD; Nunez, G				Wu, DY; Wallen, HD; Nunez, G			Interaction and regulation of subcellular localization of CED-4 by CED-9	SCIENCE			English	Article							PROGRAMMED CELL-DEATH; CAENORHABDITIS-ELEGANS; C-ELEGANS; GENE CED-3; BCL-X; PROTEIN; APOPTOSIS; MEMBRANE; ENCODES; SURVIVAL	The Caenorhabditis elegans survival gene ced-9 regulates ced-4 activity and inhibits is cell death, but the mechanism by which this occurs is unknown. Through a genetic screen for CED-4-binding proteins, CED-9 was identified as an interacting partner of CED-4. CED-9, but not loss-of-function mutants, associated specifically with CED-4 in yeast or mammalian cells. The CED-9 protein localized primarily to intracellular membranes and the perinuclear region, whereas CED-4 Was distributed in the cytosol. Expression of CED-9, but not a mutant lacking the carboxy-terminal hydrophobic domain, targeted CED-4 from the cytosol to intracellular membranes in mammalian cells. Thus, the actions of CED-4 and CED-9 are directly linked, which could provide the basis for the regulation of programmed cell death in C. elegans.	UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,CTR COMPREHENS CANC,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			Nuñez, Gabriel/A-7160-2014		NATIONAL CANCER INSTITUTE [R01CA064556] Funding Source: NIH RePORTER; NCI NIH HHS [CA-64556] Funding Source: Medline; PHS HHS [T32A107413-03] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CHENLEVY Z, 1989, MOL CELL BIOL, V9, P701, DOI 10.1128/MCB.9.2.701; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS RE, 1991, DEVELOPMENT, V112, P591; ELLIS RE, 1991, GENETICS, V129, P79; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; HEDGECOCK EM, 1983, SCIENCE, V220, P1277, DOI 10.1126/science.6857247; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; NGUYEN M, 1994, J BIOL CHEM, V269, P16521; Shaham S, 1996, CELL, V86, P201, DOI 10.1016/S0092-8674(00)80092-6; Shaham S, 1996, GENE DEV, V10, P578, DOI 10.1101/gad.10.5.578; Simonian PL, 1996, J BIOL CHEM, V271, P22764, DOI 10.1074/jbc.271.37.22764; TANAKA S, 1993, J BIOL CHEM, V268, P10920; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wu D., UNPUB; YUAN JY, 1992, DEVELOPMENT, V116, P309; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	26	294	306	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 21	1997	275	5303					1126	1129		10.1126/science.275.5303.1126	http://dx.doi.org/10.1126/science.275.5303.1126			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WJ503	9027313				2022-12-01	WOS:A1997WJ50300044
J	Taylor, SJC; Whincup, PH; Cook, DG; Papacosta, O; Walker, M				Taylor, SJC; Whincup, PH; Cook, DG; Papacosta, O; Walker, M			Size at birth and blood pressure: Cross sectional study in 8-11 year old children	BRITISH MEDICAL JOURNAL			English	Article							CARDIOVASCULAR-DISEASE; ADULT LIFE; FETAL INFLUENCES; GROWTH; CHILDHOOD; WEIGHT; HYPERTENSION; DEATH	Objective: To identify which patterns of fetal growth, represented by different measurements of size at birth, are associated with increased blood pressure in children aged 8-11 years. Design and setting: School based, cross sectional survey conducted in 10 towns in England and Wales in 1994, Subjects: 3010 singleton children (response rate 75%) with physical measurements and information on birth weight from parental questionnaires. Hospital birth records were examined for 1573, Main outcome measures: Systolic and diastolic blood pressure at age 8-11 years. Results: In the whole group birth weight was inversely related to systolic pressure (regression coefficient -1.48 mm Hg/kg; 95% confidence interval -2.20 to -0.76) after adjustment for current body size. There was no significant association between birth weight and diastolic pressure, The association with systolic pressure was much stronger in girls (-2.54 mm Hg/kg; -3.60 to -1.48) than in boys (-0,64 mm Hg/kg; -1.58 to 0.30), with a significant difference between the sexes (P=0,006), Among the other neonatal measures, head circumference and placental weight were inversely associated with subsequent blood pressure in girls, and placental ratio (placental weight:birth weight) was positively associated with blood pressure in boys, Neither ponderal index at birth nor length:head circumference ratio was related to blood pressure in either sex. Conclusions: In these contemporary children the association between birth weight and blood pressure was apparent only in girls. There was no evidence that measures of size at birth, which may be related to nutrition at critical periods of pregnancy (thinness at birth or shortness in relation to head circumference), are related to blood pressure in the offspring.			Taylor, SJC (corresponding author), ROYAL FREE HOSP,SCH MED,CARDIOVASC RES GRP,DEPT PRIMARY CARE & POPULAT SCI,LONDON NW3 2PF,ENGLAND.		TAYLOR, STEPHANIE/GYV-4768-2022	Whincup, Peter/0000-0002-5589-4107; Taylor, Stephanie/0000-0001-7454-6354; Cook, Derek/0000-0002-9723-5759; Papacosta, Olia/0000-0001-8781-6747	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Barker D J, 1992, Paediatr Perinat Epidemiol, V6, P35, DOI 10.1111/j.1365-3016.1992.tb00741.x; Barker D. J., 1994, MOTHERS BABIES DIS L, P14; Barker D. J. P., 1994, MOTHERS BABIES DIS L; BARKER DJP, 1989, BRIT MED J, V298, P564, DOI 10.1136/bmj.298.6673.564; BARKER DJP, 1993, BRIT MED J, V306, P422, DOI 10.1136/bmj.306.6875.422; BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BARKER DJP, 1994, MOTHERS BABIES DIS L, P121; CHANG TC, 1993, EARLY HUM DEV, V35, P37, DOI 10.1016/0378-3782(93)90137-J; CHINN S, 1994, PAEDIATR PERINAT EP, V8, P90, DOI 10.1111/j.1365-3016.1994.tb00438.x; EATONEVANS J, 1986, HUM NUTR-APPL NUTR, V40A, P171; Forrester TE, 1996, BRIT MED J, V312, P156; FROHLICH ED, 1988, CIRCULATION, V77, P502; Hashimoto N, 1996, ACTA PAEDIATR, V85, P132, DOI 10.1111/j.1651-2227.1996.tb13978.x; LAW C, 1995, J HUM HYPERTENS, V9, P649; Law CM, 1996, J HYPERTENS, V14, P935; LAW CM, 1991, ARCH DIS CHILD, V66, P1291, DOI 10.1136/adc.66.11.1291; Leon DA, 1996, BRIT MED J, V312, P401, DOI 10.1136/bmj.312.7028.401; MACINTYRE S, 1991, J EPIDEMIOL COMMUN H, V45, P143, DOI 10.1136/jech.45.2.143; MARTYN CN, 1995, BRIT HEART J, V73, P116; Moore VM, 1996, ARCH DIS CHILD, V74, P538, DOI 10.1136/adc.74.6.538; MORLEY R, 1994, ARCH DIS CHILD, V70, P536, DOI 10.1136/adc.70.6.536; MUTCH L, 1995, PEDIATR RES, V38, P447; OSMOND C, 1993, BRIT MED J, V307, P1519, DOI 10.1136/bmj.307.6918.1519; RAMSEY M, 1979, MED BIOL ENG COMPUT, V17, P11, DOI 10.1007/BF02440948; SEIDMAN DS, 1991, BMJ-BRIT MED J, V302, P1235, DOI 10.1136/bmj.302.6787.1235; Simpson A, 1981, HYPERTENSION YOUNG O, P153; WHINCUP P, 1995, BRIT MED J, V311, P773, DOI 10.1136/bmj.311.7008.773; WHINCUP PH, 1992, J EPIDEMIOL COMMUN H, V46, P164, DOI 10.1136/jech.46.2.164; Whincup PH, 1996, BMJ-BRIT MED J, V313, P79, DOI 10.1136/bmj.313.7049.79; WHINCUP PH, 1992, ARCH DIS CHILD, V67, P1423, DOI 10.1136/adc.67.12.1423; WHINCUP PH, 1989, BMJ-BRIT MED J, V299, P587, DOI 10.1136/bmj.299.6699.587; WILLIAMS S, 1992, J CLIN EPIDEMIOL, V45, P1257, DOI 10.1016/0895-4356(92)90167-L; [No title captured]	34	105	111	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 15	1997	314	7079					475	480		10.1136/bmj.314.7079.475	http://dx.doi.org/10.1136/bmj.314.7079.475			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WJ419	9056797	Green Published			2022-12-01	WOS:A1997WJ41900025
J	Watson, AJM; DuBois, RN				Watson, AJM; DuBois, RN			Lipid metabolism and APC: Implications for colorectal cancer prevention	LANCET			English	Editorial Material									VANDERBILT UNIV,MED CTR,NASHVILLE,TN 37232	Vanderbilt University	Watson, AJM (corresponding author), UNIV MANCHESTER,HOPE HOSP,DEPT MED,ECCLES OLD RD,SALFORD M6 8HD,LANCS,ENGLAND.		DuBois, Raymond N./AAX-8869-2020					DuBois RN, 1996, GASTROENTEROL CLIN N, V25, P773, DOI 10.1016/S0889-8553(05)70274-0; Gould KA, 1996, CELL GROWTH DIFFER, V7, P1361; HARWIG SSL, 1995, J CLIN INVEST, V95, P603, DOI 10.1172/JCI117704; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Pritchard DM, 1996, PHARMACOL THERAPEUT, V72, P149, DOI 10.1016/S0163-7258(96)00102-7; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; VANE J, 1994, NATURE, V367, P243	10	14	14	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 15	1997	349	9050					444	445		10.1016/S0140-6736(97)22007-6	http://dx.doi.org/10.1016/S0140-6736(97)22007-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH389	9040567				2022-12-01	WOS:A1997WH38900002
J	Ridker, PM; Hennekens, CH; Schmitz, C; Stampfer, MJ; Lindpaintner, K				Ridker, PM; Hennekens, CH; Schmitz, C; Stampfer, MJ; Lindpaintner, K			Pl(A1/A2) polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis	LANCET			English	Article							CORONARY INTERVENTION; IIB/IIIA INTEGRIN; RANDOMIZED TRIAL; RECEPTORS; BLOCKADE; GENE	Background The gene encoding the platelet glycoprotein I[la receptor (GPIIIa), shows polymorphism (P-A1/A2. In a previous study, men with acute coronary ischaemia were more likely than controls to carry the P/(A2) allele. This receptor has an important role in acute thrombus formation; these findings therefore raise the possibility of inherited platelet risk factors for both arterial and venous thrombosis. We investigated whether the P/(A2) allele is associated with myocardial infarction, stroke, and Venous thrombosis in a large prospective cohort of men in the USA. Methods 14916 initially healthy men participating in the Physicians' Health Study provided baseline blood specimens for DNA analysis and were followed prospectively for a mean of 8.6 years. 374 men had a first myocardial infarction, 209 stroke, and 121 venous thrombosis during follow-up (704 cases). Distribution of the P/(A1/A2) polymorphism was investigated by a PCR based on restriction-fragment length polymorphism in these men and in a sample of 704 matched study participants who remained free of thrombosis during follow-up (controls). Findings The frequency of the P/(A2) allele was similar to the control frequency (14.8%) among men who had myocardial infarction (13.5%, p=0.4), stroke (13.4%, p=0.5), or Venous thrombosis (14.5%, p=0.9). The relative risk of any Vascular event among men homozygous or heterozygous for P/(A2) compared with men homozygous for P/(A1) was 0.96 (95% CI 0.8-1.2). We found no evidence of association between the P/(A2) allele and myocardia[ infarction (relative risk 0.93 [95 0.7-1.2]), stroke (0.93 [0.7-1.3]), or venous thrombosis (1.07 [0.7-1.6]). There was no evidence of association in subgroup analyses by age, smoking status, and presence of family history of premature coronary disease, hypercholesterolaemia, hypertension, or diabetes. Aspirin use had no effect on these findings. Interpretation In a large cohort of apparently healthy men, carriage of the GPIIIa P/(A2) allele was not associated with any increase in subsequent risk of myocardial infarction, stroke, or Venous thrombosis.	BRIGHAM & WOMENS HOSP, DIV CARDIOVASC DIS, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, CHANNING LAB, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT AMBULATORY CARE & PREVENT, BOSTON, MA USA; HARVARD UNIV, SCH MED, CHILDRENS HOSP, DEPT CARDIOL, BOSTON, MA USA; HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT BIOL SCI, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Ridker, PM (corresponding author), BRIGHAM & WOMENS HOSP, DIV PREVENT MED, 900 COMMONWEALTH AVE E, BOSTON, MA 02115 USA.							BORNE AEGV, 1990, TRANSFUSION, V30, P477, DOI 10.1046/j.1537-2995.1990.30590296385.x; CALIFF RM, 1994, NEW ENGL J MED, V330, P956, DOI 10.1056/nejm199404073301402; COLLER BS, 1995, CIRCULATION, V92, P2373, DOI 10.1161/01.CIR.92.9.2373; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; JIN Y, 1993, BLOOD, V82, P2281; Kleiman NS, 1993, J AM COLL CARDIOL, V22, P381, DOI 10.1016/0735-1097(93)90041-X; LEFKOVITS J, 1995, NEW ENGL J MED, V332, P1553, DOI 10.1056/NEJM199506083322306; NEWMAN PJ, 1989, J CLIN INVEST, V83, P1778, DOI 10.1172/JCI114082; OHMAN EM, 1994, CIRCULATION, V90, P564; RIDKER PM, 1995, NEW ENGL J MED, V332, P912, DOI 10.1056/NEJM199504063321403; SCHULMAN SP, 1993, CIRCULATION, V88, P608; SIMOONS ML, 1994, CIRCULATION, V89, P596, DOI 10.1161/01.CIR.89.2.596; SIMSEK S, 1993, BLOOD, V81, P835; TCHENG JE, 1995, CIRCULATION, V91, P2151, DOI 10.1161/01.CIR.91.8.2151; THEROUX P, 1994, CIRCULATION, V90, P1; TOPOL EJ, 1994, LANCET, V343, P881, DOI 10.1016/S0140-6736(94)90007-8; Weiss EJ, 1996, NEW ENGL J MED, V334, P1090, DOI 10.1056/NEJM199604253341703	17	316	325	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 8	1997	349	9049					385	388		10.1016/S0140-6736(97)80010-4	http://dx.doi.org/10.1016/S0140-6736(97)80010-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH296	9033464				2022-12-01	WOS:A1997WH29600010
J	Naylor, AR; London, NJM; Bell, PRF				Naylor, AR; London, NJM; Bell, PRF			Carotid endarterectomy versus carotid angioplasty	LANCET			English	Editorial Material											Naylor, AR (corresponding author), LEICESTER ROYAL INFIRM,DEPT SURG,CLIN SCI BLDG,LEICESTER LE2 7LX,LEICS,ENGLAND.							Beebe HG, 1996, STROKE, V27, P197, DOI 10.1161/01.STR.27.2.197; Brown MM, 1996, STROKE, V27, P1435; BUCKENHAM T, 1996, P EUR SOC VASC SURG; *CAR VERT ART TRAN, 1996, STROKE, V27, P358; *EUR CAR SURG TRIA, 1991, LANCET, V337, P1235; HSAI DC, 1992, J VASC SURG, V16, P201; *N AM SYMPT CAR EN, 1991, NEW ENGL J MED, V325, P445; Sivaguru A, 1996, J ENDOVASC SURG, V3, P16, DOI 10.1583/1074-6218(1996)003<0016:ECAT>2.0.CO;2	8	32	32	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 18	1997	349	9046					203	204		10.1016/S0140-6736(96)07181-4	http://dx.doi.org/10.1016/S0140-6736(96)07181-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC861	9111559				2022-12-01	WOS:A1997WC86100048
J	Hollingsworth, H				Hollingsworth, H			Preventing insect sting anaphylaxis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							HYPERSENSITIVITY				Hollingsworth, H (corresponding author), BOSTON UNIV, SCH MED, CTR PULM, BOSTON, MA 02118 USA.			Hollingsworth, Helen/0000-0001-9007-9012				Golden DBK, 1996, J ALLERGY CLIN IMMUN, V97, P579, DOI 10.1016/S0091-6749(96)70302-0; HOLLINGSWORTH HM, 1996, INTENS CARE MED, P2401; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; REISMAN RE, 1992, J ALLERGY CLIN IMMUN, V90, P335, DOI 10.1016/S0091-6749(05)80012-0; REISMAN RE, 1985, J ALLERGY CLIN IMMUN, V75, P731, DOI 10.1016/0091-6749(85)90103-4; VALENTINE MD, 1992, JAMA-J AM MED ASSOC, V268, P2830, DOI 10.1001/jama.268.20.2830	6	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 16	1997	277	15					1196	1197		10.1001/jama.1997.03540390026016	http://dx.doi.org/10.1001/jama.1997.03540390026016			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WT403	9103334				2022-12-01	WOS:A1997WT40300015
J	Anker, SD; Ponikowski, P; Varney, S; Chua, TP; Clark, AL; WebbPeploe, KM; Harrington, D; Kox, WJ; PooleWilson, PA; Coats, AJS				Anker, SD; Ponikowski, P; Varney, S; Chua, TP; Clark, AL; WebbPeploe, KM; Harrington, D; Kox, WJ; PooleWilson, PA; Coats, AJS			Wasting as independent risk factor for mortality in chronic heart failure	LANCET			English	Article							TUMOR-NECROSIS-FACTOR; IDIOPATHIC DILATED CARDIOMYOPATHY; SURVIVAL; MALNUTRITION; CACHEXIA; AIDS	Background Wasting in chronic heart failure (CHF) has long been known but is little investigated. We sought to find out whether the cachectic state in CHF provides additional prognostic information about all-cause mortality. Methods Between June, 1993, and May, 1995, we studied 171 consecutive patients with CHF (mean age 60 years [SD 11; range 27-86]; 17 female). We assessed exercise capacity (peak oxygen consumption; mean 17.5 mL kg(-1) min(-1) [6.7]), functional status (New York Heart Association [NYHA] class: 21 class I, 63 class II, 68 class III, 19 class IV), and left-ventricular ejection fraction (mean 30% [SD 15]; n=115). The cachectic status was defined prospectively as a non-intentional documented weight loss of at least 75% of previous normal weight (28 patients; range 9-36% or 6-30 kg) during at least 6 months. The Cox proportional-hazards model was used to assess the association of variables with survival, and Kaplan-Meier cumulative survival plots were constructed to estimate the influence of risk factors. Findings At the end of follow-up in November, 1996, 49 patients had died (after a mean 324 days [SD 283]). The mean follow-up of the survivors was 834 days (SD 186; range 549-1269). The cachectic state was predictive of 18-month mortality independent of age, NYHA class, left-ventricular ejection fraction, and peak oxygen consumption. Mortality in the cachectic patients (n=28) was 18% at 3 months, 29% at 6 months, 39% at 12 months, and 50% at 18 months. Patients who had a peak oxygen consumption below 14 mL kg(-1) min(-1) (n=53) had mortality at 3, 6, 12, and 18 months of 19%, 30%, 40%, and 51%. 18-month survival was 23% (95% CI 0-46) for the 13 patients with both of these risk factors (cachexia and low peak oxygen consumption) compared with 93% (88-98) in those (n=103) with neither risk factor (p<0.0001). Interpretation The cachectic state is a strong independent risk factor for mortality in patients with CHF. Combined with a low peak oxygen consumption, it identifies a subset of patients at extremely high risk of death. Assessment of cachexia should be included in transplant programmes and studies that investigate the effect of interventions by survival analyses.	UNIV HALLE WITTENBERG,DEPT INTERNAL MED CARDIOL 3,HALLE,GERMANY; UNIV GLASGOW,WESTERN INFIRM,GLASGOW G11 6NT,LANARK,SCOTLAND; HUMBOLDT UNIV BERLIN,UNIV HOSP CHARITE,DEPT ANAESTHESIOL & INTENS CARE MED,BERLIN,GERMANY	Martin Luther University Halle Wittenberg; University of Glasgow; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Anker, SD (corresponding author), NATL HEART & LUNG INST,DEPT CARDIAC MED,DOVEHOUSE ST,LONDON SW3 6LY,ENGLAND.		Ponikowski, Piotr/O-6454-2015; Coats, Andrew J Stewart/E-4451-2012	Ponikowski, Piotr/0000-0002-3391-7064; Coats, Andrew J Stewart/0000-0002-2771-4260				ABEL RM, 1976, ARCH SURG-CHICAGO, V111, P45; Anker SD, 1996, LANCET, V348, P1530, DOI 10.1016/S0140-6736(05)66163-6; ANKER SD, IN PRESS CIRCULATION; CARR JG, 1989, AM J CARDIOL, V63, P709, DOI 10.1016/0002-9149(89)90256-7; CHLEBOWSKI RT, 1989, AM J GASTROENTEROL, V84, P1288; FERRARI R, 1995, CIRCULATION, V92, P1479, DOI 10.1161/01.CIR.92.6.1479; FRANCIOSA JA, 1983, AM J CARDIOL, V51, P831, DOI 10.1016/S0002-9149(83)80141-6; FRANCIS GS, 1993, CIRCULATION, V87, P40; KOTLER DP, 1989, AM J CLIN NUTR, V50, P444, DOI 10.1093/ajcn/50.3.444; LEE WH, 1986, CIRCULATION, V73, P257, DOI 10.1161/01.CIR.73.2.257; LEVINE B, 1990, NEW ENGL J MED, V323, P236, DOI 10.1056/NEJM199007263230405; MADSEN BK, 1994, EUR HEART J, V15, P303, DOI 10.1093/oxfordjournals.eurheartj.a060495; MANCINI DM, 1991, CIRCULATION, V83, P778, DOI 10.1161/01.CIR.83.3.778; Omland T, 1996, CIRCULATION, V93, P1963, DOI 10.1161/01.CIR.93.11.1963; OTAKI M, 1994, CHEST, V105, P1347, DOI 10.1378/chest.105.5.1347; Pacher R, 1996, J AM COLL CARDIOL, V27, P633, DOI 10.1016/0735-1097(95)00520-X; PARAMESHWAR J, 1992, AM HEART J, V123, P421, DOI 10.1016/0002-8703(92)90656-G; ROUL G, 1995, EUR HEART J, V16, P1387, DOI 10.1093/oxfordjournals.eurheartj.a060747; SOUHAMI RL, 1996, OXFORD TXB MED, P240; SWEDBERG K, 1990, CIRCULATION, V82, P1730, DOI 10.1161/01.CIR.82.5.1730; SZLACHCIC J, 1985, AM J CARDIOL, V55, P1037, DOI 10.1016/0002-9149(85)90742-8; TorreAmione G, 1996, J AM COLL CARDIOL, V27, P1201, DOI 10.1016/0735-1097(95)00589-7; TRACEY KJ, 1990, J CLIN INVEST, V86, P2014, DOI 10.1172/JCI114937; TSUTAMOTO T, 1995, AM J CARDIOL, V76, P803, DOI 10.1016/S0002-9149(99)80231-8	24	1005	1024	1	23	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 12	1997	349	9058					1050	1053		10.1016/S0140-6736(96)07015-8	http://dx.doi.org/10.1016/S0140-6736(96)07015-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU002	9107242				2022-12-01	WOS:A1997WU00200008
J	White, KP; Hurban, P; Watanabe, T; Hogness, DS				White, KP; Hurban, P; Watanabe, T; Hogness, DS			Coordination of Drosophila metamorphosis by two ecdysone-induced nuclear receptors	SCIENCE			English	Article							SEQUENTIAL GENE ACTIVATION; SUPERFAMILY MEMBERS; INDUCIBLE GENE; EARLY PUFF; ENCODES 2; TRANSCRIPTION; ULTRASPIRACLE; MELANOGASTER; EXPRESSION; PROTEINS	The functions of the ecdysone-induced DHR3 and E75B orphan nuclear receptors in the early stages of Drosophila metamorphosis were investigated, DHR3 represses the ecdysone induction of early genes turned on by the pulse of ecdysone that triggers metamorphosis. It also induces beta FTZF1, an orphan nuclear receptor that is essential for the appropriate response to the subsequent prepupal pulse of ecdysone. The E75B receptor, which lacks a complete DNA binding domain, inhibits this inductive function by forming a complex with DHR3 on the beta FTZF1 promoter, thereby providing a timing mechanism for beta FTZF1 induction that is dependent on the disappearance of E75B.	STANFORD UNIV,DEPT DEV BIOL,SCH MED,BECKMAN CTR B300,STANFORD,CA 94305; STANFORD UNIV,DEPT BIOCHEM,SCH MED,BECKMAN CTR B300,STANFORD,CA 94305	Stanford University; Stanford University								ANDRES AJ, 1994, METHOD CELL BIOL, V44, P565, DOI 10.1016/S0091-679X(08)60932-2; ANDRES AJ, 1993, DEV BIOL, V160, P388, DOI 10.1006/dbio.1993.1315; ARBEITMAN MN, UNPUB; Ashburner M, 1974, Cold Spring Harb Symp Quant Biol, V38, P655; BATE M, 1993, DEV DROSOPHILA METAN, V2, P1013; BERNARD HU, 1987, EMBO J, V6, P133, DOI 10.1002/j.1460-2075.1987.tb04730.x; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; BURTIS KC, 1985, THESIS STANFORD U; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; Fristrom D., 1993, DEV DROSOPHILA MELAN, P843; HARPER JW, 1993, CELL, V75, P805; HORNER MA, 1995, DEV BIOL, V168, P490, DOI 10.1006/dbio.1995.1097; HUET F, 1995, DEVELOPMENT, V121, P1195; JOHANSEN H, 1989, GENE DEV, V3, P882, DOI 10.1101/gad.3.6.882; KAGEYAMA Y, COMMUNICATION; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; KOELLE MR, 1992, P NATL ACAD SCI USA, V89, P6167, DOI 10.1073/pnas.89.13.6167; KOELLE MR, 1992, THESIS STANFORD U; LAM GT, IN PRESS DEVELOPMENT; LAVORGNA G, 1993, P NATL ACAD SCI USA, V90, P3004, DOI 10.1073/pnas.90.7.3004; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MARONI G, 1983, DROS INFORM SERV, V59, P142; RICHARDS G, 1976, DEV BIOL, V54, P264, DOI 10.1016/0012-1606(76)90304-3; Riddiford L., 1993, DEV DROSOPHILA MELAN, V2, P899; SEGRAVES WA, 1990, GENE DEV, V4, P204, DOI 10.1101/gad.4.2.204; SEGRAVES WA, 1988, THESIS STANFORD U; Seol W, 1996, SCIENCE, V272, P1336, DOI 10.1126/science.272.5266.1336; Skaer H., 1993, DEV DROSOPHILA MELAN, V2, P941; TALBOT WS, 1993, CELL, V73, P1323, DOI 10.1016/0092-8674(93)90359-X; THOMAS HE, 1993, NATURE, V362, P471, DOI 10.1038/362471a0; THUMMEL CS, 1990, CELL, V61, P101, DOI 10.1016/0092-8674(90)90218-4; THUMMEL CS, 1995, CELL, V83, P871, DOI 10.1016/0092-8674(95)90203-1; WATANABE T, UNPUB; WOODARD CT, 1994, CELL, V79, P607, DOI 10.1016/0092-8674(94)90546-0; YAO TP, 1993, NATURE, V366, P476, DOI 10.1038/366476a0; YAO TP, 1992, CELL, V71, P63, DOI 10.1016/0092-8674(92)90266-F	36	240	247	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 4	1997	276	5309					114	117		10.1126/science.276.5309.114	http://dx.doi.org/10.1126/science.276.5309.114			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WR386	9082981				2022-12-01	WOS:A1997WR38600059
J	Ishihara, H; Connolly, AJ; Zeng, DW; Kahn, ML; Zheng, YW; Timmons, C; Tram, T; Coughlin, SR				Ishihara, H; Connolly, AJ; Zeng, DW; Kahn, ML; Zheng, YW; Timmons, C; Tram, T; Coughlin, SR			Protease-activated receptor 3 is a second thrombin receptor in humans	NATURE			English	Article							MOLECULAR-CLONING; AGONIST PEPTIDES; HUMAN PLATELETS; ALPHA-THROMBIN; SPECIFICITY; MECHANISM; CLEAVAGE; HIRUDIN; CELLS	Thrombin is a coagulation protease that activates platelets, leukocytes, endothelial and mesenchymal cells at sites of vascular injury, acting partly through an unusual proteolytically activated G-protein-coupled receptor(1-3). Knockout of the gene encoding this receptor provided definitive evidence for a second thrombin receptor in mouse platelets and for tissue-specific roles for different thrombin receptors(4) We now report the cloning and characterization of a new human thrombin receptor, designated protease-activated receptor 3 (PAR3). PAR3 can mediate thrombin-triggered phosphoinositide hydrolysis and is expressed in a variety of tissues, including human bone marrow and mouse megakaryocytes, making it a candidate for the sought-after second platelet thrombin receptor. PAR3 provides a new tool for understanding thrombin signalling and a possible target for therapeutics designed selectively to block thrombotic, inflammatory and proliferative responses to thrombin.	UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DAIICHI RES CTR,DEPT PATHOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DAIICHI RES CTR,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco								AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; BRASS LF, 1992, J BIOL CHEM, V267, P13795; CHEN J, 1994, J BIOL CHEM, V269, P16041; Connolly AJ, 1996, NATURE, V381, P516, DOI 10.1038/381516a0; CONNOLLY TM, 1994, THROMB HAEMOSTASIS, V72, P627; COUGHLIN SR, 1994, TRENDS CARDIOVAS MED, V4, P77, DOI 10.1016/1050-1738(94)90013-2; DERIAN CK, 1995, THROMB RES, V78, P505, DOI 10.1016/0049-3848(95)00084-5; FENTON JW, 1988, SEMIN THROMB HEMOST, V14, P234, DOI 10.1055/s-2007-1002783; GERSZTEN RE, 1994, NATURE, V368, P648, DOI 10.1038/368648a0; GOODWIN CA, 1994, BIOCHEM BIOPH RES CO, V202, P321, DOI 10.1006/bbrc.1994.1930; HUNG DT, 1992, J CLIN INVEST, V89, P1350, DOI 10.1172/JCI115721; ISHII K, 1995, J BIOL CHEM, V270, P16435, DOI 10.1074/jbc.270.27.16435; ISHII K, 1993, J BIOL CHEM, V268, P9780; KETTNER C, 1979, THROMB RES, V14, P969, DOI 10.1016/0049-3848(79)90014-8; KRAMER RM, 1995, J BIOL CHEM, V270, P14816, DOI 10.1074/jbc.270.24.14816; LAU LF, 1994, BIOCHEM J, V303, P391, DOI 10.1042/bj3030391; LIU LW, 1991, J BIOL CHEM, V266, P16977; MATHEWS II, 1994, BIOCHEMISTRY-US, V33, P3266, DOI 10.1021/bi00177a018; Nanevicz T, 1996, J BIOL CHEM, V271, P702, DOI 10.1074/jbc.271.2.702; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; RATHBONE RK, 1993, THROMB HAEMOSTASIS, V70, P1019; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; RYDEL TJ, 1994, J BIOL CHEM, V269, P22000; SCARBOROUGH RM, 1992, J BIOL CHEM, V267, P13146; SKRZYPCZAKJANKUN E, 1991, J MOL BIOL, V221, P1379; SOIFER SJ, 1994, AM J PATHOL, V144, P60; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; WILLIAMS JA, 1988, P NATL ACAD SCI USA, V85, P4939, DOI 10.1073/pnas.85.13.4939	30	774	799	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 3	1997	386	6624					502	506		10.1038/386502a0	http://dx.doi.org/10.1038/386502a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WR256	9087410				2022-12-01	WOS:A1997WR25600054
J	Kempermann, G; Kuhn, HG; Gage, FH				Kempermann, G; Kuhn, HG; Gage, FH			More hippocampal neurons in adult mice living in an enriched environment	NATURE			English	Article							DENTATE GYRUS; RAT; BRAIN; NEUROGENESIS	Neurogenesis occurs in the dentate gyrus of the hippocampus throughout the life of a rodent(1-4), but the function of these new neurons and the mechanisms that regulate their birth are unknown, Here we show that significantly more new neurons exist in the dentate gyrus of mice exposed to an enriched environment compared with littermates housed in standard cages. We also show, using unbiased stereology, that the enriched mice have a larger hippocampal granule cell layer and 15 per cent more granule cell neurons in the dentate gyrus.	SALK INST BIOL STUDIES,GENET LAB,LA JOLLA,CA 92037	Salk Institute			Kempermann, Gerd/F-5416-2010; Kuhn, Hans-Georg/L-8127-2014	Kempermann, Gerd/0000-0002-5304-4061; Kuhn, Hans-Georg/0000-0003-4247-5613				ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; ALTMAN J, 1964, NATURE, V204, P1161, DOI 10.1038/2041161a0; CAMERON HA, 1995, J NEUROSCI, V15, P4687; CAMERON HA, 1993, NEUROSCIENCE, V56, P337, DOI 10.1016/0306-4522(93)90335-D; Coggeshall RE, 1996, J COMP NEUROL, V364, P6, DOI 10.1002/(SICI)1096-9861(19960101)364:1<6::AID-CNE2>3.0.CO;2-9; Craig CG, 1996, J NEUROSCI, V16, P2649; CUMMINS RA, 1977, SCIENCE, V197, P692, DOI 10.1126/science.877587; CUMMINS RA, 1973, NATURE, V243, P516, DOI 10.1038/243516a0; DELRIO JA, 1989, DEV BRAIN RES, V49, P311, DOI 10.1016/0165-3806(89)90033-3; FIALA BA, 1978, EXP NEUROL, V59, P372, DOI 10.1016/0014-4886(78)90229-7; GREENOUGH WT, 1975, AM SCI, V63, P37; GUNDERSEN HJG, 1988, APMIS, V96, P857, DOI 10.1111/j.1699-0463.1988.tb00954.x; KAPLAN MS, 1977, SCIENCE, V197, P1092, DOI 10.1126/science.887941; Kuhn HG, 1996, J NEUROSCI, V16, P2027; McEwen BS, 1996, CELL MOL NEUROBIOL, V16, P103, DOI 10.1007/BF02088170; MEANEY MJ, 1988, SCIENCE, V239, P766, DOI 10.1126/science.3340858; PACTEAU C, 1989, BEHAV BRAIN RES, V34, P79, DOI 10.1016/S0166-4328(89)80092-0; PALMER TD, 1995, MOL CELL NEUROSCI, V6, P474, DOI 10.1006/mcne.1995.1035; REYNOLDS BA, 1992, J NEUROSCI, V12, P4565, DOI 10.1523/jneurosci.12-11-04565.1992; ROSENZWE.MR, 1966, AM PSYCHOL, V21, P321, DOI 10.1037/h0023555; ROSENZWEIG MR, 1962, J COMP PHYSIOL PSYCH, V55, P429, DOI 10.1037/h0041137; ROSENZWEIG MR, 1978, BRAIN RES, V153, P563, DOI 10.1016/0006-8993(78)90340-2; SLOVITER RS, 1989, J COMP NEUROL, V280, P183, DOI 10.1002/cne.902800203; WAINWRIGHT PE, 1994, BEHAV BRAIN RES, V60, P125, DOI 10.1016/0166-4328(94)90139-2; WALSH RN, 1979, INT J NEUROSCI, V9, P209, DOI 10.3109/00207457909147675; WALSH RN, 1969, J COMP NEUROL, V137, P361, DOI 10.1002/cne.901370309; WEST MJ, 1993, NEUROBIOL AGING, V14, P275, DOI 10.1016/0197-4580(93)90112-O; WIMER RE, 1978, BRAIN RES, V157, P105, DOI 10.1016/0006-8993(78)90999-X	28	2640	2735	5	192	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 3	1997	386	6624					493	495		10.1038/386493a0	http://dx.doi.org/10.1038/386493a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WR256	9087407				2022-12-01	WOS:A1997WR25600051
J	Nightingale, SL				Nightingale, SL			Request for information on therapeutic switches	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 2	1997	277	13					1029	1029						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ089	9091680				2022-12-01	WOS:A1997WQ08900008
J	Madden, K; Sheu, YJ; Baetz, K; Andrews, B; Snyder, M				Madden, K; Sheu, YJ; Baetz, K; Andrews, B; Snyder, M			SBF cell cycle regulator as a target of the yeast PKC-MAP kinase pathway	SCIENCE			English	Article							SIGNAL-TRANSDUCTION PATHWAY; SACCHAROMYCES-CEREVISIAE; G1 CYCLINS; PROTEIN; GENE; TRANSCRIPTION; HOMOLOG; COMPLEX; GROWTH; CLN1	Protein kinase C (PKC) signaling is highly conserved among eukaryotes and has been implicated in the regulation of cellular processes such as cell proliferation and growth. In the budding yeast, PKC1 functions to activate the SLT2(MPK1) mitogen-activated protein (MAP) kinase cascade, which is required for the maintenance of cell integrity during asymmetric cell growth. Genetic studies, coimmunoprecipitation experiments, and analysis of protein phosphorylation in vivo and in vitro indicate that the SBF transcription factor (composed of Swi4p and Swi6p), an important regulator of gene expression at the G(1) to S phase cell cycle transition, is a target of the Slt2p(Mpk1p) MAP kinase. These studies provide evidence for a direct role of the PKC1 pathway in the regulation of the yeast cell cycle and cell growth and indicate that conserved signaling pathways can act to control key regulators of cell division.	YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06520; UNIV TORONTO,DEPT MOL & MED GENET,TORONTO,ON M5S 1A8,CANADA	Yale University; University of Toronto			Baetz, Kristin/E-6859-2013	Snyder, Michael/0000-0003-0784-7987; Sheu, Yi-Jun/0000-0003-1612-5708	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036494] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM36494] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; ANDREWS BJ, 1989, CELL, V57, P21, DOI 10.1016/0092-8674(89)90168-2; ANDREWS BJ, 1989, NATURE, V342, P830, DOI 10.1038/342830a0; BAETZ K, UNPUB; Breeden L, 1996, CURR TOP MICROBIOL, V208, P95; CLARKWALKER GD, 1974, EUR J BIOCHEM, V41, P359, DOI 10.1111/j.1432-1033.1974.tb03278.x; COSTIGAN C, 1994, MOL CELL BIOL, V14, P2391, DOI 10.1128/MCB.14.4.2391; COSTIGAN C, 1992, MOL CELL BIOL, V12, P1162, DOI 10.1128/MCB.12.3.1162; COSTIGAN C, UNPUB; CROSS FR, 1990, MOL CELL BIOL, V10, P6482, DOI 10.1128/MCB.10.12.6482; DICOMO CJ, 1995, MOL CELL BIOL, V15, P1835; ERREDE B, 1995, MOL REPROD DEV, V42, P477, DOI 10.1002/mrd.1080420416; ESPINOZA FH, 1994, SCIENCE, V266, P1388, DOI 10.1126/science.7973730; FERNANDEZSARABIA MJ, 1992, GENE DEV, V6, P2417, DOI 10.1101/gad.6.12a.2417; FLESCHER EG, 1993, J CELL BIOL, V122, P373, DOI 10.1083/jcb.122.2.373; GEHRUNG S, 1990, J CELL BIOL, V111, P1451, DOI 10.1083/jcb.111.4.1451; Harlow E LD, 1988, ANTIBODIES LAB MANUA, V1st; Ho Y, 1997, P NATL ACAD SCI USA, V94, P581, DOI 10.1073/pnas.94.2.581; Igual JC, 1996, EMBO J, V15, P5001, DOI 10.1002/j.1460-2075.1996.tb00880.x; IRIE K, 1993, MOL CELL BIOL, V13, P3076, DOI 10.1128/MCB.13.5.3076; KAIBUCHI K, 1985, J BIOL CHEM, V260, P1366; KAMADA Y, 1995, GENE DEV, V9, P1559, DOI 10.1101/gad.9.13.1559; LEE KS, 1993, MOL CELL BIOL, V13, P5843, DOI 10.1128/MCB.13.9.5843; LEE KS, 1993, MOL CELL BIOL, V13, P3067, DOI 10.1128/MCB.13.5.3067; LEE KS, 1992, MOL CELL BIOL, V12, P172, DOI 10.1128/MCB.12.1.172; LEVIN DE, 1995, CURR OPIN CELL BIOL, V7, P197, DOI 10.1016/0955-0674(95)80028-X; LEVIN DE, 1992, J CELL BIOL, V116, P1221, DOI 10.1083/jcb.116.5.1221; LEW DJ, 1993, J CELL BIOL, V120, P1305, DOI 10.1083/jcb.120.6.1305; Marini NJ, 1996, EMBO J, V15, P3040, DOI 10.1002/j.1460-2075.1996.tb00667.x; MAZZONI C, 1993, J CELL BIOL, V123, P1821, DOI 10.1083/jcb.123.6.1821; MEASDAY V, 1994, SCIENCE, V266, P1391, DOI 10.1126/science.7973731; MICHAK H, 1993, J BIOL CHEM, V268, P20110; MORGAN BA, 1995, EMBO J, V14, P5679, DOI 10.1002/j.1460-2075.1995.tb00255.x; NASMYTH K, 1991, CELL, V66, P995, DOI 10.1016/0092-8674(91)90444-4; OGAS J, 1991, CELL, V66, P1015, DOI 10.1016/0092-8674(91)90445-5; PARAVICINI G, 1992, MOL CELL BIOL, V12, P4896, DOI 10.1128/MCB.12.11.4896; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; PRIMIG M, 1992, NATURE, V358, P593, DOI 10.1038/358593a0; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; ROSENGURT E, 1984, P NATL ACAD SCI USA, V81, P5748; SHERMAN F, 1986, COLD SPRING HARBOR L; SIDOROVA J, 1993, MOL CELL BIOL, V13, P1069, DOI 10.1128/MCB.13.2.1069; SIDOROVA JM, 1995, MOL BIOL CELL, V6, P1641, DOI 10.1091/mbc.6.12.1641; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; SNYDER M, 1989, J CELL BIOL, V108, P1419, DOI 10.1083/jcb.108.4.1419; TORRES L, 1991, MOL MICROBIOL, V5, P2845, DOI 10.1111/j.1365-2958.1991.tb01993.x; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TYERS M, 1993, EMBO J, V12, P1955, DOI 10.1002/j.1460-2075.1993.tb05845.x; TYERS M, 1993, MOL CELL BIOL, V13, P5659, DOI 10.1128/MCB.13.9.5659; WATANABE Y, 1995, MOL CELL BIOL, V15, P5740; Zarzov P, 1996, EMBO J, V15, P83, DOI 10.1002/j.1460-2075.1996.tb00336.x	52	211	212	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 21	1997	275	5307					1781	1784		10.1126/science.275.5307.1781	http://dx.doi.org/10.1126/science.275.5307.1781			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WP056	9065400				2022-12-01	WOS:A1997WP05600038
J	Ardissino, D; Merlini, PA; Ariens, R; Coppola, R; Bramucci, E; Mannucci, PM				Ardissino, D; Merlini, PA; Ariens, R; Coppola, R; Bramucci, E; Mannucci, PM			Tissue-factor antigen and activity in human coronary atherosclerotic plaques	LANCET			English	Article							ARTERY DISEASE; ISCHEMIC DEATH; THROMBOSIS; PATHOGENESIS; MECHANISMS; HEMOSTASIS; EXPRESSION	Background Coronary atherosclerotic-plaque thrombosis is a key event in the pathogenesis of unstable angina and myocardial infarction. Although plaque rupture or fissuring frequently occurs in atherosclerosis, only a small proportion of ruptured plaques develop thromboses. Methods Tissue-factor antigen and activity were measured in atherectomy samples from 50 consecutive patients with coronary artery disease (stable angina n=19, unstable angina n=24, and myocardial infarction n=7). Findings Median tissue-factor antigen and activity concentrations were significantly higher in plaques from patients with unstable angina and myocardial infarction than in those from patients with stable angina (antigen: 66.1 pg/mg [interquartile range 43.8-82.5] vs 32.4 pg/mg [9.8-43.4], p=0.0001; activity: 0.22 mU/mg [0.17-0.41] vs 0.13 mU/mg [0.05-0.16], p=0.0004). Interpretation Tissue-factor, an initiator of the coagulation cascade, may account for the different thrombotic responses to the rupture of human coronary atherosclerotic plaques.	NIGUARDA HOSP,DIV CARDIOL 2,MILAN,ITALY; UNIV MILAN,IRCCS MAGGIORE HOSP,ANGELO BIANCHI BONOMI HAEMOPHILIA & THROMBOSIS CT,I-20122 MILAN,ITALY; UNIV MILAN,IRCCS MAGGIORE HOSP,INST INTERNAL MED,I-20122 MILAN,ITALY	IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan	Ardissino, D (corresponding author), IRCCS POLICLIN SAN MATTEO,DIV CARDIOL,PIAZZALE GOLGI 1,I-27100 PAVIA,ITALY.		Ardissino, Diego/AAC-4041-2022	solinas, emilia/0000-0003-3532-1317; Ariens, Robert/0000-0002-6310-5745				ANNEX BH, 1995, CIRCULATION, V91, P619, DOI 10.1161/01.CIR.91.3.619; DAVIES MJ, 1989, EUR HEART J, V10, P203, DOI 10.1093/oxfordjournals.eurheartj.a059467; DAVIES MJ, 1984, NEW ENGL J MED, V310, P1137, DOI 10.1056/NEJM198405033101801; DRAKE TA, 1989, AM J PATHOL, V134, P1087; FALK E, 1985, CIRCULATION, V71, P699, DOI 10.1161/01.CIR.71.4.699; FERNANDEZORTIZ A, 1994, J AM COLL CARDIOL, V23, P1562, DOI 10.1016/0735-1097(94)90657-2; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; FUSTER V, 1992, NEW ENGL J MED, V326, P310; Marmur JD, 1996, CIRCULATION, V94, P1226, DOI 10.1161/01.CIR.94.6.1226; NEMERSON Y, 1988, BLOOD, V71, P1; TOSCHI V, 1995, CIRCULATION S1, V92, P112; WILCOX JN, 1989, P NATL ACAD SCI USA, V86, P2839, DOI 10.1073/pnas.86.8.2839	12	206	216	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 15	1997	349	9054					769	771		10.1016/S0140-6736(96)11189-2	http://dx.doi.org/10.1016/S0140-6736(96)11189-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN124	9074577				2022-12-01	WOS:A1997WN12400012
J	Valley, JW; Eiler, JM; Graham, CM; Gibson, EK; Romanek, CS; Stolper, EM				Valley, JW; Eiler, JM; Graham, CM; Gibson, EK; Romanek, CS; Stolper, EM			Low-temperature carbonate concretions in the Martian meteorite ALH84001: Evidence from stable isotopes and mineralogy	SCIENCE			English	Article							MARS VOLATILE EVOLUTION; SNC METEORITES; SYSTEM CACO3-MGCO3-FECO3; OXYGEN; CALCITE; WATER; FRACTIONATION; QUARTZ; MODEL; THERMOMETRY	The martian meteorite ALH84001 contains small, disk-shaped concretions of carbonate with concentric chemical and mineralogical zonation. Oxygen isotope compositions of these concretions, measured by ion microprobe, range from delta(18)O = +9.5 to +20.5 parts per thousand, Most of the core of one concretion is homogeneous (16.7 +/- 1.2 parts per thousand) and over 5 parts per thousand higher in delta(18)O than a second concretion. Orthopyroxene that hosts the secondary carbonates is isotopically homogeneous (delta(18)O = 4.6 +/- 1.2 parts per thousand). Secondary SiO2 has delta(18)O = 20.4 parts per thousand. Carbon isotope ratios measured from the core of one concretion average delta(13)C = 46 +/- 8 parts per thousand, consistent with formation on Mars. The isotopic variations and mineral compositions offer no evidence for high temperature (>650 degrees C) carbonate precipitation and suggest non-equilibrium processes at low temperatures (<similar to 300 degrees C).	CALTECH, DIV GEOL & PLANETARY SCI, PASADENA, CA 91125 USA; UNIV EDINBURGH, DEPT GEOL & GEOPHYS, EDINBURGH EH9 3JW, MIDLOTHIAN, SCOTLAND; NASA, LYNDON B JOHNSON SPACE CTR, HOUSTON, TX 77058 USA; UNIV GEORGIA, SAVANNAH RIVER ECOL LAB, AIKEN, SC 29802 USA	California Institute of Technology; University of Edinburgh; National Aeronautics & Space Administration (NASA); NASA JOHNSON SPACE CENTER; United States Department of Energy (DOE); Savannah River Ecology Laboratory; University System of Georgia; University of Georgia	Valley, JW (corresponding author), UNIV WISCONSIN, DEPT GEOL & GEOPHYS, 1215 W DAYTON ST, MADISON, WI 53706 USA.		Facility, Edinburgh Ion Microprobe/AAD-8512-2020; Valley, John W./B-3466-2011	Facility, Edinburgh Ion Microprobe/0000-0001-6248-6657; Valley, John W./0000-0003-3530-2722				Anderson T. F., 1983, SOC ECON PALEONT MIN, V10, P1, DOI [DOI 10.2110/SCN.83.01.0000, 10.2110/scn.83.01.0000]; ANDERSON TF, 1969, J GEOPHYS RES, V74, P3918, DOI 10.1029/JB074i015p03918; ANOVITZ LM, 1987, J PETROL, V28, P389, DOI 10.1093/petrology/28.2.389; ARUTHUR MA, 1987, ANN REV EARTH PLANET, V15, P47; BARNES I, 1971, GEOCHIM COSMOCHIM AC, V35, P699, DOI 10.1016/0016-7037(71)90068-8; BERMAN RG, 1988, J PETROL, V29, P445, DOI 10.1093/petrology/29.2.445; Bradley JP, 1996, GEOCHIM COSMOCHIM AC, V60, P5149, DOI 10.1016/S0016-7037(96)00383-3; CARR RH, 1985, NATURE, V314, P248, DOI 10.1038/314248a0; CHERNIAK DJ, 1995, EOS, V76, pF683; CHIBA H, 1989, GEOCHIM COSMOCHIM AC, V53, P2985, DOI 10.1016/0016-7037(89)90174-9; CLARK ID, 1992, CHEM GEOL, V102, P217, DOI 10.1016/0009-2541(92)90157-Z; CLAYTON RN, 1988, GEOCHIM COSMOCHIM AC, V52, P925, DOI 10.1016/0016-7037(88)90363-8; Clayton RN, 1996, GEOCHIM COSMOCHIM AC, V60, P1999, DOI 10.1016/0016-7037(96)00074-9; CLAYTON RN, 1972, J GEOPHYS RES, V77, P3057, DOI 10.1029/JB077i017p03057; CLIFFORD SM, 1993, J GEOPHYS RES-PLANET, V98, P10973, DOI 10.1029/93JE00225; CRAIG JR, 1974, REV MINERALOGY MINER, V1; Crank J., 1979, MATH DIFFUSION; DAVIDSON PM, 1994, AM MINERAL, V79, P332; EILER JM, 1993, GEOCHIM COSMOCHIM AC, V57, P2571, DOI 10.1016/0016-7037(93)90418-V; EILER JM, 1995, AM MINERAL, V80, P757; EILER JM, IN PRESS CHEM GEOL; EILER JM, IN PRESS LUNAR PLANE; Farver JR, 1996, CONTRIB MINERAL PETR, V123, P77, DOI 10.1007/s004100050144; FARVER JR, 1994, EARTH PLANET SC LETT, V121, P575, DOI 10.1016/0012-821X(94)90092-2; GALIMOV EM, 1991, GEOCHIM COSMOCHIM AC, V55, P1697, DOI 10.1016/0016-7037(91)90140-Z; GRADY MM, 1994, METEORITICS, V29, P469; Graham CM, 1996, GEOCHIM COSMOCHIM AC, V60, P5101, DOI 10.1016/S0016-7037(96)00286-4; Harvey RP, 1996, NATURE, V382, P49, DOI 10.1038/382049a0; HARZMETZ CP, 1992, WORKSH MARS SURF ATM, P94; HAYES JM, 1993, MAR GEOL, V113, P111, DOI 10.1016/0025-3227(93)90153-M; HERVIG RL, 1995, GEOCHIM COSMOCHIM AC, V59, P2537, DOI 10.1016/0016-7037(95)00148-4; Hoefs J., 1997, STABLE ISOTOPE GEOCH, P201, DOI [DOI 10.1007/978-3-662-03377-7, 10.1007/978-3-662-03377-7]; JAKOSKY BM, 1993, GEOPHYS RES LETT, V20, P1591, DOI 10.1029/93GL01598; JAKOSKY BM, 1991, ICARUS, V94, P14, DOI 10.1016/0019-1035(91)90138-J; JOHANNES W, 1969, AM J SCI, V267, P1083, DOI 10.2475/ajs.267.9.1083; JULL AJT, 1995, METEORITICS, V30, P311, DOI 10.1111/j.1945-5100.1995.tb01129.x; Kirschvink JL, 1997, SCIENCE, V275, P1629, DOI 10.1126/science.275.5306.1629; KRONENBERG AK, 1984, PHYS CHEM MINER, V11, P101, DOI 10.1007/BF00309248; Leshin LA, 1996, GEOCHIM COSMOCHIM AC, V60, P2635, DOI 10.1016/0016-7037(96)00122-6; MARTINEZ I, 1994, EARTH PLANET SC LETT, V121, P559, DOI 10.1016/0012-821X(94)90091-4; MCCONNAUGHEY T, 1989, GEOCHIM COSMOCHIM AC, V53, P163, DOI 10.1016/0016-7037(89)90283-4; McKay DS, 1996, SCIENCE, V273, P924, DOI 10.1126/science.273.5277.924; MCSWIGGEN PL, 1993, PHYS CHEM MINER, V20, P42, DOI 10.1007/BF00202249; MINARIK WG, 1995, EARTH PLANET SC LETT, V133, P423, DOI 10.1016/0012-821X(95)00085-Q; MITTLEFEHLDT DW, 1994, METEORITICS, V29, P214, DOI 10.1111/j.1945-5100.1994.tb00673.x; MORRISON J, 1991, J GEOL, V99, P559, DOI 10.1086/629517; MORRISON J, 1988, GEOLOGY, V16, P513, DOI 10.1130/0091-7613(1988)016<0513:PGFFII>2.3.CO;2; Morse J. W., 1983, REV MINERAL, V11, P227; ONEIL JR, 1969, J CHEM PHYS, V51, P5547, DOI 10.1063/1.1671982; Reeder R.J., 1983, REV MINERAL, V11; REEDER RJ, 1992, REV MINERAL, V27, P381; ROMANEK CS, 1994, NATURE, V372, P655, DOI 10.1038/372655a0; ROSENBAUM JM, 1994, GEOCHIM COSMOCHIM AC, V58, P2653, DOI 10.1016/0016-7037(94)90135-X; SHARP ZD, 1994, GEOCHIM COSMOCHIM AC, V58, P4491, DOI 10.1016/0016-7037(94)90350-6; TREIMAN AH, 1995, METEORITICS, V30, P294, DOI 10.1111/j.1945-5100.1995.tb01127.x; VALLEY JW, 1993, SCIENCE, V259, P1729, DOI 10.1126/science.259.5102.1729; VALLEY JW, 1991, CONTRIB MINERAL PETR, V109, P38, DOI 10.1007/BF00687199; Valley JW, 1996, CONTRIB MINERAL PETR, V124, P225, DOI 10.1007/s004100050188; VALLEY JW, IN PRESS LUNAR PLANE; VALLEY JW, 1988, CRYSTALLINE BEDROCK, P156; VALLEY JW, IN PRESS REV EC GEOL, V7; VEIZER J, 1980, GEOCHIM COSMOCHIM AC, V44, P579, DOI 10.1016/0016-7037(80)90250-1; WOOD BJ, 1983, SCIENCE, V222, P413, DOI 10.1126/science.222.4622.413; WRIGHT IP, 1990, J GEOPHYS RES-SOLID, V95, P14789, DOI 10.1029/JB095iB09p14789; WRIGHT IP, 1992, GEOCHIM COSMOCHIM AC, V56, P817, DOI 10.1016/0016-7037(92)90100-W	65	146	150	0	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 14	1997	275	5306					1633	1638		10.1126/science.275.5306.1633	http://dx.doi.org/10.1126/science.275.5306.1633			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WN123	9054355				2022-12-01	WOS:A1997WN12300043
J	Moss, EG; Lee, RC; Ambros, V				Moss, EG; Lee, RC; Ambros, V			The cold shock domain protein LIN-28 controls developmental timing in C-elegans and is regulated by the lin-4 RNA	CELL			English	Article							HETEROCHRONIC GENE LIN-14; MURINE LEUKEMIA-VIRUS; ACID BINDING-PROTEINS; Y-BOX PROTEINS; CAENORHABDITIS-ELEGANS; NUCLEOCAPSID PROTEIN; MESSENGER-RNA; ZINC-FINGER; SEQUENCE-ANALYSIS; CRYSTAL-STRUCTURE	Mutations in the heterochronic gene lin-28 of C. elegans cause precocious development where diverse events specific to the second larval stage are skipped. lin-28 encodes a cytoplasmic protein with a cold shock domain and retroviral-type (CCHC) zinc finger motifs, consistent with a role for LIN-28 in posttranscriptional regulation. The 3'UTR of lin-28 contains a conserved element that is complementary to the 22 nt regulatory RNA product of lin-4 and that resembles seven such elements in the 3'UTR of the heterochronic gene lin-14. Both lin-4 activity and the lin-4-complementaty element (LCE) are necessary for stage-specific regulation of lin-28. Deleting the LCE produces a dominant gain-of-function allele that causes a retarded phenotype, indicating that lin-28 activity is a switch that controls choices of stage-specific fates.			Moss, EG (corresponding author), DARTMOUTH COLL, DEPT BIOL SCI, HANOVER, NH 03755 USA.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMBROS V, 1989, CELL, V57, P49, DOI 10.1016/0092-8674(89)90171-2; AMBROS V, 1984, SCIENCE, V226, P409, DOI 10.1126/science.6494891; AMBROS V, 1994, TRENDS GENET, V10, P123, DOI 10.1016/0168-9525(94)90213-5; AMBROS V, 1987, GENE DEV, V1, P398, DOI 10.1101/gad.1.4.398; ARASU P, 1991, GENE DEV, V5, P1825, DOI 10.1101/gad.5.10.1825; Ausubel F. M., 1994, CURRENT PROTOCOLS MO; BOUVET P, 1995, J BIOL CHEM, V270, P28297; CHALFIE M, 1981, CELL, V24, P59, DOI 10.1016/0092-8674(81)90501-8; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CLARKMAGUIRE S, 1994, GENETICS, V136, P533; DANNULL J, 1994, EMBO J, V13, P1525, DOI 10.1002/j.1460-2075.1994.tb06414.x; DARLIX JL, 1995, J MOL BIOL, V254, P523, DOI 10.1006/jmbi.1995.0635; DEOLIVEIRA DE, 1990, PLANT CELL, V2, P427, DOI 10.1105/tpc.2.5.427; DEROCQUIGNY H, 1993, NUCLEIC ACIDS RES, V21, P823; DESCHAMPS S, 1992, J BIOL CHEM, V267, P13799; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Euling S, 1996, CELL, V84, P667, DOI 10.1016/S0092-8674(00)81045-4; EVDOKIMOVA VM, 1995, J BIOL CHEM, V270, P3186, DOI 10.1074/jbc.270.7.3186; FITCH DHA, 1995, MOL BIOL EVOL, V12, P346; GORELICK RJ, 1988, P NATL ACAD SCI USA, V85, P8420, DOI 10.1073/pnas.85.22.8420; Graumann P, 1996, BIOESSAYS, V18, P309, DOI 10.1002/bies.950180409; Ha I, 1996, GENE DEV, V10, P3041, DOI 10.1101/gad.10.23.3041; JAEGER JA, 1990, METHOD ENZYMOL, V183, P281; KINGSLEY PD, 1994, PLANT CELL, V6, P1522, DOI 10.1105/tpc.6.11.1522; LADOMERY M, 1994, NUCLEIC ACIDS RES, V22, P5582, DOI 10.1093/nar/22.25.5582; LANDSMAN D, 1992, NUCLEIC ACIDS RES, V20, P2861, DOI 10.1093/nar/20.11.2861; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MERIC C, 1989, J VIROL, V63, P1558; MURRAY MT, 1992, P NATL ACAD SCI USA, V89, P11, DOI 10.1073/pnas.89.1.11; MURRAY MT, 1994, BIOCHEMISTRY-US, V33, P13910, DOI 10.1021/bi00250a046; OBOKATA J, 1991, PLANT MOL BIOL, V17, P953, DOI 10.1007/BF00037080; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; RAJAVASHISTH TB, 1989, SCIENCE, V245, P640, DOI 10.1126/science.2562787; RANJAN M, 1993, GENE DEV, V7, P1725, DOI 10.1101/gad.7.9.1725; RUVKUN G, 1989, NATURE, V338, P313, DOI 10.1038/338313a0; RUVKUN G, 1991, DEVELOPMENT, P47; SATO SM, 1991, DEVELOPMENT, V112, P747; SCHINDELIN H, 1993, NATURE, V364, P164, DOI 10.1038/364164a0; SCHRODER K, 1995, MOL MICROBIOL, V16, P699, DOI 10.1111/j.1365-2958.1995.tb02431.x; Sommerville J, 1996, FASEB J, V10, P435, DOI 10.1096/fasebj.10.4.8647342; SPIRIN AS, 1996, TRANSLATIONAL CONTRO, P319; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; TAFURI SR, 1990, P NATL ACAD SCI USA, V87, P9028, DOI 10.1073/pnas.87.22.9028; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; WIGHTMAN B, 1991, GENE DEV, V5, P1813, DOI 10.1101/gad.5.10.1813; WISTOW G, 1990, NATURE, V344, P823, DOI 10.1038/344823c0; WOLFFE AP, 1992, NEW BIOL, V4, P290; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407; Wood WB, 1988, NEMATODE CAENORHABDI	52	658	742	1	37	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 7	1997	88	5					637	646		10.1016/S0092-8674(00)81906-6	http://dx.doi.org/10.1016/S0092-8674(00)81906-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WM413	9054503	hybrid			2022-12-01	WOS:A1997WM41300009
J	Teare, EL; Barrett, SP				Teare, EL; Barrett, SP			Stop the ritual of tracing colonised people	BRITISH MEDICAL JOURNAL			English	Article							RESISTANT STAPHYLOCOCCUS-AUREUS; OUTBREAK		ST MARYS HOSP,SCH MED,DEPT MED MICROBIOL,LONDON,ENGLAND	Imperial College London	Teare, EL (corresponding author), CHELMSFORD PUBL HLTH LAB,CHELMSFORD CM2 0YX,ESSEX,ENGLAND.							BARRETT SP, 1993, J HOSP INFECT, V24, P313, DOI 10.1016/0195-6701(93)90064-7; BARRETT SP, 1988, POSTGRAD MED J, V64, P606, DOI 10.1136/pgmj.64.754.606; BENDALL RP, 1994, LANCET, V334, P819; COX RA, 1995, J HOSP INFECT, V29, P87, DOI 10.1016/0195-6701(95)90191-4; *DEP HLTH, 1990, GUID CLIN HLTH CAR W; Jepsen O B, 1980, J Hosp Infect, V1, P363, DOI 10.1016/0195-6701(80)90016-X; Marples R R, 1992, Commun Dis Rep CDR Rev, V2, pR25; MEHTAR S, 1989, J HOSP INFECT, V13, P199, DOI 10.1016/0195-6701(89)90028-5; PERDREAUREMINGTON F, 1995, J HOSP INFECT, V31, P195, DOI 10.1016/0195-6701(95)90066-7; PHILLIPS I, 1991, J HOSP INFECT, V18, P197, DOI 10.1016/0195-6701(91)90024-3; RILEY TV, 1995, J HOSP INFECT, V29, P177, DOI 10.1016/0195-6701(95)90327-5; Riley TV, 1995, MED J AUSTRALIA, V163, P412, DOI 10.5694/j.1326-5377.1995.tb124656.x; RIMIAND D, 1986, J CLIN MICROBIOL, V24, P137; Selkon J B, 1980, J Hosp Infect, V1, P41, DOI 10.1016/0195-6701(80)90030-4; VICKERY AM, 1993, J HOSP INFECT, V24, P139, DOI 10.1016/0195-6701(93)90076-C; VOSS A, 1994, EUR J CLIN MICROBIOL, V13, P50, DOI 10.1007/BF02026127; 1996, COMMUN DIS REP CDR W, V6, P197	17	51	52	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 1	1997	314	7081					665	666		10.1136/bmj.314.7081.665	http://dx.doi.org/10.1136/bmj.314.7081.665			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WL418	9066485	Green Published			2022-12-01	WOS:A1997WL41800035
J	Kong, TQ; Davidson, CJ; Meyers, SN; Tauke, JT; Parker, MA; Bonow, RO				Kong, TQ; Davidson, CJ; Meyers, SN; Tauke, JT; Parker, MA; Bonow, RO			Prognostic implication of creatine kinase elevation following elective coronary artery interventions	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIRECTIONAL ATHERECTOMY; ANGIOPLASTY; DISEASE; TRIAL; TRANSIENT; LESIONS; RELEASE; PHASE	Objective.-To determine the prognostic significance of creatine kinase (CK) elevation following elective percutaneous transluminal coronary angioplasty (PTCA). Design.-Retrospective cohort study, Setting.-Tertiary care referral center. Subjects.-A total of 253 consecutive patients with total CK and CK-MB fraction (CK-MB) elevation (case patients) and 120 patients without CK elevation (controls). Control patients had undergone interventions during the same month and year using the same devices. Main Outcome Measures.-In-hospital and late cardiac mortality, subsequent myocardial infarction, and the combined end point of cardiac mortality or myocardial infarction. Results.-Patient groups were similar with respect to age, sex, extent of coronary artery disease, left ventricular function, number of lesions treated by PTCA, and mean duration of follow-up (>3.5 years). Cardiac mortality was significantly greater (P=.02) for patients with CK elevation after PTCA, When patients were categorized according to peak CK elevation, cardiac mortality differed significantly among patient groups (P=.007), with increased cardiac mortality observed for patients with high (>3,0 times normal) and intermediate (1,5 to 3.0 times normal) CK elevations. In multivariate analyses, higher peak CK and lower ejection fraction were the most important predictors of increased cardiac mortality (both, P<.001); the relative risk for cardiac mortality was 1.05 (95% confidence interval, 1.03-1.08) per 100-U/L increment increase in CK. Conclusions.-Creatine kinase elevation following elective PTCA is associated with increased late cardiac mortality. This increase in cardiac mortality is independent of clinical variables, severity of heart disease, coronary artery lesion characteristics, interventional devices, and procedural outcomes. Even patients with lesser degrees of CK elevation are at significantly increased risk for late cardiac death.	NORTHWESTERN UNIV, SCH MED, DEPT INTERNAL MED, DIV CARDIOL, CHICAGO, IL USA	Northwestern University								ABDELMEGUID AE, 1995, CIRCULATION, V91, P2733, DOI 10.1161/01.CIR.91.11.2733; ADELMAN AG, 1993, NEW ENGL J MED, V329, P228, DOI 10.1056/NEJM199307223290402; BAIM DS, 1994, CIRCULATION, V90, P214; CALIFF RM, 1994, NEW ENGL J MED, V330, P956, DOI 10.1056/nejm199404073301402; CHESEBRO JH, 1987, CIRCULATION, V76, P142, DOI 10.1161/01.CIR.76.1.142; DETRE K, 1988, NEW ENGL J MED, V318, P265, DOI 10.1056/NEJM198802043180501; ELLIOTT JM, 1995, CIRCULATION, V91, P2158, DOI 10.1161/01.CIR.91.8.2158; ELLIS SG, 1990, CIRCULATION, V82, P1193, DOI 10.1161/01.CIR.82.4.1193; HOLMES DR, 1995, CIRCULATION, V91, P1966, DOI 10.1161/01.CIR.91.7.1966; HOSMER DW, 1989, APPL LOGISTIC REGRES, P74; KLEIN LW, 1991, J AM COLL CARDIOL, V17, P621, DOI 10.1016/S0735-1097(10)80174-3; KUGELMASS AD, 1994, AM J CARDIOL, V74, P748, DOI 10.1016/0002-9149(94)90427-8; LEON MB, 1994, CIRCULATION, V90, P213; MARK DB, 1994, CIRCULATION, V89, P2015, DOI 10.1161/01.CIR.89.5.2015; OH JK, 1985, AM HEART J, V109, P1225, DOI 10.1016/0002-8703(85)90343-6; RAVKILDE J, 1994, AM HEART J, V127, P13, DOI 10.1016/0002-8703(94)90504-5; TOPOL EJ, 1993, NEW ENGL J MED, V329, P221, DOI 10.1056/NEJM199307223290401; WAKSMAN R, 1993, CIRCULATION, V88, P299	18	250	258	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 12	1997	277	6					461	466		10.1001/jama.277.6.461	http://dx.doi.org/10.1001/jama.277.6.461			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WG054	9020269				2022-12-01	WOS:A1997WG05400032
J	Lamb, GC				Lamb, GC			Loading dose of warfarin	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							INDUCTION				Lamb, GC (corresponding author), MED COLL WISCONSIN,DEPT MED,MILWAUKEE,WI 53226, USA.							FENNERTY A, 1984, BRIT MED J, V288, P1268, DOI 10.1136/bmj.288.6426.1268; HARRISON J, 1997, ANN INTERN MED, V126, P133; HIRSH J, 1995, AM J CARDIOL, V75, pB39, DOI 10.1016/0002-9149(95)80009-H; HIRSH J, 1992, CHEST S, V102, pS313; IGUCHI A, 1994, THORAC CARDIOV SURG, V42, P222, DOI 10.1055/s-2007-1016492; OREILLY RA, 1968, CIRCULATION, V38, P169, DOI 10.1161/01.CIR.38.1.169	6	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 16	1997	277	15					1196	1196		10.1001/jama.1997.03540390026015	http://dx.doi.org/10.1001/jama.1997.03540390026015			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WT403	9103333				2022-12-01	WOS:A1997WT40300014
J	Huelsenbeck, JP; Rannala, B				Huelsenbeck, JP; Rannala, B			Phylogenetic methods come of age: Testing hypotheses in an evolutionary context	SCIENCE			English	Article							MAXIMUM-LIKELIHOOD; DNA-SEQUENCES; MOLECULAR EVOLUTION; SUBSTITUTION; RATES; INFERENCE; SIMULATION; PARSIMONY; PARASITES; OUTBREAK	The use of molecular phylogenies to examine evolutionary questions has become commonplace with the automation of DNA sequencing and the availability of efficient computer programs to perform phylogenetic analyses. The application of computer simulation and likelihood ratio tests to evolutionary hypotheses represents a recent methodological development in this field. Likelihood ratio tests have enabled biologists to address many questions in evolutionary biology that have been difficult td resolve in the past, such as whether host-parasite systems are cospeciating and whether models of DNA substitution adequately explain observed sequences.			Huelsenbeck, JP (corresponding author), UNIV CALIF BERKELEY, DEPT INTEGRAT BIOL, BERKELEY, CA 94720 USA.		Klein, Richard G/B-5910-2009; Rannala, Bruce/M-3188-2014; Huelsenbeck, John P/C-6398-2013	Rannala, Bruce/0000-0002-8355-9955; 	NIGMS NIH HHS [GM40282] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040282] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARCHIE JW, 1989, SYST ZOOL, V38, P239, DOI 10.2307/2992285; Barry D., 1987, STAT SCI, V2, P191, DOI DOI 10.1214/SS/1177013353; BROOKS DR, 1981, SYST ZOOL, V30, P229, DOI 10.2307/2413247; CAVALLISFORZA LL, 1967, AM J HUM GENET, V19, P233, DOI 10.2307/2406616; Chang JT, 1996, MATH BIOSCI, V134, P189, DOI 10.1016/0025-5564(95)00172-7; COX DR, 1962, J ROY STAT SOC B, V24, P406; COX DR, 1961, 4TH P BERK S MATH ST, V1, P105; DYKHUIZEN DE, 1991, J BACTERIOL, V173, P7257, DOI 10.1128/jb.173.22.7257-7268.1991; Edwards A.W.F., 1972, LIKELIHOOD; Edwards AWF, 1964, PHENETIC PHYLOGENETI, P67; FELSENSTEIN J, 1988, ANNU REV GENET, V22, P521, DOI 10.1146/annurev.ge.22.120188.002513; FELSENSTEIN J, 1978, SYST ZOOL, V27, P401, DOI 10.2307/2412923; FELSENSTEIN J, 1981, J MOL EVOL, V17, P368, DOI 10.1007/BF01734359; FELSENSTEIN J, 1985, AM NAT, V125, P1, DOI 10.1086/284325; FELSENSTEIN J, 1983, STAT ANAL DNA SEQUEN; GAUT BS, 1995, MOL BIOL EVOL, V12, P152, DOI 10.1093/oxfordjournals.molbev.a040183; GOLDMAN N, 1993, J MOL EVOL, V36, P182, DOI 10.1007/BF00166252; HAFNER MS, 1995, PHILOS T R SOC B, V349, P77, DOI 10.1098/rstb.1995.0093; HAFNER MS, 1988, NATURE, V332, P258, DOI 10.1038/332258a0; HAFNER MS, 1994, SCIENCE, V265, P1087, DOI 10.1126/science.8066445; Harvey P.H., 1991, COMP METHOD EVOLUTIO; HASEGAWA M, 1985, J MOL EVOL, V22, P160, DOI 10.1007/BF02101694; Henderson WW, 1995, VIROLOGY, V214, P602, DOI 10.1006/viro.1995.0071; Hibbett DS, 1996, MOL BIOL EVOL, V13, P903, DOI 10.1093/oxfordjournals.molbev.a025658; Hillis David M., 1996, P515; HILLIS DM, 1993, SYST BIOL, V42, P182, DOI 10.2307/2992540; HJELLE B, 1994, J VIROL, V68, P592, DOI 10.1128/JVI.68.2.592-596.1994; Huelsenbeck JP, 1996, SYST BIOL, V45, P92, DOI 10.2307/2413514; Huelsenbeck JP, 1996, SYST BIOL, V45, P546, DOI 10.2307/2413530; HUELSENBECK JP, 1995, MOL BIOL EVOL, V12, P843; Huelsenbeck JP, 1997, EVOLUTION, V51, P410, DOI [10.1111/j.1558-5646.1997.tb02428.x, 10.2307/2411113]; HUELSENBECK JP, 1995, SYST BIOL, V44, P17, DOI 10.2307/2413481; KING JL, 1969, SCIENCE, V164, P788, DOI 10.1126/science.164.3881.788; KUHNER MK, 1994, MOL BIOL EVOL, V11, P459; MADDISON WP, 1990, EVOLUTION, V44, P539, DOI 10.2307/2409434; NICHOL ST, 1993, SCIENCE, V262, P914, DOI 10.1126/science.8235615; OU CY, 1992, SCIENCE, V256, P1165, DOI 10.1126/science.256.5060.1165; Page RDM, 1996, SYST BIOL, V45, P151, DOI 10.2307/2413612; PALUMBI SR, 1989, J MOL EVOL, V29, P180, DOI 10.1007/BF02100116; Rice J.A, 2006, MATH STAT DATA ANAL, V3rd; RZHETSKY A, 1995, MOL BIOL EVOL, V12, P131, DOI 10.1093/oxfordjournals.molbev.a040182; SCHONIGER M, 1994, MOL PHYLOGENET EVOL, V3, P240, DOI 10.1006/mpev.1994.1026; SIMBERLOFF D, 1987, SYST ZOOL, V36, P175, DOI 10.2307/2413267; Swofford DL, 1996, SYST BIOL, V45, P575, DOI 10.2307/2413533; Swofford DL, 1996, PAUP PHYLOGENETIC AN; TATENO Y, 1994, MOL BIOL EVOL, V11, P261; Wald A, 1947, SEQUENTIAL ANAL; YANG ZB, 1994, J MOL EVOL, V39, P105; YANG ZH, 1994, MOL BIOL EVOL, V11, P316; YANG ZH, 1993, MOL BIOL EVOL, V10, P1396; YANG ZH, 1994, J MOL EVOL, V39, P306, DOI 10.1007/BF00160154; Yang ZH, 1996, J MOL EVOL, V42, P587, DOI 10.1007/BF02352289; YANG ZH, 1995, MOL BIOL EVOL, V12, P451	53	649	669	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 11	1997	276	5310					227	232		10.1126/science.276.5310.227	http://dx.doi.org/10.1126/science.276.5310.227			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WT925	9092465	Green Submitted			2022-12-01	WOS:A1997WT92500036
J	Li, J; Yen, C; Liaw, D; Podsypanina, K; Bose, S; Wang, SI; Puc, J; Miliaresis, C; Rodgers, L; McCombie, R; Bigner, SH; Giovanella, BC; Ittmann, M; Tycko, B; Hibshoosh, H; Wigler, MH; Parsons, R				Li, J; Yen, C; Liaw, D; Podsypanina, K; Bose, S; Wang, SI; Puc, J; Miliaresis, C; Rodgers, L; McCombie, R; Bigner, SH; Giovanella, BC; Ittmann, M; Tycko, B; Hibshoosh, H; Wigler, MH; Parsons, R			PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer	SCIENCE			English	Article							HUMAN GLIOMAS; REGION; IDENTIFICATION; DELETION; CLONING	Mapping of homozygous deletions on human chromosome 10q23 has led to the isolation of a candidate tumor suppressor gene, PTEN, that appears to be mutated at considerable frequency in human cancers. In preliminary screens, mutations of PTEN were detected in 31% (13/42) of glioblastoma cell lines and xenografts, 100% (4/4) of prostate cancer cell lines, 6% (4/65) of breast cancer cell lines and xenografts, and 17% (3/18) of primary glioblastomas. The predicted PTEN product has a protein tyrosine phosphatase domain and extensive homology to tensin, a protein that interacts with actin filaments at focal adhesions. These homologies suggest that PTEN may suppress tumor cell growth by antagonizing protein tyrosine kinases and may regulate tumor cell invasion and metastasis through interactions at focal adhesions.	COLUMBIA UNIV,COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032; COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724; DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710; ST JOSEPH HOSP,STEHLIN FDN CANC RES,HOUSTON,TX 77003; VET ADM MED CTR,NEW YORK,NY 10010; NYU,DEPT PATHOL,NEW YORK,NY 10010	Columbia University; Columbia University; Cold Spring Harbor Laboratory; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA); New York University				McCombie, W. Richard/0000-0003-1899-0682; Wigler, Michael/0000-0003-4396-1971; Parsons, Ramon/0000-0002-6656-3514	NATIONAL CANCER INSTITUTE [R35CA039829] Funding Source: NIH RePORTER; NCI NIH HHS [5R35 CA39829] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA SK, 1995, CANCER METAST REV, V14, P173, DOI 10.1007/BF00690290; BIGNER SH, 1988, CANCER RES, V48, P405; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; CHUANG JZ, 1995, J CELL BIOL, V128, P1095, DOI 10.1083/jcb.128.6.1095; COX DR, 1990, SCIENCE, V250, P245, DOI 10.1126/science.2218528; Denu JM, 1996, CELL, V87, P361, DOI 10.1016/S0092-8674(00)81356-2; DIAMOND RH, 1994, MOL CELL BIOL, V14, P3752, DOI 10.1128/MCB.14.6.3752; Fauman EB, 1996, TRENDS BIOCHEM SCI, V21, P413, DOI 10.1016/S0968-0004(96)10059-1; GRAY IC, 1995, CANCER RES, V55, P4800; Haynie DT, 1996, PROTEIN SCI, V5, P2643, DOI 10.1002/pro.5560051227; HOGAN E, 1992, P NATL ACAD SCI USA, V89, P3098, DOI 10.1073/pnas.89.7.3098; Hsu SC, 1996, CANCER RES, V56, P5684; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; Ittmann M, 1996, CANCER RES, V56, P2143; JAMES CD, 1988, CANCER RES, V48, P5546; Kim UJ, 1996, GENOMICS, V34, P213, DOI 10.1006/geno.1996.0268; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; RASHEED BKA, 1995, ONCOGENE, V10, P2243; ROEST PAM, 1993, HUM MOL GENET, V2, P1719, DOI 10.1093/hmg/2.10.1719; SCHUTTE M, 1995, P NATL ACAD SCI USA, V92, P5950, DOI 10.1073/pnas.92.13.5950; SHENG ZQ, 1993, J BIOL CHEM, V268, P4728; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; Trybus TM, 1996, CANCER RES, V56, P2263; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; WILKINS JA, 1986, J CELL BIOL, V103, P1483, DOI 10.1083/jcb.103.4.1483; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	31	3970	4410	6	378	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 28	1997	275	5308					1943	1947		10.1126/science.275.5308.1943	http://dx.doi.org/10.1126/science.275.5308.1943			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WQ513	9072974				2022-12-01	WOS:A1997WQ51300049
J	OByrne, PM				OByrne, PM			Treatment of mild asthma	LANCET			English	Editorial Material									MCMASTER UNIV,DEPT MED,HAMILTON,ON L8N 3ZS,CANADA	McMaster University	OByrne, PM (corresponding author), MCMASTER UNIV,ASTHMA RES GRP,HAMILTON,ON L8N 3ZS,CANADA.			O'Byrne, Paul/0000-0003-0979-281X				Drazen JM, 1996, NEW ENGL J MED, V335, P841, DOI 10.1056/NEJM199609193351202; ISRAEL E, 1993, ANN INTERN MED, V119, P1059, DOI 10.7326/0003-4819-119-11-199312010-00001; *NAT HEART LUNG BL, 1995, PUBL US DEP HLTH HUM; O'Byrne P, 1996, CAN RESPIR J, V3, P169; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; Sheffer AL, 1992, PUBLICATION US DEP H; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; SVENDSEN UG, 1987, J ALLERGY CLIN IMMUN, V80, P68	8	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 22	1997	349	9055					818	818		10.1016/S0140-6736(05)61745-X	http://dx.doi.org/10.1016/S0140-6736(05)61745-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WP403	9121251				2022-12-01	WOS:A1997WP40300004
J	Peeper, DS; Upton, TM; Ladha, MH; Neuman, E; Zalvide, J; Bernards, R; DeCaprio, JA; Ewen, ME				Peeper, DS; Upton, TM; Ladha, MH; Neuman, E; Zalvide, J; Bernards, R; DeCaprio, JA; Ewen, ME			Ras signalling linked to the cell-cycle machinery by the retinoblastoma protein	NATURE			English	Article							NIH 3T3 CELLS; GROWTH SUPPRESSION; INHIBITION; TRANSFORMATION; PROLIFERATION; D1; MICROINJECTION; NIH-3T3-CELLS; P16(INK4); P16	The Ras proto-oncogene is a central component of mitogenic signal-transduction pathways, and is essential for cells both to leave a quiescent state (G0) and to pass through the G1/S transition of the cell cycle(1-6). The mechanism by which Ras signalling regulates cell-cycle progression is unclear, however. Here we report that the retinoblastoma tumour-suppressor protein (Rb), a regulator of G1 exit(7), functionally Links pas to passage through the G1 phase. Inactivation of Ras in cycling cells-caused a decline in cyclin D1 protein levels, accumulation of the hypophosphorylated, growth-suppressive form of Rb, and G1 arrest. When Rb was disrupted either genetically or biochemically, cells failed to arrest in G1 following Ras inactivation. In contrast, inactivation of Ras in quiescent cells prevented growth-factor induction of both immediate-early gene transcription and exit from G0 in an Rb-independent manner. These data suggest that Rb is an essential G1-specific mediator that links Ras-dependent mitogenic signalling to cell-cycle regulation.	DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; NETHERLANDS CANC INST,DEPT MOL CARCINOGENESIS,NL-1066 CX AMSTERDAM,NETHERLANDS	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Netherlands Cancer Institute			Zalvide, Juan/ABG-4050-2020; Peeper, Daniel/AAA-2430-2020	Bernards, Rene/0000-0001-8677-3423; Zalvide, Juan/0000-0001-7645-156X				ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; DOBROWOLSKI S, 1994, MOL CELL BIOL, V14, P5441, DOI 10.1128/MCB.14.8.5441; EWEN ME, 1995, GENE DEV, V9, P204, DOI 10.1101/gad.9.2.204; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; FILMUS J, 1994, ONCOGENE, V9, P3627; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PRONK GJ, 1994, BBA-REV CANCER, V1198, P131, DOI 10.1016/0304-419X(94)90010-8; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Winston JT, 1996, ONCOGENE, V12, P127; ZALVIDE J, 1995, MOL CELL BIOL, V15, P5800	30	315	315	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 13	1997	386	6621					177	181		10.1038/386177a0	http://dx.doi.org/10.1038/386177a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WM973	9062190	Green Submitted			2022-12-01	WOS:A1997WM97300063
J	Buschges, R; Hollricher, K; Panstruga, R; Simons, G; Wolter, M; Frijters, A; vanDaelen, R; vanderLee, T; Diergaarde, P; Groenendijk, J; Topsch, S; Vos, P; Salamini, F; Schulze-Lefert, P				Buschges, R; Hollricher, K; Panstruga, R; Simons, G; Wolter, M; Frijters, A; vanDaelen, R; vanderLee, T; Diergaarde, P; Groenendijk, J; Topsch, S; Vos, P; Salamini, F; Schulze-Lefert, P			The barley mlo gene: A novel control element of plant pathogen resistance	CELL			English	Article							POWDERY MILDEW RESISTANCE; DISEASE RESISTANCE; INTRAGENIC RECOMBINATION; CELL-DEATH; DNA; ARABIDOPSIS; LOCUS; MEMBRANE; CLONING; INFECTION	Mutation-induced recessive alleles (mlo) of the barley Mlo locus confer a leaf lesion phenotype and broad spectrum resistance to the fungal pathogen, Erysiphe graminis f. sp. hordei. The gene has been isolated using a positional cloning approach. Analysis of 11 mutagen-induced mlo alleles revealed mutations leading in each case to alterations of the deduced Mlo wild-type amino acid sequence. Susceptible intragenic recombinants, isolated from mlo heteroallelic crosses, show restored Mlo wild-type sequences. The deduced 60 kDa protein is predicted to be membrane-anchored by at least six membrane-spanning helices. The findings are compatible with a dual negative control function of the Mlo protein in leaf cell death and in the onset of pathogen defense; absence of Mlo primes the responsiveness for the onset of multiple defense functions.	JOHN INNES CTR PLANT SCI RES, SAINSBURY LAB, NORWICH NR4 7UH, NORFOLK, ENGLAND; RHEIN WESTFAL TH AACHEN, INST BIOL 1, D-52074 AACHEN, GERMANY; KEYGENE NV, NL-6700 AE WAGENINGEN, NETHERLANDS; MAX PLANCK INST ZUCHTUNGSFORSCH, ABT ZUCHTUNGSFORSCH & ERTRAGSPHYSIOL, D-50829 COLOGNE, GERMANY	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; RWTH Aachen University; Keygene N.V.; Max Planck Society			Schulze-Lefert, Paul/A-7746-2008; Bruening, Stefan/B-8505-2011; vanderlee, Theo A.J./J-7296-2013; Schulze-Lefert, Paul/B-6707-2011; Panstruga, Ralph/F-3340-2011	Panstruga, Ralph/0000-0002-3756-8957				BAYLES CJ, 1990, PHYSIOL MOL PLANT P, V36, P63, DOI 10.1016/0885-5765(90)90092-C; BECKER J, 1995, MOL GEN GENET, V249, P65, DOI 10.1007/BF00290237; BENNETT MD, 1991, PHILOS T R SOC B, V334, P309, DOI 10.1098/rstb.1991.0120; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; CHUNWONGSE J, 1993, THEOR APPL GENET, V86, P694, DOI 10.1007/BF00222658; DANGL JL, 1995, CELL, V80, P363, DOI 10.1016/0092-8674(95)90485-9; Dangl JL, 1996, PLANT CELL, V8, P1793, DOI 10.1105/tpc.8.10.1793; DIETRICH RA, 1994, CELL, V77, P565, DOI 10.1016/0092-8674(94)90218-6; DOONER HK, 1986, GENETICS, V113, P135; Dujon B, 1996, TRENDS GENET, V12, P263, DOI 10.1016/0168-9525(96)10027-5; FLOR HH, 1971, ANNU REV PHYTOPATHOL, V9, P275, DOI 10.1146/annurev.py.09.090171.001423; FREELING M, 1978, GENETICS, V89, P211; Freialdenhoven A, 1996, PLANT CELL, V8, P5, DOI 10.1105/tpc.8.1.5; GIOVANNONI JJ, 1991, NUCLEIC ACIDS RES, V19, P6553, DOI 10.1093/nar/19.23.6553; GREENBERG JT, 1994, CELL, V77, P551, DOI 10.1016/0092-8674(94)90217-8; HABEKUSS A, 1988, WISS DDR BERLIN, V272, P229; HammondKosack KE, 1996, PLANT CELL, V8, P1773, DOI 10.1105/tpc.8.10.1773; HESLOPHARRISON JS, 1991, J CELL SCI, V100, P15; HINZE K, 1991, P NATL ACAD SCI USA, V88, P3691, DOI 10.1073/pnas.88.9.3691; JONES DT, 1994, BIOCHEMISTRY-US, V33, P3038, DOI 10.1021/bi00176a037; JONES JDG, 1994, CURR BIOL, V4, P749, DOI 10.1016/S0960-9822(00)00168-8; JORGENSEN JH, 1977, PHYTOPATHOLOGY, V67, P678; JORGENSEN JH, 1994, CRIT REV PLANT SCI, V13, P97, DOI 10.1080/713608055; JORGENSEN JH, 1992, EUPHYTICA, V63, P141, DOI 10.1007/BF00023919; KLEIN P, 1985, BIOCHIM BIOPHYS ACTA, V815, P468, DOI 10.1016/0005-2736(85)90375-X; KOORNNEEF M, 1983, GENET RES, V41, P57, DOI 10.1017/S0016672300021066; Kosslak RM, 1996, J HERED, V87, P415, DOI 10.1093/oxfordjournals.jhered.a023030; Kosuge T., 1983, GENETIC ENG PLANTS A, P431, DOI [10.1007/978-1-4684-4544-2_29, DOI 10.1007/978-1-4684-4544-2_29, DOI 10.1007/978-1-4684-4544-2_]; MOURAD G, 1994, MOL GEN GENET, V243, P178, DOI 10.1007/BF00280315; NIGG EA, 1991, CELL, V66, P15, DOI 10.1016/0092-8674(91)90135-L; OSBORNE BI, 1995, CURR OPIN CELL BIOL, V7, P406, DOI 10.1016/0955-0674(95)80097-2; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; SALAMINI F, 1970, MOL GEN GENET, V108, P225, DOI 10.1007/BF00283352; Sambrook J., 1989, MOL CLONING LAB MANU, V3; SCHMIDT R, 1995, SCIENCE, V270, P480, DOI 10.1126/science.270.5235.480; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; SOULLAM B, 1995, J CELL BIOL, V130, P15, DOI 10.1083/jcb.130.1.15; Stakman EC, 1915, J AGRIC RES, V4, P193; STASKAWICZ BJ, 1995, SCIENCE, V268, P661, DOI 10.1126/science.7732374; STEWART CN, 1993, BIOTECHNIQUES, V14, P748; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; TANKSLEY SD, 1995, TRENDS GENET, V11, P63, DOI 10.1016/S0168-9525(00)88999-4; VOS P, 1995, NUCLEIC ACIDS RES, V23, P4407, DOI 10.1093/nar/23.21.4407; Weymann K, 1995, PLANT CELL, V7, P2013, DOI 10.1105/tpc.7.12.2013; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WOLTER M, 1993, MOL GEN GENET, V239, P122, DOI 10.1007/BF00281610; ZHOU JM, 1995, CELL, V83, P925, DOI 10.1016/0092-8674(95)90208-2	48	798	928	3	159	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 7	1997	88	5					695	705		10.1016/S0092-8674(00)81912-1	http://dx.doi.org/10.1016/S0092-8674(00)81912-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WM413	9054509	Bronze			2022-12-01	WOS:A1997WM41300015
J	Tondravi, MM; McKercher, SR; Anderson, K; Erdmann, JM; Quiroz, M; Maki, R; Teitelbaum, SL				Tondravi, MM; McKercher, SR; Anderson, K; Erdmann, JM; Quiroz, M; Maki, R; Teitelbaum, SL			Osteopetrosis in mice lacking haematopoietic transcription factor PU.1	NATURE			English	Article							COLONY-STIMULATING FACTOR; C-FOS; MACROPHAGE; BONE; PROMOTER; CELLS; DIFFERENTIATION; OSTEOCLASTS; EXPRESSION; DEFICIENCY	Osteoclasts are multinucleated cells and the principal resorptive cells of bone. Although osteoclasts are of myeloid origin(1), the role of haematopoietic transcription factors in osteoclastogenesis has not been explored. Here we show that messenger RNA for the myeloid- and B-cell-specific transcription factor PU.1 progressively increases as marrow macrophages assume the osteoclast phenotype in vitro. The association between PU.1 and osteoclast differentiation was confirmed by demonstrating that PU.1 expression increased with the induction of osteoclastogenesis by either 1,25-dihydroxyvitamin D-3 or dexamethasone. Consistent with the participation of PU.1 in osteoclastogenesis, we found that the development of both osteoclasts and macrophages is arrested in PU.1-deficient mice. Reflecting the absence of osteoclasts, PU.1(-/-) mice exhibit the classic hallmarks of osteopetrosis, a family of sclerotic bone diseases(2). These animals were rescued by marrow transplantation, with complete restoration of osteoclast and macrophage differentiation, verifying that the PU.1 lesion is intrinsic to haematopoietic cells. The absence of both osteoclasts and macrophages in PU.1-mutant animals suggests that the transcription factor regulates the initial stages of myeloid differentiation, and that its absence represents the earliest developmental osteopetrotic mutant yet described.	BURNHAM INST,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute	Tondravi, MM (corresponding author), WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110, USA.			Teitelbaum, Steven/0000-0002-4054-6679				BEGG SK, 1993, J EXP MED, V177, P237, DOI 10.1084/jem.177.1.237; CLOHISY DR, 1987, J BIOL CHEM, V262, P15922; DUONG LT, 1993, J BONE MINER RES, V8, pS378; Felix R, 1996, EUR J ENDOCRINOL, V134, P143, DOI 10.1530/eje.0.1340143; FELIX R, 1990, ENDOCRINOLOGY, V127, P2592, DOI 10.1210/endo-127-5-2592; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KODAMA H, 1991, J EXP MED, V173, P1291, DOI 10.1084/jem.173.5.1291; LACEY DL, 1995, ENDOCRINOLOGY, V136, P2367, DOI 10.1210/en.136.6.2367; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; PAHL HL, 1993, J BIOL CHEM, V268, P5014; ROSMARIN AG, 1995, P NATL ACAD SCI USA, V92, P801, DOI 10.1073/pnas.92.3.801; Sambrook J., 1989, MOL CLONING LAB MANU; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHIOI A, 1994, CALCIFIED TISSUE INT, V55, P387, DOI 10.1007/BF00299320; SLY WS, 1983, P NATL ACAD SCI-BIOL, V80, P2752, DOI 10.1073/pnas.80.9.2752; TAKAHASHI N, 1991, ENDOCRINOLOGY, V128, P1792, DOI 10.1210/endo-128-4-1792; Teitelbaum Steven L., 1996, P61; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; YAMAMOTO T, 1993, J CLIN INVEST, V91, P362, DOI 10.1172/JCI116194; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085	22	415	432	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 6	1997	386	6620					81	84		10.1038/386081a0	http://dx.doi.org/10.1038/386081a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WL746	9052784				2022-12-01	WOS:A1997WL74600055
J	Ferrucci, L; Guralnik, JM; Pahor, M; Corti, MC; Havlik, RJ				Ferrucci, L; Guralnik, JM; Pahor, M; Corti, MC; Havlik, RJ			Hospital diagnoses, Medicare charges, and nursing home admissions in the year when older persons become severely disabled	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; ELDERLY PATIENTS; MAINTAINING MOBILITY; CORONARY ANGIOPLASTY; PHYSICAL-DISABILITY; BYPASS-SURGERY; LATE-LIFE; AGE; CARE; SURVIVAL	Objective.-To characterize hospital diagnoses, procedures and charges, and nursing home admissions in the year when older persons become severely disabled, comparing those in whom severe disability develops rapidly with those in whom disability develops gradually. Design.-A prospective, population-based cohort study with at least 6 annual interviews beginning in 1982. Setting.-A total of 3 communities: East Boston, Mass, New Haven, Conn, and Iowa and Washington counties in Iowa. Subjects.-A total of 6070 persons at least 70 years old with at least 1 interview after the fourth annual follow-up and without evidence of previous severe disability, defined as disability in 3 or more activities of daily living (ADLs). Main Outcome Measures.-Characteristics associated with development of severe disability after the fourth annual follow-up, in which the disability is classified as catastrophic disability if the individual did not report any ADL disability in the 2 interviews prior to severe disability onset or as progressive disability if the individual had previous disability in 1 or 2 ADLs. Results.-In the year during which severe disability developed, hospitalizations were documented for 72.1% of those developing catastrophic disability and for 48.6% of those developing progressive disability. In the corresponding year, only 14.7% of those who were stable with no disability and 22.3% of those with some disability were hospitalized, The 6 most frequent principal discharge diagnoses included stroke, hip fracture, congestive heart failure, and pneumonia in both severe disability subsets; coronary heart disease and cancer in catastrophic disability; and diabetes and dehydration in progressive disability. These diagnoses occurred in 49% of those with catastrophic disability and 25% of those with progressive disability. In both severe disability subsets, the oldest patients received less intensive hospital care as indicated by charges for surgery, diagnostics, and rehabilitation and by the percentage who received major diagnostic procedures; they were also more often admitted to nursing homes. Conclusions.-In the year when they become severely disabled, a large proportion of older persons are hospitalized for a small group of diseases. Hospital-based interventions aimed at reducing the severity and functional consequences of these diseases could have a large impact on reduction of severe disability.	NIA,EPIDEMIOL DEMOG & BIOMETRY PROGRAM,BETHESDA,MD 20892; NATL RES INST INRCA,DEPT GERIATR,FLORENCE,ITALY; UNIV TENNESSEE,DEPT PREVENT MED,MEMPHIS,TN	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); IRCCS INRCA; University of Tennessee System; University of Tennessee Health Science Center								ACKERMANN RJ, 1995, J FAM PRACTICE, V40, P129; BEARDEN D, 1994, J AM GERIATR SOC, V42, P1143, DOI 10.1111/j.1532-5415.1994.tb06979.x; BERGMAN L, 1991, BREAST CANCER RES TR, V18, P189, DOI 10.1007/BF01990035; BINSTOCK R, 1991, TOO OLD HLTH CARE; BOULT C, 1994, J GERONTOL, V49, pM28, DOI 10.1093/geronj/49.1.M28; BRACH LG, 1984, AM J PUBLIC HEALTH, V74, P266; CHELLURI L, 1993, JAMA-J AM MED ASSOC, V269, P3119, DOI 10.1001/jama.269.24.3119; CORNONIHUNTLEY J, 1993, AGING-CLIN EXP RES, V5, P27; DEGARA CJ, 1995, HEPATO-GASTROENTEROL, V42, P73; ENSRUD KE, 1994, J AM GERIATR SOC, V42, P481, DOI 10.1111/j.1532-5415.1994.tb04968.x; ETTINGER WH, 1994, J AM GERIATR SOC, V42, P1035, DOI 10.1111/j.1532-5415.1994.tb06206.x; FALCONER JA, 1994, J AM GERIATR SOC, V42, P39, DOI 10.1111/j.1532-5415.1994.tb06071.x; Ferrucci L, 1996, J GERONTOL A-BIOL, V51, pM123, DOI 10.1093/gerona/51A.3.M123; FRIED LP, 1992, AGING-CLIN EXP RES, V4, P251, DOI 10.1007/BF03324099; GILL TM, 1995, J AM GERIATR SOC, V43, P603, DOI 10.1111/j.1532-5415.1995.tb07192.x; GURALNIK JM, 1993, J GERONTOL, V48, P3, DOI 10.1093/geronj/48.Special_Issue.3; GURALNIK JM, 1995, NEW ENGL J MED, V332, P556, DOI 10.1056/NEJM199503023320902; GURALNIK JM, 1993, AM J EPIDEMIOL, V137, P845, DOI 10.1093/oxfordjournals.aje.a116746; GURWITZ JH, 1991, JAMA-J AM MED ASSOC, V265, P720; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; KOWALSKI LP, 1994, AM J SURG, V168, P485, DOI 10.1016/S0002-9610(05)80107-2; KRUMHOLZ HM, 1994, J AM GERIATR SOC, V42, P127, DOI 10.1111/j.1532-5415.1994.tb04938.x; LACROIX AZ, 1993, AM J EPIDEMIOL, V137, P858, DOI 10.1093/oxfordjournals.aje.a116747; LANDAU C, 1994, NEW ENGL J MED, V330, P981, DOI 10.1056/NEJM199404073301407; LANDEFELD CS, 1995, NEW ENGL J MED, V332, P1338, DOI 10.1056/NEJM199505183322006; MANTON KG, 1988, J GERONTOL, V43, pS153, DOI 10.1093/geronj/43.5.S153; MANTON KG, 1993, J GERONTOL, V48, pS153, DOI 10.1093/geronj/48.4.S153; MARCHIONNI N, 1995, J AM GERIATR SOC, V43, P389, DOI 10.1111/j.1532-5415.1995.tb05813.x; OKEEFE JH, 1994, J AM COLL CARDIOL, V24, P425, DOI 10.1016/0735-1097(94)90299-2; PALMER RM, 1994, J AM GERIATR SOC, V42, P545, DOI 10.1111/j.1532-5415.1994.tb04978.x; PERLER BA, 1994, SURGERY, V116, P479; ROSENTHAL GE, 1994, J AM GERIATR SOC, V42, P826, DOI 10.1111/j.1532-5415.1994.tb06553.x; SCHNEIDER EL, 1990, JAMA-J AM MED ASSOC, V263, P2335, DOI 10.1001/jama.263.17.2335; SHERRY S, 1991, J AM COLL CARDIOL, V17, P1237, DOI 10.1016/0735-1097(91)90859-8; THOMAS DR, 1995, J AM GERIATR SOC, V43, P811, DOI 10.1111/j.1532-5415.1995.tb07058.x; VLADECK BC, 1995, JAMA-J AM MED ASSOC, V274, P259, DOI 10.1001/jama.274.3.259	36	201	205	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 5	1997	277	9					728	734						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WK026	9042845				2022-12-01	WOS:A1997WK02600032
J	Davies, PA; Hanna, MC; Hales, TG; Kirkness, EF				Davies, PA; Hanna, MC; Hales, TG; Kirkness, EF			Insensitivity to anaesthetic agents conferred by a class of GABA(A) receptor subunit	NATURE			English	Article							GAMMA-AMINOBUTYRIC-ACID; SUBTHALAMIC NUCLEUS; HIPPOCAMPAL-NEURONS; CHLORIDE CHANNELS; A RECEPTORS; PHARMACOLOGY; CONDUCTANCE; ACTIVATION; EXPRESSION; PROPOFOL	A common feature of general anaesthetic agents is their ability to potentiate neuronal inhibition through GABA(A) (gamma-aminobutyric acid) receptors(1). At concentrations relevant to clinical anaesthesia, these agents cause a dramatic stimulation of the chloride currents that are evoked by the binding of the natural ligand, GABA. Although there is widespread evidence that the sensitivity of GABA(A) receptors to anaesthetic agents is heterogeneous(2-4), the structural basis of these differences is largely unknown. Variations in subunit composition can have profound effects on the sensitivity of GABA(A), receptors to modulatory agents such as benzodiazepines(5). However, strict subunit specificity has not been demonstrated for the potentiating effects of anaesthetic agents(6-10). Here we describe a new class of human GABA(A) receptor subunit (epsilon) that can assemble with alpha- and beta-subunits and confer an insensitivity to the potentiating effects of intravenous anaesthetic agents. The epsilon-subunit also abolishes the normal outward rectification of recombinant receptors in which it assembles. The expression pattern of this subunit in the brain suggests a new target for manipulation of neuronal pathways within the basal ganglia.	INST GENOM RES,ROCKVILLE,MD 20850; UNIV CALIF LOS ANGELES,MED CTR,BRAIN RES INST,DEPT ANESTHESIOL,LOS ANGELES,CA 90095	J. Craig Venter Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center			Davies, Paul A/P-4595-2017	Davies, Paul A/0000-0002-3973-3143				ADAMS MD, 1995, NATURE, V377, P3; ADODRA S, 1995, BRIT J PHARMACOL, V115, P953, DOI 10.1111/j.1476-5381.1995.tb15903.x; BELL K, 1995, SYNAPSE, V20, P10, DOI 10.1002/syn.890200103; BERGMAN H, 1990, SCIENCE, V249, P1436, DOI 10.1126/science.2402638; BORMANN J, 1987, J PHYSIOL-LONDON, V385, P243, DOI 10.1113/jphysiol.1987.sp016493; BULLER AL, 1994, MOL PHARMACOL, V46, P858; BUREAU MH, 1993, J NEUROCHEM, V61, P1479, DOI 10.1111/j.1471-4159.1993.tb13643.x; Davies PA, 1997, BRIT J PHARMACOL, V120, P899, DOI 10.1038/sj.bjp.0700987; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; GAGE PW, 1994, P ROY SOC B-BIOL SCI, V255, P167, DOI 10.1098/rspb.1994.0024; Goetz CG, 1996, NAT MED, V2, P510, DOI 10.1038/nm0596-510; GRAY R, 1985, J NEUROPHYSIOL, V54, P134, DOI 10.1152/jn.1985.54.1.134; HADINGHAM KL, 1993, MOL PHARMACOL, V44, P1211; HARRIS B, 1993, J PHARMACOL EXP THER, V265, P1392; KORPI ER, 1993, MOL PHARMACOL, V44, P87; MIHAC SJ, 1994, EUR J PHARMACOL, V268, P209; MORROW AL, 1990, MOL PHARMACOL, V37, P263; PETERS JA, 1988, BRIT J PHARMACOL, V94, P1257, DOI 10.1111/j.1476-5381.1988.tb11646.x; PRITCHETT DB, 1989, NATURE, V338, P582, DOI 10.1038/338582a0; PUIA G, 1990, NEURON, V4, P759, DOI 10.1016/0896-6273(90)90202-Q; SANNA E, 1995, J PHARMACOL EXP THER, V274, P353; SAXENA NC, 1994, J NEUROSCI, V14, P7077; SCHMIEDEN V, 1992, EMBO J, V11, P2025, DOI 10.1002/j.1460-2075.1992.tb05259.x; SEGAL M, 1984, J NEUROPHYSIOL, V51, P500, DOI 10.1152/jn.1984.51.3.500; Thompson SA, 1996, BRIT J PHARMACOL, V117, P521, DOI 10.1111/j.1476-5381.1996.tb15221.x; TOKUNAGA K, 1987, CANCER RES, V47, P5616; VERDOORN TA, 1990, NEURON, V4, P919, DOI 10.1016/0896-6273(90)90145-6; Whiting PJ, 1995, INT REV NEUROBIOL, V38, P95, DOI 10.1016/S0074-7742(08)60525-5; WISDEN W, 1992, J NEUROSCI, V12, P1040; Zhu WJ, 1996, J NEUROSCI, V16, P6648	30	344	355	1	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 27	1997	385	6619					820	823		10.1038/385820a0	http://dx.doi.org/10.1038/385820a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WK570	9039914				2022-12-01	WOS:A1997WK57000054
J	Sicheri, F; Moarefi, I; Kuriyan, J				Sicheri, F; Moarefi, I; Kuriyan, J			Crystal structure of the Src family tyrosine kinase Hck	NATURE			English	Article							AFFINITY PHOSPHOTYROSYL PEPTIDE; PROLINE-RICH PEPTIDES; SH3 DOMAIN; BINDING; PROTEIN; PP60C-SRC; DEPHOSPHORYLATION; PHOSPHORYLATION; RECOGNITION; SPECIFICITY	The crystal structure of the haematopoietic cell kinase Hck has been determined at 2.6/2.9 Angstrom resolution. Inhibition of enzymatic activity is a consequence of intramolecular interactions of the enzyme's Src-homology domains SH2 and SH3, with concomitant displacement of elements of the catalytic domain. The conformation of the active site has similarities with that of Inactive cyclln-dependent protein kinases.	ROCKEFELLER UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA; ROCKEFELLER UNIV, LAB MOL BIOPHYS, NEW YORK, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University; Rockefeller University			Sicheri, Frank/F-8856-2013					ADZHUBEI AA, 1993, J MOL BIOL, V229, P472, DOI 10.1006/jmbi.1993.1047; Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; BRIGGS SD, 1995, J BIOL CHEM, V270, P14718, DOI 10.1074/jbc.270.24.14718; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; CUNNINGHAM BDM, 1992, ANTI-CANCER DRUG DES, V7, P365; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; ERPEL T, 1995, EMBO J, V14, P963, DOI 10.1002/j.1460-2075.1995.tb07077.x; FUREY W, 1990, P AM CRYSTALLOGRAPHI, P73; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JUFFREY PD, 1995, NATURE, V376, P294; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KURIYAN J, IN PRESS ANN REV BIO; LADBURY JE, 1995, P NATL ACAD SCI USA, V92, P3199, DOI 10.1073/pnas.92.8.3199; LEE CH, 1995, EMBO J, V14, P5006, DOI 10.1002/j.1460-2075.1995.tb00183.x; Lee CH, 1996, CELL, V85, P931, DOI 10.1016/S0092-8674(00)81276-3; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; LOWELL CA, 1994, GENE DEV, V8, P387, DOI 10.1101/gad.8.4.387; Lowell CA, 1996, BLOOD, V87, P1780; MACAULEY A, 1989, MOL CELL BIOL, V9, P2648, DOI 10.1128/MCB.9.6.2648; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHENG JH, 1993, ACTA CRYSTALLOGR D, V49, P362, DOI 10.1107/S0907444993000423; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZIEGLER SF, 1987, MOL CELL BIOL, V7, P2276, DOI 10.1128/MCB.7.6.2276; [No title captured]	46	1030	1065	1	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 13	1997	385	6617					602	609		10.1038/385602a0	http://dx.doi.org/10.1038/385602a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WH294	9024658				2022-12-01	WOS:A1997WH29400041
J	Hughes, K; MacKintosh, AM; Hastings, G; Wheeler, C; Watson, J; Inglis, J				Hughes, K; MacKintosh, AM; Hastings, G; Wheeler, C; Watson, J; Inglis, J			Young people, alcohol, and designer drinks: Quantitative and qualitative study	BRITISH MEDICAL JOURNAL			English	Article							ADOLESCENT DRINKING; BRITAIN; EXPERIENCES; BEHAVIOR	Objective: To examine the appeal of ''designer drinks'' to young people Design: Qualitative and quantitative research comprising group discussions and questionnaire led interviews with young people accompanied by a self completion questionnaire. Settings: Argyll and Clyde Health Board area, west Scotland. Subjects: Eight groups aged 12-17 years; 824 aged 12-17 recruited by multistage duster probability sample from the community health index. Results: Young people were familiar with designer drinks, especially MD 20/20 and leading brands of strong white cider. Attitudes towards these drinks varied quite distinctly with age, dearly reflecting their attitudes towards and motivations for drinking in general. The brand imagery of designer drinks-in contrast with that of more mainstream drinks-matched many 14 and 15 year olds' perceptions and expectations of drinking. Popularity of designer drinks peaked between the ages of 13 and 16 while more conventional drinks showed a consistent increase in popularity with age. Consumption of designer drinks tended to be in less controlled circumstances and was associated with heavier alcohol intake and greater drunkenness. Conclusions: Designer drinks are a cause for concern. They appeal to young people, often more so than conventional drinks, and are particularly attractive to 14-16 year olds. Consumption of designer drinks is also associated with drinking in less controlled environments, heavier drinking; and greater drunkenness. There is a need for policy debate to assess the desirability of these drinks and the extent to which further controls on their marketing are required.	UNIV STRATHCLYDE,CTR SOCIAL MKT,GLASGOW G4 0RQ,LANARK,SCOTLAND; UNIV STRATHCLYDE,DEPT MKT,GLASGOW G4 0RQ,LANARK,SCOTLAND; HLTH EDUC BOARD SCOTLAND,EDINBURGH EH10 4SG,MIDLOTHIAN,SCOTLAND	University of Strathclyde; University of Strathclyde								AITKEN P, 1978, 10 14 YEAR OLDS ALCO; BAGNALL G, 1988, DRUG ALCOHOL DEPEN, V22, P241, DOI 10.1016/0376-8716(88)90024-5; BAGNALL G, 1991, ED YOUNG DRINKERS; CASSWELL S, 1993, NZ MED J, V96, P1001; DAVIES JB, 1972, TEENAGERS ALCOHOL; Franzkowiax P., 1987, HEALTH PROMOT INT, V2, P51, DOI [10.1093/ heapro/2.1.51, DOI 10.1093/HEAPRO/2.1.51]; GHODSIAN M, 1987, BRIT J ADDICT, V82, P175; GODDARD E, 1988, DRINKING ENGLAND WAL; HARFORD TC, 1983, J STUD ALCOHOL, V44, P181, DOI 10.15288/jsa.1983.44.181; HASTINGS GB, 1987, BRIT MED J, V294, P48, DOI 10.1136/bmj.294.6563.48; HAWKER A, 1978, ADOLESCENTS ALCOHOL; JAHODA G, 1972, CHILDREN ALCOHOL DEV; KEEFE K, 1994, J STUD ALCOHOL, V55, P46, DOI 10.15288/jsa.1994.55.46; MARSH A, 1986, ADOLESCENT DRINKING; MAY C, 1992, ALCOHOL ALCOHOLISM, V27, P109; MCDERMOT A, 1996, HERALD          0707, P13; McLoone P., 1991, CARSTAIRS SCORES SCO; MILGRAM CG, 1993, J STUD ALCOHOL S11, V11, P53; NEWCOMB MD, 1986, AM J PUBLIC HEALTH, V76, P525, DOI 10.2105/AJPH.76.5.525; NEWCOMBE R, 1995, ADDICT RES, V2, P319, DOI 10.3109/16066359509005552; PLANT MA, 1990, ALCOHOL ALCOHOLISM, V25, P691, DOI 10.1093/oxfordjournals.alcalc.a045067; PLANT MA, 1991, DRUG ALCOHOL DEPEN, V28, P203, DOI 10.1016/0376-8716(91)90077-C; PLANT MA, 1985, ALCOHOL DRUGS SCH LE; SHANKS J, 1990, World Health Forum, V11, P235; SHARP DL, 1994, ALCOHOL ALCOHOLISM, V29, P555; THOMAS RM, 1992, ALCOHOL DRUGS SCOTTI, P34; THOMSON L, 1995, DAILY EXPRESS    JUN, P20; 1995, OFF LICENCE NEW 0420, P12; 1994, OFF LICENCE NEW 0317, P8; 1995, OFF LICENCE NEWS JUN, P12; 1996, DAILY TELEGRAPH 0109, P7	31	70	71	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 8	1997	314	7078					414	418		10.1136/bmj.314.7078.414	http://dx.doi.org/10.1136/bmj.314.7078.414			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WH295	9040387	Green Accepted, Green Published			2022-12-01	WOS:A1997WH29500029
J	Yu, S; Mangelsdorf, M; Hewett, D; Hobson, L; Baker, E; Eyre, HJ; Lapsys, N; LePaslier, D; Doggett, NA; Sutherland, GR; Richards, RI				Yu, S; Mangelsdorf, M; Hewett, D; Hobson, L; Baker, E; Eyre, HJ; Lapsys, N; LePaslier, D; Doggett, NA; Sutherland, GR; Richards, RI			Human chromosomal fragile site FRA16B is an amplified AT-rich minisatellite repeat	CELL			English	Article							X-SYNDROME; MYOTONIC-DYSTROPHY; DNA; GENE; MUTATION; LOCUS; SUSCEPTIBILITY; POLYMORPHISM; ASSOCIATION; INSTABILITY	Fragile sites are nonstaining gaps in chromosomes induced by specific tissue culture conditions. They vary both in population frequency and in the culture conditions required for induction. Folate-sensitive fragile sites are due to expansion of p(CCG)(n) trinucleotide repeats; however, the relationship between sequence composition and the chemistry of induction of fragile sites is unclear. To clarify this relationship, the distamycin A-sensitive fragile site FRA16B was isolated by positional cloning and found to be an expanded 33 bp AT-rich minisatellite repeat, p(ATATATTATATATTATATCTAATAATATAT(C)/(A)TA)(n) (consistent with DNA sequence binding preferences of chemicals that induce its cytogenetic expression). Therefore the mutation mechanism associated with trinucleotide repeats is also a property of minisatellite repeats (variable number tandem repeats).	UNIV ADELAIDE,DEPT GENET,ADELAIDE,SA 5000,AUSTRALIA; LOS ALAMOS NATL LAB,DIV LIFE SCI,LOS ALAMOS,NM 87545; FDN JEAN DAUSSET,CTR ETUD POLYMORPHISME HUMAIN,PARIS,FRANCE	University of Adelaide; United States Department of Energy (DOE); Los Alamos National Laboratory; Foundation Jean Dausset-CEPH	Yu, S (corresponding author), WOMENS & CHILDRENS HOSP,DEPT CYTOGENET & MOL GENET,CTR MED GENET,ADELAIDE,SA 5006,AUSTRALIA.		Richards, Robert/ABE-6423-2020; Sutherland, Grant Robert/D-2606-2012; Mangelsdorf, Marie E/A-2318-2013	Mangelsdorf, Marie E/0000-0002-7855-7701; Richards, Robert Ian/0000-0002-5978-6453; Le Paslier, Denis/0000-0003-4335-9956				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BENNETT ST, 1995, NAT GENET, V9, P284, DOI 10.1038/ng0395-284; BERG ES, 1993, GENOMICS, V16, P350, DOI 10.1006/geno.1993.1196; CALLEN DF, 1990, ANN GENET-PARIS, V33, P219; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; DOGGETT NA, 1995, NATURE, V377, P335; FISHEL R, 1995, CURR OPIN GENET DEV, V5, P382, DOI 10.1016/0959-437X(95)80055-7; GARCIASAGREDO JM, 1983, HUM GENET, V65, P211, DOI 10.1007/BF00286668; Igarashi S, 1996, HUM MOL GENET, V5, P923, DOI 10.1093/hmg/5.7.923; JALAL SM, 1993, AM J MED GENET, V46, P441, DOI 10.1002/ajmg.1320460419; JEFFREYS AJ, 1994, NAT GENET, V6, P136, DOI 10.1038/ng0294-136; JONES C, 1995, NATURE, V376, P145, DOI 10.1038/376145a0; KENNEDY GC, 1995, NAT GENET, V9, P293, DOI 10.1038/ng0395-293; KLEVIT RE, 1986, BIOCHEMISTRY-US, V25, P3296, DOI 10.1021/bi00359a032; KNIGHT SJL, 1993, CELL, V74, P127, DOI 10.1016/0092-8674(93)90300-F; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; KRONTIRIS TG, 1993, NEW ENGL J MED, V329, P517, DOI 10.1056/NEJM199308193290801; LINDBLAD K, 1994, NAT GENET, V7, P124, DOI 10.1038/ng0694-124; MONCKTON DG, 1994, NAT GENET, V8, P162, DOI 10.1038/ng1094-162; NANCARROW JK, 1994, SCIENCE, V264, P1938, DOI 10.1126/science.8009225; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; OHOY KL, 1993, SCIENCE, V259, P809, DOI 10.1126/science.8094260; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; PARRISH JE, 1994, NAT GENET, V8, P229, DOI 10.1038/ng1194-229; Phelan CM, 1996, NAT GENET, V12, P309, DOI 10.1038/ng0396-309; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; RICHARDS RI, 1992, CELL, V70, P709, DOI 10.1016/0092-8674(92)90302-S; SCHMID M, 1986, HUM GENET, V74, P67; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; SUTHERLAND GR, 1995, P NATL ACAD SCI USA, V92, P3636, DOI 10.1073/pnas.92.9.3636; SUTHERLAND GR, 1995, CURR OPIN GENET DEV, V5, P323, DOI 10.1016/0959-437X(95)80046-8; SUTHERLAND GR, 1984, AM J HUM GENET, V36, P110; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; VINCENT A, 1991, NATURE, V349, P624, DOI 10.1038/349624a0; WEBER JL, 1990, GENOMICS, V7, P524, DOI 10.1016/0888-7543(90)90195-Z; Wilke CM, 1996, HUM MOL GENET, V5, P187, DOI 10.1093/hmg/5.2.187; YU S, 1992, AM J HUM GENET, V50, P968; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179	38	159	162	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 7	1997	88	3					367	374		10.1016/S0092-8674(00)81875-9	http://dx.doi.org/10.1016/S0092-8674(00)81875-9			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WG479	9039263	Bronze			2022-12-01	WOS:A1997WG47900009
J	Rao, SC; Rainer, G; Miller, EK				Rao, SC; Rainer, G; Miller, EK			Integration of what and where in the primate prefrontal cortex	SCIENCE			English	Article							INFERIOR TEMPORAL CORTEX; SHORT-TERM-MEMORY; RHESUS-MONKEYS; UNIT-ACTIVITY; TASK; PERFORMANCE; PROJECTIONS; PARIETAL; NEURONS	The visual system separates processing of an object's form and color (''what'') from its spatial location (''where''). In order to direct action to objects, the identity and location of those objects must somehow be integrated. To examine whether this process occurs within the prefrontal (PF) cortex, the activity of 195 PF neurons was recorded during a task that engaged both what and where working memory. Some neurons showed either object-tuned (what) or location-tuned (where) delay activity. However, over half (52 percent, or 64/123) of the PF neurons with delay activity showed both what and where tuning. These neurons may contribute to the linking of object information with the spatial information needed to guide behavior.	MIT,DEPT BRAIN & COGNIT SCI,CAMBRIDGE,MA 02139; MIT,CTR LEARNING & MEMORY,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)			Miller, Earl K./AAE-8187-2019; Rainer, Gregor/B-5876-2012	Miller, Earl K./0000-0002-0582-6958; Rainer, Gregor/0000-0002-5805-2220				Baddeley A.D., 1986, WORKING MEMORY; BARBAS H, 1989, J COMP NEUROL, V286, P353, DOI 10.1002/cne.902860306; BRAVER TS, 1995, P COGNIT NEUROSCI SO, V2, P95; Bullier J, 1996, BEHAV BRAIN RES, V76, P89, DOI 10.1016/0166-4328(95)00182-4; Courtney SM, 1996, CEREB CORTEX, V6, P39, DOI 10.1093/cercor/6.1.39; DIPELLEGRINO G, 1993, J NEUROSCI, V13, P227; FERRERA VP, 1994, J NEUROSCI, V14, P6171; FUNAHASHI S, 1993, NATURE, V365, P753, DOI 10.1038/365753a0; FUNAHASHI S, 1989, J NEUROPHYSIOL, V61, P331, DOI 10.1152/jn.1989.61.2.331; Fuster J.M., 1995, MEMORY CEREBRAL CORT; FUSTER JM, 1971, SCIENCE, V173, P652, DOI 10.1126/science.173.3997.652; FUSTER JM, 1982, EXP NEUROL, V77, P679, DOI 10.1016/0014-4886(82)90238-2; FUSTER JM, 1973, J NEUROPHYSIOL, V36, P61, DOI 10.1152/jn.1973.36.1.61; KUBOTA K, 1971, J NEUROPHYSIOL, V34, P337, DOI 10.1152/jn.1971.34.3.337; MAUNSELL JHR, 1987, ANNU REV NEUROSCI, V10, P363, DOI 10.1146/annurev.ne.10.030187.002051; MILLER EK, 1993, J NEUROSCI, V13, P1460; Miller EK, 1996, J NEUROSCI, V16, P5154; Pandya DN., 1987, FRONTAL LOBES REVISI, P41; PETRIDES M, 1984, J COMP NEUROL, V228, P105, DOI 10.1002/cne.902280110; RECANZONE GH, 1992, J NEUROPHYSIOL, V67, P1057, DOI 10.1152/jn.1992.67.5.1057; ROBINSON DA, 1963, IEEE T BIO-MED ENG, VBM10, P137, DOI 10.1109/TBMEL.1963.4322822; SERENO AB, 1995, INVEST OPHTH VISUAL, V36, P692; Ungerleider L, 1982, ANAL VISUAL BEHAV, P549; UNGERLEIDER LG, 1989, EXP BRAIN RES, V76, P473, DOI 10.1007/BF00248903; WILSON FAW, 1993, SCIENCE, V260, P1955, DOI 10.1126/science.8316836	25	611	617	2	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 2	1997	276	5313					821	824		10.1126/science.276.5313.821	http://dx.doi.org/10.1126/science.276.5313.821			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WW900	9115211				2022-12-01	WOS:A1997WW90000065
J	Campbell, H; Gibson, A				Campbell, H; Gibson, A			Health targets in the NHS: Lessons learned from experience with breast feeding targets in Scotland	BRITISH MEDICAL JOURNAL			English	Article							SERVICE SUPPORT; CHILDREN; MILK; SUCCESS		MARKINCH CLIN,FIFE HEALTHCARE NHS TRUST,MARKINCH KY7 6AA,FIFE,SCOTLAND		Campbell, H (corresponding author), UNIV EDINBURGH,DEPT PUBL HLTH SCI,WOLFSON UNIT PREVENT PERIPHERAL VASC DIS,TEVIOT PL,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND.		Campbell, Harry/E-2959-2010	Campbell, Harry/0000-0002-6169-6262				BEEKEN S, 1992, BRIT MED J, V305, P285, DOI 10.1136/bmj.305.6848.285; BRUCE NG, 1991, PUBLIC HEALTH, V105, P357, DOI 10.1016/S0033-3506(05)80595-5; Campbell H, 1995, J PUBLIC HEALTH MED, V17, P450; CAMPBELL H, 1994, BREAST FEEDING SCOTL; CATFORD JC, 1991, BRIT MED J, V302, P980, DOI 10.1136/bmj.302.6783.980; Chalmers J W, 1991, Midwifery, V7, P162, DOI 10.1016/S0266-6138(05)80194-9; *COMM SERV AG INF, 1989, HLTH ALL YEAR 2000 T; *DEP HLTH, 1991, HLTH NAT CONS DOC H; ENDERSON EH, 1995, ACTA PAEDIAT, V84, P719; FEACHEM RG, 1984, B WORLD HEALTH ORGAN, V62, P271; FERGUSON AE, 1994, BRIT MED J, V308, P824, DOI 10.1136/bmj.308.6932.824; FLOREY CV, 1995, INT J EPIDEMIOL, V24, P521; FRANK DA, 1987, PEDIATRICS, V80, P845; GLASS RI, 1983, NEW ENGL J MED, V308, P1389, DOI 10.1056/NEJM198306093082304; GROSSMAN LK, 1990, AM J DIS CHILD, V144, P471, DOI 10.1001/archpedi.1990.02150280093019; HELDING E, 1990, INT J GYN OBS S1, V31, P69; HOWIE PW, 1990, BRIT MED J, V300, P11, DOI 10.1136/bmj.300.6716.11; JACOBSON B, 1991, NATIONS HLTH STRATEG; LUCAS A, 1990, LANCET, V336, P1519, DOI 10.1016/0140-6736(90)93304-8; LUCAS A, 1992, LANCET, V339, P261, DOI 10.1016/0140-6736(92)91329-7; *MAN EX, 1994, MEL1994110 MAN EX SC; MOSETLANSON A, 1994, BREAT FEEDING SHOULD; NARAYAN I, 1984, LANCET, V2, P111; *NAT AUD OFF, 1996, HLTH NAT PROGR REP; *NEW ZEAL GOV, 1989, NEW REL; Neyzi O, 1991, Paediatr Perinat Epidemiol, V5, P299, DOI 10.1111/j.1365-3016.1991.tb00714.x; *NHS MAN EX, 1993, HLTH NAT LOC TARG SE; PEREZESCAMILLA R, 1994, AM J PUBLIC HEALTH, V84, P89, DOI 10.2105/AJPH.84.1.89; RIGHARD L, 1990, LANCET, V336, P1105, DOI 10.1016/0140-6736(90)92579-7; Scottish Office, 1992, SCOTL HLTH CHALL US; VICTORA CG, 1989, INT J EPIDEMIOL, V18, P918, DOI 10.1093/ije/18.4.918; WHITE AS, 1992, INFANT FEEDING 1990; WHO World Health Organisation, 1985, TARG HLTH ALL; WILLIAMS SP, 1992, BRIT MED J, V305, P522, DOI 10.1136/bmj.305.6852.522-c; *WORK PART CHIEF M, 1993, SCOTT DIET; YAMAUCHI Y, 1990, ACTA PAEDIATR SCAND, V79, P1017, DOI 10.1111/j.1651-2227.1990.tb11377.x	36	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 5	1997	314	7086					1030	1033		10.1136/bmj.314.7086.1030	http://dx.doi.org/10.1136/bmj.314.7086.1030			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WT152	9112851	Green Published			2022-12-01	WOS:A1997WT15200030
J	Nudler, E; Mustaev, A; Lukhtanov, E; Goldfarb, A				Nudler, E; Mustaev, A; Lukhtanov, E; Goldfarb, A			The RNA-DNA hybrid maintains the register of transcription by preventing backtracking of RNA polymerase	CELL			English	Article							ESCHERICHIA-COLI; TERNARY COMPLEXES; 3-DIMENSIONAL STRUCTURE; ELONGATION COMPLEXES; CHAIN ELONGATION; TERMINATION; CLEAVAGE; ENZYME; CONFORMATIONS; INITIATION	An 8-9 bp RNA-DNA hybrid in the transcription elongation complex is essential for keeping the RNA 3' terminus engaged with the active site of E. coli RNA polymerase (RNAP). Destabilization of the hybrid leads to detachment of the transcript terminus, RNAP backtracking, and shifting of the hybrid upstream. Eventually, the exposed 3' segment of RNA can be removed through transcript cleavage. At certain sites, cycles of unwinding-rewinding of the hybrid are coupled to reverse-forward sliding of the transcription elongation complex. This explains apparent discontinuous elongation, which was previously interpreted as contraction and expansion of an RNAP molecule (inch-worming). Thus, the 3'-proximal RNA-DNA hybrid plays the dual role of keeping the active site in register with the template and sensing the helix-destabilizing mismatches in RNA, launching correction through backtracking and cleavage.	EPOCH PHARMACEUT INC, BOTHELL, WA 98021 USA		Nudler, E (corresponding author), PUBL HLTH RES INST, NEW YORK, NY 10016 USA.			Nudler, Evgeny/0000-0002-8811-3071	NIGMS NIH HHS [GM49242] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049242] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTMANN CR, 1994, P NATL ACAD SCI USA, V91, P3784, DOI 10.1073/pnas.91.9.3784; ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; BUROVA E, 1995, J BACTERIOL, V177, P1388, DOI 10.1128/jb.177.5.1388-1392.1995; CHAMBERLIN MJ, 1995, HARVEY LECT, V88, P1; Chan Cathleen L., 1994, V3, P297; DARST SA, 1991, CELL, V66, P121, DOI 10.1016/0092-8674(91)90144-N; DAS A, 1993, ANNU REV BIOCHEM, V62, P893; ERIE DA, 1993, SCIENCE, V262, P867, DOI 10.1126/science.8235608; FARNHAM PJ, 1980, CELL, V20, P739, DOI 10.1016/0092-8674(80)90320-7; Gall A. A., 1979, IZV SIB OTD AN KHIM, V4, P99; GAMPER HB, 1982, CELL, V29, P81, DOI 10.1016/0092-8674(82)90092-7; Gu WG, 1996, P NATL ACAD SCI USA, V93, P6935, DOI 10.1073/pnas.93.14.6935; GU WG, 1995, J BIOL CHEM, V270, P11238, DOI 10.1074/jbc.270.19.11238; Guajardo R, 1997, J MOL BIOL, V265, P8, DOI 10.1006/jmbi.1996.0707; HANNA MM, 1983, P NATL ACAD SCI-BIOL, V80, P4238, DOI 10.1073/pnas.80.14.4238; HOARD DE, 1965, J AM CHEM SOC, V87, P1785, DOI 10.1021/ja01086a031; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; IZBAN MG, 1993, J BIOL CHEM, V268, P12874; Jeon C, 1996, P NATL ACAD SCI USA, V93, P13677, DOI 10.1073/pnas.93.24.13677; JOHNSON TL, 1994, CELL, V77, P217, DOI 10.1016/0092-8674(94)90314-X; KAINZ M, 1992, SCIENCE, V255, P838, DOI 10.1126/science.1536008; KASHLEV M, 1993, GENE, V130, P9, DOI 10.1016/0378-1119(93)90340-9; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; KOMISARROVA N, 1997, IN PRESS P NATL ACAD, V94; KOMISARROVA N, 1997, IN PRESS J BIOL CHEM, V272; KRUMMEL B, 1992, J MOL BIOL, V225, P221, DOI 10.1016/0022-2836(92)90917-9; Markovtsov V, 1996, P NATL ACAD SCI USA, V93, P3221, DOI 10.1073/pnas.93.8.3221; MASON SW, 1992, J BIOL CHEM, V267, P19418; MATSUZAKI H, 1994, J MOL BIOL, V235, P1173, DOI 10.1006/jmbi.1994.1072; MUSTAEV A, 1993, J BIOL CHEM, V268, P19185; MUSTAEV A, 1994, P NATL ACAD SCI USA, V91, P12036, DOI 10.1073/pnas.91.25.12036; NUDLER E, 1995, CELL, V81, P351, DOI 10.1016/0092-8674(95)90388-7; NUDLER E, 1994, SCIENCE, V265, P793, DOI 10.1126/science.8047884; Nudler E, 1996, SCIENCE, V273, P211, DOI 10.1126/science.273.5272.211; ORLOVA M, 1995, P NATL ACAD SCI USA, V92, P4596, DOI 10.1073/pnas.92.10.4596; PLATT T, 1997, IN PRESS RNA STRUCTU; POLYAKOV A, 1995, CELL, V83, P365, DOI 10.1016/0092-8674(95)90114-0; PUHLER G, 1989, P NATL ACAD SCI USA, V86, P4569, DOI 10.1073/pnas.86.12.4569; Reeder TC, 1996, CELL, V87, P767, DOI 10.1016/S0092-8674(00)81395-1; REINES D, 1994, TRANSCRIPTION MECHAN, P263; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; Richardson J. P., 1996, ESCHERICHIA COLI SAL, P822; RUDD MD, 1994, P NATL ACAD SCI USA, V91, P8057, DOI 10.1073/pnas.91.17.8057; Samkurashvili I, 1996, J BIOL CHEM, V271, P23495, DOI 10.1074/jbc.271.38.23495; SWEETSER D, 1987, P NATL ACAD SCI USA, V84, P1192, DOI 10.1073/pnas.84.5.1192; WANG DG, 1995, CELL, V81, P341, DOI 10.1016/0092-8674(95)90387-9; WIEST DK, 1992, J BIOL CHEM, V267, P7733; YAGER TD, 1991, BIOCHEMISTRY-US, V30, P1097, DOI 10.1021/bi00218a032; YAGER TD, 1987, ESCHERICHIA COLI SAL, P1241; YANG XJ, 1989, P NATL ACAD SCI USA, V86, P5301, DOI 10.1073/pnas.86.14.5301; ZAYCHIKOV E, 1995, P NATL ACAD SCI USA, V92, P1739, DOI 10.1073/pnas.92.5.1739; Zaychikov E, 1996, SCIENCE, V273, P107, DOI 10.1126/science.273.5271.107	53	358	364	3	17	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 4	1997	89	1					33	41		10.1016/S0092-8674(00)80180-4	http://dx.doi.org/10.1016/S0092-8674(00)80180-4			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WR685	9094712	Bronze			2022-12-01	WOS:A1997WR68500007
J	Nightingale, SL				Nightingale, SL			Simplified labeling for OTC drugs proposed	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		1997, FED REG         0227, V62, P9024	1	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 2	1997	277	13					1029	1029						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ089	9091680				2022-12-01	WOS:A1997WQ08900007
J	Ramzan, NN; Loftus, E; Burgart, LJ; Rooney, M; Batts, KP; Wiesner, RH; Fredricks, DN; Relman, DA; Persing, DH				Ramzan, NN; Loftus, E; Burgart, LJ; Rooney, M; Batts, KP; Wiesner, RH; Fredricks, DN; Relman, DA; Persing, DH			Diagnosis and monitoring of whipple disease by polymerase chain reaction	ANNALS OF INTERNAL MEDICINE			English	Article							AMPLIFICATION; BACILLUS; IDENTIFICATION; DNA	Background: Whipple disease is a chronic, multisystem disorder associated with infection with Tropheryma whippelii, an organism that has not yet been grown on artificial media. In some cases, the diagnosis of Whipple disease is uncertain if it is based on histology alone. Although antibiotic regimens of various durations have been used, the disease recurs in about one third of cases. No test for cure is available. Objective: To develop a test that is more sensitive and specific than histologic examination to diagnose Whipple disease and monitor the effects of antibiotic therapy. Design: Retrospective, laboratory-based evaluations of stored tissue specimens. Patients: 30 patients with clinically diagnosed, histologically confirmed Whipple disease and 8 patients in whom Whipple disease was clinically suspected but who did not have definitive histologic evidence. Measurements: Pretreatment and post-treatment biopsy specimens of the small bowel and lymph node were tested by polymerase chain reaction for the presence of T. whippeli DNA. Results: Results on PCR were positive in 29 of the 30 specimens from patients with histologically confirmed disease (sensitivity, 96.6%; specificity, 100%) and in 7 of the 8 specimens from patients in whom disease was clinically suspected. Small-bowel biopsy specimens were obtained after treatment from 17 patients (median duration of follow-up, 119 months); specimens from 12 of these patients had positive results on PCR. When these cases were correlated with therapeutic outcome, it was found that 7 of the 12 patients had clinical relapse during subsequent follow-up or had never responded to treatment (positive predictive value, 58% [95% CI, 28% to 85%]). In contrast, none of the 5 patients whose post-treatment biopsy specimens had negative results on PCR had relapse (negative predictive value, 100% [CI, 48% to 100%]; P = 0.044). No correlation was found between post-treatment histology and clinical outcome (P > 0.2). Conclusions: Polymerase chain reaction is highly sensitive and specific when used to confirm the diagnosis of Whipple disease, to identify inconclusive and suspicious cases, and to monitor response to therapy. A negative result on PCR may predict a low likelihood of clinical relapse; a positive test result that remains positive despite therapy may be associated with a poor clinical outcome. Histopathologic evaluation of post-treatment specimens does not predict clinical cure or relapse.	MAYO CLIN & MAYO GRAD SCH MED, DEPT LAB MED, MOL MICROBIOL LAB, ROCHESTER, MN 55905 USA; SUNY SYRACUSE, HLTH SCI CTR, DEPT ANAT PATHOL, SYRACUSE, NY 13210 USA; STANFORD UNIV, MED CTR, STANFORD, CA 94305 USA; VET AFFAIRS PALO ALTO HLTH CARE SYST, PALO ALTO, CA USA	Mayo Clinic; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System			Loftus, Edward V/E-8304-2011	Loftus, Edward V/0000-0001-7199-6851; Relman, David A./0000-0001-8331-1354; Fredricks, David/0000-0003-2735-6800	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032403, N01AI045253] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007198] Funding Source: NIH RePORTER; NIAID NIH HHS [AI32403, AI45253] Funding Source: Medline; NIDDK NIH HHS [DK07198] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CIMINO GD, 1991, NUCLEIC ACIDS RES, V19, P99, DOI 10.1093/nar/19.1.99; CLARRIDGE JE, 1993, J CLIN MICROBIOL, V31, P2049, DOI 10.1128/JCM.31.8.2049-2056.1993; DOBBINS WO, 1995, NEW ENGL J MED, V332, P390, DOI 10.1056/NEJM199502093320611; DOBBINS WO, 1988, MAYO CLIN PROC, V63, P623, DOI 10.1016/S0025-6196(12)64892-7; FEURLE GE, 1979, NEW ENGL J MED, V300, P907, DOI 10.1056/NEJM197904193001607; FLEMING JL, 1988, MAYO CLIN PROC, V63, P539, DOI 10.1016/S0025-6196(12)64884-8; GEBOES K, 1990, GASTROINTEST ENDOSC, V36, P247, DOI 10.1016/S0016-5107(90)71016-4; Genetic Computer Group, 1994, PROGR MAN WISC PACK; GREER CE, 1991, AM J CLIN PATHOL, V95, P117, DOI 10.1093/ajcp/95.2.117; KEINATH RD, 1985, GASTROENTEROLOGY, V88, P1867, DOI 10.1016/0016-5085(85)90012-5; LOWSKY R, 1994, NEW ENGL J MED, V331, P1343, DOI 10.1056/NEJM199411173312004; MANSBACH CM, 1978, ANN INTERN MED, V89, P64, DOI 10.7326/0003-4819-89-1-64; NOCTON JJ, 1994, NEW ENGL J MED, V330, P229, DOI 10.1056/NEJM199401273300401; RELMAN DA, 1993, J INFECT DIS, V168, P1; RELMAN DA, 1992, NEW ENGL J MED, V327, P293, DOI 10.1056/NEJM199207303270501; Relman David A., 1993, P496; RICKMAN LS, 1995, NEW ENGL J MED, V332, P363, DOI 10.1056/NEJM199502093320604; RIEMANN JF, 1978, ENDOSCOPY, V10, P98, DOI 10.1055/s-0028-1098273; RYS PN, 1993, J CLIN MICROBIOL, V31, P2356, DOI 10.1128/JCM.31.9.2356-2360.1993; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SPAPEN HDM, 1989, DIGEST DIS SCI, V34, P640, DOI 10.1007/BF01536345; Whipple GH, 1907, B JOHNS HOPKINS HOSP, V18, P382; WILSON KH, 1991, LANCET, V338, P474, DOI 10.1016/0140-6736(91)90545-Z; WROE SJ, 1991, J NEUROL NEUROSUR PS, V54, P989, DOI 10.1136/jnnp.54.11.989; 1983, NEW ENGL J MED, V24, P1323	25	148	153	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1997	126	7					520	+		10.7326/0003-4819-126-7-199704010-00004	http://dx.doi.org/10.7326/0003-4819-126-7-199704010-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ195	9092317				2022-12-01	WOS:A1997WQ19500013
J	Beals, CR; Sheridan, CM; Turck, CW; Gardner, P; Crabtree, GR				Beals, CR; Sheridan, CM; Turck, CW; Gardner, P; Crabtree, GR			Nuclear export of NF-ATc enhanced by glycogen synthase kinase-3	SCIENCE			English	Article							T-CELL ACTIVATION; CYCLOSPORINE-A; GENE; FAMILY; IDENTIFICATION; CALCINEURIN; PROMOTER; MEMBERS; PRODUCT; SIGNAL	The transcription factor NF-AT responds to Ca2+-calcineurin signals by translocating to the nucleus, where it participates in the activation of early immune response genes. Calcineurin dephosphorylates conserved serine residues in the amino terminus of NF-AT, resulting in nuclear import. Purification of the NF-AT kinase revealed that it is composed of a priming kinase activity and glycogen synthase kinase-3 (GSK-3). GSK-3 phosphorylates conserved serines necessary for nuclear export, promotes nuclear exit, and thereby opposes Ca2+-calcineurin signaling. Because GSK-3 responds to signals initiated by Wnt and other ligands, NF-AT family members could be effecters of these pathways.	STANFORD UNIV, DEPT MOL PHARMACOL, STANFORD, CA 94305 USA; UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA	Stanford University; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Beals, CR (corresponding author), STANFORD UNIV, HOWARD HUGHES MED INST, DEPT DEV BIOL, STANFORD, CA 94305 USA.							BEALS CR, UNPUB; BOUROUIS M, 1990, EMBO J, V9, P2877, DOI 10.1002/j.1460-2075.1990.tb07477.x; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHUVPILO S, 1993, NUCLEIC ACIDS RES, V21, P5694, DOI 10.1093/nar/21.24.5694; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COCKERILL PN, 1995, MOL CELL BIOL, V15, P2071; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; ELDARFINKELMAN H, 1995, J BIOL CHEM, V270, P987, DOI 10.1074/jbc.270.3.987; FIOL CJ, 1994, J BIOL CHEM, V269, P32187; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; GOLDFELD AE, 1993, J EXP MED, V178, P1365, DOI 10.1084/jem.178.4.1365; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; HO SN, 1995, J BIOL CHEM, V270, P19898, DOI 10.1074/jbc.270.34.19898; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; HUGHES K, 1992, EUR J BIOCHEM, V203, P305, DOI 10.1111/j.1432-1033.1992.tb19860.x; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Luo C, 1996, P NATL ACAD SCI USA, V93, P8907, DOI 10.1073/pnas.93.17.8907; MARY D, 1987, J IMMUNOL, V139, P1179; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; ROONEY JW, 1995, IMMUNITY, V2, P473, DOI 10.1016/1074-7613(95)90028-4; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; SIEGFRIED E, 1990, NATURE, V345, P825, DOI 10.1038/345825a0; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; SRINIVASAN M, 1994, J CELL BIOL, V126, P839, DOI 10.1083/jcb.126.4.839; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; Welsh GI, 1996, J BIOL CHEM, V271, P11410, DOI 10.1074/jbc.271.19.11410; Woodgett JR, 1991, METHOD ENZYMOL, V200, P564	34	611	639	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 28	1997	275	5308					1930	1933		10.1126/science.275.5308.1930	http://dx.doi.org/10.1126/science.275.5308.1930			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WQ513	9072970				2022-12-01	WOS:A1997WQ51300045
J	CleatonJones, PE				CleatonJones, PE			An ethical dilemma - Availability of antiretroviral therapy after clinical trials with HIV infected patients are ended	BRITISH MEDICAL JOURNAL			English	Article											CleatonJones, PE (corresponding author), UNIV WITWATERSRAND,COMM RES HUMAN SUBJECTS MED,JOHANNESBURG,SOUTH AFRICA.		Cleaton-Jones, Peter E/L-4090-2016					*CPMP WORK PART EF, 1990, GOOD CLIN PRACT TRIA; Quinn TC, 1996, LANCET, V348, P99, DOI 10.1016/S0140-6736(96)01029-X; *S AFR MED RES COU, 1983, GUID ETH MED RES; Schooley RT, 1996, J INFECT DIS, V173, P1354, DOI 10.1093/infdis/173.6.1354; Volberding PA, 1996, NEW ENGL J MED, V334, P729, DOI 10.1056/NEJM199603143341113; 1995, EPIDEMIOL COMMENTS, V22, P90	6	19	20	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 22	1997	314	7084					887	888						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ028	9093104	Green Published			2022-12-01	WOS:A1997WQ02800036
J	Hogerzeil, HV; Couper, MR; Gray, R				Hogerzeil, HV; Couper, MR; Gray, R			Guidelines for drug donations	BRITISH MEDICAL JOURNAL			English	Article								Drug donations are usually given in response to acute emergencies, but they can also be part of development aid. Donations may be given directly by governments, by non-governmental organisations, as corporate donations (direct or through private voluntary organisations), or as private donations to single health facilities. Although there are legitimate differences between these donations, basic rules should apply to them all. This common core of ''good donation practice'' is the basis for new guidelines which have recently been issued by the World Health Organisation after consultation with all relevant United Nations agencies, the Red Cross, and other major international agencies active in humanitarian emergency relief. This article summarises the need for such guidelines, the development process, the core principles, and the guidelines themselves and gives practical advice to recipients and donor agencies.	WHO,DIV DRUG MANAGEMENT & POLICIES,CH-1211 GENEVA,SWITZERLAND; WHO,DIV EMERGENCY & HUMANITARIAN ACT,CH-1211 GENEVA,SWITZERLAND	World Health Organization; World Health Organization	Hogerzeil, HV (corresponding author), WHO,ACT PROGRAMME ESSENTIAL DRUGS,CH-1211 GENEVA,SWITZERLAND.							AUTIER P, 1990, LANCET, V335, P1388; *CHRIST MED COMM, 1990, GUID DON REC PHARM D; COHEN S, 1990, LANCET, V335, P745; FORTE GB, 1994, OUNCE PREVENTION WOR; HOEN E, 1993, LANCET, V342, P308; HOGERZEIL HV, 1990, LANCET, V336, P1194, DOI 10.1016/0140-6736(90)92812-V; *WHO, 1990, NEW EM HLTH KIT, P5; *WHO, 1992, WHO TECH REP SER, V825, P13; *WHO, 1996, GUID DRUG DON; *WHO, 1994, MED SUPPL DON GUID W; WOLDEYESUS K, 1994, LANCET, V344, P879, DOI 10.1016/S0140-6736(94)92845-2	11	22	24	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 8	1997	314	7082					737	740		10.1136/bmj.314.7082.737	http://dx.doi.org/10.1136/bmj.314.7082.737			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM776	9116555	Green Published			2022-12-01	WOS:A1997WM77600032
J	Williams, S; Dale, J; Glucksman, E; Wellesley, A				Williams, S; Dale, J; Glucksman, E; Wellesley, A			Senior house officers' work related stressors, psychological distress, and confidence in performing clinical tasks in accident and emergency: A questionnaire study	BRITISH MEDICAL JOURNAL			English	Article							SATISFACTION; MEDICINE; DOCTORS	Objective: To investigate the relation between accident and emergency senior house officers' psychological distress and confidence in performing clinical tasks and to describe work related stressors. Design: Questionnaire survey with data collected at four points during senior house officers' six month attachment to accident and emergency departments. Subjects: 171 newly appointed accident and emergency senior house officers from 27 hospitals in the South Thames region. Main outcome measures: Psychological distress measured with a 25 item questionnaire; confidence in performing a range of 35 clinical and practical activities (visual analogue scales); reported consultation stress factors, other work related stressors, and personal stressors. Results: Overall confidence scores in carrying out a range of clinical and practical activities increased significantly between the end of the first and the end of the fourth month (Z=-6.05, P<0.001). Senior house officers with higher psychological distress scores at the end of their first and fourth month had significantly lower confidence scores (Z=-3.20, P<0.001; Z=-1.90, P<0.05). Senior house officers with lower increases in confidence between the first and fourth month had significantly higher distress than those with greater increases (Z=-2.62, P<0.001), Factors identified as causing stress during consultations included difficulties with communication, certain clinical presentations, and department organisational factors (particularly tile intensity of workload). Conclusions: Psychological distress is linked to confidence in senior house officers. This supports the need to monitor and build confidence in senior house officers and to address work related stressors. Additional communication skills training needs to be considered.	KINGS COLL HOSP,DEPT ACCID & EMERGENCY MED,LONDON SE5 9RS,ENGLAND	King's College Hospital NHS Foundation Trust; King's College Hospital	Williams, S (corresponding author), UNIV LONDON KINGS COLL,SCH MED & DENT,DEPT GEN PRACTICE & PRIMARY CARE,LONDON SE5 9PJ,ENGLAND.			Dale, Jeremy/0000-0001-9256-3553				BEECHAM L, 1995, BRIT MED J, V310, P31; COHEN A, 1990, MED TEACH, V12, P47, DOI 10.3109/01421599009010561; COLES C, 1994, MED EDUC, V28, P18, DOI 10.1111/j.1365-2923.1994.tb02680.x; *COMM POSTGR MED D, 1995, SHO TRAIN TACKL ISS; COOPER CL, 1989, BRIT MED J, V298, P366, DOI 10.1136/bmj.298.6670.366; DALE J, IN PRESS MED ED; Dowling S, 1990, BRIT MED J, V295, P926; FIRTHCOZENS J, 1987, BRIT MED J, V295, P533, DOI 10.1136/bmj.295.6597.533; GARRUD P, 1990, BRIT MED J, V300, P445, DOI 10.1136/bmj.300.6722.445; Goldberg D., 1988, USERS GUIDE GEN HLTH; HALE R, 1992, BRIT J HOSP MED, V47, P452; HEYWORTH J, 1993, ARCH EMERG MED, V10, P279; LUM G, 1995, ANN EMERG MED, V25, P81, DOI 10.1016/S0196-0644(95)70360-8; Miles M.B., 1994, QUALITATIVE DATA ANA, V2nd ed; MORGAN DR, 1992, STRESS MED PROFESSIO; Norusis M.J, 1985, SPSSX ADV STAT GUIDE; RAMIREZ AJ, 1995, BRIT J CANCER, V71, P1263, DOI 10.1038/bjc.1995.244; Ramirez AJ, 1996, LANCET, V347, P724, DOI 10.1016/S0140-6736(96)90077-X; Ware J.E., 1979, CONCEPTUALIZATION ME, V3	19	75	76	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 8	1997	314	7082					713	718		10.1136/bmj.314.7082.713	http://dx.doi.org/10.1136/bmj.314.7082.713			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WM776	9116547	Green Published			2022-12-01	WOS:A1997WM77600022
J	Lee, TT; Solomon, NA; Heidenreich, PA; Oehlert, J; Garber, AM				Lee, TT; Solomon, NA; Heidenreich, PA; Oehlert, J; Garber, AM			Cost-effectiveness of screening for carotid stenosis in asymptomatic persons	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	Society-of-General-Internal-Medicine Meeting	MAR 10, 1995	SAN DIEGO, CA	Soc Gen Internal Med		endarterectomy, carotid; mass screening; cost-benefit analysis; quality-adjusted life-years; ultrasonography, Doppler, duplex	MYOCARDIAL-INFARCTION; MR-ANGIOGRAPHY; ARTERY DISEASE; RISK-FACTORS; ENDARTERECTOMY; STROKE; PREVALENCE; POPULATION; SURVIVAL; MORTALITY	Background: The Asymptomatic Carotid Atherosclerosis Study (ACAS) showed that carotid endarterectomy was beneficial for symptom-free patients with carotid stenosis of 60% or more. This finding raises the question of whether widespread screening to identify cases of asymptomatic carotid stenosis should be implemented. Objective: To determine whether a screening program to identify cases of asymptomatic carotid stenosis would be a cost-effective strategy for stroke prevention. Design: Cost-effectiveness analysis using published data from clinical trials. Setting: General population of asymptomatic 65-year-old men. Intervention: Patients who were screened for carotid disease with duplex Doppler ultrasonography were compared with patients who were not screened. If ultrasonography found significant carotid stenosis (greater than or equal to 60%), disease was confirmed by angiography before carotid endarterectomy was done. Measurements: Quality-adjusted life-years, costs, and marginal cost-effectiveness ratios. Results: When the conditions and results of ACAS were modeled and it was assumed that the survival advantage produced by endarterectomy would last for 30 years, the lifetime marginal cost-effectiveness of screening relative to no screening was $120 000 per quality-adjusted life-year. Sensitivity analysis showed that marginal cost-effectiveness decreased to $50 000 or less per quality-adjusted life-year only under implausible conditions (for example, if a free screening instrument with perfect test characteristics was used or an asymptomatic population with a 40% prevalence of carotid stenosis was found). Conclusions: Surgery offers a real but modest absolute reduction in the rate of stroke at a substantial cost. A program to identify candidates for endarterectomy by screening asymptomatic populations for carotid stenosis costs more per quality-adjusted life-year than is usually considered acceptable.	KAISER PERMANENTE, OAKLAND, CA 94612 USA; STANFORD UNIV, SCH MED, DIV RHEUMATOL & IMMUNOL, STANFORD, CA 94305 USA	Kaiser Permanente; Stanford University			Garber, Alan M/F-1476-2010; Heidenreich, Paul/AAU-6864-2021	Heidenreich, Paul/0000-0001-7730-8490	PHS HHS [28-9, 00028-10] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Barnett H. J. M., 1992, STROKE PATHOPHYSIOLO; BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; BERNSTEIN EF, 1983, ANN SURG, V198, P80, DOI 10.1097/00000658-198307000-00016; BLAKELEY DD, 1995, ANN INTERN MED, V122, P360, DOI 10.7326/0003-4819-122-5-199503010-00007; BLATTER DD, 1993, AM J ROENTGENOL, V161, P1269, DOI 10.2214/ajr.161.6.8249741; *CAL OFF STAT HLTH, 1991, 1991 CAL AC CAR HOSP; CARACCIOLO EA, 1995, CIRCULATION, V91, P2325, DOI 10.1161/01.CIR.91.9.2325; COLGAN MP, 1988, J VASC SURG, V8, P674, DOI 10.1067/mva.1988.avs0080674; COTE R, 1995, ANN INTERN MED, V123, P649, DOI 10.7326/0003-4819-123-9-199511010-00002; DENNIS MS, 1993, STROKE, V24, P796, DOI 10.1161/01.STR.24.6.796; DIENER HC, 1991, STROKE, V22, P1229; FEUSSNER JR, 1988, ANN INTERN MED, V109, P805, DOI 10.7326/0003-4819-109-10-805; FOWL RJ, 1991, SURG GYNECOL OBSTET, V172, P13; FUCHS VR, 1990, NEW ENGL J MED, V323, P673, DOI 10.1056/NEJM199009063231011; GAGE BF, 1995, JAMA-J AM MED ASSOC, V274, P1839, DOI 10.1001/jama.274.23.1839; GRESHAM GE, 1979, ARCH PHYS MED REHAB, V60, P487; GRZYSKA U, 1990, NEURORADIOLOGY, V32, P296, DOI 10.1007/BF00593048; HANKEY GJ, 1990, STROKE, V21, P209, DOI 10.1161/01.STR.21.2.209; *HEALTHC CONS AM, 1994, PHYS FEE COD GUID; HEISERMAN JE, 1994, AM J NEURORADIOL, V15, P1401; HERTZER NR, 1985, J VASC SURG, V2, P661, DOI 10.1067/mva.1985.avs0020661; *HLTH CAR FIN ADM, 1994, HLTH CAR FIN ADM COM; *HLTH CAR INV AN, 1991, MED DRG HDB COMP CLI; HOBSON RW, 1993, NEW ENGL J MED, V328, P221, DOI 10.1056/NEJM199301283280401; JENNETT B, 1975, LANCET, V1, P480; JOSSE M O, 1987, Neuroepidemiology, V6, P150, DOI 10.1159/000110110; KEELER EB, 1983, MANAGE SCI, V29, P300, DOI 10.1287/mnsc.29.3.300; KENT KC, 1995, JAMA-J AM MED ASSOC, V274, P888, DOI 10.1001/jama.274.11.888; KRAISS LW, 1995, AM J SURG, V169, P512, DOI 10.1016/S0002-9610(99)80207-4; LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473; Lipscomb J., 1996, COST EFFECTIVENESS H; LITTENBERG B, 1990, ANN INTERN MED, V112, P192, DOI 10.7326/0003-4819-112-3-192; LUNA G, 1995, AM J SURG, V169, P516, DOI 10.1016/S0002-9610(99)80208-6; MANI RL, 1978, AM J ROENTGENOL, V131, P867, DOI 10.2214/ajr.131.5.867; MATTOS MA, 1992, J CARDIOVASC SURG, V33, P387; MITTL RL, 1994, STROKE, V25, P4, DOI 10.1161/01.STR.25.1.4; MOORE WS, 1979, AM J SURG, V138, P228, DOI 10.1016/0002-9610(79)90375-1; OSTER G, 1994, STROKE, V25, P1149, DOI 10.1161/01.STR.25.6.1149; PRATI P, 1992, STROKE, V23, P1705, DOI 10.1161/01.STR.23.12.1705; RAMSEY DE, 1987, J VASC SURG, V5, P584, DOI 10.1067/mva.1987.avs0050584; Ricco J B, 1992, Ann Vasc Surg, V6, P408, DOI 10.1007/BF02006994; ROBERTS SD, 1980, ANN INTERN MED, V92, P243, DOI 10.7326/0003-4819-92-2-243; Robins M, 1981, STROKE, V12, pI7; SHRIVER ME, 1993, CURR OPIN NEUROL NEU, V6, P74; SMITH P, 1990, NEW ENGL J MED, V323, P147, DOI 10.1056/NEJM199007193230302; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; Torrance GW, 1987, METHODS EC EVALUATIO; Torrance GW, 1996, COST EFFECTIVENESS H; TOWNE JB, 1990, J VASC SURG, V11, P252, DOI 10.1067/mva.1990.16484; TSEVAT J, 1993, MED DECIS MAKING, V13, P161, DOI 10.1177/0272989X9301300210; *US DEP HHS, 1990, VIT STAT US; WALKER MD, 1995, JAMA-J AM MED ASSOC, V273, P1421, DOI 10.1001/jama.1995.03520420037035; WARLOW C, 1991, LANCET, V337, P1235, DOI 10.1016/0140-6736(91)92916-P; WEINSTEIN MC, 1982, CIRCULATION, V66, P56; WEINSTEIN MC, 1977, NEW ENGL J MED, V296, P716, DOI 10.1056/NEJM197703312961304; Weinstein MC, 1980, CLIN DECISION ANAL; WHITE JE, 1994, AM SURGEON, V60, P340; WIEBERS DO, 1992, MAYO CLIN PROC, V67, P513; WILLEIT J, 1993, ARTERIOSCLER THROMB, V13, P661, DOI 10.1161/01.ATV.13.5.661; WILSON DL, 1994, MECH AGEING DEV, V74, P15, DOI 10.1016/0047-6374(94)90095-7; WONG JB, 1990, ANN INTERN MED, V113, P852, DOI 10.7326/0003-4819-113-11-852	62	111	113	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1997	126	5					337	+		10.7326/0003-4819-126-5-199703010-00001	http://dx.doi.org/10.7326/0003-4819-126-5-199703010-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	WL104	9054277				2022-12-01	WOS:A1997WL10400001
J	Petosa, C; Collier, RJ; Klimpel, KR; Leppla, SH; Liddington, RC				Petosa, C; Collier, RJ; Klimpel, KR; Leppla, SH; Liddington, RC			Crystal structure of the anthrax toxin protective antigen	NATURE			English	Article							LETHAL FACTOR; MAMMALIAN-CELLS; MEMBRANE; CHANNELS	Protective antigen (PA) is the central component of the three-part protein toxin secreted by Bacillus anthracis, the organism responsible for anthrax(1). After proteolytic activation on the host cell surface, PA forms a membrane-inserting heptamer that translocates the toxic enzymes, oedema factor and lethal factor, into the cytosol(2-4). PA, which has a relative molecular mass of 83,000 (M(r) 83K), can also translocate heterologous proteins, and is being evaluated for use as a general protein delivery system(5,6). Here we report the crystal structure of monomeric PA at 2.1 Angstrom resolution and the water-soluble heptamer at 4.5 Angstrom resolution, The monomer is organized mainly into antiparallel beta-sheets and has four domains: an amino-terminal domain (domain 1) containing two calcium ions and the cleavage site for activating proteases; a heptamerization domain (domain 2) containing a large flexible loop implicated in membrane insertion; a small domain of unknown function (domain 3); and a carboxy-terminal receptor-binding domain (domain 4). Removal of a 20K amino-terminal fragment from domain 1 allows the assembly of the heptamer, a ring-shaped structure with a negatively charged lumen, and exposes a large hydrophobic surface for binding the toxic enzymes. We propose a model of pH-dependent membrane insertion involving the formation of a porin-like, membrane-spanning beta-barrel.	HARVARD UNIV, SCH MED, DEPT MICROBIOL & MOL GENET, BOSTON, MA 02115 USA; NIDR, MICROBIAL ECOL LAB, NIH, BETHESDA, MD 20982 USA	Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Petosa, C (corresponding author), UNIV LEICESTER, DEPT BIOCHEM, LEICESTER LE1 7RH, LEICS, ENGLAND.			Collier, R John/0000-0002-2427-4239; Petosa, Carlo/0000-0002-9975-1167				ARORA N, 1993, J BIOL CHEM, V268, P3334; Blanke SR, 1996, P NATL ACAD SCI USA, V93, P8437, DOI 10.1073/pnas.93.16.8437; BLAUSTEIN RO, 1989, P NATL ACAD SCI USA, V86, P2209, DOI 10.1073/pnas.86.7.2209; BLAUSTEIN RO, 1990, J GEN PHYSIOL, V96, P905, DOI 10.1085/jgp.96.5.905; BRUNGER AT, 1992, X PLOR MANUAL VERSIO; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; Kelly JW, 1996, CURR OPIN STRUC BIOL, V6, P11, DOI 10.1016/S0959-440X(96)80089-3; Kleywegt G. J., 1994, P CCP4 STUD WEEK 1 M, P59; KOEHLER TM, 1991, MOL MICROBIOL, V5, P1501, DOI 10.1111/j.1365-2958.1991.tb00796.x; KREUSCH A, 1994, PROTEIN SCI, V3, P58; Leppla S. H., 1995, Bacterial toxins and virulence factors in disease., P543; Leppla S.H., 1991, SOURCEBOOK BACTERIAL, P277; Little SF, 1996, MICROBIOL-SGM, V142, P707, DOI 10.1099/13500872-142-3-707; MILNE JC, 1993, MOL MICROBIOL, V10, P647, DOI 10.1111/j.1365-2958.1993.tb00936.x; MILNE JC, 1994, J BIOL CHEM, V269, P20607; NAKAYAMA S, 1994, ANNU REV BIOPH BIOM, V23, P473, DOI 10.1146/annurev.bb.23.060194.002353; Nicholls A., 1992, GRASP GRAPHICAL REPR; NOVAK JM, 1992, J BIOL CHEM, V267, P17186; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PERELLE S, 1993, INFECT IMMUN, V61, P5147, DOI 10.1128/IAI.61.12.5147-5156.1993; PRASAD GS, 1993, BIOCHEMISTRY-US, V32, P13762, DOI 10.1021/bi00213a001; SINGH Y, 1991, J BIOL CHEM, V266, P15493; SINGH Y, 1994, J BIOL CHEM, V269, P29039; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; TURNBULL P, 1990, TOPLEY WILSONS PRINC, P365; WARREN G, 1996, Patent No. 10083; ZHAO JM, 1995, J BIOL CHEM, V270, P18626, DOI 10.1074/jbc.270.31.18626	30	648	703	0	59	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 27	1997	385	6619					833	838		10.1038/385833a0	http://dx.doi.org/10.1038/385833a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WK570	9039918				2022-12-01	WOS:A1997WK57000058
J	Goldman, MJ; Anderson, GM; Stolzenberg, ED; Kari, UP; Zasloff, M; Wilson, JM				Goldman, MJ; Anderson, GM; Stolzenberg, ED; Kari, UP; Zasloff, M; Wilson, JM			Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis	CELL			English	Article							HUMAN BRONCHIAL EPITHELIA; ANTIMICROBIAL PEPTIDE; MESSENGER-RNA; GENE-TRANSFER; PANETH CELLS; DEFENSINS; CFTR; INFLAMMATION; XENOGRAFTS; INFECTION	A human bronchial xenograft model was used to characterize the molecular basis for the previously described defect in bacterial killing that is present in the cystic fibrosis (CF) lung. Airway surface fluid from CF grafts contained abnormally high NaCl and failed to kill bacteria, defects that were corrected with adenoviral vectors. A full-length clone for the only known human beta-defensin (i.e., hBD-1) was isolated. This gene is expressed throughout the respiratory epithelia of non-CF and CF lungs, and its protein product shows salt-dependent antimicrobial activity to P. aeruginosa. Antisense oligonucleotides to hBD-1 ablated the antimicrobial activity in airway surface fluid from non-CF grafts. These data suggest that hBD-1 plays an important role in innate immunity that is compromised in CF by its salt-dependent inactivation.	UNIV PENN,MED CTR,WISTAR INST,DEPT MOL & CELLULAR ENGN,PHILADELPHIA,PA 19104; UNIV PENN,MED CTR,WISTAR INST,INST HUMAN GENE THERAPY,PHILADELPHIA,PA 19104; MAGAININ PHARMACEUT INC,MAGAININ RES INST,PLYMOUTH MEETING,PA 19462	The Wistar Institute; University of Pennsylvania; The Wistar Institute; University of Pennsylvania	Goldman, MJ (corresponding author), UNIV PENN,MED CTR,WISTAR INST,DEPT MED,PHILADELPHIA,PA 19104, USA.		Wilson, James M/F-9220-2011	Wilson, James M/0000-0002-9630-3131				ARMSTRONG DS, 1995, BRIT MED J, V310, P1571, DOI 10.1136/bmj.310.6994.1571; Armstrong DS, 1996, PEDIATR PULM, V21, P267, DOI 10.1002/(SICI)1099-0496(199605)21:5<267::AID-PPUL1>3.0.CO;2-K; BENSCH KW, 1995, FEBS LETT, V368, P331, DOI 10.1016/0014-5793(95)00687-5; BOUCHER RC, 1994, AM J RESP CRIT CARE, V150, P271, DOI 10.1164/ajrccm.150.1.8025763; CHENG PW, 1989, J CLIN INVEST, V84, P68, DOI 10.1172/JCI114171; Diamond G, 1996, P NATL ACAD SCI USA, V93, P5156, DOI 10.1073/pnas.93.10.5156; DIAMOND G, 1991, P NATL ACAD SCI USA, V88, P3952, DOI 10.1073/pnas.88.9.3952; EISENHAUER PB, 1992, INFECT IMMUN, V60, P3446, DOI 10.1128/IAI.60.8.3446-3447.1992; ENGELHARDT JF, 1995, DEVELOPMENT, V121, P2031; ENGELHARDT JF, 1992, J CLIN INVEST, V90, P2598, DOI 10.1172/JCI116155; ENGELHARDT JF, 1992, NAT GENET, V2, P240, DOI 10.1038/ng1192-240; ENGELHARDT JF, 1993, HUM GENE THER, V4, P759, DOI 10.1089/hum.1993.4.6-759; ENGELHARDT JF, 1993, NAT GENET, V4, P27, DOI 10.1038/ng0593-27; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8995; FUCHS HJ, 1994, NEW ENGL J MED, V331, P637, DOI 10.1056/NEJM199409083311003; GANZ T, 1995, PHARMACOL THERAPEUT, V66, P191, DOI 10.1016/0163-7258(94)00076-F; GANZ T, 1994, CURR OPIN IMMUNOL, V6, P584, DOI 10.1016/0952-7915(94)90145-7; GILLJAM H, 1989, SCAND J CLIN LAB INV, V49, P121, DOI 10.3109/00365518909105409; GOLDMAN MJ, 1995, NAT GENET, V9, P126, DOI 10.1038/ng0295-126; HARWIG SSL, 1994, METHOD ENZYMOL, V236, P160; HUTTNER KM, 1994, GENOMICS, V19, P448, DOI 10.1006/geno.1994.1093; JONES DE, 1993, FEBS LETT, V315, P187, DOI 10.1016/0014-5793(93)81160-2; JONES DE, 1992, J BIOL CHEM, V267, P23216; JORIS L, 1993, AM REV RESPIR DIS, V148, P1633, DOI 10.1164/ajrccm/148.6_Pt_1.1633; Kellenberger C, 1995, PEPTIDE RES, V8, P321; Mallow EB, 1996, J BIOL CHEM, V271, P4038; OUELLETTE AJ, 1989, J CELL BIOL, V108, P1687, DOI 10.1083/jcb.108.5.1687; Pier GB, 1996, SCIENCE, V271, P64, DOI 10.1126/science.271.5245.64; QUINTON PM, 1983, NATURE, V301, P421, DOI 10.1038/301421a0; Russell JP, 1996, INFECT IMMUN, V64, P1565, DOI 10.1128/IAI.64.5.1565-1568.1996; SCHONWETTER BS, 1995, SCIENCE, V267, P1645, DOI 10.1126/science.7886453; Smith JJ, 1996, CELL, V85, P229, DOI 10.1016/S0092-8674(00)81099-5; TANG H, 1995, INFECT IMMUN, V63, P1278, DOI 10.1128/IAI.63.4.1278-1285.1995; VASCONCELLOS CA, 1994, SCIENCE, V263, P969, DOI 10.1126/science.8310295; Welsh MJ, 1995, METABOLIC MOL BASES, V3, P3799; WILLUMSEN NJ, 1991, AM J PHYSIOL, V261, pC332, DOI 10.1152/ajpcell.1991.261.2.C332; Zhang YL, 1996, AM J PHYSIOL-CELL PH, V270, pC1326, DOI 10.1152/ajpcell.1996.270.5.C1326	37	863	899	0	45	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 21	1997	88	4					553	560		10.1016/S0092-8674(00)81895-4	http://dx.doi.org/10.1016/S0092-8674(00)81895-4			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WJ691	9038346	hybrid			2022-12-01	WOS:A1997WJ69100015
J	Yang, J; Liu, XS; Bhalla, K; Kim, CN; Ibrado, AM; Cai, JY; Peng, TI; Jones, DP; Wang, XD				Yang, J; Liu, XS; Bhalla, K; Kim, CN; Ibrado, AM; Cai, JY; Peng, TI; Jones, DP; Wang, XD			Prevention of apoptosis by Bcl-2: Release of cytochrome c from mitochondria blocked	SCIENCE			English	Article							PROGRAMMED CELL-DEATH; PROTEIN; CED-3; INHIBITION; SURVIVAL; ENCODES; HOMOLOG	Bcl-2 is an integral membrane protein located mainly on the outer membrane of mitochondria. Overexpression of Bcl-2 prevents cells from undergoing apoptosis in response to a variety of stimuli. Cytosolic cytochrome c is necessary for the initiation of the apoptotic program, suggesting a possible connection between Bcl-2 and cytochrome c, which is normally located in the mitochondrial intermembrane space. Cells undergoing apoptosis were found to have an elevation of cytochrome c in the cytosol and a corresponding decrease in the mitochondria. Overexpression of Bcl-2 prevented the efflux of cytochrome c from the mitochondria and the initiation of apoptosis. Thus, one possible role of Bcl-2 in prevention of apoptosis is to block cytochrome c release from mitochondria.	UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA; EMORY UNIV, SCH MED, DEPT BIOCHEM, ATLANTA, GA 30322 USA; EMORY UNIV, SCH MED,WINSHIP CANC CTR,DEPT MED, DIV HEMATOL ONCOL, ATLANTA, GA 30322 USA; EMORY UNIV, SCH MED, DEPT NEUROL, ATLANTA, GA 30322 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Emory University; Emory University; Emory University				Bhalla, Kapil/0000-0001-5209-5126; Wang, Xiaodong/0000-0001-9885-356X				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; Bullock G, 1996, LEUKEMIA, V10, P1731; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Erhardt P, 1996, J BIOL CHEM, V271, P17601, DOI 10.1074/jbc.271.30.17601; FISHER WR, 1973, J BIOL CHEM, V248, P3188; GONZALES DH, 1990, J BIOENERG BIOMEMBR, V22, P753; HANDE KR, 1984, CANCER RES, V44, P379; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1994, PHILOS T R SOC B, V345, P243, DOI 10.1098/rstb.1994.0100; KAMESAKI S, 1993, CANCER RES, V53, P4251; KAUFMANN SH, 1989, CANCER RES, V53, P4251; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; LEMASTERS JJ, 1993, METHODS TOXICOL, V2, P404; Liu X.-W., UNPUB; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Marchetti P, 1996, CANCER RES, V56, P2033; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; ODWYER PJ, 1985, NEW ENGL J MED, V312, P692, DOI 10.1056/NEJM198503143121106; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SENIOR AE, 1970, ARCH BIOCHEM BIOPHYS, V140, P257, DOI 10.1016/0003-9861(70)90030-5; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073; Yang J., UNPUB; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	37	4161	4430	13	284	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 21	1997	275	5303					1129	1132		10.1126/science.275.5303.1129	http://dx.doi.org/10.1126/science.275.5303.1129			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WJ503	9027314				2022-12-01	WOS:A1997WJ50300045
J	Bolton, PF; Griffiths, PD				Bolton, PF; Griffiths, PD			Association of tuberous sclerosis of temporal lobes with autism and atypical autism	LANCET			English	Article							EPIDEMIOLOGY	Background Tuberous sclerosis (TS) is a multisystem genetic disorder that is associated with mental retardation, autism, and atypical autism. We investigated the basis for these associations by examining whether the liability to mental retardation and autism or atypical autism is related to the number and distribution of hamartomatous brain growths (cortical tubers) that characterise TS. Methods 18 patients consecutively referred to our clinic were assessed for the presence of autism or atypical autism, and their IQs were estimated (without awareness of brain-scan results). Brain scans were reviewed by a neuroradiologist (unaware of clinical diagnoses), and the number and location of cortical tubers was examined in relation to the liability to psychopathology. Findings Nine of the 18 patients had autism or atypical autism (two with IQ greater than or equal to 70; four with IQ 51-69, three with IQ less than or equal to 50; eight with a history of epilepsy). The remaining patients had various other psychiatric disorders (five with IQ greater than or equal to 70; four with IQ 51-69; seven had a history of epilepsy). In the group as a whole, the number of tubers was significantly greater (p=0.005) in patients with mental retardation (median 6 [IQR 4-9]) than in those of normal intelligence (1 [0-3]), and the degree of mental retardation was significantly correlated with the number of brain tubers (r(s)0.64; p=0.008). Similarly, the number of tubers was significantly greater (p=0.02) in individuals with a diagnosis of autism or atypical autism (6 [4-8]) than in those without this diagnosis (2 [1-4]). Eight of the nine patients with autism or atypical autism, but none of the non-autistic individuals, had tubers located in the temporal robes (p=0.0004). Otherwise, no particular distribution of cortical tubers was associated with a diagnosis of autism or atypical autism. Interpretation Our investigation provides evidence of an association between a gross, focal brain abnormality. detectable on neuroimaging and autism or atypical autism. The results show the importance of scan findings in the prognosis of TS, and also suggest that temporal lobe neurodevelopmental abnormalities may create a risk for autism or atypical autism.	ADDENBROOKES NHS TRUST, DEPT RADIOL, CAMBRIDGE, ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital	Bolton, PF (corresponding author), UNIV CAMBRIDGE, DEPT PSYCHIAT, SECT DEV PSYCHIAT, CAMBRIDGE CB2 2AH, ENGLAND.							Baron-Cohen S., 1995, MINDBLINDNESS ESSAY; Bauman M.L, 1994, NEUROBIOLOGY AUTISM, P119; Chugani HT, 1996, ANN NEUROL, V39, P643, DOI 10.1002/ana.410390514; Clarke A, 1996, DEV MED CHILD NEUROL, V38, P139; COURCHESNE E, 1988, NEW ENGL J MED, V318, P1349, DOI 10.1056/NEJM198805263182102; CURATOLO P, 1991, ANN NY ACAD SCI, V615, P8; DELONG GR, 1992, NEUROSCI BIOBEHAV R, V16, P63, DOI 10.1016/S0149-7634(05)80052-1; FLETCHER PC, 1995, COGNITION, V57, P109, DOI 10.1016/0010-0277(95)00692-R; GILLBERG IC, 1994, DEV MED CHILD NEUROL, V36, P50; Gomez MR, 1988, TUBEROUS SCLEROSIS; GONZALEZ RC, 1994, GAC MED MEX, V130, P374; HOON AH, 1992, DEV MED CHILD NEUROL, V34, P252; HUNT A, 1993, J AUTISM DEV DISORD, V23, P323, DOI 10.1007/BF01046223; JAMBAQUE I, 1991, DEV MED CHILD NEUROL, V33, P698; MENOR F, 1992, PEDIATR RADIOL, V22, P485, DOI 10.1007/BF02012989; Minshew N.J., 1994, NEUROBIOLOGY AUTISM, P66; OSBORNE JP, 1991, ANN NY ACAD SCI, V615, P125; PERRETT DI, 1992, PHILOS T ROY SOC B, V335, P23, DOI 10.1098/rstb.1992.0003; Piven J, 1996, J AM ACAD CHILD PSY, V35, P530, DOI 10.1097/00004583-199604000-00020; ROACH ES, 1987, ARCH NEUROL-CHICAGO, V44, P301, DOI 10.1001/archneur.1987.00520150047020; SHEPHERD CW, 1995, AM J NEURORADIOL, V16, P149; SMALLEY S, 1995, PSYCHIAT GENET, V5, pS88; Webb DW, 1996, DEV MED CHILD NEUROL, V38, P146; WILLIAMSON DA, 1995, J AUTISM DEV DISORD, V25, P435, DOI 10.1007/BF02179377; WING L, 1979, J AUTISM DEV DISORD, V9, P11, DOI 10.1007/BF01531288; Young AW, 1996, NEUROPSYCHOLOGIA, V34, P31, DOI 10.1016/0028-3932(95)00062-3; [No title captured]; [No title captured]	28	195	198	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 8	1997	349	9049					392	395		10.1016/S0140-6736(97)80012-8	http://dx.doi.org/10.1016/S0140-6736(97)80012-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH296	9033466				2022-12-01	WOS:A1997WH29600012
J	Shoham, D; Hubener, M; Schulze, S; Grinvald, A; Bonhoeffer, T				Shoham, D; Hubener, M; Schulze, S; Grinvald, A; Bonhoeffer, T			Spatio-temporal frequency domains and their relation to cytochrome oxidase staining in cat visual cortex	NATURE			English	Article							ISO-ORIENTATION DOMAINS; STRIATE CORTEX; FUNCTIONAL ARCHITECTURE; CONTRAST SENSITIVITY; INTRINSIC SIGNALS; NEURONS; ORGANIZATION; AREA-17; BLOBS	Spatial and temporal frequencies are important attributes of the visual scene. It is a long-standing question whether these attributes are represented in a spatially organized way in cat primary visual cortex(1-4). Using optical imaging of intrinsic signals(5-10), we show here that grating stimuli of different spatial frequencies drifting at various speeds produce distinct activity patterns. Rather than observing a map of continuously changing spatial frequency preference across the cortical surface, we found only two distinct sets of domains, one preferring low spatial frequency and high speed, and the other high spatial frequency and low speed. We compared the arrangement of these spatio-temporal frequency domains with the cytochrome oxidase staining pattern, which, based on work in primate striate cortex, is thought to reflect the partition of the visual cortex into different processing streams. We found that the cytochrome oxidase blobs in cat striate cortex coincide with domains engaged in the processing of low spatial and high temporal frequency contents of the visual scene. Together with other recent results(11), our data suggest that spatiotemporal frequency domains are a manifestation of parallel streams in cat visual cortex, with distinct patterns of thalamic inputs and extrastriate projections.	MAX PLANCK INST PSYCHIAT,D-82152 MUNICH,GERMANY; WEIZMANN INST SCI,IL-76100 REHOVOT,ISRAEL	Max Planck Society; Weizmann Institute of Science			Bonhoeffer, Tobias/B-9481-2009	Bonhoeffer, Tobias/0000-0001-7897-6634				BERARDI N, 1982, J PHYSIOL-LONDON, V323, P603, DOI 10.1113/jphysiol.1982.sp014094; BONHOEFFER T, 1993, J NEUROSCI, V13, P4157; BONHOEFFER T, 1991, NATURE, V353, P429, DOI 10.1038/353429a0; Bonhoeffer Tobias, 1996, P55; BORN RT, 1991, P NATL ACAD SCI USA, V88, P7066, DOI 10.1073/pnas.88.16.7066; Boyd J. D., 1992, Society for Neuroscience Abstracts, V18, P298; Boyd JD, 1996, J COMP NEUROL, V365, P659; CAMPBELL FW, 1969, J PHYSIOL-LONDON, V203, P223, DOI 10.1113/jphysiol.1969.sp008861; DeValois RL, 1988, SPATIAL VISION; DYCK RH, 1993, P NATL ACAD SCI USA, V90, P9066, DOI 10.1073/pnas.90.19.9066; EDWARDS DP, 1995, VISION RES, V35, P1501, DOI 10.1016/0042-6989(94)00253-I; FROSTIG RD, 1990, P NATL ACAD SCI USA, V87, P6082, DOI 10.1073/pnas.87.16.6082; GLEZER VD, 1973, VISION RES, V13, P1875, DOI 10.1016/0042-6989(73)90061-8; GRINVALD A, 1986, NATURE, V324, P361, DOI 10.1038/324361a0; HUBENER M, 1992, J COMP NEUROL, V324, P67, DOI 10.1002/cne.903240106; HUBENER M, 1996, SOC NEUR ABSTR, V22, P951; MAFFEI L, 1977, VISION RES, V17, P257, DOI 10.1016/0042-6989(77)90089-X; MAFFEI L, 1973, VISION RES, V13, P1255, DOI 10.1016/0042-6989(73)90201-0; Malonek D, 1996, SCIENCE, V272, P551, DOI 10.1126/science.272.5261.551; Matsubara Joanne, 1994, Society for Neuroscience Abstracts, V20, P1742; MOVSHON JA, 1978, J PHYSIOL-LONDON, V283, P101, DOI 10.1113/jphysiol.1978.sp012490; MURPHY K M, 1990, Society for Neuroscience Abstracts, V16, P292; MURPHY KM, 1995, J NEUROSCI, V15, P4196; POLLEN DA, 1971, SCIENCE, V173, P74, DOI 10.1126/science.173.3991.74; ROBSON JG, 1975, HDB PERCEPTION, V5, P81; SHOHAM D, 1996, ISRAEL J MED SCI, V32, pS7; SILVERMAN MS, 1989, P NATL ACAD SCI USA, V86, P711, DOI 10.1073/pnas.86.2.711; TOLHURST DJ, 1982, EXP BRAIN RES, V48, P217; TOLHURST DJ, 1981, PROC R SOC SER B-BIO, V213, P183, DOI 10.1098/rspb.1981.0061; TOOTELL RB, 1981, SCIENCE, V214, P813, DOI 10.1126/science.7292014; TOOTELL RBH, 1988, J NEUROSCI, V8, P1610; TSO DY, 1990, SCIENCE, V249, P417, DOI 10.1126/science.2165630; WONGRILEY M, 1979, BRAIN RES, V171, P11, DOI 10.1016/0006-8993(79)90728-5	33	117	118	1	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 6	1997	385	6616					529	533		10.1038/385529a0	http://dx.doi.org/10.1038/385529a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG235	9020358				2022-12-01	WOS:A1997WG23500046
J	McShane, R; Keene, J; Gedling, K; Fairburn, C; Jacoby, R; Hope, T				McShane, R; Keene, J; Gedling, K; Fairburn, C; Jacoby, R; Hope, T			Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow up	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ALZHEIMERS-DISEASE; PSYCHOGERIATRIC PATIENTS; BEHAVIORAL DISTURBANCE; EXTRAPYRAMIDAL SIGNS; GERIATRIC-PATIENTS; SENILE DEMENTIA; PSYCHOSIS; HALOPERIDOL; SYMPTOMS; THIORIDAZINE	Objective: To investigate the contribution of neuroleptic drugs to cognitive decline in dementia. Design: Two year prospective, longitudinal study consisting of interviews every four months, with necropsy follow up. Setting: Community settings in Oxfordshire. Subjects: 71 subjects with dementia, initially living at home with informant. Main outcome measures: Cognitive function (score from expanded minimental state examination); behavioural problems (physical aggression, hallucinations, persecutory ideas, and disturbance of diurnal rhythm); and postmortem neuropathological assessment (cortical Lewy body pathology). Results: The mean (SE) decline in cognitive score in the 16 patients who took neuroleptics was twice that in the patients who did not (20.7 (2.9) v 9.3 (1.3), P=0.002). An increased rate of decline was also associated with aggression, disturbed diurnal rhythm, and persecutory ideas, However, only use of neuroleptics and severity of persecutory ideas were independently associated with more rapid cognitive decline when all other variables were adjusted for, The start of neuroleptic treatment coincided with more rapid cognitive decline: median rate of decline was 5 (interquartile range 8.5) points per year before treatment and 11 (12) points per year after treatment (P=0.02), Cortical Lewy body pathology did not account for association between neuroleptic use and more rapid decline. Conclusions: Neuroleptic drugs that are sometimes used to treat behavioural complications of dementia may worsen already poor cognitive function, Randomised controlled trials are needed to confirm a causal relation.			McShane, R (corresponding author), UNIV OXFORD, WARNEFORD HOSP, DEPT PSYCHIAT, OLD AGE PSYCHIAT SECT, OXFORD OX3 7JX, ENGLAND.		Fairburn, Christopher/AAM-9792-2020; Fairburn, Christopher/AAG-6234-2019	Fairburn, Christopher/0000-0002-9673-9795; 				BARNES R, 1982, AM J PSYCHIAT, V139, P1170; BARTON R, 1966, BRIT J PSYCHIAT, V112, P989, DOI 10.1192/bjp.112.491.989; BROWN JW, 1993, J NERV MENT DIS, V181, P695, DOI 10.1097/00005053-199311000-00008; BURNS A, 1990, BRIT J PSYCHIAT, V157, P76, DOI 10.1192/bjp.157.1.76; CHAKOS MH, 1994, AM J PSYCHIAT, V151, P1430; Chen CPLH, 1996, J NEUROCHEM, V66, P1592, DOI 10.1046/j.1471-4159.1996.66041592.x; CHUI HC, 1994, ARCH NEUROL-CHICAGO, V51, P676, DOI 10.1001/archneur.1994.00540190056015; COWLEY LM, 1979, J CLIN PSYCHIAT, V40, P411; DAVIE JW, 1981, ARCH GEN PSYCHIAT, V38, P463; DEVANAND DP, 1989, ARCH NEUROL-CHICAGO, V46, P854, DOI 10.1001/archneur.1989.00520440036018; DEVANAND DP, 1988, COMPR PSYCHIAT, V29, P387, DOI 10.1016/0010-440X(88)90020-X; DRACHMAN DA, 1974, ARCH NEUROL-CHICAGO, V30, P113, DOI 10.1001/archneur.1974.00490320001001; DREVETS WC, 1989, BIOL PSYCHIAT, V25, P39, DOI 10.1016/0006-3223(89)90145-5; ELON R, 1992, J AM GERIATR SOC, V40, P958, DOI 10.1111/j.1532-5415.1992.tb01996.x; Esiri MM, 1996, J NEUROL NEUROSUR PS, V61, P127, DOI 10.1136/jnnp.61.2.127; Figiel G S, 1991, J Geriatr Psychiatry Neurol, V4, P86, DOI 10.1177/089198879100400206; FORSTL H, 1993, ACTA PSYCHIAT SCAND, V87, P395, DOI 10.1111/j.1600-0447.1993.tb03394.x; Foster P, 1989, PHARM J, V243, P431; GALASKO D, 1994, ARCH NEUROL-CHICAGO, V51, P888, DOI 10.1001/archneur.1994.00540210060013; GILLEARD CJ, 1983, ACTA PSYCHIAT SCAND, V68, P419, DOI 10.1111/j.1600-0447.1983.tb00950.x; GOTESTAM KG, 1981, ACTA PSYCHIAT SCAND, P46; HAMILTON LD, 1962, J AM GERIATR SOC, V10, P140, DOI 10.1111/j.1532-5415.1962.tb00266.x; HOPE T, 1992, PSYCHOL MED, V22, P223, DOI 10.1017/S0033291700032888; Jellinger K., 1977, NEUROTOXICOLOGY, P25; Lehmann H E, 1967, Laval Med, V38, P588; MANN AH, 1984, PSYCHOL MED, V14, P891, DOI 10.1017/S0033291700019851; MAYEUX R, 1985, NEUROLOGY, V35, P453, DOI 10.1212/WNL.35.4.453; McGrath AM, 1996, BRIT MED J, V312, P611; MCKEITH I, 1992, BRIT MED J, V305, P673, DOI 10.1136/bmj.305.6855.673; MORTIMER JA, 1992, NEUROLOGY, V42, P1689, DOI 10.1212/WNL.42.9.1689; NYTH AL, 1992, ACTA PSYCHIAT SCAND, V86, P138, DOI 10.1111/j.1600-0447.1992.tb03242.x; RAY WA, 1987, NEW ENGL J MED, V316, P363, DOI 10.1056/NEJM198702123160702; ROSEN HJ, 1979, J CLIN PSYCHIAT, V40, P17; ROSEN J, 1991, BIOL PSYCHIAT, V29, P224, DOI 10.1016/0006-3223(91)91284-X; SCHNEIDER LS, 1990, J AM GERIATR SOC, V38, P553, DOI 10.1111/j.1532-5415.1990.tb02407.x; SCHNEIDER LS, 1992, PSYCHOPHARMACOL BULL, V28, P71; SMITH DA, 1992, ANN PHARMACOTHER, V26, P1400, DOI 10.1177/106002809202601114; SMITH GR, 1974, PSYCHOSOMATICS, V15, P134; STERN Y, 1994, NEUROLOGY, V44, P2300, DOI 10.1212/WNL.44.12.2300; SUGERMAN AA, 1964, AM J PSYCHIAT, V120, P1190, DOI 10.1176/ajp.120.12.1190; TOBIN JM, 1970, GERIATRICS, V25, P119; WILCOCK GK, 1989, J NEUROL NEUROSUR PS, V52, P693, DOI 10.1136/jnnp.52.6.693; WISNIEWSKI HM, 1994, ALZ DIS ASSOC DIS, V8, P211, DOI 10.1097/00002093-199408040-00001	43	186	189	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 25	1997	314	7076					266	270		10.1136/bmj.314.7076.266	http://dx.doi.org/10.1136/bmj.314.7076.266			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WE633	9022490	Green Published			2022-12-01	WOS:A1997WE63300025
J	Stradling, J				Stradling, J			Sleep apnoea and the misuse of evidence-based medicine	LANCET			English	Editorial Material							AIRWAY PRESSURE TREATMENT; APNEA; PERFORMANCE				Stradling, J (corresponding author), CHURCHILL HOSP,OSLER CHEST UNIT,OXFORD RADCLIFFE TRUST,OXFORD OX3 7LJ,ENGLAND.							CHESHIRE K, 1992, ARCH INTERN MED, V152, P538, DOI 10.1001/archinte.152.3.538; ENGLEMAN HM, 1994, LANCET, V343, P572, DOI 10.1016/S0140-6736(94)91522-9; FERGUSON KA, 1995, THORAX, V50, P998, DOI 10.1136/thx.50.9.998; FINDLEY LJ, 1989, AM REV RESPIR DIS, V140, P529, DOI 10.1164/ajrccm/140.2.529; FINDLEY LJ, 1988, AM REV RESPIR DIS, V138, P337, DOI 10.1164/ajrccm/138.2.337; GRUNSTEIN RR, 1995, THORAX, V50, P1106, DOI 10.1136/thx.50.10.1106; GUILLEMINAULT C, 1976, ANNU REV MED, V27, P465, DOI 10.1146/annurev.me.27.020176.002341; HARDINGE FM, 1995, RESP MED, V89, P617, DOI 10.1016/0954-6111(95)90230-9; ISSA FG, 1986, ELECTROEN CLIN NEURO, V63, P10, DOI 10.1016/0013-4694(86)90056-8; KRIBBS NB, 1993, AM REV RESPIR DIS, V147, P1162, DOI 10.1164/ajrccm/147.5.1162; Sackett DL, 1996, BRIT MED J, V312, P71, DOI 10.1136/bmj.312.7023.71; SMITH IE, 1995, J SLEEP RES, V4, P183, DOI 10.1111/j.1365-2869.1995.tb00167.x; SULLIVAN CE, 1981, LANCET, V1, P862; WRIGHT J, 1996, SYSTEMATIC REV OBSTR	14	28	28	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 18	1997	349	9046					201	202		10.1016/S0140-6736(96)08166-4	http://dx.doi.org/10.1016/S0140-6736(96)08166-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC861	9111558				2022-12-01	WOS:A1997WC86100047
J	Ota, Y; Samelson, LE				Ota, Y; Samelson, LE			The product of the proto-oncogene c-cbl: A negative regulator of the Syk tyrosine kinase	SCIENCE			English	Article							FC-EPSILON-RI; SH3 DOMAIN; T-CELL; PROTOONCOGENE PRODUCT; EGF STIMULATION; JURKAT CELLS; V-CBL; RECEPTOR; PHOSPHORYLATION; ACTIVATION	Engagement of antigen and immunoglobulin receptors on hematopoietic cells is directly coupled to activation of nonreceptor protein tyrosine kinases (PTKs) that then phosphorylate critical intracellular substrates. In mast cells stimulated through the Fc epsilon RI receptor, activation of several PTKs including Syk leads to degranulation and release of such mediators of the allergic response as histamine and serotonin. Regulation of Syk function occurred through interaction with the Cbl protein, itself a PTK substrate in this system. Overexpression of Cbl led to inhibition of Syk and suppression of serotonin release from mast cells, demonstrating its ability to inhibit a nonreceptor tyrosine kinase. Complex adaptor proteins such as Cbl can directly regulate the functions of the proteins they bind.	NICHHD,CELL BIOL & METAB BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; BOWTELL DDL, 1995, ONCOGENE, V11, P1561; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; Donovan JA, 1996, J BIOL CHEM, V271, P26369, DOI 10.1074/jbc.271.42.26369; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; HARRISON ML, 1994, J BIOL CHEM, V269, P955; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; Ota Y, 1996, J EXP MED, V184, P1713, DOI 10.1084/jem.184.5.1713; Ota Y., UNPUB; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; ROWLEY RB, 1995, J BIOL CHEM, V270, P11590, DOI 10.1074/jbc.270.19.11590; SCHARENBERG AM, 1995, CHEM IMMUNOL, V61, P72; SCHARENBERG AM, 1995, EMBO J, V14, P3385, DOI 10.1002/j.1460-2075.1995.tb07344.x; TAYLOR JA, 1995, MOL CELL BIOL, V15, P4149; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; Zhang J, 1996, J EXP MED, V184, P71, DOI 10.1084/jem.184.1.71	24	226	228	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 18	1997	276	5311					418	420		10.1126/science.276.5311.418	http://dx.doi.org/10.1126/science.276.5311.418			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WU477	9103201				2022-12-01	WOS:A1997WU47700041
J	Becerra, JX				Becerra, JX			Insects on plants: Macroevolutionary chemical trends in host use	SCIENCE			English	Article							CHRYSOMELIDAE; COLEOPTERA; BEETLES	Determining the macroevolutionary importance of plant chemistry on herbivore host shifts is critical to understanding the evolution of insect-plant interactions. Molecular phylogenies of the ancient and speciose Blepharida (Coleoptera)-Bursera (Burseraceae) system were reconstructed and terpenoid chemical profiles for the plant species obtained. Statistical analyses show that the historical patterns of host shifts strongly correspond to the patterns of host chemical similarity, indicating that plant chemistry has played a significant role in the evolution of host shifts by phytophagous insects.	UNIV NACL AUTONOMA MEXICO,INST ECOL,MEXICO CITY 04510,DF,MEXICO	Universidad Nacional Autonoma de Mexico	Becerra, JX (corresponding author), UNIV ARIZONA,DEPT ECOL & EVOLUT BIOL,TUCSON,AZ 85721, USA.			Becerra, Judith/0000-0002-3749-9058				Baldwin BG, 1992, MOL PHYLOGENET EVOL, V1, P3, DOI 10.1016/1055-7903(92)90030-K; BECERRA JX, 1990, BIOTROPICA, V22, P320, DOI 10.2307/2388545; BECERRA JX, 1994, NOVEL ASPECTS BIOL C, P327; BECERRA JX, 1994, ECOLOGY, V7, P1991; BERENBAUM M, 1983, EVOLUTION, V37, P163, DOI [10.2307/2408184, 10.1111/j.1558-5646.1983.tb05524.x]; EHRLICH PR, 1964, EVOLUTION, V18, P586, DOI 10.1111/j.1558-5646.1964.tb01674.x; FARRELL B, 1990, EVOLUTION, V44, P1389, DOI 10.1111/j.1558-5646.1990.tb03834.x; FARRIS JS, 1973, SYST ZOOL, V22, P50, DOI 10.2307/2412378; FURTH DG, 1988, OECOLOGIA, V74, P496, DOI 10.1007/BF00380045; FURTH DG, 1992, J NEW YORK ENTOMOL S, V100, P399; FURTH DG, 1982, SPIXIANA, V7, P43; FUTUYMA DG, 1991, HERBIVORES THEIR INT, V2, P439; FUTUYMA DJ, 1990, EVOLUTION, V44, P1885, DOI 10.1111/j.1558-5646.1990.tb04298.x; *GEN COD CORP INC, 1995, SEQ 3 0 US MAN; LANGENHEIM JH, 1994, J CHEM ECOL, V20, P1223, DOI 10.1007/BF02059809; MADDISON D, 1992, MACCLADE VERSION 3, P237; McVaugh R., 1965, Kew Bulletin, V18, P317, DOI 10.2307/4109252; MITTER C, 1991, TRENDS ECOL EVOL, V6, P290, DOI 10.1016/0169-5347(91)90007-K; MOONEY HA, 1968, BRITTONIA, V20, P44, DOI 10.2307/2805460; PAGE R, 1992, COMPONENT USERS MANU; RZEDOWSKI J, 1979, TAXON, V28, P103, DOI 10.2307/1219565; *SAS INST INC, 1989, SAS STAT US GUID VER, V4; Sneath Peter HA., 1973, NUMERICAL TAXONOMY P, DOI 10.2307/2412767; Swofford D, 1993, PHYLOGENETIC ANAL US	24	350	364	1	102	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 11	1997	276	5310					253	256		10.1126/science.276.5310.253	http://dx.doi.org/10.1126/science.276.5310.253			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WT925	9092474				2022-12-01	WOS:A1997WT92500045
J	Banerjee, AK				Banerjee, AK			DCC expression and prognosis in colorectal cancer	LANCET			English	Editorial Material							GENE; IDENTIFICATION				Banerjee, AK (corresponding author), ROYAL HALIFAX INFIRM,COLORECTAL UNIT,HALIFAX,NS HX1 2YP,CANADA.		Banerjee, Anjan Kumar/AAL-6375-2020	Banerjee, Anjan Kumar/0000-0002-5935-3404				BANERJEE AK, 1995, BRIT J SURG, V82, P1096; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; JEN J, 1994, NEW ENGL J MED, V331, P213, DOI 10.1056/NEJM199407283310401; JONES DJ, 1988, BRIT J SURG, V75, P28, DOI 10.1002/bjs.1800750111; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KLINGELHUTZ AJ, 1995, ONCOGENE, V10, P1581; KOKAL WA, 1989, ANN SURG, V209, P188, DOI 10.1097/00000658-198902000-00009; MOERTEL CG, 1994, NEW ENGL J MED, V330, P1136; NARAYANAN R, 1992, ONCOGENE, V7, P553; Shibata D, 1996, NEW ENGL J MED, V335, P1727, DOI 10.1056/NEJM199612053352303; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047	12	5	5	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 5	1997	349	9057					968	968		10.1016/S0140-6736(05)62888-7	http://dx.doi.org/10.1016/S0140-6736(05)62888-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR621	9100619				2022-12-01	WOS:A1997WR62100004
J	Wyncoll, DLA; Roberts, PC; Beale, RJ; McLuckie, A				Wyncoll, DLA; Roberts, PC; Beale, RJ; McLuckie, A			H-2 blockers in the intensive care unit: Ignoring the evidence? Telephone survey	BRITISH MEDICAL JOURNAL			English	Article							STRESS-ULCER; PROPHYLAXIS; PNEUMONIA				Wyncoll, DLA (corresponding author), GUYS HOSP,DEPT INTENS CARE,LONDON SE1 9RT,ENGLAND.							COOK DJ, 1994, NEW ENGL J MED, V330, P377, DOI 10.1056/NEJM199402103300601; Cook DJ, 1996, JAMA-J AM MED ASSOC, V275, P308, DOI 10.1001/jama.275.4.308; FAGON JY, 1993, AM J MED, V94, P281, DOI 10.1016/0002-9343(93)90060-3; NAVAB F, 1995, AM J GASTROENTEROL, V90, P708; TRYBA M, 1991, CRIT CARE MED, V19, P942, DOI 10.1097/00003246-199107000-00020	5	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 5	1997	314	7086					1013	1013		10.1136/bmj.314.7086.1013	http://dx.doi.org/10.1136/bmj.314.7086.1013			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WT152	9112846	Green Published			2022-12-01	WOS:A1997WT15200025
J	Farrell, HE; Vally, H; Lynch, DM; Fleming, P; Shellam, GR; Scalzo, AA; DavisPoynter, NJ				Farrell, HE; Vally, H; Lynch, DM; Fleming, P; Shellam, GR; Scalzo, AA; DavisPoynter, NJ			Inhibition of natural killer cells by a cytomegalovirus MHC class I homologue in vivo	NATURE			English	Article							NK CELLS; GENE-COMPLEX; ANTIGEN; INFECTION; VIRUS; RESISTANCE; RECEPTORS; MOLECULES; TRANSPORT; MOUSE	Herpesviruses, such as murine and human cytomegalovirus (MCMV and HCMV), can establish a persistent infection within the host and have diverse mechanisms as protection from host immune defences'. Several herpesvirus genes that are homologous to host immune modulators have been identified, and are implicated in viral evasion of the host immune response(2,3). The discovery of a viral major histocompatibility complex (MHC) class I homologue, encoded by HCMV(4), led to speculation that it might function as an immune modulator and disrupt presentation of peptides by MHC class I to cytotoxic T cells(5). However, there is no evidence concerning the biological significance of this gene during viral infection. Recent analysis of the MCMV genome has also demonstrated the presence of a MHC class I homologue(6). Here we show that a recombinant MCMV,in which. the gene encoding the class I homologue has been disrupted, has severely restricted replication during the acute stage of infection compared with wild-type MCMV, We demonstrate by in vivo depletion studies that natural killer (NK) cells are responsible for the attenuated phenotype of the mutant. Thus the viral MHC dass I homologue contributes to immune evasion through interference with NK cell-mediated clearance.			Farrell, HE (corresponding author), UNIV WESTERN AUSTRALIA,QUEEN ELIZABETH II MED CTR,DEPT MICROBIOL,NEDLANDS,WA 6907,AUSTRALIA.		Davis-Poynter, Nicholas/B-3811-2010; Vally, Hassan/AFK-2936-2022; Vally, Hassan/AAG-1307-2022; Farrell, Helen/F-8583-2011	Davis-Poynter, Nicholas/0000-0001-7368-1925; Vally, Hassan/0000-0001-5281-7459; Vally, Hassan/0000-0001-5281-7459; Farrell, Helen/0000-0002-7214-2767				BANCROFT GJ, 1981, J IMMUNOL, V126, P988; BANKS TA, 1992, CLIN INFECT DIS, V14, P933, DOI 10.1093/clinids/14.4.933; BECK S, 1988, NATURE, V331, P269, DOI 10.1038/331269a0; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BROWNE H, 1992, J VIROL, V66, P6784, DOI 10.1128/JVI.66.11.6784-6787.1992; BROWNE H, 1990, NATURE, V347, P770, DOI 10.1038/347770a0; BUKOWSKI JF, 1984, J VIROL, V52, P119, DOI 10.1128/JVI.52.1.119-128.1984; CEREDIG R, 1985, NATURE, V314, P98, DOI 10.1038/314098a0; COBBOLD SP, 1984, NATURE, V312, P548, DOI 10.1038/312548a0; DAVISPOYNTER NJ, 1996, IMMUNOL CELL BIOL, V74, P512; DELVAL M, 1992, J EXP MED, V176, P729, DOI 10.1084/jem.176.3.729; FAHNESTOCK ML, 1995, IMMUNITY, V3, P538; GUMPERZ JE, 1995, NATURE, V378, P245, DOI 10.1038/378245a0; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; KARLHOFER FM, 1991, J IMMUNOL, V146, P3662; KARRE K, 1995, SCIENCE, V267, P978, DOI 10.1126/science.7863341; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Raulet DH, 1996, CURR OPIN IMMUNOL, V8, P372, DOI 10.1016/S0952-7915(96)80127-0; Rawlinson WD, 1996, J VIROL, V70, P8833, DOI 10.1128/JVI.70.12.8833-8849.1996; SARMIENTO M, 1980, J IMMUNOL, V125, P2665; SCALZO AA, 1992, J IMMUNOL, V149, P581; SCALZO AA, 1995, IMMUNOGENETICS, V41, P148, DOI 10.1007/BF00182328; SHELLAM GR, 1985, SCAND J IMMUNOL, V22, P147, DOI 10.1111/j.1365-3083.1985.tb01867.x; Spriggs MK, 1996, ANNU REV IMMUNOL, V14, P101, DOI 10.1146/annurev.immunol.14.1.101; THALE R, 1995, J VIROL, V69, P6098; VIEIRA J, 1994, J VIROL, V68, P4837, DOI 10.1128/JVI.68.8.4837-4846.1994; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; WILEY D, 1988, NATURE, V331, P209, DOI 10.1038/331209a0; YOKOYAMA WM, 1995, CURR OPIN IMMUNOL, V7, P110, DOI 10.1016/0952-7915(95)80036-0	30	239	244	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 3	1997	386	6624					510	514		10.1038/386510a0	http://dx.doi.org/10.1038/386510a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WR256	9087412				2022-12-01	WOS:A1997WR25600056
J	GonzalezGaitan, M; Jackle, H				GonzalezGaitan, M; Jackle, H			Role of Drosophila alpha-adaptin in presynaptic vesicle recycling	CELL			English	Article							TEMPERATURE-SENSITIVE MUTATIONS; FROG NEUROMUSCULAR JUNCTION; CLATHRIN-COATED PITS; SYNAPTIC VESICLES; MEMBRANE RETRIEVAL; PLASMA-MEMBRANE; HIGH-AFFINITY; TRANSMITTER RELEASE; REVERSIBLE BLOCKAGE; NERVE-TERMINALS	Rapid flow of information in the nervous system involves presynaptic vesicle recycling by clathrin-mediated endocytosis, an event triggered by the alpha-adaptin-containing AP2 complex. We identified a Drosophila alpha-adaptin expressed in the garland cells, imaginal discs, and the CNS. Here we show its role in presynaptic vesicle recycling. In presynaptic terminals, alpha-adaptin defines a network-like membrane structure to which the GTPase dynamin is recruited. alpha-adaptin is necessary for the formation of clathrin-coated pits and participates in the dynamin-dependent release of coated vesicles from the membrane surface. Our results suggest an alpha-adaptin-dependent control of the vesicle cycle that maintains the balance between the amount of vesicle- and surface-associated membranes.			GonzalezGaitan, M (corresponding author), MAX PLANCK INST BIOPHYS CHEM,ABT MOL ENTWICKLUNGSBIOL,FASSBERG,D-37077 GOTTINGEN,GERMANY.			Gonzalez-Gaitan, Marcos/0000-0002-6295-7321				ALMERS W, 1994, NATURE, V367, P682; ATWOOD HL, 1993, J NEUROBIOL, V24, P1008, DOI 10.1002/neu.480240803; BALL CL, 1995, J CELL SCI, V108, P2865; BELTZER JP, 1991, EMBO J, V10, P3735, DOI 10.1002/j.1460-2075.1991.tb04942.x; BETZ WJ, 1995, CURR BIOL, V5, P1098, DOI 10.1016/S0960-9822(95)00220-X; BETZ WJ, 1992, J NEUROSCI, V12, P363, DOI 10.1523/jneurosci.12-02-00363.1992; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; CAMPOSORTEGA JA, 1985, EMBRYONIC DEV DROSOP, P986; CECCARELLI B, 1979, J CELL BIOL, V81, P163, DOI 10.1083/jcb.81.1.163; CECCARELLI B, 1973, J CELL BIOL, V57, P499, DOI 10.1083/jcb.57.2.499; CHANG MP, 1993, EMBO J, V12, P2169, DOI 10.1002/j.1460-2075.1993.tb05865.x; CHEN MS, 1992, J CELL SCI, V103, P619; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; DeCamilli P, 1996, NEURON, V16, P481, DOI 10.1016/S0896-6273(00)80068-9; Estes PS, 1996, J NEUROSCI, V16, P5443; Frommer G, 1996, EMBO J, V15, P1642, DOI 10.1002/j.1460-2075.1996.tb00509.x; FUKUDA M, 1995, P NATL ACAD SCI USA, V92, P10708, DOI 10.1073/pnas.92.23.10708; GONZALEZGAITAN MA, 1996, MOL BIOL INSECT DIS, P283; Goodman Corey S., 1993, P1131; GRENNINGLOH G, 1991, CELL, V67, P45, DOI 10.1016/0092-8674(91)90571-F; GRIGLIATTI TA, 1973, MOL GEN GENET, V120, P107, DOI 10.1007/BF00267238; HALTER DA, 1995, DEVELOPMENT, V121, P317; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; HEUSER JE, 1988, J CELL BIOL, V107, P877, DOI 10.1083/jcb.107.3.877; HEUSER JE, 1973, J CELL BIOL, V57, P315, DOI 10.1083/jcb.57.2.315; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; JOHANSEN J, 1989, J NEUROSCI, V9, P4318; JORGENSEN EM, 1995, NATURE, V378, P196, DOI 10.1038/378196a0; KARPEN GH, 1992, GENETICS, V132, P737; KOENIG JH, 1983, J CELL BIOL, V96, P1517, DOI 10.1083/jcb.96.6.1517; Koenig JH, 1996, J CELL BIOL, V135, P797, DOI 10.1083/jcb.135.3.797; KOENIG JH, 1989, J NEUROSCI, V9, P3844; KOSAKA T, 1983, J NEUROBIOL, V14, P207, DOI 10.1002/neu.480140305; KOSAKA T, 1983, J CELL BIOL, V97, P499, DOI 10.1083/jcb.97.2.499; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; Lindsley D.L., 1992, GENOME DROSOPHILA ME; LITTLETON JT, 1993, DEVELOPMENT, V118, P1077; MAHAFFEY DT, 1990, J BIOL CHEM, V265, P16514; MAYCOX PR, 1992, J CELL BIOL, V118, P1379, DOI 10.1083/jcb.118.6.1379; NESTEROV A, 1995, J BIOL CHEM, V270, P8320; PEARSE BMF, 1987, ANNU REV BIOPHYS BIO, V16, P49, DOI 10.1146/annurev.bb.16.060187.000405; POODRY CA, 1973, DEV BIOL, V32, P373, DOI 10.1016/0012-1606(73)90248-0; RAMASWAMI M, 1993, J NEUROGENET, V9, P73, DOI 10.3109/01677069309083451; RAMASWAMI M, 1994, NEURON, V13, P363, DOI 10.1016/0896-6273(94)90353-0; ROBINSON MS, 1989, J CELL BIOL, V108, P833, DOI 10.1083/jcb.108.3.833; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; Schmid Sandra L., 1993, Trends in Cell Biology, V3, P145, DOI 10.1016/0962-8924(93)90129-O; SHPETNER HS, 1989, CELL, V59, P421, DOI 10.1016/0092-8674(89)90027-5; Smith CB, 1996, NATURE, V380, P531, DOI 10.1038/380531a0; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; SPRADLING AC, 1995, P NATL ACAD SCI USA, V92, P10824, DOI 10.1073/pnas.92.24.10824; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; SUN BH, 1995, P NATL ACAD SCI USA, V92, P5396, DOI 10.1073/pnas.92.12.5396; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; TARELLI FT, 1990, J CELL BIOL, V110, P449; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; VALTORTA F, 1990, NEUROSCIENCE, V35, P477, DOI 10.1016/0306-4522(90)90323-V; VANDEGOOR J, 1995, P NATL ACAD SCI USA, V92, P5739, DOI 10.1073/pnas.92.12.5739; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; VONGERSDORFF H, 1994, NATURE, V367, P735, DOI 10.1038/367735a0; VONWEDEL RJ, 1981, P NATL ACAD SCI-BIOL, V78, P1014; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; ZAREMBA S, 1983, J CELL BIOL, V97, P1339, DOI 10.1083/jcb.97.5.1339; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1; ZINSMAIER KE, 1994, SCIENCE, V263, P977, DOI 10.1126/science.8310297	66	211	216	1	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 21	1997	88	6					767	776		10.1016/S0092-8674(00)81923-6	http://dx.doi.org/10.1016/S0092-8674(00)81923-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WQ100	9118220	Bronze			2022-12-01	WOS:A1997WQ10000009
J	Rambukkana, A; Salzer, JL; Yurchenco, PD; Tuomanen, EI				Rambukkana, A; Salzer, JL; Yurchenco, PD; Tuomanen, EI			Neural targeting of Mycobacterium leprae mediated by the G domain of the laminin-alpha 2 chain	CELL			English	Article							SCHWANN-CELLS; BASEMENT-MEMBRANES; HEPARIN-BINDING; PERINEURIAL CELLS; LAMININ VARIANTS; GLOBULAR DOMAIN; A-CHAIN; EXPRESSION; MEROSIN; PROTEIN	We report that the molecular basis of the neural tropism of Mycobacterium leprae is attributable to the specific binding of M. leprae to the laminin-alpha 2 (LN-alpha 2) chain on Schwann cell-axon units. Using recombinant fragments of LN-alpha 2 (rLN-alpha 2), the M. leprae-binding site was localized to the G domain. rLN-alpha PG mediated M. leprae binding to cell lines and to sciatic nerves of dystrophic dy/dy mice lacking LN-alpha 2, but expressing laminin receptors. Anti-beta(4) integrin antibody attenuated rLN-alpha 2G-mediated M. leprae adherence, suggesting that M. leprae interacts with cells by binding to beta(4) integrin via an LN-alpha 2G bridge. Our results indicate a novel role for the G domain of LN-2 in infection and reveal a model in which a host-derived bridging molecule determines nerve tropism of a pathogen.	NYU,MED CTR,DEPT CELL BIOL,NEW YORK,NY 10016; NYU,MED CTR,DEPT NEUROL,NEW YORK,NY 10016; NYU,MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT PATHOL,PISCATAWAY,NJ 08854	New York University; New York University; New York University; Rutgers State University New Brunswick; Rutgers State University Medical Center	Rambukkana, A (corresponding author), ROCKEFELLER UNIV,LAB MOL INFECT DIS,1230 YORK AVE,NEW YORK,NY 10021, USA.		Tuomanen, Elaine I/N-3081-2018	Tuomanen, Elaine I/0000-0003-0349-8716; Salzer, James/0000-0001-9126-7197; rambukkana, anura/0000-0002-6286-9145; Yurchenco, Peter/0000-0003-0387-2317	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027913] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048045, R01DK036425, R37DK036425] Funding Source: NIH RePORTER; NIAID NIH HHS [AI27913] Funding Source: Medline; NIDDK NIH HHS [DK36425, DK48045] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANTON ES, 1994, DEV BIOL, V164, P133, DOI 10.1006/dbio.1994.1186; BRADLEY WG, 1975, J NEUROL SCI, V25, P249, DOI 10.1016/0022-510X(75)90144-6; BUNGE MB, 1990, ANN NY ACAD SCI, V580, P281, DOI 10.1111/j.1749-6632.1990.tb17937.x; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; COLOGNATOPYKE H, 1995, J BIOL CHEM, V270, P9398, DOI 10.1074/jbc.270.16.9398; CORNBROOKS CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3850, DOI 10.1073/pnas.80.12.3850; Danielssen D.C., 1848, TRAITE SPEDALSKHED E; DELWEL GO, 1993, J BIOL CHEM, V268, P25865; DEUTZMANN R, 1990, EUR J BIOCHEM, V191, P513, DOI 10.1111/j.1432-1033.1990.tb19151.x; DUNCAN ME, 1984, PLACENTA, V5, P189, DOI 10.1016/S0143-4004(84)80028-4; DUNCAN ME, 1983, INT J LEPROSY, V51, P7; EINHEBER S, 1995, J CELL BIOL, V129, P443, DOI 10.1083/jcb.129.2.443; EINHEBER S, 1993, J CELL BIOL, V123, P1223, DOI 10.1083/jcb.123.5.1223; ENGVALL E, 1992, EXP CELL RES, V198, P115, DOI 10.1016/0014-4827(92)90156-3; ENGVALL E, 1993, KIDNEY INT, V43, P2, DOI 10.1038/ki.1993.2; ENGVALL E, 1990, CELL REGUL, V1, P731, DOI 10.1091/mbc.1.10.731; Engvall E, 1996, J CELL BIOCHEM, V61, P493; ESIRI MM, 1972, J PATHOL, V106, P73, DOI 10.1002/path.1711060203; FALK P, 1993, P NATL ACAD SCI USA, V90, P2035, DOI 10.1073/pnas.90.5.2035; FALKOW S, 1991, CELL, V65, P1099, DOI 10.1016/0092-8674(91)90003-H; FELTRI ML, 1994, DEVELOPMENT, V120, P1287; GAMBLE HJ, 1964, J ANAT, V98, P655; HOEPELMAN AIM, 1992, INFECT IMMUN, V60, P1729, DOI 10.1128/IAI.60.5.1729-1733.1992; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; JAAKKOLA S, 1989, J CLIN INVEST, V84, P253, DOI 10.1172/JCI114148; JAAKKOLA S, 1993, J NEUROCYTOL, V22, P215, DOI 10.1007/BF01246360; JESSEN KR, 1991, GLIA, V4, P185, DOI 10.1002/glia.440040210; JOB CK, 1989, INT J LEPROSY, V57, P532; LEIVO I, 1988, P NATL ACAD SCI USA, V85, P1544, DOI 10.1073/pnas.85.5.1544; LUMSDEN CE, 1959, LEPROSY THEORY PRACT, P221; MAEDA M, 1987, LEPROSY REV, V58, P39; MERCURIO AM, 1995, TRENDS CELL BIOL, V5, P419, DOI 10.1016/S0962-8924(00)89100-X; MOYA F, 1980, P NATL ACAD SCI-BIOL, V77, P6902, DOI 10.1073/pnas.77.11.6902; MUKHERJEE R, 1986, INT J LEPROSY, V54, P632; NIESSEN CM, 1994, J CELL SCI, V107, P543; NOORDEEN SK, 1992, B WORLD HEALTH ORGAN, V70, P7; Pearson J M, 1970, Lepr Rev, V41, P155; RAMBUKKANA A, 1993, INFECT IMMUN, V61, P1835, DOI 10.1128/IAI.61.5.1835-1845.1993; RELMAN D, 1990, CELL, V61, P1375, DOI 10.1016/0092-8674(90)90701-F; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SCHLESINGER LS, 1991, J IMMUNOL, V147, P1983; SCHOREY JS, 1995, INFECT IMMUN, V63, P2652, DOI 10.1128/IAI.63.7.2652-2657.1995; SONNENBERG A, 1990, J CELL SCI, V96, P207; SUNADA Y, 1994, J BIOL CHEM, V269, P13729; SUNG U, 1993, J CELL BIOL, V123, P1255, DOI 10.1083/jcb.123.5.1255; TIMPL R, 1994, MATRIX BIOL, V14, P275, DOI 10.1016/0945-053X(94)90192-9; TUOMANEN EI, 1995, NEW ENGL J MED, V332, P1280, DOI 10.1056/NEJM199505113321907; VANDERFLIER M, 1995, INFECT IMMUN, V63, P4317, DOI 10.1128/IAI.63.11.4317-4322.1995; VUOLTEENAHO R, 1994, J CELL BIOL, V124, P381, DOI 10.1083/jcb.124.3.381; XU H, 1994, P NATL ACAD SCI USA, V91, P5572, DOI 10.1073/pnas.91.12.5572; Yamada H, 1996, J BIOL CHEM, V271, P23418, DOI 10.1074/jbc.271.38.23418; YURCHENCO PD, 1993, J BIOL CHEM, V268, P8356; YURCHENCO PD, 1992, J CELL BIOL, V117, P1119, DOI 10.1083/jcb.117.5.1119; YURCHENCO PD, 1992, J CELL BIOL, V118, P493	57	134	138	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 21	1997	88	6					811	821		10.1016/S0092-8674(00)81927-3	http://dx.doi.org/10.1016/S0092-8674(00)81927-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WQ100	9118224	hybrid			2022-12-01	WOS:A1997WQ10000013
J	Su, WCS; Kitagawa, M; Xue, NR; Xie, B; Garofalo, S; Cho, J; Deng, CX; Horton, WA; Fu, XY				Su, WCS; Kitagawa, M; Xue, NR; Xie, B; Garofalo, S; Cho, J; Deng, CX; Horton, WA; Fu, XY			Activation of Stat1 by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism	NATURE			English	Article							TYROSINE PHOSPHORYLATION; TRANSCRIPTION FACTOR; PROTEIN; SPECIFICITY; MUTATIONS; KINASE; GENE	The achondroplasia class of chondrodysplasias comprises the most common genetic forms of dwarfism in humans and includes achondroplasia, hypochondroplasia and thanatophoric dysplasia types I and II (TDI and TDII), which are caused by different mutations in a fibroblast growth-factor receptor FGFR3 (ref, 1), The molecular mechanism and the mediators of these FGFR3-related growth abnormalities are not known, Here we show that mutant TDII FGFR3 has a constitutive tyrosine kinase activity which can specifically activate the transcription factor Stat1 (for signal transducer and activator of transcription)(2,3). Furthermore, expression of TDII FGFR3 induced nuclear translocation of Stat1, expression of the cell-cycle inhibitor p21(WAF1/CIP1), and growth arrest of the cell. Thus, TDII FGFR3 may use Stat1 as a mediator of growth retardation in bone development, Consistent with this, Stat1 activation and increased p21(WAF1/CIP1) expression was found in the cartilage cells from the TDII fetus, but not in those from the normal fetus, Thus, abnormal STAT activation and p21(WAF1/CIP1) expression by the TDII mutant receptor may be responsible for this FGFR3-related bone disease.	YALE UNIV, SCH MED, DEPT PATHOL, NEW HAVEN, CT 06520 USA; SHRINERS HOSP CRIPPLED CHILDRENS, RES DEPT, PORTLAND, OR 97201 USA; NIDDKD, BIOCHEM & METAB LAB, NIH, BETHESDA, MD 20892 USA	Yale University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			deng, chuxia/N-6713-2016; Kitagawa, Motoo/W-8468-2019	Kitagawa, Motoo/0000-0003-1036-840X; GAROFALO, SILVIO/0000-0001-7460-3179; Su, Wu-Chou/0000-0003-2953-4105				Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Colvin JS, 1996, NAT GENET, V12, P390, DOI 10.1038/ng0496-390; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MUENKE M, 1995, TRENDS GENET, V11, P308, DOI 10.1016/S0168-9525(00)89088-5; Naski MC, 1996, NAT GENET, V13, P233, DOI 10.1038/ng0696-233; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; PETERS K, 1993, DEV BIOL, V155, P423, DOI 10.1006/dbio.1993.1040; RUFFJAMISON S, 1995, P NATL ACAD SCI USA, V92, P4215, DOI 10.1073/pnas.92.10.4215; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SILLENCE DO, 1979, AM J PATHOL, V96, P813; TAVORMINA PL, 1995, NAT GENET, V9, P321, DOI 10.1038/ng0395-321; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; Webster MK, 1996, EMBO J, V15, P520, DOI 10.1002/j.1460-2075.1996.tb00384.x; Webster MK, 1996, MOL CELL BIOL, V16, P4081; Yamamoto H, 1996, EXP CELL RES, V222, P125, DOI 10.1006/excr.1996.0016	30	262	272	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 20	1997	386	6622					288	292		10.1038/386288a0	http://dx.doi.org/10.1038/386288a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WP003	9069288				2022-12-01	WOS:A1997WP00300053
J	Suzuki, H; Kurihara, Y; Takeya, M; Kamada, N; Kataoka, M; Jishage, K; Ueda, O; Sakaguchi, H; Higashi, T; Suzuki, T; Takashima, Y; Kawabe, Y; Cynshi, O; Wada, Y; Honda, M; Kurihara, H; Aburatani, H; Doi, T; Matsumoto, A; Azuma, S; Noda, T; Toyoda, Y; Itakura, H; Yazaki, Y; Horiuchi, S; Takahashi, K; Kruijt, JK; vanBerkel, TJC; Steinbrecher, UP; Ishibashi, S; Maeda, N; Gordon, S; Kodama, T				Suzuki, H; Kurihara, Y; Takeya, M; Kamada, N; Kataoka, M; Jishage, K; Ueda, O; Sakaguchi, H; Higashi, T; Suzuki, T; Takashima, Y; Kawabe, Y; Cynshi, O; Wada, Y; Honda, M; Kurihara, H; Aburatani, H; Doi, T; Matsumoto, A; Azuma, S; Noda, T; Toyoda, Y; Itakura, H; Yazaki, Y; Horiuchi, S; Takahashi, K; Kruijt, JK; vanBerkel, TJC; Steinbrecher, UP; Ishibashi, S; Maeda, N; Gordon, S; Kodama, T			A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection	NATURE			English	Article							LOW-DENSITY-LIPOPROTEIN; E-DEFICIENT MICE; APOLIPOPROTEIN-E; CHOLESTEROL; BINDING; HYPERCHOLESTEROLEMIA; MACROSIALIN; BACTERIA; ADHESION; PROTEINS	Macrophage type-I and type-II class-A scavenger receptors (MSR-A) are implicated in the pathological deposition of cholesterol during atherogenesis as a result of receptor-mediated uptake of modified low-density Lipoproteins (mLDL)(1-6). MSR-A can bind an extraordinarily wide range of ligands, including bacterial pathogens(7), and also mediates cation-independent macrophage adhesion in vitro(8). Here we show that targeted disruption of the MSR-A gene in mice results in a reduction in the size of atherosclerotic lesions in an animal deficient in apolipoprotein E. Macrophages from MSR-A-deficient mice show a marked decrease in mLDL uptake in vitro, whereas mLDL clearance from plasma occurs at a normal rate, indicating that there may be alternative mechanisms for removing mLDL from the circulation. In addition, MSR-A-knockout mice show an increased susceptibility to infection with Listeria monocytogenes or herpes simplex virus type-1, indicating that MSR-A may play a part in host defence against pathogens.	UNIV TOKYO,DEPT MOL BIOL & MED,ADV SCI & TECHNOL RES CTR,MEGURO KU,TOKYO 153,JAPAN; CHUGAI PHARMACEUT CO LTD,SHIZUOKA 412,JAPAN; CSK RES PK INC,SHIZUOKA 412,JAPAN; UNIV TOKYO,DEPT INTERNAL MED 3,TOKYO 113,JAPAN; KUMAMOTO UNIV,SCH MED,DEPT BIOCHEM,KUMAMOTO 860,JAPAN; KUMAMOTO UNIV,SCH MED,DEPT PATHOL,KUMAMOTO 860,JAPAN; OSAKA UNIV,FAC PHARMACEUT SCI,OSAKA 565,JAPAN; NATL INST HLTH & NUTR,TOKYO 162,JAPAN; UNIV TOKYO,INST MED SCI,TOKYO 108,JAPAN; JAPANESE FDN CANC RES,INST CANC,TOKYO 170,JAPAN; OBIHIRO UNIV AGR & VET MED,RES CTR PROTOZOAN MOL IMMUNOL,OBIHIRO,HOKKAIDO 080,JAPAN; LEIDEN UNIV,DIV BIOPHARMACEUT,NL-2300 RA LEIDEN,NETHERLANDS; UNIV BRITISH COLUMBIA,DEPT MED,VANCOUVER,BC V5Z 4E3,CANADA; UNIV N CAROLINA,SCH MED,DEPT PATHOL,CHAPEL HILL,NC 27599; UNIV OXFORD,SIR WILLIAM DUNN SCH PATHOL,OXFORD OX1 3RE,ENGLAND	University of Tokyo; Chugai Pharmaceutical Co., Ltd.; Roche Holding; University of Tokyo; Kumamoto University; Kumamoto University; Osaka University; National Institute of Health & Nutrition - Japan; University of Tokyo; Japanese Foundation for Cancer Research; Obihiro University of Agriculture & Veterinary Medicine; Leiden University; Leiden University - Excl LUMC; University of British Columbia; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of Oxford			Noda, Tetsuo/B-1667-2016; Van Berkel, Theo/ABD-7677-2021	Kurihara, Hiroki/0000-0002-6476-5593; Kawabe, Yoshiki/0000-0002-6465-7146				Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; AZUMA S, 1991, Japanese Journal of Animal Reproduction, V37, P37; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; Cynshi O, 1994, J Atheroscler Thromb, V1, P87; DUNNE DW, 1994, P NATL ACAD SCI USA, V91, P1863, DOI 10.1073/pnas.91.5.1863; ELOMAA O, 1995, CELL, V80, P603, DOI 10.1016/0092-8674(95)90514-6; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; FRASER I, 1993, NATURE, V364, P343, DOI 10.1038/364343a0; HOLNESS CL, 1993, J BIOL CHEM, V268, P9661; HUGHES DA, 1995, EUR J IMMUNOL, V25, P466, DOI 10.1002/eji.1830250224; IRIE H, 1989, ARCH VIROL, V105, P247, DOI 10.1007/BF01311361; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KODAMA T, 1988, P NATL ACAD SCI USA, V85, P9238, DOI 10.1073/pnas.85.23.9238; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; KURIHARA Y, 1994, NATURE, V368, P703, DOI 10.1038/368703a0; NAITO M, 1992, AM J PATHOL, V141, P591; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; RAMPRASAD MP, 1995, P NATL ACAD SCI USA, V92, P9580, DOI 10.1073/pnas.92.21.9580; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; SCHMIDT AM, 1992, J BIOL CHEM, V267, P14987; SMITH JD, 1995, P NATL ACAD SCI USA, V92, P8264, DOI 10.1073/pnas.92.18.8264; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Suzuki Hiroshi, 1994, Journal of Reproduction and Development, V40, P107, DOI 10.1262/jrd.40.107; TAKATA K, 1988, J BIOL CHEM, V263, P14819; VANBERKEL TJC, 1985, J BIOL CHEM, V260, P2203; VANREE JH, 1995, ATHEROSCLEROSIS, V118, P165, DOI 10.1016/0021-9150(95)05602-S; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543; ZHANG SH, 1994, J CLIN INVEST, V94, P937, DOI 10.1172/JCI117460	28	953	1013	3	56	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 20	1997	386	6622					292	296		10.1038/386292a0	http://dx.doi.org/10.1038/386292a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WP003	9069289				2022-12-01	WOS:A1997WP00300054
J	Tumiati, B; Casoli, P; Parmeggiani, A				Tumiati, B; Casoli, P; Parmeggiani, A			Hearing loss in the Sjogren syndrome	ANNALS OF INTERNAL MEDICINE			English	Article							ANTIPHOSPHOLIPID ANTIBODIES; ANTICARDIOLIPIN ANTIBODY; RHEUMATOID-ARTHRITIS; DISEASE; EAR	Background: Ear involvement is not unusual in autoimmune diseases, but few data on this problem in the Sjogren syndrome are available. Objectives: To determine whether the incidence of hearing loss is increased in patients with the Sjogren syndrome and to determine what factors might be involved in the pathogenesis of Sjogren syndrome-related hearing loss. Design: Cross-sectional study. Setting: Secondary referral center in Italy. Patients: 30 women with the Sjogren syndrome were evaluated for evidence of audiovestibular disorder. Their results were compared with those of 40 age-matched healthy women. Measurements: Evaluation techniques included pure tone audiometry thresholds at octave frequencies of 125 Hz to 8000 Hz, tympanometry, and the stapedial reflex test in both ears. The presence of vasculitis, the Raynaud phenomenon, nervous system involvement, and serum anticardiolipin antibodies was recorded. Results: 14 patients with the Sjogren syndrome (46% [95% CI, 28% to 66%]) had sensorineural hearing loss. Only one control (2.5% [CI, 0.06% to 13%]) had a similar hearing impairment (P < 0.001). Nine of the 14 patients who had the Sjogren syndrome and sensorineural hearing loss (64% [CI, 36% to 87%]) had anticardiolipin antibodies compared with only 3 controls (18% [CI, 4% to 45%]) (P = 0.02). Conclusion: The high prevalence of hearing loss in the Sjogren syndrome supports the value of doing audiometric studies before excluding cranial nerve involvement in this disease. The correlation of sensorineural hearing loss with anticardiolipin antibodies must be investigated further.			Tumiati, B (corresponding author), OSPED S MARIA NUOVA, DEPT INTERNAL MED 2, VIALE RISORGIMENTO, I-42100 REGGIO EMILIA, ITALY.							ALEXANDER EL, 1993, RHEUM DIS CLIN N AM, V19, P869; ANDONOPOULOS AP, 1995, CLIN EXP RHEUMATOL, V13, P137; ARROYO R A, 1989, Arthritis and Rheumatism, V32, pS73; ASHERSON RA, 1992, ANN RHEUM DIS, V51, P495, DOI 10.1136/ard.51.4.495; BUCHANAN RRC, 1989, J RHEUMATOL, V16, P757; CHISHOLM DM, 1968, J CLIN PATHOL, V21, P656, DOI 10.1136/jcp.21.5.656; DOIG JA, 1971, BMJ-BRIT MED J, V4, P460, DOI 10.1136/bmj.4.5785.460; ELWANY S, 1986, J RHEUMATOL, V13, P878; GHARAVI AE, 1987, ANN RHEUM DIS, V46, P1, DOI 10.1136/ard.46.1.1; GUSSEN R, 1977, ARCH OTO-RHINO-LARYN, V217, P263, DOI 10.1007/BF00465544; HARRIS JP, 1989, AM J OTOL, V10, P193; HISASHI K, 1993, AM J OTOLARYNG, V14, P275, DOI 10.1016/0196-0709(93)90075-I; Jerger J, 1980, OTOLARYNG HEAD NECK, V2nd, P1225; KORNBLUT AD, 1982, LARYNGOSCOPE, V92, P713, DOI 10.1288/00005537-198207000-00001; MAGARO M, 1990, CLIN EXP RHEUMATOL, V8, P487; MANOUSSAKIS MN, 1987, CLIN IMMUNOL IMMUNOP, V44, P297, DOI 10.1016/0090-1229(87)90073-0; TUMIATI B, 1995, AM J OTOLARYNG, V16, P220, DOI 10.1016/0196-0709(95)90109-4; VITALI C, 1993, ARTHRITIS RHEUM, V36, P340, DOI 10.1002/art.1780360309; VOLLERTSEN RS, 1990, RHEUM DIS CLIN N AM, V16, P433; YOON TH, 1990, LARYNGOSCOPE, V100, P707	20	88	90	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1997	126	6					450	453		10.7326/0003-4819-126-6-199703150-00005	http://dx.doi.org/10.7326/0003-4819-126-6-199703150-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM530	9072930				2022-12-01	WOS:A1997WM53000005
J	Pulliam, L; Gascon, R; Stubblebine, M; McGuire, D; McGrath, MS				Pulliam, L; Gascon, R; Stubblebine, M; McGuire, D; McGrath, MS			Unique monocyte subset in patients with AIDS dementia	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NECROSIS-FACTOR-ALPHA; CEREBROSPINAL-FLUID; MONONUCLEAR PHAGOCYTES; HIV ENCEPHALITIS; NEOPTERIN; TYPE-1; BRAIN; BLOOD; BETA-2-MICROGLOBULIN	Background 15-30% of patients infected with HIV will develop a debilitating dementia. Whilst HIV enters the brain soon after infection, presumably within monocyte-derived macrophages, not all patients with HIV become demented. Blood monocytes probably cross the blood-brain barrier and give rise ultimately to parenchyma macrophages. We looked for a specific monocyte subset in AIDS patients with dementia. Methods Peripheral blood monocytes from three groups were compared: AIDS patients with (n=12) and without (n=11) dementia, and ten HIV seronegative healthy controls. We used flow cytometry to analyse monocytes, and cell lysis and apoptosis assays to examine monocyte effects on human brain cells in vitro. Findings We found a unique subset of monocytes in patients with AIDS dementia. These monocytes were more dense and granular and expressed CD14/CD16 and CD14/CD69. Means (SD) for CD14/CD16 in HIV-negative controls and in AIDS non-dementia and AIDS dementia patients were 6.5% (4), 16% (13), and 37% (21), respectively (p=0.008 between the two groups of patients). The corresponding means for CD14/CD69 were 7% (6), 8% (10), and 69% (18) (p<0.0001). Interpretation CD69 is a member of the natural-killer-cell gene complex that is expressed after activation. Supernatants from cultures containing these dense cells can trigger apoptosis of human brain cells in vitro. The monocyte subset we found in patients with AIDS dementia might enter the brain and expose neural cells to toxic factors.	UNIV CALIF SAN FRANCISCO,DEPT LAB MED,SAN FRANCISCO,CA 94143; SAN FRANCISCO GEN HOSP,AIDS PROGRAM,SAN FRANCISCO,CA 94110; UNIV CALIF SAN FRANCISCO,DEPT NEUROL,SAN FRANCISCO,CA 94143; NEUREX CORP,MENLO PK,CA	University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco	Pulliam, L (corresponding author), VET AFFAIRS MED CTR 113A,4150 CLEMENT ST,SAN FRANCISCO,CA 94121, USA.				NCI NIH HHS [R01CA6738] Funding Source: Medline; NINDS NIH HHS [R01 NS30311S] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030311] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ACHIM CL, 1993, J CLIN INVEST, V91, P2769, DOI 10.1172/JCI116518; ADLEBIASSETTE H, 1995, NEUROPATH APPL NEURO, V21, P218, DOI 10.1111/j.1365-2990.1995.tb01053.x; BOGNER JR, 1992, CLIN INVESTIGATOR, V70, P665; Brew BJ, 1996, J INFECT DIS, V174, P294, DOI 10.1093/infdis/174.2.294; BUKRINSKY MI, 1995, J EXP MED, V181, P735, DOI 10.1084/jem.181.2.735; DEMARIA R, 1994, J EXP MED, V180, P1999, DOI 10.1084/jem.180.5.1999; Frankenberger M, 1996, BLOOD, V87, P373; GELBARD HA, 1994, J VIROL, V68, P4628, DOI 10.1128/JVI.68.7.4628-4635.1994; GENIS P, 1992, J EXP MED, V176, P1703, DOI 10.1084/jem.176.6.1703; GIULIAN D, 1990, SCIENCE, V250, P1593, DOI 10.1126/science.2148832; GLASS JD, 1995, ANN NEUROL, V38, P755, DOI 10.1002/ana.410380510; GRANT I, 1987, ANN INTERN MED, V107, P828, DOI 10.7326/0003-4819-107-6-828; HAGBERG L, 1993, J INFECT DIS, V168, P1285, DOI 10.1093/infdis/168.5.1285; HEYES MP, 1992, J NEUROIMMUNOL, V40, P71, DOI 10.1016/0165-5728(92)90214-6; HEYES MP, 1992, BIOCHEM J, V283, P633, DOI 10.1042/bj2830633; MERRILL JE, 1992, J VIROL, V66, P2217, DOI 10.1128/JVI.66.4.2217-2225.1992; MERRILL JE, 1989, J VIROL, V63, P4404, DOI 10.1128/JVI.63.10.4404-4408.1989; NOKTA MA, 1995, VIROLOGY, V208, P590, DOI 10.1006/viro.1995.1190; Nottet HSLM, 1996, J NEUROVIROL, V2, P111, DOI 10.3109/13550289609146544; PASSLICK B, 1989, BLOOD, V74, P2527, DOI 10.1182/blood.V74.7.2527.2527; PETITO CK, 1995, AM J PATHOL, V146, P1121; PRICE RW, 1988, J INFECT DIS, V158, P1079, DOI 10.1093/infdis/158.5.1079; PULLIAM L, 1991, J CLIN INVEST, V87, P503, DOI 10.1172/JCI115024; PULLIAM L, 1988, J NEUROSCI RES, V21, P521, DOI 10.1002/jnr.490210243; Pulliam L, 1996, AIDS, V10, P1495, DOI 10.1097/00002030-199611000-00006; Thieblemont N, 1995, EUR J IMMUNOL, V25, P3418, DOI 10.1002/eji.1830251232; WILEY CA, 1992, AIDS, V6, P1299, DOI 10.1097/00002030-199211000-00010; ZIEGLER SF, 1994, STEM CELLS, V2, P456; ZIEGLERHEITBROCK HWL, 1992, BLOOD, V79, P503; ZIEGLERHEITBROCK HWL, 1993, EUR J IMMUNOL, V23, P2053, DOI 10.1002/eji.1830230902	30	299	314	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 8	1997	349	9053					692	695		10.1016/S0140-6736(96)10178-1	http://dx.doi.org/10.1016/S0140-6736(96)10178-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM080	9078201				2022-12-01	WOS:A1997WM08000011
J	Greegor, RB; Pingitore, NE; Lytle, FW				Greegor, RB; Pingitore, NE; Lytle, FW			Strontianite in coral skeletal aragonite	SCIENCE			English	Article							SR/CA; REEF	An x-ray spectroscopic study of scleractinian coral skeletons indicated that, although some strontium substitutes for calcium in the aragonite structure, at concentrations of about 7500 parts per million, as much as 40 percent of the strontium resides in strontianite (SrCO3). A doubler peak in the Fourier transform of the extended x-ray absorption fine structure of the coral corresponded to six metal and 13 oxygen neighbors surrounding strontium at about 4.05 angstroms in strontium-substituted aragonite and at about 4.21 angstroms in strontianite. Thus, the mechanism of the temperature-sensitive partitioning of strontium between seawater and coral skeleton used for paleothermometry is unexpectedly complex.	UNIV TEXAS,DEPT GEOL SCI,EL PASO,TX 79968; BOEING CO,SEATTLE,WA 98124; EXAFS CO,PIOCHE,NV 89043	University of Texas System; University of Texas El Paso; Boeing								AMIEL AJ, 1973, SEDIMENTOLOGY, V20, P47, DOI 10.1111/j.1365-3091.1973.tb01606.x; Barnes DJ, 1995, J EXP MAR BIOL ECOL, V194, P251, DOI 10.1016/0022-0981(95)00091-7; Bathurst R. G. C., 1971, CARBONATE SEDIMENTS; DEVILLIERS JP, 1971, AM MINERAL, V56, P758; DEVILLIERS S, 1994, GEOCHIM COSMOCHIM AC, V58, P197, DOI 10.1016/0016-7037(94)90457-X; GUILDERSON TP, 1994, SCIENCE, V263, P663, DOI 10.1126/science.263.5147.663; Hart SR, 1996, GEOCHIM COSMOCHIM AC, V60, P3075, DOI 10.1016/0016-7037(96)00154-8; HOLLAND HD, 1963, GEOCHIM COSMOCHIM AC, V27, P957, DOI 10.1016/0016-7037(63)90105-4; LEE T, 1995, EOS, V76, P180; LYTLE FW, 1989, APPLICATIONS SYNCHRO, P135; McCulloch M, 1996, EARTH PLANET SC LETT, V138, P169, DOI 10.1016/0012-821X(95)00230-A; MCCULLOCH MT, 1994, GEOCHIM COSMOCHIM AC, V58, P2747, DOI 10.1016/0016-7037(94)90142-2; Morse J.W., 1990, GEOCHEMISTRY SEDIMEN; PLUMMER LN, 1987, GEOCHIM COSMOCHIM AC, V51, P1393, DOI 10.1016/0016-7037(87)90324-3; SHANNON RD, 1976, ACTA CRYSTALLOGR A, V32, P751, DOI 10.1107/S0567739476001551; SMITH SV, 1979, SCIENCE, V204, P404, DOI 10.1126/science.204.4391.404; SPEER JA, 1983, CARBONATES MINERALOG, P145; WEBER JN, 1973, GEOCHIM COSMOCHIM AC, V37, P2173, DOI 10.1016/0016-7037(73)90015-X; Wyckoff, 1963, CRYST STRUCT	19	83	87	1	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 7	1997	275	5305					1452	1454		10.1126/science.275.5305.1452	http://dx.doi.org/10.1126/science.275.5305.1452			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WM081	9072808				2022-12-01	WOS:A1997WM08100037
J	Sawamura, T; Kume, N; Aoyama, T; Moriwaki, H; Hoshikawa, H; Aiba, Y; Tanaka, T; Miwa, S; Katsura, Y; Kita, T; Masaki, T				Sawamura, T; Kume, N; Aoyama, T; Moriwaki, H; Hoshikawa, H; Aiba, Y; Tanaka, T; Miwa, S; Katsura, Y; Kita, T; Masaki, T			An endothelial receptor for oxidized low-density lipoprotein	NATURE			English	Article							SCAVENGER RECEPTOR; MACROPHAGE; CELLS; ATHEROSCLEROSIS; RECOGNITION; EXPRESSION; CHOLESTEROL; BINDING; DOMAINS; CLONING	Endothelial dysfunction or activation elicited by oxidatively modified low-density lipoprotein (Ox-LDL) has been implicated in the pathogenesis of atherosclerosis(1-4), characterized by intimal thickening and lipid deposition in the arteries. Ox-LDL and its lipid constituents impair endothelial production of nitric oxide, and induce the endothelial expression of leukocyte adhesion molecules and smooth-muscle growth factors, which may be involved in atherogenesis(5-7). Vascular endothelial cells in culture(8,9) and in vivo(10,11) internalize and degrade Ox-LDL through a putative receptor-mediated pathway that does not involve macrophage scavenger receptors(12-15). Here we report the molecular cloning, using expression cloning strategy, of an Ox-LDL receptor from vascular endothelial cells. The cloned receptor is a membrane protein that belongs structurally to the C-type lectin family, and is expressed in vivo in vascular endothelium and vascular-rich organs.	KYOTO UNIV,FAC MED,DEPT PHARMACOL,KYOTO 606,JAPAN; KYOTO UNIV,FAC MED,DEPT GERIATR MED,KYOTO 606,JAPAN; KYOTO UNIV,CHEST DIS RES INST,DEPT IMMUNOL,KYOTO 606,JAPAN; JAPANESE RED CROSS SAITAMA BRANCH,YONO,SAITAMA 338,JAPAN	Kyoto University; Kyoto University; Kyoto University			Miwa, Soichi/D-8468-2012; Sawamura, Tatsuya/E-7103-2010	Marchini, Julio/0000-0002-2279-1945				ACTON SL, 1994, J BIOL CHEM, V269, P21003; BICKEL PE, 1992, J CLIN INVEST, V90, P1450, DOI 10.1172/JCI116012; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; FRASER I, 1993, NATURE, V364, P343, DOI 10.1038/364343a0; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GIMBRONE MA, 1995, ANN NY ACAD SCI, V748, P122; GIORDA R, 1990, SCIENCE, V249, P1298, DOI 10.1126/science.2399464; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; IKURA T, 1994, BIOCHEM BIOPH RES CO, V203, P1417, DOI 10.1006/bbrc.1994.2343; KITA T, 1987, P NATL ACAD SCI USA, V84, P5928, DOI 10.1073/pnas.84.16.5928; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KRIEGER M, 1993, J BIOL CHEM, V268, P4569; KUGIYAMA K, 1990, NATURE, V344, P160, DOI 10.1038/344160a0; KUME N, 1991, BIOCHIM BIOPHYS ACTA, V1091, P63, DOI 10.1016/0167-4889(91)90223-K; KUME N, 1994, J CLIN INVEST, V93, P907, DOI 10.1172/JCI117047; PITAS RE, 1985, J CELL BIOL, V100, P103, DOI 10.1083/jcb.100.1.103; RAMPRASAD MP, 1995, P NATL ACAD SCI USA, V92, P9580, DOI 10.1073/pnas.92.21.9580; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SHOW G, 1986, CELL, V46, P659; STANTON LW, 1992, J BIOL CHEM, V267, P22446; STEIN O, 1980, BIOCHIM BIOPHYS ACTA, V620, P631, DOI 10.1016/0005-2760(80)90155-1; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STEPHAN ZF, 1993, J LIPID RES, V34, P325; VANBERKEL TJC, 1991, J BIOL CHEM, V266, P2282	27	1099	1239	2	68	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 6	1997	386	6620					73	77		10.1038/386073a0	http://dx.doi.org/10.1038/386073a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WL746	9052782				2022-12-01	WOS:A1997WL74600053
J	Wilmut, I; Schnieke, AE; McWhir, J; Kind, AJ; Campbell, KHS				Wilmut, I; Schnieke, AE; McWhir, J; Kind, AJ; Campbell, KHS			Viable offspring derived from fetal and adult mammalian cells	NATURE			English	Article							BOVINE EMBRYOS; NUCLEAR TRANSPLANTATION; RECIPIENT OOCYTE; CYCLE-STAGE; SHEEP; INVITRO; ZYGOTES	Fertilization of mammalian eggs is followed by successive cell divisions and progressive differentiation, first into the early embryo and subsequently into all of the cell types that make up the adult animal. Transfer of a single nucleus at a specific stage of development, to an enucleated unfertilized egg, provided an opportunity to investigate whether cellular differentiation to that stage involved irreversible genetic modification. The first offspring to develop from a differentiated cell were born after nuclear transfer from an embryo-derived cell line that had been induced to become quiescent(1). Using the same procedure, we now report the birth of live lambs from three new cell populations established from adult mammary gland, fetus and embryo. The fact that a lamb was derived from an adult cell confirms that differentiation of that cell did not involve the irreversible modification of genetic material required for development to term, The birth of lambs from differentiated fetal and adult cells also reinforces previous speculation(1,2) that by inducing donor cells to become quiescent it will be possible to obtain normal development from a wide variety of differentiated cells.	PPL THERAPEUT,ROSLIN EH25 9PP,MIDLOTHIAN,SCOTLAND		Wilmut, I (corresponding author), ROSLIN INST,ROSLIN EH25 9PS,MIDLOTHIAN,SCOTLAND.		王, 士勇/B-5170-2012	Schnieke, Angelika/0000-0002-5761-9635				BARNES FL, 1993, MOL REPROD DEV, V36, P33, DOI 10.1002/mrd.1080360106; BRADFORD GE, 1972, J REPROD FERTIL, V30, P459, DOI 10.1530/jrf.0.0300459; BRESLOW NE, 1993, J AM STAT ASSOC, V88, P9, DOI 10.1080/01621459.1993.10594284; BUCHANAN FC, 1993, MAMM GENOME, V4, P258, DOI 10.1007/BF00417432; Campbell K H, 1996, Rev Reprod, V1, P40, DOI 10.1530/ror.0.0010040; Campbell KHS, 1996, NATURE, V380, P64, DOI 10.1038/380064a0; CAMPBELL KHS, 1993, BIOL REPROD, V49, P933, DOI 10.1095/biolreprod49.5.933; CHEONG HT, 1993, BIOL REPROD, V48, P958, DOI 10.1095/biolreprod48.5.958; Finch LMB, 1996, BIOCHEM SOC T, V24, pS369, DOI 10.1042/bst024369s; GARDNER DK, 1994, BIOL REPROD, V50, P390, DOI 10.1095/biolreprod50.2.390; GURDON JB, 1975, J EMBRYOL EXP MORPH, V34, P93; GURDON JB, 1974, CONTROL GENE EXPRESS; KWON OY, 1996, J REPROD FERTIL, V17, P30; MCGRATH J, 1984, SCIENCE, V226, P1317, DOI 10.1126/science.6542249; Nash ML, 1996, VET REC, V139, P64, DOI 10.1136/vr.139.3.64; PRATHER RS, 1987, BIOL REPROD, V37, P859, DOI 10.1095/biolreprod37.4.859; QUINLIVAN TD, 1966, J REPROD FERTIL, V11, P379, DOI 10.1530/jrf.0.0110379; ROBL JM, 1987, J ANIM SCI, V64, P642, DOI 10.2527/jas1987.642642x; Solter D, 1996, NATURE, V380, P24, DOI 10.1038/380024a0; WALKER SK, 1992, THERIOGENOLOGY, V37, P111, DOI 10.1016/0093-691X(92)90250-U; Walton A, 1938, PROC R SOC SER B-BIO, V125, P311, DOI 10.1098/rspb.1938.0029; WHITTEN WK, 1968, J REPROD FERTIL, V17, P399, DOI 10.1530/jrf.0.0170399	22	3460	4117	10	477	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 27	1997	385	6619					810	813		10.1038/385810a0	http://dx.doi.org/10.1038/385810a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WK570	9039911				2022-12-01	WOS:A1997WK57000051
J	Katz, J				Katz, J			Prevention of phantom limb pain by regional anaesthesia	LANCET			English	Editorial Material							POSTOPERATIVE PAIN; AMPUTATION; ANALGESIA; NEUROPLASTICITY; SURGERY; BLOCK		TORONTO HOSP,ACUTE PAIN RES UNIT,TORONTO,ON M5T 2S8,CANADA; UNIV TORONTO,DEPT BEHAV SCI,TORONTO,ON,CANADA; UNIV TORONTO,DEPT ANAESTHESIA,TORONTO,ON,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto	Katz, J (corresponding author), TORONTO HOSP,DEPT PSYCHOL,TORONTO,ON M5T 2S8,CANADA.		Katz, Joel/HDO-1635-2022; Katz, Joel/J-7015-2014	Katz, Joel/0000-0002-8686-447X				BACH S, 1988, PAIN, V33, P297, DOI 10.1016/0304-3959(88)90288-6; Bonn D, 1996, LANCET, V347, P530, DOI 10.1016/S0140-6736(96)91154-X; CODERRE TJ, 1993, PAIN, V52, P259, DOI 10.1016/0304-3959(93)90161-H; Devor M, 1994, TXB PAIN, P79; ELIZAGA AM, 1994, J REHABIL RES DEV, V31, P179; FISHER A, 1991, ANESTH ANALG, V72, P300; JAHANGIRI M, 1994, ANN ROY COLL SURG, V76, P324; KATZ J, 1994, PAIN, V59, P395, DOI 10.1016/0304-3959(94)90026-4; KATZ J, 1992, ANESTHESIOLOGY, V77, P439, DOI 10.1097/00000542-199209000-00006; MALAWER MM, 1991, CLIN ORTHOPAEDICS, V266, P227; Pinzur MS, 1996, J BONE JOINT SURG AM, V78A, P1501, DOI 10.2106/00004623-199610000-00007; SCHUG SA, 1995, REGION ANESTH, V20, P256; Sherman RA, 1997, PHANTOM PAIN	13	40	41	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 22	1997	349	9051					519	520		10.1016/S0140-6736(97)80081-5	http://dx.doi.org/10.1016/S0140-6736(97)80081-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WJ512	9048786	Green Submitted			2022-12-01	WOS:A1997WJ51200005
J	Cochran, ST				Cochran, ST			Determination of serum creatinine level prior to administration of radiographic contrast media	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							NEPHROTOXICITY				Cochran, ST (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT RADIOL SCI,LOS ANGELES,CA 90024, USA.							BARRETT BJ, 1993, RADIOLOGY, V188, P171, DOI 10.1148/radiology.188.1.8511292; BYRD L, 1979, MEDICINE, V58, P270, DOI 10.1097/00005792-197905000-00006; CIGARROA RG, 1989, AM J MED, V86, P649, DOI 10.1016/0002-9343(89)90437-3; COCHRAN ST, 1983, AM J ROENTGENOL, V141, P1027, DOI 10.2214/ajr.141.5.1027; LEE JKT, 1995, INVEST RADIOL, V12, P700; MUDGE GH, 1980, KIDNEY INT, V18, P540, DOI 10.1038/ki.1980.172	6	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 19	1997	277	7					517	518		10.1001/jama.1997.03540310015008	http://dx.doi.org/10.1001/jama.1997.03540310015008			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH297	9032143				2022-12-01	WOS:A1997WH29700003
J	Malinin, NL; Boldin, MP; Kovalenko, AV; Wallach, D				Malinin, NL; Boldin, MP; Kovalenko, AV; Wallach, D			MAP3K-related kinase involved in NF-kappa B induction by TNF, CD95 and IL-1	NATURE			English	Article							PUTATIVE PROTEIN-KINASE; TUMOR-NECROSIS-FACTOR; SIGNAL TRANSDUCTION; DOMAIN; YEAST; STE11; GENE; ACTIVATION; ENCODES; FAMILY	Several members of the tumour-necrosis/nerve-growth factor (TNF/NGF) receptor family activate the transcription factor NF-kappa B through a common adaptor protein, Traf2 (refs 1-5), whereas the interleukin 1 type-I receptor activates NF-kappa B independently of Traf2 (ref. 4). We have now cloned a new protein kinase, NIK, which binds to Traf2 and stimulates NF-kappa B activity. This kinase shares sequence similarity with several MAPKK kinases. Expression in cells of kinase-deficient NIK mutants fails to stimulate NF-kappa B and blocks its induction by TNF, by either of the two TNF receptors or by the receptor CD95 (Fas/Apo-1), and by TRADD, RIP and MORT1/FADD, which are adaptor proteins that bind to these receptors. It also blocked NF-kappa B induction by interleukin-l. Our findings indicate that NIK participates in an NF-kappa B-inducing signalling cascade common to receptors of the TNF/NGF family and to the interleukin-1 type-I receptor.	WEIZMANN INST SCI,DEPT MEMBRANE RES & BIOPHYS,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science			Malinin, Nikolay/Z-5308-2019; Malinin, Nikolay/J-4271-2012	Malinin, Nikolay/0000-0002-2654-1783; Boldin, Mark/0000-0003-4593-0669				BANNO H, 1993, MOL CELL BIOL, V13, P4745, DOI 10.1128/MCB.13.8.4745; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Cheng GH, 1996, GENE DEV, V10, P963, DOI 10.1101/gad.10.8.963; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FANKHAUSER C, 1994, EMBO J, V13, P3011, DOI 10.1002/j.1460-2075.1994.tb06600.x; HAHN T, 1985, P NATL ACAD SCI USA, V82, P3814, DOI 10.1073/pnas.82.11.3814; HANKE T, 1992, J GEN VIROL, V73, P653, DOI 10.1099/0022-1317-73-3-653; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOLTMANN H, 1988, IMMUNOBIOLOGY, V177, P7, DOI 10.1016/S0171-2985(88)80087-1; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE KS, 1992, MOL CELL BIOL, V12, P172, DOI 10.1128/MCB.12.1.172; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; MIYOSHI J, 1991, MOL CELL BIOL, V11, P4088, DOI 10.1128/MCB.11.8.4088; PATRIOTIS C, 1993, P NATL ACAD SCI USA, V90, P2251, DOI 10.1073/pnas.90.6.2251; RHODES N, 1990, GENE DEV, V4, P1862, DOI 10.1101/gad.4.11.1862; RODRIGUEZ MS, 1995, MOL CELL BIOL, V15, P2413; Rothe M, 1996, P NATL ACAD SCI USA, V93, P8241, DOI 10.1073/pnas.93.16.8241; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; STYRKARSDOTTIR U, 1992, MOL GEN GENET, V235, P122, DOI 10.1007/BF00286189; Wallach D, 1996, EUR CYTOKINE NETW, V7, P713; WANG Y, 1991, MOL CELL BIOL, V11, P3554, DOI 10.1128/MCB.11.7.3554; WORLEY KC, 1995, GENOME RES, V5, P173, DOI 10.1101/gr.5.2.173	31	1148	1193	0	29	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 6	1997	385	6616					540	544		10.1038/385540a0	http://dx.doi.org/10.1038/385540a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG235	9020361				2022-12-01	WOS:A1997WG23500049
J	Jessopp, L; Beck, I; Hollins, L; Shipman, C; Reynolds, M; Dale, J				Jessopp, L; Beck, I; Hollins, L; Shipman, C; Reynolds, M; Dale, J			Changing the pattern out of hours: A survey of general practice cooperatives	BRITISH MEDICAL JOURNAL			English	Article							CARE		MAIDDOC,NATL ASSOC GEN PRACTICE COOPERAT,AYLESFORD ME20 7SE,KENT,ENGLAND		Jessopp, L (corresponding author), UNIV LONDON KINGS COLL,SCH MED & DENT,LAMBETH SOUTHWARK & LEWISHAM OUT HOURS PROJECT,LONDON SE5 9PJ,ENGLAND.			Dale, Jeremy/0000-0001-9256-3553				Court BV, 1996, BRIT MED J, V312, P1401; CRAGG DK, 1994, BRIT MED J, V309, P1627, DOI 10.1136/bmj.309.6969.1627; Hallam L, 1996, BRIT MED J, V312, P1402; HURWITZ B, 1995, BRIT MED J, V311, P824, DOI 10.1136/bmj.311.7009.824; REYNOLDS M, 1995, GUIDANCE NATL ASS GP, P6	5	34	34	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 18	1997	314	7075					199	200		10.1136/bmj.314.7075.199	http://dx.doi.org/10.1136/bmj.314.7075.199			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WD911	9022438	Green Published			2022-12-01	WOS:A1997WD91100033
J	Gabrieli, JDE; Brewer, JB; Desmond, JE; Glover, GH				Gabrieli, JDE; Brewer, JB; Desmond, JE; Glover, GH			Separate neural bases of two fundamental memory processes in the human medial temporal lobe	SCIENCE			English	Article							HIPPOCAMPAL-FORMATION; CORTICAL AFFERENTS; ALZHEIMERS-DISEASE; ENTORHINAL CORTEX; HUMAN BRAIN; IMPAIRMENT; MONKEYS; LESIONS; TRANSECTION; RECOGNITION	The participation of medial temporal-lobe structures in memory performance was examined by functional magnetic resonance imaging of local blood oxygenation level-dependent signals. Signals were measured during encoding into memory complex scenes or line drawings and during retrieval from memory of previously studied line drawings or words. Encoding tasks yielded increased signals for unfamiliar information in a posterior medial-temporal region that were focused in the parahippocampal cortex. Retrieval tasks yielded increased signals for successfully remembered information in an anterior medial-temporal region that were focused in the subiculum. These results indicate that separate components of the human medial temporal-lobe memory system are active during distinct memory processes.	STANFORD UNIV,PROGRAM NEUROSCI,STANFORD,CA 94305; STANFORD UNIV,DEPT RADIOL,STANFORD,CA 94305	Stanford University; Stanford University	Gabrieli, JDE (corresponding author), STANFORD UNIV,DEPT PSYCHOL,STANFORD,CA 94305, USA.		Gabrieli, John/AAJ-2869-2020		NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [P41EB015891] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		Amaral DG, 1990, HUMAN NERVOUS SYSTEM, P711; Bunsey M, 1996, NATURE, V379, P255, DOI 10.1038/379255a0; DAVIES DC, 1988, NEUROSCI LETT, V94, P228, DOI 10.1016/0304-3940(88)90300-X; Duvernoy HM, 1988, HUMAN HIPPOCAMPUS; EICHENBAUM H, 1994, BEHAV BRAIN SCI, V17, P449, DOI 10.1017/S0140525X00035391; FRISTON KJ, 1994, HUMAN BRAIN MAPPING, V1, P153, DOI DOI 10.1002/HBM.460010207; GAFFAN D, 1994, EXP BRAIN RES, V99, P411; GAFFAN D, 1991, BRAIN, V114, P2611, DOI 10.1093/brain/114.6.2611; GARDINER JM, 1988, MEM COGNITION, V16, P309, DOI 10.3758/BF03197041; GRADY CL, 1995, SCIENCE, V269, P218, DOI 10.1126/science.7618082; HYMAN BT, 1984, SCIENCE, V225, P1168, DOI 10.1126/science.6474172; INSAUSTI R, 1987, J COMP NEUROL, V264, P356, DOI 10.1002/cne.902640306; JACOBY LL, 1991, J MEM LANG, V30, P513, DOI 10.1016/0749-596X(91)90025-F; JARRARD LE, 1990, PSYCHOBIOLOGY, V18, P68; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; LEONARD BW, 1995, J NEUROSCI, V15, P5637; MANDLER G, 1980, PSYCHOL REV, V87, P252, DOI 10.1037/0033-295X.87.3.252; MEUNIER M, 1993, J NEUROSCI, V13, P5418, DOI 10.1523/JNEUROSCI.13-12-05418.1993; Murray EA, 1996, SEMIN NEUROSCI, V8, P13, DOI 10.1006/smns.1996.0003; NOLL DC, 1995, JMRI-J MAGN RESON IM, V5, P49, DOI 10.1002/jmri.1880050112; Nyberg L, 1996, NATURE, V380, P715, DOI 10.1038/380715a0; OGAWA S, 1990, MAGNET RESON MED, V14, P68, DOI 10.1002/mrm.1910140108; RempelClower NL, 1996, J NEUROSCI, V16, P5233; Schacter DL, 1996, P NATL ACAD SCI USA, V93, P321, DOI 10.1073/pnas.93.1.321; SCHACTER DL, 1995, NATURE, V376, P587, DOI 10.1038/376587a0; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SNODGRASS JG, 1980, J EXP PSYCHOL-HUM L, V6, P174, DOI 10.1037/0278-7393.6.2.174; SQUIRE LR, 1992, P NATL ACAD SCI USA, V89, P1837, DOI 10.1073/pnas.89.5.1837; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; Stern CE, 1996, P NATL ACAD SCI USA, V93, P8660, DOI 10.1073/pnas.93.16.8660; SUZUKI WA, 1994, J COMP NEUROL, V350, P497, DOI 10.1002/cne.903500402; TULVING E, 1994, NEUROREPORT, V5, P2525, DOI 10.1097/00001756-199412000-00030; ZOLAMORGAN S, 1989, J NEUROSCI, V9, P4355; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	34	457	462	1	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 11	1997	276	5310					264	266		10.1126/science.276.5310.264	http://dx.doi.org/10.1126/science.276.5310.264			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WT925	9092477				2022-12-01	WOS:A1997WT92500048
J	Maroto, M; Reshef, R; Munsterberg, AE; Koester, S; Goulding, M; Lassar, AB				Maroto, M; Reshef, R; Munsterberg, AE; Koester, S; Goulding, M; Lassar, AB			Ectopic Pax-3 activates MyoD and Myf-5 expression in embryonic mesoderm and neural tissue	CELL			English	Article							BHLH GENE-EXPRESSION; RETROVIRAL VECTORS; MUSCLE DEVELOPMENT; SKELETAL-MUSCLE; SONIC HEDGEHOG; AVIAN EMBRYOS; CHICK-EMBRYO; FLOOR PLATE; SOMITE; CELLS	To understand how the skeletal muscle lineage is induced during vertebrate embryogenesis, we have sought to identify the regulatory molecules that mediate induction of the myogenic regulatory factors MyoD and Myf-5. In this work, we demonstrate that either signals from the overlying ectoderm or Wnt and Sonic hedgehog signals can induce semitic expression of the paired box transcription factors, Pax-3 and Pax-7, concomitant with expression of Myf-5 and prior to that of MyoD. Moreover, infection of embryonic tissues in vitro with a retrovirus encoding Pax-3 is sufficient to induce expression of MyoD, Myf-5, and myogenin in both paraxial and lateral plate mesoderm in the absence of inducing tissues as well as in the neural tube. Together, these findings imply that Pax-3 may mediate activation of MyoD and Myf-5 in response to muscle-inducing signals from either the axial tissues or overlying ectoderm and identify Pax-3 as a key regulator of semitic myogenesis.	HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOL PHARMACOL, BOSTON, MA 02115 USA; SALK INST BIOL STUDIES, MOL NEUROBIOL LAB, LA JOLLA, CA 92037 USA	Harvard University; Harvard Medical School; Salk Institute			Munsterberg, Andrea E/E-2205-2011	Munsterberg, Andrea E/0000-0002-4577-4240				BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; BOBER E, 1994, DEVELOPMENT, V120, P603; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; CHEVALLIER A, 1977, J EMBRYOL EXP MORPH, V41, P245; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; CHRIST B, 1977, ANAT EMBRYOL, V150, P171, DOI 10.1007/BF00316649; CHRIST B, 1992, ANAT EMBRYOL, V186, P505; CHRIST B, 1995, ANAT EMBRYOL, V191, P381, DOI 10.1007/BF00304424; Cossu G, 1996, DEVELOPMENT, V122, P429; Daston G, 1996, DEVELOPMENT, V122, P1017; Epstein JA, 1996, P NATL ACAD SCI USA, V93, P4213, DOI 10.1073/pnas.93.9.4213; FAN CM, 1994, CELL, V79, P1175, DOI 10.1016/0092-8674(94)90009-4; FEKETE DM, 1993, MOL CELL BIOL, V13, P2604, DOI 10.1128/MCB.13.4.2604; FRANZ T, 1993, ANAT EMBRYOL, V187, P153; Gamel AJ, 1995, DEV BIOL, V172, P625, DOI 10.1006/dbio.1995.8028; GEORGEWEINSTEIN M, 1994, EXP CELL RES, V211, P263, DOI 10.1006/excr.1994.1086; GOULDING M, 1994, DEVELOPMENT, V120, P957; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; GOULDING MD, 1993, DEVELOPMENT, V117, P1001; Hammerschmidt M, 1996, GENE DEV, V10, P647, DOI 10.1101/gad.10.6.647; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; JOHNSON RL, 1994, CELL, V79, P1165, DOI 10.1016/0092-8674(94)90008-6; KAEHN K, 1988, ANAT EMBRYOL, V177, P191, DOI 10.1007/BF00321131; KENNYMOBBS T, 1987, DEVELOPMENT, V100, P449; KRENN V, 1988, ANAT EMBRYOL, V179, P49, DOI 10.1007/BF00305099; MUNSTERBERG AE, 1995, DEVELOPMENT, V121, P651; MUNSTERBERG AE, 1995, GENE DEV, V9, P2911, DOI 10.1101/gad.9.23.2911; ORDAHL CP, 1992, DEVELOPMENT, V114, P339; ORDAHL CP, 1993, MOL BASIS MORPHOGENE, P165; Pourquie O, 1996, CELL, V84, P461, DOI 10.1016/S0092-8674(00)81291-X; POURQUIE O, 1995, P NATL ACAD SCI USA, V92, P3219, DOI 10.1073/pnas.92.8.3219; Pownall ME, 1996, DEVELOPMENT, V122, P1475; RONG PM, 1992, DEVELOPMENT, V115, P657; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; STERN HM, 1995, DEVELOPMENT, V121, P3675; TAJBAKHSH S, 1994, NEURON, V13, P813, DOI 10.1016/0896-6273(94)90248-8; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; Tremblay P, 1996, DEVELOPMENT, V122, P2555; Vogan KJ, 1996, MOL CELL BIOL, V16, P6677; Weinberg ES, 1996, DEVELOPMENT, V122, P271; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WILLIAMS BA, 1994, DEVELOPMENT, V120, P785; YANG XM, 1996, CELL, V122, P2171	44	357	359	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 4	1997	89	1					139	148		10.1016/S0092-8674(00)80190-7	http://dx.doi.org/10.1016/S0092-8674(00)80190-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WR685	9094722	Bronze			2022-12-01	WOS:A1997WR68500017
J	Nakayama, JI; Saito, M; Nakamura, H; Matsuura, A; Ishikawa, F				Nakayama, JI; Saito, M; Nakamura, H; Matsuura, A; Ishikawa, F			TLP1: A gene encoding a protein component of mammalian telomerase is a novel member of WD repeats family	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; TERMINAL TRANSFERASE; TETRAHYMENA TELOMERASE; CHROMATIN STRUCTURE; MOUSE TELOMERASE; END-REPLICATION; RNA COMPONENT; DNA; SEQUENCES; TEMPLATE	We have cloned and characterized the rat telomerase protein component 1 gene (TLP1), which is related to the gene for Tetrahymena p80. The cDNA encodes a 2629 amino acid sequence and produces the TLP1 proteins p240 and p230. The anti-TLP1 antibody specifically immunoprecipitated the telomerase activity. Moreover, p240 and p230 were copurified with telomerase activity in a series of extensive purification experiments. These results strongly suggest that the TLP1 proteins are components of, or are closely associated with, the rat telomerase. A pulse-chase experiment showed that p240 is modified to p230 in vivo. p230 was the dominant form in telomerase-positive cells, suggesting that modification of the TLP1 protein may regulate telomerase activity in vivo.	MITSUBISHI CHEM CORP,YOKOHAMA RES CTR,PHARMACEUT LAB 2,AOBA KU,YOKOHAMA,KANAGAWA 227,JAPAN	Mitsubishi Chemical Holdings Corporation; Mitsubishi Chemical	Nakayama, JI (corresponding author), TOKYO INST TECHNOL,DEPT LIFE SCI,MIDORI KU,4259 NAGATSUTA,YOKOHAMA,KANAGAWA 226,JAPAN.		Matsuura, Akira/J-3864-2017; Matsuura, Akira/AAO-1572-2021; Nakayama, Jun-ichi/C-6003-2011	Matsuura, Akira/0000-0002-2300-7227; Matsuura, Akira/0000-0002-2300-7227; Nakayama, Jun-ichi/0000-0002-5597-8239; Ishikawa, Fuyuki/0000-0002-5580-2305				Avilion AA, 1996, CANCER RES, V56, P645; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; BLASCO MA, 1995, SCIENCE, V269, P1267, DOI 10.1126/science.7544492; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; COHN M, 1995, SCIENCE, V269, P396, DOI 10.1126/science.7618104; COLLINS K, 1995, CELL, V81, P677, DOI 10.1016/0092-8674(95)90529-4; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; FANG G, 1995, TELOMERES, P69; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; GOTTSCHLING DE, 1984, CELL, V38, P501, DOI 10.1016/0092-8674(84)90505-1; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1995, CURR OPIN GENET DEV, V5, P249, DOI 10.1016/0959-437X(95)80016-6; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HO PLC, 1994, SCIENCE, V266, P2011; Krauskopf A, 1996, NATURE, V383, P354, DOI 10.1038/383354a0; LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3; LIN JJ, 1995, CELL, V81, P1127, DOI 10.1016/S0092-8674(05)80017-0; LINGNER J, 1995, SCIENCE, V269, P1533, DOI 10.1126/science.7545310; LINGNER J, 1994, GENE DEV, V8, P1984, DOI 10.1101/gad.8.16.1984; Lingner J, 1996, P NATL ACAD SCI USA, V93, P10712, DOI 10.1073/pnas.93.20.10712; LUE NF, 1995, J BIOL CHEM, V270, P21453, DOI 10.1074/jbc.270.37.21453; MANTELL LL, 1994, EMBO J, V13, P3211, DOI 10.1002/j.1460-2075.1994.tb06620.x; MCEACHERN MJ, 1995, NATURE, V376, P403, DOI 10.1038/376403a0; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/pnas.92.11.4818; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; RILEY JH, 1994, CURRENT PROTOCOLS HU; RUNGE KW, 1989, MOL CELL BIOL, V9, P1488, DOI 10.1128/MCB.9.4.1488; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Tatematsu K, 1996, ONCOGENE, V13, P2265; TOMMERUP H, 1994, MOL CELL BIOL, V14, P5777, DOI 10.1128/MCB.14.9.5777; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; WRIGHT JH, 1995, NUCLEIC ACIDS RES, V23, P1454, DOI 10.1093/nar/23.9.1454; WRIGHT JH, 1992, GENE DEV, V6, P197, DOI 10.1101/gad.6.2.197	47	366	389	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 21	1997	88	6					875	884		10.1016/S0092-8674(00)81933-9	http://dx.doi.org/10.1016/S0092-8674(00)81933-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WQ100	9118230	Bronze			2022-12-01	WOS:A1997WQ10000019
J	Evans, DA; Beckett, LA; Field, TS; Feng, L; Albert, MS; Bennett, DA; Tycko, B; Mayeux, R				Evans, DA; Beckett, LA; Field, TS; Feng, L; Albert, MS; Bennett, DA; Tycko, B; Mayeux, R			Apolipoprotein E epsilon 4 and incidence of Alzheimer disease in a community population of older persons	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							E ALLELE EPSILON-4; E POLYMORPHISM; TYPE-4 ALLELE; FREQUENCIES; ASSOCIATION; GENE; RISK	Objective.-To examine the relation between apolipoprotein E status and risk of Alzheimer disease (AD) in a defined population and estimate the fraction of incident AD attributable to the epsilon 4 allele. Design.-Community-based cohort study. Setting.-East Boston, Mass. Participants.-A random sample of 578 community residents aged 65 years and older free of AD. Main Outcome Measure.-Clinical diagnosis of AD by uniform, structured evaluation. Results.-The increased risk of AD associated with the presence of the epsilon 4 allele was less than that found in most family and case-control studies. Persons with the epsilon 4/epsilon 4 or epsilon 3/epsilon 4 genotypes had 2.27 (95% confidence interval, 1.06-4.89) times the risk of incident disease compared with those with the epsilon 3/epsilon 3 genotype. The epsilon 4 allele accounted for a fairly small fraction of the incidence of AD; if the allele did not exist or had no effect on disease risk, the incidence would be reduced by only 13.7%. The effect of the epsilon 4 allele on risk of AD did not appear to vary with age. Conclusions.-The apolipoprotein E epsilon 4 allele is an important genetic risk factor for AD but accounts for a fairly small fraction of disease occurrence in this population-based study. Continued efforts to identify other environmental and genetic risk factors are warranted.	RUSH UNIV,RUSH ALZHEIMERS DIS CTR,CHICAGO,IL 60612; RUSH PRESBYTERIAN ST LUKES MED CTR,CHICAGO,IL 60612; COLUMBIA UNIV COLL PHYS & SURG,GERTRUDE H SERGIEVSKY CTR,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT NEUROL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT PSYCHIAT,NEW YORK,NY 10032; BRIGHAM & WOMENS HOSP,DIV PREVENT MED,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,DEPT PSYCHIAT,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DEPT NEUROL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT PSYCHIAT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PREVENT MED,BOSTON,MA 02115	Rush University; Rush University; Columbia University; Columbia University; Columbia University; Columbia University; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Evans, DA (corresponding author), RUSH UNIV,RUSH INST AGING,SUITE 675,1645 W JACKSON BLVD,CHICAGO,IL 60612, USA.				NATIONAL INSTITUTE ON AGING [N01AG002107, N01AG012106, R01AG005362] Funding Source: NIH RePORTER; NIA NIH HHS [AG05362, N01-AG-0-2107, N01-AG-1-2106] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Blacker D, 1997, NEUROLOGY, V48, P139, DOI 10.1212/WNL.48.1.139; BREITNER JCS, 1995, ARCH NEUROL-CHICAGO, V52, P763, DOI 10.1001/archneur.1995.00540320035011; BROUSSEAU T, 1994, NEUROLOGY, V44, P342, DOI 10.1212/WNL.44.2.342; CAULEY JA, 1993, GENET EPIDEMIOL, V10, P27, DOI 10.1002/gepi.1370100104; CORBO RM, 1995, ANN HUM GENET, V59, P197, DOI 10.1111/j.1469-1809.1995.tb00741.x; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; EVANS DA, 1989, JAMA-J AM MED ASSOC, V262, P2551, DOI 10.1001/jama.262.18.2551; HALLMAN DM, 1991, AM J HUM GENET, V49, P338; HEBERT LE, 1995, JAMA-J AM MED ASSOC, V273, P1354, DOI 10.1001/jama.273.17.1354; HENDERSON AS, 1995, LANCET, V346, P1387, DOI 10.1016/S0140-6736(95)92405-1; HIXSON J, 1991, J LIPID RES, V31, P545; KAMBOH MI, 1995, HUM BIOL, V67, P195; KUUSISTO J, 1994, BRIT MED J, V309, P636, DOI 10.1136/bmj.309.6955.636; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Myers RH, 1996, NEUROLOGY, V46, P673, DOI 10.1212/WNL.46.3.673; ORDOVAS JM, 1987, J LIPID RES, V28, P371; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Shah BV, 1997, SOFTWARE STAT ANAL C; SORBI S, 1994, NEUROSCI LETT, V177, P100, DOI 10.1016/0304-3940(94)90054-X; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; VANDUIJN CM, 1994, NAT GENET, V7, P74, DOI 10.1038/ng0594-74	23	154	156	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 12	1997	277	10					822	824		10.1001/jama.277.10.822	http://dx.doi.org/10.1001/jama.277.10.822			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM082	9052713				2022-12-01	WOS:A1997WM08200036
J	Abel, T; Nguyen, PV; Barad, M; Deuel, TAS; Kandel, ER				Abel, T; Nguyen, PV; Barad, M; Deuel, TAS; Kandel, ER			Genetic demonstration of a role for PKA in the late phase of LTP and in hippocampus-based long-term memory	CELL			English	Article							PROTEIN-SYNTHESIS; CONTEXTUAL FEAR; CA1 REGION; POTENTIATION; LESIONS; MICE; RATS; INDUCTION; AMYGDALA; BINDING	To explore the role of protein kinase A (PKA) in the late phase of long-term potentiation (L-LTP) and memory, we generated transgenic mice that express R(AB), an inhibitory form of the regulatory subunit of PKA, only in the hippocampus and other forebrain regions by using the promoter from the gene encoding Ca2+/calmodulin protein kinase II alpha. In these R(AB) transgenic mice, hippocampal PKA activity was reduced, and L-LTP was significantly decreased in area CA1, without affecting basal synaptic transmission or the early phase of LTP. Moreover, the L-LTP deficit was paralleled by behavioral deficits in spatial memory and in long-term but not short-term memory for contextual fear conditioning. These deficits in long-term memory were similar to those produced by protein synthesis inhibition. Thus, PKA plays a critical role in the consolidation of long-term memory.	COLUMBIA UNIV COLL PHYS & SURG, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA	Columbia University; Howard Hughes Medical Institute	Abel, T (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, CTR NEUROBIOL & BEHAV, 722 W 168TH ST, NEW YORK, NY 10032 USA.		Abel, Ted/AAX-2825-2021	Abel, Ted/0000-0003-2423-4592; Nguyen, Peter/0000-0002-1419-5975				Abel T, 1995, MEMORY DISTORTION, P298; ABRAHAM WC, 1993, NEUROSCIENCE, V56, P717, DOI 10.1016/0306-4522(93)90369-Q; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Blitzer RD, 1995, NEURON, V15, P1403, DOI 10.1016/0896-6273(95)90018-7; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDON EP, 1995, P NATL ACAD SCI USA, V92, P8851, DOI 10.1073/pnas.92.19.8851; CHETKOVICH DM, 1991, P NATL ACAD SCI USA, V88, P6467, DOI 10.1073/pnas.88.15.6467; CHOI T, 1991, MOL CELL BIOL, V11, P3070, DOI 10.1128/MCB.11.6.3070; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; DAVIS HP, 1984, PSYCHOL BULL, V96, P518, DOI 10.1037/0033-2909.96.3.518; Davis RL, 1996, PHYSIOL REV, V76, P299, DOI 10.1152/physrev.1996.76.2.299; Deisseroth K, 1996, NEURON, V16, P89, DOI 10.1016/S0896-6273(00)80026-4; FREY U, 1988, BRAIN RES, V452, P57, DOI 10.1016/0006-8993(88)90008-X; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; GINTY DD, 1991, J BIOL CHEM, V266, P15325; GRAF P, 1985, J EXP PSYCHOL LEARN, V11, P501, DOI 10.1037/0278-7393.11.3.501; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; Hogan B., 2014, MANIPULATING MOUSE E; Huang Y Y, 1994, Learn Mem, V1, P74; Huang YY, 1995, CELL, V83, P1211, DOI 10.1016/0092-8674(95)90146-9; Huang YY, 1996, P NATL ACAD SCI USA, V93, P8699, DOI 10.1073/pnas.93.16.8699; Impey S, 1996, NEURON, V16, P973, DOI 10.1016/S0896-6273(00)80120-8; KATZ B, 1968, J PHYSIOL-LONDON, V195, P481, DOI 10.1113/jphysiol.1968.sp008469; KIM JJ, 1993, BEHAV NEUROSCI, V107, P1093, DOI 10.1037/0735-7044.107.6.1093; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; MAYFORD M, 1995, CURR OPIN NEUROBIOL, V5, P141, DOI 10.1016/0959-4388(95)80019-0; Mayford M, 1996, P NATL ACAD SCI USA, V93, P13250, DOI 10.1073/pnas.93.23.13250; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; NGUYEN PV, 1994, SCIENCE, V265, P1104, DOI 10.1126/science.8066450; PHILLIPS RG, 1992, BEHAV NEUROSCI, V106, P274, DOI 10.1037/0735-7044.106.2.274; Pilzecker, 1900, Z PSYCHOL, V1, P1; Qi M, 1996, P NATL ACAD SCI USA, V93, P1571, DOI 10.1073/pnas.93.4.1571; RAYMOND LA, 1993, TRENDS NEUROSCI, V16, P147, DOI 10.1016/0166-2236(93)90123-4; Sambrook J., 1989, MOL CLONING LAB MANU, V3; SassoneCorsi P, 1995, ANNU REV CELL DEV BI, V11, P355, DOI 10.1146/annurev.cb.11.110195.002035; SCHENK F, 1985, EXP BRAIN RES, V58, P11; SQUIRE LR, 1995, CURR OPIN NEUROBIOL, V5, P169, DOI 10.1016/0959-4388(95)80023-9; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; Tsien JZ, 1996, CELL, V87, P1327, DOI 10.1016/S0092-8674(00)81827-9; WU ZL, 1995, P NATL ACAD SCI USA, V92, P220, DOI 10.1073/pnas.92.1.220; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; YAMAMOTO T, 1994, BEHAV BRAIN RES, V65, P123, DOI 10.1016/0166-4328(94)90097-3	43	957	1001	0	84	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 7	1997	88	5					615	626		10.1016/S0092-8674(00)81904-2	http://dx.doi.org/10.1016/S0092-8674(00)81904-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WM413	9054501	hybrid			2022-12-01	WOS:A1997WM41300007
J	Nightingale, SL				Nightingale, SL			Ivermectin approved for strongyloidiasis and onchocerciasis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 5	1997	277	9					703	703						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WK026	9042830				2022-12-01	WOS:A1997WK02600008
J	Juang, YL; Huang, J; Peters, JM; McLaughlin, ME; Tai, CY; Pellman, D				Juang, YL; Huang, J; Peters, JM; McLaughlin, ME; Tai, CY; Pellman, D			APC-mediated proteolysis of Ase 1 and the morphogenesis of the mitotic spindle	SCIENCE			English	Article							B-TYPE CYCLINS; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; BUDDING YEAST; MITOSIS; UBIQUITIN; TRANSCRIPTION; DEGRADATION; ANAPHASE; COMPLEX	The molecular mechanisms that link cell-cycle controls to the mitotic apparatus are poorly understood. A component of the Saccharomyces cerevisiae spindle, Ase1, was observed to undergo cell cycle-specific degradation mediated by the cyclosome, or anaphase promoting complex (APC). Ase1 was degraded when cells exited from mitosis and entered G(1). Inappropriate expression of stable Ase1 during G(1) produced a spindle defect that is sensed by the spindle assembly checkpoint. In addition, loss of ASE1 function destabilized telophase spindles, and expression of a nondegradable Ase1 mutant delayed spindle disassembly. APC-mediated proteolysis therefore appears to regulate both spindle assembly and disassembly.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT PEDIAT ONCOL,BOSTON,MA 02115; HARVARD UNIV,CHILDRENS HOSP,SCH MED,DEPT PEDIAT HEMATOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School			Huang, James/W-5976-2019					AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; BROWN KD, 1994, J CELL BIOL, V125, P1303, DOI 10.1083/jcb.125.6.1303; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; FITCH I, 1992, MOL BIOL CELL, V3, P805, DOI 10.1091/mbc.3.7.805; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; GALLANT P, 1994, EMBO J, V13, P595, DOI 10.1002/j.1460-2075.1994.tb06297.x; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GRANDIN N, 1993, MOL CELL BIOL, V13, P2113, DOI 10.1128/MCB.13.4.2113; Heichman KA, 1996, CELL, V85, P39, DOI 10.1016/S0092-8674(00)81080-6; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HERSHKO A, 1994, J BIOL CHEM, V269, P4940; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; JUANG YD, UNPUB; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; King RW, 1996, MOL BIOL CELL, V7, P1343, DOI 10.1091/mbc.7.9.1343; KORNITZER D, 1994, EMBO J, V13, P6021, DOI 10.1002/j.1460-2075.1994.tb06948.x; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; LIAO H, 1995, J CELL BIOL, V130, P507, DOI 10.1083/jcb.130.3.507; LUCA FC, 1991, EMBO J, V10, P4311, DOI 10.1002/j.1460-2075.1991.tb05009.x; LYDALL D, 1991, GENE DEV, V5, P2405, DOI 10.1101/gad.5.12b.2405; MAHER M, 1995, MOL CELL BIOL, V15, P3129; MCGARRY T, COMMUNICATION; NEFF MW, 1992, MOL CELL BIOL, V12, P3857, DOI 10.1128/MCB.12.9.3857; PELLMAN D, 1995, J CELL BIOL, V130, P1373, DOI 10.1083/jcb.130.6.1373; Peters JM, 1996, SCIENCE, V274, P1199, DOI 10.1126/science.274.5290.1199; SCHUYLER S, UNPUB; SIKORSKI RS, 1991, COLD SH Q B, V56, P663; SPENCER F, 1992, P NATL ACAD SCI USA, V89, P8908, DOI 10.1073/pnas.89.19.8908; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; Zachariae W, 1996, SCIENCE, V274, P1201, DOI 10.1126/science.274.5290.1201	34	217	221	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 28	1997	275	5304					1311	1314		10.1126/science.275.5304.1311	http://dx.doi.org/10.1126/science.275.5304.1311			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WK644	9036857				2022-12-01	WOS:A1997WK64400044
J	Zhang, F; Endo, S; Cleary, LJ; Eskin, A; Byrne, JH				Zhang, F; Endo, S; Cleary, LJ; Eskin, A; Byrne, JH			Role of transforming growth factor-beta in long-term synaptic facilitation in Aplysia	SCIENCE			English	Article							BONE MORPHOGENETIC PROTEIN-1; SENSORY NEURONS; GILL-WITHDRAWAL; HETEROSYNAPTIC FACILITATION; SIGNAL-TRANSDUCTION; STRUCTURAL-CHANGES; SENSITIZATION; PLASTICITY; KINASE; REQUIRES	The role of transforming growth factor-beta (TGF-beta) in long-term synaptic facilitation was examined in isolated Aplysia ganglia, Treatment with TGF-beta 1 induced long-term facilitation (24 and 48 hours), but not short-term (5 to 15 minutes) or intermediate-term (2 to 4 hours) facilitation. The long-term effects of TGF-beta 1 were not additive with those of serotonin, Moreover, serotonin-induced facilitation was blocked by an inhibitor of TGF-beta. Thus, activation of TGF-beta may be part of the cascade of events underlying long-term sensitization, consistent with the hypothesis that signaling molecules that participate in development also have roles in adult neuronal plasticity.	UNIV TEXAS,SCH MED,DEPT NEUROBIOL & ANAT,HOUSTON,TX 77030; UNIV HOUSTON,DEPT BIOCHEM & BIOPHYS SCI,HOUSTON,TX 77204	University of Texas System; University of Houston System; University of Houston					NIMH NIH HHS [K05 MH-00649] Funding Source: Medline; NINDS NIH HHS [R01-NS-28462, R01-NS-19895] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [K05MH000649] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028462, R01NS019895] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAILEY CH, 1992, NEURON, V9, P749, DOI 10.1016/0896-6273(92)90037-E; BAILEY CH, 1983, SCIENCE, V220, P91, DOI 10.1126/science.6828885; BAILEY CH, 1988, P NATL ACAD SCI USA, V85, P2373, DOI 10.1073/pnas.85.7.2373; Berninger B, 1996, CURR OPIN NEUROBIOL, V6, P324, DOI 10.1016/S0959-4388(96)80115-2; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; Bonhoeffer T, 1996, CURR OPIN NEUROBIOL, V6, P119, DOI 10.1016/S0959-4388(96)80017-1; BUONOMANO DV, 1990, SCIENCE, V249, P420, DOI 10.1126/science.2165631; BYRNE JH, 1993, ADV SEC MESS PHOSPH, V27, P47; Byrne JH, 1996, J NEUROSCI, V16, P425; CASTELLUCCI VF, 1989, J NEUROBIOL, V20, P1, DOI 10.1002/neu.480200102; DALE N, 1987, J NEUROSCI, V7, P2232; Eder IE, 1996, J UROLOGY, V156, P953, DOI 10.1016/S0022-5347(01)65670-2; EMPTAGE NJ, 1993, SCIENCE, V262, P253, DOI 10.1126/science.8211146; Figurov A, 1996, NATURE, V381, P706, DOI 10.1038/381706a0; FROST WN, 1985, P NATL ACAD SCI USA, V82, P8266, DOI 10.1073/pnas.82.23.8266; FUKAGAWA M, 1994, DEV BIOL, V163, P175, DOI 10.1006/dbio.1994.1133; GLANZMAN DL, 1989, J NEUROSCI, V9, P4200; GLANZMAN DL, 1990, SCIENCE, V249, P799, DOI 10.1126/science.2389145; Henderson CE, 1996, CURR OPIN NEUROBIOL, V6, P64, DOI 10.1016/S0959-4388(96)80010-9; KANDEL ER, 1987, SYNAPTIC FUNCTION, P471; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; Kang HJ, 1996, SCIENCE, V273, P1402, DOI 10.1126/science.273.5280.1402; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Lee W. L., 1996, Society for Neuroscience Abstracts, V22, P441; Lee W. L., 1995, Society for Neuroscience Abstracts, V21, P1680; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; Liu QR, 1997, J NEUROSCI, V17, P755; LO DC, 1995, NEURON, V15, P979, DOI 10.1016/0896-6273(95)90085-3; MACKEY SL, 1989, J NEUROSCI, V9, P4227; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Martin K. C., 1996, Society for Neuroscience Abstracts, V22, P1934; McKay S. E., 1996, Society for Neuroscience Abstracts, V22, P695; Michael D., 1996, Society for Neuroscience Abstracts, V22, P1934; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; OLEARY FA, 1995, J NEUROSCI, V15, P3519; Patterson SL, 1996, NEURON, V16, P1137, DOI 10.1016/S0896-6273(00)80140-3; SCHACHER S, 1988, SCIENCE, V240, P1667, DOI 10.1126/science.2454509; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; STOOP R, 1995, SCIENCE, V267, P695, DOI 10.1126/science.7839148; Stopfer M, 1996, J NEUROSCI, V16, P4933; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; TSANG MLS, 1995, CYTOKINE, V7, P389, DOI 10.1006/cyto.1995.0054; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; ZHANG F, 1994, J NEUROPHYSIOL, V72, P778, DOI 10.1152/jn.1994.72.2.778; ZHANG ZS, 1991, J COMP NEUROL, V311, P259, DOI 10.1002/cne.903110207	49	141	146	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 28	1997	275	5304					1318	1320		10.1126/science.275.5304.1318	http://dx.doi.org/10.1126/science.275.5304.1318			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WK644	9036859				2022-12-01	WOS:A1997WK64400046
J	Beresford, SAA; Weiss, NS; Voigt, LF; McKnight, B				Beresford, SAA; Weiss, NS; Voigt, LF; McKnight, B			Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women	LANCET			English	Article							ESTROGEN REPLACEMENT THERAPY; MENOPAUSAL WOMEN; HORMONE USE; PROGESTERONE; RELIABILITY; RECALL	Background Postmenopausal oestrogen therapy reduces the risk of osteoporosis and cardiovascular diseases but is associated with an increased risk of endometrial cancer. We have assessed the impact of a regimen of oestrogen with cyclic progestagen on risk of endometrial cancer for postmenopausal women. Methods We did a population-based case-control study of women aged 45-74 years in western Washington State, USA. Cases were identified from a regional cancer registry as having histologically confirmed endometrial cancer during 1985-91. 832 (72%) of 1154 eligible cases completed interviews. Controls were identified by random digit dialling, screened for intact uterus, frequency matched for age and county, and randomly assigned a reference date within 1985-91. Interviews with 1114 (73%) of 1526 eligible controls were done. The women provided information about use of hormone replacement therapy, and reproductive and medical history before diagnosis date (cases) or reference date (controls). Findings Relative to women who had never used hormones (for >6 months), women who had taken unopposed oestrogen had a four-fold increase (95% CI 3.1-5.1) in risk of endometrial cancer. Women who used a combined therapy of oestrogen with cyclic progestagen leg, medroxyprogesterone acetate) had a relative risk of 1.4 (1.0-1.9). Among women with fewer than 10 days of added progestagen per month, the relative risk was 3.1 (1.7-5.7), whereas that for women with 10-21 days of added progestagen was 1.3 (0.8-2.2). The use of these combined regimens for 5 or more years was associated with risks of 3.7 (1.7-8.2) and 2.5 (1.1-5.5), respectively, relative to non-users of hormones. Interpretation Postmenopausal women who use combined therapy of oestrogen with cyclic progestagen on a longterm basis have an increased risk of endometrial cancer compared with those who are not on hormone replacement, even when progestagen is added for 10 or more days per month. This increase is much smaller than that associated with unopposed oestrogen, but needs to be confirmed.	UNIV WASHINGTON,DEPT BIOSTAT,SEATTLE,WA 98195; FRED HUTCHINSON CANC RES CTR,PROGRAM EPIDEMIOL,SEATTLE,WA 98104; FRED HUTCHINSON CANC RES CTR,PROGRAM BIOSTAT,SEATTLE,WA 98104	University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center	Beresford, SAA (corresponding author), UNIV WASHINGTON,DEPT EPIDEMIOL,BOX 357236,SEATTLE,WA 98195, USA.				NATIONAL CANCER INSTITUTE [R35CA039779, R01CA047749] Funding Source: NIH RePORTER; NCI NIH HHS [R35CA39779, R01CA47749] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERESFORD SAA, 1989, AM J EPIDEMIOL, V130, P202, DOI 10.1093/oxfordjournals.aje.a115313; BRESLOW NE, 1980, ANAL CASE CONTROL ST, V1; BRINTON LA, 1993, OBSTET GYNECOL, V81, P265; ERNSTER VL, 1988, PREV MED, V17, P201, DOI 10.1016/0091-7435(88)90064-3; GAMBRELL RD, 1980, OBSTET GYNECOL, V55, P732; GENALO MA, 1988, P SECT SURV RES METH, P552; HAMMOND CB, 1979, AM J OBSTET GYNECOL, V133, P537, DOI 10.1016/0002-9378(79)90289-8; JICK SS, 1993, EPIDEMIOLOGY, V4, P20, DOI 10.1097/00001648-199301000-00005; JICK SS, 1993, EPIDEMIOLOGY, V4, P384, DOI 10.1097/00001648-199307000-00016; PAGANINIHILL A, 1982, AM J EPIDEMIOL, V116, P114; PERSSON I, 1987, INT J EPIDEMIOL, V16, P222, DOI 10.1093/ije/16.2.222; PSATY BM, 1994, ARCH INTERN MED, V154, P1333, DOI 10.1001/archinte.154.12.1333; ROBINSON D, 1994, J AM GERIATR SOC, V42, P919, DOI 10.1111/j.1532-5415.1994.tb06580.x; STADEL BV, 1975, AM J EPIDEMIOL, V102, P209, DOI 10.1093/oxfordjournals.aje.a112149; STURDEE DW, 1978, BRIT MED J, V1, P1575, DOI 10.1136/bmj.1.6127.1575; VOIGT LF, 1991, LANCET, V338, P274, DOI 10.1016/0140-6736(91)90417-N; VOIGT LF, 1992, AM J EPIDEMIOL, V136, P1393, DOI 10.1093/oxfordjournals.aje.a116452; WAKSBERG J, 1978, J AM STAT ASSOC, V73, P40, DOI 10.2307/2286513; WHITEHEAD MI, 1987, OBSTET GYN CLIN N AM, V14, P299; WHITEHEAD MI, 1981, NEW ENGL J MED, V305, P1599, DOI 10.1056/NEJM198112313052701; WHITEHEAD MI, 1990, OBSTETRICS GYNECOL S, V75, P59; *WRIT GROUP PEPI T, 1996, JAMA-J AM MED ASSOC, V275, P370; *WRIT GROUP PEPI T, 1995, JAMA-J AM MED ASSOC, V273, P199	23	361	371	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 15	1997	349	9050					458	461		10.1016/S0140-6736(96)07365-5	http://dx.doi.org/10.1016/S0140-6736(96)07365-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH389	9040575				2022-12-01	WOS:A1997WH38900010
J	Beutler, E				Beutler, E			Genetic irony beyond haemochromatosis: Clinical effects of HLA-H mutations	LANCET			English	Editorial Material											Beutler, E (corresponding author), SCRIPPS RES INST, DEPT MOL & EXPT MED, LA JOLLA, CA 92037 USA.							Beutler Ernest, 1996, Blood Cells Molecules and Diseases, V22, P187, DOI 10.1006/bcmd.1996.0027; Bulaj ZJ, 1996, NEW ENGL J MED, V335, P1799, DOI 10.1056/NEJM199612123352403; Calandro L, 1996, BLOOD CELL MOL DIS, V22, pA194; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Jazwinska EC, 1996, NAT GENET, V14, P249, DOI 10.1038/ng1196-249; Jouanolle AM, 1996, NAT GENET, V14, P251, DOI 10.1038/ng1196-251; SIMON M, 1974, NOUV PRESSE MED, V4, P1432	7	111	112	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 1	1997	349	9048					296	297		10.1016/S0140-6736(97)22005-2	http://dx.doi.org/10.1016/S0140-6736(97)22005-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF794	9024367				2022-12-01	WOS:A1997WF79400002
J	Pan, GH; ORourke, K; Chinnaiyan, AM; Gentz, R; Ebner, R; Ni, J; Dixit, VM				Pan, GH; ORourke, K; Chinnaiyan, AM; Gentz, R; Ebner, R; Ni, J; Dixit, VM			The receptor for the cytotoxic ligand TRAIL	SCIENCE			English	Article							DEATH DOMAIN; CELL-DEATH; PROTEIN; FAS; APOPTOSIS; INTERACTS	TRAIL (also known as Apo-2L) is a member of the tumor necrosis factor (TNF) ligand family that rapidly induces apoptosis in a variety of transformed cell lines. The human receptor for TRAIL was found to be an undescribed member of the TNF-receptor family (designated death receptor-4, DR4) that contains a cytoplasmic ''death domain'' capable of engaging the cell suicide apparatus but not the nuclear factor kappa B pathway in the system studied. Unlike Fas, TNFR-1, and DR3, DR4 could not use FADD to transmit the death signal, suggesting the use of distinct proximal signaling machinery. Thus, the DR4-TRAIL axis defines another receptor-ligand pair involved in regulating cell suicide and tissue homeostasis.	UNIV MICHIGAN,DEPT PATHOL,SCH MED,ANN ARBOR,MI 48109; HUMAN GENOME SCI,ROCKVILLE,MD 20850	University of Michigan System; University of Michigan; GlaxoSmithKline; Human Genome Sciences Inc			dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326	NIDA NIH HHS [DAMD17-96-1-6085] Funding Source: Medline; NIEHS NIH HHS [ES08111] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R41DA016085, R42DA016085] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ARMITAGE RJ, 1994, CURR OPIN IMMUNOL, V6, P407, DOI 10.1016/0952-7915(94)90119-8; Baker SJ, 1996, ONCOGENE, V12, P1; Bodmer JL, 1997, IMMUNITY, V6, P79, DOI 10.1016/S1074-7613(00)80244-7; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BROJATSH J, 1996, CELL, V87, P1; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; Marsters SA, 1996, CURR BIOL, V6, P750, DOI 10.1016/S0960-9822(09)00456-4; Marsters SA, 1996, CURR BIOL, V6, P1669, DOI 10.1016/S0960-9822(02)70791-4; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; PAN GZ, UNPUB; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	29	1493	1708	2	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 4	1997	276	5309					111	113		10.1126/science.276.5309.111	http://dx.doi.org/10.1126/science.276.5309.111			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WR386	9082980				2022-12-01	WOS:A1997WR38600058
J	West, GB; Brown, JH; Enquist, BJ				West, GB; Brown, JH; Enquist, BJ			A general model for the origin of allometric scaling laws in biology	SCIENCE			English	Article							MASS; METABOLISM; SIZE	Allometric scaling relations, including the 3/4 power law for metabolic rates, are characteristic of all organisms and are here derived from a general model that describes how essential materials are transported through space-filling fractal networks of branching tubes. The model assumes that the energy dissipated is minimized and that the terminal tubes do not vary with body size. It provides a complete analysis of scaling relations for mammalian circulatory systems that are in agreement with data. More generally, the model predicts structural and functional properties of vertebrate cardiovascular and respiratory systems, plant vascular systems, insect tracheal tubes, and other distribution networks.	UNIV NEW MEXICO, DEPT BIOL, ALBUQUERQUE, NM 87131 USA; SANTA FE INST, SANTA FE, NM 87501 USA; LOS ALAMOS NATL LAB, DIV THEORET, LOS ALAMOS, NM 87545 USA	University of New Mexico; The Santa Fe Institute; United States Department of Energy (DOE); Los Alamos National Laboratory			Kristoffersson, Anders/I-6497-2015; Enquist, Brian J/B-6436-2008	Kristoffersson, Anders/0000-0003-3166-9981; Enquist, Brian J/0000-0002-6124-7096				BENNETT AF, 1988, AM ZOOL, V28, P699; BENNETT PM, 1987, J ZOOL, V213, P327, DOI 10.1111/j.1469-7998.1987.tb03708.x; BONNER JT, 1983, EVOLUTION COMPLEXITY; Brown J.H., 1995, MACROECOLOGY; CANNY MJ, 1993, PHILOS T R SOC B, V341, P87, DOI 10.1098/rstb.1993.0094; CARO CG, 1978, MECHANICS CIRCULATIO; ELLSWORTH ML, 1987, MICROVASC RES, V34, P168, DOI 10.1016/0026-2862(87)90051-3; FELDMAN HA, 1983, RESP PHYSIOL, V52, P149, DOI 10.1016/0034-5687(83)90002-6; FUNG YC, 1984, BIODYNAMICS; GEHR P, 1981, RESP PHYSIOL, V44, P61, DOI 10.1016/0034-5687(81)90077-3; Harvey P.H., 1991, COMP METHOD EVOLUTIO; Hemmingsen A. M., 1950, REP STENO MEM HOSP, V4, P1; Hemmingsen A.M., 1960, REP STENO MEML HOSP, V13, P1; IBERALL A. S., 1967, MATH BIOSCI, V1, P375, DOI 10.1016/0025-5564(67)90009-0; Krogh A, 1920, PFLUG ARCH GES PHYS, V179, P95, DOI 10.1007/BF01722125; Li J K-J, 1996, COMP CARDIOVASCULAR; Mandelbrot B. B., 1977, FRACTAL GEOMETRY NAT; MCMAHON T, 1973, SCIENCE, V179, P1201, DOI 10.1126/science.179.4079.1201; McMahon T., 1983, SIZE LIFE; Murray CD, 1926, P NATL ACAD SCI USA, V12, P207, DOI 10.1073/pnas.12.3.207; Niklas K.J., 1994, PLANT ALLOMETRY SCAL; NIKLAS KJ, 1994, AM J BOT, V81, P134, DOI 10.2307/2445626; PATTERSON MR, 1992, SCIENCE, V255, P1421, DOI 10.1126/science.255.5050.1421; Portner HO, 2008, SCIENCE, V322, P690, DOI 10.1126/science.1163156; SHERMAN TF, 1981, J GEN PHYSIOL, V78, P431, DOI 10.1085/jgp.78.4.431; SHIN YM, 1994, CELL MOL NEUROBIOL, V14, P133, DOI 10.1007/BF02090781; Shinozaki K., 1964, JAPANESE J ECOL, V14, P97, DOI [10.18960/seitai.14.3_97, DOI 10.18960/SEITAI.14.3_97]; Strahler A.N., 1953, EOS T AM GEOPHYS UN, V34, P345; Thompson D.W., 1945, GROWTH FORM; TYREE MT, 1991, NEW PHYTOL, V119, P345, DOI 10.1111/j.1469-8137.1991.tb00035.x; WOMERSLEY JR, 1955, PHILOS MAG, V46, P199; WORMERSLEY JR, 1955, J PHYSL, V127, P553; ZAMIR M, 1992, J BIOMECH, V25, P1303, DOI 10.1016/0021-9290(92)90285-9; Zimmermann M.H., 1984, XYLEM STRUCTURE ASCE, V26, P165	34	3302	3453	20	837	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 4	1997	276	5309					122	126		10.1126/science.276.5309.122	http://dx.doi.org/10.1126/science.276.5309.122			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WR386	9082983				2022-12-01	WOS:A1997WR38600061
J	Lee, JT; Jaenisch, R				Lee, JT; Jaenisch, R			Long-range cis effects of ectopic X-inactivation centres on a mouse autosome	NATURE			English	Article							CHROMOSOME INACTIVATION; INSITU HYBRIDIZATION; XIST GENE; EXPRESSION; REPLICATION; EMBRYOS; NUCLEUS; RNA	In mammals, the X chromosome is unique in being capable of complete inactivation. Such X inactivation evolved to compensate for gene dosage differences between females with two X chromosomes and males with one(1). Transcriptional silencing of a, single female X chromosome is controlled in cis by Xist(2), whose RNA product coats the inactive X chromosome (X(i))(3), and the X-inactivation centre (Xic)(4). A transgenic study limited the Xic to 450 kilobases including Xist, and demonstrated that it is sufficient to initiate X inactivation(5). Here we report that ectopic Xist RNA completely coats transgenic chromosome 12. Expression of genes over 50 centimorgans was reduced two-fold and was detected only from the normal homologue in fibroblasts. Moreover, ectopic Xic action resulted in chromosome-wide changes that are characteristic of the X(i): DNA replication was delayed, and histone H4 was markedly hypoacetylated. Our findings suggest long-range cis effects on the autosome similar to those of X inactivation, and imply that the Xic can both initiate X inactivation and drive heterochromatin formation, Thus, the potential for chromosome-wide gene regulation is not intrinsic to X-chromosome DNA, but can also occur on autosomes possessing the Xic.	MIT,DEPT BIOL,CAMBRIDGE,MA 02142; MASSACHUSETTS GEN HOSP,DEPT PATHOL,BOSTON,MA 02114	Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts General Hospital	Lee, JT (corresponding author), WHITEHEAD INST BIOMED RES,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.							BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; BROWN CJ, 1994, NATURE, V368, P154, DOI 10.1038/368154a0; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; Carrel L, 1996, HUM MOL GENET, V5, P1361, DOI 10.1093/hmg/5.9.1361; CLEMSON CM, 1996, J CELL BIOL, V132, P1; DEUSTACHIO P, 1994, GENOME, V5, pS181; EICHER EM, 1970, ADV GENET, V15, P175, DOI 10.1016/S0065-2660(08)60074-7; FOLEY KP, 1993, TRENDS GENET, V9, P380, DOI 10.1016/0168-9525(93)90137-7; HARIHARAN N, 1991, P NATL ACAD SCI USA, V88, P9799, DOI 10.1073/pnas.88.21.9799; HUANG S, 1991, Genes and Development, V5, P2288, DOI 10.1101/gad.5.12a.2288; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; KAY GE, 1993, CELL, V72, P161; KEITGES EA, 1986, HUM GENET, V72, P230; KRUMLAUF R, 1986, NATURE, V319, P224, DOI 10.1038/319224a0; LAWRENCE JB, 1989, CELL, V57, P493, DOI 10.1016/0092-8674(89)90924-0; Lee JT, 1996, CELL, V86, P83, DOI 10.1016/S0092-8674(00)80079-3; LUCCHESI JC, 1987, ADV GENET, V24, P371, DOI 10.1016/S0065-2660(08)60013-9; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; Penny GD, 1996, NATURE, V379, P131, DOI 10.1038/379131a0; PRAVTCHEVA DD, 1991, DEVELOPMENT, V111, P1109; PRIEST JH, 1967, J CELL BIOL, V35, P483, DOI 10.1083/jcb.35.2.483; RASTAN S, 1983, J EMBRYOL EXP MORPH, V78, P1; RASTAN S, 1990, GENET RES, V56, P99, DOI 10.1017/S0016672300035163; SCHEMPP W, 1985, Y CHROMOSOME, P357; SHEARDOWN S, HUM MOL GENET, V5, P1355; TRASK BJ, 1991, TRENDS GENET, V7, P149, DOI 10.1016/0168-9525(91)90378-4; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B; VOGEL W, 1986, HUM GENET, V72, P129; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4	30	224	230	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 20	1997	386	6622					275	279		10.1038/386275a0	http://dx.doi.org/10.1038/386275a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WP003	9069285				2022-12-01	WOS:A1997WP00300050
J	Goldberg, LH				Goldberg, LH			Basal-cell carcinoma as predictor for other cancers	LANCET			English	Editorial Material							NON-HODGKINS-LYMPHOMA; SKIN-CANCER				Goldberg, LH (corresponding author), BAYLOR COLL MED,DEPT DERMATOL,HOUSTON,TX 77030, USA.		Goldberg, Leonard/AGR-0657-2022					ADAMI J, 1995, BRIT MED J, V310, P1491, DOI 10.1136/bmj.310.6993.1491; CARTWRIGHT R, 1994, LEUKEMIA LYMPHOMA, V14, P387, DOI 10.3109/10428199409049694; Frisch M, 1996, ANN INTERN MED, V125, P815, DOI 10.7326/0003-4819-125-10-199611150-00005; FRISCH M, 1995, AM J EPIDEMIOL, V141, P916, DOI 10.1093/oxfordjournals.aje.a117358; HALL P, 1995, INT J CANCER, V62, P19; Hjalgrim H, 1996, BRIT J CANCER, V73, P951, DOI 10.1038/bjc.1996.170; KRIPKE ML, 1994, CANCER RES, V54, P6102; McMichael AJ, 1996, BRIT J CANCER, V73, P945, DOI 10.1038/bjc.1996.169; Schottenfeld D, 1996, ANN INTERN MED, V125, P852, DOI 10.7326/0003-4819-125-10-199611150-00011; Wassberg C, 1996, BRIT J CANCER, V73, P255, DOI 10.1038/bjc.1996.45	10	6	7	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 8	1997	349	9053					664	665		10.1016/S0140-6736(05)60130-4	http://dx.doi.org/10.1016/S0140-6736(05)60130-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM080	9078194				2022-12-01	WOS:A1997WM08000004
J	Marinker, M				Marinker, M			Personal paper: Writing prescriptions is easy	BRITISH MEDICAL JOURNAL			English	Article											Marinker, M (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMASS HOSP,LONDON SE1 7EH,ENGLAND.							HAYNES RB, 1976, LANCET, V1, P1265; HORNE R, 1997, PERCEPTIONS HLTH ILL, P115; MCGAVOCK HA, 1996, REV LIT DRUG ADHEREN; ROVELLI M, 1989, TRANSPLANT P, V21, P833; *ROYAL PHARM SOC G, 1997, COMPL CONC SHAR GOAL; Sackett DL, 1979, COMPLIANCE HLTH CARE	6	47	48	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 8	1997	314	7082					747	748		10.1136/bmj.314.7082.747	http://dx.doi.org/10.1136/bmj.314.7082.747			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM776	9116558	Green Published			2022-12-01	WOS:A1997WM77600036
J	Muller, U; Wang, DN; Denda, S; Meneses, JJ; Pedersen, RA; Reichardt, LF				Muller, U; Wang, DN; Denda, S; Meneses, JJ; Pedersen, RA; Reichardt, LF			Integrin alpha 8 beta 1 is critically important for epithelial-mesenchymal interactions during kidney morphogenesis	CELL			English	Article							RECEPTOR; TENASCIN; FIBRONECTIN; EXPRESSION; MICE; VITRONECTIN; ANTIBODIES; MIGRATION; ADHESION; SUBUNIT	We present genetic evidence that integrins regulate epithelial-mesenchymal interactions during organogenesis. Mice with a mutation in the alpha 8 gene do not express the integrin alpha 8 beta 1 and exhibit profound deficits in kidney morphogenesis. In wild-type animals, inductive interactions between the ureteric epithelium and metanephric mesenchyme are essential for kidney morphogenesis. In alpha 8 mutant homozygotes, growth and branching of the ureteric bud and recruitment of mesenchymal cells into epithelial structures are defective. Consistent with these phenotypes, alpha 8 expression is induced in mesenchymal cells upon contact with the ureter. Since none of its previously identified ligands appears likely to mediate the essential functions of alpha 8 beta 1 in kidney morphogenesis, we have used an alpha 8 beta 1-alkaline phosphatase chimera to localize novel ligand(s) in the growing ureter. The distribution of these ligand(s) makes them strong candidates for regulators of kidney morphogenesis.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT OBSTET GYNECOL & REPROD SCI,REPROD GENET UNIT,SAN FRANCISCO,CA 94143	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Muller, U (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,BOX 0444,SAN FRANCISCO,CA 94143, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD026732] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019090] Funding Source: NIH RePORTER; NICHD NIH HHS [P01-HD26732] Funding Source: Medline; NINDS NIH HHS [R01 NS019090, R01 NS019090-14] Funding Source: Medline; PHS HHS [P01-16033] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AUFDERHEIDE E, 1987, J CELL BIOL, V105, P599, DOI 10.1083/jcb.105.1.599; BOSSY B, 1991, EMBO J, V10, P2375, DOI 10.1002/j.1460-2075.1991.tb07776.x; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DRESSLER GR, 1990, DEVELOPMENT, V109, P787; DUDLEY AT, 1995, GENE DEV, V9, P2795, DOI 10.1101/gad.9.22.2795; EKBLOM P, 1981, J CELL BIOL, V91, P1, DOI 10.1083/jcb.91.1.1; Ekblom P, 1996, CURR OPIN CELL BIOL, V8, P700, DOI 10.1016/S0955-0674(96)80112-8; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; GETTNER S, 1994, THESIS U CALIFORNIA; GROBSTEIN C, 1953, SCIENCE, V118, P52, DOI 10.1126/science.118.3054.52; GROBSTEIN C, 1956, ADV CANCER RES, V4, P187, DOI 10.1016/S0065-230X(08)60725-3; GURDON JB, 1992, CELL, V68, P185, DOI 10.1016/0092-8674(92)90465-O; Hatini V, 1996, GENE DEV, V10, P1467, DOI 10.1101/gad.10.12.1467; Holtfreter Johannes, 1944, REV CANADIENNE BIOL, V3, P220; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JONES KR, 1994, CELL, V76, P989, DOI 10.1016/0092-8674(94)90377-8; Joyner AL, 1993, GENE TARGETING PRACT; KADOYA Y, 1995, J CELL BIOL, V129, P521, DOI 10.1083/jcb.129.2.521; Kispert A, 1996, DEVELOPMENT, V122, P3627; KLEIN G, 1988, CELL, V55, P331, DOI 10.1016/0092-8674(88)90056-6; Kreidberg JA, 1996, DEVELOPMENT, V122, P3537; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; Liu ZZ, 1996, DEV BIOL, V178, P133, DOI 10.1006/dbio.1996.0204; LUO G, 1995, GENE DEV, V9, P2808, DOI 10.1101/gad.9.22.2808; LYONS KM, 1995, MECH DEVELOP, V50, P71, DOI 10.1016/0925-4773(94)00326-I; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; MULLER U, 1995, MOL BIOL CELL, V6, P433; PARR BA, 1994, CURR OPIN GENET DEV, V4, P523, DOI 10.1016/0959-437X(94)90067-D; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; POOLE TJ, 1981, J EMBRYOL EXP MORPH, V63, P1; POOLE TJ, 1982, DEV BIOL, V92, P144, DOI 10.1016/0012-1606(82)90159-2; Roelink H, 1996, CURR OPIN NEUROBIOL, V6, P33, DOI 10.1016/S0959-4388(96)80006-7; SAGA Y, 1992, GENE DEV, V6, P1821, DOI 10.1101/gad.6.10.1821; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; SARIOLA H, 1991, SCIENCE, V254, P571, DOI 10.1126/science.1658930; SARIOLA H, 1988, CELL, V54, P235, DOI 10.1016/0092-8674(88)90556-9; Saxen L., 1987, ORGANOGENESIS KIDNEY; SCHNAPP LM, 1995, J BIOL CHEM, V270, P23196, DOI 10.1074/jbc.270.39.23196; Schuchardt A, 1996, DEVELOPMENT, V122, P1919; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cb.11.110195.003001; SEIFFERT D, 1991, P NATL ACAD SCI USA, V88, P9402, DOI 10.1073/pnas.88.21.9402; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; SPERMANN H, 1924, ARCH ENTW MECH ORG, V100, P599; STARK K, 1994, NATURE, V372, P679, DOI 10.1038/372679a0; Torres M, 1995, DEVELOPMENT, V121, P4057; Tung TC, 1944, J ANAT, V78, P52; VARNUMFINNEY B, 1995, NEURON, V14, P1213, DOI 10.1016/0896-6273(95)90268-6; Vega QC, 1996, P NATL ACAD SCI USA, V93, P10657, DOI 10.1073/pnas.93.20.10657; WESKAMP G, 1991, NEURON, V6, P649, DOI 10.1016/0896-6273(91)90067-A; ZHANG X, 1995, P NATL ACAD SCI USA, V92, P12426	52	276	284	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 7	1997	88	5					603	613		10.1016/S0092-8674(00)81903-0	http://dx.doi.org/10.1016/S0092-8674(00)81903-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WM413	9054500	Bronze, Green Accepted			2022-12-01	WOS:A1997WM41300006
J	Webb, CD; Teleman, A; Gordon, S; Straight, A; Belmont, A; Lin, DCH; Grossman, AD; Wright, A; Losick, R				Webb, CD; Teleman, A; Gordon, S; Straight, A; Belmont, A; Lin, DCH; Grossman, AD; Wright, A; Losick, R			Bipolar localization of the replication origin regions of chromosomes in vegetative and sporulating cells of B-subtilis	CELL			English	Article							BACILLUS-SUBTILIS; ESCHERICHIA-COLI; GENE-EXPRESSION; TRANSCRIPTION; PROTEINS; DNA; IMMUNOFLUORESCENCE; IDENTIFICATION; VISUALIZATION; CONDENSATION	To investigate chromosome segregation in B. subtilis, we introduced tandem copies of the lactose operon operator into the chromosome near the replication origin or terminus. We then visualized the position of the operator cassettes with green fluorescent protein fused to the Lad repressor. In sporulating bacteria, which undergo asymmetric cell division, origins localized near each pole of the cell whereas termini were restricted to the middle. In growing cells, which undergo binary fission, origins were observed at various positions but preferentially toward the poles early in the cell cycle. In contrast, termini showed little preference for the poles. These results indicate the existence of a mitotic-like apparatus that is responsible for moving the origin regions of newly formed chromosomes toward opposite ends of the cell.	TUFTS UNIV,DEPT MOL BIOL & MICROBIOL,BOSTON,MA 02111; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV ILLINOIS,DEPT CELL & STRUCT BIOL,URBANA,IL 61801; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Tufts University; University of California System; University of California San Francisco; University of Illinois System; University of Illinois Urbana-Champaign; Massachusetts Institute of Technology (MIT)	Webb, CD (corresponding author), HARVARD UNIV,DEPT MOL & CELLULAR BIOL,CAMBRIDGE,MA 02138, USA.		Teleman, Aurelio A/E-6864-2013; Teleman, Aurelio/V-8470-2019	Teleman, Aurelio A/0000-0002-4237-9368; Teleman, Aurelio/0000-0002-4237-9368; Straight, Aaron/0000-0001-5885-7881	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM018568, R01GM038035, R01GM018568, R01GM042516] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM18568, GM38035, R01 GM042516] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barton NR, 1996, P NATL ACAD SCI USA, V93, P1735, DOI 10.1073/pnas.93.5.1735; BONE EJ, 1985, J BACTERIOL, V164, P192, DOI 10.1128/JB.164.1.192-200.1985; COOPER S, 1991, BACTERIAL GROWTH DIV, P279; Cutting S., 1990, MOL BIOL METHODS BAC; DRIKS A, 1994, GENE DEV, V8, P234, DOI 10.1101/gad.8.2.234; DUBNAU E, 1988, J BACTERIOL, V170, P1054, DOI 10.1128/jb.170.3.1054-1062.1988; EBERLE H, 1966, J MOL BIOL, V22, P183, DOI 10.1016/0022-2836(66)90190-2; FORT P, 1985, J GEN MICROBIOL, V131, P1091; GARTNER D, 1988, J BACTERIOL, V170, P3102; HARRY EJ, 1995, J BACTERIOL, V177, P3386, DOI 10.1128/jb.177.12.3386-3393.1995; HIRAGA S, 1992, ANNU REV BIOCHEM, V61, P283; HIRANO T, 1995, CURR OPIN CELL BIOL, V7, P329, DOI 10.1016/0955-0674(95)80087-5; HYMAN AA, 1995, CURR BIOL, V5, P483, DOI 10.1016/S0960-9822(95)00097-2; IRETON K, 1994, J BACTERIOL, V176, P5320, DOI 10.1128/JB.176.17.5320-5329.1994; JAACKS KJ, 1989, J BACTERIOL, V171, P4121, DOI 10.1128/JB.171.8.4121-4129.1989; JACOB F, 1963, COLD SPRING HARB SYM, V28, P329, DOI 10.1101/SQB.1963.028.01.048; LEDEAUX JR, 1995, J BACTERIOL, V177, P166, DOI 10.1128/jb.177.1.166-175.1995; MOBLEY HLT, 1984, J BACTERIOL, V158, P169, DOI 10.1128/JB.158.1.169-179.1984; MOHL DA, 1997, CELL; MORAN CP, 1982, MOL GEN GENET, V186, P339, DOI 10.1007/BF00729452; Nicholson WL., 1990, MOL BIOL METHODS BAC, P391, DOI DOI 10.1111/J.1751-1097.1991.TB02087.X; PLUTA AF, 1995, SCIENCE, V270, P1591, DOI 10.1126/science.270.5242.1591; POGLIANO K, 1995, MOL MICROBIOL, V18, P459, DOI 10.1111/j.1365-2958.1995.mmi_18030459.x; Resnekov O, 1996, GENES CELLS, V1, P529, DOI 10.1046/j.1365-2443.1996.d01-262.x; Robinett CC, 1996, J CELL BIOL, V135, P1685, DOI 10.1083/jcb.135.6.1685; ROELS S, 1995, J BACTERIOL, V177, P6263, DOI 10.1128/jb.177.21.6263-6275.1995; SANDLER N, 1988, J GEN MICROBIOL, V134, P1155; SETLOW B, 1991, J BACTERIOL, V173, P6270, DOI 10.1128/jb.173.19.6270-6278.1991; Sharpe ME, 1996, MOL MICROBIOL, V21, P501, DOI 10.1111/j.1365-2958.1996.tb02559.x; SHARPE ME, 1995, P NATL ACAD SCI USA, V92, P8630, DOI 10.1073/pnas.92.19.8630; SUN DX, 1991, J BACTERIOL, V173, P7867, DOI 10.1128/jb.173.24.7867-7874.1991; Wake RG, 1995, ANNU REV GENET, V29, P41; WEBB CD, 1995, J BACTERIOL, V177, P5906, DOI 10.1128/jb.177.20.5906-5911.1995; WOLDRINGH CL, 1987, J GEN MICROBIOL, V133, P575; WU LJ, 1995, GENE DEV, V9, P1316, DOI 10.1101/gad.9.11.1316; WU LJ, 1994, SCIENCE, V264, P572, DOI 10.1126/science.8160014; YOUNGMAN P, 1984, PLASMID, V12, P1, DOI 10.1016/0147-619X(84)90061-1; ZUBER P, 1983, CELL, V35, P275, DOI 10.1016/0092-8674(83)90230-1	39	313	316	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 7	1997	88	5					667	674		10.1016/S0092-8674(00)81909-1	http://dx.doi.org/10.1016/S0092-8674(00)81909-1			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WM413	9054506	Bronze, Green Published			2022-12-01	WOS:A1997WM41300012
J	Alpern, RJ; Sakhaee, K				Alpern, RJ; Sakhaee, K			Does hyperphosphaturia underlie hypercalciuria?	LANCET			English	Editorial Material							ABSORPTIVE HYPERCALCIURIA; AMBULATORY EVALUATION; 1,25-DIHYDROXYVITAMIN-D; NEPHROLITHIASIS; PHOSPHATE				Alpern, RJ (corresponding author), UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235, USA.							BARILLA DE, 1979, MINER ELECTROL METAB, V2, P302; BRESLAU NA, 1992, J CLIN ENDOCR METAB, V75, P1446, DOI 10.1210/jc.75.6.1446; BROADUS AE, 1984, NEW ENGL J MED, V311, P73, DOI 10.1056/NEJM198407123110201; GRAY RW, 1977, J CLIN ENDOCR METAB, V45, P299, DOI 10.1210/jcem-45-2-299; INSOGNA KL, 1985, J CLIN ENDOCR METAB, V61, P490, DOI 10.1210/jcem-61-3-490; LEVY FL, 1995, AM J MED, V98, P50, DOI 10.1016/S0002-9343(99)80080-1; PAK CYC, 1991, AM J KIDNEY DIS, V18, P624, DOI 10.1016/S0272-6386(12)80602-0; PAK CYC, 1980, AM J MED, V69, P19, DOI 10.1016/0002-9343(80)90495-7; SAKHAEE K, 1985, J CLIN ENDOCR METAB, V61, P825, DOI 10.1210/jcem-61-5-825; WILLIAMS CP, 1995, J CLIN PATHOL, V49, P881	10	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 22	1997	349	9051					518	519		10.1016/S0140-6736(97)80080-3	http://dx.doi.org/10.1016/S0140-6736(97)80080-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WJ512	9048785				2022-12-01	WOS:A1997WJ51200004
J	Mittal, V; Hernandez, N				Mittal, V; Hernandez, N			Role for the amino-terminal region of human TBP in U6 snRNA transcription	SCIENCE			English	Article							RNA-POLYMERASE-III; TATA-BINDING-PROTEIN; PROXIMAL SEQUENCE ELEMENT; CONSERVED CORE DOMAIN; ACTIVATES TRANSCRIPTION; GENE INVITRO; COMPLEX; PROMOTERS; MOUSE; EXPRESSION	Basal transcription from the human RNA polymerase III U6 promoter depends on a TATA box that recruits the TATA box-binding protein (TBP) and a proximal sequence element that recruits the small nuclear RNA (snRNA)-activating protein complex (SNAP(c)). TBP consists of a conserved carboxyl-terminal domain that performs all known functions of the protein and a nonconserved amino-terminal region of unknown function. Here, the aminoterminal region is shown to down-regulate binding oi TBP to the U6 TATA box, mediate cooperative binding with SNAP(c) to the U6 promoter, and enhance U6 transcription.	COLD SPRING HARBOR LAB, HOWARD HUGHES MED INST, COLD SPRING HARBOR, NY 11724 USA	Cold Spring Harbor Laboratory; Howard Hughes Medical Institute				Hernandez, Nouria/0000-0003-1465-4585	NIGMS NIH HHS [R01GM38810] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038810] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; CORMACK BP, 1991, CELL, V65, P341, DOI 10.1016/0092-8674(91)90167-W; GILL G, 1991, CELL, V65, P333, DOI 10.1016/0092-8674(91)90166-V; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; GOOMER RS, 1994, GENE, V148, P269, DOI 10.1016/0378-1119(94)90698-X; HANCOCK JM, 1993, NUCLEIC ACIDS RES, V21, P2823, DOI 10.1093/nar/21.12.2823; HASHIMOTO S, 1992, NUCLEIC ACIDS RES, V20, P3788, DOI 10.1093/nar/20.14.3788; HENRY RW, 1995, NATURE, V374, P653, DOI 10.1038/374653a0; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; Hernandez N, 1992, TRANSCRIPTIONAL REGU, P281; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; IMBERT G, 1994, GENOMICS, V21, P667, DOI 10.1006/geno.1994.1335; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KASSAVETIS GA, 1994, TRANSCRIPTION MECHAN, P107; KEAVENEY M, 1993, NATURE, V365, P562, DOI 10.1038/365562a0; LESCURE A, 1994, EMBO J, V13, P1166, DOI 10.1002/j.1460-2075.1994.tb06366.x; LOBO SM, 1992, CELL, V71, P1029, DOI 10.1016/0092-8674(92)90397-U; LOBO SM, 1989, CELL, V58, P55, DOI 10.1016/0092-8674(89)90402-9; LOBO SM, 1991, GENE DEV, V5, P1477, DOI 10.1101/gad.5.8.1477; LOBO SM, 1994, TRANSCRIPTION MECH R, P127; Mital R, 1996, MOL CELL BIOL, V16, P7031; Mittal V, 1996, MOL CELL BIOL, V16, P1955; MURPHY S, 1992, MOL CELL BIOL, V12, P3247, DOI 10.1128/MCB.12.7.3247; NAKASHIMA K, 1995, GENE, V152, P209, DOI 10.1016/0378-1119(94)00681-H; Pendergrast PS, 1996, J VIROL, V70, P5025, DOI 10.1128/JVI.70.8.5025-5034.1996; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; REDDY P, 1991, CELL, V65, P349, DOI 10.1016/0092-8674(91)90168-X; REDDY R, 1988, J BIOL CHEM, V263, P15980; RUDLOFF U, 1994, P NATL ACAD SCI USA, V91, P8229, DOI 10.1073/pnas.91.17.8229; SADOWSKI CL, 1993, GENE DEV, V7, P1535, DOI 10.1101/gad.7.8.1535; SCHMIDT MC, 1989, MOL CELL BIOL, V9, P3299, DOI 10.1128/MCB.9.8.3299; SIMMEN KA, 1991, EMBO J, V10, P1853, DOI 10.1002/j.1460-2075.1991.tb07711.x; STRUHL K, 1994, SCIENCE, V263, P1103, DOI 10.1126/science.8108728; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAMURA T, 1991, NUCLEIC ACIDS RES, V19, P3861, DOI 10.1093/nar/19.14.3861; TANSEY WP, 1994, GENE DEV, V8, P2756, DOI 10.1101/gad.8.22.2756; TEICHMANN M, 1995, EMBO J, V14, P5974, DOI 10.1002/j.1460-2075.1995.tb00286.x; WALDSCHMIDT R, 1991, EMBO J, V10, P2595, DOI 10.1002/j.1460-2075.1991.tb07801.x; WANG ZX, 1995, P NATL ACAD SCI USA, V92, P7026, DOI 10.1073/pnas.92.15.7026; YOON JB, 1995, MOL CELL BIOL, V15, P2019; ZHOU Q, 1991, EMBO J, V10, P1843, DOI 10.1002/j.1460-2075.1991.tb07710.x	41	78	79	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 21	1997	275	5303					1136	1140		10.1126/science.275.5303.1136	http://dx.doi.org/10.1126/science.275.5303.1136			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WJ503	9027316				2022-12-01	WOS:A1997WJ50300047
J	Scanziani, M; Salin, PA; Vogt, KE; Malenka, RC; Nicoll, RA				Scanziani, M; Salin, PA; Vogt, KE; Malenka, RC; Nicoll, RA			Use-dependent increases in glutamate concentration activate presynaptic metabotropic glutamate receptors	NATURE			English	Article							GUINEA-PIG HIPPOCAMPUS; METHYL-D-ASPARTATE; MOSSY FIBER LTP; TRANSMISSION; ACID; INHIBITION; RESPONSES; SYNAPSES; NEURONS	The classical view of fast chemical synaptic transmission is that released neurotransmitter acts locally on postsynaptic receptors and is cleared from the synaptic cleft within a few milliseconds by diffusion and by specific reuptake mechanisms. This rapid clearance restricts the spread of neurotransmitter and, combined with the low affinities of many ionotropic receptors, ensures that synaptic transmission occurs in a point-to-point fashion(1). We now show, however, that when transmitter release is enhanced at hippocampal messy fibre synapses, the concentration of glutamate increases and its clearance is delayed; this allows it to spread away from the synapse and to activate presynaptic inhibitory metabotropic glutamate receptors (mGluRs). At normal levels of glutamate release during low-frequency activity, these presynaptic receptors are not activated. When glutamate concentration is increased by higher-frequency activity or by blocking glutamate uptake, however, these receptors become activated, leading to a rapid inhibition of transmitter release. This effect may be related to the long-term depression of messy fibre synaptic responses that has recently been shown after prolonged activation of presynaptic mGluRs (refs 2, 3). The use-dependent activation of presynaptic mGluRs that we describe here thus represents a negative feedback mechanism for controlling the strength of synaptic transmission.	UNIV CALIF SAN FRANCISCO,DEPT CELLULAR & MOL PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PSYCHIAT,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco				Vogt, Kaspar/0000-0002-0859-876X; Salin, Paul/0000-0001-5221-9109				BASKYS A, 1991, J PHYSIOL-LONDON, V444, P687, DOI 10.1113/jphysiol.1991.sp018901; BERGLES DE, 1996, NEUR ABSTR, V22, P797; BRIDGES RJ, 1991, J MED CHEM, V34, P717, DOI 10.1021/jm00106a037; CHICUREL ME, 1992, J COMP NEUROL, V323, P1; Conn PJ., 1994, METABOTROPIC GLUTAMA; FORSYTHE ID, 1990, J PHYSIOL-LONDON, V429, P1; GLAUM SR, 1993, J NEUROPHYSIOL, V70, P2669, DOI 10.1152/jn.1993.70.6.2669; HAMLYN LH, 1962, J ANAT, V96, P112; HILLE B, 1992, NEURON, V9, P187, DOI 10.1016/0896-6273(92)90158-A; HSIA AY, 1995, NEUROPHARMACOLOGY, V34, P1567, DOI 10.1016/0028-3908(95)00115-M; ISAACSON JS, 1993, NEURON, V10, P165, DOI 10.1016/0896-6273(93)90308-E; Kamiya H, 1996, J PHYSIOL-LONDON, V493, P447, DOI 10.1113/jphysiol.1996.sp021395; Kobayashi K, 1996, SCIENCE, V273, P648, DOI 10.1126/science.273.5275.648; Kullmann DM, 1996, NEURON, V17, P461, DOI 10.1016/S0896-6273(00)80178-6; LANTHORN TH, 1984, BRAIN RES, V290, P174, DOI 10.1016/0006-8993(84)90750-9; MANZONI OJ, 1995, NEUROPHARMACOLOGY, V34, P965, DOI 10.1016/0028-3908(95)00060-J; NAKANISHI S, 1994, NEURON, V13, P1031, DOI 10.1016/0896-6273(94)90043-4; OLVERMAN HJ, 1988, NEUROSCIENCE, V26, P17, DOI 10.1016/0306-4522(88)90124-8; Otis TS, 1996, J NEUROSCI, V16, P1634, DOI 10.1523/jneurosci.16-05-01634.1996; PATNEAU DK, 1990, J NEUROSCI, V10, P2385; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; Salin PA, 1996, P NATL ACAD SCI USA, V93, P13304, DOI 10.1073/pnas.93.23.13304; Shigemoto R., 1995, Society for Neuroscience Abstracts, V21, P846; Silver RA, 1996, J PHYSIOL-LONDON, V494, P231, DOI 10.1113/jphysiol.1996.sp021487; TONG G, 1994, NEURON, V12, P51, DOI 10.1016/0896-6273(94)90151-1; WEISSKOPF MG, 1995, NATURE, V376, P256, DOI 10.1038/376256a0; YAMAMOTO C, 1983, EXP BRAIN RES, V51, P128; Yokoi M, 1996, SCIENCE, V273, P645, DOI 10.1126/science.273.5275.645	28	390	415	0	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 13	1997	385	6617					630	634		10.1038/385630a0	http://dx.doi.org/10.1038/385630a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WH294	9024660				2022-12-01	WOS:A1997WH29400049
J	Aurigemma, G				Aurigemma, G			Has thrombolytic therapy changed the equation for postinfarction risk stratification?	LANCET			English	Editorial Material							MYOCARDIAL-INFARCTION				Aurigemma, G (corresponding author), UNIV MASSACHUSETTS,DIV CARDIOVASC MED,WORCESTER,MA 01655, USA.							Basu S, 1996, BMJ-BRIT MED J, V313, P844; DIAMOND GA, 1993, JAMA-J AM MED ASSOC, V269, P2418, DOI 10.1001/jama.269.18.2418; GIBSON RS, 1983, CIRCULATION, V68, P321, DOI 10.1161/01.CIR.68.2.321; MARX BE, 1995, AM J MED, V98, P550; MOSS AJ, 1993, JAMA-J AM MED ASSOC, V269, P2379, DOI 10.1001/jama.269.18.2379; RYAN TJ, REPORT AM COLEGE CAR; SHAW IJ, 1996, AM J CARDIOL, V78, P1327; THEROUX P, 1979, NEW ENGL J MED, V301, P341, DOI 10.1056/NEJM197908163010701	8	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 1	1997	349	9048					298	299		10.1016/S0140-6736(05)62820-6	http://dx.doi.org/10.1016/S0140-6736(05)62820-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF794	9024369				2022-12-01	WOS:A1997WF79400004
J	Jeffery, KJM; Read, SJ; Peto, TEA; MayonWhite, RT; Bangham, CRM				Jeffery, KJM; Read, SJ; Peto, TEA; MayonWhite, RT; Bangham, CRM			Diagnosis of viral infections of the central nervous system: Clinical interpretation of PCR results	LANCET			English	Article							POLYMERASE CHAIN-REACTION; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; BARR-VIRUS DNA; CEREBROSPINAL-FLUID; ENTEROVIRAL MENINGITIS; MEDICAL LITERATURE; USERS GUIDES; AIDS; ENCEPHALITIS; MANAGEMENT	Background Standard laboratory techniques, such as viral culture and serology, provide only circumstantial or retrospective evidence of viral infections of the central nervous system (CNS). We assessed the diagnostic accuracy of PCR of cerebrospinal fluid (CSF) in the diagnosis of viral infections of the CNS. Methods We examined all the CSF samples that were received at our diagnostic virology laboratory between May, 1994, and May, 1996, by nested PCR for viruses associated with CNS infections in the UK. We collected clinical and laboratory data for 410 patients from Oxford city hospitals (the Oxford cohort) whose CSF was examined between May, 1994, and May, 1995. These patients were classified according to the likelihood of a viral infection of the CNS. We used stratified logistic regression analysis to identify the clinical factors independently associated with a positive PCR result. We calculated likelihood ratios to estimate the clinical usefulness of PCR amplification of CSF. Findings We tested 2233 consecutive CSF samples from 2162 patients. A positive PCR result was obtained in 143 patients, including 22 from the Oxford cohort. Logistic regression analysis of the Oxford cohort showed that fever, a virus-specific rash, and a CSF white-cell count of 5/mu L or more were independent predictors of a positive PCR result. The likelihood ratio for a definite diagnosis of viral infection of the CNS ir? a patient with a positive PCR result, relative to a negative PCR result, was 88.2 (95% CI 20.6-378). The likelihood ratio for a possible diagnosis of viral infection of the CNS in a patient with a negative PCR result, relative to a positive PCR result, was 0.10 (0.03-0.39). Interpretation A patient with a positive PCR result was 88 times as likely to have a definite diagnosis of viral infection of the CNS as a patient with a negative PCR result. A negative PCR result can be used with moderate confidence to rule out a diagnosis of viral infection of the CNS. We believe that PCR will become the first-line diagnostic test for viral meningitis and encephalitis.	JOHN RADCLIFFE HOSP,PUBL HLTH LAB SERV,DEPT MICROBIOL,OXFORD OX3 9DU,ENGLAND; JOHN RADCLIFFE HOSP,NUFFIELD DEPT MED,OXFORD OX3 9DU,ENGLAND; OXFORDSHIRE HLTH AUTHOR,DIRECTORATE PUBL HLTH & POLICY,OXFORD OX3 9DZ,ENGLAND	University of Oxford; University of Oxford	Jeffery, KJM (corresponding author), ST MARYS HOSP,IMPERIAL COLL SCH MED,DEPT IMMUNOL,PRAED ST,LONDON W2 1PG,ENGLAND.			Bangham, Charles/0000-0003-2624-3599				ARRIBAS JR, 1995, J CLIN MICROBIOL, V33, P1580, DOI 10.1128/JCM.33.6.1580-1583.1995; CINQUE P, 1993, LANCET, V342, P398, DOI 10.1016/0140-6736(93)92814-A; Dallal GE, 1988, AM STAT, V42, P272; DEAN AG, 1994, EPI INFO 6 VERSION 6; ECHEVARRIA JM, 1994, J MED VIROL, V43, P331, DOI 10.1002/jmv.1890430403; FONG IW, 1995, J CLIN MICROBIOL, V33, P484, DOI 10.1128/JCM.33.2.484-486.1995; GARDNER MJ, 1989, STAT CONFIDENCE CONF; GOZLAN J, 1995, AIDS, V9, P253, DOI 10.1097/00002030-199509030-00006; GUFFOND T, 1994, CLIN INFECT DIS, V18, P744, DOI 10.1093/clinids/18.5.744; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P389, DOI 10.1001/jama.271.5.389; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P703, DOI 10.1001/jama.271.9.703; Jeffery KJM, 1996, CURR OPIN INFECT DIS, V9, P132, DOI 10.1097/00001432-199604000-00018; LAKEMAN FD, 1995, J INFECT DIS, V171, P857, DOI 10.1093/infdis/171.4.857; READ SJ, 1997, IN PRESS J CLIN MICR; RICE SK, 1995, CLIN INFECT DIS, V20, P931, DOI 10.1093/clinids/20.4.931; SAWYER MH, 1994, PEDIATR INFECT DIS J, V13, P177, DOI 10.1097/00006454-199403000-00002; SCHLESINGER Y, 1995, CLIN INFECT DIS, V20, P842, DOI 10.1093/clinids/20.4.842; SCHLESINGER Y, 1994, PEDIATRICS, V94, P157; TEDDER DG, 1994, ANN INTERN MED, V121, P334, DOI 10.7326/0003-4819-121-5-199409010-00004; THOREN A, 1994, SCAND J INFECT DIS, V26, P249, DOI 10.3109/00365549409011792; WEBER T, 1994, J INFECT DIS, V169, P1138, DOI 10.1093/infdis/169.5.1138	21	119	124	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 1	1997	349	9048					313	317		10.1016/S0140-6736(96)08107-X	http://dx.doi.org/10.1016/S0140-6736(96)08107-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF794	9024374				2022-12-01	WOS:A1997WF79400010
J	FitzSimmons, SC; Burkhart, GA; Borowitz, D; Grand, RJ; Hammerstrom, T; Durie, PR; LloydStill, JD; Lowenfels, AB				FitzSimmons, SC; Burkhart, GA; Borowitz, D; Grand, RJ; Hammerstrom, T; Durie, PR; LloydStill, JD; Lowenfels, AB			High-dose pancreatic-enzyme supplements and fibrosing colonopathy in children with cystic fibrosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COLONIC STRICTURES; EPIDEMIOLOGY; DISEASE	Background Fibrosing colonopathy has been reported in young children with cystic fibrosis, the majority of whom take high-strength pancreatic-enzyme supplements to control intestinal malabsorption. We conducted a case-control study in the United States to investigate the relation between dose and type of pancreatic-enzyme supplement and fibrosing colonopathy. Methods Children with histopathologically con firmed cases of fibrosing colonopathy who required colectomy for colonic strictures from January 1, 1990, through December 31, 1994, were identified. Each of these patients was matched according to age at the time of surgery and medical center with up to four controls with cystic fibrosis who did not have fibrosing colonopathy. Results We studied 29 patients (mean age, 5.0 years) with fibrosing colonopathy (case patients) and 105 controls (mean age, 5.2 years). The mean dose of pancreatic-enzyme supplement was 50,046 units of lipase per kilogram of body weight per day for the case patients and 18,985 units per kilogram per day for the controls. A history of gastrointestinal complications attributed to cystic fibrosis and the use of histamine H-2-receptor blockers, corticosteroids, or recombinant human DNase (dornase alfa) were associated with a higher incidence of fibrosing colonopathy. After adjustment for a history of such complications and the use of these medicines, the relative risk of fibrosing colonopathy that was associated with a dose of 24,001 to 50,000 units of lipase per kilogram per day, as compared with a close of 0 to 24,000 units per kilogram per day, was 10.9 (95 percent confidence interval, 1.6 to 71.8), and that associated with a dose of more than 50,000 units per kilogram per day was 199.5 (95 percent confidence interval, 9.9 to 4026.0). The strength, coating, and manufacturer of the products used were not associated with the risk of fibrosing colonopathy. Conclusions In young children with cystic fibrosis, we found a strong relation between high daily doses of pancreatic-enzyme supplements and the development of fibrosing colonopathy. Our findings support recommendations that the daily dose of pancreatic enzymes for most patients should remain below 10,000 units of lipase per kilogram. (C) 1997, Massachusetts Medical Society.	US FDA, CTR DRUG EVALUAT & RES, ROCKVILLE, MD 20857 USA; CHILDRENS HOSP BUFFALO, DEPT PEDIAT PULMONOL, BUFFALO, NY USA; TUFTS UNIV, SCH MED, DIV PEDIAT GASTROENTEROL & NUTR, BOSTON, MA 02111 USA; HOSP SICK CHILDREN, DIV PEDIAT GASTROENTEROL & NUTR, TORONTO, ON M5G 1X8, CANADA; RUSH MED COLL, DEPT PEDIAT, CHICAGO, IL 60612 USA; NEW YORK MED COLL, DEPT SURG & COMMUNITY & PREVENT MED, VALHALLA, NY 10595 USA; EUROPEAN INST ONCOL, MILAN, ITALY	US Food & Drug Administration (FDA); Tufts University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Rush University; New York Medical College; IRCCS European Institute of Oncology (IEO)	FitzSimmons, SC (corresponding author), CYST FIBROSIS FDN, DEPT MED, 6931 ARLINGTON RD, BETHESDA, MD 20814 USA.		Lowenfels, Albert/ABD-8388-2021		NIAID NIH HHS [AI06331] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOROWITZ DS, 1995, J PEDIATR-US, V127, P681, DOI 10.1016/S0022-3476(95)70153-2; BRIARS G, 1994, LANCET, V343, P600; CROFT NM, 1995, LANCET, V346, P1265; FITZSIMMONS SC, 1993, J PEDIATR-US, V122, P1, DOI 10.1016/S0022-3476(05)83478-X; Freiman JP, 1996, J PEDIATR GASTR NUTR, V22, P153, DOI 10.1097/00005176-199602000-00005; GREENLAND S, 1995, EPIDEMIOLOGY, V6, P356, DOI 10.1097/00001648-199507000-00005; KNABE N, 1994, LANCET, V343, P1230, DOI 10.1016/S0140-6736(94)92443-0; LEBENTHAL E, 1994, J PEDIATR GASTR NUTR, V18, P423, DOI 10.1097/00005176-199405000-00002; LLOYDSTILL JD, 1995, J CLIN GASTROENTEROL, V21, P2, DOI 10.1097/00004836-199507000-00001; MACSWEENEY EJ, 1995, LANCET, V345, P752; MAHONY MJ, 1994, LANCET, V343, P599; PETTEI MJ, 1994, J PEDIATR-US, V125, P587, DOI 10.1016/S0022-3476(94)70014-1; Prestridge L, 1996, J PEDIATR GASTR NUTR, V22, P219, DOI 10.1097/00005176-199602000-00016; SCHWARZENBERG SJ, 1995, J PEDIATR-US, V127, P565, DOI 10.1016/S0022-3476(95)70113-3; SMYTH RL, 1995, LANCET, V346, P1247, DOI 10.1016/S0140-6736(95)91860-4; SMYTH RL, 1994, LANCET, V343, P85, DOI 10.1016/S0140-6736(94)90817-6; TAYLOR CJ, 1995, LANCET, V346, P1106, DOI 10.1016/S0140-6736(95)91783-7; VANVELZEN D, 1996, POSTGRAD MED J S2, V72, P39; ZERIN JM, 1995, RADIOLOGY, V194, P223, DOI 10.1148/radiology.194.1.7997557; 1995, LANCET, V346, P499; 1994, LANCET, V343, P109	21	158	190	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 1	1997	336	18					1283	1289		10.1056/NEJM199705013361803	http://dx.doi.org/10.1056/NEJM199705013361803			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW260	9113931				2022-12-01	WOS:A1997WW26000003
J	Haneji, N; Nakamura, T; Takio, K; Yanagi, K; Higashiyama, H; Saito, I; Noji, S; Sugino, H; Hayashi, Y				Haneji, N; Nakamura, T; Takio, K; Yanagi, K; Higashiyama, H; Saito, I; Noji, S; Sugino, H; Hayashi, Y			Identification of alpha-fodrin as a candidate autoantigen in primary Sjogren's syndrome	SCIENCE			English	Article							NONERYTHROID SPECTRIN; CELLS; CYTOSKELETON; PROTEOLYSIS; SECRETION; CRITERIA; BINDING; PROTEIN; ANTIGEN; MODEL	It is unclear whether organ-specific autoantigens are critical for the development of primary Sjogren's syndrome (SS). A 120-kilodalton organ-specific autoantigen was purified from salivary gland tissues of an NFS/sld mouse model of human SS. The amino-terminal residues were identical to those of the human cytoskeletal protein alpha-fodrin. The purified antigen induced proliferative T cell responses and production of interleukin-2 and interferon-gamma in vitro. Neonatal immunization with the 120-kilodalton antigen prevented the disease in mice. Sera from patients with SS reacted positively with purified antigen and recombinant human alpha-fodrin protein, whereas those from patients with systemic lupus erythematosus and rheumatoid arthritis did not. Thus, the immune response to 120-kilodalton alpha-fodrin could be important in the initial development of primary SS.	UNIV TOKUSHIMA,SCH DENT,DEPT PATHOL,TOKUSHIMA 770,JAPAN; UNIV TOKUSHIMA,INST ENZYME RES,TOKUSHIMA 770,JAPAN; INST PHYS & CHEM RES,DIV BIOMOL CHARACTERIZAT,WAKO,SAITAMA 35101,JAPAN; UNIV TOKUSHIMA,DIV BIOL IND,TOKUSHIMA 770,JAPAN	Tokushima University; Tokushima University; RIKEN; Tokushima University			Noji, Sumihare/E-3047-2010					ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; BACKKESKOV S, 1990, NATURE, V347, P151; BIRKENMEIER CS, 1985, P NATL ACAD SCI USA, V82, P5671, DOI 10.1073/pnas.82.17.5671; BLOCH KJ, 1965, MEDICINE, V44, P187, DOI 10.1097/00005792-196505000-00001; CHAN EKL, 1991, J CLIN INVEST, V87, P68, DOI 10.1172/JCI115003; FOX RI, 1986, ARTHRITIS RHEUM-US, V29, P577, DOI 10.1002/art.1780290501; GLENNEY JR, 1982, J BIOL CHEM, V257, P9781; HANEJI N, 1994, J IMMUNOL, V153, P2769; HARTWIG JH, 1992, J CELL BIOL, V118, P1421, DOI 10.1083/jcb.118.6.1421; HOOPER DC, 1987, IMMUNOL TODAY, V8, P327, DOI 10.1016/0167-5699(87)90005-3; KARLSSON FA, 1988, J CLIN INVEST, V81, P475, DOI 10.1172/JCI113344; KRUIZE AA, 1995, IMMUNOL TODAY, V16, P557, DOI 10.1016/0167-5699(95)80075-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETO TL, 1989, J BIOL CHEM, V264, P5826; LOKESHWAR VB, 1992, J BIOL CHEM, V267, P21551; MACY E, 1988, FASEB J, V2, P3003, DOI 10.1096/fasebj.2.14.3263291; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; MOON RT, 1990, J BIOL CHEM, V265, P4427; OADRI I, 1995, P NATL ACAD SCI USA, V92, P1003; PERRIN D, 1987, NATURE, V326, P498, DOI 10.1038/326498a0; PERRIN D, 1985, NATURE, V315, P589, DOI 10.1038/315589a0; PERRIN D, 1992, J CELL BIOL, V116, P127, DOI 10.1083/jcb.116.1.127; PORTMANN L, 1985, J CLIN ENDOCR METAB, V61, P1001, DOI 10.1210/jcem-61-5-1001; SAIDO TC, 1993, J BIOL CHEM, V268, P25239; STETLER DA, 1982, P NATL ACAD SCI USA, V79, P6499; TISCH R, 1993, NATURE, V366, P72, DOI 10.1038/366072a0; VANDEWATER J, 1988, J EXP MED, V167, P1791, DOI 10.1084/jem.167.6.1791; WHITE SC, 1974, J IMMUNOL, V112, P178	28	330	356	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 25	1997	276	5312					604	607		10.1126/science.276.5312.604	http://dx.doi.org/10.1126/science.276.5312.604			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WV721	9110981				2022-12-01	WOS:A1997WV72100048
J	Stebbins, CE; Russo, AA; Schneider, C; Rosen, N; Hartl, FU; Pavletich, NP				Stebbins, CE; Russo, AA; Schneider, C; Rosen, N; Hartl, FU; Pavletich, NP			Crystal structure of an Hsp90-geldanamycin complex: Targeting of a protein chaperone by an antitumor agent	CELL			English	Article							HEAT-SHOCK PROTEIN; CELL-FREE SYSTEM; STEROID-RECEPTOR; TYROSINE KINASE; PROGESTERONE-RECEPTOR; MUTATIONAL ANALYSIS; HERBIMYCIN-A; HSP90; GELDANAMYCIN; BINDING	The Hsp90 chaperone is required for the activation of several families of eukaryotic protein kinases and nuclear hormone receptors, many of which are protooncogenic and play a prominent role in cancer. The geldanamycin antibiotic has antiproliferative and antitumor effects, as it binds to Hsp90, inhibits the Hsp90-mediated conformational maturation/refolding reaction, and results in the degradation of Hsp90 substrates. The structure of the geldanamycin-binding domain of Hsp90 (residues 9-232) reveals a pronounced pocket, 15 Angstrom deep, that is highly conserved across species. Geldanamycin binds inside this pocket, adopting a compact structure similar to that of a polypeptide chain in a turn conformation. This, and the pocket's similarity to substrate-binding sites, suggest that the pocket binds a portion of the polypeptide substrate and participates in the conformational maturation/refolding reaction.	MEM SLOAN KETTERING CANC CTR, CELLULAR BIOCHEM & BIOPHYS PROGRAM, NEW YORK, NY 10021 USA; CORNELL UNIV, GRAD SCH MED SCI, DEPT BIOCHEM & STRUCT BIOL, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, CELL BIOL & GENET PROGRAM, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, DEPT MED, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center			Hartl, F. Ulrich/Y-8206-2019; Stebbins, Erec/N-2565-2018; Rosen, Neal/ABF-2677-2020	Stebbins, Erec/0000-0001-6229-5308; 				ALIGUE R, 1994, EMBO J, V13, P6099, DOI 10.1002/j.1460-2075.1994.tb06956.x; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARLOW DJ, 1988, J MOL BIOL, V201, P601, DOI 10.1016/0022-2836(88)90641-9; BOHEN SP, 1993, P NATL ACAD SCI USA, V90, P11424, DOI 10.1073/pnas.90.23.11424; BOHEN SP, 1994, BIOL HEAT SHOCK PROT; BORKOVICH KA, 1989, MOL CELL BIOL, V9, P3919, DOI 10.1128/MCB.9.9.3919; Bose S, 1996, SCIENCE, V274, P1715, DOI 10.1126/science.274.5293.1715; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; BRUNGER AT, 1991, X PLOR SYSTEM XRAY C; Chavany C, 1996, J BIOL CHEM, V271, P4974; CUTFORTH T, 1994, CELL, V77, P1027, DOI 10.1016/0092-8674(94)90442-1; DEBOER C, 1970, J ANTIBIOT, V23, P442, DOI 10.7164/antibiotics.23.442; Dittmar KD, 1996, J BIOL CHEM, V271, P12833, DOI 10.1074/jbc.271.22.12833; Duina AA, 1996, SCIENCE, V274, P1713, DOI 10.1126/science.274.5293.1713; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; Freeman BC, 1996, SCIENCE, V274, P1718, DOI 10.1126/science.274.5293.1718; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; FURUSAKI A, 1980, J ANTIBIOT, V33, P781, DOI 10.7164/antibiotics.33.781; HARTSON SD, 1994, BIOCHEMISTRY-US, V33, P8912, DOI 10.1021/bi00196a008; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; ISAACS JT, 1979, UICC MONOGRAPH PROST, V48, P112; JAKOB U, 1994, TRENDS BIOCHEM SCI, V19, P205, DOI 10.1016/0968-0004(94)90023-X; Johnson J, 1996, J STEROID BIOCHEM, V56, P31, DOI 10.1016/0960-0760(95)00221-9; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KIMURA Y, 1994, MOL GEN GENET, V242, P517, DOI 10.1007/BF00285275; KOYASU S, 1986, P NATL ACAD SCI USA, V83, P8054, DOI 10.1073/pnas.83.21.8054; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MILLER P, 1994, CANCER RES, V54, P2724; MILLER SJ, 1995, DISS ABSTR INT B, V55, P3313; MURAKAMI Y, 1994, BIOCHEM J, V301, P63, DOI 10.1042/bj3010063; Nair SC, 1996, CELL STRESS CHAPERON, V1, P237, DOI 10.1379/1466-1268(1996)001<0237:APOMCI>2.3.CO;2; NATHAN DF, 1995, MOL CELL BIOL, V15, P3917; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nieland TJF, 1996, P NATL ACAD SCI USA, V93, P6135, DOI 10.1073/pnas.93.12.6135; OMURA S, 1979, J ANTIBIOT, V32, P255, DOI 10.7164/antibiotics.32.255; ONO Y, 1982, GANN, V73, P938; OSBORNE CK, 1980, CANCER-AM CANCER SOC, V46, P2884, DOI 10.1002/1097-0142(19801215)46:12+<2884::AID-CNCR2820461429>3.0.CO;2-U; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; Pratt William B., 1994, Seminars in Cell Biology, V5, P83; Rinehart K L Jr, 1976, Fortschr Chem Org Naturst, V33, P231; SASAKI K, 1979, J ANTIBIOT, V32, P849, DOI 10.7164/antibiotics.32.849; Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536; SCHNUR RC, 1995, J MED CHEM, V38, P3813, DOI 10.1021/jm00019a011; SCHNUR RC, 1995, J MED CHEM, V38, P3806, DOI 10.1021/jm00019a010; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; SCHUMACHER RJ, 1994, J BIOL CHEM, V269, P9493; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; SULLIVAN WP, 1993, J BIOL CHEM, V268, P20373; SUPKO JG, 1995, CANCER CHEMOTH PHARM, V36, P305, DOI 10.1007/BF00689048; Wearsch PA, 1996, BIOCHEMISTRY-US, V35, P16760, DOI 10.1021/bi962068q; WHITELAW ML, 1991, J BIOL CHEM, V266, P16436; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Whitesell L, 1996, MOL ENDOCRINOL, V10, P705, DOI 10.1210/me.10.6.705; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606; [No title captured]	61	1183	1253	2	93	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 18	1997	89	2					239	250		10.1016/S0092-8674(00)80203-2	http://dx.doi.org/10.1016/S0092-8674(00)80203-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WU888	9108479	hybrid			2022-12-01	WOS:A1997WU88800011
J	deAngelis, MH; McIntyre, J; Gossler, A				deAngelis, MH; McIntyre, J; Gossler, A			Maintenance of somite borders in mice requires the Delta homologue DII1	NATURE			English	Article							CHICK-EMBRYO; CELLS; SEGMENTATION; NEUROGENESIS; MECHANISMS; EXPRESSION; GROWTH	During vertebrate embryonic development, the paraxial mesoderm is subdivided into metameric subunits called somites. The arrangement and cranio-caudal polarity of the somites governs the metamerism of all somite-derived tissues and spinal ganglia. Little is known about the molecular mechanisms underlying somite formation, segment polarity, maintenance of segment borders, and the interdependency of these processes. The mouse Delta homologue Dll1, a member of the DSL gene family, is expressed in the presomitic mesoderm and posterior halves of somites(1). Here we report that, in Dll1-deficient mouse embryos, a primary metameric pattern is established in mesoderm, and cytodifferentiation is apparently normal, but the segments have no cranio-caudal polarity, and no epithelial somites form. Caudal sclerotome halves do not condense, and the pattern of spinal ganglia and nerves is perturbed, indicating loss of segment polarity. Myoblasts span segment borders, demonstrating that these borders are not maintained. These results show that Dll1 is involved in compartmentalization of somites, that dermomyotome and sclerotome differentiation are independent of formation of epithelia and subdivision of somites in cranial and caudal halves, and that compartmentalization is essential for the maintenance of s0egment borders in paraxial mesoderm-derived structures.	JACKSON LAB,BAR HARBOR,ME 04609	Jackson Laboratory			de Angelis, Martin Hrabe/F-5531-2012	de Angelis, Martin Hrabe/0000-0002-7898-2353				BETTENHAUSEN B, 1995, DEVELOPMENT, V121, P2407; Burgess R, 1996, NATURE, V384, P570, DOI 10.1038/384570a0; BURGESS R, 1995, DEV BIOL, V168, P296, DOI 10.1006/dbio.1995.1081; CAMPOSORTEGA JA, 1995, MOL NEUROBIOL, V10, P75, DOI 10.1007/BF02740668; CANDIA AF, 1992, DEVELOPMENT, V116, P1123; CHITNIS A, 1995, NATURE, V375, P761, DOI 10.1038/375761a0; CHRIST B, 1986, SOMITES DEV EMBRYOS, P261; CONLON RA, 1995, DEVELOPMENT, V121, P1533; DAVIES JA, 1990, NEURON, V4, P11, DOI 10.1016/0896-6273(90)90439-M; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; GOLDSTEIN RS, 1990, P NATL ACAD SCI USA, V87, P4476, DOI 10.1073/pnas.87.12.4476; HARTENSTEIN AY, 1992, DEVELOPMENT, V116, P1203; KEYNES RJ, 1988, DEVELOPMENT, V103, P413; KEYNES RJ, 1984, NATURE, V310, P786, DOI 10.1038/310786a0; KOSEKI H, 1993, DEVELOPMENT, V119, P649; MEINHARDT H, 1986, SOMITES DEV EMBRYOS, P179; MONTARRAS D, 1991, NEW BIOL, V3, P592; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NEUBUSER A, 1995, DEV BIOL, V170, P701, DOI 10.1006/dbio.1995.1248; Sambrook J., 1989, MOL CLONING LAB MANU; STERN CD, 1986, J EMBRYOL EXP MORPH, V91, P209; STERN CD, 1987, DEVELOPMENT, V99, P261; TEILLET MA, 1987, DEV BIOL, V120, P329, DOI 10.1016/0012-1606(87)90236-3; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75	24	523	535	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 17	1997	386	6626					717	721		10.1038/386717a0	http://dx.doi.org/10.1038/386717a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WU387	9109488				2022-12-01	WOS:A1997WU38700056
J	Gaudreau, L; Schmid, A; Blaschke, D; Ptashne, M; Horz, W				Gaudreau, L; Schmid, A; Blaschke, D; Ptashne, M; Horz, W			RNA polymerase II holoenzyme recruitment is sufficient to remodel chromatin at the yeast PHO5 promoter	CELL			English	Article							TATA-BINDING PROTEIN; TRANSCRIPTIONAL ACTIVATION; SACCHAROMYCES-CEREVISIAE; NUCLEOSOME DISRUPTION; IN-VIVO; POSITIONED NUCLEOSOMES; GAL11 PROTEIN; DNA; GENE; COMPLEX	We examine transcriptional activation and chromatin remodeling at the PHO5 promoter in yeast by fusion proteins that are thought to act by recruiting the RNA polymerase II holoenzyme to DNA in the absence of a classic activating region. These hybrid proteins (e.g., Gal11+Pho4 or Gal4(58-97)+Pho4 in the presence of a GAL11P allele) efficiently activated transcription and remodeled chromatin. Similar chromatin remodeling was observed at a PHO5 promoter deleted for TATA and thus unable to support transcription. We conclude that recruitment of the holoenzyme or associated proteins suffices for chromatin remodeling. We also show that the SWI/SNF complex is required neither for efficient transcription of the wild-type PHO5 nor the GAL1 promoters, and we observe nearly complete chromatin remodeling at PHO5 in the absence of Snf2.	UNIV MUNICH,INST PHYSIOL CHEM,D-80336 MUNICH,GERMANY; HARVARD UNIV,DEPT MOL & CELLULAR BIOL,CAMBRIDGE,MA 02138	University of Munich; Harvard University								ALMER A, 1986, EMBO J, V5, P2689, DOI 10.1002/j.1460-2075.1986.tb04552.x; ALMER A, 1986, EMBO J, V5, P2681, DOI 10.1002/j.1460-2075.1986.tb04551.x; Apone LM, 1996, GENE DEV, V10, P2368, DOI 10.1101/gad.10.18.2368; AXELROD JD, 1993, GENE DEV, V7, P857, DOI 10.1101/gad.7.5.857; BARBERIS A, 1995, CELL, V81, P359, DOI 10.1016/0092-8674(95)90389-5; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; Bunker CA, 1996, P NATL ACAD SCI USA, V93, P10820, DOI 10.1073/pnas.93.20.10820; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; CHATTERJEE S, 1995, NATURE, V374, P820, DOI 10.1038/374820a0; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; Farrell S, 1996, GENE DEV, V10, P2359, DOI 10.1101/gad.10.18.2359; FASCHER KD, 1993, J MOL BIOL, V231, P658, DOI 10.1006/jmbi.1993.1317; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HIMMELFARB HJ, 1990, CELL, V63, P1299, DOI 10.1016/0092-8674(90)90425-E; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; JIANG YW, 1992, MOL CELL BIOL, V12, P4503, DOI 10.1128/MCB.12.10.4503; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; KLAGES N, 1995, NATURE, V374, P822, DOI 10.1038/374822a0; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KOLESKE AJ, 1992, CELL, V69, P883, DOI 10.1016/0092-8674(92)90298-Q; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LAURENT BC, 1991, P NATL ACAD SCI USA, V88, P2687, DOI 10.1073/pnas.88.7.2687; LONG RM, 1991, MOL CELL BIOL, V11, P2311, DOI 10.1128/MCB.11.4.2311; MARSOLIER MC, 1995, GENE DEV, V9, P410, DOI 10.1101/gad.9.4.410; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; Polach KJ, 1996, J MOL BIOL, V258, P800, DOI 10.1006/jmbi.1996.0288; POLACH KJ, 1995, J MOL BIOL, V254, P130, DOI 10.1006/jmbi.1995.0606; RUDOLPH H, 1987, P NATL ACAD SCI USA, V84, P1340, DOI 10.1073/pnas.84.5.1340; Sakurai H, 1996, P NATL ACAD SCI USA, V93, P9488, DOI 10.1073/pnas.93.18.9488; SAKURAI H, 1993, P NATL ACAD SCI USA, V90, P8382, DOI 10.1073/pnas.90.18.8382; SCHMID A, 1992, CELL, V71, P853, DOI 10.1016/0092-8674(92)90560-Y; Struhl K, 1996, CELL, V84, P179, DOI 10.1016/S0092-8674(00)80970-8; SUZUKI Y, 1988, MOL CELL BIOL, V8, P4991, DOI 10.1128/MCB.8.11.4991; SUZUKI Y, MOL CELL BIOL, V12, P4806; SVAREN J, 1994, EMBO J, V13, P4856, DOI 10.1002/j.1460-2075.1994.tb06812.x; SVAREN J, 1995, METH MOL G, V6, P153; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; TSUKIYAMA T, 1995, CELL, V83, P1021, DOI 10.1016/0092-8674(95)90217-1; VENTER U, 1994, EMBO J, V13, P4848, DOI 10.1002/j.1460-2075.1994.tb06811.x; VERDIN E, 1993, EMBO J, V12, P3249, DOI 10.1002/j.1460-2075.1993.tb05994.x; VIDAL M, 1991, MOL CELL BIOL, V11, P6317, DOI 10.1128/MCB.11.12.6317; VOGEL K, 1989, MOL CELL BIOL, V9, P2050, DOI 10.1128/MCB.9.5.2050; Wilson CJ, 1996, CELL, V84, P235, DOI 10.1016/S0092-8674(00)80978-2; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90300-S; XIAO H, 1995, MOL CELL BIOL, V15, P5757	49	113	113	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 4	1997	89	1					55	62		10.1016/S0092-8674(00)80182-8	http://dx.doi.org/10.1016/S0092-8674(00)80182-8			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WR685	9094714	Bronze			2022-12-01	WOS:A1997WR68500009
J	Vossler, MR; Yao, H; York, RD; Pan, MG; Rim, CS; Stork, PJS				Vossler, MR; Yao, H; York, RD; Pan, MG; Rim, CS; Stork, PJS			cAMP activates MAP kinase and Elk-1 through a B-Raf- and Rap1-dependent pathway	CELL			English	Article							DEPENDENT PROTEIN-KINASE; NERVE GROWTH-FACTOR; PC12 CELLS; CYCLIC-AMP; CATALYZED PHOSPHORYLATION; IDENTIFICATION; DOMAIN; DIFFERENTIATION; FIBROBLASTS; EXPRESSION	Cyclic adenosine monophosphate (cAMP) has tissue-specific effects on growth, differentiation, and gene expression. We show here that cAMP can activate the transcription factor Elk-1and induce neuronal differentiation of PC12 cells via its activation of the MAP kinase cascade. These cell type-specific actions of cAMP require the expression of the serine/threonine kinase B-Raf and activation of the small G protein Rap1. Rap1, activated by mutation or by the cAMP-dependent protein kinase PKA, is a selective activator of B-Raf and an inhibitor of Raf-1. Therefore, in B-Raf-expressing cells, the activation of Rap1 provides a mechanism for tissue-specific regulation of cell growth and differentiation via MAP kinase.	OREGON HLTH SCI UNIV L474,VOLLUM INST ADV BIOMED RES,PORTLAND,OR 97201; OREGON HLTH SCI UNIV L474,DIV CARDIOL,PORTLAND,OR 97201; OREGON HLTH SCI UNIV L474,DEPT MED,PORTLAND,OR 97201; OREGON HLTH SCI UNIV L474,DEPT MOL MICROBIOL & IMMUNOL,PORTLAND,OR 97201; OREGON HLTH SCI UNIV L474,GRAD PROGRAM NEUROSCI,PORTLAND,OR 97201; OREGON HLTH SCI UNIV L474,DEPT PATHOL,PORTLAND,OR 97201; OREGON HLTH SCI UNIV L474,DEPT CELL & DEV BIOL,PORTLAND,OR 97201	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University								ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ALTSCHULER D, 1993, J BIOL CHEM, V268, P7527; ALTSCHULER DL, 1995, J BIOL CHEM, V270, P10373, DOI 10.1074/jbc.270.18.10373; BARNIER JV, 1995, J BIOL CHEM, V270, P23381, DOI 10.1074/jbc.270.40.23381; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; ERHARDT P, 1995, MOL CELL BIOL, V15, P5524; FAURE M, 1995, MOL BIOL CELL, V6, P1025, DOI 10.1091/mbc.6.8.1025; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; FRODIN M, 1994, J BIOL CHEM, V269, P6207; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; HATA Y, 1991, J BIOL CHEM, V266, P6571; HEIDEMANN SR, 1985, J CELL BIOL, V100, P916, DOI 10.1083/jcb.100.3.916; Jaiswal RK, 1996, J BIOL CHEM, V271, P23626, DOI 10.1074/jbc.271.39.23626; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; Kuroda S, 1996, J BIOL CHEM, V271, P14680, DOI 10.1074/jbc.271.25.14680; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; MOODIE SA, 1994, MOL CELL BIOL, V14, P7153, DOI 10.1128/MCB.14.11.7153; Nassar N, 1996, NAT STRUCT BIOL, V3, P723, DOI 10.1038/nsb0896-723; Ohtsuka T, 1996, J BIOL CHEM, V271, P1258, DOI 10.1074/jbc.271.3.1258; Okada T, 1996, J BIOL CHEM, V271, P4671; OSHIMA M, 1991, J BIOL CHEM, V266, P23753; PAN MG, 1995, ONCOGENE, V11, P2005; Porfiri E, 1996, J BIOL CHEM, V271, P5871, DOI 10.1074/jbc.271.10.5871; RESING KA, 1995, BIOCHEMISTRY-US, V34, P2610, DOI 10.1021/bi00008a027; REUTER CWM, 1995, J BIOL CHEM, V270, P7644, DOI 10.1074/jbc.270.13.7644; SAHYOUN N, 1991, P NATL ACAD SCI USA, V88, P2643, DOI 10.1073/pnas.88.7.2643; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; YAMAMORI B, 1995, J BIOL CHEM, V270, P11723, DOI 10.1074/jbc.270.20.11723; YAO H, 1995, J BIOL CHEM, V270, P20748, DOI 10.1074/jbc.270.35.20748; YOSHIDA Y, 1992, MOL CELL BIOL, V12, P3407, DOI 10.1128/MCB.12.8.3407; YOUNG SW, 1994, FEBS LETT, V338, P212, DOI 10.1016/0014-5793(94)80367-6	44	928	953	1	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 4	1997	89	1					73	82		10.1016/S0092-8674(00)80184-1	http://dx.doi.org/10.1016/S0092-8674(00)80184-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WR685	9094716	Bronze			2022-12-01	WOS:A1997WR68500011
J	Rabkin, CS; Janz, S; Lash, A; Coleman, AE; Musaba, E; Liotta, L; Biggar, RJ; Zhuang, ZP				Rabkin, CS; Janz, S; Lash, A; Coleman, AE; Musaba, E; Liotta, L; Biggar, RJ; Zhuang, ZP			Monoclonal origin of multicentric Kaposi's sarcoma lesions	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							X-CHROMOSOME INACTIVATION; SPINDLE CELLS; CULTURE; VIRUS; BLOOD	Background Kaposi's sarcoma has features of both hyperplastic proliferation and neoplastic growth. Multiple lesions, in which spindle cells are prominent, often arise synchronously over widely dispersed areas. We tested the hypothesis that the spindle cells in these multicentric lesions originate from a single clone of precursor cells. Methods To determine whether Kaposi's sarcoma is a monoclonal disorder, we assessed the methylation patterns of the androgen-receptor gene (HUMARA) in multiple lesions from women with the acquired immunodeficiency syndrome. In polyclonal tissues, about half the copies of each HUMARA allele are methylated, whereas in cells derived from a single clone all the copies of only one allele are methylated. To minimize contamination by normal DNA, we used microdissection to isolate areas composed primarily of spindle cells, the putative tumor cells. Results Eight patients with a total of 32 tumors were studied. Of these tumors, 28 had highly unbalanced methylation patterns (i.e., predominant methylation of one HUMARA allele). In all the tumors that had unbalanced methylation from a given patient, the same allele predominated. Conclusions These data indicate that Kaposi's sarcoma is a disseminated monoclonal cancer and that the changes that permit the clonal outgrowth of spindle cells occur before the disease spreads. (C) 1997, Massachusetts Medical Society.	NCI,GENET LAB,BETHESDA,MD 20892; NCI,PATHOL LAB,BETHESDA,MD 20892; UNIV TEACHING HOSP,LUSAKA,ZAMBIA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Zambia	Rabkin, CS (corresponding author), NCI,VIRAL EPIDEMIOL BRANCH,EPN 434,BETHESDA,MD 20892, USA.			Lash, Alex/0000-0003-3787-1590				ALLEN RC, 1992, AM J HUM GENET, V51, P1229; BROWNING PJ, 1994, BLOOD, V84, P2711, DOI 10.1182/blood.V84.8.2711.bloodjournal8482711; DICTOR M, 1991, ANAL QUANT CYTOL, V13, P201; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; FIALKOW PJ, 1970, LANCET, V1, P384; FUKUNAGA M, 1990, CANCER-AM CANCER SOC, V66, P758, DOI 10.1002/1097-0142(19900815)66:4<758::AID-CNCR2820660427>3.0.CO;2-H; GALE RE, 1994, BLOOD, V83, P2899, DOI 10.1182/blood.V83.10.2899.2899; Jacobson Lisa P., 1995, Current Opinion in Oncology, V7, P450, DOI 10.1097/00001622-199509000-00011; KAAYA EE, 1992, EUR J CANCER, V28A, P1890, DOI 10.1016/0959-8049(92)90030-6; KAAYA EE, 1995, J ACQ IMMUN DEF SYND, V10, P295; KOSTIANOVSKY M, 1992, ULTRASTRUCT PATHOL, V16, P629, DOI 10.3109/01913129209023752; LUNARDIISKANDAR Y, 1995, JNCI-J NATL CANCER I, V87, P974, DOI 10.1093/jnci/87.13.974; Moore PS, 1996, J VIROL, V70, P549, DOI 10.1128/JVI.70.1.549-558.1996; MULLER JR, 1995, P NATL ACAD SCI USA, V92, P6577, DOI 10.1073/pnas.92.14.6577; NADJI M, 1981, ARCH PATHOL LAB MED, V105, P274; RAABTRAUB N, 1986, CELL, V47, P883, DOI 10.1016/0092-8674(86)90803-2; RABKIN CS, 1995, CLIN CANCER RES, V1, P257; SAFAI B, 1992, AIDS ETIOLOGY DIAGNO, P209; SAIKEVYCH IA, 1988, ARCH PATHOL LAB MED, V112, P825; VOGELSTEIN B, 1985, SCIENCE, V227, P642, DOI 10.1126/science.2982210; WILLMAN CL, 1994, NEW ENGL J MED, V331, P154, DOI 10.1056/NEJM199407213310303; Zhuang ZP, 1996, CANCER RES, V56, P1961; ZHUANG ZP, 1995, AM J PATHOL, V146, P620	23	179	185	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 3	1997	336	14					988	993		10.1056/NEJM199704033361403	http://dx.doi.org/10.1056/NEJM199704033361403			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR385	9077377				2022-12-01	WOS:A1997WR38500003
J	Dickens, BM				Dickens, BM			Legal aspects of the dementias	LANCET			English	Article											Dickens, BM (corresponding author), UNIV TORONTO,FAC LAW,84 QUEENS PK,TORONTO,ON M5S 2C5,CANADA.							Battin Margaret Pabst, 1994, LEAST WORST DEATH; BRAZIER M, 1992, MED PATIENTS LAW, P100; *BRIT MED ASS, 1993, MED ETH TOD ITS PRAC, P160; CULVER CM, 1982, PHILOS MED, P143; GRENE R, 1992, SEXUAL SCI LAW; Jones Michael A, 1996, Med Law Int, V2, P107	6	5	5	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 29	1997	349	9056					948	950		10.1016/S0140-6736(96)07513-7	http://dx.doi.org/10.1016/S0140-6736(96)07513-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WR254	9093265				2022-12-01	WOS:A1997WR25400047
J	Hayward, TL; Hanner, MS				Hayward, TL; Hanner, MS			Ground-based thermal infrared observations of comet Hale-Bopp (C/1995 O1) during 1996	SCIENCE			English	Article							EMISSION; GRAINS	Thermal infrared (IR) imaging and spectroscopy of comet Hale-Bopp (C/1995 O1) during June, August, and September 1996 traced the development of the dust coma several months before perihelion, Images revealed nightly variations in the brightness of the inner coma from 1 to 12 June that were correlated with the appearance of a northward-pointing jet. The central IR flux increased by a factor of 8 between 1 June and 30 September, and the September data showed IR jets that corresponded to similar structures that were visible in reflected sunlight at shorter wavelengths. At all epochs, 8- to 13-micrometer spectra of the central coma revealed a strong silicate emission feature, including an 11.2-micrometer feature indicative of crystalline olivine, even when the comet was at a heliocentric distance of 4.1 astronomical units.	CALTECH,JET PROP LAB,PASADENA,CA 91109	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	Hayward, TL (corresponding author), CORNELL UNIV,CTR RADIOPHYS & SPACE RES,ITHACA,NY 14853, USA.							AHEARN MF, 1984, ASTRON J, V89, P570; BREGMAN JD, 1987, ASTRON ASTROPHYS, V187, P616; CAMPINS H, 1989, ASTROPHYS J, V341, P1059, DOI 10.1086/167563; HANNER MS, 1994, ASTROPHYS J, V425, P274, DOI 10.1086/173984; HANNER MS, 1994, ICARUS, V112, P490, DOI 10.1006/icar.1994.1200; HANNER MS, 1986, ICARUS, V67, P51, DOI 10.1016/0019-1035(86)90173-9; HAYWARD TL, 1993, P SOC PHOTO-OPT INS, V1946, P334, DOI 10.1117/12.158686; LYNCH DK, 1992, ICARUS, V100, P197, DOI 10.1016/0019-1035(92)90029-7; MORRIS CS, 1993, ASTRON J, V105, P1537, DOI 10.1086/116533; RUSSELL RW, 6448 IAU	10	42	42	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 28	1997	275	5308					1907	1909		10.1126/science.275.5308.1907	http://dx.doi.org/10.1126/science.275.5308.1907			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WQ513	9072961				2022-12-01	WOS:A1997WQ51300036
J	Watanabe, Y; Yamada, N; Yokoi, H; Fujiwara, Y; Mokuno, H; Daida, H; Yamaguchi, H				Watanabe, Y; Yamada, N; Yokoi, H; Fujiwara, Y; Mokuno, H; Daida, H; Yamaguchi, H			Relationship between HLA-C locus and restenosis after coronary artery balloon angioplasty	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objectives.-To determine the relationship between human leukocyte antigen (HLA) loci and restenosis after percutaneous transluminal coronary angioplasty (PTCA). Design and Setting.-Cross-sectional study in patients treated by PTCA at Juntendo University Hospital, Tokyo, Japan. Patients.-A total of 65 patients (58 males and 7 females) with coronary artery stenosis who were consecutively selected between October 1994 and June 1995. Main Outcome Measures.-Significant relationships between the restenosis and the HLA-Cw1. Results.-Among HLA-C locus, Cw1 was negatively related to restenosis (multivariate adjusted odds ratio, 0.19; 95% confidence interval, 0.06-0.63; P=.007). Conclusions-In HLA typing, Cw1 may be a useful marker for the prediction of restenosis after PTCA.	UNIV TOKYO, DEPT INTERNAL MED 3, TOKYO 113, JAPAN; JUNTENDO UNIV, DEPT CARDIOL, TOKYO, JAPAN	University of Tokyo; Juntendo University								FALK K, 1993, P NATL ACAD SCI USA, V90, P12005, DOI 10.1073/pnas.90.24.12005; JONASSON L, 1986, ARTERIOSCLEROSIS, V6, P131, DOI 10.1161/01.ATV.6.2.131; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; STEELE PM, 1985, CIRC RES, V57, P105, DOI 10.1161/01.RES.57.1.105; TERASAKI PI, 1978, AM J CLIN PATHOL, V69, P103; TSUJI K, 1991, P 11 INT HIST WORKSH, P1065	6	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 26	1997	277	12					983	984		10.1001/jama.277.12.983	http://dx.doi.org/10.1001/jama.277.12.983			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN992	9091671				2022-12-01	WOS:A1997WN99200033
J	Rubinfeld, B; Robbins, P; ElGamil, M; Albert, I; Porfiri, E; Polakis, P				Rubinfeld, B; Robbins, P; ElGamil, M; Albert, I; Porfiri, E; Polakis, P			Stabilization of beta-catenin by genetic defects in melanoma cell lines	SCIENCE			English	Article							SIGNAL-TRANSDUCTION; ADHESION; EXPRESSION; CADHERIN; PROTEIN; PRODUCT; WNT-1	Signal transduction by beta-catenin involves its posttranslational stabilization and downstream coupling to the Lef and Tcf transcription factors, Abnormally high amounts of beta-catenin were detected in 7 of 26 human melanoma cell lines, Unusual messenger RNA splicing and missense mutations in the beta-catenin gene (CTNNB1) that result in stabilization of the protein were identified in six of the lines, and the adenomatous polyposis coli tumor suppressor protein (APC) was altered or missing in two others, In the APC-deficient cells, ectopic expression of wild-type APC eliminated the excess beta-catenin, Cells with stabilized beta-catenin contained a constitutive beta-catenin-Lef-1 complex, Thus, genetic defects that result in up-regulation of beta-catenin may play a role in melanoma progression.	ONYX PHARMACEUT,RICHMOND,CA 94806; NCI,SURG BRANCH,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)				Rubinfeld, Bonnee/0000-0001-9861-6775	NATIONAL CANCER INSTITUTE [R43CA069931] Funding Source: NIH RePORTER; NCI NIH HHS [1R43CA69931] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BRADLEY RS, 1993, J CELL BIOL, V123, P1857, DOI 10.1083/jcb.123.6.1857; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; FUNAYAMA N, 1995, J CELL BIOL, V128, P959, DOI 10.1083/jcb.128.5.959; GUMBINER BM, 1995, CURR OPIN CELL BIOL, V7, P634, DOI 10.1016/0955-0674(95)80104-9; HINCK L, 1994, J CELL BIOL, V124, P729, DOI 10.1083/jcb.124.5.729; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; KLINGENSMITH J, 1994, DEV BIOL, V166, P396, DOI 10.1006/dbio.1994.1325; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; MUNEMITSU S, 1994, CANCER RES, V54, P3676; Munemitsu S, 1996, MOL CELL BIOL, V16, P4088; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Orsulic S, 1996, J CELL BIOL, V134, P1283, DOI 10.1083/jcb.134.5.1283; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; PEIFER M, 1995, TRENDS CELL BIOL, V5, P224, DOI 10.1016/S0962-8924(00)89015-7; Prieve MG, 1996, J BIOL CHEM, V271, P7654, DOI 10.1074/jbc.271.13.7654; Robbins PF, 1996, J EXP MED, V183, P1185, DOI 10.1084/jem.183.3.1185; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; RUBINFELD B, UNPUB; TOPALIAN SL, 1989, J IMMUNOL, V142, P3714; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443	22	1116	1176	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 21	1997	275	5307					1790	1792		10.1126/science.275.5307.1790	http://dx.doi.org/10.1126/science.275.5307.1790			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WP056	9065403				2022-12-01	WOS:A1997WP05600041
J	Swerdlow, DL; Griffin, PM				Swerdlow, DL; Griffin, PM			Duration of faecal shedding of Escherichia coli O157:H7 among children in day-care centres	LANCET			English	Editorial Material							HEMOLYTIC-UREMIC SYNDROME				Swerdlow, DL (corresponding author), CTR DIS CONTROL & PREVENT,FOODBOME & DIARRHOEAL DIS BRANCH,ATLANTA,GA 30333, USA.							BELONGIA EA, 1993, JAMA-J AM MED ASSOC, V269, P883, DOI 10.1001/jama.269.7.883; BENENSON AS, 1995, CONTROL COMMUNICABLE, P141; BOYCE TG, 1995, NEW ENGL J MED, V333, P364, DOI 10.1056/NEJM199508103330608; *CDCP, 1996, ABCS SAF HLTH CHILD; CHAPMAN PA, 1994, J MED MICROBIOL, V40, P424, DOI 10.1099/00222615-40-6-424; KARCH H, 1995, J CLIN MICROBIOL, V33, P1602, DOI 10.1128/JCM.33.6.1602-1605.1995; PAI CH, 1988, J INFECT DIS, V157, P1054, DOI 10.1093/infdis/157.5.1054; Shah S, 1996, CLIN INFECT DIS, V23, P835, DOI 10.1093/clinids/23.4.835; TARR PI, 1990, J INFECT DIS, V162, P553, DOI 10.1093/infdis/162.2.553; WELLS JG, 1983, J CLIN MICROBIOL, V18, P512, DOI 10.1128/JCM.18.3.512-520.1983	10	30	32	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 15	1997	349	9054					745	746		10.1016/S0140-6736(05)60196-1	http://dx.doi.org/10.1016/S0140-6736(05)60196-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN124	9074570				2022-12-01	WOS:A1997WN12400005
J	Kirschvink, JL; Maine, AT; Vali, H				Kirschvink, JL; Maine, AT; Vali, H			Paleomagnetic evidence of a low-temperature origin of carbonate in the Martian meteorite ALH84001	SCIENCE			English	Article							MAGNETIC-PROPERTIES; NATURAL PYRRHOTITE; SNC METEORITES; GRAIN-SIZE; BEHAVIOR; MARS	Indirect evidence for life on Mars has been reported from the study of meteorite ALH84001. The formation temperature of the carbonates is controversial; some estimates suggest 20 degrees to 80 degrees C, whereas others exceed 650 degrees C. Paleomagnetism can be used to distinguish between these possibilities because heating can remagnetize ferrimagnetic minerals. Study of two adjacent pyroxene grains from the crushed zone of ALH84001 shows that each possesses a stable natural remanent magnetization (NRM), implying that Mars had a substantial magnetic field when the grains cooled. However, NRM directions from these particles differ, implying that the meteorite has not been heated significantly since the formation of the internal crushed zone about 4 billion years ago. The carbonate globules postdate this brecciation, and thus formed at low temperatures.	MCGILL UNIV,DEPT EARTH & PLANETARY SCI,MONTREAL,PQ H3A 2A7,CANADA	McGill University	Kirschvink, JL (corresponding author), CALTECH,DIV GEOL & PLANETARY SCI,PASADENA,CA 91125, USA.		Vali, Hojatollah/F-3511-2012	Vali, Hojatollah/0000-0003-3464-9943				Ash RD, 1996, NATURE, V380, P57, DOI 10.1038/380057a0; Bradley JP, 1996, GEOCHIM COSMOCHIM AC, V60, P5149, DOI 10.1016/S0016-7037(96)00383-3; Butler R.F., 1992, PALEOMAGNETISM MAGNE; CISOWSKI S, 1981, PHYS EARTH PLANET IN, V26, P56, DOI 10.1016/0031-9201(81)90097-2; CISOWSKI SM, 1986, GEOCHIM COSMOCHIM AC, V50, P1043, DOI 10.1016/0016-7037(86)90386-8; COLLINSON DW, 1986, EARTH PLANET SC LETT, V77, P159, DOI 10.1016/0012-821X(86)90157-3; DEKKERS MJ, 1988, PHYS EARTH PLANET IN, V52, P376, DOI 10.1016/0031-9201(88)90129-X; DEKKERS MJ, 1989, PHYS EARTH PLANET IN, V57, P266, DOI 10.1016/0031-9201(89)90116-7; GOODING JL, 1992, ICARUS, V99, P28, DOI 10.1016/0019-1035(92)90168-7; GRIFFITH LL, 1995, NATURE, V377, P406, DOI 10.1038/377406a0; Harvey RP, 1996, NATURE, V382, P49, DOI 10.1038/382049a0; JAGOUTZ E, 1994, METEORITICS, V29, P478; JOHNSON HP, 1975, GEOPHYS J ROY ASTR S, V41, P1, DOI 10.1111/j.1365-246X.1975.tb05480.x; Kirschvink J. L., 1983, BIOMAGNETISM, P501; KIRSCHVINK JL, 1980, GEOPHYS J ROY ASTR S, V62, P699, DOI 10.1111/j.1365-246X.1980.tb02601.x; MANN S, 1988, J EXP BIOL, V140, P35; MCFADDEN PL, 1988, EARTH PLANET SC LETT, V87, P161, DOI 10.1016/0012-821X(88)90072-6; McKay DS, 1996, SCIENCE, V273, P924, DOI 10.1126/science.273.5277.924; MITTLEFEHLDT DW, 1994, METEORITICS, V29, P214, DOI 10.1111/j.1945-5100.1994.tb00673.x; NYQUIST LE, 1995, LUNAR PLANET SCI, V26, P1065; O'Reilly W, 1984, ROCK MINERAL MAGNETI; ROMANEK CS, 1994, NATURE, V372, P655, DOI 10.1038/372655a0; RUNCORN SK, 1996, GEOCHIM COSMOCHIM AC, V60, P1206; Shearer CK, 1996, GEOCHIM COSMOCHIM AC, V60, P2921, DOI 10.1016/0016-7037(96)00165-2; SWINDLE TD, 1995, GEOCHIM COSMOCHIM AC, V59, P793, DOI 10.1016/0016-7037(94)00359-T; TANAKA H, 1995, GEOPHYS J INT, V120, P97, DOI 10.1111/j.1365-246X.1995.tb05913.x; THOMAS KL, 1996, LUNAR PLANET SCI, V27, P1327; TREIMAN AH, 1995, METEORITICS, V30, P294, DOI 10.1111/j.1945-5100.1995.tb01127.x; VALI H, 1991, IRON BIOMINERALS, P97; WACIHWA M, 1996, METEORIT PLANET SCI, V31, pA145	30	102	107	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 14	1997	275	5306					1629	1633		10.1126/science.275.5306.1629	http://dx.doi.org/10.1126/science.275.5306.1629			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WN123	9054354				2022-12-01	WOS:A1997WN12300042
J	Nyyssonen, K; Parviainen, MT; Salonen, R; Tuomilehto, J; Salonen, JT				Nyyssonen, K; Parviainen, MT; Salonen, R; Tuomilehto, J; Salonen, JT			Vitamin C deficiency and risk of myocardial infarction: Prospective population study of men from eastern Finland	BRITISH MEDICAL JOURNAL			English	Article							LOW-DENSITY-LIPOPROTEIN; CORONARY HEART-DISEASE; FINNISH MEN; LIPID-PEROXIDATION; PHYSICAL-ACTIVITY; BLOOD-PRESSURE; E CONSUMPTION; OXIDIZED LDL; SERUM COPPER; DIETARY FATS	Objective: To examine the association between plasma vitamin C concentrations and the risk of acute myocardial infarction. Design: Prospective population study. Setting: Eastern Finland, Subjects: 1605 randomly selected men aged 42, 48, 54, or 60 who did not have either symptomatic coronary heart disease or ischaemia on exercise testing at entry to the Kuopio ischaemic heart disease risk factor study in between 1984 and 1989. Main outcome measures: Number of acute myocardial infarctions; fasting plasma vitamin C concentrations at baseline. Results: 70 of the men had a fatal or non-fatal myocardial infarction between March 1984 and December 1992. 91 men had vitamin C deficiency (plasma ascorbate <11.4 mu mol/l, or 2.0 mg/l), of whom 12 (13.2%) had a myocardial infarction; 1514 men were not deficient in vitamin C, of whom 58 (3.8%) had a myocardial infarction. In a Cox proportional hazards model adjusted for age, year of examination, and season of the year examined (August to October v rest of the year) men who had vitamin C deficiency had a relative risk of acute myocardial infarction of 3.5 (95% confidence interval 1.8 to 6.7, P = 0.0002) compared with those who were not deficient In another model adjusted additionally for the strongest risk factors for myocardial infarction and for dietary intakes of tea, fibre, carotene, and saturated fats men with a plasma ascorbate concentration <11.4 mu mol/l had a relative risk of 2.5 (1.3 to 5.2, P = 0.0095) compared with men with higher plasma vitamin C concentrations. Conclusion: Vitamin C deficiency, as assessed by low plasma ascorbate concentration, is a risk factor for coronary heart disease.	UNIV KUOPIO,PUBL HLTH RES INST,KUOPIO 70211,FINLAND; KUOPIO UNIV HOSP,DEPT CLIN CHEM,KUOPIO 70211,FINLAND; NATL PUBL HLTH INST,DEPT EPIDEMIOL & HLTH PROMOT,SF-00300 HELSINKI,FINLAND	University of Eastern Finland; Kuopio University Hospital; University of Eastern Finland; Finland National Institute for Health & Welfare								BJORKHEM I, 1991, ARTERIOSCLER THROMB, V11, P15, DOI 10.1161/01.ATV.11.1.15; CAREW TE, 1987, P NATL ACAD SCI USA, V84, P7725, DOI 10.1073/pnas.84.21.7725; COX DR, 1972, J R STAT SOC B, V34, P187; Eichholzer M, 1992, EXS, V62, P398; ENSTROM JE, 1992, EPIDEMIOLOGY, V3, P194, DOI 10.1097/00001648-199205000-00003; FREI B, 1989, P NATL ACAD SCI USA, V86, P6377, DOI 10.1073/pnas.86.16.6377; FREI B, 1990, ADV EXP MED BIOL, V264, P155; FREI B, 1991, AM J CLIN NUTR, V54, pS1113, DOI 10.1093/ajcn/54.6.1113s; FREYSCHUSS A, 1993, J CLIN INVEST, V91, P1282, DOI 10.1172/JCI116326; GALE CR, 1995, BRIT MED J, V310, P1563, DOI 10.1136/bmj.310.6994.1563; GARRY PJ, 1982, AM J CLIN NUTR, V36, P332, DOI 10.1093/ajcn/36.2.332; GEY KF, 1993, CLIN INVESTIGATOR, V71, P3, DOI 10.1007/BF00210955; HALLIWELL B, 1994, LANCET, V344, P721, DOI 10.1016/S0140-6736(94)92211-X; HARATS D, 1990, ATHEROSCLEROSIS, V85, P47, DOI 10.1016/0021-9150(90)90181-H; IHANAINEN M, 1989, NUTR RES, V9, P597, DOI 10.1016/S0271-5317(89)80126-5; JIALAL I, 1991, J CLIN INVEST, V87, P597, DOI 10.1172/JCI115035; KAGAN VE, 1992, J LIPID RES, V33, P385; KAPLAN GA, 1990, BRIT MED J, V301, P1121, DOI 10.1136/bmj.301.6761.1121; KAUHANEN J, 1992, BEHAV MED, V18, P121, DOI 10.1080/08964289.1992.9936962; KNEKT P, 1994, AM J EPIDEMIOL, V139, P1180, DOI 10.1093/oxfordjournals.aje.a116964; LAKKA TA, 1994, NEW ENGL J MED, V330, P1549, DOI 10.1056/NEJM199406023302201; LAKKA TA, 1992, AM J EPIDEMIOL, V136, P806, DOI 10.1093/aje/136.7.806; MAGGI E, 1993, CORONARY ARTERY DIS, V4, P1119, DOI 10.1097/00019501-199312000-00014; NAKAZONO K, 1991, P NATL ACAD SCI USA, V88, P10045, DOI 10.1073/pnas.88.22.10045; PACKER JE, 1979, NATURE, V278, P737, DOI 10.1038/278737a0; PARVIAINEN MT, 1986, J LIQ CHROMATOGR, V9, P2185, DOI 10.1080/01483918608074142; PARVIAINEN MT, 1990, INT J VITAM NUTR RES, V60, P47; REGNSTROM J, 1992, LANCET, V339, P1183, DOI 10.1016/0140-6736(92)91129-V; RETSKY KL, 1995, BBA-LIPID LIPID MET, V1257, P279, DOI 10.1016/0005-2760(95)00089-U; RIEMERSMA RA, 1991, LANCET, V337, P1, DOI 10.1016/0140-6736(91)93327-6; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; SALONEN JT, 1994, NEW ENGL J MED, V331, P1159; SALONEN JT, 1988, AM J CLIN NUTR, V48, P1226, DOI 10.1093/ajcn/48.5.1226; SALONEN JT, 1991, AM J EPIDEMIOL, V134, P268, DOI 10.1093/oxfordjournals.aje.a116080; SALONEN JT, 1991, BRIT MED J, V302, P756, DOI 10.1136/bmj.302.6779.756; SALONEN JT, 1995, CIRCULATION, V91, P645, DOI 10.1161/01.CIR.91.3.645; SALONEN JT, 1991, CIRCULATION, V84, P129, DOI 10.1161/01.CIR.84.1.129; SALONEN JT, 1988, ANN CLIN RES, V20, P46; SALONEN JT, 1992, LANCET, V339, P883, DOI 10.1016/0140-6736(92)90926-T; SALONEN JT, 1991, ANN MED, V23, P295, DOI 10.3109/07853899109148063; SALONEN JT, 1992, CIRCULATION, V86, P803, DOI 10.1161/01.CIR.86.3.803; SALONEN JT, 1995, FREE RADICALS LIPOPR; SALONEN R, 1994, LIFE CHEM REPORTS, V12, P65; *SPSS, 1993, SPSS UNIX; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; TUOMILEHTO J, 1992, EUR HEART J, V13, P577, DOI 10.1093/oxfordjournals.eurheartj.a060219; *WHO, 1989, INT J EPIDEMIOL S1, V18, pS38; WILLIAMS RJ, 1992, ATHEROSCLEROSIS, V94, P153, DOI 10.1016/0021-9150(92)90240-H	49	170	176	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 1	1997	314	7081					634	638		10.1136/bmj.314.7081.634	http://dx.doi.org/10.1136/bmj.314.7081.634			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WL418	9066474	Green Published			2022-12-01	WOS:A1997WL41800021
J	Hunink, MGM; Goldman, L; Tosteson, ANA; Mittleman, MA; Goldman, PA; Williams, LW; Tsevat, J; Weinstein, MC				Hunink, MGM; Goldman, L; Tosteson, ANA; Mittleman, MA; Goldman, PA; Williams, LW; Tsevat, J; Weinstein, MC			The recent decline in mortality from coronary heart disease, 1980-1990 - The effect of secular trends in risk factors and treatment	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HOSPITAL CARDIAC-ARREST; DENSITY LIPOPROTEIN CHOLESTEROL; NUTRITION EXAMINATION SURVEYS; MYOCARDIAL-INFARCTION; UNITED-STATES; CARDIOVASCULAR-DISEASE; NATIONAL-HEALTH; ALAMEDA COUNTY; SURVIVAL; MINNESOTA	Objective.-To examine whether secular trends in risk factor levels and improvements in treatment can account for the observed decline in coronary heart disease mortality in the United States from 1980 to 1990 and to analyze the proportional contribution of these changes. Data Sources.-Literature review, US statistics, health surveys, and ongoing clinical trials. Study Selection.-Data representative of the US situation nationwide reported in adequate detail. Data Extraction.-A computer-simulation state-transition model of the US population between the ages of 35 and 84 years was developed to forecast coronary mortality. The input variables were estimated such that the combination of values led to an adequate agreement with reported coronary mortality figures. Subsequently, secular trends were modeled. Data Synthesis.-Actual coronary mortality in 1990 was 34% (127 000 deaths) lower than would be predicted if risk factor levels, case-fatality rates, and event rates in those with and without coronary disease remained the same as in 1980. When secular changes in these factors were included in the model, predicted coronary mortality in 1990 was within 3% (in 000 deaths) of the observed mortality and explained 92% of the decline; only 25% of the decline was explained by primary prevention, while 29% was explained by secondary reduction in risk factors in patients with coronary disease and 43% by other improvements in treatment in patients with coronary disease. Conclusions. These results suggest that primary and Secondary risk factor reductions explain about 50% of the striking decline in coronary mortality in the United States between 1980 and 1990 but that more than 70% of the overall decline in mortality has occurred among patients with coronary disease.	HARVARD UNIV, SCH PUBL HLTH, DEPT HLTH POLICY & MANAGEMENT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, NEW ENGLAND DEACONESS HOSP, SCH MED, DEPT MED, BOSTON, MA 02215 USA; UNIV CALIF SAN FRANCISCO, SCH MED, DEPT MED, SAN FRANCISCO, CA 94143 USA; DARTMOUTH HITCHCOCK MED CTR, DEPT CLIN RES, LEBANON, NH 03766 USA; UNIV CINCINNATI, MED CTR, DIV GEN INTERNAL MED, CINCINNATI, OH 45267 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; University of California System; University of California San Francisco; Dartmouth College; University System of Ohio; University of Cincinnati	Hunink, MGM (corresponding author), UNIV GRONINGEN, DEPT HLTH SCI, ANTONIUS DEUSINGLAAN 1, NL-9713 AV GRONINGEN, NETHERLANDS.			Mittleman, Murray/0000-0001-9788-7274	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS006258] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046315] Funding Source: NIH RePORTER; AHRQ HHS [R01HS06258] Funding Source: Medline; NHLBI NIH HHS [1RO1HL46315] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; BONNEUX L, 1994, AM J PUBLIC HEALTH, V84, P20, DOI 10.2105/AJPH.84.1.20; BURKE GL, 1989, INT J EPIDEMIOL, V18, pS73; COHN BA, 1988, AM J EPIDEMIOL, V127, P1143, DOI 10.1093/oxfordjournals.aje.a114908; EISENBERG MS, 1990, ANN EMERG MED, V19, P179, DOI 10.1016/S0196-0644(05)81805-0; EISENBERG MS, 1990, ANN EMERG MED, V19, P1249, DOI 10.1016/S0196-0644(05)82283-8; EISENBERG MS, 1982, NEW ENGL J MED, V306, P1340, DOI 10.1056/NEJM198206033062206; ELVEBACK LR, 1985, MAYO CLIN PROC, V60, P305, DOI 10.1016/S0025-6196(12)60537-0; ELVEBACK LR, 1986, MAYO CLIN PROC, V61, P896, DOI 10.1016/S0025-6196(12)62612-3; FEINLEIB M, 1989, CIRCULATION, V79, P13; FIORE MC, 1989, JAMA-J AM MED ASSOC, V261, P49, DOI 10.1001/jama.261.1.49; GOLDMAN L, 1984, ANN INTERN MED, V101, P825, DOI 10.7326/0003-4819-101-6-825; GOLDMAN L, 1991, JAMA-J AM MED ASSOC, V265, P1145, DOI 10.1001/jama.265.9.1145; GORDON D J, 1990, Journal of Drug Development, V3, P11; GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8; IEZZONI LI, 1988, ANN INTERN MED, V109, P745, DOI 10.7326/0003-4819-109-9-745; JACOBS D, 1992, CIRCULATION, V86, P1046, DOI 10.1161/01.CIR.86.3.1046; JAMROZIK K, 1989, MED J AUSTRALIA, V150, P14; JOHNSON CL, 1993, JAMA-J AM MED ASSOC, V269, P3002, DOI 10.1001/jama.269.23.3002; KAPLAN GA, 1988, AM J EPIDEMIOL, V127, P1131, DOI 10.1093/oxfordjournals.aje.a114907; KJELSBERG MO, 1990, JAMA-J AM MED ASSOC, V263, P1795; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; LANGA KM, 1993, NEW ENGL J MED, V329, P1784, DOI 10.1056/NEJM199312093292407; LONGSTRETH WT, 1990, JAMA-J AM MED ASSOC, V264, P2109, DOI 10.1001/jama.264.16.2109; MCGOVERN PG, 1992, JAMA-J AM MED ASSOC, V268, P753; MCGOVERN PG, 1992, CIRCULATION, V85, P172, DOI 10.1161/01.CIR.85.1.172; McGovern PG, 1996, NEW ENGL J MED, V334, P884, DOI 10.1056/NEJM199604043341403; MYERBURG RJ, 1980, AM J MED, V68, P568, DOI 10.1016/0002-9343(80)90307-1; *NAT CTR HLTH STAT, 1994, VITA STAT US 1990, V2; *NAT CTR HLTH STAT, 1987, US DEP HLTH HUM S 10, V164; *NAT CTR HLTH STAT, 1989, VIT HLTH STAT, V10; *NAT CTR HLTH STAT, 1985, VIT STAT US 1980, V2; *NAT CTR HLTH STAT, 1991, VIT STAT US 1988, V2; *NAT CTR HLTH STAT, 1989, VIT STAT US 1986, V2; *NAT CTR HLTH STAT, 1990, NAT HLTH NUTR EX SUR; *NAT CTR HLTH STAT, 1992, MMWR-MORBID MORTAL W, V41, P354; *NAT HEART LUNG BL, 1990, MORB COR HEART DIS U, P45; PEDERSEN TR, 1994, LANCET, V344, P1383; POCOCK SJ, 1989, BMJ-BRIT MED J, V298, P998, DOI 10.1136/bmj.298.6679.998; SCHAFFER WA, 1975, NEW ENGL J MED, V293, P259, DOI 10.1056/NEJM197508072930601; SEMPOS C, 1988, AM J PUBLIC HEALTH, V78, P1422, DOI 10.2105/AJPH.78.11.1422; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P373, DOI 10.1056/NEJM199108083250601; SYTKOWSKI PA, 1990, NEW ENGL J MED, V322, P1635, DOI 10.1056/NEJM199006073222304; TOSTESON ANA, 1990, AM J PUBLIC HEALTH, V80, P1481, DOI 10.2105/AJPH.80.12.1481; TSEVAT J, 1991, CIRCULATION, V83, P1194, DOI 10.1161/01.CIR.83.4.1194; *US BUR CENS, 1990, CURR POP REP US P25, V1057; *US DEPT HHS, 1992, VIT HLTH STAT, V13; *US DEPT HHS, 1991, VIT HLTH STAT, V13; *US DEPT HHS, 1988, VIT HLTH STAT, V13; *US DEPT HHS, NIH PUBL; VALENZUELA TD, 1992, JAMA-J AM MED ASSOC, V267, P272, DOI 10.1001/jama.267.2.272; WEINSTEIN MC, 1987, AM J PUBLIC HEALTH, V77, P1417, DOI 10.2105/AJPH.77.11.1417; WILCOXGOK VL, 1991, MED CARE, V29, P104, DOI 10.1097/00005650-199102000-00003	55	503	514	0	17	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 19	1997	277	7					535	542		10.1001/jama.277.7.535	http://dx.doi.org/10.1001/jama.277.7.535			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WH297	9032159				2022-12-01	WOS:A1997WH29700028
J	Xu, WQ; Harrison, SC; Eck, MJ				Xu, WQ; Harrison, SC; Eck, MJ			Three-dimensional structure of the tyrosine kinase c-Src	NATURE			English	Article							AFFINITY PHOSPHOTYROSYL PEPTIDE; SH3 DOMAIN; CRYSTAL-STRUCTURE; TRANSFORMING PROTEIN; HOMOLOGY-2 DOMAIN; BINDING-SITE; P60C-SRC; IDENTIFICATION; ACTIVATION; MECHANISM	The structure of a large fragment of the c-Src tyrosine kinase, comprising the regulatory and kinase domains and the carboxy-terminal tail, has been determined at 1.7 Angstrom resolution in a closed, inactive state. Interactions among domains, stabilized by binding of the phosphorylated tail to the SH2 domain, lock the molecule in a conformation that simultaneously disrupts the kinase active site and sequesters the binding surfaces of the SH2 and SH3 domains. The structure shows how appropriate cellular signals, or transforming mutations in v-Src, could break these interactions to produce an open, active kinase.	HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOL PHARMACOL, BOSTON, MA 02115 USA; HARVARD UNIV, CHILDRENS HOSP, SCH MED, LAB MOL MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MICROBIOL & MOL GENET, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PEDIAT, BOSTON, MA 02115 USA; HOWARD HUGHES MED INST, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute				Xu, Wenqing/0000-0002-2884-3101				Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; BISHOP JM, 1985, CELL, V42, P23, DOI 10.1016/S0092-8674(85)80098-2; Boerner RJ, 1996, BIOCHEMISTRY-US, V35, P9519, DOI 10.1021/bi960248u; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; BRUNGER A, 1992, XPLOR VERSION 3 0 SY; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; ELLIS B, 1994, J CELL BIOCH B S, V18, P276; ERPEL T, 1995, EMBO J, V14, P963, DOI 10.1002/j.1460-2075.1995.tb07077.x; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; HAYSTEAD CMM, 1993, EUR J BIOCHEM, V214, P459, DOI 10.1111/j.1432-1033.1993.tb17942.x; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; JONES TA, 1989, CRYSTALLOGRAPHIC COM; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; Koegl M, 1995, ONCOGENE, V11, P2317; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KURIYAN J, IN PRESS ANN REV BIO; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LEVY JB, 1986, P NATL ACAD SCI USA, V83, P4228, DOI 10.1073/pnas.83.12.4228; LEVY JB, 1989, MOL CELL BIOL, V9, P3332, DOI 10.1128/MCB.9.8.3332; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; MADHUSUDAN, 1994, PROTEIN SCI, V3, P176; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OKADA M, 1993, J BIOL CHEM, V268, P18070; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PAYNE G, 1993, P NATL ACAD SCI USA, V90, P4902, DOI 10.1073/pnas.90.11.4902; Potts W M, 1988, Oncogene Res, V3, P343; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SUPERTIFURGA G, 1995, BIOESSAYS, V17, P321, DOI 10.1002/bies.950170408; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; 1994, ATA CRYSTALLOGR D, V50, P760	52	1219	1252	2	48	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 13	1997	385	6617					595	602		10.1038/385595a0	http://dx.doi.org/10.1038/385595a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WH294	9024657				2022-12-01	WOS:A1997WH29400040
J	KauffmanZeh, A; RodriguezViciana, P; Ulrich, E; Gilbert, C; Coffer, P; Downward, J; Evan, G				KauffmanZeh, A; RodriguezViciana, P; Ulrich, E; Gilbert, C; Coffer, P; Downward, J; Evan, G			Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB	NATURE			English	Article							NUCLEOTIDE DISSOCIATION STIMULATOR; PROTEIN-KINASE-B; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; PLASMA-MEMBRANE; ACTIVATION; DOMAIN; GTPASE; LOCALIZATION; AKT	The viability of vertebrate cells depends on survival factors which activate signal transduction pathways that suppress apoptosis. Defects in anti-apoptotic signalling pathways are implicated in many pathologies including cancer, in which apoptosis induced by deregulated oncogenes must be forestalled for a tumour to become established. Phosphatidylinositol-3-kinase (PI(3)K) is involved in the intracellular signal transduction of many receptors and has been implicated in the transduction of survival signals in neuronal cells(1). We therefore examined the role of PI(3)K, its upstream effector Ras(2), and its putative downstream protein kinase effecters PKB/Akt(3,4) and p70(S6K) (ref. 5) in the modulation of apoptosis induced in fibroblasts by the oncoprotein c-Myc. Here we show that Ras activation of PI(3)K suppresses c-Myc-induced apoptosis through the activation of PKB/Akt but not p70(S6K). However, we also found that Ras is an effective promoter of apoptosis, through the Raf pathway. Thus Ras activates contradictory intracellular pathways that modulate cell viability. Induction of apoptosis by Ras may be an important factor in limiting the expansion of somatic cells that sustain oncogenic ras mutations.	IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND; UNIV UTRECHT HOSP,DEPT PULM DIS,NL-3584 CX UTRECHT,NETHERLANDS	Cancer Research UK; Utrecht University; Utrecht University Medical Center			Coffer, Paul/AAF-7970-2020; Downward, Julian/A-3251-2012; Coffer, Paul J/A-5769-2009	Downward, Julian/0000-0002-2331-4729				ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CADWALLADER KA, 1994, MOL CELL BIOL, V14, P4722, DOI 10.1128/MCB.14.7.4722; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; FLORES VJ, 1995, J BIOL CHEM, V270, P22473; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Park SH, 1995, ONCOGENE, V11, P2349; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; SEELY BL, 1995, J BIOL CHEM, V270, P19151, DOI 10.1074/jbc.270.32.19151; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; Takahashi A, 1996, CURR OPIN GENET DEV, V6, P50, DOI 10.1016/S0959-437X(96)90010-6; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; VICIANA PR, 1994, NATURE, V370, P5527; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WHITE MA, 1995, CELL, V80, P5533; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	30	1029	1071	0	33	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 6	1997	385	6616					544	548		10.1038/385544a0	http://dx.doi.org/10.1038/385544a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG235	9020362				2022-12-01	WOS:A1997WG23500050
J	Yu, Y; Li, W; Su, K; Yussa, M; Han, W; Perrimon, N; Pick, L				Yu, Y; Li, W; Su, K; Yussa, M; Han, W; Perrimon, N; Pick, L			The nuclear hormone receptor Ftz-F1 is a cofactor for the Drosophila homeodomain protein Ftz	NATURE			English	Article							GENE FUSHI-TARAZU; DNA-BINDING SPECIFICITY; EXPRESSION; ACTIVATION; REGULATOR; ELEMENT	Homeobox genes specify cell fate and positional identity in embryos throughout the animal kingdom(1). Paradoxically, although each has a specific function in vivo, the in vitro DNA-binding specificities of homeodomain proteins are overlapping and relatively weak. A current model is that homeodomain proteins interact with cofactors that increase specificity in vivo(2,3). Here we use a native binding site for the homeodomain protein Fushi tarazu (Ftz) to isolate Ftz-F1, a protein of the nuclear hormone-receptor superfamily and a new Ftz cofactor. Ftz and Ftz-F1 are present in a complex in Drosophila embryos. Ftz-F1 facilitates the binding of Ftz to DNA, allowing interactions with weak-affinity sites at concentrations of Ftz that alone bind only high-affinity sites. Embryos lacking Ftz-F1 display ftz-like pair-rule cuticular defects. This phenotype is a result of abnormal ftz function because it is expressed but fails to activate downstream target genes. Cooperative interaction between homeodomain proteins and cofactors of different classes may serve as a general mechanism to increase HOX protein specificity and to broaden the range of target sites they regulate.	CUNY MT SINAI SCH MED,BROOKDALE CTR MOL BIOL,NEW YORK,NY 10029; HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT GENET,BOSTON,MA 02115	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Harvard University; Harvard Medical School; Howard Hughes Medical Institute			Li, Willis X/AAL-7212-2020; Li, Willis/ABC-5695-2020	Li, Willis X/0000-0001-9041-7341; Li, Willis/0000-0001-9041-7341; Perrimon, Norbert/0000-0001-7542-472X				AYER S, 1993, NUCLEIC ACIDS RES, V21, P1619, DOI 10.1093/nar/21.7.1619; Chou TB, 1996, GENETICS, V144, P1673; Copeland JWR, 1996, NATURE, V379, P162, DOI 10.1038/379162a0; FITZPATRICK VD, 1989, NATURE, V337, P666, DOI 10.1038/337666a0; FURUKUBOTOKUNAGA K, 1992, GENE DEV, V6, P1082, DOI 10.1101/gad.6.6.1082; HAN W, 1993, MOL CELL BIOL, V13, P5549, DOI 10.1128/MCB.13.9.5549; HAN W, UNPUB J BIOL CHEM; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; HIROMI Y, 1985, CELL, V43, P603, DOI 10.1016/0092-8674(85)90232-6; HIROMI Y, 1987, CELL, V50, P963, DOI 10.1016/0092-8674(87)90523-X; Hyduk D, 1996, GENETICS, V142, P481; IKEDA Y, 1993, MOL ENDOCRINOL, V7, P852, DOI 10.1210/me.7.7.852; KRAUSE HM, 1988, GENE DEV, V2, P1021, DOI 10.1101/gad.2.8.1021; LAUGHON A, 1991, BIOCHEMISTRY-US, V30, P11357, DOI 10.1021/bi00112a001; LAVORGNA G, 1991, SCIENCE, V252, P848, DOI 10.1126/science.1709303; MAIER D, 1990, EMBO J, V9, P3957, DOI 10.1002/j.1460-2075.1990.tb07616.x; Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; OHNO CK, 1994, MOL CELL BIOL, V14, P3166, DOI 10.1128/MCB.14.5.3166; Perrimon N, 1996, GENETICS, V144, P1681; PICK L, 1990, GENE DEV, V4, P1224, DOI 10.1101/gad.4.7.1224; RAUSKOLB C, 1993, CELL, V74, P1101, DOI 10.1016/0092-8674(93)90731-5; SCHIER AF, 1992, NATURE, V356, P804, DOI 10.1038/356804a0; STRUHL G, 1985, NATURE, V318, P677, DOI 10.1038/318677a0; TREISMAN J, 1989, CELL, V59, P553; UEDA H, 1990, GENE DEV, V4, P624, DOI 10.1101/gad.4.4.624; WAKIMOTO BT, 1984, DEV BIOL, V102, P147, DOI 10.1016/0012-1606(84)90182-9; YU Y, 1995, MECH DEVELOP, V50, P163, DOI 10.1016/0925-4773(94)00333-I	28	163	164	1	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 6	1997	385	6616					552	555		10.1038/385552a0	http://dx.doi.org/10.1038/385552a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG235	9020364				2022-12-01	WOS:A1997WG23500052
J	Lipkin, WI				Lipkin, WI			European consensus on viral encephalitis	LANCET			English	Editorial Material							HERPES-SIMPLEX ENCEPHALITIS				Lipkin, WI (corresponding author), UNIV CALIF IRVINE,DEPT NEUROL,LAB NEUROVIROL,IRVINE,CA 92697, USA.		Lipkin, W. Ian/ABE-6216-2020	Lipkin, W. Ian/0000-0002-8768-9386				Cinque P, 1996, J NEUROL NEUROSUR PS, V61, P339, DOI 10.1136/jnnp.61.4.339; DAVIS LE, 1979, ANN NEUROL, V5, P2, DOI 10.1002/ana.410050103; DRACHMAN DA, 1962, ARCH NEUROL-CHICAGO, V7, P45, DOI 10.1001/archneur.1962.04210010051005; LAKEMAN FD, 1995, J INFECT DIS, V171, P857, DOI 10.1093/infdis/171.4.857; NAHMIAS AJ, 1982, J INFECT DIS, V145, P829, DOI 10.1093/infdis/145.6.829; OLSON LC, 1967, NEW ENGL J MED, V277, P1271, DOI 10.1056/NEJM196712142772401; SKOLDENBERG B, 1984, LANCET, V2, P707; WHITLEY RJ, 1977, NEW ENGL J MED, V297, P289, DOI 10.1056/NEJM197708112970601; WHITLEY RJ, 1991, INFECT CENTRAL NERVO, V1, P41	9	24	25	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 1	1997	349	9048					299	300		10.1016/S0140-6736(05)62821-8	http://dx.doi.org/10.1016/S0140-6736(05)62821-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF794	9024370				2022-12-01	WOS:A1997WF79400005
J	Platt, FM; Neises, GR; Reinkensmeier, G; Townsend, MJ; Perry, VH; Proia, RL; Winchester, B; Dwek, RA; Butters, TD				Platt, FM; Neises, GR; Reinkensmeier, G; Townsend, MJ; Perry, VH; Proia, RL; Winchester, B; Dwek, RA; Butters, TD			Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin	SCIENCE			English	Article							GLYCOLIPID BIOSYNTHESIS; REPLACEMENT THERAPY; TARGETED DISRUPTION; GAUCHER DISEASE; HEXA GENE	The glycosphingolipid (GSL) lysosomal storage diseases result from the inheritance of defects in the genes encoding the enzymes required for catabolism of GSLs within lysosomes. A strategy for the treatment of these diseases, based on an inhibitor of GSL biosynthesis N-butyldeoxynojirimycin, was evaluated in a mouse model of Tay-Sachs disease. When Tay-Sachs mice were treated with N-butyldeoxynojirimycin, the accumulation of G(M2) in the brain was prevented, with the number of storage neurons and the quantity of ganglioside stored per cell markedly reduced. Thus, limiting the biosynthesis of the substrate (G(M2)) for the defective enzyme (beta-hexosaminidase A) prevents GSL accumulation and the neuropathology associated with its lysosomal storage.	MONSANTO CO,ST LOUIS,MO 63198; UNIV OXFORD,DEPT PHARMACOL,OXFORD OX1 3QT,ENGLAND; NIDDKD,NIH,BETHESDA,MD 20892; INST CHILD HLTH,LONDON WC1N 1EH,ENGLAND	Monsanto; University of Oxford; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of London; University College London	Platt, FM (corresponding author), UNIV OXFORD,GLYCOBIOL INST,DEPT BIOCHEM,S PARKS RD,OXFORD OX1 3QU,ENGLAND.		Platt, Frances/G-1004-2010; Perry, V. Hugh/Y-2935-2019; Proia, Richard L/A-7908-2012	Platt, Frances/0000-0001-7614-0403; Proia, Richard/0000-0003-0456-1270				BARTON NW, 1991, NEW ENGL J MED, V324, P1464, DOI 10.1056/NEJM199105233242104; BEUTLER E, 1992, SCIENCE, V256, P794, DOI 10.1126/science.1589760; BEUTLER E, 1991, BLOOD, V78, P1183; BUTTERS T, UNPUB; FISCHL MA, 1994, J ACQ IMMUN DEF SYND, V7, P139; NEUFELD EF, 1991, ANNU REV BIOCHEM, V60, P257, DOI 10.1146/annurev.biochem.60.1.257; PLATT FM, 1995, TRENDS GLYCOSCI GLYC, V7, P495, DOI 10.4052/tigg.7.495; PLATT FM, 1994, J BIOL CHEM, V269, P27108; PLATT FM, 1994, J BIOL CHEM, V269, P8362; PLATT FM, UNPUB; Sandhoff K, 1989, METABOLIC BASIS INHE, VII, P1807; SANGO K, 1995, NAT GENET, V11, P170, DOI 10.1038/ng1095-170; TANIIKE M, 1995, ACTA NEUROPATHOL, V89, P296; YAMANAKA S, 1994, P NATL ACAD SCI USA, V91, P9975, DOI 10.1073/pnas.91.21.9975	14	301	334	1	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 18	1997	276	5311					428	431		10.1126/science.276.5311.428	http://dx.doi.org/10.1126/science.276.5311.428			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WU477	9103204				2022-12-01	WOS:A1997WU47700044
J	Brown, KE; Tisdale, J; Barrett, AJ; Dunbar, CE; Young, NS				Brown, KE; Tisdale, J; Barrett, AJ; Dunbar, CE; Young, NS			Hepatitis-associated aplastic anemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MARROW TRANSPLANTATION; SUPPRESSOR LYMPHOCYTES-T; NON-A; NON-B; ANTITHYMOCYTE GLOBULIN; LIVER-TRANSPLANTATION; VIRAL-HEPATITIS; GENE-EXPRESSION; FAILURE; CYCLOSPORINE	Background Hepatitis-associated aplastic anemia is a variant of aplastic anemia in which aplastic anemia follows an acute attack of hepatitis. The aplastic anemia, however, is often fatal if untreated. To characterize the illness, investigate the role of hepatitis viruses, and assess the response to immunosuppressive treatment, we studied patients with the syndrome who were referred to the National Institutes of Health (NIH). Methods Standard hematologic and biochemical tests and measurements of bone marrow cellularity were used to monitor the patients' response to treatment. Serum was assayed for antibodies and antigens related to hepatitis A, B, and C viruses and for the RNA of hepatitis C and GB virus C by the polymerase chain reaction. All patients were treated with antithymocyte globulin and cyclosporine. Results Ten patients with hepatitis-associated aplastic anemia were referred to the NIH between 1990 and 1996; all had the typical features of this syndrome. There was evidence of activated CD8 T lymphocytes in the blood. Serologic tests for hepatitis A, B, and C viruses were negative; RNA of hepatitis C virus was undetectable in all patients, but RNA of GB virus C was detected in three patients. Seven of the patients responded to intensive immunosuppressive treatment; the three who did not respond all died within one year of treatment, two from complications of stem-cell or marrow transplantation. Conclusions The hepatitis of the hepatitis-associated aplastic anemia does not appear to be caused by any of the known hepatitis viruses. We recommend immunosuppressive treatment for patients who do not have an HLA-matched related donor available for bone marrow transplantation. Several features of the syndrome suggest that it is mediated by immunopathologic mechanisms. (C) 1997, Massachusetts Medical Society.			Brown, KE (corresponding author), NHLBI,HEMATOL BRANCH,NIH,BLDG 10,RM 7C218,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.			Dunbar, Cynthia/0000-0002-7645-838X				BOTTIGER LE, 1972, ACTA MED SCAND, V192, P323; Bradley B A, 1992, Clin Transpl, P91; CAMITTA BM, 1974, BLOOD, V43, P473, DOI 10.1182/blood.V43.4.473.473; CATTRAL MS, 1994, HEPATOLOGY, V20, P813, DOI 10.1002/hep.1840200407; CHAMPLIN RE, 1989, BLOOD, V73, P606; CHISARI FV, 1995, ANNU REV IMMUNOL, V13, P29, DOI 10.1146/annurev.immunol.13.1.29; FOMINA L G, 1955, Sov Med, V19, P28; Gluckman E, 1979, Haematol Blood Transfus, V24, P171; GLUCKMAN E, 1992, BLOOD, V79, P269; HAGLER L, 1975, MEDICINE, V54, P139, DOI 10.1097/00005792-197554020-00003; HIBBS JR, 1992, JAMA-J AM MED ASSOC, V267, P2051; HIBBS JR, 1992, AM J TROP MED HYG, V46, P564, DOI 10.4269/ajtmh.1992.46.564; KAGAN WA, 1976, P NATL ACAD SCI USA, V73, P2890, DOI 10.1073/pnas.73.8.2890; KERNAN NA, 1993, NEW ENGL J MED, V328, P593, DOI 10.1056/NEJM199303043280901; KOJIMA S, 1989, BRIT J HAEMATOL, V71, P147, DOI 10.1111/j.1365-2141.1989.tb06289.x; Leary TP, 1996, J VIROL METHODS, V56, P119, DOI 10.1016/0166-0934(95)01956-1; LIANG DC, 1990, BRIT J HAEMATOL, V74, P487, DOI 10.1111/j.1365-2141.1990.tb06339.x; LIAW YF, 1995, HEPATOLOGY, V22, P1368, DOI 10.1002/hep.1840220505; Linnen J, 1996, SCIENCE, V271, P505, DOI 10.1126/science.271.5248.505; LORENZ E, 1955, Wien Med Wochenschr, V105, P19; MACIEJEWSKI JP, 1994, EXP HEMATOL, V22, P1102; Margolis D, 1996, BRIT J HAEMATOL, V94, P65, DOI 10.1046/j.1365-2141.1996.d01-1772.x; MARY JY, 1990, BLOOD, V75, P1646; MAY WS, 1993, BONE MARROW TRANSPL, V11, P459; NAKAO S, 1992, BLOOD, V79, P2532; NISTICO A, 1994, ANN INTERN MED, V120, P463, DOI 10.7326/0003-4819-120-6-199403150-00003; PASSWEG JR, IN PRESS BLOOD; POL S, 1990, ANN INTERN MED, V113, P435; ROSENFELD SJ, 1995, BLOOD, V85, P3058, DOI 10.1182/blood.V85.11.3058.bloodjournal85113058; SALLIE R, 1994, J HEPATOL, V20, P580, DOI 10.1016/S0168-8278(05)80343-5; SHANNON K, 1990, CLIN PEDIATR, V29, P25, DOI 10.1177/000992289002900103; Shimokawa T, 1990, Rinsho Ketsueki, V31, P1836; SIMONS JN, 1995, NAT MED, V1, P564, DOI 10.1038/nm0695-564; STORB R, 1994, BLOOD, V84, P941, DOI 10.1182/blood.V84.3.941.941; TZAKIS AG, 1988, NEW ENGL J MED, V319, P393, DOI 10.1056/NEJM198808183190702; YOUNG NS, 1986, BRIT J HAEMATOL, V62, P1, DOI 10.1111/j.1365-2141.1986.tb02893.x; ZOUMBOS NC, 1985, NEW ENGL J MED, V312, P257, DOI 10.1056/NEJM198501313120501	37	210	225	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 10	1997	336	15					1059	1064		10.1056/NEJM199704103361504	http://dx.doi.org/10.1056/NEJM199704103361504			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WT161	9091802				2022-12-01	WOS:A1997WT16100004
J	Gray, J; Close, PS; Briggs, SP; Johal, GS				Gray, J; Close, PS; Briggs, SP; Johal, GS			A novel suppressor of cell death in plants encoded by the Lls1 gene of maize	CELL			English	Article							DISEASE RESISTANCE; SEARCH TOOL; MUTAGENESIS; SYSTEM; MIMICS	The lls1 (lethal leaf spot1) locus of maize is defined by a recessive mutation characterized by the initiation, in a developmentally programmed manner, of necrotic lesions that expand to kill leaves cell autonomously. The loss-of-function nature of all lls1 mutants implies that the Lls1 gene is required to limit the spread of cell death in mature leaves. We have cloned the Lls1 gene by tagging with Mutator, a transposable element system in maize, and we show that it encodes a novel protein highly conserved in plants. Two consensus binding motifs of aromatic ring-hydroxylating dioxygenases are present in the predicted LLS1 protein, suggesting that it may function to degrade a phenolic mediator of cell death.	HICKMAN HIGH SCH,COLUMBIA,MO 65202; PIONEER HI BRED INT INC,JOHNSTON,IA 50131	DuPont; Pioneer Hi-Bred International, Inc.	Gray, J (corresponding author), UNIV MISSOURI,DEPT AGRON,COLUMBIA,MO 65211, USA.		Gray, John/O-7744-2018; Johal, Guri/F-5056-2017	Gray, John/0000-0003-1352-2900; Johal, Guri/0000-0001-8101-8410				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; APPEL HM, 1993, J CHEM ECOL, V19, P1521, DOI 10.1007/BF00984895; BENNETZEN JL, 1993, CRIT REV PLANT SCI, V12, P57, DOI 10.1080/713608042; Bent AF, 1996, PLANT CELL, V8, P1757, DOI 10.1105/tpc.8.10.1757; CHEN Z, 1993, SCIENCE, V242, P883; Close P, 1995, MAIZE GENET NEWSLETT, V69, P48; Dangl JL, 1996, PLANT CELL, V8, P1793, DOI 10.1105/tpc.8.10.1793; Dellaporta S.L., 1983, PLANT MOL BIOL REP, V1, P19, DOI [10.1007/BF02712670, DOI 10.1007/BF02712670]; DIETRICH RA, 1994, CELL, V77, P565, DOI 10.1016/0092-8674(94)90218-6; DIXON RA, 1995, PLANT CELL, V7, P1085, DOI 10.1105/tpc.7.7.1085; Durner J, 1996, J BIOL CHEM, V271, P28492, DOI 10.1074/jbc.271.45.28492; Freialdenhoven A, 1996, PLANT CELL, V8, P5, DOI 10.1105/tpc.8.1.5; GAHAN PB, 1981, CELL DEATH BIOL PATH, P145; GARDINER JM, 1993, GENETICS, V134, P917; GREENBERG JT, 1993, PLANT J, V4, P327, DOI 10.1046/j.1365-313X.1993.04020327.x; GREENBERG JT, 1994, CELL, V77, P551, DOI 10.1016/0092-8674(94)90217-8; HammondKosack KE, 1996, PLANT CELL, V8, P1773, DOI 10.1105/tpc.8.10.1773; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Hu GS, 1996, PLANT CELL, V8, P1367, DOI 10.1105/tpc.8.8.1367; HULBERT SH, 1991, MOL GEN GENET, V226, P377, DOI 10.1007/BF00260649; Jabs T, 1996, SCIENCE, V273, P1853, DOI 10.1126/science.273.5283.1853; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Jiang HY, 1996, J BACTERIOL, V178, P3133, DOI 10.1128/jb.178.11.3133-3139.1996; JOHAL GS, 1995, BIOESSAYS, V17, P685, DOI 10.1002/bies.950170805; JOHAL GS, 1994, MAYDICA, V39, P69; JOHAL GS, 1992, SCIENCE, V258, P985, DOI 10.1126/science.1359642; Jones AM, 1996, TRENDS PLANT SCI, V1, P114, DOI 10.1016/S1360-1385(96)90005-9; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Kosuge T., 1983, GENETIC ENG PLANTS A, P431, DOI [10.1007/978-1-4684-4544-2_29, DOI 10.1007/978-1-4684-4544-2_29, DOI 10.1007/978-1-4684-4544-2_]; MASON JR, 1992, ANNU REV MICROBIOL, V46, P277, DOI 10.1146/annurev.mi.46.100192.001425; MCKNIGHT SL, 1981, CELL, V25, P385, DOI 10.1016/0092-8674(81)90057-X; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OBANNI M, 1994, PHYSIOL MOL PLANT P, V44, P379, DOI 10.1016/S0885-5765(05)80050-5; PRYOR T, 1987, TRENDS GENET, V3, P157, DOI 10.1016/0168-9525(87)90217-4; Reinbothe S, 1996, CELL, V86, P703, DOI 10.1016/S0092-8674(00)80144-0; ROBERTSON DS, 1978, MUTAT RES, V51, P21, DOI 10.1016/0027-5107(78)90004-0; Rouault TA, 1996, TRENDS BIOCHEM SCI, V21, P174, DOI 10.1016/0968-0004(96)10024-4; Ryals JA, 1996, PLANT CELL, V8, P1809, DOI 10.1105/tpc.8.10.1809; STASKAWICZ BJ, 1995, SCIENCE, V268, P661, DOI 10.1126/science.7732374; STELLAR H, 1995, SCIENCE, V257, P1445; ULLSTRUP AJ, 1967, PHYTOPATHOLOGY, V57, P1282; WALBOT V, 1992, ANNU REV PLANT PHYS, V43, P49, DOI 10.1146/annurev.pp.43.060192.000405; WEYMAN K, 1996, PLANT CELL, V12, P2013; WOLTER M, 1993, MOL GEN GENET, V239, P122, DOI 10.1007/BF00281610; WORLEY KC, 1995, GENOME RES, V5, P173, DOI 10.1101/gr.5.2.173	45	202	246	3	22	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 4	1997	89	1					25	31		10.1016/S0092-8674(00)80179-8	http://dx.doi.org/10.1016/S0092-8674(00)80179-8			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WR685	9094711	Bronze			2022-12-01	WOS:A1997WR68500006
J	Nightingale, SL				Nightingale, SL			FDA call for applications for use of certain oral contraceptives for postcoital emergency contraception	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		1997, FED REG         0225, V62, P8610	1	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 2	1997	277	13					1029	1029						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WQ089	9091680				2022-12-01	WOS:A1997WQ08900006
J	Korinek, V; Barker, N; Morin, PJ; vanWichen, D; deWeger, R; Kinzler, KW; Vogelstein, B; Clevers, H				Korinek, V; Barker, N; Morin, PJ; vanWichen, D; deWeger, R; Kinzler, KW; Vogelstein, B; Clevers, H			Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC(-/-) colon carcinoma	SCIENCE			English	Article							TUMOR-SUPPRESSOR PROTEIN; HMG-BOX; ALPHA-ENHANCER; ASSOCIATION; FAMILY	The adenomatous polyposis coli (APC) tumor suppressor protein binds to beta-catenin, a protein recently shown to interact with Tcf and Lef transcription factors, The gene encoding hTcf-4, a Tcf family member that is expressed in colonic epithelium, was cloned and characterized, hTcf-4 transactivates transcription only when associated with beta-catenin. Nuclei of APC(-/-) colon carcinoma cells were found to contain a stable beta-catenin-hTcf-4 complex that was constitutively active, as measured by transcription of a Tcf reporter gene. Reintroduction of APC removed beta-catenin from hTcf-4 and abrogated the transcriptional transactivation, Constitutive transcription of Tcf target genes, caused by loss of APC function, may be a crucial event in the early transformation of colonic epithelium.	UNIV UTRECHT HOSP, DEPT IMMUNOL, NL-3508 GA UTRECHT, NETHERLANDS; JOHNS HOPKINS ONCOL CTR, HOWARD HUGHES MED INST, BALTIMORE, MD 21231 USA; UNIV UTRECHT HOSP, DEPT PATHOL, NL-3508 GA UTRECHT, NETHERLANDS	Utrecht University; Utrecht University Medical Center; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins Medicine; Utrecht University; Utrecht University Medical Center			Barker, Nick/A-5535-2011; Barker, Nick/AAE-9833-2021; Barker, Nick/AAS-2774-2020; Korinek, Vladimir/G-6348-2014	Barker, Nick/0000-0003-3566-4475; Korinek, Vladimir/0000-0002-9777-4664	NATIONAL CANCER INSTITUTE [R37CA057345, R01CA057345] Funding Source: NIH RePORTER; NCI NIH HHS [CA57345] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; CASTROP J, 1992, NUCLEIC ACIDS RES, V20, P611, DOI 10.1093/nar/20.3.611; Clevers HC, 1996, IMMUNOL TODAY, V17, P336, DOI 10.1016/0167-5699(96)10019-0; GUMBINER BM, 1995, CURR OPIN CELL BIOL, V7, P634, DOI 10.1016/0955-0674(95)80104-9; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KORINEK V, UNPUB; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; MORIN P, UNPUB; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; RUBINFELD B, 1995, J BIOL CHEM, V270, P5549, DOI 10.1074/jbc.270.10.5549; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; VANDEWETERING M, 1993, EMBO J, V12, P3847, DOI 10.1002/j.1460-2075.1993.tb06063.x; vandeWetering M, 1996, MOL CELL BIOL, V16, P745; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; VanHoffen E, 1996, AM J PATHOL, V149, P1991; WATERMAN ML, 1991, GENE DEV, V5, P656, DOI 10.1101/gad.5.4.656	22	2850	2991	2	80	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 21	1997	275	5307					1784	1787		10.1126/science.275.5307.1784	http://dx.doi.org/10.1126/science.275.5307.1784			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WP056	9065401				2022-12-01	WOS:A1997WP05600039
J	Kaupmann, K; Huggel, K; Heid, J; Flor, PJ; Bischoff, S; Mickel, SJ; McMaster, G; Angst, C; Bittiger, H; Froestl, W; Bettler, B				Kaupmann, K; Huggel, K; Heid, J; Flor, PJ; Bischoff, S; Mickel, SJ; McMaster, G; Angst, C; Bittiger, H; Froestl, W; Bettler, B			Expression cloning of GABA(B) receptors uncovers similarity to metabotropic glutamate receptors	NATURE			English	Article							CENTRAL-NERVOUS-SYSTEM; AMINO-ACID-TRANSPORT; RAT CEREBRAL-CORTEX; HIGH-AFFINITY; B-RECEPTORS; NUCLEOTIDE-SEQUENCES; PHYSIOLOGICAL-ROLE; BINDING-PROTEINS; BRAIN; SITES	GABA (gamma-amino-butyric acid), the principal inhibitory neurotransmitter in the brain, signals through ionotropic (GABA(A)/ GABA(C)) and metabotropic (GABA(B)) receptor systems. Here we report the cloning of GABA(B) receptors. Photoaffinity labelling experiments suggest that the cloned receptors correspond to two highly conserved GABA(B) receptor forms present in the vertebrate nervous system. The cloned receptors negatively couple to adenylyl cyclase and show sequence similarity to the metabotropic receptors for the excitatory neurotransmitter L-glutamate.	NOVARTIS PHARMA INC,RES DEPT,THERAPEUT AREA NERVOUS SYST,CH-4002 BASEL,SWITZERLAND	Novartis			Mickel, Stuart/B-1169-2008; bettler, bernhard/AAO-8018-2020; Mickel, Stuart J./AAN-9800-2020	Mickel, Stuart J./0000-0003-4508-7069; Bettler, Bernhard/0000-0003-0842-8207; Kaupmann, Klemens/0000-0001-8903-2508				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AUCHAMPACH JA, 1994, GENE, V145, P251, DOI 10.1016/0378-1119(94)90015-9; BISCHOFF S, IN PRESS J COMP NEUR; BITTIGER H, 1993, TRENDS PHARMACOL SCI, V14, P391, DOI 10.1016/0165-6147(93)90056-P; BONANNO G, 1992, J PHARMACOL EXP THER, V262, P114; BONANNO G, 1993, TRENDS PHARMACOL SCI, V14, P259, DOI 10.1016/0165-6147(93)90124-3; BORMANN J, 1995, TRENDS NEUROSCI, V18, P515, DOI 10.1016/0166-2236(95)98370-E; BOWERY NG, 1993, ANNU REV PHARMACOL, V33, P109, DOI 10.1146/annurev.pa.33.040193.000545; BOWERY NG, 1992, ARZNEIMITTELFORSCH, V42-1, P215; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; CHU DCM, 1990, NEUROSCIENCE, V34, P341, DOI 10.1016/0306-4522(90)90144-S; Cunningham MD, 1996, BRAIN RES, V720, P220, DOI 10.1016/0006-8993(96)00120-5; DAVIES CH, 1991, NATURE, V349, P609, DOI 10.1038/349609a0; DEERAUSQUIN G, 1992, MOL PHARMACOL, V42, P407; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DUTAR P, 1988, NATURE, V332, P156, DOI 10.1038/332156a0; FROESTL W, 1995, J MED CHEM, V38, P3297, DOI 10.1021/jm00017a015; FROESTL W, 1996, PHARM REV COMMUN, V8, P127; GEMIGNANI A, 1994, MOL PHARMACOL, V46, P558; Gomeza J, 1996, J BIOL CHEM, V271, P2199, DOI 10.1074/jbc.271.4.2199; HILL DR, 1984, J NEUROCHEM, V42, P652, DOI 10.1111/j.1471-4159.1984.tb02732.x; HILL DR, 1981, NATURE, V290, P149, DOI 10.1038/290149a0; HOURCADE D, 1988, J EXP MED, V168, P1255, DOI 10.1084/jem.168.4.1255; KARBON EW, 1985, MOL PHARMACOL, V27, P53; Kenakin T, 1996, PHARMACOL REV, V48, P413; KERR DIB, 1995, PHARMACOL THERAPEUT, V67, P187, DOI 10.1016/0163-7258(95)00016-A; Kerr DIB, 1996, DRUG DISCOV TODAY, V1, P371, DOI 10.1016/1359-6446(96)10034-9; Knight AR, 1996, NEUROPHARMACOLOGY, V35, P703, DOI 10.1016/0028-3908(96)84642-9; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANDICK R, 1985, J BIOL CHEM, V260, P8257; LANZA M, 1993, EUR J PHARMACOL, V237, P191, DOI 10.1016/0014-2999(93)90268-M; LAW SF, 1993, J BIOL CHEM, V268, P10721; MISGELD U, 1995, PROG NEUROBIOL, V46, P423, DOI 10.1016/0301-0082(95)00012-K; NAKANISHI S, 1994, NEURON, V13, P1031, DOI 10.1016/0896-6273(94)90043-4; NAKAYASU H, 1993, J BIOL CHEM, V268, P8658; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; OHNISHI K, 1990, J BIOCHEM-TOKYO, V107, P202, DOI 10.1093/oxfordjournals.jbchem.a123026; OLPE HR, 1993, EXPERIENTIA, V49, P542, DOI 10.1007/BF01955159; OLPE HR, 1990, EUR J PHARMACOL, V187, P27, DOI 10.1016/0014-2999(90)90337-6; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; SEEBURG PH, 1993, TRENDS NEUROSCI, V16, P359, DOI 10.1016/0166-2236(93)90093-2; SMITH GB, 1995, TRENDS PHARMACOL SCI, V16, P162, DOI 10.1016/S0165-6147(00)89009-4; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; STUART GJ, 1992, J PHYSIOL-LONDON, V447, P675, DOI 10.1113/jphysiol.1992.sp019023; TURGEON SM, 1994, NEUROSCIENCE, V62, P601, DOI 10.1016/0306-4522(94)90392-1; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WOJCIK WJ, 1990, NEUROPHARMACOLOGY, V29, P969, DOI 10.1016/0028-3908(90)90150-P; WOJCIK WJ, 1984, MOL PHARMACOL, V25, P24; Zuiderwijk M, 1996, EUR J PHARMACOL, V307, P275, DOI 10.1016/0014-2999(96)00284-1	51	819	885	1	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 20	1997	386	6622					239	246		10.1038/386239a0	http://dx.doi.org/10.1038/386239a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WP003	9069281				2022-12-01	WOS:A1997WP00300041
J	Donahue, JG; Weiss, ST; Livingston, JM; Goetsch, MA; Greineder, DK; Platt, R				Donahue, JG; Weiss, ST; Livingston, JM; Goetsch, MA; Greineder, DK; Platt, R			Inhaled steroids and the risk of hospitalization for asthma	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AIRWAY HYPERRESPONSIVENESS; CORTICOSTEROID-THERAPY; CHILDHOOD ASTHMA; FATAL ASTHMA; BUDESONIDE; DISEASE; ADULTS	Objective.-To determine if anti-inflammatory treatment for asthma reduces the risk of asthma hospitalization. Design.-Retrospective cohort study. Setting.-A health maintenance organization (HMO) in eastern Massachusetts. Participants.-Members of the HMO who were identified during the period October 1991 through September 1994 as having a diagnosis of asthma using a computerized medical record system. Main Outcome.-Hospitalization for asthma. Results.-Of the 16941 eligible persons, 742 (4.4%) were hospitalized for asthma, The overall relative risk (RR) of hospitalization among those who received inhaled steroids was 0.5 (95% confidence interval [CI], 0.4-0.6) after adjustment for beta-agonist dispensing. Additional adjustment for age, race, other asthma medications, and amount and type of ambulatory care for asthma did not substantially affect the inverse relationship between use of inhaled steroids and hospitalization. Cromolyn was similarly associated with reduced risk, especially among children (RR,0.8; 95% CI, 0.7-0.9). In contrast, increasing beta-agonist use was associated with increasing hospitalization risk even after adjustment for other factors and medications. The steroid-associated protection was most marked among individuals who received the largest amount of beta-agonist. Conclusions.-Inhaled steroids and, to a lesser extent, cromolyn confer significant protection against exacerbations of asthma leading to hospitalization. These results support the use of inhaled steroids by individuals who require more than occasional beta-agonist use to control asthma symptoms.	BRIGHAM & WOMENS HOSP,DEPT MED,CHANNING LAB,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT AMBULATORY CARE & PREVENT,BOSTON,MA; HARVARD PILGRIM HLTH CTR,BOSTON,MA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard Pilgrim Health Care								BARNES PJ, 1989, NEW ENGL J MED, V321, P1517; BARNES PJ, 1990, AM REV RESPIR DIS, V141, pS70; BARNETT GO, 1979, P IEEE, V67, P1226, DOI 10.1109/PROC.1979.11438; BARRETT TE, 1995, AM J RESP CRIT CARE, V151, P574, DOI 10.1164/ajrccm.151.2.7842223; BENATAR SR, 1986, NEW ENGL J MED, V314, P423, DOI 10.1056/NEJM198602133140706; CLARK TJH, 1985, J ALLERGY CLIN IMMUN, V76, P330, DOI 10.1016/0091-6749(85)90649-9; COLLET JP, 1994, PHARMACOEPIDEM DR S, P609; CONOLLY ME, 1971, BRIT J PHARMACOL, V43, P389; DALES RE, 1995, THORAX, V50, P520, DOI 10.1136/thx.50.5.520; DONAHUE JG, IN PRESS J ASTHMA; EVANS R, 1987, CHEST, V91, pS65, DOI 10.1378/chest.91.6_Supplement.65S; GOTTLIEB DJ, 1995, CHEST, V108, P28, DOI 10.1378/chest.108.1.28; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; HALFON N, 1986, AM J PUBLIC HEALTH, V76, P1308, DOI 10.2105/AJPH.76.11.1308; Hosmer DW, 2000, APPL LOGISTIC REGRES, V2nd; JUNIPER EF, 1990, AM REV RESPIR DIS, V142, P832, DOI 10.1164/ajrccm/142.4.832; KERREBIJN KF, 1990, AM REV RESPIR DIS, V141, pS77; KERSTJENS HAM, 1992, NEW ENGL J MED, V327, P1413, DOI 10.1056/NEJM199211123272003; MCFADDEN ER, 1995, J ALLERGY CLIN IMMUN, V95, P641, DOI 10.1016/S0091-6749(95)70166-4; *NAT ASTH ED PROGR, 1991, US DHHS PUBLICATION; OBRIENLADNER A, 1994, GERIATRICS, V49, P20; OBRIENLADNER A, 1994, GERIATRICS, V49, P30; REED CE, 1990, AM REV RESPIR DIS, V141, pS82; Rosner B., 1995, FUNDAMENTALS BIOSTAT; SHEFFER AL, 1996, MED CARE, V31, pMS20; SKORODIN MS, 1993, ARCH INTERN MED, V153, P814, DOI 10.1001/archinte.153.7.814; SPEIZER FE, 1968, BRIT MED J, V1, P335, DOI 10.1136/bmj.1.5588.335; STRUNK RC, 1989, J ALLERGY CLIN IMMUN, V83, P477, DOI 10.1016/0091-6749(89)90137-1; SUISSA S, 1994, EUR RESPIR J, V7, P1602, DOI 10.1183/09031936.94.07091602; TOOGOOD JH, 1990, AM REV RESPIR DIS, V141, pS89; TOOGOOD JH, 1993, BRONCHIAL ASTHMA MEC, P818; VANESSENZANDVLIET EE, 1992, AM REV RESPIR DIS, V146, P547, DOI 10.1164/ajrccm/146.3.547; VATHENEN AS, 1991, AM REV RESPIR DIS, V143, P1317, DOI 10.1164/ajrccm/143.6.1317; WEISS KB, 1992, CHEST, V101, pS362, DOI 10.1378/chest.101.6.362S; Wennergren G, 1996, J ALLERGY CLIN IMMUN, V97, P742, DOI 10.1016/S0091-6749(96)80150-3	35	425	428	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 19	1997	277	11					887	891		10.1001/jama.277.11.887	http://dx.doi.org/10.1001/jama.277.11.887			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM774	9062326				2022-12-01	WOS:A1997WM77400031
J	Jones, IR; Urwin, G; Feldman, RA; Banatvala, N				Jones, IR; Urwin, G; Feldman, RA; Banatvala, N			Social deprivation and bacterial meningitis in North East Thames region: Three year study using small area statistics	BRITISH MEDICAL JOURNAL			English	Article									LONDON HOSP,COLL MED,DEPT MED MICROBIOL,LONDON E1 2AD,ENGLAND; UNIV LONDON QUEEN MARY & WESTFIELD COLL,LONDON HOSP,COLL MED,DEPT EPIDEMIOL & MED STAT,LONDON E1 4NS,ENGLAND	University of London; Queen Mary University London; University of London; Queen Mary University London	Jones, IR (corresponding author), UNIV LONDON QUEEN MARY & WESTFIELD COLL,DEPT GEOG,MILE END RD,LONDON E1 4NS,ENGLAND.			Jones, Ian/0000-0002-1682-9134; Banatvala, Nick/0000-0001-8130-154X				Eachus J, 1996, BMJ-BRIT MED J, V312, P287; ENGLISH D, 1992, GEOGRAPHICAL ENV EPI; STANWELLSMITH RE, 1994, EPIDEMIOL INFECT, V112, P315, DOI 10.1017/S0950268800057733; Townsend P, 1988, HLTH DEPRIVATION INE; URWIN G, 1994, BRIT MED J, V309, P1412, DOI 10.1136/bmj.309.6966.1412	5	29	30	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 15	1997	314	7083					794	795		10.1136/bmj.314.7083.794	http://dx.doi.org/10.1136/bmj.314.7083.794			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WN646	9080999	Green Published			2022-12-01	WOS:A1997WN64600027
J	Alter, MJ; Gallagher, M; Morris, TT; Moyer, LA; Meeks, EL; Krawczynski, K; Kim, JP; Margolis, HS				Alter, MJ; Gallagher, M; Morris, TT; Moyer, LA; Meeks, EL; Krawczynski, K; Kim, JP; Margolis, HS			Acute non-A-E hepatitis in the United States and the role of hepatitis G virus infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NON-B HEPATITIS; POSTTRANSFUSION HEPATITIS; C-HEPATITIS	Background Little is known about the relation of the newly discovered hepatitis G virus (HGV) to the cause and clinical course of acute and chronic viral hepatitis. Methods We selected patients from a surveillance study of acute viral hepatitis in four U.S. counties who had acute disease during 1985 to 1986 or 1991 to 1995. Serum samples were tested for HGV RNA by the polymerase chain reaction. Results HGV RNA was detected in 4 of 45 patients with a diagnosis of non-A-E hepatitis (9 percent), 23 of 116 patients with hepatitis C (20 percent), 25 of 100 patients with hepatitis A (25 percent), and 32 of 100 patients with hepatitis B (32 percent) (P<0.05 for the comparison of hepatitis B with hepatitis non-A-E or C). The clinical characteristics of the acute illness were similar for patients with HGV alone and those with hepatitis A, B, or C with or without HGV infection. During a follow-up period of one to nine years, chronic hepatitis did not develop in any of the patients with HGV alone, but 75 percent were persistently positive for HGV RNA, as were 87 percent of those with both hepatitis C and HGV infection. The rates of chronic hepatitis were similar in patients with hepatitis C alone (60 percent) and those with both hepatitis C and HGV infection (61 percent). Conclusions The evidence from this surveillance study does not implicate HGV as an etiologic agent of non-A-E hepatitis. Persistent infection with HGV was common, but it did not lead to chronic disease and did not affect the clinical course in patients with hepatitis A, B, or C. (C) 1997, Massachusetts Medical Society.	GENELABS TECHNOL, REDWOOD CITY, CA USA		Alter, MJ (corresponding author), CTR DIS CONTROL & PREVENT, HEPATITIS BRANCH, DIV VIRAL & RICKETTSIAL DIS, NATL CTR INFECT DIS, ATLANTA, GA 30333 USA.							AACH RD, 1991, NEW ENGL J MED, V325, P1325, DOI 10.1056/NEJM199111073251901; Alter HJ, 1997, NEW ENGL J MED, V336, P747, DOI 10.1056/NEJM199703133361102; ALTER HJ, 1994, VIRAL HEPATITIS LIVE, P551; ALTER MJ, 1992, NEW ENGL J MED, V327, P1899, DOI 10.1056/NEJM199212313272702; ALTER MJ, 1990, JAMA-J AM MED ASSOC, V264, P2231, DOI 10.1001/jama.264.17.2231; ALTER MJ, 1989, JAMA-J AM MED ASSOC, V262, P1201, DOI 10.1001/jama.262.9.1201; ALTER MJ, 1990, JAMA-J AM MED ASSOC, V263, P1218, DOI 10.1001/jama.263.9.1218; Favorov MO, 1996, J MED VIROL, V50, P50, DOI 10.1002/(SICI)1096-9071(199609)50:1&lt;50::AID-JMV10&gt;3.0.CO;2-1; Feucht HH, 1996, LANCET, V347, P615, DOI 10.1016/S0140-6736(96)91309-4; Fiordalisi G, 1996, J INFECT DIS, V174, P181, DOI 10.1093/infdis/174.1.181; KORETZ RL, 1993, HEPATOLOGY, V17, P361; KRAWCZYNSKI K, 1992, GASTROENTEROLOGY, V103, P622, DOI 10.1016/0016-5085(92)90856-T; KRAWCZYNSKI K, 1996, 9 TRIENN INT S VIR H, P39; LEE SR, 1995, TRANSFUSION, V35, P845, DOI 10.1046/j.1537-2995.1995.351096026366.x; Linnen J, 1996, SCIENCE, V271, P505, DOI 10.1126/science.271.5248.505; Masuko K, 1996, NEW ENGL J MED, V334, P1485, DOI 10.1056/NEJM199606063342301; MCQUILLAN G, 1996, 9 TRIENN INT S VIR H, P8; MCQUILLAN GM, 1989, AM J MED, V3; Moaven LD, 1996, MED J AUSTRALIA, V165, P84, DOI 10.5694/j.1326-5377.1996.tb124854.x; Morris T, 1996, J CLIN MICROBIOL, V34, P2933, DOI 10.1128/JCM.34.12.2933-2936.1996; PilotMatias TJ, 1996, J MED VIROL, V48, P329, DOI 10.1002/(SICI)1096-9071(199604)48:4&lt;329::AID-JMV6&gt;3.0.CO;2-9; SIMONS JN, 1995, NAT MED, V1, P564, DOI 10.1038/nm0695-564; Tanaka E, 1996, ANN INTERN MED, V125, P740, DOI 10.7326/0003-4819-125-9-199611010-00007; YOSHIBA M, 1995, LANCET, V346, P1131, DOI 10.1016/S0140-6736(95)91802-7	24	373	373	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 13	1997	336	11					741	746		10.1056/NEJM199703133361101	http://dx.doi.org/10.1056/NEJM199703133361101			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM640	9052651				2022-12-01	WOS:A1997WM64000001
J	Watanabe, Y; ShinozakiYabana, S; Chikashige, Y; Hiraoka, Y; Yamamoto, M				Watanabe, Y; ShinozakiYabana, S; Chikashige, Y; Hiraoka, Y; Yamamoto, M			Phosphorylation of RNA-binding protein controls cell cycle switch from mitotic to meiotic in fission yeast	NATURE			English	Article							PREMEIOTIC DNA-SYNTHESIS; SCHIZOSACCHAROMYCES-POMBE; SEXUAL DEVELOPMENT; MEIOSIS; GENE; TRANSCRIPTION; INITIATION; SPORULATION; MUTANTS; PRODUCT	Meiosis generates haploid gametes from diploid cells and is an almost universal feature of eukaryotic organisms. But little is known about how the snitch from mitotic to meiotic cell cycles is molecularly controlled. In the fission yeast Schizosaccharomyces pombe, inactivation of the protein kinase Pat1(Ran1) upon nutrient deprivation triggers entry into the meiotic cell cycle(1-6). Here we show that the RNA-binding protein Mei2 is a substrate of Pat1 kinase and that dephosphorylation of Mei2 is sufficient to switch cells from the mitotic cell cycle into meiosis. Mei2 is localized mainly in the cytoplasm of proliferating cells but is seen as a single spot dose to the microtubule organizing centre in prophase nuclei during meiosis. Our results, and others from a metazoan(7), emphasize the crucial role of RNA-binding proteins in the initiation and execution of meiosis.	UNIV TOKYO, GRAD SCH SCI, DEPT BIOPHYS & BIOCHEM, TOKYO 113, JAPAN; KANSAI ADV RES CTR, COMMUN RES LAB, NISHI KU, KOBE, HYOGO 65124, JAPAN	University of Tokyo; National Institute of Information & Communications Technology (NICT) - Japan			Hiraoka, Yasushi/B-5111-2009	Hiraoka, Yasushi/0000-0001-9407-8228; Watanabe, Yoshinori/0000-0002-5488-4812				BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; BEACH D, 1985, CURR GENET, V10, P297, DOI 10.1007/BF00365626; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; Bohmann K, 1995, J CELL SCI, P107; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHIKASHIGE Y, 1994, SCIENCE, V264, P270, DOI 10.1126/science.8146661; Eberhart CG, 1996, NATURE, V381, P783, DOI 10.1038/381783a0; Egel R., 1989, MOL BIOL FISSION YEA, P31; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; Hiraoka Y, 1991, Semin Cell Biol, V2, P153; IINO Y, 1985, P NATL ACAD SCI USA, V82, P2447, DOI 10.1073/pnas.82.8.2447; IINO Y, 1985, MOL GEN GENET, V198, P416, DOI 10.1007/BF00332932; Li P, 1996, CELL, V87, P869, DOI 10.1016/S0092-8674(00)81994-7; MCLEOD M, 1986, EMBO J, V5, P3665, DOI 10.1002/j.1460-2075.1986.tb04697.x; MCLEOD M, 1987, EMBO J, V6, P729, DOI 10.1002/j.1460-2075.1987.tb04814.x; MCLEOD M, 1988, NATURE, V332, P509, DOI 10.1038/332509a0; MOCHIZUKI N, 1992, MOL GEN GENET, V233, P17, DOI 10.1007/BF00587556; NAKASHIMA N, 1995, EMBO J, V14, P4794, DOI 10.1002/j.1460-2075.1995.tb00161.x; NURSE P, 1985, MOL GEN GENET, V198, P497, DOI 10.1007/BF00332946; ROBINOW S, 1988, SCIENCE, V242, P1570, DOI 10.1126/science.3144044; SARABIA MJF, 1993, MOL GEN GENET, V238, P241, DOI 10.1007/BF00279553; SHIMODA C, 1987, J BACTERIOL, V169, P93, DOI 10.1128/jb.169.1.93-96.1987; SUGIMOTO A, 1991, GENE DEV, V5, P1990, DOI 10.1101/gad.5.11.1990; SUGIYAMA A, 1994, EMBO J, V13, P1881, DOI 10.1002/j.1460-2075.1994.tb06457.x; TAKEDA T, 1987, P NATL ACAD SCI USA, V84, P3580, DOI 10.1073/pnas.84.11.3580; WATANABE Y, 1994, CELL, V78, P487, DOI 10.1016/0092-8674(94)90426-X; WATANABE Y, 1988, EMBO J, V7, P761, DOI 10.1002/j.1460-2075.1988.tb02873.x; Yamamoto M, 1996, TRENDS BIOCHEM SCI, V21, P18, DOI 10.1016/S0968-0004(06)80022-8	29	143	146	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 13	1997	386	6621					187	190		10.1038/386187a0	http://dx.doi.org/10.1038/386187a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WM973	9062192				2022-12-01	WOS:A1997WM97300065
J	PritchardJones, K; Hawkins, MM				PritchardJones, K; Hawkins, MM			Biology of Wilms' tumour	LANCET			English	Editorial Material									CHILDHOOD CANC RES GRP,OXFORD OX2 6HJ,ENGLAND	University of Oxford	PritchardJones, K (corresponding author), ROYAL MARSDEN NHS TRUST,CANC RES INST,DOWNS RD,SUTTON SM2 5PT,SURREY,ENGLAND.		Pritchard-Jones, Kathy/F-4286-2014	Pritchard-Jones, Kathy/0000-0002-2384-9475				BIRCH JM, 1995, HEMATOL ONCOL CLIN N, V9, P1157, DOI 10.1016/S0889-8588(18)30039-X; Breslow NE, 1996, MED PEDIATR ONCOL, V27, P398; HASTIE ND, 1994, ANNU REV GENET, V28, P523; Hatada I, 1996, NAT GENET, V14, P171, DOI 10.1038/ng1096-171; HAWKINS MM, 1995, J NATL CANCER I, V87, P1323, DOI 10.1093/jnci/87.17.1323; LEISENRING WM, 1994, CANCER RES, V54, P4680; Pilia G, 1996, NAT GENET, V12, P241, DOI 10.1038/ng0396-241; Rahman N, 1996, NAT GENET, V13, P461, DOI 10.1038/ng0896-461	8	11	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 8	1997	349	9053					663	664		10.1016/S0140-6736(05)60129-8	http://dx.doi.org/10.1016/S0140-6736(05)60129-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WM080	9078193				2022-12-01	WOS:A1997WM08000003
J	Luo, GB; Ducy, P; McKee, MD; Pinero, GJ; Loyer, E; Behringer, RR; Karsenty, G				Luo, GB; Ducy, P; McKee, MD; Pinero, GJ; Loyer, E; Behringer, RR; Karsenty, G			Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein	NATURE			English	Article							TARGETED DISRUPTION; APOLIPOPROTEIN-E; MOUSE EMBRYOS; VITAMIN-K; ATHEROSCLEROSIS; LESIONS; GENE; HYPERCHOLESTEROLEMIA; PROTOONCOGENE; REGION	Calcification of the extracellular matrix (ECM) can be physiological or pathological. Physiological calcification occurs in bone when the soft ECM is converted into a rigid material capable of sustaining mechanical force; pathological calcification can occur in arteries(1) and cartilage(2) and other soft tissues. No molecular determinant regulating ECM calcification has yet been identified. A candidate molecule is matrix GLA protein (Mgp), a mineral-binding ECM protein(3) synthesized by vascular smooth-muscle cells and chondrocytes, two cell types that produce an uncalcified ECM, Mice that lack Mgp develop to term but die within two months as a result of arterial calcification which leads to blood-vessel rupture. Chondrocytes that elaborate a typical cartilage matrix can be seen in the affected arteries. Mgp-deficient mice additionally exhibit inappropriate calcification of various cartilages, including the growth plate, which eventually leads to short stature, osteopenia and fractures. These results indicate that ECM calcification must be actively inhibited in soft tissues. To our knowledge, Mgp is the first inhibitor of calcification of arteries and cartilage to be characterized in vivo.	UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT MOL GENET, HOUSTON, TX 77030 USA; UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT RADIOL, HOUSTON, TX 77030 USA; UNIV MONTREAL, FAC DENT, DEPT STOMATOL, MONTREAL, PQ H3C 3J7, CANADA; UNIV TEXAS, DENT BRANCH, DEPT BASIC SCI, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Universite de Montreal; University of Texas System			McKee, Marc D/E-2187-2011	McKee, Marc D/0000-0001-8349-965X				ANDERSON HC, 1967, J CELL BIOL, V35, P81, DOI 10.1083/jcb.35.1.81; Breslow JL, 1996, SCIENCE, V272, P685, DOI 10.1126/science.272.5262.685; DOWD P, 1995, SCIENCE, V269, P1684, DOI 10.1126/science.7569894; Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; HAUSCHKA PV, 1989, PHYSIOL REV, V69, P990, DOI 10.1152/physrev.1989.69.3.990; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; KOCHHAR DM, 1973, TERATOLOGY, V7, P289, DOI 10.1002/tera.1420070310; LUO GB, 1995, J BONE MINER RES, V10, P325; MANJIN HJ, 1989, PATHOGENESIS OSTEOAR, P1469; McKee MD, 1996, MICROSC RES TECHNIQ, V33, P141, DOI 10.1002/(SICI)1097-0029(19960201)33:2<141::AID-JEMT5>3.0.CO;2-W; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; NAKASHIMA Y, 1994, ARTERIOSCLER THROMB, V14, P133, DOI 10.1161/01.ATV.14.1.133; OBRIEN KD, 1995, CIRCULATION, V92, P2163, DOI 10.1161/01.CIR.92.8.2163; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; QIAO JH, 1994, ARTERIOSCLER THROMB, V14, P1480, DOI 10.1161/01.ATV.14.9.1480; RAMIREZSOLIS R, 1993, METHOD ENZYMOL, V225, P855; REID JD, 1993, ATHEROSCLEROSIS, V101, P213, DOI 10.1016/0021-9150(93)90118-E; ROSS R, 1971, SCI AM, V224, P44; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Singleton E B, 1973, Pediatr Radiol, V1, P2, DOI 10.1007/BF00972817; SMITHIES O, 1995, P NATL ACAD SCI USA, V92, P5266, DOI 10.1073/pnas.92.12.5266; SOLURSH M, 1984, CELL MATRIX INTERACT, P277; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SUNDIN OH, 1990, DEVELOPMENT, V108, P47; TANIMURA A, 1986, Journal of Experimental Pathology (New York), V2, P261; TANIMURA A, 1983, P SOC EXP BIOL MED, V172, P173; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P257; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	30	1605	1682	0	100	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAR 6	1997	386	6620					78	81		10.1038/386078a0	http://dx.doi.org/10.1038/386078a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WL746	9052783				2022-12-01	WOS:A1997WL74600054
J	Garbe, E; LeLorier, J; Boivin, JF; Suissa, S				Garbe, E; LeLorier, J; Boivin, JF; Suissa, S			Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							THERAPEUTIC EFFICACY; ADRENAL-FUNCTION; BECLOMETHASONE DIPROPIONATE; PHARMACOLOGICAL PROPERTIES; INTRAOCULAR-PRESSURE; DRUG-THERAPY; CORTICOSTEROIDS; ASTHMA; RHINITIS; MANAGEMENT	Objective.-To determine whether the use of inhaled and nasal glucocorticoids is associated with an increased risk of ocular hypertension or open-angle glaucoma. Design.-Case-control study. Setting.-Quebec universal health insurance program for all elderly (registered in the Regie de l'assurance maladie du Quebec [RAMQ] database). Patients.-Enrollees in the RAMQ database aged 66 years and older, The 9793 case patients were ophthalmology patients with a new diagnosis of borderline glaucoma or open-angle glaucoma or were newly started on treatment for ocular hypertension or glaucoma between 1988 and 1994, The 38 325 control patients were randomly selected among noncases with ophthalmologist visits in the same month and year as the case event (index date). Main Outcome Measures.-The odds ratio (OR) of ocular hypertension or open-angle glaucoma was determined in patients using inhaled or nasal glucocorticoids relative to nonusers, using conditional logistic regression analysis, The OR was adjusted for age, sex, diabetes mellitus, systemic hypertension, use of ophthalmic and oral glucocorticoids, and characteristics of health care system use in the year before the index date. Results.-Overall, current use of inhaled and nasal glucocorticoids was not associated with an increased risk of ocular hypertension or open-angle glaucoma, Current users of high doses of inhaled steroids prescribed regularly for 3 or more months were at an increased risk with an OR of 1.44 (95% confidence interval, 1.01-2.06). Conclusion.-Prolonged administration of high doses of inhaled glucocorticoids increases the risk of ocular hypertension or open-angle glaucoma, This finding suggests that in these patients intraocular pressure monitoring may be warranted.	ROYAL VICTORIA HOSP, DIV CLIN EPIDEMIOL, MONTREAL, PQ H3A 1A1, CANADA; MCGILL UNIV, DEPT EPIDEMIOL & BIOSTAT, MCGILL PHARMACOEPIDEMIOL RES UNIT, MONTREAL, PQ, CANADA; UNIV MONTREAL, CTR RECH, HOTEL DIEU MONTREAL, MONTREAL, PQ, CANADA	McGill University; Royal Victoria Hospital; McGill University; Universite de Montreal								ARMALY MF, 1963, ARCH OPHTHALMOL-CHIC, V70, P482, DOI 10.1001/archopht.1963.00960050484010; ARMALY MF, 1966, DRUG MECHANISMS GLAU, P191; ARMALY MF, 1986, GLAUCOMA, P697; BARNES NC, 1993, RESP MED, V87, P27, DOI 10.1016/S0954-6111(05)80254-9; BARNES PJ, 1995, NEW ENGL J MED, V332, P868, DOI 10.1056/NEJM199503303321307; BECKER B, 1963, ARCH OPHTHALMOL-CHIC, V70, P500; BROGDEN RN, 1984, DRUGS, V28, P99, DOI 10.2165/00003495-198428020-00002; BROGDEN RN, 1992, DRUGS, V44, P375, DOI 10.2165/00003495-199244030-00007; BRUBAKER RF, 1975, MAYO CLIN PROC, V50, P322; BRYSON HM, 1992, DRUGS, V43, P760, DOI 10.2165/00003495-199243050-00009; BURDE RM, 1970, J AMER MED ASSOC, V213, P2075, DOI 10.1001/jama.213.12.2075; BUTCHER JM, 1994, BRIT MED J, V309, P43, DOI 10.1136/bmj.309.6946.43; CLISSOLD SP, 1984, DRUGS, V28, P485, DOI 10.2165/00003495-198428060-00001; DIELEMANS I, 1994, OPHTHALMOLOGY, V101, P1851; DREYER EB, 1993, NEW ENGL J MED, V329, P1822, DOI 10.1056/NEJM199312093292420; ESTELLE F, 1989, DRUGS, V38, P313, DOI 10.2165/00003495-198938020-00010; FRANCOIS J, 1954, Ann Ocul (Paris), V187, P805; FRENKEL M, 1969, Illinois Medical Journal, V135, P160; GOLDMANN H, 1962, ARCH OPHTHALMOL-CHIC, V68, P621; GURWITZ JH, 1994, JAMA-J AM MED ASSOC, V272, P781, DOI 10.1001/jama.272.10.781; HABBICK B, 1995, CAN MED ASSOC J, V153, P1437; HERNANDEZ MR, 1983, INVEST OPHTH VIS SCI, V24, P1612; JACKSON RV, 1995, MED J AUSTRALIA, V162, P663, DOI 10.5694/j.1326-5377.1995.tb126057.x; KASS MA, 1989, GLAUCOMAS, P1161; KITAZAWA Y, 1981, ARCH OPHTHALMOL-CHIC, V99, P813; LESKE MC, 1983, AM J EPIDEMIOL, V118, P166, DOI 10.1093/oxfordjournals.aje.a113626; MABRY RL, 1992, OTOLARYNG HEAD NECK, V107, P855, DOI 10.1177/019459989210700608.2; MCMANUS P, 1993, MED J AUSTRALIA, V159, P832; MYGIND N, 1973, ACTA ALLERGOL, V28, P211, DOI 10.1111/j.1398-9995.1973.tb01327.x; NINAN TK, 1993, THORAX, V48, P599, DOI 10.1136/thx.48.6.599; OPATOWSKY I, 1995, OPHTHALMOLOGY, V102, P177; PAKES GE, 1980, DRUGS, V19, P397, DOI 10.2165/00003495-198019060-00001; PEARCE N, 1995, LANCET, V345, P41, DOI 10.1016/S0140-6736(95)91159-6; REED CE, 1990, AM REV RESPIR DIS, V141, pS82; ROHEN JW, 1973, EXP EYE RES, V17, P19, DOI 10.1016/0014-4835(73)90164-4; ROLL P, 1979, KLIN MONATSBL AUGENH, V174, P421; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P87; *SAS I INC, 1992, P229 SAS I INC, P435; Skuta GL, 1996, GLAUCOMAS, P1177; SMITH MJ, 1983, THORAX, V38, P676, DOI 10.1136/thx.38.9.676; SOMMER A, 1991, ARCH OPHTHALMOL-CHIC, V109, P1090, DOI 10.1001/archopht.1991.01080080050026; TAMBLYN R, 1995, J CLIN EPIDEMIOL, V48, P999, DOI 10.1016/0895-4356(94)00234-H; WEINREB RN, 1981, INVEST OPHTH VIS SCI, V21, P403; WILSON MR, 1990, INT OPHTHALMOL CLIN, V30, P153; World Health Organization, 1977, INT CLASS DIS; WYATT R, 1978, NEW ENGL J MED, V299, P1387, DOI 10.1056/NEJM197812212992504	46	265	267	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 5	1997	277	9					722	727		10.1001/jama.277.9.722	http://dx.doi.org/10.1001/jama.277.9.722			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WK026	9042844				2022-12-01	WOS:A1997WK02600031
J	Blackbourn, DJ; Ambroziak, J; Lennette, E; Adams, M; Ramachandran, B; Levy, JA				Blackbourn, DJ; Ambroziak, J; Lennette, E; Adams, M; Ramachandran, B; Levy, JA			Infectious human herpesvirus 8 in a healthy North American blood donor	LANCET			English	Article							KAPOSIS-SARCOMA; DNA-SEQUENCES; IMMUNODEFICIENCY VIRUS; AIDS; RECOVERY; CELLS	Background Molecular studies have provided strong evidence for the association of human herpesvirus 8 (HHV-8) with Kaposi's sarcoma. These data have been supported by serological studies, which have also suggested that HHV-8 can be found in the healthy population, We report the presence of infectious HHV-8 in a healthy donor to a North American blood bank. Methods We examined the peripheral blood mononuclear cells or CD19 cells of blood donors by PCR for evidence of HHV-8 infection. The CD19 cells were separated from peripheral blood mononuclear cells by immunomagnetic-bead selection. To enhance detection of HHV-8, the CD19 cells from eleven unsystematically selected blood donors were activated with phorbol ester and recombinant interleukin-6; the culture fluid was filtered and inoculated onto HHV-8-negative target CD19 cells that had been prepared from phytohaemagglutinin-stimulated peripheral blood mononuclear cells. These inoculated target cells were cultured for 3 days and then analysed for HHV-8 sequences by PCR. Serum samples were tested for antibodies to HHV-8 by an indirect immunofluorescence assay. Findings One blood donor was consistently found to be infected with HHV-8 by PCR after the cell-culture activation procedure. He was seropositive for the virus, The HHV-8 recovered was infectious, as shown by a reverse-transcription-PCR technique that detected HHV-8 RNA in the inoculated target cells. Interpretation These data provide the first indication that HHV-8 can be recovered from the blood of a healthy individual, a blood donor, and that the virus is infectious, This observation suggests that HHV-8 could be transmitted by blood transfusion, a possibility that merits further study.	UNIV CALIF SAN FRANCISCO,CANC RES INST,DEPT MED,DIV HEMATOL ONCOL,SAN FRANCISCO,CA 94143; VIROLAB INC,BERKELEY,CA; IRWIN MEM BLOOD CTR,SAN FRANCISCO,CA	University of California System; University of California San Francisco				Blackbourn, David/0000-0002-6703-4497				AMADORI A, 1991, J IMMUNOL, V146, P57; AMBROZIAK JA, 1995, SCIENCE, V268, P582, DOI 10.1126/science.7725108; BLACKBOURN DJ, 1992, J VIROL METHODS, V37, P109, DOI 10.1016/0166-0934(92)90038-F; BOSHOFF C, 1995, NAT MED, V1, P1274, DOI 10.1038/nm1295-1274; CALLARD RE, 1991, CYROKINES PRACTICAL; CASTRO BA, 1988, J CLIN MICROBIOL, V26, P2371, DOI 10.1128/JCM.26.11.2371-2376.1988; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Gao SJ, 1996, NAT MED, V2, P925, DOI 10.1038/nm0896-925; HUANG YQ, 1995, LANCET, V345, P759, DOI 10.1016/S0140-6736(95)90641-X; Kedes DH, 1996, NAT MED, V2, P918, DOI 10.1038/nm0896-918; LANDAY AL, 1993, CLIN IMMUNOL IMMUNOP, V69, P106, DOI 10.1006/clin.1993.1157; Lennette ET, 1996, LANCET, V348, P858, DOI 10.1016/S0140-6736(96)03240-0; LEVY JA, 1985, J INFECT DIS, V152, P734, DOI 10.1093/infdis/152.4.734; Mesri EA, 1996, J EXP MED, V183, P2385, DOI 10.1084/jem.183.5.2385; Moore PS, 1996, J VIROL, V70, P549, DOI 10.1128/JVI.70.1.549-558.1996; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; Renne R, 1996, NAT MED, V2, P342, DOI 10.1038/nm0396-342; Sambrook J., 1989, MOL CLONING LAB MANU; Simpson GR, 1996, LANCET, V348, P1133, DOI 10.1016/S0140-6736(96)07560-5	20	142	149	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 1	1997	349	9052					609	611		10.1016/S0140-6736(96)10004-0	http://dx.doi.org/10.1016/S0140-6736(96)10004-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WK915	9057733				2022-12-01	WOS:A1997WK91500011
J	Brunner, E; Peter, O; Schweizer, L; Basler, K				Brunner, E; Peter, O; Schweizer, L; Basler, K			pangolin encodes a Lef-1 homologue that acts downstream of Armadillo to transduce the Wingless signal in Drosophila	NATURE			English	Article							GENE; EXPRESSION; PROTEIN; MELANOGASTER; MUTATIONS; EMBRYOS; PATHWAY; PATTERN; MARGIN	Members of the Wnt/Wingless (Wg) family of signalling proteins organize many aspects of animal development by regulating the expression of particular target genes in responding cells(1-6). Recent biochemical studies(7-9) indicate that the vertebrate HMG-domain proteins Lef-1 and XTcf-3 can physically interact with beta-catenin, a homologue of Drosophila Armadillo (Arm), the most downstream component known in the Wnt signal transduction pathway(10,11). However, these studies do not address whether the endogenous Lef/Tcf family members are required in vivo to transduce Wnt signals. Using genetic methods in Drosophila, we define a new segment polarity gene, pangolin (pan), and show that its product is required in vivo for Wg signal transduction in embryos and in developing adult tissues. In addition, we show that pan encodes a Lef/Tcf homologue and provide evidence that its protein product binds to the beta-catenin homologue Armadillo in vivo, Finally, we demonstrate that Pan functions downstream of Arm to transduce the Wg signal. Thus, our results indicate that Pan is an essential component of the Wg transduction pathway and suggest that it acts directly to regulate gene transcription in response to Wg signalling.	UNIV ZURICH,INST ZOOL,CH-8057 ZURICH,SWITZERLAND	University of Zurich				Basler, Konrad/0000-0003-3534-1529; Peter, Oliver/0000-0001-7091-6653				Alexandre C, 1996, GENE DEV, V10, P2003, DOI 10.1101/gad.10.16.2003; BAKER NE, 1988, DEVELOPMENT, V102, P489; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; BENJUMEA FD, 1995, DEVELOPMENT, V121, P4215; Brook WJ, 1996, SCIENCE, V273, P1373, DOI 10.1126/science.273.5280.1373; Cadigan KM, 1996, DEVELOPMENT, V122, P2801; COUSO JP, 1994, DEVELOPMENT, V120, P621; Danielian PS, 1996, NATURE, V383, P332, DOI 10.1038/383332a0; Dominguez M, 1996, SCIENCE, V272, P1621, DOI 10.1126/science.272.5268.1621; HOCHMAN B, 1964, GENETICA, V35, P109, DOI 10.1007/BF01804879; HOCHMAN B, 1971, GENETICS, V67, P235; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; LI XL, 1993, EMBO J, V12, P4499, DOI 10.1002/j.1460-2075.1993.tb06139.x; LIN RL, 1995, CELL, V83, P599, DOI 10.1016/0092-8674(95)90100-0; LOCKE J, 1994, MOL GEN GENET, V243, P234, DOI 10.1007/BF00280321; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; MORATA G, 1977, DEV BIOL, V56, P227, DOI 10.1016/0012-1606(77)90266-4; MOTZNY CK, 1995, MECH DEVELOP, V52, P137, DOI 10.1016/0925-4773(95)00397-J; Ng M, 1996, NATURE, V381, P316, DOI 10.1038/381316a0; NOORDERMEER J, 1992, DEVELOPMENT, V116, P711; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; PEIFER M, 1991, DEVELOPMENT, V111, P1029; PHILLIPS RG, 1993, DEVELOPMENT, V118, P427; PORBES AJ, 1993, DEVELOPMENT, V119, P115; RULIFSON EJ, 1995, DEVELOPMENT, V121, P2813; Shirras AD, 1996, DEV BIOL, V175, P24, DOI 10.1006/dbio.1996.0092; SIEGFRIED E, 1994, BIOESSAYS, V16, P395, DOI 10.1002/bies.950160607; SLUSARSKI DC, 1995, GENETICS, V139, P229; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; Yu X, 1996, DEVELOPMENT, V122, P849; Zecca M, 1996, CELL, V87, P833, DOI 10.1016/S0092-8674(00)81991-1	35	434	442	0	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 27	1997	385	6619					829	833		10.1038/385829a0	http://dx.doi.org/10.1038/385829a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WK570	9039917				2022-12-01	WOS:A1997WK57000057
J	Amrein, H; Axel, R				Amrein, H; Axel, R			Genes expressed in neurons of adult male Drosophila	CELL			English	Article							REGULATING SEXUAL-DIFFERENTIATION; DOSAGE COMPENSATION REGULATORS; MUSHROOM BODIES; BINDING PROTEIN; X-CHROMOSOMES; SPLICE SITE; XIST GENE; MELANOGASTER; LETHAL; RNA	We have identified two genes, roX1 and roX2, whose expression in the adult fly is restricted to neurons of males. The two genes reside on the X chromosome, and each encodes an RNA with no apparent open reading frame. Both genes are physically linked to female-specific genes that encode proteins expressed in the ovary: opt1, a novel peptide transporter, and nod, a member of the kinesin family. The male-specific transcripts are positively regulated by the dosage compensation pathway in an all-or-none fashion. Our data suggest that the multimeric complex of dosage compensation proteins may operate in different ways on different sets of X-linked genes.			Amrein, H (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, DEPT BIOCHEM & MOL BIOPHYS, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA.		Amrein, Hubert/AAG-9480-2021	Amrein, Hubert/0000-0001-8799-7250; Axel, Richard/0000-0002-3141-4076	NCI NIH HHS [CA 23767] Funding Source: Medline; NINDS NIH HHS [NS 29832] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA023767] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS029832] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMREIN H, 1988, CELL, V55, P1025, DOI 10.1016/0092-8674(88)90247-4; BAKER BS, 1994, ANNU REV GENET, V28, P491, DOI 10.1146/annurev.ge.28.120194.002423; BAKER BS, 1980, GENETICS, V94, P383; BASHAW GJ, 1995, DEVELOPMENT, V121, P3245; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BELOTE JM, 1987, P NATL ACAD SCI USA, V84, P8026, DOI 10.1073/pnas.84.22.8026; BOPP D, 1991, GENE DEV, V5, P403, DOI 10.1101/gad.5.3.403; BRAND AH, 1993, DEVELOPMENT, V118, P401; BREEN TR, 1986, GENETICS, V112, P483; BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; BURTIS KC, 1989, CELL, V56, P997, DOI 10.1016/0092-8674(89)90633-8; CARPENTER AT, 1973, GENETICS, V73, P393; CHASE BA, 1995, GENETICS, V139, P1649; Clemson CM, 1996, J CELL BIOL, V132, P259, DOI 10.1083/jcb.132.3.259; CLINE TW, 1984, GENETICS, V107, P231; DAVIS RL, 1993, NEURON, V11, P1, DOI 10.1016/0896-6273(93)90266-T; DEBELLE JS, 1995, NEURON, V15, P245; DIANTONIO A, 1993, J NEUROSCI, V13, P4924; DULAC C, 1995, CELL, V83, P195, DOI 10.1016/0092-8674(95)90161-2; FEI YJ, 1994, NATURE, V368, P563, DOI 10.1038/368563a0; GAILEY DA, 1989, GENETICS, V121, P773; GAILEY DA, 1989, GENETICS, V122, P465; GORMAN M, 1995, DEVELOPMENT, V121, P463; GORMAN M, 1994, TRENDS GENET, V10, P376, DOI 10.1016/0168-9525(94)90135-X; HALL J C, 1978, P259; HALL JC, 1977, BEHAV GENET, V7, P291, DOI 10.1007/BF01066800; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; HEISENBERG M, 1995, J NEUROSCI, V15, P1951, DOI 10.1523/JNEUROSCI.15-03-01951.1995; HILDRETH PE, 1965, GENETICS, V51, P659; HILFIKER A, 1994, EMBO J, V13, P3542, DOI 10.1002/j.1460-2075.1994.tb06661.x; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; KELLEY RL, 1995, CELL, V81, P867, DOI 10.1016/0092-8674(95)90007-1; KELLEY RL, 1995, SCIENCE, V270, P1607, DOI 10.1126/science.270.5242.1607; KEYES LN, 1992, CELL, V68, P933, DOI 10.1016/0092-8674(92)90036-C; KURODA MI, 1991, CELL, V66, P935, DOI 10.1016/0092-8674(91)90439-6; Lee JT, 1996, CELL, V86, P83, DOI 10.1016/S0092-8674(00)80079-3; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; MATTOX W, 1992, J BIOL CHEM, V267, P19023; MORGAN T, 1943, CARNEGIE I WASH YB, V42, P171; MUKHERJEE AS, 1965, NATURE, V207, P785, DOI 10.1038/207785a0; NAGOSHI RN, 1988, CELL, V53, P229, DOI 10.1016/0092-8674(88)90384-4; NIGHORN A, 1991, NEURON, V6, P455, DOI 10.1016/0896-6273(91)90253-V; NOTHIGER R, 1987, GENET RES, V50, P113, DOI 10.1017/S001667230002351X; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; ODELL KMC, 1995, NEURON, V15, P55, DOI 10.1016/0896-6273(95)90064-0; OLIVER B, 1993, DEVELOPMENT, V119, P897; PALMER MJ, 1993, GENETICS, V134, P545; PARKHURST SM, 1990, CELL, V63, P1179, DOI 10.1016/0092-8674(90)90414-A; Penny GD, 1996, NATURE, V379, P131, DOI 10.1038/379131a0; RASTELLI L, 1995, MECH DEVELOP, V53, P223, DOI 10.1016/0925-4773(95)00438-7; Richter L, 1996, GENES CELLS, V1, P325, DOI 10.1046/j.1365-2443.1996.26027.x; RONG LA, 1995, J BIOL CHEM, V270, P6456, DOI 10.1074/jbc.270.12.6456; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Ryner LC, 1996, CELL, V87, P1079, DOI 10.1016/S0092-8674(00)81802-4; Saito H, 1996, BBA-BIOMEMBRANES, V1280, P173, DOI 10.1016/0005-2736(96)00024-7; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; STURTEVANT AH, 1945, GENETICS, V30, P297; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; WATANABE TK, 1975, JPN J GENET, V50, P269, DOI 10.1266/jjg.50.269; YANG MY, 1995, NEURON, V15, P45; ZHANG P, 1990, CELL, V62, P1053, DOI 10.1016/0092-8674(90)90383-P; ZHANG P, 1990, GENETICS, V125, P115; ZHOU SB, 1995, EMBO J, V14, P2884, DOI 10.1002/j.1460-2075.1995.tb07288.x	65	178	182	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 21	1997	88	4					459	469		10.1016/S0092-8674(00)81886-3	http://dx.doi.org/10.1016/S0092-8674(00)81886-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WJ691	9038337	hybrid			2022-12-01	WOS:A1997WJ69100006
